PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Sheth, KN; Stein, DM; Aarabi, B; Hu, P; Kufera, JA; Scalea, TM; Hanley, DF				Sheth, Kevin N.; Stein, Deborah M.; Aarabi, Bizhan; Hu, Peter; Kufera, Joseph A.; Scalea, Thomas M.; Hanley, Daniel F.			Intracranial Pressure Dose and Outcome in Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Head trauma; Trauma; Intracranial pressure; Critical care	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; HYPERTENSION; INSULTS; IMPACT; CARE	Detecting and treating elevated intracranial pressure (ICP) is a cornerstone of management in patients with severe traumatic brain injury. The aim of this study was to determine the association between area under the curve measurement of elevated ICP and clinical outcome. Single center observational study using prospectively collected data at a University hospital, level one-trauma center. Sixty prospective patients with severe traumatic brain injury were prospectively enrolled over a 2-year period. Intracranial pressure measurements were captured using a real-time automated, high resolution vital signs data recording system. Mortality and functional outcome were assessed at 30 days, 3 and 6 months using Extended Glasgow Outcome Scale. Increasing elevated intracranial pressure time dose was associated with mortality (OR 1.08; 95 % confidence interval [CI], 1.01-1.15, p = 0.03) and poor functional outcome at 3 (OR 1.04; CI 1.00-1.07, p = 0.03) and 6 months (1.04; CI 1.01-1.08, p = 0.02). However, there was no association between episodic ICP data and outcome. These results suggest that pressure time dose measurement of intracranial pressure may be used to predict outcome in severe traumatic brain injury and may be a candidate biomarker in this disease.	[Sheth, Kevin N.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; [Sheth, Kevin N.; Stein, Deborah M.; Aarabi, Bizhan] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Sheth, Kevin N.; Stein, Deborah M.; Scalea, Thomas M.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Sheth, Kevin N.; Stein, Deborah M.; Aarabi, Bizhan; Hu, Peter; Kufera, Joseph A.; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Ctr, Baltimore, MD 21201 USA; [Hanley, Daniel F.] Johns Hopkins Med Inst, Brain Injury Outcomes Program, Baltimore, MD 21205 USA		Sheth, KN (corresponding author), Univ Maryland, Sch Med, Dept Neurol, 110 S Paca St,3rd Floor, Baltimore, MD 21201 USA.	ksheth@som.umaryland.edu		Stein, Deborah/0000-0003-3683-3963; Hanley, Daniel/0000-0002-9536-4258	American Academy of Neurology Clinical Research Award	Funding support was provided through American Academy of Neurology Clinical Research Award (KNS).	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barton CW, 2007, ACAD EMERG MED, V14, P695, DOI 10.1197/j.aem.2007.03.1358; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Ditillo M, 2011, J TRAUMA, V71, P373; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; O'Phelan KH, 2009, NEUROCRIT CARE, V10, P280, DOI 10.1007/s12028-008-9183-7; Servadei F, 2011, NEW ENGL J MED, V364, P1558, DOI 10.1056/NEJMe1102998; Sorani MD, 2007, NEUROCRIT CARE, V7, P45, DOI 10.1007/s12028-007-0043-7; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; Wijman CAC, 2012, NEUROCRIT CARE, V16, P42, DOI 10.1007/s12028-011-9609-5; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	26	38	38	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2013	18	1					26	32		10.1007/s12028-012-9780-3			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	086SY	WOS:000314708500005	23055087				2022-02-06	
J	Tang, SS; Wang, XY; Hong, H; Long, Y; Li, YQ; Xiang, GQ; Jiang, LY; Zhang, HT; Liu, LP; Miao, MX; Hu, M; Zhang, TT; Hu, W; Ji, H; Ye, FY				Tang, Su-Su; Wang, Xiao-Yun; Hong, Hao; Long, Yan; Li, Yong-Qi; Xiang, Guo-Qing; Jiang, Li-Ying; Zhang, Han-Ting; Liu, Li-Ping; Miao, Ming-Xing; Hu, Mei; Zhang, Ting-Ting; Hu, Wei; Ji, Hui; Ye, Feng-Ying			Leukotriene D4 induces cognitive impairment through enhancement of CysLT(1)R-mediated amyloid-beta generation in mice	NEUROPHARMACOLOGY			English	Article						Leukotriene D4; Cognition; Cysteinyl leukotriene receptor 1; Amyloid-beta peptides; Alzheimer's disease	FACTOR-KAPPA-B; ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; CYSTEINYL-LEUKOTRIENES; MOUSE MODEL; ALZHEIMERS-DISEASE; ASTROCYTE PROLIFERATION; INFLAMMATORY RESPONSE; UP-REGULATION; A-BETA	Amyloid plaques in the extracellular parenchyma mainly consist of amyloid-beta peptides (A beta), one of the pathological hallmarks in Alzheimer's disease (AD). In the present study, we examined neuroinflammation, amyloidogenesis, and memory performance following intracerebral infusions of leukotriene D4 (LTD4) in mice. The results demonstrated that intracerebral infusions of LTD4 (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of A beta 1-40 and A beta 1-42 in the hippocampus and cortex through increased activity of beta- and gamma-secretases accompanied with increased expression of amyloid precursor protein (APP). LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-kappa B p65 in the hippocampus and cortex. Pretreatment with pranlukast (115 ng/mouse, intracerebroventricularly), a CysLT(1)R antagonist, blocked LTD4-induced amyloidogenesis, memory deficits. Pranlukast (0.6 mu M) also prevented LTD4 (20 nM)-induced amyloidogenesis in the cultured neurons in vitro. Moreover, LTD4-induced increases in CysLT(1)R and NF-kappa B p65 in the brain were also attenuated by pranlukast These results suggest that LTD4 increases A beta peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of beta- and gamma-secretases via the NF-kappa B pathway. Our findings identify CysLT(1)R signaling as a novel proinflammatory and proamyloidogenic pathway, and suggest a rationale for development of therapeutics targeting the CysLT(1)R in neuroinflammatory diseases such as AD. (C) 2012 Elsevier Ltd. All rights reserved.	[Tang, Su-Su; Wang, Xiao-Yun; Hong, Hao; Long, Yan; Li, Yong-Qi; Xiang, Guo-Qing; Jiang, Li-Ying; Miao, Ming-Xing; Hu, Mei; Zhang, Ting-Ting; Ji, Hui; Ye, Feng-Ying] China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China; [Zhang, Han-Ting] W Virginia Univ, Hlth Sci Ctr, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA; [Zhang, Han-Ting] W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; [Liu, Li-Ping; Hu, Wei] Anhui Med Univ, Hosp 2, Dept Pharm, Hefei 230031, Peoples R China		Hong, H (corresponding author), China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Peoples R China.	haohongchina@hotmail.com			college graduate research and innovation projects; Jiangsu Province; Natural Science Foundation of Anhui Province, PR ChinaNatural Science Foundation of Anhui Province [1208085MH164]	This work was supported by the college graduate research and innovation projects funded by Jiangsu Province and the Natural Science Foundation of Anhui Province (no. 1208085MH164), PR China.	Back M, 2002, LIFE SCI, V71, P611, DOI 10.1016/S0024-3205(02)01733-2; Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Boyce JA, 2008, CURR MOL MED, V8, P335, DOI 10.2174/156652408785160989; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Capra V, 2004, PHARMACOL RES, V50, P1, DOI 10.1016/j.phrs.2003.12.012; Capra V, 2007, MED RES REV, V27, P469, DOI 10.1002/med.20071; Chami L, 2012, J BIOL CHEM, V287, P24573, DOI 10.1074/jbc.M111.333054; Chinnici CM, 2007, NEUROBIOL AGING, V28, P1457, DOI 10.1016/j.neurobiolaging.2006.06.007; Chu J, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-127; Chu J, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-1; Chu J, 2011, ANN NEUROL, V69, P34, DOI 10.1002/ana.22234; Chu J, 2011, AM J PATHOL, V178, P1762, DOI 10.1016/j.ajpath.2010.12.032; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Cuenca-Lopez MD, 2010, REV NEUROLOGIA, V50, P349, DOI 10.33588/rn.5006.2009666; Dahlen SE, 2006, EUR J PHARMACOL, V533, P40, DOI 10.1016/j.ejphar.2005.12.070; Ding Q, 2007, ACTA PHARMACOL SIN, V28, P945, DOI 10.1111/j.1745-7254.2007.00576.x; Evans JF, 2003, PROSTAG LEUKOTR ESS, V69, P117, DOI 10.1016/S0952-3278(03)00072-3; Firuzi O, 2008, FASEB J, V22, P1169, DOI 10.1096/fj.07-9131.com; Giunta B, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-51; Gorelick PB, 2010, ANN NY ACAD SCI, V1207, P155, DOI 10.1111/j.1749-6632.2010.05726.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Guglielmotto M., 2010, NEUROBIOL AGING, V196, pe13; Guo JT, 2002, J NEUROSCI, V22, P5900; Hashimoto K, 2009, INT ARCH ALLERGY IMM, V149, P275, DOI 10.1159/000199724; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Huang XJ, 2008, GLIA, V56, P27, DOI 10.1002/glia.20588; Ikonomovic MD, 2008, J HISTOCHEM CYTOCHEM, V56, P1065, DOI 10.1369/jhc.2008.951855; Im DS, 2009, PROSTAG OTH LIPID M, V89, P53, DOI 10.1016/j.prostaglandins.2009.01.002; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kawano T, 2003, J ALLERGY CLIN IMMUN, V112, P369, DOI 10.1067/mai.2003.1636; Kimura R, 2010, J NEUROCHEM, V113, P248, DOI 10.1111/j.1471-4159.2010.06608.x; Krause Daniela L, 2010, Int J Alzheimers Dis, V2010, DOI 10.4061/2010/732806; Lammers CH, 1996, J NEUROCHEM, V66, P147; Lee J.W., 2008, J NEUROINFLAMM, V29, P5; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Manev H, 2011, PROG NEURO-PSYCHOPH, V35, P315, DOI 10.1016/j.pnpbp.2010.07.032; Medeiros R, 2010, BEHAV BRAIN RES, V209, P165, DOI 10.1016/j.bbr.2010.01.040; Montuschi P, 2007, DRUG DISCOV TODAY, V12, P404, DOI 10.1016/j.drudis.2007.03.004; Morris AAM, 1998, LANCET, V352, P1487, DOI 10.1016/S0140-6736(05)60322-4; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Paxinos G., 2003, MOUSE BRAIN STEREOTA, V2; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Puccio S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015163; Samuelsson B, 2000, AM J RESP CRIT CARE, V161, pS2, DOI 10.1164/ajrccm.161.supplement_1.ltta-1; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Uz T, 1998, FASEB J, V12, P439, DOI 10.1096/fasebj.12.6.439; Wang C, 2011, INT J NEUROPSYCHOPH, V9, P1; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Wang ML, 2006, BIOCHEM BIOPH RES CO, V350, P399, DOI 10.1016/j.bbrc.2006.09.057; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yuan YM, 2009, J PHARMACOL SCI, V109, P285, DOI 10.1254/jphs.08321FP; Zhang J, 2006, ACTA PHARMACOL SIN, V27, P1553, DOI 10.1111/j.1745-7254.2006.00458.x; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zotova E, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt24	62	38	39	1	33	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2013	65						182	192		10.1016/j.neuropharm.2012.08.026			11	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	076CY	WOS:000313935300023	22982445				2022-02-06	
J	Cruse, D; Thibaut, A; Demertzi, A; Nantes, JC; Bruno, MA; Gosseries, O; Vanhaudenhuyse, A; Bekinschtein, TA; Owen, AM; Laureys, S				Cruse, Damian; Thibaut, Aurore; Demertzi, Athena; Nantes, Julia C.; Bruno, Marie-Aurelie; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Bekinschtein, Tristan A.; Owen, Adrian M.; Laureys, Steven			Actigraphy assessments of circadian sleep-wake cycles in the Vegetative and Minimally Conscious States	BMC MEDICINE			English	Article						Vegetative State; Minimally Conscious State; circadian rhythms; sleep; actigraphy	BRAIN; NEUROPATHOLOGY; RHYTHMS; VARIABILITY; DISORDERS; AWARENESS; INJURY; LIGHT	Background: The Vegetative and Minimally Conscious States (VS; MCS) are characterized by absent or highly disordered signs of awareness alongside preserved sleep-wake cycles. According to international diagnostic guidelines, sleep-wake cycles are assessed by means of observations of variable periods of eye-opening and eye-closure. However, there is little empirical evidence for true circadian sleep-wake cycling in these patients, and there have been no large-scale investigations of the validity of this diagnostic criterion. Methods: We measured the circadian sleep-wake rhythms of 55 VS and MCS patients by means of wrist actigraphy, an indirect method that is highly correlated with polysomnographic estimates of sleeping/waking. Results: Contrary to the diagnostic guidelines, a significant proportion of patients did not exhibit statistically reliable sleep-wake cycles. The circadian rhythms of VS patients were significantly more impaired than those of MCS patients, as were the circadian rhythms of patients with non-traumatic injuries relative to those with traumatic injuries. The reliability of the circadian rhythms were significantly predicted by the patients' levels of visual and motor functioning, consistent with the putative biological generators of these rhythms. Conclusions: The high variability across diagnoses and etiologies highlights the need for improved guidelines for the assessment of sleep-wake cycles in VS and MCS, and advocates the use of actigraphy as an inexpensive and non-invasive alternative.	[Cruse, Damian; Nantes, Julia C.; Owen, Adrian M.] Univ Western Ontario, Brain & Mind Inst, London, ON N6A 3K7, Canada; [Thibaut, Aurore; Demertzi, Athena; Bruno, Marie-Aurelie; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Laureys, Steven] Univ Hosp, Dept Neurol, Coma Sci Grp, B-4000 Sart Tilman Par Liege, Belgium; [Thibaut, Aurore; Demertzi, Athena; Bruno, Marie-Aurelie; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Laureys, Steven] Univ Hosp, Cyclotron Res Ctr, B-4000 Sart Tilman Par Liege, Belgium; [Thibaut, Aurore; Demertzi, Athena; Bruno, Marie-Aurelie; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Laureys, Steven] Univ Liege, B-4000 Sart Tilman Par Liege, Belgium; [Bekinschtein, Tristan A.] MRC, Cognit & Brain Sci Unit, Cambridge CB2 7EF, England		Cruse, D (corresponding author), Univ Western Ontario, Brain & Mind Inst, 1151 Richmond St, London, ON N6A 3K7, Canada.	dcruse@uwo.ca	Owen, Adrian M/B-4997-2015; Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/A-3349-2011; Demertzi, Athena/I-1251-2019; Thibaut, Aurore/U-8101-2019; Cruse, Damian/ABA-6346-2021; Williams, Jackie/B-3495-2015; Vanhaudenhuyse, Audrey/AAP-2455-2020; Laureys, Steven/AAN-2097-2021	Gosseries, Olivia/0000-0001-9011-7496; Demertzi, Athena/0000-0001-8021-3759; Cruse, Damian/0000-0003-4363-5981; Laureys, Steven/0000-0002-3096-3807; Bekinschtein, Tristan/0000-0001-5501-8628	European CommissionEuropean CommissionEuropean Commission Joint Research Centre; Fonds de la Recherche ScientifiqueFonds de la Recherche Scientifique - FNRS; Mind Science Foundation; Belgian French-Speaking Community Concerted Research Action; University Hospital of Liege; University of LiegeUniversity of Liege; Wellcome TrustWellcome TrustEuropean Commission; Canada Excellence Research Chair Programme (CERC); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	This research was supported by generous funding from the European Commission, Fonds de la Recherche Scientifique, the Mind Science Foundation, the Belgian French-Speaking Community Concerted Research Action, University Hospital of Liege, University of Liege, the Wellcome Trust, the Canada Excellence Research Chair Programme (CERC), and the Canadian Institutes of Health Research (CIHR).	Adams J. H., 1992, GREENFIELDS NEUROPAT; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Ancoli-Israel S, 2002, J AM GERIATR SOC, V50, P282, DOI 10.1046/j.1532-5415.2002.50060.x; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bekinschtein TA, 2009, BRAIN INJURY, V23, P915, DOI 10.1080/02699050903283197; Bekinschtein T, 2009, PROG BRAIN RES, V177, P171, DOI 10.1016/S0079-6123(09)17712-9; Berger AM, 2008, J PAIN SYMPTOM MANAG, V36, P191, DOI 10.1016/j.jpainsymman.2007.10.008; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; BROWN A, 1990, PROG CLIN BIOL RES, V341, P77; CAMPBELL SS, 1988, PHYSIOL BEHAV, V42, P141, DOI 10.1016/0031-9384(88)90289-2; Candelieri A, 2011, J NEUROTRAUM, V28, P2013, DOI 10.1089/neu.2011.1885; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; de Souza L, 2003, SLEEP, V26, P81, DOI 10.1093/sleep/26.1.81; De Weer AS, 2011, EUR J NEUROL, V18, P1432, DOI 10.1111/j.1468-1331.2011.03477.x; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Fernandez-Espejo D, 2010, J NEUROTRAUM, V27, P1187, DOI 10.1089/neu.2010.1297; Fukudome Y, 1996, AM J PHYSIOL-REG I, V270, pR1109, DOI 10.1152/ajpregu.1996.270.5.R1109; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Guan J, 2011, J INT MED RES, V39, P2281, DOI 10.1177/147323001103900625; Isono M, 2002, BRAIN INJURY, V16, P705, DOI 10.1080/02699050210127303; Jean-Louis G, 2000, PHYSIOL BEHAV, V68, P347, DOI 10.1016/S0031-9384(99)00186-9; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Landsness E, 2011, BRAIN, V134, P2222, DOI 10.1093/brain/awr152; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Oksenberg A, 2000, SLEEP, V23, P953; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pattoneri Paolo, 1800, J Clin Hypertens (Greenwich), V7, P734, DOI 10.1111/j.1524-6175.2005.04780.x; Refinetti R., 2006, CIRCADIAN PHYSL; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Shochat T, 2000, J SLEEP RES, V9, P373, DOI 10.1046/j.1365-2869.2000.00221.x; Spivak E, 2007, SPINAL CORD, V45, P765, DOI 10.1038/sj.sc.3102040; Veasey SC, 2004, SLEEP, V27, P194, DOI 10.1093/sleep/27.2.194	44	38	39	0	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1741-7015			BMC MED	BMC Med.	JAN 24	2013	11								18	10.1186/1741-7015-11-18			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	137HJ	WOS:000318426000001	23347467	Green Published, gold			2022-02-06	
J	Cantor, JB; Gordon, W; Gumber, S				Cantor, Joshua B.; Gordon, Wayne; Gumber, Shinakee			What is post TBI fatigue?	NEUROREHABILITATION			English	Article						Traumatic Brain Injury; fatigue; epidemiology; assessment; treatment	TRAUMATIC BRAIN-INJURY; EXCESSIVE DAYTIME SLEEPINESS; CLOSED-HEAD-INJURY; QUALITY-OF-LIFE; 1ST 2 YEARS; MULTIPLE-SCLEROSIS; MENTAL FATIGUE; FUNCTIONAL MRI; ATTENTION DEFICITS; COGNITIVE FATIGUE	BACKGROUND: Fatigue is among the most common sequelae of traumatic brain injury (TBI). OBJECTIVES: To summarize the empirical and theoretical literature on Post TBI fatigue (PTBIF) and identify some of the challenges that continue to confront clinicians, researchers and individuals with TBI. METHODS: Qualitative literature review. The epidemiology, characteristics, and correlates of PTBIF are described. Challenges in the operational definition and measurement of fatigue are discussed and the empirical literature on measurement of PTBIF and theoretical models of the potential etiology of PTBIF is summarized. Existing treatments of PTBIF and the research supporting them are reviewed. Future directions for clinical research are presented. RESULTS: Although PTBIF is a high incidence condition after TBI that is related to significant suffering and reduced quality of life, it remains inadequately measured and treated. Its etiology and precipitants are poorly understood and intervention research is inadequate. CONCLUSION: Further research is necessary to develop psychometrically-sound objective and subjective measures of PTBIF and examine the efficacy of treatments for fatigue. Interventions shown to improve fatigue in other populations should be considered in treating PTBIF.	[Cantor, Joshua B.; Gordon, Wayne; Gumber, Shinakee] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Cantor, JB (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	joshua.cantor@mountsinai.org			National Institute of Disability and Rehabilitation Research, United States Department of Education [H133A020501]	The preparation of this manuscript was supported in part by grant # H133A020501 from the National Institute of Disability and Rehabilitation Research, United States Department of Education.	Aaronson L S, 1999, Image J Nurs Sch, V31, P45; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Barwick F, 2012, CLIN NEUROPHYSIOL, V123, P278, DOI 10.1016/j.clinph.2011.06.027; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Bay E, 2009, WESTERN J NURS RES, V31, P731, DOI 10.1177/0193945909334856; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor J. B., 2012, J HEAD TRAU IN PRESS; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chaudhuri A, 2000, J NEUROL SCI, V179, P34, DOI 10.1016/S0022-510X(00)00411-1; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; de Joode E., 2011, DISABILITY REHABILIT; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; DeLuca J, 2005, ISS CLIN COGN NEUROP, P319; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dijkers MPJM, 2008, J HEAD TRAUMA REHAB, V23, P3, DOI 10.1097/01.HTR.0000308716.80590.6b; Elovic EP, 2005, ISS CLIN COGN NEUROP, P89; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1008842517972; Hattori N, 2009, J NUCL MED, V50, P1054, DOI 10.2967/jnumed.108.060368; Hicks EJ, 2011, INT J SPEECH-LANG PA, V13, P145, DOI 10.3109/17549507.2011.485329; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Johansson B, 2012, BRAIN INJURY, V26, P1621, DOI 10.3109/02699052.2012.700082; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Krupp LB, 2010, EXPERT REV NEUROTHER, V10, P1437, DOI [10.1586/ern.10.99, 10.1586/ERN.10.99]; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; KRUPP LB, 1995, NEUROLOGY, V45, P1956, DOI 10.1212/WNL.45.11.1956; Levine J, 2009, PHYS MED REH CLIN N, V20, P347, DOI 10.1016/j.pmr.2008.12.006; Lundqvist A, 2008, BRAIN INJURY, V22, P295, DOI 10.1080/02699050801966133; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Merritta C, 2010, INT J REHABIL RES, V33, P109, DOI 10.1097/MRR.0b013e32832e6b37; Mitchell SA, 2010, PM&R, V2, P364, DOI 10.1016/j.pmrj.2010.03.024; Montgomery GH, 2009, HEALTH PSYCHOL, V28, P317, DOI 10.1037/a0013582; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pardini M, 2010, NEUROLOGY, V74, P749, DOI 10.1212/WNL.0b013e3181d25b6b; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Riese H, 1999, NEUROPSYCHOL REHABIL, V9, P189, DOI 10.1080/713755600; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Schnieders J., 2011, J HEAD TRAUMA REHABI; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Schwid SR, 2002, J REHABIL RES DEV, V39, P211; Stuart B., 2011, J EMERGENCY NURSING; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Toblin RL, 2012, J AFFECT DISORDERS, V136, P469, DOI 10.1016/j.jad.2011.10.048; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; Whitehead L, 2009, J PAIN SYMPTOM MANAG, V37, P107, DOI 10.1016/j.jpainsymman.2007.08.019; Wiborg JF, 2010, PSYCHOL MED, V40, P1281, DOI 10.1017/S0033291709992212; Wylie G., 2012, 14 ANN M INT NEUR SO, V18, P229; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	68	38	38	0	25	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	4					875	883		10.3233/NRE-130912			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	184QF	WOS:000321907100019	23867414				2022-02-06	
J	Lewis, M; Ghassemi, P; Hibbeln, J				Lewis, Michael; Ghassemi, Parviz; Hibbeln, Joseph			Therapeutic use of omega-3 fatty acids in severe head trauma	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							POLYUNSATURATED FATTY-ACIDS; DOCOSAHEXAENOIC ACID; BRAIN-INJURY; ENTERAL NUTRITION; TRANSIENT; APOPTOSIS	Traumatic brain injury (TBI) has long been recognized as the leading cause of traumatic death and disability. Tremendous advances in surgical and intensive care unit management of the primary injury, including maintaining adequate oxygenation, controlling intracranial pressure, and ensuring proper cerebral perfusion pressure, have resulted in reduced mortality. However, the secondary injury phase of TBI is a prolonged pathogenic process characterized by neuroinflammation, excitatory amino acids, free radicals, and ion imbalance. There are no approved therapies to directly address these underlying processes. Here, we present a case that was intentionally treated with substantial amounts of omega-3 fatty acids (n-3FA) to provide the nutritional foundation for the brain to begin the healing process following severe TBI. Recent animal research supports the use of n-3FA, and clinical experience suggests that benefits may be possible from substantially and aggressively adding n-3FA to optimize the nutritional foundation of severe TBI patients and must be in place if the brain is to be given the opportunity to repair itself to the best possible extent. Administration early in the course of treatment, in the emergency department or sooner, has the potential to improve outcomes from this potentially devastating public health problem.	[Lewis, Michael] Brain Hlth Educ & Res Fdn, Arlington, VA 22206 USA; [Hibbeln, Joseph] NIAAA, NIH, Rockville, MD 20852 USA		Lewis, M (corresponding author), Brain Hlth Educ & Res Fdn, Arlington, VA 22206 USA.	dr.michael.lewis@gmail.com; peter@arctelcom.com; Joseph.hibbeln@nih.gov			Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ZIA AA000115-12] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000115] Funding Source: NIH RePORTER		Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102; Akbar M, 2002, J NEUROCHEM, V82, P655, DOI 10.1046/j.1471-4159.2002.01015.x; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311; Bistrian BR, 2003, JPEN-PARENTER ENTER, V27, P168, DOI 10.1177/0148607103027003168; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Calderon F, 2004, J NEUROCHEM, V90, P979, DOI 10.1111/j.1471-4159.2004.02520.x; Cao DH, 2009, J NEUROCHEM, V111, P510, DOI 10.1111/j.1471-4159.2009.06335.x; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Kawakita E, 2006, NEUROSCIENCE, V139, P991, DOI 10.1016/j.neuroscience.2006.01.021; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; KIRBY DF, 1991, JPEN-PARENTER ENTER, V15, P298, DOI 10.1177/0148607191015003298; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling GSF, 2008, NEUROL CLIN, V26, P409, DOI 10.1016/j.ncl.2008.02.001; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; Michael-Titus AT, 2009, CLIN LIPIDOL, V4, P343, DOI 10.2217/CLP.09.19; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Okada M, 1996, NEUROSCIENCE, V71, P17, DOI 10.1016/0306-4522(95)00427-0; Roberts L, 2008, J AM COLL SURGEONS, V207, P276, DOI 10.1016/j.jamcollsurg.2008.02.015; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Willatts P, 1998, LANCET, V352, P688, DOI 10.1016/S0140-6736(97)11374-5; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Yavin E, 2009, NEUROSCIENCE, V162, P1011, DOI 10.1016/j.neuroscience.2009.05.012; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	29	38	41	0	27	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JAN	2013	31	1							273.e5	10.1016/j.ajem.2012.05.014			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	062WM	WOS:000312954600077	22867826	Green Accepted			2022-02-06	
J	O'Sullivan, A; Willoughby, RE; Mishchuk, D; Alcarraz, B; Cabezas-Sanchez, C; Condori, RE; David, D; Encarnacion, R; Fatteh, N; Fernandez, J; Franka, R; Hedderwick, S; McCaughey, C; Ondrush, J; Paez-Martinez, A; Rupprecht, C; Velasco-Villa, A; Slupsky, CM				O'Sullivan, Aifric; Willoughby, Rodney E.; Mishchuk, Darya; Alcarraz, Brisa; Cabezas-Sanchez, Cesar; Condori, Rene Edgar; David, Dan; Encarnacion, Rafael; Fatteh, Naaz; Fernandez, Josefina; Franka, Richard; Hedderwick, Sara; McCaughey, Conall; Ondrush, Joanne; Paez-Martinez, Andres; Rupprecht, Charles; Velasco-Villa, Andres; Slupsky, Carolyn M.			Metabolomics of Cerebrospinal Fluid from Humans Treated for Rabies	JOURNAL OF PROTEOME RESEARCH			English	Article						rabies; metabolomics; NMR spectroscopy; cerebrospinal fluid	MAGNETIC-RESONANCE SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; QUINOLINIC ACID; KYNURENINE PATHWAY; N-ACETYLASPARTATE; DIAGNOSIS; VIRUS; METABOLISM; ALCOHOL; DISEASE	Rabies is a rapidly progressive lyssavirus encephalitis that is statistically 100% fatal. There are no clinically effective antiviral drugs for rabies. An immunologically naive teenager survived rabies in 2004 through improvised supportive care; since then, 5 additional survivors have been associated with use of the so-called Milwaukee Protocol (MP). The MP applies critical care focused on the altered metabolic and physiologic states associated with rabies. The aim of this study was to examine the metabolic profile of cerebrospinal fluid (CSF) from rabies patients during clinical progression of rabies encephalitis in survivors and nonsurvivors and to compare these samples with control CSF samples. Unsupervised clustering algorithms distinguished three stages of rabies disease and identified several metabolites that differentiated rabies survivors from those who subsequently died, in particular, metabolites related to energy metabolism and cell volume control. Moreover, for those patients who survived, the trajectory of their metabolic profile tracked toward the control profile and away from the rabies profile. NMR metabolomics of human rabies CSF provide new insights into the mechanisms of rabies pathogenesis, which may guide future therapy of this disease.	[O'Sullivan, Aifric; Mishchuk, Darya; Slupsky, Carolyn M.] Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA; [Slupsky, Carolyn M.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; [Willoughby, Rodney E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Alcarraz, Brisa] Hosp Nacl Cayetano Heredia, Lima, Peru; [Cabezas-Sanchez, Cesar; Condori, Rene Edgar] Inst Nacl Salud, Lima, Peru; [David, Dan] Kimron Vet Inst, Bet Dagan, Israel; [Encarnacion, Rafael; Fernandez, Josefina] Hosp Robert Reid Cabral, Santo Domingo, Dominican Rep; [Fatteh, Naaz; Ondrush, Joanne] INOVA Fairfax Hosp, Fairfax, VA USA; [Franka, Richard; Rupprecht, Charles; Velasco-Villa, Andres] Ctr Dis Control & Prevent, Atlanta, GA USA; [Hedderwick, Sara; McCaughey, Conall] Belfast HSC Trust, Royal Hosp, Belfast, Antrim, North Ireland; [Paez-Martinez, Andres] Inst Nacl Salud, Bogota, Colombia		Slupsky, CM (corresponding author), Univ Calif Davis, Dept Food Sci & Technol, Davis, CA 95616 USA.	cslupsky@ucdavis.edu	Rupprecht, Charles/AAI-1544-2020; O'Sullivan, Aifri/AAM-9046-2020	O'Sullivan, Aifric/0000-0002-7441-1983; CABEZAS, CESAR/0000-0001-5120-0713; Velasco-Villa, Andres/0000-0003-1538-9373; PAEZ MARTINEZ, ANDRES/0000-0001-7316-3706	Zach Jones Foundation	This work was supported by the Zach Jones Foundation. The authors thank all of the patients and patients' families that were involved in this study. We gratefully acknowledge A. Jansen (Medical College of Wisconsin), J. Blanton, F. Jackson, I. Kuzmin, N. Kuzmina, X. Ma, M. Niezgoda, L. Orciari, O. Urazova, and P. Yager (CDC) for laboratory support and J. Rubin (Centro Medico La Paz, Equatorial Guinea), Y. Caicedo (Hospital Universidad del Valle, Columbia), A. Roy-Berman (Children's Hospital & Research Center, Oakland, CA), C. Glaser (California Department of Public Health, Richmond, CA), Y. Oba (University of Missouri), G. Arroyo Sanchez (Hospital Nacional Cayetano Heredia, Lima, Peru), and S. Lo (Children's Hospital of Wisconsin) for providing CSF samples.	Al-Dirbashi OY, 2007, J INHERIT METAB DIS, V30, P612, DOI 10.1007/s10545-007-0635-6; ALVAREZ L, 1994, PEDIATR INFECT DIS J, V13, P1154, DOI 10.1097/00006454-199412000-00020; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; [Anonymous], 1977, Morbidity and Mortality Weekly Report, V26, P183; [Anonymous], 2005, WHO EXPERT CONSULTAT; AOKI TT, 1975, DIABETES, V24, P463, DOI 10.2337/diabetes.24.5.463; Baslow MH, 2007, J MOL NEUROSCI, V32, P235, DOI 10.1007/s12031-007-0049-9; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Blasco H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013223; Brady MT, 2011, PEDIATRICS, V127, P785, DOI 10.1542/peds.2011-0095; BROUWERS P, 1993, J INFECT DIS, V168, P1380, DOI 10.1093/infdis/168.6.1380; Chow SL, 2005, ARCH DIS CHILD, V90, P1188, DOI 10.1136/adc.2005.075317; Clayton TA, 2009, P NATL ACAD SCI USA, V106, P14728, DOI 10.1073/pnas.0904489106; Coen M, 2005, CLIN INFECT DIS, V41, P1582, DOI 10.1086/497836; DAVIS PL, 1984, J ANAL TOXICOL, V8, P209, DOI 10.1093/jat/8.5.209; Debray FG, 2007, CLIN CHEM, V53, P916, DOI 10.1373/clinchem.2006.081166; Faber M, 2002, J VIROL, V76, P3374, DOI 10.1128/JVI.76.7.3374-3381.2002; GRATTANSMITH PJ, 1992, MED J AUSTRALIA, V156, P651, DOI 10.5694/j.1326-5377.1992.tb121465.x; HANSEN EL, 1974, ACTA MED SCAND, V196, P431; HATTWICK MA, 1972, ANN INTERN MED, V76, P931, DOI 10.7326/0003-4819-76-6-931; HEYES MP, 1995, J NEUROL SCI, V133, P112, DOI 10.1016/0022-510X(95)00164-W; Heyes MP, 1998, FASEB J, V12, P881, DOI 10.1096/fasebj.12.10.881; HIRAOKA A, 1994, BIOL PHARM BULL, V17, P1; Hunter M, 2010, J MED VIROL, V82, P1255, DOI 10.1002/jmv.21785; Janson CG, 2006, NEUROPEDIATRICS, V37, P209, DOI 10.1055/s-2006-924734; Jornvall H, 2000, PHARMACOLOGY, V61, P184, DOI 10.1159/000028399; KEILHOFF G, 1991, NEUROSCIENCE, V42, P379, DOI 10.1016/0306-4522(91)90382-X; KOMOROWSKI RA, 1978, J CLIN MICROBIOL, V8, P89; LAMAS CC, 1980, ACTA NEUROPATHOL, V51, P245, DOI 10.1007/BF00687393; LEWIS GD, 1984, J FORENSIC SCI, V29, P541; LOCKHART BP, 1992, ANTIMICROB AGENTS CH, V36, P1750, DOI 10.1128/AAC.36.8.1750; Madhusudana S. N., 2002, International Journal of Infectious Diseases, V6, P85, DOI 10.1016/S1201-9712(02)90144-X; Medana IM, 2003, J INFECT DIS, V188, P844, DOI 10.1086/377583; Medana IM, 2002, J INFECT DIS, V185, P650, DOI 10.1086/339009; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Newman HW, 1940, J PHARMACOL EXP THER, V68, P194; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; PORRAS C, 1976, ANN INTERN MED, V85, P44, DOI 10.7326/0003-4819-85-1-44; ROINE RO, 1988, BRAIN, V111, P1505, DOI 10.1093/brain/111.6.1505; Rubin J, 2009, SCAND J INFECT DIS, V41, P372, DOI 10.1080/00365540902798333; RUDDICK JA, 1972, TOXICOL APPL PHARM, V21, P102, DOI 10.1016/0041-008X(72)90032-4; Sinclair AJ, 2010, NMR BIOMED, V23, P123, DOI 10.1002/nbm.1428; Sing T M, 1996, Australas Radiol, V40, P338, DOI 10.1111/j.1440-1673.1996.tb00415.x; Slupsky CM, 2007, ANAL CHEM, V79, P6995, DOI 10.1021/ac0708588; Slupsky CM, 2010, CLIN CANCER RES, V16, P5835, DOI 10.1158/1078-0432.CCR-10-1434; Slupsky CM, 2009, J PROTEOME RES, V8, P5550, DOI 10.1021/pr9006427; STONE TW, 1993, PHARMACOL REV, V45, P309; Stoop MP, 2010, MOL CELL PROTEOMICS, V9, P2063, DOI 10.1074/mcp.M900877-MCP200; Surendran S, 2003, J CHILD NEUROL, V18, P611, DOI 10.1177/08830738030180090701; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Walsh MC, 2006, AM J CLIN NUTR, V84, P531, DOI 10.1093/ajcn/84.3.531; WARRELL DA, 1976, AM J MED, V60, P180, DOI 10.1016/0002-9343(76)90427-7; Weli SC, 2006, J VIROL, V80, P10270, DOI 10.1128/JVI.01272-06; Weljie AM, 2006, ANAL CHEM, V78, P4430, DOI 10.1021/ac060209g; Willoughby RE, 2008, DEV BIOLOGICALS, V131, P367; Willoughby RE, 2009, J INHERIT METAB DIS, V32, P65, DOI 10.1007/s10545-008-0949-z; Willoughby R. E., 2011, RABIES TREATMENT PRO; Willoughby RE, 2005, NEW ENGL J MED, V352, P2508, DOI 10.1056/NEJMoa050382; Willoughby RE, 2009, VACCINE, V27, P7173, DOI 10.1016/j.vaccine.2009.09.032; Wishart DS, 2008, J CHROMATOGR B, V871, P164, DOI 10.1016/j.jchromb.2008.05.001; Xu QW, 2011, J BIOMOL NMR, V49, P207, DOI 10.1007/s10858-011-9482-8	62	38	39	1	38	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	JAN	2013	12	1					481	490		10.1021/pr3009176			10	Biochemical Research Methods	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065NX	WOS:000313156300048	23163834	Green Accepted			2022-02-06	
J	Freund, P; Schneider, T; Nagy, Z; Hutton, C; Weiskopf, N; Friston, KJ; Wheeler-Kingshott, CA; Thompson, AJ				Freund, Patrick; Schneider, Torben; Nagy, Zoltan; Hutton, Chloe; Weiskopf, Nikolaus; Friston, Karl J.; Wheeler-Kingshott, Claudia A.; Thompson, Alan J.			Degeneration of the Injured Cervical Cord Is Associated with Remote Changes in Corticospinal Tract Integrity and Upper Limb Impairment	PLOS ONE			English	Article							VOXEL-BASED MORPHOMETRY; SPINAL-CORD; MULTIPLE-SCLEROSIS; WHITE-MATTER; WALLERIAN DEGENERATION; MRI; MOTOR; ATROPHY; PATHWAYS; RECOVERY	Background: Traumatic spinal cord injury (SCI) leads to disruption of axons and macroscopic tissue loss. Using diffusion tensor imaging (DTI), we assessed degeneration of the corticospinal tract (CST) in the cervical cord above a traumatic lesion and explored its relationship with cervical atrophy, remote axonal changes within the cranial CST and upper limb function. Methods: Nine cervical injured volunteers with bilateral motor and sensory impairment and ten controls were studied. DTI of the cervical cord and brain provided measurements of fractional anisotropy (FA), while anatomical MRI assessed cross-sectional spinal cord area (i.e. cord atrophy). Spinal and central regions of interest (ROI) included the bilateral CST in the cervical cord and brain. Regression analysis identified correlations between spinal FA and cranial FA in the CST and disability. Results: In individuals with SCI, FA was significantly lower in both CSTs throughout the cervical cord and brain when compared with controls (p <= 0.05). Reduced FA of the cervical cord in patients with SCI was associated with smaller cord area (p = 0.002) and a lower FA of the cranial CST at the internal capsule level (p = 0.001). Lower FA in the cervical CST also correlated with impaired upper limb function, independent of cord area (p = 0.03). Conclusion: Axonal degeneration of the CST in the atrophic cervical cord, proximal to the site of injury, parallels cranial CST degeneration and is associated with disability. This DTI protocol can be used in longitudinal assessment of microstructural changes immediately following injury and may be utilised to predict progression and monitor interventions aimed at promoting spinal cord repair.	[Freund, Patrick; Thompson, Alan J.] UCL, Inst Neurol, Dept Brain Repair & Rehabil, London, England; [Freund, Patrick; Nagy, Zoltan; Hutton, Chloe; Weiskopf, Nikolaus; Friston, Karl J.] UCL, Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England; [Freund, Patrick] UCL, Royal Natl Orthopaed Hosp, Spinal Cord Injury Ctr, London, England; [Freund, Patrick] Swiss Parapleg Res, Nottwil, Switzerland; [Schneider, Torben; Wheeler-Kingshott, Claudia A.] UCL, Inst Neurol, Dept Neuroinflammat, NMR Res Unit, London, England		Freund, P (corresponding author), UCL, Inst Neurol, Dept Brain Repair & Rehabil, London, England.	p.freund@ucl.ac.uk	Freund, Patrick/D-4193-2013; Wheeler-Kingshott, Claudia A M Gandini/AAH-7480-2019; Thompson, Alan J/C-2654-2008; Weiskopf, Nikolaus/B-9357-2008; Friston, Karl/D-9230-2011; Nagy, Zoltan/AAI-2485-2019	Freund, Patrick/0000-0002-4851-2246; Wheeler-Kingshott, Claudia A M Gandini/0000-0002-4832-1300; Thompson, Alan J/0000-0002-4333-8496; Weiskopf, Nikolaus/0000-0001-5239-1881; Friston, Karl/0000-0001-7984-8909; Nagy, Zoltan/0000-0001-6611-6362	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBFR33-120920]; Schweizerische Stiftung fur medizinische und biologische Stipendien [PASMP3-124194]; Swiss Paraplegic Research (Nottwil); Wellcome TrustWellcome TrustEuropean Commission; Department of Health's National Institute for Health Research Biomedical Research Centers funding scheme	This study was supported by the Swiss National Science Foundation (Grant No: PBFR33-120920), Schweizerische Stiftung fur medizinische und biologische Stipendien (Grant No: PASMP3-124194), the Swiss Paraplegic Research (Nottwil) and the Wellcome Trust. This work was undertaken at University College London Hospitals/University College London, which received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centers funding scheme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS R, 1994, IEEE T PATTERN ANAL, V16, P641, DOI 10.1109/34.295913; Andersson JLR, 2003, NEUROIMAGE, V20, P870, DOI 10.1016/S1053-8119(03)00336-7; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1986, NEUROSCIENCE, V19, P321, DOI 10.1016/0306-4522(86)90025-4; Buss A, 2005, BRAIN, V128, P356, DOI 10.1093/brain/awh355; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Cook PA, 2007, J MAGN RESON IMAGING, V25, P1051, DOI 10.1002/jmri.20905; Dietz V, 2006, LANCET NEUROL, V5, P688, DOI 10.1016/S1474-4422(06)70522-1; Draganski B, 2011, NEUROIMAGE, V55, P1423, DOI 10.1016/j.neuroimage.2011.01.052; Ellaway PH, 2011, BRAIN RES BULL, V84, P343, DOI 10.1016/j.brainresbull.2010.08.007; Ellingson BM, 2008, AM J NEURORADIOL, V29, P1976, DOI 10.3174/ajnr.A1272; Freund P, 2012, J NEUROL NEUROSUR PS, V83, P629, DOI 10.1136/jnnp-2011-301875; Freund P, 2011, EUR J NEUROSCI, V34, P1839, DOI 10.1111/j.1460-9568.2011.07895.x; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Freund P, 2010, MULT SCLER J, V16, P1193, DOI 10.1177/1352458510376180; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GOODKIN DE, 1988, ARCH PHYS MED REHAB, V69, P850; Gouw AA, 2008, BRAIN, V131, P3286, DOI 10.1093/brain/awn265; Granert O, 2011, NEUROIMAGE, V54, P32, DOI 10.1016/j.neuroimage.2010.08.013; Hoogervorst ELJ, 2002, ARCH NEUROL-CHICAGO, V59, P113, DOI 10.1001/archneur.59.1.113; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kakulas B A, 1984, Cent Nerv Syst Trauma, V1, P117; Lee JE, 2009, NEUROIMAGE, V44, P870, DOI 10.1016/j.neuroimage.2008.09.041; Lemon RN, 2008, ANNU REV NEUROSCI, V31, P195, DOI 10.1146/annurev.neuro.31.060407.125547; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Petersen JA, 2012, J NEUROTRAUM, V29, P1556, DOI 10.1089/neu.2011.2027; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Schmierer K, 2007, NEUROIMAGE, V35, P467, DOI 10.1016/j.neuroimage.2006.12.010; Schneider T, 2011, 19 ANN SCI M EXH 201, P4556; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wheeler-Kingshott CAM, 2002, NEUROIMAGE, V16, P93, DOI 10.1006/nimg.2001.1022; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072	39	38	44	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2012	7	12							e51729	10.1371/journal.pone.0051729			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	066QV	WOS:000313236200158	23251612	Green Published, gold, Green Submitted			2022-02-06	
J	Li, HF; Graber, KD; Jin, S; McDonald, W; Barres, BA; Prince, DA				Li, Huifang; Graber, Kevin D.; Jin, Sha; McDonald, Whitney; Barres, Ben A.; Prince, David A.			Gabapentin decreases epileptiform discharges in a chronic model of neocortical trauma	NEUROBIOLOGY OF DISEASE			English	Article						Gabapentin; Posttraumatic epileptiform activity; Synapse formation; EPSCs; GFAP; Gliosis; Neocortex; TSPs; Alpha2delta1 subunit; Fluoro-Jade C	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; CALCIUM-CHANNEL SUBUNIT; V PYRAMIDAL NEURONS; FLUORO-JADE; SYNAPTIC REORGANIZATION; POSTTRAUMATIC SEIZURES; NEUROPATHIC PAIN; UP-REGULATION; BRAIN-INJURY; CA2+ INFLUX	Gabapentin (GBP) is an anticonvulsant that acts at the alpha 2 delta-1 submit of the L-type calcium channel. It is recently reported that GBP is a potent inhibitor of thrombospondin (TSP)-induced excitatory synapse formation in vitro and in vivo. Here we studied effects of chronic GBP administration on epileptogenesis in the partial cortical isolation ("undercut") model of posttraumatic epilepsy, in which abnormal axonal sprouting and aberrant synaptogenesis contribute to occurrence of epileptiform discharges. Results showed that 1) the incidence of evoked epileptiform discharges in undercut cortical slices studied 1 day or similar to 2 weeks after the last GBP dose, was significantly reduced by GBP treatments, beginning on the day of injury; 2) the expression of GFAP and TSP1 protein, as well as the number of FJC stained cells was decreased in GBP treated undercut animals; 3) in vivo GBP treatment of rats with undercuts for 3 or 7 days decreased the density of vGlut1-PSD95 close appositions (presumed synapses) in comparison to saline treated controls with similar lesions;4) the electrophysiological data are compatible with the above anatomical changes, showing decreases in mEPSC and sEPSC frequency in the GBP treated animals. These results indicate that chronic administration of GBP after cortical injury is antiepileptogenic in the undercut model of post-traumatic epilepsy, perhaps by both neuroprotective actions and decreases in excitatory synapse formation. The findings may suggest the potential use of GBP as an antiepileptogenic agent following traumatic brain injury. (c) 2012 Elsevier Inc. All rights reserved.	[Li, Huifang; Graber, Kevin D.; Jin, Sha; McDonald, Whitney; Prince, David A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Barres, Ben A.] Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA		Prince, DA (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	daprince@stanford.edu	Ritter, Stefanie L/D-9312-2012		Citizens United for Research in Epilepsy (CURE); NIH from the NINDS [NS12151]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS006477, P01NS012151, P50NS012151] Funding Source: NIH RePORTER	The work was supported by a grant from the Citizens United for Research in Epilepsy (CURE) and NIH grant NS12151 from the NINDS. We thank Dr. Richard Reimer for providing vGluR1 antibody, and Isabel Parada for providing images of Fig. 4C, D, E and F. Cagla Eroglu provided valuable advice during the course of these experiments.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; BABB TL, 1992, DENDRON, V1, P7; Bauer CS, 2009, J NEUROSCI, V29, P4076, DOI 10.1523/JNEUROSCI.0356-09.2009; Baydas G, 2005, ACTA PHARMACOL SIN, V26, P417, DOI 10.1111/j.1745-7254.2005.00072.x; Bayer K, 2004, NEUROPHARMACOLOGY, V46, P743, DOI 10.1016/j.neuropharm.2003.11.010; Bertrand S, 2003, SYNAPSE, V50, P95, DOI 10.1002/syn.10247; Calabresi P, 2000, STROKE, V31, P766, DOI 10.1161/01.STR.31.3.766; Carmichael ST, 2002, J NEUROSCI, V22, P6062; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Comi A.M., 2008, PEDIATR RES, V64, P81; Cunningham MO, 2004, EUR J NEUROSCI, V20, P1566, DOI 10.1111/j.1460-9568.2004.03625.x; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Davies A, 2007, TRENDS PHARMACOL SCI, V28, P220, DOI 10.1016/j.tips.2007.03.005; ECHLIN FA, 1959, ELECTROEN CLIN NEURO, V11, P697, DOI 10.1016/0013-4694(59)90110-5; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V; Emmez H, 2010, WORLD NEUROSURG, V73, P729, DOI 10.1016/j.wneu.2010.04.008; Eroglu C, 2009, J CELL COMMUN SIGNAL, V3, P167, DOI 10.1007/s12079-009-0078-y; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Faria LC, 2010, J NEUROPHYSIOL, V104, P280, DOI 10.1152/jn.00351.2010; Field MJ, 2006, P NATL ACAD SCI USA, V103, P17537, DOI 10.1073/pnas.0409066103; Fink K, 2000, BRIT J PHARMACOL, V130, P900, DOI 10.1038/sj.bjp.0703380; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Graber KD, 2006, MODELS OF SEIZURES AND EPILEPSY, P477, DOI 10.1016/B978-012088554-1/50040-2; Hendrich J, 2008, P NATL ACAD SCI USA, V105, P3628, DOI 10.1073/pnas.0708930105; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; Ide CF, 1996, PROG BRAIN RES, V108, P365, DOI 10.1016/S0079-6123(08)62552-2; ISOKAWA M, 1993, J NEUROSCI, V13, P1511, DOI 10.1523/jneurosci.13-04-01511.1993; Jin XM, 2011, CEREB CORTEX, V21, P1094, DOI 10.1093/cercor/bhq181; Jin XM, 2006, J NEUROSCI, V26, P4891, DOI 10.1523/JNEUROSCI.4361-05.2006; Kale A, 2011, J NEUROSURG-SPINE, V15, P228, DOI 10.3171/2011.4.SPINE10583; Kato AS, 2007, CURR OPIN DRUG DISC, V10, P565; Kim YS, 2009, J PHARMACOL SCI, V109, P144, DOI 10.1254/jphs.08067SC; KORN H, 1987, P NATL ACAD SCI USA, V84, P5981, DOI 10.1073/pnas.84.16.5981; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lagreze WA, 2001, GRAEF ARCH CLIN EXP, V239, P845, DOI 10.1007/s00417-001-0383-5; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Li CY, 2006, PAIN, V125, P20, DOI 10.1016/j.pain.2006.04.022; Li H., 2009, ANN EP SOC ABSTR; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Li HF, 2011, NEUROSCI LETT, V497, P172, DOI 10.1016/j.neulet.2011.02.042; Liauw J, 2008, J CEREBR BLOOD F MET, V28, P1722, DOI 10.1038/jcbfm.2008.65; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; Liu Y, 2006, EPILEPSY RES, V70, P263, DOI 10.1016/j.eplepsyres.2006.03.007; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001; Maneuf YP, 2006, SEMIN CELL DEV BIOL, V17, P565, DOI 10.1016/j.semcdb.2006.09.003; Marco P, 1997, EXP BRAIN RES, V114, P1, DOI 10.1007/PL00005608; MASUKAWA LM, 1992, BRAIN RES, V579, P119, DOI 10.1016/0006-8993(92)90750-4; Matoth I, 2000, NEUROSCI RES, V38, P209, DOI 10.1016/S0168-0102(00)00127-9; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Ng GYK, 2001, MOL PHARMACOL, V59, P144, DOI 10.1124/mol.59.1.144; Nita DA, 2007, CEREB CORTEX, V17, P272, DOI 10.1093/cercor/bhj145; Ortinski PI, 2010, NAT NEUROSCI, V13, P584, DOI 10.1038/nn.2535; Prince D.A., 2012, JASPERS BASIC MECH E, P315; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; RADULOVIC LL, 1995, DRUG METAB DISPOS, V23, P441; ROTHSTEIN JD, 1995, J NEUROCHEM, V65, P643; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SHARPLESS SK, 1962, ELECTROEN CLIN NEURO, V14, P244, DOI 10.1016/0013-4694(62)90034-2; Staley Kevin J, 2006, Epilepsy Curr, V6, P199, DOI 10.1111/j.1535-7511.2006.00145.x; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Stewart TH, 2010, J NEUROPHYSIOL, V104, P3345, DOI 10.1152/jn.00398.2010; Striano P, 2008, DRUG TODAY, V44, P353, DOI 10.1358/dot.2008.44.5.1186403; Sur M, 2001, NAT REV NEUROSCI, V2, P251, DOI 10.1038/35067562; SUTOR B, 1995, PERSPECT DEV NEUROBI, V2, P409; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Traa BS, 2008, PEDIATR RES, V64, P81, DOI 10.1203/PDR.0b013e318174e70e; TSENG GF, 1993, J COMP NEUROL, V335, P92, DOI 10.1002/cne.903350107; van Hooft JA, 2002, EUR J PHARMACOL, V449, P221, DOI 10.1016/S0014-2999(02)02044-7; Vega-Hernandez A, 2002, CELL MOL NEUROBIOL, V22, P185, DOI 10.1023/A:1019865822069; VOLLMER KO, 1986, ARZNEIMITTEL-FORSCH, V36-1, P830; Wang L, 2008, BRAIN RES, V1241, P157, DOI 10.1016/j.brainres.2008.07.097; Watson NF, 2004, EPILEPSIA, V45, P690, DOI 10.1111/j.0013-9580.2004.59403.x; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, CHILD BRAIN, V10, P185	94	38	40	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	DEC	2012	48	3					429	438		10.1016/j.nbd.2012.06.019			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	018VG	WOS:000309694000017	22766033	Green Accepted			2022-02-06	
J	Su, E; Bell, MJ; Kochanek, PM; Wisniewski, SR; Bayir, H; Clark, RSB; Adelson, PD; Tyler-Kabara, EC; Janesko-Feldman, KL; Berger, RP				Su, E.; Bell, M. J.; Kochanek, P. M.; Wisniewski, S. R.; Bayir, H.; Clark, R. S. B.; Adelson, P. D.; Tyler-Kabara, E. C.; Janesko-Feldman, K. L.; Berger, R. P.			Increased CSF Concentrations of Myelin Basic Protein After TBI in Infants and Children: Absence of Significant Effect of Therapeutic Hypothermia	NEUROCRITICAL CARE			English	Article						Axonal injury; Pediatrics; Secondary injury	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; AXONAL INJURY; CEREBROSPINAL-FLUID; WHITE-MATTER; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; GENDER; MATURATION	Background The objectives of this study were to determine effects of severe traumatic brain injury (TBI) on cerebrospinal fluid (CSF) concentrations of myelin basic protein (MBP) and to assess relationships between clinical variables and CSF MBP concentrations. Methods We measured serial CSF MBP concentrations in children enrolled in a randomized controlled trial evaluating therapeutic hypothermia (TH) after severe pediatric TBI. Control CSF was obtained from children evaluated, but found not to be having CNS infection. Generalized estimating equation models and Wilcoxon Rank-Sum test were used for comparisons of MBP concentrations. Results There were 27 TBI cases and 57 controls. Overall mean (+/- SEM) TBI case MBP concentrations for 5 days after injury were markedly greater than controls (50.49 +/- A 6.97 vs. 0.11 +/- A 0.01 ng/ml, p < 0.01). Mean MBP concentrations were lower in TBI patients < 1 year versus > 1 year (9.18 +/- A 1.67 vs. 60.22 +/- A 8.26 ng/ml, p = 0.03), as well as in cases with abusive head trauma (AHT) versus non-abusive TBI (14.46 +/- A 3.15 vs. 61.17 +/- A 8.65 ng/ml, p = 0.03). TH did not affect MBP concentrations. Conclusions Mean CSF MBP increases markedly after severe pediatric TBI, but is not affected by TH. Infancy and AHT are associated with low MBP concentrations, suggesting that age-dependent myelination influences MBP concentrations after injury. Given the magnitude of MBP increases, axonal injury likely represents an important therapeutic target in pediatric TBI.	[Su, E.; Bell, M. J.; Kochanek, P. M.; Bayir, H.; Clark, R. S. B.; Janesko-Feldman, K. L.; Berger, R. P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bell, M. J.; Adelson, P. D.; Tyler-Kabara, E. C.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Bell, M. J.; Kochanek, P. M.; Bayir, H.; Clark, R. S. B.; Berger, R. P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Wisniewski, S. R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Adelson, P. D.] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Adelson, P. D.] Univ Arizona, Coll Med, Phoenix, AZ USA		Su, E (corresponding author), Johns Hopkins Univ Hosp, Div Pediat Anesthesia & Crit Care Med, Charlotte R Bloomberg Childrens Ctr, 1800 Orleans St, Baltimore, MD 21287 USA.	esu4@jhmi.edu	Su, Erik/AAG-9374-2019; Adelson, David/W-2083-2019; Tyler-Kabara, Elizabeth/H-4930-2013; Kochanek, Patrick M/D-2371-2015	Su, Erik/0000-0002-1054-308X; Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860	 [T32HD040686];  [RO1 NS 38448-01];  [NS30318]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, R01NS038448, P50NS030318] Funding Source: NIH RePORTER	This investigation was supported by Grant Nos.: T32HD040686 (ES, PMK), RO1 NS 38448-01(PDA), and NS30318 (PMK).	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gao W, 2009, AM J NEURORADIOL, V30, P290, DOI 10.3174/ajnr.A1363; GARCIAALIX A, 1994, PEDIATRICS, V93, P234; LEVIN SD, 1985, DEV MED CHILD NEUROL, V27, P807; Li H, 2009, J NEUROTRAUM, V26, P1905, DOI [10.1089/neu.2008.0828, 10.1089/neu.2008-0828]; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; MUKHERJEE A, 1985, CLIN BIOCHEM, V18, P304, DOI 10.1016/S0009-9120(85)80037-0; NOSEWORTHY TW, 1985, CRIT CARE MED, V13, P743, DOI 10.1097/00003246-198509000-00010; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Roelfsema V, 2004, J CEREBR BLOOD F MET, V24, P877, DOI 10.1097/01.WCB.0000123904.17746.92; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; THOMAS D G T, 1978, Lancet, V1, P113; VANENGELEN BGM, 1992, CLIN CHEM, V38, P813	28	38	41	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	DEC	2012	17	3					401	407		10.1007/s12028-012-9767-0			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	050QP	WOS:000312069400014	22890910	Green Accepted			2022-02-06	
J	Cadotte, DW; Bosma, R; Mikulis, D; Nugaeva, N; Smith, K; Pokrupa, R; Islam, O; Stroman, PW; Fehlings, MG				Cadotte, David W.; Bosma, Rachael; Mikulis, David; Nugaeva, Natalia; Smith, Karen; Pokrupa, Ronald; Islam, Omar; Stroman, Patrick W.; Fehlings, Michael G.			Plasticity of the Injured Human Spinal Cord: Insights Revealed by Spinal Cord Functional MRI	PLOS ONE			English	Article							MONOCLONAL-ANTIBODY IN-1; VASCULAR MECHANISMS; NEURITE OUTGROWTH; FMRI	Introduction: While numerous studies have documented evidence for plasticity of the human brain there is little evidence that the human spinal cord can change after injury. Here, we employ a novel spinal fMRI design where we stimulate normal and abnormal sensory dermatomes in persons with traumatic spinal cord injury and perform a connectivity analysis to understand how spinal networks process information. Methods: Spinal fMRI data was collected at 3 Tesla at two institutions from 38 individuals using the standard SEEP functional MR imaging techniques. Thermal stimulation was applied to four dermatomes in an interleaved timing pattern during each fMRI acquisition. SCI patients were stimulated in dermatomes both above (normal sensation) and below the level of their injury. Sub-group analysis was performed on healthy controls (n = 20), complete SCI (n = 3), incomplete SCI (n = 9) and SCI patients who recovered full function (n = 6). Results: Patients with chronic incomplete SCI, when stimulated in a dermatome of normal sensation, showed an increased number of active voxels relative to controls (p = 0.025). There was an inverse relationship between the degree of sensory impairment and the number of active voxels in the region of the spinal cord corresponding to that dermatome of abnormal sensation (R-2 = 0.93, p<0.001). Lastly, a connectivity analysis demonstrated a significantly increased number of intraspinal connections in incomplete SCI patients relative to controls suggesting altered processing of afferent sensory signals. Conclusions: In this work we demonstrate the use of spinal fMRI to investigate changes in spinal processing of somatosensory information in the human spinal cord. We provide evidence for plasticity of the human spinal cord after traumatic injury based on an increase in the average number of active voxels in dermatomes of normal sensation in chronic SCI patients and an increased number of intraspinal connections in incomplete SCI patients relative to healthy controls.	[Cadotte, David W.; Fehlings, Michael G.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Cadotte, David W.; Fehlings, Michael G.] Toronto Western Hosp, Dept Surg, Div Neurosurg, Toronto, ON M5T 2S8, Canada; [Cadotte, David W.; Nugaeva, Natalia; Fehlings, Michael G.] Univ Hlth Network, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON, Canada; [Bosma, Rachael; Stroman, Patrick W.] Queens Univ, Ctr Neurosci Studies, Kingston, ON, Canada; [Mikulis, David] Univ Toronto, Toronto Western Hosp, Div Neuroradiol, Dept Radiol, Toronto, ON M5T 2S8, Canada; [Smith, Karen] Providence Hlth Care, Spinal Rehabil Unit, Kingston, ON, Canada; [Pokrupa, Ronald] Queens Univ, Kingston Gen Hosp, Div Neurosurg, Kingston, ON, Canada; [Islam, Omar] Queens Univ, Kingston Gen Hosp, Div Neuroradiol & Head & Neck Imaging, Dept Radiol, Kingston, ON, Canada; [Islam, Omar] Queens Univ, Hotel Dieu Hosp, Div Neuroradiol & Head & Neck Imaging, Dept Radiol, Kingston, ON, Canada; [Stroman, Patrick W.] Queens Univ, Dept Diagnost Radiol, Kingston, ON, Canada; [Stroman, Patrick W.] Queens Univ, Dept Phys, Kingston, ON K7L 3N6, Canada; [Fehlings, Michael G.] Univ Hlth Network, Toronto Western Hosp, Toronto Western Res Inst, Div Genet & Dev, Toronto, ON, Canada		Fehlings, MG (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada.	Michael.Fehlings@uhn.ca	Mikulis, David J/H-5167-2019	Mikulis, David/0000-0003-3956-0892; Fehlings, Michael/0000-0002-5722-6364	Ontario Neurotrauma Foundation; Rick Hansen Institute; Congress of Neurological Surgeons; American Association of Neurological Surgeons (Codman Neurotrauma Award); Cervical Spine Research Society; Gerry and Tootsie Halbert Chair in Neural Repair and Regeneration at the University of Toronto	The authors are grateful to their funding sources that include the Ontario Neurotrauma Foundation, Rick Hansen Institute, Congress of Neurological Surgeons, American Association of Neurological Surgeons (Codman Neurotrauma Award), Cervical Spine Research Society and the Gerry and Tootsie Halbert Chair in Neural Repair and Regeneration at the University of Toronto. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cadotte DW, 2011, CLIN ORTHOP RELAT R, V469, P732, DOI 10.1007/s11999-010-1674-0; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Curt A, 2002, BRAIN, V125, P2567, DOI 10.1093/brain/awf250; DeVivo M, 2006, SPINAL CORD, V44, P535, DOI 10.1038/sj.sc.3101958; Endo T, 2008, EXP NEUROL, V209, P155, DOI 10.1016/j.expneurol.2007.09.017; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fehlings MG, PLOS ONE, V7; Figley CR, 2011, EUR J NEUROSCI, V33, P577, DOI 10.1111/j.1460-9568.2010.07584.x; Figley CR, 2009, NEUROIMAGE, V44, P421, DOI 10.1016/j.neuroimage.2008.08.040; Figley CR, 2012, MAGN RESON IMAGING; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Furlan JC, J NEUROTRAUMA, V28, P1371; Gesierich B, CEREB CORTEX; HANDWERKER HO, 1975, PAIN, V1, P147, DOI 10.1016/0304-3959(75)90099-8; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kakulas BA, 2004, SPINAL CORD, V42, P549, DOI 10.1038/sj.sc.3101670; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Kornelsen J, 2007, SPINAL CORD, V45, P485, DOI 10.1038/sj.sc.3102019; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lang J, 1982, Gegenbaurs Morphol Jahrb, V128, P417; Leitch JK, 2010, MAGN RESON IMAGING, V28, P1225, DOI 10.1016/j.mri.2010.03.032; Maieron M, 2007, J NEUROSCI, V27, P4182, DOI 10.1523/JNEUROSCI.3910-06.2007; Mikulis DJ, 2002, NEUROLOGY, V58, P794, DOI 10.1212/WNL.58.5.794; Murphy K, 2007, NEUROIMAGE, V34, P565, DOI 10.1016/j.neuroimage.2006.09.032; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Spillmann AA, 1997, EUR J NEUROSCI, V9, P549, DOI 10.1111/j.1460-9568.1997.tb01631.x; Stroman PW, 2008, MAGN RESON MED, V59, P700, DOI 10.1002/mrm.21534; Stroman PW, 2002, NEUROIMAGE, V17, P1854, DOI 10.1006/nimg.2002.1305; Stroman PW, 2002, MAGN RESON IMAGING, V20, P1, DOI 10.1016/S0730-725X(02)00468-X; Stroman PW, MAGN RESON MED; Stroman PW, 2011, MAGN RESON MED; Summers PE, 2010, NEUROIMAGE, V50, P1408, DOI 10.1016/j.neuroimage.2010.01.043; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023; Xuan Y, PLOS ONE, V7, pe30570	36	38	39	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2012	7	9							e45560	10.1371/journal.pone.0045560			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	014PP	WOS:000309388400105	23029097	Green Published, Green Submitted, gold			2022-02-06	
J	Mondello, S; Palmio, J; Streeter, J; Hayes, RL; Peltola, J; Jeromin, A				Mondello, Stefania; Palmio, Johanna; Streeter, Jackson; Hayes, Ronald L.; Peltola, Jukka; Jeromin, Andreas			Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure	BMC NEUROLOGY			English	Article						Biomarkers; UCH-L1; Epileptic seizures; Neuronal damage	TEMPORAL-LOBE EPILEPSY; NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; TONIC-CLONIC SEIZURES; HIPPOCAMPAL SCLEROSIS; RECURRENT SEIZURES; SYNAPTIC REORGANIZATION; S-100 PROTEIN; SERUM; DAMAGE	Background: Clinical and experimental studies have demonstrated that seizures can cause molecular and cellular responses resulting in neuronal damage. At present, there are no valid tests for assessing organic damage to the brain associated with seizure. The aim of this study was to investigate cerebrospinal fluid (CSF) and plasma concentrations of Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), a sensitive indicator of acute injury to brain neurons, in patients with tonic-clonic or partial secondarily generalized seizures due to various etiologies. Methods: CSF and plasma concentrations of UCH-L1 were assessed in 52 patients within 48 hours after epileptic seizure and in 19 controls using ELISA assays. Results: CSF obtained within 48 hours after seizure or status epilepticus (SE) presented significantly higher levels of UCH-L1 compared to controls (p = 0.008). Plasma UCH-L1 concentrations were negatively correlated with time to sample withdrawal. An analysis conducted using only the first 12 hours post-seizure revealed significant differences between concentrations of UCH-L1 in plasma and controls (p = 0.025). CSF and plasma concentrations were strongly correlated with age in patients with seizure, but not in control patients. Plasma UCH-L1 levels were also significantly higher in patients after recurrent seizures (n = 4) than in those after one or two seizures (p = 0.013 and p = 0.024, respectively). Conclusion: Our results suggest that determining levels of neuronal proteins may provide valuable information on the assessment of brain damage following seizure. These data might allow clinicians to make more accurate therapeutic decisions, to identify patients at risk of progression and, ultimately, to provide new opportunities for monitoring therapy and targeted therapeutic interventions.	[Mondello, Stefania] Banyan Biomarkers Inc, Clin Dept, Alachua, FL 32615 USA; [Palmio, Johanna; Peltola, Jukka] Tampere Univ Hosp, Dept Neurol, FIN-33521 Tampere, Finland		Mondello, S (corresponding author), Banyan Biomarkers Inc, Clin Dept, 113400 Progress Blvd, Alachua, FL 32615 USA.	smondello@banyanbio.com; ajeromin@banyanbio.com	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614	Banyan Biomarkers, Inc.	Drs. Stefania Mondello and Andreas Jeromin are employees and received salaries from Banyan Biomarkers, Inc. Drs. Streeter and Hayes own stock, receive royalties and salaries from, and are officers of Banyan Biomarkers Inc., and as such may benefit financially as a result of the outcomes of this research or work reported in this publication. Banyan Biomarkers, Inc. filled patent applications based upon the disclosure of this publication. Drs. Palmio and Peltola have no conflicts of interest.	Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Briellmann RS, 2001, NEUROLOGY, V57, P315, DOI 10.1212/WNL.57.2.315; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Buchet C, 1825, ARCH GEN MED, V9, P510; Buttner T, 1999, J NEUROL, V246, P459, DOI 10.1007/s004150050383; CAVAZOS JE, 1990, BRAIN RES, V527, P1, DOI 10.1016/0006-8993(90)91054-K; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Cross DJ, 2007, EPILEPSY RES, V73, P156, DOI 10.1016/j.eplepsyres.2006.09.004; DAM AM, 1980, EPILEPSIA, V21, P617, DOI 10.1111/j.1528-1157.1980.tb04315.x; Douglas-Escobar M, 2010, PEDIATR RES, V68, P531, DOI 10.1203/PDR.0b013e3181f85a03; Fujikawa DG, 2006, STATUS EPILEPTICUS M, V36, P463; Haas KZ, 2001, HIPPOCAMPUS, V11, P615, DOI 10.1002/hipo.1076; Hellsten J, 2005, BIOL PSYCHIAT, V58, P871, DOI 10.1016/j.biopsych.2005.05.023; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Henshall DC, 2003, J NEUROCHEM, V86, P1260, DOI 10.1046/j.1471-4159.2003.01934.x; Holmes GL, 1999, J COMP NEUROL, V404, P537, DOI 10.1002/(SICI)1096-9861(19990222)404:4<537::AID-CNE9>3.0.CO;2-#; Kalviainen R, 1998, NEUROLOGY, V50, P1377, DOI 10.1212/WNL.50.5.1377; Lee SY, 2010, J NEUROL, V257, P1708, DOI 10.1007/s00415-010-5608-2; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Liu RSN, 2001, NEUROIMAGE, V14, P231, DOI 10.1006/nimg.2001.0773; Liu Z, 1999, NEUROSCIENCE, V92, P1443, DOI 10.1016/S0306-4522(99)00064-0; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; Mathern GW, 2002, PROG BRAIN RES, V135, P237; MATHERN GW, 1992, DENDRON, V1, P69; Mondello S, NEUROSURGER IN PRESS; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; O'Regan M E, 1998, Eur J Paediatr Neurol, V2, P193, DOI 10.1016/S1090-3798(98)80019-6; Palmio J, 2001, J NEUROL SCI, V183, P27, DOI 10.1016/S0022-510X(00)00478-0; Palmio J, 2009, SEIZURE-EUR J EPILEP, V18, P474, DOI 10.1016/j.seizure.2009.04.006; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; QIAO XX, 1993, J NEUROSCI, V13, P4622; Rigau V, 2007, BRAIN, V130, P1942, DOI 10.1093/brain/awm118; Salmenpera T, 2001, EPILEPSY RES, V46, P69, DOI 10.1016/S0920-1211(01)00258-3; Steinhoff BJ, 1999, EPILEPSY RES, V36, P75, DOI 10.1016/S0920-1211(99)00026-1; Suzuki Y, 1999, NEUROLOGY, V53, P1761, DOI 10.1212/WNL.53.8.1761; Tanabe T, 2001, EPILEPSIA, V42, P504, DOI 10.1046/j.1528-1157.2001.30100.x; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Tumani H, 1999, EPILEPSIA, V40, P713, DOI 10.1111/j.1528-1157.1999.tb00768.x; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; VanLandingham KE, 1998, ANN NEUROL, V43, P413, DOI 10.1002/ana.410430403; Yilmazer-Hanke DM, 2000, J NEUROPATH EXP NEUR, V59, P907, DOI 10.1093/jnen/59.10.907	44	38	38	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	AUG 29	2012	12								85	10.1186/1471-2377-12-85			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	038GK	WOS:000311163000001	22931063	Green Published, gold			2022-02-06	
J	Neumann, D; Zupan, B; Babbage, DR; Radnovich, AJ; Tomita, M; Hammond, F; Willer, B				Neumann, Dawn; Zupan, Barbra; Babbage, Duncan R.; Radnovich, Alexander J.; Tomita, Machiko; Hammond, Flora; Willer, Barry			Affect Recognition, Empathy, and Dysosmia After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the North-American-Brain-Injury-Society	SEP 17, 2011	New Orleans, LA	N Amer Brain Injury Soc		Affect; Brain injuries; Empathy; Olfaction disorders; Rehabilitation	SMELL IDENTIFICATION TEST; FACIAL AFFECT RECOGNITION; VENTROMEDIAL PREFRONTAL CORTEX; OLFACTORY DYSFUNCTION; HEAD-INJURY; NONVERBAL-COMMUNICATION; EMOTION RECOGNITION; INDIVIDUAL-DIFFERENCES; ALZHEIMERS-DISEASE; DECODING ACCURACY	Objective: To investigate if olfaction is associated with affect recognition and empathy deficits after traumatic brain injury (TBI). Prior research has shown that TBI often leads to loss of smell. We hypothesized a relationship with emotion perception, because the neural substrates of the olfactory system overlap with the ventral circuitry of the orbital frontal cortex, which play a critical role in affective responses, such as empathy. Design: Comparative study investigating differences between participants with TBI who had impaired olfaction (dysosmia) with those with normal olfaction (normosmia). Setting: Postacute rehabilitation facilities in the United States, Canada, and New Zealand. Participants: Participants (N= 106) in the current study were a convenience sample of adults with moderate to severe TBI who were tested for olfactory function as part of a larger, related study on affect recognition. On average, participants were 11.5 years postinjury. Interventions: Not applicable. Main Outcome Measures: Olfaction (Brief Smell Identification Test), facial affect recognition (Diagnostic Assessment of Nonverbal Affect 2-Adult Faces [DANVA2-AF]), vocal affect recognition (Diagnostic Assessment of Nonverbal Affect 2-Adult Paralanguage [DANVA2-AP]), emotional inference (Emotional Inference from Stories Test [EIST]), and empathy (Interpersonal Reactivity Index [IRI]). Results: Fifty-six percent of participants were dysosrnic and only 36% of these participants were aware of their deficit. Participants with dysosmia performed significantly poorer on the DANVA2-AF (P=.003), DANVA2-AP (P=.007), EIST (P=.016), and IRI (P=.013). Medium effect sizes were found for all measures. Dysosmia had a sensitivity value of 86.4% for detecting facial affect recognition impairments and 67.8% for vocal affect recognition impairments. Conclusions: This study shows that olfactory deficits may be indicative of affect recognition impairments and reduced empathy. Early knowledge of affect recognition and empathy deficits would be valuable so that treatment could be implemented predischarge.	[Neumann, Dawn; Hammond, Flora] Dept Phys Med & Rehabil, Charlotte, NC USA; [Zupan, Barbra] Brock Univ, Dept Appl Linguist, St Catharines, ON L2S 3A1, Canada; [Babbage, Duncan R.] Massey Univ, Sch Psychol, Wellington, New Zealand; [Radnovich, Alexander J.] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Tomita, Machiko] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Rehabil Sci, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Sch Med, Dept Psychiat, Buffalo, NY 14260 USA; [Willer, Barry] SUNY Buffalo, Sch Med, Dept Rehabil Med, Buffalo, NY 14260 USA		Neumann, D (corresponding author), Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA.	dmneuman@iupui.edu		Barbra, Zupan/0000-0002-4603-333X; Babbage, Duncan/0000-0002-9259-9246			Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Adolphs R, 1996, J NEUROSCI, V16, P7678; Anderson AK, 2000, NEUROPSYCHOLOGY, V14, P526, DOI 10.1037/0894-4105.14.4.526; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Baum KM, 1998, J NONVERBAL BEHAV, V22, P89, DOI 10.1023/A:1022954014365; Brookshire R. H., 1993, DISCOURSE COMPREHENS; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Carton JS, 1999, J NONVERBAL BEHAV, V23, P91, DOI 10.1023/A:1021339410262; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Costanzo R, 2003, NEUROL DIS THER, V57, P629; COSTANZO RM, 1987, ANN NY ACAD SCI, V510, P242; Cox CL, 2011, SOC COGN AFFECT NEUR; Critchley H, 2000, HUM BRAIN MAPP, V9, P93, DOI 10.1002/(SICI)1097-0193(200002)9:2<93::AID-HBM4>3.0.CO;2-Z; Davis M. H, 1980, JSAS CATALOG SELECTE, P10; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; Doty RL, 2006, INT ARCH OCC ENV HEA, V79, P268, DOI 10.1007/s00420-005-0055-6; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; DOTY RL, 1995, NEURODEGENERATION, V4, P93, DOI 10.1006/neur.1995.0011; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; Fan Y, 2011, NEUROSCI BIOBEHAV R, V35, P903, DOI 10.1016/j.neubiorev.2010.10.009; Goudsmit N, 2003, PSYCHIAT RES, V120, P155, DOI 10.1016/S0165-1781(03)00194-X; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Haxel BR, 2008, J HEAD TRAUMA REHAB, V23, P407, DOI 10.1097/01.HTR.0000341437.59627.ec; Heywood PG, 1990, 14 ANN C REH BRAIN I; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Kjelvik G, 2007, INT J GERIATR PSYCH, V22, P1020, DOI 10.1002/gps.1783; Kohler CG, 2007, J NEUROPSYCH CLIN N, V19, P128, DOI 10.1176/appi.neuropsych.19.2.128; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V0005, P00213, DOI DOI 10.1037/0894-4105.5.3.213; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McIntosh G C, 1997, Appl Neuropsychol, V4, P62, DOI 10.1207/s15324826an0401_8; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MOTT AE, 1991, MED CLIN N AM, V75, P1321, DOI 10.1016/S0025-7125(16)30391-1; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; NORDIN S, 1995, J GERONTOL B-PSYCHOL, V50, pP187, DOI 10.1093/geronb/50B.4.P187; NOWICKI S, 1988, J SOC PSYCHOL, V128, P363, DOI 10.1080/00224545.1988.9713753; Nowicki S, 1998, GENET SOC GEN PSYCH, V124, P39; NOWICKI S, 1994, J NONVERBAL BEHAV, V18, P9, DOI 10.1007/BF02169077; NOWICKI S, 1989, J GENET PSYCHOL, V150, P39, DOI 10.1080/00221325.1989.9914572; Nowicki S, 1997, J GENET PSYCHOL, V158, P357, DOI 10.1080/00221329709596674; Phillips ML, 1998, P ROY SOC B-BIOL SCI, V265, P1809, DOI 10.1098/rspb.1998.0506; Phillips ML, 2003, BRIT J PSYCHIAT, V182, P190, DOI 10.1192/bjp.182.3.190; Pope K, 2007, NEUROSCI LETT, V422, P13, DOI 10.1016/j.neulet.2007.05.041; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Radnovich AJ, 2009, DISS ABSTR INT B; Rankin KP, 2005, COGN BEHAV NEUROL, V18, P28, DOI 10.1097/01.wnn.0000152225.05377.ab; Reiter ER, 2004, OTOLARYNG CLIN N AM, V37, P1167, DOI 10.1016/j.otc.2004.06.005; RIGGIO RE, 1989, PERS INDIV DIFFER, V10, P93, DOI 10.1016/0191-8869(89)90184-0; Rosip JC, 2004, J NONVERBAL BEHAV, V28, P267, DOI 10.1007/s10919-004-4159-6; Seubert J, 2010, NEUROIMAGE, V53, P746, DOI 10.1016/j.neuroimage.2010.07.012; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2009, BRAIN, V132, P617, DOI 10.1093/brain/awn279; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Spinella M, 2005, BIOL PSYCHOL, V70, P175, DOI 10.1016/j.biopsycho.2004.01.005; Spinella M, 2002, INT J NEUROSCI, V112, P605, DOI 10.1080/00207450290025680; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012; Zupan B., 2009, DEP APPL LING RES DA	72	38	40	2	27	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1414	1420		10.1016/j.apmr.2012.03.009			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700019	22446155				2022-02-06	
J	Kline, AE; Olsen, AS; Sozda, CN; Hoffman, AN; Cheng, JP				Kline, Anthony E.; Olsen, Adam S.; Sozda, Christopher N.; Hoffman, Ann N.; Cheng, Jeffrey P.			Evaluation of a Combined Treatment Paradigm Consisting of Environmental Enrichment and the 5-HT1A Receptor Agonist Buspirone after Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavioral outcome; controlled cortical impact; functional recovery; hippocampus; learning and memory; Morris water maze; serotonin (5-HT1A)-receptor agonist; traumatic brain injury	MEDIATED FUNCTIONAL IMPROVEMENT; COGNITIVE DEFICITS; UNITED-STATES; NEUROBEHAVIORAL BENEFIT; NEUROTROPHIC FACTOR; VOLUNTARY EXERCISE; TREATMENT REGIMEN; CLINICAL-TRIALS; GROWTH-FACTOR; 8-OH-DPAT	Environmental enrichment (EE) and serotonin(1A) (5-HT1A)-receptor agonists provide significant benefit after experimental traumatic brain injury (TBI). The aim of this study was to test the hypothesis that combining these therapies would produce an effect that is more robust than either therapy alone. Anesthetized adult male rats received a cortical impact or sham injury and then were randomly assigned to EE or standard (STD) housing where they received either buspirone (0.3 mg/kg) or vehicle (1.0 mL/kg) once daily for 3 weeks. Motor and cognitive assessments were conducted on post-injury days 1-5 and 14-19, respectively. CA1/3 neurons were quantified at 3 weeks. No differences were observed among buspirone and vehicle sham groups in any task regardless of housing condition and thus the data were pooled. CA3 cell loss was reduced in the TBI + EE + buspirone and TBI + EE + vehicle groups. Motor recovery, spatial learning, and memory retention were enhanced in the TBI + EE + buspirone, TBI + EE + vehicle, and TBI + STD + buspirone groups versus the TBI + STD + vehicle group (p <= 0.005). Moreover, spatial learning was significantly better in the TBI + EE + buspirone group versus the TBI + STD + buspirone group (p < 0.0001). No differences were revealed between the buspirone and vehicle EE groups. These data show that EE and buspirone benefit functional outcome after TBI, but their combination is not more robust than either alone, which does not support the hypothesis. The lack of an additive effect may be due to the early-and-continuous EE paradigm on its own producing marked benefits, resulting in a ceiling effect. The evaluation of buspirone in a delayed-and-abbreviated EE paradigm is ongoing in our laboratory.	[Kline, Anthony E.; Olsen, Adam S.; Sozda, Christopher N.; Hoffman, Ann N.; Cheng, Jeffrey P.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.; Olsen, Adam S.; Sozda, Christopher N.; Hoffman, Ann N.; Cheng, Jeffrey P.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA		Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207; Olsen, Adam/0000-0003-0957-9867	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD043851, HD046700, NS060005]	This work was supported, in part, by National Institutes of Health grants HD043851, HD046700, and NS060005 (A.E.K.).	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Faul M, 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Garcia AN, 2011, PM&R, V3, pS18, DOI 10.1016/j.pmrj.2011.03.017; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Gomez-Pinilla F, 2011, EUR J NEUROSCI, V33, P383, DOI 10.1111/j.1460-9568.2010.07508.x; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; National Research Council, 1996, GUID CAR US LAB AN; Olsen A.S., 2012, J NEUROTRAUM, DOI [10.1089/neu.2012.2385, DOI 10.1089/NEU.2012.2385]; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	55	38	38	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	10					1960	1969		10.1089/neu.2012.2385			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	971YV	WOS:000306244400398	22471653	Green Published			2022-02-06	
J	Biersteker, HAR; Andriessen, TMJC; Horn, J; Franschman, G; van der Naalt, J; Hoedemaekers, CWE; Lingsma, HF; Haitsma, I; Vos, PE				Biersteker, Heleen A. R.; Andriessen, Teuntje M. J. C.; Horn, Janneke; Franschman, Gaby; van der Naalt, Joukje; Hoedemaekers, Cornelia W. E.; Lingsma, Hester F.; Haitsma, Iain; Vos, Pieter E.			Factors influencing intracranial pressure monitoring guideline compliance and outcome after severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						computed tomography; Glasgow Outcome Scale; guideline adherence; intracranial pressure; multivariate analysis; traumatic brain injury	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; COMPUTERIZED-TOMOGRAPHY; PROSPECTIVE MULTICENTER; EUROPEAN BRAIN; INTENSIVE-CARE; MANAGEMENT; MODERATE; CLASSIFICATION; COMPLICATIONS	Objective: To determine adherence to Brain Trauma Foundation guidelines for intracranial pressure monitoring after severe traumatic brain injury, to investigate if characteristics of patients treated according to guidelines (ICP+) differ from those who were not (ICP-), and whether guideline compliance is related to 6-month outcome. Design: Observational multicenter study. Patients: Consecutive severe traumatic brain injury patients (>= 16 yrs, n = 265) meeting criteria for intracranial pressure monitoring. Measurements and Main Results: Data on demographics, injury severity, computed tomography findings, and patient management were registered. The Glasgow Outcome Scale Extended was dichotomized into death (Glasgow Outcome Scale Extended = 1) and unfavorable outcome (Glasgow Outcome Scale Extended 1-4). Guideline compliance was 46%. Differences between the monitored and nonmonitored patients included a younger age (median 44 vs. 53 yrs), more abnormal pupillary reactions (52% vs. 32%), and more intracranial pathology (subarachnoid hemorrhage 62% vs. 44%; intraparenchymal lesions 65% vs. 46%) in the ICP+ group. Patients with a total intracranial lesion volume of similar to 150 mL and a midline shift of similar to 12 mm were most likely to receive an intracranial pressure monitor and probabilities decreased with smaller and larger lesions and shifts. Furthermore, compliance was low in patients with no (Traumatic Coma Databank score I -10%) visible intracranial pathology. Differences in case-mix resulted in higher a priori probabilities of dying (median 0.51 vs. 0.35, p < .001) and unfavorable outcome (median 0.79 vs. 0.63, p < .001) in the ICP+ group. After correction for baseline and clinical characteristics with a propensity score, intracranial pressure monitoring guideline compliance was not associated with mortality (odds ratio 0.93, 95% confidence interval 0.47-1.85, p = .83) nor with unfavorable outcome (odds ratio 1.81, 95% confidence interval 0.88-3.73, p = .11). Conclusions: Guideline noncompliance was most prominent in patients with minor or very large computed tomography abnormalities. Intracranial pressure monitoring was not associated with 6-month outcome, but multiple baseline differences between monitored and nonmonitored patients underline the complex nature of examining the effect of intracranial pressure monitoring in observational studies. (Crit Care Med 2012; 40:1914-1922)	[Biersteker, Heleen A. R.; Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Hoedemaekers, Cornelia W. E.] Radboud Univ Nijmegen, Dept Intens Care Med, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1105 AZ Amsterdam, Netherlands; [Franschman, Gaby] Vrije Univ Amsterdam Med Ctr, Dept Anesthesiol, Amsterdam, Netherlands; [van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Lingsma, Hester F.] Ctr Med Decis Making, Dept Publ Hlth, Erasmus Med Ctr, Rotterdam, Netherlands; [Haitsma, Iain] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands		Vos, PE (corresponding author), Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6525 ED Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Hoedemaekers, C.W.E./L-4375-2015	van der Naalt, Joukje/0000-0001-9873-2418	Dutch Brain Foundation [Hersenstichting - HSN-07-01]	The POCON study is funded by the Dutch Brain Foundation (Hersenstichting - HSN-07-01).	Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bekar A, 2009, J CLIN NEUROSCI, V16, P236, DOI 10.1016/j.jocn.2008.02.008; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bremmer R, 2010, NEUROCRIT CARE, V12, P362, DOI 10.1007/s12028-009-9329-2; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Buret H, 2008, J TRAUMA, V65, P499, DOI 10.1097/TA.0b013e318180208e; Chesnut RM, 2008, J TRAUMA, V65, P500, DOI 10.1097/TA.0b013e31818020b3; Chesnut RM, 2006, CRIT CARE MED, V34, P2262, DOI 10.1097/01.CCM.0000229885.76483.F7; Compagnone C, 2009, NEUROSURGERY, V64, P690, DOI 10.1227/01.NEU.0000340796.18738.F7; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Grande PO, 2009, J TRAUMA, V67, P415, DOI 10.1097/TA.0b013e3181aa236e; Heskestad B, 2008, J TRAUMA, V65, P1309, DOI 10.1097/TA.0b013e31815e40cd; Huizenga JE, 2002, ACAD EMERG MED, V9, P806, DOI 10.1197/aemj.9.8.806; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; Lane PL, 2000, CAN J SURG, V43, P442; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Rincon Fred, 2006, Curr Neurol Neurosci Rep, V6, P507, DOI 10.1007/s11910-006-0053-4; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Salim A, 2008, AM SURGEON, V74, P1088; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stevens RD, 2005, CRIT CARE MED, V33, P2415, DOI 10.1097/01.CCM.0000182993.63691.E1; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2008, MINERVA ANESTESIOL, V74, P199; Stover JF, 2006, CRIT CARE MED, V34, P1582, DOI 10.1097/01.CCM.0000216697.37348.FC; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	54	38	38	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2012	40	6					1914	1922		10.1097/CCM.0b013e3182474bde			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	946EZ	WOS:000304335600030	22488001				2022-02-06	
J	Elbogen, EB; Johnson, SC; Wagner, HR; Newton, VM; Beckham, JC				Elbogen, Eric B.; Johnson, Sally C.; Wagner, H. Ryan; Newton, Virginia M.; Beckham, Jean C.			Financial Well-Being and Postdeployment Adjustment Among Iraq and Afghanistan War Veterans	MILITARY MEDICINE			English	Article							MENTAL-HEALTH; MILITARY VETERANS; EMPLOYMENT; DISORDERS; BARRIERS; VALIDITY; VIOLENCE; QUALITY; SCALE; MONEY	Research has yet to examine the relationship between financial well-being and community reintegration of veterans. To address this, we analyzed data from n = 1,388 Iraq and Afghanistan War Era Veterans who completed a national survey on postdeployment adjustment. The results indicated that probable major depressive disorder, post-traumatic stress disorder, and traumatic brain injury were associated with financial difficulties. However, regardless of diagnosis, veterans who reported having money to cover basic needs were significantly less likely to have postdeployment adjustment problems such as criminal arrest, homelessness, substance abuse, suicidal behavior, and aggression. Statistical analyses also indicated that poor money management (e.g., incurring significant debt or writing bad checks) was related to maladjustment, even among veterans at higher income levels. Given these findings, efforts;timed at enhancing financial literacy and promoting meaningful employment may have promise to enhance outcomes and improve quality of life among returning veterans.	[Elbogen, Eric B.; Johnson, Sally C.; Newton, Virginia M.] Univ N Carolina, Forens Psychiat Program & Clin, Dept Psychiat, Sch Med, Chapel Hill, NC 27517 USA; [Elbogen, Eric B.; Beckham, Jean C.] Durham VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 6, Durham, NC 27705 USA; [Wagner, H. Ryan; Beckham, Jean C.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA		Elbogen, EB (corresponding author), Univ N Carolina, Forens Psychiat Program & Clin, Dept Psychiat, Sch Med, 2218 Nelson Highway, Chapel Hill, NC 27517 USA.				Mid-Atlantic Mental Illness Research, Education and Clinical Center; Office of Research and Development Clinical Science, Department of Veterans AffairsUS Department of Veterans Affairs; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988]; Department of Education, National Institute on Disability and Rehabilitation Research [H133G100145]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988] Funding Source: NIH RePORTER	Preparation of this manuscript was supported by the Mid-Atlantic Mental Illness Research, Education and Clinical Center, the Office of Research and Development Clinical Science, Department of Veterans Affairs, the National Institute of Mental Health (R01MH080988), and the Department of Education, National Institute on Disability and Rehabilitation Research (H133G100145).	Agresti A., 2019, INTRO CATEGORICAL DA; Allen SF, 2010, COMMIMITY WORK FAM, V13, P89, DOI 10.1080/13668800903101581; Beckham JC, 2008, MIL MED, V173, P448, DOI 10.7205/MILMED.173.5.448; Black RA, 2008, J NERV MENT DIS, V196, P576, DOI 10.1097/NMD.0b013e31817d0535; Bradley KA, 1998, J GEN INTERN MED, V13, P379, DOI 10.1046/j.1525-1497.1998.00118.x; Commission of Financial Literacy and Education, 2011, COMM FIN LIT ED PROM; Cook JA, 2006, PSYCHIAT SERV, V57, P1391, DOI 10.1176/appi.ps.57.10.1391; Copeland LA, 2009, AM J PUBLIC HEALTH, V99, P871, DOI 10.2105/AJPH.2008.149989; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; Defense Manpower Data Center, 2010, FY2009 ANN DEM PROF; Dillman D.A., 2009, INTERNET MAIL MIXED, V3rd ed.; Elbogen EB, 2011, PSYCHIATR REHABIL J, V34, P223, DOI 10.2975/34.3.2011.223.231; FERRANS CE, 1992, RES NURS HEALTH, V15, P29, DOI 10.1002/nur.4770150106; Greenberg GA, 2008, PSYCHIAT SERV, V59, P170, DOI 10.1176/ps.2008.59.2.170; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Hill RP, 2007, J CONSUM AFF, V41, P29, DOI 10.1111/j.1745-6606.2006.00067.x; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Institute of Medicine, 2010, RET HOM IR AFGH PREL; Iversen A, 2005, EUR J PUBLIC HEALTH, V15, P175, DOI 10.1093/eurpub/cki128; Jenkins R, 2008, PSYCHOL MED, V38, P1485, DOI 10.1017/S0033291707002516; Kertesz SG, 2009, JAMA-J AM MED ASSOC, V301, P1771; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEHMAN AF, 1983, ARCH GEN PSYCHIAT, V40, P369; Marmot M, 2001, NEW ENGL J MED, V345, P134, DOI 10.1056/NEJM200107123450210; Marson DC, 2006, SCHIZOPHRENIA BULL, V32, P81, DOI 10.1093/schbul/sbj027; McDonald SD, 2009, J ANXIETY DISORD, V23, P247, DOI 10.1016/j.janxdis.2008.07.007; McFarlane AC, 2009, CURR OPIN PSYCHIATR, V22, P369, DOI 10.1097/YCO.0b013e32832c9064; Pang MF, 2010, INSTR SCI, V38, P659, DOI 10.1007/s11251-009-9094-9; Penk W, 2009, PSYCHIATR REHABIL J, V33, P297, DOI 10.2975/33.4.2010.297.307; PORTER NM, 1992, AM BEHAV SCI, V35, P820, DOI 10.1177/0002764292035006016; Riddle MS, 2008, COMPR PSYCHIAT, V49, P340, DOI 10.1016/j.comppsych.2007.07.007; ROSENHECK R, 1994, AM J PUBLIC HEALTH, V84, P466, DOI 10.2105/AJPH.84.3.466; Rosenheck RA, 2007, PSYCHIAT SERV, V58, P325, DOI 10.1176/appi.ps.58.3.325; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Siegel CE, 2006, PSYCHIAT SERV, V57, P982, DOI 10.1176/appi.ps.57.7.982; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Steadman HJ, 2000, LAW HUMAN BEHAV, V24, P83, DOI 10.1023/A:1005478820425; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; STRUMPEL B, 1976, EC MEANS HUMAN NEEDS; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Zivin K, 2011, PSYCHIAT SERV, V62, P35, DOI 10.1176/ps.62.1.pss6201_0035; Zoroya G, 2012, US TODAY        0801	43	38	38	0	30	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	JUN	2012	177	6					669	675		10.7205/MILMED-D-11-00388			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	955QP	WOS:000305036300009	22730842	Green Accepted, Green Submitted			2022-02-06	
J	Loncarevic-Vasiljkovic, N; Pesic, V; Todorovic, S; Popic, J; Smiljanic, K; Milanovic, D; Ruzdijic, S; Kanazir, S				Loncarevic-Vasiljkovic, Natasa; Pesic, Vesna; Todorovic, Smilja; Popic, Jelena; Smiljanic, Kosara; Milanovic, Desanka; Ruzdijic, Sabera; Kanazir, Selma			Caloric Restriction Suppresses Microglial Activation and Prevents Neuroapoptosis Following Cortical Injury in Rats	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; FOOD RESTRICTION; DIETARY RESTRICTION; DAMAGE; AGE; NEURODEGENERATION; MECHANISMS; APOPTOSIS; CYTOKINES; CASPASES	Traumatic brain injury (TBI) is a widespread cause of death and a major source of adult disability. Subsequent pathological events occurring in the brain after TBI, referred to as secondary injury, continue to damage surrounding tissue resulting in substantial neuronal loss. One of the hallmarks of the secondary injury process is microglial activation resulting in increased cytokine production. Notwithstanding that recent studies demonstrated that caloric restriction (CR) lasting several months prior to an acute TBI exhibits neuroprotective properties, understanding how exactly CR influences secondary injury is still unclear. The goal of the present study was to examine whether CR (50% of daily food intake for 3 months) alleviates the effects of secondary injury on neuronal loss following cortical stab injury (CSI). To this end, we examined the effects of CR on the microglial activation, tumor necrosis factor-alpha (TNF-alpha) and caspase-3 expression in the ipsilateral (injured) cortex of the adult rats during the recovery period (from 2 to 28 days) after injury. Our results demonstrate that CR prior to CSI suppresses microglial activation, induction of TNF-alpha and caspase-3, as well as neurodegeneration following injury. These results indicate that CR strongly attenuates the effects of secondary injury, thus suggesting that CR may increase the successful outcome following TBI.	[Loncarevic-Vasiljkovic, Natasa; Pesic, Vesna; Todorovic, Smilja; Popic, Jelena; Smiljanic, Kosara; Milanovic, Desanka; Ruzdijic, Sabera; Kanazir, Selma] Univ Belgrade, Dept Neurobiol, Inst Biol Res, Belgrade, Serbia		Loncarevic-Vasiljkovic, N (corresponding author), Univ Belgrade, Dept Neurobiol, Inst Biol Res, Belgrade, Serbia.	selkan@ibiss.bg.ac.rs	Kanazir, Selma/E-5495-2015	Kanazir, Selma/0000-0002-7229-5296; Pesic, Vesna/0000-0002-1415-5834; Smiljanic, Kosara/0000-0002-6790-5491; Loncarevic-Vasiljkovic, Natasa/0000-0002-8350-1390; Todorovic, Smilja/0000-0001-7155-4914; Popic, Jelena/0000-0002-0959-3856	Ministry of Education and Science, Republic of Serbia [ON173056]	This work is funded by the Ministry of Education and Science, Republic of Serbia (grant No ON173056). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arumugam TV, 2010, ANN NEUROL, V67, P41, DOI 10.1002/ana.21798; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Brown GC, 2010, MOL NEUROBIOL, V41, P242, DOI 10.1007/s12035-010-8105-9; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chiba T, 2010, BIOCHEM BIOPH RES CO, V399, P98, DOI 10.1016/j.bbrc.2010.07.048; Chopek JW, 2010, MECH AGEING DEV, V131, P650, DOI 10.1016/j.mad.2010.09.001; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hiona A, 2004, ANN NY ACAD SCI, V1019, P96, DOI 10.1196/annals.1297.018; Jeong MA, 2011, J NEUROTRAUM, V28, P479, DOI 10.1089/neu.2010.1609; Kraft AD, 2009, NEUROTOXICOLOGY, V30, P785, DOI 10.1016/j.neuro.2009.07.001; Lee LW, 2003, NEUROMOL MED, V4, P179, DOI 10.1385/NMM:4:3:179; Loncarevic-Vasiljkovic N, 2009, EXP NEUROL, V220, P198, DOI 10.1016/j.expneurol.2009.08.024; Madinier A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008101; Manzanero Silvia, 2011, Exp Transl Stroke Med, V3, P8, DOI 10.1186/2040-7378-3-8; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; Neumann H, 2001, GLIA, V36, P191, DOI 10.1002/glia.1108; Pekovic S, 2006, NEUROBIOLOGICAL STUDIES - FROM GENES TO BEHAVIOUR 2006, P143; Raivich G, 2005, TRENDS NEUROSCI, V28, P571, DOI 10.1016/j.tins.2005.09.001; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reed JL, 2010, APPL PHYSIOL NUTR ME, V35, P573, DOI 10.1139/H10-046; Roberge MC, 2008, BEHAV BRAIN RES, V187, P123, DOI 10.1016/j.bbr.2007.09.002; Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Sharma S, 2005, BRAIN RES BULL, V67, P482, DOI 10.1016/j.brainresbull.2005.07.015; Sharma S, 2008, NEUROCHEM RES, V33, P1178, DOI 10.1007/s11064-007-9503-x; Sola E, 2009, OBES SURG, V19, P571, DOI 10.1007/s11695-008-9772-8; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Tuttolomondo A, 2009, CURR TOP MED CHEM, V9, P1240, DOI 10.2174/156802609789869619; Veenith T, 2009, WORLD J EMERG SURG, V2, P4; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4	39	38	38	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2012	7	5							e37215	10.1371/journal.pone.0037215			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TM	WOS:000305336300079	22615943	gold, Green Published, Green Submitted			2022-02-06	
J	Hua, F; Reiss, JI; Tang, HL; Wang, J; Fowler, X; Sayeed, I; Stein, DG				Hua, Fang; Reiss, Jenny I.; Tang, Huiling; Wang, Jun; Fowler, Xavier; Sayeed, Iqbal; Stein, Donald G.			Progesterone and low-dose vitamin D hormone treatment enhances sparing of memory following traumatic brain injury	HORMONES AND BEHAVIOR			English	Article						Traumatic brain injury; Combination treatments; Functional repair; Progesterone; Vitamin D3 hormone	MORRIS WATER MAZE; SPATIAL WORKING-MEMORY; NERVOUS-SYSTEM; HIPPOCAMPAL-NEURONS; CEREBRAL-ISCHEMIA; CAUDATE-PUTAMEN; D TOXICITY; MALE RATS; IN-VIVO; EXPRESSION	Progesterone (PROG) has been shown to protect the brain from traumatic injury and is now in Phase III clinical trials. Our work shows that PROG's beneficial effects can be reduced in vitamin D hormone (VDH)deficient subjects. VDH can modulate neuronal apoptosis, trophic factors, inflammation, oxidative stress, excitotoxicity, and myelin and axon repair. We investigated whether VDH combined with PROG could improve behavioral outcomes more than PROG alone in VDH-sufficient rats given bilateral contusions of the medial frontal cortex. PROG and different doses of VDH (1 mu g/kg, VDH1; 2.5 mu g/kg, VDH2; 5 mu g/kg, VDH3) were injected intraperitoneally 1 h post-injury. Eight additional doses of PROG were given subcutaneously over 8 days with tapering over the last 2 days. Neurobehavioral tests, necrotic cavity, neuronal death and activation of astrocytes were evaluated 21 days post-injury. We found that PROG and PROG +VDH preserve spatial memory processing. VDH1 + PROG improved performance in acquisition more effectively than PROG alone, indicating that the low VDH dose is optimal for combination therapy. There were no significant differences in necrotic cavity size among the groups. The density of positive staining for reactive astrocytes (glial fibrillary acidic protein (GFAP)) increased and the cell bodies and processes of GFAP-positive cells were enlarged in the PROG + VDH1 group. Our data indicate that the combination of PROG and VDH is more effective than PROG alone in preserving spatial and reference memory, and that PROG plus low-dose VDH can activate GFAP reactions up to 21 days after injury. This effect may be one of the mechanisms underlying PROG's neuroprotective effects in combination with VDH. (C) 2012 Elsevier Inc. All rights reserved.	[Hua, Fang; Reiss, Jenny I.; Tang, Huiling; Wang, Jun; Fowler, Xavier; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	fhua2@emory.edu; jreiss44@gmail.com; htang9@emory.edu; jwang26@emory.edu; xfowler@emory.edu; isayeed@emory.edu; dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS048451, 1R01HD061971]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048451] Funding Source: NIH RePORTER	This work was supported by NIH 5R01NS048451 and 1R01HD061971 to DGS. A portion of this research was supported by a gift from BHR Pharma, AHA National Program SDG 0830481N to FH, and AHA 11SDG5430002 to IS. The authors thank Dr. Xiaobo Ma for his contribution to the evaluation of the necrotic cavity.	Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Baldi E, 2005, NEUROSCI LETT, V378, P176, DOI 10.1016/j.neulet.2004.12.029; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Buell JS, 2008, MOL ASPECTS MED, V29, P415, DOI 10.1016/j.mam.2008.05.001; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2010, NEUROTHERAPEUTICS, V7, P81, DOI 10.1016/j.nurt.2009.10.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Chang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012925; Chatterjee M, 2001, MUTAT RES-FUND MOL M, V475, P69, DOI 10.1016/S0027-5107(01)00080-X; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; De Keyser J, 2008, J NEUROL SCI, V267, P3, DOI 10.1016/j.jns.2007.08.044; Devan BD, 1999, BEHAV BRAIN RES, V100, P5, DOI 10.1016/S0166-4328(98)00107-7; DEVIRAGH PA, 1989, P NATL ACAD SCI USA, V86, P3887; Ehara A, 2009, ACTA HISTOCHEM CYTOC, V42, P171, DOI 10.1267/ahc.09018; Ferretti V, 2007, BEHAV BRAIN RES, V179, P43, DOI 10.1016/j.bbr.2007.01.009; Frielingsdorf H, 2006, BEHAV BRAIN RES, V168, P37, DOI 10.1016/j.bbr.2005.10.008; Gangisetty O, 2010, NEUROSCIENCE, V170, P865, DOI 10.1016/j.neuroscience.2010.07.037; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gunn BG, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00131; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hazell AS, 2007, NEUROCHEM INT, V50, P941, DOI 10.1016/j.neuint.2007.04.026; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jones G, 2008, AM J CLIN NUTR, V88, p582S, DOI 10.1093/ajcn/88.2.582S; Kajta M, 2009, NEUROCHEM INT, V55, P265, DOI 10.1016/j.neuint.2009.03.010; Lin AMY, 2005, ANN NY ACAD SCI, V1053, P319, DOI 10.1196/annals.1344.028; Losem-Heinrichs E, 2005, ARCH BIOCHEM BIOPHYS, V439, P70, DOI 10.1016/j.abb.2005.04.021; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McCann JC, 2008, FASEB J, V22, P982, DOI 10.1096/fj.07-9326rev; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; PAULSON PE, 1994, BEHAV NEUROSCI, V108, P624, DOI 10.1037/0735-7044.108.3.624; Prior H, 1997, BEHAV BRAIN RES, V87, P183, DOI 10.1016/S0166-4328(97)02282-1; Stein DG, 2009, HORMONES, BRAIN AND BEHAVIOR, VOLS 1-5, 2ND EDITION, P2223; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Stein DG, 2011, PM&R, V3, pS100, DOI 10.1016/j.pmrj.2011.03.010; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Thacher TD, 2011, MAYO CLIN PROC, V86, P50, DOI 10.4065/mcp.2010.0567; VIETH R, 1990, BONE MINER, V11, P267, DOI 10.1016/0169-6009(90)90023-9; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang JP, 2010, BEHAV BRAIN RES, V209, P119, DOI 10.1016/j.bbr.2010.01.026; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Zhang R, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-65	54	38	40	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0018-506X			HORM BEHAV	Horm. Behav.	APR	2012	61	4					642	651		10.1016/j.yhbeh.2012.02.017			10	Behavioral Sciences; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Endocrinology & Metabolism	925LW	WOS:000302763700024	22570859	Green Accepted			2022-02-06	
J	Rivara, FP; Ennis, SK; Mangione-Smith, R; MacKenzie, EJ; Jaffe, KM				Rivara, Frederick P.; Ennis, Stephanie K.; Mangione-Smith, Rita; MacKenzie, Ellen J.; Jaffe, Kenneth M.		Natl Expert Panel Dev Pediat Rehab	Quality of Care Indicators for the Rehabilitation of Children With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Quality of health care; Rehabilitation	COGNITIVE REHABILITATION; OUTCOMES; APPROPRIATENESS; MORTALITY; GUIDELINE	Rivara FP, Ennis SK, Mangione-Smith R, MacKenzie EJ, Jaffe KM, and the National Expert Panel for the Development of Pediatric Rehabilitation Quality Care Indicators. Quality of care indicators for the rehabilitation of children with traumatic brain injury. Arch Phys Med Rehabil 2012;93: 381-5. Objective: To develop measurement tools for assessing compliance with identifiable processes of inpatient care for children with traumatic brain injury (TBI) that are reliable, valid, and amenable to implementation. Design: Literature review and expert panel using the RAND/UCLA Appropriateness Method and a Delphi technique. Setting: Not applicable. Participants: Children with TBI. Interventions: Not applicable. Main Outcome Measure: Quality of care indicators. Results: A total of 119 indicators were developed across the domains of general management; family-centered care; cognitive-communication, speech, language, and swallowing impairments; gross and fine motor skill impairments; neuropsychologic, social, and behavioral impairments; school reentry; and community integration. There was a high degree of agreement on these indicators as valid and feasible quality measures for children with TBI. Conclusions: These indicators are an important step toward building a better base of evidence about the effectiveness and efficiency of the components of acute inpatient rehabilitation for pediatric patients with TBI.	[Rivara, Frederick P.; Ennis, Stephanie K.; Jaffe, Kenneth M.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Rivara, Frederick P.; Mangione-Smith, Rita] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Ennis, Stephanie K.; Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Rivara, Frederick P.; Mangione-Smith, Rita] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA		Rivara, FP (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@uw.edu		Krach, Linda/0000-0002-0993-8199; Gaebler-Spira, Deborah/0000-0001-6827-4241	Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD059049-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD059049] Funding Source: NIH RePORTER	Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant no. R21 HD059049-01A1).	Brain Trauma Foundation, 1995, GUID MAN SEV TBI; Brain Trauma Foundation, 2003, GUID AC MED MAN SEV; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; BROOK RH, 1994, METHODOLOGICAL PERSP; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Duncan PW, 2007, ARCH PHYS MED REHAB, V88, P1482, DOI 10.1016/j.apmr.2007.08.118; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fitch K, 2006, RAND UCLA APPROPRIAT; GRADY ML, 1992, MED EFFECTIVENESS RE; Hoenig H, 2002, MED CARE, V40, P1036, DOI 10.1097/00005650-200211000-00005; Hoenig H, 2001, HEALTH SERV RES, V35, P1293; Institute of Medicine, 2001, CROSSING QUALITY CHA; KAHN KL, 1988, MED CARE, V26, P415, DOI 10.1097/00005650-198804000-00010; Kravitz RL, 1997, HEALTH POLICY, V42, P135, DOI 10.1016/S0168-8510(97)00064-X; LaClair BJ, 2001, AM J PHYS MED REHAB, V80, P235, DOI 10.1097/00002060-200103000-00017; Mangione-Smith R, 2007, NEW ENGL J MED, V357, P1515, DOI 10.1056/NEJMsa064637; McGlynn EA, 1999, WOMEN HEALTH ISS, V9, P184, DOI 10.1016/S1049-3867(99)00009-2; McGory ML, 2009, ANN SURG, V250, P338, DOI 10.1097/SLA.0b013e3181ae575a; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Reker DM, 2002, ARCH PHYS MED REHAB, V83, P750, DOI 10.1053/apmr.2002.99736; Rubin HR, 2001, INT J QUAL HEALTH C, V13, P489, DOI 10.1093/intqhc/13.6.489; Schuster MA, 1997, ARCH PEDIAT ADOL MED, V151, P1085, DOI 10.1001/archpedi.1997.02170480015003; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Sills MR, 2005, ARCH PEDIAT ADOL MED, V159, P665, DOI 10.1001/archpedi.159.7.665; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Wilkerson DL, 1997, ARCH PHYS MED REHAB, V78, pS31, DOI 10.1016/S0003-9993(97)90153-2; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Zumsteg JM, 2012, ARCH PHYS MED REHAB, V93, P386, DOI 10.1016/j.apmr.2011.08.018	38	38	38	2	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2012	93	3					381	385		10.1016/j.apmr.2011.08.015			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	902GW	WOS:000301027600001	22280892	Green Accepted			2022-02-06	
J	Bregy, A; Nixon, R; Lotocki, G; Alonso, OF; Atkins, CM; Tsoulfas, P; Bramlett, HM; Dietrich, WD				Bregy, Amade; Nixon, Ryan; Lotocki, George; Alonso, Ofelia F.; Atkins, Coleen M.; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton			Posttraumatic hypothermia increases doublecortin expressing neurons in the dentate gyrus after traumatic brain injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article						Dentate gyrus; Doublecortin; Fluid-percussion; Hypothermia; Neurogenesis; Traumatic brain injury	MICROTUBULE-ASSOCIATED PROTEIN; CONTROLLED CORTICAL IMPACT; TRANSIENT GLOBAL-ISCHEMIA; NEURAL PROGENITOR CELLS; FOCAL CEREBRAL-ISCHEMIA; NECROSIS-FACTOR-ALPHA; HIPPOCAMPAL NEUROGENESIS; SUBVENTRICULAR ZONE; ENHANCED NEUROGENESIS; ADULT RATS	Previous studies have demonstrated that moderate hypothermia reduces histopathological damage and improves behavioral outcome after experimental traumatic brain injury (TBI). Further investigations have clarified the mechanisms underlying the beneficial effects of hypothermia by showing that cooling reduces multiple cell injury cascades. The purpose of this study was to determine whether hypothermia could also enhance endogenous reparative processes following TBI such as neurogenesis and the replacement of lost neurons. Male Sprague-Dawley rats underwent moderate fluid-percussion brain injury and then were randomized into normothermia (37 degrees C) or hypothermia (33 degrees C) treatment. Animals received injections of 5-bromo-2'-deoxyuridine (BrdU) to detect mitotic cells after brain injury. After 3 or 7 days, animals were perfusion-fixed and processed for immunocytochemistry and confocal analysis. Sections were stained for markers selective for cell proliferation (BrdU), neuroblasts and immature neurons (doublecortin), and mature neurons (NeuN) and then analyzed using non-biased stereology to quantify neurogenesis in the dentate gyrus (DG). At 7 days after TBI, both normothermic and hypothermic TBI animals demonstrated a significant increase in the number of BrdU-immunoreactive cells in the DG as compared to sham-operated controls. At 7 days post-injury, hypothermia animals had a greater number of BrdU (ipsilateral cortex) and doublecortin (ipsilateral and contralateral cortex) immunoreactive cells in the DG as compared to normothermia animals. Because adult neurogenesis following injury may be associated with enhanced functional recovery, these data demonstrate that therapeutic hypothermia sustains the increase in neurogenesis induced by TBI and this may be one of the mechanisms by which hypothermia promotes reparative strategies in the injured nervous system. (C) 2011 Elsevier Inc. All rights reserved.	[Bregy, Amade; Nixon, Ryan; Lotocki, George; Alonso, Ofelia F.; Atkins, Coleen M.; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Dept Neurol Surg, Neurotrauma Res Ctr, Miami Project Cure Paralysis,Miller Sch Med, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Miami Project Cure Paralysis, Lois Pope LIFE Ctr, Leonard M Miller Sch Med, 1095 NW 14th Terrace,Suite 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu		Tsoulfas, Pantelis/0000-0003-1974-6366; Nixon, Ryan/0000-0002-5759-4415; Atkins, Coleen/0000-0003-4718-7493	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291, NS42133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER	The authors wish to thank Jeremy Lytle for editorial support. This study was supported by the National Institutes of Health grants NS030291 and NS42133.	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Atkins C.M., 2010, EUR J NEUROSCI, V28, P35; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Back SA, 2002, J NEUROSCI, V22, P455, DOI 10.1523/JNEUROSCI.22-02-00455.2002; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bonde S, 2006, EUR J NEUROSCI, V23, P965, DOI 10.1111/j.1460-9568.2006.04635.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Braun H, 2002, J NEUROTRAUM, V19, P975, DOI 10.1089/089771502320317122; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Covolan L, 2000, HIPPOCAMPUS, V10, P169, DOI 10.1002/(SICI)1098-1063(2000)10:2<169::AID-HIPO6>3.0.CO;2-W; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Doetsch F, 1997, J NEUROSCI, V17, P5046; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Faul M, 2010, TRAUMATIC BRAIN INJU; Felling RJ, 2003, J NEUROSCI RES, V73, P277, DOI 10.1002/jnr.10670; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Jessberger S, 2007, J NEUROSCI, V27, P9400, DOI 10.1523/JNEUROSCI.2002-07.2007; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kalluri HSG, 2007, EUR J NEUROSCI, V25, P1041, DOI 10.1111/j.1460-9568.2007.05336.x; Kee NJ, 2001, EXP BRAIN RES, V136, P313, DOI 10.1007/s002210000591; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Kitamura T, 2009, CELL, V139, P814, DOI 10.1016/j.cell.2009.10.020; Koch JD, 2008, J CEREBR BLOOD F MET, V28, P1294, DOI 10.1038/jcbfm.2008.15; Komitova M, 2005, STROKE, V36, P1278, DOI 10.1161/01.STR.0000166197.94147.59; Lasarzik I, 2009, ANESTH ANALG, V109, P1632, DOI 10.1213/ANE.0b013e3181bab451; Lau BWM, 2009, NEUROREPORT, V20, P371, DOI 10.1097/WNR.0b013e328324edcd; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu YP, 2005, BRAIN RES, V1054, P152, DOI 10.1016/j.brainres.2005.06.085; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lu KT, 2011, J NEUROTRAUM, V28, P441, DOI 10.1089/neu.2010.1473; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; Moreno-Lopez B, 2004, J NEUROSCI, V24, P85, DOI 10.1523/JNEUROSCI.1574-03.2004; Noonan MA, 2010, J NEUROSCI, V30, P304, DOI 10.1523/JNEUROSCI.4256-09.2010; Packer MA, 2003, P NATL ACAD SCI USA, V100, P9566, DOI 10.1073/pnas.1633579100; Parent JM, 1997, J NEUROSCI, V17, P3727; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pedersen MO, 2009, HISTOL HISTOPATHOL, V24, P573, DOI 10.14670/HH-24.573; Peng H, 2008, GLIA, V56, P903, DOI 10.1002/glia.20665; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Potts MB, 2009, J NEUROSCI RES, V87, P1848, DOI 10.1002/jnr.21996; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Rossi C, 2006, EUR J NEUROSCI, V24, P1850, DOI 10.1111/j.1460-9568.2006.05059.x; Russo-Neustadt AA, 2004, NEUROPSYCHOPHARMACOL, V29, P2189, DOI 10.1038/sj.npp.1300514; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Scott BW, 2000, EXP NEUROL, V165, P231, DOI 10.1006/exnr.2000.7458; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Silasi G, 2011, J CEREBR BLOOD F MET, V31, P1725, DOI 10.1038/jcbfm.2011.25; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Takasawa K, 2002, J CEREBR BLOOD F MET, V22, P299, DOI 10.1097/00004647-200203000-00007; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Verwer RWH, 2007, BRAIN, V130, P3321, DOI 10.1093/brain/awm264; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008	117	38	39	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2012	233	2			SI		821	828		10.1016/j.expneurol.2011.12.008			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	890CV	WOS:000300123600031	22197046	Green Accepted			2022-02-06	
J	Coldren, RL; Russell, ML; Parish, RV; Dretsch, M; Kelly, MP				Coldren, Rodney L.; Russell, Michael L.; Parish, Robert V.; Dretsch, Michael; Kelly, Mark P.			The ANAM Lacks Utility as a Diagnostic or Screening Tool for Concussion More Than 10 Days Following Injury	MILITARY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT METRICS; RECOVERY; IRAQ; DEPLOYMENT; PERSONNEL; FOOTBALL; OUTCOMES; TIME	Congress has mandated that the Department of Defense perform screening for concussion. or mild traumatic brain injury, on all service members redeploying from Iraq and Afghanistan. However, the retrospective diagnosis of concussion is complicated by the subjective nature of the complaints, overlap of symptoms with other conditions, and the normally rapid recovery of neurocognitive function following a concussive event. One diagnostic and screening test in current use by the Department of Defense is the Automated Neuropsychological Assessment Metrics (ANAM). A team of researchers deployed to Iraq between January and April 2009 to test the validity of the ANA M for the diagnosis of concussion in the combat environment. Performance by concussed participants on all six ANAM subtests was compared with that of controls. The ANAM appears to have no utility as an individual diagnostic or population screening tool for the detection of neurocognitive dysfunction from a single. uncomplicated concussion when administered 10 or more days following injury. Further studies are required to determine the modalities providing optimal sensitivity and specificity for use as diagnostic or screening tests beyond the first 72-hour acute postinjury period.	[Coldren, Rodney L.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Russell, Michael L.] Lincoln Ctr, Off Surgeon Gen, R2D, San Antonio, TX 78230 USA; [Parish, Robert V.] CMR, Landstuhl Reg Med Ctr, APO, AE 09180 USA; [Dretsch, Michael] USA, Aeromed Res Lab, Ft Rucker, AL 36362 USA; [Kelly, Mark P.] Walter Reed Army Med Ctr, Dept Psychol, Washington, DC USA		Coldren, RL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.				U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland;  [W81XWH-09-2-0057]	Sponsor of this award is provided by The U.S. Army Medical Research Acquisition Activity, Fort Detrick, Maryland and is the awarding and administering acquisition office. Material provided in this presentation under award W81XWH-09-2-0057 does not necessarily reflect the position or the policy of the Government, and no of endorsement should be interred. The views expressed in this letter are those of the authors and do not reflect the official policy of the Department of Army. Department of Defense. or U.S. Government.	Barr W., 2008, TXB CLIN NEUROPSYCHO, P660; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	19	38	38	0	8	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	FEB	2012	177	2					179	183		10.7205/MILMED-D-11-00278			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	886KC	WOS:000299852300012	22360064	Bronze			2022-02-06	
J	Egea, J; Martin-de-Saavedra, MD; Parada, E; Romero, A; del Barrio, L; Rosa, AO; Garcia, AG; Lopez, MG				Egea, J.; Martin-de-Saavedra, M. D.; Parada, E.; Romero, A.; del Barrio, L.; Rosa, A. O.; Garcia, A. G.; Lopez, M. G.			Galantamine elicits neuroprotection by inhibiting iNOS, NADPH oxidase and ROS in hippocampal slices stressed with anoxia/reoxygenation	NEUROPHARMACOLOGY			English	Article						Galantamine; Ischemia; Neuroprotection; ROS	ALPHA-7 NICOTINIC RECEPTORS; NITRIC-OXIDE; ACETYLCHOLINESTERASE INHIBITORS; MEDIATED NEUROPROTECTION; GLUCOSE DEPRIVATION; ALZHEIMERS-DISEASE; CORTICAL CULTURES; INDUCED APOPTOSIS; OXIDATIVE STRESS; HEME OXYGENASE-1	Galantamine is a drug currently used to treat Alzheimer's disease (AD); in this group of patients it has been observed that concomitant ischemic brain injury can accelerate their cognitive deficit. We have previously shown that galantamine can afford neuroprotection on in vitro and in vivo models related to brain ischemia. In this context, this study was planned to investigate the intracellular signaling pathways implicated in the protective effect of galantamine on an in vitro brain ischemia-reperfusion model, namely rat hippocampal slices subjected to oxygen and glucose deprivation (OGD) followed by reoxygenation. Galantamine protected hippocampal slices subjected to OGD in a concentration-dependent manner; at 15 mu M, cell death was reduced to almost control levels. The neuroprotective effects of galantamine were reverted by mecamylamine and AG490, but not by atropine, indicating that nicotinic receptors and Jak2 participated in this action. Galantamine also prevented p65 translocation into the nucleus induced by OGD; this effect was also linked to nicotinic receptors and Jak2. Furthermore, galantamine reduced iNOS induction and production of NO caused by OGD via Jak2. ROS production by NADPH oxidase (NOX) activation was also inhibited by galantamine. In conclusion, galantamine afforded neuroprotection under OGD-reoxygenation conditions by activating a signaling pathway that involves nicotinic receptors, Jak2 and the consequent inhibition of NOX and NF kappa B/iNOS. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'. (C) 2011 Elsevier Ltd. All rights reserved.	[Egea, J.; Martin-de-Saavedra, M. D.; Parada, E.; Romero, A.; del Barrio, L.; Rosa, A. O.; Garcia, A. G.; Lopez, M. G.] Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, E-28029 Madrid, Spain; [Egea, J.; Martin-de-Saavedra, M. D.; Parada, E.; Romero, A.; del Barrio, L.; Rosa, A. O.; Garcia, A. G.; Lopez, M. G.] Univ Autonoma Madrid, Inst Teofilo Hernando, Madrid 28029, Spain; [Garcia, A. G.] Hosp Univ de la Princesa, Inst Invest Sanitaria, Serv Farmacol Clin, Madrid, Spain; [Egea, J.; Romero, A.; Lopez, M. G.] Univ Autonoma Madrid, Inst Univ la Paz IdiPaz, Madrid 28029, Spain		Egea, J (corresponding author), Univ Autonoma Madrid, Fac Med, Dept Farmacol & Terapeut, Calle Arzobispo Morcillo 4, E-28029 Madrid, Spain.	javier.egea@uam.es	Egea, Javier/X-7281-2019; Barrio, Laura/B-3767-2017; Martin-de-Saavedra, M. Dolores/AAA-3119-2019; Romero, Alejandro/N-9686-2019; Lopez, Manuela G/D-2164-2015; GARCIA, ANTONIO G/E-9961-2018; Romero, Alejandro/A-8282-2018	Egea, Javier/0000-0003-4704-3019; Barrio, Laura/0000-0001-9203-3296; Romero, Alejandro/0000-0001-5483-4973; Lopez, Manuela G/0000-0003-4461-8788; GARCIA, ANTONIO G/0000-0002-6517-3565; Romero, Alejandro/0000-0001-5483-4973; da Rosa, Angelo/0000-0003-3715-4751; Martin-de-Saavedra, Maria Dolores/0000-0001-8527-493X	Spanish Ministry of Science and InnovationSpanish Government [SAF2009-12150]; Spanish Ministry of Health (Instituto de Salud Carlos III)Instituto de Salud Carlos IIISpanish Government [RETICS-RD06/0026]; Comunidad Autonoma de MadridComunidad de Madrid [SAL2006/0275]; Agencia Lain Entralgo [NDG07/9]; Fundacion C.I.E.N.; Instituto Carlos IIIInstituto de Salud Carlos III [85016/09]; Spanish Ministry of Science and InnovationSpanish Government; Fundacion Teofilo Hernando	This work was supported in part by grants from Spanish Ministry of Science and Innovation Ref. SAF2009-12150 to MGL, the Spanish Ministry of Health (Instituto de Salud Carlos III) RETICS-RD06/0026 and Comunidad Autonoma de Madrid Ref. SAL2006/0275 to AGG and MGL, Agencia Lain Entralgo Ref. NDG07/9 and Fundacion C.I.E.N., Instituto Carlos III Ref. 85016/09. MDMS has a pre-doctoral fellowship from the Spanish Ministry of Science and Innovation. We would also like to thank "Fundacion Teofilo Hernando" for its continued support.	Abramov AY, 2007, J NEUROSCI, V27, P1129, DOI 10.1523/JNEUROSCI.4468-06.2007; Abramov AY, 2004, J NEUROSCI, V24, P565, DOI 10.1523/JNEUROSCI.4042-03.2004; Arias E, 2004, NEUROPHARMACOLOGY, V46, P103, DOI 10.1016/S0028-3908(03)00317-4; Arias E, 2005, J PHARMACOL EXP THER, V315, P1346, DOI 10.1124/jpet.105.090365; Belluardo N, 2000, ADV RES NEURODEGENER, V8, P227; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Cardenas A, 1998, EUR J PHARMACOL, V354, P161, DOI 10.1016/S0014-2999(98)00458-0; Cardenas A, 2000, J NEUROCHEM, V74, P2041, DOI 10.1046/j.1471-4159.2000.0742041.x; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Du J., 2009, AM J PHYSL CELL PHYS; Egea J, 2007, NEUROSCIENCE, V145, P866, DOI 10.1016/j.neuroscience.2006.12.036; Egea J, 2007, J NEUROCHEM, V102, P1842, DOI 10.1111/j.1471-4159.2007.04665.x; Erkinjuntti T, 2003, CLIN THER, V25, P1765, DOI 10.1016/S0149-2918(03)80168-6; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Gahring LC, 2003, J NEUROCHEM, V87, P1125, DOI 10.1046/j.1471-4159.2003.02074.x; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; Gilby KL, 2005, BRAIN RES, V1035, P196, DOI 10.1016/j.brainres.2004.12.015; Gronlien JH, 2007, MOL PHARMACOL, V72, P715, DOI 10.1124/mol.107.035410; Hejmadi MV, 2003, MOL CELL NEUROSCI, V24, P779, DOI 10.1016/S1044-7431(03)00244-6; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Ji XH, 2007, NEUROSCI LETT, V416, P92, DOI 10.1016/j.neulet.2007.01.053; Kihara T, 2004, BIOCHEM BIOPH RES CO, V325, P976, DOI 10.1016/j.bbrc.2004.10.132; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kox M, 2009, BIOCHEM PHARMACOL, V78, P863, DOI 10.1016/j.bcp.2009.06.096; Lorrio S, 2007, J PHARMACOL EXP THER, V322, P591, DOI 10.1124/jpet.107.122747; Madrigal Jose L. M., 2006, CNS & Neurological Disorders-Drug Targets, V5, P561; Marzinzig M, 1997, NITRIC OXIDE-BIOL CH, V1, P177, DOI 10.1006/niox.1997.0116; Moriguchi S, 2004, J PHARMACOL EXP THER, V310, P933, DOI 10.1124/jpet.104.067603; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Parada E, 2010, FREE RADICAL BIO MED, V49, P1815, DOI 10.1016/j.freeradbiomed.2010.09.017; Pereira EFR, 2002, J NEUROBIOL, V53, P479, DOI 10.1002/neu.10146; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rojo AI, 2006, FREE RADICAL BIO MED, V41, P247, DOI 10.1016/j.freeradbiomed.2006.04.002; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Santos MD, 2002, MOL PHARMACOL, V61, P1222, DOI 10.1124/mol.61.5.1222; Schrattenholz A, 1996, MOL PHARMACOL, V49, P1; Sethi G, 2008, EXP BIOL MED, V233, P21, DOI 10.3181/0707-MR-196; Shaw S, 2002, J BIOL CHEM, V277, P44920, DOI 10.1074/jbc.M204610200; Shen H, 2010, BRIT J PHARMACOL, V161, P127, DOI 10.1111/j.1476-5381.2010.00894.x; Sobrado M, 2004, NEUROSCI LETT, V365, P132, DOI 10.1016/j.neulet.2004.04.067; Stevens TR, 2003, J NEUROSCI, V23, P10093; Sugano N, 1998, BIOCHEM BIOPH RES CO, V252, P25, DOI 10.1006/bbrc.1998.9599; Tabet N, 2006, AGE AGEING, V35, P336, DOI 10.1093/ageing/afl027; Takada-Takatori Y, 2006, EUR J PHARMACOL, V549, P19, DOI 10.1016/j.ejphar.2006.08.017; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; THOMSEN T, 1990, LIFE SCI, V46, P1553, DOI 10.1016/0024-3205(90)90429-U; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Wilcock GK, 2000, BRIT MED J, V321, P1445, DOI 10.1136/bmj.321.7274.1445; Xu J, 2008, NEUROPHARMACOLOGY, V54, P1029, DOI 10.1016/j.neuropharm.2008.01.014; Zhou W, 2008, CELL MOL NEUROBIOL, V28, P263, DOI 10.1007/s10571-007-9251-0	56	38	38	1	22	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2012	62	2					1082	1090		10.1016/j.neuropharm.2011.10.022			9	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	909FZ	WOS:000301549300059	22085833				2022-02-06	
J	Bartsch, A; Benzel, E; Miele, V; Prakash, V				Bartsch, Adam; Benzel, Edward; Miele, Vincent; Prakash, Vikas			Impact test comparisons of 20th and 21st century American football helmets Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						concussion; American football; football helmet; high school football; youth football; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; UNITED-STATES; GAME IMPACTS; HEAD-INJURY; COLLEGIATE; RISK; EPIDEMIOLOGY	Object. Concussion is the signature American football injury of the 21st century. Modern varsity helmets, as compared with vintage leather helmets, or "leatherheads," are widely believed to universally improve protection by reducing head impact doses and head injury risk for the 3 million young football players in the US. The object of this study was to compare the head impact doses and injury risks with 11 widely used 21st century varsity helmets and 2 early 20th century leatherheads and to hypothesize what the results might mean for children wearing similar varsity helmets. Methods. In an injury biomechanics laboratory, the authors conducted front, oblique front, lateral, oblique rear, and rear head impact tests at 5.0 m/second using helmeted headforms, inducing near-and subconcussive head impact doses on par with approximately the 95th percentile of on-field collision severity. They also calculated impact dose injury risk parameters common to laboratory and on-field traumatic neuromechanics: linear acceleration, angular acceleration, angular velocity, Gadd Severity Index, diffuse axonal injury, acute subdural hematoma, and brain contusion. Results. In many instances the head impact doses and head injury risks while wearing vintage leatherheads were comparable to or better than those while wearing several widely used 21st century varsity helmets. Conclusions. The authors do not advocate reverting to leather headgear, but they do strongly recommend, especially for young players, instituting helmet safety designs and testing standards, which encourage the minimization of linear and angular impact doses and injury risks in near-and subconcussive head impacts. (DOI: 10.3171/2011.9.JNS111059)	[Bartsch, Adam; Benzel, Edward] Cleveland Clin, Spine Res Lab, Cleveland, OH 44113 USA; [Benzel, Edward; Miele, Vincent] Cleveland Clin, Neurol Inst, Dept Neurosurg, Cleveland, OH 44113 USA; [Bartsch, Adam; Benzel, Edward; Miele, Vincent; Prakash, Vikas] Case Western Reserve Univ, Cleveland Traumat Neuromech Consortium, Cleveland, OH 44106 USA; [Prakash, Vikas] Case Western Reserve Univ, Dept Mech Engn, Cleveland, OH 44106 USA; [Miele, Vincent] United Hosp Ctr, Neurospine Ctr, Bridgeport, WV USA		Bartsch, A (corresponding author), Cleveland Clin, Spine Res Lab, Luth2-C,1730 W 25th St, Cleveland, OH 44113 USA.	bartsca@ccf.org					Bandak FA, SIMON SIMULATED INJU; Bandak FA, 3 DIMENSIONAL FINITE; Battista J, 2011, NY TIMES        0323; Battista J, 2010, NY TIMES        1019; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Duma SM, 2009, IEEE ENG MED BIO, P1123, DOI 10.1109/IEMBS.2009.5333423; Fenner Jr H, 2005, FIN REP WORKSH CRIT; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gadd CW, USE WEIGHTED IMPULSE; Gennarelli TA, 2005, ABBREVIATED INJURY S; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Higgins M, 2007, J ATHL TRAINING, V42, P5; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hodgson VR, EFFECT LONG DURATION; Hodgson VR, COMP HEAD ACCELERATI; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McElhaney James H, 2005, Stapp Car Crash J, V49, pv; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mertz H, INJURY RISK CURVES C; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; National Operating Committee on Standards for Athletic Equipment, 2009, ND00298M09 NOCSAE, P1; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2008, 00108M08B NOCSAE, P1; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Prasad P, POSITION US DELEGATI; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Schwartz A, 2009, NY TIMES        1202; Society of Automotive Engineers, INSTR IMP TEST PART; Society of Automotive Engineers, SIGN CONV VEH CRASH; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Versace J, REV SEVERITY INDEX; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2	52	38	38	1	34	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2012	116	1					222	233		10.3171/2011.9.JNS111059			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	869XJ	WOS:000298632500037	22054210	Bronze			2022-02-06	
J	Iverson, GL; Lange, RT; Waljas, M; Liimatainen, S; Dastidar, P; Hartikainen, KM; Soimakallio, S; Ohman, J				Iverson, Grant L.; Lange, Rael T.; Waljas, Minna; Liimatainen, Suvi; Dastidar, Prasun; Hartikainen, Kaisa M.; Soimakallio, Seppo; Ohman, Juha			Outcome from Complicated versus Uncomplicated Mild Traumatic Brain Injury	REHABILITATION RESEARCH AND PRACTICE			English	Article							MODERATE HEAD-INJURY; COMPUTED-TOMOGRAPHY; CT-SCANS; PREDICTORS; LESIONS	Objective. To compare acute outcome following complicated versus uncomplicated mild traumatic brain injury (MTBI) using neurocognitive and self-report measures. Method. Participants were 47 patients who presented to the emergency department of Tampere University Hospital, Finland. All completed MRI scanning, self-report measures, and neurocognitive testing at 3-4 weeks after injury. Participants were classified into the complicated MTBI or uncomplicated MTBI group based on the presence/absence of intracranial abnormality on day-of-injury CT scan or 3-4 week MRI scan. Results. There was a large statistically significant difference in time to return to work between groups. The patients with uncomplicated MTBIs had a median of 6.0 days (IQR = 0.75-14.75, range = 0-77) off work compared to a median of 36 days (IQR = 13.5-53, range = 3-315) for the complicated group. There were no significant differences between groups for any of the neurocognitive or self-report measures. There were no differences in the proportion of patients who (a) met criteria for ICD-10 postconcussional disorder or (b) had multiple low scores on the neurocognitive measures. Conclusion. Patients with complicated MTBIs took considerably longer to return to work. They did not perform more poorly on neurocognitive measures or report more symptoms, at 3-4 weeks after injury compared to patients with uncomplicated MTBIs.	[Iverson, Grant L.; Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Defence & Veterans Brain, Rockville, MD 20852 USA			giverson@interchange.ubc.ca			Competitive Research Funding of the Pirkanmaa Hospital District, Tampere University Hospital	This research was funded by Competitive Research Funding of the Pirkanmaa Hospital District, Tampere University Hospital. The authors thank Pasi Jolma (M.D., Ph.D.) for help with recruiting the patients and conducting neurological examinations. This study was presented at the annual meeting of the National Academy of Neuropsychology, October 2010, Vancouver, BC, Canada. The views expressed in this article are those of the authors and do not reflect the official policy of the Department of Army, Department of Defense, or US Government.	Army Individual Test Battery, 1944, MAN DIR SCOR; BECK AT, 1996, MANUAL BECK DEPRESS; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Denk C, 2010, J MAGN RESON IMAGING, V31, P185, DOI 10.1002/jmri.21995; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MORAN SG, 1994, AM SURGEON, V60, P533; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Rauscher A, 2008, MAGN RESON IMAGING, V26, P1145, DOI 10.1016/j.mri.2008.01.029; Saboori M, 2007, CLIN NEUROL NEUROSUR, V109, P399, DOI 10.1016/j.clineuro.2007.01.013; Spreen O, 1991, COMPENDIUM NEUROPSYC; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson J. T. L, 1996, RECOVERY TRAUMATIC B, P29	35	38	39	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-2867	2090-2875		REHABIL RES PRACT	Rehabil. Res. Pract.		2012	2012								415740	10.1155/2012/415740			7	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V18NK	WOS:000214757900014	22577556	Green Published, Green Submitted, gold			2022-02-06	
J	Skoglund, K; Enblad, P; Hillered, L; Marklund, N				Skoglund, Karin; Enblad, Per; Hillered, Lars; Marklund, Niklas			The neurological wake-up test increases stress hormone levels in patients with severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						ACTH; catecholamines; cerebral perfusion pressure (CPP); cortisol; epinephrine; intracranial pressure (ICP); neurological wake-up test; norepinephrine; propofol; sedation	PITUITARY-ADRENAL AXIS; VENTILATOR-ASSOCIATED PNEUMONIA; CRITICALLY-ILL PATIENTS; SALIVARY CORTISOL; NOREPINEPHRINE TURNOVER; DYSFUNCTION; CATECHOLAMINES; HIPPOCAMPAL; BUNDLE; PLASMA	Objectives: The "neurological wake-up test" is needed to evaluate the level of consciousness in patients with severe traumatic brain injury. However, the neurological wake-up test requires interruption of continuous sedation and may induce a stress response and its use in neurocritical care is controversial. We hypothesized that the neurological wake-up test induces an additional biochemical stress response in patients with severe traumatic brain injury. Patients: Twenty-four patients who received continuous propofol sedation and mechanical ventilation after moderate to severe traumatic brain injury (Glasgow Coma Scale score <= 8; patient age 18-71 yrs old) were analyzed. Exclusion criteria were age <18 yrs old, ongoing pentobarbital infusion, or markedly increased intracranial pressure on interruption of continuous sedation. Design: Single-center prospective study. During postinjury days 1-8, 65 neurological wake-up tests were evaluated. Adrenocorticotrophic hormone, epinephrine, and norepinephrine levels in plasma and cortisol levels in saliva were analyzed at baseline (during continuous intravenous propofol sedation) and during neurological wake-up test. Data are presented using medians and 25th and 75th percentiles. Setting: The study was performed in a university hospital neurocritical care unit. Interventions: None. Measurements and Main Results: At baseline, adrenocorticotrophic hormone and cortisol levels were 10.6 (6.0-19.4) ng/L and 16.0 (10.7-31.8) nmol/L, respectively. Immediately after the neurological wake-up test, adrenocorticotrophic hormone levels increased to 20.5 (11.1-48.4) ng/L (p < .05) and cortisol levels in saliva increased to 24.0 (12.3-42.5) nmol/L (p < .05). The plasma epinephrine and norepinephrine levels increased from a baseline of 0.3 (0.3-0.6) and 1.6 (0.9-2.3) nmol/L, respectively, to 0.75 (0.3-1.4) and 2.8 (1.28-3.58) nmol/L, respectively (both p < .05). Conclusions: The neurological wake-up test induces a biochemical stress response in patients with severe traumatic brain injury. The clinical importance of this stress response remains to be established but should be considered when deciding the frequency and use of the neurological wake-up test during neurocritical care. (Crit Care Med 2012; 40:216-222)	[Skoglund, Karin; Enblad, Per; Hillered, Lars; Marklund, Niklas] Uppsala Univ, Dept Neurosci, Uppsala, Sweden		Skoglund, K (corresponding author), Uppsala Univ, Dept Neurosci, Uppsala, Sweden.	Niklas.Marklund@neurokir.uu.se		Hillered, Lars/0000-0002-2808-9292; Marklund, Niklas/0000-0002-9797-5626	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Laerdal Foundation; Uppsala University	The study was supported by funds from the Swedish Research Council, the Laerdal Foundation, and from Uppsala University.	ASTROM M, 1993, STROKE, V24, P52, DOI 10.1161/01.STR.24.1.52; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Bay Esther, 2005, J Neurosci Nurs, V37, P4; Blamoun J, 2009, AM J INFECT CONTROL, V37, P172, DOI 10.1016/j.ajic.2008.05.010; BOHNEN N, 1990, BIOL PSYCHOL, V31, P107, DOI 10.1016/0301-0511(90)90011-K; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1985, EXP NEUROL, V89, P479, DOI 10.1016/0014-4886(85)90107-4; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; COUCH RM, 1992, ACTA ENDOCRINOL-COP, V127, P115, DOI 10.1530/acta.0.1270115; DAHLGREN N, 1980, BRAIN RES, V184, P143, DOI 10.1016/0006-8993(80)90593-4; Diamond DM, 2000, ANN NY ACAD SCI, V911, P453; Dimopoulou I, 2005, INTENS CARE MED, V31, P1020, DOI 10.1007/s00134-005-2689-y; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Dinkel K, 2003, J NEUROCHEM, V84, P705, DOI 10.1046/j.1471-4159.2003.01604.x; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; Dunser Martin W, 2009, J Intensive Care Med, V24, P293, DOI 10.1177/0885066609340519; Duplessis C, 2010, MIL MED, V175, P340, DOI 10.7205/MILMED-D-09-00166; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; FEIBEL JH, 1977, JAMA-J AM MED ASSOC, V238, P1374, DOI 10.1001/jama.238.13.1374; Fields LB, 2008, J NEUROSCI NURS, V40, P291, DOI 10.1097/01376517-200810000-00007; Gozansky WS, 2005, CLIN ENDOCRINOL, V63, P336, DOI 10.1111/j.1365-2265.2005.02349.x; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; LANDON J, 1984, P 9 TEN WORKSH 1982, P300; LARSON GM, 1984, AM J SURG, V147, P97, DOI 10.1016/0002-9610(84)90041-2; Larsson CA, 2009, BMC ENDOCR DISORD, V9, DOI 10.1186/1472-6823-9-16; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; Llompart-Pou JA, 2008, NEUROCRIT CARE, V9, P230, DOI 10.1007/s12028-008-9115-6; Llompart-Pou JA, 2007, J TRAUMA, V62, P1457, DOI 10.1097/01.ta.0000219143.69483.71; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483, DOI 10.1152/ajplegacy.1976.231.2.483; Magarinos AM, 1996, J NEUROSCI, V16, P3534; Marklund N, 2004, J INTERN MED, V256, P15, DOI 10.1111/j.1365-2796.2004.01334.x; Mautes AEM, 2001, ACTA NEUROCHIR, V143, P51, DOI 10.1007/s007010170138; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; MORSE JK, 1992, EXP NEUROL, V118, P47, DOI 10.1016/0014-4886(92)90021-H; OLSSON T, 1990, J INTERN MED, V228, P287, DOI 10.1111/j.1365-2796.1990.tb00233.x; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Rhoney DH, 2001, NEUROL RES, V23, P237, DOI 10.1179/016164101101198398; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Schell E, 2008, EUR SPINE J, V17, P393, DOI 10.1007/s00586-007-0554-0; Schwarz S, 2003, J NEUROL NEUROSUR PS, V74, P725, DOI 10.1136/jnnp.74.6.725; Skoglund K, 2009, NEUROCRIT CARE, V11, P135, DOI 10.1007/s12028-009-9255-3; SmithSwintosky VL, 1996, J CEREBR BLOOD F MET, V16, P585, DOI 10.1097/00004647-199607000-00008; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TEASDALE G, 1974, LANCET, V2, P81; Tschuor C, 2008, CRIT CARE, V12, DOI 10.1186/cc6931; Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; VINING RF, 1987, J STEROID BIOCHEM, V27, P81, DOI 10.1016/0022-4731(87)90297-4; Vyas A, 2002, J NEUROSCI, V22, P6810; Wilson JD, 1998, WILLIAMS TXB ENDOCRI; WOLKOWITZ OM, 1990, AM J PSYCHIAT, V147, P1297; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Yamakoshi T, 2009, MED BIOL ENG COMPUT, V47, P449, DOI 10.1007/s11517-009-0447-y; Youngquist P, 2007, JT COMM J QUAL PATIE, V33, P219, DOI 10.1016/S1553-7250(07)33026-2; Zhang Shou-Wen, 2008, Neurosci Bull, V24, P84, DOI 10.1007/s12264-008-0084-8	74	38	39	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2012	40	1					216	222		10.1097/CCM.0b013e31822d7dbd			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866KO	WOS:000298379800031	22179339				2022-02-06	
J	Svoboda, E; Richards, B; Leach, L; Mertens, V				Svoboda, Eva; Richards, Brian; Leach, Larry; Mertens, Valerie			PDA and smartphone use by individuals with moderate-to-severe memory impairment: Application of a theory-driven training programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Cognitive rehabilitation; Memory intervention; Technology; PDA; Smartphone; Amnesia	TRAUMATIC BRAIN-INJURY; PAGING SYSTEM; COGNITIVE REHABILITATION; AID; AMNESIA	We describe a structured, theory-driven training programme for individuals with moderate-to-severe memory impairment in the use of emerging commercial technology. We demonstrate its application to 10 individuals with memory impairment from a variety of aetiologies. A within-subject, ABAB multi-case experimental design was used to evaluate the impact of personal digital assistant or smartphone use on day-to-day memory functioning at baseline, immediately post-intervention, at return to baseline, and at short-term follow-up (range = 3-8 months). An errorless fading-of-cues protocol enabled all participants to acquire the skill set necessary to operate their PDA or smartphone independently. All 10 individuals showed robust improvement in day-to-day functioning post-intervention as quantified across a number of ecologically valid questionnaire and task-based measures. This was further corroborated by family members with whom six of the participants resided. These findings demonstrate that individuals with moderate-to-severe memory impairment can acquire the skills necessary to independently, flexibly and broadly apply commercial technology to support their everyday memory functioning. Moreover the findings confirm that the gap between individuals with memory impairment and potent emerging technology can be closed by the application of a systematic theory-driven training programme.	[Svoboda, Eva; Richards, Brian; Leach, Larry; Mertens, Valerie] Baycrest Neuropsychol & Cognit Hlth Program, Toronto, ON, Canada		Svoboda, E (corresponding author), Baycrest Ctr Geriatr Care, Neuropsychol & Cognit Hlth Program, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	esvoboda@baycrest.org					Bauer RM, 2008, TXB CLIN NEUROPSYCHO, P729; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen J, 1977, STAT POWER ANAL BEHA; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; Cullen C. N., 1976, NURS TIMES, V72, P45; DePompei R, 2008, NEUROREHABILITATION, V23, P487; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; Emslie H, 2007, NEUROPSYCHOL REHABIL, V17, P567, DOI 10.1080/09602010701381933; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Gentry T., 2008, AM J OCCUPATIONAL TH, V62, P8, DOI DOI 10.5014/AJOT.62.1.18; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Gioia GA, 2005, PSYCHOL ASSESS RESOU; Goldstein G, 1998, J REHABIL RES DEV, V35, P238; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Liberty K., 1980, METHODS INSTRUCTION; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; RICHARDS B, 1990, J CLIN EXPT NEUROPSY, V12, P395; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SOHLBERG MM, 2001, COGNITIVE REHABILITA, P194; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; Stapleton S, 2007, BRAIN INJURY, V21, P401, DOI 10.1080/02699050701252030; Svoboda E, 2006, NEUROPSYCHOLOGIA, V44, P2189, DOI 10.1016/j.neuropsychologia.2006.05.023; Svoboda E, 2010, NEUROPSYCHOL REHABIL, V20, P562, DOI 10.1080/09602011003669918; Svoboda E, 2009, J INT NEUROPSYCH SOC, V15, P629, DOI 10.1017/S1355617709090791; Troyer A. K., 2002, J GERONTOLOGY SERIES, V57B, P19, DOI [10.1093/geronb/57.1.P19, DOI 10.1093/GERONB/57.1.P19, DOI 10.1093/geronb/57.1.P19]; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WALSH BF, 1979, AM J MENT DEF, V83, P473; WILSON BA, 1989, CORTEX, V25, P115, DOI 10.1016/S0010-9452(89)80011-5; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239; [No title captured]	42	38	38	0	23	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	3					408	427		10.1080/09602011.2011.652498			20	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	936BV	WOS:000303566800005	22292945				2022-02-06	
J	Zoltewicz, JS; Scharf, D; Yang, BX; Chawla, A; Newsom, KJ; Fang, LJ				Zoltewicz, J. Susie; Scharf, Dancia; Yang, Boxuan; Chawla, Aarti; Newsom, Kimberly J.; Fang, Lijuan			Characterization of Antibodies that Detect Human GFAP after Traumatic Brain Injury	BIOMARKER INSIGHTS			English	Article						GFAP; GFAP-BDP; traumatic brain injury; human		After traumatic brain injury (TBI), glial fibrillary acidic protein (GFAP) and other brain-derived proteins and their breakdown products are released into biofluids such as CSF and blood. Recently, a sandwich ELISA was constructed that measured GFAP concentrations in CSF or serum from human mild-moderate TBI patients. The goals of the present study were to characterize the same two antibodies used in this ELISA, and to determine which GFAP bands are detected by this antibody combination. Here, both antibodies recognized GFAP specifically in human brain and post-TBI CSF in a cluster of bands ranging from 50-38 kDa, that resembled bands from calpain-cleaved GFAP. By immunoprecipitation, the anti-GFAP Capture antibody recovered full length GFAP and its breakdown products from human brain lysate and post-TBI CSF. These findings demonstrate that the anti-GFAP ELISA antibodies non-preferentially detect intact GFAP and GFAP breakdown products, underscoring their utility for detecting brain injury in human patients.	[Zoltewicz, J. Susie; Yang, Boxuan; Newsom, Kimberly J.; Fang, Lijuan] Banyan Biomarkers Inc, Alachua, FL 32615 USA; [Scharf, Dancia] Banyan Biomarkers Inc, W Lafayette, IN USA; [Chawla, Aarti] Banyan Biomarkers Inc, Carlsbad, CA USA		Zoltewicz, JS (corresponding author), Banyan Biomarkers Inc, Alachua, FL 32615 USA.	szoltewicz@banyanbio.com			DoDUnited States Department of Defense [W81XWH-06-1-0517, W81XWH-10-C-0251]; NINDS-NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS052831-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831] Funding Source: NIH RePORTER	This study was supported in part by DoD W81XWH-06-1-0517, DoD W81XWH-10-C-0251, and NINDS-NIH R01-NS052831-01. Valuable contributions were made by the following individuals. Nancy Denslow read the manuscript critically, suggested revisions, and provided substantive advice. Ronald Hayes provided advice and final edits to the manuscript. Jixiang Seaney initiated the anti-GFAP Dectection antibody. Chris Jacobs made recombinant human GFAP protein. Linnet Akinyi contributed to epitope mapping. Jenna Leclerc generated the organ blots. Zhiqun Zhang and Kevin Wang contributed to experimental design. Deva Puranam contributed supporting data. Juan Martinez suggested revisions. Stefania Mondello provided advice. Sincere thanks are extended to all contributors.	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Camins A, 2006, CNS DRUG REV, V12, P135, DOI 10.1111/j.1527-3458.2006.00135.x; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Martinez JA, 2010, APOPTOSIS, V15, P1480, DOI 10.1007/s10495-010-0526-4; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Papa L, 2011, ANN EMERG MED; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078; Zhang ZQ, 2009, APOPTOSIS, V14, P1289, DOI 10.1007/s10495-009-0405-z	31	38	40	1	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1177-2719			BIOMARK INSIGHTS	Biomark. Insights		2012	7						71	79		10.4137/BMI.S9873			9	Medicine, Research & Experimental	Emerging Sources Citation Index (ESCI)	Research & Experimental Medicine	V30KP	WOS:000215561800008	22798722	gold, Green Published			2022-02-06	
J	Bali, K; Sudesh, P; Patel, S; Kumar, V; Saini, U; Dhillon, MS				Bali, Kamal; Sudesh, Pebam; Patel, Sandeep; Kumar, Vishal; Saini, Uttam; Dhillon, M. S.			Pediatric Femoral Neck Fractures: Our 10 Years of Experience	CLINICS IN ORTHOPEDIC SURGERY			English	Article						Pediatric femur neck fracture; Avascular necrosis; Open reduction and internal fixation; Ratliff; Delbet classification		Background: Femoral neck fractures are rare injuries in children, but the high incidence of long term complications make it an important clinical entity. The aim of this retrospective study was to analyze the clinical outcomes of pediatric femur neck fractures that we managed over a 10 year period. Methods: The study included 36 children (20 boys and 16 girls) who sustained femoral neck fractures and completed a minimum follow-up of one year. The children were treated either conservatively, or by open reduction and internal fixation (ORIF), or closed reduction and internal fixation (CRIF). The outcomes were analyzed using Ratliffcriteria and a detailed record of complications was kept for all patients. Results: The mean age of included patients was 10 years (range, 3 to 16 years) and the average follow-up was 3.2 years (range, 1.1 to 8.5 years). Based on Delbet's classification system, there were 0 type I (transepiphyseal), 16 type II, 11 type III, and 9 type IV fractures. There were 8 undisplaced fractures, 4 of which later displaced after being managed initially in a hip spica. A satisfactory outcome was obtained in 27 (75%) children. Avascular necrosis (AVN) was the most common complication. It was seen in 7 of our patients, all of whom had an unsatisfactory outcome. Other complications included three cases each of coxavara, nonunion, and arthritic changes; and one case each of infection, primary screw perforation of head, and premature epiphyseal closure. Complications were lowest in the group treated by ORIF. Only 2 patients managed exclusively by conservative treatment ultimately achieved a satisfactory outcome. Conclusions: We believe that internal fixation of pediatric femoral neck fractures is preferred whenever feasible because conservative treatment carries a high risk of failure of reduction. Aggressive operative treatments aimed at anatomical reduction should be the goal and there should be no hesitation in choosing ORIF over CRIF. Outcome of patients is influenced primarily by development of AVN which occurs as an independent entity without much relation to the mode of treatment carried out.	[Bali, Kamal; Sudesh, Pebam; Patel, Sandeep; Kumar, Vishal; Saini, Uttam; Dhillon, M. S.] Postgrad Inst Med Educ & Res, Dept Orthoped, Chandigarh, India		Bali, K (corresponding author), Postgrad Inst Med Educ & Res, Dept Orthoped Surg, Chandigarh 160012, India.	kamalpgi@gmail.com	PATEL, SANDEEP/Z-2945-2019; KUMAR, VISHAL/AAB-7692-2022	saini, uttam/0000-0002-6812-5470; Patel, Sandeep/0000-0002-9312-9019; Dhillon, Mandeep/0000-0002-2592-1362			CANALE ST, 1977, J BONE JOINT SURG AM, V59, P431, DOI 10.2106/00004623-197759040-00001; Cheng JCY, 1999, J PEDIATR ORTHOPED, V19, P338; Colonna PC, 1929, AM J SURG, V6, P793, DOI [10.1016/S0002-9610(29)90726-1, DOI 10.1016/S0002-9610(29)90726-1, 10.1016/s0002-9610(29)90726-1]; DAVISON BL, 1992, J PEDIATR ORTHOPED, V12, P355, DOI 10.1097/01241398-199205000-00014; HAMILTON CM, 1961, JAMA-J AM MED ASSOC, V178, P799, DOI 10.1001/jama.1961.03040470015003; HEISER JM, 1980, CLIN ORTHOP RELAT R, P177; HUGHES LO, 1994, J BONE JOINT SURG AM, V76A, P283, DOI 10.2106/00004623-199402000-00019; INGRAM AJ, 1953, J BONE JOINT SURG AM, V35-A, P867, DOI 10.2106/00004623-195335040-00006; LAM SF, 1971, J BONE JOINT SURG AM, VA 53, P1165, DOI 10.2106/00004623-197153060-00013; Meyers MH, 1985, FRACTURES OF THE HIP; MILLER WE, 1973, CLIN ORTHOP RELAT R, P155; Moon ES, 2006, J ORTHOP TRAUMA, V20, P323, DOI 10.1097/00005131-200605000-00005; MORRISSY R, 1980, CLIN ORTHOP RELAT R, P202; Ng GPK, 1996, INJURY, V27, P419, DOI 10.1016/0020-1383(96)00025-3; PFORRINGER W, 1980, ACTA ORTHOP SCAND, V51, P91, DOI 10.3109/17453678008990774; QUINLAN WR, 1980, INJURY, V11, P242, DOI 10.1016/S0020-1383(80)80051-9; RATLIFF AHC, 1974, ORTHOP CLIN N AM, V5, P903; RATLIFF AHC, 1962, J BONE JOINT SURG BR, V44, P528, DOI 10.1302/0301-620X.44B3.528; SFEROPOULOS NK, 1994, INJURY, V25, P493, DOI 10.1016/0020-1383(94)90087-6; Shrader MW, 2007, CLIN ORTHOP RELAT R, P169, DOI 10.1097/01.blo.0000238794.82466.3d; Song KS, 2010, J BONE JOINT SURG BR, V92B, P1148, DOI 10.1302/0301-620X.92B8.24482; Song KS, 2001, J PEDIATR ORTHOP B, V10, P205, DOI 10.1097/00009957-200107000-00009; Togrul E, 2005, INJURY, V36, P123, DOI 10.1016/j.injury.2004.04.010; Wenger DR, 2005, RANGS CHILDRENS FRAC, P165	24	38	53	0	8	KOREAN ORTHOPAEDIC ASSOC	SEOUL	#1111 LIFECOMBI BLDG, YOEIDO-DONG, YOUNGDEUNGPO-GU, SEOUL, 150-732, SOUTH KOREA	2005-291X	2005-4408		CLIN ORTHOP SURG	Clin. Orthop. Surg.	DEC	2011	3	4					302	308		10.4055/cios.2011.3.4.302			7	Orthopedics	Emerging Sources Citation Index (ESCI)	Orthopedics	VC3QW	WOS:000433701600007	22162793	gold, Green Published, Green Submitted			2022-02-06	
J	Hu, SK; Xi, GH; Jin, H; He, YD; Keep, RF; Hua, Y				Hu, Shukun; Xi, Guohua; Jin, Hang; He, Yangdong; Keep, Richard F.; Hua, Ya			Thrombin-induced autophagy: A potential role in intracerebral hemorrhage	BRAIN RESEARCH			English	Article						Autophagy; Cell death; Cerebral hemorrhage; Thrombin	TRAUMATIC BRAIN-INJURY; CELL-DEATH; CEREBRAL-ISCHEMIA; MICE; MECHANISM; PATHWAY	Autophagy occurs in the brain after intracerebral hemorrhage (ICH) and thrombin contributes to ICH-induced brain injury and cell death. In this study, we investigated whether thrombin may activate autophagy (in vivo and in cultured astrocytes) and its potential role in ICH. Autophagy was examined using electron microscopy, conversion of light chain 3(LC3) from the LC3-I form to LC3-II, cathepsin D Western blotting and monodansylcadaverine (MDC) staining to detect autophagic vacuoles. 3-Methyladenine (3-MA) was used as an autophagy inhibitor. In vivo, we found that intracaudate injection of thrombin increased conversion of LC3-I to LC3-II, cathepsin D levels, and formation of autophagic vacuoles in the ipsilateral basal ganglia. ICH-induced upregulation of LC3-I to LC3-II conversion and cathepsin D levels was reduced by a thrombin inhibitor, hirudin. In cultured astrocytes, thrombin enhanced the conversion of LC3-I to LC3-II and increased MDC-labeled autophagic vacuoles. 3-MA inhibited thrombin-induced autophagic vacuole formation and exacerbated thrombin-induced cell death. These results indicate that thrombin activates autophagy in the brain and that thrombin has a role in ICH-induced autophagy. (C) 2011 Elsevier B.V. All rights reserved.	[Hu, Shukun; Xi, Guohua; Jin, Hang; He, Yangdong; Keep, Richard F.; Hua, Ya] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA		Hua, Y (corresponding author), Univ Michigan, Dept Neurosurg, R5018 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	yahua@umich.edu		Keep, Richard/0000-0001-6441-5334	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-017760, NS-039866, NS-057539]; American Heart Association (AHA)American Heart Association [0840016N]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS017760, R01NS057539, R01NS039866] Funding Source: NIH RePORTER	This study was supported by grants NS-017760, NS-039866 and NS-057539 from the National Institutes of Health (NIH) and 0840016N from American Heart Association (AHA). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and AHA.	Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Araki T, 2006, CELL BIOL INT, V30, P93, DOI 10.1016/j.cellbi.2005.10.020; Gong Y, 2011, ACTA NEUROCHIR SUPPL, V111, P113, DOI 10.1007/978-3-7091-0693-8_18; He Y, 2008, J CEREBR BLOOD F MET, V28, P897, DOI 10.1038/sj.jcbfm.9600578; Hu HT, 2010, BRAIN RES, V1361, P93, DOI 10.1016/j.brainres.2010.09.025; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lee JY, 2009, BRAIN RES, V1287, P126, DOI 10.1016/j.brainres.2009.06.028; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NITATORI T, 1995, J NEUROSCI, V15, P1001; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Uchiyama Y, 2008, AUTOPHAGY, V4, P404, DOI 10.4161/auto.5598; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yang SX, 2008, STROKE, V39, P2079, DOI 10.1161/STROKEAHA.107.508911	25	38	41	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 18	2011	1424						60	66		10.1016/j.brainres.2011.09.062			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	854IG	WOS:000297487600007	22015349	Green Accepted, Green Published			2022-02-06	
J	Higgins, GC; Devenish, RJ; Beart, PM; Nagley, P				Higgins, Gavin C.; Devenish, Rodney J.; Beart, Philip M.; Nagley, Phillip			Autophagic activity in cortical neurons under acute oxidative stress directly contributes to cell death	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Article						Neurons; Oxidative stress; Programmed cell death; Autophagy; Caspases; LC3; Atg7; Beclin 1	CASPASE-MEDIATED CLEAVAGE; TRAUMATIC BRAIN-INJURY; HYPOXIA-ISCHEMIA; CROSS-TALK; IN-VITRO; BECLIN 1; APOPTOSIS; MITOCHONDRIAL; MECHANISMS; NEURODEGENERATION	Primary neurons undergo insult-dependent programmed cell death. We examined autophagy as a process contributing to cell death in cortical neurons after treatment with either hydrogen peroxide (H(2)O(2)) or staurosporine. Although caspase-9 activation and cleavage of procaspase-3 were significant following staurosporine treatment, neither was observed following H(2)O(2) treatment, indicating a non-apoptotic death. Autophagic activity increased rapidly with H(2)O(2), but slowly with staurosporine, as quantified by processing of endogenous LC3. Autophagic induction by both stressors increased the abundance of fluorescent puncta formed by GFP-LC3, which could be blocked by 3-methyladenine. Significantly, such inhibition of autophagy blocked cell death induced by H(2)O(2) but not staurosporine. Suppression of Atg7 inhibited cell death by H(2)O(2), but not staurosporine, whereas suppression of Beclin 1 prevented cell death by both treatments, suggesting it has a complex role regulating both apoptosis and autophagy. We conclude that autophagic mechanisms are activated in an insult-dependent manner and that H(2)O(2) induces autophagic cell death.	[Higgins, Gavin C.; Devenish, Rodney J.; Nagley, Phillip] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; [Devenish, Rodney J.; Nagley, Phillip] Monash Univ, Ctr Excellence Struct & Funct Microbial Genom, Australian Res Council, Clayton, Vic 3800, Australia; [Beart, Philip M.] Univ Melbourne, Florey Neurosci Inst, Parkville, Vic 3010, Australia; [Beart, Philip M.] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia		Nagley, P (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Bldg 13D,Clayton Campus, Clayton, Vic 3800, Australia.	phillip.nagley@monash.edu	Higgins, Gavin/I-3731-2019	Higgins, Gavin/0000-0003-4045-9687	National Health and Medical Research Council (Australia)National Health and Medical Research Council of Australia; Australian Research CouncilAustralian Research Council	We thank Ms. Sue Ekkel for technical assistance with Western immunoblotting and Dr. Danielle Smith for technical advice. This work was supported by the National Health and Medical Research Council (Australia), of which Philip M. Beart is a Research Fellow. Phillip Nagley and Rodney J. Devenish are also supported by the Australian Research Council.	Baba H, 2009, J VASC SURG, V50, P381, DOI 10.1016/j.jvs.2009.03.042; Barbouti A, 2007, FREE RADICAL BIO MED, V43, P1377, DOI 10.1016/j.freeradbiomed.2007.06.020; Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694; Beart PM, 2007, J NEUROCHEM, V103, P2408, DOI 10.1111/j.1471-4159.2007.04937.x; Blomgren K, 2007, APOPTOSIS, V12, P993, DOI 10.1007/s10495-007-0754-4; Boland Barry, 2006, Molecular Aspects of Medicine, V27, P503, DOI 10.1016/j.mam.2006.08.009; Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; Chakrabarti L, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-24; Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233; Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163; Cheung NS, 2000, J NEUROCHEM, V74, P1613, DOI 10.1046/j.1471-4159.2000.0741613.x; Chu CT, 2009, METHOD ENZYMOL, V453, P217, DOI 10.1016/S0076-6879(08)04011-1; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Diwakarla S, 2009, CELL MOL LIFE SCI, V66, P156, DOI 10.1007/s00018-008-8490-7; Diwakarla S, 2009, J NEUROCHEM, V109, P198, DOI 10.1111/j.1471-4159.2009.05937.x; Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519; Galluzzi L, 2008, CELL, V135, P1161, DOI 10.1016/j.cell.2008.12.004; Garcia-Arencibia M, 2010, SEMIN CELL DEV BIOL, V21, P691, DOI 10.1016/j.semcdb.2010.02.008; Gill MB, 2008, NEUROCHEM RES, V33, P2379, DOI 10.1007/s11064-008-9649-1; Haendeler J, 1997, NITRIC OXIDE-BIOL CH, V1, P282, DOI 10.1006/niox.1997.0134; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Higgins GC, 2010, J ALZHEIMERS DIS, V20, pS453, DOI 10.3233/JAD-2010-100321; Higgins GC, 2009, CELL MOL LIFE SCI, V66, P2773, DOI 10.1007/s00018-009-0079-2; Houde C, 2004, J NEUROSCI, V24, P9977, DOI 10.1523/JNEUROSCI.3356-04.2004; Jaeger PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-16; Jenner Peter, 2007, Handb Clin Neurol, V83, P507, DOI 10.1016/S0072-9752(07)83024-7; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Klionsky DJ, 2006, NATURE, V441, P819, DOI 10.1038/441819a; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lang-Rollin ICJ, 2003, J NEUROSCI, V23, P11015; Lee YJ, 2000, FREE RADICAL BIO MED, V29, P684, DOI 10.1016/S0891-5849(00)00366-X; Lim MLR, 2006, EXP CELL RES, V312, P1174, DOI 10.1016/j.yexcr.2006.01.026; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377; Maycotte P, 2010, J NEUROSCI RES, V88, P73, DOI 10.1002/jnr.22168; Mehrpour M, 2010, AM J PHYSIOL-CELL PH, V298, pC776, DOI 10.1152/ajpcell.00507.2009; Nagley P, 2010, BBA-MOL BASIS DIS, V1802, P167, DOI 10.1016/j.bbadis.2009.09.004; Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yamashima T, 2009, PROG NEUROBIOL, V89, P343, DOI 10.1016/j.pneurobio.2009.09.003; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	60	38	40	0	11	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X			CELL MOL LIFE SCI	Cell. Mol. Life Sci.	NOV	2011	68	22					3725	3740		10.1007/s00018-011-0667-9			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	849LB	WOS:000297125900011	21437645				2022-02-06	
J	Kalanithi, P; Schubert, RD; Lad, SP; Harris, OA; Boakye, M				Kalanithi, Paul; Schubert, Ryan D.; Lad, Shivanand P.; Harris, Odette A.; Boakye, Maxwell			Hospital costs, incidence, and inhospital mortality rates of traumatic subdural hematoma in the United States Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic subdural hematoma; incidence; cost; traumatic brain injury; National Inpatient Sample; mortality	STROKE RISK-FACTORS; PROGNOSTIC-FACTORS; COMATOSE PATIENTS; CRANIOTOMY; CRITERIA	Object. This study provides the first US national data regarding frequency, cost, and mortality rate of traumatic subdural hematoma (SDH), and identifies demographic factors affecting morbidity and death in patients with traumatic SDH undergoing surgical drainage. Methods. A retrospective analysis was conducted by querying the Nationwide Inpatient Sample, the largest all-payer database of nonfederal community hospitals. All cases of traumatic SDH were identified using ICD-9 codes. The study consisted of 2 parts: 1) trends data, which were abstracted from the years 1993-2006, and 2) univariate analysis and multivariate logistic regression of demographic variables on inhospital complications and deaths for the years 1993-2002. Results. Admissions for traumatic SDH increased 154% from 17,328 in 1993 to 43,996 in 2006. Inhospital deaths decreased from 16.4% to 11.6% for traumatic SDH. Average costs increased 67% to $47,315 per admission. For the multivariate regression analysis, between 1993 and 2002, 67,864 patients with traumatic SDH underwent operative treatment. The inhospital mortality rate was 14.9% for traumatic SDH drainage, with an 18% inhospital complication rate. Factors affecting inhospital deaths included presence of coma (OR = 2.45) and more than 2 comorbidities (OR = 1.60). Increased age did not worsen the inhospital mortality rate. Conclusions. Nationally, frequency and cost of traumatic SDH cases are increasing rapidly. (DOI: 10.3171/2011.6.JNS101989)	[Kalanithi, Paul; Lad, Shivanand P.; Harris, Odette A.; Boakye, Maxwell] Stanford Univ Hosp & Clin, Dept Neurosurg, Palo Alto, CA USA; [Kalanithi, Paul; Lad, Shivanand P.; Harris, Odette A.; Boakye, Maxwell] VA Palo Alto Hlth Care Syst, Outcomes Res Ctr, Palo Alto, CA USA; [Schubert, Ryan D.] Stanford Univ, Sch Med, Stanford, CA 94305 USA		Kalanithi, P (corresponding author), Stanford Univ, Dept Neurosurg, Med Ctr, Lane Bldg,300 Pasteur Dr, Palo Alto, CA 94305 USA.	paul.kalanithi@gmail.com	Kalanithi, Paul/B-1074-2012	Schubert, Ryan/0000-0002-3132-5831			Abe M, 2003, SURG NEUROL, V59, P464, DOI 10.1016/S0090-3019(03)00078-8; [Anonymous], 2011, OV NAT INP SAMPL NIS; Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Bullock MR, 2006, NEUROSURGERY S, V58, pSi; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Cruz J, 2001, NEUROSURGERY, V49, P864; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Holloway RG, 2010, NEW ENGL J MED, V362, P1757, DOI 10.1056/NEJMp0907808; Kalanithi P, 2010, AANS NEUROSURGEON, V19, P28; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kokotailo RA, 2005, STROKE, V36, P1776, DOI 10.1161/01.STR.0000174293.17959.a1; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Marion DW, 2006, NEUROSURGERY, V58, P655; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; ROSENORN J, 1978, J NEUROSURG, V48, P345, DOI 10.3171/jns.1978.48.3.0345; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; US Bureau of Labor Statistics, CONS PRIC IND ALL UR; van den Brink WA, 1999, ACTA NEUROCHIR, V141, P509, DOI 10.1007/s007010050332; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552; Zumkeller M, 1996, NEUROSURGERY, V39, P708, DOI 10.1097/00006123-199610000-00011	31	38	38	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2011	115	5					1013	1018		10.3171/2011.6.JNS101989			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	839OR	WOS:000296377800026	21819196				2022-02-06	
J	Roscigno, CI; Swanson, KM				Roscigno, Cecelia I.; Swanson, Kristen M.			Parents' Experiences Following Children's Moderate to Severe Traumatic Brain Injury: A Clash of Cultures	QUALITATIVE HEALTH RESEARCH			English	Article						brain injury; children, disability; culture / cultural competence; disability / disabled persons; lived experience; parenting; phenomenology; trauma	SCHOOL; MODEL; PERSPECTIVES; PREDICTORS; RECOVERY; SYSTEM; NEEDS; WORK; CARE; TBI	Little is understood about parents' experiences following children's moderate to severe traumatic brain injury (TBI). Using descriptive phenomenology, we explored common experiences of parents whose children were diagnosed with moderate to severe TBI. Parents from across the United States (N = 42, from 37 families) participated in two semistructured interviews (similar to 90 minutes in length and 12 to 15 months apart) in the first 5 years following children's TBI. First interviews were in person. Second interviews, done in person or by phone, facilitated updating parents' experiences and garnering their critique of the descriptive model. Parent themes were (a) grateful to still have my child, (b) grieving for the child I knew, (c) running on nerves, and (d) grappling to get what my child and family need. Parents reported cultural barriers because of others' misunderstandings. More qualitative inquiry is needed to understand how the knowledge, attitudes, beliefs, and culture-based expectations of others influence parents' interactions and the family's adjustment and well-being.	[Roscigno, Cecelia I.] Univ Illinois, Coll Nursing, Dept Women Children & Family Hlth Sci, Chicago, IL 60612 USA; [Swanson, Kristen M.] Univ N Carolina, Sch Nursing, Chapel Hill, NC USA		Roscigno, CI (corresponding author), Univ Illinois, Coll Nursing, Dept Women Children & Family Hlth Sci, 845 S Damen Ave,MC 802, Chicago, IL 60612 USA.	roscigno@uic.edu			NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [1 F31 NR009599-02, F31 NR009599, T32 NR007091] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [6 T73 MC 00041-11-03);] Funding Source: Medline; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007091, F31NR009599] Funding Source: NIH RePORTER		Aitken ME, 2004, ARCH PHYS MED REHAB, V85, P567, DOI 10.1016/j.apmr.2003.06.018; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Benn KM, 2004, BRAIN INJURY, V18, P239, DOI 10.1080/02699050310001617343; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; Bradbury-Jones Caroline, 2010, Nurse Res, V17, P25; BRONFENBRENNER U, 1977, AM PSYCHOL, V32, P513, DOI 10.1037/0003-066x.32.7.513; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Chisholm J, 2001, Axone, V23, P12; Clark Alex, 2008, Clin Child Psychol Psychiatry, V13, P565, DOI 10.1177/1359104508090607; Colaizzi P., 1978, EXISTENTIAL PHENOMEN; Conway J., 2006, PARTNERING PATIENTS; Crothers IR, 2007, BRAIN INJURY, V21, P47, DOI 10.1080/02699050601149054; Deatrick, 2003, J FAM NURS, V9, P232, DOI [10.1177/1074840703255435, DOI 10.1177/1074840703255435]; Duff Diane, 2006, Axone, V27, P9; Eker C, 2000, BRAIN INJURY, V14, P605; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gearing RE, 2004, QUAL HEALTH RES, V14, P1429, DOI 10.1177/1049732304270394; Gfroerer SD, 2008, BRAIN INJURY, V22, P649, DOI 10.1080/02699050802227162; Glang A, 2008, NEUROREHABILITATION, V23, P477; GUBA EG, 1989, 4 GENERATION EVALUAT, P228; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P467, DOI 10.1097/00001199-200611000-00002; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; Husserl E., 1982, IDEAS PERTAINING PUR; Husserl Edmund, 1965, PHENOMENOLOGY CRISIS; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Jumisko E, 2007, DISABIL REHABIL, V29, P1535, DOI 10.1080/09638280601055816; Kao Hsueh-Fen S, 2004, J Neurosci Nurs, V36, P73; Kirschner PA, 2006, EDUC PSYCHOL-US, V41, P75, DOI 10.1207/s15326985ep4102_1; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Philipsen G, 2005, LEA COMMUN SER, P355; Philipsen G., 1997, DEV COMMUNICATION TH, P119; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P378, DOI 10.1097/01.HTR.0000341433.67251.01; Reder EAK, 2009, ARCH PEDIAT ADOL MED, V163, P653, DOI 10.1001/archpediatrics.2009.87; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Ryan-Nicholls Kimberley D, 2009, Nurse Res, V16, P70; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Smith J E, 2000, Care Manag J, V2, P27; Smith Michele S, 2002, Rehabil Nurs, V27, P209; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; TEASDALE G, 1974, LANCET, V2, P81; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; Wongvatunyu S, 2005, J NURS SCHOLARSHIP, V37, P48, DOI 10.1111/j.1547-5069.2005.00015.x; [No title captured]	56	38	38	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-7323	1552-7557		QUAL HEALTH RES	Qual. Health Res.	OCT	2011	21	10			SI		1413	1426		10.1177/1049732311410988			14	Public, Environmental & Occupational Health; Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences	817HI	WOS:000294662200009	21613654	Green Accepted			2022-02-06	
J	Bay, E; de-Leon, MB				Bay, Esther; de-Leon, Marita B.			Chronic Stress and Fatigue-Related Quality of Life After Mild to Moderate Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						fatigue; psychological; quality of life; stress; traumatic brain injury	IMPACT SCALE; EVENT SCALE; HEAD-INJURY; SYMPTOMS; INDIVIDUALS; VALIDATION; COMPLAINTS; RECOVERY	Objective: To determine relationships among chronic stress, fatigue-related quality of life (QOL-F), and related covariates after mild to moderate traumatic brain injury (TBI). Design: Observational and cross-sectional. Participants: A total of 84 community-dwelling individuals with mild to moderate TBI recruited from multiple out patient rehabilitation clinics assessed on average 15 months after injury. Method: Self-report surveys and chart abstraction. Measures: Neurofunctional Behavioral Inventory, Perceived Stress Scale-14, Impact of Events Scale, McGill Pain Short-form Scale, and modified version of the Fatigue Impact Scale. Results: QOL-F was associated with somatic symptoms, perceived situational stress, but not with event-related stress (posttraumatic stress disorder symptoms) related to index TBI, preinjury demographic, or postinjury characteristics. Somatic symptoms and chronic situational stress accounted for 42% of the variance in QOL-F. Conclusions: QOL-F in community-dwelling individuals with mild to moderate TBI is associated with chronic situational stress and somatic symptoms. Symptom management strategies may need to include general stress management to reduce fatigue burden and improve quality of life.	[Bay, Esther; de-Leon, Marita B.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA		Bay, E (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower,Suite 300, Ann Arbor, MI 48108 USA.	pdq@med.umich.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Center for Medical Rehabilitation Research [5-T32-HD007422-17]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007422] Funding Source: NIH RePORTER	This study was funded by Office of Vice-President of Research to Dr. Bay at Michigan State University. Dr de-Leon was supported by the National Institutes of Health, the National Institute of Child Health and Human Development, the National Center for Medical Rehabilitation Research grant 5-T32-HD007422-17.	ARNDT M, 2009, P SPARR MED CTR MSU; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/rtnp.18.2.213.61278; Bay E, 2009, WESTERN J NURS RES, V31, P731, DOI 10.1177/0193945909334856; Bay E, 2009, BIOL RES NURS, V10, P213, DOI 10.1177/1099800408326453; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1995, MEASURING STRESS AGU; COHEN SA, 1992, PSYCHOL BULL, P155; de Leon MB, 2009, ARCH PHYS MED REHAB, V90, P956, DOI 10.1016/j.apmr.2008.12.016; DELUCA J, 2005, FATIGUE ITS DEFINITI; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Ferrans CE, 2005, J NURS SCHOLARSHIP, V37, P336, DOI 10.1111/j.1547-5069.2005.00058.x; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; Fisk JD, 2002, QUAL LIFE RES, V11, P263, DOI 10.1023/A:1015295106602; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; McEwen B., 2002, END STRESS WE KNOW I; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TEASDALE G, 1974, LANCET, V2, P81; Tellez N, 2005, MULT SCLER J, V11, P198, DOI 10.1191/1352458505ms1148oa; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Whitehead L, 2009, J PAIN SYMPTOM MANAG, V37, P107, DOI 10.1016/j.jpainsymman.2007.08.019; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	48	38	38	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2011	26	5					355	363		10.1097/HTR.0b013e3181f20146			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	814VO	WOS:000294485500004	21169862	Green Accepted			2022-02-06	
J	Kopelman, TR; Berardoni, NE; O'Neill, PJ; Hedayati, P; Vail, SJ; Pieri, PG; Feiz-Erfan, I; Pressman, MA				Kopelman, Tammy R.; Berardoni, Nicole E.; O'Neill, Patrick J.; Hedayati, Poya; Vail, Sydney J.; Pieri, Paola G.; Feiz-Erfan, Iman; Pressman, Melissa A.			Risk Factors for Blunt Cerebrovascular Injury in Children: Do They Mimic Those Seen in Adults?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Pediatric; Trauma; Blunt cerebrovascular injury; Risk factors	CAROTID-ARTERY INJURIES; SEAT-BELT; TRAUMA; DIAGNOSIS; OUTCOMES	Background: Eastern Association for the Surgery of Trauma guideline for the evaluation of blunt cerebrovascular injury (BCVI) states that pediatric trauma patients should be evaluated using the same criteria as the adult population. The purpose of our study was to determine whether adult criteria translate to the pediatric population. Methods: Retrospective evaluation was performed at a Level I trauma center of blunt pediatric trauma patients (age <15 years) presenting over a 5-year period. Data obtained included patient demographics, presence of adult risk factors for BCVI (Glasgow coma scale <= 8, skull base fracture, cervical spine fracture, complex facial fractures, and soft tissue injury to the neck), presence of signs/symptoms of BCVI, method of evaluation, treatment, and outcome. Results: A total of 1,209 pediatric trauma patients were admitted during the study period. While 128 patients met criteria on retrospective review for evaluation based on Eastern Association for the Surgery of Trauma criteria, only 52 patients (42%) received subsequent radiographic evaluation. In all, 14 carotid artery or vertebral artery injuries were identified in 11 patients (all admissions, 0.9% incidence; all screened, 21% incidence). Adult risk factors were present in 91% of patients diagnosed with an injury. Major thoracic injury was found in 67% of patients with carotid artery injuries. Cervical spine fracture was found in 100% of patients with vertebral artery injuries. Stroke occurred in four patients (36%). Stroke rate after admission for untreated patients was 38% (3/8) versus 0.0% in those treated (0/2). Mortality was 27% because of concomitant severe traumatic brain injury. Conclusion: Risk factors for BCVI in the pediatric trauma patient appear to mimic those of the adult patient.	[Kopelman, Tammy R.; O'Neill, Patrick J.; Vail, Sydney J.; Pieri, Paola G.; Feiz-Erfan, Iman; Pressman, Melissa A.] Maricopa Cty Gen Hosp, Dept Surg, Phoenix, AZ 85008 USA; [Berardoni, Nicole E.; Hedayati, Poya] Maricopa Cty Gen Hosp, Dept Radiol, Phoenix, AZ 85008 USA		Kopelman, TR (corresponding author), Maricopa Cty Gen Hosp, Dept Surg, Phoenix, AZ 85008 USA.	tammy_kopelman@dmgaz.org					Berne JD, 2001, J AM COLL SURGEONS, V192, P314, DOI 10.1016/S1072-7515(01)00772-4; Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Carrillo EH, 1999, J TRAUMA, V46, P1120, DOI 10.1097/00005373-199906000-00030; Chamoun RB, 2008, J NEUROS-PEDIATR, V2, P101, DOI 10.3171/PED/2008/2/8/101; Cothren C. Clay, 2005, Clinics, V60, P489, DOI 10.1590/S1807-59322005000600011; Cuff RF, 2005, J TRAUMA, V58, P620, DOI 10.1097/01.TA.0000078884.59598.CF; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FABIAN TC, 1990, J TRAUMA, V30, P953, DOI 10.1097/00005373-199008000-00003; Kerwin AJ, 2001, J TRAUMA, V51, P308, DOI 10.1097/00005373-200108000-00013; Levack MM, 2009, J PEDIATR SURG, V44, pE29, DOI 10.1016/j.jpedsurg.2009.05.026; Lew SM, 1999, PEDIATR NEUROSURG, V30, P239, DOI 10.1159/000028804; McConnell EJ, 1997, J TRAUMA, V43, P150, DOI 10.1097/00005373-199707000-00038; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Parikh AA, 1997, J AM COLL SURGEONS, V185, P80, DOI 10.1016/S1072-7515(97)00002-1; Riches KJ, 2002, AM J FOREN MED PATH, V23, P45, DOI 10.1097/00000433-200203000-00009; Rozycki GS, 2002, J TRAUMA, V52, P618, DOI 10.1097/00005373-200204000-00002; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; 2006, MMWR MORB MORTAL WKL, V55, P624	22	38	38	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2011	71	3					559	564		10.1097/TA.0b013e318226eadd			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	818MX	WOS:000294756900012	21908994				2022-02-06	
J	Gandhi, S; Ranganathan, LK; Solanki, M; Mathew, GC; Singh, I; Bither, S				Gandhi, Sumir; Ranganathan, Laxman Kumar; Solanki, Manisha; Mathew, George C.; Singh, Inderjot; Bither, Saurab			Pattern of maxillofacial fractures at a tertiary hospital in northern India: a 4-year retrospective study of 718 patients	DENTAL TRAUMATOLOGY			English	Article							FACIAL FRACTURES; INJURIES; NIGERIA	Purpose: Pattern and aetiology of maxillofacial injuries varies from one country to another and even within the same country depending on prevailing socio-economic, cultural and environmental factors. Various studies have been carried out in various countries to study the epidemiology and demographics of the maxillofacial injuries but the studies from India are few. Material and methods: Retrospective study was undertaken at Christian Medical College Ludhiana (India) from January 2006 to December 2009. Treatment records of the patients was checked and age, gender, aetiology of injury, associated injuries, maxillofacial fractures and treatment offered were recorded. Results: A total of 1075 fractures were recorded in 718 patients, ranging from 11 months to 85 years of age. Male: female ratio was 6.6:1. Maxillofacial injuries were most common in third decade of life. A total of 517 patients suffered injuries because of road traffic accident, 115 because of accidental fall and 67 because of interpersonal violence. A total of 184 patients had 221 associated injuries of which 56.1% head injuries, 29.0% orthopaedic injuries and 14.9% other injuries were present. Of 596 middle third fractures, 29.8% were managed conservatively; for 21.7% and 48.7% of fractures, closed reduction and open reduction were performed respectively. Of 479 mandibular fractures, 1.8% was managed conservatively; for 16.7% and 81.5% fractures, closed reduction and open reduction were performed respectively. Conclusion: Better socio-economic status of people, increased vehicular movements and non-implementation of road safety norms have increased road traffic accidents. Proper education of the people who are most commonly involved in the RTA can be one of the possible ways to reduce the maxillofacial injuries.	[Gandhi, Sumir; Ranganathan, Laxman Kumar; Solanki, Manisha; Mathew, George C.; Singh, Inderjot; Bither, Saurab] Christian Med Coll & Hosp, Christian Dent Coll, Dept Oral & Maxillofacial Surg, Ludhiana, Punjab, India		Gandhi, S (corresponding author), Christian Med Coll & Hosp, Christian Dent Coll, Dept Oral & Maxillofacial Surg, Ludhiana, Punjab, India.	sumirgandhi@gmail.com	Gandhi, Sumir/AAU-9555-2020; Solanki, Manisha/ABB-8078-2020; Singh, Inderjot/ABB-6281-2020	Solanki, Manisha/0000-0003-4766-574X; Singh, Inderjot/0000-0003-1863-3546; Gandhi, Sumir/0000-0002-3956-5768			Al-Khateeb T, 2007, J ORAL MAXIL SURG, V65, P1094, DOI 10.1016/j.joms.2006.09.013; Arosarena OA, 2009, ARCH FACIAL PLAST S, V11, P48, DOI 10.1001/archfacial.2008.507; Bakardjiev A, 2007, J CRANIO MAXILL SURG, V35, P147, DOI 10.1016/j.jcms.2007.01.005; Bither S, 2008, DENT TRAUMATOL, V24, P468, DOI 10.1111/j.1600-9657.2008.00606.x; Cheema SA, 2006, BRIT J ORAL MAX SURG, V44, P232, DOI 10.1016/j.bjoms.2005.05.017; Eggensperger NM, 2006, J ORAL MAXIL SURG, V64, P270, DOI 10.1016/j.joms.2005.10.016; Kieser J, 2002, INT J ORAL MAX SURG, V31, P206, DOI 10.1054/ijom.2002.0208; Klenk G, 2003, J CRANIOFAC SURG, V14, P78, DOI 10.1097/00001665-200301000-00014; Lee JH, 2010, J CRANIO MAXILL SURG, V38, P192, DOI 10.1016/j.jcms.2009.06.002; Oji C, 1999, BRIT J ORAL MAX SURG, V37, P106, DOI 10.1054/bjom.1997.0083; Reddy C., 2008, INDIAN J DENT RES, V19, P304; SAWHNEY CP, 1988, BRIT J ORAL MAX SURG, V26, P430, DOI 10.1016/0266-4356(88)90097-6; Subhashraj K, 2007, BRIT J ORAL MAX SURG, V45, P637, DOI 10.1016/j.bjoms.2007.03.012; Ugboko VI, 2002, BRIT J ORAL MAX SURG, V40, P433, DOI 10.1016/S0266-4356(02)00181-X; van Beek GJ, 1999, INT J ORAL MAX SURG, V28, P424, DOI 10.1016/S0901-5027(99)80055-1	15	38	41	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1600-4469			DENT TRAUMATOL	Dent. Traumatol.	AUG	2011	27	4					257	262		10.1111/j.1600-9657.2011.00996.x			6	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	790RS	WOS:000292607500003	21635691				2022-02-06	
J	Clarner, T; Parabucki, A; Beyer, C; Kipp, M				Clarner, T.; Parabucki, A.; Beyer, C.; Kipp, M.			Corticosteroids Impair Remyelination in the Corpus Callosum of Cuprizone-Treated Mice	JOURNAL OF NEUROENDOCRINOLOGY			English	Article						glucocorticoid; dexamethasone; oligodendrocyte; corpus callosum; myelin	CENTRAL-NERVOUS-SYSTEM; LYSOLECITHIN-INDUCED DEMYELINATION; BRAIN-BARRIER PERMEABILITY; MULTIPLE-SCLEROSIS; PROGENITOR CELLS; THYROID-HORMONE; GROWTH-FACTORS; MATTER PATHOLOGY; MYELIN REPAIR; RAT	Corticosteroids (CS) are effective in the treatment of many brain disorders, such as multiple sclerosis (MS) or traumatic brain injury. This has been scrutinised in different experimental animal models. However, neither the mechanisms, nor the site of CS action are fully understood. Short-term high-dose CS treatment improves MS symptoms and severity of clinical disability during an acute inflammatory exacerbation of disease. In the present study, we analysed the influence of CS on the expression of cellular and molecular markers of spontaneous endogenous remyelination in the toxic non-immune cuprizone animal model at early (9 days) and intermediate (21 days) remyelination, as well as steroidal effects in primary astrocytes and oligodendrocyte progenitor cultures. Dexamethasone (Dex) and methylprednisolone (MP) induced a higher expression of the differentiation markers myelin basic protein and proteolipid protein (PLP) in cultured oligodendrocyte progenitor cells (OPC). CS exposure of primary cultured astrocytes resulted in a greater expression of those genes involved in OPC proliferation [fibroblast growth factor 2 (FGF2) and platelet-derived growth factor (PDGF)-alpha alpha] and a reduced expression of the pro-maturation factor insulin-like growth factor 1. Pro-maturating effects of CS were completely blocked by FGF2 and PDGF-alpha alpha co-application in OPC cultures. MP treatment in vivo resulted in a reduced recovery of PLP-staining intensity, whereas the re-population of the demyelinated corpus callosum with adenomatous polyposis coli-expressing oligodendrocytes was not affected. The numbers of brain intrinsic inflammatory cells, microglia and astrocytes during remyelination were similar in placebo and MP-treated animals. Our findings suggest that treatment with CS might have, in addition to the well-known benefical effects on inflammatory processes, a negative influence on remyelination.	[Clarner, T.; Beyer, C.; Kipp, M.] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, D-52074 Aachen, Germany; [Parabucki, A.] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Neurobiol, Belgrade, Serbia		Kipp, M (corresponding author), Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, Wendlingweg 2, D-52074 Aachen, Germany.	mkipp@ukaachen.de	Kipp, Markus/K-2694-2015		Faculty of Medicine, RWTH Aachen University; Hertie-Foundation	This project was supported by the START Program (M. K.) of the Faculty of Medicine, RWTH Aachen University and by the Hertie-Foundation (M. K.). The excellent technical support by H. Helten and U. Zahn is honored.	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; ALMAZAN G, 1986, DEV NEUROSCI-BASEL, V8, P14, DOI 10.1159/000112237; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Arnett HA, 2003, J NEUROSCI, V23, P9824; BAKKER DA, 1987, J NEUROL SCI, V78, P125, DOI 10.1016/0022-510X(87)90055-4; Baracskay KL, 2002, J NEUROSCI RES, V70, P645, DOI 10.1002/jnr.10418; BARRES BA, 1994, DEVELOPMENT, V120, P1097; BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403; Biancotti JC, 2008, NEUROCHEM RES, V33, P2615, DOI 10.1007/s11064-008-9792-8; BLAKEMORE WF, 1973, J NEUROL SCI, V20, P73, DOI 10.1016/0022-510X(73)90119-6; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOHN MC, 1991, J STEROID BIOCHEM, V40, P105, DOI 10.1016/0960-0760(91)90173-3; Braun A, 2009, NEUROCHEM INT, V55, P610, DOI 10.1016/j.neuint.2009.06.004; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Chari DM, 2006, J NEUROSCI RES, V83, P594, DOI 10.1002/jnr.20763; Chesik D, 2010, NEUROSCI LETT, V468, P178, DOI 10.1016/j.neulet.2009.10.051; Ciccone A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006264.pub2; Clarner T, 2011, J MOL NEUROSCI, V43, P268, DOI 10.1007/s12031-010-9419-9; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; de Seze J, 2004, MULT SCLER J, V10, P596, DOI 10.1191/1352458504ms1079sr; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Dunlop S A, 1997, J Matern Fetal Med, V6, P309; Fernandez M, 2004, P NATL ACAD SCI USA, V101, P16363, DOI 10.1073/pnas.0407262101; Franco PG, 2008, EXP NEUROL, V212, P458, DOI 10.1016/j.expneurol.2008.04.039; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Geurts JJG, 2008, LANCET NEUROL, V7, P841, DOI 10.1016/S1474-4422(08)70191-1; Geurts JJG, 2009, J NEUROL SCI, V282, P12, DOI 10.1016/j.jns.2009.01.018; Groebe A, 2009, CEREBELLUM, V8, P163, DOI 10.1007/s12311-009-0099-3; GUMBINAS M, 1973, BIOL NEONATE, V22, P355; Halliday A M, 1981, Adv Neurol, V31, P201; Harsan LA, 2008, J NEUROSCI, V28, P14189, DOI 10.1523/JNEUROSCI.4453-08.2008; Hinkerohe D, 2010, BRAIN RES, V1329, P45, DOI 10.1016/j.brainres.2010.03.012; Holzknecht C, 2010, NEUROIMMUNOMODULAT, V17, P23, DOI 10.1159/000243082; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; Joubert L, 2010, J NEUROSCI RES, V88, P2546, DOI 10.1002/jnr.22434; Keegan BM, 2002, ANNU REV MED, V53, P285, DOI 10.1146/annurev.med.53.082901.103909; Kipp M, 2009, ACTA NEUROPATHOL, V118, P723, DOI 10.1007/s00401-009-0591-3; KOMOLY S, 1992, P NATL ACAD SCI USA, V89, P1894, DOI 10.1073/pnas.89.5.1894; KONDO A, 1987, BRAIN RES, V425, P186, DOI 10.1016/0006-8993(87)90499-9; Kramer M, 2010, J NEUROSCI METH, V187, P84, DOI 10.1016/j.jneumeth.2009.12.020; Krukowski K, 2011, BRAIN BEHAV IMMUN, V25, P239, DOI 10.1016/j.bbi.2010.07.244; KUMAR S, 1989, P NATL ACAD SCI USA, V86, P6807, DOI 10.1073/pnas.86.17.6807; Liu LP, 2010, NAT NEUROSCI, V13, P319, DOI 10.1038/nn.2491; Llanos SL, 1999, BIOCELL, V23, P29; Mason JL, 2000, J NEUROSCI, V20, P5703, DOI 10.1523/JNEUROSCI.20-15-05703.2000; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; MCKINNON RD, 1991, ANN NY ACAD SCI, V638, P378, DOI 10.1111/j.1749-6632.1991.tb49048.x; MILLER H, 1961, LANCET, V1, P127; Moore CS, 2011, J NEUROSCI RES, V89, P13, DOI 10.1002/jnr.22482; NICOLOFF JT, 1970, J CLIN INVEST, V49, P1922, DOI 10.1172/JCI106411; Njenga MK, 1999, J NEUROPATH EXP NEUR, V58, P78, DOI 10.1097/00005072-199901000-00009; Norkute A, 2010, CELLS TISSUES ORGANS, V191, P57, DOI 10.1159/000223232; Patani R, 2007, NEUROPATH APPL NEURO, V33, P277, DOI 10.1111/j.1365-2990.2007.00805.x; Patrikios P, 2006, BRAIN, V129, P3165, DOI 10.1093/brain/awl217; Pavelko KD, 1998, J NEUROSCI, V18, P2498; Pott F, 2009, BRAIN RES, V1305, P137, DOI 10.1016/j.brainres.2009.09.084; PRESTON SL, 1984, J NEUROCHEM, V42, P262, DOI 10.1111/j.1471-4159.1984.tb09727.x; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Raschke C, 2008, ANAT HISTOL EMBRYOL, V37, P95, DOI 10.1111/j.1439-0264.2007.00807.x; Richter-Landsberg C, 1998, EXP CELL RES, V244, P218, DOI 10.1006/excr.1998.4188; Shen SM, 2008, NAT NEUROSCI, V11, P1024, DOI 10.1038/nn.2172; Sloka JS, 2005, MULT SCLER J, V11, P425, DOI 10.1191/1352458505ms1190oa; SMITH KJ, 1979, NATURE, V280, P395, DOI 10.1038/280395a0; Sun YY, 2010, J NEUROSCI, V30, P9621, DOI 10.1523/JNEUROSCI.2295-10.2010; TRIARHOU LC, 1986, ARCH NEUROL-CHICAGO, V43, P121, DOI 10.1001/archneur.1986.00520020015008; Wei ZS, 2011, NEUROIMMUNOMODULAT, V18, P28, DOI 10.1159/000314736; WILBER JF, 1969, J CLIN INVEST, V48, P2096, DOI 10.1172/JCI106176; Xu J, 2009, J NEUROSCI, V29, P2022, DOI 10.1523/JNEUROSCI.2621-08.2009; Zhou Y, 2007, J NEUROCHEM, V102, P667, DOI 10.1111/j.1471-4159.2007.04535.x; Zivadinov R, 2001, NEUROLOGY, V57, P1239, DOI 10.1212/WNL.57.7.1239	71	38	38	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	JUL	2011	23	7					601	611		10.1111/j.1365-2826.2011.02140.x			11	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	788SU	WOS:000292465500007	21507085				2022-02-06	
J	Melo, JRT; Di Rocco, F; Blanot, S; Cuttaree, H; Sainte-Rose, C; Oliveira, J; Zerah, M; Meyer, PG				Tude Melo, Jose Roberto; Di Rocco, Federico; Blanot, Stephane; Cuttaree, Harry; Sainte-Rose, Christian; Oliveira-Filho, Jamary; Zerah, Michel; Meyer, Philippe G.			Transcranial Doppler can predict intracranial hypertension in children with severe traumatic brain injuries	CHILDS NERVOUS SYSTEM			English	Article						Traumatic brain injury; Brain lesion; Intracranial pressure; Cerebral perfusion pressure; Children; Transcranial Doppler	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; SUBARACHNOID HEMORRHAGE; INITIAL MANAGEMENT; SALVADOR CITY; BLOOD-FLOW; EXPERIENCE; VASOSPASM; FRANCE	Purpose The purpose of this study is to evaluate the accuracy of emergency Transcranial Doppler (TCD) to predict intracranial hypertension and abnormal cerebral perfusion pressure in children with severe traumatic brain injury (TBI). Patients and methods A descriptive and retrospective cross-sectional study was designed through data collected from medical records of children with severe TBI (Glasgow coma scale a parts per thousand currency sign8), admitted to a level I pediatric trauma center, between January 2000 and December 2005. Early TCD examination was performed upon admission, and TCD profiles were considered as altered using previously validated threshold values for diastolic velocity (< 25 cm/s) and pulsatility index (> 1.31) or when no-flow/backflow was detected. Invasive intracranial pressure (ICP) and cerebral perfusion pressure (CPP) monitoring were considered as the gold standard to measure intracranial hypertension (ICH). Statistical analyses compared TCD profiles to increased ICP (a parts per thousand yen20 mmHg) and abnormal cerebral perfusion pressure (< 50 mmHg) at admission. Results Non-invasive TCD and ICP monitoring were performed in 117 severe head-injured children. Mean age was 7.6 +/- 4.4 years, with a male prevalence (71%). Median initial Glasgow coma scale was 6. TCD had 94% of sensitivity to identify ICH at admission and a negative predict value of 95% to identify normal ICP at admission. Its sensitivity to predict abnormal cerebral perfusion pressure was 80%. Conclusions The high sensitivity of admission TCD to predict ICH and abnormal CPP after trauma demonstrates that TCD is an excellent first-line examination to determine those children who need urgent aggressive treatment and continuous invasive ICP monitoring.	[Blanot, Stephane; Cuttaree, Harry; Meyer, Philippe G.] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Pediat Surg Crit Care Unit, Paris, France; [Tude Melo, Jose Roberto; Oliveira-Filho, Jamary] Univ Fed Bahia, Sch Med, BR-41170290 Salvador, BA, Brazil; [Tude Melo, Jose Roberto; Di Rocco, Federico; Sainte-Rose, Christian; Zerah, Michel] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Dept Pediat Neurosurg, Paris, France		Melo, JRT (corresponding author), Alameda Jasmins 200,Apt 702B, BR-40296200 Salvador, BA, Brazil.	robertotude@gmail.com	ZERAH, Michel/E-6473-2012; Meyer, Philippe/ABE-4242-2020; Oliveira-Filho, Jamary/B-6441-2016; DI ROCCO, Federico/C-6343-2015	Meyer, Philippe/0000-0002-3829-6631; Oliveira-Filho, Jamary/0000-0003-1915-0423; Di Rocco, Federico/0000-0003-2145-5533	CAPES-Brazil (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	CAPES-Brazil (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) funded Jose Roberto Tude Melo's studies abroad.	Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Bardella IJ, 1999, AM FAM PHYSICIAN, V60, P1743; Bekar A, 2009, J CLIN NEUROSCI, V16, P236, DOI 10.1016/j.jocn.2008.02.008; Bekar A, 2008, NEUROL RES, V30, P465, DOI 10.1179/174313208X284269; Bellner Johan, 2005, Lakartidningen, V102, P840; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Czosnyka Marek, 1800, Neurosurg Focus, V22, pE2; De Riggo Julius, 2007, Biomedical Papers (Olomouc), V151, P285; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Figaji AA, 2009, SURG NEUROL, V72, P389, DOI 10.1016/j.surneu.2009.02.012; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Hindy-Francois C, 2009, TRANSPLANTATION, V87, P616, DOI 10.1097/TP.0b013e3181963d91; Javouhey E, 2009, PEDIATR CRIT CARE ME, V10, P472, DOI 10.1097/PCC.0b013e318198b1cb; Jesus PAP, 2006, ARQ NEURO-PSIQUIAT, V64, P207, DOI 10.1590/S0004-282X2006000200007; Melo JRT, 2004, ARQ NEURO-PSIQUIAT, V62, P711, DOI 10.1590/S0004-282X2004000400027; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; Meyer P G, 2001, Curr Opin Crit Care, V7, P81, DOI 10.1097/00075198-200104000-00005; Meyer PG, 2005, CHILD NERV SYST, V21, P133, DOI 10.1007/s00381-004-1016-1; Murillo-Cabezas F, 2002, NEUROCIRUGIA, V13, P196; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; Ng SCP, 2006, ACTA NEUROCHIR SUPPL, V96, P21; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Orliaguet GA, 1998, ANESTH ANALG, V87, P537, DOI 10.1097/00000539-199809000-00006; Orliaguet GA, 2008, PEDIATR ANESTH, V18, P455, DOI 10.1111/j.1460-9592.2008.02507.x; Philip S, 2009, CRIT CARE MED, V37, P2973, DOI 10.1097/CCM.0b013e3181a963f6; Ricard-Hibon A, 2000, ANN FR ANESTH, V19, P286; Melo JRT, 2006, ARQ NEURO-PSIQUIAT, V64, P994, DOI 10.1590/S0004-282X2006000600020; Rodriguez-Nunez A, 2008, J NEUROSURG SCI, V52, P17; SAFIN AM, 2007, ZH VOPR NEIROKHIR IM, V2, P16; Sviri GE, 2006, STROKE, V37, P2738, DOI 10.1161/01.STR.0000244765.29502.85; Takahashi K, 2008, NEUROL SURG TOKYO, V36, P901; TER MA, 2002, CRIT CARE MED, V30, P1616; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Trabold F, 2002, ANN FR ANESTH, V21, P141, DOI 10.1016/S0750-7658(01)00513-5; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Visocchi M, 2008, ACT NEUR S, V101, P137; Visocchi M, 2007, ACTA NEUROCHIR, V149, P347, DOI 10.1007/s00701-006-1102-0	41	38	40	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JUN	2011	27	6					979	984		10.1007/s00381-010-1367-8			6	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	762NU	WOS:000290487400019	21207041				2022-02-06	
J	Park, E; Gottlieb, JJ; Cheung, B; Shek, PN; Baker, AJ				Park, Eugene; Gottlieb, James J.; Cheung, Bob; Shek, Pang N.; Baker, Andrew J.			A Model of Low-Level Primary Blast Brain Trauma Results in Cytoskeletal Proteolysis and Chronic Functional Impairment in the Absence of Lung Barotrauma	JOURNAL OF NEUROTRAUMA			English	Article						electrophysiology; mild traumatic brain injury; model; neurofilament protein 200; primary blast; spectrin; white matter injury	POSTTRAUMATIC-STRESS-DISORDER; FLUID PERCUSSION INJURY; NEUROFILAMENT SUBUNITS; SHOCK-WAVE; RAT; PHOSPHORYLATION; OVERPRESSURE; ACTIVATION; PATHOLOGY; PRESSURE	Shock-wave exposure from improvised explosive devices (IEDs) has been implicated as a possible contributing factor to neurological impairment reported in combat veterans. However, evidence-based substantiation of this implication, particularly for low-level exposure in the absence of external signs of trauma, remain elusive. Accordingly, we constructed an open-ended shock tube producing a short-duration, low-amplitude shockwave. Low-level (11.5 kPa static overpressure) complex shock-wave exposure in rats resulted in no histological evidence of lung injury. By contrast, delayed cytoskeletal proteolysis of alpha II-spectrin was detected in the cortex and hippocampus by 12 h post-injury. Cell death was minimal and localized predominantly in the corpus callosum and periventricular regions. These regions, with presumably different density interfaces, exhibit biological responses to shockwaves consistent with interface turbulence described by Richtmyer-Meshkov instability. Evoked compound action potential (CAP) recordings from the corpus callosum showed a significant increase in the duration of CAP responses at 14 and 30 days post-injury, and a gradual depression in the unmyelinated fiber amplitude. Shielding the head attenuated alpha II-spectrin cytoskeletal breakdown, thus directly implicating low-level shock-wave exposure as a cause of brain injury in the rat. Despite anatomical and scaling differences in rats compared to humans, the results suggest the potential for undiagnosed traumatic brain pathologies occurring in combat veterans following shock-wave exposure.	[Baker, Andrew J.] St Michaels Hosp, Inst Med Sci,Dept Anesthesia, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; [Gottlieb, James J.] Univ Toronto, Inst Aerosp Studies, Toronto, ON, Canada; [Cheung, Bob; Shek, Pang N.] Def Res & Dev Canada DRDC, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Inst Med Sci, Dept Anesthesia, Toronto, ON M5S 1A1, Canada; [Baker, Andrew J.] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada		Baker, AJ (corresponding author), St Michaels Hosp, Inst Med Sci,Dept Anesthesia, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Cara Phelan Ctr Trauma Res, 30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca			Public Works Government Services Contract, Department of Defense Research Canada, PWGSC [W7711-078105/A]	This work is funded through the Public Works Government Services Contract, Department of Defense Research Canada, PWGSC contract #W7711-078105/A.	Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Baker W.E., 1973, EXPLOSIONS AIR; Bass CR, 2008, J TRAUMA, V65, P604, DOI 10.1097/TA.0b013e3181454ab4; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Brouillette M, 2002, ANNU REV FLUID MECH, V34, P445, DOI 10.1146/annurev.fluid.34.090101.162238; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Currey JD, 1999, J EXP BIOL, V202, P2495; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; Garner JP, 2009, WORLD J SURG, V33, P2194, DOI 10.1007/s00268-009-0105-4; Gorbunov NV, 1997, AM J PHYSIOL-LUNG C, V272, pL320, DOI 10.1152/ajplung.1997.272.2.L320; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Guy R J, 1998, J R Nav Med Serv, V84, P79; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jung CW, 2005, MOL BRAIN RES, V141, P151, DOI 10.1016/j.molbrainres.2005.08.009; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu Q, 2004, CELL MOL LIFE SCI, V61, P3057, DOI 10.1007/s00018-004-4268-8; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Meshkov E.E., 1972, FLUID DYNAM+, V4, P101, DOI 10.1007/BF01015969; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; NAMANI R, 2009, C P IEEE ENG MED BIO, V1, P1117; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rao MV, 2003, NEUROCHEM RES, V28, P1041, DOI 10.1023/A:1023259207015; RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x; RICHTMYER RD, 1960, COMMUN PUR APPL MATH, V13, P297, DOI 10.1002/cpa.3160130207; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Ruff RL, 2008, NEW ENGL J MED, V358, P2178; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Shea TB, 2008, EUR J NEUROSCI, V27, P1893, DOI 10.1111/j.1460-9568.2008.06165.x; Sihag RK, 2007, EXP CELL RES, V313, P2098, DOI 10.1016/j.yexcr.2007.04.010; SLOAN SA, 1975, J FLUID MECH, V71, P769, DOI 10.1017/S0022112075002844; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taniuchi N, 2009, INT J MED SCI, V6, P1; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Yu Q, 1996, SHOCK WAVES, V6, P249	54	38	39	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					343	357		10.1089/neu.2009.1050			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600002	21142686				2022-02-06	
J	Creamer, M; Wade, D; Fletcher, S; Forbes, D				Creamer, Mark; Wade, Darryl; Fletcher, Susan; Forbes, David			PTSD among military personnel	INTERNATIONAL REVIEW OF PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; TRAUMATIC BRAIN-INJURY; GULF-WAR VETERANS; VIETNAM VETERANS; EXPOSED ADULTS; IRAQ; SOLDIERS; COMBAT; METAANALYSIS	Although symptoms characteristic of post-traumatic stress disorder (PTSD) have been noted in military personnel for many centuries, it was not until 1980 that the disorder was formally recognized and became the focus of legitimate study. This paper reviews our current state of knowledge regarding the prevalence and course of this complex condition in past and present members of the defence forces. Although rates vary across conflicts and countries, there is no doubt that PTSD affects substantial numbers of personnel and results in considerable impairment in functioning and quality of life. The paper goes on to discuss recent attempts to build resilience and to promote adjustment following deployment, noting that there is little evidence at this stage upon which to draw firm conclusions. Finally, effective treatment for PTSD is reviewed, with particular reference to the challenges posed by this population in a treatment setting.	[Creamer, Mark] Australian Ctr Posttraumat Mental Hlth, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia		Creamer, M (corresponding author), Australian Ctr Posttraumat Mental Hlth, Level 1,340 Albert St, Melbourne, Vic 3002, Australia.	markcc@unimelb.edu.au		Fletcher, Susan/0000-0001-6359-8650; Wade, Darryl/0000-0002-8079-321X; Forbes, David/0000-0001-9145-1605			Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.ajp.2007.06091491; Australian Centre for Posttraumatic Mental Health (ACPMH), 2007, AUSTR GUID TREATM AD; BISSON J, 2009, PSYCHOL TREATMENTS P; Bowles SV, 2010, MIL MED, V175, P382, DOI 10.7205/MILMED-D-10-00099; Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214; Breslau N, 2005, ARCH GEN PSYCHIAT, V62, P1343, DOI 10.1001/archpsyc.62.12.1343; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Browne T, 2007, BRIT J PSYCHIAT, V190, P484, DOI 10.1192/bjp.bp.106.030544; Cohn A, 2008, MIL MED, V173, P1151, DOI 10.7205/MILMED.173.12.1151; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2701; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-6736(10)60672-1; Fletcher S, 2010, AUST NZ J PSYCHIAT, V44, P1064, DOI 10.3109/00048674.2010.509858; Foa EB, 1998, TREATING TRAUMA RAPE; Forbes D, 2007, AUST NZ J PSYCHIAT, V41, P637, DOI 10.1080/00048670701449161; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KUBANY ES, 1995, COGN BEHAV PRACT, V2, P27, DOI 10.1016/S1077-7229(05)80004-5; Kulka R., 1988, CONTRACTUAL REPORT F, V1; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; McFarlane AC, 2009, J AFFECT DISORDERS, V118, P166, DOI 10.1016/j.jad.2009.01.017; McNally RJ, 2007, J TRAUMA STRESS, V20, P481, DOI 10.1002/jts.20257; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; National Institute for Clinical Excellence (NICE), 2005, POSTTR STRESS DIS; O'Donnell ML, 2010, PSYCHIAT RES, V176, P257, DOI 10.1016/j.psychres.2009.05.012; O'Toole BI, 2009, AM J EPIDEMIOL, V170, P318, DOI 10.1093/aje/kwp146; Orcutt HK, 2004, J TRAUMA STRESS, V17, P195, DOI 10.1023/B:JOTS.0000029262.42865.c2; Orth U, 2006, J CONSULT CLIN PSYCH, V74, P698, DOI 10.1037/0022-006X.74.4.698; Reger MA, 2009, J CLIN PSYCHIAT, V70, P1266, DOI 10.4088/JCP.08m04361; Resick P. A., 1993, COGNITIVE PROCESSING; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Rona RJ, 2007, BRIT MED J, V335, P603, DOI 10.1136/bmj.39274.585752.BE; Sareen J, 2007, PSYCHOSOM MED, V69, P242, DOI 10.1097/PSY.0b013e31803146d8; Schnurr P. P., 2004, TRAUMA HLTH PHYS HLT; Schnurr PP, 2009, CLIN PSYCHOL REV, V29, P727, DOI 10.1016/j.cpr.2009.08.006; Shay J., 1994, ACHILLES VIETNAM COM; Shay J., 2002, ODYSSEUS AM COMBAT T; Solomon Z, 2006, AM J PSYCHIAT, V163, P659, DOI 10.1176/appi.ajp.163.4.659; Spitzer RL, 2007, J ANXIETY DISORD, V21, P233, DOI 10.1016/j.janxdis.2006.09.006; Stein DJ, 2009, CNS SPECTRUMS, V14, P25; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; US Department of Veterans Affairs, 2010, FED REGISTER, P39843; *VA DOD CLIN PRACT, 2003, MAN POSTTR STRESS	50	38	39	0	16	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0954-0261			INT REV PSYCHIATR	Int. Rev. Psych.		2011	23	2					160	165		10.3109/09540261.2011.559456			6	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	755PO	WOS:000289946800006	21521085				2022-02-06	
J	Goodman, MD; Makley, AT; Huber, NL; Clarke, CN; Friend, LAW; Schuster, RM; Bailey, SR; Barnes, SL; Dorlac, WC; Johannigman, JA; Lentsch, AB; Pritts, TA				Goodman, Michael D.; Makley, Amy T.; Huber, Nathan L.; Clarke, Callisia N.; Friend, Lou Ann W.; Schuster, Rebecca M.; Bailey, Stephanie R.; Barnes, Stephen L.; Dorlac, Warren C.; Johannigman, Jay A.; Lentsch, Alex B.; Pritts, Timothy A.			Hypobaric Hypoxia Exacerbates the Neuroinflammatory Response to Traumatic Brain Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; inflammation; neuroinflammation; aeromedical evacuation; hypobaric; hypoxia	NEURON-SPECIFIC ENOLASE; GROWTH-FACTOR PRODUCTION; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; SERUM INTERLEUKIN-6; PLASMA; CHILDREN; ALTITUDE; MODEL; ASSOCIATION	Objective. To determine the inflammatory effects of time-dependent exposure to the hypobaric environment of simulated aeromedical evacuation following traumatic brain injury (TBI). Methods. Mice were subjected to a blunt TBI or sham injury. Righting reflex response (RRR) time was assessed as an indicator of neurologic recovery. Three or 24 h (Early and Delayed groups, respectively) after TBI, mice were exposed to hypobaric flight conditions (Fly) or ground-level control (No Fly) for 5 h. Arterial blood gas samples were obtained from all groups during simulated flight. Serum and cortical brain samples were analyzed for inflammatory cytokines after flight. Neuron specific enolase (NSE) was measured as a serum biomarker of TBI severity. Results. TBI resulted in prolonged RRR time compared with sham injury. After TBI alone, serum levels of interleukin-6 (IL-6) and keratinocyte-derived chemokine (KC) were increased by 6 h post-injury. Simulated flight significantly reduced arterial oxygen saturation levels in the Fly group. Post-injury altitude exposure increased cerebral levels of IL-6 and macrophage inflammatory protein-1 alpha (MIP-1 alpha), as well as serum NSE in the Early but not Delayed Flight group compared to ground-level controls. Conclusions. The hypobaric environment of aeromedical evacuation results in significant hypoxia. Early, but not delayed, exposure to a hypobaric environment following TBI increases the neuroinflammatory response to injury and the severity of secondary brain injury. Optimization of the post-injury time to fly using serum cytokine and biomarker levels may reduce the potential secondary cerebral injury induced by aeromedical evacuation. (C) 2011 Elsevier Inc. All rights reserved.	[Goodman, Michael D.; Makley, Amy T.; Huber, Nathan L.; Clarke, Callisia N.; Friend, Lou Ann W.; Schuster, Rebecca M.; Bailey, Stephanie R.; Dorlac, Warren C.; Johannigman, Jay A.; Lentsch, Alex B.; Pritts, Timothy A.] Univ Cincinnati, Coll Med, Dept Surg, Inst Mil Med, Cincinnati, OH 45267 USA; [Barnes, Stephen L.] Univ Missouri, Sch Med, Div Acute Care Surg, Columbia, MO USA		Goodman, MD (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, Inst Mil Med, Mail Locat 0558,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	goodmamd@uc.edu		Barnes, Stephen/0000-0001-6186-1435; Pritts, Timothy/0000-0003-2495-3255	United States Air Force/Henry Jackson Foundation [FA8650-05-2-6518]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008478] Funding Source: NIH RePORTER	This work is supported by the United States Air Force/Henry Jackson Foundation award FA8650-05-2-6518. This work does not reflect the views of the United States Air Force or Department of Defense.	Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bendz B, 2000, LANCET, V356, P1657, DOI 10.1016/S0140-6736(00)03165-2; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; COTTRELL JJ, 1988, CHEST, V93, P81, DOI 10.1378/chest.93.1.81; COTTRELL JJ, 1995, AVIAT SPACE ENVIR MD, V66, P126; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gopcevic A, 2007, TOHOKU J EXP MED, V211, P387, DOI 10.1620/tjem.211.387; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hartmann G, 2000, CYTOKINE, V12, P246, DOI 10.1006/cyto.1999.0533; Johannigman JA, 2008, CRIT CARE MED, V36, pS377, DOI 10.1097/CCM.0b013e31817e31e1; Johannigman JA, 2007, J TRAUMA, V62, pS35, DOI 10.1097/TA.0b013e31806540f3; Klausen T, 1997, EUR J APPL PHYSIOL, V76, P480, DOI 10.1007/s004210050278; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Mazzeo RS, 2005, EXERC IMMUNOL REV, V11, P6; MERIC E, 2008, J EMERG MED; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Rooker S, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/90123; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Zhu Tao, 2004, Chin J Traumatol, V7, P32	37	38	41	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	JAN	2011	165	1					30	37		10.1016/j.jss.2010.05.055			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	692ET	WOS:000285136000013	20850781	Green Accepted			2022-02-06	
J	Tobinick, E				Tobinick, Edward			Rapid Improvement of Chronic Stroke Deficits after Perispinal Etanercept Three Consecutive Cases	CNS DRUGS			English	Article							TUMOR-NECROSIS-FACTOR; MONTREAL COGNITIVE ASSESSMENT; TRAUMATIC BRAIN-INJURY; FACTOR-ALPHA; ACTIVATED MICROGLIA; CEREBROSPINAL-FLUID; ISCHEMIC-STROKE; GAIT SPEED; TNF; MODEL	Background: Thrombolytic therapy reduces stroke size and disability by reperfusion and salvage of ischaemic penumbra. Emerging evidence suggests that retrieved penumbra may be the site of ongoing inflammatory pathology that includes extensive microglial activation. Microglial activation may be associated with excessive levels of tumour necrosis factor (TNF) and resultant neurotoxicity. Etanercept, a potent biologic TNF antagonist, reduces microglial activation in experimental models and has been therapeutically effective in models of brain and neuronal injury. Perispinal administration of etanercept, previously reported to be beneficial for the treatment of Alzheimer's disease, may facilitate delivery of etanercept into the brain. Objective: The objective of this report is to document the initial clinical response to perispinal etanercept in the first chronic stroke cohort so treated. Methods: Three consecutive patients with stable and persistent chronic neurological deficits due to strokes that had failed to resolve despite previous treatment and rehabilitation were evaluated at an outpatient clinic. They were treated off-label with perispinal etanercept as part of the clinic's practice of medicine. Results: All three patients had chronic hemiparesis, in addition to other stroke deficits. Their stroke distributions were right middle cerebral artery (MCA), brainstem (medulla) and left MCA. The two patients with MCA strokes had both received acute thrombolytic therapy. Each of the three patients was treated with an initial dose of perispinal etanercept 13, 35 and 36 months following their acute stroke, respectively. Significant clinical improvement following perispinal etanercept administration was observed in all patients. Onset of clinical response was evident within 10 minutes of perispinal injection in all patients. Improvements in hemiparesis, gait, hand function, hemi-sensory deficits, spatial perception, speech, cognition and behaviour were noted among the patients treated. Each patient received a second perispinal etanercept dose at 22-26 days after the first dose that was followed by additional clinical improvement. Conclusions: Open-label administration of perispinal etanercept resulted in rapid neurological improvement in three consecutive patients with chronic neurological dysfunction due to strokes occurring 13-36 months earlier. These results suggest that stroke may result in chronic TNF-mediated pathophysiology that may be amenable to therapeutic intervention long after the acute event. Randomized clinical trials of perispinal etanercept for selected patients with chronic neurological dysfunction following stroke are indicated.	[Tobinick, Edward] Neurol Res Inst, Los Angeles, CA USA		Tobinick, E (corresponding author), Univ Calif Los Angeles, Sch Med, 100 UCLA Med Plaza,Suite 205, Los Angeles, CA 90095 USA.	etmd@ucla.edu		Tobinick, Edward/0000-0001-7614-499X			Atkinson HH, 2007, J GERONTOL A-BIOL, V62, P844, DOI 10.1093/gerona/62.8.844; Back T, 1998, CELL MOL NEUROBIOL, V18, P621, DOI 10.1023/A:1020265701407; Baron JC, 2005, CEREBROVASC DIS, V20, P154, DOI 10.1159/000087199; BARON JC, 1995, STROKE, V26, P2219, DOI 10.1161/01.STR.26.12.2219; Baron JC, 1999, STROKE, V30, P1150; BATSON OV, 1957, AMER J ROENTGENOL RA, V78, P195; Beattie MS, 2010, EUR J NEUROSCI, V32, P290, DOI 10.1111/j.1460-9568.2010.07343.x; Buchhave P, 2010, NEUROBIOL AGING, V31, P1877, DOI 10.1016/j.neurobiolaging.2008.10.012; Chen YM, 2010, JOINT BONE SPINE, V77, P366, DOI 10.1016/j.jbspin.2010.01.017; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clark IA, 2010, PHARMACOL THERAPEUT, V128, P519, DOI 10.1016/j.pharmthera.2010.08.007; Elfferich MD, 2010, RESPIRATION, V80, P212, DOI 10.1159/000314225; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman P J, 1990, Int Disabil Stud, V12, P119; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Griffin WST, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-3; Hughes JL, 2010, NEUROIMAGE, V49, P19, DOI 10.1016/j.neuroimage.2009.08.047; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Kang YM, 2009, CARDIOVASC RES, V83, P737, DOI 10.1093/cvr/cvp160; Kato K, 2010, J NEUROSCI RES, V88, P360, DOI 10.1002/jnr.22202; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Lechan Ronald M, 2007, Acta Biomed, V78 Suppl 1, P84; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Marchand F, 2009, EUR J PAIN, V13, P673, DOI 10.1016/j.ejpain.2008.08.001; Menza M, 2010, PSYCHOSOMATICS, V51, P474, DOI 10.1176/appi.psy.51.6.474; Nadeau S, 1999, NEUROSCIENCE, V93, P1449, DOI 10.1016/S0306-4522(99)00225-0; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Park KM, 2010, CELL SIGNAL, V22, P977, DOI 10.1016/j.cellsig.2010.01.010; Pearse DD, 2004, EUR J NEUROSCI, V20, P3387, DOI 10.1111/j.1460-9568.2004.03799.x; Price CJS, 2006, STROKE, V37, P1749, DOI 10.1161/01.STR.0000226980.95389.0b; Purser JL, 2003, J GERONTOL A-BIOL, V58, P1125; Sarajarvi T, 2010, J ALZHEIMERS DIS, V21, P763, DOI 10.3233/JAD-2010-100597; SHEN CH, ANESTH ANALG; Shi JQ, 2011, BRAIN RES, V1368, P239, DOI 10.1016/j.brainres.2010.10.053; Smith T, 2007, CAN J PSYCHIAT, V52, P329, DOI 10.1177/070674370705200508; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Tobinick E, 2007, CURR ALZHEIMER RES, V4, P550, DOI 10.2174/156720507783018217; Tobinick Edward, 2006, MedGenMed, V8, P53; Tobinick E, 2010, EXPERT REV NEUROTHER, V10, P985, DOI 10.1586/ERN.10.52; Tobinick E, 2009, CNS DRUGS, V23, P713, DOI 10.2165/11310810-000000000-00000; Tobinick E, 2009, DRUG DISCOV TODAY, V14, P168, DOI 10.1016/j.drudis.2008.10.005; Tobinick EL, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-27; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Tobinick Edward L, 2009, BMC Res Notes, V2, P28; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; Walberer Maureen, 2010, Exp Transl Stroke Med, V2, P22, DOI 10.1186/2040-7378-2-22; Zaremba J, 2001, BIOMED PHARMACOTHER, V55, P258, DOI 10.1016/S0753-3322(01)00058-0; Zhang LC, 2003, BRAIN RES, V989, P1, DOI 10.1016/S0006-8993(03)03123-8	53	38	38	0	4	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs		2011	25	2					145	155		10.2165/11588400-000000000-00000			11	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	724DS	WOS:000287556900004	21254790				2022-02-06	
J	Cantu, RC; Guskiewicz, K; Register-Mihalik, JK				Cantu, Robert C.; Guskiewicz, Kevin; Register-Mihalik, Johna K.			A Retrospective Clinical Analysis of Moderate to Severe Athletic Concussions	PM&R			English	Article							COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; RECURRENT CONCUSSION; NEUROPSYCHOLOGICAL FUNCTION; COGNITIVE IMPAIRMENT; POSTURAL CONTROL; SEX-DIFFERENCES; SYMPTOMS; DEFICITS; MILD	Objective: To investigate differences in clinical outcomes on the basis of gender and age after a moderate or severe concussion in a cohort of physically active subjects examined by a single clinician. Design: A descriptive, cross-sectional, retrospective chart review of consecutive patients. Setting: Outpatient assessments by a single clinician with expertise in sports concussion. Patients: Physically active subjects seen for evaluation after a concussion experienced while participating in sports (N = 194; 215 concussions; age mean standard deviation = 19.19 +/- 8.53 years) were included. Interventions (Independent Variables): Intergroup differences and associations were examined by gender, age group (<18 years and 18+ years), and concussion grade for all outcome measures. Main Outcome Measurements: Separate chi(2) tests were used to assess associations between gender, age group, and symptom duration group (<= 7 days, 8-90 days, >90 days), the presence of depression, the presence of loss of consciousness, altered school or work, and concussion grade. Separate independent samples I-tests was used to examine differences in symptom reporting and time to recovery. Results: No association was observed between gender and any measured characteristics (P > .05). Subjects 18 years or older took longer to recover (315.77 days), compared with younger subjects (91.31 days) (t(213) = 2.01, P = .049). Older subjects also reported more concussions than did younger ones, 4.33 and 2.37, respectively (t(213) = -3.77, P < .001). Conclusions: All concussions included in this study were moderate to severe in nature as defined by the Revised Cantu Grading Scale. Contrary to existing literature regarding gender differences in concussion of a lesser severity, no gender differences were observed in this sample. Age differences were observed, with the population of subjects who were 18 years and older experiencing a greater number and duration of concussion symptoms than the younger group. Developing evidence-based return-to-play progressions and rehabilitation strategies in this population is the next frontier for concussion researchers. PM R 2010;2:1088-1093	[Cantu, Robert C.] Emerson Hosp, Dept Surg, Concord, MA 01742 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Cantu, Robert C.; Guskiewicz, Kevin; Register-Mihalik, Johna K.] Univ N Carolina, Matthew A Gfeller Sport Related Traumat Brain Inj, Dept Exercise & Sport Sci, Chapel Hill, NC USA		Cantu, RC (corresponding author), Emerson Hosp, Dept Surg, 131 ORNAC,Suite 820, Concord, MA 01742 USA.	rcantu@emersonhosp.org		Register-Mihalik, Johna/0000-0002-4229-4743; Guskiewicz, Kevin/0000-0002-8682-2130			Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cao C, 2008, IEEE T NEUR SYS REH, V16, P327, DOI 10.1109/TNSRE.2008.918422; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Datta SGS, 2009, NEUROL INDIA, V57, P594, DOI 10.4103/0028-3886.57810; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Rees RJ, 2007, NEUROREHABILITATION, V22, P229; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	32	38	38	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	DEC	2010	2	12					1088	1093		10.1016/j.pmrj.2010.07.483			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	V23SF	WOS:000208361800003	21145520				2022-02-06	
J	Allen, DN; Leany, BD; Thaler, NS; Cross, C; Sutton, GP; Mayfield, J				Allen, Daniel N.; Leany, Brian D.; Thaler, Nicholas S.; Cross, Chad; Sutton, Griffin P.; Mayfield, Joan			Memory and Attention Profiles in Pediatric Traumatic Brain Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Attention; Childhood brain insult; Head injury; Traumatic brain; Injury; Learning and Memory	INDEX SCORE PATTERNS; VERBAL-LEARNING TEST; III STANDARDIZATION SAMPLE; TEST-CHILDRENS VERSION; CLOSED-HEAD-INJURY; WISC-III; CLUSTER SUBTYPES; NEUROCOGNITIVE OUTCOMES; BEHAVIOR PROBLEMS; SHORT-TERM	Traumatic brain injury (TBI) causes heterogeneous patterns of neurocognitive deficits. In an attempt to identify homogenous subgroups within this heterogeneity, cluster analysis was used to examine memory and attention abilities as measured by the Test of Memory and Learning (TOMAL) in 300 children, 150 with TBI and 150 matched nonbrain injured controls (standardization sample [SS]). Significant differences were present between the TBI and the SS groups on all TOMAL subscale and index scores, with the TBI groups performing approximately 1.3 SD below the SS. Factor analysis of the TOMAL indicated six factors that assessed various aspects of verbal and nonverbal learning and memory, as well as attention/concentration. Cluster analyses of TOMAL factor scores indicated that a four-cluster solution was optimal for the SS group, and a five-cluster solution for the TBI group. For the TBI clusters, differences were present for clinical, achievement, neurocognitive, and behavioral variables, providing some support for the validity of the cluster solution. These findings suggest that TBI results in unique patterns of neurocognitive impairment that are not accounted for by individual differences in test performance commonly observed in normal populations. Additionally, neurocognitive profiles identified using cluster analysis may prove useful for identifying homogeneous subgroups of children with TBI that are differentiated by a number of important clinical, cognitive, and behavioral variables associated with treatment and outcomes.	[Allen, Daniel N.] Univ Nevada, Dept Psychol, Neuropsychol Res Program, Las Vegas, NV 89154 USA; [Cross, Chad] Univ Nevada, Epidemiol & Biostat Unit, Dept Environm & Occupat Hlth, Las Vegas, NV 89154 USA; [Mayfield, Joan] Our Childrens House Baylor, Dallas, TX USA		Allen, DN (corresponding author), Univ Nevada, Dept Psychol, Neuropsychol Res Program, 4505 Maryland Pkwy, Las Vegas, NV 89154 USA.	daniel.allen@unlv.edu		Allen, Daniel/0000-0003-4868-2242			Alexander AI, 2005, ARCH CLIN NEUROPSYCH, V20, P587, DOI 10.1016/j.acn.2004.12.005; Allen DN, 2007, NEUROPSYCHOLOGY, V21, P713, DOI 10.1037/0894-4105.21.6.713; Allen DN, 2010, PSYCHOL ASSESSMENT, V22, P57, DOI 10.1037/a0016056; Allen DN, 2000, J NERV MENT DIS, V188, P381, DOI 10.1097/00005053-200006000-00010; Allen DN, 2003, J INT NEUROPSYCH SOC, V9, P56, DOI 10.1017/S135561770391006X; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; BEERY KE, 2004, BEERYBUKTENICA DEV T; Black, 1992, MULTIVARIATE DATA AN; Blashfield R.K., 1984, CLUSTER ANAL; CARROWWOOLFOLK E, 1996, ORAL WRITTEN LANGUAG; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Conners C. K., 2000, CONNERS CONTINUOUS P; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P249, DOI 10.1080/13854049708400453; Crosson B., 1990, CLIN NEUROPSYCHOL, V4, P253, DOI 10.1080/13854049008401908; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Demery JA, 2002, J CLIN EXP NEUROPSYC, V24, P818, DOI 10.1076/jcen.24.6.818.8400; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 2001, ASSESSMENT, V8, P193, DOI 10.1177/107319110100800207; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Donders J, 1999, DEV NEUROPSYCHOL, V16, P163, DOI 10.1207/S15326942DN1602_2; Donders J, 2008, J CLIN EXP NEUROPSYC, V30, P741, DOI 10.1080/13803390701689595; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Duval J, 2008, J CHILD NEUROL, V23, P663, DOI 10.1177/0883073808314161; Everitt BS., 2001, CLUSTER ANAL, V4th ed; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Gil AM, 2003, J SCHOOL PSYCHOL, V41, P337, DOI 10.1016/S0022-4405(03)00085-2; Goldstein G, 1998, J INT NEUROPSYCH SOC, V4, P353, DOI 10.1017/S1355617798003531; Goldstein G, 2008, NEUROPSYCHOLOGY, V22, P301, DOI 10.1037/0894-4105.22.3.301; Goldstein G, 2010, BRAIN INJURY, V24, P625, DOI 10.3109/02699051003670882; Gross D, 2004, RES NURS HEALTH, V27, P413, DOI 10.1002/nur.20040; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lee S. W., 1994, BEHAV DISORDERS, V19, P87; LOEBER R, 1990, J CLIN CHILD PSYCHOL, V19, P136, DOI 10.1207/s15374424jccp1902_5; MALEC JF, 1993, CLIN NEUROPSYCHOL, V7, P48, DOI DOI 10.1080/13854049308401887; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; McAuley C, 2000, BRIT J SOC WORK, V30, P91, DOI 10.1093/bjsw/30.1.91; MCCONAUGHY SH, 1992, J AM ACAD CHILD PSY, V31, P932, DOI 10.1097/00004583-199209000-00023; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; MORRIS R, 1981, Journal of Clinical Neuropsychology, V3, P79, DOI 10.1080/01688638108403115; Mottram L, 2006, DEV NEUROPSYCHOL, V30, P865, DOI 10.1207/s15326942dn3003_6; Murji S, 2003, J INT NEUROPSYCH SOC, V9, P1, DOI 10.1017/S1355617703910010; Naglieri JA, 2005, ARCH CLIN NEUROPSYCH, V20, P385, DOI 10.1016/j.acn.2004.09.008; Palmer BW, 1997, NEUROPSYCHOLOGY, V11, P437, DOI 10.1037/0894-4105.11.3.437; Randazzo KV, 2003, J AM ACAD CHILD PSY, V42, P1343, DOI 10.1097/01.chi.0000085753.71002.da; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Reitan R.M., 1993, HALSTEADREITAN NEURO; REYNOLDS C. R., 2007, TEST MEMORY LEARNING; Reynolds C.R., 1994, TEST MEMORY LEARNING; REYNOLDS CR, 1994, ARCH CLIN NEUROPSYCH, V9, P553, DOI 10.1016/0887-6177(94)90042-6; Reynolds CR, 1996, ARCH CLIN NEUROPSYCH, V11, P29, DOI 10.1016/0887-6177(95)00027-5; Reynolds CR., 1992, BEHAV ASSESSMENT SYS; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Stolberg PC, 2009, ARCH CLIN NEUROPSYCH, V24, P476; TEASDALE G, 1974, LANCET, V2, P81; Thaler NS, 2010, CLIN NEUROPSYCHOL, V24, P246, DOI 10.1080/13854040903277305; THALER NS, 2010, AM COLL PROF NEUR AN; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Tiffin J., 1948, PURDUE PEGBOARD TEST; van der Heijden P, 2003, ASSESSMENT, V10, P115, DOI 10.1177/1073191103010002001; Verger K, 2001, BRAIN INJURY, V15, P211; Wexler BE, 2009, AM J PSYCHIAT, V166, P189, DOI 10.1176/appi.ajp.2008.08020258; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; WOODCOCK RW, 1989, WOODCOCKJOHNSON PSYC; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO., 2006, EXCEPTIONALITY, V14, P141, DOI DOI 10.1207/S15327035EX1403_; Young S, 2005, BRIT J CLIN PSYCHOL, V44, P47, DOI 10.1348/014466504X197769	80	38	39	0	33	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2010	25	7					618	633		10.1093/arclin/acq051			16	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	673KK	WOS:000283658500004	20667890				2022-02-06	
J	Moro, N; Sutton, RL				Moro, Nobuhiro; Sutton, Richard L.			Beneficial effects of sodium or ethyl pyruvate after traumatic brain injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article						Cell Death; Cytochrome oxidase; Ethyl pyruvate; Functional recovery; Inflammation; Microglia; Neuroprotection; Rats; Sodium pyruvate; Traumatic brain injury	CYTOCHROME-C-OXIDASE; CORTICAL CONTUSION INJURY; WIDE THERAPEUTIC WINDOW; FOCAL CEREBRAL-ISCHEMIA; HEMORRHAGIC-SHOCK; HUNTINGTONS-DISEASE; HEAD-INJURY; ANTIINFLAMMATORY MECHANISM; ENDOTHELIAL-CELLS; OXIDATIVE DAMAGE	Sodium pyruvate (SP) treatment initiated within 5 min post-injury is neuroprotective in a rat model of unilateral cortical contusion injury (CCI). The current studies examined: (1) effects of delayed SP treatments (1000 mg/kg, i.p., at 1, 12 and 24 h), (2) effects of single (1 h) or multiple (1, 12 and 24 h) ethyl pyruvate treatments (EP; at 20 or 40 mg/kg, i.p.), and (3) mechanisms of action for pyruvate effects after CCI. In Experiment 1, both SP and EP treatment(s) significantly reduced the number of dead/dying cells in the ipsilateral hippocampus (dentate hilus + CA3(c) and/or CA3(a-b) regions) at 72 h post-CCI. Pyruvate treatment (s) attenuated CCI-induced reductions of cerebral cytochrome oxidase activity at 72 h, significantly improving activity in peri-contusional cortex after multiple SP or EP treatments. Optical density measures of ipsilateral CD11b immuno-staining were significantly increased 72 h post-CCI, but these measures of microglia activation were not different from sham injury values in SP and EP groups with three post-CCI treatments. In Experiment 2, three treatments (1, 12 and 24 h) of SP (1000 mg/kg) or EP (40 mg/kg) significantly improved recovery of beam-walking and neurological scores in the first 3 weeks after CCI, and EP treatments significantly improved spatial working memory 1 week post-CCI. Ipsilateral CA3(b) neuronal loss, but not cortical tissue loss, was significantly reduced 1 month post-CCI with pyruvate treatments begun 1 h post-CCI. Thus, delayed pyruvate treatments after CCI are neuroprotective and improve neurobehavioral recovery; these effects may be mediated by improved metabolism and reduced inflammation. (C) 2010 Elsevier Inc. All rights reserved.	[Sutton, Richard L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Sutton, RL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	rsutton@mednet.ucla.edu			UCLA Brain Injury Research Center; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER	The authors thank Mr. Peter Nguyen for assistance with behavioral assessments and Ms. Sima Ghavim for her superb technical assistance in the histological analyses. This work was supported by the UCLA Brain Injury Research Center and Award Number P01NS058489 from the National Institute of Neurological Disorders and Stroke (NINDS). The content is the sole responsibility of the authors and does not necessarily represent official views of the NINDS or the National Institutes of Health.	Alvarez G, 2003, J NEUROSCI RES, V73, P260, DOI 10.1002/jnr.10648; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen W, 2010, NEUROCHEM RES, V35, P336, DOI 10.1007/s11064-009-0059-9; Cho IH, 2006, J NEUROSCI RES, V84, P1505, DOI 10.1002/jnr.21052; Choi JS, 2010, BIOCHEM BIOPH RES CO, V394, P854, DOI 10.1016/j.bbrc.2010.03.105; Dai W, 2009, BRAIN RES, V1251, P287, DOI 10.1016/j.brainres.2008.11.034; Das UN, 2006, NUTRITION, V22, P965, DOI 10.1016/j.nut.2006.05.009; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fink MP, 2007, J INTERN MED, V261, P349, DOI 10.1111/j.1365-2796.2007.01789.x; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Gonzalez SV, 2005, J NEUROCHEM, V95, P284, DOI 10.1111/j.1471-4159.2005.03365.x; Gonzalez-Falcon A, 2003, BRAIN RES, V990, P1, DOI 10.1016/S0006-8993(03)03378-X; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; Hollander M, 1999, NONPARAMETRIC STAT M; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hurd RE, 2010, MAGN RESON MED, V63, P1137, DOI 10.1002/mrm.22364; Huttemann M, 2008, NEUROSCIENCE, V151, P148, DOI 10.1016/j.neuroscience.2007.09.029; Kao KK, 2010, BIOCHEM PHARMACOL, V80, P151, DOI 10.1016/j.bcp.2010.03.007; Kashiwagi A, 1997, DIABETES, V46, P2088, DOI 10.2337/diabetes.46.12.2088; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kim HS, 2008, FREE RADICAL BIO MED, V45, P950, DOI 10.1016/j.freeradbiomed.2008.06.009; Kim JB, 2005, BRAIN RES, V1060, P188, DOI 10.1016/j.brainres.2005.08.029; Kim SW, 2010, NEUROTOX RES, V17, P39, DOI 10.1007/s12640-009-9075-4; Kim TY, 2007, EXP NEUROL, V208, P159, DOI 10.1016/j.expneurol.2007.08.013; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Lee JY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-20-j0002.2001; Lee YJ, 2004, J APPL PHYSIOL, V96, P793, DOI 10.1152/japplphysiol.00797.2003; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McNay EC, 2000, P NATL ACAD SCI USA, V97, P2881, DOI 10.1073/pnas.050583697; Mizutani A, 2010, PULM PHARMACOL THER, V23, P308, DOI 10.1016/j.pupt.2010.03.002; Mongan PD, 2003, J SURG RES, V112, P180, DOI 10.1016/S0022-4804(03)00148-3; Mongan PD, 2002, AM J PHYSIOL-HEART C, V283, pH1634, DOI 10.1152/ajpheart.01073.2001; Mongan PD, 2001, AM J PHYSIOL-HEART C, V281, pH854, DOI 10.1152/ajpheart.2001.281.2.H854; MONTGOMERY CM, 1956, J BIOL CHEM, V221, P359; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Park JH, 2007, NEUROSCI LETT, V413, P265, DOI 10.1016/j.neulet.2006.11.058; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Phelan H, 2002, J TRAUMA, V52, P675, DOI 10.1097/00005373-200204000-00010; Ryu JK, 2006, NEUROSCIENCE, V141, P1835, DOI 10.1016/j.neuroscience.2006.05.043; Ryu JK, 2003, EXP NEUROL, V183, P700, DOI 10.1016/S0014-4886(03)00214-0; Ryu JK, 2004, EXP NEUROL, V187, P150, DOI 10.1016/j.expneurol.2004.01.006; Sappington PL, 2003, SHOCK, V20, P521, DOI 10.1097/01.shk.0000092697.10326.8b; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SCHOLZ TD, 1995, AM J PHYSIOL-HEART C, V268, pH82, DOI 10.1152/ajpheart.1995.268.1.H82; Sharma AB, 2008, RESUSCITATION, V76, P108, DOI 10.1016/j.resuscitation.2007.04.028; Sharma P, 2003, BRAIN RES, V992, P104, DOI 10.1016/j.brainres.2003.08.043; Sharma P, 2010, SHOCK, V33, P532, DOI 10.1097/SHK.0b013e3181cc02b3; Sharma Pushpa, 2009, J Emerg Trauma Shock, V2, P67, DOI 10.4103/0974-2700.50739; Shen HX, 2010, NEUROBIOL DIS, V37, P711, DOI 10.1016/j.nbd.2009.12.010; Sims CA, 2001, CRIT CARE MED, V29, P1513, DOI 10.1097/00003246-200108000-00003; Suh SW, 2005, DIABETES, V54, P1452, DOI 10.2337/diabetes.54.5.1452; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tokumaru O, 2009, NEUROCHEM RES, V34, P775, DOI 10.1007/s11064-008-9871-x; Varma SD, 1998, FREE RADICAL RES, V28, P131, DOI 10.3109/10715769809065799; Verwer RWH, 2002, FASEB J, V16, P54, DOI 10.1096/fj.01-0504com; Wang Q, 2009, ANESTHESIOLOGY, V110, P1279, DOI 10.1097/ALN.0b013e3181a160d6; Wang Q, 2009, NEUROBIOL DIS, V36, P223, DOI 10.1016/j.nbd.2009.07.018; Yi JS, 2007, NEUROBIOL DIS, V26, P94, DOI 10.1016/j.nbd.2006.12.007; Yoo MH, 2004, INVEST OPHTH VIS SCI, V45, P1523, DOI 10.1167/iovs.03-1315; Yu YM, 2005, STROKE, V36, P2238, DOI 10.1161/01.STR.0000181779.83472.35; Zeng JY, 2007, ANESTHESIOLOGY, V107, P630, DOI 10.1097/01.anes.0000281898.01966.1e; Zlotnik A, 2008, NEUROCHEM RES, V33, P1044, DOI 10.1007/s11064-007-9548-x	68	38	40	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2010	225	2					391	401		10.1016/j.expneurol.2010.07.013			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	654SV	WOS:000282191500019	20670624	Green Accepted			2022-02-06	
J	Klein, Y; Donchik, V; Jaffe, D; Simon, D; Kessel, B; Levy, L; Kashtan, H; Peleg, K				Klein, Yoram; Donchik, Valery; Jaffe, Dena; Simon, Daniel; Kessel, Boris; Levy, Leon; Kashtan, Hanoch; Peleg, Kobi			Management of Patients With Traumatic Intracranial Injury in Hospitals Without Neurosurgical Service	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head injuries; Closed neurosurgery; Trauma centers; Telemedicine; Patients transfer	PROSPECTIVE MULTICENTER TRIAL; GLASGOW COMA SCALE; BRAIN-INJURY; IMPLEMENTATION	Background: Many patients with intracranial bleeding (ICB) are being evaluated in hospitals with no neurosurgical service. Some of the patients may be safely managed in the primary hospital without transferring them to a designated neurosurgical center. In Israel, there are three approaches to alert patients with ICB: mandatory transfer, remote telemedicine neurosurgical consultation, and clinical-radiologic guidelines. We evaluated the outcome of alert patients with low-risk ICB who were managed in centers without neurosurgical service. Methods: A retrospective cohort comparative study. Patients with ICB and a Glasgow Coma Score >12 were included. Low-risk ICB was defined as solitary brain contusion of <1 cm in diameter, limited small subarachnoid hemorrhage, or subdural hematoma of <5 mm in maximal width and length. The decision to transfer the patients to a neurosurgical center was based on one of the three models. Hospital A: mandatory transfer. Hospital B: telemedicine-based consultation with a remote neurosurgeon. Hospital C: clinical-radiologic algorithm-based guidelines. Primary endpoint was the neurologic outcome of patients at discharge. Results: There were 152 patients in group A, 98 patients in group B, and 73 patients in group C. All patients of group A were transferred to a neurosurgical center. Fifty-eight percent of patients from hospital B and 26% of patients from hospital C were hospitalized in the primary center despite a proven ICB. These patients were discharged without any neurologic sequel of their injury. Two patients from group B and one patient from group C needed a delayed transfer to a neurosurgical center. None of the patient needed delayed neurosurgical intervention. Conclusions: Despite the small sample size of this study, the presented data suggest that some patients with ICB can be safely and definitively managed in centers with no on-site neurosurgical service. The need for transfer may be based on telemedicine consultation or clinical-radiologic guidelines. Further larger scale studies are warranted.	[Klein, Yoram] Kaplan Med Ctr, Div Trauma & Emergency Surg, Rehovot, Israel; [Donchik, Valery] Kaplan Med Ctr, Div Vasc Surg, Rehovot, Israel; [Kashtan, Hanoch] Kaplan Med Ctr, Dept Surg B, Rehovot, Israel; [Jaffe, Dena; Peleg, Kobi] Sheba Med Ctr, Gertner Inst Epidemiol & Hlth Policy Res, Tel Hashomer, Israel; [Simon, Daniel] Sheba Med Ctr, Div Trauma, Tel Hashomer, Israel; [Kessel, Boris] Hillel Yaffe Med Ctr, Div Trauma, Hadera, Israel; [Levy, Leon] Rambam Med Ctr, Haifa, Israel		Klein, Y (corresponding author), Kaplan Med Ctr, Div Trauma & Emergency Surg, Rehovot, Israel.	yoramkl@clalit.org.il	Kashtan, Hanoch/AAU-4441-2021				Ashkenazi I, 2007, EMERG MED J, V24, P550, DOI 10.1136/emj.2006.044461; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Hangiandreou NJ, 1997, J DIGIT IMAGING, V10, P36, DOI 10.1007/BF03168652; Junck KL, 1998, J DIGIT IMAGING, V11, P159, DOI 10.1007/BF03168291; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Onzuka J, 2008, CAN J EMERG MED, V10, P205; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	9	38	38	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2010	69	3					544	548		10.1097/TA.0b013e3181c99936			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	649HX	WOS:000281760800013	20234328				2022-02-06	
J	Lee, JHT; Tigchelaar, S; Liu, J; Stammers, AMT; Streijger, F; Tetzlaff, W; Kwon, BK				Lee, Jae H. T.; Tigchelaar, Seth; Liu, Jie; Stammers, Anthea M. T.; Streijger, Femke; Tetzlaff, Wolfram; Kwon, Brian K.			Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Spinal cord injury; Minocycline; Simvastatin; Cervical contusion; Neuroprotection	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; IMPROVES FUNCTIONAL RECOVERY; WIDE THERAPEUTIC WINDOW; NERVOUS-SYSTEM INJURY; CYTOCHROME-C RELEASE; MESSENGER-RNA LEVELS; REDUCTASE INHIBITORS; MORPHOLOGICAL CONSEQUENCES; ASTROCYTE ACTIVATION	Minocycline, a commonly prescribed tetracycline antibiotic, has shown promise as a potential therapeutic agent in animal models of numerous neurologic disorders such as amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, stroke, and spinal cord injury (SCI). Simvastatin is one of many hydroxymethylglutaryl-coenzyme-A reductase inhibitors prescribed to lower cholesterol. These drugs are also known to reduce inflammation and oxidative stress, improve endothelial function, and modulate the immune system in stroke, traumatic brain injury, and SCI. As both drugs have translational potential, we evaluated their neuroprotective properties here in a clinically relevant model of contusive cervical spinal cord injury. Sprague-Dawley rats underwent a unilateral cervical contusion SCI at C5 and were randomized to receive: 1. Minocycline 90 mg/kg x 3 days, 2. Simvastatin 20 mg/kg x 7 days, 3. Simvastatin 20 mg/kg x 7 days then 5 mg/kg x 35 days, or 4. Saline (Control). Behavioral recovery was assessed over 6 weeks using the horizontal ladder test, cylinder rearing test, modified Montoya staircase test and grooming test Forepaw sensitivity was also assessed using the electronic von Frey Aesthesiometer. The corticospinal and rubrospinal tracts were traced and the spinal cords were harvested 7 weeks after injury. The extent of gray matter and white matter sparing and corticospinal and rubrospinal tract sprouting were evaluated in cross sections of the spinal cord. In the end, neither minocycline nor simvastatin treatment was associated with improved performance on the behavioral tests, as compared to saline controls. Performance on the horizontal ladder test, cylinder rearing test, and von Frey sensory test were similar among all groups. Animals treated for 42 days with simvastatin scored significantly higher in the grooming score compared to other groups, but retrieved significantly fewer pellets on the modified Montoya staircase test than control and minocycline treated animals. Histologically, there were no significant differences in white and gray matter sparing and in the extent of corticospinal and rubrospinal sprouting between the four groups. In conclusion, both minocycline and simvastatin failed to improve functional and histological recovery in our model of contusive cervical spinal cord injury. (C) 2010 Elsevier Inc. All rights reserved.	[Kwon, Brian K.] Univ British Columbia, Dept Orthopaed, Blusson Spinal Cord Ctr, VGH,CNOSP, Vancouver, BC V5Z 1M9, Canada; [Lee, Jae H. T.; Tigchelaar, Seth; Liu, Jie; Stammers, Anthea M. T.; Streijger, Femke; Tetzlaff, Wolfram; Kwon, Brian K.] Univ British Columbia, ICORD, Vancouver, BC V5Z 1M9, Canada; [Lee, Jae H. T.; Tetzlaff, Wolfram; Kwon, Brian K.] Univ British Columbia, Dept Zool, Vancouver, BC V5Z 1M9, Canada		Kwon, BK (corresponding author), Univ British Columbia, Dept Orthopaed, Blusson Spinal Cord Ctr, VGH,CNOSP, 6th Floor,818 W 10th Ave, Vancouver, BC V5Z 1M9, Canada.	mailjae@gmail.com; sethtig@interchange.ubc.ca; jliu@icord.org; stammers@icord.org; streijger@icord.org; tetzlaff@icord.org; brian.kwon@vch.ca	Tetzlaff, Wolfram/AAY-4430-2020	Tigchelaar, Seth/0000-0002-2207-9034	Wings for Life Spinal Cord Injury Foundation; Michael Smith FoundationMichael Smith Foundation for Health Research	This work was generously supported by the Wings for Life Spinal Cord Injury Foundation. W.T. is the Rick Hansen Man in Motion Chair in spinal cord injury research. B.K.K. holds a CIHR New Investigator Award and is a Michael Smith Foundation for Health Research Scholar.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Balduini W, 2001, STROKE, V32, P2185, DOI 10.1161/hs0901.094287; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bretzner F, 2008, EUR J NEUROSCI, V28, P1795, DOI 10.1111/j.1460-9568.2008.06462.x; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Choo AMT, 2009, J NEUROSCI METH, V181, P6, DOI 10.1016/j.jneumeth.2009.04.007; Cui X, 2009, NEUROBIOL DIS, V36, P35, DOI 10.1016/j.nbd.2009.06.012; Dergham P, 2002, J NEUROSCI, V22, P6570; Dery MA, 2009, NEUROSCI LETT, V453, P73, DOI 10.1016/j.neulet.2009.01.062; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Erschbamer MK, 2005, J COMP NEUROL, V484, P224, DOI 10.1002/cne.20471; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; FELGINES C, 1994, LIFE SCI, V54, P361, DOI 10.1016/0024-3205(94)00792-6; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Girgis J, 2007, BRAIN, V130, P2993, DOI 10.1093/brain/awm245; Ha KY, 2008, EUR SPINE J, V17, P864, DOI 10.1007/s00586-008-0653-6; Holmberg E, 2008, EXP NEUROL, V214, P78, DOI 10.1016/j.expneurol.2008.07.020; Holmberg E, 2006, J NEUROTRAUM, V23, P1366, DOI 10.1089/neu.2006.23.1366; Hurlbert RJ, 2008, CAN J NEUROL SCI, V35, P41, DOI 10.1017/S031716710000754X; JOLES J, 1992, LAB ANIM, V26, P269, DOI 10.1258/002367792780745689; KASIM SE, 1992, J LIPID RES, V33, P1; Kugi M, 2002, CARDIOVASC DRUG THER, V16, P203, DOI 10.1023/A:1020692220701; KWON BK, 2010, J NEUROTRAUMA; Kwon BK, 2010, J NEUROTRAUM, V27, P21, DOI 10.1089/neu.2009.1048; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lutton C, 1999, REPROD NUTR DEV, V39, P481, DOI 10.1051/rnd:19990407; Madura T, 2004, EMBO REP, V5, P412, DOI 10.1038/sj.embor.7400117; Mahmood A, 2009, NEUROSURGERY, V65, P187, DOI 10.1227/01.NEU.0000343540.24780.D6; Mahmood A, 2008, J NEUROTRAUM, V25, P1441, DOI 10.1089/neu.2007.0495; Mann CM, 2010, EXP NEUROL, V221, P285, DOI 10.1016/j.expneurol.2009.11.006; Marchand F, 2009, EUR J PAIN, V13, P673, DOI 10.1016/j.ejpain.2008.08.001; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Nikkhah G, 1998, BEHAV BRAIN RES, V92, P85, DOI 10.1016/S0166-4328(97)00128-9; Ohsawa M, 2008, PAIN, V134, P285, DOI 10.1016/j.pain.2007.04.031; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Piao CS, 2003, J NEUROSCI RES, V73, P537, DOI 10.1002/jnr.10671; Pinzon A, 2008, BRAIN RES, V1243, P146, DOI 10.1016/j.brainres.2008.09.047; Plunet WT, 2008, EXP NEUROL, V213, P28, DOI 10.1016/j.expneurol.2008.04.011; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Shunmugavel A, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-17; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Soblosky JS, 2001, BEHAV BRAIN RES, V119, P1, DOI 10.1016/S0166-4328(00)00328-4; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wu HT, 2009, NEUROSURGERY, V65, P1087, DOI 10.1227/01.NEU.0000360130.52812.1D; Yang LC, 2003, J NEUROSCI RES, V74, P278, DOI 10.1002/jnr.10709; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	66	38	39	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2010	225	1			SI		219	230		10.1016/j.expneurol.2010.06.018			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	643ZD	WOS:000281339300028	20599974				2022-02-06	
J	Liliang, PC; Liang, CL; Lu, K; Wang, KW; Weng, HC; Hsieh, CH; Tsai, YD; Chen, HJ				Liliang, Po-Chou; Liang, Cheng-Loong; Lu, Kang; Wang, Kuo-Wei; Weng, Hui-Ching; Hsieh, Ching-Hua; Tsai, Yu-Duan; Chen, Han-Jung			Relationship between injury severity and serum tau protein levels in traumatic brain injured rats	RESUSCITATION			English	Article						Tau protein; Biomarker; Traumatic brain injury; Immunoblotting; ELISA	CORTICAL IMPACT INJURY; CLEAVED-TAU; CEREBROSPINAL-FLUID; NEURONAL DAMAGE; S-100B PROTEIN; HEAD-INJURY; MARKER; BIOMARKER	Background: Although serum tau protein levels increase following TBI, the time course is unknown. The aim of the present study was to determine whether serum tau protein levels increased in both a severity-dependent and time-dependent manner in an experimental model of rat traumatic brain injury (TBI). Methods: A total of 24 Sprague-Dawley rats were subjected to varying grades of TBI using a contusion injury model on the right parietal cortex. Enzyme-linked Immunoabsorbent Assay (ELISA) analysis for serum was performed at 15 min pre-injury, 1, 6, 24, 48, and 168 h post-injury. Immunoblotting for serum tau protein, neurological evaluation and histological observation were also performed. Results: Tau protein levels rapidly increased after 1 h in both mild and severe TBI groups (p < 0.001), and declined after 6 h. In the sham-operated group, tau protein levels did not change significantly after TBI. Tau protein levels were severity-dependent at 1 and 6 h after TBI. The levels were higher in the severe TBI group than in the mild TBI group at 1 h (p < 0.001) and 6 h (p < 0.001). Conclusions: Serum tau protein levels were severity-dependent and time-dependent at 1 and 6 h after TBI. However, the serum tau protein may not be a useful marker 24 h after TBI. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Liliang, Po-Chou; Liang, Cheng-Loong; Lu, Kang; Wang, Kuo-Wei; Tsai, Yu-Duan; Chen, Han-Jung] I Shou Univ, Dept Neurosurg, E Da Hosp, Yan Chau Shiang 824, Kaohsiung Count, Taiwan; [Weng, Hui-Ching] I Shou Univ, Dept Hlth Management, Yan Chau Shiang 824, Kaohsiung Count, Taiwan; [Hsieh, Ching-Hua] Chang Gung Univ, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg,Coll Med, Kaohsiung, Taiwan		Chen, HJ (corresponding author), I Shou Univ, Dept Neurosurg, E Da Hosp, 1 Yi Da Rd, Yan Chau Shiang 824, Kaohsiung Count, Taiwan.	ed100172@edah.org.tw			Taiwan National Science CouncilMinistry of Science and Technology, Taiwan [NSC 95-2314-B-214-006]; E-Da Hospital [EDAHP97017]	This work was supported by research grants from Taiwan National Science Council Grant NSC 95-2314-B-214-006 and E-Da Hospital EDAHP97017 to P.C. Liliang.	ARAI H, 1995, ANN NEUROL, V38, P649, DOI 10.1002/ana.410380414; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Lin JW, 2008, ACT NEUR S, V101, P113; Lin JW, 2006, SURG NEUROL, V66, pS20, DOI 10.1016/j.surneu.2006.04.005; MARION DW, 1996, NEUROTRAUMA, P767; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Sjogren M, 2001, J NEUROL NEUROSUR PS, V70, P624, DOI 10.1136/jnnp.70.5.624; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, ACT NEUR S, V81, P205; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	27	38	42	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572	1873-1570		RESUSCITATION	Resuscitation	SEP	2010	81	9					1205	1208		10.1016/j.resuscitation.2010.05.016			4	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	653TU	WOS:000282120600028	20598429				2022-02-06	
J	Kim, N; Boone, KB; Victor, T; Lu, P; Keatinge, C; Mitchell, C				Kim, Nancy; Boone, Kyle B.; Victor, Tara; Lu, Po; Keatinge, Carolyn; Mitchell, Cary			Sensitivity and Specificity of a Digit Symbol Recognition Trial in the Identification of Response Bias	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; symptom validity testing; Forensic neuropsychology	TRAUMATIC BRAIN-INJURY; SUSPECT EFFORT; NEUROPSYCHOLOGICAL ASSESSMENT; AMERICAN-ACADEMY; SCORES; METAANALYSIS; PERFORMANCE	Recently published practice standards recommend that multiple effort indicators be interspersed throughout neuropsychological evaluations to assess for response bias, which is most efficiently accomplished through use of effort indicators from standard cognitive tests already included in test batteries. The present study examined the utility of a timed recognition trial added to standard administration of the WAIS-III Digit Symbol subtest in a large sample of "real world" noncredible patients (n=82) as compared with credible neuropsychology clinic patients (n=89). Scores from the recognition trial were more sensitive in identifying poor effort than were standard Digit Symbol scores, and use of an equation incorporating Digit Symbol Age-Corrected Scaled Scores plus accuracy and time scores from the recognition trial was associated with nearly 80% sensitivity at 88.7% specificity. Thus, inclusion of a brief recognition trial to Digit Symbol administration has the potential to provide accurate assessment of response bias.	[Kim, Nancy; Keatinge, Carolyn; Mitchell, Cary] Pepperdine Univ, Los Angeles, CA USA; [Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Los Angeles, CA USA; [Victor, Tara] Calif State Univ Dominguez Hills, Dept Psychol, Carson, CA 90747 USA; [Lu, Po] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA		Boone, KB (corresponding author), 1000 S Fremont, Alhambra, CA 91803 USA.	kboone@labiomed.org	Victor, Tara/K-6581-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; BABIKIAN T, 2007, ASSESSMENT FEIGNED C; Back C., 1996, ASSESSMENT, V3, P449, DOI [https://doi.org/10.1177/107319119600300411, DOI 10.1177/107319119600300411]; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder L. M., 1992, HDB NEUROPSYCHOLOGIC, P353; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; CARROLL LJ, 2004, J REHABILITATION MED, V37, P61; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P1; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GOLDBERG HB, 2007, ASSESSMENT FEIGNED C; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682	30	38	38	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2010	25	5					420	428		10.1093/arclin/acq040			9	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	627BN	WOS:000280013100007	20562116	Bronze			2022-02-06	
J	Harris, T; Ellis, DY; Foster, L; Lockey, D				Harris, Tim; Ellis, Daniel Y.; Foster, Liz; Lockey, David			Cricoid pressure and laryngeal manipulation in 402 pre-hospital emergency anaesthetics: Essential safety measure or a hindrance to rapid safe intubation?	RESUSCITATION			English	Article						Airway; Intubation; Pre-hospital care; Cricoid pressure; Laryngeal manipulation	TRAUMATIC BRAIN-INJURY; IN-LINE STABILIZATION; TRACHEAL INTUBATION; SEQUENCE INTUBATION; ENDOTRACHEAL INTUBATION; DIFFICULT LARYNGOSCOPY; RANDOMIZED-TRIAL; INDUCTION; SPINE; MOVEMENT	Objectives: This is the first study to look at the effects of cricoid pressure/laryngeal manipulation on the laryngeal view and intubation success in the emergency or pre-hospital environment. Cricoid pressure is applied in the hope of reducing the incidence of aspiration. However the technique has never been evaluated in a randomized trial and may adversely affect laryngeal view. In order to improve intubating conditions cricoid pressure may be released and the larynx manipulated into a more favourable position. Methods: We carried out a prospective observational study to evaluate the effects of cricoid pressure and laryngeal manipulation on laryngeal view in our physician led pre-hospital trauma service. Results: 402 patients were included over a 16-month period. We intubated 98.8% patients on the first or second attempt. In 61 intubations (in 55 patients, 13.6%) the larynx required manipulation to facilitate intubation. In 22 intubations cricoid pressure was removed with the laryngeal view improving in 50%. Bimanual laryngeal manipulation was used in 25 intubations and the larynx better visualised in 60% of these. Backwards upwards rightwards pressure was applied to the larynx in 14 intubations and the laryngeal view improved in 64%. Two patients regurgitated when cricoid pressure was released. Both had prolonged periods of bag valve mask ventilation and difficult intubations. Discussion: The results suggest that cricoid pressure should be removed if the laryngeal view obtained is not sufficient to allow immediate intubation. Further manipulation of the larynx is likely to improve the chances of successful tracheal tube placement. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Harris, Tim] Royal London Hosp, Dept Emergency Med & Prehosp Care, London E11 BB, England; [Harris, Tim; Foster, Liz; Lockey, David] Londons Air Ambulance, London, England; [Ellis, Daniel Y.] Univ Coll Hosp, London, England; [Lockey, David] Frenchay Hosp, Bristol BS16 1LE, Avon, England		Harris, T (corresponding author), Royal London Hosp, Dept Emergency Med & Prehosp Care, London E11 BB, England.	tim.harris@bartsandthelondon.nhs.uk					Bernard Stephen, 2002, Emerg Med (Fremantle), V14, P406, DOI 10.1046/j.1442-2026.2002.00382.x; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; CRISWELL JC, 1994, ANAESTHESIA, V49, P900, DOI 10.1111/j.1365-2044.1994.tb04271.x; DAVIES HML, 2001, ORG REACT NY, V57, P8; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DONALDSON WF, 1993, SPINE, V18, P2020, DOI 10.1097/00007632-199310001-00015; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Dunham CM, 2003, J TRAUMA, V55, P162, DOI 10.1097/01.ta.0000083335.93868.2c; Ellis DY, 2007, ANN EMERG MED, V50, P653, DOI 10.1016/j.annemergmed.2007.05.006; Fairweather NL, 2003, ANAESTH INTENS CARE, V31, P451, DOI 10.1177/0310057X0303100415; Gabbott DA, 1997, ANAESTHESIA, V52, P586, DOI 10.1111/j.1365-2044.1997.138-az0131.x; Haslam N, 2005, ANAESTHESIA, V60, P41, DOI 10.1111/j.1365-2044.2004.04010.x; Helliwell V, 2001, RESUSCITATION, V49, P53, DOI 10.1016/S0300-9572(00)00307-5; Helm M, 2006, BRIT J ANAESTH, V96, P67, DOI 10.1093/bja/aei275; Jacoby J, 2006, ANN EMERG MED, V47, P525, DOI 10.1016/j.annemergmed.2005.12.009; KNILL RL, 1993, CAN J ANAESTH, V40, P279, DOI 10.1007/BF03037041; Levitan RM, 2006, ANN EMERG MED, V47, P548, DOI 10.1016/j.annemergmed.2006.01.013; Mackay CA, 2001, EMERG MED J, V18, P20, DOI 10.1136/emj.18.1.20; MILLS P, 1988, ANAESTHESIA, V43, P788, DOI 10.1111/j.1365-2044.1988.tb05760.x; Putland J, 1998, ANAESTHESIA, V53, P313; Reid C, 2004, EMERG MED J, V21, P296, DOI 10.1136/emj.2003.007344; SAMS J, 1999, EMERGEN MED, V11, P84; SELLICK BA, 1961, LANCET, V2, P404; Stevenson AGM, 2007, EMERG MED J, V24, P394, DOI 10.1136/emj.2006.041988; Takahata O, 1997, ANESTH ANALG, V84, P419, DOI 10.1097/00000539-199702000-00033; Vanner R G, 1992, Int J Obstet Anesth, V1, P195, DOI 10.1016/0959-289X(92)80005-D; Vanner RG, 1999, ANAESTHESIA, V54, P1, DOI 10.1046/j.1365-2044.1999.00756.x; WALLS RM, 2000, EMERGENCY AIRWAY MAN	30	38	39	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUL	2010	81	7					810	816		10.1016/j.resuscitation.2010.02.023			7	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	623RC	WOS:000279758500009	20398995				2022-02-06	
J	Ferrier-Auerbach, AG; Erbes, CR; Polusny, MA; Rath, CM; Sponheim, SR				Ferrier-Auerbach, Amanda G.; Erbes, Christopher R.; Polusny, Melissa A.; Rath, Col Michael; Sponheim, Scott R.			Predictors of emotional distress reported by soldiers in the combat zone	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						PTSD; Trauma; Brain injury; Depression; Military; Stress	MENTAL-HEALTH PROBLEMS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; IRAQ; AFGHANISTAN; DEPLOYMENT	Objective: Few studies have examined rates of distress of military personnel during deployment to a war zone. Our study sought to (a) identify rates of self-reported posttraumatic stress disorder (PTSD) and depression symptoms during combat deployment, (b) characterize higher order dimensions of emotional distress experienced by soldiers during deployment, and (c) identify predictors of these dimensions of emotional distress. Method: Participants were 2677 National Guard soldiers deployed as part of Operation Iraqi Freedom in 2006-07. We performed a principal components factor analysis on items of the PTSD Checklist - Military Version and the Beck Depression Inventory to identify dimensions of emotional distress, followed by multiple regression analyses to identify factors that predicted these dimensions of distress. Results: Rates of PTSD and depression in our sample were 7% and 9%, respectively. Five dimensions of emotional distress emerged: negative affect/cognitions, trauma-specific re-experiencing and avoidance, vegetative symptoms, loss of interest/numbing symptoms, and arousal/irritability. Two dimensions, trauma-specific symptoms and arousal/irritability, appeared to be more indicative of trauma sequelae, while the other three dimensions were more indicative of depressive symptoms. Demographic factors, combat exposure (including injury and exposure to explosive blast), and attitudinal variables predicted trauma-specific aspects of distress. Symptoms characteristic of depression or generalized distress were predicted by female gender, recent prior deployment, and attitudinal factors but were not predicted by blast exposure or injury. Conclusions: These findings suggest specific targets for contextual and individual interventions to reduce deployment-related distress and point out the need for longitudinal follow-up to determine long-term implications for post-deployment functioning. Published by Elsevier Ltd.	[Ferrier-Auerbach, Amanda G.; Erbes, Christopher R.; Polusny, Melissa A.; Sponheim, Scott R.] Minneapolis VA Med Ctr, Minneapolis, MN USA; [Erbes, Christopher R.; Polusny, Melissa A.; Sponheim, Scott R.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA; [Polusny, Melissa A.] Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Rath, Col Michael] Adjutant Gen Off, Minnesota Army Natl Guard, St Paul, MN USA; [Sponheim, Scott R.] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA		Polusny, MA (corresponding author), VA Med Ctr 116A6,1 Vet Dr, Minneapolis, MN 55417 USA.	melissa.polusny@va.gov	Polusny, Melissa Anderson/N-8112-2014; Sponheim, Scott/J-3857-2017; Polusny, Melissa/X-8158-2019	Polusny, Melissa Anderson/0000-0002-4932-305X; Sponheim, Scott/0000-0002-2782-0856; Polusny, Melissa/0000-0002-4932-305X	VA HSR&D Rapid Response [08-252]	The authors would like to acknowledge MAJOR Cora Courage, PsyD, Minnesota Army National Guard for her consultation on troops' in-theater attitudes and for her assistance in data collection; James Hoelzle, PhD, for his statistical consultation; and Courtney Duffy, BA and Robyn Campbell, BA for their assistance in survey processing and data management. Ms. Campbell was employed as a research assistant funded by VA HSR&D Rapid Response Project #08-252; none of the other individuals acknowledged above were compensated for their assistance. The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Army or the Department of Defense.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Byrne BM, 2005, J PERS ASSESS, V85, P17, DOI 10.1207/s15327752jpa8501_02; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; Cigrang J.A., 2005, PRAGMATIC CASE STUD, V1, P1, DOI [10.14713/pcsp.v1i2.857, DOI 10.14713/PCSP.V1I2.857]; Gray MJ, 2004, J CONSULT CLIN PSYCH, V72, P909, DOI 10.1037/0022-006X.72.5.909; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; KENNEDY H, 2009, US SOLDIER ATTACKS F; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; KOENEN KC, 2009, J TRAUMA STRESS, P1; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P1390, DOI 10.1176/appi.ajp.161.8.1390; Ramchand R, 2008, INVISIBLE WOUNDS WAR, P35; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Tanielian T., 2008, INVISIBLE WOUNDS WAR; *USA SURG GEN, 2006, OP IR FREED MENT HLT; *USA SURG GEN, 2008, OP IR FREED MENT HLT; *USA SURG GEN, 2005, OP IR FREED OIF 2 ME; *USA SURG GEN, 2003, OP IR FREED OIF MENT; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P441, DOI 10.1023/A:1007781107513; WEATHERS FW, 1993, P ANN M INT SOC TRUM	25	38	44	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	MAY	2010	44	7					470	476		10.1016/j.jpsychires.2009.10.010			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	603XA	WOS:000278240200009	19939409				2022-02-06	
J	Jungner, M; Grande, PO; Mattiasson, G; Bentzer, P				Jungner, Marten; Grande, Per-Olof; Mattiasson, Gustav; Bentzer, Peter			Effects on Brain Edema of Crystalloid and Albumin Fluid Resuscitation after Brain Trauma and Hemorrhage in the Rat	ANESTHESIOLOGY			English	Article							COLLOID ONCOTIC PRESSURE; CLOSED-HEAD TRAUMA; CEREBRAL BLOOD-FLOW; INTRACRANIAL-PRESSURE; HYPERTONIC SALINE; PLASMA OSMOLALITY; CRYOGENIC INJURY; VOLUME; PERMEABILITY; HETASTARCH	Background: It has been hypothesized that resuscitation with crystalloids after brain trauma increases brain edema compared with colloids, but previous studies on the subject have been inconclusive. To test this hypothesis, the authors compared groups resuscitated with either colloid or crystalloid. Methods: After fluid percussion injury, rats were subjected to a controlled hemorrhage of 20 ml/kg and were randomized to 5% albumin at 20 ml/kg (A20), isotonic Ringer's acetate at 50 ml/kg (C50), or 90 ml/kg (C90). After 3 or 24 h, water content in the injured cortex was determined using a wet/dry weight method. Blood volume was calculated from plasma volume, measured by I-125-albumin dilution, and hematocrit. Oncotic pressure and osmolality were measured with osmometers. Results: At 3 h, blood volume was equal in the A20 and C90 groups and lower in the C50 group. Oncotic pressure was reduced by 35-40% in the crystalloid groups and unchanged in the albumin group. Cortical water content in the A20 group was lower than in the C90 group (81.3 +/- 0.5% vs. 82.1 +/- 1.1%, P < 0.05), but it was not different from the C50 group (81.8 +/- 1.1%). At 24 h, oncotic pressure and blood volume were normalized in all groups, and cortical water content was significantly lower in the albumin group than in the crystalloid groups. Osmolality and arterial pressure were equal in all groups throughout the experiment. Conclusions: When given to the same intravascular volume expansion, isotonic crystalloids caused greater posttraumatic brain edema than 5% albumin at 3 and 24 h after trauma.	[Jungner, Marten; Grande, Per-Olof; Mattiasson, Gustav; Bentzer, Peter] Univ Lund Hosp, Dept Anesthesiol & Intens Care, SE-22185 Lund, Sweden		Jungner, M (corresponding author), Univ Lund Hosp, Dept Anesthesiol & Intens Care, SE-22185 Lund, Sweden.	marten.jungner@med.lu.se			Swedish Research Council (Stockholm, Sweden)Swedish Research Council [11581]; Medical Faculty of Lund University (Lund, Sweden); Region Skane (ALF) (Lund, Sweden); Anna and Edwin Berger Foundation (Lidingo, Sweden)	Received from the Department of Anesthesiology and Intensive Care, Lund University Hospital, Lund, Sweden. Submitted for publication July 13, 2009. Accepted for publication December 30, 2009. Supported by grants from the Swedish Research Council (grant 11581) (Stockholm, Sweden), the Medical Faculty of Lund University (Lund, Sweden), Region Skane (ALF) (Lund, Sweden), and the Anna and Edwin Berger Foundation (Lidingo, Sweden).	Beaumont A, 2002, ACT NEUR S, V81, P217; Bentzer P, 2003, J NEUROTRAUM, V20, P447, DOI 10.1089/089771503765355522; Bentzer P, 2001, J NEUROTRAUM, V18, P275, DOI 10.1089/08977150151070919; Bernard F, 2008, J TRAUMA, V64, P872, DOI 10.1097/TA.0b013e31803428cc; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chorny I, 1999, J NEUROSURG ANESTH, V11, P273, DOI 10.1097/00008506-199910000-00008; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Drummond JC, 1998, ANESTHESIOLOGY, V88, P993, DOI 10.1097/00000542-199804000-00020; Dubniks M, 2007, INTENS CARE MED, V33, P2192, DOI 10.1007/s00134-007-0756-2; Eilig I, 2001, ANESTH ANALG, V92, P669, DOI 10.1213/00000539-200103000-00023; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; FALK JL, 1984, ACUTE CARE, V10, P59; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; FENSTERMACHER JD, 1981, PHARMACOL THERAPEUT, V14, P217, DOI 10.1016/0163-7258(81)90062-0; FENSTERMACHER JD, 1984, VOLUME REGULATION CE, P384; Grande PO, 2008, ACTA ANAESTH SCAND, V52, P738, DOI 10.1111/j.1399-6576.2008.01688.x; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P554, DOI 10.1097/00000542-198910000-00013; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; Kirchhoff C, 2008, EUR J MED RES, V13, P511; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; LAMKE L-O, 1976, Resuscitation, V5, P93, DOI 10.1016/0300-9572(76)90029-0; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Oqvist BW, 1999, NEPHROL DIAL TRANSPL, V14, P1898, DOI 10.1093/ndt/14.8.1898; Persson J, 2005, INTENS CARE MED, V31, P296, DOI 10.1007/s00134-004-2510-3; PODUSLO JF, 1994, P NATL ACAD SCI USA, V91, P5705, DOI 10.1073/pnas.91.12.5705; Rise IR, 1998, J NEUROSURG, V89, P454, DOI 10.3171/jns.1998.89.3.0454; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Talmor D, 1998, ANESTH ANALG, V86, P1225, DOI 10.1097/00000539-199806000-00017; TOMITA H, 1994, ACTA NEUROCHIR, P547; Unterberg AW, 1997, ACT NEUR S, V70, P106; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	39	38	40	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	MAY	2010	112	5					1194	1203		10.1097/ALN.0b013e3181d94d6e			10	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	591FL	WOS:000277284800024	20395822	Bronze			2022-02-06	
J	Kuehl, MD; Snyder, AR; Erickson, SE; McLeod, TCV				Kuehl, Matthew D.; Snyder, Alison R.; Erickson, Steven E.; McLeod, Tamara C. Valovich			Impact of Prior Concussions on Health-Related Quality of Life in Collegiate Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						brain injury; athlete; headache; outcomes; HIT-6; SF-36	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; SURVEY SF-36; GENERAL-POPULATION; NCAA CONCUSSION; HIGH-SCHOOL; SELF-REPORT; SYMPTOMS; VALIDITY	Objective: To investigate how self-reported sport-related concussion history affects health-related quality of life in collegiate athletes. Design: Cross sectional. Setting: Division I university, Division II university, and a junior college. Participants: Three hundred two collegiate athletes (210 men, 92 women). Assessment of Risk Factors: Participants completed a demographic information sheet and concussion history form; they were then grouped by number of previous self-reported concussions, designated as 0, 1-2, or 3+. Main Outcome Measures: The Medical Outcomes Short Form (SF-36) and the Headache Impact Test (HIT-6). Results: Significant differences between groups were found for the bodily pain, vitality, and social functioning subscales of the SF-36. The 3+ group had significantly lower scores for bodily pain (48.1 +/- 8.9) compared with the 1-2 group (P = 0.028, 52.1 +/- 7.7) and 0 group (P < 0.01, 53.5 +/- 8.3), for vitality (52.4 +/- 8.4) compared with the 0 group (P = 0.011, 55.9 +/- 8.6), and for social functioning (48.5 +/- 9.4) compared with the 1-2 group (P = 0.028, 51.6 +/- 7.3) and 0 group (P = 0.003, 51.9 +/- 8.1). Significant differences were noted on the HIT-6 total score. The 3+ group reported greater impact of headache (46.7 +/- 6.4) than the 1-2 group (P = 0.05, 44.6 +/- 6.4) and 0 group (P < 0.001, 42.9 +/- 5.8). The 1-2 group also had higher HIT-6 scores than the 0 group (P = 0.033). Conclusions: Results suggest that a collegiate athlete's perception of bodily pain, vitality, social functioning, and headache is adversely affected by previous sport-related concussions. However, by incorporating general and specific outcome measures into the standard evaluation of sport-related concussion, the clinician can better determine how the athlete is responding to treatment and recovery.	[McLeod, Tamara C. Valovich] AT Still Univ, Dept Interdisciplinary Hlth Sci, Athlet Training Program, Mesa, AZ 85206 USA; [Erickson, Steven E.] Arizona State Univ, Dept Sports Med, Tempe, AZ USA		McLeod, TCV (corresponding author), AT Still Univ, Dept Interdisciplinary Hlth Sci, Athlet Training Program, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722			Bayliss M., 2002, HIT 6 USERS GUIDE; Bourgeois FT, 2007, J AM MED INFORM ASSN, V14, P765, DOI 10.1197/jamia.M2134; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Heniford BT, 2008, J AM COLL SURGEONS, V206, P638, DOI 10.1016/j.jamcollsurg.2007.11.025; Honkanen K, 1999, AM J EPIDEMIOL, V150, P511; Huffman GR, 2008, J BONE JOINT SURG AM, V90A, P471, DOI 10.2106/JBJS.G.00325; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kawata AK, 2005, HEADACHE, V45, P638, DOI 10.1111/j.1526-4610.2005.05130.x; Klasser Gary D, 2005, Gen Dent, V53, P348; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McAllister DR, 2001, AM J SPORT MED, V29, P806, DOI 10.1177/03635465010290062201; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; MCLEOD TCV, 2009, BR J SPORTS MED S1, V43, P93; Ruta D A, 1994, Qual Health Care, V3, P180, DOI 10.1136/qshc.3.4.180; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Snyder AR, J SPORT REH IN PRESS; Terwindt GM, 2000, NEUROLOGY, V55, P624, DOI 10.1212/WNL.55.5.624; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; Tkachuk GA, 2003, HEADACHE, V43, P950, DOI 10.1046/j.1526-4610.2003.03185.x; Ware J.E., 2008, USERS MANUAL SF 36V2; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	37	38	38	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2010	20	2					86	91		10.1097/JSM.0b013e3181cf4534			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	567XK	WOS:000275481500003	20215889				2022-02-06	
J	Kumar, A; Singh, RL; Babu, GN				Kumar, Alok; Singh, Ram Lakhan; Babu, G. Nagesh			Cell death mechanisms in the early stages of acute glutamate neurotoxicity	NEUROSCIENCE RESEARCH			English	Article						Caspases; Bcl-2 family; GSH; ROS; Peroxynitrite; Nitric oxide synthase	TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; OXIDATIVE STRESS; TRANSGENIC MICE; MOUSE MODEL; BCL-2; RECEPTORS; NEURONS; RAT; BAX	The present study focused on the early stages of acute glutamate (L-Glu)-induced neurotoxic mechanisms, both biochemical, e.g intracellular reactive oxygen species (ROS) and associated parameters as well as gene expression of cell survival/death pathways, i.e Bcl-2 and caspases Stereotactic intracortical injections of L-Glu (1 mu mol/1 mu l) resulted in decreased size of pyramidal neurons in rat after 1 h We also observed that intracellular ROS, calcium (Ca(2+)) and peroxynitrite (ONOO(-)) production were significantly elevated, whereas, mitochondrial transmembrane potential (Delta Psi m) and total glutathione were significantly decreased by L-Glu bolus. The Bcl-2/Bax ratio in the I: Glu-injected rats was found to be significantly lower than the controls. Moreover, acute L-Glu significantly induced mRNA expression of nNOS, iNOS, caspase-3 and caspase-9 It may be concluded from the present Study that acute L-Glu administration, at an early stage. increases intracellular ROS accumulation, Ca(2+) levels and peroxynitrite production and decreases glutathione pool Furthermore, it appears that decreased mitochondrial Bcl-2/Bax ratio might have upregulated the mRNA expression of caspase-3 and caspase-9 which launch cell death cascade. Regarding the chronology of the events. we presume that acute L-GILT increases ROS and decreases Delta Psi m and glutathione rapidly and it is more likely that these events precede gene expression changes, ultimately resulting in neuronal damage/death (C) 2009 Elsevier Ireland Ltd anti the Japan Neuroscience Society All rights reserved	[Kumar, Alok; Babu, G. Nagesh] Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurol, Lucknow 226014, Uttar Pradesh, India; [Singh, Ram Lakhan] Dr RML Avadh Univ, Dept Biochem, Faizabad, Uttar Pradesh, India		Babu, GN (corresponding author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurol, Raebareh Rd, Lucknow 226014, Uttar Pradesh, India.			SINGH, RAM LAKHAN/0000-0002-1371-2600	Council of Scientific and Industrial Research, New Delhi, IndiaCouncil of Scientific & Industrial Research (CSIR) - India	We acknowledge the Council of Scientific and Industrial Research, New Delhi, India for financial support to A.K. in the form of a Senior Research Fellowship	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BREHE JE, 1976, ANAL BIOCHEM, V74, P189, DOI 10.1016/0003-2697(76)90323-7; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Dohare P, 2008, NITRIC OXIDE-BIOL CH, V19, P1, DOI 10.1016/j.niox.2008.04.020; Duan Y, 2007, J PHYSL, V15, P741; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Ha JS, 2009, BRAIN RES, V1273, P138, DOI 10.1016/j.brainres.2009.03.050; Hara A, 1996, VIRCHOWS ARCH, V429, P249; Hochman A, 1998, J NEUROCHEM, V71, P741; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Oyama Y, 1996, BRAIN RES, V728, P121; Pavlovic V, 2009, BRATISL MED J, V110, P205; Pellegrini-Giampietro DE, 2003, TRENDS PHARMACOL SCI, V24, P461, DOI 10.1016/S0165-6147(03)00231-1; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Sagara Y, 1998, J NEUROSCI, V18, P6662; Salakou S, 2007, IN VIVO, V21, P123; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Yang LC, 1998, J NEUROSCI, V18, P8145; Zimmermann AK, 2007, J BIOL CHEM, V282, P29296, DOI 10.1074/jbc.M702853200	26	38	39	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0168-0102			NEUROSCI RES	Neurosci. Res.	MAR	2010	66	3					271	278		10.1016/j.neures.2009.11.009			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	570WJ	WOS:000275708800006	19944120				2022-02-06	
J	McLeod, TCV; Gioia, GA				McLeod, Tamara C. Valovich; Gioia, Gerard A.			Cognitive Rest: The Often Neglected Aspect of Concussion Management	ATHLETIC THERAPY TODAY			English	Article							METAANALYSIS		[McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ USA; [McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Dept Interdisciplinary Hlth Sci, Interdisciplinary Res Lab, Mesa, AZ USA; [Gioia, Gerard A.] Childrens Natl Med Ctr, Div Pediat Neuropsychol, Rockville, MD USA; [McLeod, Tamara C. Valovich] AT Still Univ, Arizona Sch Hlth Sci, Dept Interdisciplinary Hlth Sci, CORE AT Practice Based Res Network, Mesa, AZ USA		McLeod, TCV (corresponding author), AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ USA.		Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722			Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; *CDCP, HEADS UP BRAIN INJ Y; Giza CC, 2001, J ATHL TRAINING, V36, P228; LOGAN K, 2009, ATHLETIC TRAINING SP, V1, P251; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214	8	38	38	0	5	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1078-7895			ATHLET THER TODAY	Athlet. Ther. Today	MAR	2010	15	2					1	3		10.1123/att.15.2.1			3	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	576CS	WOS:000276122200001					2022-02-06	
J	Mo, LH; Yang, ZY; Zhang, AF; Li, XG				Mo, Linhong; Yang, Zhaoyang; Zhang, Aifeng; Li, Xiaoguang			The repair of the injured adult rat hippocampus with NT-3-chitosan carriers	BIOMATERIALS			English	Article						Traumatic brain injury; Chitosan scaffold; Transplantation; Neurotrophin-3; Hippocampus; Cognitive function	NERVE GROWTH-FACTOR; SPINAL-CORD-INJURY; EXPERIMENTAL BRAIN-INJURY; NEURAL STEM-CELLS; NEUROTROPHIC FACTOR; SYNAPTIC-TRANSMISSION; FUNCTIONAL RECOVERY; REGENERATION; HYDROGEL; NEURONS	The injury of the CA1 region of the adult rat hippocampus causes cognitive impairment. In this study, animal models were established by mechanically injuring the CA1 region of the adult rat hippocampus, and into the injured area were implanted chitosan carriers loaded either with or without NT-3. Immunohistochemical and nerve tracer methods were adopted to observe the role of the above-mentioned carriers in repairing the injured brain and to observe the scar formation after the injury, and Morris water maze (MWM) tests were performed to evaluate the recovery degree of the cognitive function. The results showed that NT-3-chitosan carriers stimulated regeneration of a large amount of NF-positive nerve fiber and neuron-like cells into the injured area. The newly regenerated NF-positive nerve fibers in the injured area rebuilt a neural circuit with the contralateral CA1 region via corpus callosum. Comparison of the lesion control rats and the treated rats indicates that the chitosan carriers loaded either with or without NT-3 may significantly improve the cognitive function after the hippocampus injury. (C) 2009 Elsevier Ltd. All rights reserved.	[Mo, Linhong; Yang, Zhaoyang; Li, Xiaoguang] Capital Med Univ, Beijing Inst Neurosci, Beijing 100069, Peoples R China; [Yang, Zhaoyang; Li, Xiaoguang] Beihang Univ, Sch Biol Sci & Med Engn, Beijing 100191, Peoples R China; [Zhang, Aifeng] Capital Med Univ, Beijing Friendship Hosp, Beijing 100068, Peoples R China		Yang, ZY (corresponding author), Capital Med Univ, Beijing Inst Neurosci, 10 Youanmen Wai, Beijing 100069, Peoples R China.	yangzhaoyang@vip.sina.com; lxgchina@sina.com			National 863 Project [2006AA02A129]; Department of Science and Technology, Beijing, ChinaDepartment of Science & Technology (India) [D09080703660902]	This work was supported by the National 863 Project (Grant No.2006AA02A129), and Key Project of Department of Science and Technology (Grant No.D09080703660902), Beijing, China. The authors would like to express heartfelt thanks to Liwei Zhang, Tailing Wang, Weichang Chen, Hui Qiao, Xichao Ou, Yuewei Su and Suyu Zhong for their kind help and constructive comments.	Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BELLAMKONDA R, 1995, J BIOMED MATER RES, V29, P663, DOI 10.1002/jbm.820290514; Blesch A, 1999, J NEUROSCI, V19, P3556; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Huang WC, 2006, BIOCHEM BIOPH RES CO, V349, P963, DOI 10.1016/j.bbrc.2006.08.136; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; Li XG, 2009, BIOMATERIALS, V30, P4978, DOI 10.1016/j.biomaterials.2009.05.047; Li XG, 2009, BIOMATERIALS, V30, P1121, DOI 10.1016/j.biomaterials.2008.10.063; Liu Y, 1999, J NEUROSCI, V19, P4370; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Perez-Navarro E, 1999, NEUROSCIENCE, V91, P1257, DOI 10.1016/S0306-4522(98)00723-4; Piantino J, 2006, EXP NEUROL, V201, P359, DOI 10.1016/j.expneurol.2006.04.020; Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Riedel G, 1999, NAT NEUROSCI, V2, P898, DOI 10.1038/13202; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Tian WM, 2005, J CONTROL RELEASE, V102, P13, DOI 10.1016/j.jconrel.2004.09.025; Tokura S, 1996, MACROMOL SYMP, V101, P389, DOI 10.1002/masy.19961010144; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Woerly S, 1999, TISSUE ENG, V5, P467, DOI 10.1089/ten.1999.5.467; Woerly S, 2001, J NEUROSCI RES, V66, P1187; Zhang HZ, 2007, BRAIN RES, V1132, P29, DOI 10.1016/j.brainres.2006.09.117; ZHOU XF, 1994, BRAIN RES, V643, P162, DOI 10.1016/0006-8993(94)90022-1	32	38	45	2	27	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	MAR	2010	31	8					2184	2192		10.1016/j.biomaterials.2009.11.078			9	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	563WR	WOS:000275167300023	20022104				2022-02-06	
J	Walker, AJ; Nott, MT; Doyle, M; Onus, M; McCarthy, K; Baguley, IJ				Walker, Alexandra J.; Nott, Melissa T.; Doyle, Margaret; Onus, Margaret; McCarthy, Kathleen; Baguley, Ian J.			Effectiveness of a group anger management programme after severe traumatic brain injury	BRAIN INJURY			English	Article						Anger management; cognitive behaviour therapy; group intervention; acquired brain injury; challenging behaviour	AGGRESSIVE-BEHAVIOR; CHALLENGING BEHAVIORS; COMMUNITY SETTINGS; ADJUSTMENT; REDUCTION; PEOPLE; BURDEN; ADULTS; TBI	Primary objective: This study examined the effectiveness of a group approach to the treatment of anger management difficulties for people with severe traumatic brain injury (TBI). Research design: Repeated-measures design with convenience sampling. Method and procedure: Participants were community living clients of a tertiary brain injury service. The group programme consisted of 12 weekly sessions based on a cognitive behavioural therapy (CBT) model, with modifications to incorporate compensations for TBI-related cognitive impairment. Treatment effectiveness was measured using the State-Trait Anger Expression Inventory (STAXI), at pre-treatment, post-treatment and follow-up. Main outcomes and results: The programme was completed by 52 people across nine groups over the years 1998-2006 and 31 of these attended a follow-up session. Completion of the programme was associated with significant decreases in self-reported frequency with which anger was experienced (STAXI Trait Anger) and frequency of expression of anger (Anger Expression-Out), as well as a significant increase in reported attempts to control feelings of anger (Anger Control); changes were maintained at follow-up assessment. Conclusions: A group CBT approach shows promise as an effective community-based treatment for anger control issues after severe TBI. Future research directions should include a wait-list control group and objective rating of anger expression.	[Walker, Alexandra J.; Nott, Melissa T.; Doyle, Margaret; Onus, Margaret; McCarthy, Kathleen; Baguley, Ian J.] Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia		Walker, AJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	awalker@biru.wsahs.nsw.gov.au	Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013; Nott, Melissa T/M-6778-2018	Baguley, Ian J/0000-0001-5650-3705; Nott, Melissa T/0000-0001-7088-5826			Alderman N, 1999, BRAIN INJURY, V13, P669; ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; DAWSON H, 1993, ANGER MANAGEMENT MAN; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Demark J, 2002, BRAIN INJURY, V16, P91, DOI 10.1080/02699050110102059; FELD M, 2007, DISS ABSTR INT B, V68, P1302; Hagiliassis N, 2005, J INTELLECT DEV DIS, V30, P86, DOI 10.1080/13668250500124950; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; Kelly G., 2004, BRAIN IMPAIR, V5, DOI [10.1375/brim.5.1.42.35398, DOI 10.1375/brim.5.1.42.35398]; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Mela M, 2008, J FORENSIC PSYCHI PS, V19, P396, DOI 10.1080/14789940802164090; NOVACO RW, 1976, J CONSULT CLIN PSYCH, V44, P681, DOI 10.1037/0022-006X.44.4.681; Novaco RW., 1975, ANGER CONTROL DEV EV; O'Leary CA, 2000, BEHAV INTERVENT, V15, P205, DOI 10.1002/1099-078X(200007/09)15:3<205::AID-BIN56>3.3.CO;2-B; OROZCO M, 2005, DISS ABSTR INT B, V66, P2313; PEAT J, 2005, MED STAT GUID DAT AN; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; SCHMITZ MJ, 2006, DISS ABSTR INT B, V66, P4500; Speilberger C. D., 1988, STATE TRAIT ANGER EX; SPEILBERGER CD, 1979, STATE TRAIT ANGER EX; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Whitehouse A. M., 1994, J COGN PSYCHOTHER, V8, P141; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	34	38	39	0	12	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2010	24	3					517	524		10.3109/02699051003601721			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	574JR	WOS:000275985800007	20184408				2022-02-06	
J	Brasel, KJ; deRoon-Cassini, T; Bradley, CT				Brasel, Karen J.; deRoon-Cassini, Terri; Bradley, Ciaran T.			Injury Severity and Quality of Life: Whose Perspective Is Important?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma		Organ donation; Organ donor; Brain death; Consent; Medical ethics	MAJOR TRAUMA; FUNCTIONAL CONSEQUENCES; POSTTRAUMATIC-STRESS; MULTIPLE INJURIES; HEALTH; DETERMINANTS; CARE	Background: Ambiguity exists regarding factors that predict postinjury quality of life (QOL). We hypothesized that patient-perceived injury severity, not injury Severity Score (ISS), would be correlated with QOL in a model that included severity of post-traumatic stress disorder (PTSD) symptoms. Methods: Four hundred twenty-six trauma patients admitted to a Level I trauma center completed a questionnaire during inpatient stay and 6 months after injury. ne questionnaire assessed physical component Score and mental component score QOL with the SF-36, PTSD severity using the PTSD checklist, and used a four-point rating of perceived injury severity. ISS and demographic information were obtained from the trauma registry. Statistical analysis was done with Pear-son's correlation and multiple regressions. Results: ISS was not significantly correlated with perceived injury severity, PTSD symptom severity, physical component score, or mental component score. The majority of patients overestimated injury severity when compared with ISS. An increase in PTSD symptom severity and perceived injury severity significantly predicted both decreased physical and mental QOL at 6 months. Conclusions: ISS does not give the full picture of the severity of injury. Surgeons should consider early screening of patients for perception of injury severity and PTSD symptoms to determine which patients may need psychologic intervention to improve long-term QOL.	[Brasel, Karen J.] Med Coll Wisconsin, Dept Surg, Div Trauma Crit Care, Milwaukee, WI 53226 USA		Brasel, KJ (corresponding author), Med Coll Wisconsin, Dept Surg, Div Trauma Crit Care, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	kbrasel@mcw.edu					Aitken LM, 2007, INJURY, V38, P19, DOI 10.1016/j.injury.2006.05.020; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Breslau N, 2002, CAN J PSYCHIAT, V47, P923, DOI 10.1177/070674370204701003; DEROONCASSINI TA, 2008, 24 ISTSS ANN M CHIC; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Harris I, 2007, INJURY, V38, P1102, DOI 10.1016/j.injury.2007.05.004; Harris IA, 2008, J TRAUMA, V64, P969, DOI 10.1097/01.ta.0000245972.83948.1a; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Kiely JM, 2006, J TRAUMA, V61, P791, DOI 10.1097/01.ta.0000239360.29852.1d; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Ringdal M, 2009, J TRAUMA, V66, P1226, DOI 10.1097/TA.0b013e318181b8e3; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	21	38	39	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2010	68	2					263	267		10.1097/TA.0b013e3181caa58f			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	555FC	WOS:000274492600003	20154536				2022-02-06	
J	Luh, C; Kuhlmann, CR; Ackermann, B; Timaru-Kast, R; Luhmann, HJ; Behl, C; Werner, C; Engelhard, K; Thal, SC				Luh, Clara; Kuhlmann, Christoph R.; Ackermann, Bianca; Timaru-Kast, Ralph; Luhmann, Heiko J.; Behl, Christian; Werner, Christian; Engelhard, Kristin; Thal, Serge C.			Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						brain edema; MLCK; myosin light chain; phosphorylation; pMLC; traumatic brain injury	CONTROLLED CORTICAL IMPACT; B-2 RECEPTOR ANTAGONIST; BARRIER DISRUPTION; GENE-EXPRESSION; CEREBRAL EDEMA; MICE; PERMEABILITY; DYSFUNCTION; MODULATION; REDUCTION	The role of the endothelial contractile apparatus in the process of brain edema formation after brain trauma is not characterized. Phosphorylation of myosin light chains by myosin light chain kinases (MLCK) activates endothelial contractile elements and results in a rearrangement of the cytoskeleton. This may enhance post-traumatic blood-brain barrier dysfunction. In order to investigate the role of the MLCK on brain edema formation and blood-brain barrier permeability after brain injury, mice were anesthetized and subjected to a controlled cortical impact (CCI). MLCK expression is significantly up-regulated after CCI with a maximum 12 h post-injury. Specific inhibition of MLCK by ML-7 resulted in a reduction of phosphorylation of myosin light chains and improved blood-brain-barrier integrity. Accordingly, ML-7 attenuated posttraumatic brain edema formation and intracranial hypertension 24 h after CCI. Prevention of brain edema formation did not translate into improved neurological outcome or reduced brain lesion. In conclusion, the results confirm that the endothelial contractile apparatus is activated by CCI and opens the endothelial barrier leading to vasogenic brain edema formation. Lack of neurological and histological improvement suggests that specific targeting of vasogenic brain edema at the endothelial level is not sufficient to limit secondary brain damage and has, therefore, to be combined with other potential neuroprotective strategies.	[Luh, Clara; Timaru-Kast, Ralph; Werner, Christian; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55131 Mainz, Germany; [Luh, Clara; Kuhlmann, Christoph R.; Luhmann, Heiko J.] Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, Med Ctr, D-55131 Mainz, Germany; [Ackermann, Bianca; Behl, Christian] Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, Med Ctr, D-55131 Mainz, Germany		Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, Langenbeckstr 1, D-55131 Mainz, Germany.	thal@uni-mainz.de	Luhmann, Heiko J./N-8797-2019; Thal, Serge/D-6593-2011	Luhmann, Heiko J./0000-0002-7934-8661; Thal, Serge/0000-0002-1222-8729; Behl, Christian/0000-0001-8453-2378			Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Eutamene H, 2005, EUR RESPIR J, V25, P789, DOI 10.1183/09031936.05.00064704; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Ferrier L, 2003, GASTROENTEROLOGY, V125, P795, DOI 10.1016/S0016-5085(03)01057-6; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Haorah J, 2005, ALCOHOL CLIN EXP RES, V29, P999, DOI 10.1097/01.ALC.0000166944.79914.0A; Haorah J, 2007, J NEUROCHEM, V100, P324, DOI 10.1111/j.1471-4159.2006.04245.x; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Ishmael JE, 2008, ACTA HISTOCHEM, V110, P172, DOI 10.1016/j.acthis.2007.08.005; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Ma TY, 1999, AM J PHYSIOL-GASTR L, V276, pG965, DOI 10.1152/ajpgi.1999.276.4.G965; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083; Zweckberger K, 2009, NEUROSCI LETT, V454, P115, DOI 10.1016/j.neulet.2009.02.014	31	38	39	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2010	112	4					1015	1025		10.1111/j.1471-4159.2009.06514.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	546PH	WOS:000273822200015	19943851	Bronze			2022-02-06	
J	Chronister, J; Chan, F; Sasson-Gelman, EJ; Chiu, CY				Chronister, Julie; Chan, Fong; Sasson-Gelman, E. Joy; Chiu, Chung-Yi			The association of stress-coping variables to quality of life among caregivers of individuals with traumatic brain injury	NEUROREHABILITATION			English	Article							COMPETENCE RATING-SCALE; SOCIAL SUPPORT; FAMILY NEEDS; BURDEN; PREDICTORS; DISTRESS; HEALTH; TBI; STRATEGIES; APPRAISAL	The purpose of this study was to determine the degree to which stress-coping variables contribute to quality of life (QOL) among caregivers of individuals with traumatic brain injury (TBI). This study examined the direct effects of the following variables: functional competency, caregiving appraisal, coping, perceived social support, and family needs on QOL. In addition, the unique variance accounted for in QOL by each set was investigated, and whether perceived social support, coping, and family needs mediate or moderate the relationship between caregiving appraisal and QOL. The sample consisted of 108 caregivers recruited from support groups who were predominantly white females. The majority of care-recipients had a severe head injury. Measures administered were the Interpersonal Support Evaluation List, Family Needs Questionnaire, Modified Caregiving Appraisal Scale, and the World Health Organization Quality of Life - Brief Version. Results showed that the full model accounted for 68% of the variance in QOL; caregiving appraisal, perceived social support and family needs remained significant after other stress-coping variables were partialled; and of these sets, emotional social support, social needs, and perceived burden were the significant individual predictors. Emotional social support and social needs mediated the relationship between perceived burden and QOL.	[Chronister, Julie; Sasson-Gelman, E. Joy] San Francisco State Univ, Dept Counseling, San Francisco, CA 94131 USA; [Chan, Fong] Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA; [Chiu, Chung-Yi] Univ Texas SW Med Ctr Dallas, Dept Rehabil Counseling Psychol, Sch Hlth Profess, Dallas, TX 75390 USA		Chronister, J (corresponding author), San Francisco State Univ, Dept Counseling, 1600 Holloway Ave,Burk Hall 525, San Francisco, CA 94131 USA.	jcrhonis@sfsu.edu					Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Aneshensel C. S., 1995, PROFILES CAREGIVING; Brissette I, 2002, J PERS SOC PSYCHOL, V82, P102, DOI 10.1037//0022-3514.82.1.102; Campbell C H, 1988, Rehabil Nurs, V13, P320; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chandra Ashish, 2005, Hosp Top, V83, P33, DOI 10.3200/HTPS.83.2.33-37; Chronister J.A., 2009, PSYCHOSOCIAL INTERVE, P149; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Cohen J., 2013, STAT POWER ANAL BEHA; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; COHEN S, 1983, SOCIAL SUPPORT THEOR, P73; DOUGLAS JM, 2000, DISABILITY REHABILIT, V22, P683; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FALLOWFIELD L, 1990, QUALITY LIFE MISSING; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Folkman S., 1984, STRESS; Frazier PA, 2004, J COUNS PSYCHOL, V51, P115, DOI 10.1037/0022-0167.51.1.115; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Hoyt WT, 2008, REHABIL PSYCHOL, V53, P321, DOI 10.1037/a0013021; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Lazarus RS, 1987, EUR J PERSONAL, V1, P141, DOI [10.1002/per.2410010304, DOI 10.1002/PER.2410010304]; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Lim Jung-won, 2004, Health Qual Life Outcomes, V2, P50; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Livneh H, 2003, REHABIL COUNS BULL, V46, P194, DOI 10.1177/003435520304600401; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Moos R., 1993, HDB STRESS THEORETIC, P234; Moules S, 1999, BRAIN INJURY, V13, P983; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Skevington SM, 2004, QUAL LIFE RES, V13, P1511, DOI 10.1023/B:QURE.0000031344.53009.eb; Stebbins P, 2001, REHABIL PSYCHOL, V46, P178, DOI 10.1037/0090-5550.46.2.178; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; WORTMAN CB, 1985, SOCIAL SUPPORT HLTH, P281; [No title captured]	52	38	39	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	27	1					49	62		10.3233/NRE-2010-0580			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	629GA	WOS:000280182000005	20634600				2022-02-06	
J	de Guise, E; Lepage, JF; Tinawi, S; LeBlanc, J; Dagher, J; Lamoureux, J; Feyz, M				de Guise, Elaine; Lepage, Jean-Francois; Tinawi, Simon; LeBlanc, Joanne; Dagher, Jehane; Lamoureux, Julie; Feyz, Mitra			Comprehensive Clinical Picture of Patients with Complicated vs Uncomplicated Mild Traumatic Brain Injury	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; Neuropsychology; Neurology; Rivermead Post-Concussive Questionnaire; Early rehabilitation setting; Imaging	SEVERE HEAD-INJURY; RECOVERY; DEPRESSION; CONCUSSION; DISABILITY; VARIABLES; SEVERITY	To compare the acute clinical profile of patients with uncomplicated vs complicated mild TBI (MTBI), socio-demographic and medical history variables were gathered for 176 patients diagnosed with MTBI and with (complicated, N = 45) or without (uncomplicated, N = 131) positive findings on cerebral imaging. Neurological examination, neuropsychological assessment and self-evaluation of post-concussive symptoms were done at 2 weeks post trauma. Patients with complicated MTBI were more likely to show auditory and vestibular system dysfunction. Surprisingly, the uncomplicated group reported more severe post-concussive symptoms than patients with positive CT scans. The groups showed no other difference in neurological, psychological, or cognitive outcome. A complete neurological examination should be done acutely in patients with MTBI to determine more specific follow-up required.	[de Guise, Elaine; LeBlanc, Joanne; Feyz, Mitra] McGill Univ, Traumat Brain Injury Program, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; [de Guise, Elaine] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3G 1A4, Canada; [Lepage, Jean-Francois] Univ Montreal, Montreal, PQ, Canada; [Tinawi, Simon; Dagher, Jehane] McGill Univ, Dept Rehabil Med, Ctr Hlth, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; [Lamoureux, Julie] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, Canada		de Guise, E (corresponding author), McGill Univ, Traumat Brain Injury Program, Ctr Hlth, Montreal Gen Hosp Site,Room D13-124 1650 Cedar Av, Montreal, PQ H3G 1A4, Canada.	elaine.deguise@muhc.mcgill.ca		Lamoureux, Julie/0000-0002-4986-2504			ALTERMAN AI, 1985, INT J NEUROSCI, V28, P155, DOI 10.3109/00207458508985386; BECK AT, 1962, AM J PSYCHIAT, V119, P351, DOI 10.1176/ajp.119.4.351; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Corrigan J., 2005, PROBLEMATIC SUBSTANC; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; DUCKWORTH JL, 2010, CURRENT OPINION CRIT, V10, P1097; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Hawkins ML, 2003, AM SURGEON, V69, P497; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hooper HE., 1983, HOOPER VISUAL ORG TE; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KING N, 1995, J NEUROL, V242, P1432; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; LORNE S, 2003, CANADIAN ASS MED J, V30, P169; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCCREA MA, 2008, MILD TRAUMATIC BRAIN, P13; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Spreen O, 1991, COMPENDIUM NEUROPSYC; THIJS C, 1989, BRIT MED J, V298, P255, DOI 10.1136/bmj.298.6668.255; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Wechsler D., 1997, WAIS 3 MANUAL; Wechsler D., 1997, WMS 3 MANUAL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	44	38	38	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	7					1113	1130	PII 925983925	10.1080/13854046.2010.506199			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	659UM	WOS:000282592400002	20730678				2022-02-06	
J	Fortin, A; Lefebvre, MB; Ptito, M				Fortin, Audrey; Lefebvre, Mathilde Beaulieu; Ptito, Maurice			Traumatic brain injury and olfactory deficits: The tale of two smell tests!	BRAIN INJURY			English	Article						Olfaction; smell test; UPSIT; Alberta smell test; mild head injury	HEAD TRAUMA; IDENTIFICATION TEST; DEPRESSION; DYSFUNCTION; DISORDERS; SEVERITY; ANOSMIA; TASTE	Primary objective: Olfactory functions are not systematically evaluated following traumatic brain injury (TBI). This study aimed at comparing two smell tests that are used in a clinical setting. Research design: The University of Pennsylvania Smell Identification Test (UPSIT) and the Alberta Smell Test were compared in terms of assessment time, cost and diagnosis. Parameters associated with olfactory loss such as injury severity, type of cerebral lesion and depressive data were considered. Forty-nine TBI patients admitted to an outpatient rehabilitation programme took part in this experiment. Results: The scores of the two smell tests were significantly correlated. Both tests indicated that patients with frontal lesion performed significantly worse than patients with other types of lesion. Mood and injury severity were not associated with olfactory impairment when age was taken into account. Between 40-44% of the patients showing olfactory impairments were not aware of their deficit. Conclusions: Since a significant proportion of the patients showing olfactory impairments were not aware of their deficit, it is recommended than clinicians systematically evaluate olfactory functions using the Alberta Smell test. To refine their diagnosis, the UPSIT can also be used.	[Fortin, Audrey] Ctr Readaptat Lucie Bruneau, CRIR, Montreal, PQ, Canada; [Fortin, Audrey; Lefebvre, Mathilde Beaulieu; Ptito, Maurice] Univ Montreal, Ecole Optometrie, CRIR, Montreal, PQ H3C 3J7, Canada		Fortin, A (corresponding author), Ctr Readaptat Lucie Bruneau, CRIR, Montreal, PQ, Canada.	afortin.crlb@ssss.gouv.qc.ca	Ptito, Maurice/G-3422-2013	Ptito, Maurice/0000-0002-5173-5862	Reseau Provincial de Recherche en Adaptation-Readaptation (REPAR); National Science and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by a grant from the Reseau Provincial de Recherche en Adaptation-Readaptation (REPAR) to AF and MP. MBL is supported by the National Science and Engineering Research Council of Canada (NSERC).	BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Biacabe B, 2000, REV NEUROL-FRANCE, V156, P451; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Buschuter D, 2008, NEUROIMAGE, V42, P498, DOI 10.1016/j.neuroimage.2008.05.004; Callahan CD, 2002, J HEAD TRAUMA REHAB, V17, P251, DOI 10.1097/00001199-200206000-00006; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; CONSTANZO RM, 1991, SMELL TASTE HLTH DIS, P730; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; Doty RL, 1995, SMELL IDENTIFICATION, Vthird; Fujii M, 2002, AURIS NASUS LARYNX, V29, P35, DOI 10.1016/S0385-8146(01)00118-3; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 2001, NEUROREHABILITATION, V16, P237; MARCOTTE AC, 2005, ORIENTATIONS MINISTE; Nordin S, 2008, CURR OPIN ALLERGY CL, V8, P10, DOI 10.1097/ACI.0b013e3282f3f473; PEPIN M, 2008, TRAVAUX COMITE INT T, P27; Reiter ER, 2004, OTOLARYNG CLIN N AM, V37, P1167, DOI 10.1016/j.otc.2004.06.005; Renzi G, 2002, ANN PLAS SURG, V48, P355, DOI 10.1097/00000637-200204000-00003; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Savic I, 2000, NEURON, V26, P735, DOI 10.1016/S0896-6273(00)81209-X; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SUMNER D, 1964, BRAIN, V87, P107, DOI 10.1093/brain/87.1.107; ZASLER ND, 1992, J HEAD TRAUMA REHAB, V7, P66	25	38	39	2	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2010	24	1					27	33		10.3109/02699050903446815			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	554AA	WOS:000274406700003	20001480				2022-02-06	
J	Nirula, R; Diaz-Arrastia, R; Brasel, K; Weigelt, JA; Waxman, K				Nirula, R.; Diaz-Arrastia, R.; Brasel, K.; Weigelt, J. A.; Waxman, K.			Safety and Efficacy of Erythropoietin in Traumatic Brain Injury Patients: A Pilot Randomized Trial	CRITICAL CARE RESEARCH AND PRACTICE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; CEREBROSPINAL-FLUID; CEREBRAL-ISCHEMIA; MANAGEMENT; INFANTS; ALPHA	Background. Erythropoietin (EPO) is a neuroprotective agent utilized in stroke patients. This pilot study represents the first randomized trial of EPO in traumatic brain injury (TBI) patients. Methods. Adult, blunt trauma patients with evidence of TBI were randomized to EPO or placebo within 6 hours of injury. Baseline and daily serumS-100B and Neuron Specific Enolase (NSE) levels were measured. Results. TBI was worse in the EPO (n = 11) group compared to placebo patients (n = 5). The use of EPO did not impact NSE (P =.89) or S100 B (P =.53) levels compared to placebo. Conclusions. At the dose used, EPO did not reduce neuronal cell death compared to placebo; however, TBI severity was worse in the EPO group while levels of NSE and S100-B were similar to the less injured placebo group making it difficult to rule out a treatment effect. A larger, balanced study is necessary to confirm a potential treatment effect.	[Nirula, R.] Univ Utah, Sch Med, Div Gen Surg, 3B148,30 North 1900 East, Salt Lake City, UT 84132 USA; [Diaz-Arrastia, R.] UT Southwestern Med Ctr, Div Neurol, Dallas, TX 75390 USA; [Brasel, K.; Weigelt, J. A.] Med Coll Wisconsin, Div Trauma & Crit Care, Milwaukee, WI 53226 USA; [Waxman, K.] Santa Barbara Cottage Hosp, Dept Surg, Santa Barbara, CA 93105 USA		Nirula, R (corresponding author), Univ Utah, Sch Med, Div Gen Surg, 3B148,30 North 1900 East, Salt Lake City, UT 84132 USA.	raminder.nirula@hsc.utah.edu			American Association for the Surgery of Trauma Research and Education Foundation Scholarship Award	This research was funded by the American Association for the Surgery of Trauma Research and Education Foundation Scholarship Award.	Alafaci C, 2000, EUR J PHARMACOL, V406, P219, DOI 10.1016/S0014-2999(00)00691-9; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bedell Eric, 2002, Anesthesiol Clin North Am, V20, P417, DOI 10.1016/S0889-8537(01)00010-4; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Cerami A, 2002, NEPHROL DIAL TRANSPL, V17, P8, DOI 10.1093/ndt/17.suppl_1.8; Cerami A, 2001, SEMIN ONCOL, V28, P66, DOI 10.1053/sonc.2001.25401; Ehrenreich H, 2004, TRANSFUS APHER SCI, V31, P39, DOI 10.1016/j.transci.2004.05.001; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Grasso G, 2002, J NEUROSURG, V96, P565, DOI 10.3171/jns.2002.96.3.0565; Grasso G, 2001, J Neurosurg Sci, V45, P7; Hoffman SW, 2000, J NEUROTRAUM, V17, P415, DOI 10.1089/neu.2000.17.415; Hoffman SW, 1996, J NEUROSCI METH, V68, P133; Juul SE, 1999, PEDIATR RES, V46, P543, DOI 10.1203/00006450-199911000-00009; Kornecki A, 2002, CHILD NERV SYST, V18, P375, DOI 10.1007/s00381-002-0613-0; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Marti HH, 1997, KIDNEY INT, V51, P416, DOI 10.1038/ki.1997.55; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Phan TG, 2002, CLIN EXP PHARMACOL P, V29, P1, DOI 10.1046/j.1440-1681.2002.03609.x; Siddique MS, 2002, J NEUROSURG, V96, P736, DOI 10.3171/jns.2002.96.4.0736; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011; Yamaji R, 1996, EUR J BIOCHEM, V239, P494, DOI 10.1111/j.1432-1033.1996.0494u.x	26	38	38	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-1305	2090-1313		CRIT CARE RES PRACT	Crit. Care Res. Pract.		2010	2010								209848	10.1155/2010/209848			5	Critical Care Medicine	Emerging Sources Citation Index (ESCI)	General & Internal Medicine	V33VO	WOS:000215793100003	20948886	Green Submitted, Green Published, gold			2022-02-06	
J	Allon, N; Amir, A; Manisterski, E; Rabinovitz, I; Dachir, S; Kadar, T				Allon, Nahum; Amir, Adina; Manisterski, Eliau; Rabinovitz, Ishay; Dachir, Shlomit; Kadar, Tamar			Inhalation exposure to sulfur mustard in the guinea pig model: Clinical, biochemical and histopathological characterization of respiratory injuries	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Sulfur mustard; Guinea pig; LCt(50); FTIR; Respiratory parameters; Clinical symptoms; Histopathological evaluation; BAL; Abnormal epithelial regeneration; Recurrent lung injury	IRANIAN VETERANS; ADDUCTS; ASTHMA; MICE; DNA; COMPLICATIONS; HEMOGLOBIN; DRUGS	Guinea pigs (GP) were exposed (head only) in individual plethysmographs to various concentrations of sulfur Mustard vapor, determined online, using FTIR attached to flow chamber. The LCt(50) and the inhaled LD50 were calculated at different time points post exposure. Surviving animals were monitored for clinical symptoms, respiratory parameters and body weight changes for up to 30 days. Clinical symptoms were noted at 3 h post exposure, characterized by erythematic and swelling nose with extensive mucous secretion (with or without bleeding). At 6 h post exposure most of the guinea pigs had breathing difficulties, rhonchi and dyspnea and few deaths were noted. These symptoms peaked at 48 h and were noted up to 8 days, associated with few additional deaths. Thereafter, a spontaneous healing was noted, characterized by recovery of respiratory parameters and normal weight gain with almost complete apparent healing within 2 weeks. Histopathological evaluation Of lungs and trachea in the surviving GPs at 4 weeks post exposure revealed a dose-dependent residual injury in both lung and trachea expressed by abnormal recovery of the tracheal epithelium concomitant with a close-dependent increase in cellular volume in the lungs. These abnormal epithelial regeneration and lung remodeling were accompanied with significant changes in protein, LDH, differential cell count and glutathione levels in the bronchoalveolar lavage (BAL). It is suggested that the abnormal epithelial growth and cellular infiltration into the lung as well as the continuous lung inflammation Could cause recurrent lung injury similar to that reported for HD exposed human casualties. (C) 2009 Elsevier Inc. All rights reserved.	[Allon, Nahum; Amir, Adina; Manisterski, Eliau; Rabinovitz, Ishay; Dachir, Shlomit; Kadar, Tamar] Israel Inst Biol Res, Dept Pharmacol, IL-74100 Ness Ziona, Israel		Allon, N (corresponding author), Israel Inst Biol Res, Dept Pharmacol, POB 19, IL-74100 Ness Ziona, Israel.	nahuma@iibr.gov.il					Allon N, 1998, TOXICOL SCI, V43, P121; ALLON N, 1993, P 1993 MED DEF BIOSC, P133; Amir A, 2000, J APPL TOXICOL, V21, pS109; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Balali M., 1984, ARCH BELG S, P254; Balali-Mood M, 2005, FUND CLIN PHARMACOL, V19, P713, DOI 10.1111/j.1472-8206.2005.00364.x; Balali-Mood M, 2006, BASIC CLIN PHARMACOL, V99, P273, DOI 10.1111/j.1742-7843.2006.pto_429.x; Beheshti J, 2006, PATHOL RES PRACT, V202, P739, DOI 10.1016/j.prp.2006.04.008; BITRON MD, 1978, AM IND HYG ASSOC J, V39, P129, DOI 10.1080/0002889778507726; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; CALVET JH, 1994, J APPL PHYSIOL, V76, P681, DOI 10.1152/jappl.1994.76.2.681; Canning BJ, 2008, PULM PHARMACOL THER, V21, P702, DOI 10.1016/j.pupt.2008.01.004; Casillas RP, 1997, TOXICOL METHOD, V7, P381; Castranova V, 2002, INT IMMUNOPHARMACOL, V2, P163, DOI 10.1016/S1567-5769(01)00169-2; Dachir S, 2002, HUM EXP TOXICOL, V21, P197, DOI 10.1191/0960327102ht229oa; Fidder A, 1996, CHEM RES TOXICOL, V9, P788, DOI 10.1021/tx9502150; FREITAG L, 1991, CHEST, V100, P1436, DOI 10.1378/chest.100.5.1436; Gao X, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-17; GECKEL PT, 1951, COLORIMETRIC METHOD; Guyton A. C., 2005, TXB MED PHYSL; Hasenfuss G, 1998, CARDIOVASC RES, V39, P60, DOI 10.1016/S0008-6363(98)00110-2; HENDERSON RF, 1988, FUND APPL TOXICOL, V11, P546, DOI 10.1016/0272-0590(88)90119-4; Kumar O, 1998, J APPL TOXICOL, V18, P257, DOI 10.1002/(SICI)1099-1263(199807/08)18:4<257::AID-JAT501>3.3.CO;2-W; Langenberg JP, 1998, DRUG CHEM TOXICOL, V21, P131, DOI 10.3109/01480549809007407; Niu TQ, 1996, CHEM-BIOL INTERACT, V100, P77, DOI 10.1016/S0009-2797(96)03690-3; Noort D, 1997, ARCH TOXICOL, V71, P171, DOI 10.1007/s002040050372; PAPIRMEISTER B, 1991, TOXIC MECH PHARM IMP, P133; Rao PVL, 1999, TOXICOLOGY, V139, P39, DOI 10.1016/S0300-483X(99)00097-9; REES J, 1991, LANCET, V337, P430, DOI 10.1016/0140-6736(91)91208-C; Sohrabpour H, 1984, Arch Belg, VSuppl, P291; SOHRABPOUR H, 2004, MED J ISLAM REPUB IR, V1408, P32; SOMANI SM, 1989, INT J CLIN PHARM TH, V27, P419; van Helden HPM, 2004, INHAL TOXICOL, V16, P537, DOI 10.1080/08958370490442520; VIJAYARAGHAVAN R, 1997, ARCH TOXICOL, V69, P35; West KL, 2004, CARDIOVASC DRUG REV, V22, P55	36	38	38	2	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	DEC 1	2009	241	2					154	162		10.1016/j.taap.2009.08.006			9	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Toxicology	518SD	WOS:000271712600004	19682477				2022-02-06	
J	Derrett, S; Black, J; Herbison, GP				Derrett, Sarah; Black, James; Herbison, G. Peter			Outcome After Injury-A Systematic Literature Search of Studies Using the EQ-5D	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	25th Plenary Scientific Meeting of the EuroQol-Group	SEP, 2008	Maggiore, ITALY	EuroQol Grp		Wounds and injuries; Quality of life; EQ-5D	QUALITY-OF-LIFE; FEMORAL-NECK FRACTURES; RANDOMIZED CONTROLLED-TRIAL; PREVALENT VERTEBRAL FRACTURES; NOTTINGHAM HEALTH PROFILE; TRAUMATIC BRAIN-INJURY; TOTAL HIP-ARTHROPLASTY; INTERNAL-FIXATION; ELDERLY-PATIENTS; MAJOR TRAUMA	Purpose: Information is required about recovery after injury, including general health measures such as the EQ-5D. This project aimed to: (1) search for studies of injury outcome using the EQ-5D, (2) describe EQ-5D administration and analysis, (3) summarize reliability and validity, and (4) report EQ-5D outcomes. Methods: A systematic search was undertaken for publications (January 1990 to May 2008). Studies were excluded if the EQ-5D was not used or if injury was a secondary outcome or resulted from a degenerative condition. Results: Of 79 potentially eligible articles retrieved, 35 were excluded and 44 remained. Sample sizes ranged between n = 14 and n = 3,231. Two thirds of studies described injury outcomes, the remainder focused on specific treatments after injury. Of studies reporting EQ-513 index scores, most used the UK value set, and 29% did not specify a value set. In 16 studies, the EQ-5D was self-completed by participants, and in others, administration was by interviewer, proxy, or unspecified. Time of administration varied between 6 days and 7 years after injury. The absence of a cognitive dimension in the EQ-513 was a concern. Discussion: Given the global impact of injury-related disability, our search supports calls for comprehensive population-level research exploring outcomes. Many studies considered only specific treatments after injury, had small sample sizes, or were undertaken in wealthy countries. Although noting reservations about the EQ-51), such as the absence of a cognitive dimension; the EQ-SD being freely available to nonprofit-making organizations, and with many language versions available, seems suitable for studies in wealthy and poorer nations alike.	[Derrett, Sarah; Black, James] Univ Otago, Dunedin Sch Med, Injury Prevent Res Unit, Dunedin 9054, New Zealand; [Herbison, G. Peter] Univ Otago, Dunedin Sch Med, Dept Preventat & Social Med, Dunedin 9054, New Zealand		Black, J (corresponding author), Univ Otago, Dunedin Sch Med, Injury Prevent Res Unit, POB 913, Dunedin 9054, New Zealand.	james.black@otago.ac.nz	Black, James A/A-5917-2010	Black, James A/0000-0002-2200-3179; Derrett, Sarah/0000-0003-2867-0498; Herbison, Graham Peter/0000-0002-5684-024X			Alderman N, 2001, NEUROPSYCHOL REHABIL, V11, P529, DOI 10.1080/09602010042000231; Sanchez JLA, 2007, ARCH SURG-CHICAGO, V142, P50, DOI 10.1001/archsurg.142.1.50; Badia X, 2001, QUAL LIFE RES, V10, P307, DOI 10.1023/A:1012200508847; Badia X, 2001, INTENS CARE MED, V27, P1901, DOI 10.1007/s00134-001-1137-x; Badia Xavier, 2004, Health Qual Life Outcomes, V2, P41; Bahena-Salgado Yadira, 2007, Acta Ortop Mex, V21, P3; Bakar I, 2008, INJURY EXTRA, V39, P179; Baker SP, 1992, THE INJURY FACT BOOK, VSecond; Barker M, 1996, ARCH DIS CHILD, V75, P156, DOI 10.1136/adc.75.2.156; BARNES J, 2006, EXPLORATORY STUDY RO, P354; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Blomfeldt R, 2005, J BONE JOINT SURG BR, V87B, P523, DOI 10.1302/0301-620X.87B4; Blomfeldt R, 2006, ACTA ORTHOP, V77, P638, DOI 10.1080/17453670610012728; Borgstrom F, 2006, OSTEOPOROSIS INT, V17, P1781, DOI 10.1007/s00198-006-0193-z; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; BRAZIER J, 1993, QUAL LIFE RES, V2, P169, DOI 10.1007/BF00435221; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Bryan S, 2004, INT J TECHNOL ASSESS, V20, P222, DOI 10.1017/S026646230400100X; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Burton DJC, 2005, INJURY, V36, P1190, DOI 10.1016/j.injury.2005.05.030; Chung B, 2004, AM J SPORT MED, V32, P1660, DOI 10.1177/0363546503262806; Cockerill W, 2004, OSTEOPOROSIS INT, V15, P113, DOI 10.1007/s00198-003-1547-4; Cryer C, 2008, INJURY PREV, V14, P74, DOI 10.1136/ip.2007.017327; deLateur BJ, 1997, ARCH PHYS MED REHAB, V78, P237, DOI 10.1016/S0003-9993(97)90026-5; Derrett S, 2005, INT J TECHNOL ASSESS, V21, P359, DOI 10.1017/S0266462305050476; Dhillon V, 2005, OSTEOPOROSIS INT, V16, P483, DOI 10.1007/s00198-004-1705-3; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; Dolan P, 1999, OSTEOPOROSIS INT, V9, P196, DOI 10.1007/s001980050136; Dolan P, 1995, SOCIAL TARIFF EUROQO; ELVIK R, 1995, SOC SCI MED, V40, P1385, DOI 10.1016/0277-9536(94)00264-T; Enocson AG, 2006, ACTA ORTHOP, V77, P87, DOI 10.1080/17453670610045731; EssinkBot ML, 1997, MED CARE, V35, P522, DOI 10.1097/00005650-199705000-00008; Fingerhut LA, 2004, INJURY PREV, V10, P264, DOI 10.1136/ip.2004.007047; Frankema SPG, 2005, J TRAUMA, V58, P596, DOI 10.1097/01.TA.0000152551.39400.6F; Frihagen F, 2007, BMJ-BRIT MED J, V335, P1251, DOI 10.1136/bmj.39399.456551.25; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Garratt AM, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-48; *GBD INJ EXP GROUP, GBD INJ EXP GROUP HO; Giannoudis PV, 2002, INJURY, V33, P117, DOI 10.1016/S0020-1383(01)00073-0; Gobbi A, 2006, AM J SPORT MED, V34, P1763, DOI 10.1177/0363546506288853; Goodwin PC, 2003, PHYS THER, V83, P520, DOI 10.1093/ptj/83.6.520; Gopal S, 2004, J BONE JOINT SURG BR, V86B, P861, DOI 10.1302/0301-620X.86B6.13400; HADDON W, 1964, ACCIDENT RES METHODS; HOLLINGWORTH W, 1995, QUAL LIFE RES, V4, P325, DOI 10.1007/BF01593885; Holtslag HR, 2008, B WORLD HEALTH ORGAN, V86, P111, DOI 10.2471/BLT.06.033803; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Jagodic HK, 2006, CRIT CARE, V10, DOI 10.1186/cc5047; Jakob F, 2006, QJM-INT J MED, V99, P531, DOI 10.1093/qjmed/hcl073; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Keating J F, 2005, Health Technol Assess, V9, piii; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Kobusingye, 2001, INJURY SURVEILLANCE; Kovacs FM, 2005, SPINE, V30, P1786, DOI 10.1097/01.brs.0000172159.47152.dc; Kumar K, 2005, CAN J NEUROL SCI, V32, P487, DOI 10.1017/S0317167100004492; Lash N, 2002, ANZ J SURG, V72, P724, DOI 10.1046/j.1445-2197.2002.02530.x; Laukontaus SJ, 2006, ANN VASC SURG, V20, P42, DOI 10.1007/s10016-005-9283-1; LEE AY, SINGA; Lindahl H, 2006, J BONE JOINT SURG AM, V88A, P1215, DOI 10.2106/JBJS.E.00457; Lips P, 2005, OSTEOPOROSIS INT, V16, P447, DOI 10.1007/s00198-004-1762-7; Lyons RA, 2008, INJURY PREV, V14, P3, DOI 10.1136/ip.2007.018192; Madhu TS, 2007, INJURY, V38, P598, DOI 10.1016/j.injury.2006.11.005; Marcacci M, 2005, CLIN ORTHOP RELAT R, P96, DOI 10.1097/01.blo.0000165737.87628.5b; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Miedel R, 2005, J BONE JOINT SURG BR, V87B, P68, DOI 10.1302/0301-620X.87B1.15295; Morrissey MC, 2006, AM J PHYS MED REHAB, V85, P490, DOI 10.1097/01.phm.0000219280.06297.bd; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P87; Neugebauer E, 2006, EUR J TRAUMA, V32, P44, DOI 10.1007/s00068-006-0150-8; Nikken JJ, 2005, RADIOLOGY, V236, P958, DOI 10.1148/radiol.2362041130; Oleksik A, 2000, J BONE MINER RES, V15, P1384, DOI 10.1359/jbmr.2000.15.7.1384; Oppe S, 2001, ACCIDENT ANAL PREV, V33, P129, DOI 10.1016/S0001-4575(00)00023-3; Pearn J, 2004, SCI BASIS INJURY PRE, P5; Peolsson M, 2004, J REHABIL MED, V36, P28, DOI 10.1080/11026480310015530; Pirente N, 2002, UNFALLCHIRURG, V105, P413; Pirente N, 2001, UNFALLCHIRURG, V104, P57, DOI 10.1007/s001130050688; Polinder S, 2005, PEDIATRICS, V116, pE810, DOI 10.1542/peds.2005-1035; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Pollard TCB, 2006, J BONE JOINT SURG BR, V88B, P592, DOI 10.1302/0301-620X.88B5.17354; Priestley M., 2003, DISABILITY LIFE COUR; Rajzbaum G, 2008, CURR MED RES OPIN, V24, P377, DOI 10.1185/030079908X261087; RAMAN R, 2008, INJURY EXTRA, V39, P200; Ryan T, 2006, CLIN REHABIL, V20, P123, DOI 10.1191/0269215506cr933oa; Salaffi F, 2007, CLIN EXP RHEUMATOL, V25, P390; Salkeld G, 2000, BMJ-BRIT MED J, V320, P341, DOI 10.1136/bmj.320.7231.341; Sluiter JK, 2008, INT ARCH OCC ENV HEA, V81, P495, DOI 10.1007/s00420-007-0222-z; Szende A, 2004, MEASURING SELF REPOR; Tidermark J, 2003, QUAL LIFE RES, V12, P1069, DOI 10.1023/A:1026193812514; Tidermark J, 2003, ACTA ORTHOP SCAND, V74, P2; Tidermark J, 2003, J BONE JOINT SURG BR, V85B, P380, DOI 10.1302/0301-620X.85B3.13609; Tidermark J, 2003, J ORTHOP TRAUMA, V17, P193, DOI 10.1097/00005131-200303000-00007; Tidermark J, 2002, QUAL LIFE RES, V11, P473, DOI 10.1023/A:1015632114068; Tidermark J, 2002, J ORTHOP TRAUMA, V16, P34, DOI 10.1097/00005131-200201000-00008; Tidermark J, 2007, QUAL LIFE RES, V16, P321, DOI 10.1007/s11136-006-9004-4; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Tosteson ANA, 2002, PHARMACOECONOMICS, V20, P289, DOI 10.2165/00019053-200220050-00001; Townend W, 2001, J NEUROL NEUROSUR PS, V70, P267; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; van Baar ME, 2006, J BURN CARE RES, V27, P790, DOI 10.1097/01.BCR.0000245434.76697.56; Van Beeck EF, 2007, J TRAUMA, V62, P534, DOI 10.1097/TA.0b013e31802e70c7; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; WHO, 2008, GLOB BURD DIS 2004; Xie F, 2006, OSTEOARTHR CARTILAGE, V14, P1098, DOI 10.1016/j.joca.2006.05.005; Yoh K, 2005, J BONE MINER METAB, V23, P167, DOI 10.1007/s00774-004-0556-5	103	38	38	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2009	67	4					883	890		10.1097/TA.0b013e3181ae6409			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	506BE	WOS:000270747000034	19820601				2022-02-06	
J	Li, V; Brustovetsky, T; Brustovetsky, N				Li, Viacheslav; Brustovetsky, Tatiana; Brustovetsky, Nickolay			Role of cyclophilin D-dependent mitochondrial permeability transition in glutamate-induced calcium deregulation and excitotoxic neuronal death	EXPERIMENTAL NEUROLOGY			English	Article							CEREBELLAR GRANULE CELLS; PERMEANT CA2+ CHELATORS; TRAUMATIC BRAIN-INJURY; CYCLOSPORINE-A; CEREBRAL-ISCHEMIA; AMINO-ACIDS; PORE; INHIBITION; NEUROTOXICITY; DYSFUNCTION	In the present study we tested the hypothesis that the cyclophilin D-dependent (CyD) mitochondrial permeability transition (CyD-mPT) plays an important role in glutamate-triggered delayed calcium deregulation (DCD) and excitotoxic neuronal death. We used Cultured cortical neurons from wild-type C57BL/6 and cyclophilin D-knockout mice (Ppif(-/-)). Induction of the mPT was identified by following the rapid secondary acidification of mitochondrial matrices monitored with mitochondrially targeted pH-sensitive yellow fluorescent protein. Suppression of the CyD-mPT due to genetic CyD ablation deferred DCD and mitochondrial depolarization, and increased the survival rate after exposure of neurons to 10 mu m glutamate, but not to 100 mu M glutamate. Ca2+ influx into Ppif(-/-) neurons was not diminished in comparison with WT neurons judging by Ca-45 accumulation. In both types of neurons, 100 mu M glutamate produced greater Ca2+ influx than 10 mu M glutamate. We hypothesize that greater Ca2+ influx produced by higher glutamate rapidly triggered the CyD-independent mPT in both WT and Ppif(-/-) neurons equalizing their responses to supra-physiologic excitotoxic insults. In neurons exposed to moderate but pathophysiologically-relevant glutamate concentrations, an induction of the CyD-mPT appears to play an important role in mitochondrial injury contributing to DCD and cell death. (C) 2009 Elsevier Inc. All rights reserved.	[Li, Viacheslav; Brustovetsky, Tatiana; Brustovetsky, Nickolay] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Brustovetsky, Nickolay] Indiana Univ, Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA		Brustovetsky, N (corresponding author), Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, 635 Barnhill Dr,Med Sci Bldg Room 547, Indianapolis, IN 46202 USA.	nbrous@iupui.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 050131]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050131] Funding Source: NIH RePORTER	We are thankful to Dr. Jeffery D. Molkentin (University of Cincinnati) and Cincinnati Children's Research Foundation for providing us with cyclophilin D-knockout mice. Dr. Natalia Shalbuyeva is gratefully acknowledged for help with mitochondrial experiments. This work was supported by the NIH/NINDS R01 NS 050131 to NB.	Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BERNSTEIN P, 1993, ANIM BEHAV CONSULTAN, V10, P1; Bolshakov AP, 2008, CELL CALCIUM, V43, P602, DOI 10.1016/j.ceca.2007.10.005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Brustovetsky T, 2004, EXP NEUROL, V189, P222, DOI 10.1016/j.expneurol.2004.03.021; Budd SL, 1996, J NEUROCHEM, V67, P2282; Castilho RF, 1998, J NEUROSCI, V18, P10277; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; Chinopoulos C, 2004, J NEUROCHEM, V91, P471, DOI 10.1111/j.1471-4159.2004.02732.x; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; CROMPTON M, 1988, BIOCHEM J, V255, P357; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; DUBINSKY JM, 1995, J NEUROSCI, V15, P7071; DUBINSKY JM, 1993, J NEUROSCI, V13, P623; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Isaev NK, 1996, FEBS LETT, V392, P143, DOI 10.1016/0014-5793(96)00804-6; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; KIEDROWSKI L, 1995, MOL PHARMACOL, V47, P140; Korde AS, 2007, J NEUROTRAUM, V24, P895, DOI 10.1089/neu.2006.0122; Kristian T, 2007, J NEUROCHEM, V102, P1346, DOI 10.1111/j.1471-4159.2007.04626.x; Kushnareva YE, 2005, J BIOL CHEM, V280, P28894, DOI 10.1074/jbc.M503090200; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MANEV H, 1989, MOL PHARMACOL, V36, P106; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakayama R, 2002, ANESTHESIOLOGY, V96, P705, DOI 10.1097/00000542-200203000-00029; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pivovarova NB, 2004, J NEUROSCI, V24, P5611, DOI 10.1523/JNEUROSCI.0531-04.2004; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Rasola A, 2007, APOPTOSIS, V12, P815, DOI 10.1007/s10495-007-0723-y; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Shalbuyeva N, 2007, J BIOL CHEM, V282, P18057, DOI 10.1074/jbc.M702134200; Shalbuyeva N, 2006, J BIOL CHEM, V281, P37547, DOI 10.1074/jbc.M607263200; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; THAYER SA, 1990, J PHYSIOL-LONDON, V425, P85, DOI 10.1113/jphysiol.1990.sp018094; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; TYMIANSKI M, 1994, J NEUROPHYSIOL, V72, P1973, DOI 10.1152/jn.1994.72.4.1973; TYMIANSKI M, 1993, NEURON, V11, P221, DOI 10.1016/0896-6273(93)90180-Y; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Van Hemelrijek A, 2005, J NEUROSCI METH, V144, P63, DOI 10.1016/j.jneumeth.2004.10.013; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Vergun O, 2003, EXP NEUROL, V183, P682, DOI 10.1016/S0014-4886(03)00243-7; VINOGRADOV A, 1972, ARCH BIOCHEM BIOPHYS, V152, P646, DOI 10.1016/0003-9861(72)90261-5; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; White RJ, 1996, J NEUROSCI, V16, P5688; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xu W, 2007, NEURON, V53, P399, DOI 10.1016/j.neuron.2006.12.020; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; ZENKE G, 1993, ANN NY ACAD SCI, V685, P330, DOI 10.1111/j.1749-6632.1993.tb35882.x	85	38	38	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2009	218	2			SI		171	182		10.1016/j.expneurol.2009.02.007			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	472GE	WOS:000268117400002	19236863	Green Accepted			2022-02-06	
J	Baki, SGA; Kao, HY; Kelemen, E; Fenton, AA; Bergold, PJ				Baki, Samah G. Abdel; Kao, Hsin-Yi; Kelemen, Eduard; Fenton, Andre A.; Bergold, Peter J.			A hierarchy of neurobehavioral tasks discriminates between mild and moderate brain injury in rats	BRAIN RESEARCH			English	Article						Controlled cortical impact; Injury severity; Active place avoidance; Perceptual segregation; Mnemonic segregation; Reversal learning	CONTROLLED CORTICAL IMPACT; BEHAVIORAL EVIDENCE; COGNITIVE DEFICITS; MICE; MEMORY; PLACE; NEURODEGENERATION; DISSOCIATION; NAVIGATION; AVOIDANCE	Behavioral analysis commonly assesses cognitive deficits in rodents following traumatic brain injury (TBI). We examined rats that received sham, mild or moderate injury in the controlled cortical impact model of TBI. The rats were tested in a novel hierarchy of four behavioral tasks with increasing cognitive demand. All three groups had similar performance on the first two phases of training: open field exploration and passive place avoidance using a stationary shock zone on a non-rotating arena. The similar performance on the first two tasks suggested comparable sensory, motor skills and contextual memory in all three groups. In phase three, rats were tested on active place avoidance, their ability to avoid a stationary shock zone on the rotating arena. Control and mildly-injured rats learned this task within four ten-minute trials while moderately-injured animals were impaired. Moderately-injured animals were also impaired if tested 3 weeks after injury. One day after phase three, sham- and mildly-injured animals were tested on a phase four conflict active avoidance task with the shock zone shifted 180 degrees from its phase three location and mildly-injured animals were impaired. The speed in which the animals complete the four phases of testing as well as the ability to discriminate between differing injury severity suggests that this set of neurobehavioral tasks will be useful to understand cognitive deficits underlying TBI as well as a useful screening method for therapeutic drugs. (C) 2009 Elsevier B.V. All rights reserved.	[Baki, Samah G. Abdel; Kao, Hsin-Yi; Kelemen, Eduard; Fenton, Andre A.; Bergold, Peter J.] Suny Downstate Med Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA		Bergold, PJ (corresponding author), Suny Downstate Med Ctr, Dept Physiol & Pharmacol, Box 29,450 Clarkson Ave, Brooklyn, NY 11203 USA.	pbergold@downstate.edu	Kelemen, Eduard/K-3649-2017	Fenton, Andre/0000-0002-5063-1156; Bergold, Peter/0000-0002-6335-1380	Department of Defense Post-Traumatic Stress Disorder/Traumatic Brain Injury Research Program of the Office of the Congressionally Directed Medical Research Programs	We thank Dr. Susanna Popp and Mr. Dino Dvorak for assistance in setting up the place avoidance apparatus. We thank Dr. Jennifer Libien and Ms. Lorraine Braithwaite-Harte for assistance with the histological analysis. This work was supported by Concept Award PT073028 to P.J.B. from the Department of Defense Post-Traumatic Stress Disorder/Traumatic Brain Injury Research Program of the Office of the Congressionally Directed Medical Research Programs.	Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bures J, 1997, PHILOS T ROY SOC B, V352, P1515, DOI 10.1098/rstb.1997.0138; Cimadevilla JM, 2001, P NATL ACAD SCI USA, V98, P3531, DOI 10.1073/pnas.051628398; Cimadevilla JM, 2001, BRAIN RES BULL, V54, P559, DOI 10.1016/S0361-9230(01)00448-8; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Fenton A. A., 2003, NEUROBIOLOGY SPATIAL; Fenton AA, 1998, P NATL ACAD SCI USA, V95, P11493, DOI 10.1073/pnas.95.19.11493; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Kubik S, 2005, J NEUROSCI, V25, P9205, DOI 10.1523/JNEUROSCI.1707-05.2005; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; Mizumori SJ, 2008, HIPPOCAMPAL PLACE FI, P127; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Pastalkova E, 2006, SCIENCE, V313, P1141, DOI 10.1126/science.1128657; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Serrano P, 2008, PLOS BIOL, V6, P2698, DOI 10.1371/journal.pbio.0060318; Unterberg AW, 1997, ACT NEUR S, V70, P106; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Wallace DG, 2002, BEHAV BRAIN RES, V131, P185, DOI 10.1016/S0166-4328(01)00384-9; Wesierska M, 2005, J NEUROSCI, V25, P2413, DOI 10.1523/JNEUROSCI.3962-04.2005	29	38	38	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 14	2009	1280						98	106		10.1016/j.brainres.2009.05.034			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	469OS	WOS:000267909800012	19464271				2022-02-06	
J	Willemse-Van Son, AHP; Ribbers, GM; Hop, WCJ; Stam, HJ				Willemse-van Son, Agnes H. P.; Ribbers, Gerard M.; Hop, Wim C. J.; Stam, Henk J.			COMMUNITY INTEGRATION FOLLOWING MODERATE TO SEVERE TRAUMATIC BRAIN INJURY: A LONGITUDINAL INVESTIGATION	JOURNAL OF REHABILITATION MEDICINE			English	Article						prognosis; craniocerebral trauma; traumatic brain injury; community integration; participation	FUNCTIONAL ASSESSMENT MEASURE; ASSESSMENT MEASURE FIM+FAM; HEAD-INJURY; INTERRATER RELIABILITY; OUTCOMES; REHABILITATION; QUESTIONNAIRE; DISABILITY; PREDICTION; VARIABLES	Objective: To evaluate the course and identify determinants of community integration for up to 3 years following moderate to severe traumatic brain injury. Design: Prospective cohort study. Patients: A total of 119 patients with moderate to severe traumatic brain injury aged 16-67 years. Methods: The Community Integration Questionnaire was completed at 3, 6, 12, 18, 24 and 36 months post-injury. Repeated measures analysis of variance was performed to determine changes over time in the Community Integration Questionnaire and its subscales. Bivariate and multivariate regression analyses were used to identify determinants of community integration 36 months post-injury. Results: Compared with pre-injury, mean home integration, social integration, productivity, and total questionnaire scores decreased 3 months post-injury. Patient scores showed maximal improvement during the first year post-injury. Mean home integration, productivity, and total scores increased to a lesser extent during years 1-3 post-injury. Age, Barthel Index scores, hospital discharge destination, and pre-injury community integration scores were the major determinants of community integration 36 months post-injury (R-2 = 60%). Conclusion: After an initial decline, mean community integration scores gradually improve following moderate to severe traumatic brain injury. Understanding the course and determinants of community integration is necessary in order to determine functional prognosis following traumatic brain injury.	[Willemse-van Son, Agnes H. P.; Ribbers, Gerard M.; Stam, Henk J.] Erasmus MC, Dept Rehabil Med, NL-3000 CA Rotterdam, Netherlands; [Willemse-van Son, Agnes H. P.; Ribbers, Gerard M.] Erasmus MC, Rijndam Rehabil Ctr, NL-3000 CA Rotterdam, Netherlands; [Hop, Wim C. J.] Erasmus MC, Dept Biostat, NL-3000 CA Rotterdam, Netherlands		Willemse-Van Son, AHP (corresponding author), Erasmus MC, Dept Rehabil Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.vanson-willemse@erasmusmc.nl	Ribbers, Gerard/N-3623-2019; Ribbers, Gerard M/C-1454-2014	Ribbers, Gerard M/0000-0002-6114-349X	Netherlands Organisation for Health Research and DevelopmentNetherlands Organization for Health Research and Development [1435.0020]	This study was performed as part of the "Long-term prognosis of functional outcome in neurological disorders", the Department of Rehabilitation Medicine, VU Medical Centre, Amsterdam, and supported by the Netherlands Organisation for Health Research and Development (project: 1435.0020).	Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P255, DOI 10.1053/apmr.2003.50092; Collin C, 1988, Int Disabil Stud, V10, P61; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Fleming J, 1999, BRAIN INJURY, V13, P417; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAHONEY F I, 1965, Md State Med J, V14, P61; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Van Baalen B, 2007, BRAIN INJURY, V21, P925, DOI 10.1080/02699050701553197; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; World Health Organization, 2007, INT CLASS FUNCT DIS	41	38	38	1	13	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JUN	2009	41	7					521	527		10.2340/16501977-0377			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	463HD	WOS:000267421100004	19543662	Green Submitted, gold			2022-02-06	
J	Tsuru-Aoyagi, K; Potts, MB; Trivedi, A; Pfankuch, T; Raber, J; Wendland, M; Claus, CP; Koh, SE; Ferriero, D; Noble-Haeusslein, LJ				Tsuru-Aoyagi, Kyoko; Potts, Matthew B.; Trivedi, Alpa; Pfankuch, Timothy; Raber, Jacob; Wendland, Michael; Claus, Catherine P.; Koh, Seong-Eun; Ferriero, Donna; Noble-Haeusslein, Linda J.			Glutathione Peroxidase Activity Modulates Recovery in the Injured Immature Brain	ANNALS OF NEUROLOGY			English	Article							PERINATAL HYPOXIA-ISCHEMIA; DISMUTASE TRANSGENIC MICE; CLOSED-HEAD-INJURY; CELL-DEATH; OPTICAL FRACTIONATOR; NEURONAL LOSS; MURINE BRAIN; MOUSE MODEL; DAMAGE; AGE	Objective: Mice subjected to traumatic brain injury at postnatal day 21 show emerging cognitive deficits that coincide with hippocampal neuronal loss. Here we consider glutathione peroxidase (GPx) activity as a determinant of recovery in the injured immature brain. Methods: Wild-type and transgenic (GPxTg) mice overexpressing GPx were Subjected to traumatic brain injury or sham surgery at postnatal day 21. Animals were killed acutely (3 or 24 hours after injury) to assess oxidative stress and cell injury in the hippocampus or 4 months after injury after behavioral assessments. Results: In the acutely injured brains, a reduction in oxidative stress markers including nitrotyrosine was seen in the injured GPxTg group relative to wild-type control mice. In contrast, cell injury, with marked vulnerability in the dentate gyrus, was apparent despite no differences between genotypes. Magnetic resonance imaging demonstrated an emerging cortical lesion during brain maturation that was also indistinguishable between injured genotypes. Stereological analyses of cortical volumes likewise confirmed no genotypic differences between injured groups. However, behavioral tests beginning 3 months after injury demonstrated improved spatial memory learning in the GPxTg group. Moreover, stereological analysis within hippocampal subregions demonstrated a significantly greater number of neurons within the dentate of the GPx group. Interpretation: Our results implicate GPx in recovery of spatial memory after traumatic brain injury. This recovery may be attributed, in part, to a reduction in early oxidative stress and selective, long-term sparing of neurons in the dentate.	[Tsuru-Aoyagi, Kyoko; Potts, Matthew B.; Trivedi, Alpa; Claus, Catherine P.; Koh, Seong-Eun; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Pfankuch, Timothy; Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, Portland, OR 97201 USA; [Wendland, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Ferriero, Donna] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Ferriero, Donna] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy & Rehabil, San Francisco, CA 94143 USA		Noble-Haeusslein, LJ (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 521 Parnassus Ave,Room C-224, San Francisco, CA 94143 USA.	linda.noble@ucsf.edu			NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050159]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER	This research was supported by the NIH NINDS (NS050159) L. N. H.	Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Benice TS, 2006, NEUROSCIENCE, V137, P413, DOI 10.1016/j.neuroscience.2005.08.029; Bonthius DJ, 2004, BRAIN RES PROTOC, V14, P45, DOI 10.1016/j.brainresprot.2004.09.003; Camargo EE, 2001, J NUCL MED, V42, P611; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Graham EM, 2004, NEUROBIOL DIS, V17, P89, DOI 10.1016/j.nbd.2004.05.007; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hovatta I, 2005, NATURE, V438, P662, DOI 10.1038/nature04250; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; KESNER R, 2007, LEARN MEMORY, V14, P127; Khan JY, 2003, PEDIATR RES, V54, P77, DOI 10.1203/01.PDR.0000065736.69214.20; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lebesgue D, 2006, J NEUROTRAUM, V23, P1814, DOI 10.1089/neu.2006.23.1814; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; McLean CW, 2005, DEV NEUROSCI-BASEL, V27, P169, DOI 10.1159/000085989; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PANKSEPP J, 1984, NEUROSCI BIOBEHAV R, V8, P465, DOI 10.1016/0149-7634(84)90005-8; Payton KSE, 2007, DEV NEUROSCI-BASEL, V29, P403, DOI 10.1159/000105481; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Sheldon RA, 2004, PEDIATR RES, V56, P656, DOI 10.1203/01.PDR.0000139413.27864.50; Sheldon RA, 2001, NEUROSCI LETT, V304, P165, DOI 10.1016/S0304-3940(01)01788-8; Souza JM, 2000, ARCH BIOCHEM BIOPHYS, V380, P360, DOI 10.1006/abbi.2000.1940; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1	44	38	38	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	MAY	2009	65	5					540	549		10.1002/ana.21600			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	453LJ	WOS:000266611700010	19475669	Green Accepted			2022-02-06	
J	Banerjee, S; Barry, MJ; Paterson, JMH				Banerjee, Sughran; Barry, M. J.; Paterson, J. Mark H.			Paediatric pelvic fractures: 10 years experience in a trauma centre	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Pelvic fractures; Paediatric fractures; Road traffic accident	INJURIES; CLASSIFICATION; PATTERNS; CHILDREN	Fractures of the skeletally immature pelvis are relatively rare. We performed a retrospective analysis of 10 years experience of paediatric pelvic fractures in patients admitted a Level 1 Trauma Centre in London. All patients evacuated to the Royal London Hospital by the Helicopter Emergency Medical Service (HEMS) were entered on a comprehensive trauma database. This contains data about the time, date and mechanism of injury; nature of the injuries sustained; Injury Severity Score (ISS), Revised Trauma Score (RTS) and Glasgow Coma Scale (GCS). Patients were studied to obtain the following information in addition to that available from the trauma database: management of the pelvic fracture, length of stay in the intensive care unit and on the ward, and clinical outcome. Pelvic fractures were classified as open type or closed type and stable or unstable type in the database. 44 patients with pelvic fracture were admitted via HEMS in 10 years and seven patients died in that group. The mean age was 11.4 (range 6-16) and 28 male and 16 female patients. Commonest mechanism of injury was pedestrian hit by the car and predominantly stable type of injury was found in skeletally immature pelvis. Commonest associated injury was long bone fracture followed by head injury. ISS, GCS and RTS were significantly (p < 0.05) altered in the non-survivors compared to the surviving group. All patients save one were treated conservatively allowing gradual mobilisation. In conclusion, pelvic fractures in children may themselves have a good long term outcome with conservative management, but they are an indicator of serious other bodily injuries which carry a high mortality. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.	[Banerjee, Sughran] Univ London Imperial Coll Sci Technol & Med, London E11 1PW, England; [Barry, M. J.; Paterson, J. Mark H.] Royal London Hosp, London, England		Banerjee, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, 23 Malcolm Way, London E11 1PW, England.	sughran@gmail.com					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Batislam E, 1997, J TRAUMA, V42, P285, DOI 10.1097/00005373-199702000-00018; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BRYAN WJ, 1979, J TRAUMA, V19, P799, DOI 10.1097/00005373-197911000-00001; Demetriades D, 2003, J TRAUMA, V54, P1146, DOI 10.1097/01.TA.0000044352.00377.8F; Grisoni N, 2002, J ORTHOP TRAUMA, V16, P458, DOI 10.1097/00005131-200208000-00003; Guillamondegui OD, 2003, J TRAUMA, V55, P236, DOI 10.1097/01.TA.0000079250.80811.D1; HARDER JA, 1981, CAN J SURG, V24, P409; Heeg M, 2000, CLIN ORTHOP RELAT R, P80; Ismail N, 1996, J PEDIATR SURG, V31, P82, DOI 10.1016/S0022-3468(96)90324-3; Junkins EP, 2001, J TRAUMA, V51, P64, DOI 10.1097/00005373-200107000-00010; Karunakar MA, 2005, J PEDIATR ORTHOPED, V25, P34, DOI 10.1097/00004694-200501000-00009; Landgraf JM, 1996, CHILD HLTH QUESTIONN; NOVKOV H, 1998, ORTOP TRAVMATOL, V34, P152; Quicke Donald L. J., 2005, Journal of Hymenoptera Research, V14, P96; Quinby W C Jr, 1966, J Pediatr Surg, V1, P353, DOI 10.1016/0022-3468(66)90338-1; Schlickewei W, 2005, INJURY, V36, pA57, DOI 10.1016/j.injury.2004.12.014; Signorino PR, 2005, J PEDIATR SURG, V40, P107, DOI 10.1016/j.jpedsurg.2004.09.018; Silber JS, 2002, J PEDIATR ORTHOPED, V22, P22; Silber JS, 2001, J PEDIATR ORTHOPED, V21, P446, DOI 10.1097/00004694-200107000-00006; SILBER JS, 2001, J PAEDIAT ORTHOP, P148; Smith I., 2004, NZ J ARCHAEOLOGY, V24, p:5; Smith W, 2005, J BONE JOINT SURG AM, V87A, P2423, DOI 10.2106/JBJS.C.01244v; TEASDALE G, 1974, LANCET, V2, P81; Tile M, 1999, J BONE JOINT SURG BR, V81B, P941, DOI 10.1302/0301-620X.81B6.10474; TORODE I, 1985, J PEDIATR ORTHOPED, V5, P76, DOI 10.1097/01241398-198501000-00014; TORODE I, 1985, J PEDIAT ORTHOP; Vitale MG, 2005, J PEDIATR ORTHOPED, V25, P581, DOI 10.1097/01.bpo.0000175112.91122.41; WIERMAN MJ, 1996, INJURY, V27, P163	29	38	44	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	APR	2009	40	4					410	413		10.1016/j.injury.2008.10.019			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	435SC	WOS:000265362600014	19232592				2022-02-06	
J	Bruns, JJ; Jagoda, AS				Bruns, John J., Jr.; Jagoda, Andy S.			Mild Traumatic Brain Injury	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						brain-specific biomakers; computed tomography; mild brain injury; postconcussive symptoms; traumatic brain injury	MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; COMPUTED-TOMOGRAPHY; S-100B; RELIABILITY; RULE; GUIDELINES; IMPACT	Mild traumatic brain injury accounts for 1% to 2% of emergency department visits in the United States. Up to 15% of these patients will have an acute intracranial lession identified on head compute d tomography lessthan 1% of mild traumatic brain will require neurosurgical intervention. Clinical research over the past decade has focussed on identifying the subgroup of patients with mild traumatic brain injury with acute traumatic lesions of computed tomography and specifically those at risk for harboring a potentially castrophic lesion. This research has been used to generate evidence-based guidelines to assit in clinical decision making. There is no evidence to support the use of plain film radiographs in the evaluation of patients with mild traumatic brain injury. The utility of brain-specific biomakers is rapidly evolving, and a growing body of evidence supports their potential role in determining the need for neuroimaging. Clinical predictors for identifying patients with abnormal computed tomography have been established and, if used, may have a significant positive impact on traumatic brain injury-related morbidity and with negative computed tomography are at almost counseled regarding postconcussive symptoms and should and referrals at discharge. Mt. Sinai J Med 76:129-137, 2009 (C) 2009 Mount Sinai School of Medicine	[Bruns, John J., Jr.; Jagoda, Andy S.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA		Bruns, JJ (corresponding author), Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA.	john.bruns@mssm.edu					af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; AFGEIJERSTAM JL, 2006, BMJ-BRIT MED J, V333; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Bazarian JJ, 2006, RESTOR NEUROL NEUROS, V24, P163; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Bergman DA, 1999, PEDIATRICS, V104, P1407; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Buduhan G, 2000, J TRAUMA, V49, P600, DOI 10.1097/00005373-200010000-00005; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; *CDCP, 2004, TRAUM BRAIN INJ US E; *CDCP, 2003, TBI REP C MILD TRAUM; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JAGODA A, 2008, ANN EMERG MED; JAGODA A, 2000, EMERGENCY MED CLIN N, P355; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; LEVITT MA, 1995, ACAD EMERG MED, V2, P675, DOI 10.1111/j.1553-2712.1995.tb03617.x; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIZOLI SB, 1994, ACCIDENT ANAL PREV, V26, P681, DOI 10.1016/0001-4575(94)90030-2; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAUNDERS CE, 1986, ANN EMERG MED, V15, P160, DOI 10.1016/S0196-0644(86)80012-9; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	51	38	38	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0027-2507	1931-7581		MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					129	137		10.1002/msj.20101			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	427OE	WOS:000264787800006	19306376				2022-02-06	
J	Frascarelli, F; Masia, L; Di Rosa, G; Cappa, P; Petrarca, M; Castelli, E; Krebs, HI				Frascarelli, F.; Masia, L.; Di Rosa, G.; Cappa, P.; Petrarca, M.; Castelli, E.; Krebs, H. I.			The impact of robotic rehabilitation in children with acquired or congenital movement disorders	EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Rehabilitation; Cerebral palsy; Brain injuries; Stroke; Movement disorders	UPPER-LIMB; ASSISTED THERAPY; SINGLE-BLIND; STROKE; RECOVERY; ARM; REORGANIZATION; COORDINATION; HEMIPARESIS; IMPAIRMENT	Aim. The aim of this study was to evaluate if the robot-mediated therapy (RMT) can yield positive outcomes in children with acquired or congenital upper extremity movement disorders. Methods. This was an uncontrolled pilot study with pre-post treatment outcome comparison carried out by the Pediatric Rehabilitation Department of a Children's Hospital. The study enrolled 12 children, aged 5 to 15 years, suffering from acquired (at least 12 months post-onset) or congenital upper limb motor impairment. Etiology. 4 stroke, 6 traumatic brain injuries, and 2 hemiplegic cerebral palsy. RMT was provided 3 dines a week for an hour during 6 weeks for a total of 18 robot therapy sessions. The Melbourne Scale (MS) and the upper-extremity subsection of the Fugl-Meyer Assessment (FMA) were used for measurement of impairment. Secondary outcome measurements were made through the Modified Ashworth Scale (MAS); the Reaching Performance Scale (RPS); Parent's Questionnaire, and robot-based evaluation measurements. Specifically, authors compared the smoothness, as measured by the jerk metric, and average speed of unconstrained reaching movements. Results. Pre-post clinical evaluation revealed statistically significant gains for all primary and secondary metrics. In addition, significant improvement of robot-based metrics was observed. The primary outcome measurement mean (SEM) gains were 6.71 (1.29) for MS and 3.33 (0.80) for the FMA. RMT led to spasticity decreases in chronic cases, as shown by die reduction of MAS. It led to improved trunk-upper extremity postural attitude as demonstrated by improved RPS, and it was well accepted by parents and children as observed in the Parent's Questionnaire. Conclusion. This study suggests that RMT may hold rehabilitative benefits in children suffering from acquired and congenital hemiparesis.	[Frascarelli, F.; Di Rosa, G.; Cappa, P.; Petrarca, M.; Castelli, E.] Childrens Hosp Bambino Gesu, Pediat Rehabil Dept, Rome, Italy; [Masia, L.] Italian Inst Technol, Genoa, Italy; [Cappa, P.] Univ Roma La Sapienza, Dept Mech & Aeronaut, I-00184 Rome, Italy; [Krebs, H. I.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA; [Krebs, H. I.] Cornell Univ, Weill Med Coll, Burke Med Res Inst, Dept Neurol & Neurosci, White Plains, NY USA; [Krebs, H. I.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA		Frascarelli, F (corresponding author), Childrens Hosp Bambino Gesu, Pediat Rehabil Dept, Via Torre Palidoro 0050, Rome, Italy.	flaminiafrascarelli@opbg.net	MASIA, LORENZO/D-9385-2014; Castelli, Enrico/J-1887-2012; petrarca, maurizio/B-4181-2019	petrarca, maurizio/0000-0002-7330-3569; Cappa, Paolo/0000-0002-4898-9589	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-HD-045343]; NYSCORE; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045343] Funding Source: NIH RePORTER	This work has been in part supported by a grant from the Italian Ministry of University and Research ("Robotic systems for the rehabilitation" - year 2003/05) and by a grant from the Italian Ministry of Health ("Pilot study on a new class of medical devices: robotic systems for the rehabilitation and the tele-rellabilitation " - year 2007). Dr. Krebs is Supported in part by NIH Grant #R01-HD-045343 and by the NYSCORE.	Aisen ML, 1997, ARCH NEUROL-CHICAGO, V54, P443, DOI 10.1001/archneur.1997.00550160075019; Barreca S, 2003, NEUROREHAB NEURAL RE, V17, P220, DOI 10.1177/0888439003259415; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Braun C, 2001, BRAIN, V124, P2259, DOI 10.1093/brain/124.11.2259; CAO Y, 1994, P NATL ACAD SCI USA, V91, P9612, DOI 10.1073/pnas.91.20.9612; CARR LJ, 1993, BRAIN, V116, P1223, DOI 10.1093/brain/116.5.1223; Chang JJ, 2005, CLIN BIOMECH, V20, P381, DOI 10.1016/j.clinbiomech.2004.11.015; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Colombo R, 2008, NEUROREHAB NEURAL RE, V22, P50, DOI 10.1177/1545968307303401; FARMER SF, 1991, NEUROLOGY, V41, P1505, DOI 10.1212/WNL.41.9.1505; Fasoli SE, 2003, ARCH PHYS MED REHAB, V84, P477, DOI 10.1053/apmr.2003.50110; Fasoli SE, 2008, AM J PHYS MED REHAB, V87, P929, DOI 10.1097/PHM.0b013e31818a6aa4; Fasoli Susan E, 2004, Top Stroke Rehabil, V11, P11; Ferraro M, 2003, NEUROLOGY, V61, P1604, DOI 10.1212/01.WNL.0000095963.00970.68; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; FLASH T, 1991, J COGNITIVE NEUROSCI, V3, P220, DOI 10.1162/jocn.1991.3.3.220; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Gunal I, 1996, J BONE JOINT SURG AM, V78A, P1401, DOI 10.2106/00004623-199609000-00017; KELSO JAS, 1981, J MOTOR BEHAV, V13, P226; KLINGELS H, 2006, GAIT POSTURE, V24, pS245; Krebs H I, 1998, IEEE Trans Rehabil Eng, V6, P75, DOI 10.1109/86.662623; Krebs HI, 2008, IEEE ENG MED BIOL, V27, P61, DOI 10.1109/MEMB.2008.919498; Krebs HI, 2008, NEUROREHABILITATION, V23, P81; Krebs HI, 2006, P IEEE, V94, P1727, DOI 10.1109/JPROC.2006.880721; Krebs HI, 2000, J REHABIL RES DEV, V37, P639; Krebs HI, 2003, AUTON ROBOT, V15, P7, DOI 10.1023/A:1024494031121; Krebs HI, 1999, P NATL ACAD SCI USA, V96, P4645, DOI 10.1073/pnas.96.8.4645; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Levin MF, 2004, PHYS THER, V84, P8, DOI 10.1093/ptj/84.1.8; Liebermann DG, 2006, CLIN BIOMECH, V21, P8, DOI 10.1016/j.clinbiomech.2005.08.006; Masiero S, 2007, ARCH PHYS MED REHAB, V88, P142, DOI 10.1016/j.apmr.2006.10.032; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Page SJ, 2004, CRIT REV PHYS REHABI, V16, P31, DOI DOI 10.1615/CRITREVPHYSREHABILMED.V16.I1.20; Patton JL, 2004, IEEE T BIO-MED ENG, V51, P636, DOI 10.1109/TBME.2003.821035; Pohl M, 2007, CLIN REHABIL, V21, P17, DOI 10.1177/0269215506071281; Prange GB, 2006, J REHABIL RES DEV, V43, P171, DOI 10.1682/JRRD.2005.04.0076; Reid Denise T, 2002, Pediatr Rehabil, V5, P141, DOI 10.1080/1363849021000039344; Rohrer B, 2002, J NEUROSCI, V22, P8297; Shepherd Roberta B., 2001, Neural Plasticity, V8, P121, DOI 10.1155/NP.2001.121; Stein J, 2004, AM J PHYS MED REHAB, V83, P720, DOI 10.1097/01.PHM.0000137313.14480.CE; Sterr A, 2004, NEUROLOGY, V63, P2176, DOI 10.1212/01.WNL.0000145605.20476.07; TURVEY MT, 1989, NEUROSCIENCE, V33, P1, DOI 10.1016/0306-4522(89)90305-9; Volpe BT, 2001, CURR OPIN NEUROL, V14, P745, DOI 10.1097/00019052-200112000-00011; Volpe BT, 2001, NEUROL CLIN, V19, P903, DOI 10.1016/S0733-8619(05)70053-0; Woodworth W M, 1898, Science, V8, P302, DOI 10.1126/science.8.192.302	46	38	38	0	21	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	1973-9087	1973-9095		EUR J PHYS REHAB MED	Eur. J. Phys. Rehabil. Med.	MAR	2009	45	1					135	141					7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	421VO	WOS:000264386600019	19293759				2022-02-06	
J	Griesbach, GS; Sutton, RL; Hovda, DA; Ying, Z; Gomez-Pinilla, F				Griesbach, Grace Sophia; Sutton, Richard L.; Hovda, David A.; Ying, Zhe; Gomez-Pinilla, Fernando			Controlled Contusion Injury Alters Molecular Systems Associated With Cognitive Performance	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						BDNF; injury; synapsin I; CREB; CAMKII; rat	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; DEPENDENT PROTEIN-KINASE; HIPPOCAMPAL EXCITATORY SYNAPSES; NEUROTROPHIC FACTOR INCREASES; OUTCOME FOLLOWING MODERATE; SPATIAL MEMORY DEFICITS; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; VOLUNTARY EXERCISE	We investigated whether a learning impairment after a controlled cortical impact (CCI) injury was associated with alterations in molecules involved in synaptic plasticity and learning and memory. Adult male rats with moderate CCI to the left parietal cortex, tested in a Morris water maze (MWM) beginning at postinjury day 10, showed impaired cognitive performance compared with sham-treated rats. Tissue was extracted for mRNA analysis on postinjury day 21. The expression of brain-derived neurotrophic factor (BDNF), synapsin 1, cyclic-AMP response element binding protein (CREB), and calcium-calmodulin-dependent protein kinase 11 (alpha-CAMKII) were all significantly decreased compared with sham injury levels within the ipsilateral hippocampus after CCI. No significant molecular level changes were found in the contralateral hippocampus. Decreased expression of BDNF and synapsin I was also found within the ipsilateral parietal cortex of CCI-injured rats compared with shams. However, BDNF and synapsin I expressions were significantly increased in the contralateral parietal cortex of the CCI rats. CREB expression was significantly decreased within the contralateral cortex of the CCI group. These findings show enduring reductions in the expression of BDNF, synapsin 1, CREB, and alpha-CAMKII ipsilateral to a CCI injury, which seem associated with the spatial learning deficits observed in this injury model. In addition, the delayed increase in the expression of BDNF and synapsin I within the cortex contralateral to CCI may reflect restorative processes in areas homotypical to the injury. (C) 2008 Wiley-Liss, Inc.	[Griesbach, Grace Sophia] Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA 90024 USA; [Hovda, David A.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; [Ying, Zhe; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90024 USA		Griesbach, GS (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Box 957039, Los Angeles, CA 90024 USA.	ggriesbach@mednet.ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, R21NS048535] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS027544, NS27544, R21 NS048535, R21 NS048535-02] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NSO48535] Funding Source: Medline		Abel T, 1998, BRAIN RES REV, V26, P360, DOI 10.1016/S0165-0173(97)00050-7; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Ashman TA, 2006, MT SINAI J MED, V73, P999; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Babcock AM, 2002, J NEUROSCI RES, V67, P804, DOI 10.1002/jnr.10169; Babcock AM, 1995, BRAIN RES, V705, P307, DOI 10.1016/0006-8993(95)01155-2; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Cammarota M, 2002, CELL MOL NEUROBIOL, V22, P259, DOI 10.1023/A:1020763716886; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Chu D, 2000, NEUROPEDIATRICS, V31, P63, DOI 10.1055/s-2000-7475; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; de Hoz L, 2005, EUR J NEUROSCI, V22, P745, DOI 10.1111/j.1460-9568.2005.04255.x; Desmurget M, 2007, BRAIN, V130, P898, DOI 10.1093/brain/awl300; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Faddis BT, 1997, J NEUROSCI, V17, P951; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukunaga K, 1999, JPN J PHARMACOL, V79, P7, DOI 10.1254/jjp.79.7; Fukunaga K, 2000, NEUROSCI RES, V38, P3, DOI 10.1016/S0168-0102(00)00139-5; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Glazner GW, 2000, EXP NEUROL, V161, P442, DOI 10.1006/exnr.1999.7242; Gorski JA, 2003, J NEUROSCI, V23, P6856; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAN HQ, 1994, P NATL ACAD SCI USA, V91, P8557, DOI 10.1073/pnas.91.18.8557; Hanover JL, 1999, J NEUROSCI, V19, part. no.; Harris SE, 2006, MOL PSYCHIATR, V11, P505, DOI 10.1038/sj.mp.4001799; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Huh GY, 2001, NEUROSCI LETT, V316, P41, DOI 10.1016/S0304-3940(01)02371-0; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Jansen EM, 1996, BRAIN RES, V708, P93, DOI 10.1016/0006-8993(95)01288-5; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kesslak JP, 1998, BEHAV NEUROSCI, V112, P1012, DOI 10.1037/0735-7044.112.4.1012; Kozlowski DA, 1998, BEHAV BRAIN RES, V97, P89, DOI 10.1016/S0166-4328(98)00030-8; Larsson E, 2002, EXP NEUROL, V177, P1, DOI 10.1006/exnr.2002.7992; Lauterborn JC, 2007, J NEUROSCI, V27, P10685, DOI 10.1523/JNEUROSCI.2624-07.2007; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Liang ZH, 2007, J NEUROCHEM, V103, P2462, DOI 10.1111/j.1471-4159.2007.04942.x; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; Nagy Zoltan, 2002, Ideggyogy Sz, V55, P73; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Save E, 1996, BEHAV NEUROSCI, V110, P74; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Takei N, 1997, J NEUROCHEM, V68, P370; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tropea D, 2003, J NEUROSCI, V23, P7034, DOI 10.1523/JNEUROSCI.23-18-07034.2003; Tully T, 2003, NAT REV DRUG DISCOV, V2, P267, DOI 10.1038/nrd1061; Tyler WJ, 2006, J PHYSIOL-LONDON, V574, P787, DOI 10.1113/jphysiol.2006.111310; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	95	38	41	0	2	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	FEB 15	2009	87	3					795	805		10.1002/jnr.21893			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	404YX	WOS:000263190100022	18831070	Green Accepted			2022-02-06	
J	Freilich, D; Pearce, LB; Pitman, A; Greenburg, G; Berzins, M; Bebris, L; Ahlers, S; McCarron, R				Freilich, Daniel; Pearce, L. Bruce; Pitman, Arkadiy; Greenburg, Gerson; Berzins, Mara; Bebris, Lolita; Ahlers, Steven; McCarron, Richard			HBOC-201 Vasoactivity in a Phase III Clinical Trial in Orthopedic Surgery Subjects-Extrapolation of Potential Risk for Acute Trauma Trials	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Hemoglobin-based oxygen carrier; HBOC-201; Blood substitute; Blood pressure; Vasoactivity; Adverse events; Clinical trial; Serious adverse events; Cardiac biomarkers; Troponin; Trauma; Hemorrhagic shock.	CARDIAC TROPONIN-I; ACUTE CORONARY SYNDROMES; PERIOPERATIVE MYOCARDIAL-INFARCTION; POLYMERIZED HEMOGLOBIN HBOC-201; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; HEMORRHAGIC-SHOCK; BRAIN-INJURY; OXYGEN CARRIER; CREATINE-KINASE	Background: Vasoactivity has hampered progress of hemoglobin-based oxygen carriers (HBOCs) due to concern for adverse blood pressure responses and secondary complications. A recent formulation, highly polymerized HBOC-201 (Biopure, Cambridge, MA), has been found to be less vasoactive than prior less polymerized formulations, and to improve outcome in animal models of hemorrhagic shock (HS) compared with standard resuscitation fluids. HBOCs are envisioned to have life-saving potential for severe trauma patients for whom death due to HS is common despite transport to level I trauma centers. As part of a benefit:risk analysis for a proposed clinical trial of HBOC-201 in patients with traumatic HS, we analyzed data from a previoms phase III clinical trial of this HBOC that involved orthopedic surgery patients, for vasoactivity and related effects, with focus on patients more representative of the trauma population. Study Design: In a previous phase III study involving orthopedic surgery patients, HEM-0115, consented/stabilized patients were randomized to receive HBOC-201 (N = 350) (up to ten 30 g Hb units) or red blood cells (RBC) (N = 338) (up to 9 units) at the first transfusion decision. Systolic blood pressure (SBP) responses, key system and individual adverse events (AEs) and serious adverse events, and cardiac biomarker elevation incidences, were compared in the overall population and subpopulations: with stable trauma, hypotension, and with age stratification (Student's t and Fisher's exact tests, significance p < 0.05). Results: Mild to moderate peak SBP responses were common in HBOC-201 subjects and more common than with RBC in the overall population (mean, 60.8 years old), but less frequent in HBOC-201 subjects with stable trauma, younger age (<50 years old), and hypotension, in whom group differences were narrowed. SBP A responses were more common with HBOC-201 than RBC in the overall population, but not in subjects with stable trauma and <50 year olds, in whom response rates were lower. In the overall population, AEs were more common than with RBC in most systems (also, hypertension and stroke); only cardiac system serious adverse events were more common with HBOC-201. In contrast, there were few significant group differences in stable trauma, hypotensive, and <70 and especially <50-year-old subjects, in whom AE incidences were generally lower. A disproportionate number of key AEs occurred in elderly subjects. Troponin (but not CK-MB) elevation was; more frequent with HBOC-201 than RBC in the overall population but not in <50 year olds, and was not associated with acute coronary syndrome (ACS) or death. Conclusion: Our limited HEM-0115 safety analysis shows that key potentially vasoactivity- related adverse safety signals were more frequent with HBOC-201 than RBC in older patients undergoing orthopedic surgery with rapid access to safe blood transfusions. That incidences of these safety signals were generally lower and group differences narrowed in subpopulations with stable trauma, hypotension, and younger age, suggests an acceptable safety profile in younger acute trauma populations, especially in settings where rapid access to safe blood transfusions is unavailable; confirmation in controlled clinical trials is urgently warranted.	[Freilich, Daniel; Pearce, L. Bruce; Pitman, Arkadiy; Greenburg, Gerson; Berzins, Mara; Bebris, Lolita; Ahlers, Steven; McCarron, Richard] USN, Med Res Ctr, Hematomimet Program, Trauma & Resuscitat Med Dept, Silver Spring, MD USA		Freilich, D (corresponding author), 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	daniel.freilich@med.navy.mil			Biopure Corporation; the U.S. Government [A0315]; Naval Medical Research Center (NMRC) and Biopure Corp; Greenbung, were employees of Biopure Corp.	The HEM-0115 trial was funded and conducted by Biopure Corporation. Salary support for the safety analyses described herein was entirely funded by the U.S. Government (Office of Naval Research Work Unit Number A0315). Naval Medical Research Center (NMRC) and Biopure Corp. have a Cooperative Research and Development Agreement for evaluation of HBOC-201 in trauma clinical trials. No NMRC authors have Financial or other competing interests related to this article. There were no transfers, of funds in any of these agreements. L.B. Pearce, A. Pitman, and G. Greenbung, were employees of Biopure Corp. and may have Financial interest in the subject material, HBOC-201. Their contribution to this manuscript was limited to provision of data tables and editorial review.	ADAMS JE, 1994, NEW ENGL J MED, V330, P670, DOI 10.1056/NEJM199403103301003; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Ammann P, 2003, J AM COLL CARDIOL, V41, P2004, DOI 10.1016/S0735-1097(03)00421-2; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Apple FS, 1997, CLIN CHEM, V43, P2047; Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291; Burhop K, 2004, ARTIF CELL BLOOD SUB, V32, P353, DOI 10.1081/LABB-200027429; Cavallini C, 2005, EUR HEART J, V26, P1494, DOI 10.1093/eurheartj/ehi173; Feinstein AJ, 2005, J TRAUMA, V59, P876, DOI 10.1097/01.ta.0000187654.24146.22; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; George I, 2006, AM J PHYSIOL-HEART C, V291, pH1126, DOI 10.1152/ajpheart.00076.2006; GUEST TM, 1995, JAMA-J AM MED ASSOC, V273, P1945, DOI 10.1001/jama.273.24.1945; Gurney J, 2004, J TRAUMA, V57, P726, DOI 10.1097/01.TA.0000147520.84792.B4; Jaffe AS, 2000, CIRCULATION, V102, P1216, DOI 10.1161/01.CIR.102.11.1216; Jahr JS, 2008, J TRAUMA, V64, P1484, DOI 10.1097/TA.0b013e318173a93f; Jeremias A, 2005, ANN INTERN MED, V142, P786, DOI 10.7326/0003-4819-142-9-200505030-00015; Johnson T, 2006, CRIT CARE MED, V34, P1464, DOI 10.1097/01.CCM.0000215824.85190.89; Katz LM, 2002, RESUSCITATION, V54, P77, DOI 10.1016/S0300-9572(02)00053-9; Kerby JD, 2007, SHOCK, V27, P652, DOI 10.1097/01.shk.0000248584.10400.dc; Kim LJ, 2002, CIRCULATION, V106, P2366, DOI 10.1161/01.CIR.0000036016.52396.BB; LaMuraglia GM, 2000, J VASC SURG, V31, P299, DOI 10.1016/S0741-5214(00)90161-7; Landesberg G, 2005, CRIT CARE MED, V33, P1281, DOI 10.1097/01.CCM.0000166607.22550.87; LENKE LG, 1994, J SPINAL DISORD, V7, P70, DOI 10.1097/00002517-199407010-00010; Levy JH, 2002, J THORAC CARDIOV SUR, V124, P35, DOI 10.1067/mtc.2002.121505; Lim W, 2005, CRIT CARE, V9, pR636, DOI 10.1186/cc3816; Lin JC, 2004, CLIN CHEM, V50, P333, DOI 10.1373/clinchem.2003.026708; Luepker RV, 2003, CIRCULATION, V108, P2543, DOI 10.1161/01.CIR.0000100560.46946.EA; Manning JE, 2000, SHOCK, V13, P152, DOI 10.1097/00024382-200013020-00010; Martinez EA, 2005, J CARDIOTHOR VASC AN, V19, P577, DOI 10.1053/j.jvca.2005.07.002; Millham FH, 2004, J TRAUMA, V56, P1090, DOI 10.1097/01.TA.0000119689.81910.06; Ng SM, 2001, AM J CARDIOL, V87, P994, DOI 10.1016/S0002-9149(01)01436-9; Noble JS, 1999, BRIT J ANAESTH, V82, P41, DOI 10.1093/bja/82.1.41; Patel MB, 2006, J TRAUMA, V61, P46, DOI 10.1097/01.ta.0000219730.71206.3a; Reid TJ, 2003, TRANSFUSION, V43, P280, DOI 10.1046/j.1537-2995.2003.00314.x; Rice J, 2008, J TRAUMA, V64, P1240, DOI 10.1097/TA.0b013e318058245e; Rice J, 2006, J TRAUMA, V61, P1085, DOI 10.1097/01.ta.0000236640.62893.fa; Sanui M, 2006, CRIT CARE MED, V34, P433, DOI 10.1097/01.CCM.0000196206.83534.39; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Sprung J, 2002, ANESTH ANALG, V94, P799, DOI 10.1097/00000539-200204000-00006; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; Victorino GP, 2003, J AM COLL SURGEONS, V196, P679, DOI 10.1016/S1072-7515(03)00128-5; Wong CK, 2005, POSTGRAD MED J, V81, P552, DOI 10.1136/pgmj.2005.035071; WUKICH DK, 1989, J TRAUMA, V29, P375, DOI 10.1097/00005373-198903000-00017	43	38	38	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2009	66	2					365	376		10.1097/TA.0b013e3181820d5c			12	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	408NX	WOS:000263442800011	19204509				2022-02-06	
J	Resch, JA; Villarreal, V; Johnson, CL; Elliott, TR; Kwok, OM; Berry, JW; Underhill, AT				Resch, J. Aaron; Villarreal, Victor; Johnson, Caitlin L.; Elliott, Timothy R.; Kwok, Oi-Man; Berry, Jack W.; Underhill, Andrea T.			Trajectories of Life Satisfaction in the First 5 Years Following Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; life satisfaction; functional independence; hierarchical linear modeling; multilevel modeling	QUALITY-OF-LIFE; GENDER-DIFFERENCES; PUBLIC-HEALTH; UNITED-STATES; OUTCOMES; MILD; VALIDATION; DEPRESSION; MODERATE; WOMEN	Objectives: The trajectories of life satisfaction for 609 individuals who sustained a traumatic brain injury (TBI) were studied. Hierarchical linear modeling analysis examined individual level growth trends over the first 5 years following TBI using gender, functional independence, age, and time to estimate life satisfaction trajectories. Measures: Participants completed the Functional Independence Measure and the Life Satisfaction Inventory at years 1, 2, 4, and 5 after sustaining TBI. Results: Participants who reported higher functional independence at year I also had higher life satisfaction at year 1. Participants with lower functional independence across the 5-year period had life satisfaction trajectories that decreased at significantly greater rates than the individuals with more functional independence. The life satisfaction trajectory declined for the sample, but participants reporting lower cognitive and motor functional independence had significantly greater declines in life satisfaction trajectories. Age and gender were not significant factors in predicting life satisfaction trajectories following TBI. Implications: Individuals with greater cognitive and motor impairments following TBI are likely to experience significant declines in life satisfaction within 5 years of living with TBI.	[Resch, J. Aaron; Villarreal, Victor; Johnson, Caitlin L.; Elliott, Timothy R.; Kwok, Oi-Man] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77845 USA; [Berry, Jack W.; Underhill, Andrea T.] Univ Alabama Birmingham, Injury Control Res Ctr, Birmingham, AL USA		Elliott, TR (corresponding author), Texas A&M Univ, Dept Educ Psychol, 4225 TAMU, College Stn, TX 77845 USA.	telliott@tamu.edu	Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714; Kwok, Oiman/0000-0002-4617-4562	NCIPC CDC HHS [R49-CE000191] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER		ADAMS DL, 1969, J GERONTOL, V24, P470, DOI 10.1093/geronj/24.4.470; Bond T, 2001, APPL RASCH MODEL FUN; Brossart DF, 2002, J PEDIATR PSYCHOL, V27, P97, DOI 10.1093/jpepsy/27.1.97; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; CHANG WC, 1995, ARCH PHYS MED REHAB, V76, P934, DOI 10.1016/S0003-9993(95)80070-0; *COMM INJ SCAL, 1985, ABBR INJ SCAL 1985 R; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Elliott T. R., 2004, COUNSELING DIVERSE P, P151; ELLIOTT TR, 2007, PSYCHOL MANAGEMENT P, P16; ELLIOTT TR, 2002, HDB POSITIVE PSYCHOL, P00687; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fisher G. H., 1976, ADV PSYCHOL ED MEASU, P97; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; Glass TA, 2006, SOC SCI MED, V62, P1650, DOI 10.1016/j.socscimed.2005.08.044; Good GE, 2008, REHABIL PSYCHOL, V53, P39, DOI 10.1037/0090-5550.53.1.39; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hox J.J., 2002, MULTILEVEL ANAL TECH; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; KAPLAN RM, 1994, HEALTH PSYCHOL, V13, P451, DOI 10.1037/0278-6133.13.6.451; Kaplan RM, 2002, ARCH PHYS MED REHAB, V83, pS44, DOI 10.1053/apmr.2002.36955; Kaplan RM, 2005, ANNU REV CLIN PSYCHO, V1, P525, DOI 10.1146/annurev.clinpsy.1.102803.144118; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Lollar DJ, 2003, ANNU REV PUBL HEALTH, V24, P195, DOI 10.1146/annurev.publhealth.24.100901.140844; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Niemeier JP, 2008, DISABIL REHABIL, V30, P166, DOI 10.1080/09638280701532169; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Nosek MA, 2008, DISABIL REHABIL, V30, P174, DOI 10.1080/09638280701532219; Peterson David B., 2008, HDB COUNSELING PSYCH, P212; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; Raftery AE, 1995, SOCIOL METHODOL, V25, P111, DOI 10.2307/271063; RAO VN, 1998, INT J AGING HUM DEV, V14, P55; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V1; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Snijders T. A., 2011, MULTILEVEL ANAL INTR; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tucker JA, 2008, REHABIL PSYCHOL, V53, P279, DOI 10.1037/a0012963; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Wallace KA, 2002, EDUC PSYCHOL MEAS, V62, P674, DOI 10.1177/001316402128775085; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; Wright B. D., 2003, RASCH MEASUREMENT T, V17, P905; [No title captured]	55	38	38	0	12	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2009	54	1					51	59		10.1037/a0015051			9	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	410WJ	WOS:000263608700006	19618703				2022-02-06	
J	Chiaravalloti, N; Balzano, J; Moore, N; DeLuca, J				Chiaravalloti, Nancy D.; Balzano, Julie; Moore, Nancy B.; DeLuca, John			[image omitted]The Open-Trial Selective Reminding Test (OT-SRT) as a Tool for the Assessment of Learning and Memory	CLINICAL NEUROPSYCHOLOGIST			English	Article						Learning; Memory; Neuropsychological assessment; Multiple sclerosis; Selective reminding test	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; COGNITIVE DYSFUNCTION; RETRIEVAL; ACQUISITION; DEFICITS; NEUROPSYCHOLOGY; CONSOLIDATION; PERFORMANCE; STORAGE	The Open Trial Selective Reminding Test (OT-SRT) is a modification of the SRT that also evaluates new learning abilities. The examinee is asked to learn a list of 10 words over a maximum of 15 trials. Using a criterion-referenced approach, the list is repeatedly administered until a criterion of complete recall on two consecutive trials is achieved. Training to criterion provides a better assessment of learning ability than the traditional fixed trial list-learning paradigm. Recall and recognition is then tested 30 and 90 minutes following the learning trials. This paper presents normative data on the OT-SRT for 117 healthy controls (Study 1) and 151 participants with clinically definite multiple sclerosis (Study 2).	[Chiaravalloti, Nancy D.; Balzano, Julie; Moore, Nancy B.; DeLuca, John] Kessler Med Rehabil Res & Educ Ctr, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; [Chiaravalloti, Nancy D.; DeLuca, John] UMDNJ New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [DeLuca, John] UMDNJ New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ USA		Chiaravalloti, N (corresponding author), Kessler Med Rehabil Res & Educ Ctr, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	nchiaravalloti@kmrrec.org			National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [PP0752, RG 2596B2, RG2596A]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD 38249]; UMDNJ Foundation [411-68-0527]; Henry H. Kessler Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD038249] Funding Source: NIH RePORTER	Funded in part by Grant # PP0752, Grant # RG 2596B2, and Grant # RG2596A from the National Multiple Sclerosis Society; Grant # R01 HD 38249 from the National Institutes of Health; Grant # 411-68-0527 from the UMDNJ Foundation, and the Henry H. Kessler Foundation.	[Anonymous], 1993, NEUROPSYCHOLOGY, V7, P364, DOI [DOI 10.1037/0894-4105.7.3.364, 10.1037/0894-4105.7.3.364]; Baddeley A.D., 1994, NEUROPSYCHOLOGY, V8, P485, DOI [10.1037/0894-4105.8.4.485, DOI 10.1037/0894-4105.8.4.485]; BAHRICK HP, 1984, J EXP PSYCHOL GEN, V113, P1, DOI 10.1037/0096-3445.113.1.1; BAHRICK HP, 1975, J EXP PSYCHOL GEN, V104, P54, DOI 10.1037/0096-3445.104.1.54; BAHRICK HP, 1991, J EXP PSYCHOL GEN, V120, P20, DOI 10.1037/0096-3445.120.1.20; BAHRICK HP, 2000, OXFORD HDB MEMORY, P347; BANKS PG, 1987, EXP AGING RES, V13, P203; Beddeley AD., 1974, PSYCHOL LEARN MOTIV, V8, P47, DOI [DOI 10.1016/S0079-7421(08)60452-1, 10.1016/S0079-7421(08)60452-1]; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CAINE ED, 1986, ARCH NEUROL-CHICAGO, V43, P249, DOI 10.1001/archneur.1986.00520030039009; DELIS D, 1987, CALIFORNIA VERBAL LE; Delis D.C., 2000, CVLT 2 CALIFORNIA VE; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; Deluca J., 2004, COMPREHENSIVE HDB PS, P217; Demaree HA, 2000, J CLIN EXP NEUROPSYC, V22, P865, DOI 10.1076/jcen.22.6.865.961; DUQUETTE P, 1992, CAN J NEUROL SCI, V19, P466, DOI 10.1017/S0317167100041664; ERICKSON RC, 1977, PSYCHOL BULL, V84, P1130, DOI 10.1037/0033-2909.84.6.1130; Gaudino EA, 2001, NEUROPSY NEUROPSY BE, V14, P32; Grafman J, 1990, NEUROBEHAVIORAL ASPE, P102; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hart R. P., 1994, NEUROPSYCHOLOGY, V8, P325, DOI [10.1037/0894-4105.8.3.325, DOI 10.1037/0894-4105.8.3.325]; Hochstenbach J, 1998, J CLIN EXP NEUROPSYC, V20, P503, DOI 10.1076/jcen.20.4.503.1471; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lezak MD., 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; LORING DW, 1987, J CLIN EXP NEUROPSYC, V9, P340, DOI 10.1080/01688638708405055; MASUR DM, 1990, J CLIN EXP NEUROPSYC, V12, P529, DOI 10.1080/01688639008400999; MASUR DM, 1989, J CLIN EXP NEUROPSYC, V11, P615, DOI 10.1080/01688638908400920; McKinlay W, 1999, COGNITIVE BEHAV EFFE, P74; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P699, DOI 10.1080/01688638908400926; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1986, J CLIN EXP NEUROPSYC, V8, P503, DOI 10.1080/01688638608405173; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; RUFF RM, 1989, J CLIN EXP NEUROPSYC, V11, P539, DOI 10.1080/01688638908400912; Solari A, 2002, MULT SCLER, V8, P169, DOI 10.1191/1352458502ms780oa; Spreen O, 1991, COMPENDIUM NEUROPSYC; Squire L. R., 1983, MEMORY CONSOLIDATION, P185; Squire LR., 1987, MEMORY BRAIN; THAL LJ, 1983, NEW ENGL J MED, V308, P720; Torres A, 2006, ACTAS ESP PSIQUIATRI, V34, P408; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; WARRINGT.EK, 1970, NATURE, V228, P628, DOI 10.1038/228628a0; WIEDERHOLT WC, 1993, J AM GERIATR SOC, V41, P639, DOI 10.1111/j.1532-5415.1993.tb06738.x; Williams JM, 1991, COGNITIVE BEHAV RATI; [No title captured]	53	38	38	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	2					231	254	PII 793866766	10.1080/13854040802121158			24	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	399LS	WOS:000262802000003	18609311				2022-02-06	
J	Colantonio, A; McVittie, D; Lewko, J; Yin, JL				Colantonio, Angela; McVittie, Doug; Lewko, John; Yin, Junlang			Traumatic brain injuries in the construction industry	BRAIN INJURY			English	Article						Traumatic brain injury; construction	SERIOUS INJURIES; WORK; SLEEPINESS; PERFORMANCE; POPULATION; PREVALENCE; FATALITIES; COSTS; STATE; TIME	Objective: This study analyses factors associated with work-related traumatic brain injury (TBI), specifically in the construction industry in Ontario, Canada. Methods: This cross-sectional study utilized data extracted from the Ontario Workplace Safety and Insurance Board (WSIB) records indicating concussion/intracranial injury that resulted in days off work in 2004-2005. Results: Analyses of 218 TBI cases revealed that falls were the most common cause of injury, followed by being struck by or against an object. Mechanisms of injury and the temporal profile of injury also varied by age. For instance, a significantly higher proportion of injuries occurred in the mornings for young workers compared to older workers. Conclusions: The results of this study provide important information for prevention of TBI which suggest important age-specific strategies for workers in the construction industry.	[Colantonio, Angela] Univ Toronto, Toronto Rehabil Inst, Saunderson Family Chair Acquired Brain Injury Res, Toronto, ON M5G 1V7, Canada; [McVittie, Doug] Construct Safety Assoc, Toronto, ON, Canada; [Lewko, John] Laurentian Univ, Sudbury, ON P3E 2C6, Canada		Colantonio, A (corresponding author), Univ Toronto, Toronto Rehabil Inst, Saunderson Family Chair Acquired Brain Injury Res, 500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765	Ontario Ministry of Health and Long Term Care to the Toronto Rehabilitation Institute and the Toronto Rehabilitation Institute Foundation	We would like to acknowledge Jennifer Fergenbaum and Michelle Mohan for their help with this manuscript. The authors also wish to acknowledge the Ontario MOHLTC's grant to Toronto Rehabilitation Institute. This project was funded by a grant from the Ontario Neurotrauma Foundation. We acknowledge the support of the Construction Safety Association, a grant from the Ontario Ministry of Health and Long Term Care to the Toronto Rehabilitation Institute and the Toronto Rehabilitation Institute Foundation.	Breslau N, 1997, AM J PUBLIC HEALTH, V87, P1649, DOI 10.2105/AJPH.87.10.1649; DERMOLEN H, 2007, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD006251.PUB2; Dinges DF, 1997, SLEEP, V20, P267; Folkard S, 2003, OCCUP MED-OXFORD, V53, P95, DOI 10.1093/occmed/kqg047; Goldenhar LM, 2003, J SAFETY RES, V34, P215, DOI 10.1016/S0022-4375(03)00010-0; Haslam RA, 2005, APPL ERGON, V36, P401, DOI 10.1016/j.apergo.2004.12.002; HEYER NJ, 1994, AM J PUBLIC HEALTH, V84, P1106, DOI 10.2105/AJPH.84.7.1106; Janicak CA, 1998, J OCCUP ENVIRON MED, V40, P347, DOI 10.1097/00043764-199804000-00009; Kim H, 2006, NEUROREHABILITATION, V21, P269; Kim JA, 1997, OCCUPATIONAL THERAPY, V4, P180; Kines P, 2002, J SAFETY RES, V33, P195, DOI 10.1016/S0022-4375(02)00019-1; Kristman VL, 2008, BRAIN INJURY, V22, P51, DOI 10.1080/02699050701849991; MCCLURE R, 2005, COCHRANE DATABASE SY, V25; MCVITTIE DJ, 1995, OCCUP MED, V10, P285; Menard MR, 1996, J OCCUP ENVIRON MED, V38, P1161, DOI 10.1097/00043764-199611000-00017; Mittelmann M, 1991, J Insur Med, V23, P55; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ricci JA, 2007, J OCCUP ENVIRON MED, V49, P1, DOI 10.1097/01.jom.0000249782.60321.2a; RIVARA F, 2000, AM J PREV MED, V18, pS4; Sallinen M, 2004, J SLEEP RES, V13, P285, DOI 10.1111/j.1365-2869.2004.00425.x; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; *STAT CAN, LAB FORC SURV EST N; Statistics Canada, 2008, IND N AM IND CLASS S; Tricco AC, 2006, BRAIN INJURY, V20, P719, DOI 10.1080/02699050600664640; Waehrer GM, 2007, J OCCUP ENVIRON MED, V49, P1218, DOI 10.1097/JOM.0b013e318156ed24; Wrona RM, 2006, J SAFETY RES, V37, P75, DOI 10.1016/j.jsr.2005.08.008	26	38	39	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	11					873	878	PII 915243067	10.1080/02699050903036033			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300003	20100123				2022-02-06	
J	Hoane, MR; Kaufman, N; Vitek, MP; McKenna, SE				Hoane, Michael R.; Kaufman, Nicholas; Vitek, Michael P.; McKenna, Suzanne E.			COG1410 Improves Cognitive Performance and Reduces Cortical Neuronal Loss in the Traumatically Injured Brain	JOURNAL OF NEUROTRAUMA			English	Article						apoE; behavioral recovery; neuronal degeneration; neuroprotection; recovery of function; TBI; trauma	SYSTEM INFLAMMATORY RESPONSE; FLUID PERCUSSION INJURY; CLOSED-HEAD INJURY; E-DEFICIENT MICE; E-BASED PEPTIDE; APOLIPOPROTEIN-E; CONTUSION INJURY; WORKING-MEMORY; MURINE MODEL; FUNCTIONAL RECOVERY	We have previously shown that a single dose of COG1410, a small molecule ApoE-mimetic peptide derived from the apolipoprotein E (ApoE) receptor binding region, improves sensorimotor and motor outcome following cortical contusion injury (CCI). The present study evaluated a regimen of COG1410 following frontal CCI in order to examine its preclinical efficacy on cognitive recovery. Animals were prepared with a bilateral CCI of the frontal cortex. A regimen of COG1410 (0.8 mg/kg intravenously [IV]) was administered twice, at 30 min and again at 24 h post-CCI. Starting on day 11, the animals were tested for their acquisition of a reference memory task in the Morris water maze (MWM), followed by a working memory task in the MWM on day 15. Following CCI, the animals were also tested on the bilateral tactile adhesive removal test to measure sensorimotor dysfunction. On all of the behavioral tests the COG1410 group was no different from the uninjured sham group. Administration of the regimen of COG1410 significantly improved recovery on the reference and working memory tests, as well as on the sensorimotor test. Lesion analysis revealed that COG1410 significantly reduced the size of the injury cavity. Administration of COG1410 also reduced the number of degenerating neurons, as measured by Fluoro-Jade C staining, in the frontal cortex at 48 h post-CCI. These results suggest that a regimen of COG1410 appeared to block the development of significant behavioral deficits and reduced tissue loss. These combined findings suggest that COG1410 appears to have strong preclinical efficacy when administered following traumatic brain injury (TBI).	[Hoane, Michael R.; Kaufman, Nicholas] So Illinois Univ, Ctr Integrat Res Cognit & Neural Sci, Restorat Neurosci Lab, Dept Psychol, Carbondale, IL 62901 USA; [Vitek, Michael P.; McKenna, Suzanne E.] Cognosci Inc, Res Triangle Pk, NC USA; [Vitek, Michael P.] Duke Univ, Med Ctr, Div Neurol, Dept Med, Durham, NC 27710 USA; [Vitek, Michael P.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA		Hoane, MR (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Dept Psychol Life Sci 2, MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Vitek, Michael/0000-0001-8140-8048; Hoane, Michael/0000-0001-7779-2657	Cognosci Inc [R44NS048689, R44AG020473]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS048689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG020473] Funding Source: NIH RePORTER	The research was supported by Cognosci Inc. and by grants R44NS048689 and R44AG020473 from the National Institutes of Health. Dr. Vitek is an Associate Professor of Neurology and an Adjunct Professor of Neurobiology at Duke University Medical Center, and is also Chief Executive Officer of Cognosci, Inc. Cognosci, Inc. has filed for patent protection for COG1410.	Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Fitch RH, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-45; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gay EA, 2006, J PHARMACOL EXP THER, V316, P835, DOI 10.1124/jpet.105.095505; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2005, RESTOR NEUROL NEUROS, V23, P67; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; Means LW, 1996, PHYSIOL BEHAV, V60, P1239, DOI 10.1016/S0031-9384(96)00129-1; MEANS LW, 1993, NEUROBEHAVIORAL PLAS, P67; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Schallert T, 2005, BEHAV LAB RAT, P129; Schulteis G, 2008, ALCOHOL, V42, P459, DOI 10.1016/j.alcohol.2008.05.002; Smith JS, 2000, NEURAL PLAST, V7, P73, DOI 10.1155/NP.2000.73; Tlaskowitz D, 2007, PHARMACOGENOMICS, V8, P959, DOI 10.2217/14E22416.8.8.959; Zareparsi S, 2002, AM J MED GENET, V107, P156, DOI 10.1002/ajmg.10111	41	38	44	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2009	26	1					121	129		10.1089/neu.2008.0565			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	409OW	WOS:000263516700010	19119914	Green Published, Green Accepted			2022-02-06	
J	Zetterberg, H; Tanriverdi, F; Unluhizarci, K; Selcuklu, A; Kelestimur, F; Blennow, K				Zetterberg, Henrik; Tanriverdi, Fatih; Unluhizarci, Kursad; Selcuklu, Ahmet; Kelestimur, Fahrettin; Blennow, Kaj			Sustained release of neuron-specific enolase to serum in amateur boxers	BRAIN INJURY			English	Article						Boxing; biomarkers; neuron-specific enolase; brain injury	TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; ACID-BINDING PROTEINS; NEUROBIOCHEMICAL MARKERS; BIOCHEMICAL MARKERS; CEREBROSPINAL-FLUID; DAMAGE; CHILDREN; BIOMARKERS; MANAGEMENT	Primary objective: We assess the potential of a panel of serum biomarkers to identify chronic neuronal injury in amateur boxers as compared to healthy controls without any history of head trauma. Research design: Observational case-control study. Methods and procedures: A panel of serum biomarkers was measured by a novel biochip array technique on the Evidence Investigator. Serum samples were taken after a 2-month period of nonparticipation in boxing. Main outcomes and results: Boxers had higher serum levels of neuron-specific enolase (NSE, median [range] 11 [2.3-41] ng/mL) than controls (4.8 [0.78-27] ng/mL, p = 0.014) but unchanged levels of the other brain damage biomarker candidates, S-100B, brain-derived neurotrophic factor and heart-type fatty acid binding protein. Conclusions: The more than doubled median serum level of NSE in boxers after an extended resting period suggests that repetitive head trauma results in sustained release of this brain-specific protein to the peripheral circulation.	[Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, S-43180 Molndal, Sweden; [Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, Kayseri, Turkey; [Selcuklu, Ahmet] Erciyes Univ, Sch Med, Dept Neurosurg, Kayseri, Turkey		Zetterberg, H (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, S-43180 Molndal, Sweden.	henrik.zetterberg@gu.se	kelestimur, f/ABE-9873-2021		Scientific and Technical Research Council of TurkeyTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); Swedish Research CouncilSwedish Research CouncilEuropean Commission; Sahlgrenska University Hospital	We thank all study participants and Rita Persson for technical assistance. This study was funded by the Scientific and Technical Research Council of Turkey, the Swedish Research Council and the Sahlgrenska University Hospital.	Auer Johann, 2006, CJEM, V8, P13; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Canadas A., 2006, Journal of Cetacean Research and Management, V8, P13; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; FitzGerald SP, 2005, CLIN CHEM, V51, P1165, DOI 10.1373/clinchem.2005.049429; Grubb NR, 2007, HEART, V93, P1268, DOI 10.1136/hrt.2006.091314; Guleria S, 2008, J NEUROSCI RES, V86, P2271, DOI 10.1002/jnr.21664; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Jauch EC, 2006, STROKE, V37, P2508, DOI 10.1161/01.STR.0000242290.01174.9e; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kemp P L, 1995, J R Nav Med Serv, V81, P182; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; McKeating EG, 1998, ACT NEUR S, V71, P117; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Selakovic V, 2005, J CLIN NEUROSCI, V12, P542, DOI 10.1016/j.jocn.2004.07.019; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; Wunderlich MT, 2005, J NEUROL, V252, P718, DOI 10.1007/s00415-005-0725-z; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	30	38	38	0	0	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	9					723	726	PII 913450247	10.1080/02699050903120399			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	475UR	WOS:000268387600003	19636997				2022-02-06	
J	Ost, M; Nylen, K; Csajbok, L; Blennow, K; Rosengren, L; Nellgard, B				Ost, M.; Nylen, K.; Csajbok, L.; Blennow, K.; Rosengren, L.; Nellgard, B.			Apolipoprotein E polymorphism and gender difference in outcome after severe traumatic brain injury	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						Apolipoprotein E; brain injuries; child; female; Glasgow outcome scale; male; survival rate	AMYLOID BETA-PROTEIN; ALZHEIMERS-DISEASE; E GENOTYPE; APOE IMMUNOREACTIVITY; CEREBROSPINAL-FLUID; TRANSGENIC MICE; NEURONAL DAMAGE; ASSOCIATION; ALLELE; HEMORRHAGE	Background: Traumatic brain injury (TBI) is one of the most common causes of death and dismal outcome among children and young adults. The morbidity and mortality differ but more aggressive monitoring and more designated neuro intensive care units have improved the results. Studies have demonstrated a connection between apolipoprotein E (APOE) genotype and outcome after TBI, but few are prospective and none is from northern Europe. APOE has three alleles: epsilon 2, epsilon 3 and epsilon 4. Methods: A total of 96 patients with Glasgow coma score (GCS) <= 8 were prospectively and consecutively included. APOE genotypes were all analyzed at the same laboratory from blood samples by polymerase chain reaction-restriction fragment length polymorphism. Results: All patients were assessed at 1 year with Glasgow outcome scale extended (GOSE), National Institute of Health Stroke Scale (NIHSS) and the Barthel daily living index. The genotype was available in all patients. Twenty-six patients expressed APOE epsilon 4 while 70 patients did not. Outcome demonstrated that patients with APOE epsilon 4 had worse outcome vs. those lacking this allele. When subdividing patients into gender, males with APOE epsilon 4 did worse, a difference not detected among female patients. Conclusions: APOE epsilon 4 correlated to worse outcome in TBI patients. We also found that males with APOE epsilon 4 had poor outcome while females did not. Thus, the results indicate that genetic polymorphism may influence outcome after TBI.	[Ost, M.; Csajbok, L.; Nellgard, B.] Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care Med, S-41135 Gothenburg, Sweden; [Nylen, K.; Rosengren, L.] Sahlgrens Univ Hosp, Dept Neurol, S-41135 Gothenburg, Sweden; [Blennow, K.] Sahlgrens Univ Hosp, Dept Neurochem, S-41135 Gothenburg, Sweden		Ost, M (corresponding author), Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care Med, S-41135 Gothenburg, Sweden.	martin.ost@gmail.com	Ost, Martin/AAY-5827-2020	Rosengren, Lars/0000-0003-0505-8896	Laerdal Foundation; Mattson's Memorial Foundation; Swedish Medical Grants [S-160 00]	We wish to thank Ingrid Eiving, Ingrid Pettersson and Catherine Ritzen for their excellent contribution to the study. This study was supported by Laerdal Foundation, Mattson's Memorial Foundation and Swedish Medical Grant S-160 00.	Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Blennow K, 2000, J NEURAL TRANSM, V107, P1065, DOI 10.1007/s007020070052; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Corder EH, 2000, ANN NY ACAD SCI, V908, P295; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Erbagci AB, 2002, ACTA CARDIOL, V57, P197, DOI 10.2143/AC.57.3.2005389; Farace E, 2000, Neurosurg Focus, V8, pe6; Gerdes LU, 2003, CLIN CHEM LAB MED, V41, P628, DOI 10.1515/CCLM.2003.094; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Gujral IB, 2006, BRAIN INJURY, V20, P283, DOI 10.1080/02699050500488058; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 2002, J CEREBR BLOOD F MET, V22, P1189, DOI 10.1097/01.wcb.0000037991.07114.4e; Horsburgh K, 2000, EUR J NEUROSCI, V12, P4309, DOI 10.1046/j.1460-9568.2000.01339.x; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jaramillo-Correa JP, 2001, HUM HERED, V52, P14, DOI 10.1159/000053351; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Lambert JC, 2005, J NEUROL NEUROSUR PS, V76, P928, DOI 10.1136/jnnp.2004.048983; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; MAHONEY F I, 1965, Md State Med J, V14, P61; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; McCarron MO, 1999, J NEUROPATH EXP NEUR, V58, P711, DOI 10.1097/00005072-199907000-00005; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Niskakangas T, 2001, STROKE, V32, P1181, DOI 10.1161/01.STR.32.5.1181; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; PEACOCK ML, 1994, NEUROLOGY, V44, P339, DOI 10.1212/WNL.44.2.339; Qiu C, 2004, J NEUROL NEUROSUR PS, V75, P828, DOI 10.1136/jnnp.2003.021493; Thelandersson A, 2006, ACTA ANAESTH SCAND, V50, P937, DOI 10.1111/j.1399-6576.2006.01037.x; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	38	38	39	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2008	52	10					1364	1369		10.1111/j.1399-6576.2008.01675.x			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	361ME	WOS:000260131000011	19025529				2022-02-06	
J	Aquilani, R; Boselli, M; Boschi, F; Viglio, S; Iadarola, P; Dossena, M; Pastoris, O; Verri, M				Aquilani, Roberto; Boselli, Mirella; Boschi, Federica; Viglio, Simona; Iadarola, Paolo; Dossena, Maurizia; Pastoris, Ornella; Verri, Manuela			Branched-chain amino acids may improve recovery from a vegetative or minimally conscious state in patients with traumatic brain injury: A pilot study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amino acids; branched-chain; minimally conscious state; rehabilitation	HIPPOCAMPAL ACETYLCHOLINE-RELEASE; AXONAL INJURY; HEAD-INJURY; INSULIN; METABOLISM; MEMORY; DYSFUNCTION; DISABILITY; INHIBITION; RECEPTORS	Objective: To investigate whether Supplementation With branched-chain amino acids (BCAAs) may improve recovery of patients with a posttramatic vegetative or minimally conscious state. Design: Patients were randomly assigned to 15 days of intravenous BCAA Supplementation (n=22., 19.6g/d) or all isonitrogenous placebo (n = 19). Setting: Tertiary care rehabilitation setting. Participants: Patients (N=41: 29 men, 12 women, mean age,49.5 +/- 21y) with a posttraumatic vegetative or minimally conscious state. 47 24 days after the index traumatic event. Intervention: Supplementation with BCAAs. Main Outcome Measure: Disability Rating Scale (DRS) as log(10)DRS. Results: Fifteen days after admission to the rehabilitation department, the log(10)DRS score improved significantly only in patients who had received BCAAs (log(10)DRS score, 1.365 +/- 0.08 to 1.294 +/- 0.05-, P<.001), while the log(10)DRS score in the placebo recipients remained virtually unchanged (log(10)DRS score, 1.373 +/- 10.03 to 1.37 +/- 10.03; P not significant). The difference in improvement of log(10)DRS score between the 2 groups was highly significant (P<.000). Moreover 682% (n 15) of treated patients achieved a log(10))DRS point score of 477 or higher Q as geometric mean) that allowed them to exit the vegetative or minimally Conscious state. Conclusions: Supplemented BCAAs may improve the recovery from a vegetative or minimally conscious state in patients with posttraumatic vegetative or minimally conscious state.	[Pastoris, Ornella] Univ Pavia, Fac Sci MM FF NN, Sez Farmacol & Biotecnol Farmacol, Dipartimento Sci Fisiol Farmacol Cellulari Mol, I-27100 Pavia, Italy; [Aquilani, Roberto] Fdn S Maugeri, Ist Sci Montescano, Serv Fistopatol Metab Nutr, Pavia, Italy; [Aquilani, Roberto] Fdn S Maugeri, Ist Sci Montescano, Nutr Clin, Pavia, Italy; [Boselli, Mirella] Fdn S Maugeri, Ist Sci Montescano, Div Neuroriabilitaz 2, Pavia, Italy; [Viglio, Simona; Iadarola, Paolo] Univ Pavia, Dipartimento Biochim A Castellani, I-27100 Pavia, Italy		Pastoris, O (corresponding author), Univ Pavia, Fac Sci MM FF NN, Sez Farmacol & Biotecnol Farmacol, Dipartimento Sci Fisiol Farmacol Cellulari Mol, Piazza Botta Pavia 1, I-27100 Pavia, Italy.	labmio@unipv.it		Boselli, Mirella/0000-0003-4545-5271; Pastoris, Ornella/0000-0003-0273-1010; Viglio, Simona/0000-0001-5020-478X			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Aquilani R, 2005, ARCH PHYS MED REHAB, V86, P1729, DOI 10.1016/j.apmr.2005.03.022; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Biolo G, 1997, AM J PHYSIOL-ENDOC M, V273, pE122, DOI 10.1152/ajpendo.1997.273.1.E122; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; CHAPLIN ER, 1976, J NEUROCHEM, V26, P701, DOI 10.1111/j.1471-4159.1976.tb04440.x; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Christie JM, 1999, J NEUROCHEM, V72, P1523, DOI 10.1046/j.1471-4159.1999.721523.x; Clarke D.D., 1998, BASIC NEUROCHEMISTRY, P637; COSTANTINIDIS C, 2002, NAT NEUROSCI, V5, P175; COTMAN CW, 1981, PHYSIOL REV, V61, P684, DOI 10.1152/physrev.1981.61.3.684; DAVIS SN, 1995, J CLIN INVEST, V95, P593, DOI 10.1172/JCI117703; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; FERNSTROM JD, 1978, J NEUROCHEM, V30, P1531, DOI 10.1111/j.1471-4159.1978.tb10489.x; FLIGLEWICZ DP, 1999, HORM METAB RES, V31, P335; GAITONDE MK, 1983, J NEUROCHEM, V41, P1253, DOI 10.1111/j.1471-4159.1983.tb00819.x; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Hall ED, 1996, J NEUROSCI RES, V44, P293, DOI 10.1002/(SICI)1097-4547(19960501)44:3<293::AID-JNR10>3.0.CO;2-6; HENNEBERG N, 1994, NEUROSCI LETT, V175, P153, DOI 10.1016/0304-3940(94)91102-9; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; Jonas EA, 1997, NATURE, V385, P343, DOI 10.1038/385343a0; Kern W, 2001, NEUROENDOCRINOLOGY, V74, P270, DOI 10.1159/000054694; Kern W, 2002, DRUG DEVELOP RES, V56, P511, DOI 10.1002/ddr.10101; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Layman DK, 2002, CAN J APPL PHYSIOL, V27, P646, DOI 10.1139/h02-038; LEHNINGER AL, 1983, PRINCIPI BIOCH; Ma XH, 2003, J NEUROSCI, V23, P1159, DOI 10.1523/JNEUROSCI.23-04-01159.2003; MARKS JL, 1991, ADV EXP MED BIOL, V293, P459; MASTERS BA, 1987, BRAIN RES, V417, P247, DOI 10.1016/0006-8993(87)90449-5; Mattson MP, 1997, NEUROSCI BIOBEHAV R, V21, P193, DOI 10.1016/S0149-7634(96)00010-3; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; Park CR, 2000, PHYSIOL BEHAV, V68, P509, DOI 10.1016/S0031-9384(99)00220-6; Park CR, 2001, NEUROSCI BIOBEHAV R, V25, P311, DOI 10.1016/S0149-7634(01)00016-1; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Ragozzino ME, 1998, J NEUROSCI, V18, P1595; Ragozzino ME, 1996, P NATL ACAD SCI USA, V93, P4693, DOI 10.1073/pnas.93.10.4693; RAIZADA MK, 1988, NEUROCHEM RES, V13, P297, DOI 10.1007/BF00972477; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Spanswick D, 2000, NAT NEUROSCI, V3, P757, DOI 10.1038/77660; STENOIDEN DL, 1998, BASIC NEUROCHEMISTRY, P565; Stockhorst U, 2004, PHYSIOL BEHAV, V83, P47, DOI 10.1016/j.physbeh.2004.07.022; Sweeney G, 1998, MOL CELL BIOCHEM, V182, P121, DOI 10.1023/A:1006805510749; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Volpi E, 1998, J CLIN INVEST, V101, P2000, DOI 10.1172/JCI939; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; ZAMPOLINI M, 2005, EUR MED PHYS S1, V41, P81; Zhao WQ, 2001, MOL CELL ENDOCRINOL, V177, P125, DOI 10.1016/S0303-7207(01)00455-5; 1995, N ENGL J MED, V333, P130	62	38	39	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2008	89	9					1642	1647		10.1016/j.apmr.2008.02.023			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	346GR	WOS:000259057300002	18760149				2022-02-06	
J	Nguyen, HX; Galvan, MD; Anderson, AJ				Nguyen, Hal X.; Galvan, Manuel D.; Anderson, Aileen J.			Characterization of early and terminal complement proteins associated with polymorphonuclear leukocytes in vitro and in vivo after spinal cord injury	JOURNAL OF NEUROINFLAMMATION			English	Article							CENTRAL-NERVOUS-SYSTEM; C5A RECEPTOR; REGULATORY PROTEINS; ALZHEIMERS-DISEASE; ANAPHYLATOXIN C3A; MEMBRANE ATTACK; SLICE CULTURES; CELL-DEATH; EXPRESSION; COMPONENT	Background: The complement system has been suggested to affect injury or disease of the central nervous system (CNS) by regulating numerous physiological events and pathways. The activation of complement following traumatic CNS injury can also result in the formation and deposition of C5b-9 membrane attack complex (C5b-9/MAC), causing cell lysis or sublytic effects on vital CNS cells. Although complement proteins derived from serum/blood-brain barrier breakdown can contribute to injury or disease, infiltrating immune cells may represent an important local source of complement after injury. As the first immune cells to infiltrate the CNS within hours post-injury, polymorphonuclear leukocytes (PMNs) may affect injury through mechanisms associated with complement-mediated events. However, the expression/association of both early and terminal complement proteins by PMNs has not been fully characterized in vitro, and has not observed previously in vivo after traumatic spinal cord injury (SCI). Method: We investigated the expression of complement mRNAs using rt-PCR and the presence of complement proteins associated with PMNs using immunofluroescence and quantitative flow cytometry. Results: Stimulated or unstimulated PMNs expressed mRNAs encoding for C1q, C3, and C4, but not C5, C6, C7 or C9 in culture. Complement protein C1q or C3 was also detected in less than 30% of cultured PMNs. In contrast, over 70% of PMNs that infiltrated the injured spinal cord were associated with C1q, C3, C7 and C5b-9/MAC 3 days post-SCI. The localization/association of C7 or C5b-9/MAC with infiltrating PMNs in the injured spinal cord suggests the incorporation or internalization of C7 or C5b-9/MAC bound cellular debris by infiltrating PMNs because C7 and C5b-9/MAC were mostly localized to granular vesicles within PMNs at the spinal cord epicenter region. Furthermore, PMN presence in the injured spinal cord was observed for many weeks post-SCI, suggesting that this infiltrating cell population could chronically affect complement-mediated events and SCI pathogenesis after trauma. Conclusion: Data presented here provide the first characterization of early and terminal complement proteins associated with PMNs in vitro and in vivo after SCI. Data also suggest a role for PMNs in the local internalization or deliverance of complement and complement activation in the post-SCI environment.	[Nguyen, Hal X.; Anderson, Aileen J.] Univ Calif Irvine, Irvine, CA 92697 USA; [Nguyen, Hal X.] Univ Calif Irvine, Sue & Bill Gross Stem Cell Res Ctr, Irvine, CA 92697 USA; [Anderson, Aileen J.] Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92697 USA		Anderson, AJ (corresponding author), Univ Calif Irvine, 1105 Gillespie Neurosci Res Facil, Irvine, CA 92697 USA.	hnguyen@uci.edu; mgalvan@uci.edu; aja@uci.edu	Anderson, Aileen J/H-5926-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043428] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS43428-01, R01 NS043428] Funding Source: Medline		Anderson Aileen J, 2002, J Spinal Cord Med, V25, P70; Anderson AJ, 2004, J NEUROTRAUM, V21, P1831, DOI 10.1089/0897715042664894; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Bagamery K, 2005, CYTOM PART A, V65A, P84, DOI 10.1002/cyto.a.20133; BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Benard M, 2004, J BIOL CHEM, V279, P43487, DOI 10.1074/jbc.M404124200; Bohana-Kashtan O, 2004, MOL IMMUNOL, V41, P583, DOI 10.1016/j.molimm.2004.04.007; Boos L, 2004, J IMMUNOL, V173, P4708, DOI 10.4049/jimmunol.173.7.4708; BOTTO M, 1992, J IMMUNOL, V149, P1348; Danet GH, 2002, P NATL ACAD SCI USA, V99, P10441, DOI 10.1073/pnas.162104799; Duce JA, 2006, NEUROBIOL AGING, V27, P633, DOI 10.1016/j.neurobiolaging.2005.03.027; Fan R, 2004, EXP NEUROL, V185, P241, DOI 10.1016/j.expneurol.2003.09.023; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; GASQUE P, 1995, J IMMUNOL, V154, P4726; Gasque P, 1997, AM J PATHOL, V150, P31; Ghiran I, 2003, J BIOL CHEM, V278, P21024, DOI 10.1074/jbc.M302306200; HAYS AP, 1988, J NEUROIMMUNOL, V18, P231, DOI 10.1016/0165-5728(88)90101-4; HOGASEN AKM, 1995, J IMMUNOL, V154, P4734; JACK RM, 1988, J IMMUNOL, V140, P4286; Johns TG, 1997, MOL IMMUNOL, V34, P33, DOI 10.1016/S0161-5890(97)00005-9; JOHNSON E, 1988, SCAND J IMMUNOL, V27, P489, DOI 10.1111/j.1365-3083.1988.tb02375.x; Jones TB, 2005, J NEUROSCI, V25, P6576, DOI 10.1523/JNEUROSCI.0305-05.2005; Jurianz K, 2001, INT J CANCER, V93, P848, DOI 10.1002/ijc.1406; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Krickhahn M, 2001, Ann Transplant, V6, P48; Lukasser-Vogl E, 2000, FEMS IMMUNOL MED MIC, V28, P15, DOI 10.1111/j.1574-695X.2000.tb01452.x; MARCHBANK KJ, 1995, IMMUNOLOGY, V85, P146; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Nataf S, 2001, BRAIN RES, V894, P321, DOI 10.1016/S0006-8993(01)02003-0; Nguyen HX, 2003, J PHYSIOL-LONDON, V547, P125, DOI 10.1113/jphysiol.2002.031450; NGUYEN HX, J NEUROCHEM IN PRESS, P7; Oka R, 2001, EUR J CANCER, V37, P1158, DOI 10.1016/S0959-8049(01)00089-2; OKUDA T, 1991, INT IMMUNOL, V3, P293, DOI 10.1093/intimm/3.4.293; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; PETTERSEN HB, 1990, SCAND J IMMUNOL, V31, P15, DOI 10.1111/j.1365-3083.1990.tb02738.x; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Qian ZP, 1999, AM J PATHOL, V155, P1293, DOI 10.1016/S0002-9440(10)65231-5; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; QUIGG RJ, 1995, J IMMUNOL, V155, P1481; Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004; Read RW, 2006, EXP EYE RES, V82, P389, DOI 10.1016/j.exer.2005.07.011; Reynolds DN, 2004, ANN NY ACAD SCI, V1035, P165, DOI 10.1196/annals.1332.011; Rus H, 2005, IMMUNOL RES, V33, P103, DOI 10.1385/IR:33:2:103; Rus H, 2001, IMMUNOL RES, V24, P79, DOI 10.1385/IR:24:1:79; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Tenner AJ, 2001, NEUROBIOL AGING, V22, P849, DOI 10.1016/S0197-4580(01)00301-3; van Beek J, 2001, NEUROREPORT, V12, P289, DOI 10.1097/00001756-200102120-00022; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; Walker DG, 1998, BRAIN RES, V809, P31, DOI 10.1016/S0006-8993(98)00811-7; Weaver KD, 2000, J TRAUMA, V48, P1081, DOI 10.1097/00005373-200006000-00014; WOOD A, 1993, J NEUROSCI, V13, P3319; Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com; WURZNER R, 1994, J IMMUNOL, V152, P4624; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Yu Chia-Lu, 1995, Proceedings of the National Science Council Republic of China Part B Life Sciences, V19, P225	60	38	40	1	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUN 25	2008	5								26	10.1186/1742-2094-5-26			13	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	325SD	WOS:000257607700001	18578885	Green Published, gold			2022-02-06	
J	von Arx, T; Flury, R; Tschan, J; Buergin, W; Geiser, T				von Arx, T.; Flury, R.; Tschan, J.; Buergin, W.; Geiser, T.			Exercise capacity in athletes with mouthguards	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						spiroergometry; exercise capacity; mouthguard; athlete; breathing; performance	OROFACIAL INJURIES; CUSTOM-MADE; DENTAL INJURIES; MOUTH GUARDS; CONCUSSIONS; SPORTS	The objective of this study was to determine the effect of wearing a mouthguard on maximal exercise capacity and cardiopulmonary parameters at peak workload, and to assess the athletes' attitudes toward wearing a mouthguard. Thirteen volunteer male athletes (18 to 27 years old) were interviewed before and after delivery of a custom-made laminated mouthguard. A visual analogue scale (VAS, 0-100 mm) was used for judgment of interference with breathing, speaking, concentration and athletic performance. In addition, the athletes were subjected to a cardiorespiratory examination on a cycle ergometer with and without mouthguards. Subjectively, the athletes rated the mean interference with performance to be 37 mm VAS at the beginning of the study. Mean scores of impairment decreased to 23 mm VAS (p = 0.081) after wearing the mouthguard for four weeks, and further improved to 12 mm VAS (p < 0.001) after the test on the cycle ergometer. Objectively, the maximum workload during spiroergometry was even slightly elevated during exercise with the mouthguard (330.2 W) compared to exercise without the mouthguard (314.5 W). Peak minute ventilation and oxygen uptake were not different during exercise with and without the mouthguard. The present study demonstrated that a custom-made mouthguard does not significantly affect or reduce maximum exercise performance of athletes.	[von Arx, T.; Tschan, J.; Buergin, W.] Univ Bern, Dept Oral Surg & Stomatol, CH-3010 Bern, Switzerland; [Flury, R.; Geiser, T.] Univ Bern, Dept Pulm Med, CH-3010 Bern, Switzerland		von Arx, T (corresponding author), Univ Bern, Dept Oral Surg & Stomatol, Freiburgstr 7, CH-3010 Bern, Switzerland.	thomas.vonarx@zmk.unibe.ch					Amis T, 2000, MED SCI SPORT EXER, V32, P284, DOI 10.1097/00005768-200002000-00006; Brunner E., 2002, NONPARAMETRIC ANAL L; Chapman PJ, 1996, AUST DENT J, V41, P252, DOI 10.1111/j.1834-7819.1996.tb04869.x; Cornwell H, 2003, DENT TRAUMATOL, V19, P193, DOI 10.1034/j.1600-9657.2003.00202.x; Delaney JS, 2005, CLIN J SPORT MED, V15, P154, DOI 10.1097/01.jsm.0000158256.85664.8d; DEYOUNG AK, 1994, J AM DENT ASSOC, V125, P1112, DOI 10.14219/jada.archive.1994.0121; Eroglu E, 2006, DENT TRAUMATOL, V22, P193, DOI 10.1111/j.1600-9657.2006.00385.x; FLANDERS RA, 1995, J AM DENT ASSOC, V126, P491, DOI 10.14219/jada.archive.1995.0213; Francis K T, 1991, Br J Sports Med, V25, P227; Kececi AD, 2005, DENT TRAUMATOL, V21, P276, DOI 10.1111/j.1600-9657.2005.00354.x; Kvittem B, 1998, J PUBLIC HEALTH DENT, V58, P288, DOI 10.1111/j.1752-7325.1998.tb03011.x; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Lieger O, 2006, DENT TRAUMATOL, V22, P1, DOI 10.1111/j.1600-9657.2006.00328.x; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; MORROW RM, 1991, J ATHL TRAINING, V26, P344; SCOTT J, 1994, BRIT DENT J, V176, P310, DOI 10.1038/sj.bdj.4808433; SEALS RR, 1985, J AM DENT ASSOC, V110, P904, DOI 10.14219/jada.archive.1985.0005; Takeda T, 2005, DENT TRAUMATOL, V21, P134, DOI 10.1111/j.1600-9657.2005.00320.x; Tschan Jorg D, 2003, Schweiz Monatsschr Zahnmed, V113, P20; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Woodmansey KF, 1997, J AM COLL HEALTH, V45, P179, DOI 10.1080/07448481.1997.9936880; Yamada T, 1998, ENDOD DENT TRAUMATOL, V14, P84	22	38	38	1	11	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	MAY	2008	29	5					435	438		10.1055/s-2007-965341			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	306GV	WOS:000256237200015	17614035				2022-02-06	
J	Gueorguieva, I; Clark, SR; McMahon, CJ; Scarth, S; Rothwell, NJ; Tyrell, PJ; Hopkins, SJ; Rowland, M				Gueorguieva, Ivelina; Clark, Simon R.; McMahon, Catherine J.; Scarth, Sylvia; Rothwell, Nancy J.; Tyrell, Pippa J.; Hopkins, Stephen J.; Rowland, Malcolm			Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						interleukin-1 receptor antagonist; pharmacokinetics; CSF; patients; modelling; subarachnoid haemmorage; ischemia	BLOOD-BRAIN-BARRIER; CEREBRAL-ISCHEMIA; STROKE PATIENTS; RAT; INFARCTION; ANAKINRA; SYSTEM; INJURY; SAFETY; DAMAGE	AIM The naturally occurring interlukin-1 receptor antagonist (IL-1RA) markedly protects rodents against ischaemic, excitotoxic and traumatic brain injury, suggesting it may be of therapeutic value. The aim was to determine the pharmacokinetics of IL-1RA in cerebrospinal fluid (CSF) of patients, to allow modelling that would aid development of therapeutic regimens. METHODS When administered intravenously to patients soon after stroke, IL-1RA is safe and reduces the peripheral inflammatory response. However, IL-1RA is a large protein (17 kDa), which may limit brain penetration, thereby limiting its potential utility in brain injury. In seven patients with subarchnoid haemorrhage (SAH), IL-1RA was administered by intravenous bolus, then infusion for 24 h, and both blood and CSF, via external ventricular drains, were sampled during and after stopping the infusion. RESULTS Plasma steady-state concentrations were rapidly attained and maintained throughout the infusion, whereas CSF concentrations rose slowly towards a plateau during the 24-h infusion, reaching at best only 4% of that in plasma. Plasma kinetic parameters were within the literature range. Modelling of the combined data yielded rate constants entering and leaving the CSF of 0.0019 h(-1) [relative standard error (RSE) = 19%] and 0.1 h(-1) (RSE = 19%), respectively. CONCLUSIONS Peripherally administered IL-1RA crosses slowly into and out of the CSF of patients with SAH. However, there is a large concentration gradient of IL-1RA between plasma and CSF. These CSF:plasma data are consistent with very low permeation of IL-1RA into the CSF and elimination kinetics from it controlled by the volumetric turnover of CSF.	[Gueorguieva, Ivelina] Eli Lilly & Co, Global PK PD, Windlesham GU20 6PH, Surrey, England; [Gueorguieva, Ivelina; Rowland, Malcolm] Univ Manchester, Ctr Appl Pharmacokinet Res, Sch Pharm & Pharmaceut Sci, Manchester, Lancs, England; [Clark, Simon R.; McMahon, Catherine J.; Scarth, Sylvia; Tyrell, Pippa J.; Hopkins, Stephen J.] Hope Hosp, Stroke Serv, Salford M6 8HD, Lancs, England; [Clark, Simon R.; Rothwell, Nancy J.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Clark, Simon R.] Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Liverpool, Merseyside, England		Gueorguieva, I (corresponding author), Eli Lilly & Co, Global PK PD, Sunninghill Rd,EMC Bldg, Windlesham GU20 6PH, Surrey, England.	gueorguieva_ivelina@lilly.com	Hopkins, Stephen/I-7363-2015; Clark, Simon/AAT-5610-2020	Hopkins, Stephen/0000-0001-7644-2823; Tyrrell, Pippa/0000-0001-9609-1231	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G19/24] Funding Source: UKRI; The Sir Jules Thorn Charitable Trust [02JTA] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G19/24] Funding Source: Medline		ALKASSAB S, 1981, ACTA NEUROL SCAND, V64, P438; Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; BEAL S, 1980, AM STAT, V34, P118, DOI 10.2307/2684123; BERNE RM, 1990, PRINCIPLES PHYSL, P66; Clark SR, 2008, J CEREBR BLOOD F MET, V28, P387, DOI 10.1038/sj.jcbfm.9600537; CLARK SR, 2005, J CEREBRAL FLOW META, V25, pS45; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; GRANOWTIZ EV, 1992, CYTOKINE, V4, P353, DOI 10.1016/1043-4666(92)90078-6; GUTIERREZ EG, 1994, J NEUROIMMUNOL, V55, P153, DOI 10.1016/0165-5728(94)90005-1; Hammarlund-Udenaes M, 2000, ADV DRUG DELIVER REV, V45, P283, DOI 10.1016/S0169-409X(00)00109-5; KANDEL ER, 2000, PRINCIPLES NEURAL SC, P1296; Kosteljanetz M, 1988, Br J Neurosurg, V2, P161, DOI 10.3109/02688698808992665; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Luetmer PH, 2002, NEUROSURGERY, V50, P534, DOI 10.1097/00006123-200203000-00020; MAHONEY F I, 1965, Md State Med J, V14, P61; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; Nuki G, 2002, ARTHRITIS RHEUM, V46, P2838, DOI 10.1002/art.10578; Rapoport S. I., 1976, BLOOD BRAIN BARRIER; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Rothwell NJ, 1997, INT REV NEUROBIOL, V40, P281; Sheiner L, 1998, NONMEM USERS GUIDES; TEASDALE G, 1974, LANCET, V2, P81; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; VEROTTA D, 1995, J PHARMACOKINET BIOP, V23, P1, DOI 10.1007/BF02353780; Yang BB, 2003, CLIN PHARMACOL THER, V74, P85, DOI 10.1016/S0009-9236(03)00094-8	32	38	40	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	MAR	2008	65	3					317	325		10.1111/j.1365-2125.2007.03026.x			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	268VD	WOS:000253607000004	17875190	Green Published, Bronze			2022-02-06	
J	Sheth, RN; Manzano, G; Li, XM; Levi, AD				Sheth, Rishi N.; Manzano, Glen; Li, Xiuming; Levi, Allan D.			Transplantation of human bone marrow-derived stromal cells into the contused spinal cord of nude rats - Laboratory investigation	JOURNAL OF NEUROSURGERY-SPINE			English	Article						bone marrow stromal cells; differentiation; neuroprotection; rat; spinal cord injury; transplantation	MESENCHYMAL STEM-CELLS; COLONY-STIMULATING FACTOR; PROMOTE FUNCTIONAL RECOVERY; TRAUMATIC BRAIN-INJURY; IN-VITRO; SCHWANN-CELL; ADULT-RAT; NEURONAL DIFFERENTIATION; NEUROTROPHIC FACTORS; CEREBROSPINAL-FLUID	Object. Human bone marrow stromal cells (hMSCs) constitute a potential source of pluripotent stem cells. In the present study, hMSCs were transplanted into an area of spinal cord contusion in nude rats to determine their survival, differentiation, potential for neuroprotection, and influence on axonal growth and functional recovery. Methods. Twenty-nine animals received 6 x 10(5) hMSCs in 6 mu l medium 1 week after a contusion, while 14 control animals received an injection of 6 RI medium alone. Basso-Beattie-Bresnahan (BBB) tests were performed weekly. The spinal cords were collected at 6 weeks posttransplantation for histological analysis and assessment of tissue injury. Results. Immunostaining with anti-human mitochondria antibody and pretransplantation labeling with green fluorescent protein demonstrated that the grafted hMSCs survived and were capable of achieving a flattened appearance in the grafted area; however, none of the transplanted cells stained positively for human-specific neuronal, anti-neurofilament H or glial fibrillary acidic protein within the sites of engraftment. While neuronal or astrocytic differentiation was not seen, cells lining blood vessels in the vicinity of the transplant stained positively for antihuman endothelium CD 105 antibody. Staining for anti-neurofilament H antibody demonstrated abundant axonlike structures around the transplanted area in the hMSC group. Tissue sparing analysis showed that animals with grafted hMSCs had a smaller area of contusion cyst compared with controls, but there was no significant difference between the two groups in BBB scores. Conclusions. The grafted hMSCs survived for >= 6 weeks posttransplantation, although they did not differentiate into neural or glial cells. Cells with human endothelial characteristics were observed. Spinal cord-injured rats grafted with hMSCs had smaller contusion cavities, which did not have a significant influence on functional recovery.	[Sheth, Rishi N.; Manzano, Glen; Levi, Allan D.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Lois Pope LIFE Ctr, Miami, FL 33136 USA; [Li, Xiuming; Levi, Allan D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA		Levi, AD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Lois Pope LIFE Ctr, 1095 NW 14th Terrace,D4-6, Miami, FL 33136 USA.	alevi@med.miami.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P40RR017447] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P40RR017447] Funding Source: NIH RePORTER		Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059; Abouelfetouh A, 2004, BRAIN RES, V1029, P114, DOI 10.1016/j.brainres.2004.07.092; Akiyama Y, 2002, J NEUROSCI, V22, P6623; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BASSO DM, 1996, NEUROTRAUMA, V13, P343; BERESFORD JN, 1992, J CELL SCI, V102, P341; Blits B, 2005, RESTOR NEUROL NEUROS, V23, P313; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Casella GTB, 2002, EXP NEUROL, V173, P63, DOI 10.1006/exnr.2001.7827; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Corti S, 2002, J NEUROSCI RES, V70, P721, DOI 10.1002/jnr.10455; Deng YB, 2006, CYTOTHERAPY, V8, P210, DOI 10.1080/14653240600760808; Du Y, 2005, BLOOD, V106, P3932, DOI 10.1182/blood-2005-03-1113; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Grove JE, 2004, STEM CELLS, V22, P487, DOI 10.1634/stemcells.22-4-487; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Guest JD, 1997, EXP NEUROL, V148, P502, DOI 10.1006/exnr.1997.6693; Hamano K, 2000, CELL TRANSPLANT, V9, P439, DOI 10.1177/096368970000900315; Hess DC, 2004, EXP NEUROL, V186, P134, DOI 10.1016/j.expneurol.2003.11.005; Hill CE, 2006, GLIA, V53, P338, DOI 10.1002/glia.20287; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Inoue M, 2003, GLIA, V44, P111, DOI 10.1002/glia.10285; Jin KL, 2003, EXP NEUROL, V184, P78, DOI 10.1016/S0014-4886(03)00133-X; Kitchel SH, 2005, NEUROSURGERY, V57, P286, DOI 10.1227/01.NEU.0000176412.17360.95; Koda M, 2007, BRAIN RES, V1149, P223, DOI 10.1016/j.brainres.2007.02.058; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Koshizuka S, 2004, J NEUROPATH EXP NEUR, V63, P64, DOI 10.1093/jnen/63.1.64; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; LENNON DP, 1995, EXP CELL RES, V219, P211, DOI 10.1006/excr.1995.1221; LEVI ADO, 1994, EXP NEUROL, V130, P41, DOI 10.1006/exnr.1994.1183; LEVI ADO, 1994, J NEUROSCI, V14, P1309, DOI 10.1523/JNEUROSCI.14-03-01309.1994; Lou SJ, 2003, BRAIN RES, V968, P114, DOI 10.1016/S0006-8993(03)02224-8; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu P, 2005, EXP NEUROL, V193, P273, DOI 10.1016/j.expneurol.2005.01.031; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Munoz-Elias G, 2003, STEM CELLS, V21, P437, DOI 10.1634/stemcells.21-4-437; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Ono K, 2003, J NEUROSCI RES, V72, P503, DOI 10.1002/jnr.10588; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Padovan CS, 2003, CELL TRANSPLANT, V12, P839, DOI 10.3727/000000003771000183; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Plant GW, 2003, J NEUROTRAUM, V20, P1, DOI 10.1089/08977150360517146; Prockop DJ, 2001, CYTOTHERAPY, V3, P393, DOI 10.1080/146532401753277229; Rismanchi N, 2003, BRAIN RES, V991, P46, DOI 10.1016/j.brainres.2003.07.004; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Satake K, 2004, SPINE, V29, P1971, DOI 10.1097/01.brs.0000138273.02820.0a; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Sigurjonsson OE, 2005, P NATL ACAD SCI USA, V102, P5227, DOI 10.1073/pnas.0501029102; Suzuki H, 2004, BIOCHEM BIOPH RES CO, V322, P918, DOI 10.1016/j.bbrc.2004.07.201; Swanger SA, 2005, CELL TRANSPLANT, V14, P775, DOI 10.3727/000000005783982594; Sykova E, 2006, CELL TRANSPLANT, V15, P675, DOI 10.3727/000000006783464381; Sykova E, 2006, CELL MOL NEUROBIOL, V26, P1113, DOI 10.1007/s10571-006-9007-2; Takami T, 2002, J NEUROSCI, V22, P6670; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; TEWARIE RDN, 2006, CELL TRANSPLANT, V15, P563, DOI DOI 10.3727/000000006783981602; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; Wakitani S, 2004, CELL TRANSPLANT, V13, P595, DOI 10.3727/000000004783983747; Walczak P, 2004, J NEUROSCI RES, V76, P244, DOI 10.1002/jnr.20042; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Ye M, 2005, NEUROREPORT, V16, P581, DOI 10.1097/00001756-200504250-00013; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004	86	38	50	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654			J NEUROSURG-SPINE	J. Neurosurg.-Spine	FEB	2008	8	2					153	162		10.3171/SPI/2008/8/2/153			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	259JD	WOS:000252934700008	18248287				2022-02-06	
J	Dolce, G; Quintieri, M; Serra, S; Lagani, V; Pignolo, L				Dolce, G.; Quintieri, M.; Serra, S.; Lagani, V.; Pignolo, L.			Clinical signs and early prognosis in vegetative state: A decisional tree, data-mining study	BRAIN INJURY			English	Article						vegetative state; early prognosis; data mining; classification and regression tree	TRAUMATIC BRAIN-INJURY; INTRATHECAL BACLOFEN; OWN NAME; CONSCIOUSNESS; STIMULATION; UNAWARENESS; PREDICTION; DYSTONIA; RECOVERY	Background and purpose: Residual brain function has been documented in vegetative state patients, yet early prognosis remains difficult. The purpose of this study was to identify by artificial intelligence procedures (classification and regression trees, data-mining) the significant neurological signs correlated to and predictive of outcome. Methods: Three hundred and thirty-three patients in vegetative state of traumatic or non-traumatic aetiology referred to the S.Anna Institute were retrospectively studied. Twenty-two neurological signs were assessed according to criteria included in the UNI ENI ISO 9001 : 2000 quality standards at admission (Time(0)) and after 50, 100 or 180 days and entered into a CART (classification and regression tree) data-mining procedure with a decisional tree j48 (Weka software and 10-fold cross-validation). Outcome was conventionally rated by the Glasgow outcome scale. Results and conclusions: Re-appearance with proper timing of spontaneous motility, eye tracking and oculo-cephalic reflex and disappearance of oral automatisms proved highly correlated to outcome and allowed early and reliable prognosis. These findings are consistent with the brain functional organization thought to sustain consciousness and warrant systematic investigation. Classification and regression trees and data-mining procedures proved applicable in neurology to sort out significant clinical signs also in clinical conditions characterized by paucity of signs such as the vegetative state. Extended application in clinical medicine is conceivable based on the approach peculiarities.	[Dolce, G.; Quintieri, M.; Serra, S.] S Anna Inst, Intens Care Unit Vegetat State, I-88900 Crotone, Italy; [Lagani, V.; Pignolo, L.] Univ Calabria, Dept Elect Informat & Syst, I-87036 Cosenza, Italy		Dolce, G (corresponding author), S Anna Inst, Intens Care Unit Vegetat State, Via Siris 11, I-88900 Crotone, Italy.	giulianodolce@libero.it	Serra, Sebastiano/AAP-8391-2021				ANDREWS K, 1996, INT WORKING PARTY RE; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Barton John, 2005, Stud Health Technol Inform, V117, P89; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; Breiman L., 1984, CLASSIFICATION REGRE; BRICOLO A, 1976, HDB CLIN NEUROLOGY, P699; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; DOLCE G, 1973, ELECTROEN CLIN NEURO, V34, P647, DOI 10.1016/0013-4694(73)90010-2; Dolce G., 2002, POSTTRAUMATIC VEGETA; ERMES M, 2007, C P IEEE ENG MED BIO, V1, P3056; Fins JJ, 2007, CURR OPIN NEUROL, V20, P650, DOI 10.1097/WCO.0b013e3282f11f6d; FRANK E, 2004, MACHINE LEARNING WEK; Han J., 2001, DATA MINING CONCEPTS; HASSLER R, 1969, ELECTROEN CLIN NEURO, V27, P306, DOI 10.1016/0013-4694(69)90060-1; Hassler R., 1972, PATHOPHISIOLOGIE BEW, P1; Hildebrandt H, 2007, J NEUROL SCI, V260, P150, DOI 10.1016/j.jns.2007.04.035; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; Jennett B., 2002, VEGETATIVE STATE; Jimenez-Fernandez Silvia, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P2064; JOHN ER, 2008, LANCET IN PRESS; JUNG R, 1967, PSYCHIAT GEGENWART, V1, P612; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, NEUROLOGY, V63, P916, DOI 10.1212/01.WNL.0000137421.30792.9B; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Laureys S, 2007, CONSCIOUS COGN, V16, P722, DOI 10.1016/j.concog.2007.04.004; Machado C, 2007, CLIN EEG NEUROSCI, V38, P124, DOI 10.1177/155005940703800306; Morita I, 2007, ACTA NEUROCHIR SUPPL, V97, P455; Owen AM, 2007, ARCH NEUROL-CHICAGO, V64, P1098, DOI 10.1001/archneur.64.8.1098; Owen AM, 2007, CURR OPIN NEUROL, V20, P632, DOI 10.1097/WCO.0b013e3282f15669; Owen AM, 2005, NEUROPSYCHOL REHABIL, V15, P290, DOI 10.1080/09602010443000579; Pang BC, 2007, J NEUROTRAUM, V24, P136, DOI 10.1089/neu.2006.0113; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Qiu J, 2007, LANCET NEUROL, V6, P946, DOI 10.1016/S1474-4422(07)70255-7; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Richard I, 2007, ACTA NEUROCHIR SUPPL, V97, P213; Riva G, 2003, CYBERPSYCHOL BEHAV, V6, P295, DOI 10.1089/109493103322011597; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Rubel Paul, 2004, Stud Health Technol Inform, V108, P123; SAMSON WT, 2004, KNOWLEDGE BASED DECI; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SAZBON L, 1991, ACTA NEUROCHIR, V112, P110, DOI 10.1007/BF01405137; SAZBON L, 1993, J NEUROL NEUROSUR PS, V56, P407, DOI 10.1136/jnnp.56.4.407; Staffen W, 2006, J NEUROL NEUROSUR PS, V77, P1383, DOI 10.1136/jnnp.2006.095166; STEINBERG D, 1997, CART CLASSIFICATION; STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/j.2517-6161.1974.tb00994.x; Taira T, 2007, ACTA NEUROCHIR SUPPL, V97, P227; TEASDALE G, 1974, LANCET, V2, P81; VANBEMMEL JH, 1997, HDB MED INFORM; Witten IH, 1999, DATA MINING PRACTICA; XIAO YXA, 2007, BRAIN INJURY, V21, P575; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	55	38	39	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					617	623		10.1080/02699050802132503			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300014	18568716				2022-02-06	
S	Ratan, RR; Siddiq, A; Aminova, L; Langley, B; McConoughey, S; Karpisheva, K; Lee, HH; Carmichael, T; Kornblum, H; Coppola, G; Geschwind, DH; Hoke, A; Smirnova, N; Rink, C; Roy, S; Sen, C; Beattie, MS; Hart, RP; Grumet, M; Sun, DM; Freeman, RS; Semenza, GL; Gazaryan, I		Gibson, GE; Ratan, RR; Beal, MF		Ratan, Rajiv R.; Siddiq, Ambreena; Aminova, Leila; Langley, Brett; McConoughey, Stephen; Karpisheva, Ksenia; Lee, Hsin-Hwa; Carmichael, Thomas; Kornblum, Harley; Coppola, Giovanni; Geschwind, Daniel H.; Hoke, Ahmet; Smirnova, Natalya; Rink, Cameron; Roy, Sashwati; Sen, Chandan; Beattie, Michael S.; Hart, Ron P.; Grumet, Martin; Sun, Dongming; Freeman, Robert S.; Semenza, Gregg L.; Gazaryan, Irina			Small Molecule Activation of Adaptive Gene Expression Tilorone or Its Analogs Are Novel Potent Activators of Hypoxia Inducible Factor-1 That Provide Prophylaxis against Stroke and Spinal Cord Injury	MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Mitochondria and Oxisative Stress in Neurodegenerative Disorders	SEP 26-29, 2007	New York Acad Sci, New York, NY	Weill Med Coll, Cornell Univ, Grad Sch Med Sci, Ellison Med Fdn, Burke Med Res Inst	New York Acad Sci	homeostasis; hypoxia; hypoxia inducible factor; iron; hypoxia response element; erythropoietin; vascular endothelial growth factor; tilorone; desferrioxamine; prolyl hydroxylase	FOCAL CEREBRAL-ISCHEMIA; SIGNALING PATHWAY; INHIBITION; RATS; NEUROPROTECTION; HYDROCHLORIDE; INFARCTION; RECOVERY; DAMAGE	A major challenge for neurological therapeutics is the development of small molecule drugs that can activate a panoply of downstream pathways without toxicity. Over the past decade our group has shown that a family of enzymes that regulate posttranscriptional and transcriptional adaptive responses to hypoxia are viable targets for neuronal protection and repair. The family is a group of iron, oxygen, and 2-oxoglutarate-dependent dioxygenases, known as the HIF prolyl 4-hydroxylases (HIF PHDs). We have previously shown that pluripotent protection offered by iron chelators is mediated, in part, via the ability of these agents to inhibit the HIF PHDs. Our group and others have implicated the transcriptional activator HIF-1 in some of the salutary effects of iron chelation-induced PHD inhibition. While some iron chelators are currently employed in humans for conditions such as hemochromatosis, the diverse utilization of iron in physiological processes in the brain makes the development of HIF activators that do not bind iron a high priority. Here we report the development of a high throughput screen to develop novel HIF activators and/or PHD inhibitors for therapeutic use in the central nervous system (CNS). We show that tilorone, a low-molecular weight, antiviral, immunomodulatory agent is the most effective activator of the HIF pathway in a neuronal line. We also show that tilorone enhances HIF protein levels and increases the expression of downstream target genes independent of iron chelation and HIF PHD inhibition in vitro. We further demonstrate that tilorone can activate an HIF-regulated reporter gene in the CNS. These studies confirm that tilorone can penetrate the blood-brain barrier to activate HIF in the CNS. As expected from these findings, we show that tilorone provides effective prophylaxis against permanent ischemic stroke and traumatic spinal cord injury in male rodents. Altogether these findings identify tilorone as a novel and potent modulator of HIF-mediated gene expression in neurons with neuroprotective properties.	[Ratan, Rajiv R.; Siddiq, Ambreena; Langley, Brett; McConoughey, Stephen; Karpisheva, Ksenia; Lee, Hsin-Hwa; Smirnova, Natalya; Gazaryan, Irina] Cornell Univ, Weill Med Coll, Burke Cornell Med Res Inst, White Plains, NY USA; [Aminova, Leila] Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02138 USA; [Carmichael, Thomas; Kornblum, Harley; Coppola, Giovanni; Geschwind, Daniel H.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Hoke, Ahmet] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Rink, Cameron; Roy, Sashwati; Sen, Chandan] Ohio State Univ, Heart Blood & Lung Inst, Columbus, OH 43210 USA; [Hart, Ron P.; Grumet, Martin; Sun, Dongming] Rutgers State Univ, Keck Ctr Collaborat Neurosci, Piscataway, NJ 08855 USA; [Freeman, Robert S.] Univ Rochester, Dept Pharmacol, Rochester, NY 14642 USA; [Semenza, Gregg L.] Johns Hopkins Univ, Sch Med, Dept Genet, Inst Cell Engn, Baltimore, MD USA; [Ratan, Rajiv R.; Siddiq, Ambreena; Langley, Brett; McConoughey, Stephen; Karpisheva, Ksenia; Lee, Hsin-Hwa; Smirnova, Natalya; Gazaryan, Irina] New York State Ctr Res Excellence Spinal Cord Inj, New York, NY USA; [Beattie, Michael S.] Univ Calif San Francisco, Brain & Spinal Cord Injury Ctr, San Francisco, CA 94143 USA; [Aminova, Leila] Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA		Ratan, RR (corresponding author), Cornell Univ, Weill Med Coll, Burke Cornell Med Res Inst, 785 Mamaroneck Ave, White Plains, NY USA.		Rink, Cameron/E-3954-2011; Langley, Brett C/P-7207-2017; grumet, martin/ABC-6462-2020; Beattie, Michael S/A-8953-2009; Gazaryan, Irina G/T-8578-2017; Hart, Ronald/D-5219-2009; Rink, Cameron/AAA-4484-2021; Hart, Ronald/G-6530-2019	Langley, Brett C/0000-0003-4009-2109; Gazaryan, Irina G/0000-0002-9670-5579; Hart, Ronald/0000-0003-4836-8712; Hoke, Ahmet/0000-0003-1215-3373; Carmichael, S Thomas/0000-0002-1169-9203; Rink, Cameron/0000-0002-3149-3624	New York State Department of Health [CO 19972]; Center for Research Excellence in Spinal Cord Injury; Adelson Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS045242, R01NS058868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG014930] Funding Source: NIH RePORTER	We would like to gratefully acknowledge the technical and intellectual input of Dr. Juan Chavez who contributed several figures to this manuscript and Dr. Joe LaManna. The work was funded by New York State Department of Health Contract (CO 19972); the Center for Research Excellence in Spinal Cord Injury, and the Adelson Foundation for Neurorehabilitation and Repair.	Alcaro S, 2005, J CHEM INF MODEL, V45, P602, DOI 10.1021/ci0496595; Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; BELAYEV L, 1996, STROKE, V27, P1623; Briggs CA, 2008, BRIT J PHARMACOL, V153, P1054, DOI 10.1038/sj.bjp.0707649; Chandra P, 1977, Top Curr Chem, V72, P125; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Freeman RS, 2005, CNS NEUROL DISORD-DR, V4, P85, DOI 10.2174/1568007053005154; Freret T, 2006, EUR J NEUROSCI, V23, P1757, DOI 10.1111/j.1460-9568.2006.04699.x; Ghosh P, 2004, EUR J CELL BIOL, V83, P257, DOI 10.1078/0171-9335-00374; Hashimoto M, 2007, J NEUROSCI, V27, P3603, DOI 10.1523/JNEUROSCI.4805-06.2007; Heemskerk Jill, 2002, Trends in Neurosciences, V25, P494, DOI 10.1016/S0166-2236(02)02236-1; KRUEGER RF, 1970, SCIENCE, V169, P1213, DOI 10.1126/science.169.3951.1213; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; Nishi K, 2008, ANTIOXID REDOX SIGN, V10, P983, DOI 10.1089/ars.2007.1825; POLLACK A, 1980, CYTOMETRY, V1, P57, DOI 10.1002/cyto.990010112; Ratan RR, 2007, J MOL MED, V85, P1331, DOI 10.1007/s00109-007-0283-1; Ratan RR, 2004, STROKE, V35, P2687, DOI 10.1161/01.STR.0000143216.85349.9e; Savitz SI, 2007, ANN NEUROL, V61, P396, DOI 10.1002/ana.21127; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SEMENZA GL, 2007, SCI STKE, pCM8, DOI DOI 10.1126/STKE.4072007CM8; Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389; Siddiq A, 2005, J BIOL CHEM, V280, P41732, DOI 10.1074/jbc.M504963200; Siddiq A, 2007, NEUROCHEM RES, V32, P931, DOI 10.1007/s11064-006-9268-7; Stoize I. P., 2006, NOVART FDN SYMP, V272, P25; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Woo KJ, 2006, BIOCHEM BIOPH RES CO, V343, P8, DOI 10.1016/j.bbrc.2006.02.116	29	38	40	0	9	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-713-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2008	1147						383	394		10.1196/annals.1427.033			12	Cell Biology; Multidisciplinary Sciences; Neurosciences; Physiology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Physiology	BIR99	WOS:000262397800034	19076458	Green Accepted			2022-02-06	
J	Larson, MJ; Kaufman, DAS; Schmalfuss, IM; Perlstein, WM				Larson, Michael J.; Kaufman, David A. S.; Schmalfuss, Ilona M.; Perlstein, William M.			Performance monitoring, error processing, and evaluative control following severe TBI	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; event-related potentials; error-related negativity; stroop; cognitive control; error monitoring	ANTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSIVE DISORDER; EVENT-RELATED POTENTIALS; MEDIAL FRONTAL-CORTEX; CLOSED-HEAD INJURY; COGNITIVE CONTROL; PREFRONTAL CORTEX; WORKING-MEMORY; FUNCTIONAL-SIGNIFICANCE	Patients with severe traumatic brain injury (TBI) often demonstrate impairments in performance monitoring - an evaluative control process that can be measured using the error-negativity/error-related negativity (Ne/ERN) and post-error positivity (Pe). The Ne/ERN and Pe are event-related potential (ERP) components generated following errors, with current theories suggesting the Ne/ERN reflects automatic performance monitoring and the Pe reflects error processing and awareness. To elucidate the electrophysiological mechanisms of performance monitoring deficits following severe TBI, behavioral and ERP measurements were obtained, whereas participants with severe TBI and neurologically-healthy comparison participants performed a modified color-naming version of the Stroop task. Behaviorally, both groups demonstrated robust response-time (RT) and error-rate interference. Participants with TBI exhibited generalized RT slowing; no significant between-groups interactions were present for RTs or error rates. ERP results indicate Ne/ERN amplitude was attenuated in participants with TBI, whereas the pattern of Pe amplitude did not clearly differentiate groups. Findings suggest the Ne/ERN as a potential electrophysiological marker of evaluative control/performance monitoring impairment following TBI. Implications for future research and potential clinical application as well as potential limitations in conducting electrophysiological research in neurologically-impaired populations are discussed.	Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; N Florida S Georgia Vet Adm Hosp, Gainesville, FL USA; Univ Florida, Dept Med, Gainesville, FL USA; Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL USA		Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC Box 100165, Gainesville, FL 32610 USA.	wmp@phhp.ufl.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01 MH01857, R21 MH073076] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31 NS053335] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH073076, K01MH001857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS053335] Funding Source: NIH RePORTER		Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Benedict, 2001, HOPKINS VERBAL LEARN; Benton A., 1976, MULTILINGUAL APHASIA; BERTRAND O, 1985, ELECTROEN CLIN NEURO, V62, P462, DOI 10.1016/0168-5597(85)90058-9; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Braver TS, 1999, BIOL PSYCHIAT, V46, P312, DOI 10.1016/S0006-3223(99)00116-X; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; CLARK JH, 1924, J PHYSL OPTICS, V5, P269; Cohen J., 2013, STAT POWER ANAL BEHA; Dias R, 2000, EUR J NEUROSCI, V12, P4457, DOI 10.1046/j.0953-816X.2000.01323.x; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; FONTAINE A, 1996, P AUST BRAIN INJ SOC, V1, P98; Gehring WJ, 2001, J NEUROSCI, V21, P9430, DOI 10.1523/JNEUROSCI.21-23-09430.2001; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Hajcak G, 2003, PSYCHOPHYSIOLOGY, V40, P895, DOI 10.1111/1469-8986.00107; Hajcak G, 2003, BIOL PSYCHOL, V64, P77, DOI 10.1016/S0301-0511(03)00103-0; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P615, DOI 10.1017/S1355617707070762; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Larson MJ, 2006, NEUROREPORT, V17, P329, DOI 10.1097/01.wnr.0000199461.01542.db; Levine B., 2002, PRINCIPLES FRONTAL L, P448; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Mathalon DH, 2002, J ABNORM PSYCHOL, V111, P22, DOI 10.1037//0021-843X.111.1.22; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miltner WHR, 2003, BIOL PSYCHOL, V64, P157, DOI 10.1016/S0301-0511(03)00107-8; MOCKS J, 1988, PSYCHOPHYSIOLOGY, V25, P217; Neter J., 1985, APPL LINEAR STAT MOD; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Picton T. W., 1995, HDB NEUROPSYCHOLOGY, V10, P3; RABBITT PMA, 1968, Q J EXP PSYCHOL, V20, P179, DOI 10.1080/14640746808400146; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; RATCLIFF R, 1993, PSYCHOL BULL, V114, P510, DOI 10.1037/0033-2909.114.3.510; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Ruchsow M, 2006, J PSYCHIATR RES, V40, P37, DOI 10.1016/j.jpsychires.2005.02.002; Ruchsow M, 2004, PSYCHOPHYSIOLOGY, V41, P833, DOI 10.1111/j.1469-8986.2004.00237.x; Rushworth MFS, 2003, J COGNITIVE NEUROSCI, V15, P338, DOI 10.1162/089892903321593072; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Speilberger C, 1983, MANUAL STATE TRAIT A; Stemmer B, 2004, NEUROPSYCHOLOGIA, V42, P118, DOI 10.1016/S0028-3932(03)00121-0; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; TEASDALE G, 1974, LANCET, V2, P81; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Vidal F, 2000, BIOL PSYCHOL, V51, P109, DOI 10.1016/S0301-0511(99)00032-0; Walton ME, 2003, J NEUROSCI, V23, P6475; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WOODY CD, 1967, MED BIOL ENG, V5, P539, DOI 10.1007/BF02474247; Yeung N, 2006, PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-9280.2006.01680.x	69	38	39	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2007	13	6					961	971		10.1017/S1355617707071305			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	227GK	WOS:000250645000006	17942014				2022-02-06	
J	Vaccari, JCDR; Corriveau, RA; Belousov, AB				Vaccari, Juan Carlos de Rivero; Corriveau, Roderick A.; Belousov, Andrei B.			Gap junctions are required for NMDA receptor-dependent cell death in developing neurons	JOURNAL OF NEUROPHYSIOLOGY			English	Article							DEVELOPING RAT-BRAIN; GLOBAL-ISCHEMIA; INTERCELLULAR COMMUNICATION; ELECTRICAL SYNAPSES; EFFECTIVE REDUCTION; CEREBRAL-ISCHEMIA; TRAUMATIC INJURY; OXIDATIVE STRESS; NERVOUS-SYSTEM; RODENT MODEL	A number of studies have indicated an important role for N-methyl-D-aspartate (NMDA) receptors in cell survival versus cell death decisions during neuronal development, trauma, and ischemia. Coupling of neurons by electrical synapses (gap junctions) is high or increases in neuronal networks during all three of these conditions. However, whether neuronal gap junctions contribute to NMDA receptor-regulated cell death is not known. Here we address the role of neuronal gap junction coupling in NMDA receptor-regulated cell death in developing neurons. We report that inactivation or hyperactivation of NMDA receptors induces neuronal cell death in primary hypothalamic cultures, specifically during the peak of developmental gap junction coupling. In contrast, increasing or decreasing NMDA receptor function when gap junction coupling is low has no or greatly reduced impact on cell survival. Pharmacological inactivation of gap junctions or knockout of neuronal connexin 36 prevents the cell death caused by NMDA receptor hypofunction or hyperfunction. The results indicate the critical role of neuronal gap junctions in cell death caused by increased or decreased NMDA receptor function in developing neurons. Based on these data, we propose the novel hypothesis that NMDA receptors and gap junctions work in concert to regulate neuronal survival.	Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, Baton Rouge, LA 70803 USA; Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA; Coriell Inst Med Res, Camden, NJ USA		Belousov, AB (corresponding author), Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, 2146 W 39th Ave,MS 3051, Kansas City, KS 66160 USA.	abelousov@kumc.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR-16816] Funding Source: Medline; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA-015088] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR016816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA015088] Funding Source: NIH RePORTER		Adams SM, 2004, J NEUROSCI, V24, P9441, DOI 10.1523/JNEUROSCI.3290-04.2004; Al-Ubaidi MR, 2000, J NEUROSCI RES, V59, P813, DOI 10.1002/(SICI)1097-4547(20000315)59:6<813::AID-JNR14>3.3.CO;2-R; Arumugam H, 2005, NAT NEUROSCI, V8, P1720, DOI 10.1038/nn1588; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bani-Yaghoub M, 1999, DEV GENET, V24, P69, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<69::AID-DVG8>3.0.CO;2-M; Becker DL, 1999, EXP NEUROL, V156, P326, DOI 10.1006/exnr.1999.7027; Belluardo N, 2000, BRAIN RES, V865, P121, DOI 10.1016/S0006-8993(00)02300-3; Belousov AB, 2001, J NEUROSCI, V21, P2015, DOI 10.1523/JNEUROSCI.21-06-02015.2001; Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Blanc EM, 1998, J NEUROCHEM, V70, P958; Buss Robert R., 2004, Anatomical Science International, V79, P191, DOI 10.1111/j.1447-073x.2004.00088.x; Chang QA, 2000, J NEUROSCI, V20, P674, DOI 10.1523/JNEUROSCI.20-02-00674.2000; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; CHOI DW, 1987, J NEUROSCI, V7, P357; Cole K, 2004, INT J DEV NEUROSCI, V22, P485, DOI 10.1016/j.ijdevneu.2004.07.015; CONNORS BW, 1983, J NEUROSCI, V3, P773; Contestabile A, 2000, BRAIN RES REV, V32, P476, DOI 10.1016/S0165-0173(00)00018-7; Cusato K, 2006, CELL DEATH DIFFER, V13, P1707, DOI 10.1038/sj.cdd.4401876; Cusato K, 2003, J NEUROSCI, V23, P6413; Davis EC, 1996, BRAIN RES, V734, P10, DOI 10.1016/0006-8993(96)00298-3; de Pina-Benabou MH, 2005, STROKE, V36, P2232, DOI 10.1161/01.STR.0000182239.75969.d8; De Vuyst E, 2006, EMBO J, V25, P34, DOI 10.1038/sj.emboj.7600908; Deans MR, 2001, NEURON, V31, P477, DOI 10.1016/S0896-6273(01)00373-7; Farahani R, 2005, GLIA, V50, P351, DOI 10.1002/glia.20213; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Frantseva MV, 2002, J CEREBR BLOOD F MET, V22, P453, DOI 10.1097/00004647-200204000-00009; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Gulisano M, 2000, NEUROREPORT, V11, P3823, DOI 10.1097/00001756-200011270-00045; Hardingham GE, 2002, BBA-PROTEINS PROTEOM, V1600, P148, DOI 10.1016/S1570-9639(02)00455-7; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Kandler Karl, 1995, Current Opinion in Neurobiology, V5, P98, DOI 10.1016/0959-4388(95)80093-X; Long MA, 2005, NAT NEUROSCI, V8, P61, DOI 10.1038/nn1361; LOTURCO JJ, 1991, SCIENCE, V252, P563, DOI 10.1126/science.1850552; Nakase T, 2003, STROKE, V34, P1987, DOI 10.1161/01.STR.0000079814.72027.34; Nakazawa K, 2004, NAT REV NEUROSCI, V5, P361, DOI 10.1038/nrn1385; Nodin C, 2005, J NEUROCHEM, V94, P1111, DOI 10.1111/j.1471-4159.2005.03241.x; OBRIETAN K, 1995, J NEUROPHYSIOL, V73, P1524, DOI 10.1152/jn.1995.73.4.1524; Oguro K, 2001, J NEUROSCI, V21, P7534, DOI 10.1523/JNEUROSCI.21-19-07534.2001; Ozog MA, 2002, J NEUROPATH EXP NEUR, V61, P132, DOI 10.1093/jnen/61.2.132; PARSON SH, 1995, NEURODEGENERATION, V4, P99, DOI 10.1006/neur.1995.0012; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Rami A, 2000, EXP NEUROL, V170, P297, DOI 10.1006/exnr.2001.7712; Rash JE, 2000, P NATL ACAD SCI USA, V97, P7573, DOI 10.1073/pnas.97.13.7573; Rawanduzy A, 1997, J NEUROSURG, V87, P916, DOI 10.3171/jns.1997.87.6.0916; Scemes E, 1998, GLIA, V24, P74, DOI 10.1002/(SICI)1098-1136(199809)24:1<74::AID-GLIA8>3.3.CO;2-J; SCHEETZ AJ, 1994, FASEB J, V8, P745, DOI 10.1096/fasebj.8.10.8050674; SIMPSON I, 1977, SCIENCE, V195, P294, DOI 10.1126/science.831276; Siushansian R, 2001, J COMP NEUROL, V440, P387, DOI 10.1002/cne.1392; Sohl G, 1998, FEBS LETT, V428, P27, DOI 10.1016/S0014-5793(98)00479-7; Striedinger K, 2005, EUR J NEUROSCI, V22, P605, DOI 10.1111/j.1460-9568.2005.04228.x; Thompson RJ, 2006, SCIENCE, V312, P924, DOI 10.1126/science.1126241; Udawatte C, 2005, APOPTOSIS, V10, P1019, DOI 10.1007/s10495-005-0776-8; Vaccari JCD, 2006, P NATL ACAD SCI USA, V103, P16971, DOI 10.1073/pnas.0608068103; Valiunas V, 2004, AM J PHYSIOL-CELL PH, V287, pC1596, DOI 10.1152/ajpcell.00225.2004; Velazquez JLP, 2006, EUR J NEUROSCI, V23, P1, DOI 10.1111/j.1460-9568.2005.04523.x; Velazquez JLP, 2003, NEUROSCIENTIST, V9, P5, DOI 10.1177/1073858402239586; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; Yoon WJ, 2003, J NEUROCHEM, V85, P525, DOI 10.1046/j.1471-4159.2003.01724.x; Yoshida M, 2000, NEUROSCI RES, V36, P1, DOI 10.1016/S0168-0102(99)00100-5; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008	64	38	39	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	NOV	2007	98	5					2878	2886		10.1152/jn.00362.2007			9	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	230UB	WOS:000250900300035	17855590				2022-02-06	
J	Clark, RSB; Vagni, VA; Nathaniel, PD; Jenkins, LW; Dixon, CE; Szabo, C				Clark, Robert S. B.; Vagni, Vincent A.; Nathaniel, Paula D.; Jenkins, Larry W.; Dixon, C. Edward; Szabo, Csaba			Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD(+) depletion and improves water maze performance after traumatic brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; head injury; ideno-isoquinolone; nicotinamide adenine dinucleotide; poly(ADP-ribose) synthetase	NF-KAPPA-B; CELL-DEATH; PEROXYNITRITE; TRANSCRIPTION; RIBOSYLATION; ACTIVATION; STRESS; P53	Poly( ADP-ribose) polymerase-1 (PARP-1) is an enzyme best known for its role in DNA repair and as a mediator of NAD(+) depletion and energy failure- induced cell death. We tested the effect of the potent and selective ideno-isoquinolone PARP-1 inhibitor INO-1001 after controlled cortical impact (CCI) in mice. Anesthetized adult male mice were subjected to moderate CCI ( velocity 6 m/sec, depth 1.2 mm) or sham-injury. Immediately after CCI or sham-injury mice received either INO1001 (1.6 mg/kg) or vehicle via intracerebral injection (5 mu l over 5 min) in a randomized fashion. At 2 h, contused brain tissue was dissected and NAD(+) levels were measured. Separate mice underwent neuropathological outcome tests that included spatial memory acquisition ( Morris water maze days 14 - 20), and assessment of contusion volume and hippocampal cell death at day 21. Local treatment with INO-1001 preserved brain NAD(+) levels 2 h after CCI (vehicle = 67 +/- 7.6, INO-1001 = 95.8 +/- 4.4% uninjured hemisphere; n = 6/group, p = 0.03). In the Morris water maze, treatment with INO-1001 reduced the latency to find the hidden platform and increased the time spent in the target quadrant versus vehicle after CCI (n = 11/group, p <= 0.05). Histological damage did not differ between vehicle and INO-1001-treated mice after CCI. Treatment with INO-1001 prevented NAD(+) depletion and improved outcome, although modestly, identifying PARP-mediated energy failure as a contributor to the pathological sequelae of TBI. Further study testing the effects of PARP inhibitors is warranted, specifically in models of brain injury where energy failure is seen.	Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA		Clark, RSB (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Szabo, Csaba/ABG-2644-2021; Szabo, Csaba/D-1882-2013		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS30318, R01 NS38620, R44 NS37985] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, R44NS037985, P50NS030318] Funding Source: NIH RePORTER		Abusaad I, 1999, J COMP NEUROL, V408, P560, DOI 10.1002/(SICI)1096-9861(19990614)408:4<560::AID-CNE9>3.0.CO;2-P; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Cohen-Armon M, 2004, SCIENCE, V304, P1820, DOI 10.1126/science.1096775; DAWSON TM, 1995, NEW HORIZONS, V3, P86; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Jagtap PG, 2005, J MED CHEM, V48, P5100, DOI 10.1021/jm0502891; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; Pacher P, 2004, J PHARMACOL EXP THER, V311, P485, DOI 10.1124/jpet.104.069658; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	22	38	38	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1399	1405		10.1089/neu.2007.0305			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500011	17711401				2022-02-06	
J	Giovannetti, T; Bettcher, BM; Libon, DJ				Giovannetti, Tania; Bettcher, Brianne Magouirk; Libon, David J.			Environmental adaptations improve everyday action performance in Alzheimer's disease: Empirical support from performance-based assessment	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		naturalistic action; activities of daily living; instrumental activities of daily living; rehabilitation; remediation	PROCEDURAL MEMORY STIMULATION; SUBCORTICAL VASCULAR DEMENTIA; CLOSED-HEAD-INJURY; NATURALISTIC ACTION; ACTION IMPAIRMENT; INTERVENTION; DEFICITS; NEUROPSYCHOLOGY; REHABILITATION; CAREGIVERS	Neuropsychologists often recommend that patients with dementia and their caregivers use environmental adaptations to improve everyday functioning. Although these recommendations are intuitive (e.g., reduce clutter), most have never been experimentally tested. This study examined whether and how environmental adaptations improved everyday action in Alzheimer's disease (AD). Forty-six outpatients completed the Naturalistic Action Test (NAT; M. F. Schwartz, L. J. Buxbaum, M. Ferraro, T. Veramonti, & M. Segal, 2003), which requires completion of 3 everyday tasks. The NAT was administered under 2 conditions: standard and user centered. The standard NAT followed the procedures of the manual; object placement was standardized, but objects were not meaningfully arranged on the tabletop. In the user-centered NAT, objects were arranged in the order needed in the task, and a visual cue to monitor performance was placed on the table. These conditions were counterbalanced across participants. The user-centered condition improved performance on all NAT items and reduced commission and omission error rates. However, post hoc examination of commission error types showed improvement of substitution and off-task errors but no difference in anticipation and perseveration errors. Thus, environmental adaptations improved everyday performance in AD by facilitating task accomplishment, object selection, and task-congruent actions.	Temple Univ, Dept Psychol, Philadelphia, PA 19122 USA; Univ Med & Dent New Jersey, Sch Osteopath Med, New Jersey Inst Successful Aging, Newark, NJ 07103 USA		Giovannetti, T (corresponding author), Temple Univ, Dept Psychol, Weiss Hall,1701 N 13th St, Philadelphia, PA 19122 USA.	tgio@temple.edu	Giovannetti, Tania/H-3491-2019	Giovannetti, Tania/0000-0001-5661-152X			Adam S, 2000, NEUROPSYCHOL REHABIL, V10, P485, DOI 10.1080/09602010050143568; AKRITAS MG, 1994, J AM STAT ASSOC, V89, P336, DOI 10.2307/2291230; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Avila R, 2004, BRAZ J MED BIOL RES, V37, P1721, DOI 10.1590/S0100-879X2004001100018; Brawley EC, 2001, AGING MENT HEALTH, V5, pS79; Buxbaum LJ, 1998, COGNITIVE NEUROPSYCH, V15, P617, DOI 10.1080/026432998381032; Charness N, 2001, Aging Ment Health, V5, P65; CICERONE K, 1991, NEUROPSYCHOLOGY EVER; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Cohen J., 2013, STAT POWER ANAL BEHA; CORCORAN MA, 1992, AM J OCCUP THER, V46, P801, DOI 10.5014/ajot.46.9.801; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Farina E, 2002, ACTA NEUROL SCAND, V105, P365, DOI 10.1034/j.1600-0404.2002.01086.x; Faverjon S, 2002, NEUROLOGY, V59, P1356, DOI 10.1212/01.WNL.0000033588.59005.55; FITTS PM, 1953, J EXP PSYCHOL, V46, P199, DOI 10.1037/h0062827; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forde EME, 2002, NEUROCASE, V8, P151, DOI 10.1076/neur.8.1.151.16236; Giovannetti T, 2006, J INT NEUROPSYCH SOC, V12, P45, DOI 10.1017/S1355617706060012; Giovannetti T, 2002, J INT NEUROPSYCH SOC, V8, P633, DOI 10.1017/S135561770280131X; Giovannetti T, 2002, NEUROPSYCHOLOGIA, V40, P1220, DOI 10.1016/S0028-3932(01)00229-9; Giovannetti T, 2006, ARCH CLIN NEUROPSYCH, V21, P607, DOI 10.1016/j.acn.2006.05.005; GIOVANNETTICARE.T, 1997, NEUROPSYCHOLOGY, V11, P400; Gitlin LN, 2001, GERONTOLOGIST, V41, P4, DOI 10.1093/geront/41.1.4; Guilarte TR, 2003, ANN NEUROL, V53, P50, DOI 10.1002/ana.10399; Hartmann K, 2005, NEUROPSYCHOLOGIA, V43, P625, DOI 10.1016/j.neuropsychologia.2004.07.015; Humphreys GW, 1998, COGN NEUROPSYCHOL, V15, P771; Irvine GI, 2006, HIPPOCAMPUS, V16, P149, DOI 10.1002/hipo.20142; JOSEPHSSON S, 1993, INT J GERIATR PSYCH, V8, P395, DOI 10.1002/gps.930080505; JOSEPHSSON S, 1995, OCCUP THER J RES, V15, P36, DOI 10.1177/153944929501500103; Kaplan E, 1983, BOSTON NAMING TEST; Kempermann G, 1999, HIPPOCAMPUS, V9, P321, DOI 10.1002/(SICI)1098-1063(1999)9:3<321::AID-HIPO11>3.0.CO;2-C; KNOPMAN DS, 1988, J AM GERIATR SOC, V36, P108, DOI 10.1111/j.1532-5415.1988.tb01778.x; Lamar M, 2002, NEUROPSYCHOLOGIA, V40, P435, DOI 10.1016/S0028-3932(01)00125-7; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LEVINE B, 2000, J CLIN EXPT NEUROPSY, V20, P30; Libon DJ, 2004, CLIN NEUROPSYCHOL, V18, P83, DOI 10.1080/13854040490507181; Libon DJ, 1996, ARCH CLIN NEUROPSYCH, V11, P193; LIBON DJ, 2005, J INT NEUROPSYCHO S1, V11, P92; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Noale M, 2003, DEMENT GERIATR COGN, V16, P7, DOI 10.1159/000069987; NORMAN D, 1990, NEUROLOGY, V65, P376; REASON J, 1990, HUAMN ERROR; Rusted J, 2002, NEUROCASE, V8, P111, DOI 10.1093/neucas/8.1.111; Schwartz MF, 1999, NEUROPSYCHOLOGIA, V37, P51; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; Segal, 2003, NATURALISTIC ACTION; Seigal S, 1988, NONPARAMETRIC STAT B; SELNICK L, 2000, BEHAV INTERVENT, V15, P243; Sestito N., 2005, J INT NEUROPSYCHO S1, V11, P90; Spreen O, 1991, COMPENDIUM NEUROPSYC; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Winocur G, 2000, BRAIN COGNITION, V42, P120, DOI 10.1006/brcg.1999.1179; Yesavage J., 1986, HDB CLIN MEMORY ASSE, P213; Zanetti O, 1997, ACTA NEUROL SCAND, V95, P152, DOI 10.1111/j.1600-0404.1997.tb00087.x; Zanetti O, 2001, NEUROPSYCHOL REHABIL, V11, P263, DOI 10.1080/09602010042000088; [No title captured]	60	38	38	0	12	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2007	21	4					448	457		10.1037/0894-4105.21.4.448			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology; Neurosciences & Neurology	184GJ	WOS:000247628800006	17605578				2022-02-06	
J	Haukoos, JS; Gill, MR; Rabon, RE; Gravitz, CS; Green, SM				Haukoos, Jason S.; Gill, Michelle R.; Rabon, Rick E.; Gravitz, Craig S.; Green, Steven M.			Validation of the simplified motor score for the prediction of brain injury outcomes after trauma	ANNALS OF EMERGENCY MEDICINE			English	Article							GLASGOW COMA SCALE; HEAD-INJURIES; FIELD TRIAGE; RELIABILITY	Study objective: The Glasgow Coma Scale (GCS) score is widely used in the initial evaluation of patients with traumatic brain injury. This 15-point score, however, has been criticized as unnecessarily complex. Recently, a 3-point Simplified Motor Score (defined as obeys commands=2; localizes pain=1; withdrawals to pain or worse=0) was developed from the motor component of the GCS and was found to have a similar test performance for predicting outcomes after traumatic brain injury when compared with the GCS score as the criterion standard. The purpose of this study was to validate the Simplified Motor Score in a large heterogeneous trauma population. Methods: This was a secondary analysis of a prospectively maintained trauma registry with consecutive trauma patients who presented to a Level I trauma center from 1995 through 2004. Test performance of the GCS and the Simplified Motor Score relative to 4 clinically relevant traumatic brain injury outcomes (emergency intubation, clinically significant brain injury, neurosurgical intervention, and mortality) was evaluated with areas under the receiver operating characteristic curves (AUCs). Results: Of 21,170 patients included in the analysis, 18% underwent emergency intubation, 14% had clinically significant brain injuries, 7% underwent neurosurgical intervention, and 5% died. The AUCs for the GCS and its components ranged from 0.76 to 0.92 across the 4 outcome measures. The AUCs for the Simplified Motor Score ranged from 0.71 to 0.89, and the relative differences from the GCS AUCs ranged from 3% to 7%, with a median difference of 5%. Conclusion: In this external validation study, the 3-point Simplified Motor Score demonstrated similar test performance when compared with the 15-point GCS score and its components for the prediction of 4 clinically important traumatic brain injury outcomes.	Denver Hlth Med Ctr, Dept Emergency Med, Denver, CO 80204 USA; Denver Hlth Med Ctr, Dept Surg, Denver, CO 80204 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Loma Linda Univ, Sch Med, Dept Emergency Med, Loma Linda, CA USA		Haukoos, JS (corresponding author), Denver Hlth Med Ctr, Dept Emergency Med, 777 Bannock St,Mail Code 0108, Denver, CO 80204 USA.	jason.haukoos@dhha.org					Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; *AM COLL SURG COMM, 1998, MAN HEAD INJ; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; GORMICAN SP, 1982, ANN EMERG MED, V11, P132, DOI 10.1016/S0196-0644(82)80237-0; Grzybowski M, 1997, ACAD EMERG MED, V4, P818, DOI 10.1111/j.1553-2712.1997.tb03793.x; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1977, LANCET, V1, P878; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; SEGATORE M, 1992, HEART LUNG, V21, P548; STARMARK JE, 1991, LANCET, V337, P1042, DOI 10.1016/0140-6736(91)92705-7; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; Stevens RD, 2006, CRIT CARE MED, V34, P31, DOI 10.1097/01.CCM.0000194534.42661.9F; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Tinkoff GH, 2002, J TRAUMA, V52, P1153, DOI 10.1097/00005373-200206000-00022; Tsao JW, 2005, ARCH NEUROL-CHICAGO, V62, P1126, DOI 10.1001/archneur.62.7.1126; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; [No title captured]	33	38	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUL	2007	50	1					18	24		10.1016/j.annemergmed.2006.10.004			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	186IX	WOS:000247773500006	17113193				2022-02-06	
J	Ai, JL; Liu, E; Wang, JL; Chen, YH; Yu, J; Baker, AJ				Ai, Jinglu; Liu, Elaine; Wang, Jianli; Chen, Yonghong; Yu, Julie; Baker, Andrew J.			Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid-precursor protein (beta APP) accumulation; calpain inhibitor; compound action potential; corpus callosum; fluid percussion injury; MDL-28170; rat; therapeutic time window	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; SPINAL-CORD; MODEL; PATHOPHYSIOLOGY; ANTIBODIES; BREAKDOWN; RECOVERY; THERAPY	It is known that calpain activation is involved in human traumatic brain injury (TBI) and that calpain inhibition can have neuroprotective effects on both gray matter and white matter injury of TBI models. However, the role of calpain activation in the corpus callosum remains unclear and requires elucidation given its potential clinical relevance. We evaluated the neuroprotective effects of calpain inhibitor MDL-281-70 on corpus callosum function and structural destruction using a fluid percussion injury (FPI) model. The therapeutic time window for a single administration of MDL-28170 was up to 4 h post injury in protecting the corpus callosum structural integrity, and up to 30 min in protecting the axonal function evaluated 1 day following injury. When given 30 min prior injury, MDL-28170 showed neuroprotective effects that lasted up to 7 days. However, 30 min post injury administration of the drug afforded neuroprotection only up to 3 days. In contrast, two additional reinforcement injections at 24 and 48 h in addition to 30 min post FPI significantly protected both axonal function and structural integrity that lasted 14 days following FPI. Our data indicated that calpain inhibitor MDL-28170 is an effective neuroprotectant for axonal injury in corpus callosum following FPI with a therapeutic time window tip to 4 hours. Although delayed treatment (2 or 4 h post FPI) was effective in protecting the axonal structure, the axons saved may not be as functional as normal fibers. Multiple drug administrations may be necessary for achieving a persisting effectiveness of this compound.	Univ Toronto, St Michaels Hosp, Cara Phelan Ctr Trauma Res, Traumat Brain Injury Lab, Toronto, ON M5B 1W8, Canada		Baker, AJ (corresponding author), Univ Toronto, St Michaels Hosp, Cara Phelan Ctr Trauma Res, Traumat Brain Injury Lab, 30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca		AI, JINGLU/0000-0001-7414-0207			Ai JL, 2007, EXP BRAIN RES, V177, P95, DOI 10.1007/s00221-006-0654-9; ARLINGHAUS L, 1991, EUR J PHARMACOL, V209, P123, DOI 10.1016/0014-2999(91)90022-I; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRORSON JR, 1995, J NEUROSCI, V15, P4515; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Chen ZF, 1997, BRAIN RES, V769, P188, DOI 10.1016/S0006-8993(97)00848-2; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Hirokawa N, 1994, Prog Clin Biol Res, V390, P117; Hirokawa Nobutaka, 1993, Current Opinion in Neurobiology, V3, P724, DOI 10.1016/0959-4388(93)90144-N; Jiang QB, 2000, J NEUROCHEM, V74, P2101, DOI 10.1046/j.1471-4159.2000.0742101.x; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Li PA, 1998, NEUROSCI LETT, V247, P17, DOI 10.1016/S0304-3940(98)00266-3; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Maas Andrew I.R., 2000, Curr Opin Crit Care, V6, P281, DOI 10.1097/00075198-200008000-00008; Machado SS, 1999, BIOCATAL BIOTRANSFOR, V17, P179, DOI 10.3109/10242429909040114; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MORLEY P, 1994, BRAIN PATHOL, V4, P37; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pierce JES, 1996, J NEUROSCI, V16, P1083; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang K K, 1997, Adv Pharmacol, V37, P117; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182	57	38	40	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					960	978		10.1089/neu.2006.0224			19	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700005	17600513				2022-02-06	
J	Taylor, CM; Aird, VH; Tate, RL; Lanumi, MH				Taylor, Christine M.; Aird, Vanessa H.; Tate, Robyn L.; Lanumi, Michele H.			Sequence of recovery during the course of emergence from the minimally conscious state	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; minimally conscious state; rehabilitation	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC AMNESIA	Objective: To document and examine recovery profiles of persons during the course of emergence from a minimally conscious state (MCS) after traumatic brain injury (TBI). Design: Case series. Setting: Participants in an inpatient brain injury rehabilitation program. Participants: Nine people with TBI who emerged from MCS. Interventions: Not applicable. Main Outcome Measure: The Western Neuro Sensory Stimulation Profile. Results: In all cases, stereotyped (nonreflexive) movement was the first behavior to resolve, yet by itself it was never sufficient to indicate emergence from the MCS. Two of the 9 patients showed consistent object manipulation before all 3 elements of functional communication. Conversely, in 2 patients, all 3 components of functional communication emerged before object manipulation. In the remaining 5 patients, object manipulation occurred along with components of functional communication. Conclusions: During the course of data collection, issues were raised about differentiation between the MCS and posttraumatic amnesia. The data are also discussed within the context of the work of Giacino et al and the development of their scale to measure duration of the MCS. These data support the theory that functional communication and object manipulation are the 2 key indicators of emergence from MCS.	Royal Rehabil Ctr Sydney, Brain Injury Rehabil Serv, Ryde, NSW 1680, Australia; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia		Taylor, CM (corresponding author), Royal Rehabil Ctr Sydney, Brain Injury Rehabil Serv, POB 6, Ryde, NSW 1680, Australia.	christine.taylor@royalrehab.com.au					ANSELL BJ, 1989, W NEURO SENSORY STIM; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MALKMUS D, 1980, REHABILITATION HEAD; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Smith VH, 2001, BRAIN IMPAIR, V2, P29, DOI DOI 10.1375/BRIM.2.1.29; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; Tate R.L., 2000, BRAIN IMPAIR, V1, P116, DOI [10.1375/brim.1.2.116, DOI 10.1375/BRIM.1.2.116]; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178	13	38	38	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2007	88	4					521	525		10.1016/j.apmr.2007.01.013			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	160CC	WOS:000245913400019	17398255				2022-02-06	
J	Hellmich, HL; Eidson, KA; Capra, BA; Garcia, JM; Boone, DR; Hawkins, BE; Uchida, T; DeWitt, DS; Prough, DS				Hellmich, Helen L.; Eidson, Kristine A.; Capra, Bridget A.; Garcia, Jeanna M.; Boone, Deborah R.; Hawkins, Bridget E.; Uchida, Tatsuo; DeWitt, Douglas S.; Prough, Donald S.			Injured Fluoro-Jade-positive hippocampal neurons contain high levels of zinc after traumatic brain injury	BRAIN RESEARCH			English	Article						zinc neurotoxicity; Fluoro-Jade; Newport Green; traumatic brain injury; hippocampal injury; gene expression	RAT; CONTRIBUTES; DYSFUNCTION; RESPONSES; ISCHEMIA; RELEASE	Hippocampal damage contributes to cognitive dysfunction after traumatic brain injury (TBI). We previously showed that Fluoro-Jade, a fluorescent stain that labels injured, degenerating brain neurons, quantifies the extent of hippocampal injury after experimental fluid percussion TBI in rats. Coincidentally, we observed that injured neurons in the rat hippocampus also stained with Newport Green, a fluorescent dye specific for free ionic zinc. Here, we show that, regardless of injury severity or therapeutic intervention, the post-TBI population of injured neurons in rat hippocampal subfields CA1, CA3 and dentate gyrus is indistinguishable, both in numbers and anatomical distribution, from the population of neurons containing high levels of zinc. Treatment with lamotrigine, which inhibits presynaptic release of glutamate and presumably zinc that is co-localized with glutamate, reduced numbers of Fluoro-Jade-positive and Newport Green-positive neurons equally as did treatment with nicardipine, which blocks voltage-gated calcium channels through which zinc enters neurons. To confirm using molecular techniques that Fluoro-Jade and Newport Green-positive neurons are equivalent populations, we isolated total RNA from 25 Fluoro-Jade-positive and 25 Newport Green-positive pyramidal neurons obtained by laser capture microdissection (LCM) from the CA3 subfield, linearly amplified the mRNA and used quantitative ribonuclease protection analysis to demonstrate similar expression of mRNA for selected TBI-induced genes. Our data suggest that therapeutic interventions aimed at reducing neurotoxic zinc levels after TBI may reduce hippocampal neuronal injury. (c) 2006 Elsevier B.V. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA		Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu	Hawkins, Bridget/H-4933-2015; Prough, Donald S/G-5793-2013	Hawkins, Bridget/0000-0002-1887-3657; Prough, Donald S/0000-0001-7994-532X	NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32 ES007254] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042849-04, R01 NS042849-01A1, R01 NS042849] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES007254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER		Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004; Canzoniero LMT, 1999, J NEUROSCI, V19; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duckworth EAM, 2005, BRAIN RES, V1042, P29, DOI 10.1016/j.brainres.2005.02.021; FREDERICKSON CJ, 1988, NUTRITIONAL MODULATI, P289; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; Hellmich HL, 2005, BRAIN RES, V1044, P144, DOI 10.1016/j.brainres.2005.02.054; Hinkle DA, 2003, BIOL PSYCHIAT, V54, P413, DOI 10.1016/S0006-3223(03)00322-6; Koh JY, 2001, MOL NEUROBIOL, V24, P99, DOI 10.1385/MN:24:1-3:099; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *SAS I I, 1999, SAS STAT US GUID VER; Schiff ND, 2002, NEUROL RES, V24, P116, DOI 10.1179/016164102101199576; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Sensi SL, 2002, NEUROBIOL DIS, V10, P100, DOI 10.1006/nbdi.2002.0493; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Thompson K, 2001, N C Med J, V62, P376; Thompson RB, 2002, J NEUROSCI METH, V118, P63, DOI 10.1016/S0165-0270(02)00144-9; Thompson RB, 2002, J BIOMED OPT, V7, P555, DOI 10.1117/1.1501886; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Wei G, 2004, NEUROSCI LETT, V370, P118, DOI 10.1016/j.neulet.2004.08.027; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005	36	38	39	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 5	2007	1127	1					119	126		10.1016/j.brainres.2006.09.094			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	130VP	WOS:000243827400015	17109824	Green Accepted			2022-02-06	
J	Fiorello, CA; Hale, JB; Holdnack, JA; Kavanagh, JA; Terrell, J; Long, L				Fiorello, Catherine A.; Hale, James B.; Holdnack, James A.; Kavanagh, Jack A.; Terrell, Joy; Long, Lisa			Interpreting intelligence test results for children with disabilities: Is global intelligence relevant?	APPLIED NEUROPSYCHOLOGY			English	Article						ADHD; general intelligence; IQ; LD; profile analysis; TBI; test interpretation	SUBTEST ANALYSIS; FACTOR SCORES; IQ; ACHIEVEMENT; DISCREPANCY; PROFILES; AGE	School psychological and neuropsychological evaluations typically include intellectual and other standardized assessment tools in the identification of children with disabilities. The clinical utility of intellectual assessment in the identification and treatment of these children has been repeatedly challenged, with alternatives such as a response to intervention or global intelligence score interpretation offered to replace the long-held tradition of idiographic interpretation of intellectual factors or subtests for the purpose of differential diagnosis and individualized intervention. Replicating previous work, this study examined the structure of intellectual functioning for children diagnosed with Learning Disability (LD; n = 128), Attention-Deficit/Hyperactivity Disorder (ADHD; n = 71), and traumatic brain injury (TBI; n = 29) using regression commonality analysis. Across groups, results provide substantial evidence for a multifactorial representation of intellectual functioning for children with LD, ADHD, or TBI, with little shared variance among factor predictors of FSIQ in each analysis. As global intellectual functioning, represented by the shared variance among all predictors, was largely absent and instead composed of several discrete elements with the requisite specificity for individual interpretation, idiographic interpretation appears to be warranted for children with disabilities.	Temple Univ, Sch Psychol Program, Philadelphia, PA 19122 USA; Philadelphia Coll Osteopath Med, Philadelphia, PA USA; Psychol Corp, San Antonio, TX USA; Loyola Univ, Chicago, IL 60611 USA; SUNY Coll Plattsburgh, Plattsburgh, NY 12901 USA		Fiorello, CA (corresponding author), Temple Univ, Sch Psychol Program, RA 269,1301 Cecil B Moore Ave, Philadelphia, PA 19122 USA.	catherine.fiorello@temple.edu	Berger, Emily/N-7268-2017	Berger, Emily/0000-0001-5550-807X; Fiorello, Catherine/0000-0002-9938-0407			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Barkley R.A., 1997, ADHD NATURE SELF CON; BERNINGER V, 1992, LEARN DISABILITY Q, V15, P103, DOI 10.2307/1511012; Bowman DB, 2001, LEARN INDIVID DIFFER, V13, P127, DOI 10.1016/S1041-6080(02)00076-6; Bryan KL, 2001, J INT NEUROPSYCH SOC, V7, P655, DOI 10.1017/S1355617701766015; CRONBACH LJ, 1975, AM PSYCHOL, V30, P1; Daniel MH, 1997, AM PSYCHOL, V52, P1038; Denckla MB, 1996, J DEV BEHAV PEDIATR, V17, P114; FENNELL EB, 1997, HDB CLIN CHILD NEURO, P204; Fiorello CA, 2001, LEARN INDIVID DIFFER, V13, P115, DOI 10.1016/S1041-6080(02)00075-4; FLANAGAN DP, 2004, ESSENTIALS WISC IV A; FLETCHER JM, 1994, J EDUC PSYCHOL, V86, P6, DOI 10.1037//0022-0663.86.1.6; Georgas J., 2003, PRACTICAL RESOURCES, P277; Glutting JJ, 1997, PSYCHOL ASSESSMENT, V9, P295, DOI 10.1037/1040-3590.9.3.295; Glutting JJ, 1997, SCHOOL PSYCHOL REV, V26, P176; Glutting JJ, 1998, SCHOOL PSYCHOL REV, V27, P599; Goldberg E., 2001, EXECUTIVE BRAIN FRON; GOLDBERG E, 2001, EXECUTIVE BRAIN FROT; Gottfredson LS, 1997, INTELLIGENCE, V24, P79, DOI 10.1016/S0160-2896(97)90014-3; Gresham FM, 1997, SCHOOL PSYCHOL QUART, V12, P249, DOI 10.1037/h0088961; Groth-Marnat G., 2000, NEUROPSYCHOLOGICAL A, P129; Hale J. B., 2004, SCH NEUROPSYCHOLOGY; Hale JB, 2001, SCHOOL PSYCHOL QUART, V16, P31, DOI 10.1521/scpq.16.1.31.19158; HALE JB, 2003, SCH PSYCHOL, V58, P6; HORN JL, 1967, ACTA PSYCHOL, V26, P107, DOI 10.1016/0001-6918(67)90011-X; Jensen A.R., 1998, G FACTOR SCI MENTAL; KAVALE KA, 2003, NAT RES CTR LEARN DI; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mayes SD, 2003, AUTISM, V7, P65, DOI 10.1177/1362361303007001006; MCDERMOTT PA, 1992, J SPEC EDUC, V25, P504, DOI 10.1177/002246699202500407; MCDERMOTT PA, 1990, J PSYCHOEDUC ASSESS, V8, P290, DOI 10.1177/073428299000800307; MCGHEE RL, 2002, LEARN INDIVID DIFFER, V13, P197; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; Pedhazur, 1997, MULTIPLE REGRESSION; Pfeiffer SI, 2000, SCHOOL PSYCHOL QUART, V15, P376, DOI 10.1037/h0088795; RESCHLY DJ, 2002, BEST PRACTICES SCH P, V1, P3; Reynolds C. R., 1997, HDB CLIN CHILD NEURO, P180; Riccio CA, 2000, SCHOOL PSYCHOL QUART, V15, P386, DOI 10.1037/h0088796; ROID GH, 1993, J PSYCHOEDUC ASSESS, P6; ROURKE BP, 1994, FRAMES REFERENCE ASS, P475; Sattler J.M., 2001, ASSESSMENT CHILDREN; Siegel LS, 2003, J LEARN DISABIL-US, V36, P2, DOI 10.1177/00222194030360010101; Spearman C, 1904, AM J PSYCHOL, V15, P201, DOI 10.2307/1412107; Sternberg RJ, 2001, MERRILL PALMER QUART, V47, P1, DOI 10.1353/mpq.2001.0005; Thurstone L.L., 1938, PRIMARY MENTAL ABILI; TULSKY DS, 2003, CLIN INTERPRETATION; Watkins MW, 2004, PSYCHOL ASSESSMENT, V16, P133, DOI 10.1037/1040-3590.16.2.133; Watkins MW, 2000, SCHOOL PSYCHOL QUART, V15, P465, DOI 10.1037/h0088802; WECHSLER D, 1975, AM PSYCHOL, V30, P135, DOI 10.1037/h0076868; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; YSSELDYKE JE, 1973, ACAD THER, V8, P415, DOI 10.1177/105345127300800407; [No title captured]	53	38	38	0	15	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2007	14	1					2	12		10.1080/09084280701280338			11	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	171JA	WOS:000246730800002	17439365				2022-02-06	
J	Han, BS; Kim, SH; Kim, OL; Cho, SH; Kim, YH; Jang, SH				Han, Bong Soo; Kim, Seong Ho; Kim, Oh Lyong; Cho, Soo Ho; Kim, Yun-Hee; Jang, Sung Ho			Recovery of corticospinal tract with diffuse axonal injury: A diffusion tensor image study	NEUROREHABILITATION			English	Article						motor recovery; diffusion tensor image; corticospinal tract; diffuse axonal injury	TRAUMATIC BRAIN-INJURY; STROKE; DEGENERATION; MRI	Objectives: The purpose of this study is to identity the recovery process of the corticospinal tract with diffuse axonal injury (DAI) using diffusion tensor imaging (DTI). Design: A 47-year-old female patient and six age-matched control subjects were evaluated. The patient presented with quadriparesis (more severe in the right extremities than the left ones) due to DAI at the onset of traumatic brain injury. Over the 24-month period following the onset of the injury, motor function of the four extremities slowly recovered to range which was close to normal. Two longitudinal DTIs were acquired from the patient (at 10 weeks and 24 months from onset) and from the control subjects. Fractional anisotropy (FA) and an apparent diffusion coefficient were measured using the region of interest (ROI) method. Results: On the 10-week DTL FAs of ROIs of the brainstem in both hemispheres of the patient were significantly lower than those of the control subjects. Compared to normal controls, the patient showed significantly increased FA in both sides of the brainstem at 24 months after the onset, which occurred in parallel with the improvement in motor function. Conclusions: Recovery in this patient could be attributed to the recovery of the corticospinal tract with diffuse axonal injury.	Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea; Yonsei Univ, Coll Hlth Sci, Dept Radiol Sci, Kangwon, South Korea; Yeungnam Univ, Sch Med, Dept Neurosurg, Taegu, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Phys Med & Rehabil, Sch Med, Seoul, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, 317-1,Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net	Han, Bong Soo/AAL-6704-2020				Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P11; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Jang SH, 2004, ARCH PHYS MED REHAB, V85, P506, DOI 10.1016/S0003-9993(03)00468-4; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Maeda Takahiro, 2005, Brain and Nerve (Tokyo), V57, P27; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Werring DJ, 2000, J NEUROL NEUROSUR PS, V69, P269, DOI 10.1136/jnnp.69.2.269; Yamada K, 2003, STROKE, V34, DOI 10.1161/01.STR.0000085827.54986.89; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	17	38	40	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	2					151	155					5	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	195LB	WOS:000248412600012	17656842				2022-02-06	
J	Leon-Carrion, J; Leal-Cerro, A; Murillo Cabezas, F; Atutxa, AM; Gomez, SG; Cordero, JMF; Moreno, AS; Ferrari, MDR; Dominguez-Morales, MR				Leon-Carrion, J.; Leal-Cerro, A.; Murillo Cabezas, F.; Atutxa, A. Madrazo; Gomez, S. Garcia; Cordero, J. M. Flores; Moreno, A. Soto; Ferrari, M. D. Rincon; Dominguez-Morales, M. R.			Cognitive deterioration due to GH deficiency in patients with traumatic brain injury: A preliminary report	BRAIN INJURY			English	Article						hypopituitarism; brain injury; cognitive disorder; hormonal deficiency; emotional disorder	QUALITY-OF-LIFE; GROWTH-HORMONE DEFICIENCY; ADULTS; HYPOPITUITARISM; DYSFUNCTION; THERAPY; IMPACT	Primary objective: To determine whether cognitive and behavioural disorders observed in TBI patients are due to hormonal deficits or to the brain injury itself. Research design: Transversal, between-group design. Methods and procedures: Studied 22 severe TBI patients (GCS < 8): 11 had isolated GH deficiency and 11 did not. Prepared detailed clinical reports on patients and performed physical examinations, standard biochemical and full blood count analysis. Patients underwent neuropsychological assessment and hormonal evaluation 6 months after TBI diagnosis. Results: TBI patients with GH deficiency show greater deficits in attention, executive functioning, memory and emotion than those without GH deficiency. Conclusions: Results show GH-related cognitive impairment in patients who develop GH deficiency after TBI and suggest that treatment of GH deficiency would improve cognition. The clinical importance of these findings should be established to better understand the nature, magnitude and meaning of GH-related cognitive impairment in patients who develop GH deficiency after TBI.	Univ Seville, Dept Expt Psychol, Human Neuropsychol Lab, Seville, Spain; Univ Hosp Virgen Rocio, Div Endocrinol, Seville, Spain; Univ Hosp Virgen Rocio, Crit Care & Emergency Dept, Seville, Spain; Ctr Brain Injury Rehabil CRECER, Seville, Spain		Leon-Carrion, J (corresponding author), Univ Seville, Dept Expt Sychol, Human Neuropsychol Lab, C Camilo, Seville, Spain.	leoncarrion@us.es	IBIS, NEUROCRITICOS/C-1805-2016; Murillo-Cabezas, Francisco/AAO-3348-2021				Aleman A, 2000, NEUROPSYCHOBIOLOGY, V41, P73, DOI 10.1159/000026636; Arwert LI, 2005, NEUROENDOCRINOLOGY, V82, P32, DOI 10.1159/000090123; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Baum HBA, 1998, J CLIN ENDOCR METAB, V83, P3184, DOI 10.1210/jc.83.9.3184; Bennett PA, 2000, CONT ENDOCRINOL, V19, P145; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bulow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x; Burman P, 1998, PSYCHOTHER PSYCHOSOM, V67, P154, DOI 10.1159/000012276; BURMAN P, 1995, J CLIN ENDOCR METAB, V80, P3585, DOI 10.1210/jc.80.12.3585; CARRION JL, 1998, NEUROREHABILITATION, V11, P11129; Deijen J. B., 1999, Journal of Endocrinological Investigation, V22, P127; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; Dik MG, 2003, NEUROBIOL AGING, V24, P573, DOI 10.1016/S0197-4580(02)00136-7; Fiasche R, 1995, PSYCHONEUROENDOCRINO, V20, P727, DOI 10.1016/0306-4530(95)00027-5; FISHER DA, 1998, QUEST DIAGNOSTIC MAN, P312; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; HOWLETT TA, 1997, DIAGNOSIS TREATMENT, P81; Lamberts SWJ, 1998, LANCET, V352, P127; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leon Carrion J, 1997, NEUROPSYCHOLOGICAL R; Leon-Carrion J, 2006, BRAIN INJURY TREATME; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; LEONCARRION J, 2006, BRAIN INJURY GUIDE F; LEONCARRION JL, 1998, BATERIA NEUROPSICOLO; Nyberg F, 1996, HORM RES, V45, P18, DOI 10.1159/000184753; Popovic V, 2005, FRONT HORM RES, V33, P33, DOI 10.1159/000088399; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Stabler B, 2001, HORM RES, V56, P55, DOI 10.1159/000048136; TOOGOOD AA, 1994, CLIN ENDOCRINOL, V41, P511, DOI 10.1111/j.1365-2265.1994.tb02583.x; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; Wiren L, 2001, J CLIN ENDOCR METAB, V86, P3494, DOI 10.1210/jc.86.8.3494	33	38	39	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	8					871	875		10.1080/02699050701484849			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	202YZ	WOS:000248942400008	17676444				2022-02-06	
J	Riley, GA				Riley, Gerard A.			Stress and depression in family carers following traumatic brain injury: the influence of beliefs about difficult behaviours	CLINICAL REHABILITATION			English	Article							ATTRIBUTIONS; CHILDREN; MOTHERS	Objective: Difficult behaviours are significant contributors to the distress experienced by carers of people with a traumatic brain injury. This study investigated whether the beliefs carers hold about such behaviours also contribute to the distress. Design: Questionnaire survey. Participants: Forty family carers recruited from Headway, a traumatic brain injury support organization. Main measures: Zung's Self-Rating Depression Scale, Perceived Stress Scale, Social Support Questionnaire, a measure of the severity of difficult behaviours shown by the person cared for and two measures of carer beliefs about the behaviour (including the Controlling Beliefs Scale). Results: Higher depression and stress scores were associated with more severe behaviours and less social support. Carer belief in their own ability to control the behaviours was associated with less stress. Belief that the behaviour was under the control of the person with traumatic brain injury and/or was motivated by hostile intentions was associated with more depression but less stress. Taken together, severity of behaviour and social support accounted for about 19% of the variance in both depression and stress scores. Carer beliefs accounted for another 5% of the depression scores, and another 11% of the stress scores. Conclusions: The results were consistent with the idea that carer beliefs about difficult behaviour contribute to carer distress, but longitudinal and treatment studies are needed to establish causality.	Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England		Riley, GA (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.	rileyga@bham.ac.uk	Riley, Gerard Anthony/J-1646-2012; Riley, Gerard/A-4328-2008; riley, gerard/AAP-1439-2020	Riley, Gerard Anthony/0000-0002-1167-8023; 			Bolton C, 2003, J CHILD PSYCHOL PSYC, V44, P242, DOI 10.1111/1469-7610.00117; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Dagnan D, 2004, BEHAV COGN PSYCHOTH, V32, P501, DOI 10.1017/S1352465804001675; Dopke CA, 2000, CHILD ABUSE NEGLECT, V24, P493, DOI 10.1016/S0145-2134(00)00110-1; Hastings RP, 2002, AM J MENT RETARD, V107, P222, DOI 10.1352/0895-8017(2002)107<0222:BPOCWA>2.0.CO;2; Jones C, 2003, BRIT J CLIN PSYCHOL, V42, P189, DOI 10.1348/014466503321903599; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MITCHLEY N, 1996, CLIN REHABIL, V10, P3; Nix RL, 1999, CHILD DEV, V70, P896, DOI 10.1111/1467-8624.00065; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; Williamson G., 1988, PERCEIVED STRESS PRO; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	12	38	38	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JAN	2007	21	1					82	88		10.1177/0269215506071279			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	130PM	WOS:000243811500011	17213245				2022-02-06	
J	Schofield, PW; Butler, TG; Hollis, SJ; Smith, NE; Lee, SJ; Kelso, WM				Schofield, Peter W.; Butler, Tony G.; Hollis, Stephanie J.; Smith, Nadine E.; Lee, Stephen J.; Kelso, Wendy M.			Neuropsychiatric correlates of traumatic brain injury (TBI) among Australian prison entrants	BRAIN INJURY			English	Article						neuropsychiatric; psychiatric; symptoms; prisoners; traumatic brain injury; inmates; criminal; head injury; and brain injury	PSYCHIATRIC-ILLNESS; MENTAL-DISORDERS; SUBSTANCE-ABUSE; PSYCHOTIC SYMPTOMS; FOLLOW-UP; PREVALENCE; SCHIZOPHRENIA; ASSOCIATION; POPULATION; PREDICTION	Primary objective: To investigate the association between reported past traumatic brain injury (TBI) and demographic, neuropsychiatric and criminographic parameters among individuals recently received into custody. Research design: A random sample of men recently received into the New South Wales (Australia) criminal justice system were screened for a history of TBI and the details of up to five separate TBI episodes were obtained. We also screened for depression, psychosis, personality disorder, drug and alcohol use, and 'social connectedness'. Main outcome and results: Among the 200 study participants, 82% reported past TBI. TBI was associated with a history of engagement in contact sports, school expulsion, daily illicit drug use, depression and psychosis. Conclusions: Past TBI is common among prisoners entering the criminal justice system and, amongst other correlates, appears to be highly associated with increased rates of major mental illness.	Univ Newcastle, Ctr Mental Hlth Studies, Newcastle, NSW, Australia; Univ New S Wales, Sch Publ Hlth & Community Med, Kensington, NSW 2033, Australia		Schofield, PW (corresponding author), James Feltcher Hosp, Neuropsychiat Serv, Watt St, Newcastle, NSW 2300, Australia.	peter.schofield@hnehealth.nsw.gov.au	Butler, Tony/F-4614-2012; Schofield, Peter/J-7133-2013; Hollis, Stephanie J/B-5977-2011	Butler, Tony/0000-0002-2679-2769; Schofield, Peter/0000-0001-8298-8590			ANDREWS G, 2002, J PUBLIC HEALTH, V25, P494; *AUSTR BUR STAT, 1997, 12340 AUSTR BUR STAT; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Boles SM, 2003, AGGRESS VIOLENT BEH, V8, P155, DOI 10.1016/S1359-1789(01)00057-X; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; BOYLE MJ, 1991, J ROY SOC MED, V84, P608; Butler T, 2006, AUST NZ J PSYCHIAT, V40, P272, DOI 10.1111/j.1440-1614.2006.01785.x; Butler T, 2005, AUST NZ J PSYCHIAT, V39, P407, DOI 10.1111/j.1440-1614.2005.01589.x; COHEN BJ, 1994, BRIT J PSYCHIAT, V165, P493, DOI 10.1192/bjp.165.4.493; Deb S, 1999, AM J PSYCHIAT, V156, P374; Degenhardt L, 2001, PSYCHOL MED, V31, P659, DOI 10.1017/S0033291701003865; DIRKMEN SS, 1989, MILD HEAD INJURY, P229; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; Jablensky A, 2000, AUST NZ J PSYCHIAT, V34, P221, DOI 10.1046/j.1440-1614.2000.00728.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; KOENIG HG, 1993, PSYCHOSOMATICS, V34, P61, DOI 10.1016/S0033-3182(93)71928-3; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Loranger AW, 1997, ICD 10 INT PERSONALI; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Poulton R, 2000, ARCH GEN PSYCHIAT, V57, P1053, DOI 10.1001/archpsyc.57.11.1053; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; SAMUELS JF, 1994, AM J PSYCHIAT, V151, P1055; *SAS I, 1999, SAS STAT SOFTW VERS; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; TEPLIN LA, 1989, LAW HUMAN BEHAV, V13, P1, DOI 10.1007/BF01056159; Verdoux H, 2002, SCHIZOPHR RES, V54, P59, DOI 10.1016/S0920-9964(01)00352-8; *WHO AUDIT, 2001, ALC US DIS IT TEST G; Yui K, 1999, MOL PSYCHIATR, V4, P512, DOI 10.1038/sj.mp.4000575; Yung AR, 2003, SCHIZOPHR RES, V60, P21, DOI 10.1016/S0920-9964(02)00167-6; [No title captured]	41	38	38	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2006	20	13-14					1409	1418		10.1080/02699050601130443			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	130GF	WOS:000243787100011	17378233				2022-02-06	
J	Ezaki, Y; Tsutsumi, K; Morikawa, M; Nagata, I				Ezaki, Y.; Tsutsumi, K.; Morikawa, M.; Nagata, I.			Role of diffusion-weighted magnetic resonance imaging in diffuse axonal injury	ACTA RADIOLOGICA			English	Article						diffuse axonal injury; diffusion-weighted imaging; head injury	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; MR; CT; SEVERITY; HUMANS	Purpose: To determine whether the signal changes on magnetic resonance imaging (MRI), including fluid attenuated inversion recovery ( FLAIR), T2*-weighted gradient echo (GE) imaging, and diffusion-weighted imaging (DWI) in diffuse axonal injury (DAI) patients correlate with the clinical outcome. Material and Methods: We diagnosed patients with DAI based on the following criteria: 1) a loss of consciousness from the time of injury that persisted beyond 6 h; 2) no apparent hemorrhagic contusion on computed tomography (CT); 3) the presence of white matter injury on MRI. Twenty-one DAI patients were analyzed ( 19 M, 2 F, mean age 34 years) with MRI ( FLAIR, T2*-weighted GE imaging, and DWI). Results: 325 abnormalities were detected by MRI within a week after injury. The T2*weighted GE imaging was significantly more sensitive than FLAIR and DWI in diagnosing DAI. DWI detected only 32% of all lesions, but could depict additional shearing injuries not visible on either T2*-weighted GE imaging or FLAIR. The mean number of lesions in brainstem detected by DWI in the favorable group ( good recovery/ moderately disabled) was significantly smaller than in the unfavorable group ( severely disabled/vegetative survival/death). This trend was not observed on the T2*-weighted GE imaging and FLAIR findings. Conclusion: DWI cannot detect all DAI-related lesions, but is a potentially useful imaging modality for both diagnosing and assessing patients with DAI.	Nagasaki Univ, Grad Sch Med, Dept Neurosurg, Nagasaki 852, Japan; Nagasaki Univ, Grad Sch Med, Dept Radiol, Nagasaki 852, Japan		Ezaki, Y (corresponding author), Sasebo City Gen Hosp, Dept Neurosurg, 9-3 Hirasemachi, Sasebo 8578511, Japan.	ezaki-nsu@umin.ac.jp					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1994, RADIOLOGY, V191, P1; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Murray JG, 1996, SEMIN ULTRASOUND CT, V17, P185, DOI 10.1016/S0887-2171(96)90035-9; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	24	38	47	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0284-1851	1600-0455		ACTA RADIOL	Acta Radiol.	SEP	2006	47	7					733	740		10.1080/02841850600771486			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	080GK	WOS:000240235700024	16950714				2022-02-06	
J	Giannoudis, PV; Mushtaq, S; Harwood, P; Kambhampati, S; Dimoutsos, M; Stavrou, Z; Pape, HC				Giannoudis, P. V.; Mushtaq, S.; Harwood, P.; Kambhampati, S.; Dimoutsos, M.; Stavrou, Z.; Pape, H. C.			Accelerated bone heating and excessive callus formation in patients with femoral fracture and head injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						head injury; femoral fracture; bone heating; callus formation	TRAUMATIC BRAIN-INJURY; ENHANCED OSTEOGENESIS; DIAPHYSIS; ADULTS; LINK	The effect of head injury on systemic physiology, including bone heating is still a topic of vivid discussion. Whether the observed changes genuinely represent accelerated fracture heating or are a form of local heterotopic ossification remains unclear. We aimed to investigate whether in patients with tong bone fractures the presence of head injury is associated with accelerated bone heating and excessive callus formation. In total 67 patients were studied 17 with head injury and 50 without head injury (25 treated with reamed and the other 25 with the unreamed nailing technique). Both groups were comparable in terms of age, sex, ISS. All underwent stabilisation of their femora[ fracture with intramedullary nailing. The quantification of fracture heating response was estimated by taking the radiological ratio of the largest diameter of callus formed into two planes and the adjacent normal diameter of femoral canal. The minimum follow up of the patients was 12 months. In patients with head injury, the mean time to fracture union was significantly shorter than either the reamed or unreamed group (10.5 weeks compared with 20.5 and 26.9 weeks, (p < 0.001). The difference between the mean callus to diaphyseal ratio was statistically significant for both the AP and Lateral projections (AP: mean difference 0.462, 95% CI 0.312 to 0.602, p < 0.0001, LAT: mean difference 0.289, 95% CI 0.142 to 0.436, p < 0.001) with the head injured patients having more florid callus compared to the control group. (C) 2006 Elsevier Ltd. All rights reserved.	Univ Leeds, St Jamess Univ Hosp, Acad Dept Orthopaed Trauma Surg, Leeds LS9 7TF, W Yorkshire, England; Evagelismos Gen Hosp, Dept Microbiol, Athens, Greece; Evagelismos Gen Hosp, Dept Traumat & Orthopaed Surg, Athens, Greece; Pittsburgh Med Sch, Dept Trauma Surg, Pittsburgh, PA USA		Giannoudis, PV (corresponding author), Univ Leeds, St Jamess Univ Hosp, Acad Dept Orthopaed Trauma Surg, Chancellor Wing,Beckett St, Leeds LS9 7TF, W Yorkshire, England.	Pgiannoudi@aol.com	Harwood, Paul/I-2360-2019; Giannoudis, Peter/AAA-3617-2020	Giannoudis, Peter/0000-0002-5205-7696; Harwood, Paul/0000-0003-4564-4689; kambhampati, srinivas/0000-0002-4978-3590; Pape, Hans-Christoph/0000-0002-2059-4980			Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BAITO K, 2001, INFECT IMMUN, V69, P744; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; BOULET M, 1961, ARCH BIOCH, V93, P57; BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P832, DOI 10.2106/00004623-199173060-00006; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; Dattatreyamurty B, 2001, EXP NEUROL, V172, P273, DOI 10.1006/exnr.2001.7728; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; GARLAND DE, 1983, CLIN ORTHOP RELAT R, P190; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P219; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P38; GARLAND DE, 1980, CLIN ORTHOP RELAT R, P198; Giannoudis PV, 2000, J BONE JOINT SURG BR, V82B, P655, DOI 10.1302/0301-620X.82B5.9899; Giannoudis PV, 1997, INJURY, V28, P15, DOI 10.1016/S0020-1383(96)00146-5; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; Lewen A, 1997, NEUROREPORT, V8, P475, DOI 10.1097/00001756-199701200-00020; Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623-200206000-00022; LINDHOLM TS, 1987, ACTA ORTHOP SCAND, V49, P485; MALISANO LP, 1994, J ORTHOP TRAUMA, V8, P1, DOI 10.1097/00005131-199402000-00001; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; Pape HC, 2001, J ORTHOP TRAUMA, V15, P229, DOI 10.1097/00005131-200105000-00001; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; RUEDI T, MANUAL INTERNAL FIXA, P151; Sevitt S, 1981, BONE REPAIR FRACTURE; SMITH R, 1987, J BONE JOINT SURG BR, V69, P518, DOI 10.1302/0301-620X.69B4.3611149; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319	33	38	45	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2006	37			3			S18	S24		10.1016/j.injury.2006.08.020			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	096JW	WOS:000241374400003	16963358				2022-02-06	
J	Holavanahalli, RK; Lezotte, DC; Hayes, MP; Minhajuddin, A; Fauerbach, JA; Engrav, LH; Helm, PA; Kowalske, KJ				Holavanahalli, Radha K.; Lezotte, Dennis C.; Hayes, Michael P.; Minhajuddin, Abu; Fauerbach, James A.; Engrav, Loren H.; Helm, Phala A.; Kowalske, Karen J.			Profile of patients lost to follow-up in the burn injury rehabilitation model systems' longitudinal database	JOURNAL OF BURN CARE & RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; SUBSTANCE-ABUSERS; ATTRITION; COHORT; INTERVENTION; PREVENTION; RATES; OLDER; BIAS	We sought to identify whether patterns exist in the Burn Injury Rehabilitation Model Systems' database among participants lost to follow-up at 6, 12, or 24 months after injury and to define characteristics that reliably discriminate between persons who are lost to follow-up and those who are not. All participants met the American Burn Association criteria for major burn injury, were 18 years of age or older, received care from one of four burn model systems, and consented to participate in a 2-year prospective data-collection process. Step-wise logistic regression was used to develop three prediction models for the probability of loss to follow-up. The percent of individuals successfully contacted for follow-up were 64% at 6 months, 54% at 12 months, and 42% at 24 months after injury. Individuals who were younger, not employed at time of burn, with less than a high school level education, a history of drug abuse, circumstances of injury involving suspected assault, and having no insurance for care were lost to follow-up. Longer stay in the hospital, on the other hand, increased the likelihood of follow-up. The same risk factors remained significant with or with out adjusting for site indicating that these factors are independent and significant in spite of any potential site differences. Successful follow-up at 6- and 12-month intervals increased the likelihood of achieving a follow-up at 24 months after injury. The sociodemographic risk factors for attrition identified in this study represent significant enduring vulnerabilities. The findings necessitate a close examination of several factors and the use of strategies to reduce the risk of attrition.	Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA		Holavanahalli, RK (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Hayes, Michael/0000-0002-3392-6163			Agosti V, 1996, AM J DRUG ALCOHOL AB, V22, P29, DOI 10.3109/00952999609001643; Altman DG, 2000, STAT MED, V19, P3275, DOI 10.1002/1097-0258(20001215)19:23<3275::AID-SIM626>3.0.CO;2-M; Boys A, 2003, J ADOLESCENCE, V26, P363, DOI 10.1016/S0140-1971(03)00011-3; Canupp KC, 1997, SPINAL CORD, V35, P314, DOI 10.1038/sj.sc.3100367; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cottler LB, 1996, DRUG ALCOHOL DEPEN, V41, P209, DOI 10.1016/0376-8716(96)01254-9; Deeg DJH, 2002, J CLIN EPIDEMIOL, V55, P213, DOI 10.1016/S0895-4356(01)00472-3; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Edwards AGK, 1997, ADDICTION, V92, P1699, DOI 10.1111/j.1360-0443.1997.tb02890.x; Fairclough DL, 2002, DESIGN ANAL QUALITY; Fauerbach JA, 1998, J BURN CARE REHABIL, V19, P247; Frack SA, 1997, AM J PREV MED, V13, P131, DOI 10.1016/S0749-3797(18)30210-1; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; Hansten ML, 2000, ADDICTION, V95, P1403, DOI 10.1046/j.1360-0443.2000.959140310.x; JEBSEN R H, 1969, Archives of Physical Medicine and Rehabilitation, V50, P311; Kristman V, 2004, EUR J EPIDEMIOL, V19, P751, DOI 10.1023/B:EJEP.0000036568.02655.f8; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Laursen P, 1997, Acta Neurol Scand Suppl, V172, P7; Mihelic AH, 1997, J GERONTOL B-PSYCHOL, V52, pS37, DOI 10.1093/geronb/52B.1.S37; Milliken G.A., 1996, SAS SYSTEM MIXED MOD, P633; Minder CE, 2002, AM J PUBLIC HEALTH, V92, P445, DOI 10.2105/AJPH.92.3.445; Nishimoto RH, 1998, SUBST USE MISUSE, V33, P1291, DOI 10.3109/10826089809062218; PSATY BM, 1994, AM J EPIDEMIOL, V140, P161, DOI 10.1093/oxfordjournals.aje.a117226; Richards J. Scott, 1995, P10; Rubin D.B., 1987, MULTIPLE IMPUTATION; SAS, 1999, SAS STAT US GUID VER, P3884; Scott CK, 2004, DRUG ALCOHOL DEPEN, V74, P21, DOI 10.1016/j.drugalcdep.2003.11.007; Siddiqui O, 1996, PREV MED, V25, P554, DOI 10.1006/pmed.1996.0089; Spotts D, 1996, SUBST USE MISUSE, V31, P1891, DOI 10.3109/10826089609064004; VACH W, 1991, AM J EPIDEMIOL, V134, P895, DOI 10.1093/oxfordjournals.aje.a116164; Van Beijsterveldt CEM, 2002, J CLIN EPIDEMIOL, V55, P216, DOI 10.1016/S0895-4356(01)00473-5; Walton MA, 1998, AM J COMMUN PSYCHOL, V26, P233, DOI 10.1023/A:1022128519196; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Zunzunegui MV, 2001, J CLIN EPIDEMIOL, V54, P501, DOI 10.1016/S0895-4356(00)00325-5	37	38	38	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1559-047X			J BURN CARE RES	J. Burn Care Res.	SEP-OCT	2006	27	5					703	712		10.1097/01.BCR.0000238085.87863.81			10	Critical Care Medicine; Dermatology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Dermatology; Surgery	089MQ	WOS:000240885100021	16998404				2022-02-06	
J	Moein, H; Khalili, HA; Keramatian, K				Moein, Houshang; Khalili, Hossein A.; Keramatian, Kamyar			Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Ritalin; methylphenidate; severe traumatic brain injury; moderate traumatic brain injury	CONTROLLED-TRIAL; DISORDERS	Objective: Traumatic brain injury is one of the major causes of death and disability among young people. Methylphenidate, a neural stimulant and protective drug, which has been mainly used for childhood attention deficit/hyperactivity disorder, has shown some benefits in late psychosocial problems in patients with traumatic brain injury. Its effect on arousal and consciousness has been also revealed in the sub-acute phase of traumatic brain injury. We studied its effect on the acute phase of moderate and severe traumatic brain injury (TBI) in relation to the length of ICU and hospital admission. Patients and methods: Severely and moderately TBI patients (according to inclusion and exclusion criteria) were randomized to treatment and control groups. The treatment group received methylphenidate 0.3 mg/kg per dose PO BID by the second day of admission until the time of discharge, and the control group received a placebo. Admission information and daily Glasgow Coma Scale (GCS) were recorded. Medical, surgical, and discharge plans for patients were determined by the attending physician, blinded to the study. Results: Forty patients with severe TBI (GCS = 5-8) and 40 moderately TBI patients (GCS = 9-12) were randomly divided into treatment and control groups on the day of admission. In the severely TBI patients, both hospital and ICU length of stay, on average, were shorter in the treatment group compared with the control group. In the moderately TBI patients while ICU stay was shorter in the treatment group, there was no significant reduction of the period of hospitalization. Conclusion: There were no significant differences between the treatment and control groups in terms of age, sex, post resuscitation GCS, or brain CT scan findings, in either severely or moderately TBI patients. Methylphenidate was associated with reductions in ICU and hospital length of stay by 23% in severely TBI patients (P = 0.06 for ICU and P = 0.029 for hospital stay time). However, in the moderately TBI patients who received methylphenidate, there was 26% fall (P = 0.05) only in ICU length of stay. (c) 2005 Elsevier B.V. All rights reserved.	Isfahan Univ Med Sci, Dept Neurosurg, Esfahan, Iran; Univ British Columbia, Dept Neurosci, Vancouver, BC V5Z 1M9, Canada		Khalili, HA (corresponding author), Kashani Hosp, Dept Neurosurg, Esfahan, Iran.	khalilih@yahoo.com; keramatian@gmail.com	Khalili, Hosseinali/I-1087-2016	Khalili, Hosseinali/0000-0002-3390-4212; Keramatian, Kamyar/0000-0003-4958-6025			Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; Burke DT, 2003, AM J PHYS MED REHAB, V82, P493, DOI 10.1097/00002060-200307000-00001; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Forsyth R., 2003, COCHRANE DB SYST REV, V1; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Husson I, 2004, NEUROSCIENCE, V125, P163, DOI 10.1016/j.neuroscience.2004.01.010; Jin C, 2004, CNS SPECTRUMS, V9, P217, DOI 10.1017/S1092852900009019; Kajs-Wyllie Marylyn, 2002, J Neurosci Nurs, V34, P303; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rosati DL, 2002, AM J PHYS MED REHAB, V81, P90, DOI 10.1097/00002060-200202000-00003; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Worzniak M, 1997, J FAM PRACTICE, V44, P495; WROBLEWSKI BA, 1992, J CLIN PSYCHIAT, V53, P86	18	38	38	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	SEP	2006	108	6					539	542		10.1016/j.clineuro.2005.09.003			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	082EJ	WOS:000240369200003	16226371				2022-02-06	
J	McCauley, SR; Pedroza, C; Brown, SA; Boake, C; Levin, HS; Goodman, HS; Merritt, SG				McCauley, SR; Pedroza, C; Brown, SA; Boake, C; Levin, HS; Goodman, HS; Merritt, SG			Confirmatory factor structure of the Center for Epidemiologic Studies-Depression scale (CES-D) in mild-to-moderate traumatic brain injury	BRAIN INJURY			English	Article						Center for Epidemiologic Studies-Depression Scale (CES-D); traumatic brain injury (TBI); depression; prediction	CLOSED-HEAD INJURY; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; AXIS-I; EMOTIONAL DISTURBANCE; MULTIPLE-SCLEROSIS; COMMUNITY SAMPLE; AMERICAN ADULTS; MOOD DISORDERS; FOLLOW-UP	Primary objective: The Center for Epidemiologic Studies Depression scale (CES-D) is a frequently-used self-report measure of depressive symptom severity. Brief depression screening measures can be important in the identification and prediction of depression following traumatic brain injury. The objective of this study was to investigate the validity of the CES-D in measuring depressive symptoms in patients with mild-to-moderate TBI as it has been rarely used in neurologically compromised populations. Research design: Inception cohort. Methods and procedures: The CES-D was administered to 340 participants with mild-to-moderate TBI at 3-months post-injury. Main outcomes and results: Confirmatory factor analysis of the CES-D indicated that the data are a reasonable fit similar to that of Radloff's original 4-factor model. Conclusions: These findings suggest that the CES- D may be appropriate for use in patients with mild-to-moderate TBI.	Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; Univ Texas, Sch Med, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA		McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Phys Med & Rehabil Alliance, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mccauley@bcm.edu		Pedroza, Claudia/0000-0003-4235-1282	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR612707] Funding Source: Medline		Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; *ASS ADV AUT MED, 1990, COMMINJ SCAL ABBR IN; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Boisvert JA, 2003, DEPRESS ANXIETY, V17, P19, DOI 10.1002/da.10080; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Bowen A, 1999, BRAIN INJURY, V13, P547; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; CALLAHAN CM, 1994, MED CARE, V32, P341, DOI 10.1097/00005650-199404000-00003; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Chwastiak L, 2002, AM J PSYCHIAT, V159, P1862, DOI 10.1176/appi.ajp.159.11.1862; CLARK VA, 1981, PSYCHIAT RES, V5, P171, DOI 10.1016/0165-1781(81)90047-0; CRAIG TJ, 1985, AM J PSYCHIAT, V142, P1272; da Silveira DX, 2002, PSYCHOL REP, V91, P865, DOI 10.2466/pr0.2002.91.3.865; DAVIDSON H, 1994, J GERONTOL, V49, pP159, DOI 10.1093/geronj/49.4.P159; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Edman JL, 1999, SOC PSYCH PSYCH EPID, V34, P211, DOI 10.1007/s001270050135; Falcon LM, 2000, J GERONTOL B-PSYCHOL, V55, pS108, DOI 10.1093/geronb/55.2.S108; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; GARCIA M, 1989, PSYCHIAT RES, V27, P137, DOI 10.1016/0165-1781(89)90129-7; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; GOLDING JM, 1989, PSYCHOL ASSESSMENT, V0001; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Grant MM, 2000, ANN BEHAV MED, V22, P149, DOI 10.1007/BF02895779; Gualtari CT, 1991, BRAIN INJURY, V5, P219; GUARNACCIA PJ, 1989, SOC SCI MED, V29, P85, DOI 10.1016/0277-9536(89)90131-7; Haarasilta L, 2001, PSYCHOL MED, V31, P1169, DOI 10.1017/S0033291701004573; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jonas BS, 2003, SOC PSYCH PSYCH EPID, V38, P618, DOI 10.1007/s00127-003-0682-8; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kanetani Kouichi, 2003, Journal of Nippon Medical School, V70, P313; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KUO WH, 1984, J NERV MENT DIS, V172, P449, DOI 10.1097/00005053-198408000-00002; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; Manson SM, 1991, PSYCHOL ASSESS, V3, P623, DOI [DOI 10.1037/1040-3590.3.4.623, 10.1037/1040-3590.3.4.623]; MANSON SM, 1990, PSYCHOL ASSESSMENT, V2, P231, DOI DOI 10.1037/1040-3590.2.3.231; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MEYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; Miller TQ, 1997, J GERONTOL B-PSYCHOL, V52, pS259, DOI 10.1093/geronb/52B.5.S259; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; MUTHEN LK, 2004, MPLUS USERS GUIDE; *NAT CTR INJ PREV, TRAUM BRAIN INJ; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; Paterniti S, 2002, BRIT J PSYCHIAT, V181, P111; Perna RB, 2003, J HEAD TRAUMA REHAB, V18, P201; Posner SF, 2001, ETHNIC HEALTH, V6, P137, DOI 10.1080/13557850120068469; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; ROBERTS RE, 1990, PSYCHOL ASSESS, V0002, P00122, DOI DOI 10.1037/1040-3590.2.2.122; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Sapolsky RM, 2001, P NATL ACAD SCI USA, V98, P12320, DOI 10.1073/pnas.231475998; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; *SAS I INC, 2003, STAT AN SOFTW WIND; SHEEHAN TJ, 1995, J PERS ASSESS, V64, P507, DOI 10.1207/s15327752jpa6403_9; SHINAR D, 1986, STROKE, V17, P241, DOI 10.1161/01.STR.17.2.241; SHROUT PE, 1989, J CLIN EPIDEMIOL, V42, P69, DOI 10.1016/0895-4356(89)90027-9; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; STOMMEL M, 1993, PSYCHIAT RES, V49, P239, DOI 10.1016/0165-1781(93)90064-N; Stroup-Benham CA, 2000, J AM GERIATR SOC, V48, P250, DOI 10.1111/j.1532-5415.2000.tb02642.x; TEASDALE G, 1974, LANCET, V2, P84; THORSON JA, 1993, B PSYCHONOMIC SOC, V31, P577, DOI 10.3758/BF03337359; Vedhara K, 1999, BEHAV MED, V25, P43, DOI 10.1080/08964289909596738; Verdier-Taillefer MH, 2001, NEUROEPIDEMIOLOGY, V20, P262, DOI 10.1159/000054800; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; WRIGHTSON P, 1989, MILD HEAD INJURY, P245; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; YING YW, 1988, J CLIN PSYCHOL, V44, P739, DOI 10.1002/1097-4679(198809)44:5<739::AID-JCLP2270440512>3.0.CO;2-0; ZICH JM, 1990, INT J PSYCHIAT MED, V20, P259, DOI 10.2190/LYKR-7VHP-YJEM-MKM2; [No title captured]; [No title captured]	92	38	38	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2006	20	5					519	527		10.1080/02699050600676651			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	045GO	WOS:000237730800008	16716998				2022-02-06	
J	Naeimi, ZS; Weinhofer, A; Sarahrudi, K; Heinz, T; Vecsei, V				Naeimi, ZS; Weinhofer, A; Sarahrudi, K; Heinz, T; Vecsei, V			Predictive value of S-100B protein and neuron specific-enolase as markers of traumatic brain damage in clinical use	BRAIN INJURY			English	Article						S100B; NSE; traumatic brain injury; Marshall	MINOR HEAD-INJURY; CALCIUM-BINDING PROTEINS; NEUROBIOCHEMICAL MARKERS; NERVOUS-SYSTEM; S100 PROTEINS; TUMOR-MARKERS; SERUM MARKER; RELEASE; AGE; EXPRESSION	Objective: S-100B and NSE proteins are considered to be neurobiochemical markers for the brain damage. The aim of this study was to consider the diagnostic and prognostic validity of the initial serum levels of S-100B and NSE in clinical use. Methods: Forty-five patients with traumatic brain injury were included in this prospective study. Neurologic examination and CCT-scan were performed. S-100B and NSE were analysed. Patients were divided in two groups depending on the severity of injury. Results: The results showed a significant difference between the S-100B serum concentration and the two groups-minor head injuries and severe head injuries. A statistically significant correlation was observed between an increase of S-100B and NSE serum values and a cerebral pathological finding in CT scans. Conclusion: The clear correlation between S-100B and NSE serum concentrations and CCT findings does not validate both markers as an independent predictor of diagnosis and prognosis of brain injury.	Med Univ Vienna, Dept Traumatol, A-1090 Vienna, Austria		Naeimi, ZS (corresponding author), Med Univ Vienna, Dept Traumatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	zahra.naeimi@meduniwien.ac.at					Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; COOPER EH, 1987, BRIT J CANCER, V56, P65, DOI 10.1038/bjc.1987.155; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; GERBITZ KD, 1986, J CLIN CHEM CLIN BIO, V24, P1009; GERBITZ KD, 1989, TUMORDIAGN THER, V10, P45; Heizmann CW, 1999, NEUROCHEM RES, V24, P1097, DOI 10.1023/A:1020700117665; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; HULLIN DA, 1980, BIOCHIM BIOPHYS ACTA, V628, P98, DOI 10.1016/0304-4165(80)90355-4; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; ISHIGURO Y, 1983, CANCER RES, V43, P6080; JENNETT B, 1975, LANCET, V2, P480; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Lara DR, 2001, J PSYCHIATR RES, V35, P11, DOI 10.1016/S0022-3956(01)00003-6; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Portela LVC, 2002, CLIN CHEM, V48, P950; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sheng JG, 1996, NEUROBIOL AGING, V17, P359, DOI 10.1016/0197-4580(96)00037-1; Stein S. C., 1996, NEUROTRAUMA, P31; Taggart DP, 1997, ANN THORAC SURG, V63, P492; Walz R, 2000, NEUROLOGY, V54, P2021, DOI 10.1212/WNL.54.10.2021; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	46	38	46	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2006	20	5					463	468		10.1080/02699050600664418			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	045GO	WOS:000237730800002	16716992				2022-02-06	
J	Gemmell, C; Leathem, JM				Gemmell, C; Leathem, JM			A study investigating the effects of Tai Chi Chuan: Individuals with traumatic brain injury compared to controls	BRAIN INJURY			English	Article						Tai Chi; traumatic brain injury; rehabilitation	CARDIORESPIRATORY FUNCTION; AEROBIC EXERCISE; BALANCE; STRENGTH; REHABILITATION; PRACTITIONERS; RESPONSES; STRESS; WOMEN; TRIAL	Objective: To explore the effects of a 6-week course in Tai Chi associated with traumatic brain injury (TBI) symptoms. Method: Eighteen participants, with TBI assigned to a control (waiting list) group (n = 9) or Tai Chi group (n = 9) completed the Medical Outcome Scale Short Form 36 (SF-36) and Rosenberg Self-Esteem Scale (RSES) before, during, immediately after and 3 weeks after completion of the Tai Chi course. The Tai Chi group completed the Visual Analogue Mood Scales (VAMS) before and after each class. Results: Tai Chi was associated with significant improvement on all VAMS scores (except fatigue) with decreases in sadness, confusion, anger, tension, fear and increases in energy and happiness. There were no significant between-group differences on the SF-36 or RSES. Conclusions: Tai Chi provides short-term benefits after TBI, with rigorous outcome measurement needed to examine long-term benefits.	Massey Univ, Sch Psychol, Wellington, New Zealand		Leathem, JM (corresponding author), Massey Univ, Sch Psychol, POB 756, Wellington, New Zealand.	j.m.leathem@massey.ac.nz					ALDER P, 2000, J NURS SCHOLARSHIP, V32, P377; ARRUDA JE, 1997, J NEUROPSYCHIATRY CL, V9, P152; BROWN DD, 1989, RES Q EXERCISE SPORT, V60, P246, DOI 10.1080/02701367.1989.10607447; Chan KM, 2004, ARCH PHYS MED REHAB, V85, P717, DOI 10.1016/j.apmr.2003.08.091; Channer KS, 1996, POSTGRAD MED J, V72, P349, DOI 10.1136/pgmj.72.848.349; Chen K M, 1999, J Holist Nurs, V17, P267, DOI 10.1177/089801019901700304; FUZHONG L, 2001, PREV SCI, V2, P229; FUZHONG L, 2004, J AM GERIATR SOC, V52, P892; GEMMELL R, 1992, REELING SILK GUIDE T; Jacobson BH, 1997, PERCEPT MOTOR SKILL, V84, P27, DOI 10.2466/pms.1997.84.1.27; JIN P, 1989, J PSYCHOSOM RES, V33, P197, DOI 10.1016/0022-3999(89)90047-0; JIN PT, 1992, J PSYCHOSOM RES, V36, P361, DOI 10.1016/0022-3999(92)90072-A; KIRSTEINS AE, 1991, AM J PHYS MED REHAB, V70, P136, DOI 10.1097/00002060-199106000-00005; Kutner NG, 1997, J GERONTOL B-PSYCHOL, V52, pP242, DOI 10.1093/geronb/52B.5.P242; LAI JS, 1995, J AM GERIATR SOC, V43, P1222, DOI 10.1111/j.1532-5415.1995.tb07397.x; Lan C, 1998, MED SCI SPORT EXER, V30, P345, DOI 10.1097/00005768-199803000-00003; Lan C, 2000, ARCH PHYS MED REHAB, V81, P604, DOI 10.1053/mr.2000.3849; Lan C, 1996, ARCH PHYS MED REHAB, V77, P612, DOI 10.1016/S0003-9993(96)90305-6; LAN C, 1993, J FORMOS MED ASSOC, V92, P894; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; Li FZ, 2005, J GERONTOL A-BIOL, V60, P187, DOI 10.1093/gerona/60.2.187; McGibbon CA, 2004, J VESTIBUL RES-EQUIL, V14, P467; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rosenberg M., 1965, SOC ADOLESCENT SELF; Sandlund ES, 2000, INT J STRESS MANAGE, V7, P139, DOI 10.1023/A:1009536319034; Song R, 2003, J RHEUMATOL, V30, P2039; Stern R. A., 1997, VISUAL ANALOGUE MOOD; Taylor SK, 2003, TECHNIQUES ORTHOPAED, V18, P110; Taylor-Piliae Ruth E, 2003, J Cardiopulm Rehabil, V23, P90; Tsang WWN, 2004, MED SCI SPORT EXER, V36, P658, DOI 10.1249/01.MSS.0000122077.87090.2E; WAN Q, 1989, TAI CHI CHUAN J, V63, P33; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Wayne PM, 2004, ARCH PHYS MED REHAB, V85, P142, DOI 10.1016/S0003-9993(03)00652-X; Wolf SL, 1997, ARCH PHYS MED REHAB, V78, P886, DOI 10.1016/S0003-9993(97)90206-9; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x; Wolfson L, 1996, J AM GERIATR SOC, V44, P498, DOI 10.1111/j.1532-5415.1996.tb01433.x; Yan JH, 1998, J AGING PHYS ACTIV, V6, P350, DOI 10.1123/japa.6.4.350; YAN JH, 1999, J GERONTOL A-BIOL, V54, P1; YANG JM, 1990, C KUNG HLTH MARTIAL; Young DR, 1999, J AM GERIATR SOC, V47, P277, DOI 10.1111/j.1532-5415.1999.tb02989.x; ZHOU H, 1994, MAGIC Q GONG	43	38	38	2	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2006	20	2					151	156		10.1080/02699050500442998			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	003KX	WOS:000234681700004	16421063				2022-02-06	
J	Da Rocha, AB; Zanoni, C; De Freitas, GR; Himelfarb, S; Schneider, RF; Grivicich, I; Borges, L; Schwartsmann, G; Kaufmann, M; Regner, A				Da Rocha, AB; Zanoni, C; De Freitas, GR; Himelfarb, S; Schneider, RF; Grivicich, I; Borges, L; Schwartsmann, G; Kaufmann, M; Regner, A			Serum Hsp70 as an early predictor of fatal outcome after severe traumatic brain injury in males	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; heat shock proteins; humans; outcome; traumatic brain injury	HEAT-SHOCK PROTEINS; CELL-DEATH; HEAT-SHOCK-PROTEIN-70; EXPRESSION; CHAPERONE; STRESS; PROTECTION; REGULATORS; INDUCTION; MARKER	Severe traumatic brain injury (TBI) is associated with a 35-70% mortality rate. Biochemical markers of cellular stress/injury have been proposed to indicate outcome after head injury. Therefore, our aim was to determine whether Hsp70 could be detected in the serum of patients after severe TBI and whether serum levels of Hsp70 correlate with primary outcome in severe TBI. Twenty consecutive male patients, victims of severe TBI (GCS 3-8), were enrolled in this prospective study. Clinical outcome variables of severe TBI comprised: survival, time for ICU discharge, and neurological assessment using the Glasgow Outcome Scale (GOS) at the ICU discharge. Venous blood samples were taken at admission in the ICU (study entry), 24 h later, and 7 days later. A control group consisting of eight healthy male volunteers was also included. Serum Hsp70 levels were measured by an enzyme-linked immunosorbent assay. Mean serum Hsp70 concentrations were significantly increased in the TBI (97.6, 48.1, and 39.2 ng/mL, at study entry, 24 h later, and 7 days later, respectively) compared with the control group (12.2 ng/mL). Severe TBI was associated with a 50% mortality rate. On study entry (mean time 10.8 h after injury), a higher proportion of patients with fatal outcome had elevated serum Hsp70 (mean 143.5 ng/mL) concentrations when compared with survivors (mean 51.6 ng/mL). There was a significant correlation between higher initial serum Hsp70 concentrations and fatal outcome. The sensitivity of serum Hsp70 predicting mortality according to the cutoff of 62 ng/mL is 70% within 20 h after injury. Increased serum Hsp70 levels may constitute an early predictor of unfavorable outcome in severe TBI in males.	Univ Luterana Brasil, Lab Marcadores Estresse Celular, Ctr Pesquisas Ciencias Med, BR-92420280 Canoas, RS, Brazil; Univ Luterana Brasil, Programa Posgrad Diagnost Genet & Mol, BR-92420280 Canoas, RS, Brazil; Univ Fed Rio de Janeiro, Serv Neurol, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil; S Amer Off Drug Dev, Porto Alegre, RS, Brazil; Hosp Cristo Redentor, Unidade Terapia Intensiva, Porto Alegre, RS, Brazil; Hosp Municipal Pronto Socorro, SAMU, Porto Alegre, RS, Brazil		Regner, A (corresponding author), Univ Luterana Brasil, Lab Marcadores Estresse Celular, Ctr Pesquisas Ciencias Med, Miguel Tostes 101,Predio 22,5 Andar, BR-92420280 Canoas, RS, Brazil.	regner@uol.com.br	Grivicich, Ivana/A-6777-2013; Schwartsmann, Gilberto/G-4256-2016; Regner, Andrea/M-2596-2014	Grivicich, Ivana/0000-0001-9820-5730; Schwartsmann, Gilberto/0000-0002-7850-1644; Regner, Andrea/0000-0002-6657-7991			Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Calabrese V, 2000, J NEUROSCI RES, V60, P613, DOI 10.1002/(SICI)1097-4547(20000601)60:5<613::AID-JNR6>3.0.CO;2-8; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001; Dinh HKB, 2001, PHYSIOL GENOMICS, V7, P3, DOI 10.1152/physiolgenomics.2001.7.1.3; DUFF D, 2003, AXONE, V23, P18; Dutcher SA, 1998, J NEUROTRAUM, V15, P421, DOI 10.1089/neu.1998.15.421; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; JACQUIERSARLIN MR, 1994, EXPERIENTIA, V50, P1031, DOI 10.1007/BF01923458; Kraus J, 1996, NEUROTRAUMA, P13; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Okada M, 2004, J BIOL CHEM, V279, P4221, DOI 10.1074/jbc.M309014200; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Pockley AG, 1998, IMMUNOL INVEST, V27, P367, DOI 10.3109/08820139809022710; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.3.CO;2-V; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Reynolds LPR, 2003, CEREBELLUM, V2, P171, DOI 10.1080/14734220310016114; Rokutan Kazuhito, 1998, Journal of Medical Investigation, V44, P137; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sarto C, 2000, ELECTROPHORESIS, V21, P1218, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1218::AID-ELPS1218>3.3.CO;2-8; Seidberg NA, 2003, J NEUROCHEM, V84, P514, DOI 10.1046/j.1471-4159.2003.01547.x; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; Todryk SM, 2003, IMMUNOLOGY, V110, P1, DOI 10.1046/j.1365-2567.2003.01725.x; UDELSMAN R, 1993, J CLIN INVEST, V91, P465, DOI 10.1172/JCI116224; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; YUAN XQ, 1996, NEUROENDOCRINOLOGY, V12, P209; ZAGARA G, 1992, J NEUROSURG SCI, V35, P77; Zhang H, 2003, RESPIROLOGY, V8, P17, DOI 10.1046/j.1440-1843.2003.00433.x; Zugel U, 1999, CLIN MICROBIOL REV, V12, P19, DOI 10.1128/CMR.12.1.19; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	45	38	40	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					966	977		10.1089/neu.2005.22.966			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600004	16156712				2022-02-06	
J	Slobounov, S; Sebastianelli, W; Moss, R				Slobounov, S; Sebastianelli, W; Moss, R			Alteration of posture-related cortical potentials in mild traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						movement-related cortical potentials (MRCP); mild traumatic brain injury (MTBI); posture; balance	MOVEMENT-RELATED POTENTIALS; INSTABILITY; CONCUSSION; TIME; MRI; EEG	This paper presents additional evidence showing the persistent functional deficits in concussed athletes as revealed by altered movement-related cortical potentials (MRCP) preceding whole body postural movements at, least 30 days post-injury. Eight student-athletes participated in this study (a) prior to injury; and (b) 3, 10 and 30 days after MTBI. EEG was recorded while subjects produced static balance tasks and dynamic postural movements. All subjects were cleared for sport participation within 10 days post-injury based upon neurological and neuropsychological assessments as well as upon clinical symptoms resolution. There was a persistent reduction of MRCP amplitude prior to initiation of postural movement up to 30 days post-injury, although abnormal postural responses basically recovered within 10 days post-injury. The frontal lobe MRCP effects were larger than posterior areas. This supports the notion that behavioral symptoms resolution may not be indicative of brain injury resolution. Overall, persistent alteration of movement-related cortical potentials after MTBI may indicate residual disturbance of neuronal networks involved in preparation and execution of postural movements and a lower threshold for brain re/injury. (c) 2005 Published by Elsevier Ireland Ltd.	Penn State Univ, University Pk, PA 16802 USA		Slobounov, S (corresponding author), Penn State Univ, 19 Recreat Hall, University Pk, PA 16802 USA.	sms18@psu.edu					Barth JT, 2001, J ATHL TRAINING, V36, P253; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; GEVINS AS, 1979, SCIENCE, V203, P665, DOI 10.1126/science.760212; GRUNEWALD G, 1983, BIOL PSYCHOL, V31, P71; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jahanshahi M., 2003, BEREITSCHAFTSPOTENTI, P1, DOI DOI 10.1007/978-1-4615-0189-3; JENNINGS JR, 1987, PSYCHOPHYSIOLOGY, V24, P474, DOI 10.1111/j.1469-8986.1987.tb00320.x; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; KRISTEVA R, 1990, ELECTROEN CLIN NEURO, V75, P410, DOI 10.1016/0013-4694(90)90086-Y; Madeleine P, 2004, ARCH PHYS MED REHAB, V85, P432, DOI 10.1016/j.apmr.2003.03.003; MCCALLUM WC, 1993, NATO ADV SCI INST SE, V254, P1; NIEMANN J, 1994, COGNITIVE PSYCHOPHYS, P265; Saitou K, 1996, ELECTROEN CLIN NEURO, V98, P449, DOI 10.1016/0013-4694(96)95004-X; SHIBASAKI H, 1980, ELECTROEN CLIN NEURO, V49, P213, DOI 10.1016/0013-4694(80)90216-3; Slobounov S, 2005, CLIN NEUROPHYSIOL, V116, P315, DOI 10.1016/j.clinph.2004.09.007; Slobounov S, 2004, CLIN NEUROPHYSIOL, V115, P2391, DOI 10.1016/j.clinph.2004.05.021; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov SM, 1998, EXP BRAIN RES, V123, P461, DOI 10.1007/s002210050590; Slobounov SM, 1998, J GERONTOL A-BIOL, V53, pB71, DOI 10.1093/gerona/53A.1.B71; SLOBUNOV S, 2000, MOT CONTROL, V45, P247; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; Thatcher RW, 2001, CLIN NEUROPHYSIOL, V112, P1729, DOI 10.1016/S1388-2457(01)00609-5; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P2677, DOI 10.1016/j.clinph.2004.06.015; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1	28	38	38	2	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 5	2005	383	3					251	255		10.1016/j.neulet.2005.04.039			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	940LJ	WOS:000230145700011	15876490				2022-02-06	
J	Childs, C; Vail, A; Protheroe, R; King, AT; Dark, PM				Childs, C; Vail, A; Protheroe, R; King, AT; Dark, PM			Differences between brain and rectal temperatures during routine critical care of patients with severe traumatic brain injury	ANAESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the Society-of-British-Neurological-Surgeons	SEP 17-19, 2003	Cardiff, WALES	Soc British Neurol Surg			SEVERE SUBARACHNOID HEMORRHAGE; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; INTENSIVE-CARE; SYSTEMIC TEMPERATURE; BODY-TEMPERATURE; ACUTE STROKE; HYPERTHERMIA; ISCHEMIA; WORSENS	Theoretical models suggest that small differences only exist between brain and body temperature in health. Once the brain is injured, brain temperature is generally regarded to rise above body temperature. However, since reports of the magnitude of the temperature gradient between brain and body vary, it is still not clear whether conventional body temperature monitoring accurately predicts brain temperature at all times. In this prospective, descriptive study, 20 adults with severe primary brain trauma were studied during their stay in the neurointensive care unit. Brain temperature ranged from 33.4 to 39.9 degrees C. Comparisons between paired brain and rectal temperature measurements revealed no evidence of a systematic difference [mean difference -0.04 degrees C (range -0.13 to 0.05 degrees C, 95% CI), p = 0.39]. Contrary to popular belief, brain temperature did not exceed systemic temperature in this relatively homogeneous patient series. The mean values masked inconsistent and unpredictable individual brain-rectal temperature differences (range 1.8 to -2.9 degrees C) and reversal of the brain-body temperature gradient occurred in some patients. Brain temperature could not be predicted from body temperature at all times.	Univ Manchester, Hope Hosp, Div Med & Neurosci, Salford M6 8HD, Lancs, England; Univ Manchester, Biostat Grp, Salford M6 8HD, Lancs, England; Hope Hosp, Dept Neurosurg, Salford M6 8HD, Lancs, England		Childs, C (corresponding author), Univ Manchester, Hope Hosp, Div Med & Neurosci, Salford M6 8HD, Lancs, England.	cchilds@manchester.ac.uk	Protheroe, Richard/AAT-9329-2021; King, Andrew/AAR-1656-2020; Childs, Charmaine/G-9928-2012	King, Andrew/0000-0002-6546-7248; Dark, Paul/0000-0003-3309-0164; Vail, Andy/0000-0001-8274-2726			Awaya S, 1993, Nihon Ika Daigaku Zasshi, V60, P37; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bommadevara M, 2002, BIOMECH MODEL MECHAN, V1, P137, DOI 10.1007/s10237-002-0011-2; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Childs C, 2004, ANAESTHESIA, V59, P192, DOI 10.1111/j.1365-2044.2003.03638.x; Childs C, 1999, ARCH DIS CHILD, V80, P262, DOI 10.1136/adc.80.3.262; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Fountas KN, 2003, J NEUROSURG ANESTH, V15, P87, DOI 10.1097/00008506-200304000-00004; GRAF W, 1959, ACTA PHYSL SCAND, V46, P38; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; Lefrant JY, 2003, INTENS CARE MED, V29, P414, DOI 10.1007/s00134-002-1619-5; Mcilvoy Laura, 2004, J Neurosci Nurs, V36, P23; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Otawara Y, 2003, SURG NEUROL, V60, P549, DOI 10.1016/S0090-3019(03)00293-3; Otawara Y, 2003, SURG NEUROL, V60, P159, DOI 10.1016/S0090-3019(03)00083-1; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Sakurai A, 2003, ACTA NEUROCHIR SUPPL, V86, P251; Soukup J, 2002, J NEUROTRAUM, V19, P559, DOI 10.1089/089771502753754046; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Zhu L, 2001, MED BIOL ENG COMPUT, V39, P681, DOI 10.1007/BF02345442; [No title captured]	33	38	40	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	AUG	2005	60	8					759	765		10.1111/j.1365-2044.2005.04193.x			7	Anesthesiology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	945HL	WOS:000230493500005	16029224	Bronze			2022-02-06	
J	Delaney, JS; Abuzeyad, F; Correa, JA; Foxford, R				Delaney, JS; Abuzeyad, F; Correa, JA; Foxford, R			Recognition and characteristics of concussions in the emergency department population	JOURNAL OF EMERGENCY MEDICINE			English	Article						concussion; Emergency Department; head injury; risk factors; sports	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; ICE-HOCKEY INJURIES; SOCCER PLAYERS; FOOTBALL PLAYERS; HEAD-INJURY; CEREBRAL CONCUSSION; MULTIVARIATE-ANALYSIS; COMPUTED-TOMOGRAPHY; MANAGEMENT	An anonymous survey was conducted over a 6-month period of time using consenting Emergency Department (ED) patients in an attempt to better understand concussions occurring in the ED population. Calculations were made using the respondents' history and self-reported symptoms during the previous 12 months. Five hundred twenty-two of 700 approached patients responded to the anonymous questionnaire. Of respondents, 20.1% (105/522) answered that they had experienced symptoms of a concussion after being hit in the head during the previous 12 months. Of the 105 respondents who experienced a concussion, 88.6% (93/105) did not recognize that they had suffered a concussion. There were 28.2% (147/522) of all respondents who were actively engaging in at least one activity that was considered to be at high risk for concussions. Headache was the most common symptom for both recognized and unrecognized concussions. Respondents who experienced nausea after being hit in the head were the most likely to seek some form of medical attention, followed by people who suffered a loss of consciousness. Those patients who suffered a loss of consciousness were the most likely to visit an ED. Many patients have a poor understanding of concussions and these patients may be actively participating in high-risk activities while still suffering symptoms from a concussion. Therefore, these patients may be at risk for further concussions and Second Impact Syndrome. (c) 2005 Elsevier Inc.	McGill Univ, Dept Emergency Med, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, McGill Sport Med Clin, Montreal, PQ, Canada; Bahrain Def Force Hosp, Accident & Emergency Dept, Manama, Bahrain; McGill Univ, Dept Math & Stat, Montreal, PQ, Canada		Delaney, JS (corresponding author), McGill Univ, Dept Emergency Med, Ctr Hlth, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.						Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bazarian J, 2000, BRAIN INJURY, V14, P285; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; CLINE DM, 1988, ANN EMERG MED, V17, P127, DOI 10.1016/S0196-0644(88)80297-X; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; DELANEY JS, 2001, INT S CONC SPORT; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gillogly S D, 2000, J Med Assoc Ga, V89, P39; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Molsa J, 1997, AM J SPORT MED, V25, P495, DOI 10.1177/036354659702500412; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Schneider RC., 1973, HEAD NECK INJURIES F; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Walshaw L K, 2000, Accid Emerg Nurs, V8, P210, DOI 10.1054/aaen.2000.0172; Warren WL, 1998, CLIN SPORT MED, V17, P99, DOI 10.1016/S0278-5919(05)70064-8; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	59	38	38	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	AUG	2005	29	2					189	197		10.1016/j.jemermed.2005.01.020			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	949FT	WOS:000230771200013	16029831				2022-02-06	
J	Ehlhardt, LA; Sohlberg, MM; Glang, A; Albin, R				Ehlhardt, LA; Sohlberg, MM; Glang, A; Albin, R			TEACH-M: A pilot study evaluating an instructional sequence for persons with impaired memory and executive functions	BRAIN INJURY			English	Article						cognitive rehabilitation; direct instruction; errorless learning; spaced retrieval; memory impairment; executive function impairment	FACE-NAME ASSOCIATIONS; ERRORLESS; ACQUISITION; REHABILITATION; WORK	Primary objective: The purpose of this pilot study was to evaluate an instructional package that facilitates learning and retention of multi-step procedures for persons with severe memory and executive function impairments resulting from traumatic brain injury. Research design: The study used a multiple baseline across participants design. Methods and procedures: Four participants, two males and two females, ranging in age from 36-58 years, were taught a 7-step e-mail task. The instructional package (TEACH-M) was the experimental intervention and the number of correct e-mail steps learned was the dependent variable. Main outcomes and results: Treatment effects were replicated across the four participants and maintained at 30 days post-treatment. Generalization and social validity data further supported the treatment programme. Conclusions: The results suggest that individuals with severe cognitive impairments are capable of learning new skills. Directions for future research include application of the instructional package to other multi-step procedures.	Western Oregon Univ, Teaching Res Inst Eugene, Eugene, OR 97401 USA; Univ Oregon, Eugene, OR 97403 USA		Ehlhardt, LA (corresponding author), Western Oregon Univ, Teaching Res Inst Eugene, 99 W 10th Ave,Suite 370, Eugene, OR 97401 USA.	lehlhart@oregon.uoregon.edu					Baker S., 2002, LEARNING DISABILITIE, V17, P65, DOI DOI 10.1111/1540-5826.00032; BRUSH JA, 1998, CLIN GERONTOLOGIST, V19, P51, DOI DOI 10.1300/J018V19N01_; Burgess P, 1996, BEHAV ASSESSMENT DYS; Carnine D., 1991, THEORY INSTRUCTION; CICERONE KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Clare L, 2002, NEUROPSYCHOLOGY, V16, P538, DOI 10.1037//0894-4105.16.4.538; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Delis DC, 1987, CALIFORNIA VERBAL LE; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Frattali C. M., 1998, MEASURING OUTCOMES S; FRY E, 1968, J READING        APR, P512; GLANG A, 1992, J HEAD TRAUMA REHAB, V7, P93; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Goodglass H., 2000, BOSTON DIAGNOSTIC AP; HORNER RD, 1978, J APPL BEHAV ANAL, V11, P189, DOI 10.1901/jaba.1978.11-189; Horner RH., 1986, ED LEARNERS SEVERE H, P289; Hunkin NM, 1998, NEUROPSYCHOL REHABIL, V8, P433, DOI 10.1080/713755581; Kalla T, 2001, NEUROPSYCHOL REHABIL, V11, P1; Kazdin A., 1982, SINGLE CASE RES DESI; Kern RS, 2002, AM J PSYCHIAT, V159, P1921, DOI 10.1176/appi.ajp.159.11.1921; Komatsu S, 2000, NEUROPSYCHOL REHABIL, V10, P113, DOI 10.1080/096020100389200; Landauer T. K., 1978, OPTIMUM REHEARSAL PA; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; MADIGAN KA, 1997, STUDENTS ACQUIRED BR, P123; Mozzoni MP, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199602000-00003; PARSONSON BS, 1986, RES METHODS APPL BEH, P00157; Richards S. B., 1999, SINGLE SUBJECT RES A; Smith GJ, 1999, PERCEPT MOTOR SKILL, V89, P951, DOI 10.2466/PMS.89.7.951-965; Sohlberg M., 2001, COGNITIVE REHABILITA; SOHLBERG MM, 2002, PERSPECTIVES NEUROPH, V12, P4; SPOONER F, 1984, EDUC TRAIN MENT RET, V19, P114; Stein M, 1998, INTERV SCH CLIN, V33, P227, DOI 10.1177/105345129803300405; Swanson HL, 1998, REV EDUC RES, V68, P277, DOI 10.3102/00346543068003277; SWANSON HL, 1999, LEARN DISABIL RES PR, V14, P129, DOI DOI 10.1207/SLDRP1403_; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; WILSON B, 1985, RIVERMEAND BEHAV MEM; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Young DA, 2002, NEUROPSYCHOL REHABIL, V12, P257, DOI 10.1080/0960201044000066; [No title captured]	42	38	38	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2005	19	8					569	583		10.1080/002699050400013550			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	933IS	WOS:000229622700002	16175811				2022-02-06	
J	Belanger, HG; Scott, SG; Scholten, J; Curtiss, G; Vanderploeg, RD				Belanger, HG; Scott, SG; Scholten, J; Curtiss, G; Vanderploeg, RD			Utility of mechanism-of-injury-based assessment and treatment: Blast Injury Program case illustration	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast injury; case-finding; diagnosis; mechanism; parallel; prevention; rehabilitation; sequential; traumatic brain injury; veteran	TRAUMATIC BRAIN-INJURY; SECONDARY PREVENTION; MILD; INVOLVEMENT; DECISION; HISTORY; FACTS	While medicine typically proceeds in a sequential fashion based on primary symptoms, sometimes relying on a parallel, mechanism-of-injury-based approach is advantageous, particularly when the mechanism of injury is associated with a variety of known sequelae. A mechanism-of-injury-based approach relies on knowledge of the typical sequelae associated with that mechanism Of injury to guide assessment and treatment. Thus, it represents an active, rather than passive, case-finding approach. This article describes an example of a mechanism-of-injury-based program, namely, a Blast Injury Program at the James A. Haley Veterans Hospital in Tampa, Florida. Case examples illustrate the utility of this approach with regard to more comprehensive assessment and treatment, as well as the possibility for secondary prevention.	James A Haley Vet Hosp, Dept Vet Affairs VA, Tampa, FL 33612 USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Henry M Jackson Fdn Adv Mil Med, Rockville, MD USA; Def & Vet Brain Injury Ctr, Washington, DC USA; Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat, Tampa, FL 33612 USA		Belanger, HG (corresponding author), James A Haley Vet Hosp, Dept Vet Affairs VA, Tampa, FL 33612 USA.	Heather.Belanger@med.va.gov	Curtiss, Glenn/ABB-5566-2020				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Arlinger S., 2003, INT J AUDIOL S2, V42; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Danese MD, 1996, JAMA-J AM MED ASSOC, V276, P285, DOI 10.1001/jama.276.4.285; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Gonzalez D, 2002, CALCIFIED TISSUE INT, V71, P141, DOI 10.1007/s00223-001-1027-9; Guy R J, 2000, J R Nav Med Serv, V86, P27; Hafner H, 2004, EUR ARCH PSY CLIN N, V254, P117, DOI 10.1007/s00406-004-0508-z; Helgason CM, 2002, THROMB HAEMOSTASIS, V88, P210; HILL JF, 1979, ANN ROY COLL SURG, V61, P4; Ho PM, 2004, J AM COLL CARDIOL, V43, P1517, DOI 10.1016/j.jacc.2003.12.037; Hull JB, 1996, J TRAUMA, V40, pS198, DOI 10.1097/00005373-199603001-00044; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; KERR AG, 1980, J LARYNGOL OTOL, V94, P107, DOI 10.1017/S0022215100088538; KUIPERS B, 1984, COGNITIVE SCI, V8, P363; MARTINO RL, 1994, SCIENCE, V265, P902, DOI 10.1126/science.8052847; McSherry D, 1997, ARTIF INTELL MED, V10, P269, DOI 10.1016/S0933-3657(97)00396-5; Neil HA, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI [10.3310/hta4290, DOI 10.3310/HTA4290]; Norman A, 2001, CAN FAM PHYSICIAN, V47, P2009; SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020; Sosin DM, 1996, BRAIN INJURY, V10, P47; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE; Zunic G, 2000, NITRIC OXIDE-BIOL CH, V4, P123, DOI 10.1006/niox.2000.0276	30	38	38	0	2	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	JUL-AUG	2005	42	4					403	411		10.1682/JRRD.2004.08.0095			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	995NB	WOS:000234105900005	16320137				2022-02-06	
J	Majetschak, M; King, DR; Krehmeier, U; Busby, LT; Thome, C; Vajkoczy, S; Proctor, KG				Majetschak, M; King, DR; Krehmeier, U; Busby, LT; Thome, C; Vajkoczy, S; Proctor, KG			Ubiquitin immunoreactivity in cerebrospinal fluid after traumatic brain injury: Clinical and experimental findings	CRITICAL CARE MEDICINE			English	Article						ubiquitin; cerebrospinal fluid; traumatic brain injury; nontraumatic subarachnoid hemorrhage; hemolysis; swine	EXTRACELLULAR UBIQUITIN; EXOGENOUS UBIQUITIN; RESUSCITATION; APOPTOSIS; CELLS; PRESSURE; DISEASE; BLOOD; CSF	Objective: Recent data indicate that ubiquitin is increased in serum after trauma and might regulate immune functions. Its cellular source is unknown. Because there have been no previous studies after traumatic brain injury (TBI), we determined whether ubiquitin immunoreactivity is increased in cerebrospinal fluid (CSF) after TBI. Design and Setting: Prospective observational study of patients, with a subsequent interventional study of animals. Subjects: The subjects were 14 patients with TBI, five patients with nontraumatic subarachnoid hemorrhage, ten nonneurologic controls, and seven cross-bred swine. Interventions: Standardized TBI. Measurements and Main Results: Ubiquitin immunoreactivity was analyzed by enzyme-linked immunosorbent assay and immunoblotting. Hemolysis was assessed spectrophotometrically. CSF ubiquitin levels (mean +/- SD) were 19 +/- 3 ng/mL in nonneurologic control patients, 81 +/- 48 ng/mL at 7 +/- 2 hrs after TBI (p = .002), and at the end of operation in patients with nontraumatic subarachnoid hemorrhage they were 104 68 ng/mL (p = .001). CSF and serum ubiquitin were measured for 7 days in six patients with TBI. In survivors (n = 3), CSF ubiquitin levels progressively recovered, whereas in nonsurvivors (n = 3), the levels increased until death. There was no difference in serum ubiquitin levels between survivors/nonsurvivors and there was no correlation between serum and CSF ubiquitin levels. In swine, CSF ubiquitin levels peaked at 8- to 30-fold higher than baseline at 60 min post-TBI and then declined with a half-life of 1.3 hrs. In CSF with hemolysis, peak ubiquitin levels were five-fold higher than without hemolysis (p < .05). Ubiquitin and hemoglobin correlations in CSF and after in vitro lysis of erythrocytes suggested that erythrolysis could account for no more than 23 +/- 16% of the CSF ubiquitin. Conclusions: CSF ubiquitin levels are increased more than four-fold in patients after TBI and nontraumatic subarachnoid hemorrhage. Peak CSF ubiquitin measurements in patients with TBI probably underestimated the actual peak, on the basis of data from the animal model. The progressive rise in CSF ubiquitin in patients with TBI who died suggests that lack of clearance could reflect lethal progression to irreversible brain damage. Erythrolysis is one potential source of CSF ubiquitin.	Univ Miami, Miller Sch Med, Div Trauma, DeWitt Daughtry Family Dept Surg, Miami, FL USA; Univ Miami, Miller Sch Med, Div Surg Crit Care, DeWitt Daughtry Family Dept Surg, Miami, FL USA; Univ Heidelberg Hosp, Dept Trauma Surg, D-68135 Mannheim, Germany; Univ Heidelberg Hosp, Dept Neurosurg, D-68135 Mannheim, Germany; Univ Heidelberg Hosp, Dept Anaesthesiol, D-68135 Mannheim, Germany; Univ Heidelberg, Heidelberg, Germany		Majetschak, M (corresponding author), Univ Miami, Miller Sch Med, Div Trauma, DeWitt Daughtry Family Dept Surg, Miami, FL USA.		Proctor, Kenneth/AAA-2199-2022	Proctor, Kenneth/0000-0003-1326-6628; King, David/0000-0003-1028-1478			Cruickshank AM, 2001, J CLIN PATHOL, V54, P827, DOI 10.1136/jcp.54.11.827; Daino H, 2000, BLOOD, V95, P2577; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; GOETZ CG, 2003, TXB CLIN NEUROLOGY, P513; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; KUDO T, 1994, BRAIN RES, V639, P1, DOI 10.1016/0006-8993(94)91757-4; Kurimura M, 1997, Rinsho Shinkeigaku, V37, P963; Majetschak M, 2004, SURGERY, V135, P536, DOI 10.1016/j.surg.2003.09.006; Majetschak M, 2004, J TRAUMA, V56, P991, DOI 10.1097/01.TA.0000127770.29009.5A; Majetschak M, 2003, BLOOD, V101, P1882, DOI 10.1182/blood-2002-03-0918; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Moore DJ, 2003, NEUROMOL MED, V4, P95, DOI 10.1385/NMM:4:1-2:95; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Ohe Y, 1996, J NEUROCHEM, V67, P964; *ROYAL SWED AC SCI, 2004, ADV INF NOB PRIZ CHE; Takada K, 1997, CLIN CHEM, V43, P1188; Yin W, 2002, J CLIN NEUROSCI, V9, P425, DOI 10.1054/jocn.2001.0968	23	38	39	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JUL	2005	33	7					1589	1594		10.1097/01.CCM.0000169883.41245.23			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	947GB	WOS:000230630300017	16003067				2022-02-06	
J	Sills, MR; Libby, AM; Orton, HD				Sills, MR; Libby, AM; Orton, HD			Prehospital and in-hospital mortality - A comparison of intentional and unintentional traumatic brain injuries in Colorado children	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							NURSE HOME VISITATION; SEVERITY SCORE ICISS; LENGTH-OF-STAY; INTERNATIONAL CLASSIFICATION; RANDOMIZED TRIAL; HEAD-INJURY; ABUSE; PREDICTORS; SURVIVAL; DISEASES	Objectives: To describe the incidence and case-fatality rates of traumatic brain injury (TBI) in young children in Colorado, to compare these injuries based on intentionality and outcome (prehospital death, in-hospital death, or survival), and to model the association of intentionality with TBI-related mortality. Methods: Cases were drawn from the 1994-2002 Colorado Traumatic Brain Injury Surveillance System. Incidence and case-fatality rates for intentional and unintentional TBI were calculated. We performed univariate comparisons based on the intentionality and outcome of the TBI. Multivariate logistic regression was used to estimate the association of intentionality and mortality, controlling for injury severity. Results: Of the 1333 children aged 0 to 36 months with TBI, 340 had intentional and 993 had unintentional TBI. Incidence for intentional and unintentional TBI was 16.1 and 47.0 per 100 000, respectively. Children with intentional TBI had a higher case-fatality rate, in-hospital death rate, and injury severity. Intentional TBI deaths were twice as likely to occur in hospital than prehospital, whereas unintentional TBI deaths were twice as likely to occur prehospital. Intentionality was significantly associated with mortality, with the effect increasing with increasing age. Conclusion: Intentionality-independent of severity-raises the mortality of TBI in young children.	Univ Colorado, Dept Pediat, Denver, CO 80218 USA; Univ Colorado, Dept Psychiat, Denver, CO 80218 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA		Sills, MR (corresponding author), Univ Colorado, Dept Pediat, 1056 E 19th Ave,B-251, Denver, CO 80218 USA.	sills.marion@tchden.org	Nordenholz, Kristen/K-3476-2015; Libby, Anne M/B-6984-2013	Libby, Anne M/0000-0002-4564-9407; Sills, Marion/0000-0003-1322-0822	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [D14HP00153] Funding Source: Medline		Berkowitz Carol D., 1995, Emergency Medicine Clinics of North America, V13, P321; *COL DEP PUBL HLTH, COL HLTH INF DAT DEA; *COL DEP PUBL HLTH, COL HLTH INF DAT POP; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Fluke JD, 1999, CHILD ABUSE NEGLECT, V23, P633, DOI 10.1016/S0145-2134(99)00039-3; Hannan EL, 1999, J TRAUMA, V47, P8, DOI 10.1097/00005373-199907000-00003; Herman-Giddens ME, 1999, JAMA-J AM MED ASSOC, V282, P463, DOI 10.1001/jama.282.5.463; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; JOHNSON CF, 2000, NELSONS TXB PEDIAT, P113; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kim Y, 2003, J TRAUMA, V54, P775, DOI 10.1097/01.TA.0000028251.15629.1D; Kim Y, 2000, J TRAUMA, V48, P280, DOI 10.1097/00005373-200002000-00014; Libby AM, 2003, PEDIATRICS, V112, P58, DOI 10.1542/peds.112.1.58; OLDS D, 1995, PEDIATRICS, V95, P365; OLDS DL, 1986, PEDIATRICS, V78, P65; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; Olsen SJ, 1996, EPIDEMIOLOGY, V7, P644, DOI 10.1097/00001648-199611000-00015; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Osler TM, 1998, J TRAUMA, V45, P234, DOI 10.1097/00005373-199808000-00006; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Rubin D, 2001, CURR OPIN PEDIATR, V13, P388, DOI 10.1097/00008480-200110000-00002; Rutledge R, 1997, J TRAUMA, V42, P477, DOI 10.1097/00005373-199703000-00016; Rutledge R, 1998, J TRAUMA, V45, P791, DOI 10.1097/00005373-199810000-00032; Rutledge R, 1998, J TRAUMA, V44, P41, DOI 10.1097/00005373-199801000-00003; Southall DP, 1997, PEDIATRICS, V100, P735, DOI 10.1542/peds.100.5.735; Thurman DJ., 1995, GUIDELINES SURVEILLA; US Department of Health and Human Services, 2001, ADM CHILDR YOUTH FAM; World Health Organization, 1977, INT CLASS DIS 9 REV	31	38	40	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JUL	2005	159	7					665	670		10.1001/archpedi.159.7.665			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	941QP	WOS:000230229600012	15997001	Bronze			2022-02-06	
J	Uzan, M; Tanriverdi, T; Baykara, O; Kafadar, A; Sanus, GZ; Tureci, E; Ozkara, C; Uysal, O; Buyra, N				Uzan, M; Tanriverdi, T; Baykara, O; Kafadar, A; Sanus, GZ; Tureci, E; Ozkara, C; Uysal, O; Buyra, N			Association between interleukin-1 beta (IL-1 ss) gene polymorphism and outcome after head injury: an early report	ACTA NEUROCHIRURGICA			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Neurological-Surgeons/Congress-of-Neurological-Surgeons	APR 30-MAY 01, 2003	SAN DIEGO, CA	Amer Assoc Neurol Surg		head injury; interleukin; interleukin-1 beta; outcome; polymorphism	AMYLOID PROTEIN DEPOSITION; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; RECEPTOR ANTAGONIST; CEREBRAL-ISCHEMIA; NERVOUS-SYSTEM; PRECURSOR PROTEIN; TEMPORAL PROFILE; EXPRESSION; CYTOKINES	Background. Recent studies focusing on the genetic influences on outcome after head injury (HI) have suggested that different alleles of certain genes are associated with different outcomes. Interleukin-1 beta (IL-1 beta) gene, especially beta 2 polymorphism, is frequently observed in Alzheimer's disease, a remarkable degenerative state in which HI is among the known risk factors. Therefore, the aim of this paper was to search for the possible association between the outcome and IL-1 beta gene polymorphism in human HI. Methods. The study group was composed of the 69 patients admitted to the neurosurgery department after HI. The severity of the initial injury was evaluated by means of the Glasgow Coma Scale and outcome six months later was assessed by means of the Glasgow Outcome Scale. IL-1 beta genotypes were determined from blood samples by standard methods. Findings. Fourteen of 25 (56%) patients with IL-1 beta +3953 allele 2 had an unfavourable outcome (dead, vegetative state or severe disability) compared with eight of 44 (18.1%) patients without IL-1 beta 3953 (p = 0.0004). Similarly, 20 of 28 (71.4%) patients with IL-1 beta allele 2 had an unfavourable outcome compared with two of 41 (4.8%) patients without IL-1 beta -511 (p = 0.005). Patients who had a composite of IL-1 beta 2/2 or 1/2 genotype from both -511 and +3953 region of the chromosome 2 were more prone to have bad prognosis. Conclusion. Results of our study demonstrated that there might be a significant association between IL-1 beta gene polymorphism and outcome after HI, supporting the hypothesis of a genetically determined influence.	Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Med Biol, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Reanimat & Anaesthesiol, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Biostat, Istanbul, Turkey		Uzan, M (corresponding author), POB 5,Cerrahpasa, TR-34301 Istanbul, Turkey.	uzan@istanbul.edu.tr	Kafadar, Ali/AAH-9387-2019; Baykara, Onur/V-5990-2018; Uzan, Mustafa/D-6571-2019; Buyru, Nur/D-1810-2019; Tanriverdi, Taner/C-9003-2019; Ozkara, Cigdem/AAA-2562-2020; Sanus, Galip Zihni/D-6715-2019	Kafadar, Ali/0000-0002-3312-3192; Baykara, Onur/0000-0002-9754-8456; Buyru, Nur/0000-0002-6920-1455; Ozkara, Cigdem/0000-0003-0548-1838; Uzan, Mustafa/0000-0001-7214-380X; uysal, omer/0000-0002-8833-697X			Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; DERESKI MO, 1992, NEUROSCI RES COMMUN, V11, P179; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; GARCIA JH, 1995, AM J PATHOL, V147, P1477; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Griffin WST, 2002, J LEUKOCYTE BIOL, V72, P233; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HONG XY, 1993, PAINT COATINGS IND, V1, P1; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Huang D, 1998, J NEUROIMMUNOL, V81, P76, DOI 10.1016/S0165-5728(97)00161-6; Kanemoto K, 2000, ANN NEUROL, V47, P571, DOI 10.1002/1531-8249(200005)47:5<571::AID-ANA3>3.0.CO;2-A; Kinouchi T, 2002, BIOL GROW ANIM, V1, P203, DOI 10.1016/S1877-1823(09)70123-7; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; MANSFIELD JC, 1994, GASTROENTEROLOGY, V106, P637, DOI 10.1016/0016-5085(94)90696-3; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCDOWELL TL, 1995, ARTHRITIS RHEUM, V38, P221, DOI 10.1002/art.1780380210; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Mrak RE, 2000, J NEUROPATH EXP NEUR, V59, P471, DOI 10.1093/jnen/59.6.471; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; Muller N, 1998, PROG NEURO-PSYCHOPH, V22, P1, DOI 10.1016/S0278-5846(97)00179-6; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; OCALLAGHAN JP, 1993, ANN NY ACAD SCI, V679, P195, DOI 10.1111/j.1749-6632.1993.tb18299.x; Pantoni L, 1998, ARTERIOSCL THROM VAS, V18, P503, DOI 10.1161/01.ATV.18.4.503; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; POCIOT F, 1992, EUR J CLIN INVEST, V22, P396, DOI 10.1111/j.1365-2362.1992.tb01480.x; REIER PJ, 1986, ASTROCYTES, P263; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; ROTHWELL N, 1997, J CLIN INVEST, V100, P2658; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Rothwell NJ, 1996, PHARMACOL THERAPEUT, V69, P85, DOI 10.1016/0163-7258(95)02033-0; Santtila S, 1998, SCAND J IMMUNOL, V47, P195; Sciacca FL, 1999, NEUROLOGY, V52, P1896, DOI 10.1212/WNL.52.9.1896; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155	46	38	41	0	7	SPRINGER WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUL	2005	147	7					715	720		10.1007/s00701-005-0529-z			6	Clinical Neurology; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	938AK	WOS:000229972100006	15891809				2022-02-06	
J	McAdoo, JD; Warner, DS; Goldberg, RN; Vitek, MP; Pearlstein, R; Laskowitz, DT				McAdoo, JD; Warner, DS; Goldberg, RN; Vitek, MP; Pearlstein, R; Laskowitz, DT			Intrathecal. administration of a novel apoE-derived therapeutic peptide improves outcome following perinatal hypoxic-ischemic injury	NEUROSCIENCE LETTERS			English	Article						apolipoprotein E; neuroprotection; hypoxia-ischemia; MK-801; perinatal hypoxia-ischemia	E-DEFICIENT MICE; APOLIPOPROTEIN-E POLYMORPHISM; GLIAL CELL-CULTURES; CLOSED-HEAD INJURY; BRAIN-INJURY; CEREBRAL-ISCHEMIA; MIMETIC PEPTIDES; E PROTECTS; RAT; EXCITOTOXICITY	Perinatal hypoxic-ischemic brain injury remains a significant clinical problem for which there remains no adequate therapeutic intervention. Apolipoprotein E (apoE) is a 299 amino acid protein that has been demonstrated to modify functional recovery following acute ischemic and traumatic brain injury. The aim of the current study was to evaluate whether administration of an apoE-derived peptide could reduce CNS injury in a rodent model of perinatal hypoxia and ischemia. We found that intrathecal delivery of an apoE-mimetic peptide caused a significant reduction in post-ischemic brain necrosis, as reflected by decreased reduction in ipsilateral brain weight 7 days following hypoxic-ischemic injury. These results suggest that administration of an apoE-derived therapeutic peptide represents a novel therapeutic strategy in the clinical setting of perinatal hypoxic-ischemic injury. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Duke Univ, Med Ctr, Neonatal Perinatal Res Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; Cognosci Inc, Res Triangle Pk, NC 27709 USA		Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Neonatal Perinatal Res Inst, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu		Vitek, Michael/0000-0001-8140-8048	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD043494] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS38994-01A1, R21NS4487-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD043494] Funding Source: NIH RePORTER		Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GIDDAY JM, 1994, NEUROSCI LETT, V168, P221, DOI 10.1016/0304-3940(94)90455-3; GOLDSTEIN RF, 2001, PEDIATR RES, V49, P352; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; LINTON MF, 1991, J CLIN INVEST, V88, P270, DOI 10.1172/JCI115288; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Schauwecker PE, 1998, EXP NEUROL, V149, P87, DOI 10.1006/exnr.1997.6679; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3	22	38	40	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 24	2005	381	3					305	308		10.1016/j.neulet.2005.02.036			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	932MR	WOS:000229558300021	15896489				2022-02-06	
J	Wright, DW; Ritchie, JC; Mullins, RE; Kellermann, AL; Denson, DD				Wright, DW; Ritchie, JC; Mullins, RE; Kellermann, AL; Denson, DD			Steady-state serum concentrations of progesterone following continuous intravenous infusion in patients with acute moderate to severe traumatic brain injury	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						traumatic brain injury; pharmacokinetics; continuous infusion; progesterone	SEVERE HEAD-INJURY; HIGH-DOSE PROGESTERONE; CONTUSION INJURY; RATS; MANAGEMENT; EDEMA; GUIDELINES; PROTECTS	Progesterone ( PG) has been shown to provide substantial neuroprotection after traumatic brain injury ( TBI) in multiple animal models. As a first step in assessing applicability to humans, the authors examined the effects of acute TBI and extracranial trauma on the pharmacokinetics of PG given by intravenous infusion. Multiple blood samples were obtained from 11 female and 21 male trauma patients receiving PG and 1 female and 3 male patients receiving placebo infusions for 72 hours. Values for C-SS, CL, t(1/ 2), and V-d were obtained using AUC((0-72)) and postinfusion blood samples. C-SS values were 337 +/- 135 ng/ mL, which were significantly lower than the target concentration of 450 +/- 100 ng/ mL. The lower C-SS is attributed to the CL, which was higher than anticipated. In addition, t(1/2) was longer and V-d was higher than anticipated. These results demonstrate that stable PG concentrations can be rapidly achieved following TBI.	Emory Univ, Sch Med, Dept Emergency Med, Emergency Med Res Ctr, Atlanta, GA 30303 USA; Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30303 USA; Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30303 USA		Wright, DW (corresponding author), Emory Univ, Sch Med, Dept Emergency Med, Emergency Med Res Ctr, 49 Jessie Hill Jr Dr, Atlanta, GA 30303 USA.		Wright, David/F-1209-2013	Wright, David/0000-0002-7145-9105	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS-39097-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039097] Funding Source: NIH RePORTER		Aebi S, 1999, CANCER CHEMOTH PHARM, V44, P259, DOI 10.1007/s002800050976; Allolio B, 1995, EUR J ENDOCRINOL, V133, P696, DOI 10.1530/eje.0.1330696; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boucher BA, 1998, CLIN PHARMACOKINET, V35, P209, DOI 10.2165/00003088-199835030-00004; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carlin CB, 1999, DIGEST SURG, V16, P192, DOI 10.1159/000018726; *CDCP NAT CTR INJ, 2003, TRAUM BRAIN INJ; CHAKMAKJIAN ZH, 1987, J REPROD MED, V32, P443; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHRISTEN RD, 1993, J CLIN ONCOL, V11, P2417, DOI 10.1200/JCO.1993.11.12.2417; Goldfien A, 1989, BASIC CLIN PHARM, P493; HARGROVE JT, 1989, AM J OBSTET GYNECOL, V161, P948, DOI 10.1016/0002-9378(89)90759-X; Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/s001340050261; KRAUS J, 1997, HEAD INJURY, P1; Lancel M, 1996, AM J PHYSIOL-ENDOC M, V271, pE763, DOI 10.1152/ajpendo.1996.271.4.E763; McIntosh TK, 1996, LAB INVEST, V74, P315; McKindley DS, 1998, PHARMACOTHERAPY, V18, P759; MONTVALE NJ, 1998, PHYS DESK REFERENCE; MURAD F, 1990, P1384; NILLIUS SJ, 1971, AM J OBSTET GYNECOL, V110, P470, DOI 10.1016/0002-9378(71)90686-7; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; PETTUS E, 2002, J NEUROTRAUM, V19, P1286; POISINDEX, 1997, DRUG EVALUATIONS TOX; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; ROOF RL, 1997, J NEUROTRAUM, V14, P760; Segall A, 1999, J PHARMACEUT BIOMED, V19, P803, DOI 10.1016/S0731-7085(98)00120-4; SELECKI BR, 1982, AUST NZ J SURG, V52, P93, DOI 10.1111/j.1445-2197.1982.tb05297.x; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; STAMBROOK M, 1990, CAN J SURG, V33, P115; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; VENGPEDERSEN P, 1989, CLIN PHARMACOKINET, V17, P424, DOI 10.2165/00003088-198917060-00005; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	39	38	39	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2700			J CLIN PHARMACOL	J. Clin. Pharmacol.	JUN	2005	45	6					640	648		10.1177/0091270005276201			9	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	928VZ	WOS:000229301100004	15901745				2022-02-06	
J	Fu, ES; Tummala, RP				Fu, Eugene S.; Tummala, Ramachandra P.			Neuroprotection in brain and spinal cord trauma	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						neuroprotection; neurotrauma; spinal cord injury; traumatic brain injury		Purpose of review Traumatic brain and spinal cord injuries continue to be a public health problem. These types of injuries often occur in early adulthood and have a major impact for society. This review discusses strategies and therapeutic agents for perioperative neuroprotection in the management of brain and spinal cord trauma. Recent findings There are no definitive drugs or strategies that can be utilized to provide perioperative neuroprotection in brain and spinal cord trauma patients. Phase III trials of several pharmacologic agents, including inhibitors of oxidative and excitotoxic injury, have been unable to demonstrate clinical efficacy. Although experimental animal data for hypothermia have been promising over the years, clinical application of therapeutic hypothermia cannot be recommended for routine use in neurotrauma patients. Administration of methylprednisolone, which has become common practice in acute spinal cord injury, has come under close scrutiny. Various experimental animal investigations suggest that potential therapeutic agents include estrogen, progesterone, minocycline, erythropoietin, and magnesium. Summary The main priority in the initial treatment of brain and spinal cord trauma is to maintain oxygenation and perfusion in order to avoid aggravating secondary injury. Future progress will depend on the translation of neuroprotective strategies into well designed clinical trials with promising outcomes.	[Fu, Eugene S.] Univ Miami, Dept Anesthesiol, Sch Med, Miami, FL 33136 USA; [Tummala, Ramachandra P.] Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA		Fu, ES (corresponding author), Univ Miami, Dept Anesthesiol, Sch Med, 1611 NW 12th Ave,C-301, Miami, FL 33136 USA.	efu@med.miami.edu					*AM ASS NEUR SURG, 2002, NEUROSURGERY S, V50, P63; Baughman Verna L, 2002, Anesthesiol Clin North Am, V20, P315, DOI 10.1016/S0889-8537(01)00004-9; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bedell Eric, 2002, Anesthesiol Clin North Am, V20, P417, DOI 10.1016/S0889-8537(01)00010-4; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2004, ACT NEUR S, V89, P101; Fritz HG, 2004, J NEUROSURG ANESTH, V16, P43, DOI 10.1097/00008506-200401000-00009; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Gunnarsson T, 2003, CURR OPIN NEUROL, V16, P717, DOI 10.1097/00019052-200312000-00012; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Inamasu J, 2003, J NEUROL SCI, V209, P55, DOI 10.1016/S0022-510X(02)00463-X; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kaptanoglu E, 2003, J CLIN NEUROSCI, V10, P329, DOI 10.1016/S0967-5868(03)00031-6; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Kramer JH, 2003, EXP BIOL MED, V228, P665, DOI 10.1177/153537020322800604; Lee JS, 2004, J NEUROTRAUM, V21, P549, DOI 10.1089/089771504774129883; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Limmroth V, 1996, BRIT J PHARMACOL, V117, P99, DOI 10.1111/j.1476-5381.1996.tb15160.x; Liu XZ, 1997, J NEUROSCI, V17, P5395; Maas AIR, 2004, ACT NEUR S, V89, P113; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Sasaki R, 2003, INTERNAL MED, V42, P142, DOI 10.2169/internalmedicine.42.142; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; Short D, 2001, CURR OPIN NEUROL, V14, P759, DOI 10.1097/00019052-200112000-00013; Stevens RD, 2003, J NEUROSURG ANESTH, V15, P215, DOI 10.1097/00008506-200307000-00009; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suzer T, 1999, SPINAL CORD, V37, P480, DOI 10.1038/sj.sc.3100874; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; Vink R, 2004, J AM COLL NUTR, V23, p538S, DOI 10.1080/07315724.2004.10719398; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Weisner C., 2001, J CEREB BLOOD FLOW M, V21, P857; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Yu CG, 2000, J NEUROSURG, V93, P85, DOI 10.3171/spi.2000.93.1.0085; Zhao LQ, 2004, BRAIN RES, V1010, P22, DOI 10.1016/j.brainres.2004.02.066; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	59	38	45	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	APR	2005	18	2					181	187		10.1097/01.aco.0000162838.56344.88			7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	V40ZO	WOS:000209516700012	16534336				2022-02-06	
J	de Haro, J; Zurita, M; Ayllon, L; Vaquero, J				de Haro, J; Zurita, M; Ayllon, L; Vaquero, J			Detection of In-111-oxine-labeled bone marrow stromal cells after intravenous or intralesional administration in chronic paraplegic rats	NEUROSCIENCE LETTERS			English	Article						bone marrow stromal cells; stem cells; spinal cord injury; paraplegia; In-111-labeled cells	TRAUMATIC BRAIN-INJURY; SPINAL-CORD; INTRACEREBRAL TRANSPLANTATION; FUNCTIONAL RECOVERY; ADULT RATS; STEM-CELLS; IN-111	Recent studies suggested that bone marrow stromal cells (BMSC) may have a therapeutic role in the treatment of paraplegia secondary to severe spinal cord injury (SCI). For this reason, we have studied the possibility of using nuclear medicine imaging techniques to evaluate the permanency and migration of BNISC after transplantation procedures in chronic paraplegic Wistar rats. After intravenous administration of (111) In-oxine- labeled BMSC, gammagraphic images showed that the activity distributed all over the organism, but in the spinal cord only scarce activity was identified. When (111) In-oxine-labeled BMSC were injected within the traumatic centromedullary cavity of paraplegic animals, the gammagraphic images showed persistent activity in the lesion zone, without any activity migrating to the rest of the organism, at least during the whole time of the study (10 days after transplantation procedures). Our results show the utility of (111) In labeling for to know the permanency and distribution of BMSC after grafting procedures, and suggest the convenience of the intralesional administration of BMSC, instead of the intravenous administration, in the treatment of chronic traumatic paraplegia. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Autonomous Univ Madrid, Neurosci Res Unit, Mapfre Med Fdn, Neurosurg Serv,Puerta de Hierro Hosp, Madrid 28035, Spain; Autonomous Univ Madrid, Neurosci Res Unit, Mapfre Med Fdn, Nucl Med Serv,Puerta de Hierro Hosp, Madrid 28035, Spain		Vaquero, J (corresponding author), Autonomous Univ Madrid, Neurosci Res Unit, Mapfre Med Fdn, Neurosurg Serv,Puerta de Hierro Hosp, San Martin de Porres 4, Madrid 28035, Spain.	jvaqueroc@telefonica.net					Bai JZ, 2004, NEUROREPORT, V15, P1117, DOI 10.1097/00001756-200405190-00007; Bulte JWM, 2001, NAT BIOTECHNOL, V19, P1141, DOI 10.1038/nbt1201-1141; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Faraggi M, 1998, EUR J NUCL MED, V25, P205, DOI 10.1007/s002590050218; FROST P, 1978, P SOC EXP BIOL MED, V157, P61; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; ISSEKUTZ T, 1980, CLIN EXP IMMUNOL, V39, P215; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; THIERENS HMA, 1992, J NUCL MED, V33, P1167; Zurita M, 2004, NEUROREPORT, V15, P1105, DOI 10.1097/00001756-200405190-00004	14	38	38	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 22	2005	377	1					7	11		10.1016/j.neulet.2004.11.060			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	903FD	WOS:000227410100002	15722177				2022-02-06	
J	Tennant, A				Tennant, A			Admission to hospital following head injury in England: Incidence and socio-economic associations	BMC PUBLIC HEALTH			English	Article							TRAUMATIC BRAIN-INJURY; SOCIAL DEPRIVATION; COMMUNITY	Background: Head injury in England is common. Evidence suggests that socio- economic factors may cause variation in incidence, and this variation may affect planning for services to meet the needs of those who have sustained a head injury. Methods: Socio- economic data were obtained from the UK Office for National Statistics and merged with Hospital Episodes Statistics obtained from the Department of Health. All patients admitted for head injury with ICD- 10 codes S00.0 - S09.9 during 2001 - 2 and 2002 - 3 were included and collated at the level of the extant Health Authorities ( HA) for 2002, and Primary Care Trust ( PCT) for 2003. Incidence was determined, and cluster analysis and multiple regression analysis were used to look at patterns and associations. Results: 112,718 patients were admitted during 2001 - 2 giving a hospitalised incidence rate for England of 229 per 100,000. This rate varied across the English HA's ranging from 91 - 419 per 100,000. The rate remained unchanged for 2002 - 3 with a similar magnitude of variation across PCT's. Three clusters of HA's were identified from the 2001 - 2 data; those typical of London, those of the Shire counties, and those of Other Urban authorities. Socio- economic factors were found to account for a high proportion of the variance in incidence for 2001 - 2. The same pattern emerged for 2002 - 3 at the PCT level. The use of public transport for travel to work is associated with a decreased incidence and lifestyle indicators, such as the numbers of young unemployed, increase the incidence. Conclusion: Head injury incidence in England varies by a factor of 4.6 across HA's and PCT's. Planning head injury related services at the local level thus needs to be based on local incidence figures rather than regional or national estimates. Socio- economic factors are shown to be associated with admission, including travel to work patterns and lifestyle indicators, which suggests that incidence is amenable to policy initiatives at the macro level as well as preventive programmes targeted at key groups.	Univ Leeds, Acad Unit Musculoskeletal & Rehabil Med, Leeds LS2 9JT, W Yorkshire, England		Tennant, A (corresponding author), Univ Leeds, Acad Unit Musculoskeletal & Rehabil Med, Leeds LS2 9JT, W Yorkshire, England.	alantennant@compuserve.com					ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BENSHLOMO Y, 1992, J EPIDEMIOL COMMUN H, V46, P532, DOI 10.1136/jech.46.5.532; BROOKES M, 1990, J EPIDEMIOL COMMUN H, V44, P147, DOI 10.1136/jech.44.2.147; Carolei A, 1997, STROKE, V28, P2500, DOI 10.1161/01.STR.28.12.2500; Deb S, 1999, BRAIN INJURY, V13, P369, DOI 10.1080/026990599121557; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; *HC, 2001, HEAD INJ REH HLTH CO; Horowitz I, 1983, Int Rehabil Med, V5, P32; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; LYLE DM, 1990, COMMUNITY HEALTH ST, V14, P118; Martin RCG, 2002, AM SURGEON, V68, P477; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; *NAT I CLIN EXC, 2003, TRIAG ASS INV EARL M, V4; Sosin DM, 1996, BRAIN INJURY, V10, P47; Swann IJ, 2001, EMERG MED J, V18, P352, DOI 10.1136/emj.18.5.352; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; TENNANT A, 1995, TRAUMATIC BRAIN INJU, P12; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Townsend P, 1988, HLTH DEPRIVATION INE; VIAZQUEZBARQUER.A, 1990, NEUROLOGIA, V5, P155; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	29	38	39	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2458			BMC PUBLIC HEALTH	BMC Public Health	MAR 4	2005	5								21	10.1186/1471-2458-5-21			8	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	908NG	WOS:000227793100001	15748288	Green Published, Green Accepted, gold			2022-02-06	
J	Luukinen, H; Viramo, P; Herala, M; Kervinen, K; Kesaniemi, YA; Savola, O; Winqvist, S; Jokelainen, J; Hillbom, M				Luukinen, H; Viramo, P; Herala, M; Kervinen, K; Kesaniemi, YA; Savola, O; Winqvist, S; Jokelainen, J; Hillbom, M			Fall-related brain injuries and the risk of dementia in elderly people: a population-based study	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						ApoE epsilon 4; brain injury; dementia; falling aged	APOLIPOPROTEIN-E EPSILON-4; SEVERE HEAD-INJURY; AMYLOID PROTEIN DEPOSITION; ONSET ALZHEIMERS-DISEASE; COGNITIVE DECLINE; E POLYMORPHISM; OLDER-ADULTS; E GENOTYPE; TRAUMA; AGE	Severe head injury in early adulthood may increase the risk of dementia in older age, but it is not known whether head injury in later life also increases the risk of dementia. A representative sample (82%) of persons aged 70 years or older with a Mini-Mental State Examination (MMSE) test score of greater than or equal to26 (n = 325) were followed-up for 9 years to record all their fall-related head injuries resulting in traumatic brain injury (TBI). At the end of the follow-up period, 152 persons (81% of the surviving population) were examined for clinical dementia, according to DSM-IV criteria. Eight persons sustained a TBI and 34 developed dementia. Brain injury was associated with younger age at detection of dementia even when adjusted for sex and educational status (low educational status significantly associated with dementia); age-specific hazard ratio (95% confidence interval) 2.80 (1.35-5.81). In a population scoring greater than or equal to28 points in the baseline MMSE an apolipoprotein E (ApoE) epsilon4 phenotype was also associated with younger age at the time of detecting dementia; 3.56 (1.35-9.34), and the effect of brain injury and ApoE epsilon4 phenotype was synergistic; 7.68 (2.32-25.3). We conclude that fall-related TBI predicts earlier onset of dementia and the effect is especially high amongst subjects who carry the ApoE epsilon4 allele.	Oulu Univ, Dept Publ Hlth Sci & Gen Practice, FIN-90014 Oulu, Finland; Oulu Univ Hosp, Unit Gen Practice, Oulu, Finland; Tornio Hlth Ctr, Tornio, Finland; Univ Oulu, Dept Internal Med, SF-90220 Oulu, Finland; Univ Oulu, Bioctr, SF-90220 Oulu, Finland; Univ Hosp Oulu, Dept Neurosurg, Oulu, Finland; Univ Hosp Oulu, Dept Neurol, Oulu, Finland		Luukinen, H (corresponding author), Oulu Univ, Dept Publ Hlth Sci & Gen Practice, PB 5000, FIN-90014 Oulu, Finland.	heikki.luukinen@oulu.fi		Jokelainen, Jari/0000-0003-4629-0560			AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Commenges D, 1998, STAT MED, V17, P1973, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1973::AID-SIM892>3.0.CO;2-5; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; EHNHOLM C, 1986, J LIPID RES, V27, P227; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; FERINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39, DOI 10.1159/000110750; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Juva K, 2000, NEUROLOGY, V54, P412, DOI 10.1212/WNL.54.2.412; Katzman R, 1996, NEUROLOGY, V46, P889; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; KUUSISTO J, 1994, BRIT MED J, V309, P636, DOI 10.1136/bmj.309.6955.636; LAMMI UK, 1989, SCAND J SOC MED, V17, P67, DOI 10.1177/140349488901700111; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; LUUKINEN H, 1995, J AM GERIATR SOC, V43, P871, DOI 10.1111/j.1532-5415.1995.tb05529.x; LUUKINEN H, 1994, J CLIN EPIDEMIOL, V47, P843, DOI 10.1016/0895-4356(94)90187-2; Luukinen H, 1999, J AM GERIATR SOC, V47, P1451, DOI 10.1111/j.1532-5415.1999.tb01566.x; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	56	38	38	0	5	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	FEB	2005	12	2					86	92		10.1111/j.1468-1331.2004.00953.x			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	892ID	WOS:000226642900002	15679695				2022-02-06	
J	Bauer, L; Yantz, CL; Ryan, LM; Warden, DL; McCaffrey, RJ				Bauer, L; Yantz, CL; Ryan, LM; Warden, DL; McCaffrey, RJ			An examination of the california verbal learning test II to detect incomplete effort in a traumatic brain-injury sample	APPLIED NEUROPSYCHOLOGY			English	Article						California Verbal Learning Test II; effort testing; traumatic brain-injury		Clinical neuropsychologists are frequently called on to distinguish people who appear impaired on neuropsychological testing due to putting forth incomplete effort from those who have genuine cognitive deficits. Because traditional measures of effort are becoming accessible over the Internet and within the legal community and their purpose may be obvious to potential malingerers, nontraditional effort measures have been newly investigated. Using discriminant function analysis, this study explores whether five California Verbal Learning Test-Second Edition (CVLT-II) variables could differentiate between head-injured patients who were putting forth full effort and those who were putting forth incomplete effort. The discriminant function seemed to best predict those who put forth adequate effort while testing (95.6% correct) but not those who failed to put forth adequate effort during testing (only 13.8% correct). Hence, although the overall classification rate was moderately impressive (75.8%), the model's sensitivity in classification of the incomplete effort group was low. Cautious applications for these findings are discussed.	SUNY Albany, Dept Psychol, Albany, NY 12222 USA; SUNY Albany, Dept Psychol, New York, NY USA; Walter Reed Army Med Ctr, Defense & Vet Brain Injury Ctr, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA		McCaffrey, RJ (corresponding author), SUNY Albany, Dept Psychol, Albany, NY 12222 USA.	rm188@albany.edu					Allen L, 1999, ARCH CLIN NEUROPSYCH, V14, P789, DOI 10.1016/S0887-6177(99)80328-X; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; TOMBAUGH TN, 2003, J FORENSIC NEUROPSYC, V2, P69, DOI DOI 10.1300/J151V02N03_04; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; [No title captured]; [No title captured]	13	38	39	0	3	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2005	12	4					202	207		10.1207/s15324826an1204_3			6	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	006EH	WOS:000234877800003	16422661				2022-02-06	
J	Howes, H; Benton, D; Edwards, S				Howes, H; Benton, D; Edwards, S			Women's experience of brain injury: An interpretative phenomenological analysis	PSYCHOLOGY & HEALTH			English	Article						brain injury; women; adaptation; qualitative	SEVERE HEAD-INJURY; DISABILITY; REHABILITATION; RELATIVES; SELF	Acquired traumatic brain injury (TBI) can leave the survivor with a complex range of psychological sequalae. This study aims to investigate the experience from the perspective of women with acquired TBI. Using a qualitative research method, six women with a TBI were interviewed about their experience, and the interviews were transcribed verbatim and analysed according to Interpretative Phenomenological Analysis (IPA). The major themes that emerged were: awareness of change; the emotional reaction; struggling to make sense; adaptation and acceptance. This article describes the process of adaptation, and the implications for rehabilitation are discussed. It is suggested that an intervention based on these themes might be an effective tool in rehabilitation.	Univ Coll Swansea, Dept Psychol, Swansea SA2 8PP, W Glam, Wales		Howes, H (corresponding author), Univ Coll Swansea, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	hannah.howes@nbt.nhs.uk					BOWLBY J, 1981, SADNESS DEPRESSION, V3; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHARMAZ K, 1989, STUD SYM IN, V10, P127; CIOCCA CL, 1995, DISS ABSTR INT B, V56, P2846; DIENER E, 1994, SOC INDIC RES, V31, P103, DOI 10.1007/BF01207052; Dombrowski LK, 2000, REHABIL PSYCHOL, V45, P299, DOI 10.1037/0090-5550.45.3.299; Drench M E, 1994, Rehabil Nurs, V19, P31; EARLL L, 1995, HEALTH PSYCHOL, P283; Folkman S, 2000, AM PSYCHOL, V55, P647, DOI 10.1037//0003-066X.55.6.647; FOLKMAN S, 1997, PL S STRESS, P293; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Fortune DG, 2002, BRIT J CLIN PSYCHOL, V41, P157, DOI 10.1348/014466502163949; GOFFMAN, 1963, SOCIETY; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HAHN H, 1983, SOCIETY, V20, P36, DOI 10.1007/BF02700073; HARRELL MM, 1991, COGNITIVE REHABILITA, V9, P12; Imrie R, 1997, DISABIL REHABIL, V19, P263, DOI 10.3109/09638289709166537; JACKSON LA, 1988, SEX ROLES, V19, P429, DOI 10.1007/BF00289717; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Judd D. P., 1999, COUNSELLING PSYCHOL, V14, P4; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Littlewood Jane, 1992, ASPECTS GRIEF BEREAV; Maker C, 2003, PSYCHOL HEALTH, V18, P403, DOI 10.1080/0887044031000069343; MCKEE KJ, 1998, J BRIT SOC GERONTOLO, V8, P11; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCKNIGHT JL, 1990, MAPPING COMMUNITY CA, P9; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; MOSKOWITZ J, 1998, ANN M AM PSYCH ASS S; Moskowitz JT, 2003, DEATH STUD, V27, P471, DOI 10.1080/07481180390197624; Moustakas C.E., 1994, PHENOMENOLOGICAL RES; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Parkes C.M, 1998, BEREAVEMENT STUDIES; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M, P157; RUSSELL DM, 2001, DISS ABSTR INT B, V61, P3860; SALTER S, 1997, ALTERED BODY IMAGE, P1; Smith JA, 2000, PSYCHOL HEALTH, V15, P1, DOI 10.1080/08870440008400284; Smith JA, 1996, PSYCHOL HEALTH, V11, P261, DOI 10.1080/08870449608400256; Smith JA, 1999, BRIT J SOC PSYCHOL, V38, P409, DOI 10.1348/014466699164248; Stroebe M., 2001, HDB BEREAVEMENT RES; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VANZOMEREN EAH, 2002, EVV REH COGN DEF C C; WESTBROOK MT, 1990, AUSTR SOCIAL WORK, V43, P27; WILLIAMS CA, 2002, BRIT J HEALTH PSYCH, V2, P153; WILSONBARNETT J, 1980, NURSING, V2, P432	50	38	38	1	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0887-0446	1476-8321		PSYCHOL HEALTH	Psychol. Health	JAN	2005	20	1					129	142		10.1080/0887044042000272903			14	Public, Environmental & Occupational Health; Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Psychology	889ZW	WOS:000226482500009					2022-02-06	
J	Kiraly, MA; Kiraly, SJ				Kiraly, MA; Kiraly, SJ			The effect of exercise on hippocampal integrity: Review of recent research	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article						aging; Alzheimer's disease; antioxidant; cortisol; dementia; depression; exercise; hippocampus; ischemia; neuroprotection; stress; stroke; traumatic brain injury	MESSENGER-RNA EXPRESSION; GROWTH-FACTOR-I; PHYSICAL-ACTIVITY; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; CELL-PROLIFERATION; DENTATE GYRUS; ANTIDEPRESSANT TREATMENT; ANTIOXIDANT SYSTEM; TREADMILL EXERCISE	Objectives: To review salient basic research regarding physical exercise as a major protective factor against hippocampal degradation and to emphasize its relevance to humans. Method: Recent mammalian and human research literature search and theoretical discussion. Results: The cascade of cellular damages from oxidative stress, nitrosative stress and gluco-corticoid effects are cumulative and age related. Exercise training reduces oxidative stress, nitro-sative stress and improves neuroendocrine autoregulation which counteracts damages from stress- and age-related neuronal degeneration, brain ischemia and traumatic brain injury. Conversely, lack of exercise and motility restrictions are associated with increased vulnerability from oxidative stress, nitrosative stress and glucocorticoid excesses, all of which precede amyloid deposition and are fundamental in the cascade of events resulting in neuronal degradation, especially in the hippocampi. Conclusions: Despite the paucity of human research, basic animal models and clinical data overwhelmingly support the notion that exercise treatment is a major protective factor against neurodegeneration of varied etiologies. The final common pathway of degradation is clearly related to oxidative stress, nitrosative stress, glucocorticoid dysregulation, inflammation and amyloid deposition. We conclude that people prone to chronic distress, brain ischemia, brain trauma, and the aged are at increased risk for neurodegenerative diseases such as Alzheimer's. Exercise training may be a major protective factor but without clinical guidelines, its prescription and success with treatment adherence remain elusive.	York Univ, N York, ON M3J 1P3, Canada; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada		Kiraly, SJ (corresponding author), B-51 Hummingbird Lane, Bowen Isl, BC V0N 1G0, Canada.	kiraly@shaw.ca					Albert MS, 1995, PSYCHOL AGING, V10, P578, DOI 10.1037/0882-7974.10.4.578; Anderson MF, 2002, DEV BRAIN RES, V134, P115; Ang ET, 2003, NEUROSCIENCE, V118, P335, DOI 10.1016/S0306-4522(02)00989-2; Asanuma M, 2004, CURR PHARM DESIGN, V10, P695, DOI 10.2174/1381612043453072; Behl C, 1998, EXP GERONTOL, V33, P689, DOI 10.1016/S0531-5565(98)00019-9; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Blair SN, 2001, MED SCI SPORT EXER, V33, pS379, DOI 10.1097/00005768-200106001-00007; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; Bunce DJ, 1996, PSYCHOL AGING, V11, P671, DOI 10.1037/0882-7974.11.4.671; Cadet P, 2003, INT J MOL MED, V12, P485; CALABRESE V, 1989, Bollettino Societa Italiana Biologia Sperimentale, V65, P917; CAMERON HA, 1995, J NEUROSCI, V15, P4687; COHEN G, 1998, OXYGEN RADICAL TISSU, P130; Devi SA, 2004, NEUROBIOL AGING, V25, P501, DOI 10.1016/S0197-4580(03)00112-X; Ding Y, 2004, NEUROSCIENCE, V124, P583, DOI 10.1016/j.neuroscience.2003.12.029; Ellekjaer H, 2000, STROKE, V31, P14, DOI 10.1161/01.STR.31.1.14; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Evenson KR, 1999, STROKE, V30, P1333, DOI 10.1161/01.STR.30.7.1333; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V246, P359; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Fillit HM, 2002, MAYO CLIN PROC, V77, P681, DOI 10.4065/77.7.681; Friedland RP, 2001, P NATL ACAD SCI USA, V98, P3440, DOI 10.1073/pnas.061002998; Ganguli M, 1999, J AM GERIATR SOC, V47, P842, DOI 10.1111/j.1532-5415.1999.tb03842.x; Garza AA, 2004, PHARMACOL BIOCHEM BE, V77, P209, DOI 10.1016/j.pbb.2003.10.020; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Greenlund KJ, 2002, STROKE, V33, P565, DOI 10.1161/hs0202.102882; Grundman M, 2000, AM J CLIN NUTR, V71, p630S; Gutteridge J.M., 1985, FREE RADICALS BIOL M; HENSLEY K, 1995, P W PHARMACOL SOC, V38, P113; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Hu FB, 2000, JAMA-J AM MED ASSOC, V283, P2961, DOI 10.1001/jama.283.22.2961; JENKINS RR, 1984, INT J SPORTS MED, V5, P11, DOI 10.1055/s-2008-1025872; Jin KL, 2000, J MOL NEUROSCI, V14, P197, DOI 10.1385/JMN:14:3:197; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Khatri P, 2001, J AGING PHYS ACTIV, V9, P43, DOI 10.1123/japa.9.1.43; Kim YP, 2003, INT J SPORTS MED, V24, P114, DOI 10.1055/s-2003-38202; Kiraly SJ, 1997, CAN J PSYCHIAT, V42, P415, DOI 10.1177/070674379704200409; Kitamura T, 2003, NEUROSCI RES, V47, P55, DOI 10.1016/S0168-0102(03)00171-8; KOCHANEK KD, 2002, NATL VITAL STAT REPO, V52; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Koppal T, 1999, J NEUROCHEM, V72, P310, DOI 10.1046/j.1471-4159.1999.0720310.x; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; KURODA K, 1992, ACTA NEUROL SCAND, V86, P55, DOI 10.1111/j.1600-0404.1992.tb08054.x; LAMANNA JC, 1992, J APPL PHYSIOL, V72, P2238, DOI 10.1152/jappl.1992.72.6.2238; Lanska DJ, 1998, NEUROLOGY, V50, P362, DOI 10.1212/WNL.50.2.362; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Lee CD, 2003, STROKE, V34, P2475, DOI 10.1161/01.STR.0000091843.02517.9D; Lee IM, 1999, STROKE, V30, P1, DOI 10.1161/01.STR.30.1.1; Lee MH, 2003, LIFE SCI, V73, P2455, DOI 10.1016/S0024-3205(03)00655-6; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; McIntosh LJ, 1998, BRAIN RES, V791, P209, DOI 10.1016/S0006-8993(98)00115-2; MURRAY KD, 1994, NEUROSCIENCE, V60, P37, DOI 10.1016/0306-4522(94)90202-X; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; NOVELLI GP, 1999, FREE RADICAL BIO MED, V9, P9; Ra SM, 2002, NEUROSCI LETT, V333, P123, DOI 10.1016/S0304-3940(02)01031-5; Radak Z, 2001, NEUROCHEM INT, V39, P33, DOI 10.1016/S0197-0186(01)00003-1; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Sapolsky R.M, 1992, STRESS AGING BRAIN M; SASCO AJ, 1992, ARCH NEUROL-CHICAGO, V49, P360, DOI 10.1001/archneur.1992.00530280040020; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; SOMANI SM, 1995, PHARMACOL BIOCHEM BE, V50, P635, DOI 10.1016/0091-3057(94)00357-2; Sumitani Kazunori, 2002, Nihon Seirigaku Zasshi, V64, P152; Trejo JL, 2002, REV NEUROSCIENCE, V13, P365; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; U.S. Department of Health and Human Services, 1990, DHHS PUBL, V90-8416; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Wannamethee SG, 2001, SPORTS MED, V31, P101, DOI 10.2165/00007256-200131020-00003; Widenfalk J, 1999, NEUROSCI RES, V34, P125, DOI 10.1016/S0168-0102(99)00051-6; Wilkins K, 1999, Chronic Dis Can, V20, P26; Williams P, 1997, AUST NZ J PUBL HEAL, V21, P45, DOI 10.1111/j.1467-842X.1997.tb01653.x; Wilson RS, 2003, NEUROLOGY, V61, P1479, DOI 10.1212/01.WNL.0000096167.56734.59; Yaffe K, 2001, ARCH INTERN MED, V161, P1703, DOI 10.1001/archinte.161.14.1703; Yanamoto H, 1998, BRAIN RES, V784, P239, DOI 10.1016/S0006-8993(97)01344-9; Young R J, 1979, Br J Sports Med, V13, P110; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	83	38	39	0	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2174	1541-3527		INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		2005	35	1					75	89		10.2190/HX7L-4B40-PQNY-2A4P			15	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	936PL	WOS:000229867800006	15977946				2022-02-06	
J	Pape, TLB; Heinemann, AW; Kelly, JP; Hurder, AG; Lundgren, S				Pape, TLB; Heinemann, AW; Kelly, JP; Hurder, AG; Lundgren, S			A measure of neurobehavioral functioning after coma. Part I: Theory, reliability, and validity of the Disorders of Consciousness Scale	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain injury; coma; consciousness; measure; outcome; psychometrics; recovery	TRAUMATIC BRAIN-INJURY; VEGETATIVE STATE; REHABILITATION; MANAGEMENT; TOOL	This longitudinal validation study describes the psychometric properties of the Disorders of Consciousness Scale (DOCS). This is Part I of a two-part series. Part II illustrates and describes the clinical and scientific implementation of the DOCS measure. The study was conducted at one intensive care unit, two acute rehabilitation hospitals, and one long-term acute cl-ironic care hospital. Participants were unconscious after severe brain in injury (BI). We conducted interrater reliability using ratings, from interdisciplinary pairs. Results indicated a higher-than-expected level of agreement and no significant difference between any pairs (chi-square 8(5df) P = 0.15) (df = degrees of freedom). Examinations of ratings by discipline groups indicated that the DOCS is' impacted minimally by discipline. Validity analyses demonstrate that 23 of 34 test stimuli remain stable over time with no floor or ceiling effect. DOCS measures obtained within 94 days of injury predicted recovery of consciousness up to 1 year after injury (c-indices of 0.70 and 0.86). Positive (0.71) and negative (0.68) predictive values indicate that the DOCS predicts recovery and lack of recovery. Twenty-three of the DOCS test stimuli produce a reliable, valid, and stable measure of neurobehavioral recovery after severe BI that predicts recovery and lack of recovery of consciousness 1 year after injury.	Edward Hines Jr VA Hosp, Vet Hlth Adm, Res Serv, Dept Vet Affairs, Hines, IL 60141 USA; Marianjoy Rehab Hosp, Wheaton, IL USA; Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; Inst Hlth Serv Res & Policy Studies, Chicago, IL 60611 USA; Rehabil Inst Chicago, Ctr Rehab Outcomes Res, Chicago, IL 60611 USA; Univ Colorado, Sch Med, Dept Neurosurg, Denver, CO USA; Edward Hines Jr Vet Adm Hosp, Cooperat Studies Program, Coordinating Ctr, Hines, IL 60141 USA; Minneapolis VA Med Ctr, Mental Behav Hlth Patient Serv Line, Minneapolis, MN USA		Pape, TLB (corresponding author), Edward Hines Jr VA Hosp, Vet Hlth Adm, Res Serv, Dept Vet Affairs, POB 5000,MC 151H, Hines, IL 60141 USA.	Theresa.Pape@med.va.gov	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326; Bender Pape, Theresa/0000-0001-7738-5963			Andrews K, 1996, BRAIN INJURY, V10, P797, DOI 10.1080/026990596123918; ANSELL BJ, 1989, ARCH PHYS MED REHAB, V70, P104; Bernat JL, 2002, NEUROLOGY, V58, P337, DOI 10.1212/WNL.58.3.337; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Fisher RA, 1925, P CAMB PHILOS SOC, V22, P700, DOI 10.1017/S0305004100009580; Fisher W., 1992, RASCH MEAS T, V6, P238; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GillThwaites H, 1997, BRAIN INJURY, V11, P723, DOI 10.1080/026990597123098; Halper AS, 1991, CLIN MANAGEMENT COMM; Hedeker D, 2000, STAT METHODS MED RES, V9, P161, DOI 10.1191/096228000667253473; Heinemann AW, 2000, J HEAD TRAUMA REHAB, V15, pVI, DOI 10.1097/00001199-200002000-00001; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1976, LANCET, V1, P1031; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; Linacre JM., 1999, RASCH MEAS T, V13, P675; Linacre M., 1994, MANY FACET RASCH MEA; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; PAPE T, 2001, 84133F CFDA US DEP E; PAPE T, 1999, THESSI U ILLINOIS CH; Pape TLB, 2004, J REHABIL RES DEV, V41, P155, DOI 10.1682/JRRD.2004.02.0155; PAPE TLB, 1999, AM J PUBLIC HEALTH, V89, P1281; Wilson SL, 2000, BRAIN INJURY, V14, P319; Wright B, 1994, MEASUREMENT T, V8, P370; Wright B.D, 1994, RASCH MEASUREMENT T, V8, P360; Wright B. D., 1996, RASCH MEASUREMENT T, V9; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; Wright BD., 1982, RATING SCALE ANAL; WRIGHT BD, 1998, RASCH MEAS T, V11, P602; Zasler ND, 1996, NEUROREHABILITATION, V6, P3, DOI 10.3233/NRE-1996-6102	32	38	39	0	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.	JAN-FEB	2005	42	1					1	17		10.1682/JRRD.2004.03.0032			17	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	914DL	WOS:000228205100004	15742245				2022-02-06	
J	Sayyah, M; Beheshti, S; Shokrgozar, MA; Eslami-Far, A; Deljoo, Z; Khabiri, AR; Rohani, AH				Sayyah, M; Beheshti, S; Shokrgozar, MA; Eslami-Far, A; Deljoo, Z; Khabiri, AR; Rohani, AH			Antiepileptogenic and anticonvulsant activity of interleukin-1 beta in amygdala-kindled rats	EXPERIMENTAL NEUROLOGY			English	Article						amygdala kindling; interleukin-1 beta; seizure; nitric oxide; prostaglandins	PENTYLENETETRAZOL-INDUCED SEIZURES; NITRIC-OXIDE SYNTHASE; MESSENGER-RNA; KAINIC ACID; INFLAMMATORY CYTOKINES; SYNAPTIC-TRANSMISSION; RECEPTOR ANTAGONIST; TNF-ALPHA; BRAIN; EPILEPSY	Ischaemic, excitotoxic and traumatic brain injuries have been associated with the occurrence of epileptic seizures. Microglia, the principal immune cells in the brain, produce a variety of proinflammatory and cytotoxic factors especially interleukin-1 (IL-1) early after an acute insult. We studied the effect of intracerebroventricularly administered IL-1beta on seizure acquisition and on fully kindled seizures in amygdala kindling model of epilepsy. IL-1beta (0.01 ng/rat) retarded acquisition of kindled behavioral seizures and growth of afterdischarges (AD). IL-1beta (0.01-10 ng/rat) also exhibited significant anticonvulsant effect on established kindled seizures and AD duration. This effect began 0.5 h after administration and was continued up to 72 h. Pretreatment of the kindled animals with nitric oxide synthase inhibitor, N-G-nitro-L-arginine methyl ester, or cyclooxygenase inhibitor, piroxicam, reversed the anticonvulsant effect of IL-1beta at early time points. Although most of the previous studies indicate a proconvulsant or convulsant property of IL-1, our results support a protective and antiepileptogenic role of IL-1beta. (C) 2004 Elsevier Inc. All rights reserved.	Inst Pasteur, Dept Physiol & Pharmacol, Tehran 13164, Iran; Univ Tehran, Fac Sci, Dept Physiol, Tehran, Iran; Inst Pasteur, Natl Cell Bank Iran, Tehran, Iran; Inst Pasteur, Dept Clin Res, Tehran, Iran; Inst Pasteur, Dept Parasitol, Tehran, Iran		Sayyah, M (corresponding author), Inst Pasteur, Dept Physiol & Pharmacol, Pasteur Ave, Tehran 13164, Iran.	sayyah@pasteur.ac.ir	shokrgozar, mohammad ali/L-4149-2017; Sayyah, Mohammad/K-4871-2017; Beheshti, Siamak/AAB-2169-2021	shokrgozar, mohammad ali/0000-0001-5123-4155; Sayyah, Mohammad/0000-0003-0603-2444; Beheshti, Siamak/0000-0002-5128-8935			Akarsu ES, 1998, EPILEPSY RES, V30, P63; AKARSU ES, 1992, METHOD FIND EXP CLIN, V14, P517; Alexander CB, 1998, EUR J PHARMACOL, V344, P15, DOI 10.1016/S0014-2999(97)01551-3; Avital A, 2003, HIPPOCAMPUS, V13, P826, DOI 10.1002/hipo.10135; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; CARSON FL, 1990, AM SOC CLIN PATHOL, P170; Coogan A, 1997, NEUROREPORT, V8, P2107, DOI 10.1097/00001756-199707070-00004; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; de Vasconcelos AP, 2000, EPILEPSIA, V41, P363; DelBel EA, 1997, BRAZ J MED BIOL RES, V30, P971, DOI 10.1590/S0100-879X1997000800010; Eriksson C, 1998, MOL BRAIN RES, V58, P195, DOI 10.1016/S0169-328X(98)00125-9; Gahring LC, 1997, NEUROBIOL DIS, V3, P263, DOI 10.1006/nbdi.1996.0123; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Jayakumar AR, 1999, BRAIN RES BULL, V48, P387, DOI 10.1016/S0361-9230(99)00011-8; Jelenkovic A, 2002, ANN NY ACAD SCI, V962, P296, DOI 10.1111/j.1749-6632.2002.tb04075.x; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Krueger JM, 1998, ANN NY ACAD SCI, V856, P148, DOI 10.1111/j.1749-6632.1998.tb08323.x; Marangoz C, 2001, JPN J PHARMACOL, V86, P297, DOI 10.1254/jjp.86.297; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; Medeiros FD, 1997, ARQ NEURO-PSIQUIAT, V55, P677; MILLER LG, 1991, MOL PHARMACOL, V39, P105; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; Murray CA, 1998, J NEUROSCI, V18, P2974; OPP MR, 1991, AM J PHYSIOL, V260, pR453, DOI 10.1152/ajpregu.1991.260.2.R453; Paoletti AM, 1998, EXP NEUROL, V149, P349, DOI 10.1006/exnr.1997.6741; Plata-Salaman CR, 2000, MOL BRAIN RES, V75, P248, DOI 10.1016/S0169-328X(99)00306-X; Porter R. J., 2001, BASIC CLIN PHARM, P395; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RONDOUIN G, 1992, NEUROREPORT, V3, P805, DOI 10.1097/00001756-199209000-00021; Ross FM, 2003, J NEUROIMMUNOL, V144, P61, DOI 10.1016/j.jneuroim.2003.08.030; Roth J, 1998, LIFE SCI, V62, pPL345, DOI 10.1016/S0024-3205(98)00179-9; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sayyah M, 2003, EPILEPSY RES, V57, P175, DOI 10.1016/j.eplepsyres.2003.11.002; SHENG JG, 1994, J NEUROCHEM, V63, P1872; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vezzani A, 2002, EPILEPSIA, V43, P30, DOI 10.1046/j.1528-1157.43.s.5.14.x; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; YABUUCHI K, 1993, MOL BRAIN RES, V20, P153, DOI 10.1016/0169-328X(93)90121-5; YU BJ, 1994, J PHARMACOL EXP THER, V271, P590; ZEISE ML, 1992, REGUL PEPTIDES, V39, P1, DOI 10.1016/0167-0115(92)90002-C	44	38	46	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2005	191	1					145	153		10.1016/j.expneurol.2004.08.032			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	886KK	WOS:000226225900015	15589521				2022-02-06	
J	Hillard, VH; Peng, H; Zhang, Y; Das, K; Murali, R; Etlinger, JD; Zeman, RJ				Hillard, VH; Peng, H; Zhang, Y; Das, K; Murali, R; Etlinger, JD; Zeman, RJ			Tempol, a nitroxide antioxidant, improves locomotor and histological outcomes after spinal cord contusion in rats	JOURNAL OF NEUROTRAUMA			English	Article						cavitation; contusion; locomotor function; spinal cord injury; tempol; white matter	TRANSIENT FOCAL ISCHEMIA; CLOSED-HEAD INJURY; STABLE NITROXIDE; SUPEROXIDE-DISMUTASE; CEREBRAL-ISCHEMIA; BLOOD-PRESSURE; BRAIN-INJURY; MODEL; METHYLPREDNISOLONE; RECOVERY	We have determined whether the nitroxide antioxidant, tempol, can oppose tissue loss and improve recovery of locomotor function following contusion injury of the spinal cord. Contusion injury was produced in rats at the level of T10 with a weight-drop device and locomotor recovery was determined with the 21-point Basso, Beattie and Bresnahan (BBB) scale. Locomotor function recovered progressively during the 6-week postinjury observation period and was significantly greater in tempol-treated (275 mg/kg ip, 20 min postinjury) compared to vehicle-treated rats (final BBB scores: 9.1 versus 6.4). Similarly enhanced locomotor recovery was observed with doses of tempol in the range of 138-550, but not 69 mg/kg, and with injection at 48 h postinjury indicating a therapeutic time-window of at least several days. The extent of recovery correlated with measurements of sparing of spinal cord white matter in a region several millimeters in length extending rostrally from the contusion epicenter. In contrast, loss of gray matter was unaffected by tempol treatment. Since tempol acts by scavenging reactive oxygen species (ROS) such as superoxide and hydroxyl radicals, the improved locomotor recovery and spared spinal cord tissue following contusion injury provides evidence of a direct role of ROS-mediated neurodegeneration in spinal cord injury.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; New York Med Coll, Dept Neurosurg, Valhalla, NY 10595 USA; MotoGen Inc, Mt Kisco, NY USA		Zeman, RJ (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.	zeman@nymc.edu		Hillard, Virany Huynh/0000-0003-2218-8182; Peng, Hong/0000-0001-5522-072X			Banik NL, 1997, BRAIN RES, V748, P205, DOI 10.1016/S0006-8993(96)01302-9; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hahn SM, 1998, INT J RADIAT ONCOL, V42, P839, DOI 10.1016/S0360-3016(98)00317-4; Hahn SM, 2000, FREE RADICAL BIO MED, V28, P953, DOI 10.1016/S0891-5849(00)00176-3; HAHN SM, 1992, CANCER RES, V52, P1750; Hall E D, 2001, J Spinal Cord Med, V24, P142; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hu GH, 2003, J NEUROSURG, V98, P393, DOI 10.3171/jns.2003.98.2.0393; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kato N, 2003, BRAIN RES, V979, P188, DOI 10.1016/S0006-8993(03)02918-4; Kwon TH, 2003, J NEUROTRAUM, V20, P337, DOI 10.1089/089771503765172291; Leker RR, 2002, EXP NEUROL, V176, P355, DOI 10.1006/exnr.2002.7910; Liu XZ, 1997, J NEUROSCI, V17, P5395; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; Nakauchi K, 1996, J NEUROTRAUM, V13, P573, DOI 10.1089/neu.1996.13.573; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Park Youn-Kwan, 1998, Journal of Korean Medical Science, V13, P638; Rabchevsky AG, 2000, EXP NEUROL, V164, P280, DOI 10.1006/exnr.2000.7399; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; RATAN RR, 1994, J NEUROSCI, V14, P4385; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Schultke E, 2003, J NEUROTRAUM, V20, P583, DOI 10.1089/089771503767168500; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Xu H, 2001, AM J PHYSIOL-HEART C, V281, pH975, DOI 10.1152/ajpheart.2001.281.2.H975; Zeman RJ, 2001, EXP NEUROL, V172, P228, DOI 10.1006/exnr.2001.7803; Zeman RJ, 1999, EXP NEUROL, V159, P267, DOI 10.1006/exnr.1999.7146; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	39	38	41	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2004	21	10					1405	1414		10.1089/neu.2004.21.1405			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	867BT	WOS:000224817800005	15672631				2022-02-06	
J	Oppermann, JD				Oppermann, JD			Interpreting the meaning individuals ascribe to returning to work after traumatic brain injury: a qualitative approach	BRAIN INJURY			English	Article							COMMUNITY INTEGRATION; OF-LIFE; EMPLOYMENT; REHABILITATION; PREDICTION; OUTCOMES; TBI	Objective: The purpose of this study was to describe, qualitatively, the meaning individuals ascribe to returning to work after traumatic injury to the brain. Design: A qualitative multiple-case study design was used for this study to allow for flexibility during data collection and to support naturalistic generalizations. Methods: A random sample of two participants was included in the study using snowball sampling. Semi-structured interviews and written documentation was used to collect data. Cross-case analysis was used to identify phenomenological themes. Results: While defining the meaning of work, thematic analysis revealed three themes: (a) experience of finding work after injury, (b) experience of maintaining work and (c) independence related to work. Conclusion: The several important points that were identified throughout semi-structured interviews were how individuals subjectively and objectively define work, important points about personal experiences finding and maintaining work and the societal value individuals relate to work. Important themes found in this study could be addressed by intermittent long-term interventions following traumatic brain injury (TBI).	Creighton Univ, Sch Med, Omaha, NE 68178 USA		Oppermann, JD (corresponding author), Creighton Univ, Sch Med, 2500 Calf Plaza, Omaha, NE 68178 USA.						Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Creswell J.W., 2017, RES DESIGN QUALITATI; Creswell JW., 1998, QUAL INQ; DEPOY E, 1998, INTRO RES UNDERSTAND; DREW P, TURN YOUR GUIDE FEDE, pCH11; Fleming J, 1999, BRAIN INJURY, V13, P417; Hirsh A, 1996, J VOCAT REHABIL, V7, P217; Hoofien D, 2001, BRAIN INJURY, V15, P189; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; KREFTING L, 1991, AM J OCCUP THER, V45, P214, DOI 10.5014/ajot.45.3.214; Lincoln Yvonna S., 1985, NATURALISTIC INQUIRY; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Nagele D.A, 1999, PHYS MED REHABIL STA, V13, P161; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; ROCCHIO C, 1998, FAMILY NEWS VIEWS MO, V5; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sherer M, 1999, BRAIN INJURY, V13, P973; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stake R., 1995, ART CASE STUDY RES; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Wolcott HF., 1994, TRANSFORMING QUALITA; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	27	38	38	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2004	18	9					941	955		10.1080/02699050410001671919			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	831FG	WOS:000222178700009	15223746				2022-02-06	
J	Levin, HS; Hanten, G; Zhang, LF; Swank, PR; Hunter, J				Levin, HS; Hanten, G; Zhang, LF; Swank, PR; Hunter, J			Selective impairment of inhibition after TBI in children	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; INFERIOR PREFRONTAL CORTEX; COGNITIVE-DEVELOPMENT; RESPONSE-INHIBITION; WORKING-MEMORY; PERFORMANCE; GO; MATURATION	Inhibition was studied in 12 children who had sustained a severe traumatic brain injury (TBI) at least 1year earlier and in 15 control children. On the flanker task, which involved pressing a button corresponding to the direction of an arrow, the TBI group performed less accurately than controls under interference (flankers were incongruent with arrow) and go-no-go (adjacent stimulus signaled child to withhold response) conditions, but not neutral or facilitation (flankers were congruent) conditions. Response latency was related to age and task condition, but not to group. Severe TBI in children may disrupt development of distributed networks mediating inhibition.	Univ Texas, Hlth Sci Ctr, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Baylor Coll Med, Houston, TX 77030 USA		Levin, HS (corresponding author), Univ Texas, Hlth Sci Ctr, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin St,Ste 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; BJORKLUND DF, 1990, DEV REV, V10, P48, DOI 10.1016/0273-2297(90)90004-N; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; CASE R, 1992, BRAIN COGNITION, V20, P51, DOI 10.1016/0278-2626(92)90061-P; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; DEMPSTER FN, 1992, DEV REV, V12, P45, DOI 10.1016/0273-2297(92)90003-K; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; DREWE E A, 1975, Cortex, V11, P8; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; JENNETT B, 1975, LANCET, V1, P480; Kawashima R, 1996, BRAIN RES, V728, P79, DOI 10.1016/0006-8993(96)00389-7; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; Konishi S, 1999, CEREB CORTEX, V9, P745, DOI 10.1093/cercor/9.7.745; Konrad KN, 2000, BRAIN INJURY, V14, P859; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Luna B, 2001, NEUROIMAGE, V13, P786, DOI 10.1006/nimg.2000.0743; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; PETRIDES M, 1986, J NEUROSCI, V6, P2054; *PSYCH SOFTW TOOLS, 2002, E PRIM COMP SOFTW; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rubia K, 2000, NEUROSCI BIOBEHAV R, V24, P13, DOI 10.1016/S0149-7634(99)00055-X; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, Vxiv; [No title captured]	40	38	38	1	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	2004	26	5					589	597		10.1080/13803390490504434			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	862HE	WOS:000224480800001	15370381				2022-02-06	
J	Schmitt, DM; Hertel, J; Evans, TA; Olmsted, LC; Putukian, M				Schmitt, DM; Hertel, J; Evans, TA; Olmsted, LC; Putukian, M			Effect of an acute bout of soccer heading on postural control and self-reported concussion symptoms	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	Meeting and Clinical Symposium of the National-Athletic-Trainer-Association	JUN 15-28, 2002	Dallas, TX			balance; cerebral concussion; football	BRAIN-INJURY; NEUROPSYCHOLOGICAL IMPAIRMENT; COLLEGIATE; STABILITY	Our purpose was to determine if an acute bout of heading soccer balls adversely affected postural control and self-reported symptoms of cerebral concussion. Thirty-one college-aged soccer players were randomly placed into either a kicking group or a heading group. Subjects either kicked or headed 18 soccer balls over the course of 40 minutes. Subjects had their postural control assessed while standing on a force plate and completed a concussion symptoms checklist on three separate occasions: prior to, immediately following, and 24 hours after kicking or heading. There were no significant differences between the heading and kicking groups on the postural control measures prior to, immediately following, and 24 hours after kicking/heading. The heading group did, however, report significantly more concussion symptoms than the kicking group immediately after heading, but not 24 hours after heading. The number of previous concussions sustained by subjects did not influence the effects of heading. An acute bout of soccer heading appears to cause an increase in self-reported symptoms of cerebral concussion lasting less than 24 hours but no quantifiable deficits in postural control. Further research is needed to investigate the cumulative effects of soccer heading on postural control and other objective measures of brain function.	Penn State Univ, Athlet Training Res Lab, University Pk, PA 16802 USA		Hertel, J (corresponding author), Penn State Univ, Athlet Training Res Lab, 269 Recreat Bldg, University Pk, PA 16802 USA.	jnh3@psu.edu					Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Randolph C, 2001, J ATHL TRAINING, V36, P288; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421	23	38	38	0	8	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	JUL	2004	25	5					326	331		10.1055/s-2004-819941			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	837OY	WOS:000222646200001	15241710				2022-02-06	
J	McCrory, P				McCrory, P			Preparticipation assessment for head injury	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head injury; concussion; athletic injuries; injury prevention	SPORT-RELATED CONCUSSION; APOLIPOPROTEIN; FOOTBALL	Objective: To determine the evidence base for recommendations regarding the pre-participation screening for head injury. Data Sources: The relevant literature was searched through the use of Medline (1966 to 2004), Google and Sport Discus (1975 to 2004) searches, hand searches of journals and reference lists and discussions with experts and sporting organisations worldwide. Data Synthesis/Methods: Consensus recommendations are summarized. No formal statistical analysis is presented Results: Although pre-participation examinations are widely performed, there are no evidence-based guidelines to direct physicians as to the minimum requirements for the baseline assessment of head injury. Conclusions: Expert consensus would suggest that a baseline neuropsychological examination, preferably using a computerised test battery, should be performed in order to guide return to play following subsequent concussive injuries. In addition, there are important medicolegal considerations in regard to the value of a documented assessment both at the start and end of an athlete's career with any team.	Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia; Univ Melbourne, Brain Res Inst, Parkville, Vic 3052, Australia		McCrory, P (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia.		McCrory, Paul/Q-8688-2019				ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; COLLIE A, 2004, IN PRESS BR J SPORTS; COLLIE A, 2004, IN PRESS J INT NEURO; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1995, ANN NEUROL, V38, P698, DOI 10.1002/ana.410380429; McCrory P, 2000, SPORTS MED, V30, P221, DOI 10.2165/00007256-200030030-00006; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; MCCRORY P, 2001, EVIDENCE BASED SPORT; McCrory Paul, 2002, Curr Sports Med Rep, V1, P28; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3	19	38	38	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2004	14	3					139	144		10.1097/00042752-200405000-00006			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	943BQ	WOS:000230327200006	15166902				2022-02-06	
J	Schmitter-Edgecombe, M; Wright, MJ				Schmitter-Edgecombe, M; Wright, MJ			Event-based prospective memory following severe closed-head injury	NEUROPSYCHOLOGY			English	Article							PERFORMANCE; AGE; RETRIEVAL; TIME	Twenty-four severe closed-head injury (CHI) participants and 24 controls completed event-based prospective memory tasks concurrently with an ongoing working memory task. The event cue was either integrated with the ongoing working memory task (focal cue) or peripheral to it. Prospective remembering was poorer for the CHI group in both the focal- and peripheral-cue conditions. The groups did not differ on the ongoing task. The peripheral cue and the integrated focal cue also did not differ in ability to trigger prospective remembering. The results suggest that, even with highly salient event cues, severe CHI participants (> 1 year postinjury) are more likely than controls to exhibit prospective memory failures. The data revealed a link between CHI participants' prospective memory failures and momentary lapses of intention.	Washington State Univ, Dept Psychol, Pullman, WA 99164 USA		Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, POB 644820, Pullman, WA 99164 USA.	schmitter-e@wsu.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03 HD35838] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD035838] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Benton A., 1976, MULTILINGUAL APHASIA; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1972, J NEUROL NEUROSUR PS, V39, P593; Brunfaut E, 2000, NEUROPSYCHOLOGIA, V38, P975, DOI 10.1016/S0028-3932(00)00016-6; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Craik FI., 1986, HUMAN MEMORY COGNITI, V5, P409; CRAIK FIM, 1996, PROSPECTIVE MEMORY T, P227; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; Delis DC, 1987, CALIFORNIA VERBAL LE; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Fahy JF., 1993, NEUROPSYCHOLOGY, V7, P136, DOI [10.1037/0894-4105.7.2.136, DOI 10.1037/0894-4105.7.2.136]; FAHY JF, 1990, 10 ANN M NAT AC NEUR; Golden J. C., 1978, STROOP COLOR WORD TE; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Heaton RK, 1981, MANUAL WISCONSIN CAR; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kuera H., 1967, COMPUTATIONAL ANAL P; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; Marsh RL, 2000, APPL COGNITIVE PSYCH, V14, pS29, DOI 10.1002/acp.769.abs; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; Mattis S, 1988, DEMENTIA RATING SCAL; Maylor EA, 1996, PSYCHOL AGING, V11, P74, DOI 10.1037/0882-7974.11.1.74; McDaniel M A, 1993, Memory, V1, P23, DOI 10.1080/09658219308258223; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; Meier B, 2000, APPL COGNITIVE PSYCH, V14, pS11, DOI 10.1002/acp.768; Nissley HM, 2002, NEUROPSYCHOLOGY, V16, P111, DOI 10.1037//0894-4105.16.1.111; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; OReilly R.C., 1996, PROSPECTIVE MEMORY T, P267; Park DC, 1997, PSYCHOL AGING, V12, P314, DOI 10.1037/0882-7974.12.2.314; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sattler J. M., 1988, ASSESSMENT CHILDREN; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SchmitterEdgecombe M, 1997, NEUROPSYCHOLOGY, V11, P296, DOI 10.1037/0894-4105.11.2.296; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith A., 1991, SYMBOL DIGIT MODALIT; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Sohlberg M., 2001, COGNITIVE REHABILITA; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; TEASDALE G, 1974, LANCET, V2, P81; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; van den Broek MD, 2000, BRAIN INJURY, V14, P455; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D, 1981, WECHSLER ADULT INTEL; West R, 1999, PSYCHOL AGING, V14, P264, DOI 10.1037/0882-7974.14.2.264; West R, 2000, APPL COGNITIVE PSYCH, V14, pS115, DOI 10.1002/acp.774; West R, 2000, CEREB CORTEX, V10, P748, DOI 10.1093/cercor/10.8.748	51	38	39	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	APR	2004	18	2					353	361		10.1037/0894-4105.18.2.353			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	810SX	WOS:000220725100016	15099157				2022-02-06	
J	Evans, RW				Evans, RW			Post-traumatic headaches	NEUROLOGIC CLINICS			English	Article							MINOR HEAD-INJURY; BRAIN-INJURY; MILD; MIGRAINE; EPIDEMIOLOGY; CONCUSSION; RECOVERY; TRAUMA	Post-traumatic headaches are one of the most common and controversial secondary headache types. After mild head injury, up to 50% of people develop a post concussion syndrome, which has been controversial for over 135 years. Headache is estimated as present in 30% to 90% of patients after mild head injury. Most headaches are of the tension type, although migraines can increase in frequency or occur acutely or chronically de novo. The treatments are the same as for the primary headaches. Approximately 20% of patients have persistent post-traumatic headaches for more than 1 year, which may not resolve despite the settlement of any pending litigation.	Univ Texas, Houston Med Sch, Pk Plaza Hosp, Dept Neurol, Houston, TX 77004 USA		Evans, RW (corresponding author), Univ Texas, Houston Med Sch, Pk Plaza Hosp, Dept Neurol, 1200 Binz 1370, Houston, TX 77004 USA.	rwevans@pol.net					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andrikopoulos J, 2003, HEADACHE, V43, P553; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BENOIT BG, 1982, CAN J NEUROL SCI, V9, P321, DOI 10.1017/S0317167100044140; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Denker P., 1944, NY STATE J MED, V44, P379; Edna T H, 1987, J Oslo City Hosp, V37, P41; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Erichsen J.E., 1867, RAILWAY OTHER INJURI; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; EVANS RW, 2000, PROGNOSIS NEUROLOGIC, P366; EVANS RW, 2004, MEDLINK NEUROLOGY; EVANS RW, 2000, HDB HEADACHE, P117; Fukutake T, 2000, NEUROLOGY, V54, P264, DOI 10.1212/WNL.54.1.264; Gee JR, 2003, HEADACHE, V43, P276, DOI 10.1046/j.1526-4610.2003.03053.x; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GRAHAM DI, 1996, NEUROLOGY TRAUMA, P53; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Headache Classification Subcommittee of the International headache Society, 2004, CEPHALALGIA S1, V24, P59; Jennett B, 1990, HDB CLIN NEUROLOGY, V13, P1; Jensen TS, 2000, HEADACHES, P781; Kelly JP, 1997, NEUROLOGY, V48, P581; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Lay CL, 1999, HEADACHE, V39, P275, DOI 10.1046/j.1526-4610.1999.3904275.x; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lewine JD, 1999, AM J NEURORADIOL, V20, P857; Limmroth V, 1991, AM J EPIDEMIOL, V134, P1111; Loder E, 2002, CLIN J PAIN, V18, pS169, DOI 10.1097/00002508-200211001-00009; LORD SM, 1994, J NEUROL NEUROSUR PS, V57, P1187, DOI 10.1136/jnnp.57.10.1187; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILO R, 1987, ACTA NEUROCHIR, V84, P13, DOI 10.1007/BF01456345; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; Rigler I, 1879, UEBER VERLETZUNGEN E; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; Russell MB, 1996, EUR J NEUROL, V3, P424, DOI 10.1111/j.1468-1331.1996.tb00243.x; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Soloman S, 1998, HEADACHE, V38, P772, DOI 10.1046/j.1526-4610.1998.3810772.x; Soriani S, 2000, ARCH PEDIAT ADOL MED, V154, P90; SYMONDS C, 1962, LANCET, V1, P1; TRIMBLE M, 1981, POSTTRAUMTIC NEUROSI; VILMING ST, 2000, LOW CEREBROSPINAL FL, P831; WEINSTOCK A, 1995, NEUROLOGY, V45, pA347; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; WRIGHTSON P, 1989, MILD HEAD INJURY, P245	54	38	39	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	FEB	2004	22	1					237	+		10.1016/S0733-8619(03)00097-5			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	779DZ	WOS:000189281300014	15062537				2022-02-06	
J	von Holst, H; Cassidy, JD				von Holst, H; Cassidy, JD			Mandate of the who collaborating centre task force on mild traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; epidemiology; diagnosis; treatment; prognosis		In collaboration with outside experts, the WHO Collaborating Centre for Neurotrauma at the Karolinska Institute, Stockholm, Sweden, has assembled a task force to undertake a best-evidence synthesis of the literature on mild traumatic brain injury. The task force has addressed the epidemiology, diagnosis, prognosis, treatment and economic costs of mild traumatic brain injury in order to make recommendations to reduce the medical as well as the social consequences of mild traumatic brain injury.	Karolinska Hosp, Dept Neurosurg, WHO, Collaborating Ctr Neurotrauma Task Force MTBI, SE-17176 Stockholm, Sweden; Royal Inst Technol, Ctr Technol Hlth, Stockholm, Sweden; Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden		von Holst, H (corresponding author), Karolinska Hosp, Dept Neurosurg, WHO, Collaborating Ctr Neurotrauma Task Force MTBI, SE-17176 Stockholm, Sweden.	hans.vonholst@ks.se					Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Levin H.S., 1989, MILD HEAD INJURY; Slavin R. E., 1986, EDUC RES, V15, P5, DOI [DOI 10.3102/0013189X015009005, 10.3102/0013189X015009005]; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; SPITZER WO, 1990, CLIN INVEST MED, V13, P17; SPITZER WO, 1995, SPINE, V20, P2372; SPITZER WO, 1995, SPINE, V20, pS1; SPITZER WO, 1987, SPINE, V12, pS1; TEASDALE G, 1974, LANCET, V2, P81; *WHO, WHAT IS WHO COLL CTR	10	38	39	0	2	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			8	10		10.1080/16501960410023633			3	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	800QR	WOS:000220043300003	15083866	gold			2022-02-06	
J	Wiese, H; Stude, P; Nebel, K; Osenberg, D; Volzke, V; Ischebeck, W; Stolke, D; Diener, HC; Keidel, M				Wiese, H; Stude, P; Nebel, K; Osenberg, D; Volzke, V; Ischebeck, W; Stolke, D; Diener, HC; Keidel, M			Impaired movement-related potentials in acute frontal traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						traumatic brain injury; frontal lobe; EEG; Bereitschaftspotential; movement related potential; supplementary motor area	SUPPLEMENTARY MOTOR AREA; HUMAN CEREBRAL-CORTEX; HIGH-RESOLUTION EEG; FUNCTIONAL REORGANIZATION; POSTSTROKE HEMIPARESIS; MAGNETIC STIMULATION; UNILATERAL MOVEMENTS; PREMOTOR CORTEX; RHESUS-MONKEY; STROKE	Objective: Focal brain lesions due to traumatic brain injury (TBI) do not only lead to functional deficits in the lesion area, but also disturb the structurally intact neuronal network connected to the lesion site. Therefore we hypothesized dysfunctions of the cortical motor network after frontal TBI. The movement related potential (MRP) is an EEG component related to voluntary movement consisting of the Bereitschaftspotential (BP), the negative slope (NS), and the motor potential (MP). The aim of our study was to demonstrate alterations in the movement related cortical network in the acute stage after TBI by comparing our patients' MRPs to those of a healthy control group. Methods: EEGs of 22 patients with magnetic resonance imaging defined contusions of the prefrontal cortex were recorded within 8 weeks after TBI. We further recruited a healthy control group. The paradigm consisted of self-paced abductions of the right index finger. Results: Compared to healthy controls, the BP in the patient group was significantly reduced and its onset delayed. Moreover, an enhanced contribution of the postrolandic hemisphere ipsilateral to the movement and a reduced contribution of the left frontal cortex, ipsilateral to the lesion in the majority of the patients, were observed during motor execution (MP). Conclusions: Anatomical connections between the prefrontal cortex and the supplementary motor area (SMA) are known to exist. We suggest that prefrontal lesions lead to reduced neuronal input into the SMA. This deficit in the preparatory motor network may cause the reduced BPs in our patients. Moreover, an increased need for attentional resources might explain the enhanced motor potentials during movement execution. In conclusion, we demonstrated altered MRPs in the acute stage after frontal TBI, which are a consequence of disturbed neuronal networks involved in the preparation and execution of voluntary movements. (C) 2003 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Univ Essen Gesamthsch, Dept Neurol, D-45122 Essen, Germany; Klin Holthausen, Hattingen, Germany; Univ Essen Gesamthsch, Dept Neurosurg, D-45122 Essen, Germany; Dist Hosp Bayreuth, Dept Neurol, Bayreuth, Germany; Dist Hosp Bayreuth, Dept Neurorehabil, Bayreuth, Germany		Wiese, H (corresponding author), Univ Essen Gesamthsch, Dept Neurol, Hufelandstr 55, D-45122 Essen, Germany.	holger.wiese@uni-essen.de	Diener, Hans-Christoph/AAF-7275-2019; Wiese, Holger/M-5281-2014	Wiese, Holger/0000-0003-4928-0771			BARBAS H, 1987, J COMP NEUROL, V256, P211, DOI 10.1002/cne.902560203; BATES JF, 1993, J COMP NEUROL, V336, P211, DOI 10.1002/cne.903360205; Cao Y, 1998, STROKE, V29, P112, DOI 10.1161/01.STR.29.1.112; Caramia MD, 1996, NEUROREPORT, V7, P1756, DOI 10.1097/00001756-199607290-00012; Caramia MD, 2000, CLIN NEUROPHYSIOL, V111, P1990, DOI 10.1016/S1388-2457(00)00430-2; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Cui RQ, 1999, NEUROIMAGE, V9, P124, DOI 10.1006/nimg.1998.0388; CUNNINGTON R, 1995, BRAIN, V118, P935, DOI 10.1093/brain/118.4.935; Cunnington R, 2002, NEUROIMAGE, V15, P373, DOI 10.1006/nimg.2001.0976; DEECKE L, 1969, EXP BRAIN RES, V7, P158; DEECKE L, 1987, J NEUROL NEUROSUR PS, V50, P1430, DOI 10.1136/jnnp.50.11.1430; Green JB, 1999, STROKE, V30, P2659, DOI 10.1161/01.STR.30.12.2659; IKEDA A, 1995, ELECTROEN CLIN NEURO, V95, P323, DOI 10.1016/0013-4694(95)00086-E; JAHANSHAHI M, 1995, BRAIN, V118, P913, DOI 10.1093/brain/118.4.913; JASON GW, 1986, NEUROPSYCHOLOGIA, V24, P181, DOI 10.1016/0028-3932(86)90051-5; JURGENS U, 1984, BRAIN RES, V300, P63, DOI 10.1016/0006-8993(84)91341-6; KEIDEL M, 1983, NATURWISSENSCHAFTEN, V70, P180, DOI 10.1007/BF01047555; KELLER I, 1990, ELECTROEN CLIN NEURO, V76, P351, DOI 10.1016/0013-4694(90)90036-J; Knosche T, 1996, ELECTROEN CLIN NEURO, V99, P183, DOI 10.1016/0013-4694(96)95648-5; KOLB B, 1981, NEUROPSYCHOLOGIA, V19, P491, DOI 10.1016/0028-3932(81)90016-6; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; Lee KM, 1999, NEUROIMAGE, V9, P117, DOI 10.1006/nimg.1998.0393; LEONARD G, 1988, NEUROPSYCHOLOGIA, V26, P79, DOI 10.1016/0028-3932(88)90032-2; LIBET B, 1982, ELECTROEN CLIN NEURO, V54, P322, DOI 10.1016/0013-4694(82)90181-X; LU MT, 1994, J COMP NEUROL, V341, P375, DOI 10.1002/cne.903410308; LUPPINO G, 1993, J COMP NEUROL, V338, P114, DOI 10.1002/cne.903380109; MCADAM DW, 1971, ELECTROEN CLIN NEURO, V30, P511, DOI 10.1016/0013-4694(71)90148-9; MCADAM DW, 1969, ELECTROEN CLIN NEURO, V27, P73, DOI 10.1016/0013-4694(69)90111-4; NATIV A, 1994, ARCH PHYS MED REHAB, V75, P1322; NATIV A, 1991, PHYS THER, V71, P48, DOI 10.1093/ptj/71.1.48; NESHIGE R, 1988, BRAIN, V111, P719; Netz J, 1997, BRAIN, V120, P1579, DOI 10.1093/brain/120.9.1579; Praamstra P, 1996, ELECTROEN CLIN NEURO, V98, P468, DOI 10.1016/0013-4694(96)95643-6; Richer F, 1999, NEUROPSYCHOLOGIA, V37, P1427, DOI 10.1016/S0028-3932(99)00029-9; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; Seitz RJ, 1998, ARCH NEUROL-CHICAGO, V55, P1081, DOI 10.1001/archneur.55.8.1081; SHIBASAKI H, 1980, ELECTROEN CLIN NEURO, V49, P213, DOI 10.1016/0013-4694(80)90216-3; SINGH J, 1990, BRAIN RES, V531, P45, DOI 10.1016/0006-8993(90)90756-2; TEASDALE G, 1974, LANCET, V2, P81; Turton A, 1996, ELECTROMYOGR MOTOR C, V101, P316, DOI 10.1016/0924-980X(96)95560-5; Urbano A, 1996, NEUROREPORT, V8, P203, DOI 10.1097/00001756-199612200-00041; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WEILLER C, 1993, ANN NEUROL, V33, P181; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Zimmermann PFB., 1994, TESTBATTERIE AUFMERK	46	38	38	0	7	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	FEB	2004	115	2					289	298		10.1016/S1388-2457(03)00348-1			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774KL	WOS:000188978600004	14744568				2022-02-06	
J	Cho, IH; Im, JY; Kim, D; Kim, KS; Lee, JK; Han, PL				Cho, IH; Im, JY; Kim, D; Kim, KS; Lee, JK; Han, PL			Protective effects of extracellular glutathione against Zn2+-induced cell death in vitro and in vivo	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						Zn2+ toxicity; glutathione; kainic acid; astrocytes; neurons	CULTURED CORTICAL-NEURONS; OXIDATIVE STRESS; ZINC TOXICITY; BRAIN-INJURY; ASTROCYTES; CADMIUM; NEUROTOXICITY; EXPRESSION; INDUCTION; ACID	The central nervous system reserves high concentrations of free Zn2+ in certain excitatory synaptic vesicles. In pathological conditions such as transient cerebral ischemia, traumatic brain injury, and kainic acid (KA)-induced seizure, free Zn2+ is released in excess at synapses, which causes neuronal and glial death. We report here that glutathione (GSH) can be used as an effective means for protection of neural cells from Zn2+-induced cell death in vitro and in vivo. Chronic treatment with 35 muM Zn2+ led to death of primary cortical neurons and primary astrocytes. The Zn2+ toxicity of cortical neurons was partially protected by 1 mM of GSH, whereas the Zn2+ toxicity of primary astrocyte cultures was blocked completely by 100 pM of GSH. To evaluate the beneficial effects of GSH in vivo, an excitotoxin-induced neural cell death model was established by intracerebroventricular (i.c.v.) injection of 0.94 nmol (0.2 mug) KA, which produced selective neuronal death, especially in CA1 and CA3 hippocampal regions. The i.c.v. co-injection of 200 pmol of GSH significantly attenuated KA-induced neuronal cell death and reactive gliosis in hippocampus. The results of this study suggest the contribution of Zn2+ in the excitotoxin-induced neural cell death model and a potential value of GSH as a therapeutic means against Zn2+-induced pathogenesis in brain. (C) 2003 Wiley-Liss, Inc.	Ewha Womans Univ, Sch Med, Ewha Inst Neurosci, Dept Neurosci, Seoul 11783, South Korea; Ewha Womans Univ, Sch Med, Med Res Ctr, Seoul 11783, South Korea; Inha Univ, Sch Med, Dept Anat, Inchon, South Korea		Han, PL (corresponding author), Ewha Womans Univ, Sch Med, Ewha Inst Neurosci, Dept Neurosci, 70 Jongno 6 Ga, Seoul 11783, South Korea.	plhan@ewha.ac.kr					Andrews GK, 2001, BIOMETALS, V14, P223, DOI 10.1023/A:1012932712483; Burgalassi S, 2001, TOXICOL LETT, V122, P1, DOI 10.1016/S0378-4274(01)00261-2; Che YZ, 2001, MOL BRAIN RES, V94, P157, DOI 10.1016/S0169-328X(01)00233-9; Chen CJ, 2003, J NEUROCHEM, V85, P443, DOI 10.1046/j.1471-4159.2003.01691.x; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CHOI DW, 1987, J NEUROSCI, V7, P357; Conti F, 1996, GLIA, V17, P254, DOI 10.1002/(SICI)1098-1136(199607)17:3<254::AID-GLIA7>3.0.CO;2-0; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Dineley KE, 2000, NEUROBIOL DIS, V7, P310, DOI 10.1006/nbdi.2000.0303; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; DRINGEN R, 2000, PROG NEUROBIOL, V618, P181; DUGAN LL, 1995, J NEUROSCI, V15, P4545; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; Figueiredo-Pereira ME, 1999, MOL BIOL REP, V26, P65, DOI 10.1023/A:1006909918866; Fitch MT, 1999, J NEUROSCI, V19, P8182; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; FUHR BJ, 1973, J AM CHEM SOC, V95, P6944, DOI 10.1021/ja00802a013; GRILL E, 1991, METHOD ENZYMOL, V205, P333; HAYASHI Y, 1991, METHOD ENZYMOL, V205, P348; Janssens N, 2001, J NEUROCHEM, V77, P1457, DOI 10.1046/j.1471-4159.2001.00369.x; Kim JM, 2002, INT PSYCHOGERIATR, V14, P187, DOI 10.1017/S1041610202008384; Kim U., 1999, ASIAN J SOC PSYCHOL, V2, P1; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Marotti T, 2000, NEUROPEPTIDES, V34, P121, DOI 10.1054/npep.2000.0801; McNaught KSP, 1999, J NEUROCHEM, V73, P2469, DOI 10.1046/j.1471-4159.1999.0732469.x; Noh KM, 1999, J NEUROCHEM, V72, P1609, DOI 10.1046/j.1471-4159.1999.721609.x; Noh KM, 2000, J NEUROSCI, V20; Piao CS, 2002, MOL BRAIN RES, V107, P137, DOI 10.1016/S0169-328X(02)00456-4; Rizzardini M, 2003, J NEUROL SCI, V207, P51, DOI 10.1016/S0022-510X(02)00357-X; Ryu JR, 2002, EXP BRAIN RES, V143, P257, DOI 10.1007/s00221-001-0991-7; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; SLIVKA A, 1987, BRAIN RES, V409, P275, DOI 10.1016/0006-8993(87)90712-8; Son MH, 2001, BIOCHEM PHARMACOL, V62, P1379, DOI 10.1016/S0006-2952(01)00780-8; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; White AR, 2003, J NEUROSCI RES, V71, P889, DOI 10.1002/jnr.10537	43	38	40	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 1	2003	74	5					736	743		10.1002/jnr.10794			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	748EN	WOS:000186849700010	14635224				2022-02-06	
J	Broglio, SP; Ju, YY; Broglio, MD; Sell, TC				Broglio, SP; Ju, YY; Broglio, MD; Sell, TC			The efficacy of soccer headgear	JOURNAL OF ATHLETIC TRAINING			English	Article						soccer heading; impact force; head injury	BRAIN-INJURY; COMPUTED-TOMOGRAPHY; PROTECTIVE HEADGEAR; PLAYERS; IMPACT; CONCUSSION; BALL	Objective: The potential for risks associated with chronic soccer heading has led some soccer leagues to mandate the use of soccer headgear. Although manufacturers have designed and promoted these headbands to decrease the forces associated with heading a soccer ball, their efficacy has not been tested. Therefore, we investigated the efficacy of 3 brands of soccer headgear: Headers, Headblast, and Protector, as compared with a non-headband condition. Design and Setting: A force platform was mounted vertically with each headband attached with a length of hook-and-loop tape. A JUGS Soccer Machine projected balls at the platform and headband at 56.45 kph (35 mph). Measurements: We measured vertical ground reaction force for 50 trials of each condition and calculated peak force, time to peak force, and impulse. Results: We found a significant reduction in peak force of impact with all 3 headbands. The Protector headband also showed the greatest decrease in time to peak force and impulse, whereas the Headers headband showed a significant increase in impulse. Conclusions: All 3 headbands were effective at reducing the peak impact force. The Protector headband appeared the most effective at reducing time to peak force and impulse within the design of this study. The clinical effectiveness of these products remains to be seen.	Univ Pittsburgh, Pittsburgh, PA 15213 USA		Broglio, SP (corresponding author), Univ Pittsburgh, Pittsburgh, PA 15213 USA.						ARMSTRONG C, 1994, SCIENCE FOOTBALL, P394; Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Broglio SP, 2001, ATHLET THER TODAY, V6, P28, DOI 10.1123/att.6.1.28; CARMACK B, 2000, NAT ATHL TRAIN ASS 5; Carroll EJ, 1936, AM J MED SCI, V191, P706, DOI 10.1097/00000441-193619150-00014; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DAILEY SW, 1992, PHYSICIAN SPORTSMED, V20, P79, DOI 10.1080/00913847.1992.11947468; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Dvorak J, 2000, AM J SPORT MED, V28, pS3; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GROSS L, 2001, SPORTS INJURIES, P320; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lees K., 1988, SCI FOOTBALL, P385; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; LOHNES JH, 2001, SPORTS INJURIES, P703; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Pettersen JA, 2002, BRIT J SPORT MED, V36, P19, DOI 10.1136/bjsm.36.1.19; REID SE, 1975, J TRAUMA, V15, P150, DOI 10.1097/00005373-197502000-00007; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	31	38	38	2	20	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2003	38	3					220	224					5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	732CJ	WOS:000185923000009	14608431				2022-02-06	
J	Canning, CG; Shepherd, RB; Carr, JH; Alison, JA; Wade, L; White, A				Canning, CG; Shepherd, RB; Carr, JH; Alison, JA; Wade, L; White, A			A randomized controlled trial of the effects of intensive sit-to-stand training after recent traumatic brain injury on sit-to-stand performance	CLINICAL REHABILITATION			English	Article							STROKE PATIENTS; EXERCISE; REHABILITATION; PROGRAM	Objective: To examine the effectiveness of intensive practice of sit-to-stand on motor performance, exercise capacity and exercise efficiency in traumatic brain-injured patients during early inpatient rehabilitation. Design: Single-blind randomized controlled pilot study. Setting: Brain injury rehabilitation unit. Subjects: Twenty-four subjects who had recently sustained a severe traumatic brain injury (TBI) were randomized into an experimental (n = 13) and a control (n = 11) group. Interventions: In addition to their usual rehabilitation programme, subjects in the experimental group participated in four weeks of intensive training of sit-to-stand and step-up exercises with the aim of improving performance of sit-to-stand. The control group did no additional sit-to-stand or step-up training. Main outcome measures: Total number of sit-to-stands in 3 min as a measure of motor performance; peak oxygen consumption during a maximal 3-min sit-to-stand test (VO(2)peak) as a measure of exercise capacity; oxygen consumption during a 3-min equivalent workload sit-to-stand test (VO(2)equiv) as a measure of exercise efficiency. Pre- and post-training measurements were made. Results: The exercise programme resulted in a 62% improvement in motor performance (number of repetitions of sit-to-stand in 3 min) for the experimental group compared with the control group's 18% improvement (p < 0.05). There was no significant difference between groups for changes in exercise capacity or efficiency. In the experimental group, the increase in VO(2)peak from pre-test to post-test correlated with the increase in sit-to-stand repetitions (p < 0.05). Conclusions: Intensive task-specific training is recommended as an important component of rehabilitation early following severe traumatic brain injury.	Univ Sydney, Fac Hlth Sci, Sch Physiotherapy, Lidcombe, NSW 1825, Australia; Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW, Australia		Canning, CG (corresponding author), Univ Sydney, Fac Hlth Sci, Sch Physiotherapy, POB 170, Lidcombe, NSW 1825, Australia.		Alison, Jennifer/B-6250-2012				Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Berger R. A., 1988, P 34 ANN M ORTH RES; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; Convertino VA, 1997, MED SCI SPORT EXER, V29, P187, DOI 10.1097/00005768-199702000-00004; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; Jackson D, 2001, CLIN REHABIL, V15, P535, DOI 10.1191/026921501680425252; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Macko RF, 1997, STROKE, V28, P326, DOI 10.1161/01.STR.28.2.326; NEISTADT ME, 1994, AM J OCCUP THER, V48, P877, DOI 10.5014/ajot.48.10.877; Platz T, 2001, ARCH PHYS MED REHAB, V82, P961, DOI 10.1053/apmr.2001.23982; SALTIN B, 1968, CIRCULATION       S7, V38, P1, DOI DOI 10.1161/01.CIR.38.6.1104; Wolman RL, 1994, CLIN REHABIL, V8, P253	15	38	44	1	15	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	JUL	2003	17	4					355	362		10.1191/0269215503cr620oa			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	678RY	WOS:000182881300002	12785242				2022-02-06	
J	Knudsen, SK; Oen, EO				Knudsen, SK; Oen, EO			Blast-induced neurotrauma in whales	NEUROSCIENCE RESEARCH			English	Article						blast injury; brain; penthrite; explosives; traumatic brain injury; minke whale; Balaenoptera acutorostrata; Cetacea	TRAUMATIC BRAIN-INJURY; ADULT-RAT BRAIN; PRESSURE WAVE INJURIES; DIFFUSE AXONAL INJURY; LASTING IMPULSE NOISE; NON-PENETRATIVE BLAST; SUBDURAL-HEMATOMA; NERVOUS-SYSTEM; MINKE WHALES; EXPOSURE	A majority of investigations on primary blast injuries have focused on gas-containing organs, while the likelihood of blast-induced neurotrauma remains underrated. In Norway minke whales (Balaenoptera acutorostrata) are hunted using small fishing boats rigged with harpoon guns, which fire harpoons tipped with a grenade containing a charge of 30-g penthrite. The grenade detonates 60-70 cm inside the animal. The present study was undertaken to characterize the neuropathological changes caused by the penthrite blast and evaluate its role in the loss of consciousness and death in hunted whales. The study included 37 minke whales that were examined shipboard. The brains were later subjected to gross and light microscopy examination. The results showed that intra-body detonation of the grenade in near vicinity of the brain resulted in trauma similar to severe traumatic brain injury associated with a direct blow to the head. Detonation in more distant areas of the body resulted in injuries resembling acceleration-induced diffuse traumatic brain injury. The authors conclude that even if several vital organs were fatally injured in most whales, the neurotrauma induced by the blast-generated pressure waves were the primary cause for the immediate or very rapid loss of consciousness and death. (C) 2003 Elsevier Science Ireland Ltd. and the Japan Neuroscience Society. All rights reserved.	Norwegian Sch Vet Sci, Dept Arctic Vet Med, NO-9292 Tromso, Norway		Knudsen, SK (corresponding author), Norwegian Sch Vet Sci, Dept Arctic Vet Med, NO-9292 Tromso, Norway.						Abbott WD, 1943, J AMER MED ASSOC, V121, P739, DOI 10.1001/jama.1943.02840100025007; AITA J A, 1946, Bull U S Army Med Dep, V6, P411; Ascroft PB, 1943, LANCET, V1, P234; BAYTOS JF, 1980, LASL EXPLOSIVE PROPE, P130; Berlin R, 1976, Acta Chir Scand Suppl, V459, P1; BOSTROM K, 1992, ACTA NEUROCHIR SUPP, V55, pS25; BOSTROM K, 1986, ACTA NEUROCHIR SUPP, V36, pS51; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; CERNAK I, 1996, J TRAUMA, V40, pS418; CLEMEDSON C. J., 1954, MILITARY SURGEON, V114, P424; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336, DOI 10.1152/physrev.1956.36.3.336; Coupland RM, 1999, BRIT MED J, V319, P407, DOI 10.1136/bmj.319.7207.407; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; CROOKS DA, 1991, VIRCHOWS ARCH A, V418, P479, DOI 10.1007/BF01606496; CULLING CF, 1985, CELLULAR PATHOLOGY T, P160; DEGIROLANI U, 1994, ROBBINS PATHOLOGICAL, P1305; DEMANN D, 1990, INT J NEUROSCI, V54, P101, DOI 10.3109/00207459008986624; DENNYBROWN D, 1943, AM NEURAL ASS, V68, P98; Dobratz B.M., 1981, LLNL EXPLOSIVE HDB P; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; ESIRI MM, 1996, OPPENHEIMERS DIAGNOS, P7; FABING HD, 1947, ARCH NEURO PSYCHIATR, V57, P14, DOI 10.1001/archneurpsyc.1947.02300240030002; Fulton J. F., 1942, NEW ENGL J MED, V226, P1; Guy R J, 2000, J R Nav Med Serv, V86, P27; Guy RJ, 1998, J TRAUMA, V45, P983, DOI 10.1097/00005373-199812000-00001; HAUG T, 1998, SJOPATTEDYR OM HVAL, P1; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; JACOBS GB, 1968, MIL MED, V133, P132; JONSGARD A, 1992, PUBLICATION KOMMANDO, V27, P25; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; Knudsen SK, 2002, J NEUROSCI METH, V120, P35, DOI 10.1016/S0165-0270(02)00182-6; Krohn PL, 1942, LANCET, V1, P252; Li B, 2001, Chin J Traumatol, V4, P97; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; McIntosh TK, 1996, LAB INVEST, V74, P315; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1916, LANCET, V1, P331; Mott FW, 1916, LANCET, V1, P545; Mott FW, 1917, J ROY ARMY MED CORPS, V29, P662; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; MYERS CS, 1940, SHELL SHOCK FRANCE 1, P1; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; OEN EO, 1995, ACTA VET SCAND, V36, P111; OEN EO, 1983, NORD VET MED, V35, P314; OEN EO, 1995, ACTA VET SCAND, V36, P103; OEN EO, 1999, IWC51WK10; OEN EO, 2002, IWC54WK7AWI6; OEN EO, 1995, KILLING METHODS MINK; OEN EO, 1995, ACTA VET SCAND, V36, P152; OEN EO, 1999, IWC51WK11; Phillips Y., 1990, TXB MILITARY MED 1, V5, P221; PHILLIPS YY, 1986, ANN EMERG MED, V15, P1446, DOI 10.1016/S0196-0644(86)80940-4; POLLOCK LJ, 1943, ILLINOIS M J, V83, P165; ROGERS L, 1945, MED J AUSTRALIA, V2, P209; Rosen Leif, 1992, Tidsskrift for den Norske Laegeforening, V112, P1590; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; SHARPNACK DD, 1990, TXB MILITARY MED 1, V5, P271; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Stewart OW, 1941, LANCET, V1, P172; STUHMILLER JH, 1990, TXB MILITARY MED 1, V5, P241; SUNESON A, 1987, J TRAUMA, V27, P782, DOI 10.1097/00005373-198707000-00016; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; SUNESON A, 1989, J TRAUMA, V29, P10, DOI 10.1097/00005373-198901000-00003; SUNESON A, 1988, J TRAUMA, V28, P197; Sylvia FR, 2001, MIL MED, V166, P918, DOI 10.1093/milmed/166.10.918; Tomita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P213; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VLVERTON JT, 1996, J TRAUMA, V40, pS111; WOOD H, 1946, U S Nav Med Bull, V46, P51; Zhao WG, 1999, NEUROL MED-CHIR, V39, P735, DOI 10.2176/nmc.39.735; 1996, IWC484	81	38	43	0	11	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0168-0102			NEUROSCI RES	Neurosci. Res.	JUL	2003	46	3					377	386		10.1016/S0168-0102(03)00101-9			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	694QR	WOS:000183785900013	12804799				2022-02-06	
J	Libby, AM; Sills, MR; Thurston, MK; Orton, HD				Libby, AM; Sills, MR; Thurston, MK; Orton, HD			Costs of childhood physical abuse: Comparing inflicted and unintentional traumatic brain injuries	PEDIATRICS			English	Article						child abuse; craniocerebral trauma; traumatic brain injury; direct service costs; health care costs; health expenditures; head injuries; hospital costs; length of stay; severity of illness; trauma; nervous system	NURSE HOME VISITATION; HEAD-INJURY; RANDOMIZED TRIAL; STRESS-DISORDER; MALTREATMENT; CHILDREN; INFANTS; NEGLECT; POLICY	Objectives. To estimate the effect of early childhood abuse (ie, inflicted injury) on medical costs of head trauma. Methods. Abstracts of patient records were drawn from the annual 1993-2000 Colorado state-mandated hospital discharge database maintained by the Colorado Hospital Association. The 2 dependent variables were total charges (TC) and length of stay. Our key independent variable was the nature of injury, ie, inflicted or unintentional; other independent variables were age, severity level, death, and trauma designation of the hospital. Comparisons of variables between patients with inflicted and unintentional head trauma were performed using Student's t tests or chi(2) statistics. Ordinary least squares regression was used to estimate the marginal and total effects of inflicted injury on TC and LOS. Results. Of the 1097 head trauma patients <3 years old, 814 had unintentional and 283 had inflicted head trauma. Head trauma was defined using the Centers for Disease Control definition of traumatic brain injury. Patients with inflicted injuries were younger and had a higher average severity level and overall mortality rate than did patients with unintentional head trauma. The regression models showed that, controlling for age and severity, patients with inflicted head trauma stayed in the hospital 52% longer (2 days), and had a mean total bill 89% higher ($4232 more) than did patients with unintentional head trauma. Conclusions. The findings from multivariate models of TC and length of stay corroborate the simpler univariate findings of earlier studies. By focusing on the impact of those cases of child abuse that lead to a specific, severe clinical entity (traumatic brain injury), we isolated a significant economic impact of abuse on health care expenditures for injury.	Univ Colorado, Hlth Sci Ctr, Dept Emergency Med, Denver, CO USA; Childrens Hosp, Denver, CO 80218 USA; Brigham Young Univ, Dept Econ, Provo, UT 84602 USA; Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Denver, CO 80262 USA		Libby, AM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Box 6508,Mail Stop F800, Aurora, CO 80045 USA.		Nordenholz, Kristen/K-3476-2015; Libby, Anne M/B-6984-2013	Libby, Anne M/0000-0002-4564-9407; Sills, Marion/0000-0003-1322-0822			Berkowitz Carol D., 1995, Emergency Medicine Clinics of North America, V13, P321; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; De Bellis MD, 2001, CHILD ABUSE NEGLECT, V25, P923, DOI 10.1016/S0145-2134(01)00247-2; Deb S, 1999, AM J PSYCHIAT, V156, P374; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Famularo R, 1996, CHILD ABUSE NEGLECT, V20, P1245, DOI 10.1016/S0145-2134(96)00119-6; FAMULARO R, 1994, ARCH PEDIAT ADOL MED, V148, P1032, DOI 10.1001/archpedi.1994.02170100030007; Finkelhor D, 1998, JAMA-J AM MED ASSOC, V280, P1864, DOI 10.1001/jama.280.21.1864; Forjuoh SN, 2000, CHILD ABUSE NEGLECT, V24, P1019, DOI 10.1016/S0145-2134(00)00163-0; FREEMAN JL, 1995, MED CARE, V33, P806, DOI 10.1097/00005650-199508000-00006; Gedeit R, 2001, Pediatr Rev, V22, P118, DOI 10.1542/pir.22-4-118; Irazuzta JE, 1997, CHILD ABUSE NEGLECT, V21, P751, DOI 10.1016/S0145-2134(97)00036-7; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; JOHNSON CF, 2000, NELSONS TXB PEDIAT, P113; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Krugman RD, 1997, PEDIATRICS, V100, P890, DOI 10.1542/peds.100.5.890; Macfie J, 2001, DEV PSYCHOPATHOL, V13, P233, DOI 10.1017/S0954579401002036; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; *NAT PED TRAUM REG, 1996, CHILDR AD DIS DUE TR, P3; NORUSIS MJ, 1999, SPSS 9 0 WINDOWS USE; OLDS D, 1995, PEDIATRICS, V95, P365; OLDS DL, 1986, PEDIATRICS, V78, P65; Olds DL, 1997, JAMA-J AM MED ASSOC, V278, P637, DOI 10.1001/jama.278.8.637; Osberg JS, 1997, BRAIN INJURY, V11, P11; PECLET MH, 1990, J PEDIATR SURG, V25, P85, DOI 10.1016/S0022-3468(05)80169-1; PEREZ CM, 1994, CHILD ABUSE NEGLECT, V18, P617, DOI 10.1016/0145-2134(94)90012-4; *PREV CHILD AB AM, 2001, TOT EST COST CHILD A; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rubin D, 2001, CURR OPIN PEDIATR, V13, P388, DOI 10.1097/00008480-200110000-00002; Runge J W, 1993, Emerg Med Clin North Am, V11, P241; Rutledge R, 1998, J TRAUMA, V45, P791, DOI 10.1097/00005373-199810000-00032; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; SUMMERS CL, 1992, ARCH DIS CHILD, V67, P905, DOI 10.1136/adc.67.7.905; Theodore AD, 1999, PEDIATRICS, V104, P168; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 2001, CHILD MALT 1999; WESSON DE, 1992, J TRAUMA, V33, P252, DOI 10.1097/00005373-199208000-00015	43	38	39	0	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2003	112	1					58	65		10.1542/peds.112.1.58			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	696WR	WOS:000183911000025	12837868				2022-02-06	
J	Kirchner, TR; Sayette, MA				Kirchner, TR; Sayette, MA			Effects of alcohol on controlled and automatic memory processes	EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY			English	Article							PROCESS-DISSOCIATION PROCEDURE; IN-PROCESS DISSOCIATION; APPRAISAL-DISRUPTION MODEL; CLOSED-HEAD INJURY; DIVIDED ATTENTION; IMPLICIT MEMORY; EXPLICIT MEMORY; STRESS; VIOLATIONS; RECOLLECTION	The authors used the process-dissociation procedure (L. L. Jacoby, 1998) to examine the effects of alcohol on controlled and automatic influences on memory performance. Participants studied 1 of 2 word lists and subsequently were cued with word stems to recall the words from both lists. Fifty-four men were administered either a moderate dose of alcohol (0.82 g/kg) or placebo prior to studying the word list. Results indicated that alcohol decreased estimates of controlled contributions to performance on the task. In contrast, alcohol did not appear to affect automatic influences on this task. Integrated with recent findings using a different cognitive task, these data suggest that alcohol impairs performance on implicit, conceptually driven tasks but not on implicit, perceptually driven tasks.	Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA		Sayette, MA (corresponding author), Univ Pittsburgh, Dept Psychol, 604 Old Engn Hall, Pittsburgh, PA 15260 USA.	sayette@pitt.edu					BALOTA DA, 1986, J EXP PSYCHOL LEARN, V12, P336, DOI 10.1037/0278-7393.12.3.336; BIRNBAUM IM, 1980, J EXP PSYCHOL-HUM L, V6, P293, DOI 10.1037/0278-7393.6.3.293; BIRNBAUM IM, 1977, ALCOHOL HUMAN MEMORY, P99; BLAXTON TA, 1992, MEM COGNITION, V20, P549, DOI 10.3758/BF03199587; CURRAN HV, 2000, OXFORD HDB MEMORY, P245; CURRAN T, 1995, J EXP PSYCHOL LEARN, V21, P531, DOI 10.1037/0278-7393.21.3.531; Curran T, 1997, J EXP PSYCHOL LEARN, V23, P496, DOI 10.1037/0278-7393.23.2.496; Fillmore MT, 1999, EXP CLIN PSYCHOPHARM, V7, P372, DOI 10.1037/1064-1297.7.4.372; Grattan KE, 2001, ALCOHOL CLIN EXP RES, V25, P192, DOI 10.1097/00000374-200102000-00006; HARRISON G, 1985, ANN INTERN MED, V103, P489; HASHTROUDI S, 1984, J EXP PSYCHOL LEARN, V10, P156, DOI 10.1037/0278-7393.10.1.156; Hay JF, 1996, J EXP PSYCHOL LEARN, V22, P1323, DOI 10.1037/0278-7393.22.6.1323; HOLENDER D, 1986, BEHAV BRAIN SCI, V9, P1, DOI 10.1017/S0140525X00021269; Hull J. G., 1987, PSYCHOL THEORIES DRI, P272; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P505, DOI 10.1037/0278-7393.23.2.505; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; Jacoby LL, 1998, J EXP PSYCHOL LEARN, V24, P3, DOI 10.1037/0278-7393.24.1.3; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; Jacoby LL, 1997, CARN S COGN, P13; Jacoby LL, 1997, J EXP PSYCHOL LEARN, V23, P484, DOI 10.1037/0278-7393.23.2.484; Koob GF, 1997, PHARMACOL BIOCHEM BE, V57, P513, DOI 10.1016/S0091-3057(96)00438-8; MARTIN CS, 1993, J STUD ALCOHOL, V54, P750, DOI 10.15288/jsa.1993.54.750; Mulligan NW, 1998, J EXP PSYCHOL LEARN, V24, P27, DOI 10.1037/0278-7393.24.1.27; Neely J., 1991, BASIC PROCESSES READ; NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037/0033-295X.84.3.231; PERRUCHET P, 1989, MEM COGNITION, V17, P77, DOI 10.3758/BF03199559; Reingold E.M., 1990, MIND LANGUAGE, V5, P9, DOI [10.1111/j.1468-0017.1990.tb00150.x, DOI 10.1111/J.1468-0017.1990.TB00150.X]; Robins RW, 2001, J PERS SOC PSYCHOL, V80, P340, DOI 10.1037//0022-3514.80.2.340; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; ROHSENOW DJ, 1981, ADDICT BEHAV, V6, P107, DOI 10.1016/0306-4603(81)90003-4; ROOM R, 1983, NATL I ALCOHOL ABUSE, V12; ROSEN LJ, 1976, J ABNORM PSYCHOL, V85, P309, DOI 10.1037/0021-843X.85.3.309; RYBACK RS, 1970, PSYCHON SCI, V20, P353, DOI 10.3758/BF03335686; Sayette M.A., 1999, PSYCHOL THEORIES DRI, V2nd ed., P247; SAYETTE MA, 1991, J ABNORM PSYCHOL, V100, P56, DOI 10.1037/0021-843X.100.1.56; SAYETTE MA, 1993, PSYCHOL BULL, V114, P459, DOI 10.1037/0033-2909.114.3.459; Sayette MA, 1996, J CLIN EXP NEUROPSYC, V18, P678, DOI 10.1080/01688639608408291; Sayette MA, 2001, EXP CLIN PSYCHOPHARM, V9, P409, DOI 10.1037/1064-1297.9.4.409; Sayette MA, 2001, J STUD ALCOHOL, V62, P247, DOI 10.15288/jsa.2001.62.247; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; Schmitter-Edgecombe M, 1999, MEM COGNITION, V27, P512, DOI 10.3758/BF03211545; Schmitter-Edgecombe M, 2000, NEUROPSYCHOLOGY, V14, P559; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; Schneider W., 1984, VARIETIES ATTENTION, P1; SHER KJ, 1999, PSYCHOL THEORIES DRI, P00054; Shiffrin, 1988, STEVENS HDB EXPT PSY, V1-2, P739; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; STADLER MA, 1995, J EXP PSYCHOL LEARN, V21, P674, DOI 10.1037/0278-7393.21.3.674; STEELE CM, 1988, J ABNORM PSYCHOL, V97, P196, DOI 10.1037/0021-843X.97.2.196; SteMarie DM, 1996, CLIN NEUROPSYCHOL, V10, P25, DOI 10.1080/13854049608406660; TIFFANY ST, 1991, BRIT J ADDICT, V86, P617; Tolstoy L., 1982, WAR PEACE; TOTH JP, 2000, OXFORD HDB MEMORY, P245; Tracy JI, 1999, NEUROPSYCHOLOGY, V13, P282, DOI 10.1037/0894-4105.13.2.282; VAKIL E, 1994, J CLIN EXP NEUROPSYC, V16, P539, DOI 10.1080/01688639408402665; Vidailhet P, 1996, PSYCHOPHARMACOLOGY, V127, P63, DOI 10.1007/BF02805976; VONHIPPEL W, 1994, EFFECTS ALCOHOL SOCI	57	38	38	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1064-1297			EXP CLIN PSYCHOPHARM	Exp. Clin. Psychopharmacol.	MAY	2003	11	2					167	175		10.1037/1064-1297.11.2.167			9	Psychology, Biological; Psychology, Clinical; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pharmacology & Pharmacy; Psychiatry	677DM	WOS:000182791700006	12755461				2022-02-06	
J	Rapoport, MJ; McCullagh, S; Streiner, D; Feinstein, A				Rapoport, MJ; McCullagh, S; Streiner, D; Feinstein, A			Age and major depression after mild traumatic brain injury	AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY			English	Article; Proceedings Paper	15th Annual Meeting of the American-Association-for-Geriatric-Psychiatry	FEB 24-27, 2002	ORLANDO, FLORIDA	Amer Assoc Geriatr Psychiat			HEAD-INJURY; SEQUELAE	The authors investigated the relationship between age and major depression in the acute period following mild traumatic brain injury (TBI). Methods: Patients with mild TBI (N=210) were assessed for the presence of major depression with the Structured Clinical Interview for DSM-IV. Results: Older patients (age 60 plus) had lower rates of major depression than younger patients. Conclusion: Older patients seem to be relatively resilient to major depression shortly after mild TBI.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Traumat Brain Injury Clin, Toronto, ON M4N 3M5, Canada		Rapoport, MJ (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Psychiat, 2075 Bayview Ave,FG37, Toronto, ON M4N 3M5, Canada.		Rapoport, Mark/AAD-8581-2020; Streiner, David/E-6563-2011	Streiner, David/0000-0003-0610-6271			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Beekman ATF, 1997, PSYCHOL MED, V27, P1397, DOI 10.1017/S0033291797005734; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; First M.B., 1996, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P196; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; REIGER DA, 1988, ARCH GEN PSYCHIAT, V45, P977	11	38	38	0	6	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	1064-7481			AM J GERIAT PSYCHIAT	Am. J. Geriatr. Psychiatr.	MAY-JUN	2003	11	3					365	369		10.1176/appi.ajgp.11.3.365			5	Geriatrics & Gerontology; Gerontology; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Psychiatry	673DQ	WOS:000182565300015	12724117				2022-02-06	
J	Zimmermann, C; Haberl, RL				Zimmermann, C; Haberl, RL			L-arginine improves diminished cerebral CO2 reactivity in patients	STROKE			English	Article						arginine; risk; vasomotor reactivity	TRANSCRANIAL DOPPLER SONOGRAPHY; CORTICAL IMPACT INJURY; NITRIC-OXIDE; CEREBROVASCULAR REACTIVITY; CARDIOVASCULAR-DISEASE; VASOMOTOR REACTIVITY; BLOOD-FLOW; ATHEROSCLEROSIS; ENDOTHELIUM; RELAXATION	Background and Purpose-There is experimental evidence that L-arginine restores diminished CO, reactivity after mild traumatic brain injury in rats. This effect is believed to be mediated by L-arginine-derived nitric oxide, which is a permissive substrate for CO2 reactivity. To clarify whether these findings can be transferred to the clinical situation and have beneficial effects in patients, we studied the effects Of L-arginine on CO2 reactivity of the cerebral vessels in patients with impaired vasomotor reactivity (VMR) and compared them with patients with normal VMR. Methods-Twenty-two patients with cardiovascular risk factors and VMR <50% with no extracranial or intracranial stenoses were examined by bilateral transcranial Doppler sonography of the right and left middle cerebral arteries and compared with 20 age- and risk-matched patients with normal VMR (>50%). VMR was tested by 1-minute hyperventilation, followed by a 3-minute inhalation of 5% CO2. Examinations were performed before and after infusion of 30 g L-arginine over 30 minutes. The 22 patients with reduced VMR (<50%) were compared with 20 patients with normal VMR (>50%). Results-Initial mean VMR of the 42 patients was 50+/-12%. There was no difference between the right- and the left-side VMR. In the 22 patients with reduced VMR in the first examination (42+/-8%), VMR increased significantly after infusion Of L-arginine (52+/-14%, P=0.005). In contrast, values did not change after infusion Of L-arginine in the 20 patients with normal VMR (59+/-8% before versus 59+/-13% after L-arginine). There was a negative correlation of initial CO2 vasoreactivity and the percentage of VMR increase after infusion Of L-arginine. Conclusions-Our data support the hypothesis that in humans L-arginine is able to improve impaired CO2 reactivity of the cerebral vessels. This effect can be found in patients at cardiovascular risk with impaired VMR and might have therapeutic implications in the future.	Krankenhaus Munchen Harlaching, Dept Neurol, D-81545 Munich, Germany		Zimmermann, C (corresponding author), Krankenhaus Munchen Harlaching, Dept Neurol, Sanatoriumspl 2, D-81545 Munich, Germany.						BURKE GL, 1995, STROKE, V26, P386, DOI 10.1161/01.STR.26.3.386; Cannon RO, 1998, CLIN CHEM, V44, P1809; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P359, DOI 10.1111/j.1399-6576.1977.tb01232.x; Cupini LM, 2001, ARCH NEUROL-CHICAGO, V58, P577, DOI 10.1001/archneur.58.4.577; Didion SP, 2001, STROKE, V32, P761, DOI 10.1161/01.STR.32.3.761; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; Giraldez RR, 1997, J BIOL CHEM, V272, P21420, DOI 10.1074/jbc.272.34.21420; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; Golding EM, 2000, J CEREBR BLOOD F MET, V20, P820, DOI 10.1097/00004647-200005000-00008; Iadecola C, 1996, AM J PHYSIOL-REG I, V271, pR990, DOI 10.1152/ajpregu.1996.271.4.R990; LADECOLA C, 1992, P NATL ACAD SCI USA, V89, P3913; Maccario M, 1997, J ENDOCRINOL INVEST, V20, P488, DOI 10.1007/BF03348006; MADDEN JA, 1993, PHARMACOL THERAPEUT, V59, P229, DOI 10.1016/0163-7258(93)90045-F; Micieli G, 1997, J NEUROL SCI, V150, P71, DOI 10.1016/S0022-510X(97)05380-X; Pfefferkorn T, 2001, STROKE, V32, P17, DOI 10.1161/01.STR.32.1.17; Reutens DC, 1997, J CEREBR BLOOD F MET, V17, P309, DOI 10.1097/00004647-199703000-00008; RINGELSTEIN EB, 1988, STROKE, V19, P963, DOI 10.1161/01.STR.19.8.963; SANDOR P, 1994, J CEREBR BLOOD F MET, V14, P49, DOI 10.1038/jcbfm.1994.8; Sterzer P, 2001, STROKE, V32, P2817, DOI 10.1161/hs1201.099663; TAYSTMAN RJ, 1997, PRIMER CEREBROVASCUL, P55; Terborg C, 2000, STROKE, V31, P924, DOI 10.1161/01.STR.31.4.924; TRUELSEN T, 1994, STROKE, V25, P802, DOI 10.1161/01.STR.25.4.802; VANSWIETEN JC, 1990, J NEUROL NEUROSUR PS, V53, P1080, DOI 10.1136/jnnp.53.12.1080; WIDDER B, 1995, DOPPLER DUPLEXSONOGR, P296	24	38	40	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAR	2003	34	3					643	647		10.1161/01.STR.0000056526.35630.47			5	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	653ZJ	WOS:000181466700017	12624285	Bronze			2022-02-06	
J	Hart, T; Millis, S; Novack, T; Englander, J; Fidler-Sheppard, R; Bell, KR				Hart, T; Millis, S; Novack, T; Englander, J; Fidler-Sheppard, R; Bell, KR			The relationship between neuropsychologic function and level of caregiver supervision at 1 year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; cognition; outcomes research; rehabilitation	PRACTICAL SCALE; RATING-SCALE; OUTCOMES; TESTS; INDIVIDUALS; INTEGRATION; PREDICTION; DISABILITY; VALIDITY; ABILITY	Objectives: To evaluate distribution of levels of caregiver supervision at 1 year after traumatic brain injury, and to determine neuropsychologic predictors of supervision level. Design: Prospective longitudinal design, concurrent measurement of neuropsychologic function and supervision level. Setting: Seventeen Traumatic Brain Injury Model Systems centers. Participants: A total of 563 adults tested at 1 year postinjury; and a subgroup of 452 studied for neuropsychologic function in the absence of impairment in mobility or basic self-care, as assessed by high FIM(TM) instrument motor scores. Interventions: Not applicable. Main Outcome Measure: Supervision level measured by scores on Supervision Rating Scale (SRS). Results: Two thirds (69%) of the sample was rated as independent of supervision. Participants without significant dysfunction on motor FIM were grouped into supervision groups differing in intensity of time commitment from caregiver (independent, moderate supervision, heavy supervision). In univariate analyses, groups differed on demographic variables (education, race, productivity prior to injury), duration of altered consciousness, and all but 1 neuropsychologic measure. A binomial regression model (complementary log-log model) revealed that supervision at 1 year was predicted by education and scores on the Trail Making Test Part B and digits backward. Conclusions: Findings confirm the importance of preinjury status and measures of working memory and cognitive flexibility in predicting functional independence after TBI. The SRS appears prone to ceiling effects in persons followed prospectively after moderate to severe TBI.	Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19141 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Alabama, Spain Rehabil Ctr, Birmingham, AL USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA		Hart, T (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Bell, Kathleen/0000-0002-0928-2046			Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cahn-Weiner DA, 2000, CLIN NEUROPSYCHOL, V14, P187, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT187; Carlson MC, 1999, J GERONTOL B-PSYCHOL, V54, pS262, DOI 10.1093/geronb/54B.5.S262; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall P, 1998, THEOR COMP FLUID DYN, V10, P1; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P133; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Neese LE, 2000, BRAIN INJURY, V14, P719; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rapport LJ, 1998, ARCH PHYS MED REHAB, V79, P629, DOI 10.1016/S0003-9993(98)90035-1; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A M, 1998, Rehabil Nurs, V23, P252; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; [No title captured]	40	38	40	0	17	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					221	230		10.1053/apmr.2003.50023			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700011	12601653				2022-02-06	
J	Gibbons, H; Sato, TA; Dragunow, M				Gibbons, H; Sato, TA; Dragunow, M			Hypothermia suppresses inducible nitric oxide synthase and stimulates cyclooxygenase-2 in lipopolysaccharide stimulated BV-2 cells	MOLECULAR BRAIN RESEARCH			English	Article						hypothermia; inducible nitric oxide synthase; pro-inflammatory cytokines; cyclooxygenase-2; nuclear factor-kappa B	KAPPA-B KINASE; TRANSIENT CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; POSTISCHEMIC HYPOTHERMIA; MILD HYPOTHERMIA; MICROGLIAL ACTIVATION; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDINS; CYTOKINE PRODUCTION	Hypothermia is neuroprotective, possibly through suppression of microglial activation. We investigated the effects of hypothermia on lipopolysaccharide (LPS) stimulated BV-2 cells. At 37degreesC, LPS elicited strong increases in inducible nitric oxide synthase (iNOS), nitric oxide (NO), cyclooxygenase-2 (COX-2), tumour necrosis factor-alpha. (TNF-alpha), and interleukin-6 (IL-6), accompanied by translocation of nuclear factor-kappaB (NF-kappaB) to the nucleus. Hypothermia (33degreesC) caused complete suppression of iNOS and NO, a partial reduction of IL-6 but did not prevent TNF-alpha production or NF-kappaB translocation. In contrast, LPS induced cyclooxygenase-2 (COX-2) to higher levels under hypothermic conditions. These results show that hypothermia selectively suppresses iNOS in microglia, (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Auckland, Dept Pharmacol & Clin Pharmacol, Fac Med & Hlth Sci, Auckland 1, New Zealand; Univ Auckland, Liggins Inst, Fac Med & Hlth Sci, Auckland 1, New Zealand		Dragunow, M (corresponding author), Univ Auckland, Dept Pharmacol & Clin Pharmacol, Fac Med & Hlth Sci, Auckland 1, New Zealand.						Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Ehrlich LC, 1998, NEUROREPORT, V9, P1723, DOI 10.1097/00001756-199806010-00010; Elmquist JK, 1997, J COMP NEUROL, V381, P119, DOI 10.1002/(SICI)1096-9861(19970505)381:2<119::AID-CNE1>3.0.CO;2-6; Fairchild KD, 2000, J INTERF CYTOK RES, V20, P1049, DOI 10.1089/107999000750053708; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gunn AJ, 1997, J CLIN INVEST, V99, P248, DOI 10.1172/JCI119153; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; Jeohn GH, 2000, MOL BRAIN RES, V79, P18, DOI 10.1016/S0169-328X(00)00081-4; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kataoka K, 1998, NEUROSCI RES, V32, P103, DOI 10.1016/S0168-0102(98)00076-5; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Ko HK, 2001, BRAIN RES, V894, P297, DOI 10.1016/S0006-8993(00)03188-7; Kumar K, 1997, NEUROREPORT, V8, P947, DOI 10.1097/00001756-199703030-00026; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; Langford D, 2001, BRAIN PATHOL, V11, P306; Luhm J, 1998, EUR J BIOCHEM, V256, P325, DOI 10.1046/j.1432-1327.1998.2560325.x; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Mirzoeva S, 1999, BRAIN RES, V844, P126, DOI 10.1016/S0006-8993(99)01911-3; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Nakajima Y, 1997, BRAIN RES, V765, P113, DOI 10.1016/S0006-8993(97)00522-2; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Russwurm S, 2002, J INTERF CYTOK RES, V22, P215, DOI 10.1089/107999002753536185; Sawada M, 1999, J NEUROCHEM, V72, P1466, DOI 10.1046/j.1471-4159.1999.721466.x; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; Si QS, 1997, NEUROSCIENCE, V81, P223, DOI 10.1016/S0306-4522(97)00172-3; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Sirimanne ES, 1996, PEDIATR RES, V39, P591, DOI 10.1203/00006450-199604000-00005; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; Trautman MS, 1996, PLACENTA, V17, P239, DOI 10.1016/S0143-4004(96)90044-2; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Walton M, 1998, J NEUROSCI RES, V53, P330, DOI 10.1002/(SICI)1097-4547(19980801)53:3<330::AID-JNR7>3.0.CO;2-B; Walton M, 1998, MOL BRAIN RES, V61, P11, DOI 10.1016/S0169-328X(98)00169-7; Walton MR, 2000, J NEUROIMMUNOL, V104, P109, DOI 10.1016/S0165-5728(99)00262-3; Williams K, 1996, NEUROCHEM INT, V29, P55, DOI 10.1016/0197-0186(95)00138-7	57	38	38	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	JAN 31	2003	110	1					63	75	PII S0169-328X(02)00585-5	10.1016/S0169-328X(02)00585-5			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	703WX	WOS:000184306100008	12573534				2022-02-06	
J	Peru, A; Beltramello, A; Moro, V; Sattibaldi, L; Berlucchi, G				Peru, A; Beltramello, A; Moro, V; Sattibaldi, L; Berlucchi, G			Temporary and permanent signs of interhemispheric disconnection after traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						CUD; corpus callosum; head trauma	SIMPLE REACTION-TIMES; CORPUS-CALLOSUM; HEMISPHERIC DISCONNECTION; AXONAL INJURY; LIGHT DETECTION; TOPOGRAPHY; COMMUNICATION; CALLOSOTOMY; RESPONSES; SPLENIUM	The corpus callosum is frequently damaged by closed head traumas, and the resulting deficits of interhemispheric communication may vary according to the specific position of the lesion within the corpus callosum. This paper describes a single case who suffered a severe traumatic brain injury resulting in a lesion of the posterior body of the corpus callosum. Among the classical symptoms of interhemispheric disconnection, left hand anomia, left upper limb ideomotor dyspraxia, left visual field dyslexia and dysnomia, and left ear suppression in a dichotic listening task were observed shortly after the injury but recovered completely or almost completely with the passage of time. The only symptom of interhemispheric disconnection which was found to persist more than 4 years after the injury was an abnormal prolongation of the crossed-uncrossed difference in a simple visuomotor reaction time task. This prolongation was comparable with that observed in subjects with complete callosal lesions or agenesis. The results suggest that the posterior body of the corpus callosum may be an obligatory interhemispheric communication channel for mediating fast visuo-motor responses. The transient nature of other symptoms of interhemispheric disconnection suggests a relatively wide dispersion of fibers with different functions through the callosal body, such that parts of them can survive a restricted lesion and allow functional recovery of hemispheric interactions. An assessment of the evolution in time of symptoms of interhemispheric disconnection following restricted callosal lesions may reveal fine and coarse features of the anatomo-functional topography of the corpus callosum. (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ Verona, Sez Fisiol Umana, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy; Osped Maggiore Borgo Trento, Dipartimento Neuroradiol, Verona, Italy; Osped Sacrp Cuore, Serv Rieducaz & Riabilitaz Funz, Negrar, Italy		Berlucchi, G (corresponding author), Univ Verona, Sez Fisiol Umana, Dipartimento Sci Neurol & Vis, Strada Grazie 8, I-37134 Verona, Italy.	giovanni.berlucchi@univr.it	Moro, Valentina/K-6464-2016; Moro, Valentina/AAM-2224-2021	Moro, Valentina/0000-0002-7119-7264; Moro, Valentina/0000-0002-7119-7264; peru, andrea/0000-0002-8032-0551			AGLIOTI S, 1993, EXP BRAIN RES, V95, P151; ALEXANDER MP, 1988, NEUROLOGY, V38, P802, DOI 10.1212/WNL.38.5.802; BASHORE TR, 1981, PSYCHOL BULL, V89, P352, DOI 10.1037/0033-2909.89.2.352; BEREK K, 1994, J NEUROL SCI, V123, P2, DOI 10.1016/0022-510X(94)90195-3; BERLUCCHI G, 1995, NEUROPSYCHOLOGIA, V33, P923, DOI 10.1016/0028-3932(95)00031-W; Berlucchi G, 1997, NEUROPSYCHOLOGIA, V35, P941, DOI 10.1016/S0028-3932(97)00022-5; BERLUCCHI G, 1999, HDB CLIN EXPT NEUROP, P635; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bogen J.E., 1993, INT J CLIN NEUROPSYC, Vthird, P337; BOLDRINI P, 1992, CORTEX, V28, P135, DOI 10.1016/S0010-9452(13)80172-4; BRIGGS G G, 1975, Cortex, V11, P230; BRION S, 1975, TROUBLES TRANSFERT I; CECCALDI M, 1994, REV NEUROL-FRANCE, V150, P229; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHELAZZI L, 1988, VISION RES, V28, P95, DOI 10.1016/S0042-6989(88)80010-5; CLARKE JM, 1989, BRAIN, V112, P849, DOI 10.1093/brain/112.4.849; CLARKE S, 1995, EXP BRAIN RES, V104, P534, DOI 10.1007/BF00231988; Corballis MC, 2002, NEUROPSYCHOLOGIA, V40, P423, DOI 10.1016/S0028-3932(01)00097-5; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; Deloche Gerard, 1993, Brain Injury, V7, P363, DOI 10.3109/02699059309034963; Funnell MG, 2000, ARCH NEUROL-CHICAGO, V57, P185, DOI 10.1001/archneur.57.2.185; Gazzaniga MS, 2000, BRAIN, V123, P1293, DOI 10.1093/brain/123.7.1293; GESCHWIND DH, 1995, NEUROLOGY, V45, P802, DOI 10.1212/WNL.45.4.802; GESCHWIND N, 1985, EPILEPSY CORPUS CALL, P349; GORDON HW, 1971, BRAIN, V94, P327, DOI 10.1093/brain/94.2.327; Habib M, 1998, NEUROCHIRURGIE, V44, P102; Iacoboni M, 2000, NEUROPSYCHOLOGIA, V38, P535, DOI 10.1016/S0028-3932(99)00121-9; IACOBONI M, 1994, NEUROREPORT, V5, P2521; Ihori N, 2000, EUR NEUROL, V44, P65, DOI 10.1159/000008199; Intriligator J, 2000, NEUROREPORT, V11, P2639, DOI 10.1097/00001756-200008210-00007; KAGA K, 1990, Brain Topography, V3, P175, DOI 10.1007/BF01128874; KAZUI S, 1993, ANN NEUROL, V33, P401, DOI 10.1002/ana.410330413; Lakmache Y, 1998, P NATL ACAD SCI USA, V95, P9042, DOI 10.1073/pnas.95.15.9042; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Levander MB, 1998, BRAIN INJURY, V12, P165, DOI 10.1080/026990598122791; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; LINDENBERG R, 1955, AM J PATHOL, V31, P297; MARZI CA, 1991, NEUROPSYCHOLOGIA, V29, P1163, DOI 10.1016/0028-3932(91)90031-3; MATSUNAMI K, 1994, NEUROSCI RES, V20, P137, DOI 10.1016/0168-0102(94)90031-0; MILNER AD, 1985, NEUROPSYCHOLOGIA, V23, P323, DOI 10.1016/0028-3932(85)90019-3; MILNER B, 1968, SCIENCE, V161, P184, DOI 10.1126/science.161.3837.184; Moses P, 2000, CEREB CORTEX, V10, P1200, DOI 10.1093/cercor/10.12.1200; Pandya DN., 1986, 2 HEMISPHERES ONE BR, P47; Pollmann S, 2002, NEUROPSYCHOLOGY, V16, P56, DOI 10.1037//0894-4105.16.1.56; Polster T, 2001, J NEUROL NEUROSUR PS, V70, P459, DOI 10.1136/jnnp.70.4.459; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; SCHOTT B, 1969, REV NEUROL, V20, P359; Sparks R., 1968, CORTEX, V4, P3, DOI DOI 10.1016/S0010-9452(68)80009-7; Sperry R.W., 1969, HDB CLIN NEUROLOGY, P4, DOI DOI 10.1023/B:HUMP.0000036333.34541.54; SPRINGER SP, 1975, NEUROPSYCHOLOGIA, V13, P341, DOI 10.1016/0028-3932(75)90011-1; SUGISHITA M, 1995, BRAIN, V118, P417, DOI 10.1093/brain/118.2.417; TASSINARI G, 1994, BEHAV BRAIN RES, V64, P141, DOI 10.1016/0166-4328(94)90126-0; Tokutomi T, 1997, ACT NEUR S, V70, P80; Tomaiuolo F, 2001, NEUROREPORT, V12, P1469, DOI 10.1097/00001756-200105250-00035; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; VUILLEUMIER P, 1995, NEUROCHIRURGIE, V41, P98; Yamadori A, 1988, Behav Neurol, V1, P11, DOI 10.3233/BEN-1988-1103	58	38	41	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2003	41	5					634	643	PII S0028-3932(02)00203-8	10.1016/S0028-3932(02)00203-8			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	654FQ	WOS:000181483900012	12559156				2022-02-06	
J	Willinger, R; Baumgartner, D				Willinger, R; Baumgartner, D			Numerical and physical modelling of the human head under impact - towards new injury criteria	INTERNATIONAL JOURNAL OF VEHICLE DESIGN			English	Article						accident reconstruction; brain; dummy head; finite element method; injury criteria		This paper presents original physical and numerical human head models followed by their modal and temporal validation against human head vibration analysis in vivo and cadaver impact tests. The human head FE model developed by ULP presents two particularities: one at the brain-skull interface level where fluid-structure interaction is taken into account, the other at the skull modelling level by integrating the bone fracture simulation. Validation shows that the model correlated well with a number of experimental cadaver tests and predicted intracranial pressure accurately. However, for long duration impacts the model reaches its limits. The skull stiffness and fracture force were very accurately predicted when compared with values from the literature. In a second step a new dummy head prototype named Bimass is presented. It has been constructed using a Hybrid III headform and comprises two masses: a skull and a mass to represent the brain attached to the skull with a damped spring system. The novel feature of this device is that it can simulate the brain-skull relative displacement at a frequency close to 150 Hz as recorded under vibration analysis in vivo. Helmet damage from thirteen motorcycle accidents was replicated in drop tests conducted in collaboration with Transport Research Laboratory (UK). Simulation of these accidents using both FE model and Bimass dummy head led to the first tentative proposals for tolerance limits and injury criteria relative to specific injury mechanisms.	Univ Strasbourg, CNRS 7507, Inst Fluid & Solid Mech, F-67000 Strasbourg, France		Willinger, R (corresponding author), Univ Strasbourg, CNRS 7507, Inst Fluid & Solid Mech, 2 Rue Boussingault, F-67000 Strasbourg, France.	willi@imfs.u-strasbg.fr					ALBSHARAT AS, 1999, P ASME SUMM M BIG SK; BRINN J, 1970, P 14 STAPP CAR CRASH; CHINN BP, 1999, P IRCOBI C, P53; Domont A., 1992, P 36 STAPP CAR CRASH, DOI [10.4271/922527, DOI 10.4271/922527]; FERNER H, 1985, EDITION MED INT PARI; HARRIS CM, 1988, SHOCK VIBRATION HDB; HODGSON VR, 1967, P 11 STAPP CAR CRASH, P79; HUBBARD RP, 1971, J BIOMECH, V4, P251, DOI 10.1016/0021-9290(71)90031-5; Kang HS, 1997, P 41 STAPP CAR CRASH, P329; KENNER VH, 1973, J BIOMECH, V6, P1, DOI 10.1016/0021-9290(73)90032-8; KHALIL TB, 1977, J BIOMECH, V10, P119, DOI 10.1016/0021-9290(77)90075-6; LOWENHIELM P, 1973, IRCOBI LYON, P423; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; Nahum A. M., 1977, P 21 STAPP CAR CRASH, P339; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J.A., 1999, P INT RES C BIOM I 1, P17; PIEKARSKI K, 1970, J APPL PHYS, V41, P215, DOI 10.1063/1.1658323; RUAN JS, 1993, P 37 STAPP CAR CRASH, P69; STALNAKER RL, 1971, J BIOMECH, V4, P127, DOI 10.1016/0021-9290(71)90023-6; TSAIWU, 1971, J COMPOSITE MAT; VIANO DC, 1988, P 32 STAPP CAR CRASH, P1; WILLIAMS TG, 1995, J CONSUM MARK, V12, P4, DOI DOI 10.1108/07363769510147218; Willinger R, 2000, J SOUND VIB, V235, P611, DOI 10.1006/jsvi.1999.2931; Willinger R, 1999, CR ACAD SCI II B, V327, P125, DOI 10.1016/S1287-4620(99)80021-0; WILLINGER R, 1992, ACCIDENT ANAL PREV, V26, P767; WILLINGER R, 2000, 327 COST; WILLINGER R, 1990, INT C BIOM IMP, P203; Willinger Rm, 2000, P INT RES COUNCIL BI, P209; WOODWARD AS, 1901, CATALOGUE FOSSIL FIS, V4, P1; YOGONANDAN N, 1994, P HEAD INJ 94 S WASH; ZHOU C, 1996, AGARD	31	38	40	1	16	INDERSCIENCE ENTERPRISES LTD	GENEVA	WORLD TRADE CENTER BLDG, 29 ROUTE DE PRE-BOIS, CASE POSTALE 856, CH-1215 GENEVA, SWITZERLAND	0143-3369	1741-5314		INT J VEHICLE DES	Int. J. Veh. Des.		2003	32	1-2					94	115		10.1504/IJVD.2003.003239			22	Engineering, Mechanical; Transportation Science & Technology	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Transportation	691PK	WOS:000183614500008					2022-02-06	
J	Seibert, PS; Reedy, DP; Hash, J; Webb, A; Stridh-Igo, P; Basom, J; Zimmerman, CG				Seibert, PS; Reedy, DP; Hash, J; Webb, A; Stridh-Igo, P; Basom, J; Zimmerman, CG			Brain injury: quality of life's greatest challenge	BRAIN INJURY			English	Article							PREFERENCE-BASED MEASURES; SEVERE HEAD-INJURY; OF-LIFE; COMMUNITY INTEGRATION; VALIDATION; VALIDITY; SCALE; COMA	The objectives of this investigation were to (1) identify elements that comprise an acceptable quality of life (Q-L) post-traumatic brain injury (TBI) from the perspectives of patients and families, and (2) explore patient and family satisfaction with treatment decisions relevant to QoL. The authors created, tested, and administered two forms (patient; family) of a 35-question interview to 33 participants in a longitudinal TBI study (14 women, 19 men) and 33 associated family members. Men associated ratings of QoL with numerous variables, while women's responses revealed no significant relationships shared by QoL and other variables. Women reported a poorer QoL than did men. Older patients reported a better QoL than did younger patients. Families emphasized the family relationship, emotional control, and ability to concentrate when considering overall QoL. Patients did not. The majority of patients and families expressed satisfaction with decisions made about acute treatment. QoL research is essential to illuminate best practice models.	St Alphonsus Reg Med Ctr, Idaho Neurol Inst, Boise, ID 83706 USA; Boise State Univ, Boise, ID 83725 USA		Seibert, PS (corresponding author), St Alphonsus Reg Med Ctr, Idaho Neurol Inst, 1055 N Curtis Rd, Boise, ID 83706 USA.		Stridh, Pernilla/J-2918-2012	Stridh, Pernilla/0000-0003-4855-0039			Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; *BRAIN INJ ASS, 2000, COSTS CAUS TRAUM BRA; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Carr AJ, 2001, BMJ-BRIT MED J, V322, P1240, DOI 10.1136/bmj.322.7296.1240; Collins R, 2000, J HEAD TRAUMA REHAB, V15, P1139, DOI 10.1097/00001199-200010000-00007; *CTR FUNCT ASS RES, 1990, GUID US UN DAT SET M; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Dempster M, 2000, SOC WORK HEALTH CARE, V32, P45; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Helm-Estabrooks N., 1990, BRIEF TEST HEAD INJU; Higginson IJ, 2001, BRIT MED J, V322, P1297, DOI 10.1136/bmj.322.7297.1297; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Lenert L, 2000, MED CARE, V38, P138; Leplege A, 1997, JAMA-J AM MED ASSOC, V278, P47, DOI 10.1001/jama.278.1.47; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Maslow Abraham., 1954, MOTIVATION PERSONALI; Mezzich JE, 2000, J NERV MENT DIS, V188, P301, DOI 10.1097/00005053-200005000-00008; MIRR MP, 1991, HEART LUNG, V20, P228; Murrell R, 1999, NEUROPSYCHOL REV, V9, P209, DOI 10.1023/A:1021686606648; Nease RF, 2000, MED CARE, V38, P155; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pearlman R A, 1992, J Clin Ethics, V3, P114; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stewart AL, 2000, MED CARE, V38, P102; Swenson JR, 2000, J PSYCHOSOM RES, V48, P405, DOI 10.1016/S0022-3999(99)00092-6; Testa MA, 2000, MED CARE, V38, P166; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Weitzner MA, 1996, J NEUROSURG, V84, P29, DOI 10.3171/jns.1996.84.1.0029; WHITENECK GG, 1992, ARCH PHYSICAL MED RE, V73, P1186; Withrow SJ, 1998, CLIN TECH SMALL AN P, V13, P1	40	38	39	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2002	16	10					837	848		10.1080/02699050210131939			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	599VG	WOS:000178355400001	12418997				2022-02-06	
J	Yokota, H; Naoe, Y; Nakabayashi, M; Unemoto, K; Kushimoto, S; Kurokawa, A; Node, Y; Yamamo, Y				Yokota, H; Naoe, Y; Nakabayashi, M; Unemoto, K; Kushimoto, S; Kurokawa, A; Node, Y; Yamamo, Y			Cerebral endothelial injury in severe head injury: The significance of measurements of serum thrombomodulin and the von Willebrand factor	JOURNAL OF NEUROTRAUMA			English	Article						cerebral endothelial injury; severe head injury; thrombomodulin; von Willebrand factor	VONWILLEBRAND-FACTOR; TRAUMA; COAGULOPATHY	Thrombomodulin (TM), which is located in the surface of the endothelium in the arteries, veins, and capillaries of major organs such as the brain, lungs, liver, kidneys, skeletal muscles, and gastrointestinal tract, is one of several indicators of endothelial injury. Von Willebrand factor (vWf), which is synthesized by endothelial cells, is also an endothelial specific glycoprotein. The serum level of vWf increases in response to various stimuli without endothelial injury. An elevated serum level of vWf may suggest endothelial activation in severe head injury. We hypothesize that the degree of cerebral endothelial activation or injury depends on the type of head injury and that measuring the TM and vWf is useful for predicting delayed traumatic intracerebral. hematoma (DTICH), produced by weakness of the vessel wall, occuring either as a direct or indirect effect of head injury. The values of vWf in focal brain injury (ranging from 332.5 +/- 52.8% to 361.7 +/- 86.2%) were significantly higher than those in diffuse axonal injury from 2 h to 7 days after the injury occurred (ranging from 201.6 +/- 59.5% to 242.5 +/- 51.7%). The serum level of TM in focal brain injury (ranging from 3.84 +/- 1.54 to 4.12 +/- 1.46 U/mL) was higher than that in diffuse axonal injury (ranging from 2.96 +/- 0.63 to 3.67 +/- 1.70 U/mL), but these differences were not statistically significant. In patients with DTICH, TM was significantly higher than in patients without DTICH (p < 0.01). The results of our study demonstrate that the degree of endothelial activation in focal brain injury was significantly higher than in diffuse brain injury. In addition, the serum level of TM in patients with DTICH was significantly higher than in patients without DTICH. These findings suggest that cerebral tissue injury is often accompanied by cerebral endothelial activation, and that these two phenomena should be distinguished from each other. The levels of serum TM and vWf appear to be good indicators of the cerebral endothelial injury and of endothelial activation in severe head injury.	Tama Nagayama Hosp, Nippon Med Sch, Dept Emergency & Crit Care, Tokyo 2068512, Japan; Main Hosp, Nippon Med Sch, Dept Crit Care Med, Tokyo, Japan		Yokota, H (corresponding author), Tama Nagayama Hosp, Nippon Med Sch, Dept Emergency & Crit Care, 1-7-1 Nagayama Tama City, Tokyo 2068512, Japan.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; ATRAS S, 1969, J TRAUMA, V9, P522; BARATHAM G, 1972, J NEUROL NEUROSUR PS, V35, P698, DOI 10.1136/jnnp.35.5.698; BOLLINGER O, 1891, VIRCHOW, V2, P457; BOROWIECKI B, 1969, J TRAUM, V9, P522; COOPER PR, 1985, COMMENT NEUROSURGERY, V19, P531; FAN L, 1993, SOC NEUR ABSTR, V76, P9; Gennarelli T A, 1984, Emerg Med Clin North Am, V2, P749; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; HANDIN IR, 2000, HARRISONS, P745; Ikegami K, 1998, J TRAUMA, V44, P789, DOI 10.1097/00005373-199805000-00008; INNEE D, 1964, J CLIN PATHOL, V17, P113; ISHII H, 1994, THROMBIN THROMBOMODU, P121; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; MELLION BT, 1992, COMPLICATIONS SEQUEL, P51; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; SIMMONS RL, 1969, ANN SURG, V169, P455, DOI 10.1097/00000658-196904000-00001; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TAKANO S, 1990, BLOOD, V76, P2024; TAKASHIMA S, 1969, BRIT J EXP PATHOL, V50, P533; TOVI D, 1973, ACTA NEUROL SCAND, V49, P152; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718; VERWEIJ CL, 1988, HAEMOSTASIS, V18, P224; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; YOKOTA H, 1995, NEUROCHEMICAL MONITO, P98	32	38	43	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2002	19	9					1007	1015		10.1089/089771502760341929			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	598KW	WOS:000178275900002	12482114				2022-02-06	
J	Kumar, A; Cook, IA				Kumar, A; Cook, IA			White matter injury, neural connectivity and the pathophysiology of psychiatric disorders	DEVELOPMENTAL NEUROSCIENCE			English	Article						white matter; connectivity; myelin; axons; mood disorder; psychiatric disorders	MAGNETIC-RESONANCE SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; PREFRONTAL CORTEX; BASAL GANGLIA; HEAD-INJURY; MRI; LESIONS	Psychiatric disorders are characterized by diverse clinical manifestations that include deficits in cognition, perception, mood and arousal. These complex processes are not mediated by any specific brain region but require the coordinated activity of several areas that are anatomically connected. Impairments in these neural circuits may therefore be expected to result in an attenuation of the functions regulated by them. The white matter provides the structural and physiological substrate of neural circuits in the central nervous system. We propose that injury to the white matter, from diverse biological sources, may compromise neural connectivity by associated axonal injury or impaired conductivity. Either mechanism could result in clusters of signs and symptoms that are currently recognized as psychiatric disorders. The role of white matter impairment in the pathophysiology of psychiatric illness is under-appreciated in the neurosciences. Focused translational research aimed at identifying the links between white matter compromise and specific behaviors are necessary for a more thorough understanding of the etiology of mental illness to emerge. Copyright (C) 2002 S. Karger AG, Basel.	Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90024 USA		Kumar, A (corresponding author), Univ Calif Los Angeles, Inst Neuropsychiat, 37-384B,760 Westwood Plaza, Los Angeles, CA 90024 USA.	akumar@mednet.ucla.edu					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Akbarian S, 1996, ARCH GEN PSYCHIAT, V53, P425; ALEXANDER MP, 1987, NEUROBEHAVIORAL RECO, P191; Alexopoulos GS, 1997, ARCH GEN PSYCHIAT, V54, P915; BENNETT DA, 1994, DEMENTIA, V5, P148, DOI 10.1159/000106713; Bjartmar C, 1999, J NEUROCYTOL, V28, P383, DOI 10.1023/A:1007010205037; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; Buchsbaum MS, 1998, NEUROREPORT, V9, P425, DOI 10.1097/00001756-199802160-00013; Callicott JH, 2000, CEREB CORTEX, V10, P1078, DOI 10.1093/cercor/10.11.1078; Campagnoni A, 2001, BRAIN PATHOL, V11, P74; Catalaa I, 1999, AM J NEURORADIOL, V20, P1613; COOK IA, IN PRESS ARCH NEUROL; de Groot JC, 2000, ANN NEUROL, V47, P145; Dichgans M, 1999, NEUROLOGY, V52, P1361, DOI 10.1212/WNL.52.7.1361; Duman RS, 2002, NEUROPSYCHOPHARMACOL, V26, P141, DOI 10.1016/S0893-133X(01)00415-8; Evangelou N, 2000, ANN NEUROL, V47, P391, DOI 10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.0.CO;2-J; FEINSTEIN A, 1992, J NEUROL NEUROSUR PS, V55, P869, DOI 10.1136/jnnp.55.10.869; Filley CM, 1998, NEUROLOGY, V50, P1535, DOI 10.1212/WNL.50.6.1535; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FILLEY CM, 2001, BEHAV NEUROLOGY WHIT; Foong J, 2001, BRAIN, V124, P882, DOI 10.1093/brain/124.5.882; Fuster JM, 2001, NEURON, V30, P319, DOI 10.1016/S0896-6273(01)00285-9; GALASKO D, 1988, PSYCHIAT CLIN N AM, V11, P151; GESCHWIN.N, 1965, BRAIN, V88, P585, DOI 10.1093/brain/88.3.585; Geula C, 1998, NEUROLOGY, V51, pS18, DOI 10.1212/WNL.51.1_Suppl_1.S18; Gitelman DR, 1999, BRAIN, V122, P1093, DOI 10.1093/brain/122.6.1093; Goldman-Rakic P.S., 2011, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Hamakawa H, 1998, EUR ARCH PSY CLIN N, V248, P53, DOI 10.1007/s004060050017; Harrison JE, 1999, AM J MED GENET, V88, P642, DOI 10.1002/(SICI)1096-8628(19991215)88:6<642::AID-AJMG12>3.3.CO;2-F; HONER WG, 1987, ARCH NEUROL-CHICAGO, V44, P187, DOI 10.1001/archneur.1987.00520140053017; HYDE TM, 1992, ARCH NEUROL-CHICAGO, V49, P401, DOI 10.1001/archneur.1992.00530280095028; Kato T, 1996, J PSYCHIATR NEUROSCI, V21, P248; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Krishnan KRR, 1997, AM J PSYCHIAT, V154, P497; Kumar A, 2002, NEUROPSYCHOPHARMACOL, V26, P229, DOI 10.1016/S0893-133X(01)00331-1; KUMAR A, IN PRESS FRONTAL WHI; Lewis DA, 2002, NEUROPSYCHOPHARMACOL, V26, P143, DOI 10.1016/S0893-133X(01)00393-1; Lim KO, 1998, ARCH GEN PSYCHIAT, V55, P346, DOI 10.1001/archpsyc.55.4.346; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Morris JS, 1999, NEUROIMAGE, V10, P163, DOI 10.1006/nimg.1999.0455; Murata T, 2001, INT J GERIATR PSYCH, V16, P1129, DOI 10.1002/gps.501; Nicholl CR, 2001, CLIN REHABIL, V15, P657, DOI 10.1191/0269215501cr427oa; O'Sullivan M, 2001, NEUROLOGY, V57, P632, DOI 10.1212/WNL.57.4.632; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Rajkowska G, 2000, BIOL PSYCHIAT, V48, P766, DOI 10.1016/S0006-3223(00)00950-1; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Rosebush PI, 1999, J NEUROPSYCH CLIN N, V11, P315, DOI 10.1176/jnp.11.3.315; SADOVNICK AD, 1991, NEUROLOGY, V41, P1193, DOI 10.1212/WNL.41.8.1193; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; Steffens DC, 2002, DEPRESS ANXIETY, V15, P23, DOI 10.1002/da.1081; STUSS DT, 1990, SUBCORTICAL DEMENTIA, P145; Taylor WD, 2001, BIOL PSYCHIAT, V50, P179, DOI 10.1016/S0006-3223(01)01160-X; Thomas AJ, 2001, J NEUROL NEUROSUR PS, V70, P83, DOI 10.1136/jnnp.70.1.83; Thomas MA, 2001, MAGNET RESON MED, V46, P58, DOI 10.1002/mrm.1160; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; WALLIN A, 1989, ACTA NEUROL SCAND, V80, P518, DOI 10.1111/j.1600-0404.1989.tb03920.x	60	38	39	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.	JUL-AUG	2002	24	4					255	261		10.1159/000066746			7	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	629BV	WOS:000180031300001	12457063				2022-02-06	
J	Ding, YC; Zhou, YD; Lai, Q; Li, J; Park, H; Diaz, FG				Ding, YC; Zhou, YD; Lai, Q; Li, J; Park, H; Diaz, FG			Impaired motor activity and motor learning function in rat with middle cerebral artery occlusion	BEHAVIOURAL BRAIN RESEARCH			English	Article						motor activity; motor learning; motor behavior tasks; ischemic stroke; neurological deficits; infarct	TRAUMATIC BRAIN INJURY; COGNITIVE IMPAIRMENT; ALCOHOL EXPOSURE; ISCHEMIC STROKE; INFARCT VOLUME; ADULT-RATS; RECOVERY; CORTEX; DEFICITS; SENSORIMOTOR	The poor quality of life after a stroke is largely attributed to deficits in cognitive-motor functioning. The goals of this study were to detect if damaged motor learning function were attributed to motor deficits in rats following a transient middle cerebral artery (MCA) occlusion. Stroke was induced by a 2-h occlusion of the MCA using an intraluminal filament. Motor functions were evaluated from 5 up to 28 days after reperfusion in ischemic and control rats. Motor function was detected by a series of motor tests (runway traversing and beam balancing, as well Lis foot fault placing, parallel bar crossing, rope and ladder climbing), and motor learning behavior was determined by analyzing the rate of improvement of impaired function during performance of the motor tasks. Significant (P < 0.001) motor deficits were detected in the stroke group (n = 10) while performing motor tasks that involve extensive coordination, in comparison to the controls (n = 12). Although motor behavior was improved with repeated behavior testing, unparalleled rate of improvement of motor performance on rope and ladder climbing tests was found between the two groups. suggesting an impaired motor learning function. Brain tissue damage was detected in the ischemic animals 28 days after surgery, demonstrated by 40% infaret volume of contralateral hemisphere. Both motor learning and motor function were impaired in ischemic rats. The motor tests used in this study are sensitive, semi-quantitative, and reproducible measurements of functional impairment in rats following an ischemic stroke. (C) 2002 Elsevier Science B.V. All rights reserved.	Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Educ, Div Hlth Phys Educ & Recreat, Detroit, MI 48201 USA		Ding, YC (corresponding author), Wayne State Univ, Sch Med, Dept Neurol Surg, Lande Med Res Bldg,Room 48,550 E Canfield, Detroit, MI 48201 USA.	yding@neurosurgery.wayne.edu					Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; BORLONGAN CV, 1995, PHARMACOL BIOCHEM BE, V52, P225, DOI 10.1016/0091-3057(95)00108-9; BORLONGAN CV, 1995, PHYSIOL BEHAV, V58, P909, DOI 10.1016/0031-9384(95)00103-P; Borlongan CV, 2000, NEUROREPORT, V11, P4063, DOI 10.1097/00001756-200012180-00031; CARR JH, 1989, PHYSIOTHERAPY, V75, P372; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eccles J C, 1978, Exp Brain Res, V31, P153; Friel KM, 1998, SOMATOSENS MOT RES, V15, P173, DOI 10.1080/08990229870745; Goodlett CR, 1996, PHARMACOL BIOCHEM BE, V55, P531, DOI 10.1016/S0091-3057(96)00248-1; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hanlon RE, 1996, ARCH PHYS MED REHAB, V77, P811, DOI 10.1016/S0003-9993(96)90262-2; HIRAKAWA M, 1994, STROKE, V25, P2471, DOI 10.1161/01.STR.25.12.2471; HUNTER AJ, 1995, TRENDS PHARMACOL SCI, V16, P123, DOI 10.1016/S0165-6147(00)88999-3; Jones TA, 1999, J NEUROSCI, V19, P10153; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Kleim JA, 1996, J NEUROSCI, V16, P4529; Klintsova AY, 1998, BRAIN RES, V800, P48, DOI 10.1016/S0006-8993(98)00495-8; KOIZUMI J, 1985, P 10 M JAP STOK SOC; Kwa VIH, 1996, J NEUROL, V243, P599, DOI 10.1007/BF00900948; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MARKGRAF CG, 1994, STROKE, V25, P153, DOI 10.1161/01.STR.25.1.153; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; MARSTON HM, 1995, NEUROREPORT, V6, P1067, DOI 10.1097/00001756-199505090-00029; MELCER T, 1995, NEUROTOXICOL TERATOL, V17, P103, DOI 10.1016/0892-0362(94)00058-L; MEYER LS, 1990, ALCOHOL CLIN EXP RES, V14, P23, DOI 10.1111/j.1530-0277.1990.tb00440.x; Mohr J.P., 1986, STROKE PATHOPHYSIOLO, P377; MORI S, 1995, STROKE, V26, P620, DOI 10.1161/01.STR.26.4.620; Nudo RJ, 2000, NEUROPHARMACOLOGY, V39, P733, DOI 10.1016/S0028-3908(99)00254-3; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144, DOI 10.1152/jn.1996.75.5.2144; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P505, DOI 10.1038/jcbfm.1995.62; Robertson IH, 1997, NEUROPSYCHOLOGY, V11, P290, DOI 10.1037/0894-4105.11.2.290; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; SAITO I, 1987, STROKE, V18, P863, DOI 10.1161/01.STR.18.5.863; Sakai N, 1996, BEHAV BRAIN RES, V77, P181, DOI 10.1016/0166-4328(95)00232-4; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TOMINAGA T, 1989, STROKE, V20, P513, DOI 10.1161/01.STR.20.4.513; vanderStaay FJ, 1996, BRAIN RES, V715, P180, DOI 10.1016/0006-8993(95)01581-7; WADE DT, 1985, J NEUROL NEUROSUR PS, V48, P7, DOI 10.1136/jnnp.48.1.7; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; YAMAMOTO M, 1988, BRAIN RES, V452, P323, DOI 10.1016/0006-8993(88)90036-4; Yonemori F, 1998, J CEREBR BLOOD F MET, V18, P1099, DOI 10.1097/00004647-199810000-00006; Yonemori F, 1996, J CEREBR BLOOD F MET, V16, P973, DOI 10.1097/00004647-199609000-00022; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438	50	38	43	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	APR 15	2002	132	1					29	36	PII S0166-4328(01)00405-3	10.1016/S0166-4328(01)00405-3			8	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	539PR	WOS:000174880100004	11853855				2022-02-06	
J	Fortin, S; Godbout, L; Braun, CMJ				Fortin, S; Godbout, L; Braun, CMJ			Strategic sequence planning and prospective memory impairments in frontally lesioned head trauma patients performing activities of daily living	BRAIN AND COGNITION			English	Article; Proceedings Paper	12th Annual Meeting on Tennet - Theoretical and Experimental Neuropsychology	JUN 21-23, 2001	UNIV QUEBEC, MONTREAL, CANADA		UNIV QUEBEC		BRAIN-DAMAGE; DEFICITS; INJURY	The aim of this research was to study strategic sequence planning and prospective memory in activities of daily living (ADL) in 10 patients with frontal lobe lesions after a mild to moderate closed head injury (CHI). The lesions were documented radiologically. The CHI patients were compared to 12 normal controls with a neuropsychological test battery and a realistic simulation of complex multitask ADL (planning and preparing a meal). Though the CHI patients were significantly slow on one test and subject to interference on an attention test. they manifested no basic executive or memory deficit on the paper-pencil tests. However, the CHI patients manifested marked anomalies in the organization of behavior in the meal preparation task. While small sequences of actions were easily produced, large action sets could not be correctly executed. An outstanding difficulty in strategic planning and prospective memory, particularly time-based more than event-based, appears to be an important underpinning of the impairment of ADL observed in the CHI patients with frontal lobe lesions. (C) 2002 Elsevier Science (USA).	Univ Quebec, Ctr Neurosci Cognit, Dept Psychol, Montreal, PQ H3C 3P8, Canada; Univ Quebec, Dept Psychol, Lab Neuropsychol Expt & Comparee, Trois Rivieres, PQ GA9 5H7, Canada		Braun, CMJ (corresponding author), Univ Quebec, Ctr Neurosci Cognit, Dept Psychol, BP 8888,Succ Ctr Ville, Montreal, PQ H3C 3P8, Canada.						Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; Godbout L, 2000, BRAIN COGNITION, V43, P220; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; McDaniel MA, 1999, NEUROPSYCHOLOGY, V13, P103, DOI 10.1037/0894-4105.13.1.103; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; Schwartz MF, 1995, COGNITIVE NEUROPSYCH, V12, P863, DOI 10.1080/02643299508251406; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; van den Broek MD, 2000, BRAIN INJURY, V14, P455	13	38	38	1	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	MAR-APR	2002	48	2-3					361	365		10.1006/brcg.2001.1378			5	Neurosciences; Psychology, Experimental	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	536ED	WOS:000174687000075	12030468				2022-02-06	
J	Dillman, RO; Beutel, LD; Barth, NM; de Leon, C; O'Connor, AA; DePriest, C; Nayak, SK				Dillman, RO; Beutel, LD; Barth, NM; de Leon, C; O'Connor, AA; DePriest, C; Nayak, SK			Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: Induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival	CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS			English	Article						cancer; vaccines; tumor cell lines; delayed type tumor hypersensitivity	ACTIVE-SPECIFIC IMMUNOTHERAPY; COLORECTAL-CANCER; GENE-THERAPY; MELANOMA; IMMUNIZATION; CARCINOMA; CULTURES	Objective: We established short-term cultures of pure tumor cells for use as autologous tumor cell vaccines in an effort to study the effects of patient-specific immunotherapy. Patients and Methods: Surgically, resected fresh tumor was obtained from patients with metastatic cancer. Successful tumor cell lines (5 X 10(7)) were expanded to 10(8) cells, irradiated, and cryopreserved for clinical use. Following a baseline test of delayed-type hypersensitivity (DTH) to an i.d. injection of 106 irradiated autologous tumor cells, patients received 3 weekly s.c. injections of 10(7) cells, had a repeat DTH test at week-4, then received monthly vaccinations for 5 months. A positive DTH test was defined as greater than or equal to 10 mm induration; survival was determined from the first DTH test. Results: Short-term cell lines were successfully established for 299/695 patients (43%). Vaccines were prepared for 231 patients, 142 of whom were treated, and 125 had a baseline DTH test recorded. Median follow Lip at the time of analysis was greater than 5 years. There was no difference in survival for any of the following: gender, age > 50 years, melanoma histology, anergy to common recall antigens or baseline DTH test result. Only 17 patients had a positive DTH at baseline (14%), but DTH converted from negative to positive in 31/80 (39%) of those mho were tested, and in 31/108 (29%) of all patients (intent-to-convert analysis). For the 48 patients who were DTH-positive at entry, or converted to DTH-positive, the median survival was 30.5 months and 5-year survival 41% compared to 11.4 months and 9% 5-year survival for 77 patients whose DTH was never positive (P-2=0.003). However, survival was even better for patients whose DTH test converted to positive compared to patients who were DTH-positive at baseline (median 37.5 vs 11.9 mos, P-2=0.066). Concussion: This patient-specific, cell culture-derived, autologous tumor cell vaccine induced anti-tumor immune reactivity that was associated with improved survival in patients with advanced cancer.	Hoag Canc Ctr, Newport Beach, CA 92658 USA		Dillman, RO (corresponding author), Hoag Canc Ctr, 1 Hoag Dr,Bldg 41, Newport Beach, CA 92658 USA.	rdillman@hoaghospital.org					BAILAR JC, 1992, MED USES STAT; BARTH A, 1994, CANCER RES, V54, P3342; Berd D, 1998, SEMIN ONCOL, V25, P646; Berd D, 1998, SEMIN ONCOL, V25, P605; BERD D, 1990, J CLIN ONCOL, V8, P1858, DOI 10.1200/JCO.1990.8.11.1858; BYSTRYN JC, 1992, CANCER, V69, P157; Chan AD, 1998, SEMIN ONCOL, V25, P611; DILLMAN RO, 1993, J IMMUNOTHER, V14, P65, DOI 10.1097/00002371-199307000-00009; Dillman RO, 2001, CRIT REV ONCOL HEMAT, V39, P115, DOI 10.1016/S1040-8428(01)00110-X; Dillman RO, 1997, CANCER BIOTHER RADIO, V12, P229, DOI 10.1089/cbr.1997.12.229; Dillman RO, 1999, CANCER BIOTHER RADIO, V14, P443, DOI 10.1089/cbr.1999.14.443; Dillman RO, 2001, CANCER BIOTHER RADIO, V16, P205, DOI 10.1089/10849780152389393; Dillman RO, 2000, CANCER BIOTHER RADIO, V15, P161, DOI 10.1089/cbr.2000.15.161; Dillman RO, 1998, CANCER BIOTHER RADIO, V13, P165, DOI 10.1089/cbr.1998.13.165; HASPEL MV, 1985, CANCER RES, V45, P3951; HOOVER HC, 1984, CANCER RES, V44, P1671; HOOVER HC, 1993, J CLIN ONCOL, V11, P390, DOI 10.1200/JCO.1993.11.3.390; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KESSLER DA, 1993, NEW ENGL J MED, V329, P1169, DOI 10.1056/NEJM199310143291607; Livingston P, 1998, SEMIN ONCOL, V25, P636; MILLER K, 1995, CANCER, V75, P495, DOI 10.1002/1097-0142(19950115)75:2<495::AID-CNCR2820750212>3.0.CO;2-S; Mitchell MS, 1998, SEMIN ONCOL, V25, P623; MITCHELL MS, 1990, J CLIN ONCOL, V8, P856, DOI 10.1200/JCO.1990.8.5.856; Nayak SK, 2000, IN VITRO CELL DEV-AN, V36, P188; NAYAK SK, 1991, CLIN BIOTECHNOL, V3, P237; Salgaller ML, 1997, J IMMUNOTHER, V20, P1, DOI 10.1097/00002371-199701000-00001; Schirrmacher V, 1998, SEMIN ONCOL, V25, P677; Simons JW, 1998, SEMIN ONCOL, V25, P661; SZNOL M, 1999, PPO UPDATES, V13, P1	29	38	38	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1084-9785	1557-8852		CANCER BIOTHER RADIO	Cancer Biother. Radiopharm.	FEB	2002	17	1					51	66		10.1089/10849780252824073			16	Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging	528FG	WOS:000174233300007	11915174				2022-02-06	
J	Ding, YC; Yao, B; Zhou, YD; Park, H; McAllister, JP; Diaz, FG				Ding, YC; Yao, B; Zhou, YD; Park, H; McAllister, JP; Diaz, FG			Prereperfusion flushing of ischemic territory: a therapeutic study in which histological and behavioral assessments were used to measure ischemia-reperfusion injury in rats with stroke	JOURNAL OF NEUROSURGERY			English	Article						cerebral ischemia; infarction; neurological deficit; reperfusion damage; microcirculation; motor response; rat	CEREBRAL-ARTERY OCCLUSION; TRANSIENT FOCAL ISCHEMIA; POSTISCHEMIC HYPOTHERMIA; FOREBRAIN ISCHEMIA; FREE-RADICALS; NEOCORTICAL INFARCTION; MOLECULAR MECHANISMS; GERBIL HIPPOCAMPUS; ALCOHOL EXPOSURE; NEURONAL INJURY	Object. In ischemic stroke, the ischemic crisis activates a cascade of traumatic events that are potentiated by reperfusion and eventually lead to neuronal degeneration. The primary aim of this study was to investigate a procedure that could minimize this damage by interfering with the interactions between reestablished blood flow and ischemically damaged tissue, as well as by improving regional microcirculation. Methods. Using a novel hollow filament, the authors flushed the ischemic territory with heparinized saline before vascular reperfusion after occlusion of the middle cerebral artery (MCA). The results demonstrate a statistically significant (p < 0.001) reduction in infarct volume (75%; from 45.3 +/- 3.6% to 11.4 +/- 1.7%, determined with Nissl staining) in rats in which a 2-hour MCA occlusion was followed by a 48-hour reperfusion. Infarction and neuronal degeneration were confirmed using silver staining, which revealed a significantly larger infarct (36.3%, p < 0.05) than that detected with Nissl staining. The long-term neuroprotection of the prereperfusion flushing was also evaluated. This was determined by a series of motor behavior tasks (foot placing parallel bar traversing, rope and ladder climbing) performed up to 28 days after reperfusion. Motor deficits were found to be significantly ameliorated in animals that underwent the flushing procedure (p < 0.001). In addition, neurological outcome was also improved significantly (p < 0.001) in the same animals. Conclusions. These results indicate that interaction between reperfusion and the metabolically and biochemically compromised tissue could be interrupted by the prereperfusion flushing procedure, which could lead to a reduction in brain injury from stroke. Mechanical reopening of the cerebral occlusion with local flushing and isolated reperfusion of the regionally injured brain might offer new treatment options for patients with stroke.	Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA		Ding, YC (corresponding author), Wayne State Univ, Sch Med, Dept Neurol Surg, Lande Med Res Bldg,Room 48,550 E Canfield, Detroit, MI 48201 USA.		McAllister, James P./N-9657-2019				ADAMS JH, 1997, NEUROSURG CLIN N AM, V8, P207; Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647-199710000-00006; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BECK J, 2000, RESTOR NEUROL NEUROS, V16, P162; Becker KJ, 1998, CURR OPIN NEUROL, V11, P45, DOI 10.1097/00019052-199802000-00008; Bivin W. S., 1979, The laboratory rat. Volume I. Biology and diseases., P73; BULKLEY GB, 1987, J VASC SURG, V5, P512, DOI 10.1067/mva.1987.avs0050512b; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; CHEN H, 1992, J NEUROL SCI, V107, P191, DOI 10.1016/0022-510X(92)90288-V; CHIANG J, 1968, AM J PATHOL, V52, P455; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; Choudhri TF, 1998, J CLIN INVEST, V102, P1301, DOI 10.1172/JCI3338; CLARK RK, 1994, BRAIN RES BULL, V35, P387, DOI 10.1016/0361-9230(94)90119-8; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; DeGraba TJ, 1998, NEUROLOGY, V51, pS62, DOI 10.1212/WNL.51.3_Suppl_3.S62; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DIETRICH WD, 1984, J NEUROPATH EXP NEUR, V43, P72, DOI 10.1097/00005072-198401000-00006; Ding YC, 2001, NEUROL RES, V23, P193, DOI 10.1179/016164101101198334; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DOUGHERTY JH, 1907, NEUROLOGY, V27, P382; Emerich DF, 1999, STROKE THERAPY, P195; Fischer M, 1996, INTENS CARE MED, V22, P1214; GARCIA JH, 1994, AM J PATHOL, V144, P188; GINSBERG MD, 1990, CEREBROVAS BRAIN MET, V2, P58; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Goodlett CR, 1996, PHARMACOL BIOCHEM BE, V55, P531, DOI 10.1016/S0091-3057(96)00248-1; HABERL RL, 1994, THROMB RES, V74, pS13, DOI 10.1016/S0049-3848(10)80003-9; Hall ED, 1999, STROKE THERAPY, P245; HALLENBECK JM, 1990, ARCH NEUROL-CHICAGO, V47, P1245, DOI 10.1001/archneur.1990.00530110107027; HARA A, 1995, NEUROL RES, V17, P461, DOI 10.1080/01616412.1995.11740364; Hossmann KA, 1997, SHOCK, V8, P95, DOI 10.1097/00024382-199708000-00004; Huang J, 1999, NEUROSURGERY, V45, P328, DOI 10.1097/00006123-199908000-00027; HUNTER AJ, 1995, TRENDS PHARMACOL SCI, V16, P123, DOI 10.1016/S0165-6147(00)88999-3; IWAI T, 1993, LIFE SCI, V52, P1031, DOI 10.1016/0024-3205(93)90195-9; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; Jones TA, 1999, J NEUROSCI, V19, P10153; Kato H, 1999, CELL MOL NEUROBIOL, V19, P93, DOI 10.1023/A:1006920725663; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; KIESSLING M, 1994, BRAIN PATHOL, V4, P21; Klintsova AY, 1998, BRAIN RES, V800, P48, DOI 10.1016/S0006-8993(98)00495-8; KOIZUMI J, 1985, P 10 M JAP STROK SOC, P4; KORTHUIS RJ, 1985, CIRC RES, V57, P599, DOI 10.1161/01.RES.57.4.599; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MELCER T, 1995, NEUROTOXICOL TERATOL, V17, P103, DOI 10.1016/0892-0362(94)00058-L; MEYER LS, 1990, ALCOHOL CLIN EXP RES, V14, P23, DOI 10.1111/j.1530-0277.1990.tb00440.x; Mohr J.P., 1986, STROKE PATHOPHYSIOLO, P377; MULLER TB, 1994, INT J MICROCIRC, V14, P289, DOI 10.1159/000178843; OLSSON Y, 1971, ACTA NEUROPATHOL, V17, P68, DOI 10.1007/BF00684742; OVERGAARD K, 1994, CEREBROVAS BRAIN MET, V6, P257; PHILLIS JW, 1997, PRIMER CEREBROVASCUL, P261; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; SAITO I, 1987, STROKE, V18, P863, DOI 10.1161/01.STR.18.5.863; Samama MM, 1997, THROMB HAEMOSTASIS, V78, P173; SCHMIDLEY JW, 1990, STROKE, V21, P1086, DOI 10.1161/01.STR.21.7.1086; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1993, PROG BRAIN RES, V96, P1; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Watson BD, 1998, CELL MOL NEUROBIOL, V18, P581, DOI 10.1023/A:1020209616428; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P617, DOI 10.1038/jcbfm.1991.112; White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5; WOOD JH, 1985, STROKE, V16, P765, DOI 10.1161/01.STR.16.5.765; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438	75	38	42	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2002	96	2					310	319		10.3171/jns.2002.96.2.0310			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	517BU	WOS:000173591900016	11838805				2022-02-06	
J	Donaldson, J; Shi, R; Borgens, R				Donaldson, J; Shi, R; Borgens, R			Polyethylene glycol rapidly in damaged sciatic restores physiological functions nerves of guinea pigs	NEUROSURGERY			English	Article						axon sealing; axotomy; nerve injury; neurotrauma; peripheral nerve; polyethylene glycol	SPINAL-CORD INJURY; MEMBRANE-FUSION; RECOVERY; NEURONS; REPAIR; DOGS	OBJECTIVE: We have studied the ability of the hydrophilic polymer polyethylene glycol (PEG) to anatomically and physiologically reconnect damaged axons of the adult guinea pig spinal cord. Here we have extended this approach to test whether completely severed guinea pig sciatic nerves in isolation could be fused and whether PEG was able to repair severe standardized crush injuries to sciatic nerves in vivo. METHODS: The fusion test was performed with isolated sciatic nerves maintained in a double-sucrose gap recording chamber. For in vivo experiments, the sciatic nerve was surgically exposed in the hind leg of deeply anesthetized adult guinea pigs and was crushed proximal to its insertion in the gastrocnemius muscle. PEG was injected just beneath the epineurium with a 29-gauge needle, allowed to remain in the damaged axon region for 2 minutes, and removed. Sham-treated guinea pigs received an injection of water or Krebs' solution. Three indices of recovery were simultaneously monitored in response to electrical stimulation of the proximal nerve, i.e., 1) recovery of compound muscle action potentials (in millivolts), 2) contraction force of the muscle (in dynes), and 3) displacement of the muscle (in millimeters). RESULTS: When isolated sciatic nerves were severed within the double-sucrose gap chamber, compound action potential propagation through the transection plane was eliminated. After abutment of the two segments and 2-minute PEG application to this site, variable compound action potential recovery was measured in all four cases. The crush injuries to the sciatic nerve in vivo eliminated the three functional responses to sciatic nerve stimulation in all animals. Within the first 30 minutes after treatment, only 1 of 12 control animals exhibited spontaneous recovery in any of these measures, compared with six of eight PEG-treated animals. By 45 minutes, two more sham-treated animals and one more PEG-treated animal had recovered at least one functional response. This difference in proportions between PEG-treated and sham-treated animals was statistically significant (P less than or equal to 0.02). CONCLUSION: We conclude that these preliminary data suggest that PEG application may be a way to interfere with the steady dissolution of peripheral nerve fibers after mechanical damage and to even functionally fuse or reconnect severed proximal and distal segments.	Purdue Univ, Ctr Paralysis Res, Sch Vet Med, Inst Appl Neurol, W Lafayette, IN 47907 USA; Indiana Univ, Sch Med, Div Neurosurg, Wishard Mem Hosp, Indianapolis, IN USA		Borgens, R (corresponding author), Purdue Univ, Ctr Paralysis Res, Sch Vet Med, Inst Appl Neurol, 1244 VCPR, W Lafayette, IN 47907 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 39288-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039288] Funding Source: NIH RePORTER		Bisby Mark A., 1995, P553; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 1999, J NEUROTRAUM, V16, P639, DOI 10.1089/neu.1999.16.639; BORGENS RB, 1993, RESTOR NEUROL NEUROS, V5, P305, DOI 10.3233/RNN-1993-55601; CARAFOLI E, 1985, SCI AM, V253, P70, DOI 10.1038/scientificamerican1185-70; Hannig J, 1999, INT J RADIAT BIOL, V75, P379, DOI 10.1080/095530099140555; Honmou Osamu, 1995, P480; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LENTZ BR, 1994, CHEM PHYS LIPIDS, V73, P91, DOI 10.1016/0009-3084(94)90176-7; Lucas JH, 1997, NEUROSCIENTIST, V3, P89; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Rosenberg LJ, 1996, BRAIN RES, V734, P349; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 1997, NEUROSCIENCE, V77, P553, DOI 10.1016/S0306-4522(96)00477-0; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	26	38	41	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2002	50	1					147	156		10.1097/00006123-200201000-00023			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	506AC	WOS:000172946900034	11844245				2022-02-06	
J	Weise, J; Isenmann, S; Bahr, M				Weise, J; Isenmann, S; Bahr, M			Increased expression and activation of poly(ADP-ribose) polymerase (PARP) contribute to retinal ganglion cell death following rat optic nerve transection	CELL DEATH AND DIFFERENTIATION			English	Article						PARP; retinal ganglion cell death; optic nerve transection; neuroprotection; 3-aminobenzamide; necrosis	NITRIC-OXIDE SYNTHASE; ISCHEMIA-REPERFUSION INJURY; IN-VIVO; NEUROTROPHIC FACTOR; ADULT-RATS; CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; NUCLEAR PROTEINS; FOCAL ISCHEMIA; UP-REGULATION	Excessive activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by free-radical damaged DNA mediates necrotic cell death in injury models of cerebral ischemia-reperfusion and excitotoxicity. We recently reported that secondary retinal ganglion cell (RGC) death following rat optic nerve (ON) transection is mainly apoptotic and can significantly but not entirely be blocked by caspase inhibition. In the present study, we demonstrate transient, RGC specific PARP activation and increased retinal PARP expression early after ON axotomy. In addition, intravitreal injections of 3-aminobenzamide blocked PARP activation in RGCs and resulted in an increased number of surviving RGCs when compared to control animals 14 days after ON transection. These data indicate that secondary degeneration of a subset of axotomized RGCs results from a necrotic-type cell death mediated by PARP activation and increased PARP expression. Furthermore, PARP inhibition may constitute a relevant strategy for clinical treatment of traumatic brain injury.	Univ Gottingen, Sch Med, Dept Neurol, D-37075 Gottingen, Germany; Univ Tubingen, Dept Neurol, Sch Med, D-72076 Tubingen, Germany		Weise, J (corresponding author), Univ Gottingen, Sch Med, Dept Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany.		Baehr, Mathias/K-2188-2014; Isenmann, Stefan/AAJ-3788-2020				BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Chatterjee PK, 2000, FASEB J, V14, P641, DOI 10.1096/fasebj.14.5.641; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/0006-8993(96)00571-9; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; ESCHWEILER GW, 1993, J NEUROL SCI, V116, P34, DOI 10.1016/0022-510X(93)90086-E; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; IKAI K, 1980, J HISTOCHEM CYTOCHEM, V28, P670, DOI 10.1177/28.7.6993553; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Kermer P, 1999, EXP NEUROL, V158, P202, DOI 10.1006/exnr.1999.7094; Kermer P, 1999, FEBS LETT, V453, P361, DOI 10.1016/S0014-5793(99)00747-4; Kermer P, 1998, J NEUROSCI, V18, P4656; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; Klocker N, 1999, J NEUROSCI, V19, P8517; Klocker N, 2000, J NEUROSCI, V20, P6962, DOI 10.1523/JNEUROSCI.20-18-06962.2000; Kreutz MR, 1998, J NEUROSCI, V18, P8278; LAMM TT, 1997, RES COMMUN MOL PATH, V95, P241; Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; RusselakisCarneiro M, 1996, J NEUROCYTOL, V25, P393, DOI 10.1007/BF02284810; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Wagenknecht B, 1998, CELL DEATH DIFFER, V5, P894, DOI 10.1038/sj.cdd.4400435; Walisser JA, 1999, EXP CELL RES, V251, P401, DOI 10.1006/excr.1999.4589; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	49	38	42	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	1350-9047			CELL DEATH DIFFER	Cell Death Differ.	AUG	2001	8	8					801	807		10.1038/sj.cdd.4400872			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	454YN	WOS:000169999500005	11526433	Bronze			2022-02-06	
J	Jury, MA; Flynn, MC				Jury, MA; Flynn, MC			Auditory and vestibular sequelae to traumatic brain injury: a pilot study	NEW ZEALAND MEDICAL JOURNAL			English	Article							HEAD-INJURY; HEARING-LOSS	Aim. To investigate the incidence of persisting auditory and vestibular sequelae in a group of 30 young adults recovering from Traumatic Brain Injury (TBI). Methods. 30 participants, aged 21-45 years, with TBI suffered 19 months to 27 years previously, underwent a semi-structured interview and pure-tone hearing test in their home. Participants who failed the hearing screen then undertook a more comprehensive audiological evaluation. Results. A variety of sequelae to TBI were reported. These were interpreted as tinnitus (53%), vestibular dysfunction (83%), abnormal facial sensory symptoms (27%) and intolerance to loud/sudden noises (87%). Ten (33%) participants demonstrated significant sensorineural hearing impairment in addition to speech recognition performance significantly worse than would have been predicted from their hearing impairment. Conclusions. Findings from this study will be of benefit to health professionals working in this area of rehabilitation as they seek to provide functional assessments and devise programmes to treat the often devastating auditory processing problems of people recovering from TBI.	Univ Canterbury, Dept Speech & Language Therapy, Christchurch 1, New Zealand		Flynn, MC (corresponding author), Univ Canterbury, Dept Speech & Language Therapy, Private Bag 4800, Christchurch 1, New Zealand.			Flynn, Mark/0000-0002-6162-9510			AGUILAR EA, 1986, ARCH OTOLARYNGOL, V94, P211; ASHA (American Speech-Language-Hearing Association), 1990, ASHA S2, V32, P17; Barnfield TV, 1998, BRAIN INJURY, V12, P951, DOI 10.1080/026990598122007; Beukelman D., 1991, COMMUNICATION DISORD, P1; Ceranic BJ, 1998, J NEUROL NEUROSUR PS, V65, P523, DOI 10.1136/jnnp.65.4.523; COCKRELL J L, 1992, Brain Injury, V6, P261, DOI 10.3109/02699059209029667; LARKINS B, 1998, TRAUMATIC BRAIN INJU; Lubinski R, 1997, BRAIN INJURY, V11, P103, DOI 10.1080/026990597123692; LYOS AT, 1995, ARCH OTOLARYNGOL, V121, P795; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; PODOSHIN L, 1975, ARCH OTOLARYNGOL, V101, P15; VARTIAINEN E, 1985, ACTA OTO-LARYNGOL, V99, P529, DOI 10.3109/00016488509182257; WILSON D, 1998, HEARING IMPAIRMENT A	13	38	40	0	4	SOUTHERN COLOUR PRINT	DUNEDIN	PO BOX 920, DUNEDIN, NEW ZEALAND	0028-8446			NEW ZEAL MED J	N. Z. Med. J.	JUN 22	2001	114	1134					286	288					3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447BC	WOS:000169547800004	11480511				2022-02-06	
J	Feeney, TJ; Ylvisaker, M; Rosen, BH; Greene, P				Feeney, TJ; Ylvisaker, M; Rosen, BH; Greene, P			Community supports for individuals with challenging behavior after brain injury: An analysis of the New York State Behavioral Resource Project	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavioral challenges; behavior disorders; behavior impairment; cost-benefit analysis; HCBS-TBI Waiver; positive person-centered behavioral supports		Objective: To articulate a framework for supporting individuals with behavioral challenges following brain injury. to describe a state-funded clinical intervention program established to provide community support to individuals with challenging behaviors following brain injury using such a framework, to present data from which it can be concluded that such a program is cost-effective. and to offer policy recommendations. Design: Retrospective analysis of cost data and living arrangements for individuals with behavioral challenges served for a period of 3-4 years through the New York State Home and Community-Based Services Traumatic Brain Injury (HCBS-TBI) Waiver program and the State Behavioral Resource Project. Subjects: 80 individuals with TBI and severe behavioral challenges that included criminal behavior, physical threats, assault and physical aggression, sexually inappropriate behavior. substance abuse, refusal to participate in intervention programs, and psychiatric disturbances, all of whom were at least 2 years postinjury ((X) over bar = 7.33 years postinjury). Results: The majority of individuals (82% of the 1996 cohort; 89% of the 1997 cohort) with challenging behaviors were living successfully in their home communities 3-4 years after the initiation of behavioral supports. In addition, the costs of serving these individuals decreased in the first year of community integration and for that last year that a cost analysis was completed. Conclusions: Many individuals with behavioral impairments can be supported successfully in community settings, so long as those supports are flexibly implemented to meet the changing needs of those individuals. Moreover, even with intensive supports, it is cost-effective to serve this population in the community.	Wildwood Traumat Brain Injury Behav Resource Proj, Schenectady, NY USA; Coll St Rose, Albany, NY USA; New York State Dept Hlth, Off Continuing Care, Delmar, NY USA		Feeney, TJ (corresponding author), Wildwood Inst, 219 Liberty St, Schenectady, NY 12305 USA.	tfeeney@wildwood.edu					ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Anderson, 1989, TRANSFER COGNITIVE S; BAER D, 1981, PLAN GEN; BASSUK EL, 1984, AM J PSYCHIAT, V141, P1546; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Carr E. G., 1999, POSITIVE BEHAV SUPPO; Damasio A., 1994, DESCARTES ERROR EMOT; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Fairweather G.W, 1969, COMMUNITY LIFE MENTA; FEENEY T, 1997, STUDENTS ACQUIRED BR, P229; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; GARCIA J, 1994, REHABIL ED, V8, P259; HAMMELL KRW, 1994, INT J REHABIL RES, V17, P319; Levine B, 2000, MEMORY, CONSCIOUSNESS, AND THE BRAIN, P200; Levine B, 1999, NEUROCASE, V5, P263, DOI 10.1080/13554799908402731; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MITCHLEY N, 1996, CLIN REHABIL, V10, P3; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; SIERT L, 2000, BRAIN INJ SOURCE, V4, P24; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; Vygotsky LS., 1978, MIND SOC DEV HIGHER; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; Ylvisaker M., 1999, CLIN PRACTICE MANAGE, P117; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, P429; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, IN PRESS LANGUAGE IN; Ylvisaker M., 2000, BRAIN IMPAIR, V1, P12, DOI [DOI 10.1375/BRIM.1.1.12, 10.1375/brim.1.1.12]; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P271; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100; [No title captured], DOI DOI 10.1097/00001199-198812000-00004; [No title captured]	32	38	41	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2001	16	1					61	75		10.1097/00001199-200102000-00008			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	403ZC	WOS:000167072100010	11277851				2022-02-06	
J	Davey, NJ; Nowicky, AV; Zaman, R				Davey, NJ; Nowicky, AV; Zaman, R			Somatotopy of perceptual threshold to cutaneous electrical stimulation in man	EXPERIMENTAL PHYSIOLOGY			English	Article							2-POINT DISCRIMINATION; NEUROPATHY	Neurological testing tools for measuring and monitoring somatosensory function lack resolution and are often dependent on the clinician testing. In this study we have measured perceptual threshold (PT) to electrical stimulation of the skin and compared it with two-point discriminative ability (TPDA) in 12 control subjects. Tests were made on both sides of the body at American Spinal Injury Association (ASIA) key points on seven spinal dermatomes (C3 (neck), C4 (shoulder), C5 (upper arm), C6 (thumb), T8 (abdomen), L3 (knee), L5 (foot)) and in the mandibular (chin) and maxillary (cheek) fields of the trigeminal (V) nerve. Electrical stimulation (0.5 ms pulse width; 3 Hz) was applied via a self-adhesive cathode and an anode strapped to the wrist or ankle. The stimulus intensity was adjusted and PT was recorded as the lowest current at which the subject reported sensation. Sites were tested in random order. Indices for both TPDA and PT differed according to the dermatome tested but there was no correlation between TPDA and PT for any dermatome. There was good correlation between results from equivalent dermatomes on left and right sides for both PT and TPDA. Women frequently had lower mean (+/- S.E.) PTs and better TPDA than men; differences were significant (P < 0.05) for PT on the knee (women, 1.31 +/- 0.15 mA; men, 2.05 +/- 0.26 mA) and the foot (women, 2.90 +/- 0.19 mA; men, 4.13 +/- 0.28 mA) and for TPDA on the thumb (women, 3.8 +/- 0.2 mm; men, 7.8 +/- 1.3 mm) and the knee (women, 17.8 +/- 1.6 mm; men, 27.1 +/- 4.0 mm). Four subjects repeated the experiment on another day and the results correlated well with the first test for PT (r(2), 0.62) and TPDA (r(2), 0.48). PT differs between dermatomes in a predictable way but does not relate to TPDA. PT is easy to measure and may be a useful assessment tool with which to monitor recovery or deterioration in neuropathies, neurotrauma or after surgery.	Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England; Brunel Univ, Dept Sport Sci, London TW7 5DU, England		Davey, NJ (corresponding author), Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England.		Nowicky, Alexander/AAI-7299-2020	Nowicky, Alexander/0000-0001-8955-4349			Aszmann OC, 1998, J RECONSTR MICROSURG, V14, P417, DOI 10.1055/s-2007-1000202; Chu NS, 1996, MUSCLE NERVE, V19, P183, DOI 10.1002/(SICI)1097-4598(199602)19:2<183::AID-MUS9>3.0.CO;2-A; DELLON AL, 1987, J HAND SURG-AM, V12A, P693, DOI 10.1016/S0363-5023(87)80049-7; DONAGHUE VM, 1995, DIABETES RES CLIN PR, V29, P37, DOI 10.1016/0168-8227(95)01107-O; IRNICH W, 1989, BIOMED TECH, V34, P207, DOI 10.1515/bmte.1989.34.9.207; Kozarski J, 1999, Vojnosanit Pregl, V56, P599; Lincoln N.B., 1991, CLIN REHABIL, V5, P273, DOI [DOI 10.1177/026921559100500403, 10.1177/026921559100500403]; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; MERCHUT M P, 1990, Electromyography and Clinical Neurophysiology, V30, P293; PITEI DL, 1994, DIABETIC MED, V11, P872, DOI 10.1111/j.1464-5491.1994.tb00371.x; RENDELL MS, 1989, DIABETES CARE, V12, P636, DOI 10.2337/diacare.12.9.636; SHIMOKATA H, 1995, GERONTOLOGY, V41, P267; Takekuma K, 2000, J Epidemiol, V10, pS33; Zamyslowska-Szmytke Ewa, 1995, Medycyna Pracy, V46, P47	14	38	39	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0958-0670			EXP PHYSIOL	Exp. Physiol.	JAN	2001	86	1					127	130		10.1113/eph8602086			4	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	401EJ	WOS:000166914100016	11434326	Bronze			2022-02-06	
J	Mazzini, L; Zaccala, M; Gareri, F; Giordano, A; Angelino, E				Mazzini, L; Zaccala, M; Gareri, F; Giordano, A; Angelino, E			Long-latency auditory-evoked potentials in severe traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						auditory; brain injuries; evoked potentials; rehabilitation	EVENT-RELATED POTENTIALS; HEAD-INJURY; ODDBALL PARADIGM; RATING-SCALE; COMA; STIMULI; P300; COMPONENTS; RESPONSES; EMERGENCE	Objective: To detect the effects of different deviant stimuli on long-latency auditory-evoked potentials (LLAEPs) in patients with severe impairment of consciousness from traumatic brain injury (TBI) and to define their prognostic value for late functional outcome. Design: Correlational study on a prospective cohort. Setting: Brain injury rehabilitation center, Patients: Eleven volunteers and 21 consecutively sampled patients with severe TBI referred to the inpatient intensive rehabilitation unit of primary care in a university-based system. Main Outcome Measures: The LLAEPs recorded with different paradigms; and the Glasgow Outcome Scale (GOS), Disability Rating Scale (DRS), FIM(TM) instrument, and Neurobehavioural Rating Scale (NBHRS). Results: N100-P150 complex showed high reliability. Patients with good outcomes showed N100 and P150 mean latencies similar to those of unimpaired patients and shorter than patients with unfavorable outcomes. When the deviant stimulus was the patient's name, N100 latency showed high correlations with DRS (p <.007), FIM (p <.01), and NBHRS (p <.009). P250 and P300 showed a low percentage of occurrence with passive paradigms in both patients and controls. Their scores were inversely correlated to the Glasgow Coma Scale (p <.03) and the Innsbruck Coma Scale (p <.003), but no significant correlations were found with functional and behavioral outcomes. Patients with COS score 1-2 1 year posttrauma had significantly longer latency and lower amplitude of N100 and P150 than those with GOS score 4-5. Conclusions: LLAEPs can be recorded in patients with severe impairment of consciousness by means of passive paradigms, The use of a stimulus that is relevant for the patient can enhance the accuracy of the test and its relationship with functional outcome.	IRCCS, Fdn Salvatore Maugeri, Ctr Med Veruno, Dept Neurol Rehabil,Med Ctr Rehabil, I-28010 Veruno, NO, Italy; IRCCS, Fdn Salvatore Maugeri, Bioengn Serv, Med Ctr Rehabil, I-28010 Veruno, NO, Italy; IRCCS, Fdn Salvatore Maugeri, Psychol Serv, Med Ctr Rehabil, I-28010 Veruno, NO, Italy		Mazzini, L (corresponding author), IRCCS, Fdn Salvatore Maugeri, Ctr Med Veruno, Dept Neurol Rehabil,Med Ctr Rehabil, I-28010 Veruno, NO, Italy.	lmazzini@fsm.it	Mazzini, Letizia/AAA-2262-2021; Giordano, Andrea/E-8442-2019	Mazzini, Letizia/0000-0003-2479-9120; Giordano, Andrea/0000-0002-6051-0067			ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BARNES MP, 1991, CURR OPIN NEUROL NEU, V4, P12; BASTUJI H, 1995, J CLIN NEUROPHYSIOL, V12, P155, DOI 10.1097/00004691-199503000-00006; BENZER A, 1991, LANCET, V338, P977, DOI 10.1016/0140-6736(91)91840-Q; BERLAD I, 1995, EVOKED POTENTIAL, V96, P472, DOI 10.1016/0168-5597(95)00116-A; Boutros N, 1997, PSYCHIAT RES, V69, P183, DOI 10.1016/S0165-1781(96)02919-8; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; DOEBRICH HM, 1986, SURG NEUROL, V26, P112; FARWELL LA, 1991, PSYCHOPHYSIOLOGY, V28, P531, DOI 10.1111/j.1469-8986.1991.tb01990.x; FRUHSTOR.H, 1969, ELECTROEN CLIN NEURO, V27, P346, DOI 10.1016/0013-4694(69)91443-6; GARCIALARREA L, 1992, NEUROPSYCHOLOGIA, V30, P723, DOI 10.1016/0028-3932(92)90042-K; GOODIN DS, 1978, BRAIN, V101, P635, DOI 10.1093/brain/101.4.635; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GREENBERG RP, 1982, J NEUROSURG, V56, P1, DOI 10.3171/jns.1982.56.1.0001; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; HEGERL U, 1993, BIOL PSYCHIAT, V33, P173, DOI 10.1016/0006-3223(93)90137-3; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; KEVANISHVILI ZS, 1979, ELECTROEN CLIN NEURO, V47, P280, DOI 10.1016/0013-4694(79)90280-3; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, TRAUMATIC BRAIN INJU, V2, P53; Mazzini L, 1999, ARCH PHYS MED REHAB, V80, P33, DOI 10.1016/S0003-9993(99)90304-0; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Nordby H, 1996, NEUROREPORT, V7, P1082, DOI 10.1097/00001756-199604100-00026; PFEFFERBAUM A, 1990, ELECTROEN CLIN NEURO, V76, P6, DOI 10.1016/0013-4694(90)90052-L; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; PICTON TW, 1974, ELECTROEN CLIN NEURO, V36, P179, DOI 10.1016/0013-4694(74)90155-2; POLICH J, 1989, ELECTROEN CLIN NEURO, V74, P312, DOI 10.1016/0168-5597(89)90061-0; POLICH J, 1987, ELECTROENCEPHALOGR C, V63, P311; por Chapman y Hall/CRC, 1990, PRACTICAL STAT MED R; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROTH WT, 1973, PSYCHOPHYSIOLOGY, V10, P125, DOI 10.1111/j.1469-8986.1973.tb01097.x; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUMPL E, 1988, J CLIN NEUROPHYSIOL, V5, P237, DOI 10.1097/00004691-198807000-00002; Starr A, 1988, HDB ELECTROENCEPHALO, P97; TEASDALE G, 1974, LANCET, V2, P81; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; WOODS DL, 1980, SCIENCE, V207, P655, DOI 10.1126/science.7352278; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O	42	38	43	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2001	82	1					57	65		10.1053/apmr.2001.18076			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	389WY	WOS:000166262700010	11239287				2022-02-06	
J	Ricker, JH; Muller, RA; Zafonte, RD; Black, KM; Millis, SR; Chugani, H				Ricker, JH; Muller, RA; Zafonte, RD; Black, KM; Millis, SR; Chugani, H			Verbal recall and recognition following traumatic brain injury: A [O-15]-water positron emission tomography study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CROSSED CEREBELLAR DIASCHISIS; CLOSED HEAD-INJURY; FUNCTIONAL NEUROANATOMY; LEARNING TEST; GLUCOSE-METABOLISM; PREFRONTAL CORTEX; EPISODIC MEMORY; PET IMAGES; SHORT-TERM; PERFORMANCE	Although several studies exist which have examined static functional neuroimaging following traumatic brain injury (TBI), controlled cognitive activation studies of episodic memory in this population have not been published. The present investigation studied verbal recall using [O-15]-water positron emission tomography (PET) in 5 individuals who sustained severe TBI (M GCS = 6.8; M years post-injury = 3.18), and 4 non-injured control participants. Statistical image analysis demonstrated changes in frontoparietal regional cerebral blood flow (rCBF) in both groups, but there were interesting differences between groups and across conditions. Frontal lobe rCBF changes in TBI patients were reduced during free recall but enhanced during recognition, when compared to controls. Changes in cerebellar rCBF were observed in the control group during free recall, but not in the TBI sample. In both groups, bifrontal rCBF increases were noted on recognition tasks. The present findings provide evidence of alterations in specific substrates involved in verbal recall following brain injury.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Univ Calif San Diego, Dept Cognit Sci, San Diego, CA 92103 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, MI USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Kessler Med Rehabil Res & Educ Corp, Dept Res, W Orange, NJ USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI USA		Ricker, JH (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	jricker@kmrrec.org		Ricker, Joseph/0000-0003-3415-991X			Alavi A, 1997, J NUCL MED, V38, P1717; ANDREASEN NC, 1995, P NATL ACAD SCI USA, V92, P5111, DOI 10.1073/pnas.92.11.5111; BARON JC, 1995, REV NEUROL, V151, P511; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 1997, J COGNITIVE NEUROSCI, V9, P254, DOI 10.1162/jocn.1997.9.2.254; Catalan MJ, 1998, BRAIN, V121, P253, DOI 10.1093/brain/121.2.253; CHERTKOW H, 1994, FUNCTIONAL ACTIVATIO; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; DELUCA J, IN PRESS ARCH PHYSIC; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Eisenberg H.M., 1989, MILD HEAD INJURY, P133; Fiez JA, 1996, J NEUROSCI, V16, P808; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; KAPUR S, 1995, NEUROREPORT, V6, P1880, DOI 10.1097/00001756-199510020-00014; Keenan PA, 1996, CLIN NEUROPSYCHOL, V10, P455, DOI 10.1080/13854049608406706; KERTESZ A, LOCALIZATION NEUROIM, P151; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS., 1982, NEUROBEHAVIORAL CONS; METTER EJ, 1987, NEUROLOGY, V37, P1599, DOI 10.1212/WNL.37.10.1599; Millis Scott R., 1993, Brain Injury, V7, P53, DOI 10.3109/02699059309008156; MILLIS SR, 1995, BRAIN INJURY, V9, P509, DOI 10.3109/02699059509008210; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; MINOSHIMA S, 1993, INT CONGR SER, V1030, P409; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Mottaghy FM, 1999, EXP BRAIN RES, V128, P332, DOI 10.1007/s002210050853; Nolde SF, 1998, NEUROREPORT, V9, P3509, DOI 10.1097/00001756-199810260-00032; PANTANO P, 1986, BRAIN, V109, P677, DOI 10.1093/brain/109.4.677; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; Roland Per E, 1993, BRAIN ACTIVATION; ROSENTHAL M, 2000, HDB REHABILITATION P, pCH26; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schmahmann JD, 1997, INT REV NEUROBIOL, V41, P31, DOI 10.1016/S0074-7742(08)60346-3; Seidman LJ, 1998, NEUROPSYCHOLOGY, V12, P505, DOI 10.1037/0894-4105.12.4.505; Talairach J., 1988, COPLANAR STEREOTAXIC; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Woodard JL, 1998, NEUROPSYCHOLOGY, V12, P491, DOI 10.1037/0894-4105.12.4.491; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZAFONTE RD, 1996, MED REHABILITATION T, P251; [No title captured]	54	38	38	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	2					196	206		10.1076/jcen.23.2.196.1204			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	412QZ	WOS:000167567000006	11309673				2022-02-06	
J	Stover, JF; Unterberg, AW				Stover, JF; Unterberg, AW			Increased cerebrospinal fluid glutamate and taurine concentrations are associated with traumatic brain edema formation in rats	BRAIN RESEARCH			English	Article						amino acid; cell swelling; controlled cortical impact injury; excitotoxicity; high-performance liquid chromatography; volume-regulation	EXCITATORY AMINO-ACIDS; CORTICAL EXTRACELLULAR LEVELS; HIPPOCAMPAL SLICES; CONTUSION TRAUMA; CEREBRAL-CORTEX; IMPACT INJURY; RELEASE; BARRIER; ASTROCYTES; DISRUPTION	Glutamate-mediated excitotoxicity results in cell swelling and contributes to brain edema formation. Since increased extracellular taurine reflects glutamate-induced cell swelling in vitro, elevated CSF taurine could therefore unmask glutamate-mediated cytotoxic edema formation under in vivo conditions. For this, the temporal profile of brain edema and changes in cisternal CSF glutamate and taurine levels were determined in 28 rats following focal traumatic brain injury. Compared to six non-traumatized rats, CSF glutamate (4.8+/-0.3 vs. 10+/-0.9 mu M) and taurine levels (12+/-1.3 vs. 41+/-3 mu M) were significantly increased at 8 h after trauma (P<0.001). Over time, CSF glutamate and taurine were significantly increased by 24 (glutamate: 38+/-4.4 mu M) and 48 h (taurine: 51+/-4 mu M), respectively. While CSF glutamate closely reflected changes in hemispheric water content, alterations in CSF taurine occurred diametrically to those seen for glutamate. Under the present study design, increased CSF taurine could reflect glutamate-induced cell swelling. In addition, neuronal release of taurine with its inhibitory and antiexcitotoxic functions could explain the observed diametric changes in CSF glutamate, CSF taurine, and hemispheric water content. Therefore, increasing taurine could be a therapeutic approach in attenuating post-traumatic glutamate-mediated cell damage. (C) 2000 Elsevier Science B,V. All rights reserved.	Charite Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany		Stover, JF (corresponding author), Charite Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl 01, D-13353 Berlin, Germany.	john.stover@charite.de					Baskaya MK, 1997, NEUROSCI LETT, V226, P33; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DUTTON GR, 1991, ANN NY ACAD SCI, V633, P489; French E D, 1986, Adv Exp Med Biol, V203, P349; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HOLOPAINEN I, 1989, NEUROSCIENCE, V29, P425, DOI 10.1016/0306-4522(89)90069-9; KAMISAKI Y, 1993, BRAIN RES, V627, P181; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1992, BRAIN RES, V577, P121, DOI 10.1016/0006-8993(92)90544-J; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; KURIYAMA K, 1980, FED PROC, V39, P2680; MADL JE, 1993, J NEUROSCI, V13, P4429; MAGNUSSON KR, 1991, BRAIN RES, V549, P1, DOI 10.1016/0006-8993(91)90592-J; Mayhan WG, 1996, STROKE, V27, P965, DOI 10.1161/01.STR.27.5.965; MENENDEZ N, 1989, NEUROSCI LETT, V102, P64, DOI 10.1016/0304-3940(89)90308-X; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OJA SS, 1983, ACTA NEUROL SCAND, V67, P5; OKAMOTO K, 1983, BRAIN RES, V265, P163, DOI 10.1016/0006-8993(83)91350-1; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PASANTESMORALES H, 1990, GLIA, V3, P427, DOI 10.1002/glia.440030514; Saransaari P, 1999, NEUROSCIENCE, V94, P949, DOI 10.1016/S0306-4522(99)00384-X; SARANSAARI P, 1991, NEUROSCIENCE, V45, P451, DOI 10.1016/0306-4522(91)90240-O; SCHNEIDER GH, 1992, CAN J PHYSIOL PHARM, V70, pS334, DOI 10.1139/y92-280; SCHOUSBOE A, 1992, CAN J PHYSIOL PHARM, V70, pS356, DOI 10.1139/y92-283; SCHURR A, 1987, LIFE SCI, V40, P2059, DOI 10.1016/0024-3205(87)90098-1; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Stroop R, 1998, ACT NEUR S, V71, P303; TABER KH, 1986, BRAIN RES, V386, P113, DOI 10.1016/0006-8993(86)90147-2; VOLTERRA A, 1994, MOL PHARMACOL, V46, P986; ZUCCARELLO M, 1993, J NEUROTRAUM, V10, P397, DOI 10.1089/neu.1993.10.397	38	38	38	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 1	2000	875	1-2					51	55		10.1016/S0006-8993(00)02597-X			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	352DM	WOS:000089199300006	10967298				2022-02-06	
J	McColl, MA; Bickenbach, J; Johnston, J; Nishihama, S; Schumaker, M; Smith, K; Smith, M; Yealland, B				McColl, MA; Bickenbach, J; Johnston, J; Nishihama, S; Schumaker, M; Smith, K; Smith, M; Yealland, B			Changes in spiritual beliefs after traumatic disability	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						disability; spirituality; life change events; rehabilitation	HEALTH; NEEDS; SURVIVORS; CANCER; PEOPLE; SELF	Objectives: To discover the effect of sudden-onset disability on spirituality, specifically, to investigate changes following the onset of disability in spiritual concepts and to outline a theoretical framework consisting of relationships with the self, others, the world, and a supreme power. Study Design: The study used a cross-sectional, qualitative approach to understand changes in spirituality from the perspective of the disabled person. Intensive semistructured interviews were conducted with 16 participants, each of whom had either a spinal cord injury or brain injury, within the 2-year period after discharge from rehabilitation. Changes in spiritual concepts were explored in relation to 3 types of relationships (intrapersonal, interpersonal, and transpersonal) and 5 themes (awareness, closeness, trust, purpose, and vulnerability). Results: Specific changes in spirituality described by sample members were: greater awareness of the self; a change in their view of their own independence; a sense of purpose in life that was not present before the onset of the disability; greater awareness of their own mortality and vulnerability; a new understanding of trust, especially when depending on others; loss of some significant relationships; greater appreciation and closeness with others and the world; and greater understanding of other disadvantaged groups. Conclusions: The interviews portrayed a significant ability to conceptualize issues in a spiritual context in the 2-year period after discharge from rehabilitation. Further, the changes reported suggest a positive effect of spirituality in the adjustment period following onset.	Queens Univ, Sch Rehabil Therapy, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Philosophy, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Theol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Rehabil Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Chaplaincy, Kingston, ON K7L 3N6, Canada; Reg Community Brain Injury Serv, Kingston, ON, Canada		McColl, MA (corresponding author), Queens Univ, Sch Rehabil Therapy, Kingston, ON K7L 3N6, Canada.						ANDERSON JM, 1993, ARCH PHYS MED REHAB, V74, P574, DOI 10.1016/0003-9993(93)90154-3; Berggren-Thomas P, 1995, J Gerontol Nurs, V21, P5; Bowers C C, 1987, Rehabil Nurs, V12, P90; CARSON V, 1988, J PSYCHOL THEOL, V16, P159, DOI 10.1177/009164718801600205; CONDELUCI A, 1991, INTERDEPENDENCE ROUT; DIMATTEO MR, 1981, SOCIAL NETWORKS SOCI, P117; Elsdon R, 1995, Prof Nurse, V10, P641; Erikson E. H., 1963, CHILDHOOD SOC; FINE SB, 1991, AM J OCCUP THER, V45, P493, DOI 10.5014/ajot.45.6.493; Fitzgerald J, 1997, DISABIL REHABIL, V19, P407, DOI 10.3109/09638289709166565; Fowler J, 1981, STAGES FAITH; FOWLER JW, 1985, LIFE MAPS, P94; Frankl V., 1984, MANS SEARCH MEANING; FRAZEE C, 1999, INTRO DISABILITY HAN, P59; HALSTEAD MT, 1994, CANCER NURS, V17, P94; Herth K A, 1989, Oncol Nurs Forum, V16, P67; Horsburgh M, 1997, DISABIL REHABIL, V19, P398, DOI 10.3109/09638289709166564; JOHNSON SC, 1991, J RELIG HEALTH, V30, P21, DOI 10.1007/BF00986676; Lindsey E, 1996, J ADV NURS, V24, P465, DOI 10.1046/j.1365-2648.1996.02135.x; MCCOLL MA, 1994, PARAPLEGIA, V32, P261, DOI 10.1038/sc.1994.46; MCCOLL MA, 1995, PHYSIOTHERAPY OLDER; MCCOLL MA, IN PRESS DISABIL REH; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; REED PG, 1992, RES NURS HEALTH, V15, P349, DOI 10.1002/nur.4770150505; Robinson A, 1994, Holist Nurs Pract, V8, P1; ROSS L, 1995, INT J NURS STUD, V32, P457, DOI 10.1016/0020-7489(95)00007-K; SCHMIDT KH, 1988, STUDIA CELTICA JAPON, V1, P1; Schuetz B, 1995, Aust Fam Physician, V24, P775; Selway D, 1998, DISABIL SOC, V13, P429, DOI 10.1080/09687599826722; SMITH DW, 1995, NURS SCI QUART, V8, P133, DOI 10.1177/089431849500800309; SOEKEN KL, 1987, NURS CLIN N AM, V22, P603; Walter T, 1997, PALLIATIVE MED, V11, P21, DOI 10.1177/026921639701100103; Watkins E, 1997, J SUBST ABUSE TREAT, V14, P581, DOI 10.1016/S0740-5472(97)00138-4; Young C, 1993, Geriatr Nurs, V14, P298, DOI 10.1016/S0197-4572(06)80054-6; Young E W, 1984, J Am Coll Health, V32, P273	35	38	38	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2000	81	6					817	823		10.1016/S0003-9993(00)90117-5			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	320EN	WOS:000087389000023	10857530				2022-02-06	
J	Whyte, J; Schuster, K; Polansky, M; Adams, J; Coslett, HB				Whyte, J; Schuster, K; Polansky, M; Adams, J; Coslett, HB			Frequency and duration of inattentive behavior after traumatic brain injury: Effects of distraction, task, and practice	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain injuries; attention; distraction	CLOSED-HEAD-INJURY; ATTENTION; AROUSAL; SCALE; COMA	Traumatic brain injury (TBI) is associated with impairments of attention, most typically measured through tests of information processing, or by subjective symptom endorsement by patients, families, and clinicians. We have previously shown increased rates of off-task behavior among patients with TBI versus controls as defined by videotaped records of independent work in distracting environments. In this research, we report on a more detailed method of coding such videotaped records which allows measurement of the precise number of off-task behaviors, their durations, and their relationship to distracting events. Using this method, we studied 20 patients with recent moderate-to-severe TBI and 20 demographically comparable controls as they performed independent work tasks while being subjected to controlled distracting events. This research confirms that patients are markedly less attentive than controls both in the presence of distractions and in their absence, that distractions have an influence on off-task behavior in both groups, and that the disruptive impact of distracters wanes relatively quickly for controls but not for patients. The duration of distraction produced by various classes of distracting events appeared similar for patients and controls, although the power to detect differences in behavioral duration between groups was limited. The pattern of inattentiveness among patients showed minimal relationship to measures of injury severity within this sample.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Temple Univ, Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA; Allegheny Univ Hlth Sci, Sch Publ Hlth, Philadelphia, PA 19102 USA; Drexel Univ, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Dept Neurol, Philadelphia, PA 19122 USA		Whyte, J (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS027715] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS27715] Funding Source: Medline		AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; LEVIN HS, 1989, COMPREHENSIVE NEUROL, V2, P53; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schmidt H. L., 1992, SENSORS COMPREHENSIV, V3, P717; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; TEASDALE G, 1974, LANCET, V2, P81; *TRIANGL RES COLL, 1995, OBS COD SYST TOOLS V; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; Whyte J, 1997, NEUROPSYCHOLOGIA, V35, P313, DOI 10.1016/S0028-3932(96)00092-9; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WHYTE J, 1994, AM J PHYS MED REHAB, V73, P2; WHYTE J, 1998, REHABILITATION MED P, P1191	20	38	38	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2000	6	1					1	11		10.1017/S1355617700611013			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	276KD	WOS:000084876200001	10761362				2022-02-06	
J	Chapman, EH; Weintraub, RJ; Milburn, MA; Pirozzi, TO; Woo, E				Chapman, EH; Weintraub, RJ; Milburn, MA; Pirozzi, TO; Woo, E			Homeopathic treatment of mild traumatic brain injury: A randomized, double-blind, placebo-controlled clinical trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							MINOR HEAD-INJURY; UNITED-STATES; MEDICINE; METAANALYSIS	Bachground: Mild traumatic brain injury (MTBI) affects 750,000 persons in the United States annually Five to fifteen percent have persistent dysfunction and disability. No effective, standard pharmacological treatment exists specifically for this problem. We designed a pilot research project to study the clinical effectiveness of homeopathic medicine in the treatment of persistent MTBI. Method: A randomized, double-blind, placebo-controlled trial of GO patients, with a four-month follow-up (N = 50), was conducted at Spaulding Rehabilitation Hospital (SRH). Patients with persistent MTBI (mean 2.93 years since injury, SD 3.1) were randomly assigned to receive a homeopathic medicine or placebo. The primary outcome measure was the subject-rated SRH-MBTI Functional Assessment, composed of three subtests: a Difficulty with Situations Scale (DSS), a Symptom Rating Scale (SRS), and a Participation in Daily Activities Scale (PDAS). The SRH Cognitive-Linguistic Test Battery was used as the secondary measure. Results: Analysis of covariance demonstrated that the homeopathic treatment was the only significant or near-significant predictor of improvement on DSS subtests (P = .009; 95% CI -.895 to -.15), SRS (P = .058; 95% CI -.548 to .01) and the Ten Most Common Symptoms of MTBI (P = .027; 35% CI -.766 to -.048). These results indicate a significant improvement from the homeopathic treatment versus the control and translate into clinically significant outcomes. Conclusions: This study suggests that homeopathy may have a role in treating persistent,MTBI. Our findings require large-scale, independent replication.	Harvard Univ, Sch Med, Boston, MA USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA; Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA		Chapman, EH (corresponding author), 91 Cornell St, Newton, MA 02462 USA.						ALVES W, 1993, J HEAT TRAUMA REHABI, V8, P13; BOISSEL JP, 1996, REPORT HOMEOPATHIC M; BONAVIDA B, 1997, P 1 INT S PHYS CHEM, P4; CHAPMAN E, 1992, J AM I HOMEOPATHY, V83, P74; CHIPKIN P, 1990, P 1990 PROF CAS C SE, P87; Cohen J, 1977, STAT POWER ANAL BEHA; Committee on Mild Traumatic Brain Injury American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DANTES F, 1996, P 51 C LMHI, P335; Davidson J R, 1997, Altern Ther Health Med, V3, P46; DIEM K, 1970, DOCUMENTA GEIGY SCI, P31; DIKMEN SS, 1989, MILD HEAD INJURY, P229; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 1996, ARCH INTERN MED, V156, P2162, DOI 10.1001/archinte.156.19.2162; FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall DM, 1974, PSYCHOL EFFECTS CONS; HAHNEMANN S, 1996, ORGONON MED ART, P171; HAYES R, 1948, HOMEOPATHIC RECORDER, V64, P152; *HOM PHARM CONV US, 1995, HOM PHARM CONV US HP; HORN LJ, 1992, REHABILITATION POSTC; JACOBS J, 1994, PEDIATRICS, V93, P719; JONAS W, 1996, HEALING HOMEOPATHY, P9; KAY T, 1988, MINOR HEAD INJURY IN; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; Kayne SB, 1997, HOMEOPATHIC PHARM, P366; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KRAUS JF, 1989, MILD HEAD INJURY, P245; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LINDE K, 1994, HUM EXP TOXICOL, V13, P481, DOI 10.1177/096032719401300706; Linde K, 1997, LANCET, V350, P834, DOI 10.1016/S0140-6736(97)02293-9; Lo SY, 1996, MOD PHYS LETT B, V10, P921, DOI 10.1142/S0217984996001048; Lo SY, 1996, MOD PHYS LETT B, V10, P909, DOI 10.1142/S0217984996001036; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; POSTHUMA A, 1988, COGNIT REHABIL, V3, P22; REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3; REILLY DT, 1986, LANCET, V2, P881; RILEY D, 1994, J AM I HOOMEOPATHY, V84, P144; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SCHOENHUBER R, 1989, MILD HEAD INJURY, P142; SHERR JY, 1994, DYNAMIC METHODOLOGY; SINITSYN AP, 1997, P 1 INT S PHYS CHEM, P6; *SPSS INC, 1997, SPSS ADV STAT 7 5; Turkey J.W., 1977, EXPLORATORY DATA ANA; TURNER RJ, 1983, RES COMMUNITY MENTAL, V0003, P00067; *US FDA, 1998, COMP POL GUID; Vithoulkas G., 1980, SCI HOMEOPATHY; WARKENTIN DK, 1992, MACREPERTORY 3 4; WOODCOCK RW, 1990, WOODCOCKJOHNSON PSYC; WRIGHTSON P, 1989, MILD HEAD INJURY, P245; ZASLER N, 1993, J HEAD TRAUMA REHAB, V8, P48	55	38	38	0	11	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					521	542		10.1097/00001199-199912000-00002			22	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300001	10671699				2022-02-06	
J	Mackay, LE; Morgan, AS; Bernstein, BA				Mackay, LE; Morgan, AS; Bernstein, BA			Factors affecting oral feeding with severe traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aspiration; brain injury; dysphagia	HEAD-INJURY; DYSPHAGIA; ADULTS	Safe and adequate nutrition, vital to the recovery from a traumatic brain injury; can be severely compromised by the presence of dysphagia. This study identified injury severity and swallowing factors that were associated with impaired oral intake in patients with severe brain injury, An admitting Glasgow Coma Scale (GSC) 3-5; a Rancho Los Amigos Scale of Cognitive Functioning OVA) Level II; a computed tomography (CT) scan exhibiting, midline shift, brainstem involvement, or brain pathology requiring emergent operative procedures; or ventilation time greater than or equal to 15 days identified patients at highest risk for abnormal swallowing, aspiration, and delay in initiation of oral feeding and achievement of total oral feeding. When combined in multivariate models, RLA Level, CT scan, ventilation time and aspiration emerged as significant independent predictors of impaired oral intake.	St Francis Hosp & Med Ctr, Med Surg Program, Hartford, CT 06105 USA; Univ Connecticut, Sch Med, Otolaryngol Sect, Farmington, CT USA; St Francis Hosp & Med Ctr, Trauma Serv, Hartford, CT 06105 USA; St Francis Hosp & Med Ctr, Dept Surg, Hartford, CT 06105 USA; St Francis Hosp & Med Ctr, Dept Pediat, Hartford, CT 06105 USA		Mackay, LE (corresponding author), St Francis Hosp & Med Ctr, Med Surg Program, MS 20904,114 Woodland St, Hartford, CT 06105 USA.						Aviv JE, 1997, AM J MED, V103, p74S, DOI 10.1016/S0002-9343(97)00327-6; Caruso Anthony J., 1997, Seminars in Speech and Language, V18, P181; Cherney LR, 1989, J HEAD TRAUMA REHAB, V4, P42; COOPER KR, 1989, TXB HEAD INJURY, P255; Dejaeger E, 1996, AGING-CLIN EXP RES, V8, P130, DOI 10.1007/BF03339567; Field L H, 1989, Brain Inj, V3, P19, DOI 10.3109/02699058909008069; Hagen C, 1981, TOP LANG DIS, V1, P73; Jaradeh Safwan, 1994, Dysphagia, V9, P218, DOI 10.1007/BF00301913; KASHIMA HK, 1989, GERIATRIC OTORHINOLA, P122; Kosta JC, 1998, GERIATR NURS, V19, P195, DOI 10.1016/S0197-4572(98)90154-9; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; Logemann J, 1983, EVALUATION TREATMENT, P132; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; Logemann JA, 1983, EVALUATION TREATMENT; Logemann JA., 1986, MANUAL VIDEOFLUOROGR; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; MACKAY LE, 1997, MAXIMIZING BRAIN INJ; MACKAY LE, 1997, MAXIMIZING BRAIN INJ, P444; MORGUN A, 1997, MODERN SOIL MICROBIO, P331; Paterson WG, 1996, CAN FAM PHYSICIAN, V42, P925; PEPE J, 1997, MAXIMIZING BRAIN INJ, P396; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; Plant RL, 1998, OTOLARYNG CLIN N AM, V31, P477, DOI 10.1016/S0030-6665(05)70065-7; Shaker Reza, 1994, Dysphagia, V9, P221, DOI 10.1007/BF00301914; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; TEASDALE G, 1974, LANCET, V2, P81; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992; YOUNG B, 1992, J NEUROTRAUM, V9, pS375	28	38	41	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1999	14	5					435	447		10.1097/00001199-199910000-00004			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	245MW	WOS:000083113600004	10653939				2022-02-06	
J	Zahn, TP; Mirsky, AF				Zahn, TP; Mirsky, AF			Reaction time indicators of attention deficits in closed head injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; VISUAL DOMINANCE; SCHIZOPHRENIA; DYSFUNCTION	The nature of deficits in attention in closed head injury (CHI) was studied by three reaction time RT) paradigms given to 20 patients who had a CHI 2 or more years previously and to 25 controls. We studied the effects of temporal uncertainty by varying the length and regularity of the preparatory interval, the effects of stimulus modality uncertainty on simple RT to tones and lights, and the effects of response selection in choice RT. The CHI group showed slower and more variable RT than controls under all conditions. In addition, a long preparatory interval on the preceding trial retarded RT more in the CHI group, and they showed greater effects of stimulus modality uncertainty. Both of these findings suggest a difficulty in shifting attention to unexpected stimuli. These greater effects on RT of variations of attention or preparation in CHI may account for their greater within-subject variability possibly due to frontal lobe damage.	NIMH, Lab Brain & Cognit, Sect Clin & Expt Neuropsychol, Bethesda, MD 20892 USA		Zahn, TP (corresponding author), NIMH, Lab Brain & Cognit, Sect Clin & Expt Neuropsychol, Bldg 10,Room 4C104,10 Ctr Dr,MSC 1366, Bethesda, MD 20892 USA.						BENTON AL, 1962, J NERV MENT DIS, V136, P413; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; COLAVITA FB, 1974, PERCEPT PSYCHOPHYS, V16, P409, DOI 10.3758/BF03203962; COSTA LD, 1962, PERCEPT MOTOR SKILL, V14, P391; Dixon WJ, 1992, BMDP STAT SOFTWARE M; EGETH HE, 1977, PERCEPT PSYCHOPHYS, V22, P77, DOI 10.3758/BF03206083; GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; KRISTOFFERSON MW, 1967, J ABNORM PSYCHOL, V72, P388, DOI 10.1037/h0020107; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; NIEMI P, 1981, PSYCHOL BULL, V89, P133, DOI 10.1037/0033-2909.89.1.133; NUECHTERLEIN KH, 1977, SCHIZOPHRENIA BULL, V3, P373, DOI 10.1093/schbul/3.3.373; OLBRICH R, 1972, J NERV MENT DIS, V155, P356; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1976, PSYCHOL REV, V83, P157, DOI 10.1037/0033-295X.83.2.157; RIST F, 1991, HDB SCHIZOPHRENIA, V5, P241; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; SUTTON S, 1961, AM J PSYCHOL, V74, P224, DOI 10.2307/1419407; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VONZOMEREN AH, 1994, CLIN NEUROPSYCHOLOGY; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; ZAHN TP, 1991, J ABNORM CHILD PSYCH, V19, P233, DOI 10.1007/BF00909980; Zahn TP, 1998, J ABNORM PSYCHOL, V107, P97, DOI 10.1037/0021-843X.107.1.97; ZAHN TP, 1999, IN PRESS INT J PSYCH	28	38	41	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1999	21	3					352	367		10.1076/jcen.21.3.352.924			16	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	234FW	WOS:000082474700007	10474174				2022-02-06	
J	Hamilton, BB; Deutsch, A; Russell, C; Fiedler, RC; Granger, CV				Hamilton, BB; Deutsch, A; Russell, C; Fiedler, RC; Granger, CV			Relation of disability costs to function: Spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; INDEPENDENCE MEASURE FIM; ASSESSMENT SCALES; UNITED-STATES; AGREEMENT; STROKE; PERFORMANCE; RELIABILITY; PREVALENCE; STABILITY	Objective: This study evaluated the validity of the Functional Independence Measure (FIM(TM) instrument) in predicting (1) the number of minutes of daily assistance provided, (2) the cost of durable goods currently used, and (3) the number of paid helper hours provided daily to persons with spinal cord injury living in the community. Design: A cross-sectional study. Subjects: One hundred nine persons with spinal cord injury who were a median 6 years postdischarge from initial medical rehabilitation. Results: A significant inverse linear relationship was observed between FIM scores and the square root values of the three cost-related measures. The FIM-18 and the FIM motor scores were the best single predictors of the square root of minutes of assistance (paid and/or unpaid) per day, explaining 85% of variance. The FIM motor measure was the best single predictor of square root of cost of durable goods, explaining 29% of variance. The Self-Care, FIM motor, and FIM-ls scores equally predicted square root of hours of paid help per day, explaining 58% of variance. Conclusion: The findings indicate FIM-related scores pre diet the amount of assistance needed and certain costs for persons with spinal cord injury disability. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	SUNY Buffalo, Dept Rehabil Med, Ctr Funct Assessment Res, Buffalo, NY 14214 USA; Duke Univ, Med Ctr, Div Geriatr, Durham, NC USA; Youville Coll, Div Rehabil Sci, Buffalo, NY USA		Granger, CV (corresponding author), SUNY Buffalo, Dept Rehabil Med, Ctr Funct Assessment Res, 232 Parker Hall,3435 Main St, Buffalo, NY 14214 USA.		Deutsch, Anne/B-7530-2017	Deutsch, Anne/0000-0003-2290-7757			BERKOWITZ M, EC CONSEQUENCES TRAU; Chau N, 1994, Disabil Rehabil, V16, P63; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Fiedler R., 1996, FUNCTIONAL ELEVATION, P75; FISHER WP, 1995, ARCH PHYS MED REHAB, V76, P113, DOI 10.1016/S0003-9993(95)80020-4; FORTINSKY RH, 1981, MED CARE, V19, P489, DOI 10.1097/00005650-198105000-00002; Fricke J, 1993, AUST OCCUP THER J, V40, P7; Go Bette K., 1995, P21; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HAMILTON BB, 1997, H133G90157 STAT U NY; Heinemann Allen W, 1994, Top Stroke Rehabil, V1, P1; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Jaworski DM, 1994, REHABIL NURS RES, V3, P141; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; LAPLANTE MP, 1996, DISABILITY STAT REHA; LASFARGUES JE, 1995, PARAPLEGIA, V33, P62, DOI 10.1038/sc.1995.16; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; MCNEIL JM, 1993, P7033 US BUR CENS; OTTENBACHER KJ, 1994, ARCH PHYS MED REHAB, V75, P1297; SEGAL ME, 1993, PARAPLEGIA, V31, P622, DOI 10.1038/sc.1993.101; Segal ME, 1996, AM J PHYS MED REHAB, V75, P208, DOI 10.1097/00002060-199605000-00013; SEGAL ME, 1994, STROKE, V25, P2391, DOI 10.1161/01.STR.25.12.2391; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Stineman MG, 1996, AM J PHYS MED REHAB, V75, P68, DOI 10.1097/00002060-199601000-00018; WATSON AH, 1995, AM J OCCUP THER, V49, P229, DOI 10.5014/ajot.49.3.229; World Health Organization, 1980, INT CLASS IMP DIS HA; [No title captured], DOI DOI 10.1177/026921559000400405	39	38	38	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1999	80	4					385	391		10.1016/S0003-9993(99)90274-5			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	184TG	WOS:000079629100005	10206599				2022-02-06	
J	Pearce, S; McDonald, S; Coltheart, M				Pearce, S; McDonald, S; Coltheart, M			Interpreting ambiguous advertisements: The effect of frontal lobe damage	BRAIN AND COGNITION			English	Article							CLOSED-HEAD-INJURY; LANGUAGE; DEFICITS; ABILITY; REQUESTS	Despite intact primary language processes patients with frontal lobe deficits often have impaired communication skills including impaired capacity to understand conversational inference. This study examined the ability of three patients with demonstrated frontal lobe pathology to interpret lexically ambiguous advertisements, When compared to a nonbrain-damaged control group it was found that the frontal lobe patients were poorer at comprehending the abstract or inferred meanings inherent in the advertisements. The pattern of performance across the patients did, nevertheless, differ despite a similar end result. These findings are discussed in relation to theories concerning the contribution of the frontal Lobes to language function. (C) 1998 Academic Press.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Royal Brisbane Hosp, Brisbane, Qld 4029, Australia; Macquarie Univ, Dept Psychol, N Ryde, NSW, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094; Coltheart, Max/0000-0002-6580-0047			ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Baddeley A. D., 1990, WORKING MEMORY; Benson D.F., 1986, FRONTAL LOBES; Bowden S., 1992, CLIN NEUROPSYCHOL, V6, P43, DOI [10.1080/13854049208404116, DOI 10.1080/13854049208404116]; BROWNELL HH, 1986, BRAIN LANG, V27, P310, DOI 10.1016/0093-934X(86)90022-2; Damasio A., 1983, NEUROPSYCHOLOGY HUMA; Heaton RK, 1981, MANUAL WISCONSIN CAR; HOLLAND A, 1984, LANGUAGE DISORDERS A; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luria A.R., 1973, WORKING BRAIN; Luria AR., 1976, BASIC PROBLEMS NEURO; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; MCDONALD S, 1986, BRAIN LANG, V29, P68, DOI 10.1016/0093-934X(86)90034-9; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; Milner B., 1964, FRONTAL GRANULAR COR; NIPPOLD MA, 1988, J SPEECH HEAR RES, V31, P466, DOI 10.1044/jshr.3103.466; NOVOA OP, 1987, BRAIN LANG, V30, P206, DOI 10.1016/0093-934X(87)90099-X; RUBENS AB, 1976, STUDIES NEUROLINGUIS; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1978, NEUROLOGY, V28, P1166, DOI 10.1212/WNL.28.11.1166; Walsh K., 1987, NEUROPSYCHOLOGY CLIN; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1981, WAIS R MANUAL; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4; WIIG EH, 1988, NEUROPSYCHOLOGICAL S	34	38	39	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	NOV	1998	38	2					150	164		10.1006/brcg.1998.1018			15	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	137LV	WOS:000076917000003	9853094				2022-02-06	
J	Yablon, SA; Jackson, MS; Meythaler, JM; Birmingham, JD; Englander, JSG				Yablon, SA; Jackson, MS; Meythaler, JM; Birmingham, JD; Englander, JSG		Brain Injury Special Interest Grp Amer Acad Ph	Practice parameter: Antiepileptic drug treatment of posttraumatic seizures	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							POST-TRAUMATIC EPILEPSY; SEVERE BRAIN INJURIES; FOLLOW-UP; PHENYTOIN; CARBAMAZEPINE; PROPHYLAXIS; ANTICONVULSANT; HEAD; PREVENTION; RECURRENCE	The practice of antiepileptic drug (AED) prophylaxis for posttraumatic seizures (PTS) is common, although results of clinical trials raise questions regarding the benefits of such treatment. A subcommittee of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation was impaneled to review published literature regarding AED prophylaxis of PTS and formulate recommendations in the form of a practice parameter. The subcommittee presents the following recommendations: (1) Treatment standard: Prophylactic use of phenytoin (PHT), carbamazepine (CBZ), sodium valproate (VPA), or phenobarbital (PB) is not recommended for preventing late PTS, defined as seizures that occur after 1 week of injury, in the patient in whom there has been no history of seizures following a nonpenetrating traumatic brain injury (TBI). (2) It is recommended as a treatment option that PHT, PB, and CBZ may be used to prevent early PTS in patients at high risk for seizures following TBI. (3) Prophylactic use of PHT, CBZ, VPA, or PB is not recommended for preventing late PTS following penetrating TBI. (C) 1998 by the American Academy of Physical Medicine and Rehabilitation.	Amer Acad Phys Med & Rehabil, Brain Injury Special Interest Grp, Chicago, IL 60611 USA		Yablon, SA (corresponding author), Amer Acad Phys Med & Rehabil, Brain Injury Special Interest Grp, Chicago, IL 60611 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BIRKMAYER W, 1951, Wien Klin Wochenschr, V63, P606; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; BRODIE MJ, 1990, LANCET, V336, P350, DOI 10.1016/0140-6736(90)91886-F; Bullock R, 1995, GUIDELINES MANAGEMEN; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; DEUTSCHMAN CS, 1985, NEUROSURGERY, V17, P510, DOI 10.1227/00006123-198509000-00021; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; ENGEL J, 1990, SEIZURES EPILEPSY; FARWELL JR, 1990, NEW ENGL J MED, V322, P364, DOI 10.1056/NEJM199002083220604; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GOOCH LAW, 1995, ARCH PHYS MED REHAB, V76, P1041; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; Hoff H, 1947, MON PSYCHIATR NEUROL, V114, P105; JENNETT B, 1990, REHABILITATION ADULT, P89; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kollevold T, 1978, J OSLO CITY HOSP, V28, P78; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MASSAGLI TL, 1991, ARCH PHYS MED REHAB, V72, P219; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; MCCARTHY A D, 1991, Archives of Physical Medicine and Rehabilitation, V72, P818; MCNAMARA JO, 1989, ANN NEUROL, V26, P675, DOI 10.1002/ana.410260514; MEADOR KJ, 1993, EPILEPSIA, V34, P153, DOI 10.1111/j.1528-1157.1993.tb02389.x; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P628, DOI 10.1016/S0003-9993(96)90308-1; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; PECHADRE JC, 1991, PRESSE MED, V20, P841; PENRY JK, 1979, NEUROLOGY, V29, P600; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; SCHEUER ML, 1990, NEW ENGL J MED, V323, P1468; SCHMUTZ M, 1988, J NEURAL TRANSM, V72, P245, DOI 10.1007/BF01243423; SHEUER ML, 1990, NEW ENGL J MED, V323, P1468; Temkin N R, 1991, Neurosurg Clin N Am, V2, P425; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TEMPKIN NR, 1997, EPILEPSIA S8, V38, P102; TURNER IM, 1977, ANN NEUROL, V2, P221, DOI 10.1002/ana.410020307; WADA JA, 1976, ARCH NEUROL-CHICAGO, V33, P426, DOI 10.1001/archneur.1976.00500060032008; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; 1986, INT DICT MED BIOL	41	38	40	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1998	79	5					594	597					4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	ZM198	WOS:000073514500023	9596407				2022-02-06	
J	Raskin, SA; Mateer, CA; Tweeten, R				Raskin, SA; Mateer, CA; Tweeten, R			Neuropsychological assessment of individuals with mild traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							HEAD-INJURY; SYMPTOMS; DISEASE; MEMORY	The cognitive sequelae of mild traumatic brain injury (MTBI) remain to be clearly delineated. Although the majority of studies have demonstrated deficits on tests of complex attention and working memory, the appropriate clinical tools to be used in an evaluation are still not clearly known. In this study 148 subjects who met the criteria for MTBI were assessed with a comprehensive neuropsychological battery, including a measure of personality. Subjects performed significantly worse than normative data on tests of time dependent attention, and on tests of verbal memory. Cognitive performance was found to be related to demographic variables of gender and age, but not to education, educational status, length of loss of consciousness, or length of time post injury. No emotional or personality variable was related to performance on cognitive neuropsychological measures.	Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; Trinity Coll, Neurosci Program, Hartford, CT 06106 USA; Univ Victoria, Dept Psychol, Victoria, BC, Canada; Good Samaritan Neuropsychol Serv, Puyallup, WA USA		Raskin, SA (corresponding author), Trinity Coll, Dept Psychol, Hartford, CT 06106 USA.		Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; CICERONE K, 1993, AM C REH MED DENV CO; CROSSON B, 1988, J CLIN EXPT NEUROPSY, V10, P769; DAHLSTROM WG, 1975, MMPI HDB, V1; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Grimsley G., 1971, EMPLOYEE APTITUDE SU; GRONWALL D, 1974, LANCET, V2, P1452; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; HOLLINGSHEAD AS, 1977, 4 FACTOR INDEX SOCIA; JASTAJK J, 1965, WIDE RANGE ACHIEVEME; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kramer JH, 1989, NEUROPSYCHOLOGY, V3, P111, DOI 10.1037//0894-4105.3.2.111; KRAUS J, 1988, BRAIN INJURY, V3, P177; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; MASSMAN PJ, 1990, J CLIN EXP NEUROPSYC, V12, P729, DOI 10.1080/01688639008401015; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NORUSIS MJ, 1988, SPSS PC PLUS MANUAL; Osterrieth P., 1944, ARCH PSYCHOLOGIE, V30, P206; Ruff R., 1989, MILD HEAD INJURY, P152; SIMON E, 1994, J CLIN EXP NEUROPSYC, V16, P414, DOI 10.1080/01688639408402652; Smith, 1973, SYMBOL DIGIT MODALIT; SOHLBERG M, 1989, ATTENTION PROCESS TE; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler D., 1981, WAIS R MANUAL; WECHSLER D, 1984, WMS R MANUAL; Yarnell P R, 1988, Brain Inj, V2, P255, DOI 10.3109/02699058809150950	38	38	38	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	1998	12	1					21	30		10.1076/clin.12.1.21.1724			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	ZE592	WOS:000072810000003					2022-02-06	
J	Narotam, PK; Rodell, TC; Nadvi, SS; Bhoola, KD; Troha, JM; Parbhoosingh, R; van Dellen, JR				Narotam, PK; Rodell, TC; Nadvi, SS; Bhoola, KD; Troha, JM; Parbhoosingh, R; van Dellen, JR			Traumatic brain contusions: A clinical role for the kinin antagonist CP-0127	ACTA NEUROCHIRURGICA			English	Article						brain injury; brain contusion; kinin-kallikrein system; bradykinin receptor antagonist	CEREBRAL ARTERIOLAR DILATION; BRADYKININ ANTAGONIST; KALLIKREIN; EDEMA; INJURY; SYSTEM; MEDIATOR; ANGIOTENSIN; INHIBITION; RECEPTORS	Focal cerebral contusions can be dynamic and expansive, leading to delayed neurological deterioration. Due to the high mortality associated with such cerebral contusions, our standard practice had evolved into evacuating contusions in patients who had a deterioration in level of consciousness, lesions > 30 cc and CT suggestion of raised ICP. Experimental brain edema studies have implicated kinins in causing 2 degrees brain swelling. CP-0127 (Bradycor (TM)), a specific bradykinin antagonist, has been found to reduce cerebral edema in a cold lesion model in rats. In a randomized, single blind pilot study, a 7 day infusion of CP-0127 (3.0 mu g/kg/min) was compared to placebo in patients with focal cerebral contusions presenting within 24-96 hours of closed head injury with an initial GCS 9-14. The ICP, GCS, and vital signs were monitored hourly. The total lesion burden (TLB) was measured on serial CT scans. There were no differences in age, baseline GCS, TLB, initial ICP, or laboratory findings between the two groups (n = 20). The mean (+/- s.d) rise in peak ICP from baseline was greater in the placebo group than with CP-0127 (21.9 +/- 4.7 vs 9.5 +/- 2.0, P = 0.018). In addition, the mean reduction in GCS in the placebo group was significantly greater than in the CP-0127 group (4 +/- 1.0 vs 0.6 +/- 0.4, P = 0.002). Significantly raised ICP and clinically significant neurological deterioration occurred in 7/9 patients on placebo (77%) and only in 1 patient (9%; n = 11) on CP-0127, mandating surgery (P = 0.005). There were no adverse drug reactions, significant changes in vital signs or variations in the laboratory values. The cerebral perfusion pressure was adequately maintained in all patients irrespective of therapy. These preliminary results with CP-0127 provide supporting evidence that the kinin-kallikrein system could be involved in cerebral edema. In this study, treatment with CP-0127 appeared to alter the natural history of traumatic brain contusions by preventing the 2 degrees brain swelling. In addition, CP-0127 obviated the need for surgery in the majority of treated patients. CP-0127 could act on the cerebral vasculature to limit dys-autoregulation and brain swelling or on the blood brain barrier to reduce cerebral edema.	Univ Manitoba, Hlth Sci Ctr, Neurosurg Sect, Winnipeg, MB, Canada; St Boniface Gen Hosp, Winnipeg, MB R2H 2A6, Canada; OXIS Int Inc, Portland, OR USA; Univ KwaZulu Natal, Dept Neurosurg, ZA-4001 Durban, South Africa; Wentworth Provincial Hosp, Durban, South Africa; Univ KwaZulu Natal, Dept Expt & Clin Pharmacol, ZA-4001 Durban, South Africa; Cortech Inc, Denver, CO USA; MRC S Africa, Cape Town, South Africa		Narotam, PK (corresponding author), Z3020,409 Tache Ave, Winnipeg, MB R2H 2A6, Canada.		Parboosing, Raveen/T-1933-2019	Parboosing, Raveen/0000-0002-5476-1011			AUER LM, 1979, ACTA NEUROCHIR, V49, P207, DOI 10.1007/BF01808960; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BULLOCK R, 1990, ACT NEUR S, V51, P286; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CHERONIS JC, 1992, J MED CHEM, V35, P1563, DOI 10.1021/jm00087a010; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHU CS, 1994, J BIOMECH, V27, P187, DOI 10.1016/0021-9290(94)90208-9; CZERNICKI Z, 1979, ACTA NEUROCHIR, V50, P311, DOI 10.1007/BF01808530; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397, DOI 10.1152/ajpheart.1988.255.2.H397; ELLIS EF, 1987, STROKE, V18, P792, DOI 10.1161/01.STR.18.4.792; ELLIS EF, 1990, NEW TRENDS LIPID MED, V4, P129; Fein AM, 1997, JAMA-J AM MED ASSOC, V277, P482, DOI 10.1001/jama.277.6.482; FIGUEROA C D, 1990, Human Psychopharmacology, V5, P183, DOI 10.1002/hup.470050303; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; GENDELL HM, 1985, MINN MED, V68, P556; GREENBAUM LM, 1968, FED PROC, V27, P90; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; HORI S, 1968, JPN J PHYSIOL, V18, P772; KAMITANI T, 1985, CIRC RES, V57, P545, DOI 10.1161/01.RES.57.4.545; KARIYA K, 1982, BIOCHEM BIOPH RES CO, V107, P1461, DOI 10.1016/S0006-291X(82)80163-0; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Mathiesen T, 1995, ACTA NEUROCHIR, V137, P155, DOI 10.1007/BF02187188; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MULLERESTERL W, 1986, J NEUROSURG, V64, P269; NAROTAM PK, 1993, BRIT J NEUROSURG, V7, P281, DOI 10.3109/02688699309023810; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V33, P104, DOI 10.1016/0162-3109(96)00021-5; REILLY PL, 1975, LANCET, V2, P375; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SNYMAN C, 1994, BRAZ J MED BIOL RES, V27, P1877; STEWART JM, 1989, ADV EXP MED BIOL, V274, P81; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; VAVREK RJ, 1989, ADV EXP MED BIOL, V274, P395; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WHALLEY ET, 1983, PFLUG ARCH EUR J PHY, V398, P175, DOI 10.1007/BF00581069; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V324, P296, DOI 10.1007/BF00502627; WHITTLE IR, 1992, ACTA NEUROCHIR, V115, P53, DOI 10.1007/BF01400591; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x	46	38	39	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1998	140	8					793	803		10.1007/s007010050181			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	123UY	WOS:000076144700019	9810446				2022-02-06	
J	Max, JE; Lindgren, SD; Knutson, C; Pearson, CS; Ihrig, D; Welborn, A				Max, JE; Lindgren, SD; Knutson, C; Pearson, CS; Ihrig, D; Welborn, A			Child and adolescent traumatic brain injury: psychiatric findings from a paediatric outpatient speciality clinic	BRAIN INJURY			English	Article							HEAD-INJURIES; SCALE; COMA	A record review focused on children and adolescents, with a history of traumatic brain injury, who were consecutively admitted to a brain injury clinic in which all new patients are psychiatrically evaluated. The development of a 'novel' psychiatric disorder (not present before injury) occurred in 76% (38/50) of the cohort and was correlated significantly with family psychiatric history and family function, but not with severity of injury, preinjury psychiatric status, intellectual/educational functioning, or socioeconomic status. Psychiatric consultation is often necessary in this paediatric population even though much of the psychopathology, particularly following mild injury, may not be directly related to brain trauma.	UNIV IOWA,DEPT PSYCHIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242					Ihrig, Damien/0000-0002-5083-5853			American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HARRINGTON JA, 1958, J MENT SCI, V104, P1205, DOI 10.1192/bjp.104.437.1205; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JEFFREY R, 1986, IOWAS SEVERITY RATIN; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEMKUHL G, 1991, BRAIN BEHAV CHILD PS, P267; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; MARTINI DR, 1992, SCI P 39 ANN M AM AC, V8; Max J. E., 1992, NEUROPSYCHIATRIC RAT; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SHAFFER D, 1975, CIBA FDN S, V34; *SPSS INC, 1995, SPSS WIND PROF STAT; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wilkinson, 1984, WIDE RANGE ACHIEVEME	26	38	38	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1997	11	10					699	711					13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	XY415	WOS:A1997XY41500001	9354246				2022-02-06	
J	Cicerone, KD				Cicerone, KD			Clinical sensitivity of four measures of attention to mild traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							CLOSED-HEAD INJURY; SUSTAINED ATTENTION; CONCUSSION; DEFICITS	The percentage of mild traumatic brain-injury patients receiving impaired scores was determined for four neuropsychological measures of attention: Digit Span, Trail Making Test, Paced Auditory Serial Addition test (PASAT), and an auditory Continuous Performance Test of Attention (CPTA). Sensitivity was also determined based on overall criteria for multiple measures. Significant variability among the attention measures was apparent, with patients more likely to demonstrate impaired performance on the PASAT and CPTA. This appeared due to the interaction of demands upon information processing speed and capacity in response to externally paced stimuli. The results are relevant to concerns regarding the clinical interpretation of neuropsychological measures of attention.			Cicerone, KD (corresponding author), JFK JOHNSON REHABIL INST,2048 OAK TREE RD,EDISON,NJ 08820, USA.						Baribeau J, 1989, J NEUROL REHABIL, V3, P71; DEARY IJ, 1994, BIOL PSYCHOL, V38, P1, DOI 10.1016/0301-0511(94)90046-9; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; GRONWALL D, 1975, LANCET, V2, P995; Heaton RK, 1991, COMPREHENSIVE NORMS; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ingraham LJ, 1996, NEUROPSYCHOLOGY, V10, P120, DOI 10.1037/0894-4105.10.1.120; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Patton J.H., 1991, CLIN NEUROPSYCHOL, V5, P33, DOI [10.1080/13854049108401840, DOI 10.1080/13854049108401840]; PICANO JJ, 1992, ARCH CLIN NEUROPSYCH, V7, P271, DOI 10.1016/0887-6177(92)90168-M; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1992, NEUROPSYCHOLOGY CONS, P9; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SCHMIDT S, 1994, J AM SOC NEPHROL, V5, P383; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; Shum DHK, 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; VANZOMERAN AH, 1994, CLIN NEUROPSYCHOLOGY; Wechsler D, 1987, MEMORY SCALE REVISED; Wolfson, 1993, HALSTEAD REITAN NEUR	23	38	38	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	1997	11	3					266	272		10.1080/13854049708400455			7	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	XL666	WOS:A1997XL66600005					2022-02-06	
J	Scott, JG; Krull, KR; Williamson, DJG; Adams, RL; Iverson, GL				Scott, JG; Krull, KR; Williamson, DJG; Adams, RL; Iverson, GL			Oklahoma Premorbid Intelligence Estimation (OPIE): Utilization in clinical samples	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	22nd Annual Meeting of the International-Neuropsychological-Society	FEB 02-06, 1994	CINCINNATI, OH	Int Neuropsychol Soc			ADULT READING TEST; WAIS-R; DEMOGRAPHIC-VARIABLES; CROSS-VALIDATION; INDEX; PERFORMANCE; UTILITY	The present research is an effort to evaluate a new method of estimating premorbid IQ in which both demographic and current performance methods are utilized in a regression algorithm. Two hundred and twenty-seven patient files from the archives of the University of Oklahoma Health Sciences Center were used to evaluate the Oklahoma Premorbid Intelligence Estimation (OPIE) procedure. This procedure combines both premorbid demographic variables of age, education, occupation, and race with current performance on the WAIS-R Vocabulary and Picture Completion subtests in estimating premorbid IQ. The results are presented for clinical populations including those with dementia, traumatic brain injury, cerebral vascular accident, neoplasm, epilepsy, and a medical control chronic pain group. Results indicate that the OPIE produces a less restricted range of scores than other currently available methods of estimating premorbid IQ without systematic under- or over-estimation of IQ. Considerations for the use of this method with diffuse and cerebrally lateralized populations are discussed.	UNIV HOUSTON,HOUSTON,TX 77004; UNIV BRITISH COLUMBIA,VANCOUVER,BC V5Z 1M9,CANADA		Scott, JG (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT PSYCHIAT & BEHAV SCI,POB 26901,OKLAHOMA CITY,OK 73190, USA.		Krull, Kevin R/N-3882-2018	Krull, Kevin R/0000-0002-0476-7001; Iverson, Grant/0000-0001-7348-9570			ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BRITTAIN JL, 1991, CLIN NEUROPSYCHOL, V5, P163, DOI DOI 10.1080/13854049108403300; BRYAN J, 1992, J CLIN EXPT NEUROPSY, V14, P64; CORRIGAN S, 1991, ARCH CLIN NEUROPSYCH, V17, P323; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EPPINGER MG, 1987, J CONSULT CLIN PSYCH, V55, P86, DOI 10.1037/0022-006X.55.1.86; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; Heaton RK, 1991, COMPREHENSIVE NORMS; Ivnik R.J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; Kareken DA, 1994, PSYCHOL ASSESSMENT, V6, P83, DOI [10.1037/1040-3590.6.2.83, DOI 10.1037/1040-3590.6.2.83]; KLESGES R E C, 1981, Clinical Neuropsychology, V3, P32; KLESGES RC, 1987, INT J CLIN NEUROPSYC, V9, P1; Krull K R, 1995, Appl Neuropsychol, V2, P35, DOI 10.1207/s15324826an0201_6; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; Kurland, 1992, CLIN NEUROPSYCHOL, V6, P31, DOI [10.1080/13854049208401878, DOI 10.1080/13854049208401878]; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MORTENSEN EL, 1991, J CLIN EXP NEUROPSYC, V13, P361, DOI 10.1080/01688639108401050; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; SHERER M, 1994, ARCH CLIN NEUROPSYCH, V9, P427, DOI 10.1016/0887-6177(94)90005-1; SILVERSTEIN AB, 1987, J CLIN PSYCHOL, V43, P493, DOI 10.1002/1097-4679(198709)43:5<493::AID-JCLP2270430511>3.0.CO;2-V; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; SWEET JJ, 1990, PSYCHOL ASSESSMENT J, V2, P41; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1958, MEASUREMENT APPRAISA; WEINS AN, 1993, CLIN NEUROPSYCHOL, V7, P70; WILLSHIRE D, 1991, J CLIN EXP NEUROPSYC, V13, P204, DOI 10.1080/01688639108401038; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554	28	38	38	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAY	1997	11	2					146	154		10.1080/13854049708407043			9	Psychology, Clinical; Clinical Neurology; Psychology	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	XE119	WOS:A1997XE11900005					2022-02-06	
J	Lu, YC; Liu, SL; Gong, QZ; Hamm, RJ; Lyeth, BG				Lu, YC; Liu, SL; Gong, QZ; Hamm, RJ; Lyeth, BG			Inhibition of nitric oxide synthase potentiates hypertension and increases mortality in traumatically brain-injured rats	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						L-NAME; mortality; morbidity; blood pressure; fluid percussion; traumatic brain injury; rat	FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; BLOOD-FLOW; L-ARGININE; NEUROTRANSMITTER RELEASE; RELAXING FACTOR; MODEL; ACTIVATION; IMPAIRMENT; RECEPTORS	We examined the effects of N-omega-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide synthase (NOS), on mortality, morbidity, and cardiovascular parameters following traumatic brain injury (TBI) in the rat. Rats were anesthetized with 2% isoflurane prior to moderate (2.0 atmosphere), central fluid percussion TBI. Temporalis muscle temperature was maintained at 37 +/- 0.5 degrees C. L-NAME (10 mg/kg iv) was administered once at either 5 min before, 5 min after, or 15 min after TBI. Sensorimotor deficits and spatial learning/memory deficits were assessed after injury. Separate groups of rats were monitored for cardiovascular parameters. Preinjury administration of L-NAME significantly increased mortality from 13 (vehicle) to 70% (associated with pulmonary edema), whereas postinjury, L-NAME had no effect on mortality (14 and 25%). L-NAME administered at 5 or 15 min after injury had no significant effect on motor performance or cognitive performance deficits associated with TBI. L-NAME in uninjured rats increased arterial blood pressure by 25 mmHg within 2 min. L-NAME injected 5 min before TBI greatly prolonged the hypertensive episode associated with TBI (1 min in vehicle vs 60 min in L-NAME). L-NAME injected 5 min after TBI caused a sustained 35 mmHg increase in blood pressure. These findings suggest that acute inhibition of NOS has detrimental consequences on mortality that may be owing to its cardiovascular effects.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298					Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587, R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 12587] Funding Source: Medline		ASHWAL S, 1993, J NEUROSURG ANESTH, V5, P241; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BUCHANAN JE, 1993, BRAIN RES, V610, P248, DOI 10.1016/0006-8993(93)91408-K; BUISSON A, 1992, BRIT J PHARMACOL, V106, P766, DOI 10.1111/j.1476-5381.1992.tb14410.x; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; BULLOCK R, 1994, INTRACRANIAL PRESSUR, V9, P238; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DIRNAGL U, 1993, NEUROSCI LETT, V149, P43, DOI 10.1016/0304-3940(93)90343-J; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELKARIB AO, 1993, CLIN EXP HYPERTENS, V15, P819, DOI 10.3109/10641969309041644; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; FELDMAN PL, 1993, CHEM ENG NEWS, V12, P26; GARDINER SM, 1990, HYPERTENSION, V15, P486, DOI 10.1161/01.HYP.15.5.486; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERBERG LJ, 1995, PSYCHOPHARMACOLOGY, V119, P115, DOI 10.1007/BF02246062; HIRSCH DB, 1993, CURR BIOL, V3, P749, DOI 10.1016/0960-9822(93)90022-G; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P884; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAGGIO R, 1995, BRAIN RES, V679, P184, DOI 10.1016/0006-8993(95)00217-E; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MOLLACE V, 1992, NEUROSCI LETT, V137, P87, DOI 10.1016/0304-3940(92)90305-Q; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NISHIKAWA T, 1994, STROKE, V25, P877, DOI 10.1161/01.STR.25.4.877; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; QUAST MJ, 1995, BRAIN RES, V677, P204, DOI 10.1016/0006-8993(95)00134-C; REES DD, 1989, P NATL ACAD SCI USA, V86, P3375, DOI 10.1073/pnas.86.9.3375; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.ne.17.030194.001101; TANAKA K, 1993, NEUROREPORT, V4, P267, DOI 10.1097/00001756-199303000-00010; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; WEISSMAN BA, 1992, NEUROSCI LETT, V146, P139, DOI 10.1016/0304-3940(92)90062-C; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZORUMSKI CF, 1993, BIOCHEM PHARMACOL, V46, P777, DOI 10.1016/0006-2952(93)90484-E	44	38	38	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	JAN-FEB	1997	30	1-2					125	137		10.1007/BF02815154			13	Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	WK182	WOS:A1997WK18200009	9138424				2022-02-06	
J	Betz, P; Puschel, K; Miltner, E; Lignitz, E; Eisenmenger, W				Betz, P; Puschel, K; Miltner, E; Lignitz, E; Eisenmenger, W			Morphometrical analysis of retinal hemorrhages in the shaken baby syndrome	FORENSIC SCIENCE INTERNATIONAL			English	Article						shaken baby syndrome; child abuse; retinal hemorrhage; morphometry	CARDIOPULMONARY-RESUSCITATION; CHILD-ABUSE; AUTOPSY FINDINGS; INFANT SYNDROME; HEAD-INJURY; EYES	A morphometrical analysis of retinal hemorrhages was performed in cases of physical child abuse including the shaken baby syndrome and in controls (severe head injury, intravital brain death, non-traumatic intracranial hemorrhage, SIDS including cardiopulmonary resuscitation). The extent of the retinal hemorrhages was significantly different between both groups. In all cases of physical child abuse, massive retinal hemorrhages in at least one eye could be found ranging between a maximum value of 19.2 and 73.2% of the entire retinal area. In contrast, only two cases of the control group (severe head injury with skull fractures and intracranial bleeding following traffic accident or fall) showed slight hemorrhages of 3.33 or 1.18% of the retinal area but only in one eye. Therefore, the results provide evidence that massive intraretinal hemorrhages indicate violent shaking - in particular in association with other signs of physical child abuse.	UNIV HAMBURG,DEPT LEGAL MED,D-20246 HAMBURG,GERMANY; UNIV GREIFSWALD,DEPT LEGAL MED,O-2200 GREIFSWALD,GERMANY		Betz, P (corresponding author), UNIV MUNICH,DEPT LEGAL MED,FRAUENLOBSTR 7A,D-80337 MUNICH,GERMANY.						BACON CJ, 1978, BRIT MED J, V1, P281, DOI 10.1136/bmj.1.6108.281; BENNETT HS, 1980, CLIN PEDIATR, V19, P633, DOI 10.1177/000992288001900912; BUDENZ DL, 1994, OPHTHALMOLOGY, V101, P559; CAFFEY J, 1974, PEDIATRICS, V54, P396; COLLAN Y, 1983, ACTA STEREOL, V2, P214; DAVID DB, 1994, BRIT J OPHTHALMOL, V78, P234, DOI 10.1136/bjo.78.3.234; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EGGE K, 1980, ACTA OPHTHALMOL, V58, P231; EGGE K, 1981, ACTA OBSTET GYN SCAN, V60, P153; EISENBREY AB, 1979, CHILD BRAIN, V5, P40; GILKES MJ, 1967, LANCET, V2, P468; GILLILAND MGF, 1994, FORENSIC SCI INT, V68, P117, DOI 10.1016/0379-0738(94)90309-3; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; GOETTING MG, 1990, PEDIATRICS, V85, P585; GREENWALD MJ, 1986, OPHTHALMOLOGY, V93, P618; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HARCOURT B, 1971, BMJ-BRIT MED J, V3, P398, DOI 10.1136/bmj.3.5771.398; HERTLE RW, 1990, PEDIATRICS, V86, P649; JAIN BK, 1994, BRIT J OPHTHALMOL, V78, P236, DOI 10.1136/bjo.78.3.236; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; KANTER RK, 1986, J PEDIATR-US, V108, P430, DOI 10.1016/S0022-3476(86)80890-3; KELLEY JS, 1972, AM J OPHTHALMOL, V74, P278, DOI 10.1016/0002-9394(72)90545-4; KIRSCHNER RH, 1985, AM J DIS CHILD, V139, P873, DOI 10.1001/archpedi.1985.02140110027022; LAMBERT SR, 1986, ARCH OPHTHALMOL-CHIC, V104, P1509; MCLELLAN NJ, 1986, ARCH DIS CHILD, V61, P1130, DOI 10.1136/adc.61.11.1130; MORGAN OG, 1945, T OPHTHAL SOC UK, V65, P366; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; MUSHIN A, 1971, BRIT J OPHTHALMOL, V55, P343, DOI 10.1136/bjo.55.5.343; NASHELSKY MB, 1995, AM J FOREN MED PATH, V16, P154, DOI 10.1097/00000433-199506000-00016; RAO N, 1988, FORENSIC SCI INT, V39, P293, DOI 10.1016/0379-0738(88)90133-8; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; RIFFENBURGH RS, 1991, J FORENSIC SCI, V36, P741; Sethi S K, 1990, N C Med J, V51, P246; SEZEN F, 1971, BRIT J OPHTHALMOL, V55, P248, DOI 10.1136/bjo.55.4.248; SPAIDE RF, 1987, J CLIN NEURO-OPHTHAL, V7, P108; Terson A, 1926, ANN OCUL, V163, P666; TOMASI LG, 1975, AM J DIS CHILD, P1335; UNTERHARNSCHEID.F, 1993, SPEZIELLE PATHOLOGIS; WEEDN VW, 1990, AM J FOREN MED PATH, V11, P79, DOI 10.1097/00000433-199003000-00012; WEIBEL ER, 1979, STEREOLOGICAL METHOD	42	38	39	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	MAR 5	1996	78	1					71	80		10.1016/0379-0738(95)01866-2			10	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	UC269	WOS:A1996UC26900009	8855047				2022-02-06	
J	ROSNER, MJ				ROSNER, MJ			INTRODUCTION TO CEREBRAL PERFUSION-PRESSURE MANAGEMENT	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article							SEVERE HEAD-INJURY; PHENYLEPHRINE-INDUCED HYPERTENSION; TRAUMATIC BRAIN INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; AUTO-REGULATION; EXPANDING MASS; PLATEAU WAVES; MANNITOL; ISCHEMIA	This article offers a broad review of cerebral autoregulation to help understand the principles of cerebral perfusion pressure (CPP) management. Discussed are cerebral autoregulation, Poiseuille's law, mannitol-induced hypertension and CPP, prognosis by CPP, management of CPP, and a summary of physiologic basis for CPP management.			ROSNER, MJ (corresponding author), UNIV ALABAMA, DIV NEUROL SURG, UNIV STN, BIRMINGHAM, AL 35294 USA.						ASHWAL S, 1992, NEUROLOGY, V42, P739, DOI 10.1212/WNL.42.4.739; BISHOP R, 1994, INTRACRANIAL PRESSUR, V9, P189; BOREL CO, 1987, AM J PHYSIOL, V253, pH1342; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BURKE AM, 1981, J NEUROSURG, V55, P550, DOI 10.3171/jns.1981.55.4.0550; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLD GE, 1981, ACTA ANAESTH SCAND, V25, P332, DOI 10.1111/j.1399-6576.1981.tb01662.x; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DRUMMOND JC, 1991, J NEUROSURG ANESTH, V3, P4, DOI 10.1097/00008506-199103000-00002; DRUMMOND JC, 1989, STROKE, V20, P1538, DOI 10.1161/01.STR.20.11.1538; ELADAWY Y, 1988, INTRACRANIAL PRESSUR, P829; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; FEIN JM, 1983, J NEUROSURG, V59, P51, DOI 10.3171/jns.1983.59.1.0051; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GOH D, 1993, ARCH DIS CHILD, V68, P111, DOI 10.1136/adc.68.1.111; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; GUYTON AC, 1986, TXB MED PHYSL, P206; HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; JONES MD, 1981, AM J PHYSIOL, V240, pH209, DOI 10.1152/ajpheart.1981.240.2.H209; KAJITA Y, 1994, J NEUROSURG, V80, P476, DOI 10.3171/jns.1994.80.3.0476; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KAUFMANN GE, 1970, J NEUROSURG, V33, P145, DOI 10.3171/jns.1970.33.2.0145; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; KONTOS HA, 1981, AM J PHYSIOL, V240, pH511, DOI 10.1152/ajpheart.1981.240.4.H511; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Langfitt T W, 1969, Clin Neurosurg, V16, P436; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1964, J NEUROSURG, V21, P989, DOI 10.3171/jns.1964.21.11.0989; LANGFITT TW, 1964, J NEUROSURG, V21, P998, DOI 10.3171/jns.1964.21.11.0998; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MATSUDA M, 1979, J NEUROSURG, V50, P483, DOI 10.3171/jns.1979.50.4.0483; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MCPHERSON RW, 1988, AM J PHYSIOL, V255, pH1516; MOORE FD, 1975, MANUAL SURGICAL NUTR, P169; MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1992, AM J PHYSIOL, V262, pH949, DOI 10.1152/ajpheart.1992.262.4.H949; NAKATANI S, 1983, INTRACRANIAL PRESSUR, V5, P784; NELSON RJ, 1992, NEUROSURGERY, V31, P705; NEWELL DW, 1992, J NEUROSURG, V76, P415, DOI 10.3171/jns.1992.76.3.0415; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PIEK J, 1988, ACTA NEUROCHIR, V93, P129, DOI 10.1007/BF01402894; POLLAY M, 1983, J NEUROSURG, V59, P945, DOI 10.3171/jns.1983.59.6.0945; PROCTOR HJ, 1984, SURGERY, V96, P273; ROSENWASSER RH, 1989, J NEUROSURG, V71, P503, DOI 10.3171/jns.1989.71.4.0503; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; Rosner Michael J., 1993, P57; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; ROSNER MJ, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P293; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P540; ROSNER MJ, 1995, J NEUROSURG; ROSNER MJ, 1986, INTRACRANIAL PRESSUR, V6, P37; ROSNER MJ, 1994, INTRACRANIAL PRESSUR, P218; ROSNER MJ, 1994, NEUROSURGICAL EMERGE, P5; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P414; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P686; ROSNER MJ, 1993, P INT C RECENT ADV N, P313; SCHETTINI A, 1972, ANESTHESIOLOGY, V36, P4, DOI 10.1097/00000542-197201000-00002; SCHRADER H, 1985, ACTA NEUROL SCAND, V71, P453; SCHRADER H, 1985, ACTA NEUROL SCAND, V71, P114; SHALMON E, 1995, INTRACRANIAL PRESSUR, V9, P357; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SULLIVAN HG, 1987, J NEUROSURG, V67, P525, DOI 10.3171/jns.1987.67.4.0525; SYROGIANNOPOULOS GA, 1987, PEDIATR RES, V22, P118, DOI 10.1203/00006450-198708000-00002; TAKAGI H, 1983, INTRACRANIAL PRESSUR, V5, P729; TRAUB YM, 1982, CLIN EXP HYPERTENS A, V4, P1193, DOI 10.3109/10641968209060783; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; WEINSTEI.JD, 1968, J NEUROSURG, V28, P513, DOI 10.3171/jns.1968.28.6.0513; WOISCHNECK D, 1989, INTRACRANIAL PRESSUR, V7, P850; Wolff HG, 1928, ARCH NEURO PSYCHIATR, V20, P1035, DOI 10.1001/archneurpsyc.1928.02210170142002; YOSHIDA A, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P309; ZEMAN FJ, 1983, CLIN NUTRITION DIETE, P555; [No title captured]	96	38	40	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	1995	6	4					761	+					1	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	RZ142	WOS:A1995RZ14200016	8527917				2022-02-06	
J	DUSART, I; MOREL, MP; SOTELO, C				DUSART, I; MOREL, MP; SOTELO, C			PARASAGITTAL COMPARTMENTATION OF ADULT-RAT PURKINJE-CELLS EXPRESSING THE LOW-AFFINITY NERVE GROWTH-FACTOR RECEPTOR - CHANGES OF PATTERN EXPRESSION AFTER A TRAUMATIC LESION	NEUROSCIENCE			English	Article							SPINAL-CORD; CEREBELLUM; IMMUNOREACTIVITY; BANDS; BRAIN	The pattern of expression of p75, the low affinity nerve growth factor receptor, in the adult rat cerebellum and its fate after a traumatic lesion were analysed using immunohistochemical localization of this receptor. A subset of Purkinje cells was immunoreactive for low affinity nerve growth factor receptor in the intact adult cerebellum. These cells were arranged in alternating positive and negative parasagittal compartments along the cerebellar cortex. This pattern of expression had 90% homology with zebrin I. After a traumatic lesion, the specific pattern of expression of zebrin I remained unchanged, whereas the low affinity nerve growth factor receptor pattern changed as early as one day: Purkinje cells near the lesion site, independent of zebrin I staining, became immunoreactive. During the first week, the increase in immunoreactivity remained high. Thereafter, there was a short, fast decrease followed by a long period in which a faint immunostaining on lesioned Purkinje cells is maintained for up to one year. The increase in the expression of the low affinity nerve growth factor receptor by all traumatically affected Purkinje cells suggests a correlation between this specific up-regulation and the high resistance of these neurons to axotomy or other traumatic injuries.			DUSART, I (corresponding author), HOP LA PITIE SALPETRIERE,INSERM,U106,47 BLVD HOP,F-75651 PARIS 13,FRANCE.		Sotelo, Constantino/AAS-5475-2021	Sotelo, Constantino/0000-0001-8051-2492; Dusart, Isabelle/0000-0002-3211-4323			ARMSTRONG DM, 1987, J COMP NEUROL, V264, P421, DOI 10.1002/cne.902640309; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; COHENCORY S, 1989, EXP NEUROL, V105, P104, DOI 10.1016/0014-4886(89)90177-5; DAVIES AM, 1994, NATURE, V368, P193, DOI 10.1038/368193a0; DUSART I, 1994, J COMP NEUROL, V347, P211, DOI 10.1002/cne.903470206; GAGE FH, 1989, NEURON, V2, P1177, DOI 10.1016/0896-6273(89)90184-0; GORENSTEIN C, 1987, BRAIN RES, V418, P68, DOI 10.1016/0006-8993(87)90963-2; GOULD E, 1987, DEV BRAIN RES, V34, P303, DOI 10.1016/0165-3806(87)90218-5; HAWKES R, 1987, J COMP NEUROL, V256, P29, DOI 10.1002/cne.902560104; KOH S, 1991, J COMP NEUROL, V313, P494, DOI 10.1002/cne.903130310; MARTINEZMURILLO R, 1993, NEUROSCIENCE, V52, P587, DOI 10.1016/0306-4522(93)90408-8; PIORO EP, 1990, NEUROSCIENCE, V34, P89, DOI 10.1016/0306-4522(90)90305-N; PIORO EP, 1988, BRAIN RES, V455, P182, DOI 10.1016/0006-8993(88)90131-X; RENDE M, 1993, J COMP NEUROL, V338, P560, DOI 10.1002/cne.903380406; SOTELO C, 1991, PHILOS T R SOC B, V331, P307, DOI 10.1098/rstb.1991.0022; YAN Q, 1988, J NEUROSCI, V8, P3481	16	38	38	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience	NOV	1994	63	2					351	356		10.1016/0306-4522(94)90534-7			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PV683	WOS:A1994PV68300001	7891850				2022-02-06	
J	MILLIS, SR; PUTNAM, SH				MILLIS, SR; PUTNAM, SH			THE RECOGNITION MEMORY TEST IN THE ASSESSMENT OF MEMORY IMPAIRMENT AFTER FINANCIALLY COMPENSABLE MILD HEAD-INJURY - A REPLICATION	PERCEPTUAL AND MOTOR SKILLS			English	Article								The current investigation replicated the findings from a 1992 study by Millis. 20 subjects with claimed mild head injury who were seeking financial compensation obtained significantly lower scores on both subtests of the Recognition Memory Test than did 66 rehabilitation inpatients with documented moderate and severe traumatic brain injuries. The direct discriminant function derived by Millis was cross-validated on the current sample and yielded an improved over-all correct classification rate of 83%, with 85% and 82% of the mild and severe traumatic brain-injured subjects classified correctly, respectively. Over-all correct classification rate in the original study was 76%.			MILLIS, SR (corresponding author), WAYNE STATE UNIV,SCH MED,REHABIL INST MICHIGAN,261 MACK BLVD,DETROIT,MI 48201, USA.						BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; LEVIN H, 1975, J NERV MENT DIS, V167, P675; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Warrington E, 1984, RECOGNITION MEMORY T, V1	4	38	38	0	1	PERCEPTUAL MOTOR SKILLS	MISSOULA	PO BOX 9229, MISSOULA, MT 59807	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	AUG	1994	79	1	2				384	386		10.2466/pms.1994.79.1.384			3	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	PJ038	WOS:A1994PJ03800004	7808871				2022-02-06	
J	PAPERO, PH; PRIGATANO, GP; SNYDER, HM; JOHNSON, DL				PAPERO, PH; PRIGATANO, GP; SNYDER, HM; JOHNSON, DL			CHILDRENS ADAPTIVE BEHAVIORAL COMPETENCE AFTER HEAD-INJURY	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							BRAIN-DAMAGE; SEQUELAE; TRAUMA	Eighty-six children were evaluated in a cross-sectional study 1 to 3 years after hospitalization for closed head injury in order to ascertain the effects of head injury severity, age, and chronicity of injury on the development of adaptive behavioural competence as measured by the Vineland Adaptive Behavior Scales. Twenty-three subjects had sustained moderate to severe injuries and 63 had sustained mild injuries, based on neurosurgical criteria including the Glasgow Coma Score, CT scans, and other medical variables. It was hypothesised that severity of head injury would adversely affect overall adaptive competence. It was also predicted that social competence would be less well developed in children with moderate to severe injury than in those with mild injury. Study findings provided partial support for these hypotheses. An unavoidable confounding of age and gender resulted in the decision to examine the data by gender to determine whether the data could be analysed without regard for this factor. An unexpected gender effect was observed. Severity of injury did adversely influence the adaptive competence of boys, especially in the area of social competency, but hypotheses were not upheld for girls. Discussion focuses on issues related to gender and adaptive outcome, parent report of adaptive functioning in light of gender and cultural factors, the relationship of neuropsychological functioning and adaptive competence, and the nature of social deficits following pediatric traumatic brain injury.	GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,WASHINGTON,DC 20010; BARROW NEUROL INST,PHOENIX,AZ								Beery K, 1989, VMI DEV TEST VISUAL; BROOKS N, 1984, CLOSED HEAD INJURY P; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; DODRILL CB, 1984, J CONSULT CLIN PSYCH, V54, P520; EIBAN CF, 1984, ARCH PHYSICAL MED RE, V65, P168; EICHELBERGER MR, 1991, EMSC FOCUS TRAUMATIC; EWINGCOBBS L, 1987, J CLIN EXPT NEUROPSY, V2, P575; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Fuld P. A., 1977, FULD OBJECT MEMORY E; GAGNON J, 1989, SUPERANOVA ACCESSIBL; Gleason J.B., 1987, LANGUAGE GENDER SEX, P189; Jennett B, 1981, MANAGEMENT HEAD INJU; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MACCOBY EE, 1990, AM PSYCHOL, V45, P513, DOI 10.1037/0003-066X.45.4.513; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; ODDY M, 1978, BRIT J PSYCHIAT, V122, P567; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1991, J CLIN EXP NEUROPSYC, V13, P437; Reitan R, 1985, HALSTEAD REITAN NEUR; RICHARDSON SA, 1986, AM J MENT RETARD, V91, P250; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wechsler D., 1974, WECHSLER INTELLIGENC; 1987, LEARNING DISABILITIE	30	38	38	0	1	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		1993	3	4					321	340		10.1080/09602019308401445			20	Neurosciences; Psychology	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	MR361	WOS:A1993MR36100003					2022-02-06	
J	VILKKI, J				VILKKI, J			COGNITIVE FLEXIBILITY AND MENTAL PROGRAMMING AFTER CLOSED HEAD-INJURIES AND ANTERIOR OR POSTERIOR CEREBRAL EXCISIONS	NEUROPSYCHOLOGIA			English	Article							FRONTAL-LOBE LESIONS; COMPUTERIZED-TOMOGRAPHY; DEFICITS; DAMAGE	Cognitive inflexibility and deficient mental programming are specifically related to frontal lobe lesions. The aim was to demonstrate that closed head injury (CHI) patients with brain lesions verified by computed tomography have such cognitive deficits, and are inferior in these respects to patients with posterior cerebral excisions mainly for tumours. This hypothesis was confirmed using a Category Identification and Sorting test as well as a measure of mental programming in a Spatial Learning task. Furthermore, CHI patients who had non-frontal parenchymal lesions were inferior by these measures to patients with posterior excisions. This result suggests that diffuse axonal lesion in CHI causes the deficits similar to those following frontal lobe excision.			VILKKI, J (corresponding author), UNIV CENT HOSP HELSINKI,DEPT NEUROSURG,TOPELIUKSENKATU 5,SF-00260 HELSINKI,FINLAND.						ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Benson D.F., 1986, FRONTAL LOBES; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Fuster JM., 1980, PREFRONTAL CORTEX; Goldberg E., 1987, FRONTAL LOBES REVISI, P159; Goldman-Rakic P.S., 2011, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; Grafman J., 1987, NEUROBEHAVIORAL RECO, P43; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; KARNATH HO, 1991, NEUROPSYCHOLOGIA, V29, P271, DOI 10.1016/0028-3932(91)90042-7; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Milner B., 1964, FRONTAL GRANULAR COR, P313; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Teuber H.-L., 1964, FRONTAL GRANULAR COR; TEUBER H-L, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P615; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; VILKKI J, 1989, NEUROPSYCHOLOGIA, V27, P971, DOI 10.1016/0028-3932(89)90072-9; VILKKI J, 1992, IN PRESS J CLIN EXP, V14; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; WILSON JTL, 1991, BRAIN INJURY, V4, P349; [No title captured]	33	38	38	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	SEP	1992	30	9					807	814		10.1016/0028-3932(92)90084-Y			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	JP951	WOS:A1992JP95100005	1407495				2022-02-06	
J	SZYMANSKI, HV; LINN, R				SZYMANSKI, HV; LINN, R			A REVIEW OF THE POSTCONCUSSION SYNDROME	INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE			English	Article						BRAIN INJURY; BRAIN CONCUSSION; PSYCHOPHARMACOLOGY; TOMOGRAPHY; EMISSION-COMPUTED; DEPRESSION; TOMOGRAPHY; X-RAY COMPUTED; ATTENTION; MEMORY; MAGNETIC RESONANCE IMAGING	MINOR HEAD-INJURY; BRAIN INJURY; COMPUTERIZED-TOMOGRAPHY; REACTION-TIME; POPULATION; TRAUMA; ATTENTION; SEQUELAE; SCANS; DRUGS	Objective: This review will focus on aspects of the postconcussion syndrome (PCS), including accompanying symptomatology, neuropsychological changes, brain imaging studies and treatment. Method: In each topic area, those research studies resulting in the most interpretable data are reported. Since there is little research in some aspects of the PCS, some studies of limited merit are described, with their limitations outlined, in lieu of not reporting any study. The section on psychopharmacology largely consists of opinions of recognized clinicians, since there is almost no research on the psychopharmacology of PCS. Results: Mild traumatic brain injury is a relatively frequent occurrence which often results in the postconcussion syndrome (PCS), consisting of complaints of irritability, fatigue, headache, difficulty concentrating, dizziness, and memory problems. Anxiety and depression are also frequently present, especially later in its course. Although the PCS has often been thought to reflect a psychological response to injury, there is considerable recent evidence to suggest that it is primarily a physiologic disturbance. For most individuals, treatment consists primarily of education of the patient and his/her family, along with supportive counseling regarding emerging problems at work or at home. A subgroup of patients, however, may require psychopharmacologic intervention. Conclusion: More research is needed in all aspects of PCS, especially its neurophysiology and pharmacologic treatment. Relationships between neurophysiological changes and behavioral and neuropsychological changes are unknown. New imaging techniques, such as single-photon emission tomography, and positron emission tomography will likely play an important role in understanding the physiology of this disorder.	SUNY BUFFALO,BUFFALO,NY 14260								ALAVI A, 1989, J NEUROPSYCHIAT, V1, pS45; ALEXANDER MP, 1987, NEUROBEHAVIORAL RECO; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAILEY BN, 1989, MINOR HEAD INJURY; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BLACK P, 1969, LATE EFFECTS HEAD IN, pCH14; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CARTLIDGE NEF, 1982, HEAD INJURY; CASSIDY JW, 1989, NEUROBEHAVIOURAL SEQ; COPE DN, 1989, NEUROBEHAVIORAL SEQU; COURVILLE CB, 1987, PATHOLOGY CENTRAL NE; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DENCKER SJ, 1960, ARCH GEN PSYCHIAT, V2, P569; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN S, 1989, MILD HEAD INJURY; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEENEY DM, 1988, PHARM APPROACHES TRE; GRAVES EJ, 1989, VITAL HLTH STATIS 13, V100; GRAY BG, 1992, J NUCL MED, V33, P52; GREBER R, 1985, ATTENTION SHORT TERM; GRONWALL D, 1974, LANCET, V2, P605; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; GUTTMANN E, 1946, J MENT SCI, V92, P1; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; Holbourn AHS, 1943, LANCET, V2, P438; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENKINS A, 1986, LANCET, V2, P445; JONES RR, 1974, SURGICAL NEUROLOGY, V22, P101; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KILLIAN GA, 1984, J ABNORM PSYCHOL, V93, P58, DOI 10.1037/0021-843X.93.1.58; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1987, MILD MODERATE HEAD I; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LANGFITT TW, 1982, CLIN NEUROSURG, V29, P3523; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LIDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; LINN RT, 1992, J CLIN EXPT NEUROPSY, V14, P78; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISTER RG, 1985, NEUROSCI BIOBEHAV R, V9, P87, DOI 10.1016/0149-7634(85)90034-X; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; MCLEAN A, 1986, NOV ANN M NAT HEAD I; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; Meyer A, 1904, AM J INSANITY, V60, P373, DOI 10.1176/ajp.60.3.373; MILLER JD, 1989, MILD MODERATE HEAD I; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; MYSIW WJ, 1986, ARCH PHYS MED REHAB, V67, P677; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1989, MILD HEAD INJURY; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUFF RM, 1987, MILD HEAD INJURY; RUTHERFORD WH, 1977, LANCET, V2, P1021; RUTHERFORD WH, 1989, MILD HEAD INJURY; SEKINO H, 1981, Neurologia Medico-Chirurgica, V21, P677; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; STARKSTEIN SE, 1990, ANN NEUROL, V27, P652, DOI 10.1002/ana.410270612; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Symonds C P, 1937, Proc R Soc Med, V30, P1081; TARSH MJ, 1985, BRIT J PSYCHIAT, V146, P18, DOI 10.1192/bjp.146.1.18; TEASDALE G, 1974, LANCET, V2, P81; TUNE LE, 1982, AM J PSYCHIAT, V139, P1460; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1989, TRAUMATIC BRAIN INJU; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WISE RA, 1982, BEHAV BRAIN SCI, V5, P39, DOI 10.1017/S0140525X00010372; Wood R. L. L., 1989, PHYS MED REHABIL, V3, P123; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; WRIGHTSON P, 1989, MILD HEAD INJURY; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; [No title captured]; [No title captured]; [No title captured]	82	38	38	0	6	BAYWOOD PUBL CO INC	AMITYVILLE	26 AUSTIN AVE, AMITYVILLE, NY 11701	0091-2174			INT J PSYCHIAT MED	Int. J. Psychiatr. Med.		1992	22	4					357	375		10.2190/XARA-B1EF-J2HC-VAE0			19	Psychiatry	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychiatry	KN858	WOS:A1992KN85800005	1293065				2022-02-06	
J	MONTANE, I; EISMONT, FJ; GREEN, BA				MONTANE, I; EISMONT, FJ; GREEN, BA			TRAUMATIC OCCIPITOATLANTAL DISLOCATION	SPINE			English	Article								Four patients with traumatic occipitoatlantal dislocation are presented. The dislocations were the result of rapid deceleration motor vehicle accidents. The mechanism of injury was by hyperextension-rotation combined with a distraction force. Three patients sustained multiple injuries. Neurologic findings were variable. One patient with complete cord transection and closed head trauma died 4 days after the injury. In the three surviving patients, the occipitoatlantal dislocation was not diagnosed by the initial examiner. Prompt recognition and stabilization are essential to avoid further neurologic injury. Care must be taken not to increase the dislocation. A halo applied before operation facilitates reduction and allows posterior occipitoatlantal fusion to be performed under optimum conditions.	UNIV MIAMI,SCH MED,DEPT ORTHOPAED & REHABIL,MIAMI,FL 33152									0	38	39	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0362-2436			SPINE	SPINE	FEB	1991	16	2					112	116		10.1097/00007632-199116020-00002			5	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	EX676	WOS:A1991EX67600002	2011763				2022-02-06	
J	SCHENCK, CH; MAHOWALD, MW				SCHENCK, CH; MAHOWALD, MW			INJURIOUS SLEEP BEHAVIOR DISORDERS (PARASOMNIAS) AFFECTING PATIENTS ON INTENSIVE-CARE UNITS	INTENSIVE CARE MEDICINE			English	Article						SLEEP INJURY; PARASOMNIAS; INTENSIVE CARE UNIT; NIGHT TERRORS; SLEEPWALKING; REM SLEEP BEHAVIOR DISORDER; POLYSOMNOGRAPHY	OPEN-HEART SURGERY	There are no previous reports on parasomnias (sleep behavior disorders) affecting patients on intensive care units (ICUs). During 8 years of clinical practice, we evaluated over 200 adults with complaints of injurious, sleep-related behaviors, 20 of whom had ICU admissions while their parasomnias had been active and generally undiagnosed/untreated. Mean age during ICU confinement was 62.8 (+/- SD 13.1) years; 85.0% (17/20) were males. Patients underwent comprehensive clinical examinations along with extensive polysomnographic and audiovisual monitoring (electrooculogram, 9 channel EEG with paper speeds of 15 and 30 mm/sec, electromyogram [submental and 4 limbs], EKG, airflow). The polysomnographic studies were diagnostic for the REM sleep behavior disorder (vigorous dream-enactment during rapid eye movement [REM] sleep) in 85.0% (17/20) of patients, and for night terrors/sleepwalking in 15.0% (3/20). Three groups of parasomnia-ICU relationships were identified: i) Parasomnias originating in ICUs, stroke-induced (n = 3); ii) Admission to ICUs resulting from parasomnia-induced injuries: C2 odontoid process fracture and C3 spinous process fracture with severe concussion (n = 2); iii) Parasomnias in patients admitted to ICUs for various other medical problems (n = 15). Physicians should be thus alerted about the possibility of injurious, but usually treatable, parasomnias in ICU patients.	HENNEPIN CTY MED CTR,DEPT PSYCHIAT,MINNEAPOLIS,MN 55415; HENNEPIN CTY MED CTR,DEPT NEUROL,MINNEAPOLIS,MN 55415; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455		SCHENCK, CH (corresponding author), HENNEPIN CTY MED CTR,MINNESOTA REG SLEEP DISORDERS CTR,701 PK AVE S,MINNEAPOLIS,MN 55415, USA.						AURELL J, 1985, BRIT MED J, V290, P1029, DOI 10.1136/bmj.290.6474.1029; BOYSEN PG, 1989, TXB CRITICAL CARE, P572; BROUGHTON R, 1978, ELECTROEN CLIN NEURO, V45, P348, DOI 10.1016/0013-4694(78)90187-6; CARSKADON MA, 1990, PRINCIPLES PRACTICE, P3; DOHNO S, 1979, PERCEPT MOTOR SKILL, V48, P199, DOI 10.2466/pms.1979.48.1.199; JOHNS MW, 1974, BRIT J SURG, V61, P377, DOI 10.1002/bjs.1800610513; JOUVET M, 1965, CR SOC BIOL, V159, P895; KARACAN I, 1974, STRESS HEART, P163; KAVEY NB, 1990, NEUROLOGY, V49, P749; MAHOWALD M W, 1990, Pediatrician, V17, P21; MAHOWALD MW, 1990, J CLIN NEUROPHYSIOL, V7, P119, DOI 10.1097/00004691-199001000-00009; MAHOWALD MW, 1990, J FORENSIC SCI, V35, P413; MAHOWALD MW, 1989, PRINCIPLES PRACTICE, P389; MAHOWALD MW, 1990, HDB SLEEP DISORDERS, P567; ORR WC, 1977, AM J CARDIOL, V39, P196, DOI 10.1016/S0002-9149(77)80191-4; Rechtschaffen A., 1968, MANUAL STANDARDIZED; RICHARDSON GS, 1978, ELECTROEN CLIN NEURO, V45, P621, DOI 10.1016/0013-4694(78)90162-1; SCHENCK CH, 1989, AM J PSYCHIAT, V146, P1166; SCHENCK CH, 1987, JAMA-J AM MED ASSOC, V257, P1786, DOI 10.1001/jama.257.13.1786; SCHENCK CH, 1986, SLEEP, V9, P293, DOI 10.1093/sleep/9.2.293; SCHENCK CH, 1990, CLEVE CLIN J MED S, V57, pS9; SCHENCK CH, 1989, DISSOCIATION, V2, P194; SIEGEL JM, 1990, J CLIN NEUROPHYSIOL, V7, P49, DOI 10.1097/00004691-199001000-00005; [No title captured]; 1990, INT CLASSIFICATION S	25	38	38	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0342-4642			INTENS CARE MED	Intensive Care Med.		1991	17	4					219	224		10.1007/BF01709881			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GC112	WOS:A1991GC11200008	1744307				2022-02-06	
J	TORG, JS; SENNETT, B; VEGSO, JJ; PAVLOV, H				TORG, JS; SENNETT, B; VEGSO, JJ; PAVLOV, H			AXIAL LOADING INJURIES TO THE MIDDLE CERVICAL-SPINE SEGMENT - AN ANALYSIS AND CLASSIFICATION OF 25 CASES	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article								Injuries to the cervical spine at the C3-C4 level involving the bony elements, intervertebral disks, and ligamentous structures are rare. We present 25 cases of traumatic C3-C4 injuries sustained by young athletes and documented by the National Football Head and Neck Injury Registry. Review of the cases reveals that the response of energy inputs at the C3-C4 level differ from those involving the upper (C1-C2) and lower (C4-C5-C6-C7) cervical segments. Specifically, the C3-C4 lesions appear to be unique with regard to the infrequency of bony fracture, difficulty in effecting and maintaining reduction, and a more favorable recovery following early, aggressive treatment. In the majority of instances, injury at this level results from axial loading of the cervical spine. Lesions were distributed into specific categories: 1) acute intervertebral disc herniation (N = 4), 2) anterior subluxation of C3 on C4 (N = 4), 3) unilateral facet dislocation (N = 6), 4) bilateral facet dislocation (N = 7), and 5) fracture of vertebral body C4 (N = 4). Analysis of these 25 cases suggests that traumatic lesions of the cervical spine in general can be classified as involving the upper (C1-C2), middle (C3-C4), or lower (C4-C7) segments. This is based on our observations from this series that C3-C4 lesions 1) generally do not involve fracture of the bony elements; 2) acute intervertebral disc herniations are frequenty associated with transient quadriplegia; 3) reduction of anterior subluxation of C3 on C4 is difficult to maintain; 4) reduction of unilateral facet dislocation is difficult to obtain by skeletal traction and is best managed by closed manipulation and reduction under general anesthesia; and 5) reduction of bilateral facet dislocation is difficult to obtain by skeletal traction and is best managed by open methods. The more favorable results observed in this series of immediate reduction of both unilateral and bilateral facet dislocations deserves emphasis. In two cases of unilateral facet dislocation reduced within 3 hours of injury and subsequently fused anteriorly, significant neurologic recovery occurred. The other four patients, two who underwent an open reduction and laminectomy and two treated closed with skeletal traction, remained quadriplegic. In the four instances of bilateral facet dislocation where reduction was achieved by either closed or open methods, although there was no neurologic recovery, all four patients survived their injuries. However, the three patients who were not successfully reduced died.			TORG, JS (corresponding author), UNIV PENN,CTR SPORTS MED,WEIGHTMAN HALL,235 S 33RD ST,PHILADELPHIA,PA 19104, USA.							0	38	39	0	3	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	1991	19	1					6	20		10.1177/036354659101900103			15	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	EV643	WOS:A1991EV64300003	2008932				2022-02-06	
J	Denny-Brown, D; Russell, WR				Denny-Brown, D; Russell, WR			Experimental cerebral concussion	JOURNAL OF PHYSIOLOGY-LONDON			English	Article																	DURET H, 1920, TRAUMATISMES CRANIOC, V2; KOCHER T, 1901, HIRNERSCHUTTERUNG 2, V3; Miller GG, 1927, ARCH SURG-CHICAGO, V14, P891, DOI 10.1001/archsurg.1927.01130160100005; POLIS A, 1894, REV CHIR, V14, P645; Polis A, 1894, REV CHIR, V14, P273	5	38	38	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	DEC	1940	99	1					153	153		10.1113/jphysiol.1940.sp003887			1	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	V40IS	WOS:000202726600015	16995229	Green Published			2022-02-06	
J	Dolce, G; Quintieri, M; Leto, E; Milano, M; Pileggi, A; Lagani, V; Pignolo, L				Dolce, Giuliano; Quintieri, Maria; Leto, Elio; Milano, Michele; Pileggi, Antonio; Lagani, Vincenzo; Pignolo, Loris			Dysautonomia and Clinical Outcome in Vegetative State	JOURNAL OF NEUROTRAUMA			English	Article						dysautonomia; outcome; vegetative state		A dramatic disorder tentatively attributed to diencephalic-hypothalamic damage or dysfunction, dysautonomia, affects recovery from brain injury. Its incidence, correlation with etiology, and relevance as a predictor of outcome were retrospectively surveyed in 333 patients in vegetative state (VS) for more than 2 weeks at admission. Outcome was assessed according to the Glasgow Outcome Scale. Data were treated statistically by multi-variate analyses. Dysautonomia occurred in 26.1% of patients, with greater incidence among post-traumatic (31.9%) than non-traumatic (15.8%) patients. Outcome was worse among non-traumatic than post-traumatic patients irrespective of dysautonomia, and worst among non-traumatic patients with dysautonomia. Dysautonomia proved common among patients in VS (with incidence depending on etiology and age) and influenced the patients' outcome through mechanisms still to be defined, but conceivably mediated by diencephalic-hypothalamic unbalance.	[Dolce, Giuliano; Quintieri, Maria; Leto, Elio; Milano, Michele; Pileggi, Antonio] St Anna Inst, Crotone, Italy; [Lagani, Vincenzo; Pignolo, Loris] Univ Calabria, Dept Elect Informat & Systemist, Cosenza, Italy		Dolce, G (corresponding author), S Anna Inst, Via Siris 11, I-88900 Crotone, Italy.	giulianodolce@libero.it					ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2005, BRAIN INJURY, V19, P545, DOI 10.1080/02699050400025075; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; Dolce G., 2002, POSTTRAUMATIC VEGETA; Enna SJ, 2006, ADV PHARMACOL, V54, P1, DOI 10.1016/S1054-3589(06)54001-3; Gloeckner G.W., 2001, SPSS WINDOWS INTRO U; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2002, J NEUROL NEUROSUR PS, V73, P355, DOI 10.1136/jnnp.73.4.355; JENNETT B, 2002, VEGETATIVE STATE MED; Kang YM, 2004, INT J NEUROSCI, V114, P299, DOI 10.1080/00207450490264115; Laureys S, 2000, LANCET, V355, P1825, DOI 10.1016/S0140-6736(05)73084-1; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; O'Brien Brian P, 2006, Crit Care Resusc, V8, P200; Ong J, 2005, CNS DRUG REV, V11, P317; Shiel A, 2004, BRIT J NEUROSURG, V18, P5, DOI 10.1080/02688690410001660625; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Young GB, 2004, J CLIN NEUROPHYSIOL, V21, P379; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076	23	37	41	2	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2021	38	10					1441	1444		10.1089/neu.2008.0536			4	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	RZ6DB	WOS:000648685300009	18771395		Y	N	2022-02-06	
J	McCrea, M; Broglio, S; McAllister, T; Zhou, WX; Zhao, S; Katz, B; Kudela, M; Harezlak, J; Nelson, L; Meier, T; Marshall, SW; Guskiewicz, KM; Hoy, AM; Hazzard, JB; Kelly, LA; Ortega, JD; Port, N; Putukian, M; Langford, TD; Tierney, R; Pasquina, P; Campbell, DE; Jackson, J; McGinty, G; O'Donnell, P; Cameron, K; Houston, M; Svoboda, S; Giza, C; Goldman, J; DiFiori, J; Benjamin, HJ; Buckley, T; Kaminski, TW; Clugston, JR; Schmidt, JD; Feigenbaum, LA; Eckner, JT; Mihalik, JP; Miles, JD; Anderson, S; Arbogast, K; Master, CL; Collins, M; Kontos, AP; Bazarian, JJ; Chrisman, SPD; Brooks, MA; Duma, S; Rowson, S; Miles, CM; Dykhuizen, BH; Lintner, L				McCrea, Michael; Broglio, Steven; McAllister, Thomas; Zhou, Wenxian; Zhao, Shi; Katz, Barry; Kudela, Maria; Harezlak, Jaroslaw; Nelson, Lindsay; Meier, Timothy; Marshall, Stephen William; Guskiewicz, Kevin M.; Hoy, April Marie (Reed); Hazzard, Joseph B., Jr.; Kelly, Louise A.; Ortega, Justus D.; Port, Nicholas; Putukian, Margot; Langford, T. Dianne; Tierney, Ryan; Pasquina, Paul; Campbell, Darren E.; Jackson, Jonathan; McGinty, Gerald; O'Donnell, Patrick; Cameron, Kenneth; Houston, Megan; Svoboda, Steven; Giza, Christopher; Goldman, Joshua; DiFiori, Jon; Benjamin, Holly J.; Buckley, Thomas; Kaminski, Thomas W.; Clugston, James R.; Schmidt, Julianne D.; Feigenbaum, Luis A.; Eckner, James T.; Mihalik, Jason P.; Miles, Jessica Dysart; Anderson, Scott; Arbogast, Kristy; Master, Christina L.; Collins, Micky; Kontos, Anthony P.; Bazarian, Jeffrey J.; Chrisman, Sara P. D.; Brooks, M. Alison; Duma, Stefan; Rowson, Steven; Miles, Christopher M.; Dykhuizen, Brian H.; Lintner, Laura		CARE Consortium Investigators	Return to play and risk of repeat concussion in collegiate football players: comparative analysis from the NCAA Concussion Study (1999-2001) and CARE Consortium (2014-2017)	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; FREE WAITING PERIOD; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; MANAGEMENT; ZURICH	Objective We compared data from the National Collegiate Athletic Association (NCAA) Concussion Study (1999-2001) and the NCAA-Department of Defense Concussion Assessment, Research and Education (CARE) Consortium (2014-2017) to examine how clinical management, return to play (RTP) and risk of repeat concussion in collegiate football players have changed over the past 15 years. Methods We analysed data on reported duration of symptoms, symptom-free waiting period (SFWP), RTP and occurrence of within-season repeat concussion in collegiate football players with diagnosed concussion from the NCAA Study (n=184) and CARE (n=701). Results CARE athletes had significantly longer symptom duration (CARE median=5.92 days, IQR=3.02-9.98 days; NCAA median=2.00 days, IQR=1.00-4.00 days), SFWP (CARE median=6.00 days, IQR=3.49-9.00 days; NCAA median=0.98 days, IQR=0.00-4.00 days) and RTP (CARE median=12.23 days, IQR=8.04-18.92 days; NCAA median=3.00 days, IQR=1.00-8.00 days) than NCAA Study athletes (all p<0.0001). In CARE, there was only one case of repeat concussion within 10 days of initial injury (3.7% of within-season repeat concussions), whereas 92% of repeat concussions occurred within 10 days in the NCAA Study (p<0.001). The average interval between first and repeat concussion in CARE was 56.41 days, compared with 5.59 days in the NCAA Study (M difference=50.82 days; 95% CI 38.37 to 63.27; p<0.0001). Conclusion Our findings indicate that concussion in collegiate football is managed more conservatively than 15 years ago. These changes in clinical management appear to have reduced the risk of repetitive concussion during the critical period of cerebral vulnerability after sport-related concussion (SRC). These data support international guidelines recommending additional time for brain recovery before athletes RTP after SRC.	[McCrea, Michael] Med Coll Wisconsin, Neurosurg, Milwaukee, WI 53226 USA; [Broglio, Steven] Univ Michigan, Kinesiol, Ann Arbor, MI 48109 USA; [McAllister, Thomas] Indiana Univ Sch Med, Psychiat, Indianapolis, IN 46202 USA; [Zhou, Wenxian; Zhao, Shi; Katz, Barry] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA; [Kudela, Maria] Takeda Pharmaceut, Osaka, Japan; [Harezlak, Jaroslaw] Indiana Univ Syst, Sch Publ Hlth Bloomington, Dept Epidemiol & Biostat, Bloomington, IN USA; [Nelson, Lindsay] Med Coll Wisconsin, Neurosurg & Neurol, Milwaukee, WI 53226 USA; [Meier, Timothy] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Meier, Timothy] Med Coll Wisconsin, Dept Cell Biol, Milwaukee, WI 53226 USA; [Marshall, Stephen William] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27515 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Sports Med Res Lab, Chapel Hill, NC 27515 USA; [Hoy, April Marie (Reed)] Azusa Pacific Univ, Azusa, CA 91702 USA; [Hazzard, Joseph B., Jr.] Bloomsburg Univ, Bloomsburg, PA USA; [Kelly, Louise A.] Calif Lutheran Univ, Thousand Oaks, CA USA; [Ortega, Justus D.] Humboldt State Univ, Arcata, CA 95521 USA; [Port, Nicholas] Indiana Univ, Bloomington, IN 47405 USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Langford, T. Dianne; Tierney, Ryan] Temple Univ, Philadelphia, PA 19122 USA; [Pasquina, Paul] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Campbell, Darren E.; Jackson, Jonathan; McGinty, Gerald] US Air Force Acad, Colorado Springs, CO 80840 USA; [O'Donnell, Patrick] US Coast Guard Acad, New London, CT USA; [Cameron, Kenneth; Houston, Megan; Svoboda, Steven] US Mil Acad, West Point, NY 10996 USA; [Giza, Christopher; Goldman, Joshua; DiFiori, Jon] Univ Calif Los Angeles, Los Angeles, CA USA; [Benjamin, Holly J.] Univ Chicago, Chicago, IL 60637 USA; [Buckley, Thomas; Kaminski, Thomas W.] Univ Delaware, Newark, DE 19716 USA; [Clugston, James R.] Univ Florida, Gainesville, FL 32611 USA; [Schmidt, Julianne D.] Univ Georgia, Athens, GA 30602 USA; [Feigenbaum, Luis A.] Univ Miami, Coral Gables, FL 33124 USA; [Eckner, James T.] Univ Michigan, Ann Arbor, MI 48109 USA; [Mihalik, Jason P.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Miles, Jessica Dysart] Univ North Georgia, Dahlonega, GA USA; [Anderson, Scott] Univ Oklahoma, Norman, OK 73019 USA; [Arbogast, Kristy; Master, Christina L.] Univ Penn, Philadelphia, PA 19104 USA; [Collins, Micky; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Bazarian, Jeffrey J.] Univ Rochester, Rochester, NY 14627 USA; [Chrisman, Sara P. D.] Univ Washington, Seattle, WA 98195 USA; [Brooks, M. Alison] Univ Wisconsin, Madison, WI 53706 USA; [Duma, Stefan; Rowson, Steven] Virginia Tech, Blacksburg, VA USA; [Miles, Christopher M.] Wake Forest Univ, Winston Salem, NC 27101 USA; [Dykhuizen, Brian H.] Wilmington Coll, Wilmington, OH USA; [Lintner, Laura] Winston Salem State Univ, Winston Salem, NC USA		McCrea, M (corresponding author), Med Coll Wisconsin, Neurosurg, Milwaukee, WI 53226 USA.	mmccrea@mcw.edu	Buckley, Thomas A/B-7525-2016; Rowson, Steven/B-1270-2012; Harezlak, Jaroslaw/P-8557-2014	Buckley, Thomas A/0000-0002-0515-0150; Rowson, Steven/0000-0002-3227-0596; Clugston, James/0000-0002-2103-1039; Harezlak, Jaroslaw/0000-0002-3070-7686; Cameron, Kenneth/0000-0002-6276-4482	Grand Alliance Concussion Assessment, Research and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Department of Defense (DOD)United States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research and Education (CARE) Consortium, funded, in part by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DOD). The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No W81XWH-14-2-0151.	Broglio SP, 2017, SPORTS MED, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Ferrara Michael S., 2001, J Athl Train, V36, P145; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kamins J, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097464; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Lancaster MA, 2016, HUM BRAIN MAPP, V37, P3821, DOI 10.1002/hbm.23278; LaRoche AA, 2016, CLIN J SPORT MED, V26, P33, DOI 10.1097/JSM.0000000000000192; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2017, BR J SPORTS MED, V26; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; NCAA Sports Science Institute, CONC ED RES; NCAA Sports Science Institute, CONC SAF PROT MAN; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pfaller AY, 2016, AM J SPORT MED, V44, P2941, DOI 10.1177/0363546516651821; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Sarmiento K, 2014, J SAFETY RES, V50, P143, DOI 10.1016/j.jsr.2014.05.003; Svan Buuren, 2011, J STAT SOFTWARE, V45; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Yang J, 2017, AM J PUBLIC HLTH, V107, pe1	35	37	37	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2020	54	2					102	109		10.1136/bjsports-2019-100579			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	KD4WR	WOS:000507867100010	31036562	Green Submitted, Bronze			2022-02-06	
J	Griffin, AD; Turtzo, LC; Parikh, GY; Tolpygo, A; Lodato, Z; Moses, AD; Nair, G; Perl, DP; Edwards, NA; Dardzinski, BJ; Armstrong, RC; Ray-Chaudhury, A; Mitra, PP; Latour, LL				Griffin, Allison D.; Turtzo, L. Christine; Parikh, Gunjan Y.; Tolpygo, Alexander; Lodato, Zachary; Moses, Anita D.; Nair, Govind; Perl, Daniel P.; Edwards, Nancy A.; Dardzinski, Bernard J.; Armstrong, Regina C.; Ray-Chaudhury, Abhik; Mitra, Partha P.; Latour, Lawrence L.			Traumatic microbleeds suggest vascular injury and predict disability in traumatic brain injury	BRAIN			English	Article						radiological-pathological analysis; MRI biomarkers of traumatic brain injury; traumatic vascular injury; traumatic microbleeds; mild traumatic brain injury	DIFFUSE AXONAL INJURY; LONG-TERM DISABILITY; CEREBRAL MICROBLEEDS; UNITED-STATES; HEAD-INJURY; LESIONS; MICROHEMORRHAGES; CHILDREN; RECOVERY; DISEASE	Traumatic microbleeds are small foci of hypointensity seen on T-2*-weighted MRI in patients following head trauma that have previously been considered a marker of axonal injury. The linear appearance and location of some traumatic microbleeds suggests a vascular origin. The aims of this study were to: (i) identify and characterize traumatic microbleeds in patients with acute traumatic brain injury; (ii) determine whether appearance of traumatic microbleeds predict clinical outcome; and (iii) describe the pathology underlying traumatic microbleeds in an index patient. Patients presenting to the emergency department following acute head trauma who received a head CT were enrolled within 48 h of injury and received a research MRI. Disability was defined using Glasgow Outcome Scale-Extended <= 6 at follow-up. All magnetic resonance images were interpreted prospectively and were used for subsequent analysis of traumatic microbleeds. Lesions on T-2* MRI were stratified based on 'linear' streak-like or 'punctate' petechial-appearing traumatic microbleeds. The brain of an enrolled subject imaged acutely was procured following death for evaluation of traumatic microbleeds using MRI targeted pathology methods. Of the 439 patients enrolled over 78 months, 31% (134/439) had evidence of punctate and/or linear traumatic microbleeds on MRI. Severity of injury, mechanism of injury, and CT findings were associated with traumatic microbleeds on MRI. The presence of traumatic microbleeds was an independent predictor of disability (P < 0.05; odds ratio = 2.5). No differences were found between patients with punctate versus linear appearing microbleeds. Post-mortem imaging and histology revealed traumatic microbleed co-localization with iron-laden macrophages, predominately seen in perivascular space. Evidence of axonal injury was not observed in co-localized histopathological sections. Traumatic microbleeds were prevalent in the population studied and predictive of worse outcome. The source of traumatic microbleed signal on MRI appeared to be iron-laden macrophages in the perivascular space tracking a network of injured vessels. While axonal injury in association with traumatic microbleeds cannot be excluded, recognizing traumatic microbleeds as a form of traumatic vascular injury may aid in identifying patients who could benefit from new therapies targeting the injured vasculature and secondary injury to parenchyma.	[Griffin, Allison D.; Lodato, Zachary; Moses, Anita D.; Perl, Daniel P.; Dardzinski, Bernard J.; Armstrong, Regina C.; Latour, Lawrence L.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Griffin, Allison D.; Turtzo, L. Christine; Moses, Anita D.; Latour, Lawrence L.] Natl Inst Neurol Disorders & Stroke, Acute Cerebrovasular Diagnost Unit, Bethesda, MD USA; [Parikh, Gunjan Y.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Program Trauma, Baltimore, MD 21201 USA; [Parikh, Gunjan Y.] Univ Maryland, Sch Med, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Baltimore, MD 21201 USA; [Tolpygo, Alexander; Lodato, Zachary; Mitra, Partha P.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Nair, Govind; Latour, Lawrence L.] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA; [Perl, Daniel P.; Dardzinski, Bernard J.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Edwards, Nancy A.; Ray-Chaudhury, Abhik] Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, Bethesda, MD USA		Latour, LL (corresponding author), Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA.; Latour, LL (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.	LatourL@ninds.nih.gov	Parikh, Gunjan/AAS-1375-2020; Latour, Larry/AAH-5663-2021	Parikh, Gunjan/0000-0002-8447-1349; Latour, Larry/0000-0001-6160-5263; Griffin, Allison/0000-0001-7055-068X	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Crick-Clay Professorship; Mathers Foundation; Intramural Research Programs at the NIH Clinical CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This work was supported by the Department of Defense in the Center for Neuroscience and Regenerative Medicine, the Intramural Research Programs at the NIH Clinical Center and NINDS, the Crick-Clay Professorship and the Mathers Foundation. The contents of this article are solely the responsibility of the authors and do not represent the official views of the Department of Defense or the Center for Neuroscience and Regenerative Medicine.	Absinta M, 2014, J NEUROPATH EXP NEUR, V73, P780, DOI 10.1097/NEN.0000000000000096; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Conijn MMA, 2011, AM J NEURORADIOL, V32, P1043, DOI 10.3174/ajnr.A2450; Cota MR, 2019, J NEUROTRAUM, V36, P1335, DOI 10.1089/neu.2018.5772; Fisher M, 2010, STROKE, V41, P2782, DOI 10.1161/STROKEAHA.110.593657; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Huang Y-L, 2015, J NEUROL NEUROPHYSIO, V6, P321; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Izzy S, 2017, NEUROCRIT CARE, V27, P199, DOI 10.1007/s12028-017-0399-2; Keene CD, 2018, ACTA NEUROPATHOL, V135, P303, DOI 10.1007/s00401-017-1801-z; Kenney K, 2018, ANN CLIN TRANSL NEUR, V5, P418, DOI 10.1002/acn3.541; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Lawrence TP, 2017, NEUROSCI LETT, V655, P143, DOI 10.1016/j.neulet.2017.06.046; Lee B, 2018, INT J MIGR HEALTH SO, V14, P1, DOI 10.1108/IJMHSC-01-2016-0003; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Loftus TJ, 2016, SHOCK, V46, P341, DOI 10.1097/SHK.0000000000000636; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mizuma A, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00467; Naka H, 2004, AM J NEURORADIOL, V25, P714; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pinskiy V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0102363; Ramos-Cejudo J, 2018, EBIOMEDICINE, V28, P21, DOI 10.1016/j.ebiom.2018.01.021; Ricciardi MC, 2017, J NEUROTRAUM, V34, P23, DOI 10.1089/neu.2015.4338; Riedy G, 2016, RADIOLOGY, V279, P207, DOI 10.1148/radiol.2015150438; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Tatsumi S, 2008, CEREBROVASC DIS, V26, P142, DOI 10.1159/000139661; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Toth A, 2016, NEUROSCI LETT, V617, P207, DOI 10.1016/j.neulet.2016.02.028; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; van Veluw SJ, 2015, JOVE-J VIS EXP, DOI 10.3791/53125; van Veluw SJ, 2013, J CEREBR BLOOD F MET, V33, P322, DOI 10.1038/jcbfm.2012.196; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang RL, 2006, J NEUROSCI RES, V83, P1213, DOI 10.1002/jnr.20813	50	37	37	1	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV	2019	142		11				3550	3564		10.1093/brain/awz290			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	JY3MS	WOS:000504323200031	31608359	Green Published, hybrid			2022-02-06	
J	Mayhew, LJ; Bergin, C				Mayhew, Laura J.; Bergin, Colleen			Impact of e-scooter injuries on Emergency Department imaging	JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY			English	Article						electric scooter; emergency; e-scooter; imaging; radiology		Introduction Since the introduction of a shared e-scooter service to Auckland in October there have been multiple media reports of associated injuries, but no quantitation of the number or severity of these injuries, or the impact on hospital emergency department services in Auckland. Methods We performed a retrospective chart review on all patients referred to Auckland hospital ED radiology with the indication containing 'e-scooter' between 15 August 2018 and 15 December 2018. All requests were screened to ensure that the injury was caused by an e-scooter. Recorded data included patient demographics, type of imaging utilised, injury type, and whether admission or surgery was required. Results Sixty-four patients met the inclusion criteria, only one of these was prior to introduction of shared e-scooters on 15 October 2018. Of these, there were 27 limb fractures, 3 dislocations, a fractured spine, 12 patients with concussion, 1 extra-dural bleed, 9 facial/skull fractures and multiple soft tissue injuries. Almost 40% of the patients required admission to a specialty service following imaging, and 25.4% required surgery. A total of 221 plain films and 47 CT scans were performed for e-scooter injuries in the 2-month period after their introduction. Conclusion Introduction of shared e-scooters has resulted in a large number of serious related injuries that have required urgent radiology imaging. Many of these patients required further specialist consultation or surgery, and place an increased burden on overstretched emergency department services.	[Mayhew, Laura J.] Auckland City Hosp, Dept Radiol, 2 Pk Rd, Auckland 1023, New Zealand; [Bergin, Colleen] Univ Auckland, FMHS, Auckland, New Zealand		Mayhew, LJ (corresponding author), Auckland City Hosp, Dept Radiol, 2 Pk Rd, Auckland 1023, New Zealand.	lmay023@aucklanduni.ac.nz					[Anonymous], 2019, LOW POW VEH; Azad A, 2018, CNN; Holley Peter, 2018, WASH POST; Leahy B, 2018, NZ HERALD; Marshall A, 2018, WIRED           0417; Olivier J, 2017, INT J EPIDEMIOL, V46, P278, DOI [10.1093/ije/dyw153, 10.1093/ije/dyw360]; Orsman B, 2019, NZ HERALD; Pritchard C, 2018, AUSTIN MONITOR  0430	8	37	37	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1754-9477	1754-9485		J MED IMAG RADIAT ON	J. Med. Imag. Radiat. Oncol.	AUG	2019	63	4					461	466		10.1111/1754-9485.12889			6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	IN8PV	WOS:000478942900005	30972936				2022-02-06	
J	Nicholson, SE; Watts, LT; Burmeister, DM; Merrill, D; Scroggins, S; Zou, Y; Lai, Z; Grandhi, R; Lewis, AM; Newton, LM; Eastridge, BJ; Schwacha, MG				Nicholson, Susannah E.; Watts, Lora T.; Burmeister, David M.; Merrill, Daniel; Scroggins, Shannon; Zou, Yi; Lai, Zhao; Grandhi, Ramesh; Lewis, Aaron M.; Newton, Larry M.; Eastridge, Brian J.; Schwacha, Martin G.			MODERATE TRAUMATIC BRAIN INJURY ALTERS THE GASTROINTESTINAL MICROBIOME IN A TIME-DEPENDENT MANNER	SHOCK			English	Article						Brain-gut axis; gastrointestinal (GI); gut; commensals; microbiome; traumatic brain injury (TBI)	GUT MICROBIOTA; BIOMARKERS; PERFUSION; AXIS	The microbiome is defined as the collective genomes of the microbes (composed of bacteria, bacteriophage, fungi, protozoa, and viruses) that colonize the human body, and alterations have been associated with a number of disease states. Changes in gut commensals can influence the neurologic system via the brain-gut axis, and systemic insults such as trauma or traumatic brain injury (TBI) may alter the gut microbiome. The objective of this study was to evaluate the gut microbiome in a preclinical TBI cortical impact model. Male rats underwent craniotomy and randomized to a sham group (n = 4), or a moderate TBI (n = 10) using a pneumatic impactor. MRI and behavioral assessments were performed pre-TBI and on days 2, 7, and 14 days thereafter. Microbiome composition was determined with 16s rRNA sequencing from fecal sample DNA pre-TBI and 2 hrs, 1, 3, and 7 days afterward. Alpha- and beta-bacterial diversity, as well as organizational taxonomic units (OTUs), were determined. Significant changes in the gut microbiome were evident as early as 2 h after TBI as compared with pre-injured samples and sham rats. While there were varying trends among the phylogenetic families across time, some changes persisted through 7 days in the absence of therapeutic intervention. While large structural lesions and behavioral deficits were apparent post-TBI, there were modest but significant decreases in alpha-diversity. Moreover, both changes in representative phyla and alpha-diversity measures were significantly correlated with MRI-determined lesion volume. These results suggest that changes in the microbiome may represent a novel biomarker to stage TBI severity and predict functional outcome.	[Nicholson, Susannah E.; Merrill, Daniel; Scroggins, Shannon; Grandhi, Ramesh; Lewis, Aaron M.; Newton, Larry M.; Eastridge, Brian J.; Schwacha, Martin G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; [Watts, Lora T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Burmeister, David M.; Schwacha, Martin G.] US Army, Inst Surg Res, Ft Sam Houston, TX 78234 USA; [Zou, Yi; Lai, Zhao] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA		Nicholson, SE (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	Nicholson@uthscsa.edu	Scroggins, Shannon/AAY-5909-2020; Nicholson, Susannah/AAI-2757-2021	Sayyadioskoie, Shannon/0000-0002-2542-8877	National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001118]; University of Texas Health Science Center at San Antonio Military Health Institute; Bob Kelso Endowment; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001118] Funding Source: NIH RePORTER	The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2 TR001118. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Department of the Army and the Department of Defense. Support was also received by the University of Texas Health Science Center at San Antonio Military Health Institute, the Bob Kelso Endowment awarded to the UTHSCSA Department of Surgery and The Greehey Children's Cancer Research Institute Genome Sequencing Facility's Illumina MiSeq Pilot Grant.	Adelson PD, 1998, ACT NEUR S, V71, P104; Ahluwalia V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26800; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Braniste V, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009759; Caricilli Andrea Moro, 2014, World J Gastrointest Pathophysiol, V5, P18, DOI 10.4291/wjgp.v5.i1.18; Carlucci C, 2016, EBIOMEDICINE, V13, P37, DOI 10.1016/j.ebiom.2016.09.029; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Earley ZM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129996; Faith DP, 2006, EVOL BIOINFORM, V2, P121; Garrett WS, 2010, CELL HOST MICROBE, V8, P292, DOI 10.1016/j.chom.2010.08.004; Grenham S, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00094; Houlden A, 2016, BRAIN BEHAV IMMUN, V57, P10, DOI 10.1016/j.bbi.2016.04.003; Ivanov II, 2012, CELL HOST MICROBE, V12, P496, DOI 10.1016/j.chom.2012.09.009; Keenan JI, 2016, ANAEROBE, V40, P50, DOI 10.1016/j.anaerobe.2016.05.004; Korley FK, 2019, J NEUROTRAUM, V36, P182, DOI 10.1089/neu.2017.5623; Korley FK, 2016, J NEUROTRAUM, V33, P215, DOI 10.1089/neu.2015.3949; Krezalek MA, 2016, SHOCK, V45, P475, DOI 10.1097/SHK.0000000000000534; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Liu ZHM, 2004, MAGN RESON MED, V52, P277, DOI 10.1002/mrm.20148; Lloyd-Price J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0307-y; Mayer EA, 2015, J CLIN INVEST, V125, P926, DOI 10.1172/JCI76304; Paziana K, 2015, FUTUR NEUROL, V10, P281, DOI 10.2217/FNL.15.13; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Scheperjans F, 2015, MOVEMENT DISORD, V30, P350, DOI 10.1002/mds.26069; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Singh V, 2016, J NEUROSCI, V36, P7428, DOI 10.1523/JNEUROSCI.1114-16.2016; Solomon S, 2003, AM J INFECT CONTROL, V31, P481; Travagli RA, 2006, ANNU REV PHYSIOL, V68, P279, DOI 10.1146/annurev.physiol.68.040504.094635; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071108	35	37	38	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	AUG	2019	52	2					240	248		10.1097/SHK.0000000000001211			9	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	IQ5NG	WOS:000480798900014	29953417	Bronze			2022-02-06	
J	Sanchez, EJ; Gabler, LF; Good, AB; Funk, JR; Crandall, JR; Panzer, MB				Sanchez, Erin J.; Gabler, Lee F.; Good, Ann B.; Funk, James R.; Crandall, Jeff R.; Panzer, Matthew B.			A reanalysis of football impact reconstructions for head kinematics and finite element modeling	CLINICAL BIOMECHANICS			English	Article						Laboratory reconstructions; Head kinematics; Finite element model; Brain strain; Concussion; Football	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; IN-VIVO; CONCUSSION; RESPONSES; STRAIN; ACCELERATIONS; PREDICTORS; PLAYERS	Background: Head kinematics generated by laboratory reconstructions of professional football helmet impacts have been applied to computational models to study the biomechanics of concussion. Since the original publication of this data, techniques for evaluating accelerometer consistency and error correction have been developed. This study applies these techniques to the original reconstruction data and reanalyzes the results given the current state of concussion biomechanics. Methods: Consistency checks were applied to the sensor data collected in the head of each test dummy. Inconsistent data were corrected using analytical techniques, and head kinematics were recalculated from the corrected data. Reconstruction videos were reviewed to identify artefactual impacts during the reconstruction to establish the region of applicability for simulations. Corrected head kinematics were input into finite element brain models to investigate strain response to the corrected dataset. Findings: Multiple reconstruction cases had inconsistent sensor arrays caused by a problematic sensor; corrections to the arrays caused changes in calculated rotational head motion. These corrections increased median peak angular velocity for the concussion cases from 35.6 to 41.5 rad/s. Using the original kinematics resulted in an average error of 20% in maximum principal strain results for each case. Simulations of the reconstructions also demonstrated that simulation lengths less than 40 ms did not capture the entire brain strain response and under-predicted strain. Interpretation This study corrects data that were used to determine concussion risk, and indicates altered head angular motion and brain strain response for many reconstructions. Conclusions based on the original data should be re-examined based on this new study.	[Sanchez, Erin J.; Gabler, Lee F.; Crandall, Jeff R.; Panzer, Matthew B.] Univ Virginia, Dept Mech & Aerosp Engn, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA; [Good, Ann B.; Funk, James R.; Crandall, Jeff R.] Biocore LLC, 1621 Quail Run, Charlottesville, VA 22911 USA		Panzer, MB (corresponding author), Univ Virginia, Dept Mech & Aerosp Engn, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA.	mbp2q@virginia.edu			Football Research, Inc. (FRI)	Portions of the reanalysis presented in this paper were made possible by a grant from Football Research, Inc. (FRI). The views expressed are solely those of the authors and do not represent those of FRI or any of its affiliates or funding sources. The authors would like to thank Biokinetics and Associates Ltd. for their assistance in providing data and discussing the reanalysis procedures.	BANDAK FA, 1995, J NEUROTRAUM, V12, P635, DOI 10.1089/neu.1995.12.635; Beusenberg MC., 2000, P INT RES C BIOM IMP; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Chamouard F., 1987, SAE TECHNICAL PAPER; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Giordano C, 2017, BIOMECH MODEL MECHAN, V16, P1269, DOI 10.1007/s10237-017-0887-5; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Ho J, 2017, J BIOMECH, V60, P243, DOI 10.1016/j.jbiomech.2017.06.023; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kang HS, 1997, P STAPP CAR CRASH J, V41, P329; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; King A. I., 2003, IRCOBI C LISB PORT; Kjellstr?m, 2006, BASIC EPIDEMIOLOGY; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Newman J., 1999, INT RES COUNC BIOM I, P17; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Patton DA, 2016, APPL BIONICS BIOMECH, V2016, DOI 10.1155/2016/7049743; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson B, 2015, ANN BIOMED ENG, V43, P2429, DOI 10.1007/s10439-015-1278-7; Sanchez E, 2017, J NEUROTRAUM, V34, pA30; Sanchez EJ, 2017, J NEUROTRAUM, V34, P2410, DOI 10.1089/neu.2016.4681; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Siegmund G. P., 2015, ANN BIOMED ENG, P1; Takhounts E. G., 2009, P INT TECHN C ENH SA; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Willinger R, 2003, INT J CRASHWORTHINES, V8, P605, DOI 10.1533/ijcr.2003.0264; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhao W, 2017, ANN BIOMED ENG, V45, P2437, DOI 10.1007/s10439-017-1888-3; Zhao W, 2017, BIOMECH MODEL MECHAN, V16, P1709, DOI 10.1007/s10237-017-0915-5	43	37	37	0	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0268-0033	1879-1271		CLIN BIOMECH	Clin. Biomech.	APR	2019	64				SI		82	89		10.1016/j.clinbiomech.2018.02.019			8	Engineering, Biomedical; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Orthopedics; Sport Sciences	HY6ON	WOS:000468249700011	29559201				2022-02-06	
J	Lochhead, JJ; Kellohen, KL; Ronaldson, PT; Davis, TP				Lochhead, Jeffrey J.; Kellohen, Kathryn L.; Ronaldson, Patrick T.; Davis, Thomas P.			Distribution of insulin in trigeminal nerve and brain after intranasal administration	SCIENTIFIC REPORTS			English	Article							ALZHEIMER-DISEASE; RAT-BRAIN; TRANSPORT; IMPAIRMENT; DELIVERY; MODEL; MECHANISMS; RESISTANCE; RECEPTORS; PATHOLOGY	In the brain, insulin acts as a growth factor, regulates energy homeostasis, and is involved in learning and memory acquisition. Many central nervous system (CNS) diseases are characterized by deficits in insulin signaling. Pre-clinical studies have shown that intranasal insulin is neuroprotective in models of Alzheimer's disease, Parkinson's disease, and traumatic brain injury. Clinical trials have also shown that intranasal insulin elicits beneficial cognitive effects in patients with Alzheimer's disease. It is known that insulin can be detected in the CNS within minutes following intranasal administration. Despite these advances, the anatomical pathways that insulin utilizes to reach the CNS and the cellular CNS targets after intranasal administration are not fully understood. Here, we intranasally administered fluorescently labeled insulin and imaged its localization within the brain and trigeminal nerves. Our data indicates that intranasal insulin can reach cellular CNS targets along extracellular components of the trigeminal nerve. Upon CNS entry, we found insulin significantly increased levels of an activated form of the insulin receptor. These findings suggest that the intranasal route of administration is able to effectively deliver insulin to CNS targets in a biologically active form.	[Lochhead, Jeffrey J.; Kellohen, Kathryn L.; Ronaldson, Patrick T.; Davis, Thomas P.] Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA		Lochhead, JJ (corresponding author), Univ Arizona, Coll Med, Dept Pharmacol, Tucson, AZ 85724 USA.	lochhead@email.arizona.edu	Lochhead, Jeffrey/Q-1295-2018	Lochhead, Jeffrey/0000-0001-5554-4812	National Institutes of Health: National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [042652]; American Heart AssociationAmerican Heart Association [18CDA34110454]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042652] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health: National Institute of Neurological Disorders and Stroke (042652) (T.P.D.) and the American Heart Association (18CDA34110454) (J.J.L.). The authors wish to thank James Averill and Madeline Martinez for technical assistance.	Aldridge GM, 2008, J NEUROSCI METH, V172, P250, DOI 10.1016/j.jneumeth.2008.05.003; ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; Arnold SE, 2018, NAT REV NEUROL, V14, P168, DOI 10.1038/nrneurol.2017.185; Athauda D, 2016, PROG NEUROBIOL, V145, P98, DOI 10.1016/j.pneurobio.2016.10.001; Banks WA, 1997, PEPTIDES, V18, P1257, DOI 10.1016/S0196-9781(97)00198-8; Banks WA, 2012, PHARMACOL THERAPEUT, V136, P82, DOI 10.1016/j.pharmthera.2012.07.006; BASKIN DG, 1986, DIABETES, V35, P246, DOI 10.2337/diabetes.35.2.246; Benedict C, 2004, PSYCHONEUROENDOCRINO, V29, P1326, DOI 10.1016/j.psyneuen.2004.04.003; Born J, 2002, NAT NEUROSCI, V5, P514, DOI 10.1038/nn849; Brabazon F, 2017, J CEREBR BLOOD F MET, V37, P3203, DOI 10.1177/0271678X16685106; Carpenter MC, 2014, BIOCHEMISTRY-US, V53, P1296, DOI 10.1021/bi4016567; Cholerton B, 2013, EUR J PHARMACOL, V719, P170, DOI 10.1016/j.ejphar.2013.08.008; Craft S, 2012, ARCH NEUROL-CHICAGO, V69, P29, DOI 10.1001/archneurol.2011.233; Dodd GT, 2017, J NEUROENDOCRINOL, V29, DOI 10.1111/jne.12513; DREJER K, 1992, DIABETIC MED, V9, P335, DOI 10.1111/j.1464-5491.1992.tb01792.x; Freiherr J, 2013, CNS DRUGS, V27, P505, DOI 10.1007/s40263-013-0076-8; Ghasemi R, 2013, MOL NEUROBIOL, V47, P1045, DOI 10.1007/s12035-013-8404-z; Gray SP, 2017, DIABETOLOGIA, V60, P927, DOI 10.1007/s00125-017-4215-5; Heni M, 2015, NAT REV ENDOCRINOL, V11, P701, DOI 10.1038/nrendo.2015.173; Hersom M, 2018, AM J PHYSIOL-ENDOC M, V315, pE531, DOI 10.1152/ajpendo.00350.2016; Hjorth CF, 2016, J PHARM SCI-US, V105, P1376, DOI 10.1016/j.xphs.2016.01.003; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Kirshner ZZ, 2018, MOL CELL ENDOCRINOL, V473, P156, DOI 10.1016/j.mce.2018.01.015; Konishi M, 2017, P NATL ACAD SCI USA, V114, pE8478, DOI 10.1073/pnas.1710625114; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Lioutas VA, 2015, TRANSL STROKE RES, V6, P264, DOI 10.1007/s12975-015-0409-7; Lochhead JJ, 2015, J CEREBR BLOOD F MET, V35, P371, DOI 10.1038/jcbfm.2014.215; Lochhead JJ, 2012, ADV DRUG DELIVER REV, V64, P614, DOI 10.1016/j.addr.2011.11.002; Mao YF, 2016, AGING CELL, V15, P893, DOI 10.1111/acel.12498; MCDANIEL ML, 1980, METABOLISM, V29, P762, DOI 10.1016/0026-0495(80)90200-0; MESSINA JL, 1992, EXP CELL RES, V200, P532, DOI 10.1016/0014-4827(92)90206-N; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Nedelcovych MT, 2018, ACS CHEM NEUROSCI, V9, P809, DOI 10.1021/acschemneuro.7b00434; Pang Y, 2016, NEUROSCIENCE, V318, P157, DOI 10.1016/j.neuroscience.2016.01.020; Peng WG, 2016, NEUROBIOL DIS, V93, P215, DOI 10.1016/j.nbd.2016.05.015; Pizzo ME, 2018, J PHYSIOL-LONDON, V596, P445, DOI 10.1113/JP275105; Plum L, 2005, TRENDS ENDOCRIN MET, V16, P59, DOI 10.1016/j.tem.2005.01.008; Ramalingam M, 2014, J NEURAL TRANSM, V121, P611, DOI 10.1007/s00702-013-1147-1; Renner DB, 2012, J PHARM PHARMACOL, V64, P1709, DOI 10.1111/j.2042-7158.2012.01555.x; Rhea EM, 2018, J PHYSIOL-LONDON, V596, P4753, DOI 10.1113/JP276149; Rhea EM, 2017, J ALZHEIMERS DIS, V57, P241, DOI 10.3233/JAD-161095; Salameh TS, 2015, J ALZHEIMERS DIS, V47, P715, DOI 10.3233/JAD-150307; Schmid V, 2018, DIABETES OBES METAB, V20, P1563, DOI 10.1111/dom.13279; Spitzer N, 2011, J NEUROSCI METH, V197, P48, DOI 10.1016/j.jneumeth.2011.01.029; Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Tsuchiya A, 2014, J PHARMACOL SCI, V126, P337, DOI 10.1254/jphs.14182FP; Tsuchiya A, 2013, CELL PHYSIOL BIOCHEM, V32, P1451, DOI 10.1159/000356582; Wang C, 1992, Brain Res Mol Brain Res, V13, P289; Wang MH, 2017, J NEUROSCI, V37, P2870, DOI 10.1523/JNEUROSCI.2112-16.2017	51	37	38	5	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	FEB 22	2019	9								2621	10.1038/s41598-019-39191-5			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HM3UI	WOS:000459399400090	30796294	Green Published, gold			2022-02-06	
J	Lee, SW; Vaccari, JPD; Truettner, JS; Dietrich, WD; Keane, RW				Lee, Stephanie W.; Vaccari, Juan Pablo de Rivero; Truettner, Jessie S.; Dietrich, W. Dalton; Keane, Robert W.			The role of microglial inflammasome activation in pyroptotic cell death following penetrating traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Inflammasome; ASC; Pyroptosis; Microglia; Infiltrating leukocytes; Traumatic brain injury; Penetrating traumatic brain injury; PTBI; Penetrating ballistic-brain injury; PBBI	CIVILIAN GUNSHOT WOUNDS; GASDERMIN D; RAT MODEL; UNITED-STATES; ASC; NEUROINFLAMMATION; HEAD; NEUROPROTECTION; INHIBITION; PREDICTORS	BackgroundTraumatic brain injury remains a significant cause of death and disability in the USA. Currently, there are no effective therapies to mitigate disability except for surgical interventions necessitating a need for continued research into uncovering novel therapeutic targets. In a recent study, we used a rodent model of penetrating traumatic brain injury known as penetrating ballistic-like brain injury (PBBI) to examine the role of innate immunity in post-traumatic secondary injury mechanisms. We previously reported that the inflammasome, a multiprotein complex composed of apoptosis-associated speck-like protein containing card and caspase-1, plays a role in secondary cell death mechanisms after PBBI, including inflammatory cell death (pyroptosis).MethodsIn the current study, we used flow cytometry analysis to evaluate activated microglia and CD11b-positive leukocytes after PBBI and assessed inflammasome activation and pyroptosis of specific cellular populations. Sprague-Dawley male rats underwent PBBI or sham-operated procedures and ipsilateral cortical regions processed for flow cytometry and cellular analysis. Flow cytometry results were compared using one-way ANOVA followed by Tukey's multiple comparisons.ResultsAt 48h following PBBI, there was an increase in activated microglia and infiltrating leukocytes compared to sham controls that were associated with increased caspase-1 activity. Using a florescent probe to identify caspase-1 activity and a fluorescent assay to determine cell viability, evidence for pyroptosis in CD11b+ cells was also determined. Finally, while post-traumatic treatment with an anti-ASC antibody had no effect on the number of activated microglia and infiltrating leukocytes, antibody treatment decreased caspase-1 activity in both resident microglia and infiltrating leukocytes and reduced pyroptotic CD11b+ cell death.ConclusionsThese results provide evidence for inflammasome activation in microglia and infiltrating leukocytes after penetrating traumatic brain injury and a role for pyroptotic cell death in the pathophysiology. In addition to inhibiting neuronal cell death, therapeutic treatments targeting inflammasome activation may also provide beneficial effects by reducing the potentially detrimental consequences of activated microglia and infiltrating CD11b+ leukocytes following penetrating traumatic brain injury.	[Lee, Stephanie W.; Vaccari, Juan Pablo de Rivero; Truettner, Jessie S.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA		Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA.	swlee@med.miami.edu; rkeane@miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020; de Rivero Vaccari, Juan Pablo/H-5718-2019	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; 	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS089443, RO1 NS042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS089443] Funding Source: NIH RePORTER	This work was supported by NIH awards RO1 NS089443 and RO1 NS042133.	Aarabi B, 2014, J NEUROSURG, V120, P1138, DOI 10.3171/2014.1.JNS131869; Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Bakir A, 2005, NEUROL MED-CHIR, V45, P281, DOI 10.2176/nmc.45.281; Beaman V, 2000, ANN EMERG MED, V35, P258, DOI 10.1016/S0196-0644(00)70077-1; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Broderick L, 2015, ANNU REV PATHOL-MECH, V10, P395, DOI 10.1146/annurev-pathol-012414-040431; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Cartagena CM, 2013, NEUROMOL MED, V15, P504, DOI 10.1007/s12017-013-8236-z; Cartagena CM, 2013, J MOL NEUROSCI, V49, P301, DOI 10.1007/s12031-012-9828-z; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00209; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Defense and Veterans Brain Injury Center, 2018, DOD WORLDW NUMB TRAU; Deng-Bryant Y, 2015, RESTOR NEUROL NEUROS, V33, P189, DOI 10.3233/RNN-140455; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Du LL, 2017, MOL NEUROBIOL, V54, P1992, DOI 10.1007/s12035-016-9758-9; Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005; FORD AL, 1995, J IMMUNOL, V154, P4309; Franklin BS, 2014, NAT IMMUNOL, V15, P727, DOI 10.1038/ni.2913; Gajavelli S, 2015, J CEREBR BLOOD F MET, V35, P773, DOI 10.1038/jcbfm.2014.243; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gressot LV, 2014, J NEUROSURG, V121, P645, DOI 10.3171/2014.5.JNS131872; Greter M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00249; Hanisch UK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00065; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; Hellwig S, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00071; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Ji KA, 2007, GLIA, V55, P1577, DOI 10.1002/glia.20571; Joseph B, 2014, J AM COLL SURGEONS, V218, P58, DOI 10.1016/j.jamcollsurg.2013.08.018; Kabba J. A., 2017, CELL MOL NEUROBIOL, P1; Kerr NA, 2018, J NEUROTRAUM, V35, P2067, DOI 10.1089/neu.2017.5430; Kim JY, 2015, ONCOTARGET, V6, P44161, DOI 10.18632/oncotarget.6592; Lee SW, 2018, J NEUROTRAUM, V35, P1681, DOI 10.1089/neu.2017.5530; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Liu YG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.460; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu A, 2014, CELL, V156, P1193, DOI 10.1016/j.cell.2014.02.008; Lu XCM, 2016, THER HYPOTHERMIA TEM, V6, P30, DOI 10.1089/ther.2015.0017; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Oehmichen M, 2000, J NEUROTRAUM, V17, P155, DOI 10.1089/neu.2000.17.155; Oehmichen M, 2001, FORENSIC SCI INT, V115, P189, DOI 10.1016/S0379-0738(00)00335-2; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Perfetto SP, 2006, J IMMUNOL METHODS, V313, P199, DOI 10.1016/j.jim.2006.04.007; Qiu Z, 2017, OXID MED CELL LONGEV, V2017; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Rathkey JK, 2017, J BIOL CHEM, V292, P14649, DOI 10.1074/jbc.M117.797217; Sarkar S, 2017, NPJ PARKINSON DIS, V3, DOI 10.1038/s41531-017-0032-2; Shi FS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-73; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Taabazuing CY, 2017, CELL CHEM BIOL, V24, P507, DOI 10.1016/j.chembiol.2017.03.009; Tan MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.348; Torres-Platas SG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-12; Truettner JS, 2018, J NEUROTRAUM, V35, P940, DOI 10.1089/neu.2017.5303; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Venegas C, 2017, NATURE, V552, P355, DOI 10.1038/nature25158; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yao CP, 2008, BRAIN INJURY, V22, P723, DOI 10.1080/02699050802304706	77	37	39	2	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 8	2019	16								27	10.1186/s12974-019-1423-6			12	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	HK7EK	WOS:000458150700002	30736791	Green Published, gold			2022-02-06	
J	Ponsford, J; Nguyen, S; Downing, M; Bosch, M; McKenzie, JE; Turner, S; Chau, M; Mortimer, D; Gruen, RL; Knott, J; Green, S				Ponsford, Jennie; Nguyen, Sylvia; Downing, Marina; Bosch, Marije; McKenzie, Joanne E.; Turner, Simon; Chau, Marisa; Mortimer, Duncan; Gruen, Russell L.; Knott, Jonathan; Green, Sally			FACTORS ASSOCIATED WITH PERSISTENT POST-CONCUSSION SYMPTOMS FOLLOWING MILD TRAUMATIC BRAIN INJURY IN ADULTS	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; post-concussion symptoms; anxiety; quality of life	HEAD-INJURY; EARLY PREDICTORS; OUTCOMES; POPULATION; DEPRESSION; VALIDITY; ANXIETY; SCALES; RISK	Objectives: Debate regarding factors associated with persistent symptoms following mild traumatic brain injury continues. Nested within a trial aiming to change practice in emergency department management of mild traumatic brain injury, this study investigated the nature of persistent symptoms, work/ study outcomes, anxiety and quality of life and factors associated with persistent symptoms following injury, including the impact of receiving information about mild traumatic brain injuries in the emergency department. Methods: A total of 343 individuals with mild traumatic brain injury completed the Rivermead Post-Concussion Symptom Questionnaire, Hospital Anxiety Depression Scale - Anxiety Scale, and Quality of Life - Short Form an average 7 months post-injury. Results: Overall, 18.7% of participants reported 3 or more post-concussional symptoms, most commonly fatigue (17.2%) and forgetfulness (14.6%). Clinically significant anxiety was reported by 12.8%, and was significantly associated with symptom reporting, as were mental and physical quality of life scores. Significant predictors of post-concussional symptoms at follow-up were pre-injury psychological issues, experiencing loss of consciousness, and having no recall of receiving information about brain injury in the emergency department. Conclusion: This study confirms that loss of consciousness and pre-injury psychological issues are associated with persistent symptom reporting. Not receiving injury information in the emergency department may also negatively influence symptom reporting.	[Ponsford, Jennie; Nguyen, Sylvia; Downing, Marina] Epworth Healthcare, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie; Nguyen, Sylvia; Downing, Marina] Monash Univ, Sch Psychol Sci, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia; [Bosch, Marije; Chau, Marisa] Monash Univ, Cent Clin Sch, Dept Surg, Melbourne, Vic, Australia; [Bosch, Marije; Chau, Marisa] Alfred & Monash Univ, Natl Trauma Res Inst, Melbourne, Vic, Australia; [McKenzie, Joanne E.; Turner, Simon; Green, Sally] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Mortimer, Duncan] Monash Univ, Ctr Hlth Econ, Monash Business Sch, Melbourne, Vic, Australia; [Gruen, Russell L.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Gruen, Russell L.] Alfred Hosp, Dept Trauma, Melbourne, Vic, Australia; [Gruen, Russell L.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Knott, Jonathan] Univ Melbourne, Melbourne Med Sch, Melbourne, Vic, Australia; [Knott, Jonathan] Royal Melbourne Hosp, Dept Emergency Med, Melbourne, Vic, Australia; [Bosch, Marije] Univ Groningen, Fac Econ & Business, Groningen, Netherlands		Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Downing, Marina/AAX-2380-2020; McKenzie, Joanne/I-2925-2014	Downing, Marina/0000-0002-3126-6632; McKenzie, Joanne/0000-0003-3534-1641; Mortimer, Duncan Stuart/0000-0002-7211-6454; Turner, Simon/0000-0001-9163-4524	Victorian Transport Accident Commission (TAC), Australia	The authors would like to thank all the hospital emergency departments (ED) involved in this study, in particular the ED staff who recruited patients for this study. We would like to also thank all MERRC staff who conducted the follow-up interviews. This study is part of a 5-year grant (the Neurotrauma Evidence Translation (NET) Program), funded by the Victorian Transport Accident Commission (TAC), Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews G, 2002, AUST NZ J PUBL HEAL, V26, P508, DOI 10.1111/j.1467-842X.2002.tb00357.x; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bosch M, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-281; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chiang CC, 2016, QUAL LIFE RES, V25, P2009, DOI 10.1007/s11136-015-1215-0; Cnossen MC, 2018, J NEUROTRAUM, V35, P2691, DOI 10.1089/neu.2017.5486; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Hadanny A, 2016, EXPERT REV NEUROTHER, V16, P875, DOI 10.1080/14737175.2016.1205487; Hilbe, 2012, GEN ESTIMATING EQUAT; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; King NS, 2014, BRAIN INJURY, V28, P1639, DOI 10.3109/02699052.2014.954271; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kumar RG, 2014, AM J PHYS MED REHAB, V93, P687, DOI 10.1097/PHM.0000000000000077; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TURNERSTOKES L, 2015, COCHRANE DATABASE SY; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wojcik SM, 2014, BRAIN INJURY, V28, P422, DOI 10.3109/02699052.2014.884241; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	37	38	2	12	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JAN	2019	51	1					32	39		10.2340/16501977-2492			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	HF1LG	WOS:000453927200006	30426138	Green Published, gold			2022-02-06	
J	Mentiplay, BF; Banky, M; Clark, RA; Kahn, MB; Williams, G				Mentiplay, Benjamin F.; Banky, Megan; Clark, Ross A.; Kahn, Michelle B.; Williams, Gavin			Lower limb angular velocity during walking at various speeds	GAIT & POSTURE			English	Article						Gait; Angular velocity; Kinematics; Biomechanics; Mobility	TOTAL KNEE ARTHROPLASTY; TRAUMATIC BRAIN-INJURY; HIP-JOINT CENTER; CEREBRAL-PALSY; GAIT ANALYSIS; NEUROLOGIC REHABILITATION; OLDER-PEOPLE; SPASTICITY; CHILDREN; STROKE	Background: Although it is well established that lower limb joint angles adapt to walking at various speeds, limited research has examined the modifications in joint angular velocity. There is currently no normative dataset for joint angular velocity during walking, which would be useful to allow comparisons for patient cohorts. Additionally, understanding normal joint angular velocity may assist clinical assessment and treatment procedures to incorporate methods that replicate the movement speed of the lower limb joints during walking. Research Question: This study aimed to examine lower limb joint angles and angular velocities in a healthy population walking at various gait speeds. Methods: Thirty-six healthy adult participants underwent three-dimensional gait analysis while walking at various speeds during habitual and slowed walking. The peak joint angles and angular velocities during important phases of the gait cycle were examined for the hip, knee and ankle in the sagittal plane. Data were grouped in 0.2 m/s increments from a walking speed of 0.4 m/s to 1.6 m/s to represent the range of walking speeds reported in studies of people with gait impairments. Results: For joint angles and angular velocities, the shape of the gait traces were consistent regardless of the walking speed. However as walking speed increased, so did the peak joint angles and angular velocities for the hip, knee and ankle. The largest angular velocity occurred when the knee joint extended at the terminal swing phase of gait. For the ankle and hip joints, the largest angular velocity occurred during the push-off phase. Significance: This study examined how lower limb joint angular velocities change with various walking speeds. These data can be used as a comparator for data from clinical cohorts, and has the potential to be used to match clinical assessment and treatment methods to joint angular velocity during walking.	[Mentiplay, Benjamin F.; Banky, Megan; Kahn, Michelle B.; Williams, Gavin] Epworth HealthCare, Dept Physiotherapy, Richmond, Vic, Australia; [Mentiplay, Benjamin F.] La Trobe Univ, La Trobe Sport & Exercise Med Res Ctr, Bundoora, Vic 3086, Australia; [Mentiplay, Benjamin F.] Murdoch Childrens Res Inst, Victorian Infant Brain Studies, Melbourne, Vic, Australia; [Banky, Megan; Clark, Ross A.; Kahn, Michelle B.] Univ Sunshine Coast, Sch Hlth & Sport Sci, Sippy Downs, Qld, Australia; [Williams, Gavin] Univ Melbourne, Dept Physiotherapy, Melbourne, Vic, Australia		Mentiplay, BF (corresponding author), La Trobe Univ, La Trobe Sport & Exercise Med Res Ctr, Bundoora, Vic 3086, Australia.	b.mentiplay@latrobe.edu.au	Mentiplay, Benjamin/A-2279-2019; Clark, Ross/K-7613-2019; Clark, Ross A/R-5664-2018	Mentiplay, Benjamin/0000-0002-4360-8310; Clark, Ross/0000-0002-7291-8553; Clark, Ross A/0000-0002-7291-8553	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [1090415]	Author RAC is supported by a RD Wright Biomedical Fellowship (#1090415) from the National Health and Medical Research Council.	Afilalo J, 2010, J AM COLL CARDIOL, V56, P1668, DOI 10.1016/j.jacc.2010.06.039; Akman MN, 1999, SPINAL CORD, V37, P638, DOI 10.1038/sj.sc.3100892; Baker R., 2003, ALL YOU EVER WANTED; Banky M, 2017, BRAIN INJURY, V31, P440, DOI 10.1080/02699052.2016.1271455; Bean JF, 2002, J AM GERIATR SOC, V50, P461; Beaulieu ML, 2010, GAIT POSTURE, V32, P269, DOI 10.1016/j.gaitpost.2010.05.007; Carse B, 2013, PHYSIOTHERAPY, V99, P347, DOI 10.1016/j.physio.2013.03.001; Collins TD, 2009, GAIT POSTURE, V30, P173, DOI 10.1016/j.gaitpost.2009.04.004; Cuoco A, 2004, J GERONTOL A-BIOL, V59, P1200, DOI 10.1093/gerona/59.11.1200; Damiano DL, 2006, GAIT POSTURE, V23, P1, DOI 10.1016/j.gaitpost.2004.10.007; Dietz V, 2007, LANCET NEUROL, V6, P725, DOI 10.1016/S1474-4422(07)70193-X; Harrington ME, 2007, J BIOMECH, V40, P595, DOI 10.1016/j.jbiomech.2006.02.003; Hendrey G, 2018, ARCH PHYS MED REHAB, V99, P2430, DOI 10.1016/j.apmr.2018.04.032; Hof A.L., 1996, GAIT POSTURE, V4, P222; Liu MQ, 2008, J BIOMECH, V41, P3243, DOI 10.1016/j.jbiomech.2008.07.031; Lord SE, 2004, ARCH PHYS MED REHAB, V85, P234, DOI 10.1016/j.apmr.2003.05.002; Lu TW, 1999, J BIOMECH, V32, P129, DOI 10.1016/S0021-9290(98)00158-4; McGinley JL, 2009, GAIT POSTURE, V29, P360, DOI 10.1016/j.gaitpost.2008.09.003; Mentiplay BF, 2018, GAIT POSTURE, V64, P75, DOI 10.1016/j.gaitpost.2018.05.033; OLNEY SJ, 1996, GAIT POSTURE, V4, P136, DOI 10.1016/0966-6362(96)01063-6; Pohl PS, 2000, CLIN REHABIL, V14, P601, DOI 10.1191/0269215500cr367oa; Pua YH, 2017, SEMIN ARTHRITIS RHEU, V46, P544, DOI 10.1016/j.semarthrit.2016.10.012; Pua YH, 2013, ARCH PHYS MED REHAB, V94, P503, DOI 10.1016/j.apmr.2012.10.008; Roberts M., 2017, PHYS THER REHABIL, V4, P6, DOI 10.7243/2055-2386-4-6; SAHRMANN SA, 1977, ANN NEUROL, V2, P460, DOI 10.1002/ana.410020604; Salter K, 2016, TOP STROKE REHABIL, V23, P366, DOI 10.1080/10749357.2016.1160656; Sangeux M, 2014, GAIT POSTURE, V40, P20, DOI 10.1016/j.gaitpost.2014.01.024; Schwartz MH, 2008, J BIOMECH, V41, P1639, DOI 10.1016/j.jbiomech.2008.03.015; Scianni A, 2009, AUST J PHYSIOTHER, V55, P81, DOI 10.1016/S0004-9514(09)70037-6; Sinclair J, 2013, J HUM KINET, V39, P25, DOI 10.2478/hukin-2013-0065; Sofuwa O, 2005, ARCH PHYS MED REHAB, V86, P1007, DOI 10.1016/j.apmr.2004.08.012; Stansfield BW, 2001, J PEDIATR ORTHOPED, V21, P395, DOI 10.1097/00004694-200105000-00026; Thewlis D, 2013, J APPL BIOMECH, V29, P112, DOI 10.1123/jab.29.1.112; Tuzson AE, 2003, ARCH PHYS MED REHAB, V84, P1363, DOI 10.1016/S0003-9993(03)00199-0; Umberger BR, 2007, J EXP BIOL, V210, P3255, DOI 10.1242/jeb.000950; van Kan GA, 2009, J NUTR HEALTH AGING, V13, P881; Williams G, 2015, BRAIN INJURY, V29, P1232, DOI 10.3109/02699052.2015.1035328; Williams G, 2015, J HEAD TRAUMA REHAB, V30, pE49, DOI 10.1097/HTR.0000000000000094; Williams G, 2014, AM J PHYS MED REHAB, V93, P828, DOI 10.1097/PHM.0000000000000139; Williams G, 2014, AM J PHYS MED REHAB, V93, P511, DOI 10.1097/PHM.0000000000000058; WINTER DA, 1983, J MOTOR BEHAV, V15, P302; Wren TAL, 2008, GAIT POSTURE, V27, P530, DOI 10.1016/j.gaitpost.2007.07.006; Zeni JA, 2008, GAIT POSTURE, V27, P710, DOI 10.1016/j.gaitpost.2007.07.007	43	37	40	1	61	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362	1879-2219		GAIT POSTURE	Gait Posture	SEP	2018	65						190	196		10.1016/j.gaitpost.2018.06.162			7	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Orthopedics; Sport Sciences	GQ6YO	WOS:000441877300032					2022-02-06	
J	Gugliandolo, E; D'Amico, R; Cordaro, M; Fusco, R; Siracusa, R; Crupi, R; Impellizzeri, D; Cuzzocrea, S; Di Paola, R				Gugliandolo, Enrico; D'Amico, Ramona; Cordaro, Marika; Fusco, Roberta; Siracusa, Rosalba; Crupi, Rosalie; Impellizzeri, Daniela; Cuzzocrea, Salvatore; Di Paola, Rosanna			Neuroprotective Effect of Artesunate in Experimental Model of Traumatic Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; neuroin flammation; neurodegeneration; artesunate; artemisin	CONTROLLED CORTICAL IMPACT; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; POSTTRAUMATIC NEURODEGENERATION; NLRP3 INFLAMMASOME; IN-VIVO; EXPRESSION; MICE; ACTIVATION; ARTEMISININ	Traumatic brain injuries (TBI) are an important public health challenge. In addition, subsequent events at TBI can compromise the quality of life of these patients. In fact, TBI is associated with several complications for both long and short term, some evidence shows how TBI is associated with a decline in cognitive functions such as the risk of developing dementia, cerebral atrophy, and Parkinson disease. After the direct damage from TBI, a key role in TBI injury is played by the inflammatory response and oxidative stress, that contributes to tissue damage and to neurodegenerative processes, typical of secondary injury, after TBI. Given the complex series of events that are involved after TBI injury, a multitarget pharmacological approach is needed. Artesunate is a more stable derivative of its precursor artemisin, a sesquiterpene lactone obtained from a Chinese plant Artemisia annua, a plant used for centuries in traditional Chinese medicine. artesunate has been shown to be a pluripotent agent with different pharmacological actions. therefore, in this experimental model of TBI we evaluated whether the treatment with artesunate at the dose of 30mg\Kg, had an efficacy in reducing the neuroinflammatory process after TBI injury, and in inhibiting the NLRP3 inflammasome pathway, which plays a key role in the inflammatory process. We also assessed whether treatment with artesunate was able to exert a neuroprotective action by modulating the release of neurotrophic factors. our results show that artesunate was able to reduce the TBI-induced lesion, it also showed an anti-inflammatory action through the inhibition of Nf-kappa b, release of proinflammatory cytokines IL-1 beta and TNF-alpha and through the inhibition NLRP3 inflammasome complex, furthermore was able to reduce the activation of astrocytes and microglia (GFAP, Iba-1). Finally, our results show that the protective effects of artesunate also occur through the modulation of neurotrophic factors (BDNF, GDNF, NT-3) that play a key role in neuronal survival.	[Gugliandolo, Enrico; D'Amico, Ramona; Cordaro, Marika; Fusco, Roberta; Siracusa, Rosalba; Crupi, Rosalie; Impellizzeri, Daniela; Cuzzocrea, Salvatore; Di Paola, Rosanna] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Messina, Italy; [Cuzzocrea, Salvatore] St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO 63103 USA		Cuzzocrea, S (corresponding author), Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Messina, Italy.	salvator@unime.it	FUSCO, Roberta/AAC-1745-2019; D'Amico, Ramona/AAC-9061-2019; Cordaro, Marika/K-7329-2016; Siracusa, Rosalba/AAC-3110-2022; di paola, rosanna/U-4356-2019; Gugliandolo, Enrico/AAB-9972-2019	FUSCO, Roberta/0000-0003-0223-1403; D'Amico, Ramona/0000-0003-0389-3871; Cordaro, Marika/0000-0002-3980-0043; Siracusa, Rosalba/0000-0001-7868-2505; di paola, rosanna/0000-0001-6725-8581; Gugliandolo, Enrico/0000-0001-6840-3154; Crupi, Rosalia/0000-0002-7629-3132; Impellizzeri, Daniela/0000-0001-9492-3161			Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Beccafico S, 2015, CARCINOGENESIS, V36, P1071, DOI 10.1093/carcin/bgv098; Berger TG, 2005, ONCOL REP, V14, P1599; Breunig JJ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00026; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Campolo M, 2018, METHODS MOL BIOL, V1727, P385, DOI 10.1007/978-1-4939-7571-6_30; Campolo M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0196-1; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Carbo-Gas M, 2014, ADDICT BIOL, V19, P61, DOI 10.1111/adb.12042; Cheng C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020932; Clemmer L, 2011, ANTIMICROB AGENTS CH, V55, P1383, DOI 10.1128/AAC.01277-10; Cordaro M, 2016, J NEUROTRAUM, V33, P132, DOI 10.1089/neu.2014.3460; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Efferth T, 2010, CRIT REV TOXICOL, V40, P405, DOI 10.3109/10408441003610571; Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286; Esposito E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041880; Esposito E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-66; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Guevara AB, 2015, J HEAD TRAUMA REHAB, V30, pE26, DOI 10.1097/HTR.0000000000000046; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Impellizzeri D, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00458; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Ismael S, 2018, J NEUROTRAUM, V35, P1294, DOI 10.1089/neu.2017.5344; Jennings JS, 2008, MINI-REV MED CHEM, V8, P689, DOI 10.2174/138955708784567377; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Li B, 2010, INT IMMUNOPHARMACOL, V10, P344, DOI 10.1016/j.intimp.2009.12.006; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Minnich JE, 2010, RESTOR NEUROL NEUROS, V28, P293, DOI 10.3233/RNN-2010-0528; Miranda AS, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-388; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mueller FJ, 2005, E SCHERING RES FDN W, V53, P83; Nosten F, 2007, AM J TROP MED HYG, V77, P181, DOI 10.4269/ajtmh.2007.77.181; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Patsouris D, 2008, CELL METAB, V8, P301, DOI 10.1016/j.cmet.2008.08.015; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RINK A, 1995, AM J PATHOL, V147, P1575; Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Singh IN, 2013, J CEREBR BLOOD F MET, V33, P593, DOI 10.1038/jcbfm.2012.211; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Vazquez-Sanroman D, 2013, BEHAV BRAIN RES, V243, P118, DOI 10.1016/j.bbr.2012.12.047; Wang DJ, 2015, INFLAMMATION, V38, P1925, DOI 10.1007/s10753-015-0172-7; Woodrow CJ, 2005, POSTGRAD MED J, V81, P71, DOI 10.1136/pgmj.2004.028399; Zhao MF, 2016, MOL MED REP, V13, P13, DOI 10.3892/mmr.2015.4551; Zhou DJ, 2011, J INFECT DIS, V203, P1647, DOI 10.1093/infdis/jir163; Zuo SL, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1489050	59	37	38	2	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JUL 31	2018	9								590	10.3389/fneur.2018.00590			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GO8MY	WOS:000440346000001	30108544	Green Published, gold			2022-02-06	
J	Walker, WC; Stromberg, KA; Marwitz, JH; Sima, AP; Agyemang, AA; Graham, KM; Harrison-Felix, C; Hoffman, JM; Brown, AW; Kreutzer, JS; Merchant, R				Walker, William C.; Stromberg, Katharine A.; Marwitz, Jennifer H.; Sima, Adam P.; Agyemang, Amma A.; Graham, Kristin M.; Harrison-Felix, Cynthia; Hoffman, Jeanne M.; Brown, Allen W.; Kreutzer, Jeffrey S.; Merchant, Randall			Predicting Long-Term Global Outcome after Traumatic Brain Injury: Development of a Practical Prognostic Tool Using the Traumatic Brain Injury Model Systems National Database	JOURNAL OF NEUROTRAUMA			English	Article						classification tree; functional outcome; Glasgow Outcome Scale; prognosis; traumatic brain injury classification tree	WORKING-AGE INDIVIDUALS; GLASGOW COMA SCALE; REHABILITATION; DISABILITY; TBI; INSTITUTE; TREE; REPRESENTATIVENESS; TRAJECTORIES; RELIABILITY	For patients surviving serious traumatic brain injury (TBI), families and other stakeholders often desire information on longterm functional prognosis, but accurate and easy-to-use clinical tools are lacking. We aimed to build utilitarian decision trees from commonly collected clinical variables to predict Glasgow Outcome Scale (GOS) functional levels at 1, 2, and 5 years after moderate-to-severe closed TBI. Flexible classification tree statistical modeling was used on prospectively collected data from the TBI-Model Systems (TBIMS) inception cohort study. Enrollments occurred at 17 designated, or previously designated, TBIMS inpatient rehabilitation facilities. Analysis included all participants with nonpenetrating TBI injured between January 1997 and January 2017. Sample sizes were 10,125 (year-1), 8,821 (year-2), and 6,165 (year-5) after cross-sectional exclusions (death, vegetative state, insufficient post-injury time, and unavailable outcome). In our final models, post-traumatic amnesia (PTA) duration consistently dominated branching hierarchy and was the lone injury characteristic significantly contributing to GOS predictability. Lower-order variables that added predictability were age, pre-morbid education, productivity, and occupational category. Generally, patient outcomes improved with shorter PTA, younger age, greater pre-morbid productivity, and higher pre-morbid vocational or educational achievement. Across all prognostic groups, the best and worst good recovery rates were 65.7% and 10.9%, respectively, and the best and worst severe disability rates were 3.9% and 64.1%. Predictability in test data sets ranged from C-statistic of 0.691 (year-1; confidence interval [CI], 0.675, 0.711) to 0.731 (year-2; CI,0.724, 0.738). In conclusion, we developed a clinically useful tool to provide prognostic information on long-term functional outcomes for adult survivors of moderate and severe closed TBI. Predictive accuracy for GOS level was demonstrated in an independent test sample. Length of PTA, a clinical marker of injury severity, was by far the most critical outcome determinant.	[Walker, William C.; Marwitz, Jennifer H.; Agyemang, Amma A.; Graham, Kristin M.; Kreutzer, Jeffrey S.; Merchant, Randall] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980677, Richmond, VA 23298 USA; [Stromberg, Katharine A.; Sima, Adam P.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Harrison-Felix, Cynthia] Craig Hosp, Traumat Brain Injury Model Syst Natl Data & Stat, Englewood, CO USA; [Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA		Walker, WC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980677, Richmond, VA 23298 USA.	william.walker@vcuhealth.org		Sima, Adam/0000-0001-8426-9987	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RHD089097A]; National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90 DP0013]; NIDILRRUnited States Department of Health & Human Services [90AR5025]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD089097] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health (NIH) #RHD089097A.; The data contents for this manuscript were developed under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR; grant number 90 DP0013). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). Post-doctoral fellows were supported by NIDILRR grant number 90AR5025.	Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bonds B, 2021, J NEUROTRAUM, V38, P1168, DOI 10.1089/neu.2014.3742; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; Centers for Disease Control and Prevention, 1988, BEH RISK FACT SURV S; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2015, ARCH PHYS MED REHAB, V96, pS209, DOI 10.1016/j.apmr.2015.03.026; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Cuthbert JP, 2015, ARCH PHYS MED REHAB, V96, P2128, DOI 10.1016/j.apmr.2015.07.020; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P160, DOI 10.1097/HTR.0000000000000090; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Dams-O'Connor K, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000073; Forslund MV, 2017, BRAIN INJURY, V31, P329, DOI 10.1080/02699052.2016.1255778; Hand DJ, 2001, MACH LEARN, V45, P171, DOI 10.1023/A:1010920819831; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; JENNETT B, 1975, LANCET, V1, P480; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kim H, 2001, J AM STAT ASSOC, V96, P589, DOI 10.1198/016214501753168271; Kothari S., 2006, BRAIN INJURY MED PRI, P529; Kreutzer JS, 2016, ARCH PHYS MED REHAB, V97, P708, DOI 10.1016/j.apmr.2015.12.003; Lefebvre H, 2012, BRAIN INJURY, V26, P1084, DOI 10.3109/02699052.2012.666364; Lemeshow S, 2000, APPL LOGISTIC REGRES; Levi Y, 2013, J INT NEUROPSYCH SOC, V19, P664, DOI 10.1017/S1355617713000192; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P2486, DOI 10.1016/j.apmr.2013.06.021; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Walker W.C., 2017, J NEUROL NEUROSUR PS, V81, P87; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Walker WC, 2015, J HEAD TRAUMA REHAB, V30, P231, DOI 10.1097/HTR.0000000000000127; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276	42	37	37	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1587	1595		10.1089/neu.2017.5359		MAY 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000432412600001	29566600	Green Published, Bronze, Green Submitted			2022-02-06	
J	Prexl, O; Bruckbauer, M; Voelckel, W; Grottke, O; Ponschab, M; Maegele, M; Schochl, H				Prexl, Oliver; Bruckbauer, Martin; Voelckel, Wolfgang; Grottke, Oliver; Ponschab, Martin; Maegele, Marc; Schoechl, Herbert			The impact of direct oral anticoagulants in traumatic brain injury patients greater than 60-years-old	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						DOAC; Vitamin K antagonist; Brain trauma; Mortality; Intracranial haematoma	PROTHROMBIN COMPLEX CONCENTRATE; PREINJURY WARFARIN USE; INTRACRANIAL HEMORRHAGE; REVERSAL; DABIGATRAN; COMPLICATIONS; RIVAROXABAN; MANAGEMENT; MORTALITY; SURGERY	Background: Traumatic brain injury (TBI) is the leading cause of death among trauma patients. Patients under antithrombotic therapy (ATT) carry an increased risk for intracranial haematoma (ICH) formation. There is a paucity of data about the role of direct oral anticoagulants (DOACs) among TBI patients. Methods: In this retrospective study, we investigated all TBI patients >= 60-years-old who were admitted to the intensive care unit (ICU) from January 2014 until May 2017. Patients were grouped into those receiving vitamin K antagonists (VKA), platelet inhibitors (PI), DOACs and no antithrombotic therapy (no-ATT). Results: One-hundred-eighty-six, predominantly male (52.7%) TBI patients with a median age of 79 years (range: 70-85 years) were enrolled in the study. Glasgow Coma Scale and S-100 beta were not different among the groups. Patients on VKA and DOACs had a higher Charlson Comorbidity Index compared to the PI group and no-ATT group (p = 0.0021). The VKA group received reversal agents significantly more often than the other groups (p < 0.0001). Haematoma progression in the follow-up cranial computed tomography (CCT) was lowest in the DOAC group. The number of CCT and surgical interventions were low with no differences between the groups. No relevant differences in ICU and hospital length of stay were observed. Mortality in the VKA group was significantly higher compared to DOAC, PI and no-ATT group (p = 0.047). Discussion: Data from huge registry studies displayed higher efficacy and lower fatal bleeding rates for DOACs compared to VKAs. The current study revealed comparable results. Despite the fact that TBI patients on VKAs received reversal agents more often than patients on DOACs (84.4% vs. 24.2%, p < 0.001), mortality rate was significantly higher in the VKA group (p = 0.047). Conclusion: In patients >= 60 years suffering from TBI, anticoagulation with DOACs appears to be safer than with VKA. Anti-thrombotic therapy with VKA resulted in a worse outcome compared to DOACs and PI. Further studies are warranted to confirm this finding.	[Prexl, Oliver; Bruckbauer, Martin; Voelckel, Wolfgang; Schoechl, Herbert] Paracelsus Med Univ, Acad Teaching Hosp, AUVA Trauma Ctr Salzburg, Dept Anaesthesiol & Intens Care Med, Dr Franz Rehrl Pl 5, A-5020 Salzburg, Austria; [Prexl, Oliver; Bruckbauer, Martin] Paracelsus Med Univ, Salzburg, Austria; [Grottke, Oliver] RWTH Aachen Univ Hosp, Dept Anaesthesiol, Aachen, Germany; [Ponschab, Martin] Paracelsus Med Univ, Acad Teaching Hosp, AUVA Trauma Ctr Linz, Dept Anaesthesiol & Intens Care Med, Salzburg, Austria; [Maegele, Marc] UW H, CMMC, Dept Trauma & Orthopaed Surg, Campus Cologne Merheim, Cologne, Germany; [Schoechl, Herbert] Ludwig Boltzmann Inst Expt & Clin Traumatol, AUVA Trauma Res Ctr, Vienna, Austria		Schochl, H (corresponding author), Paracelsus Med Univ, Acad Teaching Hosp, AUVA Trauma Ctr Salzburg, Dept Anaesthesiol & Intens Care Med, Dr Franz Rehrl Pl 5, A-5020 Salzburg, Austria.; Schochl, H (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, AUVA Trauma Res Ctr, Vienna, Austria.	herbert.schoechl@auva.at		Grottke, Oliver/0000-0002-0722-3122			Barletta JF, 2017, EUR J TRAUMA EMERG S, V43, P445, DOI 10.1007/s00068-017-0772-z; Barnes GD, 2015, AM J MED, V128, P1300, DOI 10.1016/j.amjmed.2015.05.044; Beynon C, 2015, THROMB RES, V136, P560, DOI 10.1016/j.thromres.2015.07.001; Brown KS, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1422-2; Chai-Adisaksopha C, 2014, BLOOD, V124, P2450, DOI 10.1182/blood-2014-07-590323; Collins CE, 2014, AM J SURG, V208, P544, DOI 10.1016/j.amjsurg.2014.05.019; Connolly SJ, 2016, NEW ENGL J MED, V375, P1131, DOI 10.1056/NEJMoa1607887; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Dossett LA, 2011, ARCH SURG-CHICAGO, V146, P565, DOI 10.1001/archsurg.2010.313; Douxfils J, 2017, SEMIN THROMB HEMOST, V43, P277, DOI 10.1055/s-0036-1597296; Feeney JM, 2017, INJURY, V48, P47, DOI 10.1016/j.injury.2016.08.016; Frontera JA, 2016, NEUROCRIT CARE, V24, P6, DOI 10.1007/s12028-015-0222-x; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Goldstein JN, 2015, LANCET, V385, P2077, DOI 10.1016/S0140-6736(14)61685-8; Gonsalves WI, 2013, MAYO CLIN PROC, V88, P495, DOI 10.1016/j.mayocp.2013.03.006; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Kirchhof P, 2016, EUR J CARDIO-THORAC, V50, pE1, DOI 10.1093/ejcts/ezw313; Kobayashi L, 2017, J TRAUMA ACUTE CARE, V82, P827, DOI 10.1097/TA.0000000000001414; Le Roux P, 2014, J NEUROSURG, V121, P1, DOI 10.3171/2014.8.paradigm; Luchette F, 2010, SURGERY, V148, P729; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Maung AA, 2016, J TRAUMA ACUTE CARE, V81, P652, DOI 10.1097/TA.0000000000001189; Myers SP, 2017, J TRAUMA ACUTE CARE, V82, P542, DOI 10.1097/TA.0000000000001340; Nishijima DK, 2013, ACAD EMERG MED, V20, P140, DOI 10.1111/acem.12074; Pabinger I, 2008, J THROMB HAEMOST, V6, P622, DOI 10.1111/j.1538-7836.2008.02904.x; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pollack CV, 2017, NEW ENGL J MED, V377, P431, DOI 10.1056/NEJMoa1707278; Pozzessere A, 2015, AM SURGEON, V81, P1039; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Sarode R, 2013, CIRCULATION, V128, P1234, DOI 10.1161/CIRCULATIONAHA.113.002283; Siracuse JJ, 2010, SURGERY, V148, P724, DOI 10.1016/j.surg.2010.07.014; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Wood B, 2017, SCAND J TRAUMA RESUS, V25, DOI 10.1186/s13049-017-0420-y	35	37	37	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	MAR 27	2018	26								20	10.1186/s13049-018-0487-0			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	GB2XN	WOS:000428919300001	29580268	Green Published, gold			2022-02-06	
J	Kaupp, C; Pearcey, GEP; Klarner, T; Sun, Y; Cullen, H; Barss, TS; Zehr, EP				Kaupp, Chelsea; Pearcey, Gregory E. P.; Klarner, Taryn; Sun, Yao; Cullen, Hilary; Barss, Trevor S.; Zehr, E. Paul			Rhythmic arm cycling training improves walking and neurophysiological integrity in chronic stroke: the arms can give legs a helping hand in rehabilitation	JOURNAL OF NEUROPHYSIOLOGY			English	Article						arm cycling; cutaneous reflex; locomotor training; stretch reflex; stroke	H-REFLEX AMPLITUDE; SPINAL-CORD-INJURY; NEURAL-CONTROL; CUTANEOUS REFLEXES; HUMAN LOCOMOTION; HOFFMANN REFLEX; ASHWORTH SCALE; ELECTRICAL-STIMULATION; TREADMILL WALKING; PHYSICAL-ACTIVITY	Training locomotor central pattern-generating networks (CPGs) through arm and leg cycling improves walking in chronic stroke. These outcomes are presumed to result from enhanced interlimb connectivity and CPG function. The extent to which rhythmic arm training activates interlimb CPG networks for locomotion remains unclear and was assessed by studying chronic stroke participants before and after 5 wk of arm cycling training. Strength was assessed bilaterally via maximal voluntary isometric contractions in the legs and hands. Muscle activation during arm cycling and transfer to treadmill walking were assessed in the more affected (MA) and less affected (LA) sides via surface electromyography. Changes to interlimb coupling during rhythmic movement were evaluated using modulation of cutaneous reflexes elicited by electrical stimulation of the superficial radial nerve at the wrist. Bilateral soleus stretch reflexes were elicited at rest and during 1-Hz arm cycling. Clinical function tests assessed walking, balance, and motor function. Results show significant changes in function and neurophysiological integrity. Training increased bilateral grip strength, force during MA plantar-flexion, and muscle activation. "Normalization" of cutaneous reflex modulation was found during arm cycling. There was enhanced activity in the dorsiflexor muscles on the MA side during the swing phase of walking. Enhanced interlimb coupling was shown by increased modulation of MA soleus stretch reflex amplitudes during arm cycling after training. Clinical evaluations showed enhanced walking ability and balance. These results are consistent with training-induced changes in CPG function and interlimb connectivity and underscore the need for arm training in the functional rehabilitation of walking after neurotrauma. NEW & NOTEWORTHY It has been suggested but not tested that training the arms may influence rehabilitation of walking due to activation of interneuronal patterning networks after stroke. We show that arm cycling training improves strength, clinical function, coordination of muscle activity during walking, and neurological connectivity between the arms and the legs. The arms can, in fact, give the legs a helping hand in rehabilitation of walking after stroke.	[Kaupp, Chelsea; Pearcey, Gregory E. P.; Klarner, Taryn; Sun, Yao; Cullen, Hilary; Zehr, E. Paul] Univ Victoria, Rehabil Neurosci Lab, POB 3010 STN CSC, Victoria, BC V8W 3P1, Canada; [Kaupp, Chelsea; Pearcey, Gregory E. P.; Klarner, Taryn; Sun, Yao; Cullen, Hilary; Zehr, E. Paul] ICORD, Human Discovery Sci, Vancouver, BC, Canada; [Kaupp, Chelsea; Pearcey, Gregory E. P.; Klarner, Taryn; Sun, Yao; Cullen, Hilary; Zehr, E. Paul] Univ Victoria, Ctr Biomed Res, Victoria, BC, Canada; [Barss, Trevor S.] Univ Alberta, Human Neurophysiol Lab, Edmonton, AB, Canada; [Zehr, E. Paul] Univ Victoria, Div Med Sci, Victoria, BC, Canada		Zehr, EP (corresponding author), Univ Victoria, Rehabil Neurosci Lab, POB 3010 STN CSC, Victoria, BC V8W 3P1, Canada.	pzehr@uvic.ca	Barss, Trevor/L-7045-2019	Barss, Trevor/0000-0003-3466-2750; Pearcey, Gregory/0000-0002-6751-4351			Ada L, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-8; Bakheit AMO, 2003, J NEUROL NEUROSUR PS, V74, P646, DOI 10.1136/jnnp.74.5.646; BALLESTEROS ML, 1965, ACTA PHYSIOL SCAND, V63, P296, DOI 10.1111/j.1748-1716.1965.tb04069.x; Balter JE, 2007, J NEUROPHYSIOL, V97, P1809, DOI 10.1152/jn.01038.2006; Barzi Y, 2008, CLIN NEUROPHYSIOL, V119, P1443, DOI 10.1016/j.clinph.2008.02.016; Burke RE, 1999, EXP BRAIN RES, V128, P263, DOI 10.1007/s002210050847; Burridge JH, 2001, MED ENG PHYS, V23, P427, DOI 10.1016/S1350-4533(01)00061-3; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Cohen J., 1988, SET CORRELATION MULT; Cummings G., 2013, UNDERSTANDING NEW ST; de Kam D, 2013, J APPL PHYSIOL, V115, P34, DOI 10.1152/japplphysiol.00510.2012; Dietz V, 2002, TRENDS NEUROSCI, V25, P462, DOI 10.1016/S0166-2236(02)02229-4; Dietz V, 2001, EUR J NEUROSCI, V14, P1906, DOI 10.1046/j.0953-816x.2001.01813.x; Dragert K, 2013, EXP BRAIN RES, V225, P93, DOI 10.1007/s00221-012-3351-x; Dragert K, 2011, EXP BRAIN RES, V208, P217, DOI 10.1007/s00221-010-2472-3; Dragert K, 2009, NEUROSCI LETT, V450, P235, DOI 10.1016/j.neulet.2008.11.034; Elftman HO, 1939, FUNCTION ARMS WALKIN; Enright Paul L, 2003, Respir Care, V48, P783; Ferris DP, 2006, EXERC SPORT SCI REV, V34, P113, DOI 10.1249/00003677-200607000-00005; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Frigon A, 2004, J NEUROPHYSIOL, V91, P1516, DOI 10.1152/jn.00695.2003; Frigon A, 2017, J NEUROPHYSIOL, V117, P2224, DOI 10.1152/jn.00978.2016; Gadidi V, 2011, ARCH PHYS MED REHAB, V92, P1802, DOI 10.1016/j.apmr.2011.06.014; Gordon NF, 2004, STROKE, V35, P1230, DOI 10.1161/01.STR.0000127303.19261.19; GOWLAND C, 1993, STROKE, V24, P58, DOI 10.1161/01.STR.24.1.58; HAGE JJ, 1995, J HAND SURG-AM, V20A, P227; Haridas C, 2003, J NEUROPHYSIOL, V90, P2850, DOI 10.1152/jn.00531.2003; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Hundza SR, 2009, EXP BRAIN RES, V193, P297, DOI 10.1007/s00221-008-1625-0; Hundza SR, 2006, EXP BRAIN RES, V168, P165, DOI 10.1007/s00221-005-0089-8; Kim CM, 2003, PHYS THER, V83, P49, DOI 10.1093/ptj/83.1.49; Klamer T, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00095; Klarner T, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6040054; Klarner T, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/1517968; Kline TL, 2007, BRAIN, V130, P159, DOI 10.1093/brain/awl278; Lagerquist O, 2006, EXP BRAIN RES, V170, P1, DOI 10.1007/s00221-005-0172-1; Lamont EV, 2007, J NEUROPHYSIOL, V98, P433, DOI 10.1152/jn.00002.2007; Liston RAL, 1996, ARCH PHYS MED REHAB, V77, P425, DOI 10.1016/S0003-9993(96)90028-3; Loadman PM, 2007, EXP BRAIN RES, V179, P199, DOI 10.1007/s00221-006-0782-2; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; Mezzarane RA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00136; Mezzarane RA, 2011, EXP BRAIN RES, V208, P157, DOI 10.1007/s00221-010-2467-0; Nakajima T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104910; Nakajima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076313; Nakajima T, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-28; Nielsen JB, 2003, NEUROSCIENTIST, V9, P195, DOI 10.1177/1073858403009003012; Palomino AF, 2011, EXP BRAIN RES, V214, P529, DOI 10.1007/s00221-011-2851-4; Pandyan AD, 2003, CLIN REHABIL, V17, P290, DOI 10.1191/0269215503cr610oa; Pang MYC, 2006, CLIN REHABIL, V20, P97, DOI 10.1191/0269215506cr926oa; Patrick E, 2006, CLIN REHABIL, V20, P173, DOI 10.1191/0269215506cr922oa; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; RICHARDS CL, 1996, GAIT POSTURE, V4, P149; Scherr J, 2013, EUR J APPL PHYSIOL, V113, P147, DOI 10.1007/s00421-012-2421-x; Shiavi R, 1987, J Rehabil Res Dev, V24, P24; STEIN RB, 1993, PROG BRAIN RES, V97, P189; Sun Y, 2015, APPL PHYSIOL NUTR ME, V40, P858, DOI 10.1139/apnm-2014-0523; Tang A, 2006, ARCH PHYS MED REHAB, V87, P1100, DOI 10.1016/j.apmr.2006.04.016; Tester NJ, 2011, SPINAL CORD, V49, P451, DOI 10.1038/sc.2010.128; Vasudevan EVL, 2011, EXP BRAIN RES, V211, P299, DOI 10.1007/s00221-011-2687-y; Wannier T, 2001, EXP BRAIN RES, V141, P375, DOI 10.1007/s002210100875; Zehr EP, 2016, EXP BRAIN RES, V234, P3059, DOI 10.1007/s00221-016-4715-4; Zehr EP, 2007, J NEUROPHYSIOL, V98, P1810, DOI 10.1152/jn.00562.2007; Zehr EP, 2012, J NEUROPHYSIOL, V108, P891, DOI 10.1152/jn.01152.2011; Zehr EP, 2012, CLIN NEUROPHYSIOL, V123, P796, DOI 10.1016/j.clinph.2011.07.049; Zehr EP, 2011, APPL PHYSIOL NUTR ME, V36, pS214, DOI [10.1139/h11-055, 10.1139/H11-055]; Zehr EP, 2005, EXERC SPORT SCI REV, V33, P54; Zehr EP, 2004, CAN J PHYSIOL PHARM, V82, P556, DOI 10.1139/Y04-056; Zehr EP, 1998, J NEUROPHYSIOL, V79, P848, DOI 10.1152/jn.1998.79.2.848; Zehr EP, 2004, EXP BRAIN RES, V159, P382, DOI 10.1007/s00221-004-2092-x; Zehr EP, 2004, NEUROSCIENTIST, V10, P347, DOI 10.1177/1073858404264680; Zehr EP, 2003, EXP BRAIN RES, V149, P260, DOI 10.1007/s00221-003-1377-9; Zehr EP, 2003, J NEUROPHYSIOL, V89, P12, DOI 10.1152/jn.00416.2002; Zehr EP, 2002, EUR J APPL PHYSIOL, V86, P455, DOI 10.1007/s00421-002-0577-5; Zehr EP, 2001, EXP BRAIN RES, V140, P495; Zhou R, 2017, J NEUROPHYSIOL, V118, P2507, DOI 10.1152/jn.00663.2016	77	37	37	0	18	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	MAR	2018	119	3					1095	1112		10.1152/jn.00570.2017			18	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	FZ1PC	WOS:000427348200030	29212917	Bronze, Green Published			2022-02-06	
J	Dolle, JP; Jaye, A; Anderson, SA; Ahmadzadeh, H; Shenoy, VB; Smith, DH				Dolle, Jean-Pierre; Jaye, Andrew; Anderson, Stewart A.; Ahmadzadeh, Hossein; Shenoy, Vivek B.; Smith, Douglas H.			Newfound sex differences in axonal structure underlie differential outcomes from in vitro traumatic axonal injury	EXPERIMENTAL NEUROLOGY			English	Article						Sexual dimorphism; Traumatic axonal injury; Undulations; Calcium; Axon diameter; Microtubules	PLURIPOTENT STEM-CELLS; DYNAMIC STRETCH INJURY; BRAIN-INJURY; WHITE-MATTER; CORPUS-CALLOSUM; UNMYELINATED AXONS; SODIUM-CHANNELS; CALCIUM INFLUX; UNITED-STATES; TAU PROTEINS	Since traumatic axonal injury (TAI) is implicated as a prominent pathology of concussion, we examined potential sex differences in axon structure and responses to TAI. Rat and human neurons were used to develop micro patterned axon tracts in vitro that were genetically either male or female. Ultrastructural analysis revealed for the first time that female axons were consistently smaller with fewer microtubules than male axons. Computational modeling of TAI showed that these structural differences place microtubules in female axons at greater risk of failure during trauma under the same applied loads than in male axons. Likewise, in an in vitro model of TAI, dynamic stretch-injury to axon tracts induced greater pathophysiology of female axons than male axons, including more extensive undulation formations resulting from mechanical breaking of microtubules, and greater calcium influx shortly after the same level of injury. At 24 h post-injury, female axons exhibited significantly more swellings and greater loss of calcium signaling function than male axons. Accordingly, sexual dimorphism of axon structure in the brain may also contribute to more extensive axonal pathology in females compared to males exposed to the same mechanical injury.	[Dolle, Jean-Pierre; Jaye, Andrew] Univ Penn, Dept Neurosurg, Penn Ctr Brain Injury & Repair, 220 South 33rd St,283 Towne Bldg, Philadelphia, PA 19104 USA; [Anderson, Stewart A.] Childrens Hosp Philadelphia, Dept Psychiat, Philadelphia, PA 19104 USA; [Ahmadzadeh, Hossein; Shenoy, Vivek B.] Univ Penn, Res Struct Matter Lab, Dept Mat Sci & Engn, 3231 Walnut St,Room 309, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Dept Neurosurg, Perm Ctr Brain Injury & Repair, 3320 Smith Walk Hayden Hall 105, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, Perm Ctr Brain Injury & Repair, 3320 Smith Walk Hayden Hall 105, Philadelphia, PA 19104 USA.	dollej@pennmedicine.upenn.edu; andrew.h.jaye@gmail.com; sande@pennmedicine.upenn.edu; hossein@seas.upenn.edu; vshenoy@seas.upenn.edu; smithdou@pennmedicine.upenn.edu	Shenoy, Vivek/ABD-5075-2021		Paul G. Allen Family Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS092398, NS038104, EB021293, MH110185]; US Department of DefenseUnited States Department of Defense [PT110785]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB021293] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH110185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, R01NS094003, R01NS092398, T32NS043126] Funding Source: NIH RePORTER	This work was supported by the Paul G. Allen Family Foundation, National Institutes of Health grants NS092398 (D.H.S), NS038104 (D.H.S), EB021293 (D.H.S and V.B.S), MH110185 (S.A.A) and the US Department of Defense Grant PT110785 (D.H.S).	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Abrahams S, 2014, BRIT J SPORT MED, V48, P91, DOI 10.1136/bjsports-2013-092734; Ahmadzadeh H, 2015, BIOPHYS J, V109, P2328, DOI 10.1016/j.bpj.2015.09.010; Ahmadzadeh H, 2014, BIOPHYS J, V106, P1123, DOI 10.1016/j.bpj.2014.01.024; Alexander DC, 2010, NEUROIMAGE, V52, P1374, DOI 10.1016/j.neuroimage.2010.05.043; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Covassin T, 2003, J ATHL TRAINING, V38, P238; DEKABAN AS, 1978, ANN NEUROL, V4, P345, DOI 10.1002/ana.410040410; Espuny-Camacho I, 2013, NEURON, V77, P440, DOI 10.1016/j.neuron.2012.12.011; Fairbanks SL, 2013, JOVE-J VIS EXP, DOI 10.3791/50758; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Gaw CE, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0071-8; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Gur RC, 1999, J NEUROSCI, V19, P4065; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Lin MY, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0366-0; Lu W, 2016, P NATL ACAD SCI USA, V113, pE4995, DOI 10.1073/pnas.1522424113; MACK CM, 1995, BRAIN RES, V697, P152, DOI 10.1016/0006-8993(95)00804-Y; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MIYATA Y, 1986, J BIOL CHEM, V261, P3026; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; Ozdogmus O, 2009, ANAT SCI INT, V84, P2, DOI 10.1007/s12565-008-0001-2; Paus T, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.014.2009; Pedrosa E, 2011, J NEUROGENET, V25, P88, DOI 10.3109/01677063.2011.597908; Perrin JS, 2009, NEUROIMAGE, V45, P1055, DOI 10.1016/j.neuroimage.2009.01.023; Perrin JS, 2008, J NEUROSCI, V28, P9519, DOI 10.1523/JNEUROSCI.1212-08.2008; Pesaresi M, 2015, NEUROIMAGE, V115, P191, DOI 10.1016/j.neuroimage.2015.04.048; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sendek A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104965; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Staal JA, 2011, J NEUROTRAUM, V28, P841, DOI 10.1089/neu.2010.1658; Suresh S, 2007, ACTA BIOMATER, V3, P413, DOI 10.1016/j.actbio.2007.04.002; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Vorstman JAS, 2006, HUM MUTAT, V27, P814, DOI 10.1002/humu.20330; Wang SSH, 2008, J NEUROSCI, V28, P4047, DOI 10.1523/JNEUROSCI.5559-05.2008; Wegmann S, 2011, J BIOL CHEM, V286, P20512, DOI 10.1074/jbc.M111.237875; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuan A, 2017, COLD SPRING HARB PER, V9; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhang YS, 2013, NEURON, V78, P785, DOI 10.1016/j.neuron.2013.05.029	53	37	37	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2018	300						121	134		10.1016/j.expneurol.2017.11.001			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT1JZ	WOS:000422893300013	29104114	Green Accepted			2022-02-06	
J	Stephens, JA; Liu, PY; Lu, HZ; Suskauer, SJ				Stephens, Jaclyn A.; Liu, Peiying; Lu, Hanzhang; Suskauer, Stacy J.			Cerebral Blood Flow after Mild Traumatic Brain Injury: Associations between Symptoms and Post-Injury Perfusion	JOURNAL OF NEUROTRAUMA			English	Article						adolescents; arterial spin labeling; mild traumatic brain injury; sports-related concussion; symptomology	CONCUSSION; SPORT; CONNECTIVITY; NETWORKS	Arterial spin labeling (ASL) has emerged as a technique for assessing mild traumatic brain injury (mTBI), as it can noninvasively evaluate cerebrovascular physiology. To date, there is substantial variability in methodology and findings of ASL studies of mTBI. While both increased and decreased perfusion are reported after mTBI, more consistency is emerging when perfusion is examined with regard to symptomology. We evaluated 15 teenage athletes two and six weeks after sports-related concussion (SRC group) using pseudo-continuous ASL. We acquired comparison data from 15 matched controls from a single time point. At each time point, we completed whole-brain contrasts to evaluate differences between the SRC group and controls in relative cerebral blood flow (rCBF). Cluster-level findings directed region of interest (ROI) analyses to test for group differences in rCBF across the left dorsal anterior cingulate cortex (ACC) and left insula. Finally, we evaluated ROI rCBF and symptomology in the SRC group. At two weeks post-injury, the SRC group had significantly higher rCBF in the left dorsal ACC and left insula than controls; at six weeks post-injury, elevated rCBF persisted in the SRC group in the left dorsal ACC. Perfusion in the left dorsal ACC was higher in athletes reporting physical symptoms six weeks post-injury compared with asymptomatic athletes and controls. Overall, these findings are inconsistent with reports of reduced rCBF after mTBI but coherent with studies that report increased perfusion in persons with greater or persistent mTBI-related symptomology. Future work should continue to assess how CBF perfusion relates to symptomology and recovery after mTBI.	[Stephens, Jaclyn A.; Suskauer, Stacy J.] Kennedy Krieger Inst, 716 N Broadway, Baltimore, MD 21205 USA; [Stephens, Jaclyn A.] Colorado State Univ, Dept Occupat Therapy, Ft Collins, CO 80523 USA; [Stephens, Jaclyn A.; Suskauer, Stacy J.] Johns Hopkins Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Liu, Peiying; Lu, Hanzhang] Johns Hopkins Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA; [Suskauer, Stacy J.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA		Suskauer, SJ (corresponding author), Kennedy Krieger Inst, 716 N Broadway, Baltimore, MD 21205 USA.	Suskauer@kennedykrieger.org	Liu, Peiying/D-7512-2017	Liu, Peiying/0000-0003-0830-5960	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD007414, R01MH084021, P41 EB015909, R21HD080378]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH084021] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health (J.S. 5T32HD007414); (H.L., R01MH084021, P41 EB015909); (S.S., R21HD080378).	Alsop DC, 2015, MAGN RESON MED, V73, P102, DOI 10.1002/mrm.25197; Andre Jalal B, 2015, Top Magn Reson Imaging, V24, P275, DOI 10.1097/RMR.0000000000000065; Aslan S, 2010, MAGN RESON IMAGING, V28, P928, DOI 10.1016/j.mri.2010.03.037; Barlow KM, 2017, J NEUROTRAUM, V34, P996, DOI 10.1089/neu.2016.4634; Borsook D, 2013, PROG NEUROBIOL, V104, P93, DOI 10.1016/j.pneurobio.2013.02.003; Churchill NW, 2017, NEUROIMAGE-CLIN, V14, P480, DOI 10.1016/j.nicl.2017.02.015; Doshi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118061; Hermans EJ, 2011, SCIENCE, V334, P1151, DOI 10.1126/science.1209603; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Li Y., 2017, P INT SOC MAG RESON, V25, P3808; Lin CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149109; Liu AA, 2011, NEUROLOGY, V77, P1518, DOI 10.1212/WNL.0b013e318233b229; Liu P., 2016, P INT SOC MAG RESON, V24, P2877; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Militana AR, 2016, BRAIN IMAGING BEHAV, V10, P559, DOI 10.1007/s11682-015-9407-3; Mori S, 2016, COMPUT SCI ENG, V18, P21, DOI 10.1109/MCSE.2016.93; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Peng SP, 2016, NEURAL REGEN RES, V11, P257, DOI 10.4103/1673-5374.177733; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sours C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134019; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; van der Horn HJ, 2016, J NEUROTRAUM, V33, P1, DOI 10.1089/neu.2015.3905; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Wang Y, 2015, DEV NEUROPSYCHOL, V40, P40, DOI 10.1080/87565641.2014.979927	29	37	39	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2018	35	2					241	248		10.1089/neu.2017.5237			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	FT1TA	WOS:000422918000004	28967326	Green Published			2022-02-06	
J	Schroll, R; Swift, D; Tatum, D; Couch, S; Heaney, JB; Llado-Farrulla, M; Zucker, S; Gill, F; Brown, G; Buffin, N; Duchesne, J				Schroll, Rebecca; Swift, David; Tatum, Danielle; Couch, Stuart; Heaney, Jiselle B.; Llado-Farrulla, Monica; Zucker, Shana; Gill, Frances; Brown, Griffin; Buffin, Nicholas; Duchesne, Juan			Accuracy of shock index versus ABC score to predict need for massive transfusion in trauma patients	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Shock index; ABC score; Massive transfusion; Trauma; Hemorrhagic shock; Resuscitation	DAMAGE CONTROL RESUSCITATION; MORTALITY; SURGERY; HEMORRHAGE; SEVERITY; SURVIVAL; UTILITY	Background: Various scoring systems have been developed to predict need for massive transfusion in traumatically injured patients. Assessments of Blood Consumption (ABC) score and Shock Index (SI) have been shown to be reliable predictors for Massive Transfusion Protocol (MTP) activation. However, no study has directly compared these two scoring systems to determine which is a better predictor for MTP activation. The primary objective was to determine whether ABC or SI better predicted the need for MTP in adult trauma patients with severe hemorrhage. Methods: This was a retrospective cohort study which included all injured patients who were trauma activations between January 1, 2009 and December 31, 2013 at an urban Level I trauma center. Patients <18 years old or with traumatic brain injury (TBI) were excluded. ABC and SI were calculated for each patient. MTP was defined as need for >10 units PRBC transfusion within 24 h of emergency department arrival. Sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC) were used to evaluate scoring systems' ability to predict effective MTP utilization. Results: A total of 645 patients had complete data for analysis. Shock Index >= 1 had sensitivity of 67.7% (95% CI 49.5%-82.6%) and specificity of 81.3% (95% CI 78.0%-84.3%) for predicting MTP, and ABC score >= 2 had sensitivity of 47.0% (95% CI 29.8%-64.9%) and specificity of 89.8% (95% CI 87.2%-92.1%). AUROC analyses showed SI to be the strongest predictor followed by ABC score with AUROC values of 0.83 and 0.74, respectively. SI had a significantly greater sensitivity (P = 0.035), but a significantly weaker specificity (P < 0.001) compared to ABC score. Conclusion: ABC score and Shock Index can both be used to predict need for massive transfusion in trauma patients, however SI is more sensitive and requires less technical skill than ABC score. (C) 2017 Elsevier Ltd. All rights reserved.	[Schroll, Rebecca; Swift, David; Couch, Stuart; Heaney, Jiselle B.; Llado-Farrulla, Monica; Zucker, Shana; Gill, Frances; Brown, Griffin; Buffin, Nicholas; Duchesne, Juan] Tulane Sch Med, New Orleans, LA 70112 USA; [Tatum, Danielle] Our Lady Lake Reg Med Ctr, Trauma Specialist Program, Baton Rouge, LA USA		Schroll, R (corresponding author), Tulane Sch Med, Dept Surg, 1430 Tulane Ave,8622, New Orleans, LA 70112 USA.	rschroll@tulane.edu	Zucker, Shana/AAL-3779-2020	Zucker, Shana/0000-0003-4090-3303			Barbosa RR, 2011, J TRAUMA, V71, pS364, DOI 10.1097/TA.0b013e318227f170; Birkhahn RH, 2005, AM J EMERG MED, V23, P323, DOI 10.1016/j.ajem.2005.02.029; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brockamp T, 2012, CRIT CARE, V16, DOI 10.1186/cc11432; Cannon CM, 2009, J TRAUMA, V67, P1426, DOI 10.1097/TA.0b013e3181bbf728; Cannon JW, 2017, J TRAUMA ACUTE CARE, V82, P605, DOI 10.1097/TA.0000000000001333; Cantle PM, 2017, CRIT CARE CLIN, V33, P71, DOI 10.1016/j.ccc.2016.08.002; Cotton BA, 2008, J TRAUMA, V64, P1177, DOI 10.1097/TA.0b013e31816c5c80; Cotton BA, 2010, J TRAUMA, V69, pS33, DOI 10.1097/TA.0b013e3181e42411; DeMuro JP, 2013, AM J EMERG MED, V31, P1260, DOI 10.1016/j.ajem.2013.05.027; Duchesne JC, 2010, J TRAUMA, V69, P46, DOI 10.1097/TA.0b013e3181df91fa; Duchesne JC, 2009, J TRAUMA, V67, P33, DOI 10.1097/TA.0b013e31819adb8e; Era S, 2015, J OBSTET GYNAECOL RE, V41, P39, DOI 10.1111/jog.12480; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; King RW, 1996, ACAD EMERG MED, V3, P1041, DOI 10.1111/j.1553-2712.1996.tb03351.x; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Mcnab A, 2012, SURGERY, V152, P473, DOI 10.1016/j.surg.2012.07.010; Moffat B, 2013, CRIT CARE, V17, DOI 10.1186/cc13040; Mutschler M, 2013, CRIT CARE, V17, DOI 10.1186/cc12851; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; O'Reilly DJ, 2014, J TRAUMA ACUTE CARE, V77, pS66, DOI 10.1097/TA.0000000000000342; Ogura T, 2014, J TRAUMA ACUTE CARE, V76, P1243, DOI 10.1097/TA.0000000000000200; Ohmori T, 2017, INJURY, V48, P1006, DOI 10.1016/j.injury.2016.12.028; PHILLIPS TF, 1987, J TRAUMA, V27, P903, DOI 10.1097/00005373-198708000-00010; RADY MY, 1992, RESUSCITATION, V23, P227, DOI 10.1016/0300-9572(92)90006-X; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schuster KM, 2010, TRANSFUSION, V50, P1545, DOI 10.1111/j.1537-2995.2010.02587.x; Sumida M P, 2000, Air Med J, V19, P140, DOI 10.1016/S1067-991X(00)90007-5; Trajman A, 2008, SCAND J CLIN LAB INV, V68, P77, DOI 10.1080/00365510701666031; Vandromme MJ, 2011, J TRAUMA, V70, P384, DOI 10.1097/TA.0b013e3182095a0a	31	37	41	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2018	49	1					15	19		10.1016/j.injury.2017.09.015			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	FS9VT	WOS:000422767800003	29017765				2022-02-06	
J	Hsieh, TH; Lee, HHC; Hameed, MQ; Pascual-Leone, A; Hensch, TK; Rotenberg, A				Hsieh, Tsung-Hsun; Lee, Henry Hing Cheong; Hameed, Mustafa Qadir; Pascual-Leone, Alvaro; Hensch, Takao K.; Rotenberg, Alexander			Trajectory of Parvalbumin Cell Impairment and Loss of Cortical Inhibition in Traumatic Brain Injury	CEREBRAL CORTEX			English	Article						intracortical inhibition; Otx2; oxidative stress; perineuronal nets; transcranial magnetic stimulation	TRANSCRANIAL MAGNETIC STIMULATION; FLUID PERCUSSION INJURY; OXIDATIVE STRESS; PERINEURONAL NETS; POSTTRAUMATIC EPILEPTOGENESIS; EXTRACELLULAR-MATRIX; OTX2 HOMEOPROTEIN; GABAERGIC NEURONS; N-ACETYLCYSTEINE; MOOD DISORDERS	Many neuropsychiatric symptoms that follow traumatic brain injury (TBI), including mood disorders, sleep disturbance, chronic pain, and posttraumatic epilepsy (PTE) are attributable to compromised cortical inhibition. However, the temporal trajectory of cortical inhibition loss and its underlying mechanisms are not known. Using paired-pulse transcranial magnetic stimulation (ppTMS) and immunohistochemistry, we tracked functional and cellular changes of cortical inhibitory network elements after fluid-percussion injury (FPI) in rats. ppTMS revealed a progressive loss of cortical inhibition as early as 2 weeks after FPI. This profile paralleled the increasing levels of cortical oxidative stress, which was accompanied by a gradual loss of parvalbumin (PV) immunoreactivity in perilesional cortex. Preceding the PV loss, we identified a degradation of the perineuronal net (PNN)-a specialized extracellular structure enwrapping cortical PV-positive (PV+) inhibitory interneurons which binds the PV+ cell maintenance factor, Otx2. The trajectory of these impairments underlies the reduced inhibitory tone, which can contribute to posttraumatic neurological conditions, such as PTE. Taken together, our results highlight the use of ppTMS as a biomarker to track the course of cortical inhibitory dysfunction post-TBI. Moreover, the neuroprotective role of PNNs on PV+ cell function suggests antioxidant treatment or Otx2 enhancement as a promising prophylaxis for post-TBI symptoms.	[Hsieh, Tsung-Hsun; Hameed, Mustafa Qadir; Rotenberg, Alexander] Harvard Med Sch, Boston Childrens Hosp, Div Epilepsy & Clin Neurophysiol, Neuromodulat Program,Dept Neurol, Boston, MA 02115 USA; [Hsieh, Tsung-Hsun] Chang Gung Univ, Dept Phys Therapy, Coll Med, Taoyuan 33302, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Univ, Grad Inst Rehabil Sci, Coll Med, Taoyuan 33302, Taiwan; [Hsieh, Tsung-Hsun] Chang Gung Mem Hosp, Neurosci Res Ctr, Linkou Med Ctr, Taoyuan 33305, Taiwan; [Lee, Henry Hing Cheong; Hameed, Mustafa Qadir; Hensch, Takao K.; Rotenberg, Alexander] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Hameed, Mustafa Qadir] Harvard Med Sch, Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Pascual-Leone, Alvaro; Rotenberg, Alexander] Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; [Hensch, Takao K.] Harvard Univ, Dept Mol & Cellular Biol, Ctr Brain Sci, Cambridge, MA 02138 USA		Hensch, TK; Rotenberg, A (corresponding author), Boston Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.	takao.hensch@childrens.harvard.edu; alexander.rotenberg@childrens.harvard.edu	Hsieh, Tung-Hsun/AAZ-5010-2020; Pascual-Leone, Alvaro/AAC-5101-2019; Hensch, Takao/L-4182-2019; Lee, Henry HC/S-6014-2016	Hsieh, Tung-Hsun/0000-0002-1794-7941; Pascual-Leone, Alvaro/0000-0001-8975-0382; Lee, Henry HC/0000-0003-4975-7330	Boston Children's Hospital Translational Research Program; NIH National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS088583]; Assimon Family Fund; Ministry of Science and Technology of TaiwanMinistry of Science and Technology, Taiwan [MOST 103-2320-B-182-033-MY2, MOST 105-2314-B-182-016]; Chang Gung Memorial HospitalChang Gung Memorial Hospital [CMRPD1F0501]; Croucher Foundation (Hong Kong); Georgetown University Center for Brain Plasticity and Recovery; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD090255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088583] Funding Source: NIH RePORTER	Boston Children's Hospital Translational Research Program (A.R. and T.K.H.), NIH National Institute of Neurological Disorders and Stroke (NINDS) R01 NS088583 (A.R. and T.K.H.), the Assimon Family Fund (A.R.), the Ministry of Science and Technology of Taiwan (MOST 103-2320-B-182-033-MY2, MOST 105-2314-B-182-016) and Chang Gung Memorial Hospital (CMRPD1F0501) to T.H.H.. H.H.C.L. was further supported by a postdoctoral fellowship from the Croucher Foundation (Hong Kong) and funding from the Georgetown University Center for Brain Plasticity and Recovery (to T.K.H.).	Andary MT, 1997, CLIN J PAIN, V13, P244, DOI 10.1097/00002508-199709000-00010; Andre V, 2001, HIPPOCAMPUS, V11, P452, DOI 10.1002/hipo.1060; Ascoli GA, 2008, NAT REV NEUROSCI, V9, P557, DOI 10.1038/nrn2402; Avramescu S, 2009, J NEUROTRAUM, V26, P799, DOI 10.1089/neu.2008.0739; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Badawy RAB, 2014, EPILEPSY RES, V108, P153, DOI 10.1016/j.eplepsyres.2013.11.014; BARKER AT, 1984, LANCET, V1, P994; Bashir S, 2012, RESTOR NEUROL NEUROS, V30, P277, DOI 10.3233/RNN-2012-110207; Benali A, 2011, J NEUROSCI, V31, P1193, DOI 10.1523/JNEUROSCI.1379-10.2011; Berezin V, 2014, PROG BRAIN RES, V214, P353, DOI 10.1016/B978-0-444-63486-3.00015-3; Beurdeley M, 2012, J NEUROSCI, V32, P9429, DOI 10.1523/JNEUROSCI.0394-12.2012; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Cabungcal JH, 2013, P NATL ACAD SCI USA, V110, P9130, DOI 10.1073/pnas.1300454110; Cabungcal JH, 2013, BIOL PSYCHIAT, V73, P574, DOI 10.1016/j.biopsych.2012.09.020; Cantu D, 2015, CEREB CORTEX, V25, P2306, DOI 10.1093/cercor/bhu041; Carulli D, 2007, J COMP NEUROL, V501, P83, DOI 10.1002/cne.21231; Carulli D, 2010, BRAIN, V133, P2331, DOI 10.1093/brain/awq145; Cepeda S, 2016, J NEUROTRAUM, V33, P1034, DOI 10.1089/neu.2015.4153; Chen TW, 2013, NATURE, V499, P295, DOI 10.1038/nature12354; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Eggers SDZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132075; Fawcett JW, 2015, PROG BRAIN RES, V218, P213, DOI 10.1016/bs.pbr.2015.02.001; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Fraser DD, 2009, CRIT CARE MED, V37, P787, DOI 10.1097/CCM.0b013e318194be10; Gherardini L, 2015, CEREB CORTEX, V25, P202, DOI 10.1093/cercor/bht217; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Hameed MQ, 2014, NEUROREPORT, V25, P532, DOI 10.1097/WNR.0000000000000132; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Hou LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076087; Hsieh TH, 2012, J NEUROPHYSIOL, V107, P966, DOI 10.1152/jn.00690.2011; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Huusko N, 2014, NEUROSCIENCE, V267, P30, DOI 10.1016/j.neuroscience.2014.02.026; Imbrosci B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111105; Immonen R, 2013, J NEUROTRAUM, V30, P1305, DOI 10.1089/neu.2012.2815; JENSEN FE, 2009, EPILIPSIA, V50, P1, DOI DOI 10.1111/J.1528-1167.2009.02293.X; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Joshi RL, 2011, FEBS LETT, V585, P1573, DOI 10.1016/j.febslet.2011.05.006; Kelsom C, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-19; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Kwok JCF, 2011, DEV NEUROBIOL, V71, P1073, DOI 10.1002/dneu.20974; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Lefebvre G, 2015, BRAIN INJURY, V29, P1032, DOI 10.3109/02699052.2015.1028447; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Lucke-Wold BP, 2015, SEIZURE-EUR J EPILEP, V33, P13, DOI 10.1016/j.seizure.2015.10.002; Major BP, 2015, CLIN EXP PHARMACOL P, V42, P394, DOI 10.1111/1440-1681.12363; Makino Y, 2004, J NEUROTRAUM, V21, P585, DOI 10.1089/089771504774129919; McIntosh TK, 1996, LAB INVEST, V74, P315; MITTMANN T, 1994, NEUROSCIENCE, V60, P891, DOI 10.1016/0306-4522(94)90270-4; Mix A, 2010, EUR J NEUROSCI, V32, P1575, DOI 10.1111/j.1460-9568.2010.07425.x; Morawski M, 2014, PROG BRAIN RES, V214, P207, DOI 10.1016/B978-0-444-63486-3.00010-4; Morishita H, 2015, BIOL PSYCHIAT, V78, P396, DOI 10.1016/j.biopsych.2014.12.026; Muller PA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091065; Nagel S, 2005, BRAIN RES, V1056, P43, DOI 10.1016/j.brainres.2005.07.036; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Orlando C, 2015, BRAIN STRUCT FUNCT, V220, P1077, DOI 10.1007/s00429-013-0701-9; Pandya JD, 2014, EXP NEUROL, V257, P106, DOI 10.1016/j.expneurol.2014.04.020; Petronilho F, 2010, J SURG RES, V164, P316, DOI 10.1016/j.jss.2009.04.031; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Prince DA, 1998, EPILEPSY RES, V32, P83, DOI 10.1016/S0920-1211(98)00042-4; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rakhade SN, 2009, NAT REV NEUROL, V5, P380, DOI 10.1038/nrneurol.2009.80; Rankin-Gee EK, 2015, EPILEPSIA, V56, P1124, DOI 10.1111/epi.13026; Rao V, 2014, BRAIN INJURY, V28, P20, DOI 10.3109/02699052.2013.847210; Ratzliff AD, 2000, HIPPOCAMPUS, V10, P162; Ren LK, 2015, NEUROLOGY, V84, P602, DOI 10.1212/WNL.0000000000001234; Rodgers KM, 2012, J NEUROTRAUM, V29, P1886, DOI 10.1089/neu.2011.2273; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Rotenberg A, 2010, BRAIN TOPOGR, V22, P257, DOI 10.1007/s10548-009-0116-3; Rowe RK, 2014, SLEEP, V37, P743, DOI 10.5665/sleep.3582; Rudy B, 2011, DEV NEUROBIOL, V71, P45, DOI 10.1002/dneu.20853; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sawyer K, 2015, ARCH PHYS MED REHAB, V96, P2000, DOI 10.1016/j.apmr.2015.07.006; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Sebe JY, 2011, DEV NEUROBIOL, V71, P107, DOI 10.1002/dneu.20813; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Skopin MD, 2015, J NEUROTRAUM, V32, P289, DOI 10.1089/neu.2014.3664; Soleman S, 2013, NEUROSCIENCE, V253, P194, DOI 10.1016/j.neuroscience.2013.08.050; Spatazza J, 2013, CELL REP, V3, P1815, DOI 10.1016/j.celrep.2013.05.014; Sugiyama S, 2009, DEV GROWTH DIFFER, V51, P369, DOI 10.1111/j.1440-169X.2009.01093.x; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Sundman M, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00334; Szaflarski JP, 2010, EPILEPSY BEHAV, V18, P404, DOI 10.1016/j.yebeh.2010.05.009; Theadom A, 2015, SLEEP MED, V16, P926, DOI 10.1016/j.sleep.2015.04.013; Torbic H, 2013, AM J HEALTH-SYST PH, V70, P759, DOI 10.2146/ajhp120203; Vahabzadeh-Hagh AM, 2012, NEUROMODULATION, V15, P296, DOI 10.1111/j.1525-1403.2012.00482.x; Vahabzadeh-Hagh AM, 2011, J NEUROPHYSIOL, V105, P615, DOI 10.1152/jn.00660.2010; Valk-Kleibeuker L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087414; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Ziemann U, 2015, CLIN NEUROPHYSIOL, V126, P1847, DOI 10.1016/j.clinph.2014.08.028	100	37	37	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	DEC	2017	27	12					5509	5524		10.1093/cercor/bhw318			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FN8MV	WOS:000416280200007	27909008	Bronze, Green Published			2022-02-06	
J	Gracies, JM; Esquenazi, A; Brashear, A; Banach, M; Kocer, S; Jech, R; Khatkova, S; Benetin, J; Vecchio, M; McAllister, P; Ilkowski, J; Ochudlo, S; Catus, F; Grandoulier, AS; Vilain, C; Picaut, P				Gracies, Jean-Michel; Esquenazi, Alberto; Brashear, Allison; Banach, Marta; Kocer, Serdar; Jech, Robert; Khatkova, Svetlana; Benetin, Jan; Vecchio, Michele; McAllister, Peter; Ilkowski, Jan; Ochudlo, Stanislaw; Catus, France; Grandoulier, Anne Sophie; Vilain, Claire; Picaut, Philippe		Int AbobotulinumtoxinA Adult Lower	Efficacy and safety of abobotulinumtoxinA in spastic lower limb Randomized trial and extension	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; TOXIN TYPE-A; BOTULINUM TOXIN; DOUBLE-BLIND; HEMIPARETIC PATIENTS; STROKE; PLACEBO; PARESIS; GAIT; ADULTS	Objective: To demonstrate single abobotulinumtoxinA injection efficacy in lower limb vs placebo for adults with chronic hemiparesis and assess long-term safety and efficacy of repeated injections. Methods: In a multicenter, double-blind, randomized, placebo-controlled, single-cycle study followed by a 1-year open-label, multiple-cycle extension, adults >= 6 months after stroke/brain injury received one lower limb injection (abobotulinumtoxinA 1,000 U, abobotulinumtoxinA 1,500 U, placebo) followed by <= 4 open-label cycles (1,000, 1,500 U) at >= 12-week intervals. Efficacy measures included Modified Ashworth Scale (MAS) in gastrocnemius-soleus complex (GSC; double-blind primary endpoint), physician global assessment (PGA), and comfortable barefoot walking speed. Safety was the open-label primary endpoint. Results: After a single injection, mean (95% confidence interval) MAS GSC changes from baseline at week 4 (double-blind, n = 381) were as follows: -0.5 (-0.7 to -0.4) (placebo, n = 128), -0.6 (-0.8 to -0.5) (abobotulinumtoxinA 1,000 U, n = 125; p = 0.28 vs placebo), and -0.8 (-0.9 to -0.7) (abobotulinumtoxinA 1,500 U, n = 128; p = 0.009 vs placebo). Mean week 4 PGA scores were as follows: 0.7 (0.5, 0.9) (placebo), 0.9 (0.7, 1.1) (1,000 U; p = 0.067 vs placebo), and 0.9 (0.7, 1.1) (1,500 U; p = 0.067); walking speed was not significantly improved vs placebo. At cycle 4, week 4 (open-label), mean MAS GSC change reached -1.0. Incremental improvements in PGA and walking speed occurred across open-label cycles; by cycle 4, week 4, mean PGA was 1.9, and walking speed increased 125.3% (17.5, 33.2), with 16% of participants walking >0.8 m/s (associated with community mobility; 0% at baseline). Tolerability was good and consistent with the known abobotulinumtoxinA safety profile. Conclusions: In chronic hemiparesis, single abobotulinumtoxinA (Dysport Ipsen) administration reduced muscle tone. Repeated administration over a year was well-tolerated and improved walking speed and likelihood of achieving community ambulation.	[Gracies, Jean-Michel] Univ Paris Est, Hosp Albert Chenevier Henri Mondor, Serv Reeducat Neurolocomotrice, EA BIOTN 7377, Creteil, France; [Esquenazi, Alberto] Moss Rehab, Gait & Mot Anal Lab, Elkins Pk, PA USA; [Brashear, Allison] Wake Forest Sch Med, Dept Neurol, Winston Salem, NC USA; [Banach, Marta] Jagiellonian Univ, Coll Med, Dept Neurol, Krakow, Poland; [Kocer, Serdar] Ctr Reeducat Hop Jura, Porrentruy, Switzerland; [Jech, Robert] Charles Univ Prague, Dept Neurol, Fac Med 1, Prague, Czech Republic; Gen Fac Hosp, Prague, Czech Republic; [Khatkova, Svetlana] Minist Hlth & Social Dev Russian Federat, Dept Neurol, Fed State Hosp, Treatments & Rehabil, Moscow, Russia; [Benetin, Jan] Slovak Med Univ Bratislava, Dept Neurol, Fac Med, Bratislava, Slovakia; Univ Hosp Bratislava, Bratislava, Slovakia; [Vecchio, Michele] AOU OVE Policlin, Dept Med Sci, UOC Phys Med & Rehabilitat, Catania, Italy; [McAllister, Peter] New England Inst Neurol & Headache, Stamford, CT USA; [Ilkowski, Jan] Nzoz Neuro Card, Ilkowski Partner, Poznan, Poland; [Ochudlo, Stanislaw] Cent Clin Hosp, Stroke Dept, Katowice, Poland; [Ochudlo, Stanislaw] Cent Clin Hosp, Dept Neurol, Katowice, Poland; [Catus, France] Assesoria Croissance, Santiago, Chile; [Grandoulier, Anne Sophie; Vilain, Claire; Picaut, Philippe] Ipsen Innovat, Les Ulis, France		Gracies, JM (corresponding author), Univ Paris Est, Hosp Albert Chenevier Henri Mondor, Serv Reeducat Neurolocomotrice, EA BIOTN 7377, Creteil, France.	jean-michel.gracies@aphp.fr	DECAVEL, Pierre/H-4032-2017; Kocer, Serdar/AAG-2708-2019	DECAVEL, Pierre/0000-0002-0567-7171; Ilkowski, Jan/0000-0002-9277-7532; Jech, Robert/0000-0002-9732-8947; Vecchio, Michele/0000-0001-5254-3283	IpsenIpsen	This study was sponsored by Ipsen. Jean-Michel Gracies wrote the first draft of the manuscript. Medical writing assistance (technical editing, preparation of figures and tables) was provided by Catherine Risebro of Mudskipper Business Ltd., funded by Ipsen. The clinical research organization responsible for the study was INC Research. The Article Processing Charge was funded by Ipsen.	Bakheit AMO, 2000, STROKE, V31, P2402, DOI 10.1161/01.STR.31.10.2402; Bakheit AMO, 2004, J NEUROL NEUROSUR PS, V75, P1558, DOI 10.1136/jnnp.2003.035139; Burbaud P, 1996, J NEUROL NEUROSUR PS, V61, P265, DOI 10.1136/jnnp.61.3.265; de Bruin M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101038; Dobkin BH, 2010, NEUROREHAB NEURAL RE, V24, P235, DOI 10.1177/1545968309357558; Esquenazi A, 2015, TOXICON S, V93, pS24; Gracies JM, 2015, ANN PHYS REHABIL MED, V58, P173, DOI 10.1016/j.rehab.2015.04.004; Gracies JM, 2010, EUR J PHYS REHAB MED, V46, P411; Gracies JM, 2015, LANCET NEUROL, V14, P992, DOI 10.1016/S1474-4422(15)00216-1; Gracies JM, 2005, MUSCLE NERVE, V31, P535, DOI 10.1002/mus.20284; Hesse S, 1995, NEUROSCI LETT, V201, P37, DOI 10.1016/0304-3940(94)12124-9; Hutin E, 2012, GAIT POSTURE, V36, P205, DOI 10.1016/j.gaitpost.2012.02.016; Kaji R, 2010, J NEUROL, V257, P1330, DOI 10.1007/s00415-010-5526-3; Kollen B, 2006, PHYS THER, V86, P618, DOI 10.1093/ptj/86.5.618; Martin A, 2014, NEUROPSYCH DIS TREAT, V10, P111, DOI 10.2147/NDT.S53913; Moseley AM, 2004, J HEAD TRAUMA REHAB, V19, P341, DOI 10.1097/00001199-200407000-00008; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; Perera S, 2016, J GERONTOL A-BIOL, V71, P63, DOI 10.1093/gerona/glv126; Pittock SJ, 2003, CEREBROVASC DIS, V15, P289, DOI 10.1159/000069495; Schmid A, 2007, STROKE, V38, P2096, DOI 10.1161/STROKEAHA.106.475921; Simpson DM, 2008, NEUROLOGY, V70, P1691, DOI 10.1212/01.wnl.0000311391.00944.c4; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Suputtitada A, 2005, DISABIL REHABIL, V27, P176, DOI 10.1080/09638280400009360	23	37	45	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 28	2017	89	22					2245	2253		10.1212/WNL.0000000000004687			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	FP5RI	WOS:000417678300012	29093068	hybrid, Green Published			2022-02-06	
J	Wang, TW; Chang, KC; Chen, LH; Liao, SY; Yeh, CW; Chuang, YJ				Wang, Tzu-Wei; Chang, Kai-Chieh; Chen, Liang-Hsin; Liao, Shih-Yung; Yeh, Chia-Wei; Chuang, Yung-Jen			Effects of an injectable functionalized selfassembling nanopeptide hydrogel on angiogenesis and neurogenesis for regeneration of the central nervous system	NANOSCALE			English	Article							TRAUMATIC BRAIN-INJURY; ASSEMBLING PEPTIDE HYDROGEL; NEURAL PROGENITOR CELLS; ANIMAL-MODEL; IN-VIVO; ZEBRAFISH; SVVYGLR; REPAIR; OSTEOPONTIN; SCAFFOLDS	Brain injury is a devastating medical condition and represents a major health problem. Tissue and organ reconstruction have been regarded as promising therapeutic strategies. Here, we propose a regenerative methodology focusing on the provision of functionalized nanopeptide scaffolds to facilitate angiogenesis and neurogenesis at the brain injury site. The peptide RADA16-SVVYGLR undergoes self-assembly to construct an interconnected network with intertwining nanofibers, and can be controlled to display various physicochemical properties by the adjustment of microenvironmental factors such as pH and ion concentration. Such scaffolds can support endothelial cells to form tube-like structures and neural stem cells to survive and proliferate. In an in vivo zebrafish brain injury model, sprouting angiogenesis and developmental neurogenesis were achieved, and functional recovery of the severed optic tectum was enhanced in RADA16-SVVYGLR hydrogel-implanted zebrafish. This nanopeptide hydrogel was non-toxic to zebrafish embryos during early developmental stages. This angiogenic self-assembling peptide hydrogel had programmable physical properties, good biocompatibility, and regenerative ability for functional recovery in the injured brain. We suggest that functionalized self-assembling peptides encapsulated with neural stem cells or used alone could be an attractive and effective therapeutic modality for brain injury and diseases (e.g., trauma, stroke, tumor, degenerative neurological disorders, etc.).	[Wang, Tzu-Wei; Chang, Kai-Chieh; Chen, Liang-Hsin; Yeh, Chia-Wei] Natl Tsing Hua Univ, Dept Mat Sci & Engn, Hsinchu, Taiwan; [Liao, Shih-Yung] Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu, Taiwan; [Chuang, Yung-Jen] Natl Tsing Hua Univ, Dept Med Sci, Hsinchu, Taiwan; [Chuang, Yung-Jen] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu, Taiwan		Wang, TW (corresponding author), Natl Tsing Hua Univ, Dept Mat Sci & Engn, Hsinchu, Taiwan.	twwang@mx.nthu.edu.tw		Chuang, Yung-Jen/0000-0002-6022-0107; Wang, Tzu-Wei/0000-0003-0669-6240	 [MOST 104-2628-E-007-002-MY3];  [MOST 104-2221-E-007-140-MY2];  [MOST 104-2622-E-007-018-CC2]	The authors are greatly thankful for advice and valuable suggestions from Professor Jia-Cherng Horng (Department of Chemistry, National Tsing Hua University) and Shu-Wei Chang (Department of Civil Engineering, National Taiwan University). We also thank Professor Chi-Shiun Chiang (Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University) for help in cryostat microtome analyses. The authors also thank the funding support from MOST 104-2628-E-007-002-MY3, MOST 104-2221-E-007-140-MY2 and MOST 104-2622-E-007-018-CC2.	Ahmadi F, 2015, RES PHARM SCI, V10, P1; Alunni A, 2016, DEVELOPMENT, V143, P741, DOI 10.1242/dev.122796; Alvarez XA, 2013, FUTUR NEUROL, V8, P175, DOI 10.2217/FNL.12.95; Aramvash A, 2015, J CLUST SCI, V26, P631, DOI 10.1007/s10876-014-0836-8; Arosio P, 2012, BIOPHYS J, V102, P1617, DOI 10.1016/j.bpj.2012.03.012; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Barbolt TA, 2001, NEUROL RES, V23, P813, DOI 10.1179/016164101101199405; Chan LY, 2011, BLOOD, V118, P6709, DOI 10.1182/blood-2011-06-359141; Cheng TY, 2013, NANOSCALE, V5, P2734, DOI 10.1039/c3nr33710c; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Delov V, 2014, AQUAT TOXICOL, V150, P189, DOI 10.1016/j.aquatox.2014.03.010; Eskandari S, 2017, ADV DRUG DELIVER REV, V110, P169, DOI 10.1016/j.addr.2016.06.013; Estroff LA, 2004, CHEM REV, V104, P1201, DOI 10.1021/cr0302049; Font MA, 2010, CURR CARDIOL REV, V6, P238, DOI 10.2174/157340310791658802; Francis NL, 2016, ACS BIOMATER SCI ENG, V2, P1030, DOI 10.1021/acsbiomaterials.6b00156; Hamada Y, 2004, DENT MATER J, V23, P650, DOI 10.4012/dmj.23.650; Hamada Y, 2003, BIOCHEM BIOPH RES CO, V310, P153, DOI 10.1016/j.bbrc.2003.09.001; Ito K, 2009, MATRIX BIOL, V28, P11, DOI 10.1016/j.matbio.2008.10.002; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Loo Y, 2012, BIOTECHNOL ADV, V30, P593, DOI 10.1016/j.biotechadv.2011.10.004; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maaswinkel H, 2003, VISION RES, V43, P21, DOI 10.1016/S0042-6989(02)00395-4; Marz M, 2011, DEV DYNAM, V240, P2221, DOI 10.1002/dvdy.22710; Meng FW, 2014, REGEN MED, V9, P367, DOI [10.2217/rme.14.9, 10.2217/RME.14.9]; Orive G, 2009, NAT REV NEUROSCI, V10, P682, DOI 10.1038/nrn2685; Owczarz M, 2015, BIOMACROMOLECULES, V16, P3792, DOI 10.1021/acs.biomac.5b01092; Reddy DS, 2010, PROG BRAIN RES, V186, P113, DOI 10.1016/B978-0-444-53630-3.00008-7; Rodriguez AL, 2014, J MATER CHEM B, V2, P7771, DOI 10.1039/c4tb01391c; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Shen XP, 2016, GREEN CHEM, V18, P53, DOI 10.1039/c5gc02396c; Somaa FA, 2017, CELL REP, V20, P1964, DOI 10.1016/j.celrep.2017.07.069; SPRINGER AD, 1977, BRAIN RES, V128, P393, DOI 10.1016/0006-8993(77)90166-4; Stendahl JC, 2006, ADV FUNCT MATER, V16, P499, DOI 10.1002/adfm.200500161; Tal TL, 2014, REPROD TOXICOL, V48, P51, DOI 10.1016/j.reprotox.2014.05.014; Tam RY, 2014, NEUROPSYCHOPHARMACOL, V39, P169, DOI 10.1038/npp.2013.237; Uchinaka A, 2013, CARDIOVASC RES, V99, P102, DOI 10.1093/cvr/cvt088; Wang TW, 2017, ACTA BIOMATER, V58, P54, DOI 10.1016/j.actbio.2017.06.008; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Ye ZY, 2008, J PEPT SCI, V14, P152, DOI 10.1002/psc.988; Yokoi H, 2005, P NATL ACAD SCI USA, V102, P8414, DOI 10.1073/pnas.0407843102; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; Zhou A, 2016, DRUG DES DEV THER, V10, P3043, DOI 10.2147/DDDT.S109545; Zweckberger K, 2016, ACTA BIOMATER, V42, P77, DOI 10.1016/j.actbio.2016.06.016	44	37	39	4	65	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2040-3364	2040-3372		NANOSCALE	Nanoscale	NOV 14	2017	9	42					16281	16292		10.1039/c7nr06528k			12	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	FL6IT	WOS:000414349100022	29046917				2022-02-06	
J	Fann, JR; Bombardier, CH; Temkin, N; Esselman, P; Warms, C; Barber, J; Dikmen, S				Fann, Jesse R.; Bombardier, Charles H.; Temkin, Nancy; Esselman, Peter; Warms, Catherine; Barber, Jason; Dikmen, Sureyya			Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						antidepressant; clinical trial; depression; head injury; placebo; quality of life; traumatic brain injury; treatment	COGNITIVE-BEHAVIORAL THERAPY; RATING-SCALE; 1ST YEAR; SEVERITY; SYMPTOMS; ANXIETY; REHABILITATION; METAANALYSIS; DISABILITY; DISORDERS	Objective: Major depressive disorder (MDD) is common and associated with impaired functioning after traumatic brain injury (TBI). Few placebo-controlled antidepressant trials exist in this population. We evaluated the efficacy and tolerability of sertraline for MDD within 1 year of sustaining a TBI. Setting: Level I trauma center. Participants: Adults with MDD within 1 year of hospitalization for complicated mild to severe TBI. Design: Randomized, double-blind, placebo-controlled trial. Main Measures: Twelve-week treatment response on the 17-item Hamilton Depression Rating Scale. We also assessed symptom improvement and remission. Results: We randomized 62 participants: 32% sustained a severe TBI, 68% had significant anxiety, 63% had a history of prior MDD, and 69% had a history of alcohol or drug dependence. Depression significantly improved from baseline to 12 weeks in both treatment groups (P < .001). There were no significant differences between the sertraline and placebo groups over 12 weeks on depression severity, response, or remission. The sertraline group had significant improvement on speed of information processing compared with the placebo group (P < .006). Conclusion: Sertraline monotherapy was not superior to placebo for MDD in people with post-acute complicated mild to severe TBI. Research is needed on the effectiveness of interventions that also address the significant psychosocial needs of this population.	[Fann, Jesse R.; Dikmen, Sureyya] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560,1959 NE Pacific St, Seattle, WA 98195 USA; [Fann, Jesse R.; Bombardier, Charles H.; Esselman, Peter; Warms, Catherine; Dikmen, Sureyya] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy; Barber, Jason] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA		Fann, JR (corresponding author), Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Box 356560,1959 NE Pacific St, Seattle, WA 98195 USA.	fann@uw.edu	Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283	National Center for Medical Rehabilitation Research; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD39415]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039415] Funding Source: NIH RePORTER	This work was supported by the National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and National Institutes of Health grant R01HD39415. Pfizer supplied masked sertraline and placebo for the controlled trial. The authors thank Erika Pelzer, BS, University of Washington School of Medicine, who provided expert assistance and oversight in data collection efforts.	AMADOBOCCARA I, 1995, NEUROSCI BIOBEHAV R, V19, P479, DOI 10.1016/0149-7634(94)00068-C; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Banos JH, 2010, J HEAD TRAUMA REHAB, V25, P357, DOI 10.1097/HTR.0b013e3181d6c715; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Baune BT, 2014, PSYCHIAT RES, V219, P25, DOI 10.1016/j.psychres.2014.05.013; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; Dyer JR, 2016, J HEAD TRAUMA REHAB, V31, P225, DOI 10.1097/HTR.0000000000000177; Entsuah R, 2002, J PSYCHIATR RES, V36, P437, DOI 10.1016/S0022-3956(02)00024-9; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faries D, 2000, J PSYCHIAT RES, V34, P3, DOI 10.1016/S0022-3956(99)00037-0; First Michael B, 2001, USERS GUIDE STRUCTUR; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; Guillamondegui OD., 2011, TRAUMATIC BRAIN INJU; Guy W., 1976, ECDEU ASSESSMENT MAN, P218; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Hammond FM, 2015, ARCH PHYS MED REHAB, V96, pS256, DOI 10.1016/j.apmr.2015.01.025; Hart T, 2016, ARCH PHYS MED REHAB, V97, P701, DOI 10.1016/j.apmr.2015.08.436; HOLM S, 1979, SCAND J STAT, V6, P65; Iosifescu DV, 2007, PSYCHIAT CLIN N AM, V30, P77, DOI 10.1016/j.psc.2006.12.008; Jorge RE, 2016, JAMA PSYCHIAT, V73, P1041, DOI 10.1001/jamapsychiatry.2016.2189; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; MAIER W, 1985, PHARMACOPSYCHIATRY, V18, P114, DOI 10.1055/s-2007-1017335; Maiuro R. D., 1987, J INTERPERS VIOLENCE, V2, P166, DOI [10.1177/088626087002002003, DOI 10.1177/088626087002002003]; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Ponsford J, 2016, PSYCHOL MED, V46, P1079, DOI 10.1017/S0033291715002640; Previc FH, 1999, BRAIN COGNITION, V41, P299, DOI 10.1006/brcg.1999.1129; Ricker, 1994, Assessment, V1, P47, DOI 10.1177/1073191194001001007; Ruhe HG, 2005, COMPR PSYCHIAT, V46, P417, DOI 10.1016/j.comppsych.2005.03.001; Sheehan DV, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199606003-00015; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Yengo-Kahn AM, 2015, PHYSICIAN SPORTSMED, V43, P227, DOI 10.1080/00913847.2015.1071638	50	37	37	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2017	32	5					332	342		10.1097/HTR.0000000000000322			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FG2DW	WOS:000409893800013	28520672	Green Accepted			2022-02-06	
J	von Leden, RE; Khayrullina, G; Moritz, KE; Byrnes, KR				von Leden, Ramona E.; Khayrullina, Guzal; Moritz, Kasey E.; Byrnes, Kimberly R.			Age exacerbates microglial activation, oxidative stress, inflammatory and NOX2 gene expression, and delays functional recovery in a middle-aged rodent model of spinal cord injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Spinal cord injury; Aging; NOX2; Microglia; Inflammation	TRAUMATIC BRAIN-INJURY; THERAPEUTIC TARGETS; LOCOMOTOR RECOVERY; NADPH OXIDASE; RATS; MACROPHAGES; MICE; CNS; HYPERALGESIA; MECHANISMS	Background: Spinal cord injury (SCI) among people over age 40 has been steadily increasing since the 1980s and is associated with worsened outcome than injuries in young people. Age-related increases in reactive oxygen species (ROS) are suggested to lead to chronic inflammation. The NADPH oxidase 2 (NOX2) enzyme is expressed by microglia and is a primary source of ROS. This study aimed to determine the effect of age on inflammation, oxidative damage, NOX2 gene expression, and functional performance with and without SCI in young adult (3 months) and middle-aged (12 months) male rats. Methods: Young adult and middle-aged rats were assessed in two groups-naive and moderate contusion SCI. Functional recovery was determined by weekly assessment with the Basso, Beattie, and Breshnahan general motor score (analyzed two-way ANOVA) and footprint analysis (analyzed by Chi-square analysis). Tissue was analyzed for markers of oxidative damage (8-OHdG, Oxyblot, and 3-NT), microglial-related inflammation (Iba1), NOX2 component (p47(PHOX), p22(PHOX), and gp91(PHOX)), and inflammatory (CD86, CD206, TNF alpha, and NF kappa B) gene expression (all analyzed by unpaired Student's t test). Results: In both naive and injured aged rats, compared to young rats, tissue analysis revealed significant increases in 8-OHdG and Iba1, as well as inflammatory and NOX2 component gene expression. Further, injured aged rats showed greater lesion volume rostral and caudal to the injury epicenter. Finally, injured aged rats showed significantly reduced Basso-Beattie-Bresnahan (BBB) scores and stride length after SCI. Conclusions: These results show that middle-aged rats demonstrate increased microglial activation, oxidative stress, and inflammatory gene expression, which may be related to elevated NOX2 expression, and contribute to worsened functional outcome following injury. These findings are essential to elucidating the mechanisms of age-related differences in response to SCI and developing age-appropriate therapeutics.	[von Leden, Ramona E.; Khayrullina, Guzal; Moritz, Kasey E.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Neurosci Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [von Leden, Ramona E.; Khayrullina, Guzal; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA		von Leden, RE (corresponding author), Uniformed Serv Univ Hlth Sci, Neurosci Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; von Leden, RE (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Ramona.von-leden.ctr@usush.edu			NINDS/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS073667-01A1, 1F31NS090737-01A1]; Uniformed Services University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS090737, R01NS073667] Funding Source: NIH RePORTER	This work was funded by the NINDS/NIH (Grant number 1R01NS073667-01A1) and a pilot grant from the Uniformed Services University. R. von Leden was supported by the NINDS/NIH (Grant number 1F31NS090737-01A1).	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; Beare JE, 2009, J NEUROTRAUM, V26, P2045, DOI 10.1089/neu.2009.0914; Blakeman KH, 2003, NEUROSCIENCE, V117, P221, DOI 10.1016/S0306-4522(02)00779-0; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Cooney SJ, 2014, FREE RADICAL RES, V48, P929, DOI 10.3109/10715762.2014.927578; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Fouad K, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00085; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Groah SL, 2012, AM J PHYS MED REHAB, V91, P80, DOI 10.1097/PHM.0b013e31821f70bc; Gwak YS, 2004, J NEUROTRAUM, V21, P983, DOI 10.1089/0897715041650999; Gwak YS, 2004, NEUROSCI LETT, V362, P232, DOI 10.1016/j.neulet.2004.03.019; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; Hooshmand MJ, 2014, IMMUN AGEING, V11, DOI 10.1186/1742-4933-11-15; Hygge-Blakeman K, 2004, BRAIN RES, V1025, P152, DOI 10.1016/j.brainres.2004.07.078; Jain NB, 2015, JAMA-J AM MED ASSOC, V313, P2236, DOI 10.1001/jama.2015.6250; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Khayrullina G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0391-8; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Loy DN, 2002, EXP NEUROL, V177, P575, DOI 10.1006/exnr.2002.7959; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Moritz KE, 2014, RESTOR NEUROL NEUROS, V32, P701, DOI 10.3233/RNN-140414; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; NSCISC, 2016, FACTS FIG GLANC, P2016; Ritzel RM, 2015, NEUROBIOL AGING, V36, P2153, DOI 10.1016/j.neurobiolaging.2015.02.016; Ronsyn MW, 2008, SPINAL CORD, V46, P532, DOI 10.1038/sc.2008.13; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Zhang B, 2014, EXP NEUROL, V258, P112, DOI 10.1016/j.expneurol.2014.04.007; Zhang B, 2016, NEUROBIOL AGING, V47, P157, DOI 10.1016/j.neurobiolaging.2016.07.029; Zhang B, 2015, EXP NEUROL, V273, P83, DOI 10.1016/j.expneurol.2015.08.001	43	37	37	3	10	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 18	2017	14								161	10.1186/s12974-017-0933-3			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	FE0YI	WOS:000407945200001	28821269	gold, Green Published			2022-02-06	
J	Schallmo, MS; Weiner, JA; Hsu, WK				Schallmo, Michael S.; Weiner, Joseph A.; Hsu, Wellington K.			Sport and Sex-Specific Reporting Trends in the Epidemiology of Concussions Sustained by High School Athletes	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							DIAGNOSIS; EDUCATION; RECOVERY; GENDER; AGE	Background: Approximately 300,000 U.S. adolescents sustain concussions annually while participating in organized athletics. This study aimed to track sex and sport-specific trends among high school sports-related concussions over time, to identify whether a particular sport predisposes athletes to a higher risk, and to assess whether traumatic brain injury law enactments have been successful in improving recognition. Methods: Injury data for academic years 2005 to 2014 were collected from annual reports generated by High School RIO (Reporting Information Online). The relative proportions of total estimated concussions to total estimated injuries were compared using an injury proportion ratio. The concussion rate was defined as the number of concussions per 10,000 athlete exposures (1 athlete participating in 1 practice or competition), with rates compared using a rate ratio. To evaluate the impact of legislation on sports-related concussions in this population, trends in concussion rates and proportions were analyzed before enactment (academic years 2005-2009) and after enactment (academic years 2010-2014). Results: Between 2005-2006 and 2014-2015, a significant increase (p < 0.0001) in the overall number of concussions for all sports combined, the overall concussion rate (rate ratio, 2.30 [95% confidence interval, 2.04 to 2.59]), and the overall proportion of concussions (injury proportion ratio, 2.68 [95% confidence interval, 2.66 to 2.70]) was seen. Based on the injury proportion ratio, during the 2014-2015 academic year, concussions were more common in girls' soccer than in any other sport (p < 0.0001). Conclusions: Because of potentially devastating consequences, concussion prevention and recognition measures continue to be emphasized in high school contact sports. The data in our study suggest that significant increases in the overall rate and proportion of reported concussions during the past decade could have been affected by traumatic brain injury legislation. To our knowledge, this is the first study to show that girls' soccer players may have an even greater risk of sustaining a concussion than all other sports.	[Schallmo, Michael S.; Weiner, Joseph A.; Hsu, Wellington K.] Northwestern Univ, Feinberg Sch Med, Dept Orthopaed Surg, Chicago, IL 60611 USA; [Schallmo, Michael S.] Wake Forest Sch Med, Dept Orthopaed Surg, Winston Salem, NC USA		Hsu, WK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Orthopaed Surg, Chicago, IL 60611 USA.	wkhsu@yahoo.com					Bodin D, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P9, DOI 10.1007/978-0-387-89545-1_2; Comstock D, 2016, HIGH SCH RIO REPORTI; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey H., 2015, YOUTH SPORTS TRAUMAT; Harvey Hosea H, 2014, Yale J Health Policy Law Ethics, V14, P66; Knowles SB, 2010, J ATHL TRAINING, V45, P475, DOI 10.4085/1062-6050-45.5.475; Kroshus E, 2015, HEALTH EDUC BEHAV, V42, P153, DOI 10.1177/1090198114543011; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Madden C, 2009, NETTERS SPORTS MED, P317; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; National Federation of State High School Association, 2015, 2014 2015 HIGH SCH A; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Ono KE, 2016, AM J SPORT MED, V44, P748, DOI 10.1177/0363546515617746; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Snyder TD, 2014, US DEP ED DIGEST ED; The Centers for Disease Control and Prevention (CDC), 2006, JAMA-J AM MED ASSOC, V296, P2673	23	37	37	1	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	AUG 2	2017	99	15					1314	1320		10.2106/JBJS.16.01573			7	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	FC3ST	WOS:000406760100014	28763417				2022-02-06	
J	Nguyen, S; McKay, A; Wong, DN; Rajaratnam, SM; Spitz, G; Williams, G; Mansfield, D; Ponsford, JL				Nguyen, Sylvia; McKay, Adam; Wong, Dana; Rajaratnam, Shantha M.; Spitz, Gershon; Williams, Gavin; Mansfield, Darren; Ponsford, Jennie L.			Cognitive Behavior Therapy to Treat Sleep Disturbance and Fatigue After Traumatic Brain Injury: A Pilot Randomized Controlled Trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Mid-Year Meeting of the International-Neuropsychological-Society	JUL 06-08, 2016	London, ENGLAND	Int Neuropsychol Soc		Brain injuries; Cognitive therapy; Fatigue; Rehabilitation; Sleep; Traumatic	PLACEBO-CONTROLLED TRIAL; MULTIPLE-SCLEROSIS; CANCER-PATIENTS; COMORBID INSOMNIA; QUALITY INDEX; METAANALYSIS; DEPRESSION; SEVERITY; ANXIETY; SCALE	Objective: To evaluate the efficacy of adapted cognitive behavioral therapy (CBT) for sleep disturbance and fatigue in individuals with traumatic brain injury (TBI). Design: Parallel 2-group randomized controlled trial. Setting: Outpatient therapy. Participants: Adults (N=24) with history of TBI and clinically significant sleep and/or fatigue complaints were randomly allocated to an 8 session adapted CBT intervention or a treatment as usual (TAU) condition. Interventions: Cognitive behavior therapy. Main Outcome Measures: The primary outcome was the Pittsburgh Sleep Quality Index (PSQI) posttreatment and at 2-month follow-up. Secondary measures included the Insomnia Severity Index, Fatigue Severity Scale, Brief Fatigue Inventory (BFI), Epworth Sleepiness Scale, and Hospital Anxiety and Depression Scale. Results: At follow-up, CBT recipients reported better sleep quality than those receiving TAU (PSQI mean difference, 4.85; 95% confidence interval [CI], 2.56-7.14). Daily fatigue levels were significantly reduced in the CBT group (BFI difference, 1.54; 95% CI, 0.66-2.42). Secondary improvements were significant for depression. Large within-group effect sizes were evident across measures (Hedges g=1.14-1.93), with maintenance of gains 2 months after therapy cessation. Conclusions: Adapted CBT produced greater and sustained improvements in sleep, daily fatigue levels, and depression compared with TAU. These pilot findings suggest that CBT is a promising treatment for sleep disturbance and fatigue after TBI. (C) 2017 by the American Congress of Rehabilitation Medicine	[Nguyen, Sylvia; McKay, Adam; Wong, Dana; Rajaratnam, Shantha M.; Spitz, Gershon; Mansfield, Darren; Ponsford, Jennie L.] Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia; [Nguyen, Sylvia; McKay, Adam; Wong, Dana; Rajaratnam, Shantha M.; Spitz, Gershon; Mansfield, Darren; Ponsford, Jennie L.] Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia; [Nguyen, Sylvia; McKay, Adam; Wong, Dana; Spitz, Gershon; Ponsford, Jennie L.] Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Williams, Gavin] Epworth Healthcare, Melbourne, Vic, Australia		Nguyen, S (corresponding author), Monash Epworth Rehabil Res Ctr, 185-187 Hoddle St, Richmond, Vic 3121, Australia.	sylvia.nguyen@monash.edu	; McKay, Adam/M-6003-2017; Spitz, Gershon/H-7755-2014	Rajaratnam, Shantha/0000-0001-7527-8558; McKay, Adam/0000-0002-0479-7681; Williams, Gavin/0000-0003-2758-7473; Spitz, Gershon/0000-0002-7810-1480; Wong, Dana/0000-0001-9619-1929	Centre of Research Excellence for Brain Recovery [1023043]; Epworth Research Institute [80969]	Supported by the Centre of Research Excellence for Brain Recovery (grant no. 1023043) and the Epworth Research Institute (grant no. 80969).	Ashworth DK, 2015, J COUNS PSYCHOL, V62, P115, DOI 10.1037/cou0000059; Beaulieu-Bonneau Simon, 2017, Neuropsychol Rehabil, V27, P983, DOI 10.1080/09602011.2016.1162176; Beck AT., 1979, COGNITIVE THERAPY DE; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castell BD, 2011, CLIN PSYCHOL-SCI PR, V18, P311, DOI 10.1111/j.1468-2850.2011.01262.x; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Delis D. C., 2000, MANUAL CALIFORNIAN V; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Fleming L, 2014, PSYCHO-ONCOLOGY, V23, P679, DOI 10.1002/pon.3468; Geiger-Brown JM, 2015, SLEEP MED REV, V23, P54, DOI 10.1016/j.smrv.2014.11.007; Gielissen MFM, 2006, J CLIN ONCOL, V24, P4882, DOI 10.1200/JCO.2006.06.8270; Heckler CE, 2016, SUPPORT CARE CANCER, V24, P2059, DOI 10.1007/s00520-015-2996-y; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P585, DOI 10.1080/09602011.2012.678860; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Juengst S, 2013, ARCH PHYS MED REHAB, V94, P74, DOI 10.1016/j.apmr.2012.07.025; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lakens D, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00863; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Mollayeva T, 2014, NEUROSCI BIOBEHAV R, V47, P684, DOI 10.1016/j.neubiorev.2014.10.024; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; Ponsford J, 2015, J HEAD TRAUMA REHAB, V30, P277, DOI 10.1097/HTR.0000000000000049; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Raina KD, 2016, J HEAD TRAUMA REHAB, V31, pE41, DOI 10.1097/HTR.0000000000000196; Roscoe JA, 2015, J CLIN ONCOL, V33, P165, DOI 10.1200/JCO.2014.57.6769; Schnieders J, 2012, J HEAD TRAUMA REHAB, V27, P404, DOI 10.1097/HTR.0b013e3182306341; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Shekleton JA, 2014, SLEEP, V37, P107, DOI 10.5665/sleep.3318; Shekleton JA, 2010, SLEEP MED REV, V14, P47, DOI 10.1016/j.smrv.2009.06.001; Taylor DJ, 2014, INT REV PSYCHIATR, V26, P205, DOI 10.3109/09540261.2014.902808; Trauer JM, 2015, ANN INTERN MED, V163, P191, DOI 10.7326/M14-2841; van den Akker LE, 2016, J PSYCHOSOM RES, V90, P33, DOI 10.1016/j.jpsychores.2016.09.002; van Kessel K, 2008, PSYCHOSOM MED, V70, P205, DOI 10.1097/PSY.0b013e3181643065; White PD, 2011, LANCET, V377, P823, DOI 10.1016/S0140-6736(11)60096-2; Wiseman-Hakes C, 2013, BRAIN INJURY, V27, P1364, DOI 10.3109/02699052.2013.823663; Yun YH, 2012, J CLIN ONCOL, V30, P1296, DOI 10.1200/JCO.2011.37.2979; Zedlitz AMEE, 2012, STROKE, V43, P1046, DOI 10.1161/STROKEAHA.111.632117; Zgaljardic DJ, 2014, BRAIN INJURY, V28, P389, DOI 10.3109/02699052.2014.884242; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	52	37	37	1	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2017	98	8					1508	1517		10.1016/j.apmr.2017.02.031			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	FD1OF	WOS:000407305900002	28400181				2022-02-06	
J	Garcia-Gonzalez, D; Jayamohan, J; Sotiropoulos, SN; Yoon, SH; Cook, J; Siviour, CR; Arias, A; Jerusalem, A				Garcia-Gonzalez, D.; Jayamohan, J.; Sotiropoulos, S. N.; Yoon, S. -H.; Cook, J.; Siviour, C. R.; Arias, A.; Jerusalem, A.			On the mechanical behaviour of PEEK and HA cranial implants under impact loading	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Finite element head model; Cranial implant; PEEK; Macroporous HA; Impact loading	CONSTITUTIVE MODEL; STRAIN-RATE; IN-VIVO; FAILURE CHARACTERISTICS; DYNAMIC-RESPONSE; HEAD RESPONSE; BRAIN-TISSUE; FRACTURE; INJURIES; STRESS	The human head can be subjected to numerous impact loadings such as those produced by a fall or during sport activities. These accidents can result in skull fracture and in some complex cases, part of the skull may need to be replaced by a biomedical implant. Even when the skull is not damaged, such accidents can result in brain swelling treated by decompressive craniectomy. Usually, after recovery, the part of the skull that has been removed is replaced by a prosthesis. In such situations, a computational tool able to analyse the choice of prosthesis material depending on the patient's specific activity has the potential to be extremely useful for clinicians. The work proposed here focusses on the development and use of a numerical model for the analysis of cranial implants under impact conditions. In particular, two main biomaterials commonly employed for this kind of prosthesis are polyether-ether-ketone (PEEK) and macroporous hydroxyapatite (HA). In order to study the suitability of these implants, a finite element head model comprising scalp, skull, cerebral falx, cerebrospinal fluid and brain tissues, with a cranial implant replacing part of the skull has been developed from magnetic resonance imaging data. The human tissues and these two biocompatible materials have been independently studied and their constitutive models are provided here. A computational model of the human head under impact loading is then implemented and validated, and a numerical comparison of the mechanical impact response of PEEK and HA implants is presented. This comparison was carried out in terms of the effectiveness of both implants in ensuring structural integrity and preventing traumatic brain injury. The results obtained in this work highlight the need to take into account environmental mechanical considerations to select the optimal implant depending on the specific patient: whereas HA implants present attractive biointegration properties, PEEK implant can potentially be a much more appropriate choice in a demanding mechanical life style. Finally, a novel methodology is proposed to assess the need for further clinical evaluation in case of impact with both implants over a large range of impact conditions.	[Garcia-Gonzalez, D.; Arias, A.] Univ Carlos III Madrid, Dept Continuum Mech & Struct Anal, Avda Univ 30, Madrid 28911, Spain; [Jayamohan, J.] Oxford Univ Hosp, Dept Neurosurg, John Radcliffe Hosp, Oxford OX3 9DU, England; [Sotiropoulos, S. N.] John Radcliffe Hosp, Oxford Ctr Funct Magnet Resonance Imaging Brain, Oxford OX3 9DU, England; [Yoon, S. -H.; Cook, J.; Siviour, C. R.; Jerusalem, A.] Univ Oxford, Dept Engn Sci, Parks Rd, Oxford OX1 3PJ, England		Jerusalem, A (corresponding author), Univ Oxford, Dept Engn Sci, Parks Rd, Oxford OX1 3PJ, England.	antoine.jerusalem@eng.ox.ac.uk	Arias, Angel/K-4550-2014; Garcia-Gonzalez, Daniel/K-7349-2017; Sotiropoulos, Stamatios/I-1163-2019	Arias, Angel/0000-0003-4696-7754; Garcia-Gonzalez, Daniel/0000-0003-4692-3508; Sotiropoulos, Stamatios/0000-0003-4735-5776	University Carlos III are indebted to the Ministerio de Economia y Competitividad de Espana [DPI2014-57989-P]; Vicerrectorado de Politica Cientifica UC3M [2013-00219-002]; European Union's Seventh Framework ProgrammeEuropean Commission [306587]; 16 NIH Institutes and CentersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Clinical Center (CC); McDonnell Center for Systems Neuroscience at Washington University; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/M02833X/1]; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/M02833X/1] Funding Source: researchfish	The researchers of the University Carlos III are indebted to the Ministerio de Economia y Competitividad de Espana (Project DPI2014-57989-P) and Vicerrectorado de Politica Cientifica UC3M (Project 2013-00219-002) for the financial support.; A.J. acknowledges funding from the European Union's Seventh Framework Programme (FP7 2007-2013) ERC Grant Agreement No. 306587.; MRI data were provided by the Human Connectome Project, WUMimi Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. Finally, we would like to thank Dr. S Barhli and Prof. J Marrow for valuable assistance with the X-ray tomography; the machine used was bought from EPSRC Grant EP/M02833X/1 "University of Oxford: experimental equipment upgrade".	Adetchessi AT, 2012, NEUROCHIRURGIE, V58, P382, DOI 10.1016/j.neuchi.2012.06.001; Al-Bsharat A. S., 1999, STAPP CAR CRASH J, V43, P321; Anand L, 1996, COMPUT MECH, V18, P339; Annaidh AN, 2012, J MECH BEHAV BIOMED, V5, P139, DOI 10.1016/j.jmbbm.2011.08.016; Baumgartner D, 2005, EUR J COMPUT MECH, V14, P421; Boyce MC, 2000, POLYMER, V41, P2183, DOI 10.1016/S0032-3861(99)00406-1; Boyde A, 1999, BONE, V24, P579, DOI 10.1016/S8756-3282(99)00083-6; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chan M., 1980, P 24 STAPP CAR CRASH, P347; Chen F, 2016, J MECH BEHAV BIOMED, V53, P427, DOI 10.1016/j.jmbbm.2015.08.037; Chistolini P, 1999, J MATER SCI-MATER M, V10, P739, DOI 10.1023/A:1008939524807; Dassault Systemes Abaqus v6.12, 2012, DOC ABAQUS AN US MAN; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Deng Y, 2016, COMPOS STRUCT, V140, P534, DOI 10.1016/j.compstruct.2016.01.020; Doblare M, 2004, ENG FRACT MECH, V71, P1809, DOI 10.1016/j.engfracmech.2003.08.003; DUNN MG, 1983, CONNECT TISSUE RES, V12, P59, DOI 10.3109/03008208309005612; El Halabi F, 2011, J MECH BEHAV BIOMED, V4, P1819, DOI 10.1016/j.jmbbm.2011.05.039; El-Qoubaa Z, 2016, MECH MATER, V95, P15, DOI 10.1016/j.mechmat.2015.12.008; Eolchiyan S. A., 2014, VOPROSY NEIROKHIRURG, V75, P3; Fahlstedt M., 2012, 2012 IRCOBI C P INT, P787, DOI DOI 10.1177/1753193412460139; FEI, 2015, FEI AMIRA 6 0 1; Frassanito P, 2013, CLIN NEUROL NEUROSUR, V115, P1496, DOI 10.1016/j.clineuro.2012.11.032; Fredriksson R., 2001, P 17 ESV C AMST NETH; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gambarotta L, 2005, J BIOMECH, V38, P2237, DOI 10.1016/j.jbiomech.2004.09.034; Gao C., 2007, THESIS; Garcia-Gonzalez D, 2017, INT J PLASTICITY, V88, P27, DOI 10.1016/j.ijplas.2016.09.011; Garcia-Gonzalez D, 2015, COMPOS STRUCT, V133, P1116, DOI 10.1016/j.compstruct.2015.08.028; Garcia-Gonzalez D, 2015, COMPOS STRUCT, V124, P88, DOI 10.1016/j.compstruct.2014.12.061; Giovanni B., 2005, P 19 INT TECHN C ENH; Goh JCH, 2002, P I MECH ENG H, V216, P359, DOI 10.1243/095441102321032157; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; HAWARD RN, 1968, PROC R SOC LON SER-A, V302, P453, DOI 10.1098/rspa.1968.0029; Hing KA, 1999, J MATER SCI-MATER M, V10, P135, DOI 10.1023/A:1008929305897; Honeybul S., 2016, INJURY; Horak Z, 2010, ACTA CHIR ORTHOP TR, V77, P463; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Jacquemoud C, 2007, J BIOMECH, V40, P468, DOI 10.1016/j.jbiomech.2005.12.010; Jerusalem A, 2012, ACTA BIOMATER, V8, P3360, DOI 10.1016/j.actbio.2012.04.039; Jirousek O, 2005, SOLID MECH APPL, V124, P459; JOCKISCH KA, 1992, J BIOMED MATER RES, V26, P133, DOI 10.1002/jbm.820260202; Kang HS, 1997, P STAPP CAR CRASH J, V41, P329; KHALIL TB, 1977, J BIOMECH, V10, P119, DOI 10.1016/0021-9290(77)90075-6; Khatam H, 2014, ACTA MECH SINICA-PRC, V30, P125, DOI 10.1007/s10409-014-0042-9; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Liu ZS, 2007, J BIOMECH, V40, P861, DOI 10.1016/j.jbiomech.2006.03.022; Loyd AM, 2014, ACCIDENT ANAL PREV, V72, P219, DOI 10.1016/j.aap.2014.06.022; Marcacci M, 1999, CALCIFIED TISSUE INT, V64, P83, DOI 10.1007/s002239900583; Melvin JW., 1969, DEV, V5, P811; Milchenko M, 2013, NEUROINFORMATICS, V11, P65, DOI 10.1007/s12021-012-9160-3; Olmi R, 1984, Chir Organi Mov, V69, P383; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; Ottenio M, 2015, J MECH BEHAV BIOMED, V41, P241, DOI 10.1016/j.jmbbm.2014.10.006; Piitulainen JM, 2015, WORLD NEUROSURG, V83, P708, DOI 10.1016/j.wneu.2015.01.014; Posti JP, 2016, J MECH BEHAV BIOMED, V55, P191, DOI 10.1016/j.jmbbm.2015.10.030; Rae PJ, 2007, POLYMER, V48, P598, DOI 10.1016/j.polymer.2006.11.032; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Rivard CH, 2002, J BIOMED MATER RES, V62, P488, DOI 10.1002/jbm.10159; Rosenthal G, 2014, NEUROSURGERY, V75, P523, DOI 10.1227/NEU.0000000000000477; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Sadigh S, 2004, J COMMUN HEALTH, V29, P129, DOI 10.1023/B:JOHE.0000016717.22032.03; Sahoo D, 2016, J MECH BEHAV BIOMED, V57, P24, DOI 10.1016/j.jmbbm.2015.11.014; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; Schulz BW, 2008, J REHABIL RES DEV, V45, P1227, DOI 10.1682/JRRD.2007.06.0092; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Smith S, 2005, P 11 ANN M ORG HUM B; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stalnaker R. L, 1969, THESIS; Stefini R., 2013, SURG NEUROL INT, P4; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Takhounts EG, 2008, STAPP CAR C, V52, P1; TONG P, 1976, J BIOMECH, V9, P649, DOI 10.1016/0021-9290(76)90107-X; Tse KM, 2015, ACCIDENT ANAL PREV, V79, P13, DOI 10.1016/j.aap.2015.03.012; Ueno K., 1989, CRASHWORTHINESS OCCU, V106; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; VOGEL HG, 1972, BIOCHIM BIOPHYS ACTA, V286, P79, DOI 10.1016/0304-4165(72)90090-6; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Willinger Rm, 2000, P INT RES COUNCIL BI, P209; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8; Zahouani H, 2009, SKIN RES TECHNOL, V15, P68, DOI 10.1111/j.1600-0846.2008.00329.x; Vinuela JZ, 2015, COMPOS STRUCT, V134, P613, DOI 10.1016/j.compstruct.2015.08.091; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhou C, 1995, P STAPP CAR CRASH J, V39, P121, DOI DOI 10.4271/952714; Zhou Z, 2016, COMPUT METH PROG BIO, V131, P13, DOI 10.1016/j.cmpb.2016.04.013	88	37	39	3	39	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	MAY	2017	69						342	354		10.1016/j.jmbbm.2017.01.012			13	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	ET3SK	WOS:000400199600037	28160738	Green Published, hybrid			2022-02-06	
J	Lane, SM; Briffa, M				Lane, Sarah M.; Briffa, Mark			The price of attack: rethinking damage costs in animal contests	ANIMAL BEHAVIOUR			English	Article						animal contests; cumulative assessment model; damage costs; injurious contests; self-inflicted damage	RECURRENT CONCUSSION; ACTINIA-EQUINA; FOOTBALL; AGGRESSION; STRATEGY; BEHAVIOR; SPIDER; SELF	Theoretical models of injurious animal contests, such as the cumulative assessment model (CAM), predict that an individual's decision to give up and retreat from a fight is determined by reaching a maximum cost threshold (C-max). Under this model, an individual gives up when the accumulated costs of persisting exceed this threshold. CAM predicts that the velocity with which C-max is reached depends on both the energetic (physiological) costs of remaining in the fight and the damage costs of injuries received. Here we propose that damage costs are accumulated not only by receiving injuries, but in some cases also by inflicting injury (attacking). We argue that these self-inflicted damage costs need to be incorporated into theoretical frameworks to fully understand what drives an individual to make the decision to give up, and we call for further research into this area. (C) 2017 The Association for the Study of Animal Behaviour. Published by Elsevier Ltd. All rights reserved.	[Lane, Sarah M.; Briffa, Mark] Plymouth Univ, Marine Biol & Ecol Res Ctr, Davy 620,Drake Circus, Plymouth PL4 8AA, Devon, England		Lane, SM (corresponding author), Plymouth Univ, Marine Biol & Ecol Res Ctr, Davy 620,Drake Circus, Plymouth PL4 8AA, Devon, England.	sarah.lane@plymouth.ac.uk	Lane, Sarah M/O-3153-2017; Briffa, Mark/M-9041-2013	Lane, Sarah M/0000-0002-3797-3178; Briffa, Mark/0000-0003-2520-0538	BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/M019772/1]; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/M019772/1] Funding Source: researchfish	We thank Ian C.W. Hardy and an anonymous referee for helpful comments on the manuscript. This work was supported by BBSRC grant BB/M019772/1.	BANKS WJ, 1968, ANAT REC, V162, P387, DOI 10.1002/ar.1091620401; Bartosz G, 2008, TOXICON, V51, P1038, DOI 10.1016/j.toxicon.2008.01.017; Batchelor TP, 2012, ANIM BEHAV, V83, P111, DOI 10.1016/j.anbehav.2011.10.014; Batchelor TP, 2011, P ROY SOC B-BIOL SCI, V278, P3243, DOI 10.1098/rspb.2011.0062; Batchelor TP, 2010, ANIM BEHAV, V80, P443, DOI 10.1016/j.anbehav.2010.05.030; BIGGER CH, 1982, J MORPHOL, V173, P259, DOI 10.1002/jmor.1051730303; BIGGER CH, 1980, BIOL BULL, V159, P117, DOI 10.2307/1541013; Bonnin J. P., 1964, Bull Biol, V98, P225; BRACE RC, 1979, ANIM BEHAV, V27, P553, DOI 10.1016/0003-3472(79)90190-8; Briffa M, 2009, ANIM BEHAV, V77, P759, DOI 10.1016/j.anbehav.2008.11.010; CLUTTONBROCK TH, 1982, BEHAVIOUR, V79, P108, DOI 10.1163/156853982X00201; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Davidson DW, 2007, BIOTROPICA, V39, P468, DOI 10.1111/j.1744-7429.2007.00304.x; Davidson DW, 2012, ACTA ZOOL-STOCKHOLM, V93, P487, DOI 10.1111/j.1463-6395.2011.00523.x; Edmonds E, 2016, BIOL LETTERS, V12, DOI 10.1098/rsbl.2015.0884; Goubault M, 2008, BIOL J LINN SOC, V94, P837, DOI 10.1111/j.1095-8312.2008.01022.x; Goubault M, 2006, P ROY SOC B-BIOL SCI, V273, P2853, DOI 10.1098/rspb.2006.3655; Green C. M., 2007, SCANDINAVIAN J MED S, V17, P20; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hurst A., 1917, MED DIS WAR, P308; Johnson HE, 2007, EUR J WILDLIFE RES, V53, P9, DOI 10.1007/s10344-006-0060-4; Johnson SA, 1999, ANIM BEHAV, V57, P957, DOI 10.1006/anbe.1998.1058; McCullough EL, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0696; McCullough EL, 2013, ANIM BEHAV, V86, P977, DOI 10.1016/j.anbehav.2013.08.017; McCullough EL, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0197; Murray M. G., 1987, ANIM BEHAV, V38, P186; Nuchter T, 2006, CURR BIOL, V16, pR316, DOI 10.1016/j.cub.2006.03.089; Palaoro AV, 2017, BEHAV ECOL, V28, P328, DOI 10.1093/beheco/arw163; PARKER GA, 1981, ANIM BEHAV, V29, P221, DOI 10.1016/S0003-3472(81)80170-4; Patek SN, 2004, NATURE, V428, P819, DOI 10.1038/428819a; Payne RJH, 1998, ANIM BEHAV, V56, P651, DOI 10.1006/anbe.1998.0835; Rudin FS, 2011, BEHAV ECOL, V22, P1278, DOI 10.1093/beheco/arr125; Ryan A J, 1991, Br J Sports Med, V25, P81; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; Shackleton K, 2015, BEHAV ECOL SOCIOBIOL, V69, P273, DOI 10.1007/s00265-014-1840-6; Shorter J. R., 2015, INSECT SOC, V59, P1; SMITH JM, 1976, ANIM BEHAV, V24, P159, DOI 10.1016/S0003-3472(76)80110-8; Sobotnik J, 2012, SCIENCE, V337, P436, DOI 10.1126/science.1219129; Stabili L, 2015, MAR DRUGS, V13, P5276, DOI 10.3390/md13085276; Swartz EE, 2015, J ATHL TRAINING, V50, P1219, DOI 10.4085/1062-6050-51.1.06; Szinicz L, 2005, TOXICOLOGY, V214, P167, DOI 10.1016/j.tox.2005.06.011; Taylor PW, 2003, ANIM BEHAV, V65, P787, DOI 10.1006/anbe.2003.2104; Uematsu K, 2007, SOCIOBIOLOGY, V50, P711; Uematsu K, 2010, CURR BIOL, V20, P1182, DOI 10.1016/j.cub.2010.04.057; Varnon J., 1995, SWAFS J, V17, P19; Wilde G J, 1998, Inj Prev, V4, P89; WILKINSON PF, 1976, ANIM BEHAV, V24, P756, DOI 10.1016/S0003-3472(76)80004-8; WILLIAMS RB, 1978, J MAR BIOL ASSOC UK, V58, P787	49	37	37	1	28	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0003-3472	1095-8282		ANIM BEHAV	Anim. Behav.	APR	2017	126						23	29		10.1016/j.anbehav.2017.01.015			7	Behavioral Sciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Zoology	ET6LH	WOS:000400402700004		Green Submitted			2022-02-06	
J	Staton, CA; Msilanga, D; Kiwango, G; Vissoci, JR; de Andrade, L; Lester, R; Hocker, M; Gerardo, CJ; Mvungi, M				Staton, Catherine A.; Msilanga, Daniel; Kiwango, George; Vissoci, Joao Ricardo; de Andrade, Luciano; Lester, Rebecca; Hocker, Michael; Gerardo, Charles J.; Mvungi, Mark			A prospective registry evaluating the epidemiology and clinical care of traumatic brain injury patients presenting to a regional referral hospital in Moshi, Tanzania: challenges and the way forward	INTERNATIONAL JOURNAL OF INJURY CONTROL AND SAFETY PROMOTION			English	Article						traumatic brain injury; epidemiology; Tanzania; quality of care	URBAN; AREA; QCA	Traumatic brain injury (TBI) is the most common cause of death and disability globally disproportionately affecting low- and middle-income countries where increasing injury rates are compounded by limited quality care. The objective of this study is to describe quality of care for TBI patients who presented to Kilimanjaro Christian Medical Center, Moshi, Tanzania. We evaluated a prospective quality improvement TBI registry that enrolled consecutive patients with acute TBI. Descriptive statistics and qualitative comparative analysis was performed. Overall, 893 TBI patients were enrolled during the study period, with a mean age of 32.1 years and who were mostly (80%) male. 12.9% suffered severe TBI (GCS < 9). Most injuries were road traffic (66%) especially motorcyclists (49%) and 26.8% were alcohol related. One intubation occurred, and 22.9% of hypoxic patients received oxygen. Severe TBI mortality was 47%. TBI affects men 15-45 years old in traffic crashes with high mortality for severe TBI (47%) patients. Care addressing secondary injury, hypoxemia, and hypotension is limited.	[Staton, Catherine A.; Hocker, Michael; Gerardo, Charles J.] Duke Univ, Med Ctr, Duke Div Emergency Med, Durham, NC 27710 USA; [Staton, Catherine A.; Hocker, Michael; Gerardo, Charles J.] Duke Univ, Duke Global Hlth Inst, Durham, NC 27710 USA; [Msilanga, Daniel; Kiwango, George; Mvungi, Mark] Kilimanjaro Christian Med Ctr, Moshi, Tanzania; [Vissoci, Joao Ricardo] Fac INGA, Fac Med, Maringa, Parana, Brazil; [de Andrade, Luciano] State Univ West Parana Unioeste, Foz Do Iguacu, Brazil; [Lester, Rebecca] London Sch Hyg & Trop Med, London, England		Staton, CA (corresponding author), Duke Univ, Med Ctr, Duke Div Emergency Med, Durham, NC 27710 USA.; Staton, CA (corresponding author), Duke Univ, Duke Global Hlth Inst, Durham, NC 27710 USA.	catherine.staton@duke.edu		Staton, Catherine/0000-0002-6468-2894; Kiwango, George/0000-0002-4796-833X	HRSAUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [T84HA21123-02]; U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Duke Division of Emergency Medicine	This project was made possible by the Mentored Research Training Programme in collaboration with the HRSA-funded KCMC MEPI [grant number T84HA21123-02]; U.S. National Institutes of Health and the Duke Division of Emergency Medicine.	Alexander T, 2009, S AFR J SURG, V47, P120; [Anonymous], 2015, R PROJECT STAT COMPU; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Casey ER, 2012, INT J EMERG MED, V5, DOI 10.1186/1865-1380-5-28; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chandran A, 2010, EPIDEMIOL REV, V32, P110, DOI 10.1093/epirev/mxq009; Constant A, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000228; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Dusa A, 2010, QUAL QUANT, V44, P99, DOI 10.1007/s11135-008-9183-x; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Georgoff P, 2010, WORLD NEUROSURG, V74, P331, DOI 10.1016/j.wneu.2010.03.025; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kesinger MR, 2014, INJURY, V45, P1350, DOI 10.1016/j.injury.2014.04.037; Kolaczyk E. D., 2014, STAT ANAL NETWORK R; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Maier D, 2014, WORLD NEUROSURG, V81, P478, DOI 10.1016/j.wneu.2013.08.014; Marx A., 2011, METHODOLOGICAL INNOV, V6, P103, DOI DOI 10.4256/MIO.2010.0037; Mortality in the KCMC Intensive Care Unit, 2012, GRAND ROUND C MOSH; Moshiro C, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-11; MUNIU E, 1994, E AFR MED J, V71, P346; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; Muyembe VM, 1999, E AFR MED J, V76, P200; Peden M., 2007, ALCOHOL INJURY EMERG; Ragin C.C., 2009, REDESIGNING SOCIAL I; Ragin CC., 1987, COMP METHOD MOVING Q; Rihoux B, 2006, INT SOCIOL, V21, P679, DOI 10.1177/0268580906067836; Sumner SA, 2014, INJURY, V45, P1681, DOI 10.1016/j.injury.2014.04.034; Thiem A, 2013, R J, V5, P87; van Pelt ED, 2011, EUR J PAEDIATR NEURO, V15, P519, DOI 10.1016/j.ejpn.2011.05.005; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winkler AS, 2010, WORLD NEUROSURG, V73, P264, DOI 10.1016/j.wneu.2010.03.037; World Health Organization, 2010, VIOL INJ DIS BIENN R	34	37	37	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1745-7300	1745-7319		INT J INJ CONTROL SA	Int. J. Inj. Control Saf. Promot.	MAR	2017	24	1					69	77		10.1080/17457300.2015.1061562			9	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	EK1TG	WOS:000393708100008	26239625				2022-02-06	
J	Ashendorf, L; Clark, EL; Sugarman, MA				Ashendorf, Lee; Clark, Erika L.; Sugarman, Michael A.			Performance validity and processing speed in a VA Polytrauma sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Validity; effort; processing speed; veterans	TRAUMATIC BRAIN-INJURY; ADULT INTELLIGENCE SCALE; DIGIT SPAN; TRAIL; SPECIFICITY; STRATEGIES; INDEXES; RATES	Objective: While recognition memory has been the primary tool for the assessment of performance validity in neuropsychological evaluations, some consideration has also been given to embedded measures from other cognitive domains, including processing speed. The present study evaluated the classification accuracy of several speed-based measures in a Veterans Affairs Medical Center Polytrauma sample. Method: The present sample consisted of 114 military veterans (Mean age=35.5, SD=9.4) referred for a suspected history of mild traumatic brain injury who were administered a full neuropsychological protocol that included several validity checks. Veterans were assigned to Valid (n=80) or Invalid (n=34) groups based on outcomes of performance validity measures (PVMs). Results: Several processing speed measures yielded acceptable or excellent classification accuracy; sensitivity values ranged from 29 to 53% with specificity values above 90%. Efforts to identify an improved algorithm that would collapse across multiple processing speed PVMs were unsuccessful compared to classification based on single measures. Conclusions: Processing speed measures can serve as efficient performance validity assessment tools.	[Ashendorf, Lee; Clark, Erika L.; Sugarman, Michael A.] Edith Nourse Rogers Mem Vet Hosp, Bedford, MA 01730 USA; [Ashendorf, Lee] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Clark, Erika L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Clark, Erika L.] Home Base, Boston, MA USA		Ashendorf, L (corresponding author), Edith Nourse Rogers Mem Vet Hosp, Bedford, MA 01730 USA.; Ashendorf, L (corresponding author), Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.	Lee.Ashendorf@va.gov	Ashendorf, Lee/R-7206-2019	Ashendorf, Lee/0000-0003-0479-4023	Department of Veterans Affairs, Veterans Health AdministrationUS Department of Veterans Affairs	This study was supported by salary and research support from the Department of Veterans Affairs, Veterans Health Administration. The authors report no financial relationships with commercial interests.	Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P828, DOI 10.1093/arclin/acs086; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Ashendorf L, 2003, CLIN NEUROPSYCHOL, V17, P255, DOI 10.1076/clin.17.2.255.16502; Ashendorf L, 2016, CLIN NEUROPSYCHOL, V30, P599, DOI 10.1080/13854046.2016.1172668; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Boone K., 2002, DOT COUNTING TEST; Boone K.B., 2007, ASSESSMENT FEIGNED C; Bush, 2012, MILD TRAUMATIC BRAIN; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Delis DC., 2001, DELIS KAPLAN EXECUTI; Erdodi L. A., PSYCHOL ASS IN PRESS; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Hosmer D.W., 2000, APPL LOGISTIC REGRES, P375, DOI [10.1002/0471722146, DOI 10.1002/0471722146]; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Meyers JE., 1995, REY COMPLEX FIGURE T; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P50, DOI 10.1080/13854049508402057; RUFF RM, 1996, RUFF 2 7 SELECTIVE A; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; WechslerD, 2001, WECHSLER TEST ADULT; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	43	37	37	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	5					857	866		10.1080/13854046.2017.1285961			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	EY2WQ	WOS:000403833900004	28276866				2022-02-06	
J	Devoto, C; Arcurio, L; Fetta, J; Ley, M; Rodney, T; Kanefsky, R; Gill, J				Devoto, Christina; Arcurio, Lindsay; Fetta, Joseph; Ley, Mary; Rodney, Tamar; Kanefsky, Rebekah; Gill, Jessica			Inflammation Relates to Chronic Behavioral and Neurological Symptoms in Military Personnel with Traumatic Brain Injuries	CELL TRANSPLANTATION			English	Article						mild traumatic brain injury; inflammation; biomarkers; post-traumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; PTSD; MORTALITY; VETERANS; HEART; IRAQ; RISK; COMORBIDITY; ACTIVATION; DEPRESSION	Studies have shown that the presence of acute inflammation during recovery is indicative of poor outcomes after a traumatic brain injury (TBI); however, the role of chronic inflammation in predicting post-TBI-related symptoms remains poorly understood. The purpose of this study was to compare inflammatory biomarkers (tumor necrosis factor [TNF]-alpha, interleukin [IL]-6, and IL-10) in active duty personnel who either sustained or did not sustain a TBI. Service members were also assessed for post-traumatic stress disorder (PTSD), depression, and quality of life through self-reported measures. IL-6 and TNF-alpha concentrations were greater in the TBI group than in the control group. Of those with a TBI, IL-6 and TNF-a concentrations were greater in the high-PTSD group than the low-PTSD group. No significant differences were found in IL-10 or the IL-6/IL-10 ratios between those with low and high PTSD. Exploratory factor analysis was conducted to describe the latent structure of variables relating to emotional and physical health (i.e., Short Form 36 subcomponents, etc.) and their relationships within the TBI group with inflammatory cytokines. Four symptom profiles were found, with the third component most relating to PTSD and depression symptoms and high inflammation. This study indicates that the comorbidity of TBI and PTSD is associated with inflammation in a military sample, emphasizing the necessity for intervention in order to mitigate the risks associated with inflammation.	[Devoto, Christina; Arcurio, Lindsay; Fetta, Joseph; Ley, Mary; Kanefsky, Rebekah; Gill, Jessica] NINR, NIH, 1 Cloisters Dr, Bethesda, MD 20892 USA; [Rodney, Tamar] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA		Devoto, C (corresponding author), NINR, NIH, 1 Cloisters Dr, Bethesda, MD 20892 USA.	christina.devoto@nih.gov	Gill, Gill M/Q-2020-2017	Fetta, Joseph/0000-0002-7654-2864	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institutes of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000027] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work was performed at the Madigan Army Medical Center, Tacoma, WA. Support for this work included funding from the Intramural department of the National Institutes of Health, National Institutes of Nursing Research, and the Department of Defense in the Center for Neuroscience and Regenerative Medicine.	Armed Forces Health Surveillance Center, 2010, INS ACT COMP, P12; Boscarino JA, 2008, PSYCHOSOM MED, V70, P668, DOI 10.1097/PSY.0b013e31817bccaf; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Brewer-Smyth K, 2014, REHABIL NURS, V39, P183, DOI 10.1002/rnj.150; Brown GC, 2015, BRAIN RES, V1628, P288, DOI 10.1016/j.brainres.2015.08.031; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Centers for disease control and prevention, 2014, INJ PREV CONTR TRAUM; Dallmeier D, 2012, J AM HEART ASSOC, V1, P1; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Edwards R.D., 2010, NATL BUREAU EC RES W, DOI [10.3386/w16163, DOI 10.3386/w16163]; Field A., 2017, DISCOVERING STAT USI, V5th; Field A., 2018, DISCOVERING STAT USI, V5th ed.; Fisher H., 2010, US MILITARY CASUALTY; Gill J, 2014, PSYCHIAT RES, V216, P116, DOI 10.1016/j.psychres.2014.01.046; Gill J, 2010, BIOL PSYCHIAT, V68, P999, DOI 10.1016/j.biopsych.2010.07.033; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Grenon SM, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003010; Groer MW, 2015, BIOL RES NURS, V17, P303, DOI 10.1177/1099800414544949; Kim EJ, 2015, LEARN MEMORY, V22, P411, DOI 10.1101/lm.037291.114; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kumar RG, 2016, BRAIN BEHAV IMMUN, V53, P183, DOI 10.1016/j.bbi.2015.12.008; Levkovitz Y, 2015, EUR NEUROPSYCHOPHARM, V25, P124, DOI 10.1016/j.euroneuro.2014.11.012; Lindqvist D, 2014, BRAIN BEHAV IMMUN, V42, P81, DOI 10.1016/j.bbi.2014.06.003; Lustenberger T, 2016, IMMUNOBIOLOGY, V221, P427, DOI 10.1016/j.imbio.2015.11.011; MacKenzie EJ, 2002, QUAL LIFE RES, V11, P797, DOI 10.1023/A:1020820017658; Maes M, 2012, PROG NEURO-PSYCHOPH, V36, P169, DOI 10.1016/j.pnpbp.2011.09.006; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; O'Donovan A, 2015, PSYCHONEUROENDOCRINO, V51, P557, DOI 10.1016/j.psyneuen.2014.11.010; Oosthuizen Frasia, 2005, Neuropsychiatr Dis Treat, V1, P109, DOI 10.2147/nedt.1.2.109.61049; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Paulus EJ, 2013, J TRAUMA STRESS, V26, P169, DOI 10.1002/jts.21785; Phillips AC, 2009, PSYCHOSOM MED, V71, P395, DOI 10.1097/PSY.0b013e31819e6706; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Pugh MJV, 2014, MED CARE, V52, P172, DOI 10.1097/MLR.0000000000000059; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Rusiecki Jennifer A, 2013, Front Psychiatry, V4, P56, DOI 10.3389/fpsyt.2013.00056; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Scherrer JF, 2010, AM HEART J, V159, P772, DOI 10.1016/j.ahj.2010.02.033; Schlenger WE, 2015, AM J EPIDEMIOL, V182, P980, DOI 10.1093/aje/kwv217; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Srikanthan K, 2016, INT J MED SCI, V13, P25, DOI 10.7150/ijms.13800; Sun J, 2016, CLIN J AM SOC NEPHRO, V11, P1163, DOI 10.2215/CJN.10441015; Sussman D, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0247-x; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Tsai JCG, 2010, NEUROREHABILITATION, V26, P85, DOI [10.3233/NRE-2010-0538, 10.3233/NRE-2011-0538]; van Zuiden M, 2012, PSYCHONEUROENDOCRINO, V37, P1822, DOI 10.1016/j.psyneuen.2012.03.018; Varatharaj A, 2017, BRAIN BEHAV IMMUN, V60, P1, DOI 10.1016/j.bbi.2016.03.010; Veer IM, 2015, PSYCHIAT RES-NEUROIM, V233, P436, DOI 10.1016/j.pscychresns.2015.07.016; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Zen AL, 2012, HEALTH PSYCHOL, V31, P194, DOI 10.1037/a0025989	54	37	38	2	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2017	26	7					1169	1177		10.1177/0963689717714098			9	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Cell Biology; Research & Experimental Medicine; Transplantation	EZ4GO	WOS:000404671800006	28933225	Green Published, gold			2022-02-06	
J	Janssen, PHH; Mandrekar, J; Mielke, MM; Ahlskog, JE; Boeve, BF; Josephs, K; Savica, R				Janssen, Pieter H. H.; Mandrekar, Jay; Mielke, Michelle M.; Ahlskog, J. Eric; Boeve, Bradley F.; Josephs, Keith; Savica, Rodolfo			High School Football and Late-Life Risk of Neurodegenerative Syndromes, 1956-1970	MAYO CLINIC PROCEEDINGS			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; MEDICAL-RECORDS LINKAGE; HEAD TRAUMA; EPIDEMIOLOGY; DISEASE; SCLEROSIS; EXERCISE; DEMENTIA; INJURY	Objective: To assess whether athletes who played American varsity high school football between 1956 and 1970 have an increased risk of neurodegenerative diseases later in life. Patients and Methods: We identified all male varsity football players between 1956 and 1970 in the public high schools of Rochester, Minnesota, and nonefootball-playing male varsity swimmers, wrestlers, and basketball players. Using the medical records linkage system of the Rochester Epidemiology Project, we ascertained the incidence of late-life neurodegenerative diseases: dementia, parkinsonism, and amyotrophic lateral sclerosis. We also recorded medical record-documented head trauma during high school years. Results: We identified 296 varsity football players and 190 athletes engaging in other sports. Football players had an increased risk of medically documented head trauma, especially if they played football for more than 1 year. Compared with nonfootball athletes, football players did not have an increased risk of neurodegenerative disease overall or of the individual conditions of dementia, parkinsonism, and amyotrophic lateral sclerosis. Conclusion: In this community-based study, varsity high school football players from 1956 to 1970 did not have an increased risk of neurodegenerative diseases compared with athletes engaged in other varsity sports. This was from an era when there was a generally nihilistic view of concussion dangers, less protective equipment, and no prohibition of spearing (head-first tackling). However, the size and strength of players from previous eras may not be comparable with that of current high school athletes. (C) 2016 Mayo Foundation for Medical Education and Research	[Janssen, Pieter H. H.] Radboud Univ Nijmegen, Nijmegen, Netherlands; [Janssen, Pieter H. H.; Mielke, Michelle M.; Ahlskog, J. Eric; Boeve, Bradley F.; Josephs, Keith; Savica, Rodolfo] Mayo Clin, Coll Med, Dept Neurol, Rochester, MN USA; [Mandrekar, Jay; Mielke, Michelle M.; Savica, Rodolfo] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA		Savica, R (corresponding author), Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA.	savica.rodolfo@mayo.edu		Mielke, Michelle/0000-0001-7177-1185	Rochester Epidemiology Project [R01-AG034676]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034676] Funding Source: NIH RePORTER	This study was made possible by the Rochester Epidemiology Project (grant number R01-AG034676; Principal Investigators: Walter A. Rocca, MD, MPH, and Jennifer St Sauver, PhD).	Abel EL, 2007, PERCEPT MOTOR SKILL, V104, P1251, DOI 10.2466/PMS.104.4.1251-1254; Ahlskog JE, 2011, MAYO CLIN PROC, V86, P876, DOI 10.4065/mcp.2011.0252; Ahlskog JE, 2011, NEUROLOGY, V77, P288, DOI 10.1212/WNL.0b013e318225ab66; Albin RL, 2016, NEUROLOGY, V86, P1929, DOI 10.1212/01.wnl.0000484015.90990.ab; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; CLARKE KS, 1979, MED SCI SPORT EXER, V11, P138; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Goodwin Linda, 2006, J Insur Med, V38, P300; Kokkinos Peter, 2012, ISRN Cardiol, V2012, P718789, DOI 10.5402/2012/718789; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Rocca WA, 2012, MAYO CLIN PROC, V87, P1202, DOI 10.1016/j.mayocp.2012.08.012; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; St Sauver JL, 2012, MAYO CLIN PROC, V87, P151, DOI 10.1016/j.mayocp.2011.11.009; St Sauver JL, 2011, AM J EPIDEMIOL, V173, P1059, DOI 10.1093/aje/kwq482; Vanacore N, 2006, PARKINSONISM RELAT D, V12, P327, DOI 10.1016/j.parkreldis.2005.11.007	21	37	38	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0025-6196	1942-5546		MAYO CLIN PROC	Mayo Clin. Proc.	JAN	2017	92	1					66	71		10.1016/j.mayocp.2016.09.004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	EK4QQ	WOS:000393912300014	27979411	Green Accepted			2022-02-06	
J	Mac Donald, CL; Barber, J; Andre, J; Evans, N; Panks, C; Sun, S; Zalewski, K; Sanders, RE; Temkin, N				Mac Donald, Christine L.; Barber, Jason; Andre, Jalal; Evans, Nicole; Panks, Chris; Sun, Samantha; Zalewski, Kody; Sanders, R. Elizabeth; Temkin, Nancy			5-Year imaging sequelae of concussive blast injury and relation to early clinical outcome	NEUROIMAGE-CLINICAL			English	Article						Diffusion tensor imaging; Concussion; Neurodegeneration; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; WHITE-MATTER ABNORMALITIES; POSTTRAUMATIC-STRESS-DISORDER; US MILITARY PERSONNEL; DIFFUSE AXONAL INJURY; ROBUST ESTIMATION; IRAQI FREEDOM; MOUSE MODEL; TENSOR; MILD	Current imaging diagnostic techniques are often insensitive to the underlying pathological changes following mild traumatic brain injury (TBI) or concussion so much so that the explicit definition of these uncomplicated mild brain injuries includes the absence of radiological findings. In the US military, this is complicated by the natural tendency of service members to down play symptoms for fear of removal from their unit particularly in combat making it challenging for clinicians to definitively diagnose and determine course of treatment. Questions remain regarding the long-term impact of these war-time brain injuries. The objective of the current study was to evaluate the long-term imaging sequelae of blast concussion in active-duty US military and leverage previous longitudinal data collected in these same patients to identify predictors of sustained DTI signal change indicative of chronic neurodegeneration. In total, 50 blast TBI and 44 combat-deployed controls were evaluated at this 5-year follow up by advanced neuroimaging techniques including diffusion tensor imaging and quantitative volumetry. While cross-sectional analysis of regions of white matter on DTI images did not reveal significant differences across groups after statistical correction, an approach flexible to the heterogeneity of brain injury at the single-subject level identified 74% of the concussive blast TBI cohort to have reductions in fractional anisotropy indicative of chronic brain injury. Logistic regression leveraging clinical and demographic data collected in the acute/sub-acute and 1-year follow up to determine predictors of these long-term imaging changes determined that brain injury diagnosis, older age, verbal memory and verbal fluency best predicted the presence of DTI abnormalities 5 years post injury with an AUC of 0.78 indicating good prediction strength. These results provide supporting evidence for the evolution not resolution of this brain injury pathology, adding to the growing body of literature describing imaging signatures of chronic neurodegeneration even after mild TBI and concussion. (C) 2017 The Author(s). Published by Elsevier Inc.	[Mac Donald, Christine L.; Barber, Jason; Evans, Nicole; Panks, Chris; Sun, Samantha; Zalewski, Kody; Temkin, Nancy] Univ Washington, Dept Neurol Surg, 352 9th Ave,Box 959924, Seattle, WA 98104 USA; [Andre, Jalal] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Sanders, R. Elizabeth] Univ Washington, Dept Internal Med, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Mac Donald, CL (corresponding author), Univ Washington, Dept Neurol Surg, 352 9th Ave,Box 959924, Seattle, WA 98104 USA.	cmacd@uw.edu		Sun, Samantha/0000-0002-5971-066X; Temkin, Nancy/0000-0002-6392-5292; Andre, Jalal/0000-0002-0896-183X	Department of Defense through Chronic Effects of Neurotrauma Consortium [W81XWH-13-2-0095]; NIH RO1 from NINDS [1R01NS091618-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091618] Funding Source: NIH RePORTER	Support for this study was provided by a Department of Defense grant through the Chronic Effects of Neurotrauma Consortium (W81XWH-13-2-0095) and by an NIH RO1 grant from NINDS (1R01NS091618-01).	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Akaike H., 1973, P 2 INT S INF THEOR, V1973, P267, DOI 10.1007/978-1-4612-1694-0; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Chang LC, 2005, MAGN RESON MED, V53, P1088, DOI 10.1002/mrm.20426; Chang LC, 2012, MAGN RESON MED, V68, P1654, DOI 10.1002/mrm.24173; DVBIC, 2016, DOD WORLDW TBI NUMB; Farbota KD, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00160; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; HOLM S, 1979, SCAND J STAT, V6, P65; Hoy AR, 2014, NEUROIMAGE, V103, P323, DOI 10.1016/j.neuroimage.2014.09.053; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Irfanoglu MO, 2015, NEUROIMAGE, V106, P284, DOI 10.1016/j.neuroimage.2014.11.042; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Koay CG, 2006, J MAGN RESON, V182, P115, DOI 10.1016/j.jmr.2006.06.020; Koay CG, 2009, J MAGN RESON, V197, P108, DOI 10.1016/j.jmr.2008.11.015; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mac Donald CL, 2016, J NEUROTRAUMA; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mangin JF, 2002, MED IMAGE ANAL, V6, P191, DOI 10.1016/S1361-8415(02)00079-8; Matthews SC, 2012, PSYCHIAT RES-NEUROIM, V204, P149, DOI 10.1016/j.pscychresns.2012.04.018; Miller DR, 2016, HUM BRAIN MAPP, V37, P220, DOI 10.1002/hbm.23022; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Morey RA, 2012, ARCH GEN PSYCHIAT, V69, P1169, DOI 10.1001/archgenpsychiatry.2012.50; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Oishi K., 2011, MRI ATLAS HUMAN WHIT, V2nd Edn.; Oishi K, 2009, NEUROIMAGE, V46, P486, DOI 10.1016/j.neuroimage.2009.01.002; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Pierpaoli C., 2010, INT SOC MAGN RES MED; Pierpaoli C., 2010, P INT SOC MAGNETIC R, P1597; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rohde GK, 2005, NEUROIMAGE, V26, P673, DOI 10.1016/j.neuroimage.2005.02.023; Rohde GK, 2004, MAGN RESON MED, V51, P103, DOI 10.1002/mrm.10677; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Ware JB, 2016, RADIOLOGY, V280, P212, DOI 10.1148/radiol.2016151013; Wu M, 2008, LECT NOTES COMPUT SC, V5242, P321, DOI 10.1007/978-3-540-85990-1_39; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	60	37	37	1	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	14						371	378		10.1016/j.nicl.2017.02.005			8	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FB2OY	WOS:000405984300040	28243574	Green Published, gold			2022-02-06	
J	Moore, L; Evans, D; Hameed, SM; Yanchar, NL; Stelfox, HT; Simons, R; Kortbeek, J; Bourgeois, G; Clement, J; Lauzier, F; Nathens, A; Turgeon, AF				Moore, Lynne; Evans, David; Hameed, Sayed M.; Yanchar, Natalie L.; Stelfox, Henry T.; Simons, Richard; Kortbeek, John; Bourgeois, Gilles; Clement, Julien; Lauzier, Francois; Nathens, Avery; Turgeon, Alexis F.			Mortality in Canadian Trauma Systems A Multicenter Cohort Study	ANNALS OF SURGERY			English	Article						injury; mortality; quality of care; trauma systems	BRAIN-INJURY; QUALITY INDICATOR; CARE; OUTCOMES; VALIDATION; DERIVATION; AUSTRALIA; EVOLUTION; VICTORIA	Objective: To measure the variation in trauma center mortality across Canadian trauma systems, assess the contribution of traumatic brain injury and thoracoabdominal injury to observed variations, and evaluate whether the presence of recommended trauma system components is associated with mortality. Summary Background Data: Injuries represent one of the leading causes of mortality, disability, and health care costs worldwide. Trauma systems have improved injury outcomes, but the impact of trauma system configuration on mortality is unknown. Methods: We conducted a retrospective cohort study of adults admitted for major injury to trauma centers across Canada (2006-2012). Multilevel logistic regression was used to estimate risk-adjusted hospital mortality and assess the impact of 13 recommended trauma system components. Results: Of 78,807 patients, 8382 (10.6%) died in hospital including 6516 (78%) after severe traumatic brain injury and 749 (9%) after severe thoracoabdominal injury. Risk-adjusted mortality varied from 7.0% to 14.2% across provinces (P < 0.0001); 11.1% to 26.0% for severe traumatic brain injury (P < 0.0001), and 4.7% to 5.9% for thoracoabdominal injury (P = 0.2). Mortality decreased with increasing number of recommended trauma system elements; adjusted odds ratio = 0.93 (0.87-0.99). Conclusions: We observed significant variation in trauma center mortality across Canadian provinces, specifically for severe traumatic brain injury. Provinces with more recommended trauma system components had better patient survival. Results suggest that trauma system configuration may be an important determinant of injury mortality. A better understanding of which system processes drive optimal outcomes is required to reduce the burden of injury worldwide.	[Moore, Lynne] Univ Laval, Dept Social & Preventat Med, Quebec City, PQ, Canada; [Moore, Lynne; Lauzier, Francois; Turgeon, Alexis F.] Univ Laval, Axe Sante Populat & Prat Optim Sante,CHU Quebec,H, Populat Hlth & Optimal Hlth Practices Res Unit,Ct, Traumatol Urgence Soins Intensifs Trauma Emergenc, Quebec City, PQ, Canada; [Evans, David; Hameed, Sayed M.; Simons, Richard] Univ British Columbia, Dept Surg, Vancouver, BC, Canada; [Yanchar, Natalie L.] Dalhousie Univ, Dept Surg, Halifax, NS, Canada; [Stelfox, Henry T.] Univ Calgary, Inst Publ Hlth, Dept Crit Care Med Med & Community Hlth Sci HTS, Calgary, AB, Canada; [Kortbeek, John] Univ Calgary, Dept Surg, Div Gen Surg, Calgary, AB, Canada; [Kortbeek, John] Univ Calgary, Div Crit Care, Calgary, AB, Canada; [Bourgeois, Gilles] INESSS, Quebec City, PQ, Canada; [Clement, Julien] Univ Laval, Dept Surg, Quebec City, PQ, Canada; [Lauzier, Francois; Turgeon, Alexis F.] Univ Laval, Dept Anesthesiol & Crit Care Med, Div Crit Care Med, Quebec City, PQ, Canada; [Nathens, Avery] Sunnybrook Hlth Sci Ctr, Div Gen Surg, Toronto, ON, Canada		Moore, L (corresponding author), CHU Quebec, Traumatol Urgence Soins Intensifs Trauma Emergenc, Axe Sante Populat & Prat Optim Sante,Enfant Jesus, Populat Hlth & Optimal Hlth Practices Res Unit,Re, 1401,18e Rue,Local H-012a, Quebec City, PQ G1J 1Z4, Canada.	lynne.moore@fmed.ulaval.ca	Lauzier, Francois/B-9237-2015; Kortbeek, John B/AAO-5298-2020	Lauzier, Francois/0000-0002-6530-5513; Stelfox, Henry/0000-0003-1231-1490	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [110996]; Fonds de la Recherche du Quebec - SanteFonds de la Recherche en Sante du Quebec	Canadian Institutes of Health Research: New Investigator Award (HTS and LM) and research grant (LM; #110996); Fonds de la Recherche du Quebec - Sante: clinician-scientist award (AFT, FL).	Accreditation Guidelines, 2015, ACCR GUID; American College of Surgeons Committee on Trauma, 2014, RESOURCES OPTIMAL CA; [Anonymous], 2013, CAN TOT POP EST; Association for the Advancement of Automotive Medicine, 1990, ABBREVIATED INJURY S; Canada P., 2015, COST INJURY CANADA; Cheng CH, 2008, ANN SURG, V247, P335, DOI 10.1097/SLA.0b013e31815ccc2e; Cote N, 2013, NEUROCRIT CARE, V18, P154, DOI 10.1007/s12028-012-9787-9; Donabedian A., 2003, INTRO QUALITY ASSURA; Evans CC, 2013, CJEM, V15, P1; Evans DC, 2007, CAN J SURG, V50, P364; Gabbe BJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020545; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; Hameed SM, 2010, J TRAUMA, V69, P1350, DOI 10.1097/TA.0b013e3181e751f7; Levit K, 2009, HCUP FACTS FIG STAT; Little RJ, 2002, STAT ANAL MISSING DA, V539; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; Moore L, 2006, J TRAUMA, V60, P802, DOI 10.1097/01.ta.0000200838.55420.ad; Moore L, 2005, J TRAUMA, V59, P698, DOI 10.1097/01.ta.0000177700.54943.ee; Moore L, 2015, WORLD J SURG, V39, P1397, DOI 10.1007/s00268-015-2977-9; Moore L, 2014, ANN SURG, V260, P1121, DOI 10.1097/SLA.0000000000000648; Moore L, 2014, J TRAUMA ACUTE CARE, V76, P1310, DOI 10.1097/TA.0000000000000202; Moore L, 2010, ANN SURG, V251, P952, DOI 10.1097/SLA.0b013e3181d97589; Moore L, 2009, J AM COLL SURGEONS, V209, P572, DOI 10.1016/j.jamcollsurg.2009.07.004; Moore L, 2009, ANN SURG, V249, P1040, DOI 10.1097/SLA.0b013e3181a6cd97; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; Nathens AB, 2008, REGIONAL TRAUMA SYST; Royston P, 1999, INT J EPIDEMIOL, V28, P964, DOI 10.1093/ije/28.5.964; Shafi S, 2006, J TRAUMA, V61, P1374, DOI 10.1097/01.ta.0000246698.07125.c0; Tisherman SA, 2015, ANN SURG, V261, P586, DOI 10.1097/SLA.0000000000000837; Trunkey DD, 2008, CURRENT THERAPY TRAU; Turgeon AF, 2013, CRIT CARE MED, V41, P1086, DOI 10.1097/CCM.0b013e318275d046; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Utter GH, 2006, J TRAUMA, V60, P529, DOI 10.1097/01.ta.0000204022.36214.9e	33	37	38	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	JAN	2017	265	1					212	217		10.1097/SLA.0000000000001614			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	EH9QS	WOS:000392106500039	28009748				2022-02-06	
J	Iverson, GL; Atkins, JE; Zafonte, R; Berkner, PD				Iverson, Grant L.; Atkins, Joseph E.; Zafonte, Ross; Berkner, Paul D.			Concussion History in Adolescent Athletes with Attention-Deficit Hyperactivity Disorder	JOURNAL OF NEUROTRAUMA			English	Article						adolescents; attention-deficit hyperactivity disorder; concussion; mild traumatic brain injury; surveillance	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; DEFICIT/HYPERACTIVITY DISORDER; PSYCHIATRIC-ILLNESS; NONFATAL INJURIES; CHILDREN; POPULATION; PREDICTORS; COHORT	Little is known about the rate of concussions in adolescents with attention-deficit hyperactivity disorder (ADHD). We hypothesized that high school athletes with ADHD would report a greater history of concussion than students without ADHD. A total of 6529 adolescent and young adult student athletes, between the ages of 13 and 19 years (mean, 15.9; standard deviation, 1.3), completed a preseason health survey in 2010. Of those with ADHD, 26.1% reported a history of one or more concussions, compared to 17.1% of those without ADHD (p < 0.00001; odds ratio [OR], 1.71). Stratified by gender, 27.0% of boys with ADHD reported a history of one or more concussions, compared to 20.0% of boys without ADHD (p < 0.004; OR, 1.48), and 23.6% of girls with ADHD reported a history of one or more concussions, compared to 13.6% of girls without ADHD (p < 0.003; OR, 1.97). Of those with ADHD, 9.8% reported a history of two or more concussions, compared to 5.5% of those without ADHD (p < 0.0003; OR, 1.87). Stratified by gender, 10.0% of boys with ADHD reported a history of two or more concussions, compared to 6.7% of boys without ADHD (p < 0.033; OR, 1.54), and 9.1% of girls with ADHD reported a history of two or more concussions, compared to 3.8% of girls without ADHD (p < 0.006; OR, 2.51). In this large-scale, retrospective survey study, boys and girls with ADHD were significantly more likely to report a history of concussion. Additional research is needed to determine whether students with ADHD are more susceptible to injury (i.e., have a lower threshold) or have different recovery trajectories.	[Iverson, Grant L.; Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] MassGen Hosp Children Sport Concuss Program, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.; Zafonte, Ross] Spaulding Rehabil Hosp, Charlestown, MA USA; [Atkins, Joseph E.] Colby Coll, Dept Psychol, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Dept Biol, Waterville, ME 04901 USA		Iverson, GL (corresponding author), Harvard Med Sch, Dept Phys Med & Rehabil, Ctr Hlth & Rehabil, 79-96 Thirteenth St, Charlestown, MA 02129 USA.	giverson@mgh.harvard.edu		Iverson, Grant/0000-0001-7348-9570	Goldfarb Center for Public Policy; Civic Engagement/Colby College; Bill and Joan Alfond Foundation; Harvard Integrated Program to Protect and Improve the Health of NFLPA Members	This work was funded, in part, by the Goldfarb Center for Public Policy and Civic Engagement/Colby College and the Bill and Joan Alfond Foundation. R.Z. was supported, in part, by the Harvard Integrated Program to Protect and Improve the Health of NFLPA Members.	Adeyemo BO, 2014, J ATTEN DISORD, V18, P576, DOI 10.1177/1087054714543371; BIJUR PE, 1990, PEDIATRICS, V86, P337; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Kaya A, 2008, J INT MED RES, V36, P9, DOI 10.1177/147323000803600102; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; Lam L T, 2002, J Atten Disord, V6, P77, DOI 10.1177/108705470200600204; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Merrill RM, 2009, ADV MED SCI-POLAND, V54, P20, DOI 10.2478/v10039-009-0022-7; Pastor PN, 2006, AMBUL PEDIATR, V6, P38, DOI 10.1016/j.ambp.2005.07.002; Reuben C.A., 2008, VITAL HLTH STAT, V10, P1; Sabuncuoglu O, 2005, DENT TRAUMATOL, V21, P249, DOI 10.1111/j.1600-9657.2005.00317.x; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Shilon Y, 2012, CHILD CARE HLTH DEV, V38, P366, DOI 10.1111/j.1365-2214.2011.01278.x; Swensen, 2004, J ADOLESCENT HEALTH, V35, DOI [DOI 10.1016/J.JAD0HEALTH.2003.12.003, 10.1016/j.jadohealth.2003.12.003]; Xiang HY, 2005, AM J PUBLIC HEALTH, V95, P1970, DOI 10.2105/AJPH.2004.057505	24	37	37	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2016	33	23					2077	2080		10.1089/neu.2014.3424			4	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	ED2JG	WOS:000388669800002	25375785				2022-02-06	
J	Vieira, RDA; Paiva, WS; de Oliveira, DV; Teixeira, MJ; de Andrade, AF; de Sousa, RMC				Almeida Vieira, Rita de Cassia; Paiva, Wellingson Silva; de Oliveira, Daniel Vieira; Teixeira, Manoel Jacobsen; de Andrade, Almir Ferreira; Cardoso de Sousa, Regina Marcia			Diffuse Axonal Injury: Epidemiology, Outcome and Associated Risk Factors	FRONTIERS IN NEUROLOGY			English	Article						head trauma; diffuse axonal injury; Glasgow Outcome Scale; recovery; severe traumatic brain inju cohort study	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; SEVERITY SCORE; INTRACRANIAL-PRESSURE; MAGNETIC-RESONANCE; MODERATE; PREDICTORS; MRI; HYPOTENSION	Diffuse axonal injury (DAI), a type of traumatic injury, is known for its severe consequences. However, there are few studies describing the outcomes of DAI and the risk factors associated with it. This study aimed to describe the outcome for patients with a primary diagnosis of DAI 6 months after trauma and to identify sociodemographic and clinical factors associated with mortality and dependence at this time point. Seventy-eight patients with DAI were recruited from July 2013 to February 2014 in a prospective cohort study. Patient outcome was analyzed using the Extended Glasgow Outcome Scale (GOS-E) within 6 months of the traumatic injury. The mean Injury Severity Score was 35.0 (SD = 11.9), and the mean New Injury Severity Score (NISS) was 46.2 (SD = 15.9). Mild DAI was observed in 44.9% of the patients and severe DAI in 35.9%. Six months after trauma, 30.8% of the patients had died, and 45.1% had shown full recovery according to the GOS-E. In the logistic regression model, the severity variables - DAI with hypoxia, as measured by peripheral oxygen saturation, and hypotension with NISS value - had a statistically significant association with patient mortality; on the other hand, severity of DAI and length of hospital stay were the only significant predictors for dependence. Therefore, severity of DAI emerged as a risk factor for both mortality and dependence.	[Almeida Vieira, Rita de Cassia; Cardoso de Sousa, Regina Marcia] Univ Sao Paulo, Sch Nursing, Sao Paulo, Brazil; [Paiva, Wellingson Silva; de Oliveira, Daniel Vieira; Teixeira, Manoel Jacobsen; de Andrade, Almir Ferreira] Univ Sao Paulo, Sch Med, Dept Neurol, Sao Paulo, Brazil		Vieira, RDA (corresponding author), Univ Sao Paulo, Sch Nursing, Sao Paulo, Brazil.	ritavieira@usp.br	Paiva, Wellingson S/G-5517-2013; de Oliveira, Daniel Vieira/AAH-1071-2019; Sousa, Regina M/H-1108-2012; Almeida Vieira, Rita de Cassia/E-3262-2013	Paiva, Wellingson S/0000-0002-5165-7040; de Oliveira, Daniel Vieira/0000-0002-6768-3286; Sousa, Regina M/0000-0002-2575-7937; Almeida Vieira, Rita de Cassia/0000-0002-7981-9822; Vieira, Rita de Cassia/0000-0001-9210-4445	Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/21804-0]; Conselho Nacional de Desenvolvimento Cientifico and Tecnologico Universal MCTI-CNPq [444855/214-9]	This project was supported by Sao Paulo Research Foundation (FAPESP) 2013/21804-0 and Conselho Nacional de Desenvolvimento Cientifico and Tecnologico Universal MCTI-CNPq (444855/214-9).	Association for the Advancement of Automotive Medicine (AAAM), 2008, ABBR INJ SCAL AIS 20; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bennet L, 2013, CLIN EXP PHARMACOL P, V40, P774, DOI 10.1111/1440-1681.12135; Bilotta F, 2009, J NEUROSURG ANESTH, V21, P2, DOI 10.1097/ANA.0b013e31818f8a5c; Brenner M, 2012, J TRAUMA ACUTE CARE, V72, P1135, DOI 10.1097/TA.0b013e31824af90b; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa; Dantas VP, 2004, ARQ NEURO-PSIQUIAT, V62, P313, DOI 10.1590/S0004-282X2004000200022; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Esbjornsson E, 2013, J REHABIL MED, V45, P771, DOI 10.2340/16501977-1170; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Gennarelli T. A., 1987, HEAD INJURY, P108; Gennarelli TA, 1993, HEAD INJURY, P137; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; IWADATE Y, 1990, Neurological Surgery, V18, P915; Jeong JH, 2010, J NEUROSURG, V113, P532, DOI 10.3171/2009.10.JNS091152; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Lagares A, 2006, NEUROCIRUGIA, V17, P105; Lane PL, 2000, CAN J SURG, V43, P442; Ley EJ, 2013, J TRAUMA ACUTE CARE, V75, P682, DOI 10.1097/TA.0b013e31829d024f; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Liew B S, 2009, Med J Malaysia, V64, P280; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Lorente L, 2014, THROMB RES, V134, P832, DOI 10.1016/j.thromres.2014.07.034; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Mata-Mbemba D, 2015, J NEUROTRAUM, V32, P359, DOI 10.1089/neu.2014.3453; Matsukawa H, 2013, BRAIN INJURY, V27, P1409, DOI 10.3109/02699052.2013.823655; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Nogueira LD, 2008, REV LAT-AM ENFERM, V16, P314, DOI 10.1590/S0104-11692008000200022; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Parchani A, 2014, WORLD NEUROSURG, V82, pE639, DOI 10.1016/j.wneu.2014.06.022; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Rosa CM, 2011, J TRAUMA, V70, P447, DOI 10.1097/TA.0b013e3182095e14; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Sobuwa S, 2014, SAMJ S AFR MED J, V104, P492, DOI [10.7196/SAMJ.7720, 10.7196/samj.7720]; Sousa Regina Márcia Cardoso de, 2005, Acta paul. enferm., V18, P354, DOI 10.1590/S0103-21002005000400003; Sousa RMC, 2006, REV ESC ENFERM USP, V40, P203, DOI DOI 10.1590/S0080-62342006000200008; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Taw BBT, 2012, ASIAN J SURG, V35, P117, DOI 10.1016/j.asjsur.2012.04.027; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomei G, 1991, J Neurosurg Sci, V35, P61; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Yanagawa Y, 2009, J TRAUMA, V66, P162, DOI 10.1097/TA.0b013e3181469857	54	37	38	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	OCT 20	2016	7								178	10.3389/fneur.2016.00178			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DZ3WM	WOS:000385780300002	27812349	Green Published, gold			2022-02-06	
J	Calcagnile, O; Anell, A; Unden, J				Calcagnile, Olga; Anell, Anders; Unden, Johan			The addition of S100B to guidelines for management of mild head injury is potentially cost saving	BMC NEUROLOGY			English	Article							COMPUTED-TOMOGRAPHY; BRAIN-INJURY; SERUM-LEVELS; ADULTS; TRAUMA; STRATEGIES; PROTEIN; S-100B; RULE	Background: Mild traumatic brain injury (TBI) is associated with substantial costs due to over-triage of patients to computed tomography (CT) scanning, despite validated decision rules. Serum biomarker S100B has shown promise for safely omitting CT scans but the economic impact from clinical use has never been reported. In 2007, S100B was adapted into the existing Scandinavian management guidelines in Halmstad, Sweden, in an attempt to reduce CT scans and save costs. Methods: Consecutive adult patients with mild TBI (GCS 14-15, loss of consciousness and/or amnesia), managed with the aid of S100B, were prospectively included in this study. Patients were followed up after 3 months with a standardized questionnaire. Theoretical and actual cost differences were calculated. Results: Seven hundred twenty-six patients were included and 29 (4.7 %) showed traumatic abnormalities on CT. No further significant intracranial complications were discovered on follow-up. Two hundred twenty-nine patients (27 %) had normal S100B levels and 497 patients (73 %) showed elevated S100B levels. Over-triage occurred in 73 patients (32 %) and under-triage occurred in 39 patients (7 %). No significant intracranial complications were missed. The introduction of S100B could save 71 (sic) per patient if guidelines were strictly followed. As compliance to the guidelines was not perfect, the actual cost saving was 39 (sic) per patient. Conclusion: Adding S100B to existing guidelines for mild TBI seems to reduce CT usage and costs, especially if guideline compliance could be increased.	[Calcagnile, Olga] Halmstad Reg Hosp, Dept Paediat Med, Halmstad, Sweden; [Calcagnile, Olga] Hallandssjukhus Halmstad, Barnkliniken, S-30185 Halmstad, Sweden; [Anell, Anders] Lund Univ, Inst Econ Res, Sch Econ & Management, Lund, Sweden; [Unden, Johan] Skane Univ Hosp, Dept Anaesthesiol & Intens Care, Malmo, Sweden		Calcagnile, O (corresponding author), Halmstad Reg Hosp, Dept Paediat Med, Halmstad, Sweden.; Calcagnile, O (corresponding author), Hallandssjukhus Halmstad, Barnkliniken, S-30185 Halmstad, Sweden.	olga.calcagnile@regionhalland.se					Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Bouvier D, 2009, ANN BIOL CLIN-PARIS, V67, P425, DOI 10.1684/abc.2009.0347; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Morton MJ, 2012, ANN EMERG MED; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI 10.1089/neu.2009-0928; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	22	37	37	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	OCT 20	2016	16								200	10.1186/s12883-016-0723-z			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DZ7ZK	WOS:000386087300002	27765016	Green Published, gold			2022-02-06	
J	Claassen, J; Velazquez, A; Meyers, E; Witsch, J; Falo, MC; Park, S; Agarwal, S; Schmidt, JM; Schiff, ND; Sitt, JD; Naccache, L; Connolly, ES; Frey, HP				Claassen, Jan; Velazquez, Angela; Meyers, Emma; Witsch, Jens; Falo, M. Cristina; Park, Soojin; Agarwal, Sachin; Schmidt, J. Michael; Schiff, Nicholas D.; Sitt, Jacobo D.; Naccache, Lionel; Connolly, E. Sander; Frey, Hans-Peter			Bedside Quantitative Electroencephalography Improves Assessment of Consciousness in Comatose Subarachnoid Hemorrhage Patients	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NONCONVULSIVE SEIZURES; VEGETATIVE STATE; OF-LIFE; DISORDERS; PROPOFOL; CARE; AWARENESS; OSCILLATIONS; INFORMATION	Objective: Accurate behavioral assessments of consciousness carry tremendous significance in guiding management, but are extremely challenging in acutely brain-injured patients. We evaluated whether electroencephalography (EEG) and multimodality monitoring parameters may facilitate assessment of consciousness in patients with subarachnoid hemorrhage. Methods: A retrospective analysis was performed of 83 consecutively treated adults with subarachnoid hemorrhage. All patients were initially comatose and had invasive brain monitoring placed. Behavioral assessments were performed during daily interruption of sedation and categorized into 3 groups based on their best examination as (1) comatose, (2) arousable (eye opening or attending toward a stimulus), and (3) aware (command following). EEG features included spectral power and complexity measures. Comparisons were made using bootstrapping methods and partial least squares regression. Results: We identified 389 artifact-free EEG clips following behavioral assessments. Increasing central gamma, posterior alpha, and diffuse theta-delta oscillations differentiated patients who were arousable from those in coma. Command following was characterized by a further increase in central gamma and posterior alpha, as well as an increase in alpha permutation entropy. These EEG features together with basic neurological examinations (eg, pupillary light reflex) contributed heavily to a linear model predicting behavioral state, whereas brain physiology measures (eg, brain oxygenation), structural injury, and clinical course added less. Interpretation: EEG measures of behavioral states provide distinctive signatures that complement behavioral assessments of patients with subarachnoid hemorrhage shortly after the injury. Our data support the hypothesis that impaired connectivity of cortex with both central thalamus and basal forebrain underlies decreasing levels of consciousness.	[Claassen, Jan; Velazquez, Angela; Meyers, Emma; Witsch, Jens; Falo, M. Cristina; Park, Soojin; Agarwal, Sachin; Schmidt, J. Michael; Frey, Hans-Peter] Columbia Univ, Dept Neurol, New York, NY USA; [Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA; [Sitt, Jacobo D.; Naccache, Lionel] Natl Inst Hlth & Med Res, Inst Brain & Spinal Cord Res Ctr, Paris, France; [Connolly, E. Sander] Columbia Univ, Dept Neurosurg, New York, NY USA		Claassen, J (corresponding author), Columbia Univ, Neurol Inst, 177 Ft Washington Ave,MHB 8 Ctr,Room 300, New York, NY 10032 USA.	jc1439@columbia.edu	Claassen, Jan/AAA-5451-2020; Witsch, Jens/AAL-3997-2020; Sitt, Jacobo/A-9834-2015	Witsch, Jens/0000-0001-8924-851X; Sitt, Jacobo/0000-0002-3878-4846; naccache, lionel/0000-0002-2874-1009; Schmidt, J. Michael/0000-0001-8141-2944	NIH National Library of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM011826]; NIH National Center for Advancing Translational Sciences [UL1 TR000040, UL1 RR024156]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000040] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM011826] Funding Source: NIH RePORTER	This work was supported by the NIH National Library of Medicine (R01LM011826, J.C.) and NIH National Center for Advancing Translational Sciences (UL1 TR000040 [formerly the National Center for Research Resources, UL1 RR024156], J.C.).	Bandt C, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.174102; Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Barry RJ, 2007, CLIN NEUROPHYSIOL, V118, P2765, DOI 10.1016/j.clinph.2007.07.028; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bokil H., 2008, OBSERVED BRAIN DYNAM; Boly M, 2012, J NEUROSCI, V32, P7082, DOI 10.1523/JNEUROSCI.3769-11.2012; Breshears JD, 2010, P NATL ACAD SCI USA, V107, P21170, DOI 10.1073/pnas.1011949107; Ching SN, 2010, P NATL ACAD SCI USA, V107, P22665, DOI 10.1073/pnas.1017069108; Choi HA, 2015, NEUROCRIT CARE, V22, P423, DOI 10.1007/s12028-014-0073-x; Cimenser A, 2011, P NATL ACAD SCI USA, V108, P8832, DOI 10.1073/pnas.1017041108; Claassen J, 2014, ANN NEUROL, V75, P771, DOI 10.1002/ana.24166; Claassen J, 2013, ANN NEUROL, V74, P53, DOI 10.1002/ana.23859; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Dehaene S, 2011, NEURON, V70, P200, DOI 10.1016/j.neuron.2011.03.018; Farzan F, 2010, BRAIN, V133, P1505, DOI 10.1093/brain/awq046; Forgacs PB, 2015, ANN NEUROL, V77, P185, DOI 10.1002/ana.24311; Forgacs PB, 2014, ANN NEUROL, V76, P869, DOI 10.1002/ana.24283; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Gosseries O, 2011, FUNCT NEUROL, V26, P25; Hall SD, 2010, CLIN NEUROPHYSIOL, V121, P549, DOI 10.1016/j.clinph.2009.11.084; JAHNSEN H, 1984, ARCH ITAL BIOL, V122, P73; John ER, 2001, CONSCIOUS COGN, V10, P165, DOI 10.1006/ccog.2001.0507; King JR, 2013, CURR BIOL, V23, P1914, DOI 10.1016/j.cub.2013.07.075; Komotar RJ, 2009, NEUROSURGERY, V64, pN10, DOI 10.1227/01.neu.0000351422.52956.17; Komotar RJ, 2009, NEUROSURGERY, V64, P397, DOI 10.1227/01.NEU.0000338946.42939.C7; Leon-Carrion J, 2012, BRAIN RES, V1476, P22, DOI 10.1016/j.brainres.2012.03.055; Lerch C, 2006, NEUROCRIT CARE, V5, P85, DOI 10.1385/NCC:5:2:85; Llinas R, 1998, PHILOS T ROY SOC B, V353, P1841, DOI 10.1098/rstb.1998.0336; Lule D, 2009, PROG BRAIN RES, V177, P339, DOI 10.1016/S0079-6123(09)17723-3; Mikell CB, 2015, STROKE, V46, P49, DOI 10.1161/STROKEAHA.114.007645; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Peng HC, 2005, IEEE T PATTERN ANAL, V27, P1226, DOI 10.1109/TPAMI.2005.159; Posner JB, 2007, PLUM POSNERS DIAGNOS; Purdon PL, 2013, P NATL ACAD SCI USA, V110, pE1142, DOI 10.1073/pnas.1221180110; Riker RR, 2014, NEUROCRIT CARE, V21, P27, DOI 10.1007/s12028-014-0025-5; Schiff N.D., 2016, BRAIN FUNCTION RESPO, P195, DOI [10.1007/978-3-319-21425-2_15, DOI 10.1007/978-3-319-21425-2_15]; Schiff ND, 2014, CURR OPIN NEUROBIOL, V25, P7, DOI 10.1016/j.conb.2013.10.007; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Sitt JD, 2014, BRAIN, V137, P2258, DOI 10.1093/brain/awu141; Sohal VS, 2012, BIOL PSYCHIAT, V71, P1039, DOI 10.1016/j.biopsych.2012.01.024; Supp GG, 2011, CURR BIOL, V21, P1988, DOI 10.1016/j.cub.2011.10.017; Suwatcharangkoon S, 2016, JAMA NEUROL, V73, P28, DOI 10.1001/jamaneurol.2015.3188; Tallon-Baudry C, 2009, FRONT BIOSCI-LANDMRK, V14, P321, DOI 10.2741/3246; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Vinck M, 2010, NEUROIMAGE, V51, P112, DOI 10.1016/j.neuroimage.2010.01.073; Williams ST, 2013, ELIFE, V2, DOI 10.7554/eLife.01157	54	37	39	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2016	80	4					541	553		10.1002/ana.24752			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ED0XZ	WOS:000388568700007	27472071	Green Accepted			2022-02-06	
J	Maung, AA; Bhattacharya, B; Schuster, KM; Davis, KA				Maung, Adrian A.; Bhattacharya, Bishwajit; Schuster, Kevin M.; Davis, Kimberly A.			Trauma patients on new oral anticoagulation agents have lower mortality than those on warfarin	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	29th Annual Scientific Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 09-16, 2016	San Antonio, TX	Eastern Assoc Surg Trauma		Warfarin; trauma; dabigatran; apixaban; rivaroxaban; outcomes; mortality	PREINJURY WARFARIN; ATRIAL-FIBRILLATION; RISK; DABIGATRAN; REVERSAL; OUTCOMES	BACKGROUND Although anticoagulation with warfarin has been associated with increased risk of adverse outcomes after trauma, the effects of the new oral agents (NOA) such as dabigatran, apixaban, rivaroxaban are not yet well characterized. METHODS A retrospective review of a level 1 trauma center database identified all patients aged 50 admitted after trauma during a 24 month period starting September 2013. Demographics, including preadmission anticoagulation agents, injuries, hospital course and outcomes were abstracted from the electronic medical record. RESULT Over the 24-month period, 3,392 patients were admitted; 112 (3.3%) were anticoagulated with NOA and 373 (11.0%) with warfarin with a trend toward increasing utilization of the new agents compared with warfarin over that period. Although comparable in age, injury severity scores, and mechanism of injury, patients anticoagulated with warfarin had both a higher overall mortality (10.9%) compared with the NOA (6.25%) and the non-anticoagulated control (5.5%) groups (p < 0.001) as well as a higher trauma-related mortality (9.0%) versus NOA (2.8%) and control (3.7%) groups (p < 0.001). Patients on warfarin or NOA were admitted to intensive care unit or step down unit more frequently than control patients. (45.0% and 41.9% vs. 35.7% respectively; p < 0.001). The incidence of traumatic brain injury was similar among the three groups. Although it did not reach statistical significance, trauma-specific mortality in the traumatic brain injury subset was higher in the warfarin group (19.3%) than the NOA (16.7%) or control (10.9%) groups (p = 0.08). In a multivariable logistic regression, warfarin (odds ratio, 2.215; 95% confidence interval, 1.365-3.596; p = 0.001), but not the NOA (odds ratio, 0.871; 95% confidence interval, 0.258-2.939; p = 0.823), was an independent predictor for mortality. CONCLUSIONS Although the experience with the new oral anticoagulation agents is still limited, patients on these agents appear to have lower mortality after traumatic injury than patients on warfarin. LEVEL OF EVIDENCE Epidemiologic study, level III.	[Maung, Adrian A.; Bhattacharya, Bishwajit; Schuster, Kevin M.; Davis, Kimberly A.] Yale Sch Med, New Haven, CT USA		Maung, AA (corresponding author), Dept Surg, Sect Gen Surg Trauma & Surg Crit Care, 330 Cedar St BB310, New Haven, CT 06520 USA.	adrian.maung@yale.edu		Bhattacharya, Bishwajit/0000-0002-7118-7621			Collins CE, 2014, AM J SURG, V208, P544, DOI 10.1016/j.amjsurg.2014.05.019; Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747; Falzon CM, 2013, EMERG MED J, V30, P809, DOI 10.1136/emermed-2012-201687; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gallego P, 2012, CIRCULATION, V126, P1573, DOI 10.1161/CIRCULATIONAHA.112.135681; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Greinacher A, 2015, THROMB HAEMOSTASIS, V113, P931, DOI 10.1160/TH14-11-0982; Hernandez I, 2015, JAMA INTERN MED, V175, P18, DOI 10.1001/jamainternmed.2014.5398; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Mookadam M, 2015, J AM BOARD FAM MED, V28, P510, DOI 10.3122/jabfm.2015.04.140297; Mountain D, 2010, MED J AUSTRALIA, V193, P202, DOI 10.5694/j.1326-5377.2010.tb03868.x; Pakraftar S, 2014, WORLD J CLIN CASES, V2, P362, DOI 10.12998/wjcc.v2.i8.362; Parra MW, 2013, J NEUROSURG, V119, P760, DOI 10.3171/2013.3.JNS12503; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Siegal DM, 2015, NEW ENGL J MED, V373, P2413, DOI 10.1056/NEJMoa1510991; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	16	37	37	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	OCT	2016	81	4					652	657		10.1097/TA.0000000000001189			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	DZ2FX	WOS:000385658800005	27438683				2022-02-06	
J	Wu, LC; Laksari, K; Kuo, C; Luck, JF; Kleiven, S; Bass, CR; Camarillo, DB				Wu, Lyndia C.; Laksari, Kaveh; Kuo, Calvin; Luck, Jason F.; Kleiven, Svein; Bass, Cameron R. 'Dale'; Camarillo, David B.			Bandwidth and sample rate requirements for wearable head impact sensors	JOURNAL OF BIOMECHANICS			English	Article						Traumatic brain injury; Head impact biomechanics; Wearable sensors; Bandwidth; Sample rate; Head injury criteria	BRAIN-INJURY; ACCELERATION MEASUREMENT; AMERICAN FOOTBALL; CONCUSSION; FREQUENCY; EXPOSURE; PLAYERS; MODEL	Wearable inertial sensors measure human head impact kinematics important to the on-going development and validation of head injury criteria. However, sensor specifications have not been scientifically justified in the context of the anticipated field impact dynamics. The objective of our study is to determine the minimum bandwidth and sample rate required to capture the impact frequency response relevant to injury. We used high-bandwidth head impact data as ground-truth measurements, and investigated the attenuation of various injury criteria at lower bandwidths. Given a 10% attenuation threshold, we determined the minimum bandwidths required to study injury criteria based on skull kinematics and brain deformation in three different model systems: helmeted cadaver (no neck), unhelmeted cadaver (no neck), and helmeted dummy impacts (with neck). We found that higher bandwidths are required for unhelmeted impacts in general and for studying strain rate injury criteria. Minimum gyroscope bandwidths of 300 Hz in helmeted sports and 500 Hz in unhelmeted sports are necessary to study strain rate based injury criteria. A minimum accelerometer bandwidth of 500 Hz in unhelmeted sports is necessary to study most injury criteria. Current devices typically sample at 1000 Hz, with gyroscope bandwidths below 200 Hz, which are not always sufficient according to these requirements. With hard contact test conditions, the identified requirements may be higher than most soft contacts on the field, but should be satisfied to capture the worst contact, and often higher risk, scenarios relative to the specific sport or activity. Our findings will help establish standard guidelines for sensor choice and design in traumatic brain injury research. (C) 2016 Elsevier Ltd. All rights reserved.	[Wu, Lyndia C.; Laksari, Kaveh; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Kuo, Calvin; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Luck, Jason F.; Bass, Cameron R. 'Dale'] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Kleiven, Svein] KM Royal Inst Technol, Dept Neuron Engn, Stockholm, Sweden		Wu, LC (corresponding author), 443 Via Ortega, Stanford, CA 94305 USA.	lyndiacw@stanford.edu	Kuo, Calvin/AAH-1933-2019; Wu, Lyndia/AAQ-1106-2020	Kuo, Calvin/0000-0001-8401-9136; Wu, Lyndia/0000-0002-8236-032X	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; Stanford Child Health Research Institute Transdisciplinary Initiatives Programs; Stanford Bio-X Graduate Research Fellowship Program; Natural Sciences and Engineering Research Council of Canada Postgraduate ScholarshipNatural Sciences and Engineering Research Council of Canada (NSERC); University of Pennsylvania Prime; US Army Research Office [W911NF-10-1-0526]; Duke University Pratt School of Engineering	We would like to thank Dr. Jason Mihalik's team at University of North Carolina at Chapel Hill for their involvement in the collaborative effort to collect cadaver drop test data. This work was mainly supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, the Stanford Child Health Research Institute Transdisciplinary Initiatives Programs, the Stanford Bio-X Graduate Research Fellowship Program, and the Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarship. We appreciate additional funding from the University of Pennsylvania Prime, US Army Research Office W911NF-10-1-0526 and the Duke University Pratt School of Engineering.	[Anonymous], 2007, J2111 SAE, P4970; ANTONSSON EK, 1985, J BIOMECH, V18, P39, DOI 10.1016/0021-9290(85)90043-0; Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fijalkowski RJ, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3078182; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Kang YS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4005427; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laituri T. R., 2015, 2015011437 SAE; Laksari K, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0331; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; PELLMAN EJ, 2003, NEUROSURGERY, V53, P796; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts EG, 2008, STAPP CAR C, V52, P1; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153	30	37	38	0	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 6	2016	49	13					2918	2924		10.1016/j.jbiomech.2016.07.004			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	DY9RH	WOS:000385472300047	27497499				2022-02-06	
J	Bernard, CO; Ponsford, JA; McKinlay, A; McKenzie, D; Krieser, D				Bernard, Coco O.; Ponsford, Jennie A.; McKinlay, Audrey; McKenzie, Dean; Krieser, David			Predictors of Post-concussive Symptoms in Young Children: Injury versus Non-injury Related Factors	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Mild traumatic brain injury; Concussion; Post concussive symptoms; Child; Predictors; Child; Pediatric; Behavior	TRAUMATIC-BRAIN-INJURY; MILD HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; PSYCHOSOCIAL OUTCOMES; EMERGENCY-DEPARTMENT; PEDIATRIC CONCUSSION; ADOLESCENTS; CHILDHOOD; RECOVERY; IDENTIFICATION	Objectives: A notable minority of children will experience persistent post-concussive symptoms (PCS) following mild traumatic brain injury (mTBI), likely maintained by a combination of injury and non-injury related factors. Adopting a prospective longitudinal design, this study aimed to investigate the relative influence of child, family, and injury factors on both acute and persistent PCS in young children. Methods: Participants were 101 children aged 2-12 who presented to an Emergency Department, with either mTBI or minor bodily trauma (control). PCS were assessed at time of injury, 1 week, and 1, 2, and 3 months post-injury. Predictors included injury and demographic variables, premorbid child behavior, sleep hygiene, and parental stress. Random effects ordinal logistic regression models were used to analyze the relative influence of these predictors on PCS at early (acute - 1 week) and late (1-3 month) post-injury phases. Results: Presence of mTBI was a stronger predictor of PCS in the early [odds ratio (OR)=18.2] compared with late (OR=7.3) post-injury phase. Older age at injury and pre-existing learning difficulties were significant predictors of PCS beyond 1 month post-injury. Family factors, including higher levels of parental stress, higher socio-economic status, and being of Anglo-Saxon descent, consistently predicted greater PCS. Conclusions: Injury characteristics were significantly associated with PCS for 3 months following mTBI but the association weakened over time. On the other hand, pre-existing child and family factors displayed an increasingly strong association with PCS over time. Follow-up for these at-risk children which also addresses family stress may minimize longer-term complications.	[Bernard, Coco O.; Ponsford, Jennie A.] Monash Univ, Sch Psychol Sci, Melbourne, Vic, Australia; [McKinlay, Audrey] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic 3010, Australia; [McKenzie, Dean] Epworth HealthCare, Melbourne, Vic, Australia; [McKenzie, Dean] Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Krieser, David] Sunshine Hosp, Emergency Dept, Melbourne, Vic, Australia		Bernard, CO (corresponding author), Monash Univ, Sch Psychol Sci, Clin Neuropsychol, Clayton, Vic 3800, Australia.	coco.bernard@monash.edu	Krieser, David/AAA-1370-2021	Krieser, David/0000-0002-7173-6993; McKinlay, Audrey/0000-0001-9846-8514	Monash University Doctoral Research Fund; Jack Brockoff Foundation	Coco O. Bernard and Jennie A. Ponsford, School of Psychological Sciences, Monash University, Melbourne, Australia; Audrey McKinlay, Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Australia; Dean McKenzie, Epworth HealthCare and School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; David Krieser, Sunshine Hospital Emergency Department, Melbourne, Australia. The authors have indicated that they have no financial relationships relevant to this article, potential conflicts of interest, to disclose. Research funding was awarded to Professor Jennie A. Ponsford and Dr. Audrey McKinlay by the Jack Brockoff Foundation, and to Coco O. Bernard from the Monash University Doctoral Research Fund. This research was conducted as part of Coco O. Bernard's Doctoral Thesis (Doctorate of Clinical Neuropsychology).	Abidin R., 1983, PARENTAL STRESS INDE; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V., 1997, J INT NEUROPSYCH SOC, V3, P553; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Araujo GC, 2014, CLIN NEUROPSYCHOL, V28, P786, DOI 10.1080/13854046.2014.896415; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bracken B.A., 2004, CLIN ASSESSMENT BEHA; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan LG, 2015, J HEAD TRAUMA REHAB, V30, pE67, DOI 10.1097/HTR.0000000000000119; Connery AK, 2016, CLIN NEUROPSYCHOL, V30, P579, DOI 10.1080/13854046.2016.1177596; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goodlin-Jones BL, 2008, J DEV BEHAV PEDIATR, V29, P82, DOI 10.1097/DBP.0b013e318163c39a; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Grubenhoff JA, 2016, J PEDIATR-US, V174, P27, DOI 10.1016/j.jpeds.2016.03.027; Guo S., 2015, PROPENSITY SCORE ANA; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2014, PEDIATRICS, V133, P643, DOI 10.1542/peds.2013-3195; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; Kolb B, 2012, DEV PSYCHOBIOL, V54, P311, DOI 10.1002/dev.20515; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Lloyd J, 2015, BRAIN INJURY, V29, P539, DOI 10.3109/02699052.2014.1002003; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2014, J HEAD TRAUMA REHAB, V29, P233, DOI 10.1097/HTR.0b013e3182a2dd7f; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Osberg JS, 1996, PEDIATRICS, V98, P890; Owens JA, 2000, SLEEP, V23, P1043; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Prigatano GP, 2007, BRAIN INJURY, V21, P721, DOI 10.1080/02699050701481605; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Saltapidas H, 2007, J HEAD TRAUMA REHAB, V22, P132, DOI 10.1097/01.HTR.0000265101.75177.8d; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Scott C, 2015, NEUROPSYCHOLOGY, V29, P501, DOI 10.1037/neu0000074; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; Stavinoha PL, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P135, DOI 10.1007/978-0-387-89545-1_11; Sturdivant RX, 2013, APPL LOGISTIC REGRES, V3rd; Tabachnick B.G., 2013, USING MULTIVARIATE S; Taylor H., 1995, RECOVERY TRAUMATIC B, P188; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Theadom A, 2015, SLEEP MED, V16, P926, DOI 10.1016/j.sleep.2015.04.013; Melo JRT, 2010, ARQ NEURO-PSIQUIAT, V68, P381, DOI 10.1590/S0004-282X2010000300010; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Winkler R, 2015, J HEAD TRAUMA REHAB, V30, P324, DOI 10.1097/HTR.0000000000000114; Woodrome SE, 2011, J INT NEUROPSYCH SOC, V17, P317, DOI 10.1017/S1355617710001700; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	79	37	37	0	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2016	22	8					793	803		10.1017/S1355617716000709			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	DX4BU	WOS:000384324800001	27619107				2022-02-06	
J	Titus, DJ; Wilson, NM; Freund, JE; Carballosa, MM; Sikah, KE; Furones, C; Dietrich, WD; Gurney, ME; Atkins, CM				Titus, David J.; Wilson, Nicole M.; Freund, Julie E.; Carballosa, Melissa M.; Sikah, Kevin E.; Furones, Concepcion; Dietrich, W. Dalton; Gurney, Mark E.; Atkins, Coleen M.			Chronic Cognitive Dysfunction after Traumatic Brain Injury Is Improved with a Phosphodiesterase 4B Inhibitor	JOURNAL OF NEUROSCIENCE			English	Article						cAMP; cognition; learning; long-term potentiation; phosphodiesterase; traumatic brain injury	NECROSIS-FACTOR-ALPHA; WORKING-MEMORY DYSFUNCTION; FLUID PERCUSSION INJURY; LONG-TERM POTENTIATION; A-META-ANALYSIS; RAT-BRAIN; ALZHEIMERS-DISEASE; PDE4 INHIBITORS; MICE DEFICIENT; MESSENGER-RNAS	Learning and memory impairments are common in traumatic brain injury (TBI) survivors. However, there are no effective treatments to improve TBI-induced learning and memory impairments. TBI results in decreased cAMP signaling and reduced cAMP-response-element binding protein (CREB) activation, a critical pathway involved in learning and memory. TBI also acutely upregulates phosphodiesterase 4B2 (PDE4B2), which terminates cAMP signaling by hydrolyzing cAMP. We hypothesized that a subtype-selective PDE4B inhibitor could reverse the learning deficits induced by TBI. To test this hypothesis, adult male Sprague-Dawley rats received sham surgery or moderate parasagittal fluid-percussion brain injury. At 3 months postsurgery, animals were administered a selective PDE4B inhibitor or vehicle before cue and contextual fear conditioning, water maze training and a spatial working memory task. Treatment with the PDE4B inhibitor significantly reversed the TBI-induced deficits in cue and contextual fear conditioning and water maze retention. To further understand the underlying mechanisms of these memory impairments, we examined hippocampal long-term potentiation (LTP). TBI resulted in a significant reduction in basal synaptic transmission and impaired expression of LTP. Treatment with the PDE4B inhibitor significantly reduced the deficits in basal synaptic transmission and rescued LTP expression. The PDE4B inhibitor reduced tumor necrosis factor-alpha levels and increased phosphorylated CREB levels after TBI, suggesting that this drug inhibited molecular pathways in the brain known to be regulated by PDE4B. These results suggest that a subtype-selective PDE4B inhibitor is a potential therapeutic to reverse chronic learning and memory dysfunction and deficits in hippocampal synaptic plasticity following TBI.	[Titus, David J.; Wilson, Nicole M.; Freund, Julie E.; Carballosa, Melissa M.; Sikah, Kevin E.; Furones, Concepcion; Dietrich, W. Dalton; Atkins, Coleen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Gurney, Mark E.] Tetra Discovery Partners, Grand Rapids, MI 49503 USA		Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 Northwest 14 Terrace, Miami, FL 33136 USA.	catkins@med.miami.edu			National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS069721, R01 NS056072, F31 NS089351]; Miami Project to Cure Paralysis; National Institutes of Health/National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R44 MH091791]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R44MH091791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056072, R01NS069721, F31NS089351, R25NS083064, R41NS090666] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke R01 NS069721 to C.M.A., R01 NS056072 to C.M.A. and W.D.D., F31 NS089351 to N.M.W., and The Miami Project to Cure Paralysis. M.E.G. acknowledges support by the National Institutes of Health/National Institute of Mental Health R44 MH091791. We thank Jonathan Mendoza, Rosmery Santos, and David Sequeira for technical support, and Dr Xuesheng Mo for synthesis of A33.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Ahmed T, 2005, BRAIN RES, V1041, P212, DOI 10.1016/j.brainres.2005.02.023; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Atkins CM, 2012, J NEUROSCI RES, V90, P1861, DOI 10.1002/jnr.23069; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Atkins CM, 2013, NEUROSCI LETT, V532, P1, DOI 10.1016/j.neulet.2012.10.019; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Burgin AB, 2010, NAT BIOTECHNOL, V28, P63, DOI 10.1038/nbt.1598; Cherry JA, 1999, J COMP NEUROL, V407, P287; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Clapcote SJ, 2007, NEURON, V54, P387, DOI 10.1016/j.neuron.2007.04.015; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox D, 2014, CELL SIGNAL, V26, P657, DOI 10.1016/j.cellsig.2013.12.003; Garcia-Osta A, 2012, ACS CHEM NEUROSCI, V3, P832, DOI 10.1021/cn3000907; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Hansen RT, 2014, PSYCHOPHARMACOLOGY, V231, P2941, DOI 10.1007/s00213-014-3480-y; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Jin SLC, 2005, J IMMUNOL, V175, P1523, DOI 10.4049/jimmunol.175.3.1523; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Johansson EM, 2012, NEUROSCI LETT, V525, P1, DOI 10.1016/j.neulet.2012.07.050; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Klann E, 1998, J BIOL CHEM, V273, P4516, DOI 10.1074/jbc.273.8.4516; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lakics V, 2010, NEUROPHARMACOLOGY, V59, P367, DOI 10.1016/j.neuropharm.2010.05.004; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Li YF, 2011, J NEUROSCI, V31, P172, DOI 10.1523/JNEUROSCI.5236-10.2011; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; McDonnell MN, 2011, ARCH PHYS MED REHAB, V92, P1044, DOI 10.1016/j.apmr.2011.01.021; McGirr A, 2016, NEUROPSYCHOPHARMACOL, V41, P1080, DOI 10.1038/npp.2015.240; Naganuma K, 2009, BIOORG MED CHEM LETT, V19, P3174, DOI 10.1016/j.bmcl.2009.04.121; Oliva AA, 2012, J NEUROCHEM, V123, P1019, DOI 10.1111/jnc.12049; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Perez-Torres S, 2000, J CHEM NEUROANAT, V20, P349, DOI 10.1016/S0891-0618(00)00097-1; Potts MB, 2009, J NEUROSCI RES, V87, P1848, DOI 10.1002/jnr.21996; Press NJ, 2009, PROGR MED CHEM, V47, P37, DOI 10.1016/S0079-6468(08)00202-6; Reyes-Irisarri E, 2008, SYNAPSE, V62, P74, DOI 10.1002/syn.20459; Robichaud A, 2002, BRIT J PHARMACOL, V135, P113, DOI 10.1038/sj.bjp.0704457; Robichaud A, 2001, NEUROPHARMACOLOGY, V40, P262, DOI 10.1016/S0028-3908(00)00142-8; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Rudy JW, 1999, BEHAV NEUROSCI, V113, P867, DOI 10.1037/0735-7044.113.5.867; Rutten K, 2008, EUR J NEUROSCI, V28, P625, DOI 10.1111/j.1460-9568.2008.06349.x; Rutten K, 2011, NEUROPHARMACOLOGY, V61, P138, DOI 10.1016/j.neuropharm.2011.03.020; Sakurai H, 2013, GERIATR GERONTOL INT, V13, P90, DOI 10.1111/j.1447-0594.2012.00866.x; Schaefer TL, 2012, GENES BRAIN BEHAV, V11, P614, DOI 10.1111/j.1601-183X.2012.00796.x; Schwam EM, 2014, CURR ALZHEIMER RES, V11, P413, DOI 10.2174/1567205011666140505100858; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Shim YS, 2014, INT J IMPOT RES, V26, P76, DOI 10.1038/ijir.2013.38; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Siuciak JA, 2008, PSYCHOPHARMACOLOGY, V197, P115, DOI 10.1007/s00213-007-1014-6; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Titus DJ, 2013, NEUROSCIENCE, V231, P182, DOI 10.1016/j.neuroscience.2012.12.002; Titus DJ, 2013, J NEUROSCI, V33, P5216, DOI 10.1523/JNEUROSCI.5133-12.2013; Tsai MC, 2015, J NEUROIMMUNE PHARM, V10, P45, DOI 10.1007/s11481-014-9570-0; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wheaton P, 2011, J CLIN PSYCHOPHARM, V31, P745, DOI 10.1097/JCP.0b013e318235f4ac; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Wilson NM, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00005; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang HT, 2008, NEUROPSYCHOPHARMACOL, V33, P1611, DOI 10.1038/sj.npp.1301537	72	37	37	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 6	2016	36	27					7095	7108		10.1523/JNEUROSCI.3212-15.2016			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DQ2GX	WOS:000379021800004	27383587	Green Published, Bronze			2022-02-06	
J	Erdodi, LA; Tyson, BT; Abeare, CA; Lichtenstein, JD; Pelletier, CL; Rai, JK; Roth, RM				Erdodi, Laszlo A.; Tyson, Bradley T.; Abeare, Christopher A.; Lichtenstein, Jonathan D.; Pelletier, Chantalle L.; Rai, Jaspreet K.; Roth, Robert M.			The BDAE Complex Ideational Material-a Measure of Receptive Language or Performance Validity?	PSYCHOLOGICAL INJURY & LAW			English	Article						Complex Ideational Material; Performance validity assessment; Embedded validity indicators; Psychogenic interference	TRAUMATIC BRAIN-INJURY; PSYCHOGENIC NONEPILEPTIC SEIZURES; CARD SORTING TEST; LEARNING TEST-II; NEUROPSYCHOLOGICAL TESTS; CLASSIFICATION ACCURACY; INVALID PERFORMANCE; RESPONSE BIAS; DIGIT SPAN; INDICATORS	Scores on the Complex Ideational Material (CIM) were examined in reference to various performance validity tests (PVTs) in 106 adults clinically referred for neuropsychological assessment. The main diagnostic categories, reflecting a continuum between neurological and psychiatric disorders, were epilepsy, psychiatric disorders, postconcussive disorder, and psychogenic non-epileptic seizures. Cross-validation analyses suggest that in the absence of bona fide aphasia, a raw score <= 9 or T score <= 29 on the CIM is more likely to reflect non-credible presentation than impaired receptive language skills. However, these cutoffs may be associated with unacceptably high false positive rates in patients with longstanding, documented neurological deficits. Therefore, more conservative cutoffs (<= 8/23) are recommended in such populations. Contrary to the widely accepted assumption that psychiatric disorders are unrelated to performance validity, results were consistent with the psychogenic interference hypothesis, suggesting that emotional distress increases the likelihood of PVT failures even in the absence of apparent external incentives to underperform on cognitive testing.	[Erdodi, Laszlo A.; Tyson, Bradley T.; Abeare, Christopher A.; Rai, Jaspreet K.] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Erdodi, Laszlo A.; Lichtenstein, Jonathan D.; Pelletier, Chantalle L.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03755 USA; [Tyson, Bradley T.] Western Washington Med Grp, Everett, WA USA		Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.; Erdodi, LA (corresponding author), Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03755 USA.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434			American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Benbadis SR, 2000, SEIZURE-EUR J EPILEP, V9, P280, DOI 10.1053/seiz.2000.0409; Boone K.B., 2013, CLIN PRACTICE FORENS; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Borod JC, 1980, J CLIN NEUROPSYCHOLO, V2, P209, DOI DOI 10.1080/01688638008403793; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Considine CM, 2011, ARCH CLIN NEUROPSYCH, V26, P445, DOI 10.1093/arclin/acr041; Cragar DE, 2006, CLIN NEUROPSYCHOL, V20, P552, DOI 10.1080/13854040590947380; Dodrill CB, 2008, EPILEPSIA, V49, P691, DOI 10.1111/j.1528-1167.2007.01457.x; Egeland J, 2005, ACTA PSYCHIAT SCAND, V112, P434, DOI 10.1111/j.1600-0447.2005.00599.x; Erdodi L. A., 2016, PSYCHOL ASSESSMENT; Erdodi L. A., 2016, APPL NEUROPSYCHOLOGY; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Heaton R. K., 2004, REVISED COMPREHENSIV; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Langenecker SA, 2005, J CLIN EXP NEUROPSYC, V27, P320, DOI 10.1080/13803390490490515720; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Myers L, 2014, PSYCHOGENIC NONEPILE; Pearson, 2009, ADV CLIN SOL WAIS 4; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Stenclik JH, 2013, APPL NEUROPSYCH-ADUL, V20, P243, DOI 10.1080/09084282.2012.704603; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; World Health Organization, 2014, ICD10 WHO	37	37	37	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1938-971X	1938-9728		PSYCHOL INJ LAW	Psychol. Inj. Law	JUN	2016	9	2					112	120		10.1007/s12207-016-9254-6			9	Psychology, Clinical	Emerging Sources Citation Index (ESCI)	Psychology	FG6MZ	WOS:000410496200004					2022-02-06	
J	Harris, NG; Verley, DR; Gutman, BA; Sutton, RL				Harris, N. G.; Verley, D. R.; Gutman, B. A.; Sutton, R. L.			Bi-directional changes in fractional anisotropy after experiment TBI: Disorganization and reorganization?	NEUROIMAGE			English	Article						Plasticity; Structural reorganization; Connectivity; Controlled cortical impact; Rat; Imaging; MRI	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; DIFFUSION TENSOR MRI; AXONAL INJURY; MOUSE MODEL; MILD; ROBUST; MICE; RAT; NEURODEGENERATION	The current dogma to explain the extent of injury-related changes following rodent controlled cortical impact (CCI) injury is a focal injury with limited axonal pathology. However, there is in fact good, published histologic evidence to suggest that axonal injury is far more widespread in this model than generally thought. One possibility that might help to explain this is the often-used region-of-interest data analysis approach taken by experimental traumatic brain injury (TBI) diffusion tensor imaging (DTI) or histologic studies that might miss more widespread damage, when compared to the whole brain, statistically robust method of tract-based analysis used more routinely in clinical research. To determine the extent of DTI changes in this model, we acquired in vivo DTI data before and at 1 and 4 weeks after CCI injury in 17 adult male rats and analyzed parametric maps of fractional anisotropy (FA), axial, radial, and mean diffusivity (AD, RD, MD), tensor mode (MO), and fiber tract density (FTD) using tract-based spatial statistics. Contusion volume was used as a surrogate marker of injury severity and as a covariate for investigating severity dependence of the data. Mean fiber tract length was also computed from seeds in the cortical spinal tract regions. In parallel experiments (n = 3-5/group), we investigated corpus callosum neurofilaments and demyelination using immunohistochemistry (IHC) at 3 days and 6 weeks, callosal tract patency using dual-label retrograde tract tracing at 5 weeks, and the contribution of gliosis to DTI parameter maps using GFAP IHC at 4 weeks post-injury. The data show widespread ipsilateral regions of significantly reduced FA at 1 week post-injury, driven by temporally changing values of AD, RD, and MD that persist to 4 weeks. Demyelination, retrograde label tract loss, and reductions in MO (tract degeneration) and FTD were shown to underpin these data. Significant FA increases occurred in subcortical and corticospinal tract regions that were spatially distinct from regions of FA decrease, grossly affected gliotic areas, and MO changes. However, there was good spatial correspondence between regions of increased FA and areas of increased FTD and mean fiber length. We discuss these widespread changes in DTI parameters in terms of axonal degeneration and potential reorganization, with reference to a resting state fMRI companion paper (Harris et al., 2016, Exp. Neurol. 227: 124-138) that demonstrated altered functional connectivity data acquired from the same rats used in this study. (C) 2016 Elsevier Inc. All rights reserved.	[Harris, N. G.; Verley, D. R.; Sutton, R. L.] Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA USA; [Gutman, B. A.] Univ So Calif, Dept Neurol, Imaging Genet Ctr, Keck USC Sch Med,Inst Neuroimaging & Informat, Los Angeles, CA USA		Harris, NG (corresponding author), Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA USA.; Harris, NG (corresponding author), UCLA, Dept Neurosurg, David Geffen Sch Med, 300 Stein Plaza,Ste 535,Box 956901, Los Angeles, CA 90095 USA.	ngharris@mednet.ucla.edu	Verley, Derek/J-4550-2015	Verley, Derek/0000-0002-2670-6568; Gutman, Boris/0000-0001-5388-897X; Harris, Neil/0000-0002-1965-6750	UCLA Brain Injury Research Center; NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS091222, NS27544]; MRI Core of the Semel Institute of Neuroscience at UCLA; Intellectual Development and Disabilities Research Center from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [U54HD087101-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD087101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, R01NS091222] Funding Source: NIH RePORTER	Funding source: UCLA Brain Injury Research Center; NIH NINDS NS091222 and NS27544. The project described was also supported in part by the MRI Core of the Semel Institute of Neuroscience at UCLA, which is supported by the Intellectual Development and Disabilities Research Center grant number U54HD087101-01 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development or the National Institutes of Health. NGH is a fellow of The Center for Neuroskills, Bakersfield, California.	Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen S., 2002, J NEUROTRAUM, V19, P1300; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Chiang CW, 2014, NEUROIMAGE, V101, P310, DOI 10.1016/j.neuroimage.2014.06.064; Choe AS, 2012, NMR BIOMED, V25, P900, DOI 10.1002/nbm.1810; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Crum WR, 2013, J NEUROSCI METH, V218, P170, DOI 10.1016/j.jneumeth.2013.05.009; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Douaud G, 2009, NEUROIMAGE, V46, P958, DOI 10.1016/j.neuroimage.2009.03.044; Ennis DB, 2006, MAGN RESON MED, V55, P136, DOI 10.1002/mrm.20741; Haberg A.K., 2014, J NEUROSCI RES; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Harris NG, 2016, EXP NEUROL, V277, P124, DOI 10.1016/j.expneurol.2015.12.020; Harris N, 2009, J NEUROTRAUM, V26, pA37; Harris NG, 2013, J NEUROTRAUM, V30, P1137, DOI 10.1089/neu.2012.2785; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; Harris NG, 2010, J NEUROTRAUM, V27, P1971, DOI 10.1089/neu.2010.1470; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Kindlmann G, 2007, IEEE T MED IMAGING, V26, P1483, DOI 10.1109/TMI.2007.907277; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Laitinen T, 2010, NEUROIMAGE, V51, P521, DOI 10.1016/j.neuroimage.2010.02.077; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Long JA, 2015, J NEUROTRAUM, V32, P598, DOI 10.1089/neu.2014.3563; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mayer A.R., 2010, NEUROLOGY; Mayer AR, 2015, J NEUROTRAUM, V32, P723, DOI 10.1089/neu.2014.3534; Messe A., 2010, HUM BRAIN MAPP; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Paxinos G, 1997, RAT BRAIN STEREOTAXI; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rulseh AM, 2013, J MAGN RESON IMAGING, V38, P1103, DOI 10.1002/jmri.24065; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schlegel AA, 2012, J COGNITIVE NEUROSCI, V24, P1664, DOI 10.1162/jocn_a_00240; Scholz J, 2015, NEUROIMAGE, V107, P182, DOI 10.1016/j.neuroimage.2014.12.003; Scholz J, 2009, NAT NEUROSCI, V12, P1370, DOI 10.1038/nn.2412; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sierra A, 2011, BRAIN STRUCT FUNCT, V216, P123, DOI 10.1007/s00429-010-0299-0; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Valdes-Hernandez Pedro Antonio, 2011, Front Neuroinform, V5, P26, DOI 10.3389/fninf.2011.00026; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zheng X, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00229; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	65	37	38	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JUN	2016	133						129	143		10.1016/j.neuroimage.2016.03.012			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DN4PB	WOS:000377048600012	26975556	Green Accepted			2022-02-06	
J	Kehoe, A; Smith, JE; Bouamra, O; Edwards, A; Yates, D; Lecky, F				Kehoe, A.; Smith, J. E.; Bouamra, O.; Edwards, A.; Yates, D.; Lecky, F.			Older patients with traumatic brain injury present with a higher GCS score than younger patients for a given severity of injury	EMERGENCY MEDICINE JOURNAL			English	Article							GLASGOW COMA SCALE; SEVERE HEAD-INJURY; MAJOR TRAUMA; AGE; EVACUATION; MORTALITY; CRITERIA; TRIAGE; NEED	Introduction Recent evidence suggests that presenting GCS may be higher in older rather than younger patients for an equivalent anatomical severity of traumatic brain injury (TBI). The aim of this study was to confirm these observations using a national trauma database and to test explanatory hypotheses. Methods The Trauma Audit Research Network database was interrogated to identify all adult cases of severe isolated TBI from 1988 to 2013. Cases were categorised by age into those under 65 years and those 65 years and older. Median presenting GCS was compared between the groups at abbreviated injury score (AIS) level (3, 4 and 5). Comparisons were repeated for subgroups defined by mechanism of injury and type of isolated intracranial injury. Results 25 082 patients with isolated TBI met the inclusion criteria, 10 936 in the older group and 14 146 in the younger group. Median or distribution of presenting GCS differed between groups at each AIS level. AIS 3: 14 (11-15) vs 15 (13-15), AIS 4: 14 (9-15) vs 14 (13-15), AIS 5: 9 (4-14) vs 14 (5-15) all p < 0.001. Similar differences between the groups were observed across all mechanisms of injury and types of isolated intracranial injury. We detected no influence of gender on results. Conclusions For an equivalent severity of intracranial injury, presenting GCS is higher in older patients than in the young. This observation is unlikely to be explained by differences in mechanism of injury or types of intracranial injury between the two groups.	[Kehoe, A.; Smith, J. E.] Derriford Hosp, Emergency Dept, Plymouth PL6 8DH, Devon, England; [Kehoe, A.; Smith, J. E.] Univ Plymouth, Peninsula Sch Med, Ctr Clin Trials & Populat Studies, Plymouth PL4 8AA, Devon, England; [Kehoe, A.; Smith, J. E.] Univ Plymouth, Peninsula Sch Dent, Ctr Clin Trials & Populat Studies, Plymouth PL4 8AA, Devon, England; [Smith, J. E.] Royal Ctr Def Med Res & Acad, Acad Dept Mil Emergency Med, Med Directorate, Birmingham, W Midlands, England; [Bouamra, O.; Edwards, A.; Yates, D.; Lecky, F.] Univ Manchester, Hope Hosp, TARN, Salford M6 8HD, Lancs, England; [Lecky, F.] Univ Sheffield, Sch Hlth & Related Res, Hlth Serv, EMRiS Grp,Res Sect, Sheffield, S Yorkshire, England		Kehoe, A (corresponding author), Derriford Hosp, Emergency Dept, Plymouth PL6 8DH, Devon, England.	tony.kehoe@nhs.net	Smith, Jason Edward/H-9380-2013	Smith, Jason Edward/0000-0002-6143-0421; bouamra, omar/0000-0002-3155-4634			Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Hart A, 2001, BRIT MED J, V323, P391, DOI 10.1136/bmj.323.7309.391; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ichwan B, 2015, ANN EMERG MED, V65, P92, DOI 10.1016/j.annemergmed.2014.04.019; JENNETT B, 1976, LANCET, V1, P1031; Kehoe A, 2015, EMERG MED J, V32, P911, DOI 10.1136/emermed-2015-205265; Kehoe A, 2015, EMERG MED J, V32, P613, DOI 10.1136/emermed-2013-203488; Lau D, 2012, J NEUROSURG, V116, P234, DOI 10.3171/2011.7.JNS11396; Mak CHK, 2012, CURR GERIATR REP, V1, P171, DOI 10.1007/s13670-012-0017-2; Nakamura Y, 2012, ANN EMERG MED, V60, P335, DOI 10.1016/j.annemergmed.2012.04.006; Pascual JL, 2013, AM J SURG, V206, P5; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Patel HC, 2010, ACTA NEUROCHIR WIEN, V152, P7; Potter D, 2013, J R Nav Med Serv, V99, P16; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Salottolo K, 2014, JAMA SURG, V149, P727, DOI 10.1001/jamasurg.2014.13; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Wong George K C, 2011, J Emerg Trauma Shock, V4, P346, DOI 10.4103/0974-2700.83861; Xiang HY, 2014, AM J EMERG MED, V32, P997, DOI 10.1016/j.ajem.2014.05.038; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117	26	37	37	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	JUN	2016	33	6					381	+		10.1136/emermed-2015-205180			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	DN2UZ	WOS:000376919800003	26825613	Bronze, Green Published, Green Accepted			2022-02-06	
J	Nicholson, AM; Finch, NA; Almeida, M; Perkerson, RB; van Blitterswijk, M; Wojtas, A; Cenik, B; Rotondo, S; Inskeep, V; Almasy, L; Dyer, T; Peralta, J; Jun, G; Wood, AR; Frayling, TM; Fuchsberger, C; Fowler, S; Teslovich, TM; Manning, AK; Kumar, S; Curran, J; Lehman, D; Abecasis, G; Duggirala, R; Pottier, C; Zahir, HA; Crook, JE; Karydas, A; Mitic, L; Sun, Y; Dickson, DW; Bu, GJ; Herz, J; Yu, G; Miller, BL; Ferguson, S; Petersen, RC; Graff-Radford, N; Blangero, J; Rademakers, R				Nicholson, Alexandra M.; Finch, NiCole A.; Almeida, Marcio; Perkerson, Ralph B.; van Blitterswijk, Marka; Wojtas, Aleksandra; Cenik, Basar; Rotondo, Sergio; Inskeep, Venette; Almasy, Laura; Dyer, Thomas; Peralta, Juan; Jun, Goo; Wood, Andrew R.; Frayling, Timothy M.; Fuchsberger, Christian; Fowler, Sharon; Teslovich, Tanya M.; Manning, Alisa K.; Kumar, Satish; Curran, Joanne; Lehman, Donna; Abecasis, Goncalo; Duggirala, Ravindranath; Pottier, Cyril; Zahir, Haaris A.; Crook, Julia E.; Karydas, Anna; Mitic, Laura; Sun, Ying; Dickson, Dennis W.; Bu, Guojun; Herz, Joachim; Yu, Gang; Miller, Bruce L.; Ferguson, Shawn; Petersen, Ronald C.; Graff-Radford, Neill; Blangero, John; Rademakers, Rosa			Prosaposin is a regulator of progranulin levels and oligomerization	NATURE COMMUNICATIONS			English	Article							FRONTOTEMPORAL LOBAR DEGENERATION; TRAUMATIC BRAIN-INJURY; DISEASE MOUSE MODELS; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH; GENE-EXPRESSION; RISK-FACTOR; PROTEIN; DEMENTIA; SORTILIN	Progranulin (GRN) loss-of-function mutations leading to progranulin protein (PGRN) haploinsufficiency are prevalent genetic causes of frontotemporal dementia. Reports also indicated PGRN-mediated neuroprotection in models of Alzheimer's and Parkinson's disease; thus, increasing PGRN levels is a promising therapeutic for multiple disorders. To uncover novel PGRN regulators, we linked whole-genome sequence data from 920 individuals with plasma PGRN levels and identified the prosaposin (PSAP) locus as a new locus significantly associated with plasma PGRN levels. Here we show that both PSAP reduction and overexpression lead to significantly elevated extracellular PGRN levels. Intriguingly, PSAP knockdown increases PGRN monomers, whereas PSAP overexpression increases PGRN oligomers, partly through a protein-protein interaction. PSAP-induced changes in PGRN levels and oligomerization replicate in human-derived fibroblasts obtained from a GRN mutation carrier, further supporting PSAP as a potential PGRN-related therapeutic target. Future studies should focus on addressing the relevance and cellular mechanism by which PGRN oligomeric species provide neuroprotection.	[Nicholson, Alexandra M.; Finch, NiCole A.; Perkerson, Ralph B.; van Blitterswijk, Marka; Wojtas, Aleksandra; Pottier, Cyril; Zahir, Haaris A.; Crook, Julia E.; Dickson, Dennis W.; Bu, Guojun; Rademakers, Rosa] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Almeida, Marcio; Almasy, Laura; Dyer, Thomas; Peralta, Juan; Kumar, Satish; Curran, Joanne; Duggirala, Ravindranath; Blangero, John] Univ Texas Rio Grande Valley Sch Med, South Texas Diabet & Obes Inst, Brownsville, TX 78520 USA; [Cenik, Basar] Univ Texas Southwestern Med Ctr, Dept Neurosci Mol Genet & Psychiat, Dallas, TX 75390 USA; [Rotondo, Sergio; Ferguson, Shawn] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; [Rotondo, Sergio; Ferguson, Shawn] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06510 USA; [Inskeep, Venette; Sun, Ying] Cincinnati Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH 45229 USA; [Jun, Goo] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA; [Wood, Andrew R.; Frayling, Timothy M.] Univ Exeter, Sch Med, Genet Complex Traits, St Lukes Campus, Exeter EX1 2LU, Devon, England; [Fuchsberger, Christian; Teslovich, Tanya M.; Abecasis, Goncalo] Univ Michigan, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA; [Fowler, Sharon] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Manning, Alisa K.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; [Lehman, Donna] Univ Texas Hlth Sci Ctr, Dept Med Cardiol & Cellular & Struct Biol, San Antonio, TX 78229 USA; [Karydas, Anna; Mitic, Laura; Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA; [Herz, Joachim; Yu, Gang] Univ Texas SW Med Ctr Dallas, Dept Mol Genet Neurosci Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Petersen, Ronald C.] Mayo Clin, Dept Neurol, Rochester, MN 55902 USA; [Graff-Radford, Neill] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA		Rademakers, R (corresponding author), Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA.	rademakers.rosa@mayo.edu	Almasy, Laura/V-3156-2019; Fuchsberger, Christian/ABD-7127-2021; Jun, Goo/M-5235-2016; van Blitterswijk, Marka/H-7274-2012; Manning, Alisa Knodle/ABC-7711-2021; Blangero, John/ABA-7175-2021; van Blitterswijk, Marka/AAL-4126-2021; Jun, Goo/F-1941-2017	Fuchsberger, Christian/0000-0002-5918-8947; Jun, Goo/0000-0003-0891-0204; van Blitterswijk, Marka/0000-0002-3054-7053; van Blitterswijk, Marka/0000-0002-3054-7053; Jun, Goo/0000-0003-0891-0204; Curran, Joanne/0000-0002-6898-155X; Blangero, John/0000-0001-6250-5723; Afonso de Almeida, Marcio Augusto/0000-0002-8114-3892; Peralta, Juan Manuel/0000-0002-8811-5579	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS076471, P50 AG016574, UO1 AG006786, U01 DK085524, U01 DK085584, U01 DK085501, U01 DK085526, U01 DK085545, P01 HL045222, R01 DK047482, R01 DK053889]; Younkin Scholarship; Consortium for Frontotemporal Degeneration Research; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR020547] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01DK085526, U01DK085524, R01DK047482, U01DK085584, U01DK085545, R01DK053889, U01DK085501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS093382, R01NS076471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG006786, P50AG016574] Funding Source: NIH RePORTER	We are deeply indebted to Richard Gibson (deceased) for his many years of commitment to science, the Department of Molecular Genetics at UT Southwestern and for his help with producing anti-progranulin antibodies. We thank the T2D-GENES consortium for sequencing data sharing. This work was funded by NIH grants R01 NS076471, P50 AG016574 and UO1 AG006786 awarded to Rosa Rademakers, the Younkin Scholarship awarded to Alexandra Nicholson, and the Consortium for Frontotemporal Degeneration Research. T2D-GENES Consortium is supported by NIH grants U01 DK085524, U01 DK085584, U01 DK085501, U01 DK085526 and U01 DK085545. The San Antonio Family Studies is supported by NIH grants P01 HL045222, R01 DK047482 and R01 DK053889.	Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Almasy Laura, 2014, BMC Proc, V8, pS2, DOI 10.1186/1753-6561-8-S1-S2; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Banzhaf-Strathmann J, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-16; Bateman A, 1998, J ENDOCRINOL, V158, P145, DOI 10.1677/joe.0.1580145; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; BHANDARI V, 1992, BIOCHEM BIOPH RES CO, V188, P57, DOI 10.1016/0006-291X(92)92349-3; Bossu P, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-65; Brouwers N, 2008, NEUROLOGY, V71, P656, DOI 10.1212/01.wnl.0000319688.89790.7a; Capell A, 2011, J NEUROSCI, V31, P1885, DOI 10.1523/JNEUROSCI.5757-10.2011; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Carrasquillo MM, 2010, AM J HUM GENET, V87, P890, DOI 10.1016/j.ajhg.2010.11.002; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Cenik B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.193433; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Daniel R, 2003, DEV DYNAM, V227, P593, DOI 10.1002/dvdy.10341; Dickson DW, 2010, NEURODEGENER DIS, V7, P170, DOI 10.1159/000289231; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; Gao X, 2010, PROTEIN CELL, V1, P552, DOI 10.1007/s13238-010-0067-1; Gass J, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-33; Gotzl JK, 2014, ACTA NEUROPATHOL, V127, P845, DOI 10.1007/s00401-014-1262-6; He ZH, 1999, CANCER RES, V59, P3222; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Hsiung GYR, 2011, J NEUROL SCI, V300, P28, DOI 10.1016/j.jns.2010.10.009; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Jawaid A, 2009, NEURODEGENER DIS, V6, P219, DOI 10.1159/000258704; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Kohlschutter A, 2009, BRAIN DEV-JPN, V31, P499, DOI 10.1016/j.braindev.2008.12.008; Laird AS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013368; Lefrancois S, 2003, EMBO J, V22, P6430, DOI 10.1093/emboj/cdg629; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; Mateo I, 2013, EUR J NEUROL, V20, P1571, DOI 10.1111/ene.12090; Meyer RC, 2014, BRAIN RES, V1585, P1, DOI 10.1016/j.brainres.2014.08.022; Minami SS, 2014, NAT MED, V20, P1157, DOI 10.1038/nm.3672; Mitchell BD, 1996, CIRCULATION, V94, P2159, DOI 10.1161/01.CIR.94.9.2159; Nguyen AD, 2013, J BIOL CHEM, V288, P8627, DOI 10.1074/jbc.M112.441949; Nicholson AM, 2014, NEUROLOGY, V82, P1871, DOI 10.1212/WNL.0000000000000445; Nuytemans K, 2008, NEUROLOGY, V71, P1147, DOI 10.1212/01.wnl.0000327563.10320.2b; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Okura H, 2010, J ATHEROSCLER THROMB, V17, P568, DOI 10.5551/jat.3921; Petersen RC, 2010, NEUROLOGY, V75, P889, DOI 10.1212/WNL.0b013e3181f11d85; Rademakers R, 2008, HUM MOL GENET, V17, P3631, DOI 10.1093/hmg/ddn257; RECKLIES AD, 1985, BIOCHEM BIOPH RES CO, V131, P402, DOI 10.1016/0006-291X(85)91816-9; Roberts RO, 2008, NEUROEPIDEMIOLOGY, V30, P58, DOI 10.1159/000115751; Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790; Schulze H, 2014, BBA-MOL CELL BIOL L, V1841, P799, DOI 10.1016/j.bbalip.2013.10.015; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Sleegers K, 2009, ANN NEUROL, V65, P603, DOI 10.1002/ana.21621; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Sun Y, 2005, J LIPID RES, V46, P2102, DOI 10.1194/jlr.M500202-JLR200; Sun Y, 2002, MOL GENET METAB, V76, P271, DOI 10.1016/S1096-7192(02)00114-2; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; WERB Z, 1974, J EXP MED, V140, P1482, DOI 10.1084/jem.140.6.1482; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Yuan LB, 2010, J HISTOCHEM CYTOCHEM, V58, P287, DOI 10.1369/jhc.2009.955203	63	37	38	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	JUN	2016	7								11992	10.1038/ncomms11992			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DQ3NN	WOS:000379109100001	27356620	gold, Green Submitted, Green Published			2022-02-06	
J	Ponsford, JL; Spitz, G; McKenzie, D				Ponsford, Jennie L.; Spitz, Gershon; McKenzie, Dean			Using Post-Traumatic Amnesia To Predict Outcome after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						outcome prediction; post-traumatic amnesia; traumatic brain injury	GLASGOW COMA SCALE; HEAD-INJURY; MULTICENTER; SEVERITY; DURATION; UTILITY	Duration of post-traumatic amnesia (PTA) has emerged as a strong measure of injury severity after traumatic brain injury (TBI). Despite the growing international adoption of this measure, there remains a lack of consistency in the way in which PTA duration is used to classify severity of injury. This study aimed to establish the classification of PTA that would best predict functional or productivity outcomes. We conducted a cohort study of 1041 persons recruited from inpatient admissions to a TBI rehabilitation center between 1985 and 2013. Participants had a primary diagnosis of TBI, emerged from PTA before discharge from inpatient hospital, and engaged in productive activities before injury. Eight models that classify duration of PTA were evaluatedsix that were based on the literature and two that were statistically driven. Models were assessed using area under the receiver operating characteristic curve (AUC) as well as model-based Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) statistics. All categorization models showed longer PTA to be associated with a greater likelihood of being nonproductive at 1 year after TBI. Classification systems with a greater number of categories performed better than two-category systems. The dimensional (continuous) form of PTA resulted in the greatest AUC, and lowest AIC as well as BIC, of the classification systems examined. This finding indicates that the greatest accuracy in prognosis is likely to be achieved using PTA as a continuous variable. This enables the probability of productive outcomes to be estimated with far greater precision than that possible using a classification system. Categorizing PTA to classify severity of injury may be reducing the precision with which clinicians can plan the treatment of patients after TBI.	[Ponsford, Jennie L.; Spitz, Gershon] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Ponsford, Jennie L.; Spitz, Gershon] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [McKenzie, Dean] Epworth Healthcare, Res Dev & Governance, Melbourne, Vic, Australia; [McKenzie, Dean] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia		Ponsford, JL (corresponding author), Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia.	Jennie.Ponsford@monash.edu	Spitz, Gershon/H-7755-2014	Spitz, Gershon/0000-0002-7810-1480	Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR)	This project is funded by the Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR).	Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Breiman L., 1984, CLASSIFICATION REGRE; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Chatterjee S., 2012, REGRESSION ANAL EXAM, V5th ed; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Field A., 2018, DISCOVERING STAT USI, V5th ed.; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Jennett B, 1981, MANAGEMENT HEAD INJU; MacCallum RC, 2002, PSYCHOL METHODS, V7, P19, DOI 10.1037//1082-989X.7.1.19; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Osborne J.W., 2015, BEST PRACTICES LOGIS; Ponsford J., 2012, TRAUMATIC BRAIN INJU, V2nd Edition; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Salford Systems, 2013, CART VERS 7; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; StataCorp, 2011, STAT STAT SOFTW REL; Symonds C., 1943, LANCET, V241, P7, DOI DOI 10.1016/S0140-6736(00)70687-8; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Williams JS, 2011, J HEALTH SERV RES PO, V16, P147, DOI 10.1258/jhsrp.2010.010063	32	37	37	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2016	33	11					997	1004		10.1089/neu.2015.4025			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DN3SU	WOS:000376984600003	26234939				2022-02-06	
J	Shetty, VS; Reis, MN; Aulino, JM; Berger, KL; Broder, J; Choudhri, AF; Kendi, AT; Kessler, MM; Kirsch, CF; Luttrull, MD; Mechtler, LL; Prall, JA; Raksin, PB; Roth, CJ; Sharma, A; West, OC; Wintermark, M; Cornelius, RS; Bykowski, J				Shetty, Vilaas S.; Reis, Martin N.; Aulino, Joseph M.; Berger, Kevin L.; Broder, Joshua; Choudhri, Asim F.; Kendi, A. Tuba; Kessler, Marcus M.; Kirsch, Claudia F.; Luttrull, Michael D.; Mechtler, Laszlo L.; Prall, J. Adair; Raksin, Patricia B.; Roth, Christopher J.; Sharma, Aseem; West, O. Clark; Wintermark, Max; Cornelius, Rebecca S.; Bykowski, Julie			ACR Appropriateness Criteria Head Trauma	JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY			English	Article						Appropriateness Criteria; head trauma; traumatic brain injury; vascular; cerebrospinal fluid leak; neuroimaging	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; NEW-ORLEANS CRITERIA; BRAIN-INJURY; TECHNETIUM-99M-HMPAO SPECT; MILD; CT; MANAGEMENT; VALIDATION; GUIDELINES; RULE	Neuroimaging plays an important role in the management of head trauma. Several guidelines have been published for identifying which patients can avoid neuroimaging. Noncontrast head CT is the most appropriate initial examination in patients with minor or mild acute, closed head injury who require neuroimaging as well as patients with moderate to severe acute closed head injury. In short-term follow-up neuroimaging of acute traumatic brain injury, CT and MRI may have complementary roles. In subacute to chronic traumatic brain injury, MRI is the most appropriate initial examination, though CT may have a complementary role in select circumstances. Advanced neuroimaging techniques are areas of active research but are not considered routine clinical practice at this time. In suspected intracranial vascular injury, CT angiography or venography or MR angiography or venography is the most appropriate imaging study. In suspected posttraumatic cerebrospinal fluid leak, high-resolution noncontrast skull base CT is the most appropriate initial imaging study to identify the source, with cisternography reserved for problem solving. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every three years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.	[Shetty, Vilaas S.] St Louis Univ Hosp, 3635 Vista Ave, St Louis, MO 63110 USA; [Reis, Martin N.] St Louis Univ, Sch Med, St Louis, MO USA; [Aulino, Joseph M.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; [Berger, Kevin L.] Chesapeake Med Imaging, Annapolis, MD USA; [Broder, Joshua] Duke Univ, Div Emergency Med, Cary, NC USA; [Broder, Joshua] Amer Coll Emergency Phys, Irving, TX USA; [Choudhri, Asim F.] Univ Tennessee, Ctr Hlth Sci, Le Bonheur Childrens Hosp, Memphis, TN 38163 USA; [Kendi, A. Tuba] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA; [Kessler, Marcus M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Kirsch, Claudia F.; Luttrull, Michael D.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA; [Mechtler, Laszlo L.] Dent Neurol Inst, Amherst, NY USA; [Mechtler, Laszlo L.] Amer Acad Neurol, Vancouver, BC, Canada; [Prall, J. Adair] Litdeton Adventist Hosp, Littleton, CO USA; [Raksin, Patricia B.] Rush Univ, Chicago, IL 60612 USA; [Roth, Christopher J.] Duke Univ, Med Ctr, Durham, NC USA; [Sharma, Aseem] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA; [West, O. Clark] Univ Texas Houston, Houston, TX USA; [Wintermark, Max] Stanford Med Ctr, Stanford, CA USA; [Cornelius, Rebecca S.] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA; [Bykowski, Julie] Univ Calif San Diego, Ctr Hlth, San Diego, CA 92103 USA		Shetty, VS (corresponding author), St Louis Univ Hosp, 3635 Vista Ave, St Louis, MO 63110 USA.	vshetty@slu.edu	Roth, Christopher/L-3395-2016; Kirsch, Claudia Francoise Eve/H-7122-2019	Roth, Christopher/0000-0002-9634-7126; Kirsch, Claudia Francoise Eve/0000-0002-4978-4198			Almandoz JED, 2010, RADIOLOGY, V255, P570, DOI 10.1148/radiol.10091565; American College of Radiology, ACR APPR CRIT CLIN C; American College of Radiology, ACRAPPROPRIATENESS C; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Baugnon KL, 2014, NEUROIMAG CLIN N AM, V24, P439, DOI 10.1016/j.nic.2014.03.001; Bell RB, 2004, J ORAL MAXIL SURG, V62, P676, DOI 10.1016/j.joms.2003.08.032; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Bousser MG, 2007, LANCET NEUROL, V6, P162, DOI 10.1016/S1474-4422(07)70029-7; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Fiser SM, 1998, AM SURGEON, V64, P1088; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Haydel MJ, 2005, JAMA-J AM MED ASSOC, V294, P1551, DOI 10.1001/jama.294.12.1551; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Khandelwal N, 2006, AM J ROENTGENOL, V187, P1637, DOI 10.2214/AJR.05.1249; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; LANG DA, 1991, ACTA NEUROCHIR, V109, P5, DOI 10.1007/BF01405689; Manolakaki D, 2009, J TRAUMA, V66, P1008, DOI 10.1097/TA.0b013e31819adba2; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; National Collaborating Centre for Acute Care (UK), 2007, HEAD INJ TRIAG ASS I; Patterson BO, 2012, BRIT J SURG, V99, P494, DOI 10.1002/bjs.7763; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Reinus WR, 1996, INVEST RADIOL, V31, P101, DOI 10.1097/00004424-199602000-00007; Reljic T, 2014, J NEUROTRAUM, V31, P78, DOI 10.1089/neu.2013.2873; Rice Dale H, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P19, DOI 10.1097/00020840-200302000-00004; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shutter L, 2006, J HEAD TRAUMA REHAB, V21, P334, DOI 10.1097/00001199-200607000-00005; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stone JA, 1999, AM J NEURORADIOL, V20, P706; Tavender EJ, 2011, ACAD EMERG MED, V18, P880, DOI 10.1111/j.1553-2712.2011.01134.x; TEASDALE G, 1974, LANCET, V2, P81; Wang X, 2014, NEUROL SCI, V35, P1533, DOI 10.1007/s10072-014-1788-3; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; Wei SC, 2010, AM J NEURORADIOL, V31, P334, DOI 10.3174/ajnr.A1824; Wintermark M, 2015, AJNR Am J Neuroradiol, V36, pE1, DOI 10.3174/ajnr.A4181; Wintermark Max, 2015, J Am Coll Radiol, V12, pe1, DOI 10.1016/j.jacr.2014.10.014; Yilmazlar S, 2006, NEUROSURG REV, V29, P64, DOI 10.1007/s10143-005-0396-3; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zacharia TT, 2010, EMERG RADIOL, V17, P97, DOI 10.1007/s10140-009-0842-6; Zapalac JS, 2002, OTOLARYNG HEAD NECK, V126, P669, DOI 10.1067/mhn.2002.125755	65	37	37	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1546-1440			J AM COLL RADIOL	J. Am. Coll. Radiol.	JUN	2016	13	6					668	679		10.1016/j.jacr.2016.02.023			12	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	DN4QY	WOS:000377053500016	27262056				2022-02-06	
J	Vardjan, N; Horvat, A; Anderson, JE; Yu, D; Croom, D; Zeng, X; Luznik, Z; Kreft, M; Teng, YD; Kirov, SA; Zorec, R				Vardjan, Nina; Horvat, Anemari; Anderson, Jamie E.; Yu, Dou; Croom, Deborah; Zeng, Xiang; Luznik, Zala; Kreft, Marko; Teng, Yang D.; Kirov, Sergei A.; Zorec, Robert			Adrenergic Activation Attenuates Astrocyte Swelling Induced by Hypotonicity and Neurotrauma	GLIA			English	Article						astrocytes; contusion trauma; cerebral cortex; spinal cord; cytotoxic edema; epinephrine	BRAIN EDEMA; FUNCTIONAL DEFICITS; WATER-INTOXICATION; VOLUME REGULATION; DENDRITIC INJURY; CELL; RELEASE; CAMP; PHOSPHORYLATION; AQUAPORIN-4	Edema in the central nervous system can rapidly result in life-threatening complications. Vasogenic edema is clinically manageable, but there is no established medical treatment for cytotoxic edema, which affects astrocytes and is a primary trigger of acute post-traumatic neuronal death. To test the hypothesis that adrenergic receptor agonists, including the stress stimulus epinephrine protects neural parenchyma from damage, we characterized its effects on hypotonicity-induced cellular edema in cortical astrocytes by in vivo and in vitro imaging. After epinephrine administration, hypotonicity-induced swelling of astrocytes was markedly reduced and cytosolic 3'-5'-cyclic adenosine monophosphate (cAMP) was increased, as shown by a fluorescence resonance energy transfer nanosensor. Although, the kinetics of epinephrine-induced cAMP signaling was slowed in primary cortical astrocytes exposed to hypotonicity, the swelling reduction by epinephrine was associated with an attenuated hypotonicity-induced cytosolic Ca2+ excitability, which may be the key to prevent astrocyte swelling. Furthermore, in a rat model of spinal cord injury, epinephrine applied locally markedly reduced neural edema around the contusion epicenter. These findings reveal new targets for the treatment of cellular edema in the central nervous system.	[Vardjan, Nina; Kreft, Marko; Zorec, Robert] BIOMEDICAL, Celica, Tehnol Pk 24, Ljubljana 1000, Slovenia; [Vardjan, Nina; Horvat, Anemari; Luznik, Zala; Kreft, Marko; Zorec, Robert] Univ Ljubljana, Fac Med, Inst Pathophysiol, Lab Neuroendocrinol Mol Cell Physiol, Zaloska 4, Ljubljana 1000, Slovenia; [Anderson, Jamie E.; Yu, Dou; Zeng, Xiang; Teng, Yang D.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA; [Anderson, Jamie E.; Yu, Dou; Zeng, Xiang; Teng, Yang D.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Croom, Deborah; Kirov, Sergei A.] Med Coll Georgia, Brain & Behav Discovery Inst, Augusta, GA 30912 USA; [Croom, Deborah; Kirov, Sergei A.] Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA; [Kreft, Marko] Univ Ljubljana, Biotech Fac, Dept Biol, Vecna Pot 111, Ljubljana 1000, Slovenia; [Teng, Yang D.] VA Boston Healthcare Syst, Div SCI Res, Boston, MA USA		Zorec, R (corresponding author), BIOMEDICAL, Celica, Tehnol Pk 24, Ljubljana 1000, Slovenia.; Zorec, R (corresponding author), Univ Ljubljana, Fac Med, Inst Pathophysiol, Lab Neuroendocrinol Mol Cell Physiol, Zaloska 4, Ljubljana 1000, Slovenia.; Teng, YD (corresponding author), Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA.; Teng, YD (corresponding author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.; Kirov, SA (corresponding author), Med Coll Georgia, Brain & Behav Discovery Inst, Augusta, GA 30912 USA.; Kirov, SA (corresponding author), Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA.; Teng, YD (corresponding author), VA Boston Healthcare Syst, Div SCI Res, Boston, MA USA.	yang_teng@hms.harvard.edu; skirov13@gmail.com; robert.zorec@mf.uni-lj.si	Vardjan, Nina/AAP-1496-2021; Zeng, Xiang/AAB-6565-2020; Zorec, Robert/AAD-7180-2021	Zeng, Xiang/0000-0003-4577-749X; Zorec, Robert/0000-0002-7478-3875; Luznik Marzidovsek, Zala/0000-0002-3164-1586	Slovenian Research AgencySlovenian Research Agency - Slovenia [P3 310, J3 4051, J3 3632, J3 6790, J3 4146]; Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins; COST ActionEuropean Cooperation in Science and Technology (COST) [BM1002]; EduGlia ITN EU grant; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS083858]; American Heart AssociationAmerican Heart Association [12GRNT16570006]; US Department of Veterans Affairs Rehabilitation Research and DevelopmentUS Department of Veterans Affairs [B7076R]; US Department of Defense-Center for Integration of Medicine & Innovative Technology grants; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS083858, R01NS083858] Funding Source: NIH RePORTER	We thank Dr. Martin Lohse and Dr. Viacheslav Olegowitsch Nikolaev (University of Wurzburg, Wurzburg, Germany) for providing the Epac1-camps FRET plasmid construct. We also thank Ursa Gubensek for assistance with the experiments. This work was supported by the Slovenian Research Agency (P3 310 to R.Z., J3 4051 to R.Z., J3 3632 to R.Z., J3 6790 to R.Z., J3 4146 to M.K.), the Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins to R.Z., the COST Action BM1002 to R.Z., the EduGlia ITN EU grant to R.Z., the National Institute of Health (NS083858 to S.A.K.), the American Heart Association (12GRNT16570006 to S.A.K.), the US Department of Veterans Affairs Rehabilitation Research and Development (B7076R to Y.D.T.), and the US Department of Defense-Center for Integration of Medicine & Innovative Technology grants to Y.D.T.	Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; Appaix F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035169; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; BENDER AS, 1992, CAN J PHYSIOL PHARM, V70, pS362, DOI 10.1139/y92-284; Betzenhauser MJ, 2009, J BIOL CHEM, V284, P25116, DOI 10.1074/jbc.M109.010132; Borner S, 2011, NAT PROTOC, V6, P427, DOI 10.1038/nprot.2010.198; Conner MT, 2012, J BIOL CHEM, V287, P11516, DOI 10.1074/jbc.M111.329219; Darby M, 2003, J NEUROPHYSIOL, V89, P1870, DOI 10.1152/jn.00510.2002; Dredge BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021585; Fischer R, 1997, GLIA, V20, P51; Galizia L, 2012, J CELL BIOCHEM, V113, P580, DOI 10.1002/jcb.23382; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054/ceca.1999.0095; Green R, 2015, CLIN LAB MED, V35, P1, DOI 10.1016/j.cll.2014.11.003; Harukuni Izumi, 2002, J Anesth, V16, P229, DOI 10.1007/s005400200030; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Horvat A, 2016, CELL CALCIUM, V59, P156, DOI 10.1016/j.ceca.2016.01.002; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Khanna A, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.10.FOCUS13404; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kirischuk S, 1996, EUR J NEUROSCI, V8, P1198, DOI 10.1111/j.1460-9568.1996.tb01288.x; Kozler P, 2013, PHYSIOL RES, V62, pS75, DOI 10.33549/physiolres.932566; KramerGuth A, 1997, AM J PHYSIOL-CELL PH, V273, pC1409, DOI 10.1152/ajpcell.1997.273.4.C1409; Liu XB, 2006, J BIOL CHEM, V281, P15485, DOI 10.1074/jbc.M600549200; Liu XZ, 1997, J NEUROSCI, V17, P5395; Malarkey EB, 2008, NEUROCHEM INT, V52, P142, DOI 10.1016/j.neuint.2007.06.005; Mamenko M, 2013, J BIOL CHEM, V288, P20306, DOI 10.1074/jbc.M113.466797; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; NAGELHUS EA, 1993, NEUROSCIENCE, V54, P615, DOI 10.1016/0306-4522(93)90233-6; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; Nimmerjahn A, 2004, NAT METHODS, V1, P31, DOI 10.1038/nmeth706; Nolte C, 2001, GLIA, V33, P72; OCONNOR ER, 1993, J NEUROSCI, V13, P2638, DOI 10.1523/JNEUROSCI.13-06-02638.1993; Pangrsic T, 2006, J NEUROCHEM, V99, P514, DOI 10.1111/j.1471-4159.2006.04042.x; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Potokar M, 2013, GLIA, V61, P917, DOI 10.1002/glia.22485; Potokar M, 2009, BIOCHEM BIOPH RES CO, V390, P1192, DOI 10.1016/j.bbrc.2009.10.119; Raslan Ahmed, 2007, Neurosurg Focus, V22, pE12; Reetz G, 1997, NEUROCHEM RES, V22, P621, DOI 10.1023/A:1022430305491; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Risher WC, 2009, GLIA, V57, P207, DOI 10.1002/glia.20747; SALM AK, 1989, GLIA, V2, P346, DOI 10.1002/glia.440020507; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; SELYE H, 1967, SCIENCE, V156, P1262, DOI 10.1126/science.156.3779.1262; SHAIN W, 1987, J CELL BIOL, V105, P2307, DOI 10.1083/jcb.105.5.2307; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Song YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034936; Srinivas SP, 2004, EXP EYE RES, V78, P15, DOI 10.1016/j.exer.2003.10.001; Stokum JA, 2015, J CEREB BLOOD FLOW M; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; TAUC M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P278, DOI 10.1016/0167-4889(90)90222-Y; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Teng YD, 1997, J NEUROSCI, V17, P4359; Thrane AS, 2014, TRENDS NEUROSCI, V37, P620, DOI 10.1016/j.tins.2014.08.010; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Vardjan N, 2014, GLIA; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Wang YF, 2013, GLIA, V61, P529, DOI 10.1002/glia.22453; Wurm A, 2010, J NEUROCHEM, V112, P1261, DOI 10.1111/j.1471-4159.2009.06541.x; YAGODIN S, 1995, MOL CELL BIOCHEM, V149, P137, DOI 10.1007/BF01076572; Yamaguchi M, 1997, ACT NEUR S, V70, P152; Yoshioka A, 1998, J NEUROCHEM, V70, P2416; Yu D, 2013, P NATL ACAD SCI USA, V110, pE746, DOI 10.1073/pnas.1300083110; Zorec R, 2012, ASN NEUROL, V4	69	37	38	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUN	2016	64	6					1034	1049		10.1002/glia.22981			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DJ6ME	WOS:000374326600012	27018061	Green Accepted			2022-02-06	
J	Barekat, A; Gonzalez, A; Mauntz, RE; Kotzebue, RW; Molina, B; El-Mecharrafie, N; Conner, CJ; Garza, S; Melkani, GC; Joiner, WJ; Lipinski, MM; Finley, KD; Ratliff, EP				Barekat, Ayeh; Gonzalez, Arysa; Mauntz, Ruth E.; Kotzebue, Roxanne W.; Molina, Brandon; El-Mecharrafie, Nadja; Conner, Catherine J.; Garza, Shannon; Melkani, Girish C.; Joiner, William J.; Lipinski, Marta M.; Finley, Kim D.; Ratliff, Eric P.			Using Drosophila as an integrated model to study mild repetitive traumatic brain injury	SCIENTIFIC REPORTS			English	Article							MOUSE MODEL; CELL-DEATH; AUTOPHAGY; SLEEP; CONSEQUENCES; MELANOGASTER; CONCUSSION; GUIDELINES; LONGEVITY; PROTEINS	Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide. In addition, there has been a growing appreciation that even repetitive, milder forms of TBI (mTBI) can have long-term deleterious consequences to neural tissues. Hampering our understanding of genetic and environmental factors that influence the cellular and molecular responses to injury has been the limited availability of effective genetic model systems that could be used to identify the key genes and pathways that modulate both the acute and long-term responses to TBI. Here we report the development of a severe and mild-repetitive TBI model using Drosophila. Using this system, key features that are typically found in mammalian TBI models were also identified in flies, including the activation of inflammatory and autophagy responses, increased Tau phosphorylation and neuronal defects that impair sleep-related behaviors. This novel injury paradigm demonstrates the utility of Drosophila as an effective tool to validate genetic and environmental factors that influence the whole animal response to trauma and to identify prospective therapies needed for the treatment of TBI.	[Barekat, Ayeh; Gonzalez, Arysa; Mauntz, Ruth E.; Kotzebue, Roxanne W.; Molina, Brandon; El-Mecharrafie, Nadja; Finley, Kim D.; Ratliff, Eric P.] San Diego State Univ, Donald P Shiley BioSci Ctr, San Diego, CA 92182 USA; [Barekat, Ayeh; Kotzebue, Roxanne W.; Molina, Brandon; El-Mecharrafie, Nadja; Conner, Catherine J.; Garza, Shannon; Melkani, Girish C.; Finley, Kim D.; Ratliff, Eric P.] San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; [Joiner, William J.] San Diego State Univ, Dept Pharmacol, San Diego, CA 92182 USA; [Lipinski, Marta M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Lipinski, Marta M.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Finley, Kim D.; Ratliff, Eric P.] San Diego State Univ, Dept Chem, San Diego, CA 92182 USA		Finley, KD; Ratliff, EP (corresponding author), San Diego State Univ, Donald P Shiley BioSci Ctr, San Diego, CA 92182 USA.; Finley, KD; Ratliff, EP (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.; Finley, KD; Ratliff, EP (corresponding author), San Diego State Univ, Dept Chem, San Diego, CA 92182 USA.	kfinley@mail.sdsu.edu; eratliff@mail.sdsu.edu		Melkani, Girish/0000-0003-0353-4633; Lipinski, Marta/0000-0002-7537-9014	NIH/NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG039628]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG039628] Funding Source: NIH RePORTER	We would like to thank Dr. James Atwood, TJ Gray, and Shari Garrett at Omni International for generating high speed videos and providing kinetic energy calculations of the flies undergoing traumatic injury using the Bead Ruptor system. We would also like to thank Dr. Natalie A. Gude and Dr. Mark A. Sussman for use of and expert assistance with the Leica SP8 confocal microscope and Dr. Sanford I. Bernstein and Dr. Greg L. Harris for helpful discussions. This work was supported by R01AG039628 from NIH/NIA (KDF).	Bartlett BJ, 2011, AUTOPHAGY, V7, P572, DOI 10.4161/auto.7.6.14943; Blake MR, 2015, NEUROBIOL DIS, V77, P117, DOI 10.1016/j.nbd.2015.02.012; DeVorkin Lindsay, 2014, Cold Spring Harb Protoc, V2014, P959, DOI 10.1101/pdb.prot080333; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Joiner WJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003605; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Katzenberger RJ, 2015, FLY, V9, P68, DOI 10.1080/19336934.2015.1085623; Katzenberger RJ, 2015, ELIFE, V4, DOI 10.7554/eLife.04790; Katzenberger RJ, 2013, P NATL ACAD SCI USA, V110, pE4152, DOI 10.1073/pnas.1316895110; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Kobeissy F., 2015, BRAIN NEUROTRAUMA MO; Koh K, 2006, P NATL ACAD SCI USA, V103, P13843, DOI 10.1073/pnas.0605903103; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Lipinski MM, 2015, NEURAL REGEN RES, V10, P892, DOI 10.4103/1673-5374.158344; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mullington JM, 2010, BEST PRACT RES CL EN, V24, P775, DOI 10.1016/j.beem.2010.08.014; Nagy P, 2015, METHODS, V75, P151, DOI 10.1016/j.ymeth.2014.11.016; Nezis IP, 2008, J CELL BIOL, V180, P1065, DOI 10.1083/jcb.200711108; Nezis Ioannis P, 2012, Int J Cell Biol, V2012, P146767, DOI 10.1155/2012/146767; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Peschel N, 2011, FEBS LETT, V585, P1435, DOI 10.1016/j.febslet.2011.02.028; Ratliff EP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132768; Rera M, 2012, P NATL ACAD SCI USA, V109, P21528, DOI 10.1073/pnas.1215849110; Rera M, 2011, CELL METAB, V14, P623, DOI 10.1016/j.cmet.2011.09.013; Rieger D, 2006, J NEUROSCI, V26, P2531, DOI 10.1523/JNEUROSCI.1234-05.2006; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Sehgal A, 2011, CELL, V146, P194, DOI 10.1016/j.cell.2011.07.004; Simon AF, 2006, MECH AGEING DEV, V127, P647, DOI 10.1016/j.mad.2006.02.006; Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Takats S, 2013, J CELL BIOL, V201, P531, DOI 10.1083/jcb.201211160; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178	55	37	37	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAY 4	2016	6								25252	10.1038/srep25252			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL1YC	WOS:000375428200002	27143646	Green Published, Green Submitted, gold			2022-02-06	
J	Guardado, P; Olivera, A; Rusch, HL; Roy, M; Martin, C; Lejbman, N; Lee, H; Gill, JM				Guardado, Pedro; Olivera, Anlys; Rusch, Heather L.; Roy, Michael; Martin, Christiana; Lejbman, Natasha; Lee, Hwyunhwa; Gill, Jessica M.			Altered gene expression of the innate immune, neuroendocrine, and nuclear factor-kappa B (NF-kappa B) systems is associated with posttraumatic stress disorder in military personnel	JOURNAL OF ANXIETY DISORDERS			English	Article						Gene expression; Innate immune; Neuroendocrine; NF-kappa B; PTSD; Trauma	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; COMBAT VETERANS; IMPROVED SLEEP; ANIMAL-MODEL; PTSD RISK; SYMPTOMS; MEMORY; HIPPOCAMPAL; DEPRESSION	Whole transcriptome analysis provides an unbiased examination of biological activity, and likely, unique insight into the mechanisms underlying posttraumatic stress disorder (PTSD) and comorbid depression and traumatic brain injury. This study compared gene-expression profiles in military personnel with PTSD (n =28) and matched controls without PTSD (n =27) using HG-U133 Plus 2.0 microarrays (Affymetrix), which contain 54,675 probe sets representing more than 38,500 genes. Analysis of expression profiles revealed 203 differentially expressed genes in PTSD, of which 72% were upregulated. Using Partek Genomics Suite 6.6, differentially expressed transcription clusters were filtered based on a selection criterion of <= 1.5 relative fold change at a false discovery rate of <= 5%. Ingenuity Pathway Analysis (Qiagen) of the differentially expressed genes indicated a dysregulation of genes associated with the innate immune, neuroendocrine, and NF-kappa B systems. These findings provide novel insights that may lead to new pharmaceutical agents for PTSD treatments and help mitigate mental and physical comorbidity risk. (c) 2016 Published by Elsevier Ltd.	[Guardado, Pedro; Olivera, Anlys; Rusch, Heather L.; Martin, Christiana; Lejbman, Natasha; Gill, Jessica M.] NINR, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Rusch, Heather L.] Henry M Jackson Fdn Adv Mil Med, 6720A Rockledge Dr 100, Bethesda, MD 20817 USA; [Roy, Michael] Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Lee, Hwyunhwa] Univ Nevada, Sch Nursing, 4505 South Maryland Pkwy, Las Vegas, NV 89154 USA		Gill, JM (corresponding author), 1 Cloister Court 256, Bethesda, MD 20892 USA.	gillj@mail.nih.gov	Gill, Gill M/Q-2020-2017	Rusch, Heather/0000-0002-4061-8628; Martin, Christiana/0000-0002-4484-6134			Acheson DT, 2012, NEUROPHARMACOLOGY, V62, P674, DOI 10.1016/j.neuropharm.2011.04.029; Anderson G, 2015, ADV INTEGR MED, V2, P31, DOI 10.1016/j.aimed.2014.12.007; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Beck IME, 2009, ENDOCR REV, V30, P830, DOI 10.1210/er.2009-0013; Breen MS, 2015, MOL PSYCHIAT; Buckenmaier C, 2010, CURR PAIN HEADACHE R, V14, P1, DOI 10.1007/s11916-009-0090-1; Cohen H, 2014, EUR NEUROPSYCHOPHARM, V24, P1925, DOI 10.1016/j.euroneuro.2014.09.009; Cohen H, 2011, NEUROPSYCHOPHARMACOL, V36, P2286, DOI 10.1038/npp.2011.118; de Kloet CS, 2007, MOL PSYCHIATR, V12, P443, DOI 10.1038/sj.mp.4001934; Deppermann S, 2014, NEUROSCIENCE, V283, P166, DOI 10.1016/j.neuroscience.2014.08.037; Edwards R. D., 2010, NATL BUREAU EC RES W, V38; Fuchikami M, 2016, PROG NEURO-PSYCHOPH, V64, P320, DOI 10.1016/j.pnpbp.2015.03.010; Garate I, 2013, BIOL PSYCHIAT, V73, P32, DOI 10.1016/j.biopsych.2012.07.005; Gill J, 2014, PSYCHIAT RES, V216, P116, DOI 10.1016/j.psychres.2014.01.046; Gill J, 2010, BIOL PSYCHIAT, V68, P999, DOI 10.1016/j.biopsych.2010.07.033; Gill J, 2008, J TRAUMA STRESS, V21, P530, DOI 10.1002/jts.20372; Gill JM, 2013, J PSYCHOSOM RES, V74, P301, DOI 10.1016/j.jpsychores.2012.10.013; Gill JM, 2009, PERSPECT PSYCHIATR C, V45, P262, DOI 10.1111/j.1744-6163.2009.00229.x; Glatt SJ, 2013, AM J MED GENET B, V162B, P313, DOI 10.1002/ajmg.b.32167; Gupte R, 2013, P NATL ACAD SCI USA, V110, P14616, DOI 10.1073/pnas.1309898110; Heinzelmann M., 2014, MILITARY PERSONNEL B; Heinzelmann M, 2014, SLEEP MED, V15, P1565, DOI 10.1016/j.sleep.2014.08.004; Heinzelmann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00198; Hollifield M, 2013, MOL MED REP, V8, P238, DOI 10.3892/mmr.2013.1475; Irwin MR, 2011, NAT REV IMMUNOL, V11, P625, DOI 10.1038/nri3042; Jovanovic T., 2015, BIOL PSYCHIAT, V11, P954; Kubo Y, 2012, PHARMACOL BIOCHEM BE, V102, P495, DOI 10.1016/j.pbb.2012.06.017; Labarthe A, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00163; Laudenslager ML, 1998, BRAIN BEHAV IMMUN, V12, P74, DOI 10.1006/brbi.1997.0513; Liberzon I, 2014, JAMA PSYCHIAT, V71, P1174, DOI 10.1001/jamapsychiatry.2014.999; Livingston WS, 2015, FRONT PSYCHIATRY, V6, DOI 10.3389/fpsyt.2015.00059; Logue MW, 2015, PSYCHONEUROENDOCRINO, V57, P1, DOI 10.1016/j.psyneuen.2015.03.016; McGowan Patrick O, 2013, Front Psychiatry, V4, P110, DOI 10.3389/fpsyt.2013.00110; Mehta D, 2012, NEUROPHARMACOLOGY, V62, P654, DOI 10.1016/j.neuropharm.2011.03.009; Miller GE, 2008, BIOL PSYCHIAT, V64, P266, DOI 10.1016/j.biopsych.2008.03.017; Morris P, 2004, PSYCHONEUROENDOCRINO, V29, P269, DOI 10.1016/S0306-4530(03)00027-1; MULLER KE, 1992, J AM STAT ASSOC, V87, P1209, DOI 10.2307/2290663; MULLER KE, 1992, NEUROTOXICOL TERATOL, V14, P211, DOI 10.1016/0892-0362(92)90019-7; Pace TWW, 2006, AM J PSYCHIAT, V163, P1630, DOI 10.1176/appi.ajp.163.9.1630; Pace TWW, 2011, BRAIN BEHAV IMMUN, V25, P6, DOI 10.1016/j.bbi.2010.10.003; Ramos BP, 2005, BIOL PSYCHIAT, V58, P894, DOI 10.1016/j.biopsych.2005.05.022; Rusch HL, 2015, J CLIN SLEEP MED, V11, P615, DOI 10.5664/jcsm.4770; Sarapas C, 2011, DIS MARKERS, V30, P101, DOI [10.1155/2011/328054, 10.3233/DMA-2011-0764]; Shvil E, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0358-3; Smith AK, 2011, AM J MED GENET B, V156B, P700, DOI 10.1002/ajmg.b.31212; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Suh HS, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-37; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Tylee DS, 2015, PSYCHONEUROENDOCRINO, V51, P472, DOI 10.1016/j.psyneuen.2014.09.024; Tylee DS, 2013, AM J MED GENET B, V162, P595, DOI 10.1002/ajmg.b.32150; Uddin M, 2010, P NATL ACAD SCI USA, V107, P9470, DOI 10.1073/pnas.0910794107; Uher R, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00048; van Liempt S, 2013, PSYCHONEUROENDOCRINO, V38, P155, DOI 10.1016/j.psyneuen.2012.05.015; van Liempt S, 2011, PSYCHONEUROENDOCRINO, V36, P1361, DOI 10.1016/j.psyneuen.2011.03.009; Van Voorhees EE, 2014, AGGRESSIVE BEHAV, V40, P582, DOI 10.1002/ab.21554; van Zuiden M, 2013, BRAIN BEHAV IMMUN, V30, P12, DOI 10.1016/j.bbi.2012.08.015; van Zuiden M, 2012, PSYCHONEUROENDOCRINO, V37, P1822, DOI 10.1016/j.psyneuen.2012.03.018; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Williams SG, 2015, SLEEP BREATH, V19, P175, DOI 10.1007/s11325-014-0984-y; Wilson CB, 2014, BEHAV BRAIN RES, V268, P72, DOI 10.1016/j.bbr.2014.03.029; Xing GQ, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00196; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zimmerman G, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.4; Zoladz PR, 2013, NEUROSCI BIOBEHAV R, V37, P860, DOI 10.1016/j.neubiorev.2013.03.024	65	37	37	0	22	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6185	1873-7897		J ANXIETY DISORD	J. Anxiety Disord.	MAR	2016	38						9	20		10.1016/j.janxdis.2015.12.004			12	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Psychiatry	DF6EQ	WOS:000371449100002	26751122				2022-02-06	
J	Guley, NH; Rogers, JT; Del Mar, NA; Deng, YP; Islam, RM; D'Surney, L; Ferrell, J; Deng, BW; Hines-Beard, J; Bu, W; Ren, HL; Elberger, AJ; Marchetta, JG; Rex, TS; Honig, MG; Reiner, A				Guley, Natalie H.; Rogers, Joshua T.; Del Mar, Nobel A.; Deng, Yunping; Islam, Rafiqul M.; D'Surney, Lauren; Ferrell, Jessica; Deng, Bowei; Hines-Beard, Jessica; Bu, Wei; Ren, Huiling; Elberger, Andrea J.; Marchetta, Jeffrey G.; Rex, Tonia S.; Honig, Marcia G.; Reiner, Anton			A Novel Closed-Head Model of Mild Traumatic Brain Injury Using Focal Primary Overpressure Blast to the Cranium in Mice	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; mild TBI; motor deficits; overpressure blast; visual deficits	CONTROLLED CORTICAL IMPACT; POSTTRAUMATIC-STRESS-DISORDER; STRIATAL PROJECTION NEURON; FLUID PERCUSSION INJURY; GAMMA PKC-GAMMA; MOUSE MODEL; CONTRAST SENSITIVITY; AXONAL INJURY; ANIMAL-MODEL; OPTIC-NERVE	Mild traumatic brain injury (TBI) from focal head impact is the most common form of TBI in humans. Animal models, however, typically use direct impact to the exposed dura or skull, or blast to the entire head. We present a detailed characterization of a novel overpressure blast system to create focal closed-head mild TBI in mice. A high-pressure air pulse limited to a 7.5mm diameter area on the left side of the head overlying the forebrain is delivered to anesthetized mice. The mouse eyes and ears are shielded, and its head and body are cushioned to minimize movement. This approach creates mild TBI by a pressure wave that acts on the brain, with minimal accompanying head acceleration-deceleration. A single 20-psi blast yields no functional deficits or brain injury, while a single 25-40psi blast yields only slight motor deficits and brain damage. By contrast, a single 50-60psi blast produces significant visual, motor, and neuropsychiatric impairments and axonal damage and microglial activation in major fiber tracts, but no contusive brain injury. This model thus reproduces the widespread axonal injury and functional impairments characteristic of closed-head mild TBI, without the complications of systemic or ocular blast effects or head acceleration that typically occur in other blast or impact models of closed-skull mild TBI. Accordingly, our model provides a simple way to examine the biomechanics, pathophysiology, and functional deficits that result from TBI and can serve as a reliable platform for testing therapies that reduce brain pathology and deficits.	[Guley, Natalie H.; Rogers, Joshua T.; Del Mar, Nobel A.; Deng, Yunping; Islam, Rafiqul M.; D'Surney, Lauren; Ferrell, Jessica; Deng, Bowei; Bu, Wei; Ren, Huiling; Elberger, Andrea J.; Honig, Marcia G.; Reiner, Anton] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA; [D'Surney, Lauren; Hines-Beard, Jessica; Rex, Tonia S.; Reiner, Anton] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN 38163 USA; [Hines-Beard, Jessica; Rex, Tonia S.] Vanderbilt Univ, Dept Ophthalmol & Visual Sci, 221 Kirkland Hall, Nashville, TN 37235 USA; [Marchetta, Jeffrey G.] Univ Memphis, Dept Mech Engn, Memphis, TN 38152 USA; [Islam, Rafiqul M.] Bangladesh Agr Univ, Dept Anat & Histol, Mymensingh, Bangladesh		Reiner, A (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA.	areiner@uthsc.edu	Reiner, Anton/AAG-8860-2020	Reiner, Anton/0000-0002-2146-5232	NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY022349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS081370] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY-005298, EY-022349] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-081370] Funding Source: Medline		ABE H, 1993, OPHTHALMOLOGICA, V207, P100, DOI 10.1159/000310413; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Akimov NP, 2012, BEHAV BRAIN RES, V226, P601, DOI 10.1016/j.bbr.2011.09.030; Al-Hashmi AM, 2011, EXP BRAIN RES, V215, P293, DOI 10.1007/s00221-011-2896-4; Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Bareyre FM, 2005, NAT MED, V11, P1355, DOI 10.1038/nm1331; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bose P, 2013, J NEUROTRAUM, V30, P1177, DOI 10.1089/neu.2012.2740; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bricker-Anthony C, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0192-5; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cuthbertson S, 2003, INVEST OPHTH VIS SCI, V44, P3713, DOI 10.1167/iovs.02-1207; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; de la Cuadra Patricio, 2007, Journal of Flow Visualization and Image Processing, V14, P355, DOI 10.1615/JFlowVisImageProc.v14.i4.20; Deng YP, 2013, NEUROBIOL DIS, V60, P89, DOI 10.1016/j.nbd.2013.08.009; DILEO MAS, 1992, DIABETES CARE, V15, P620, DOI 10.2337/diacare.15.5.620; DRAGER UC, 1980, J COMP NEUROL, V191, P383, DOI 10.1002/cne.901910306; Drai D, 2001, NEUROSCI BIOBEHAV R, V25, P409, DOI 10.1016/S0149-7634(01)00022-7; Drai D, 2000, J NEUROSCI METH, V96, P119, DOI 10.1016/S0165-0270(99)00194-6; Ebneter A, 2010, INVEST OPHTH VIS SCI, V51, P6448, DOI 10.1167/iovs.10-5284; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M, 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Franklin KBJ., 2012, MOUSE BRAIN STEREOTA; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gorski JA, 2002, J NEUROSCI, V22, P6309; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Hashemi H, 2012, OPHTHALMOLOGY, V119, P541, DOI 10.1016/j.ophtha.2011.08.030; Heffernan ME, 2013, J NEUROTRAUM, V30, P1007, DOI 10.1089/neu.2012.2366; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Hua Y, 2014, J COMPUT NONLIN DYN, V9, DOI 10.1115/1.4026156; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Jasnow AM, 2013, J NEUROSCI, V33, P10396, DOI 10.1523/JNEUROSCI.5539-12.2013; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jovanovic Milos, 2012, Acta Chir Iugosl, V59, P73; Kafkafi N, 2003, BEHAV NEUROSCI, V117, P464, DOI 10.1037/0735-7044.117.3.464; Kafkafi N, 2001, J NEUROSCI METH, V109, P111, DOI 10.1016/S0165-0270(01)00392-2; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; King CE, 1997, NEUROREPORT, V8, P1663; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovacs SK, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00047; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Laksari K, 2014, J MECH BEHAV BIOMED, V32, P132, DOI 10.1016/j.jmbbm.2013.12.021; Lamy Michael, 2011, Ann Adv Automot Med, V55, P125; Li Y, 2011, J NEUROTRAUM, V28, P1767, DOI 10.1089/neu.2010.1687; Lieu A, 2013, J NEUROIMMUNOL, V256, P43, DOI 10.1016/j.jneuroim.2013.01.003; Lipkind D, 2004, J APPL PHYSIOL, V97, P347, DOI 10.1152/japplphysiol.00148.2004; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; MARMOR MF, 1986, BRIT J OPHTHALMOL, V70, P553, DOI 10.1136/bjo.70.7.553; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meade CA, 2000, EXP NEUROL, V166, P307, DOI 10.1006/exnr.2000.7530; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Miller G, 2011, SCIENCE, V333, P517, DOI 10.1126/science.333.6042.517; Miller G, 2011, SCIENCE, V333, P514, DOI 10.1126/science.333.6042.514; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MULLER M, 1988, EXP BRAIN RES, V71, P611, DOI 10.1007/BF00248754; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Ono I., 1980, 24 STAPP CAR CRASH C; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Osier N. D., 2015, J NEUROTRAUMA; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; Redell JB, 2007, NEUROSCI LETT, V413, P36, DOI 10.1016/j.neulet.2006.11.060; Reiner A, 2012, NEUROBIOL DIS, V47, P75, DOI 10.1016/j.nbd.2012.03.025; Reiner A, 2007, J COMP NEUROL, V505, P603, DOI 10.1002/cne.21515; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saito N, 2002, J BIOCHEM, V132, P683, DOI 10.1093/oxfordjournals.jbchem.a003274; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Swan AA, 2011, J NEUROTRAUM, V28, P431, DOI 10.1089/neu.2010.1519; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Taylor PA, 2014, BRAIN INJURY, V28, P879, DOI 10.3109/02699052.2014.888478; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Weinberger S, 2011, NATURE, V477, P390, DOI 10.1038/477390a; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zakaria N, 2012, BRAIN RES, V1467, P81, DOI 10.1016/j.brainres.2012.05.046	155	37	37	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2016	33	4					403	422		10.1089/neu.2015.3886			20	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DD2NH	WOS:000369758800009	26414413	Green Published			2022-02-06	
J	Li, XQ; Fang, B; Tan, WF; Wang, ZL; Sun, XJ; Zhang, ZL; Ma, H				Li, Xiao-Qian; Fang, Bo; Tan, Wen-Fei; Wang, Zhi-Lin; Sun, Xi-Jia; Zhang, Zai-Li; Ma, Hong			miR-320a affects spinal cord edema through negatively regulating aquaporin-1 of blood-spinal cord barrier during bimodal stage after ischemia reperfusion injury in rats	BMC NEUROSCIENCE			English	Article						Blood-spinal cord barrier; MicroRNAs; Aquaporin; Ischemia reperfusion injury	TRAUMATIC BRAIN-INJURY; ISCHEMIA/REPERFUSION INJURY; AQP1 EXPRESSION; UP-REGULATION; PERMEABILITY; DAMAGE; DYSFUNCTION; DISRUPTION; PROTEINS; CELLS	Background: Spinal cord edema is a serious complication and pathophysiological change after ischemia reperfusion (IR) injury. It has been demonstrated closely associated with bimodal disruption of blood-spinal cord barrier (BSCB) in our previous work. Aquaporin (AQP) 1 plays important but contradictory roles in water homeostasis. Recently, microRNAs (miRs) effectively regulate numerous target mRNAs during ischemia. However, whether miRs are able to protect against dimodal disruption of BSCB by regulating perivascular AQP1 remains to be elucidated. Results: Spinal water content and EB extravasation were suggested as a bimodal distribution in directly proportion to AQP1, since all maximal changes were detected at 12 and 48 h after reperfusion. Further TEM and double immunofluorescence showed that former disruption of BSCB at 12 h was attributed to cytotoxic edema by up-regulated AQP1 expressions in astrocytes, whereas the latter at 48 h was mixed with vasogenic edema with both endothelial cells and astrocytes involvement. Microarray analysis revealed that at 12 h post-injury, ten miRs were upregulated (>2.0 fold) and seven miRs were downregulated (<0.5 fold) and at 48 h, ten miRs were upregulated and eleven were downregulated compared to Sham-operated controls. Genomic screening and luciferase assays identified that miR-320a was a potential modulator of AQP1 in spinal cord after IR in vitro. In vivo, compared to rats in IR and negative control group, intrathecal infusion of miR-320a mimic attenuated IR-induced lower limb motor function deficits and BSCB dysfunction as decreased EB extravasation and spinal water content through down-regulating AQP1 expressions, whereas pretreated with miR-320a AMO reversed above effects. Conclusion: These findings indicate miR-320a directly and functionally affects spinal cord edema through negatively regulating AQP1 of BSCB after IR.	[Li, Xiao-Qian; Fang, Bo; Tan, Wen-Fei; Wang, Zhi-Lin; Sun, Xi-Jia; Zhang, Zai-Li; Ma, Hong] China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Shenyang 110001, Liaoning, Peoples R China		Ma, H (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Shenyang 110001, Liaoning, Peoples R China.	mahong5466@yahoo.com		Li, Xiao-Qian/0000-0001-6676-735X	Fund of Doctoral Fund of the Ministry of Education of ChinaMinistry of Education, China [20092104110009]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271370]; Science and Technology Program of Liaoning [2012408002]	Funding for this project was provided by Fund of Doctoral Fund of the Ministry of Education of China (No. 20092104110009), the Natural Science Foundation of China (No. 81271370) and the Science and Technology Program of Liaoning (No. 2012408002).	Aung LL, 2015, J NEUROIMMUNOL, V278, P185, DOI 10.1016/j.jneuroim.2014.11.004; Badaut J, 2003, ACTA NEUROCHIR SUPPL, V86, P495; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Brandenburger T, 2012, NEUROSCI LETT, V506, P281, DOI 10.1016/j.neulet.2011.11.023; Fang B, 2013, J VASC SURG, V58, P1043, DOI 10.1016/j.jvs.2012.11.087; Gao JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046379; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Geis C, 2015, EXP NEUROL, V265, P8, DOI 10.1016/j.expneurol.2014.12.015; He B, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-22; He F, 2015, J THORAC CARDIOV SUR, V150, P398, DOI 10.1016/j.jtcvs.2015.03.066; Huang XN, 2011, ANAT REC, V294, P46, DOI 10.1002/ar.21286; Jin LJ, 2014, MOL BIOL REP, V41, P3169, DOI 10.1007/s11033-014-3176-8; Kim J, 2011, ANAT CELL BIOL, V44, P295, DOI 10.5115/acb.2011.44.4.295; Li XQ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0246-3; Li XQ, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-28; Li XQ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-62; Lopez-Ramirez MA, 2014, FASEB J, V28, P2551, DOI 10.1096/fj.13-248880; Lu H, 2013, CHINESE MED J-PEKING, V126, P4316, DOI 10.3760/cma.j.issn.0366-6999.20131139; Moftakhar P, 2010, J NEUROPATH EXP NEUR, V69, P1201, DOI 10.1097/NEN.0b013e3181fd252c; Mohammadi MT, 2015, PATHOL RES PRACT, V211, P43, DOI 10.1016/j.prp.2014.07.014; Nesic O, 2006, NEUROSCIENCE, V143, P779, DOI 10.1016/j.neuroscience.2006.08.079; Nyberg F, 2002, AMINO ACIDS, V23, P231, DOI 10.1007/s00726-001-0134-2; Oklinski MK, 2014, J HISTOCHEM CYTOCHEM, V62, P598, DOI 10.1369/0022155414537495; Oshio K, 2003, ACT NEUR S, V86, P525; Qiu B, 2014, MOL MED REP, V9, P916, DOI 10.3892/mmr.2014.1899; Ren XP, 2009, CIRCULATION, V119, P2357, DOI 10.1161/CIRCULATIONAHA.108.814145; Schrottmaier WC, 2014, ATHEROSCLEROSIS, V235, P1, DOI 10.1016/j.atherosclerosis.2014.03.026; Sepramaniam S, 2012, J BIOL CHEM, V287, P12006, DOI 10.1074/jbc.M111.280701; Sepramaniam S, 2010, J BIOL CHEM, V285, P29223, DOI 10.1074/jbc.M110.144576; Stokum JA, 2015, NEUROCHEM RES, V40, P317, DOI 10.1007/s11064-014-1374-3; Wang DW, 2011, MOL CELL NEUROSCI, V46, P318, DOI 10.1016/j.mcn.2010.10.003; Wang YF, 2011, BRAIN RES, V1370, P220, DOI 10.1016/j.brainres.2010.11.016; Wang YF, 2009, NEUROREPORT, V20, P145, DOI 10.1097/WNR.0b013e32831c6c44; Wu QB, 2014, J MOL NEUROSCI, V54, P714, DOI 10.1007/s12031-014-0430-4; Yang JCS, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/410721; Zhang J, 2013, NEUROSCIENCE, V252, P68, DOI 10.1016/j.neuroscience.2013.08.006; Zhi XF, 2014, FEBS LETT, V588, P757, DOI 10.1016/j.febslet.2014.01.022	37	37	41	2	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	FEB 5	2016	17								10	10.1186/s12868-016-0243-1			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DC8OH	WOS:000369478400001	26850728	Green Published, gold			2022-02-06	
J	Harris, JP; Struzyna, LA; Murphy, PL; Adewole, DO; Kuo, E; Cullen, DK				Harris, J. P.; Struzyna, L. A.; Murphy, P. L.; Adewole, D. O.; Kuo, E.; Cullen, D. K.			Advanced biomaterial strategies to transplant preformed micro-tissue engineered neural networks into the brain	JOURNAL OF NEURAL ENGINEERING			English	Article						neurotransplantation; transplantation; bioengineering; cell replacement; axonal tracts; tissue engineering; biomaterials	LONG-TERM SURVIVAL; STEM-CELL TRANSPLANTATION; IN-VITRO; FUNCTIONAL RECOVERY; NEURITE OUTGROWTH; CORTICAL-NEURONS; REGENERATION; CONSTRUCTS; MATURATION; MIGRATION	Objective. Connectome disruption is a hallmark of many neurological diseases and trauma with no current strategies to restore lost long-distance axonal pathways in the brain. We are creating transplantable micro-tissue engineered neural networks (micro-TENNs), which are preformed constructs consisting of embedded neurons and long axonal tracts to integrate with the nervous system to physically reconstitute lost axonal pathways. Approach. We advanced micro-tissue engineering techniques to generate micro-TENNs consisting of discrete populations of mature primary cerebral cortical neurons spanned by long axonal fascicles encased in miniature hydrogel micro-columns. Further, we improved the biomaterial encasement scheme by adding a thin layer of low viscosity carboxymethylcellulose (CMC) to enable needle-less insertion and rapid softening for mechanical similarity with brain tissue. Main results. The engineered architecture of cortical micro-TENNs facilitated robust neuronal viability and axonal cytoarchitecture to at least 22 days in vitro. Micro-TENNs displayed discrete neuronal populations spanned by long axonal fasciculation throughout the core, thus mimicking the general systems-level anatomy of gray matter-white matter in the brain. Additionally, micro-columns with thin CMC-coating upon mild dehydration were able to withstand a force of 893 +/- 457 mN before buckling, whereas a solid agarose cylinder of similar dimensions was predicted to withstand less than 150 mu N of force. This thin CMC coating increased the stiffness by three orders of magnitude, enabling needle-less insertion into brain while significantly reducing the footprint of previous needle-based delivery methods to minimize insertion trauma. Significance. Our novel micro-TENNs are the first strategy designed for minimally invasive implantation to facilitate nervous system repair by simultaneously providing neuronal replacement and physical reconstruction of long-distance axon pathways in the brain. The micro-TENN approach may offer the ability to treat several disorders that disrupt the connectome, including Parkinson's disease, traumatic brain injury, stroke, and brain tumor excision.	[Harris, J. P.; Struzyna, L. A.; Murphy, P. L.; Adewole, D. O.; Kuo, E.; Cullen, D. K.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Harris, J. P.; Struzyna, L. A.; Adewole, D. O.; Kuo, E.; Cullen, D. K.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA; [Struzyna, L. A.; Adewole, D. O.] Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA		Cullen, DK (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.; Cullen, DK (corresponding author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.	dkacy@mail.med.upenn.edu		Murphy, Patricia/0000-0002-5843-5440; Harris, James/0000-0002-8458-5434; Adewole, Dayo/0000-0003-4685-6974	Penn Medicine Neuroscience Center; National Science FoundationNational Science Foundation (NSF) [DGE-1321851]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32-NS043126, T32-GM007517]; Department of Veterans Affairs (RRD Merit Review)US Department of Veterans Affairs [B1097-I]; US Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program [W81XWH-13-207 004]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS094340, T32NS043126] Funding Source: NIH RePORTER	Financial support was provided by the Penn Medicine Neuroscience Center, National Science Foundation (Graduate Research Fellowship DGE-1321851), National Institutes of Health (T32-NS043126 & T32-GM007517), Department of Veterans Affairs (RR&D Merit Review #B1097-I), and the US Army Medical Research and Materiel Command through the Joint Warfighter Medical Research Program (#W81XWH-13-207 004). The authors would like to thank Rob Mauck and Mike Hast in the Penn Center for Musculoskeletal Disorders Core for help in mechanical testing. Additional thanks go to Vincent Wu, Norma Alexis Brown, Alan He, Camila Robles-Oteiza, and Parker Schabel for technical contributions.	BAR A, 1995, FOOD CHEM TOXICOL, V33, P909, DOI 10.1016/0278-6915(95)00069-E; BENARI Y, 1994, PROG BRAIN RES, V102, P261; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Borisoff JF, 2003, MOL CELL NEUROSCI, V22, P405, DOI 10.1016/S1044-7431(02)00032-5; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Cancedda L, 2007, J NEUROSCI, V27, P5224, DOI 10.1523/JNEUROSCI.5169-06.2007; Chen G, 1996, J PHYSIOL-LONDON, V494, P451, DOI 10.1113/jphysiol.1996.sp021505; Chen ZJ, 2004, J NEUROSURG, V101, P314, DOI 10.3171/jns.2004.101.2.0314; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Cullen DK, 2007, J NEUROSCI RES, V85, P3642, DOI 10.1002/jnr.21434; Cullen DK, 2007, J NEURAL ENG, V4, P159, DOI 10.1088/1741-2560/4/2/015; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Cullen DK, 2012, TISSUE ENG PT A, V18, P2280, DOI [10.1089/ten.tea.2011.0534, 10.1089/ten.TEA.2011.0534]; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P201; Cullen DK, 2010, BRAIN RES, V1359, P44, DOI 10.1016/j.brainres.2010.08.058; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Deng L, 2007, J NEUROSCI, V27, P10860, DOI 10.1523/JNEUROSCI.2744-07.2007; Denham M, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00011; Dubois-Dauphin ML, 2010, BIOMATERIALS, V31, P7032, DOI 10.1016/j.biomaterials.2010.06.017; Elliot J. H., 1974, Rheologica Acta, V13, P670, DOI 10.1007/BF01527058; FAWCETT JW, 1995, EXP BRAIN RES, V106, P275; Feng XH, 2006, IND ENG CHEM RES, V45, P6665, DOI 10.1021/ie060511f; Filous AR, 2010, DEV NEUROBIOL, V70, P826, DOI 10.1002/dneu.20820; Ghanbarzadeh B, 2011, INT J BIOL MACROMOL, V48, P44, DOI 10.1016/j.ijbiomac.2010.09.014; Grealish S, 2014, CELL STEM CELL, V15, P653, DOI 10.1016/j.stem.2014.09.017; Harris JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/066011; Harris JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046010; Harris James P., 2013, Critical Reviews in Biomedical Engineering, V41, P435; He ZG, 2010, J BIOMED RES, V24, P2, DOI 10.1016/S1674-8301(10)60002-4; Hopkins AM, 2015, PROG NEUROBIOL, V125, P1, DOI 10.1016/j.pneurobio.2014.11.003; Huang JH, 2009, TISSUE ENG PT A, V15, P1677, DOI 10.1089/ten.tea.2008.0294; Irons HR, 2008, J NEURAL ENG, V5, P333, DOI 10.1088/1741-2560/5/3/006; Iwata A, 2006, TISSUE ENG, V12, P101, DOI 10.1089/ten.2006.12.101; Jain A, 2004, J NEUROSCI RES, V77, P299, DOI 10.1002/jnr.20161; Jensen W, 2006, IEEE T BIO-MED ENG, V53, P934, DOI 10.1109/TBME.2006.872824; Karumbaiah L, 2013, BIOMATERIALS, V34, P8061, DOI 10.1016/j.biomaterials.2013.07.016; Kato-Negishi M, 2013, ADV HEALTHC MATER, V2, P1564, DOI 10.1002/adhm.201300052; Kim H J, 2010, BIOCH BIOPHYS ACTA; Kozai TDY, 2014, BIOMATERIALS, V35, P9255, DOI 10.1016/j.biomaterials.2014.07.039; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; LaPlaca MC, 2010, ARTECH HSE METH BIOE, P187; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Liu WM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031675; Mauck RL, 2000, J BIOMECH ENG-T ASME, V122, P252, DOI 10.1115/1.429656; Mine Y, 2013, NEUROBIOL DIS, V52, P191, DOI 10.1016/j.nbd.2012.12.006; Mingorance A, 2006, FASEB J, V20, P491, DOI 10.1096/fj.05-5121fje; Moore MJ, 2006, BIOMATERIALS, V27, P419, DOI 10.1016/j.biomaterials.2005.07.045; Moshayedi P, 2014, BIOMATERIALS, V35, P3919, DOI 10.1016/j.biomaterials.2014.01.038; NAJAFI K, 1990, IEEE T BIO-MED ENG, V37, P474, DOI 10.1109/10.55638; Nguyen JK, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/5/056014; O'Connor SM, 2001, NEUROSCI LETT, V304, P189, DOI 10.1016/S0304-3940(01)01769-4; Orlacchio A, 2010, CURR MED CHEM, V17, P595, DOI 10.2174/092986710790416272; Ouardouz M, 2005, DEV BRAIN RES, V160, P78, DOI 10.1016/j.devbrainres.2005.09.001; Paralikar Kunal J, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P2958; Ren HM, 2013, INT J CLIN EXP PATHO, V6, P230; Seymour JP, 2007, BIOMATERIALS, V28, P3594, DOI 10.1016/j.biomaterials.2007.03.024; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Silva NA, 2010, TISSUE ENG PT A, V16, P45, DOI [10.1089/ten.tea.2008.0559, 10.1089/ten.TEA.2008.0559]; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sinclair SR, 1999, EUR J NEUROSCI, V11, P4341, DOI 10.1046/j.1460-9568.1999.00867.x; Stabenfeldt SE, 2006, J BIOMED MATER RES A, V77A, P718, DOI 10.1002/jbm.a.30638; Stabenfeldt SE, 2010, TISSUE ENG PT A, V16, P3747, DOI [10.1089/ten.tea.2009.0837, 10.1089/ten.TEA.2009.0837]; Stabenfeldt SE, 2011, ACTA BIOMATER, V7, P4102, DOI 10.1016/j.actbio.2011.07.026; Steinschneider R, 1996, DEV BRAIN RES, V95, P15, DOI 10.1016/0165-3806(96)00052-1; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; Struzyna LA, 2015, TISSUE ENG PT A, V21, P2744, DOI [10.1089/ten.tea.2014.0557, 10.1089/ten.TEA.2014.0557]; Struzyna LA, 2015, NEURAL REGEN RES, V10, P679, DOI 10.4103/1673-5374.156943; Sudheimer K D, 2014, HUMAN BRAIN ATLAS; Tang XQ, 2007, J NEUROSCI, V27, P6068, DOI 10.1523/JNEUROSCI.1442-07.2007; Tang-Schomer MD, 2014, P NATL ACAD SCI USA, V111, P13811, DOI 10.1073/pnas.1324214111; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tate MC, 2004, MOL CELL NEUROSCI, V27, P22, DOI 10.1016/j.mcn.2004.05.001; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Tsai EC, 2004, J NEUROTRAUM, V21, P789, DOI 10.1089/0897715041269687; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Vukasinovic J, 2009, BIOMED MICRODEVICES, V11, P1155, DOI 10.1007/s10544-009-9332-6; Wagenaar DA, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-11; Warnock F V, 1965, MECH SOLIDS STRENGTH; Yip PK, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000399; Yoo Sang Jin, 2011, Exp Neurobiol, V20, P110, DOI 10.5607/en.2011.20.2.110	83	37	41	2	42	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	1741-2560	1741-2552		J NEURAL ENG	J. Neural Eng.	FEB	2016	13	1							016019	10.1088/1741-2560/13/1/016019			19	Engineering, Biomedical; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology	DF7XD	WOS:000371570200020	26760138	Green Accepted			2022-02-06	
J	Reynolds, BB; Patrie, J; Henry, EJ; Goodkin, HP; Broshek, DK; Wintermark, M; Druzgal, TJ				Reynolds, Bryson B.; Patrie, James; Henry, Erich J.; Goodkin, Howard P.; Broshek, Donna K.; Wintermark, Max; Druzgal, T. Jason			Practice type effects on head impact in collegiate football	JOURNAL OF NEUROSURGERY			English	Article						biomechanics; football; athlete; subconcussion; traumatic brain injury; accelerometer	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL; EXPOSURE; CONCUSSION; PLAYERS; FREQUENCY	OBJECTIVE This study directly compares the number and severity of subconcussive head impacts sustained during helmet -only practices, shell practices, full -pad practices, and competitive games in a National Collegiate Athletic Association (NCAA) Division I -A football team. The goal of the study was to determine whether subconcussive head impact in collegiate athletes varies with practice type, which is currently unregulated by the NCAA. METHODS Over an entire season, a cohort of 20 collegiate football players wore impact -sensing mastoid patches that measured the linear and rotational acceleration of all head impacts during a total of 890 athletic exposures. Data were analyzed to compare the number of head impacts, head impact burden, and average impact severity during helmet -only, shell, and full -pad practices, and games. RESULTS Helmet -only, shell, and full -pad practices and games all significantly differed from each other (p 5. 0.05) in the mean number of impacts for each event, with the number of impacts being greatest for games, then full -pad practices, then shell practices, and then helmet -only practices. The cumulative distributions for both linear and rotational acceleration differed between all event types (p < 0.01), with the acceleration distribution being similarly greatest for games, then full -pad practices, then shell practices, and then helmet -only practices. For both linear and rotational acceleration, helmet -only practices had a lower average impact severity when compared with other event types (p < 0.001). However, the average impact severity did not differ between any comparisons of shell and full -pad practices, and games. CONCLUSIONS Helmet -only, shell, and full -pad practices, and games result in distinct head impact profiles per event, with each succeeding event type receiving more impacts than the one before. Both the number of head impacts and cumulative impact burden during practice are categorically less than in games. In practice events, the number and cumulative burden of head impacts per event increases with the amount of equipment worn. The average severity of individual impacts is relatively consistent across event types, with the exception of helmet -only -practices. The number of hits experienced during each event type is the main driver of event type differences in impact burden per athletic exposure, rather than the average severity of impacts that occur during the event. These findings suggest that regulation of practice equipment could be a fair and effective way to substantially reduce subconcussive head impact in thousands of collegiate football players.	[Reynolds, Bryson B.; Henry, Erich J.; Druzgal, T. Jason] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA; [Patrie, James] Univ Virginia, Publ Hlth Sci, Charlottesville, VA USA; [Goodkin, Howard P.] Univ Virginia, Dept Neurol, Charlottesville, VA USA; [Broshek, Donna K.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA; [Wintermark, Max] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA		Druzgal, TJ (corresponding author), Univ Virginia Hosp Med Ctr, Div Neuroradiol, Dept Radiol & Med Imaging, Box 800170, Charlottesville, VA 22908 USA.	tjd4m@hscmail.mcc.virginia.edu	Broshek, Donna/ABA-4208-2021	Broshek, Donna/0000-0002-7175-7815; Druzgal, Jason/0000-0001-7240-9487; Goodkin, Howard/0000-0003-0528-4949	UVa Health System Research Award; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2 T32 GM 8328-21]; UVa Department of Radiology and Medical Imaging; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008328] Funding Source: NIH RePORTER	Financial support was provided by a UVa Health System Research Award (T.J.D.), NIH grant 2 T32 GM 8328-21 (B.B.R.), and the UVa Department of Radiology and Medical Imaging (B.B.R., J.P., and T.J.D.). Access to the xPatch impact sensors was obtained through a research agreement with X2 Biosystems.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hardin James W., 2003, GEN ESTIMATING EQUAT, DOI [10.1201/b13880, DOI 10.1201/B13880]; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Johnson B.D., 2014, CONCUSSIONS ATHLETIC, P331, DOI [10.1007/978-1-4939-0295-8_19, DOI 10.1007/978-1-4939-0295-8_19]; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McCulloch CE, 2001, GEN LINEAR MIXED MOD; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; National Collegiate Athletic Association, FOOTB PRACT GUID; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Therneau T.M., 2000, STAT BIOL HEALTH; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036	36	37	38	0	19	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2016	124	2					501	510		10.3171/2015.5.JNS15573			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DB9VR	WOS:000368866300034	26238972	Bronze, Green Accepted			2022-02-06	
J	Taher, A; Pilehvari, Z; Poorolajal, J; Aghajanloo, M				Taher, Abbas; Pilehvari, Zahra; Poorolajal, Jalal; Aghajanloo, Mashhood			Effects of Normobaric Hyperoxia in Traumatic Brain Injury: A Randomized Controlled Clinical Trial	TRAUMA MONTHLY			English	Article						Brain Injuries; Oxygen Inhalation Therapy; Hyperbaric Oxygenation; Glasgow Outcome Scale	HYPERBARIC-OXYGEN THERAPY; ACUTE ISCHEMIC-STROKE; HEAD-INJURY; CEREBRAL METABOLISM; INSPIRED OXYGEN; TISSUE OXYGEN; PENUMBRA; GLUCOSE; IMPROVEMENT; PRESSURE	Background: Traumatic brain injury (TBI) is one of the important causes of morbidity and mortality throughout the world, especially in young people. In recent years normobaric hyperoxia has become an important and useful step for recovery and improvement of outcome in TBI. Objectives: The purpose of this study was to evaluate the effects of normobaric hyperoxia on clinical neurological outcomes of patients with severe traumatic brain injuries. We used the Glasgow outcome scale (GOS), barthel index, and modified rankin scale (mRS) to measure the outcomes of patients with TBI. Patients and Methods: Sixty-eight consecutive patients with severe TBI (mean Glasgow coma scale [GCS] score: 7.4) who met the inclusion criteria were entered in this randomized controlled clinical trial. The patients were randomized into two groups, as follows: 1) experimental: received 80% oxygen via mechanical ventilator in the first 6 hours of admission, 2) control: received 50% oxygen by mechanical ventilator in the first 6 hours of admission and then standard medical care. We measured the GOS, Barthel Index, and mRS at the time of discharge from hospital and reassessed these measurements at the 6-month follow-up after injury. Results: According to our study, there were no significant sex or age differences between the two groups (P = 0.595 and 0.074). The number of days in the intensive care unit (ICU) in the control group and experimental group were 11.4 and 9.4 days, respectively (P = 0.28), while the numbers of days of general ward admission were 13.9 and 11.4 days (P = 0.137) respectively. The status of GOS at time of discharge were severe = 13 and 10, moderate = 16 and 19, and low = 5 and 5 in the control and experimental groups, respectively (P = 0.723); 6 months after injury, the scores were as follows: moderate = 16 and 9, low = 15 and 25, and severe = 3 and 0 (P = 0.024). The Barthel index scores in the control and experimental groups were 59.7 and 63.9 at time of discharge (P = 0.369) and 82.7 and 91.3 at 6 months after injury (P = 0.018), respectively. The mRS results were 2.6 and 2.3 at time of discharge (P = 0.320) and 1.6 and 0.7 at 6 months after injury (P = 0.006) for the control and experimental groups, respectively. Conclusions: According to the results of this study, oxygen therapy by mechanical ventilator in the first 6 hours after injury in patients with severe TBI can improve the final GOS, Barthel index, and mRS scores. It could also improve long-term outcomes and enhance rehabilitation and the quality of life.	[Taher, Abbas; Pilehvari, Zahra] Hamadan Univ Med Sci, Dept Anesthesiol & Crit Care, Hamadan, Iran; [Poorolajal, Jalal] Hamadan Univ Med Sci, Sch Publ Hlth, Dept Epidemiol, Modeling Noncommunicable Dis Res Ctr, Hamadan, Iran; [Aghajanloo, Mashhood] Hamadan Univ Med Sci, Dept Neurosurg, Hamadan, Iran		Pilehvari, Z (corresponding author), Hamadan Univ Med Sci, Besat Hosp, Dept Anesthesiol & Crit Care, Hamadan, Iran.	dr_manijeh@yahoo.com	taher, abbas/G-4808-2017; aghajanloo, mashhood/O-8047-2017; Poorolajal, Jalal/D-3506-2013	taher, abbas/0000-0002-8977-9350; aghajanloo, mashhood/0000-0002-9462-2200; 			Abate MG, 2008, NEUROCRIT CARE, V9, P319, DOI 10.1007/s12028-008-9119-2; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BENNETT MH, 2012, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD004609.PUB3; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; Bulte DP, 2007, J CEREBR BLOOD F MET, V27, P69, DOI 10.1038/sj.jcbfm.9600319; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Kellert L, 2012, CEREBROVASC DIS EXTR, V2, P99, DOI 10.1159/000343731; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Martin DS, 2013, CRIT CARE MED, V41, P423, DOI 10.1097/CCM.0b013e31826a44f6; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Narotam PK, 2013, CRIT CARE, V17, DOI 10.1186/cc13065; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Raj R, 2013, CRIT CARE, V17, DOI 10.1186/cc12856; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Robertson CA, 2011, J CEREBR BLOOD F MET, V31, P1778, DOI 10.1038/jcbfm.2011.66; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2013, J NEUROSURG, V118, P1317, DOI 10.3171/2013.2.JNS121468; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rusyniak DE, 2003, STROKE, V34, P571, DOI 10.1161/01.STR.0000050644.48393.D0; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Strong AJ, 2005, ADV TECH STAND NEUR, V30, P3, DOI 10.1007/3-211-27208-9_1; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377	32	37	41	0	8	NATL CENTER TRAUMA RESEARCH	TEHRAN	NATL CENTER TRAUMA RESEARCH, TEHRAN, IRAN	2251-7464	2251-7472		TRAUMA MON	Trauma Mon.	FEB	2016	21	1							e26772	10.5812/traumamon.26772			5	Emergency Medicine	Emerging Sources Citation Index (ESCI)	Emergency Medicine	DV5NI	WOS:000382974200020	27218057	Green Published			2022-02-06	
J	Hesdorffer, DC; Ishihara, L; Webb, DJ; Mynepalli, L; Galwey, N; Hauser, WA				Hesdorffer, Dale C.; Ishihara, Lianna; Webb, David J.; Mynepalli, Lakshmi; Galwey, NicholasW.; Hauser, W. Allen			Occurrence and Recurrence of Attempted Suicide Among People With Epilepsy	JAMA PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; RISK-FACTORS; ANTIEPILEPTIC DRUGS; MULTIPLE-SCLEROSIS; PREMATURE MORTALITY; UNPROVOKED SEIZURES; ALZHEIMERS-DISEASE; MAJOR DEPRESSION; POPULATION	IMPORTANCE People with epilepsy have a 5-fold increased risk of suicide. Less is known about attempted suicide and whether psychiatric disorders and antiepileptic drugs modify the risk of attempted suicide. OBJECTIVES To estimate the magnitude of the association between attempted suicide and epilepsy by comparing a first suicide attempt and a second suicide attempt (hereafter referred to as a recurrent suicide attempt) among people before they received a diagnosis of epilepsy (case patients) with a first suicide attempt and a recurrent suicide attempt among people without epilepsy (control patients), and to evaluate the effect of comorbid psychiatric disorders and the exclusion of antiepileptic drug prescriptions on this association. DESIGN, SETTING, AND PARTICIPANTS Population-based retrospective cohort study in the United Kingdom of case patients with incident epilepsy and control patients without a history of epilepsy in a general practice setting using Clinical Practice Research Datalink. The case patients with incident epilepsy were identified between 1987 and 2013 and were 10 to 60 years of age. The control patients for each case patient were 4 randomly selected people who did not receive a diagnosis of epilepsy before the case patient's epilepsy was diagnosed (the index date), matched by year of birth, sex, and general practice for a control to case ratio of 4 to 1. MAIN OUTCOMES AND MEASURES Hazard ratio for incident and recurrent suicide attempts among case patients with epilepsy compared with control patients without. RESULTS For 14 059 case patients (median age, 36 years [range, 10-60 years]) who later had an onset of epilepsy vs 56 184 control patients (median age, 36 years [range, 10-60 years]), the risk was increased 2.9-fold (95% CI, 2.5-to 3.4-fold) for a first suicide attempt during the time period before the case patients received a diagnosis of epilepsy. For 278 case patients (median age, 37 years [range, 10-61 years]) who later had an onset of epilepsy vs 434 control patients (median age, 35 years [range, 11-61 years]), the risk was increased 1.8-fold (95% CI, 1.3-to 2.5-fold) for a recurrent suicide attempt up to and including the day that epilepsy was diagnosed. Exclusion of antiepileptic drugs prescribed before the index date did not meaningfully alter the findings, nor did separate analyses of patients with and patients without diagnosed psychiatric disorders. CONCLUSIONS AND RELEVANCE Suicide attempts and recurrent suicide attempts are associated with epilepsy even before epilepsy manifests, suggesting a common underlying biology. Our findings indicate that both incident and recurrent suicide attempts are associated with incident epilepsy in the absence of antiepileptic drugs and in the absence of diagnosed psychiatric disorders, further strengthening the evidence for a common underlying etiology with an as-yet-unknown mechanism.	[Hesdorffer, Dale C.; Hauser, W. Allen] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; [Hesdorffer, Dale C.; Hauser, W. Allen] Columbia Univ, Dept Epidemiol, New York, NY 10032 USA; [Ishihara, Lianna] GlaxoSmithKline GSK, Worldwide Epidemiol, London, England; [Ishihara, Lianna] Lundbeck SAS, Paris, France; [Webb, David J.] GSK, Observat Data Analyt, London, England; [Mynepalli, Lakshmi] GSK Pharmaceut Ltd, Stat & Programming, Quantitat Sci India, Bangalore, Karnataka, India; [Galwey, NicholasW.] GSK, London, England; [Hauser, W. Allen] Columbia Univ, Dept Neurol, New York, NY 10032 USA		Hesdorffer, DC (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, 630 W 168th St,P&S Unit 16, New York, NY 10032 USA.	dch5@columbia.edu	Hauser, W Allen/AAB-5277-2020		GlaxoSmithKlineGlaxoSmithKline	GlaxoSmithKline provided funding for their employees who were involved in this study.	Adelow C, 2012, NEUROLOGY, V78, P396, DOI 10.1212/WNL.0b013e318245f461; Alper K, 2007, BIOL PSYCHIAT, V62, P345, DOI 10.1016/j.biopsych.2006.09.023; Andersohn F, 2010, NEUROLOGY, V75, P335, DOI 10.1212/WNL.0b013e3181ea157e; Arana A, 2010, NEW ENGL J MED, V363, P542, DOI 10.1056/NEJMoa0909801; Barak Y, 2002, DEMENT GERIATR COGN, V14, P101, DOI 10.1159/000064931; Baram TZ, 1998, TRENDS NEUROSCI, V21, P471, DOI 10.1016/S0166-2236(98)01275-2; BARRACLOUGH BM, 1987, ACTA PSYCHIAT SCAND, V76, P339, DOI 10.1111/j.1600-0447.1987.tb05616.x; BRESLAU N, 1991, PSYCHIAT RES, V37, P11, DOI 10.1016/0165-1781(91)90102-U; Christensen J, 2007, EPILEPSY BEHAV, V11, P324, DOI 10.1016/j.yebeh.2007.06.003; Christensen J, 2007, LANCET NEUROL, V6, P693, DOI 10.1016/S1474-4422(07)70175-8; Christiansen E, 2007, AUST NZ J PSYCHIAT, V41, P257, DOI 10.1080/00048670601172749; Chronis-Tuscano A, 2010, ARCH GEN PSYCHIAT, V67, P1044, DOI 10.1001/archgenpsychiatry.2010.127; Coulter DA, 2012, GLIA, V60, P1215, DOI 10.1002/glia.22341; Dong JY, 2012, STROKE, V43, P32, DOI 10.1161/STROKEAHA.111.630871; Ernst C, 2009, PROG NEUROBIOL, V89, P315, DOI 10.1016/j.pneurobio.2009.09.001; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Fazel S, 2013, LANCET, V382, P1646, DOI 10.1016/S0140-6736(13)60899-5; Fazel S, 2013, BIPOLAR DISORD, V15, P491, DOI 10.1111/bdi.12053; Fergusson DM, 2000, PSYCHOL MED, V30, P23, DOI 10.1017/S003329179900135X; Geerlings MI, 2000, BRIT J PSYCHIAT, V176, P568, DOI 10.1192/bjp.176.6.568; Gilboa T, 2012, EPILEPSIA, V53, pe29, DOI 10.1111/j.1528-1167.2011.03342.x; Hackett ML, 2005, STROKE, V36, P2296, DOI 10.1161/01.STR.0000183622.75135.a4; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; Heaney DC, 2002, BMJ-BRIT MED J, V325, P1013, DOI 10.1136/bmj.325.7371.1013; Herrett E, 2010, BRIT J CLIN PHARMACO, V69, P4, DOI 10.1111/j.1365-2125.2009.03537.x; Hesdorffer DC, 2012, ANN NEUROL, V72, P184, DOI 10.1002/ana.23601; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Hesdorffer DC, 2005, EPILEPSIA, V46, P1297, DOI 10.1111/j.1528-1167.2005.10705.x; Hesdorffer DC, 2004, ARCH GEN PSYCHIAT, V61, P731, DOI 10.1001/archpsyc.61.7.731; Hesdorffer DC, 2000, ANN NEUROL, V47, P246, DOI 10.1002/1531-8249(200002)47:2<246::AID-ANA17>3.3.CO;2-5; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; Jones JE, 2003, EPILEPSY BEHAV, V4, pS31, DOI 10.1016/j.yebeh.2003.08.019; Kanner AM, 2003, EPILEPSY BEHAV, V4, P597, DOI 10.1016/j.yebeh.2003.09.013; Kotsopoulos IAW, 2002, EPILEPSIA, V43, P1402, DOI 10.1046/j.1528-1157.2002.t01-1-26901.x; Ludvigsson P, 2006, ANN NEUROL, V59, P210, DOI 10.1002/ana.20745; Mann JJ, 2010, EUR PSYCHIAT, V25, P268, DOI 10.1016/j.eurpsy.2010.01.009; Meeraus WH, 2013, ARCH DIS CHILD, V98, P195, DOI 10.1136/archdischild-2012-302237; Murray PS, 2014, BIOL PSYCHIAT, V75, P542, DOI 10.1016/j.biopsych.2013.08.020; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; Nicoletti A, 2003, EPILEPSIA, V44, P1445, DOI 10.1046/j.1528-1157.2003.09203.x; Olesen JB, 2010, PHARMACOEPIDEM DR S, V19, P518, DOI 10.1002/pds.1932; Patorno E, 2010, JAMA-J AM MED ASSOC, V303, P1401, DOI 10.1001/jama.2010.410; Patten SB, 2003, NEUROLOGY, V61, P1524, DOI 10.1212/01.WNL.0000095964.34294.B4; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; Prudhomme C, 1941, J NERV MENT DIS, V94, P722, DOI 10.1097/00005053-194112000-00006; Pugh MJV, 2013, NEUROLOGY, V81, P1900, DOI 10.1212/01.wnl.0000436614.51081.2e; Richard YF, 2015, AM J EPIDEMIOL, V182, P177, DOI 10.1093/aje/kwv014; Scharfman HE, 2014, ADV EXP MED BIOL, V813, P133, DOI 10.1007/978-94-017-8914-1_11; Seifert G, 2013, EXP NEUROL, V244, P4, DOI 10.1016/j.expneurol.2011.08.024; Seo JH, 2007, EPILEPSIA, V48, P801, DOI 10.1111/j.1528-1167.2007.01025.x; Shneker BF, 2009, NEUROLOGY, V72, P987, DOI 10.1212/01.wnl.0000344403.13815.8d; Sigurdardottir KR, 1998, EPILEPSIA, V39, P749, DOI 10.1111/j.1528-1157.1998.tb01161.x; STENAGER EN, 1992, J NEUROL NEUROSUR PS, V55, P542, DOI 10.1136/jnnp.55.7.542; Teasdale TW, 2001, J EPIDEMIOL COMMUN H, V55, P863, DOI 10.1136/jech.55.12.863; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; VanCott AC, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-4	59	37	38	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	JAN	2016	73	1					80	86		10.1001/jamapsychiatry.2015.2516			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	DA5CP	WOS:000367820000013	26650853	Bronze			2022-02-06	
S	Jayakumar, AR; Norenberg, MD		Schousboe, A; Sonnewald, U		Jayakumar, Arumugam R.; Norenberg, Michael D.			Glutamine Synthetase: Role in Neurological Disorders	GLUTAMATE/GABA-GLUTAMINE CYCLE: AMINO ACID NEUROTRANSMITTER HOMEOSTASIS	Advances in Neurobiology		English	Article; Book Chapter						Ammonia; Astrocytes; Glutamine synthetase; Glutamine; Excitotoxicity; Neurological disorders; Neurotoxicity; Therapy	FIBRILLARY ACIDIC PROTEIN; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; FULMINANT HEPATIC-FAILURE; METHIONINE-S-SULFOXIMINE; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; ORNITHINE-L-ASPARTATE; ACUTE LIVER-FAILURE; ALZHEIMERS-DISEASE	Glutamine synthetase (GS) is an ATP-dependent enzyme found in most species that synthesizes glutamine from glutamate and ammonia. In brain, GS is exclusively located in astrocytes where it serves to maintain the glutamate-glutamine cycle, as well as nitrogen metabolism. Changes in the activity of GS, as well as its gene expression, along with excitotoxicity, have been identified in a number of neurological conditions. The literature describing alterations in the activation and gene expression of GS, as well as its involvement in different neurological disorders, however, is incomplete. This review summarizes changes in GS gene expression/activity and its potential contribution to the pathogenesis of several neurological disorders, including hepatic encephalopathy, ischemia, epilepsy, Alzheimer's disease, amyotrophic lateral sclerosis, traumatic brain injury, Parkinson's disease, and astroglial neoplasms. This review also explores the possibility of targeting GS in the therapy of these conditions.	[Jayakumar, Arumugam R.; Norenberg, Michael D.] Vet Affairs Med Ctr, Neuropathol Lab, Miami, FL 33125 USA; [Norenberg, Michael D.] Univ Miami, Sch Med, Dept Pathol, POB 016960, Miami, FL 33101 USA		Norenberg, MD (corresponding author), Vet Affairs Med Ctr, Neuropathol Lab, Miami, FL 33125 USA.; Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu			NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK063311] Funding Source: Medline		Agostinho P, 2010, CURR PHARM DESIGN, V16, P2766, DOI 10.2174/138161210793176572; Akinmoladun AC, 2015, NEUROCHEM RES, V40, P777, DOI 10.1007/s11064-015-1527-z; Aksenov MY, 1996, J NEUROCHEM, V66, P2050; Allen RS, 2014, EXP NEUROL, V254, P206, DOI 10.1016/j.expneurol.2014.02.005; Anlauf Enrico, 2013, Front Endocrinol (Lausanne), V4, P144, DOI 10.3389/fendo.2013.00144; Babu CS, 2009, PHARMACOL BIOCHEM BE, V92, P424, DOI 10.1016/j.pbb.2009.01.010; Bak LK, 2006, J NEUROCHEM, V98, P641, DOI 10.1111/j.1471-4159.2006.03913.x; Bame M, 2012, GENDER MED, V9, P524, DOI 10.1016/j.genm.2012.10.014; Battaglia F, 2007, BIOL PSYCHIAT, V62, P1405, DOI 10.1016/j.biopsych.2007.02.027; BAUDRY M, 1986, J NEUROSCI, V6, P3430; Behrens PF, 2002, BRAIN, V125, P1908, DOI 10.1093/brain/awf180; Bender AS, 1996, NEUROCHEM RES, V21, P567, DOI 10.1007/BF02527755; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bernstein HG, 2013, CNS NEUROL DISORD-DR, V12, P900, DOI 10.2174/18715273113129990091; BLEI AT, 1994, HEPATOLOGY, V19, P1437, DOI 10.1002/hep.1840190619; Bondy SC, 1998, MOL CHEM NEUROPATHOL, V34, P219, DOI 10.1007/BF02815081; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; Bruneau EG, 2005, SCHIZOPHR RES, V75, P27, DOI 10.1016/j.schres.2004.12.012; Burbaeva GS, 2005, NEUROCHEM RES, V30, P1443, DOI 10.1007/s11064-005-8654-x; Butterfield DA, 1997, J NEUROCHEM, V68, P2451; CAPOCACCIA L, 1991, DIGEST DIS SCI, V36, P775, DOI 10.1007/BF01311236; Cardenas-Rodriguez N, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/759293; CARTER CJ, 1983, LIFE SCI, V32, P1949, DOI 10.1016/0024-3205(83)90046-2; CARTER CJ, 1982, LIFE SCI, V31, P1151, DOI 10.1016/0024-3205(82)90090-X; CARTER CJ, 1981, LANCET, V1, P782; Castegna A, 2011, NEUROSCIENCE, V185, P97, DOI 10.1016/j.neuroscience.2011.04.041; CHAO CC, 1992, J CLIN INVEST, V90, P1786, DOI 10.1172/JCI116053; Chatauret N, 2006, J HEPATOL, V44, P1083, DOI 10.1016/j.jhep.2005.11.048; Chiu IM, 2009, P NATL ACAD SCI USA, V106, P20960, DOI 10.1073/pnas.0911405106; Chiu IM, 2008, P NATL ACAD SCI USA, V105, P17913, DOI 10.1073/pnas.0804610105; Choudary PV, 2005, P NATL ACAD SCI USA, V102, P15653, DOI 10.1073/pnas.0507901102; CHUNG SH, 1984, PROC R SOC SER B-BIO, V221, P145, DOI 10.1098/rspb.1984.0028; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crunelli V, 2015, NEUROSCIENTIST, V21, P62, DOI 10.1177/1073858414523320; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Dam G, 2011, AM J PHYSIOL-GASTR L, V301, pG269, DOI 10.1152/ajpgi.00062.2011; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Desjardins P, 1999, METAB BRAIN DIS, V14, P273, DOI 10.1023/A:1020741226752; DiGiacomo C, 1997, NEUROCHEM RES, V22, P1145, DOI 10.1023/A:1027321420075; Dorfman D, 2013, EXP NEUROL, V240, P146, DOI 10.1016/j.expneurol.2012.11.017; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; Dugan L.L., 1999, BASIC NEUROCHEMISTRY, V6th; Dutuit M, 2000, GLIA, V32, P15, DOI 10.1002/1098-1136(200010)32:1<15::AID-GLIA20>3.0.CO;2-#; EDE RJ, 1986, SEMIN LIVER DIS, V6, P107, DOI 10.1055/s-2008-1040594; Eid T, 2013, NEUROCHEM INT, V63, P670, DOI 10.1016/j.neuint.2013.06.008; Eid T, 2008, BRAIN, V131, P2061, DOI 10.1093/brain/awn133; Fernandez DC, 2009, J NEUROCHEM, V111, P488, DOI 10.1111/j.1471-4159.2009.06334.x; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FOLBERGROVA J, 1993, J CEREBR BLOOD F MET, V13, P145, DOI 10.1038/jcbfm.1993.17; Fujioka M, 2003, ANN NEUROL, V54, P732, DOI 10.1002/ana.10751; Garrett R., 2007, BIOCHEMISTRY; Ghoddoussi F, 2010, J NEUROL SCI, V290, P41, DOI 10.1016/j.jns.2009.11.013; GIRARD G, 1993, METAB BRAIN DIS, V8, P207, DOI 10.1007/BF01001062; Gorovits R, 1996, MOL BRAIN RES, V43, P321, DOI 10.1016/S0169-328X(96)00213-6; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRIFFITH OW, 1978, J BIOL CHEM, V253, P2333; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Haussinger D, 2005, METAB BRAIN DIS, V20, P285, DOI 10.1007/s11011-005-7908-2; HAWKINS RA, 1993, J NEUROCHEM, V60, P1000, DOI 10.1111/j.1471-4159.1993.tb03247.x; Hensley K, 2006, ANTIOXID REDOX SIGN, V8, P2075, DOI 10.1089/ars.2006.8.2075; HERBERG LJ, 1992, EPILEPSY RES, V11, P3, DOI 10.1016/0920-1211(92)90015-L; Hertz L, 2004, TRENDS NEUROSCI, V27, P735, DOI 10.1016/j.tins.2004.10.008; Hertz Leif, 2013, Front Endocrinol (Lausanne), V4, P59, DOI 10.3389/fendo.2013.00059; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; Hilgier W, 1981, Neuropatol Pol, V19, P351; Hirata T, 1996, STROKE, V27, P729, DOI 10.1161/01.STR.27.4.729; Hirata T, 1999, AM J PHYSIOL-HEART C, V276, pH456; Holownia Adam, 1994, Materia Medica Polona, V26, P25; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; Itzen A, 2011, TRENDS BIOCHEM SCI, V36, P219, DOI 10.1016/j.tibs.2010.12.004; Jalan R, 2007, MED HYPOTHESES, V69, P1064, DOI 10.1016/j.mehy.2006.12.061; Jarrett SG, 2008, J NEUROCHEM, V106, P1044, DOI 10.1111/j.1471-4159.2008.05460.x; JOHNSON WL, 1965, ELECTROEN CLIN NEURO, V18, P229, DOI 10.1016/0013-4694(65)90089-1; Jones EA, 1997, J NEUROL NEUROSUR PS, V63, P279, DOI 10.1136/jnnp.63.3.279; Justin A, 2014, PHARMACOL BIOCHEM BE, V122, P61, DOI 10.1016/j.pbb.2014.03.009; Kalkman HO, 2011, MED HYPOTHESES, V76, P905, DOI 10.1016/j.mehy.2011.03.005; KANAMORI K, 1993, NMR BIOMED, V6, P21, DOI 10.1002/nbm.1940060104; Kim S, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-413; Klempan TA, 2009, MOL PSYCHIATR, V14, P175, DOI 10.1038/sj.mp.4002110; Kosenko E, 2003, NEUROCHEM INT, V43, P493, DOI 10.1016/S0197-0186(03)00039-1; Kruchkova Y, 2001, J NEUROCHEM, V77, P1641, DOI 10.1046/j.1471-4159.2001.00390.x; LAVOIE J, 1987, METAB BRAIN DIS, V2, P283, DOI 10.1007/BF00999698; Lee A, 2010, J CHEM NEUROANAT, V39, P211, DOI 10.1016/j.jchemneu.2009.12.002; Lee DR, 2003, BRAIN RES, V989, P221, DOI 10.1016/S0006-8993(03)03373-0; Lee Y, 2013, J PSYCHIATR NEUROSCI, V38, P183, DOI 10.1503/jpn.120024; Leite MC, 2006, BRAIN RES BULL, V70, P179, DOI 10.1016/j.brainresbull.2006.05.003; LEPRINCE G, 1995, NEUROCHEM RES, V20, P859, DOI 10.1007/BF00969698; LEVENTAL M, 1972, ARCH INT PHYSIOL BIO, V80, P861; LIAW SH, 1994, BIOCHEMISTRY-US, V33, P675, DOI 10.1021/bi00169a007; LOCKWOOD AH, 1991, J CEREBR BLOOD F MET, V11, P337, DOI 10.1038/jcbfm.1991.67; Loeppen S, 2002, CANCER RES, V62, P5685; Master S, 1999, HEPATOLOGY, V30, P876, DOI 10.1002/hep.510300428; Matos M, 2008, NEUROSCIENCE, V156, P898, DOI 10.1016/j.neuroscience.2008.08.022; Matsumoto M, 2008, SURG NEUROL, V70, P122, DOI 10.1016/j.surneu.2007.07.011; MCCORMICK D, 1990, NEUROPATH APPL NEURO, V16, P205, DOI 10.1111/j.1365-2990.1990.tb01157.x; Miguel-Hidalgo JJ, 2002, BRAIN RES, V958, P210, DOI 10.1016/S0006-8993(02)03731-9; Miguel-Hidalgo JJ, 2010, J AFFECT DISORDERS, V127, P230, DOI 10.1016/j.jad.2010.06.003; Nagele RG, 2004, NEUROBIOL AGING, V25, P663, DOI 10.1016/j.neurobiolaging.2004.01.007; Nakajima K, 2015, NEUROSCI LETT, V591, P99, DOI 10.1016/j.neulet.2015.02.021; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; Ngugi AK, 2010, EPILEPSIA, V51, P883, DOI 10.1111/j.1528-1167.2009.02481.x; Nielsen HM, 2009, GLIA, V57, P978, DOI 10.1002/glia.20822; Norenberg MD, 2007, METAB BRAIN DIS, V22, P219, DOI 10.1007/s11011-007-9062-5; NORENBERG MD, 1977, LAB INVEST, V36, P618; NORENBERG MD, 1979, J HISTOCHEM CYTOCHEM, V27, P756, DOI 10.1177/27.3.39099; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; NORENBERG MD, 1983, GLUTAMINE GLUTAMATE, P95; Olabarria M, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-55; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PAHLMARK K, 1993, STROKE, V24, P731, DOI 10.1161/01.STR.24.5.731; Pascual JM, 1998, STROKE, V29, P1048, DOI 10.1161/01.STR.29.5.1048; PERRY TL, 1981, LANCET, V1, P1261; PETITO CK, 1992, BRAIN RES, V569, P275, DOI 10.1016/0006-8993(92)90639-Q; PHILLIS JW, 1994, PROG NEUROBIOL, V42, P441, DOI 10.1016/0301-0082(94)90046-9; Pike CJ, 1996, EXP NEUROL, V139, P167, DOI 10.1006/exnr.1996.0091; PILKINGTON GJ, 1982, NEUROPATH APPL NEURO, V8, P227, DOI 10.1111/j.1365-2990.1982.tb00277.x; PROLER M, 1962, EPILEPSIA, V3, P117, DOI 10.1111/j.1528-1157.1962.tb05237.x; PROLER ML, 1965, NEUROLOGY, V15, P931, DOI 10.1212/WNL.15.10.931; Radford RA, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00414; Rajkowska G, 2013, CURR DRUG TARGETS, V14, P1225; Rao KVR, 2012, NEUROCHEM INT, V61, P575, DOI 10.1016/j.neuint.2012.01.012; REINER L, 1950, ARCH BIOCHEM, V25, P447; Revett TJ, 2013, J PSYCHIATR NEUROSCI, V38, P6, DOI 10.1503/jpn.110190; RICHMAN PG, 1973, J BIOL CHEM, V248, P6684; Robinson SR, 2000, NEUROCHEM INT, V36, P471, DOI 10.1016/S0197-0186(99)00150-3; Rosati A, 2013, NEURO-ONCOLOGY, V15, P618, DOI 10.1093/neuonc/nos338; Rosati A, 2009, J NEURO-ONCOL, V93, P319, DOI 10.1007/s11060-008-9794-z; Rose C, 1998, METAB BRAIN DIS, V13, P147, DOI 10.1023/A:1020613314572; Rose C, 1999, HEPATOLOGY, V30, P636, DOI 10.1002/hep.510300311; ROWE WB, 1970, P NATL ACAD SCI USA, V66, P500, DOI 10.1073/pnas.66.2.500; Safwen K, 2015, INT J STROKE, V10, P415, DOI 10.1111/ijs.12391; SALLANON M, 1992, CR ACAD SCI III-VIE, V315, P109; SCHATZ RA, 1975, J NEUROCHEM, V24, P63, DOI 10.1111/j.1471-4159.1975.tb07628.x; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sequeira A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006585; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Shin JY, 2005, J CELL BIOL, V171, P1001, DOI 10.1083/jcb.200508072; Silvestrin RB, 2013, BRAIN RES, V1495, P52, DOI 10.1016/j.brainres.2012.11.048; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Stryer L, 2007, BIOCHEMISTRY-US, P679; Suarez I, 1997, NEUROPATH APPL NEURO, V23, P254, DOI 10.1046/j.1365-2990.1997.9198091.x; Suarez I, 1996, METAB BRAIN DIS, V11, P369, DOI 10.1007/BF02029497; Suarez I, 2002, NEUROCHEM INT, V41, P123, DOI 10.1016/S0197-0186(02)00033-5; Sugimoto H, 1997, J CEREBR BLOOD F MET, V17, P44, DOI 10.1097/00004647-199701000-00006; Sun HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066885; Sunil AG, 2011, BRAIN RES BULL, V84, P394, DOI 10.1016/j.brainresbull.2011.01.008; TAKAHASHI H, 1991, AM J PHYSIOL, V261, pH825, DOI 10.1152/ajpheart.1991.261.3.H825; TAKAHASHI H, 1992, CIRC RES, V71, P1220, DOI 10.1161/01.RES.71.5.1220; TAKAHASHI K, 1993, NEUROSCI LETT, V151, P51, DOI 10.1016/0304-3940(93)90043-K; TANAKA H, 1992, EXP NEUROL, V116, P264, DOI 10.1016/0014-4886(92)90006-C; Tanigami H, 2005, NEUROSCIENCE, V131, P437, DOI 10.1016/j.neuroscience.2004.10.045; THOMAS JW, 1988, METAB BRAIN DIS, V3, P81, DOI 10.1007/BF01001011; Thompson MD, 2011, J HEPATOL, V54, P506, DOI 10.1016/j.jhep.2010.07.020; THORN W, 1958, J NEUROCHEM, V2, P166, DOI 10.1111/j.1471-4159.1958.tb12361.x; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; TIFFANYCASTIGLIONI EC, 1990, J NEUROSCI RES, V25, P223, DOI 10.1002/jnr.490250210; Toro CT, 2006, NEUROSCI LETT, V404, P276, DOI 10.1016/j.neulet.2006.05.067; Torres-Vega MA, 2015, GENE THER, V22, P58, DOI 10.1038/gt.2014.89; Tumani H, 1999, ARCH NEUROL-CHICAGO, V56, P1241, DOI 10.1001/archneur.56.10.1241; van den Berg C. J, 1970, HANDBOOK NEUROCHEMIS, P355; van der Hel WS, 2005, NEUROLOGY, V64, P326, DOI 10.1212/01.WNL.0000149636.44660.99; van der Vos KE, 2012, AUTOPHAGY, V8, P1862, DOI 10.4161/auto.22152; van der Vos KE, 2012, NAT CELL BIOL, V14, P829, DOI 10.1038/ncb2536; van Gassen KLI, 2009, GENES BRAIN BEHAV, V8, P290, DOI 10.1111/j.1601-183X.2008.00471.x; VARDIMON L, 1988, P NATL ACAD SCI USA, V85, P5981, DOI 10.1073/pnas.85.16.5981; Veerhuis R, 2011, CURR ALZHEIMER RES, V8, P34, DOI 10.2174/156720511794604589; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Walker FO, 2007, LANCET, V369, P218, DOI 10.1016/S0140-6736(07)60111-1; Walls AB, 2015, NEUROCHEM RES, V40, P402, DOI 10.1007/s11064-014-1473-1; Wang XF, 2013, NEUROSCI LETT, V549, P69, DOI 10.1016/j.neulet.2013.06.013; Wang Y, 2009, EXP NEUROL, V220, P293, DOI 10.1016/j.expneurol.2009.08.034; WANIEWSKI RA, 1992, J NEUROCHEM, V58, P167, DOI 10.1111/j.1471-4159.1992.tb09292.x; WARREN KS, 1964, J LAB CLIN MED, V64, P442; WillardMack CL, 1996, NEUROSCIENCE, V71, P589, DOI 10.1016/0306-4522(95)00462-9; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; YAMAMOTO T, 1989, ACTA NEUROPATHOL, V77, P357, DOI 10.1007/BF00687370; ZHANG HY, 1991, J BIOL CHEM, V266, P24332; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; ZIEVE L, 1986, METAB BRAIN DIS, V1, P25, DOI 10.1007/BF00998474; Zou J, 2011, NEUROCHEM INT, V58, P404, DOI 10.1016/j.neuint.2010.12.018	181	37	42	0	4	SPRINGER INT PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	2190-5215		978-3-319-45096-4; 978-3-319-45094-0	ADV NEUROBIOL	Adv. Neurobiol.		2016	13						327	350		10.1007/978-3-319-45096-4_13	10.1007/978-3-319-45096-4		24	Biology; Neurosciences	Book Citation Index – Science (BKCI-S)	Life Sciences & Biomedicine - Other Topics; Neurosciences & Neurology	BH5HC	WOS:000400933900013	27885636				2022-02-06	
J	Tweedie, D; Rachrnany, L; Rubovitch, V; Li, YZ; Holloway, HW; Lehrmann, E; Zhang, YQ; Becker, KG; Perez, E; Hoffer, BJ; Pick, CG; Greig, NH				Tweedie, David; Rachrnany, Lital; Rubovitch, Vardit; Li, Yazhou; Holloway, Harold W.; Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.; Perez, Evelyn; Hoffer, Barry J.; Pick, Chaim G.; Greig, Nigel H.			Blast traumatic brain injury-induced cognitive deficits are attenuated by preinjury or postinjury treatment with the glucagon-like peptide-1 receptor agonist, exendin-4	ALZHEIMERS & DEMENTIA			English	Article						Exendin-4; Blast injury; Traumatic brain injury; Neurodegeneration; Alzheimer's disease; Parkinson's disease; Behavioral deficits; Gene expression; Glucagon-like peptide-1	DEPENDENT INSULINOTROPIC POLYPEPTIDE; REVERSES BEHAVIORAL IMPAIRMENTS; GENE-EXPRESSION; CELL-DEATH; TNF-ALPHA; DRUG CANDIDATES; INCREASED RISK; HEAD-INJURY; DEMENTIA; MECHANISMS	Introduction: Blast traumatic brain injury (B-TBI) affects military and civilian personnel. Presently, there are no approved drugs for blast brain injury. Methods: Exendin-4 (Ex-4), administered subcutaneously, was evaluated as a pretreatment (48 hours) and postinjury treatment (2 hours) on neurodegeneration, behaviors, and gene expressions in a marine open field model of blast injury. Results: B-TBI induced neurodegeneration, changes in cognition, and genes expressions linked to dementia disorders. Ex-4, administered preinjury or postinjury, ameliorated B-TBI induced neurodegeneration at 72 hours, memory deficits from days 7-14, and attenuated genes regulated by blast at day 14 postinjury. Discussion: The present data suggest shared pathologic processes between concussive and B-TBI, with end points amenable to beneficial therapeutic manipulation by Ex-4. B-TBI induced dementia-related gene pathways and cognitive deficits in mice somewhat parallel epidemiologic studies of Barnes et al. who identified a greater risk in US military veterans who experienced diverse TBIs, for dementia in later life. Published by Elsevier Inc. on behalf of the Alzheimer's Association.	[Tweedie, David; Li, Yazhou; Holloway, Harold W.; Greig, Nigel H.] NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Rachrnany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.] NIA, Genet Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Perez, Evelyn] NIA, Lab Behav Neurosci, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH USA; [Hoffer, Barry J.] Taipei Med Univ, Grad Program Neuroregenerat, Taipei, Taiwan; [Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel		Tweedie, D (corresponding author), NIA, Translat Gerontol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA.	tweedieda@grc.nia.nih.gov		Lehrmann, Elin/0000-0002-9869-9475	Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG000333-07]; Sackler School of Medicine, Tel Aviv University; Israel Science FoundationIsrael Science Foundation [108/09]; Joseph Sagol Fellowship; National Science Council TaiwanMinistry of Science and Technology, Taiwan [NSC101-2632-B-038-001-MY3]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZICAG000616, ZIAAG000333] Funding Source: NIH RePORTER	This research was supported in part by (1) the Intramural Research Program of the National Institute on Aging, National Institutes of Health, grant AG000333-07; (2) the Sackler School of Medicine, Tel Aviv University; (3) a grant from the Israel Science Foundation, grant number 108/09; (4) the Joseph Sagol Fellowship, and (5) the National Science Council Taiwan, grant NSC101-2632-B-038-001-MY3.	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Aviles-Olmos I, 2014, J PARKINSON DIS, V4, P337, DOI 10.3233/JPD-140364; Aviles-Olmos I, 2013, J CLIN INVEST, V123, P2730, DOI 10.1172/JCI68295; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Brandt-Bohne U, 2007, BIOCHEM J, V401, P447, DOI 10.1042/BJ20060691; Campbell JE, 2013, CELL METAB, V17, P819, DOI 10.1016/j.cmet.2013.04.008; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00117; CHOI DW, 1987, J NEUROSCI, V7, P357; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Czibere L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023604; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Darsalia V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103114; Dong SZ, 2007, EUR J NEUROSCI, V26, P101, DOI 10.1111/j.1460-9568.2007.05641.x; Duarte AI, 2013, BBA-MOL BASIS DIS, V1832, P527, DOI 10.1016/j.bbadis.2013.01.008; Eakin K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082016; Faivre E, 2011, J NEUROPHYSIOL, V105, P1574, DOI 10.1152/jn.00866.2010; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gitton Y, 2002, NATURE, V420, P586, DOI 10.1038/nature01178; Goel MD, 2012, DEFENCE SCI J, V62, P300, DOI 10.14429/dsj.62.1149; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hayashi K, 2006, J NEUROCHEM, V99, P237, DOI 10.1111/j.1471-4159.2006.04113.x; Holscher C, 2012, CNS DRUGS, V26, P871, DOI 10.2165/11635890-000000000-00000; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Holscher Christian, 2010, Recent Pat CNS Drug Discov, V5, P109; Hosek J., 2011, IS DEPLOYMENT IRAQ A; Jones SAV, 2014, BRIT J SPORT MED, V48, P159, DOI 10.1136/bjsports-2013-092758; Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Li YZ, 2015, J NEUROCHEM, V135, P1203, DOI 10.1111/jnc.13169; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Mirza Z, 2014, CNS NEUROL DISORD-DR, V13, P501, DOI 10.2174/18715273113126660154; Miu J, 2008, INFECT IMMUN, V76, P1812, DOI 10.1128/IAI.01650-07; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Nyberg J, 2007, J NEUROSCI RES, V85, P2099, DOI 10.1002/jnr.21349; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Perry T, 2002, J ALZHEIMERS DIS, V4, P487; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Poulain FE, 2007, MOL CELL NEUROSCI, V34, P137, DOI 10.1016/j.mcn.2006.10.012; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Rachmany L, 2013, AGE, V35, P1621, DOI 10.1007/s11357-012-9464-0; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rappaport N, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat018; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Tweedie D, 2013, EXP NEUROL, V239, P170, DOI 10.1016/j.expneurol.2012.10.001; Valiyaveettil M, 2013, CHEM-BIOL INTERACT, V203, P371, DOI 10.1016/j.cbi.2012.10.022; Valiyaveettil M, 2012, J REHABIL RES DEV, V49, P1153, DOI 10.1682/JRRD.2011.09.0182; Wang HK, 2012, J NEUROL NEUROSUR PS, V83, P1080, DOI 10.1136/jnnp-2012-302633; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yamada K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008596	80	37	39	1	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JAN	2016	12	1					34	48		10.1016/j.jalz.2015.07.489			15	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DC1HU	WOS:000368968200005	26327236	Green Accepted			2022-02-06	
J	Addington, CP; Heffernan, JM; Millar-Haskell, CS; Tucker, EW; Sirianni, RW; Stabenfeldt, SE				Addington, C. P.; Heffernan, J. M.; Millar-Haskell, C. S.; Tucker, E. W.; Sirianni, R. W.; Stabenfeldt, S. E.			Enhancing neural stem cell response to SDF-1 alpha gradients through hyaluronic acid-laminin hydrogels	BIOMATERIALS			English	Article						Chemotaxis; SDF-1 alpha-CXCR4 axis; Tissue engineering; Brain injury; Regenerative medicine	TRAUMATIC BRAIN-INJURY; FOCAL ADHESION; STEM/PROGENITOR CELLS; EXTRACELLULAR-MATRIX; COLLAGEN SCAFFOLDS; VASCULAR NICHE; RAT MODEL; MIGRATION; EXPRESSION; CD44	Traumatic brain injury (TBI) initiates an expansive biochemical insult that is largely responsible for the long-term dysfunction associated with TBI; however, current clinical treatments fall short of addressing these underlying sequelae. Pre-clinical investigations have used stem cell transplantation with moderate success, but are plagued by staggeringly low survival and engraftment rates (2-4%). As such, providing cell transplants with the means to better dynamically respond to injury-related signals within the transplant microenvironment may afford improved transplantation survival and engraftment rates. The chemokine stromal cell-derived factor-1 alpha (SDF-1 alpha) is a potent chemotactic signal that is readily present after TBI. In this study, we sought to develop a transplantation vehicle to ultimately enhance the responsiveness of neural transplants to injury-induced SDF-1 alpha. Specifically, we hypothesize that a hyaluronic acid (HA) and laminin (Lm) hydrogel would promote 1. upregulated expression of the SDF-1 alpha receptor OCCR4 in neural progenitor/stem cells (NPSCs) and 2. enhanced NPSC migration in response to SDF-1 alpha gradients. We demonstrated successful development of a HA-Lm hydrogel and utilized standard protein and cellular assays to probe NPSC CXCR4 expression and NPSC chemotactic migration. The findings demonstrated that NPSCs significantly increased CXCR4 expression after 48 h of culture on the HA-Lm gel in a manner critically dependent on both HA and laminin. Moreover, the HA-Lm hydrogel significantly increased NPSC chemotactic migration in response to SDF-1 alpha at 48 h, an effect that was critically dependent on HA, laminin and the SDF-1 alpha gradient. Therefore, this hydrogel serves to 1. prime NPSCs for the injury microenvironment and 2. provide the appropriate infrastructure to support migration into the surrounding tissue, equipping cells with the tools to more effectively respond to the injury microenvironment. (C) 2015 Elsevier Ltd. All rights reserved.	[Addington, C. P.; Heffernan, J. M.; Millar-Haskell, C. S.; Tucker, E. W.; Sirianni, R. W.; Stabenfeldt, S. E.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85287 USA; [Heffernan, J. M.; Sirianni, R. W.] Barrow Neurol Inst, Barrow Brain Tumor Res Ctr, Phoenix, AZ 85013 USA		Stabenfeldt, SE (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, POB 879709, Tempe, AZ 85287 USA.	sarah.stabenfeldt@asu.edu		Addington, Caroline/0000-0003-4534-8222	ASU startup funds; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1DP2HD084067]; ARCS, Inc.; Barrow Neurological Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [DP2HD084067] Funding Source: NIH RePORTER	The authors acknowledge David Lowry and the College of Liberal Arts and Sciences Bioimaging Facility for assistance with electron microscopy, Sanjay Srinivasan for assistance with monomer preparation and the following funding sources: ASU startup funds (SES), NIH 1DP2HD084067 (SES), and ARCS, Inc. Fellowship (CPA), the Barrow Neurological Foundation (JMH, RWS).	Addington CP, 2014, BIOMATERIALS, V35, P3263, DOI 10.1016/j.biomaterials.2013.12.102; Arbour RB, 2013, CRIT CARE NURS CLIN, V25, P297, DOI 10.1016/j.ccell.2013.02.010; Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; Azari H, 2011, JOVE-J VIS EXP, DOI 10.3791/2457; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; Bonneh-Barkay D, 2009, BRAIN PATHOL, V19, P573, DOI 10.1111/j.1750-3639.2008.00195.x; Brannvall K, 2007, J NEUROSCI RES, V85, P2138, DOI 10.1002/jnr.21358; Cohen M, 2006, EMBO J, V25, P302, DOI 10.1038/sj.emboj.7600960; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Deboux C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057430; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fraley SI, 2010, NAT CELL BIOL, V12, P598, DOI 10.1038/ncb2062; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Heffernan JM, 2015, ANN BIOMED ENG, V43, P1965, DOI 10.1007/s10439-014-1223-1; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Huang YS, 2012, BRAIN DEV-JPN, V34, P674, DOI 10.1016/j.braindev.2011.10.011; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jacques TS, 1998, DEVELOPMENT, V125, P3167; Jensen JB, 2006, MOL NEUROBIOL, V34, P153, DOI 10.1385/MN:34:3:153; Kim MS, 2005, CANCER RES, V65, P686; Kokovay E, 2010, CELL STEM CELL, V7, P163, DOI 10.1016/j.stem.2010.05.019; Lee JL, 2008, MOL CELL BIOL, V28, P5710, DOI 10.1128/MCB.00186-08; Lindwall C, 2013, BRAIN RES, V1503, P62, DOI 10.1016/j.brainres.2013.01.045; Lisignoli G, 2006, J CELL PHYSIOL, V207, P364, DOI 10.1002/jcp.20572; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Naruse M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053109; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Preston M., 2012, FRONT BIOSCI, V3, P1165; PRICE J, 1985, J NEUROSCI, V5, P2205; Purcell BP, 2012, BIOMATERIALS, V33, P7849, DOI 10.1016/j.biomaterials.2012.07.005; Qu CS, 2011, BRAIN RES, V1371, P129, DOI 10.1016/j.brainres.2010.10.088; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; ROONEY P, 1993, J CELL SCI, V105, P213; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shu XZ, 2006, J BIOMED MATER RES A, V79A, P902, DOI 10.1002/jbm.a.30831; Shu XZ, 2004, J BIOMED MATER RES A, V68A, P365, DOI 10.1002/jbm.a.20002; Shu XZ, 2003, BIOMATERIALS, V24, P3825, DOI 10.1016/S0142-9612(03)00267-9; Suri S, 2010, TISSUE ENG PT A, V16, P1703, DOI 10.1089/ten.tea.2009.0381; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; Tran PB, 2007, J COMP NEUROL, V500, P1007, DOI 10.1002/cne.21229; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vercruysse KP, 1997, BIOCONJUGATE CHEM, V8, P686, DOI 10.1021/bc9701095; Wang TY, 2012, BIOMATERIALS, V33, P9188, DOI 10.1016/j.biomaterials.2012.09.013; Wang Y, 2011, PHARM RES-DORDR, V28, P1406, DOI 10.1007/s11095-011-0452-3; Wang ZF, 2014, MATER RES-IBERO-AM J, V17, P33, DOI [10.1590/S1516-14392014000100005, 10.1590/S1516-14392013005000155]; Wei YT, 2007, BIOMED MATER, V2, pS142, DOI 10.1088/1748-6041/2/3/S11; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Wu PH, 2014, P NATL ACAD SCI USA, V111, P3949, DOI 10.1073/pnas.1318967111; Yu XL, 2012, J NEUROL SCI, V316, P141, DOI 10.1016/j.jns.2012.01.001; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	67	37	39	2	96	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	DEC	2015	72						11	19		10.1016/j.biomaterials.2015.08.041			9	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	CT6MH	WOS:000362926600002	26340314	Green Accepted			2022-02-06	
J	Cuthbert, JP; Pretz, CR; Bushnik, T; Fraser, RT; Hart, T; Kolakowsky-Hayner, SA; Malec, JF; O'Neil-Pirozzi, TM; Sherer, M				Cuthbert, Jeffrey P.; Pretz, Christopher R.; Bushnik, Tamara; Fraser, Robert T.; Hart, Tessa; Kolakowsky-Hayner, Stephanie A.; Malec, James F.; O'Neil-Pirozzi, Therese M.; Sherer, Mark			Ten-Year Employment Patterns of Working Age Individuals After Moderate to Severe Traumatic Brain Injury: A National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Employment; Rehabilitation	QUALITY-OF-LIFE; GALVESTON ORIENTATION; AMNESIA TEST; OUTCOME 2; UNEMPLOYMENT; RETURN; STABILITY; PREDICTORS; IMPACT; MEN	Objective: To describe the 10-year patterns of employment for individuals of working age discharged from a Traumatic Brain Injury Model Systems (TBIMS) center between 1989 and 2009. Design: Secondary data analysis. Setting: Inpatient rehabilitation centers. Participants: Patients aged 16 to 55 years (N=3618) who were not retired at injury, received inpatient rehabilitation at a TBIMS center, were discharged alive between 1989 and 2009, and had at least 3 completed follow-up interviews at postinjury years 1, 2, 5, and 10. Interventions: Not applicable. Main Outcomes Measure: Employment. Results: Patterns of employment were generated using a generalized linear mixed model, where these patterns were transformed into temporal trajectories of probability of employment via random effects modeling. Covariates demonstrating significant relations to growth parameters that govern the trajectory patterns were similar to those noted in previous cross-sectional research and included age, sex, race/ethnicity, education, preinjury substance misuse, preinjury vocational status, and days of posttraumatic amnesia. The calendar year in which the injury occurred also greatly influenced trajectories. An interactive tool was developed to provide visualization of all postemployment trajectories, with many showing decreasing probabilities of employment between 5 and 10 years postinjury. Conclusions: These results highlight that postinjury employment after moderate to severe traumatic brain injury (TBI) is a dynamic process, with varied patterns of employment for individuals with specific characteristics. The overall decline in trajectories of probability of employment between 5 and 10 years postinjury suggests that moderate to severe TBI may have unfavorable chronic effects and that employment outcome is highly influenced by national labor market forces. Additional research targeting the underlying drivers of the decline between 5 and 10 years postinjury is recommended, as are interventions that target influencing factors. (C) 2015 by the American Congress of Rehabilitation Medicine	[Cuthbert, Jeffrey P.; Pretz, Christopher R.] Craig Hosp, Rocky Mt Reg Brain Injury Syst, Englewood, CO 80132 USA; [Pretz, Christopher R.] Traumat Brain Injury Model Syst Natl Stat & Data, Englewood, CO USA; [Bushnik, Tamara] NYU, Langone Sch Med, Rusk Inst Rehabil Med, New York, NY USA; [Fraser, Robert T.] Univ Washington, Seattle, WA 98195 USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Kolakowsky-Hayner, Stephanie A.] Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Indiana Univ, Dept Phys Med & Rehabil, Indianapolis, IN 46204 USA; [O'Neil-Pirozzi, Therese M.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA; [Sherer, Mark] Inst Rehabil & Res Mem Hermann, Houston, TX USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA		Cuthbert, JP (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80132 USA.	jcuthbert@craighospital.org	Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Bushnik, Tamara/0000-0003-3328-257X	Traumatic Brain Injury Model Systems (TBIMS) National Data and Statistical Center Grant from the National Institute on Disability and Rehabilitation Research (NIDRR) [H133A110006]; TBIMS Centers grants from NIDRR [H133A120032]; Institute for Rehabilitation and Research Memorial Hermann [H133A120020]; Moss Rehabilitation Research Institute [H133A120037]; Spaulding Rehabilitation Hospital, Harvard Medical School [H133A120085]; Rusk Rehabilitation at New York University School of Medicine [H133A120100]; Indiana University School of Medicine [H133A120035]; TBIMS Follow-up Center subcontract via an NIDRR Prime Award [H133A110006]; NIDRR	Supported by the Traumatic Brain Injury Model Systems (TBIMS) National Data and Statistical Center Grant from the National Institute on Disability and Rehabilitation Research (NIDRR) (grant no. H133A110006); TBIMS Centers grants from NIDRR (grant no. H133A120032); The Institute for Rehabilitation and Research Memorial Hermann (grant no. H133A120020); Moss Rehabilitation Research Institute (grant no. H133A120037); Spaulding Rehabilitation Hospital, Harvard Medical School (grant no. H133A120085); Rusk Rehabilitation at New York University School of Medicine (grant no. H133A120100); Indiana University School of Medicine (grant no. H133A120035), and a TBIMS Follow-up Center subcontract via an NIDRR Prime Award (award no. H133A110006).; The TBIMS National Database is supported by the NIDRR and created and maintained by the TBIMS Centers Program.	Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Argyle M., 1999, WELL BEING FDN HEDON; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Bornstein M.H., 2003, WELL BEING POSITIVE; BROMAN CL, 1990, AM J COMMUN PSYCHOL, V18, P643, DOI 10.1007/BF00931235; [Bureau of Labor Statistics U.S. Department of Labor], 2012, REC 2007 2009; Carlier BE, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-503; [Centers for Disease Control and Prevention National Center for Injury Prevention and Control], 2013, WHAT AR POT EFF TBI; Corrigan J.D., 2003, TECHNICAL REPORT PRO; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P160, DOI 10.1097/HTR.0000000000000090; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Forslund MV, 2014, BRAIN INJURY, V28, P980, DOI 10.3109/02699052.2014.888770; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2010, J VOCAT REHABIL, V33, P65, DOI 10.3233/JVR-2010-0516; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langdon DS, 2002, MON LABOR REV, V125, P3; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Litz B.T., 2011, RESILIENCE MENTAL HL, P149; Lucas RE, 2004, PSYCHOL SCI, V15, P8, DOI 10.1111/j.0963-7214.2004.01501002.x; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McKee-Ryan FM, 2005, J APPL PSYCHOL, V90, P53, DOI 10.1037/0021-9010.90.1.53; Montgomery SM, 1999, INT J EPIDEMIOL, V28, P95, DOI 10.1093/ije/28.1.95; [National Institutes of Health National Institute of Neurological Disorders and Stroke], 2013, NINDS TRAUM BRAIN IN; Ponsford JL, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000033; Pretz CR, 2014, J HEAD TRAUMA REHAB, V29, pE65, DOI 10.1097/HTR.0000000000000025; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; Rotman D., 2013, MIT TECHNOLOGY REV; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Shigaki CL, 2009, DISABIL REHABIL, V31, P484, DOI 10.1080/09638280802240449; Soares Joaquim J. F., 2008, Cognitive Behaviour Therapy, V37, P50, DOI 10.1080/16506070701628016; The traumatic Brain Injury Model Systems National Data and statistical Center, 2014, TBI MOD SYST PRES; Thompkins A, 2014, APPLY NOT APPLY EMPL; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Westman M, 2004, HUM RELAT, V57, P823, DOI 10.1177/0018726704045767; WINEFIELD AH, 1991, BRIT J PSYCHOL, V82, P473, DOI 10.1111/j.2044-8295.1991.tb02414.x	50	37	37	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2015	96	12					2128	2136		10.1016/j.apmr.2015.07.020			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	CY6SZ	WOS:000366540400007	26278493				2022-02-06	
J	Varsos, GV; Werndle, MC; Czosnyka, ZH; Smielewski, P; Kolias, AG; Phang, I; Saadoun, S; Bell, BA; Zoumprouli, A; Papadopoulos, MC; Czosnyka, M				Varsos, Georgios V.; Werndle, Melissa C.; Czosnyka, Zofia H.; Smielewski, Peter; Kolias, Angelos G.; Phang, Isaac; Saadoun, Samira; Bell, B. Anthony; Zoumprouli, Argyro; Papadopoulos, Marios C.; Czosnyka, Marek			Intraspinal pressure and spinal cord perfusion pressure after spinal cord injury: an observational study	JOURNAL OF NEUROSURGERY-SPINE			English	Article						intraspinal pressure; spinal cord injury; biophysics; observation	INTRACRANIAL-PRESSURE; WAVE-FORM; OUTFLOW; ICP; CSF	OBJECT In contrast to intracranial pressure (ICP) in traumatic brain injury (TBI), intraspinal pressure (ISP) after traumatic spinal cord injury (TSCI) has not received the same attention in terms of waveform analysis. Based on a recently introduced technique for continuous monitoring of ISP, here the morphological characteristics of ISP are observationally described. It was hypothesized that the waveform analysis method used to assess ICP could be similarly applied to ISP. METHODS Data included continuous recordings of ISP and arterial blood pressure (ABP) in 18 patients with severe TSCI. RESULTS The morphology of the ISP pulse waveform resembled the ICP waveform shape and was composed of 3 peaks representing percussion, tidal, and dicrotic waves. Spectral analysis demonstrated the presence of slow, respiratory, and pulse waves at different frequencies. The pulse amplitude of ISP was proportional to the mean ISP, suggesting a similar exponential pressure-volume relationship as in the intracerebral space. The interaction between the slow waves of ISP and ABP is capable of characterizing the spinal autoregulatory capacity. CONCLUSIONS This preliminary observational study confirms morphological and spectral similarities between ISP in TSCI and ICP. Therefore, the known methods used for ICP waveform analysis could be transferred to ISP analysis and, upon verification, potentially used for monitoring TSCI patients.	[Varsos, Georgios V.; Czosnyka, Zofia H.; Smielewski, Peter; Kolias, Angelos G.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB3 0BN, England; [Werndle, Melissa C.; Phang, Isaac; Saadoun, Samira; Bell, B. Anthony; Papadopoulos, Marios C.] St Georges Univ London, Acad Neurosurg Unit, London, England; [Zoumprouli, Argyro] St George Hosp, Dept Anaesthesia, London, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland		Varsos, GV (corresponding author), Univ Cambridge, St Edmunds Coll, Cambridge CB3 0BN, England.	gv249@cam.ac.uk		Papadopoulos, Marios/0000-0001-9174-4176; Zoumprouli, Argyro/0000-0003-0890-690X; Saadoun, Samira/0000-0002-5480-5678; czosnyka, marek/0000-0003-2446-8006; Kolias, Angelos/0000-0003-3992-0587; Smielewski, Peter/0000-0001-5096-3938	A.G. Leventis Foundation Scholarship; St. Edmund's College, Cambridge, United Kingdom; Royal College of Surgeons of England Research Fellowship; National Institute for Health Research (NIHR) Academic Clinical FellowshipNational Institute for Health Research (NIHR); Raymond and Beverly Sackler Studentship; UK Spinal Cord Injuries Research Network (UKSCIRN); Neurosciences Research Foundation; UKSCIRN; Guthy Jackson Charitable Foundation; Wings for Life Spinal Cord Research Foundation; NIHR Cambridge Biomedical Center; Cambridge Enterprise, Cambridge, United Kingdom	Mr. Varsos is supported by an A.G. Leventis Foundation Scholarship and a Charter Studentship from St. Edmund's College, Cambridge, United Kingdom. Dr. Kolias is supported by a Royal College of Surgeons of England Research Fellowship, a National Institute for Health Research (NIHR) Academic Clinical Fellowship, and a Raymond and Beverly Sackler Studentship. Dr. Werndle is supported by the UK Spinal Cord Injuries Research Network (UKSCIRN), a Royal College of Surgeons of England Research Fellowship, and the Housham Fellowship from the Neurosciences Research Foundation. Dr. Papadopoulos is supported by the UKSCIRN and the Guthy Jackson Charitable Foundation, and is also funded by the Wings for Life Spinal Cord Research Foundation. Dr. Czosnyka is supported by NIHR Cambridge Biomedical Center. Drs. Czosnyka and Smielewski have a financial interest in a fraction of the licensing fee for ICM+Software, which is licensed by Cambridge Enterprise, Cambridge, United Kingdom, and used in this study.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; BORGESEN SE, 1982, BRAIN, V105, P65, DOI 10.1093/brain/105.1.65; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; Carrera E, 2010, J NEUROTRAUM, V27, P317, DOI 10.1089/neu.2009.0951; Czosnyka M, 2006, ACTA NEUROCHIR SUPPL, V96, P114; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; CZOSNYKA M, 1994, ACTA NEUROCHIR, V126, P113, DOI 10.1007/BF01476419; Czosnyka M, 1999, J NEUROSURG, V90, P752, DOI 10.3171/jns.1999.90.4.0752; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Czosnyka Marek, 1800, Neurosurg Focus, V22, pE10; DAVSON H, 1970, Brain Behavior and Evolution, V93, P665, DOI 10.1093/brain/93.4.665; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Howells T, 2012, INTENS CARE MED, V38, P1061, DOI 10.1007/s00134-012-2571-7; Kolias Angelos G, 2013, Pract Neurol, V13, P228, DOI 10.1136/practneurol-2012-000268; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P557; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; Miller J D, 1972, Prog Brain Res, V35, P411; Pearce JMS, 2006, J NEUROL NEUROSUR PS, V77, P728, DOI 10.1136/jnnp.2005.083618; RYDER HW, 1953, J LAB CLIN MED, V41, P428; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028	25	37	38	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	DEC	2015	23	6					763	771		10.3171/2015.3.SPINE14870			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CX0FI	WOS:000365371900012	26273764	Bronze			2022-02-06	
J	Qin, YB; Chen, ZS; Han, XL; Wu, HH; Yu, Y; Wu, J; Liu, S; Hou, YN				Qin, Yabin; Chen, Zesha; Han, Xiaolei; Wu, Honghai; Yu, Yang; Wu, Jie; Liu, Sha; Hou, Yanning			Progesterone attenuates A beta(25-35)-induced neuronal toxicity via JNK inactivation and progesterone receptor membrane component 1-dependent inhibition of mitochondrial apoptotic pathway	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						beta-Amyloid progesterone apoptosis PGRMC1 JNK	TRAUMATIC BRAIN-INJURY; SPINAL-CORD; UP-REGULATION; NEUROTROPHIC FACTOR; CELL-DEATH; IN-VIVO; EXPRESSION; ALLOPREGNANOLONE; PROTECTION; PEPTIDE	Progesterone, which acts as a neurosteroid in nervous system, has been shown to have neuroprotective effects in different experiments in vitro and in vivo. Our previous study demonstrates that progesterone exerts neuroprotections in Alzheimer's disease-like rats. Present study attempted to evaluate the protective effects of progesterone on A beta-treated neurons and potential mechanisms involved in neuroprotection. Results showed that treatment with progesterone protected primary cultured rat cortical neurons against A beta(25-35)-induced apoptosis. Furthermore, we observed that progesterone alleviated mitochondrial dysfunction by rescuing mitochondrial membrane potential under A beta challenge. Moreover, progesterone could also attenuate Bax/Bcl-2 proteins ratio upregulation and inhibit the activation of caspase-3 in A beta-treated neurons. These indicate that progesterone attenuates A beta(25-35)-induced neuronal toxicity by inhibiting mitochondria-associated apoptotic pathway. Both classic progesterone receptors (classic PR) and progesterone receptor membrane component 1 (PGRMC1), a special progesterone membrane receptor, are broadly expressed throughout the brain. The protective effect of progesterone was partially abolished by PGRMC1 inhibitor AG205 rather than classic PR antagonist RU486 in this study. Additionally, progesterone protected neurons by inhibiting A beta-induced activation of JNK, which was an upstream signaling component in A beta-induced mitochondria-associated apoptotic pathway. But this process was independent of PGRMC1. Taken together, these results suggest that progesterone exerts a protective effect against A beta(25-35)-induced insults at least in part by two complementary pathways: (1) progesterone receptor membrane component 1-dependent inhibition of mitochondrial apoptotic pathway, and (2) blocking A beta-induced JNK activation. The present study provides new insights into the mechanism by which progesterone brings neuroprotection. This article is part of a Special Issue entitled 'Steroids 82 Nervous System'. (C) 2015 Elsevier Ltd. All rights reserved.	[Qin, Yabin; Chen, Zesha; Wu, Jie; Liu, Sha; Hou, Yanning] Hebei Med Univ, Shijiazhuang 050017, Hebei Province, Peoples R China; [Han, Xiaolei; Wu, Honghai; Yu, Yang] Bethune Int Peace Hosp Chinese PLA, Dept Pharm, Shijiazhuang 050082, Hebei Province, Peoples R China		Hou, YN (corresponding author), Bethune Int Peace Hosp Chinese PLA, Dept Pharm, Shijiazhuang 050082, Hebei Province, Peoples R China.	biph2011@163.com		Hou, Yanning/0000-0001-7405-5643			Afrazi S, 2014, J STEROID BIOCHEM, V139, P98, DOI 10.1016/j.jsbmb.2013.10.010; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; Borowicz K.K., 2011, FRONT ENDOCRINOL, V2, P89; Carroll JC, 2010, ENDOCRINOLOGY, V151, P2713, DOI 10.1210/en.2009-1487; Cha MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034929; Chan WH, 2007, BIOCHEM J, V404, P317, DOI 10.1042/BJ20061875; Clement ME, 2006, BIOCHEM BIOPH RES CO, V342, P206, DOI 10.1016/j.bbrc.2006.01.137; Compagnone NA, 2008, J STEROID BIOCHEM, V109, P307, DOI 10.1016/j.jsbmb.2008.03.022; Cooke PS, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00108; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Espinosa-Garcia C, 2014, BRAIN RES, V1545, P23, DOI 10.1016/j.brainres.2013.11.030; Coronel MF, 2011, PAIN MED, V12, P1249, DOI 10.1111/j.1526-4637.2011.01178.x; Frye CA, 2008, NEUROBIOL LEARN MEM, V89, P17, DOI 10.1016/j.nlm.2007.09.008; Deniselle MCG, 2012, J NEUROCHEM, V122, P185, DOI 10.1111/j.1471-4159.2012.07753.x; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Guennoun R, 2015, J STEROID BIOCHEM, V146, P48, DOI 10.1016/j.jsbmb.2014.09.001; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hroudova J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/175062; Intlekofer KA, 2011, NEUROSCIENCE, V172, P55, DOI 10.1016/j.neuroscience.2010.10.051; Ishihara Y, 2013, J STEROID BIOCHEM, V135, P1, DOI 10.1016/j.jsbmb.2012.12.013; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Keil U, 2004, J BIOL CHEM, V279, P50310, DOI 10.1074/jbc.M405600200; Lazcano Z., 2014, SYNAPSE, V41, P126; Li JL, 2013, BASIC CLIN PHARMACOL, V113, P411, DOI 10.1111/bcpt.12124; Liu R, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-105; Liu S, 2013, NEURAL REGEN RES, V8, P2800, DOI 10.3969/j.issn.1673-5374.2013.30.002; Lopez V, 2009, J COMP NEUROL, V512, P124, DOI 10.1002/cne.21883; Ma SB, 2014, CELL DEATH DIFFER, V21, P1925, DOI 10.1038/cdd.2014.119; Nilsen J, 2006, GYNECOL ENDOCRINOL, V22, P355, DOI 10.1080/09513590600863337; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Paradis E, 1996, J NEUROSCI, V16, P7533; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Peluso JJ, 2006, ENDOCRINOLOGY, V147, P3133, DOI 10.1210/en.2006-0114; Peluso JJ, 2005, BIOL REPROD, V73, P261, DOI 10.1095/biolreprod.105.041061; Peluso JJ, 2008, ENDOCRINOLOGY, V149, P534, DOI 10.1210/en.2007-1050; Peluso JJ, 2009, J CLIN ENDOCR METAB, V94, P2644, DOI 10.1210/jc.2009-0147; Petersen S., 2013, FRONT NEUROSCI, V7, P489; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Singh M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00159; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Sun QR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098866; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.t01-1-00218.x; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Yan JP, 2013, J ETHNOPHARMACOL, V147, P456, DOI 10.1016/j.jep.2013.03.039; Yao MZ, 2007, J NEUROSCI, V27, P1422, DOI 10.1523/JNEUROSCI.2382-06.2007; Yousuf S, 2014, PSYCHOPHARMACOLOGY, V231, P3313, DOI 10.1007/s00213-014-3556-8; Zhang L, 2010, NEUROCHEM INT, V57, P547, DOI 10.1016/j.neuint.2010.06.021; Zhao X.D., 2008, J SURG RES, V171, pe47	51	37	40	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	NOV	2015	154						302	311		10.1016/j.jsbmb.2015.01.002			10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CV4QI	WOS:000364251200034	25576906				2022-02-06	
J	Caron, JG; Bloom, GA; Falcao, WR; Sweet, SN				Caron, Jeffrey G.; Bloom, Gordon A.; Falcao, William R.; Sweet, Shane N.			An examination of concussion education programmes: a scoping review methodology	INJURY PREVENTION			English	Article							ASSOCIATION POSITION STATEMENT; FOR-DISEASE-CONTROL; HIGH-SCHOOL; CDC HEADS; KNOWLEDGE; HOCKEY; SPORT; MANAGEMENT; CONSENSUS; COACHES	Objectives The primary purpose was to review the literature on concussion education programmes. The secondary purpose was to inform knowledge translation strategies for concussion researchers and practitioners. Design Research on concussion education programmes is relatively new. As a result, the current study implemented a scoping review methodology, which is a type of literary search used to provide a preliminary assessment of the size and scope of a body of literature, as well as identify strengths, weaknesses and gaps in the research. Methods A five-stage process for conducting a scoping review was followed for this study: (a) identifying the research questions, (b) identifying relevant studies, (c) identifying the study selection criteria, (d) charting the data and (e) reporting the results. Results Concussion education programmes have been developed and implemented with populations ranging in age from 9 to 49 years and have used interactive oral presentations, educational videos and computer-based learning programmes. Although the content of these programmes varied, the topics generally addressed salient aspects of concussion injury and recovery. Quantitative instruments have been the preferred methods for assessment. Conclusions Education programmes aimed at improving participants' long-term concussion knowledge, behaviours and attitudes of concussions are needed. Researchers must consider using a knowledge translation framework to enhance concussion education programmes. The application of such a framework can lead to novel and interesting ways of disseminating information about concussive injury and recovery.	[Caron, Jeffrey G.; Bloom, Gordon A.; Falcao, William R.; Sweet, Shane N.] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ H2W 1S4, Canada		Caron, JG (corresponding author), McGill Univ, Dept Kinesiol & Phys Educ, 475 Pine Ave West, Montreal, PQ H2W 1S4, Canada.	jeffrey.caron@mail.mcgill.ca					Adler RH, 2011, ARCH PHYS MED REHAB, V3, P468; Affoo RH, 2013, J AM GERIATR SOC, V61, P2203, DOI 10.1111/jgs.12553; Ahmed OH, 2012, BRIT J SPORT MED, V46, P675, DOI 10.1136/bjsm.2010.081620; Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Canadian Institutes of Health Research, KNOWL TRANSL COMM; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Carroll Linda, 2012, CONCUSSION CRISIS AN; Centers for Disease Control and Prevention, CONC SPORT POL; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Creswell J. W., 2016, QUAL INQ; Cusimano MD, 2014, BRIT J SPORT MED, V48, P141, DOI 10.1136/bjsports-2012-091660; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; DeMatteo C, 2015, DISABIL REHABIL, V37, P1107, DOI 10.3109/09638288.2014.952452; Echlin P. S., 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2010.9FOCUS10187; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Graham ID, 2006, J CONTIN EDUC HEALTH, V26, P13, DOI 10.1002/chp.47; Grant MJ, 2009, HEALTH INFO LIBR J, V26, P91, DOI 10.1111/j.1471-1842.2009.00848.x; Grimshaw JM, 2001, MED CARE, V39, pII2; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Koh JO, 2011, J SPORT MED PHYS FIT, V51, P625; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Krueger R.A., 2000, FOCUS GROUP PRACTICA; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Manasse-Cohick NJ, 2014, COMMUN DISORD Q, V35, P182, DOI 10.1177/1525740113506605; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Moore L, 2013, J TRAUMA ACUTE CARE, V74, P1331, DOI 10.1097/TA.0b013e31828c4787; O'Brien K, 2010, AIDS BEHAV, V14, P448, DOI 10.1007/s10461-009-9528-z; Paradis E, 2013, J CRIT CARE, V28, P1062, DOI 10.1016/j.jcrc.2013.05.015; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Riekert K., 2014, HDB HLTH BEHAV CHANG; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Rubin IS, 2012, QUALITATIVE INTERVIE; Sarmiento K, 2014, J SAFETY RES, V50, P143, DOI 10.1016/j.jsr.2014.05.003; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Straus SE, 2013, KNOWLEDGE TRANSLATION IN HEALTH CARE: MOVING FROM EVIDENCE TO PRACTICE, 2ND EDITION, P1, DOI 10.1002/9781118413555; Straus SE, 2013, KNOWLEDGE TRANSLATION IN HEALTH CARE: MOVING FROM EVIDENCE TO PRACTICE, 2ND EDITION, P227; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Williams D, 2014, BRIT J SPORT MED, V48, P107, DOI 10.1136/bjsports-2012-091853	52	37	37	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	OCT	2015	21	5					301	308		10.1136/injuryprev-2014-041479			8	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	CT4MC	WOS:000362779600003	25825353	Green Submitted, Bronze			2022-02-06	
J	Ruozi, B; Belletti, D; Sharma, HS; Sharma, A; Muresanu, DF; Mossler, H; Forni, F; Vandelli, MA; Tosi, G				Ruozi, Barbara; Belletti, Daniela; Sharma, Hari S.; Sharma, Aruna; Muresanu, Dafin F.; Moessler, Herbert; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni			PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Nanoparticles (NPs); Polylactic-co-glycolide (PLGA); Cerebrolysin; Long-termstability; Serumstability; Traumatic brain injury; Neuroprotection	WHOLE-BODY HYPERTHERMIA; CEREBRAL BLOOD-FLOW; NORMOTENSIVE YOUNG-RATS; SPINAL-CORD-INJURY; BARRIER PERMEABILITY; NEUROTROPHIC FACTORS; SOLVENT EVAPORATION; EDEMA FORMATION; DRUG-DELIVERY; 5-HT LEVEL	Cerebrolysin is a peptide mixture able to ameliorate symptomatology and delay progression of neurological disorders such as Alzheimer's disease and dementia. The administration of this drug in humans presents several criticisms due to its short half-life, poor stability, and high doses needed to achieve the effect. This paper investigates the potential of polylactic-co-glycolide (PLGA) nanoparticles (NPs) as sustained release systems for iv administration of cerebrolysin in normal and brain injured rats. NPs were prepared by water-in-oil-in-water (w/o/w) double emulsion technique and characterized by light scattering for mean size and zeta potential and by scanning electron microscopy (SEM) for surface morphology. The NPs produced by double sonication under cooling at 60 W for 45 s, 12 mL of 1 % w:v of PVA, and 1:0.6 w:w drug/PLGA ratio (C-NPs4) displayed an adequate loading of drug (24 +/- 1 mg/100 mg of NPs), zeta potential value (-13 mV), and average diameters (ranged from 250 to 330 nm) suitable to iv administration. SEM images suggested that cerebrolysin was molecularly dispersed into matricial systems and partially adhered to the NP surface. A biphasic release with an initial burst effect followed by sustained release over 24 h was observed. Long-term stability both at room and at low temperature of freeze-dried NPs was investigated. To gain deeper insight into NP stability after in vivo administration, the stability of the best NP formulation was also tested in serum. These PLGA NPs loaded with cerebrolysin were able to reduce brain pathology following traumatic brain injury. However, the size, the polydispersivity, and the surface properties of sample were significantly affected by the incubation time and the serum concentration.	[Ruozi, Barbara; Belletti, Daniela; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni] Univ Modena & Reggio Emilia, Dept Life Sci, Lab Pharmaceut Technol, I-41125 Modena, Italy; [Sharma, Hari S.; Sharma, Aruna] Uppsala Univ, Univ Uppsala Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden; [Muresanu, Dafin F.] Univ Med & Pharm, Univ Hosp, Dept Clin Neurosci, Cluj Napoca, Romania; [Moessler, Herbert] Ever Neuro Pharma, Oberburgau, Austria; [Sharma, Hari S.] Univ Uppsala Hosp, IECNSIR, SE-75421 Uppsala, Sweden		Sharma, HS (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden.	Sharma@surgsci.uu.se	Muresanu, Fior-Dafin/AAI-8120-2021; Belletti, Daniela/L-5288-2016; Tosi, Giovanni/D-4547-2011	Belletti, Daniela/0000-0003-2872-445X; Tosi, Giovanni/0000-0001-8318-667X	Air Force Office of Scientific Research (EOARD, London, UK)United States Department of DefenseAir Force Office of Scientific Research (AFOSR); Air Force Material Command, USAF [FA8655-05-1-3065]; Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [Nr 2710-HSS]; Swedish Strategic Research Foundation, Stockholm, Sweden; Goran Gustafsson Foundation, Stockholm, Sweden; Astra Zeneca, Molndal, SwedenAstraZeneca; University Grants Commission, New Delhi, IndiaUniversity Grants Commission, India; Ministry of Science and Technology, Govt. of India and Govt. of Sweden; Indian Medical Research Council, New Delhi, India; India-EU Research Co-operation Program	This investigation is supported in part by grants from the Air Force Office of Scientific Research (EOARD, London, UK), and Air Force Material Command, USAF, under grant number FA8655-05-1-3065; Swedish Medical Research Council (Nr 2710-HSS), Swedish Strategic Research Foundation, Stockholm, Sweden; Goran Gustafsson Foundation, Stockholm, Sweden (HSS), Astra Zeneca, Molndal, Sweden (HSS/AS), The University Grants Commission, New Delhi, India (HSS/AS), Ministry of Science and Technology, Govt. of India and Govt. of Sweden (HSS/AS), Indian Medical Research Council, New Delhi, India (HSS/AS); and India-EU Research Co-operation Program (AS/HSS).	Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017; Belletti D, 2012, INT J PHARMACEUT, V436, P753, DOI 10.1016/j.ijpharm.2012.07.070; Biswal I., 2011, INT J PHARM PHARM SC, V3, P256; BODMEIER R, 1987, PHARMACEUT RES, V4, P465, DOI 10.1023/A:1016419303727; Costantino L, 2005, J CONTROL RELEASE, V108, P84, DOI 10.1016/j.jconrel.2005.07.013; DEY PK, 1983, INDIAN J MED RES, V77, P554; Dobson J, 2006, GENE THER, V13, P283, DOI 10.1038/sj.gt.3302720; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; Feczko T, 2011, CHEM ENG PROCESS, V50, P757, DOI 10.1016/j.cep.2011.06.008; Gromova OA, 2003, ZH NEVROPATOL PSIKH, V103, P59; Hartbauer M, 2001, J NEURAL TRANSM, V108, P459, DOI 10.1007/s007020170067; Heurtault B, 2003, BIOMATERIALS, V24, P4283, DOI 10.1016/S0142-9612(03)00331-4; JOSHI DP, 1979, ANAL CHIM ACTA, V104, P153, DOI 10.1016/S0003-2670(01)83825-3; Katas H, 2013, J NANOMATER, V2013, DOI 10.1155/2013/536291; Liu WM, 2001, SPECTROSC SPECT ANAL, V21, P397; Menon JU, 2012, J BIOMED MATER RES A, V100A, P1998, DOI 10.1002/jbm.a.34040; MOHANTY S, 1989, J NEUROL SCI, V90, P87, DOI 10.1016/0022-510X(89)90048-8; Naahidi S, 2013, J CONTROL RELEASE, V166, P182, DOI 10.1016/j.jconrel.2012.12.013; Rosca ID, 2004, J CONTROL RELEASE, V99, P271, DOI 10.1016/j.jconrel.2004.07.007; Ruozi B, 2012, INT REV NEUROBIOL, V102, P207, DOI 10.1016/B978-0-12-386986-9.00009-0; Ruozi B, 2014, CNS NEUROL DISORD-DR, V13, P1475, DOI 10.2174/1871527313666140806145540; Sharma A, 2012, CNS NEUROL DISORD-DR, V11, P7, DOI 10.2174/187152712799960790; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P112, DOI 10.1196/annals.1403.008; Sharma HS, 2007, PROG BRAIN RES, V162, P173, DOI 10.1016/S0079-6123(06)62010-4; Sharma HS, 2014, J NANOSCI NANOTECHNO, V14, P577, DOI 10.1166/jnn.2014.9213; Sharma HS, 2012, INT REV NEUROBIOL, V102, P249, DOI 10.1016/B978-0-12-386986-9.00010-7; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P125, DOI 10.1111/j.1749-6632.2009.05329.x; Sharma HS, 2010, ACTA NEUROCHIR SUPPL, V106, P321, DOI 10.1007/978-3-211-98811-4_60; Sharma HS, 2010, ACTA NEUROCHIR SUPPL, V106, P295, DOI 10.1007/978-3-211-98811-4_55; SHARMA HS, 1986, NEUROPHARMACOLOGY, V25, P161, DOI 10.1016/0028-3908(86)90037-7; SHARMA HS, 1987, NEUROPHARMACOLOGY, V26, P85, DOI 10.1016/0028-3908(87)90049-9; SHARMA HS, 1995, RESTOR NEUROL NEUROS, V7, P207, DOI 10.3233/RNN-1994-7403; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SHARMA HS, 1987, BRAIN RES, V424, P153, DOI 10.1016/0006-8993(87)91205-4; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; Tosi G, 2010, J CONTROL RELEASE, V145, P49, DOI 10.1016/j.jconrel.2010.03.008; Tosi G, 2012, NANOMEDICINE-UK, V7, P365, DOI [10.2217/NNM.11.98, 10.2217/nnm.11.98]; Westman, 2004, BLOOD SPINAL CORD BR, P117; Zhang Y, 2013, ADV DRUG DELIVER REV, V65, P104, DOI 10.1016/j.addr.2012.10.003	40	37	38	0	25	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	OCT	2015	52	2			SI		899	912		10.1007/s12035-015-9235-x			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CQ6AQ	WOS:000360687200009	26108180				2022-02-06	
J	Ventura, RE; Balcer, LJ; Galetta, SL				Ventura, Rachel E.; Balcer, Laura J.; Galetta, Steven L.			The Concussion Toolbox: The Role of Vision in the Assessment of Concussion	SEMINARS IN NEUROLOGY			English	Article						concussion; vision; testing; head impact; neuro-ophthalmology	TRAUMATIC BRAIN-INJURY; ERROR SCORING SYSTEM; MAGNETIC-RESONANCE-SPECTROSCOPY; SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; VISUAL SCREENING TOOL; HIGH-SCHOOL; STANDARDIZED ASSESSMENT; EYE-MOVEMENTS; OCULOMOTOR DEFICITS	Concussion may lead to subtle changes in brain function, and tests involving the visual system probe higher cortical functioning and increase our sensitivity in detecting these changes. Concussions are acutely and sometimes more persistently associated with abnormalities in balance, cognition, and vision. The visual system involves roughly half of the brain's circuits, including many regions susceptible to head impacts. After a concussion, the neuro-ophthalmologic exam commonly detects abnormalities in convergence, accommodation, the vestibulo-ocular reflex, ocular muscle balance, saccades, and pursuit. The King-Devick (K-D) test is a visual performance measure that may increase the sensitivity of detecting concussions on the sideline when used in combination with tests of cognition and balance that are part of the Sports Concussion Assessment Tool (3rd ed.; SCAT3). Portable eye movement trackers and pupillometry may in the future improve our neuro-ophthalmic assessment after concussions. Combining visual tasks with neuroimaging and neurophysiology has allowed subtle changes to be detected, may refine our ability to make appropriate return-to-play decisions, and could potentially determine susceptibility to long-term sequelae of concussion.	[Ventura, Rachel E.; Balcer, Laura J.; Galetta, Steven L.] NYU, Sch Med, Dept Neurol, 240 East 38th St,20th Floor, New York, NY 10016 USA		Galetta, SL (corresponding author), NYU, Sch Med, Dept Neurol, 240 East 38th St,20th Floor, New York, NY 10016 USA.	Steven.Galetta@nyumc.org		Ventura, Rachel/0000-0001-8155-0546			Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Capo-Aponte J.E., 2013, J SPINE, V4, DOI [10.4172/2165-7939.S4-004, DOI 10.4172/2165-7939.S4-004]; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chang JO, 2014, CLIN J SPORT MED, V24, P256, DOI 10.1097/JSM.0000000000000016; Cifu DX, 2015, J HEAD TRAUMA REHAB, V30, P21, DOI 10.1097/HTR.0000000000000036; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Beaumont L, 2013, J CLIN EXP NEUROPSYC, V35, P596, DOI 10.1080/13803395.2013.800023; Dean PJA, 2013, NEUROREPORT, V24, P677, DOI 10.1097/WNR.0b013e3283637aa4; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; FitzGerald DB, 2011, INT J PSYCHOPHYSIOL, V82, P79, DOI 10.1016/j.ijpsycho.2011.02.011; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEUROOPHTHALMOL; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gosselin N, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12253; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harpham JA, 2014, ANN BIOMED ENG, V42, P1, DOI 10.1007/s10439-013-0881-8; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132090, 10.3171/2013.12.JNS132093]; Hutton SB, 2008, BRAIN COGNITION, V68, P327, DOI 10.1016/j.bandc.2008.08.021; Johnson B, 2015, BRAIN IMAGING BEHAV, V9, P564, DOI 10.1007/s11682-014-9316-x; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Jones NS, 2014, CLIN J SPORT MED, V24, P284, DOI 10.1097/JSM.0000000000000031; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Liu GT, 2010, NEUROOPHTHALMOLOGY D, P551; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Luoto TM, 2014, J NEUROTRAUM, V31, P728, DOI 10.1089/neu.2013.3174; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marinides Zoe, 2015, Neurol Clin Pract, V5, P25, DOI 10.1212/CPJ.0000000000000060; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meier TB, 2015, J SCI MED SPORT, V18, P507, DOI 10.1016/j.jsams.2014.07.008; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Pierrot-Deseilligny C, 2003, BRAIN, V126, P1460, DOI 10.1093/brain/awg148; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schneiders AG, 2012, SCAND J MED SCI SPOR, V22, P85, DOI 10.1111/j.1600-0838.2010.01141.x; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Singman E., 2013, MED INSTRUM, DOI [10.7243/2052-6962-1-3, DOI 10.7243/2052-6962-1-3]; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Thiagarajan P, 2014, J REHABIL RES DEV, V51, P175, DOI 10.1682/JRRD.2013.01.0027; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Truong JQ, 2014, BRAIN INJURY, V28, P1283, DOI 10.3109/02699052.2014.915989; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Valovich TC, 2003, J ATHL TRAINING, V38, P51; White OB, 2012, J NEURO-OPHTHALMOL, V32, P266, DOI 10.1097/WNO.0b013e3182688230	79	37	37	0	37	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	OCT	2015	35	5					599	606		10.1055/s-0035-1563567			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CS9AZ	WOS:000362382800015	26444405				2022-02-06	
J	Johnson, B; Hallett, M; Slobounov, S				Johnson, Brian; Hallett, Mark; Slobounov, Semyon			Follow-up evaluation of oculomotor performance with fMRI in the subacute phase of concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; EYE-MOVEMENT	Objective:To expand on our previous study by performing a follow-up testing session in the subacute phase of injury for participants recently diagnosed with a concussion.Methods:A battery of oculomotor tests were administered to participants 30 days postconcussion while simultaneous fMRI was performed.Results:Three of the 7 oculomotor tasks (antisaccade, self-paced saccade, and memory-guided saccade) administered showed significant differences between the recently concussed group compared with normal volunteers. However, performance in these 3 tasks did show improvement from the acute phase of injury. The fMRI analysis revealed significant differences in brain activation patterns compared with normal volunteers, with the concussed group still demonstrating increased and larger areas of activation. Similar to the oculomotor performance, the fMRI analysis showed that at 30 days postinjury, the concussed group more closely mirrored that of the normal volunteer group compared with at 7 days following insult.Conclusions:Even at 30 days postinjury, and despite being clinically asymptomatic, advanced techniques are able to detect subtle lingering alterations in the concussed brain. Therefore, progressive neuroimaging techniques such as fMRI in conjunction with assessment of oculomotor performance may be beneficial in clinical management of concussion.	[Johnson, Brian; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Slobounov, Semyon] Penn State Milton S Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA; [Hallett, Mark; Slobounov, Semyon] NINDS, NIH, Bethesda, MD 20892 USA		Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA.	sms18@psu.edu					Bartels A, 2008, TRENDS NEUROSCI, V31, P444, DOI 10.1016/j.tins.2008.06.004; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Brown MRG, 2006, NEUROIMAGE, V33, P644, DOI 10.1016/j.neuroimage.2006.07.002; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Johnson B, 2014, BRAIN IMAGING BEHAV; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Wade NJ, 2010, PERCEPTION, V39, P1150	10	37	37	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP 29	2015	85	13					1163	1166		10.1212/WNL.0000000000001968			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CX4CF	WOS:000365645100002	26320202	Green Published			2022-02-06	
J	Dretsch, MN; Silverberg, ND; Iverson, GL				Dretsch, Michael N.; Silverberg, Noah D.; Iverson, Grant L.			Multiple Past Concussions Are Associated with Ongoing Post-Concussive Symptoms but Not Cognitive Impairment in Active-Duty Army Soldiers	JOURNAL OF NEUROTRAUMA			English	Article						post-concussion symptoms; military; concussion; neurocognitive; PTSD	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHOLOGICAL PERFORMANCE; POSTCONCUSSIVE SYMPTOMS; RECURRENT CONCUSSION; IRAQI FREEDOM; HISTORY; INSTRUMENT; TBI	The extent to which multiple past concussions are associated with lingering symptoms or mental health problems in military service members is not well understood. The purpose of this study was to examine the association between lifetime concussion history, cognitive functioning, general health, and psychological health in a large sample of fit-for-duty U.S. Army soldiers preparing for deployment. Data on 458 active-duty soldiers were collected and analyzed. A computerized cognitive screening battery (CNS-Vital Signs((R))) was used to assess complex attention (CA), reaction time (RT), processing speed (PS), cognitive flexibility (CF), and memory. Health questionnaires included the Neurobehavioral Symptom Inventory (NSI), PTSD Checklist-Military Version (PCL-M), Zung Depression and Anxiety Scales (ZDS; ZAS), Perceived Stress Scale (PSS), Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and the Alcohol Use and Dependency Identification Test (AUDIT). Soldiers with a history of multiple concussions (i.e., three or more concussions) had significantly greater post-concussive symptom scores compared with those with zero (d=1.83, large effect), one (d=0.64, medium effect), and two (d=0.64, medium effect) prior concussions. Although the group with three or more concussions also reported more traumatic stress symptoms, the results revealed that traumatic stress was a mediator between concussions and post-concussive symptom severity. There were no significant differences on neurocognitive testing between the number of concussions. These results add to the accumulating evidence suggesting that most individuals recover from one or two prior concussions, but there is a greater risk for ongoing symptoms if one exceeds this number of injuries.	[Dretsch, Michael N.] US Army Aeromed Res Lab, Ft Rucker, AL USA; [Dretsch, Michael N.] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD 20889 USA; [Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC V5Z 1M9, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA		Dretsch, MN (corresponding author), Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, 4860 South Palmer Rd, Bethesda, MD 20889 USA.	Michael.n.dretsch.mil@mail.mil		Iverson, Grant/0000-0001-7348-9570	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]; U.S. Army Aeromedical Research Laboratory	The views expressed in this article are those of the authors and do not reflect the official policy of the Department of Defense or the U.S. government. Primary funding for this study was provided by the U.S. Army Medical Research and Materiel Command (provided to Dr. Michael Dretsch as the PI). Dr. Grant Iverson notes that this work was supported in part by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). The authors wish to thank the U.S. Army Aeromedical Research Laboratory for its support during the time this study was conducted. Preliminary findings from this study were presented at the 2014 Annual Military Health System Research Symposium, Fort Lauderdale, FL.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Campbell DW, 1970, RADIOLOGY, V94, P198, DOI 10.1148/94.1.198b; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Coldren RL, 2012, MIL MED, V177, P179, DOI 10.7205/MILMED-D-11-00278; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GOODMAN LA, 1960, J AM STAT ASSOC, V55, P708, DOI 10.2307/2281592; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kelly MP, 2012, ARCH CLIN NEUROPSYCH, V27, P375, DOI 10.1093/arclin/acs036; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; Miller KJ, 2013, J HEAD TRAUMA REHAB, V28, P31, DOI 10.1097/HTR.0b013e318255ceae; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Orsillo S.M., 2001, PRACTITIONERS GUIDE, P255, DOI DOI 10.1007/0-306-47628-2_20; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2006, NEUROLOGY, V66, pA235; Soble JR, 2014, CLIN NEUROPSYCHOL, V28, P614, DOI 10.1080/13854046.2014.894576; Spira JL, 2014, J NEUROTRAUM, V31, P1823, DOI 10.1089/neu.2014.3363; Stemper BD, 2014, PROG NEUROL SURG, V28, P14, DOI 10.1159/000358748; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Waldron-Perrine B, 2014, MIL MED, V179, P856, DOI 10.7205/MILMED-D-13-00282; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371; ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P164	42	37	37	2	28	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2015	32	17					1301	1306		10.1089/neu.2014.3810			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CP0KP	WOS:000359564500003	25763565				2022-02-06	
J	Lepeta, K; Kaczmarek, L				Lepeta, Katarzyna; Kaczmarek, Leszek			Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia	SCHIZOPHRENIA BULLETIN			English	Article						synaptic plasticity; glutamate; extracellular matrix	LONG-TERM POTENTIATION; FRAGILE-X-SYNDROME; MATRIX-METALLOPROTEINASE ACTIVITY; TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; GENE-EXPRESSION; DOUBLE-BLIND; FUNCTIONAL POLYMORPHISM; NEGATIVE SYMPTOMS; BIPOLAR DISORDER	Recent findings implicate alterations in glutamate signaling, leading to aberrant synaptic plasticity, in schizophrenia. Matrix metalloproteinase-9 (MMP-9) has been shown to regulate glutamate receptors, be regulated by glutamate at excitatory synapses, and modulate physiological and morphological synaptic plasticity. By means of functional gene polymorphism, gene responsiveness to antipsychotics and blood plasma levels MMP-9 has recently been implicated in schizophrenia. This commentary critically reviews these findings based on the hypothesis that MMP-9 contributes to pathological synaptic plasticity in schizophrenia.	[Lepeta, Katarzyna; Kaczmarek, Leszek] M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, PL-02093 Warsaw, Poland		Kaczmarek, L (corresponding author), M Nencki Inst Expt Biol, Dept Mol & Cellular Neurobiol, 3 Pasteur St, PL-02093 Warsaw, Poland.	l.kaczmarek@nencki.gov.pl	Kaczmarek, Leszek/B-6171-2008	Kaczmarek, Leszek/0000-0002-7207-3490; Lepeta, Katarzyna/0000-0002-6870-0009	European Innovative Economy Operational Program	The Foundation for Polish Science (FNP) TEAM grant financed by the European Innovative Economy Operational Program.	Akil M, 1999, AM J PSYCHIAT, V156, P1580, DOI 10.1176/ajp.156.10.1580; [Anonymous], 2015, REUTERS; Aujla PK, 2014, J COMP NEUROL, V522, P1249, DOI 10.1002/cne.23468; Bilousova TV, 2009, J MED GENET, V46, P94, DOI 10.1136/jmg.2008.061796; Bunney WE, 2000, BRAIN RES REV, V31, P138, DOI 10.1016/S0165-0173(99)00031-4; Chang SH, 2011, PSYCHIAT RES, V187, P341, DOI 10.1016/j.psychres.2010.04.049; Chopra K, 2014, EXPER OPIN THER TAR, P1; Domenici E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009166; Dziembowska M, 2013, AM J MED GENET A, V161, P1897, DOI 10.1002/ajmg.a.36023; Dziembowska M, 2012, J NEUROSCI, V32, P14538, DOI 10.1523/JNEUROSCI.6028-11.2012; Favalli G, 2012, J PSYCHIATR RES, V46, P1, DOI 10.1016/j.jpsychires.2011.09.022; Fragkouli A, 2012, J NEUROCHEM, V121, P239, DOI 10.1111/j.1471-4159.2011.07637.x; Fromer M, 2014, NATURE, V506, P179, DOI 10.1038/nature12929; Fujita Y, 2008, PROG NEURO-PSYCHOPH, V32, P336, DOI 10.1016/j.pnpbp.2007.08.031; Gawlak M, 2009, NEUROSCIENCE, V158, P167, DOI 10.1016/j.neuroscience.2008.05.045; Gkogkas CG, 2014, CELL REP, V9, P1742, DOI 10.1016/j.celrep.2014.10.064; Groszewska A, 2011, PSYCHIATR POL, V45, P317; Gurling HMD, 2001, AM J HUM GENET, V68, P661, DOI 10.1086/318788; Han HY, 2011, PSYCHIAT RES, V190, P163, DOI 10.1016/j.psychres.2011.04.026; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Huntley GW, 2012, NAT REV NEUROSCI, V13, P743, DOI 10.1038/nrn3320; Janusz A, 2013, J NEUROSCI, V33, P18234, DOI 10.1523/JNEUROSCI.2207-13.2013; Je HS, 2012, P NATL ACAD SCI USA, V109, P15924, DOI 10.1073/pnas.1207767109; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Kelly EA, 2014, J COMP NEUROL, V522, P676, DOI 10.1002/cne.23440; Knapska E, 2013, J NEUROSCI, V33, P14591, DOI 10.1523/JNEUROSCI.5239-12.2013; Konopacki FA, 2007, NEUROSCIENCE, V150, P31, DOI 10.1016/j.neuroscience.2007.08.026; Kumarasinghe N, 2013, INT J NEUROPSYCHOPH, V16, P1483, DOI 10.1017/S1461145713000035; Leigh MJS, 2013, J DEV BEHAV PEDIATR, V34, P147, DOI 10.1097/DBP.0b013e318287cd17; Levkovitz Y, 2010, J CLIN PSYCHIAT, V71, P138, DOI 10.4088/JCP.08m04666yel; Lin CY, 2012, NEUROBIOL DIS, V45, P48, DOI 10.1016/j.nbd.2011.08.025; Liu F, 2014, SCHIZOPHR RES, V153, P169, DOI 10.1016/j.schres.2014.01.011; Mackowiak M, 2014, PHARMACOL REP, V66, P830, DOI 10.1016/j.pharep.2014.04.011; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Mash DC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001187; Meyer-Lindenberg A, 2012, NAT NEUROSCI, V15, P663, DOI 10.1038/nn.3083; Michaluk P, 2007, CELL DEATH DIFFER, V14, P1255, DOI 10.1038/sj.cdd.4402141; Michaluk P, 2011, J CELL SCI, V124, P3369, DOI 10.1242/jcs.090852; Michaluk P, 2009, J NEUROSCI, V29, P6007, DOI 10.1523/JNEUROSCI.5346-08.2009; Mizoguchi H, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/681385; Moyer CE, 2014, NEUROSCI LETT; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Niitsu T, 2014, PSYCHIAT RES, V215, P268, DOI 10.1016/j.psychres.2013.12.009; O'Dushlaine C, 2015, NAT NEUROSCI, V18, P199, DOI 10.1038/nn.3922; Okulski P, 2007, BIOL PSYCHIAT, V62, P359, DOI 10.1016/j.biopsych.2006.09.012; Oya K, 2014, HUM PSYCHOPHARM CLIN, V29, P483, DOI 10.1002/hup.2426; Paribello C, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-91; Peixoto RT, 2012, NEURON, V76, P396, DOI 10.1016/j.neuron.2012.07.006; Rivera S, 2010, J NEUROSCI, V30, P15337, DOI 10.1523/JNEUROSCI.3467-10.2010; Roberts RC, 1996, NEUROREPORT, V7, P1214, DOI 10.1097/00001756-199604260-00024; Rybakowski JK, 2009, NEUROMOL MED, V11, P128, DOI 10.1007/s12017-009-8072-3; Rybakowski JK, 2009, SCHIZOPHR RES, V109, P90, DOI 10.1016/j.schres.2009.02.005; Samochowiec A, 2010, BRAIN RES, V1327, P103, DOI 10.1016/j.brainres.2010.02.072; Sidhu H, 2014, J NEUROSCI, V34, P9867, DOI 10.1523/JNEUROSCI.1162-14.2014; Smith ACW, 2014, NAT NEUROSCI, V17, P1655, DOI 10.1038/nn.3846; Stawarski M, 2014, BIOMATERIALS, V35, P1402, DOI 10.1016/j.biomaterials.2013.11.033; STJEAN PL, 1995, ANN HUM GENET, V59, P17; Szepesi Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098274; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Szklarczyk A., 2005, BIOTECHNOLOGY INT, V17, P15; Tsilibary E, 2014, PROG BRAIN RES, V214, P135, DOI 10.1016/B978-0-444-63486-3.00006-2; van der Kooij MA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5995; Wang LW, 2010, NEUROTHERAPEUTICS, V7, P264, DOI 10.1016/j.nurt.2010.05.005; Wang XB, 2008, P NATL ACAD SCI USA, V105, P19520, DOI 10.1073/pnas.0807248105; Wiera G, 2013, HIPPOCAMPUS, V23, P529, DOI 10.1002/hipo.22112; Wilczynski GM, 2008, J CELL BIOL, V180, P1021, DOI 10.1083/jcb.200708213; Wright JW, 2004, BRAIN RES, V1023, P1, DOI 10.1016/j.brainres.2004.06.083; Yamamori H, 2013, NEUROSCI LETT, V556, P37, DOI 10.1016/j.neulet.2013.09.059; Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788	70	37	39	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	SEP	2015	41	5					1003	1009		10.1093/schbul/sbv036			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	CV0YM	WOS:000363979800002	25837304	Green Published, Bronze			2022-02-06	
J	Weaver, LC; Bao, F; Dekaban, GA; Hryciw, T; Shultz, SR; Cain, DP; Brown, A				Weaver, Lynne C.; Bao, Feng; Dekaban, Gregory A.; Hryciw, Todd; Shultz, Sandy R.; Cain, Donald P.; Brown, Arthur			CD11d integrin blockade reduces the systemic inflammatory response syndrome after traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Systemic inflammatory response; Lung damage; Anti-integrin treatment; Lung	SPINAL-CORD-INJURY; ACUTE LUNG INJURY; ACUTE-PHASE RESPONSE; TRANSCRIPTION FACTOR NRF2; FLUID PERCUSSION INJURY; LEUKOCYTE MOBILIZATION; ORGAN DYSFUNCTION; ALPHA-D; PROTEIN; EXPRESSION	Traumatic CNS injury triggers a systemic inflammatory response syndrome (SIRS), in which circulating inflammatory cells invade body organs causing local inflammation and tissue damage. We have shown that the SIRS caused by spinal cord injury is greatly reduced by acute intravenous treatment with an antibody against the CD11d subunit of the CD11d/CD18 integrin expressed by neutrophils and monocyte/macrophages, a treatment that reduces their efflux from the circulation. Traumatic brain injury (TBI) is a frequently occurring injury after motor vehicle accidents, sporting and military injuries, and falls. Our studies have shown that the anti-CD11d treatment diminishes brain inflammation and oxidative injury after moderate or mild TB!, improving neurological outcomes. Accordingly, we examined the impact of this treatment on the SIRS triggered by TBI. The anti-CD11d treatment was given at 2 h after a single moderate (2.5-3.0 atm) or 2 and 24 h after each of three consecutive mild (1.0-1.5 atm) fluid percussion TBIs. Sham-injured, saline-treated rats served as controls. At 24 h, 72 h, and 4 or 8 weeks after the single TBI and after the third of three TBIs, lungs of rats were examined histochemically, immunocytochemically and biochemically for downstream effects of SIRS including inflammation, tissue damage and expression of oxidative enzymes. Lung sections revealed that both the single moderate and repeated mild TBI caused alveolar disruption, thickening of inter-alveolar tissue, hemorrhage into the parenchyma and increased density of intra-and pen-alveolar macrophages. The anti-CD11d treatment decreased the intrapulmonary influx of neutrophils and the density of activated macrophages and the activity of myeloperoxidase after these TBIs. Moreover, Western blotting studies showed that the treatment decreased lung protein levels of oxidative enzymes gp91(Phox), inducible nitric oxide synthase and cyclooxygenase-2, as well as the apoptotic pathway enzyme caspase-3 and levels of 4-hydroxynonenal-bound proteins (an indicator of lipid peroxidation). Decreased expression of the cytoprotective transcription factor Nrf2 reflected decreased lung oxidative stress. Anti-CD11d treatment also diminished the lung concentration of free radicals and tissue aldehydes. In conclusion, the substantial lung component of the SIRS after single or repeated TBIs is significantly decreased by a simple, minimally invasive and short-lasting anti-inflammatory treatment. (C) 2015 Elsevier Inc. All rights reserved.	[Weaver, Lynne C.; Bao, Feng; Dekaban, Gregory A.; Hryciw, Todd; Brown, Arthur] Univ Western Ontario, Robarts Res Inst, Spinal Cord Injury Team, Mol Med, London, ON N6A 5B7, Canada; [Shultz, Sandy R.; Cain, Donald P.; Brown, Arthur] Univ Western Ontario, Program Neurosci, London, ON N6A 5B7, Canada; [Weaver, Lynne C.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5B7, Canada; [Brown, Arthur] Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5B7, Canada; [Dekaban, Gregory A.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5B7, Canada; [Shultz, Sandy R.; Cain, Donald P.] Univ Western Ontario, Dept Psychol, London, ON N6A 5B7, Canada		Weaver, LC (corresponding author), Univ Western Ontario, Robarts Res Inst, Spinal Cord Injury Team, Mol Med, 1151 Richmond St N, London, ON N6A 5B7, Canada.	lcweaver@robarts.ca	Weaver, Lynne C/K-8491-2013; Dekaban, Gregory/L-1987-2013; Brown, Arthur/K-8328-2013	Dekaban, Gregory/0000-0002-3087-4660; Brown, Arthur/0000-0002-8725-3195	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	This research was supported by grants from the Canadian Institutes of Health Research (CIHR) (LW and AB) and the Natural Sciences and Engineering Research Council of Canada (NSERC) (DPC). The authors thank Eli Lilly and Company for donating the anti-CD11d mAb (217L) and isotype matched control mAb (1B7) and Dr. Kathy Xu for her contributions to some of the experiments. We appreciate the critical editing of this manuscript by Dr. Canio Polosa.	Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; BAIGELMAN W, 1981, NEUROSURGERY, V9, P729, DOI 10.1227/00006123-198112000-00021; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Bao F, 2012, J NEUROTRAUM, V29, P1626, DOI 10.1089/neu.2011.2190; Bao F, 2011, EXP NEUROL, V231, P272, DOI 10.1016/j.expneurol.2011.07.001; Baskaran H, 2000, J SURG RES, V93, P88, DOI 10.1006/jsre.2000.5955; Bhatia RK, 2005, INJURY, V36, P956, DOI 10.1016/j.injury.2005.03.009; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cho HY, 2004, FASEB J, V18, P1258, DOI 10.1096/fj.03-1127fje; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Dinkova-Kostova AT, 2005, BIOCHEMISTRY-US, V44, P6889, DOI 10.1021/bi047434h; FAN L, 1995, MOL BRAIN RES, V30, P125; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fleming JC, 2008, EXP NEUROL, V214, P147, DOI 10.1016/j.expneurol.2008.04.024; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Galea J, 2013, J INFLAMM RES, V6, P121, DOI 10.2147/JIR.S35629; Glantz SA, 2012, PRIMER BIOSTATISTICS; Grayson MH, 1998, J EXP MED, V188, P2187, DOI 10.1084/jem.188.11.2187; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Gris D, 2008, EXP NEUROL, V211, P259, DOI 10.1016/j.expneurol.2008.01.033; Gris P, 2009, J NEUROIMMUNOL, V209, P104, DOI 10.1016/j.jneuroim.2009.02.002; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hopkins RO, 2006, BRAIN INJURY, V20, P263, DOI 10.1080/02699050500488199; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kemp CD, 2008, AM SURGEON, V74, P866; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; KUSHNER I, 1993, PERSPECT BIOL MED, V36, P611; Kyono W, 2002, PEDIATR CLIN N AM, V49, P929, DOI 10.1016/S0031-3955(02)00030-5; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lou MQ, 2013, CLIN NEUROL NEUROSUR, V115, P904, DOI 10.1016/j.clineuro.2012.09.001; Marzec JM, 2007, FASEB J, V21, P2237, DOI 10.1096/fj.06-7759com; Mochizuki M, 2005, AM J RESP CRIT CARE, V171, P1260, DOI 10.1164/rccm.200406-755OC; Oatway MA, 2005, J NEUROSCI, V25, P637, DOI 10.1523/JNEUROSCI.3960-04.2005; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pelosi P, 2011, CRIT CARE, V15, DOI 10.1186/cc10259; Pillay NS, 2007, BRAIN RES, V1153, P158, DOI 10.1016/j.brainres.2007.03.056; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Ryugo M, 2006, SURG TODAY, V36, P321, DOI 10.1007/s00595-005-3160-y; Sauerbeck AD, 2015, J NEUROTRAUM, V32, P159, DOI 10.1089/neu.2014.3497; Shanley TP, 1998, J IMMUNOL, V160, P1014; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Snedecor GW., 1989, STAT METHODS, V8th; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Van der Vieren M, 1999, J IMMUNOL, V163, P1984; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Vermeij JD, 2013, J NEUROTRAUM, V30, P2073, DOI 10.1089/neu.2013.3060; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Yan W, 2008, BRAIN INJURY, V22, P802, DOI 10.1080/02699050802372174	62	37	37	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2015	271						409	422		10.1016/j.expneurol.2015.07.003			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT2JG	WOS:000362627200042	26169930	Green Accepted			2022-02-06	
J	Huang, XJ; Glushakova, O; Mondello, S; Van, K; Hayes, RL; Lyeth, BG				Huang, Xian-jian; Glushakova, Olena; Mondello, Stefania; Van, Ken; Hayes, Ronald L.; Lyeth, Bruce G.			Acute Temporal Profiles of Serum Levels of UCH-L1 and GFAP and Relationships to Neuronal and Astroglial Pathology following Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; fluid percussion; GFAP; rat; TBI; UCH-L1	C-TERMINAL HYDROLASE; FIBRILLARY ACIDIC PROTEIN; FLUID-PERCUSSION MODEL; NEUROSURGICAL INTERVENTION; INTRACRANIAL LESIONS; CHOROID-PLEXUS; FLUORO-JADE; BLOOD; BARRIER; MARKERS	A number of potential traumatic brain injury (TBI) biomarkers have been proposed and evaluated in the laboratory and clinic. This study investigated the temporal profile of circulating biomarkers of astrocytic and neuronal injury over the first 24h and relevant histopathological changes after experimental moderate TBI. Twenty male rats were randomly assigned to either moderate parasagittal fluid percussion or sham injury. Blood serum samples were collected 2d prior to TBI (baseline) and at 3, 6, and 24h after TBI. A single cerebrospinal fluid (CSF) sample was collected from the cisterna magna 24h after TBI, followed by euthanasia and brain harvesting for histology. Serum and CSF samples were analyzed for neuronal (ubiquitin carboxy-terminal hydrolase L1 [UCH-L1]) and astroglial (glial fibrillary acidic protein [GFAP]) protein levels using enzyme-linked immunosorbent assay. Brain histology included GFAP immunostaining and Fluoro-Jade histofluorescence. Serum and CSF levels of GFAP were near zero in sham animals. Serum GFAP levels were significantly elevated at 3 and 6h post-TBI, compared with baseline and time-matched sham values, while UCH-L1 was significantly elevated only at 3h post-TBI. Both CSF GFAP and UCH-L1 at 24h post-TBI were significantly elevated, compared with sham. GFAP immunohistochemistry and FJ histofluorescence of degenerating neurons were performed in the same animals after 24h survival. Histology revealed characteristic acute neuronal degeneration in the ipsilateral hippocampus and parietal cortex and reduction in GFAP immunostaining in areas of neuronal cell loss. The data provide evidence of a causal relationship between TBI-induced acute brain pathology and circulating neuronal and glial markers, further demonstrating their role as candidate markers for TBI. Studies of relative changes in biomarker levels in CSF and serum suggest that different mechanisms may underlie the transport and/or clearance of UCH-L1 and GFAP in these two compartments.	[Huang, Xian-jian] Shenzhen Univ, Affiliated Hosp 2, Dept Neurosurg, Shenzhen, Peoples R China; [Huang, Xian-jian; Van, Ken; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Glushakova, Olena; Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,One Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu	Mondello, Stefania/A-1813-2012; Glushakova, Olena/AAY-1130-2021	Mondello, Stefania/0000-0002-8587-3614; Glushakova, Olena/0000-0002-2109-3651; Lyeth, Bruce/0000-0003-4811-1474	Banyan Biomarkers, Inc.; UC Davis Department of Neurological Surgery	This research was supported by funds from Banyan Biomarkers, Inc. and the UC Davis Department of Neurological Surgery.	Arnaoutakis GJ, 2011, J THORAC CARDIOV SUR, V142, P902, DOI 10.1016/j.jtcvs.2011.06.027; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Cikriklar HI, 2013, EUR REV MED PHARMACO, V17, P3391; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Deeken JF, 2007, CLIN CANCER RES, V13, P1663, DOI 10.1158/1078-0432.CCR-06-2854; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Faul M, 2010, TRAUMATIC BRAIN INJU; Ghabriel MN, 2010, ACTA NEUROCHIR SUPPL, V106, P239, DOI 10.1007/978-3-211-98811-4_45; Glushakova OY, 2012, TOXICOL SCI, V130, P158, DOI 10.1093/toxsci/kfs224; Gong B, 2007, DRUG NEWS PERSPECT, V20, P365, DOI 10.1358/dnp.2007.20.6.1138160; Graff CL, 2004, CURR DRUG METAB, V5, P95, DOI 10.2174/1389200043489126; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Iliff JJ, 2013, STROKE, V44, pS93, DOI 10.1161/STROKEAHA.112.678698; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; RANSOM BR, 1992, J CLIN NEUROPHYSIOL, V9, P224, DOI 10.1097/00004691-199204010-00005; Rao VV, 1999, P NATL ACAD SCI USA, V96, P3900, DOI 10.1073/pnas.96.7.3900; Ren CH, 2013, BRAIN RES, V1540, P84, DOI 10.1016/j.brainres.2013.09.051; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Setsuie R, 2007, NEUROCHEM INT, V51, P105, DOI 10.1016/j.neuint.2007.05.007; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; Woertgen C, 2002, ACT NEUR S, V81, P205; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	40	37	38	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2015	32	16					1179	1189		10.1089/neu.2015.3873			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CU9RU	WOS:000363883400001	25763798				2022-02-06	
J	Diamond, ML; Ritter, AC; Jackson, EK; Conley, YP; Kochanek, PM; Boison, D; Wagner, AK				Diamond, Matthew L.; Ritter, Anne C.; Jackson, Edwin K.; Conley, Yvette P.; Kochanek, Patrick M.; Boison, Detlev; Wagner, Amy K.			Genetic variation in the adenosine regulatory cycle is associated with posttraumatic epilepsy development	EPILEPSIA			English	Article						Traumatic brain injury; Posttraumatic epilepsy; Epileptogenesis; Genetics; Adenosine; Rehabilomics	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; KINASE; SEIZURES; ASTROGLIOSIS; METHYLATION; OVEREXPRESSION; ASTROCYTES; PREVENTION; RELEASE	ObjectiveDetermine if genetic variation in enzymes/transporters influencing extracellular adenosine homeostasis, including adenosine kinase (ADK), [ecto-5-nucleotidase (NT5E), cluster of differentiation 73 (CD73)], and equilibrative nucleoside transporter type-1 (ENT-1), is significantly associated with epileptogenesis and posttraumatic epilepsy (PTE) risk, as indicated by time to first seizure analyses. MethodsNine ADK, three CD73, and two ENT-1 tagging single nucleotide polymorphisms (SNPs) were genotyped in 162 white adults with moderate/severe traumatic brain injury (TBI) and no history of premorbid seizures. Kaplan-Meier models were used to screen for genetic differences in time to first seizure occurring >1week post-TBI. SNPs remaining significant after correction for multiple comparisons were examined using Cox proportional hazards analyses, adjusting for subdural hematoma, injury severity score, and isolated TBI status. SNPs significant in multivariate models were then entered simultaneously into an adjusted Cox model. ResultsComparing Kaplan-Meier curves, rs11001109 (ADK) rare allele homozygosity and rs9444348 (NT5E) heterozygosity were significantly associated with shorter time to first seizure and an increased seizure rate 3years post-TBI. Multivariate Cox proportional hazard models showed that these genotypes remained significantly associated with increased PTE hazard up to 3years post-TBI after controlling for variables of interest (rs11001109: hazard ratio (HR) 4.47, 95% confidence interval (CI) 1.27-15.77, p=0.020; rs9444348: HR 2.95, 95% CI 1.19-7.31, p=0.019) . SignificanceGenetic variation in ADK and NT5E may help explain variability in time to first seizure and PTE risk, independent of previously identified risk factors, after TBI. Once validated, identifying genetic variation in adenosine regulatory pathways relating to epileptogenesis and PTE may facilitate exploration of therapeutic targets and pharmacotherapy development.	[Diamond, Matthew L.; Ritter, Anne C.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Jackson, Edwin K.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Dept Hlth Promot & Human Genet, Pittsburgh, PA 15213 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Conley, Yvette P.; Kochanek, Patrick M.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Boison, Detlev] Legacy Res Inst, RS Dow Neurobiol Labs, Portland, OR USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Res, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Boison, Detlev/ABE-6302-2020	Conley, Yvette/0000-0002-1784-6067; Boison, Detlev/0000-0002-7740-5781; Jackson, Edwin/0000-0002-8101-6009	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NR013342]; DODUnited States Department of Defense [W81XWH-12-1-0283];  [NIH-R01HD048162];  [DODW81XWH-071-0701];  [NIH-R01NS087978]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS087978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013342] Funding Source: NIH RePORTER	This work was supported by NIH-R01HD048162, DODW81XWH-071-0701, NIH R01NR013342, DOD W81XWH-12-1-0283, and NIH-R01NS087978. Thanks to Sandra Deslouche for support with genotyping and Dr. Candice Kammerer for statistical genetic guidance, and the subjects and their families for their generous participation. Thanks to the UPMC Trauma Registry for assisting with some elements of data collection.	Aronica E, 2011, EPILEPSIA, V52, P1645, DOI 10.1111/j.1528-1167.2011.03115.x; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bjursell MK, 2011, AM J HUM GENET, V89, P507, DOI 10.1016/j.ajhg.2011.09.004; Boison D, 2013, PHARMACOL REV, V65, P906, DOI 10.1124/pr.112.006361; Boison D, 2012, GLIA, V60, P1234, DOI 10.1002/glia.22285; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chu S, 2014, PURINERG SIGNAL, V10, P603, DOI 10.1007/s11302-014-9421-8; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Diogenes MJ, 2014, CEREB CORTEX, V24, P67, DOI 10.1093/cercor/bhs284; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fedele DE, 2005, BRAIN, V128, P2383, DOI 10.1093/brain/awh555; Fedele DE, 2006, EXP NEUROL, V200, P184, DOI 10.1016/j.expneurol.2006.02.133; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Gomes CV, 2011, BBA-BIOMEMBRANES, V1808, P1380, DOI 10.1016/j.bbamem.2010.12.001; Gouder N, 2004, J NEUROSCI, V24, P692, DOI 10.1523/JNEUROSCI.4781-03.2004; Ke RH, 2009, NEUROSCI RES, V65, P280, DOI 10.1016/j.neures.2009.08.002; Knapp K, 2012, STRUCTURE, V20, P2161, DOI 10.1016/j.str.2012.10.001; Kobow K, 2011, EPILEPSIA, V52, P15, DOI 10.1111/j.1528-1167.2011.03145.x; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kolakowsky-Hayner SA, 2013, BRAIN INJURY, V27, P578, DOI 10.3109/02699052.2013.765595; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Li TF, 2012, GLIA, V60, P83, DOI 10.1002/glia.21250; Lo Nigro C, 2012, BRIT J CANCER, V107, P75, DOI 10.1038/bjc.2012.212; Lovatt D, 2012, P NATL ACAD SCI USA, V109, P6265, DOI 10.1073/pnas.1120997109; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Parkinson FE, 2004, J NEUROCHEM, V88, P1305, DOI 10.1046/j.1471-4159.2003.02266.x; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Robel S, 2015, J NEUROSCI, V35, P3330, DOI 10.1523/JNEUROSCI.1574-14.2015; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schumacher MA, 2000, J MOL BIOL, V298, P875, DOI 10.1006/jmbi.2000.3753; Strater Norbert, 2006, Purinergic Signal, V2, P343, DOI 10.1007/s11302-006-9000-8; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Wiesner JB, 1999, J PHARMACOL EXP THER, V289, P1669; Williams-Karnesky RL, 2013, J CLIN INVEST, V123, P3552, DOI 10.1172/JCI65636	46	37	39	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	AUG	2015	56	8					1198	1206		10.1111/epi.13044			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CO2AX	WOS:000358958700005	26040919	Bronze, Green Accepted			2022-02-06	
J	Fuhrmann, T; Obermeyer, J; Tator, CH; Shoichet, MS				Fuehrmann, T.; Obermeyer, J.; Tator, C. H.; Shoichet, M. S.			Click-crosslinked injectable hyaluronic acid hydrogel is safe and biocompatible in the intrathecal space for ultimate use in regenerative strategies of the injured spinal cord	METHODS			English	Article						Hydrogel; Spinal cord injury; Drug delivery	DELIVERY-SYSTEM; BRAIN; EXPRESSION; PROTEIN; DIFFERENTIATION; MACROPHAGES; SURVIVAL; MATTER; IBA1; BDNF	Traumatic spinal cord injury (SCI) causes damage and degeneration at and around the lesion site resulting in a loss of function. SCI presents a complex regenerative problem due to the multiple aspects of growth inhibition and the heterogeneity in size, shape and extent of injury. Currently, there is no widely accepted treatment strategy available and delivering biomolecules to the central nervous system remains a challenge. With a view towards achieving local release, we designed a hydrogel that can be injected into the intrathecal space. Here we describe the synthesis and characterization of a click-crosslinked hyaluronic acid hydrogel and demonstrate controlled in vitro release of bioactive brain derived neurotrophic factor. Importantly, we demonstrate that this new hydrogel is both biocompatible in the intrathecal space based on immunohistochemistry of the host tissue response and safe based on behavioral analysis of locomotor function. (C) 2015 Elsevier Inc. All rights reserved.	[Fuehrmann, T.; Obermeyer, J.; Shoichet, M. S.] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3E5, Canada; [Fuehrmann, T.; Obermeyer, J.; Shoichet, M. S.] Inst Biomat & Biomed Engn, Toronto, ON M5S 3E1, Canada; [Tator, C. H.] Univ Toronto, Toronto Western Res Inst, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada; [Tator, C. H.] Univ Toronto, Dept Surg, Toronto, ON M5T 2S8, Canada		Shoichet, MS (corresponding author), Univ Toronto, Dept Chem Engn & Appl Chem, 200 Coll St, Toronto, ON M5S 3E5, Canada.	molly.shoichet@utoronto.ca	Fuhrmann, Tobias/D-3880-2014	Fuhrmann, Tobias/0000-0003-1857-4806	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); CIHR TPRM training grantCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council (NSERC) graduate student scholarshipNatural Sciences and Engineering Research Council of Canada (NSERC)	We are grateful to Mrs. Rita van Bendegem for tissue processing. We thank Peter Poon for animal surgery, Jennifer Chan for the assistance with immunohistochemistry and fluorescence imaging, Shawn Owen for discussions regarding xHA chemistry and the Fehlings lab for help with animal care. We thank the Canadian Institutes of Health Research (CIHR) for operating funding (to M.S.S.), the CIHR TPRM training grant (to T.F.) and the Natural Sciences and Engineering Research Council (NSERC) graduate student scholarship (to J.O.).	Abbott NJ, 1996, MOL MED TODAY, V2, P106, DOI 10.1016/1357-4310(96)88720-X; AHMED S, 1995, J NEUROSCI, V15, P5765; [Anonymous], ANIMAL MODELS ACUTE, V2; BARRETT CP, 1981, EXP NEUROL, V73, P365, DOI 10.1016/0014-4886(81)90272-7; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Baumann MD, 2010, BIOMATERIALS, V31, P7631, DOI 10.1016/j.biomaterials.2010.07.004; Buchwalow I, 2011, SCI REP-UK, V1, DOI 10.1038/srep00028; Caicco MJ, 2013, J CONTROL RELEASE, V166, P197, DOI 10.1016/j.jconrel.2013.01.002; Chen WYJ, 1999, WOUND REPAIR REGEN, V7, P79, DOI 10.1046/j.1524-475X.1999.00079.x; Consortium for Spinal Cord Medicine, 2008, J SPINAL CORD MED, V31, P408; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Fehlings MG, 2005, INJURY, V36, P13, DOI 10.1016/j.injury.2005.06.011; Guo J, 2007, NANOMED-NANOTECHNOL, V3, P311, DOI 10.1016/j.nano.2007.09.003; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Hamann MCJ, 2005, EXP NEUROL, V194, P106, DOI 10.1016/j.expneurol.2005.01.030; Hamann MCJ, 2003, EXP NEUROL, V182, P300, DOI 10.1016/S0014-4886(03)00040-2; Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Jakeman LB, 2012, ANIMAL MODELS ACUTE, P417, DOI DOI 10.1007/978-1-61779-782-8_37; Johnson PJ, 2010, J BIOMED MATER RES A, V92A, P152, DOI 10.1002/jbm.a.32343; Jones LL, 2001, MICROSC RES TECHNIQ, V54, P317, DOI 10.1002/jemt.1144; Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5; Kwon BK, 2007, SPINE, V32, P1164, DOI 10.1097/BRS.0b013e318053ec35; Macaya D, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/1/012001; MILLIGAN CE, 1991, J COMP NEUROL, V314, P125, DOI 10.1002/cne.903140112; Mueller CA, 2006, J NEUROSURG-SPINE, V4, P233, DOI 10.3171/spi.2006.4.3.233; Nimmo CM, 2011, BIOMACROMOLECULES, V12, P824, DOI 10.1021/bm101446k; Otto S, 2003, ORG BIOMOL CHEM, V1, P2809, DOI 10.1039/b305672d; Pardridge WM, 2005, MOL BIOTECHNOL, V30, P57, DOI 10.1385/MB:30:1:057; Pawar R, 2004, EXPERT OPIN BIOL TH, V4, P1203, DOI 10.1517/14712598.4.8.1203; Poon PC, 2007, SPINE, V32, P2853, DOI 10.1097/BRS.0b013e31815b7e6b; RIDEOUT DC, 1980, J AM CHEM SOC, V102, P7816, DOI 10.1021/ja00546a048; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Roth A, 2005, ARTHRITIS RES THER, V7, pR677, DOI 10.1186/ar1725; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Sheehan KM, 2003, J ORTHOP RES, V21, P744, DOI 10.1016/S0736-0266(03)00007-X; Shetty AK, 1998, J NEUROBIOL, V35, P395, DOI 10.1002/(SICI)1097-4695(19980615)35:4<395::AID-NEU7>3.0.CO;2-U; Shu XZ, 2002, BIOMACROMOLECULES, V3, P1304, DOI 10.1021/bm025603c; Stanwick JC, 2012, J CONTROL RELEASE, V160, P666, DOI 10.1016/j.jconrel.2012.03.024; Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5; Terada H, 2001, J THORAC CARDIOV SUR, V122, P979, DOI 10.1067/mtc.2001.117278; Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P600; Volpato F.Z., 2013, BIOMATERIALS; Wang YF, 2013, J CONTROL RELEASE, V172, P1, DOI 10.1016/j.jconrel.2013.07.032; Ward RE, 2014, NEUROSCIENCE, V260, P227, DOI 10.1016/j.neuroscience.2013.12.024; Weishaupt N, 2012, EXP NEUROL, V238, P254, DOI 10.1016/j.expneurol.2012.09.001; WINTER HH, 1986, J RHEOL, V30, P367, DOI 10.1122/1.549853; Yaksh TL, 2004, TOXICOL SCI, V80, P322, DOI 10.1093/toxsci/kfh168; Yung SS, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/180594	53	37	37	3	48	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1046-2023	1095-9130		METHODS	Methods	AUG	2015	84						60	69		10.1016/j.ymeth.2015.03.023			10	Biochemical Research Methods; Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CO5DP	WOS:000359180100008	25846399				2022-02-06	
J	Yoo, C; Yong, MH; Chung, J; Yang, Y				Yoo, Chanuk; Yong, Mi-hyun; Chung, Jaeyeop; Yang, Yeongae			Effect of computerized cognitive rehabilitation program on cognitive function and activities of living in stroke patients	JOURNAL OF PHYSICAL THERAPY SCIENCE			English	Article						Computerized cognitive rehabilitation; Cognitive function; Activities of daily living	TRAUMATIC BRAIN-INJURY; THERAPY	[Purpose] The objective of this study was to examine the effect of cognitive rehabilitation using a computer on cognitive function and activities of daily living in stroke patients presenting impairment of cognitive function. [Subjects] Forty-six stroke patients were divided into two groups ( a training group and control group) through random assignment. [Methods] The training group received rehabilitation therapy and an additional computerized cognitive rehabilitation program using The RehaCom software 30 minutes/day, 5 times/week for 5 weeks. The control group received only rehabilitation therapy including physical and occupational therapy. A comparative analysis on all subjects was conducted before and after the experiment using a cognitive test and activities of daily living test. [Results] After 5 weeks of therapy, the training group presented statistically significant improvement in cognitive function assessment items of digit span, visual span, visual learning, auditory continuous performance, visual continuous performance, and others compared with the control group but did not present statistically significant improvement in activities of daily living. [Conclusion] It was revealed through this study that computerized cognitive rehabilitation with the RehaCom program results in improvement in cognitive function and can be used as a treatment tool beneficial to stroke patients presenting cognitive impairment.	[Yoo, Chanuk] Hanlyo Univ, Dept Occupat Therapy, Gwangyang Si, South Korea; [Yong, Mi-hyun] Kyungwoon Univ, Coll Hlth, Dept Occupat Therapy, Gumi Si, South Korea; [Chung, Jaeyeop] Kyongbuk Sci Coll, Dept Occupat Therapy, Gimcheon, South Korea; [Yang, Yeongae] Inje Univ, Coll Biomed Sci & Engn, Dept Occupat Therapy, Gimhae, South Korea		Yang, Y (corresponding author), Inje Univ, Coll Biomed Sci & Engn, Dept Occupat Therapy, Gimhae, South Korea.	otyya62@inje.ac.kr					Chen SHA, 1997, BRAIN INJURY, V11, P197; DAM M, 1993, STROKE, V24, P1186, DOI 10.1161/01.STR.24.8.1186; Dickson HG, 1995, SCAND J REHABIL MED, V27, P253; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; Gontkovsky ST, 2002, NEUROREHABILITATION, V17, P195; Gunther VK, 2003, AGING MENT HEALTH, V7, P200, DOI 10.1080/1360786031000101175; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Lee IH, 2012, J PHYS THER SCI, V24, P503, DOI 10.1589/jpts.24.503; Lee YM, 2013, J PHYS THER SCI, V25, P1475, DOI 10.1589/jpts.25.1475; MCALLISTER TW, 1981, COMPR PSYCHIAT, V22, P572, DOI 10.1016/0010-440X(81)90006-7; Palmese CA, 2000, BRAIN INJURY, V14, P535; Patel MD, 2002, J AM GERIATR SOC, V50, P700, DOI 10.1046/j.1532-5415.2002.50165.x; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489	13	37	41	0	7	SOC PHYSICAL THERAPY SCIENCE	TOKYO	C/O PUBLICATION CENTER, 1-24-12 SUGAMO, TOSHIMA-KU, TOKYO, 170-0002, JAPAN	0915-5287	2187-5626		J PHYS THER SCI	J. Phys. Ther. Sci.	AUG	2015	27	8					2487	2489		10.1589/jpts.27.2487			3	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	CP6SX	WOS:000360019600018	26355244	Green Submitted, gold, Green Published			2022-02-06	
J	Ahadi, R; Khodagholi, F; Daneshi, A; Vafaei, A; Mafi, AA; Jorjani, M				Ahadi, Reza; Khodagholi, Fariba; Daneshi, Abdolhadi; Vafaei, Ali; Mafi, Amir Ali; Jorjani, Masoumeh			Diagnostic Value of Serum Levels of GFAP, pNF-H, and NSE Compared With Clinical Findings in Severity Assessment of Human Traumatic Spinal Cord Injury	SPINE			English	Article							FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; NEUROFILAMENT HEAVY-CHAIN; CERVICAL-SPINE; CEREBROSPINAL-FLUID; INFLAMMATORY CYTOKINES; IMAGING EVALUATION; AXONAL INJURY; BRAIN-INJURY; BIOMARKERS	Study Design. An analytical cohort study. Objective. This study aimed to evaluate severity of traumatic spinal cord injury (SCI) based on the serum levels of phosphorylated form of heavy subunit of neurofilament (pNF-H), neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP), which are axonal, neural cell body, and glial cell injury markers, respectively. Summary of Background Data. Prior studies have reported elevated serum levels of pNF-H, NSE, and GFAP as biomarkers for the detection of traumatic SCI in animals. However, in this study, these biomarkers were studied in humans and with an extended level of timing. Methods. The study included 35 patients with SCI with a mean age of 36.5 years. All patients were evaluated using the American Spinal Injury Association Impairment Scale, followed by examinations including radiography and spinal computed tomography for determining the injury level. Serum levels of NSE, pNF-H, and GFAP were determined using enzyme-linked immunosorbent assay. Results. The mean serum level of GFAP was significantly higher in patients with SCI than in the control group. Mean serum levels of pNF-H and NSE were significantly higher during 24 and 48 hours after injury in patients with SCI than in the control group. The serum level of GFAP was appropriate for estimating the severity of SCI in the first 24 hours after injury. Conclusion. Our findings suggest that increased serum levels of GFAP, NSE, and pNF-H can be used for the diagnosis and degree of SCI severity in trauma patients. During 48 hours after injury, estimation of serum levels of pNF-H, NSE, and GFAP, combined with neurological testing, could predict the presence of SCI and severity prior to spinal computed tomography and surgical or conservative interventions. Level of Evidence: 2	[Ahadi, Reza] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran; [Khodagholi, Fariba; Jorjani, Masoumeh] Shahid Beheshti Univ Med Sci, Neurobiol Res Ctr, Tehran, Iran; [Daneshi, Abdolhadi; Vafaei, Ali] Shohadye Haftom Tir Hosp, Dept Emergency Med, Tehran, Iran; [Mafi, Amir Ali] Shahid Beheshti Univ Med Sci, Tehran, Iran; [Jorjani, Masoumeh] Shahid Beheshti Univ Med Sci, Fac Med, Dept Pharmacol, Tehran, Iran		Jorjani, M (corresponding author), Shahid Beheshti Univ Med Sci, Fac Med, Dept Pharmacol, Tehran, Iran.	msjorjani@sbmu.ac.ir	VAFAEI, ALI/AAU-9473-2021; Jorjani, Masoumeh/AAV-5596-2021; ahadi, reza/AAN-1578-2021; Khodagholi, Fariba/AAZ-4436-2020; Mafi, Amir/ABH-7659-2020	VAFAEI, ALI/0000-0002-7129-6457; Khodagholi, Fariba/0000-0002-4911-4530; Daneshi, Abdolhadi/0000-0001-7255-4692; Mafi, Amir Ali/0000-0002-4917-7312	Shahid Beheshti University Medical Science funds	Shahid Beheshti University Medical Science funds were received in support of this work.	Al-Chalabi A, 2003, BIOESSAYS, V25, P346, DOI 10.1002/bies.10251; Benzel EC, 1996, J NEUROSURG, V85, P824, DOI 10.3171/jns.1996.85.5.0824; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104; Brisby H, 1999, SPINE, V24, P742, DOI 10.1097/00007632-199904150-00003; BURGHUBER OC, 1990, CANCER, V65, P1386, DOI 10.1002/1097-0142(19900315)65:6<1386::AID-CNCR2820650623>3.0.CO;2-9; D'Alise MD, 1999, J NEUROSURG, V91, P54, DOI 10.3171/spi.1999.91.1.0054; Daffner RH, 2006, INJURY, V37, P652, DOI 10.1016/j.injury.2006.01.018; Foerch C, 2009, NEUROLOGY, V73, P393, DOI 10.1212/WNL.0b013e3181b05ef9; Ghanta MK, 2002, AM SURGEON, V68, P563; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; HASHIMOTO T, 1988, SPINE, V13, P1268, DOI 10.1097/00007632-198811000-00011; Holmes JF, 2002, J TRAUMA, V53, P524, DOI 10.1097/00005373-200209000-00021; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hu YY, 2002, NEUROSCI LETT, V320, P156, DOI 10.1016/S0304-3940(02)00047-2; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lima JE, 2004, BRAZ J MED BIOL RES, V37, P19, DOI 10.1590/S0100-879X2004000100003; Liu Q, 2004, CELL MOL LIFE SCI, V61, P3057, DOI 10.1007/s00018-004-4268-8; Loy DN, 2005, NEUROSURGERY, V56, P391, DOI 10.1227/01.NEU.0000148906.83616.D2; Loy DN, 2006, NEUROSURGERY, V58, pE590; Missler U, 1999, CLIN CHEM, V45, P138; Munera F, 2012, RADIOLOGY, V263, P645, DOI 10.1148/radiol.12110526; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2004, J NEUROL NEUROSUR PS, V75, P1178, DOI 10.1136/jnnp.2003.017236; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Saltzherr TP, 2009, INJURY, V40, P795, DOI 10.1016/j.injury.2009.01.015; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stammers AT, 2012, J NEUROSCI RES, V90, P782, DOI 10.1002/jnr.22820; Tator CH, 2012, J NEUROSURG-SPINE, V17, P157, DOI 10.3171/2012.5.AOSPINE12116; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Zhang B, 2011, J TRAUMA, V71, P1680, DOI 10.1097/TA.0b013e318231bce7; Ziemann U, 2011, PROG NEUROBIOL, V95, P670, DOI 10.1016/j.pneurobio.2011.04.007	38	37	41	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	JUL 15	2015	40	14					E823	E830		10.1097/BRS.0000000000000654			8	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	CM8JF	WOS:000357945400004	25341992				2022-02-06	
J	Lillis, KP; Wang, ZM; Mail, M; Zhao, GQ; Berdichevsky, Y; Bacskai, B; Staley, KJ				Lillis, Kyle P.; Wang, Zemin; Mail, Michelle; Zhao, Grace Q.; Berdichevsky, Yevgeny; Bacskai, Brian; Staley, Kevin J.			Evolution of Network Synchronization during Early Epileptogenesis Parallels Synaptic Circuit Alterations	JOURNAL OF NEUROSCIENCE			English	Article						calcium imaging; homeostasis; network; two-photon	EPILEPTIFORM ACTIVITY; PYRAMIDAL CELLS; POSTTRAUMATIC EPILEPTOGENESIS; OPTICAL ELECTROPHYSIOLOGY; FUNCTIONAL CONNECTIVITY; TEMPORAL LOBECTOMY; WEIGHTED NETWORKS; INTERICTAL SPIKES; DENTATE GYRUS; CULTURE MODEL	In secondary epilepsy, a seizure-prone neural network evolves during the latent period between brain injury and the onset of spontaneous seizures. The nature of the evolution is largely unknown, and even its completeness at the onset of seizures has recently been challenged by measures of gradually decreasing intervals between subsequent seizures. Sequential calcium imaging of neuronal activity, in the pyramidal cell layer of mouse hippocampal in vitro preparations, during early post-traumatic epileptogenesis demonstrated rapid increases in the fraction of neurons that participate in interictal activity. This was followed by more gradual increases in the rate at which individual neurons join each developing seizure, the pairwise correlation of neuronal activities as a function of the distance separating the pair, and network-wide measures of functional connectivity. These data support the continued evolution of synaptic connectivity in epileptic networks beyond the latent period: early seizures occur when recurrent excitatory pathways are largely polysynaptic, while ongoing synaptic remodeling after the onset of epilepsy enhances intranetwork connectivity as well as the onset and spread of seizure activity.	[Lillis, Kyle P.; Wang, Zemin; Mail, Michelle; Bacskai, Brian; Staley, Kevin J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Lillis, Kyle P.; Wang, Zemin; Mail, Michelle; Bacskai, Brian; Staley, Kevin J.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Zhao, Grace Q.] Stanford Univ, Dept Neurobiol, Stanford, CA 94305 USA; [Berdichevsky, Yevgeny] Lehigh Univ, Dept Elect & Comp Engn, Bethlehem, PA 18015 USA		Staley, KJ (corresponding author), 114 16th St,2600, Charlestown, MA 02129 USA.	staley.kevin@mgh.harvard.edu	wang, zemin/K-4088-2018; Bacskai, Brian/AAE-9583-2021	wang, zemin/0000-0002-8784-8105; Lillis, Kyle/0000-0003-0219-8113; Berdichevsky, Yevgeny/0000-0001-7539-601X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS034700, NS074772, NS077908, EB000768]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045776, R29NS034700, R01NS074772, R01NS077908, R37NS077908, R01NS034700] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grants NS034700, NS074772, and NS077908 (to K.S.), and EB000768 (to B.B.).	Albus K, 2013, J NEUROSCI METH, V217, P1, DOI 10.1016/j.jneumeth.2013.04.014; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Avanzini G, 2014, ADV EXP MED BIOL, V813, P95, DOI 10.1007/978-94-017-8914-1_8; Badea A, 2007, NEUROIMAGE, V37, P683, DOI 10.1016/j.neuroimage.2007.05.046; Bains JS, 1999, NAT NEUROSCI, V2, P720, DOI 10.1038/11184; Bausch SB, 2006, J NEUROPHYSIOL, V96, P2151, DOI 10.1152/jn.00355.2006; Berdichevsky Y, 2013, J NEUROSCI, V33, P9056, DOI 10.1523/JNEUROSCI.3870-12.2013; Berdichevsky Y, 2012, NEUROBIOL DIS, V45, P774, DOI 10.1016/j.nbd.2011.11.001; Berg AT, 2006, ANN NEUROL, V60, P73, DOI 10.1002/ana.20852; Bernhardt BC, 2013, NEUROLOGY, V81, P1840, DOI 10.1212/01.wnl.0000436069.20513.92; Bonifazi P, 2009, SCIENCE, V326, P1419, DOI 10.1126/science.1175509; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Bushong EA, 2004, INT J DEV NEUROSCI, V22, P73, DOI 10.1016/j.ijdevneu.2003.12.008; Buzsaki G, 2004, TRENDS NEUROSCI, V27, P186, DOI 10.1016/j.tins.2004.02.007; Cao G, 2013, CELL, V154, P904, DOI 10.1016/j.cell.2013.07.027; Clasadonte J., 2012, JASPERS BASIC MECH E; Cohen R, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.058701; Dailey ME, 1996, J NEUROSCI, V16, P2983; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; De Simoni A, 2003, J PHYSIOL-LONDON, V550, P135, DOI 10.1113/jphysiol.2003.039099; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282, DOI 10.1152/jn.1995.73.3.1282; Dwyer JM, 2013, BIOL PSYCHIAT, V73, P1189, DOI 10.1016/j.biopsych.2012.11.011; Dyhrfjeld-Johnsen J, 2010, J CLIN NEUROPHYSIOL, V27, P418, DOI 10.1097/WNP.0b013e3181fe0709; Dyhrfjeld-Johnsen J, 2007, J NEUROPHYSIOL, V97, P1566, DOI 10.1152/jn.00950.2006; ELWES RDC, 1988, BRIT MED J, V297, P948, DOI 10.1136/bmj.297.6654.948; Fawcett James W, 2012, Handb Clin Neurol, V109, P503, DOI 10.1016/B978-0-444-52137-8.00031-0; Feldt S, 2010, PHYS BIOL, V7, DOI 10.1088/1478-3975/7/4/046004; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fisher RS, 2014, ADV EXP MED BIOL, V813, P3, DOI 10.1007/978-94-017-8914-1_1; FISHER RS, 1992, J CLIN NEUROPHYSIOL, V9, P441; FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GEIGER LR, 1978, ARCH NEUROL-CHICAGO, V35, P276, DOI 10.1001/archneur.1978.00500290022005; Glass HC, 2011, PEDIATR RES, V70, P535, DOI 10.1203/PDR.0b013e31822f24c7; Gleich D.F., 2009, THESIS STANFORD U; Goldberg EM, 2013, NAT REV NEUROSCI, V14, P337, DOI 10.1038/nrn3482; GomezDiCesare CM, 1997, J COMP NEUROL, V384, P165, DOI 10.1002/(SICI)1096-9861(19970728)384:2<165::AID-CNE1>3.0.CO;2-#; Gutierrez R, 1999, BRAIN RES, V815, P304, DOI 10.1016/S0006-8993(98)01101-9; Hamilton LS, 2013, NEURON, V80, P1066, DOI 10.1016/j.neuron.2013.08.017; Heinrich C, 2011, NEUROBIOL DIS, V42, P35, DOI 10.1016/j.nbd.2011.01.001; Hellier JL, 2009, NEUROPHARMACOLOGY, V56, P414, DOI 10.1016/j.neuropharm.2008.09.009; Heng K, 2013, EPILEPSIA, V54, P1535, DOI 10.1111/epi.12246; Hochbaum DR, 2014, NAT METHODS, V11, P825, DOI [10.1038/NMETH.3000, 10.1038/nmeth.3000]; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Huberfeld G, 2011, NAT NEUROSCI, V14, P627, DOI 10.1038/nn.2790; Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079; Huusko N, 2015, BRAIN STRUCT FUNCT, V220, P153, DOI 10.1007/s00429-013-0644-1; Ikegaya Y, 2004, SCIENCE, V304, P559, DOI 10.1126/science.1093173; Jirsa VK, 2014, BRAIN, V137, P2210, DOI 10.1093/brain/awu133; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Kavoi BM, 2011, INT J MORPHOL, V29, P939, DOI 10.4067/S0717-95022011000300047; Knickmeyer RC, 2008, J NEUROSCI, V28, P12176, DOI 10.1523/JNEUROSCI.3479-08.2008; Kramer MA, 2012, P NATL ACAD SCI USA, V109, P21116, DOI 10.1073/pnas.1210047110; LIEB JP, 1986, EPILEPSIA, V27, P286, DOI 10.1111/j.1528-1157.1986.tb03541.x; Lillis KP, 2008, J NEUROSCI METH, V172, P178, DOI 10.1016/j.jneumeth.2008.04.024; Lillis KP, 2012, NEUROBIOL DIS, V47, P358, DOI 10.1016/j.nbd.2012.05.016; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Magloczky Z, 2005, TRENDS NEUROSCI, V28, P334, DOI 10.1016/j.tins.2005.04.002; Markov NT, 2013, SCIENCE, V342, P578, DOI 10.1126/science.1238406; MCBAIN CJ, 1989, J NEUROSCI METH, V27, P35, DOI 10.1016/0165-0270(89)90051-4; McIntosh AM, 2004, BRAIN, V127, P2018, DOI 10.1093/brain/awh221; McIntosh AM, 2012, EPILEPSIA, V53, P970, DOI 10.1111/j.1528-1167.2012.03430.x; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; Netoff TI, 2004, J NEUROSCI, V24, P8075, DOI 10.1523/JNEUROSCI.1509-04.2004; Newman MEJ, 2001, PHYS REV E, V64, DOI [10.1103/PhysRevE.64.016132, 10.1103/PhysRevE.64.016131, 10.1103/PhysRevE.64.026118]; Noebels J., 2012, JASPERS BASIC MECH E; Opsahl T, 2010, SOC NETWORKS, V32, P245, DOI 10.1016/j.socnet.2010.03.006; Pavlidis P, 1999, J NEUROPHYSIOL, V81, P2787, DOI 10.1152/jn.1999.81.6.2787; Perin R, 2011, P NATL ACAD SCI USA, V108, P5419, DOI 10.1073/pnas.1016051108; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Pozo K, 2010, NEURON, V66, P337, DOI 10.1016/j.neuron.2010.04.028; Prince DA, 2012, JASPERS BASIC MECH E; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Rengachary SS, 2005, PRINCIPLES NEUROSURG; Sabolek HR, 2012, J NEUROSCI, V32, P3009, DOI 10.1523/JNEUROSCI.5853-11.2012; Schreiber T, 1996, PHYS REV LETT, V77, P635, DOI 10.1103/PhysRevLett.77.635; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Snyder AC, 2015, NAT NEUROSCI, V18, P736, DOI 10.1038/nn.3979; Soltesz I., 2006, DIVERSITY NEURONAL M; Steinmetz S, 2013, EPILEPSIA, V54, P580, DOI 10.1111/epi.12071; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; TAJIMA A, 1993, HYPERTENSION, V21, P105, DOI 10.1161/01.HYP.21.1.105; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Thind KK, 2010, J COMP NEUROL, V518, P647, DOI 10.1002/cne.22235; Trevelyan AJ, 2006, J NEUROSCI, V26, P12447, DOI 10.1523/JNEUROSCI.2787-06.2006; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Tyzio R, 2003, J NEUROPHYSIOL, V90, P2964, DOI 10.1152/jn.00172.2003; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; WEINAND ME, 1992, J NEUROSURG, V77, P20, DOI 10.3171/jns.1992.77.1.0020; White A, 2010, EPILEPSIA, V51, P371, DOI 10.1111/j.1528-1167.2009.02339.x; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Yoo JY, 2014, EPILEPSIA, V55, P289, DOI 10.1111/epi.12505; Zhang ZJ, 2012, J NEUROSCI, V32, P2499, DOI 10.1523/JNEUROSCI.4247-11.2012; Zou P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5625	95	37	37	0	18	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUL 8	2015	35	27					9920	9934		10.1523/JNEUROSCI.4007-14.2015			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CN2LT	WOS:000358253400013	26156993	Bronze, Green Published			2022-02-06	
J	Rodgers, KM; Dudek, FE; Barth, DS				Rodgers, Krista M.; Dudek, F. Edward; Barth, Daniel S.			Progressive, Seizure-Like, Spike-Wave Discharges Are Common in Both Injured and Uninjured Sprague-Dawley Rats: Implications for the Fluid Percussion Injury Model of Post-Traumatic Epilepsy	JOURNAL OF NEUROSCIENCE			English	Article						absence; acquired epilepsy; epilepsy; fluid percussion; genetic epilepsy; seizure	COMPLEX PARTIAL SEIZURES; PHOTOTHROMBOTIC BRAIN INFARCTION; GENETIC ABSENCE EPILEPSY; TEMPORAL-LOBE EPILEPSY; LONG-EVANS RATS; ELECTRICAL-STIMULATION; STATUS EPILEPTICUS; AWAKE RATS; EEG; NETWORKS	Variable-duration oscillations and repetitive, high-voltage spikes have been recorded in the electrocorticogram (ECoG) of rats weeks and months after fluid percussion injury (FPI), a model of traumatic brain injury. These ECoG events, which have many similarities to spike-wave-discharges (SWDs) and absence seizures, have been proposed to represent nonconvulsive seizures characteristic of post-traumatic epilepsy (PTE). The present study quantified features of SWD episodes in rats at different time points after moderate to severe FPI, and compared them with age-matched control rats. Control and FPI-injured rats at 1 year of age displayed large-amplitude and frequent SWD events at frontal and parietal recording sites. At 3-6 months, SWDs were shorter in duration and less frequent; extremely brief SWDs (i.e., "larval") were detected as early as 1 month. The onset of the SWDs was nearly always synchronous across electrodes and of larger amplitude in frontal regions. A sensory stimulus, such as a click, immediately and consistently stopped the occurrence of the SWDs. SWDs were consistently accompanied by behavioral arrest. All features of SWDs in control and experimental (FPI) rats were indistinguishable. None of the FPI-treated rats developed nonconvulsive or convulsive seizures that could be distinguished electro-graphically or behaviorally from SWDs. Because SWDs have features similar to genetic absence seizures, these results challenge the hypothesis that SWDs after FPI reflect PTE.	[Rodgers, Krista M.; Barth, Daniel S.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA; [Dudek, F. Edward] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT 84108 USA		Barth, DS (corresponding author), Univ Colorado, Dept Psychol & Neurosci, Campus Box 345, Boulder, CO 80309 USA.	daniel.barth@colorado.edu	Rodgers, Krista/AAC-5063-2020	RODGERS, KRISTA/0000-0003-4393-6389	US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [PR100040]; Epitel	This work was supported by the US Army Medical Research and Material Command (Grant PR100040).; F.E.D. has equity interest in and receives consultant fees from Epitel, which is a company that makes telemetric recording devices; however, this work did not use these devices. The remaining authors declare no competing financial interests.	Afra P, 2008, EPILEPSIA, V49, P677, DOI 10.1111/j.1528-1167.2007.01420.x; Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; ALDINIO C, 1985, METHOD FIND EXP CLIN, V7, P563; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; BERTRAM EH, 1994, BRAIN RES, V661, P157, DOI 10.1016/0006-8993(94)91192-4; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; BUZSAKI G, 1990, NEUROSCIENCE, V36, P1, DOI 10.1016/0306-4522(90)90345-5; BUZSAKI G, 1990, NEUROSCIENCE, V38, P323, DOI 10.1016/0306-4522(90)90031-X; Campbell John N, 2014, Int J Neurol Brain Disord, V1, P1; COENEN AML, 1987, EPILEPSY RES, V1, P297, DOI 10.1016/0920-1211(87)90005-2; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Danober L, 1998, PROG NEUROBIOL, V55, P27, DOI 10.1016/S0301-0082(97)00091-9; DEVINSKY O, 1988, NEUROLOGY, V38, P1347, DOI 10.1212/WNL.38.9.1347; Dudek FE, 2010, EPILEPSY CURR, V10, P91, DOI 10.1111/j.1535-7511.2010.01368.x; Eastman CL, 2015, EXP NEUROL, V264, P150, DOI 10.1016/j.expneurol.2014.12.010; Engel J, 2013, SEIZURES EPILEPSY, V83; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; HAMMOND EJ, 1979, EPILEPSIA, V20, P511, DOI 10.1111/j.1528-1157.1979.tb04833.x; Huang HY, 2012, EPILEPSIA, V53, P2005, DOI 10.1111/j.1528-1167.2012.03664.x; Jenssen S, 2006, EPILEPSIA, V47, P1499, DOI 10.1111/j.1528-1167.2006.00622.x; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; KAPLAN BJ, 1985, EXP NEUROL, V88, P425, DOI 10.1016/0014-4886(85)90204-3; Kelly KM, 2006, EXP NEUROL, V201, P495, DOI 10.1016/j.expneurol.2006.05.006; Kelly KM, 2001, EPILEPSY RES, V47, P189, DOI 10.1016/S0920-1211(01)00294-7; Kendirli MT, 2014, EPILEPSIA, V55, P1969, DOI 10.1111/epi.12854; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kim Daeyoung, 2011, J Epilepsy Res, V1, P57, DOI 10.14581/jer.11011; KLEINLOGEL H, 1985, NEUROPSYCHOBIOLOGY, V13, P206, DOI 10.1159/000118189; LOTHMAN EW, 1993, EPILEPSIA, V34, pS59, DOI 10.1111/j.1528-1157.1993.tb05907.x; Luttjohann A, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00016; Meeren H, 2005, ARCH NEUROL-CHICAGO, V62, P371, DOI 10.1001/archneur.62.3.371; Meeren HKM, 2002, J NEUROSCI, V22, P1480, DOI 10.1523/JNEUROSCI.22-04-01480.2002; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Orru G, 2012, NEUROSCI BIOBEHAV R, V36, P1140, DOI 10.1016/j.neubiorev.2012.01.004; Pearce PS, 2014, EPILEPSY BEHAV, V32, P121, DOI 10.1016/j.yebeh.2014.01.004; Pearl P.L., 2008, PEDIAT EPILEPSY, P323; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; ROBINSON PF, 1980, BRAIN RES, V201, P452, DOI 10.1016/0006-8993(80)91052-5; Rodgers KM, 2012, J NEUROTRAUM, V29, P1886, DOI 10.1089/neu.2011.2273; Sato S., 1983, PEDIAT EPILEPTOLOGY, P65; SEMBA K, 1984, NEUROSCIENCE, V12, P761, DOI 10.1016/0306-4522(84)90168-4; SEMBA K, 1980, BRAIN RES, V195, P281, DOI 10.1016/0006-8993(80)90065-7; Shaw FZ, 2004, J NEUROPHYSIOL, V91, P63, DOI 10.1152/jn.00487.2003; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; THEODORE WH, 1994, NEUROLOGY, V44, P1403, DOI 10.1212/WNL.44.8.1403; THEODORE WH, 1983, NEUROLOGY, V33, P1115; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Van Hese P, 2003, PHYS MED BIOL, V48, P1685; Van Hese P, 2009, IEEE T BIO-MED ENG, V56, P706, DOI 10.1109/TBME.2008.2008858; VANDERWOLF CH, 1975, J COMP PHYSIOL PSYCH, V88, P300, DOI 10.1037/h0076211; VERGNES M, 1982, NEUROSCI LETT, V33, P97, DOI 10.1016/0304-3940(82)90136-7; Wiest MC, 2003, NAT NEUROSCI, V6, P913, DOI 10.1038/nn1107; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; WILLIAMSON PD, 1985, ANN NEUROL, V18, P497, DOI 10.1002/ana.410180413	61	37	39	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 17	2015	35	24					9194	9204		10.1523/JNEUROSCI.0919-15.2015			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CN2KU	WOS:000358250700021	26085641	Green Published, Bronze			2022-02-06	
J	Joyce, AS; Labella, CR; Carl, RL; Lai, JS; Zelko, FA				Joyce, Aisha S.; Labella, Cynthia R.; Carl, Rebecca L.; Lai, Jin-Shei; Zelko, Frank A.			The Postconcussion Symptom Scale: Utility of a Three-Factor Structure	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; MILD TRAUMATIC BRAIN INJURY; PEDIATRIC; ATHLETE; SPORTS	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; PREDICTORS; RECOVERY; VALIDITY; IMPACT	Purpose: This study aimed to determine the factor structure of a 19-item Postconcussion Symptom Scale and to examine associations between factor scores and sex, previous history of concussion, and length of time since injury. Methods: This is a retrospective medical record review of pediatric patients with concussion seen in a sports medicine clinic from April 2008 to September 2012. We performed an exploratory factor analysis (EFA) followed by a confirmatory factor analysis (CFA). ANOVA and regression analysis were used to examine associations between factor scores and sex, previous history of concussion, mood disorder, anxiety disorder or attention-deficit disorder, and length of time since injury. Results: EFA supported a three-factor solution for postconcussive symptoms employing 18 of the original 19 scale items. Factor 1 consisted of eight cognition-related items, factor 2 consisted of six somatic-related items, and factor 3 consisted of four emotional-related items. CFA results confirmed the unidimensionality of factors 1 (neurocognitive), 2 (somatic) and 3 (emotional), with factor 3 being considered borderline. Females and patients with anxiety disorders had significantly worse (higher) scores on all three factors. Patients seen >14 d after the concussive injury had worse (higher) factor 3 (emotional) scores than those seen <14 d after the injury. There was no significant difference in postconcussive symptom factor structures between those with and without a previous history of concussion. Conclusions: Our investigation demonstrates a consistent symptom 3-factor structure of the Postconcussion Symptom Scale in pediatric patients with concussions. Females and patients with anxiety disorders had higher scores than males for all three factors. Patients seen >14 d after concussive injury had higher scores for emotional symptoms, suggesting that prolonged concussion symptoms may affect emotional health.	[Joyce, Aisha S.; Labella, Cynthia R.; Carl, Rebecca L.] Ann & Robert H Lurie Childrens Hosp Chicago, Div Orthopaed Surg & Sports Med, Chicago, IL 60611 USA; [Joyce, Aisha S.; Labella, Cynthia R.; Carl, Rebecca L.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Lai, Jin-Shei] Northwestern Univ, Dept Med Social Sci, Feinberg Sch Med, Chicago, IL 60611 USA; [Zelko, Frank A.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Child & Adolescent Psychiat, Chicago, IL 60611 USA; [Zelko, Frank A.] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA		Joyce, AS (corresponding author), 601 Childrens Lane, Norfolk, VA 23507 USA.	aishasophia@gmail.com	Meijer, Anna/K-5118-2016				CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cook KF, 2009, QUAL LIFE RES, V18, P447, DOI 10.1007/s11136-009-9464-4; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	18	37	37	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUN	2015	47	6					1119	1123		10.1249/MSS.0000000000000534			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	CI4TC	WOS:000354745500003	25268538				2022-02-06	
J	Peterson, BL; Won, S; Geddes, RI; Sayeed, I; Stein, DG				Peterson, Bethany L.; Won, Soonmi; Geddes, Rastafa I.; Sayeed, Iqbal; Stein, Donald G.			Sex-related differences in effects of progesterone following neonatal hypoxic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Cell proliferation; CNS repair; Development; Microglia; Neuroplasticity; Sex difference	CORTICAL PLASTICITY; GENDER-DIFFERENCES; PREFRONTAL CORTEX; ISCHEMIC INJURY; IMMATURE BRAIN; NEWBORN RATS; NEUROPROTECTION; EXPRESSION; RECOVERY; BEHAVIOR	There is no satisfactory therapeutic intervention for neonatal hypoxic ischemic (HI) encephalopathy. Progesterone is known to be effective in treating traumatic brain injury in adult animals but its effects in neonatal brains have not been reported. Brain injuries were induced by a unilateral common carotid artery ligation plus hypoxia exposure. Progesterone was administered immediately after hypoxia and daily for 5 days at 8 mg/kg, followed by a tapered dose for two days. At six weeks post-injury, lesion size and inflammatory factors were evaluated. Progesterone-treated, HI-injured male animals, but not females, showed significant long-term tissue protection compared to vehicle, suggesting an important sex difference in neuroprotection. Progesterone-treated, HI-injured male rats had fewer activated microglia in the cortex and hippocampus compared to controls. The rats were tested for neurological reflexes, motor asymmetry, and cognitive performance at multiple time points. The injured animals exhibited few detectable motor deficits, suggesting a high level of age- and injury-related neuroplasticity. There were substantial sex differences on several behavioral tests, indicating that immature males and females should be analyzed separately. Progesterone-treated animals showed modest beneficial effects in both sexes compared to vehicle-treated injured animals. Sham animals given progesterone did not behave differently from vehicle-treated sham animals on any measures. (C) 2015 Elsevier B.V. All rights reserved.	[Peterson, Bethany L.; Won, Soonmi; Geddes, Rastafa I.; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA		Stein, DG (corresponding author), 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020	Geddes, Rastafa/0000-0002-7313-761X	Besins Critical Care; Marcus Foundation; Allen and Company	We thank the Emory Institute for Drug Development for providing the progesterone serum assays used in this experiment. This research was partially supported by an unrestricted gift from Besins Critical Care; the majority of funding was donated by the Marcus Foundation and Allen and Company.	Balduini W, 2000, BRAIN RES, V859, P318, DOI 10.1016/S0006-8993(00)01997-1; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; BARTH TM, 1990, J NEUROSCI, V10, P3449; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Clancy B, 2001, NEUROSCIENCE, V105, P7, DOI 10.1016/S0306-4522(01)00171-3; Doverhag C, 2010, NEUROBIOL DIS, V38, P36, DOI 10.1016/j.nbd.2009.12.024; Fan XY, 2010, CURR NEUROPHARMACOL, V8, P324, DOI 10.2174/157015910793358150; Geddes RI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087252; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Goldman PS, 1972, PLASTICITY RECOVERY, P149; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grobin AC, 2003, J NEUROSCI, V23, P1832; Guillet R, 2012, PEDIATR RES, V71, P205, DOI 10.1038/pr.2011.30; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Halliwell C, 2009, DEV NEUROREHABIL, V12, P269, DOI 10.3109/17518420903087715; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1333, DOI 10.1097/01.WCB.0000141559.17620.36; Hedtjarn M, 2004, J CEREBR BLOOD F MET, V24, P1317, DOI 10.1097/01.WCB.0000141558.40491.75; Hill CA, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/867531; Hoeger H, 2000, LIFE SCI, V66, P947, DOI 10.1016/S0024-3205(99)00678-5; HUTTENLOCHER PR, 1989, DEV BRAIN RES, V47, P59, DOI 10.1016/0165-3806(89)90108-9; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Kaore SN, 2012, J PHARM PHARMACOL, V64, P1040, DOI 10.1111/j.2042-7158.2012.01464.x; KARTJETILLOTSON G, 1985, BRAIN RES, V332, P103, DOI 10.1016/0006-8993(85)90393-2; Kaur C, 2013, J NEUROIMMUNE PHARM, V8, P66, DOI 10.1007/s11481-012-9347-2; Kellogg CK, 1999, DEV BRAIN RES, V115, P17, DOI 10.1016/S0165-3806(99)00041-3; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; Kolb B, 2013, PROG BRAIN RES, V207, P35, DOI 10.1016/B978-0-444-63327-9.00005-9; Kolb B, 2011, DEV MED CHILD NEUROL, V53, P4, DOI 10.1111/j.1469-8749.2011.04054.x; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Lenz KM, 2013, J NEUROSCI, V33, P2761, DOI 10.1523/JNEUROSCI.1268-12.2013; Li HF, 2011, J CEREBR BLOOD F MET, V31, P2106, DOI 10.1038/jcbfm.2011.75; Liu YQ, 2002, PEDIATR RES, V51, P25, DOI 10.1203/00006450-200201000-00007; Lubics A, 2005, BEHAV BRAIN RES, V157, P157, DOI 10.1016/j.bbr.2004.06.019; Luoma JI, 2012, J STEROID BIOCHEM, V131, P30, DOI 10.1016/j.jsbmb.2011.11.002; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Nakajima W, 2000, J NEUROSCI, V20, P7994; Nemati F, 2012, BEHAV BRAIN RES, V229, P168, DOI 10.1016/j.bbr.2012.01.002; Nudi ET, 2014, J NEUROTRAUMA; Ong J, 2005, PEDIATR RES, V58, P600, DOI 10.1203/01.PDR.0000179381.86809.02; Qiu L, 2007, J CEREBR BLOOD F MET, V27, P785, DOI 10.1038/sj.jcbfm.9600385; Reglodi D, 2003, BEHAV BRAIN RES, V140, P131, DOI 10.1016/S0166-4328(02)00289-9; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Rogers E, 2006, J HEAD TRAUMA REHAB, V21, P279, DOI 10.1097/00001199-200605000-00008; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sabir H, 2012, STROKE, V43, P3364, DOI 10.1161/STROKEAHA.112.674481; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Shankaran S, 2012, ARCH DIS CHILD-FETAL, V97, pF398, DOI 10.1136/archdischild-2011-301524; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith AL, 2014, EXP NEUROL, V254, P54, DOI 10.1016/j.expneurol.2014.01.003; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Ten VS, 2003, BEHAV BRAIN RES, V145, P209, DOI 10.1016/S0166-4328(03)00146-3; Thornton C, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/506320; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Wagner CK, 2008, ENDOCRINOLOGY, V149, P2743, DOI 10.1210/en.2008-0049; Wang XY, 2009, J IMMUNOL, V183, P7471, DOI 10.4049/jimmunol.0900762; Wang XY, 2014, INT J NEUROSCI, V124, P42, DOI 10.3109/00207454.2013.817407; Whitaker-Azmitia PM, 2014, MED HYPOTHESES, V82, P313, DOI 10.1016/j.mehy.2013.12.018; Wong R, 2013, J CEREBR BLOOD F MET, V33, P1362, DOI 10.1038/jcbfm.2013.120; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright DW, 2014, ACAD EMERG MED, V21, P1414, DOI 10.1111/acem.12532; Xu Chun-Yang, 2010, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V26, P370; Zhu CL, 2009, J CEREBR BLOOD F MET, V29, P342, DOI 10.1038/jcbfm.2008.124	68	37	39	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 1	2015	286						152	165		10.1016/j.bbr.2015.03.005			14	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	CG8XS	WOS:000353599600023	25746450				2022-02-06	
J	Mayer, AR; Hanlon, FM; Ling, JM				Mayer, Andrew R.; Hanlon, Faith M.; Ling, Josef M.			Gray Matter Abnormalities in Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; gray matter; diffusion tensor imaging; pediatric; prospective	SPORTS-RELATED CONCUSSION; BLUNT HEAD-INJURY; FUNCTIONAL CONNECTIVITY; DIFFUSIONAL KURTOSIS; SYMPTOMS; RECOVERY; MRI; TRACTOGRAPHY; ADOLESCENCE; ANISOTROPY	Pediatric mild traumatic brain injury (pmTBI) is the most prevalent neurological insult in children and is associated with both acute and chronic neuropsychiatric sequelae. However, little is known about underlying pathophysiology changes in gray matter diffusion and atrophy from a prospective stand-point. Fifteen semi-acute pmTBI patients and 15 well-matched healthy controls were evaluated with a clinical and neuroimaging battery, with a subset of participants returning for a second visit. Clinical measures included tests of attention, processing speed, executive function, working memory, memory, and self-reported post-concussive symptoms. Measures of diffusion (fractional anisotropy [FA]) and atrophy were also obtained for cortical and subcortical gray matter structures to characterize effects of injury as a function of time. Patients exhibited decreased scores in the domains of attention and processing speed relative to controls during the semi-acute injury stage, in conjunction with increased anisotropic diffusion in the left superior temporal gyrus and right thalamus. Evidence of increased diffusion in these regions was also present at four months post-injury, with performance on cognitive tests partially normalizing. In contrast, signs of cortical atrophy in bilateral frontal areas and other left-hemisphere cortical areas only emerged at four months post-injury for patients. Current results suggest potentially differential time-courses of recovery for neurobehavioral markers, anisotropic diffusion and atrophy following pmTBI. Importantly, these data suggest that relying on patient self-report or standard clinical assessments may underestimate the time for true injury recovery.	[Mayer, Andrew R.; Hanlon, Faith M.; Ling, Josef M.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Meijer, Anna/K-5118-2016		Mind Research Network [DOE]United States Department of Energy (DOE) [DE-FG02-99ER62764]	This research was supported by grants from The Mind Research Network [DOE Grant No. DE-FG02-99ER62764] to A.R.M.	Akpinar E, 2007, J COMPUT ASSIST TOMO, V31, P657, DOI 10.1097/RCT.0b013e318033df1a; Babikian T, 2010, J NEUROTRAUM, V27, P473, DOI 10.1089/neu.2009.1058; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Bell MJ, 2013, CRIT CARE CLIN, V29, P223, DOI 10.1016/j.ccc.2012.11.004; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Conti AC, 1998, J NEUROSCI, V18, P5663; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Faul M, 2010, TRAUMATIC BRAIN INJU; Fieremans E, 2011, NEUROIMAGE, V58, P177, DOI 10.1016/j.neuroimage.2011.06.006; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Keightley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00139; Korgaonkar MS, 2011, HUM BRAIN MAPP, V32, P2161, DOI 10.1002/hbm.21178; Lenroot RK, 2007, NEUROIMAGE, V36, P1065, DOI 10.1016/j.neuroimage.2007.03.053; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Nemati F, 2012, BEHAV BRAIN RES, V229, P168, DOI 10.1016/j.bbr.2012.01.002; Newcombe VFJ, 2013, J CEREBR BLOOD F MET, V33, P855, DOI 10.1038/jcbfm.2013.11; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; PAUS T, 2007, UNDERST COMPLEX SYST, P463; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	56	37	37	1	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2015	32	10					723	730		10.1089/neu.2014.3534			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CH3ZP	WOS:000353970200007	25313896				2022-02-06	
J	Collins, JM; King, AE; Woodhouse, A; Kirkcaldie, MTK; Vickers, JC				Collins, Jessica M.; King, Anna E.; Woodhouse, Adele; Kirkcaldie, Matthew T. K.; Vickers, James C.			The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease	EXPERIMENTAL NEUROLOGY			English	Article						Brain injury; Alzheimer's disease; Beta-amyloid; APP/PS1; Microglia; Synapses	A-BETA; HEAD-INJURY; TRANSGENIC MICE; GLIAL-CELLS; METALLOTHIONEIN EXPRESSION; PROTEIN DEPOSITION; PRECURSOR PROTEINS; RAPID APPEARANCE; RISK-FACTOR; ASTROCYTES	Traumatic brain injury is a risk factor for Alzheimer's disease (AD), however the effect of such neural damage on the onset and progression of beta-amyloid (A beta) plaque pathology is not well understood. This study utilized an in vivo model of focal brain injury to examine how localized damage may acutely affect the onset and progression of A beta plaque deposition as well as inflammatory and synaptic changes, in the APP/PS1 (APP(SWE), PSEN1dE9) transgenic model of AD relative to wild-type (Wt) mice. Acute focal brain injury in 3- and 9-month-old APP/PS1 and Wt mice was induced by insertion of a needle into the somatosensory neocortex, as compared to sham surgery, and examined at 24 h and 7 d post-injury (PI). Focal brain injury did not induce thioflavine-S stained or (pan-A beta antibody) MOAB-2-labeled plaques at either 24 h or 7 d PI in 3-month-old APP/PS1 mice or Wt mice. Nine-month-old APP/PS1 mice demonstrate cortical A beta plaques but focal injury had no statistically significant (p > 0.05) effect on thioflavine-S or MOAB-2 plaque load surrounding the injury site at 24 h PI or 7 d PI. There was a significant (p < 0.001) increase in cross-sectional cortical area occupied by lba-1 positive microglia in injured mice compared to sham animals, however this response did not differ between APP/PS1 and Wt mice (p > 0.05). For both Wt and APP/PS1 mice alike, synaptophysin puncta near the injury site were significantly reduced 24 h PI (compared to sites distant to the injury and the corresponding area in sham mice; p < 0.01), but not after 7 d PI (p > 0.05). There was no significant effect of genotype on this response (p > 0.05). These results indicate that focal brain injury and the associated microglial response do not acutely alter A beta plaque deposition in the APP/PS1 mouse model. Furthermore the current study demonstrated that the brains of both Wt and APP/PS1 mice are capable of recovering lost synaptophysin immunoreactivity post-injury, the latter in the presence of A beta plaque pathology that causes synaptic degeneration. (C) 2015 Elsevier Inc. All rights reserved.	[Collins, Jessica M.; King, Anna E.; Woodhouse, Adele; Kirkcaldie, Matthew T. K.; Vickers, James C.] Univ Tasmania, Wicking Dementia Res & Educ Ctr, Hobart, Tas 7001, Australia; [Kirkcaldie, Matthew T. K.; Vickers, James C.] Univ Tasmania, Sch Med, Hobart, Tas 7001, Australia		Collins, JM (corresponding author), Univ Tasmania, Wicking Dementia Res & Educ Ctr, Private Bag 34, Hobart, Tas 7001, Australia.	jessica.Collins@utas.edu.au	Kirkcaldie, Matthew TK/J-4418-2012; Vickers, James C/J-7464-2014; King, Anna/J-7927-2014	Kirkcaldie, Matthew TK/0000-0003-3285-0168; Vickers, James C/0000-0001-5671-4879; King, Anna/0000-0003-1792-0965; Woodhouse, Adele/0000-0002-4246-7624; Collins, Jessica/0000-0002-1938-2470	JO and JR Wicking Trust	This study was funded by JO and JR Wicking Trust.	Blizzard CA, 2013, J NEUROTRAUM, V30, P1908, DOI 10.1089/neu.2013.2850; Blizzard CA, 2011, CEREB CORTEX, V21, P281, DOI 10.1093/cercor/bhq091; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Calhoun ME, 1996, J NEUROCYTOL, V25, P821, DOI 10.1007/BF02284844; Chung RS, 2007, CELL MOL LIFE SCI, V64, P2716, DOI 10.1007/s00018-007-7267-8; Chung RS, 2008, J BIOL CHEM, V283, P15349, DOI 10.1074/jbc.M708446200; Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x; Chung RS, 2003, J NEUROSCI, V23, P3336; Dickson TC, 2001, NEUROSCIENCE, V105, P99, DOI 10.1016/S0306-4522(01)00169-5; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Funato H, 1998, AM J PATHOL, V152, P983; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GOLDSTEIN ME, 1983, P NATL ACAD SCI-BIOL, V80, P3101, DOI 10.1073/pnas.80.10.3101; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jankowsky JL, 2001, BIOMOL ENG, V17, P157, DOI 10.1016/S1389-0344(01)00067-3; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Katsouri L, 2015, NEUROBIOL AGING, V36, P821, DOI 10.1016/j.neurobiolaging.2014.10.004; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Lindgren M, 2010, FEBS J, V277, P1380, DOI 10.1111/j.1742-4658.2010.07571.x; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Mitew S, 2013, NEUROBIOL AGING, V34, P2341, DOI 10.1016/j.neurobiolaging.2013.04.010; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nagele RG, 2004, NEUROBIOL AGING, V25, P663, DOI 10.1016/j.neurobiolaging.2004.01.007; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Perez SE, 2013, J COMP NEUROL, V521, P4318, DOI 10.1002/cne.23428; Pierce JES, 1996, J NEUROSCI, V16, P1083; PIKE CJ, 1995, EXP NEUROL, V132, P172, DOI 10.1016/0014-4886(95)90022-5; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Verkhratsky A, 2010, NEUROTHERAPEUTICS, V7, P399, DOI 10.1016/j.nurt.2010.05.017; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Winton MJ, 2011, J NEUROSCI, V31, P7691, DOI 10.1523/JNEUROSCI.6637-10.2011; Woodhouse A, 2009, NEUROBIOL AGING, V30, P864, DOI 10.1016/j.neurobiolaging.2007.09.003; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Youmans KL, 2012, J BIOL CHEM, V287, P41774, DOI 10.1074/jbc.M112.407957; Youmans KL, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-8; Zhao W, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00210; Zhao WJ, 2014, HUM MOL GENET, V23, P1365, DOI 10.1093/hmg/ddt525	55	37	38	1	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2015	267						219	229		10.1016/j.expneurol.2015.02.034			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CH1AZ	WOS:000353754800021	25747037				2022-02-06	
J	Gu, XH; Wei, ZZ; Espinera, A; Lee, JH; Ji, XY; Wei, L; Dix, TA; Yu, SP				Gu, Xiaohuan; Wei, Zheng Zachory; Espinera, Alyssa; Lee, Jin Hwan; Ji, Xiaoya; Wei, Ling; Dix, Thomas A.; Yu, Shan Ping			Pharmacologically induced hypothermia attenuates traumatic brain injury in neonatal rats	EXPERIMENTAL NEUROLOGY			English	Article						Drug-induced hypothermia; Neonates; Traumatic brain injury; Cell death; Brain protection; Functional recovery	FOCAL CEREBRAL-ISCHEMIA; THERAPEUTIC HYPOTHERMIA; MILD HYPOTHERMIA; NEUROPROTECTION; MODEL; INDUCTION; ERYTHROPOIETIN; SEIZURES; BENEFIT; STATE	Neonatal brain trauma is linked to higher risks of mortality and neurological disability. The use of mild to moderate hypothermia has shown promising potential against brain injuries induced by stroke and traumatic brain injury (TBI) in various experimental models and in clinical trials. Conventional methods of physical cooling, however, are difficult to use in acute treatments and in induction of regulated hypothermia. In addition, general anesthesia is usually required to mitigate the negative effects of shivering during physical cooling. Our recent investigations demonstrate the potential therapeutic benefits of pharmacologically induced hypothermia (PIH) using the neurotensin receptor (NTR) agonist HPI201 (formerly known as ABS201) in stroke and TBI models of adult rodents. The present investigation explored the brain protective effects of HPI201 in a P14 rat pediatric model of TBI induced by controlled cortical impact. When administered via intraperitoneal (i.p.) injection, HPI201 induced dose-dependent reduction of body and brain temperature. A 6-h hypothermic treatment providing an overall 2-3 degrees C reduction of brain and body temperature, showed significant effect of attenuating the contusion volume versus TBI controls. Attenuation occurs whether hypothermia is initiated 15 min or 2 h after TBI. No shivering response was seen in HPI201-treated animals. HPI201 treatment also reduced TUNEL-positive and TUNEL/NeuN-colabeled cells in the contusion area and pen-injury regions. TBI-induced blood-brain barrier damage was attenuated by HPI201 treatment, evaluated using the Evans Blue assay. HPI201 significantly decreased MMP-9 levels and caspase-3 activation, both of which are pro-apototic, while it increased antiapoptotic Bcl-2 gene expression in the pen-contusion region. In addition, HPI201 prevented the up-regulation of pro-inflammatory tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta) and IL-6. In sensorimotor activity assessments, rats in the HPI201 treated group exhibited improved functional recovery after TBI versus controls. These data support that PIH therapy using our NTR agonist is effective in reducing neuronal and BBB damage, attenuating inflammatory response and detrimental cellular signaling, and promoting functional recovery after TEL in the developing brain, supporting its potential for further evaluation towards clinical development. (C) 2015 Elsevier Inc. All rights reserved.	[Gu, Xiaohuan; Wei, Zheng Zachory; Espinera, Alyssa; Lee, Jin Hwan; Ji, Xiaoya; Wei, Ling; Yu, Shan Ping] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Wei, Zheng Zachory; Yu, Shan Ping] Atlanta VA Med Ctr, Ctr Visual & Neurocognit Rehabil, Decatur, GA 30033 USA; [Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Dix, Thomas A.] Med Univ S Carolina, Dept Drug Discovery Biomed Sci, Charleston, SC 29425 USA; [Dix, Thomas A.] JT Pharmaceut Inc, Mt Pleasant, SC 29464 USA		Yu, SP (corresponding author), Emory Univ, Sch Med, Dept Anesthesiol, 101 Woodruff Circle,WMB 620, Atlanta, GA 30322 USA.	spyu@emory.edu	Wei, Zheng Zachory/I-2109-2019	Wei, Zheng Zachory/0000-0001-7682-9286	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045810, R41NS073378, NS057255, NS075338]; AHA Established Investigator AwardAmerican Heart Association [0840110N]; VA national merit grant; O. Wayne Rolling's Endowed Chair fund;  [12GRNT12060222]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045810, R01NS085568, R41NS073378, R21NS075338, R01NS057255] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000666] Funding Source: NIH RePORTER	This work was supported by NIH grants (NS045810 to SPY, R41NS073378 to SPY and TAD, NS057255 and NS075338 to LW), AHA Established Investigator Award (0840110N to LW), a Grant-in-Aid award (12GRNT12060222 to SPY) and a VA national merit grant (SPY). It was also supported by the O. Wayne Rolling's Endowed Chair fund to SPY.	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; Ahmad FU, 2014, WORLD NEUROSURG, V82, P207, DOI 10.1016/j.wneu.2013.01.008; Alexander ML, 2012, DEV NEUROSCI-BASEL, V34, P515, DOI 10.1159/000345645; Chang I, 2013, J CLIN INVEST, V123, P2643, DOI 10.1172/JCI66735; Chen J, 2013, STROKE, V44, P260, DOI 10.1161/STROKEAHA.112.675462; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; D'Ambrosio R, 2013, ANN NEUROL, V73, P199, DOI 10.1002/ana.23764; Egginton S, 2013, J EXP BIOL, V216, P2140, DOI 10.1242/jeb.079160; Fan XY, 2013, PEDIATR RES, V73, P18, DOI 10.1038/pr.2012.139; Finnie JW, 2012, AUST VET J, V90, P301, DOI 10.1111/j.1751-0813.2012.00955.x; Fugate JE, 2013, NEUROLOGY, V81, P40, DOI 10.1212/WNL.0b013e318297ee7e; Garfinkle J, 2013, EUR J PAEDIATR NEURO, V17, P492, DOI 10.1016/j.ejpn.2013.03.006; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Gong P, 2013, J CEREBR BLOOD F MET, V33, P928, DOI 10.1038/jcbfm.2013.33; Groger M, 2013, CRIT CARE MED, V41, pE105, DOI 10.1097/CCM.0b013e31827c0b1f; Harris B, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16450; Inoue S, 2013, J THORAC CARDIOV SUR, V146, P696, DOI 10.1016/j.jtcvs.2012.11.040; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jia F, 2014, J NEUROTRAUM, V31, P387, DOI 10.1089/neu.2008.0814; Katz LM, 2012, THER HYPOTHERMIA TEM, V2, P61, DOI 10.1089/ther.2012.0011; Kim JH, 2013, CURR PROTEIN PEPT SC, V14, P51; Kuboi T, 2013, PEDIATR INT, V55, pE23, DOI 10.1111/j.1442-200X.2012.03730.x; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Li WL, 2013, NEUROSCIENCE, V244, P16, DOI 10.1016/j.neuroscience.2013.03.045; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Matsui T, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/436263; Mohr J, 2013, J TRAUMA ACUTE CARE, V74, P1014, DOI 10.1097/TA.0b013e3182826edd; Motamedi GK, 2013, EPILEPSIA, V54, P959, DOI 10.1111/epi.12144; Muzzi M, 2013, J CEREBR BLOOD F MET, V33, P183, DOI 10.1038/jcbfm.2012.157; Rey-Funes M, 2013, INVEST OPHTH VIS SCI, V54, P2836, DOI 10.1167/iovs.12-11198; See K C, 2012, Med J Malaysia, V67, P265; Seo M, 2012, ELECTROPHORESIS, V33, P3835, DOI 10.1002/elps.201200331; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; Srinivasakumar P, 2013, J PEDIATR-US, V163, P465, DOI 10.1016/j.jpeds.2013.01.041; Testori C, 2013, RESUSCITATION, V84, P1051, DOI 10.1016/j.resuscitation.2013.03.013; Tupone D, 2013, AUTON NEUROSCI-BASIC, V176, P1, DOI 10.1016/j.autneu.2013.02.004; Wei S, 2013, NEUROSCIENCE, V252, P489, DOI 10.1016/j.neuroscience.2013.07.052; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Zgavc T, 2013, BRAIN RES, V1501, P81, DOI 10.1016/j.brainres.2013.01.034; Zhang MJ, 2013, CNS NEUROL DISORD-DR, V12, P371, DOI 10.2174/1871527311312030010; Zhao H, 2013, AM J TRANSPLANT, V13, P2006, DOI 10.1111/ajt.12293	43	37	38	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2015	267						135	142		10.1016/j.expneurol.2015.02.029			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CH1AZ	WOS:000353754800014	25725354	Green Accepted			2022-02-06	
J	Neumann, D; Babbage, DR; Zupan, B; Willer, B				Neumann, Dawn; Babbage, Duncan R.; Zupan, Barbra; Willer, Barry			A Randomized Controlled Trial of Emotion Recognition Training After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						affect; emotion recognition; randomized controlled trial; traumatic brain injury; treatment	FACIAL AFFECT RECOGNITION; PERCEPTION DEFICITS; NEUROPSYCHIATRIC INVENTORY; NONVERBAL-COMMUNICATION; INDIVIDUAL-DIFFERENCES; EMPATHY; DEMENTIA; ABILITY; MIND	Objective: To examine the effectiveness of 2 affect recognition interventions (Faces and Stories) in people with a traumatic brain injury. Setting: Postacute rehabilitation facilities. Participants: A total of 203 participants with moderate to severe traumatic brain injury were screened; 71 were eligible and randomized to the Faces (n = 24), Stories (n = 23), and Control interventions (n = 24). Participants were an average of 39.8 years of age and 10.3 years postinjury; 74% of participants were male. Design: Randomized controlled trial with immediate, 3-month, and 6-month follow-up posttests. Interventions were 9 hours of computer-based training with a therapist. Measures: Diagnostic Assessment of Nonverbal Accuracy 2-Adult Faces; Emotional Inference From Stories Test; Empathy (Interpersonal Reactivity Index); and Irritability and Aggression (Neuropsychiatric Inventory). Results: The Faces Intervention did significantly better than the Control Intervention on the Diagnostic Assessment of Nonverbal Accuracy 2-Adult Faces (P = .031) posttreatment; no time effect or group interaction was observed. No other significant differences were noted for the Faces Intervention. No significant differences were observed between the Stories and the Control Interventions; however, a significant time effect was found for the Emotional Inference From Stories Test. Conclusion: The Faces Intervention effectively improved facial affect recognition in participants with chronic post-traumatic brain injury, and changes were maintained for 6 months. Future work should focus on generalizing this skill to functional behaviors.	[Neumann, Dawn] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Neumann, Dawn] Rehabil Hosp Indiana, Indianapolis, IN 46254 USA; [Babbage, Duncan R.] Auckland Univ Technol, Ctr Person Ctr Res, Auckland, New Zealand; [Zupan, Barbra] Brock Univ, Dept Appl Linguist, St Catharines, ON L2S 3A1, Canada; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Sch Med, Buffalo, NY 14260 USA		Neumann, D (corresponding author), Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46254 USA.	dmneuman@iupui.edu		Barbra, Zupan/0000-0002-4603-333X; Babbage, Duncan/0000-0002-9259-9246			ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; Andersen PA, 1998, HDB COMMUNICATION EM, P29; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Bornhofen C, 2008, J HEAD TRAUMA REHAB, V23, P103, DOI 10.1097/01.HTR.0000314529.22777.43; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Bowers D., 1991, FLORIDA AFFECT BATTE; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; Brookshire R, 1993, DISCOURSE COMPREHENS, P105; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; Decety J, 2006, THESCIENTIFICWORLDJO, V6, P1146, DOI 10.1100/tsw.2006.221; Driscoll DM, 2011, J NEUROTRAUM, V28, P319, DOI 10.1089/neu.2010.1523; Dywan JRR, 1995, J INT NEUROPSYCHOL S, V1; Ferstl EC, 2005, J COGNITIVE NEUROSCI, V17, P724, DOI 10.1162/0898929053747658; Guercio JM, 2004, BRAIN INJURY, V18, P593, DOI 10.1080/02699050310001646116; Kilmer RP, 2006, REHABIL PSYCHOL, V51, P232, DOI 10.1037/0090-5550.51.3.232; Knox L, 2009, BRAIN COGNITION, V69, P442, DOI 10.1016/j.bandc.2008.09.009; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McIntire K. A., 1999, N AM J PSYCHOL, V1, P261; MEHRABIAN A, 1981, SILENT MESSAGES IMPL; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Munro BH, 2004, STAT METHODS HLTH CA, V1; Neumann D, 2014, J HEAD TRAUMA REHAB, V29, pE18, DOI 10.1097/HTR.0b013e31827fb0b5; Neumann D, 2012, ARCH PHYS MED REHAB, V93, P1414, DOI 10.1016/j.apmr.2012.03.009; NOWICKI S, 1993, J SOC PSYCHOL, V133, P749, DOI 10.1080/00224545.1993.9713934; NOWICKI S, 1994, J NONVERBAL BEHAV, V18, P9, DOI 10.1007/BF02169077; Planalp S, 1996, COGNITION EMOTION, V10, P137, DOI 10.1080/026999396380303; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Radice-Neumann D, 2009, J HEAD TRAUMA REHAB, V24, P313, DOI 10.1097/HTR.0b013e3181b09160; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P166, DOI 10.1176/appi.neuropsych.22.2.166; RIGGIO RE, 1989, PERS INDIV DIFFER, V10, P93, DOI 10.1016/0191-8869(89)90184-0; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Yim J, 2013, BRAIN INJURY, V27, P1155, DOI 10.3109/02699052.2013.804203; YIRMIYA N, 1992, CHILD DEV, V63, P150, DOI 10.2307/1130909; Zupan B., 2009, DEP APPL LING RES DA; Zupan B, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e31829dded6; Zupan B, 2009, J COMMUN DISORD, V42, P1, DOI 10.1016/j.jcomdis.2008.06.001	47	37	38	1	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2015	30	3					E12	E23		10.1097/HTR.0000000000000054			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CH8PJ	WOS:000354298100002	24842590				2022-02-06	
J	Ryan, NP; Catroppa, C; Cooper, JM; Beare, R; Ditchfield, M; Coleman, L; Silk, T; Crossley, L; Beauchamp, MH; Anderson, VA				Ryan, Nicholas P.; Catroppa, Cathy; Cooper, Janine M.; Beare, Richard; Ditchfield, Michael; Coleman, Lee; Silk, Timothy; Crossley, Louise; Beauchamp, Miriam H.; Anderson, Vicki A.			The Emergence of Age-Dependent Social Cognitive Deficits After Generalized Insult to the Developing Brain: A Longitudinal Prospective Analysis Using Susceptibility-Weighted Imaging	HUMAN BRAIN MAPPING			English	Article						child; brain injuries; magnetic resonance imaging; Theory of Mind; neurobiology	DIFFUSE AXONAL INJURY; WHITE-MATTER DAMAGE; CLINICAL-APPLICATIONS; EMOTION RECOGNITION; HEAD-INJURY; CHILDREN; MIND; CHILDHOOD; PLASTICITY; OUTCOMES	Childhood and adolescence are critical periods for maturation of neurobiological processes that underlie complex social and emotional behavior including Theory of Mind (ToM). While structural correlates of ToM are well described in adults, less is known about the anatomical regions subsuming these skills in the developing brain or the impact of cerebral insult on the acquisition and establishment of high-level social cognitive skills. This study aimed to examine the differential influence of age-at-insult and brain pathology on ToM in a sample of children and adolescents with traumatic brain injury (TBI). Children and adolescents with TBI (n=112) were categorized according to timing of brain insult: (i) middle childhood (5-9 years; n=41); (ii) late childhood (10-11 years; n=39); and (iii) adolescence (12-15 years; n=32) and group-matched for age, gender, and socioeconomic status to a typically developing (TD) control group (n=43). Participants underwent magnetic resonance imaging including a susceptibility-weighted imaging (SWI) sequence 2-8 weeks postinjury and were assessed on a battery of ToM tasks at 6- and 24-months after injury. Results showed that for adolescents with TBI, social cognitive dysfunction at 6- and 24-months postinjury was associated with diffuse neuropathology and a greater number of lesions detected using SWI. In the late childhood TBI group, we found a time-dependent emergence of social cognitive impairment, linked to diffuse neuropathology. The middle childhood TBI group demonstrated performance unrelated to SWI pathology and comparable to TD controls. Findings indicate that the full extent of social cognitive deficits may not be realized until the associated skills reach maturity. Evidence for brain structure-function relationships suggests that the integrity of an anatomically distributed network of brain regions and their connections is necessary for the acquisition and establishment of high-level social cognitive skills. Hum Brain Mapp 36:1677-1691, 2015. (c) 2014 Wiley Periodicals, Inc.	[Ryan, Nicholas P.; Catroppa, Cathy; Cooper, Janine M.; Crossley, Louise; Anderson, Vicki A.] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Ryan, Nicholas P.; Catroppa, Cathy; Anderson, Vicki A.] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Beare, Richard; Silk, Timothy] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia; [Ditchfield, Michael] Monash Hlth, Dept Paediat Imaging, Melbourne, Vic, Australia; [Ditchfield, Michael] Monash Univ, Dept Paediat, Meloburne, Australia; [Coleman, Lee] Royal Childrens Hosp, Dept Radiol, Melbourne, Vic, Australia; [Silk, Timothy] Univ Melbourne, Dept Pediat, Melbourne, Vic, Australia; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Res Ctr, Montreal, PQ, Canada		Ryan, NP (corresponding author), Murdoch Childrens Res Inst, Child Neuropsychol, Flemington Rd, Parkville, Vic 3052, Australia.	nicholas.ryan@mcri.edu.au	Ryan, Nicholas/K-5445-2019; Silk, Tim/K-4295-2019; Catroppa, Cathy/AAX-9458-2021	Ryan, Nicholas/0000-0002-0878-8889; Catroppa, Cathy/0000-0002-9750-0436; Beare, Richard/0000-0002-7530-5664; Silk, Tim/0000-0002-7290-512X	Victoria Neurotrauma Initiative, Australia; Victorian Government	This work was supported by a grant from the Victoria Neurotrauma Initiative, Australia and the Victorian Government Operational Infrastructure Support Program. The funding bodies did not play a role in the design of the study, collection, analysis and interpretation of the data, or writing of the manuscript.	Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2010, BRAIN, V133, P45; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Belsky J, 2011, J CHILD PSYCHOL PSYC, V52, P409, DOI 10.1111/j.1469-7610.2010.02281.x; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Blakemore SJ, 2011, CHILD PSYCHOLOGY AND PSYCHIATRY: FRAMEWORKS FOR PRACTICE, 2ND EDITION, P62; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Coffey CE, 1991, PSYCHOPATHOL BRAIN, P243; Cohen J., 2013, STAT POWER ANAL BEHA; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Crowe LM, 2012, J PEDIATR PSYCHOL, V37, P745, DOI 10.1093/jpepsy/jss070; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M., 2000, AUTISM INT J RES PRA, V4, P370, DOI DOI 10.1177/1362361300004004003; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P85; Dennis M, 2014, NEUROPSYCHOL REV, V24, P389, DOI 10.1007/s11065-014-9261-x; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Follett PL, 2009, J CHILD NEUROL, V24, P1205, DOI 10.1177/0883073809338627; Geraci A, 2010, BRAIN INJURY, V24, P978, DOI 10.3109/02699052.2010.487477; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Herbet G, 2014, BRAIN, V137, P944, DOI 10.1093/brain/awt370; Herbet G, 2013, CORTEX, V49, P2711, DOI 10.1016/j.cortex.2013.08.003; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Johnson MH, 2001, NAT REV NEUROSCI, V2, P475, DOI 10.1038/35081509; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Mosch SC, 2005, COGN BEHAV NEUROL, V18, P5, DOI 10.1097/01.wnn.0000152207.80819.3c; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Nelson EE, 2005, PSYCHOL MED, V35, P163, DOI 10.1017/S0033291704003915; Paus T, 2005, TRENDS COGN SCI, V9, P60, DOI 10.1016/j.tics.2004.12.008; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; Scherf KS, 2013, HORM BEHAV, V64, P298, DOI 10.1016/j.yhbeh.2013.05.011; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; Sengpiel F, 2007, CURR BIOL, V17, pR742, DOI 10.1016/j.cub.2007.06.017; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Sodian B, 2007, DEVELOPMENTAL SCI, V10, P199, DOI 10.1111/j.1467-7687.2007.00580.x; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Surian L, 2007, PSYCHOL SCI, V18, P580, DOI 10.1111/j.1467-9280.2007.01943.x; Tabachnick B.G., 2001, USING MULTIVARIATE S; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tonks J, 2007, BRAIN INJURY, V21, P623, DOI 10.1080/02699050701426865; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yurgelun-Todd D, 2007, CURR OPIN NEUROBIOL, V17, P251, DOI 10.1016/j.conb.2007.03.009; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015	85	37	37	0	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2015	36	5					1677	1691		10.1002/hbm.22729			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CG1XH	WOS:000353068300004	25537228	Green Published			2022-02-06	
J	Panenka, WJ; Lange, RT; Bouix, S; Shewchuk, JR; Heran, MKS; Brubacher, JR; Eckbo, R; Shenton, ME; Iverson, GL				Panenka, William J.; Lange, Rael T.; Bouix, Sylvain; Shewchuk, Jason R.; Heran, Manraj K. S.; Brubacher, Jeffrey R.; Eckbo, Ryan; Shenton, Martha E.; Iverson, Grant L.			Neuropsychological Outcome and Diffusion Tensor Imaging in Complicated versus Uncomplicated Mild Traumatic Brain Injury	PLOS ONE			English	Article							POST-CONCUSSION SYNDROME; COMPUTED-TOMOGRAPHY; HEAD-INJURY; AXONAL INJURY; MODERATE; CT; PREDICTION; ASSOCIATION; SYMPTOMS; CHILDREN	This study examined whether intracranial neuroimaging abnormalities in those with mild traumatic brain injury (MTBI) (i.e., "complicated" MTBIs) are associated with worse subacute outcomes as measured by cognitive testing, symptom ratings, and/or diffusion tensor imaging (DTI). We hypothesized that (i) as a group, participants with complicated MTBIs would report greater symptoms and have worse neurocognitive outcomes than those with uncomplicated MTBI, and (ii) as a group, participants with complicated MTBIs would show more Diffusion Tensor Imaging (DTI) abnormalities. Participants were 62 adults with MTBIs (31 complicated and 31 uncomplicated) who completed neurocognitive testing, symptom ratings, and DTI on a 3T MRI scanner approximately 6-8 weeks post injury. There were no statistically significant differences between groups on symptom ratings or on a broad range of neuropsychological tests. When comparing the groups using tract-based spatial statistics for DTI, no significant difference was found for axial diffusivity or mean diffusivity. However, several brain regions demonstrated increased radial diffusivity (purported to measure myelin integrity), and decreased fractional anisotropy in the complicated group compared with the uncomplicated group. Finally, when we extended the DTI analysis, using a multivariate atlas based approach, to 32 orthopedic trauma controls (TC), the findings did not reveal significantly more areas of abnormal DTI signal in the complicated vs. uncomplicated groups, although both MTBI groups had a greater number of areas with increased radial diffusivity compared with the trauma controls. This study illustrates that macrostructural neuroimaging changes following MTBI are associated with measurable changes in DTI signal. Of note, however, the division of MTBI into complicated and uncomplicated subtypes did not predict worse clinical outcome at 6-8 weeks post injury.	[Panenka, William J.; Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Bouix, Sylvain; Eckbo, Ryan; Shenton, Martha E.] Harvard Univ, Sch Med, Brigham Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA USA; [Shewchuk, Jason R.; Heran, Manraj K. S.] Univ British Columbia, Dept Radiol, Vancouver, BC V5Z 1M9, Canada; [Brubacher, Jeffrey R.] Univ British Columbia, Dept Emergency Med, Vancouver, BC V5Z 1M9, Canada; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton, MA USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA		Panenka, WJ (corresponding author), Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada.	wpanenka@mail.ubc.ca	Shenton, Martha/V-8780-2019	Panenka, William/0000-0001-7143-6512; Iverson, Grant/0000-0001-7348-9570; Brubacher, Jeffrey/0000-0002-4866-4231	Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [200903MOP-200377-BSB-CAAA-161276]; INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]	Primary funding for this study was provided by the Canadian Institute of Health Research (200903MOP-200377-BSB-CAAA-161276); provided to RTL as PI). MES and GLI note that this work was supported in part by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program (X81XWH-07-CC-CSDoD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anstey KJ, 2009, AM J GERIAT PSYCHIAT, V17, P542, DOI 10.1097/JGP.0b013e3181a2fd07; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bay Esther H, 2009, Res Theory Nurs Pract, V23, P42; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beck AT, 1993, BECK ANXIETY INVENTO; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brandstack N, 2013, RADIOLOGY, V267, P231, DOI 10.1148/radiol.12112570; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cohen J., 2013, STAT POWER ANAL BEHA; Dagher JH, 2013, BRAIN INJURY, V27, P189, DOI 10.3109/02699052.2012.729288; de Guise E, 2010, CLIN NEUROPSYCHOL, V24, P1113, DOI 10.1080/13854046.2010.506199; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Gering DT, 2001, J MAGN RESON IMAGING, V13, P967, DOI 10.1002/jmri.1139; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hiekkanen H, 2009, BRAIN INJURY, V23, P396, DOI 10.1080/02699050902926259; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/415740; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Iverson GL, 2011, BRAIN INJURY, V25, P1325, DOI 10.3109/02699052.2011.608409; Kaddurah-Daouk R, 2007, MOL PSYCHIATR, V12, P934, DOI 10.1038/sj.mp.4002000; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kumar RG, 2014, AM J PHYS MED REHAB, V93, P687, DOI 10.1097/PHM.0000000000000077; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lange RT, 2014, J NEUROTRAUM, V31, P198, DOI 10.1089/neu.2013.2866; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Lannsjo M, 2013, EUR J NEUROL, V20, P124, DOI 10.1111/j.1468-1331.2012.03813.x; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mori A, 2005, MRI ATLAS HUMAN WHIT; Muller K, 2009, NEUROSURGERY, V64, P698, DOI 10.1227/01.NEU.0000340978.42892.78; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Pandor A, 2012, J NEUROTRAUM, V29, P707, DOI 10.1089/neu.2011.1967; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thiruppathy SP, 2004, ACTA NEUROCHIR, V146, P1075, DOI 10.1007/s00701-004-0335-z; Tombaugh T.N., 1996, TEST MEMORY MALINGER; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Waljas M, 2013, J NEUROTRAUMA; White T, 2003, NAB DEMOGRAPHICALLY; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 2004, ICD 10 INT STAT CLAS; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc	85	37	37	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2015	10	4							e0122746	10.1371/journal.pone.0122746			27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CG9SB	WOS:000353659100011	25915776	gold, Green Published			2022-02-06	
J	Iverson, KM; Pogoda, TK				Iverson, Katherine M.; Pogoda, Terri K.			Traumatic Brain Injury Among Women Veterans An Invisible Wound of Intimate Partner Violence	MEDICAL CARE			English	Article						Veterans health administration; concussion; abuse; domestic violence; strangulation	HEALTH; STRANGULATION; SCALES	Background: Intimate partner violence (IPV) is prevalent among women Veterans and is known to increase women's risk for traumatic brain injury (TBI). IPV-related TBI has not been examined in the women Veteran population. Objectives: To identify the occurrence of IPV-related TBI in a sample of women Veterans and examine the associations of IPV-related TBI with sociodemographic characteristics, health symptoms, health care utilization, and IPV experiences. Research Design: Cross-sectional mail survey conducted in 2013. Subjects: The sample comprised 176 New England Department of Veterans Affairs (VA) women Veteran patients. Measures: Self-reported IPV-related TBI was assessed with a modified VA TBI screening tool. The survey included validated measures of depression (Center for Epidemiologic Studies Depression Scale) and posttraumatic stress disorder (PTSD; Posttraumatic Disorder Checklist) symptoms, as well as overall mental and physical health (SF-12), and IPV (Conflict Tactics Scales-Revised-2). Questions assessed past-year VA and non-VA health care use. Results: A total of 18.8% (n = 33) met screening criteria for IPV-related TBI history. Women who experienced IPV-related TBI reported significantly higher depression (mean Center for Epidemiologic Studies Depression Scale scores: 26.6 vs. 20.7, P < 0.0001) and PTSD (mean Posttraumatic Disorder Checklist scores: 53.2 vs. 34.1, P < 0.0001) symptoms, and poorer perceptions of physical health (mean SF-12 34.6 vs. 42.3, P < 0.01) than women who experienced IPV to the head without TBI. IPV-related TBI was also associated with poorer perceptions of mental health, as well as more frequent VA health care utilization and overall IPV. Conclusions: IPV-related TBI is associated with poorer mental and physical health in women Veterans. This invisible injury is associated with greater VA health care utilization and IPV exposure. Implications for VA practice and policy are discussed.	[Iverson, Katherine M.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA; [Iverson, Katherine M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Iverson, Katherine M.; Pogoda, Terri K.] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA		Iverson, KM (corresponding author), VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA.	katherine.iverson@va.gov	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780	Department of Veterans Affairs, Office of Research and Development, Health Services Research & Development (HSRD) ServiceUS Department of Veterans Affairs [CDA 10-029]	Supported by the Department of Veterans Affairs, Office of Research and Development, Health Services Research & Development (HSR&D) Service as part of KMI's HSR&D Career Development Award (CDA 10-029).	Amara J, 2014, WOMEN HEALTH ISS, V24, pE171, DOI 10.1016/j.whi.2013.12.004; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Broomfield J., 2014, SYNERGY, P1; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Dichter M.E., 2013, MILITARY BEHAV HLTH, V1, P107, DOI [10.1080/21635781.2013.830062, DOI 10.1080/21635781.2013.830062]; Dichter ME, 2011, WOMEN HEALTH ISS, V21, pS190, DOI 10.1016/j.whi.2011.04.008; Dillman DA., 2007, MAIL INTERNET SURVEY; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Gerber MR, 2014, J WOMENS HEALTH, V23, P302, DOI 10.1089/jwh.2013.4513; Glass N, 2008, J EMERG MED, V35, P329, DOI 10.1016/j.jemermed.2007.02.065; Hendricks AM, 2013, BRAIN INJURY, V27, P125, DOI 10.3109/02699052.2012.729284; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Institute of Medicine, 2011, CLIN PREV SERV WOM C; Iverson KM, 2014, RES NURS HEALTH, V37, P302, DOI 10.1002/nur.21602; Iverson KM, 2013, J TRAUMA STRESS, V26, P767, DOI 10.1002/jts.21867; Iverson KM, 2013, J FAM VIOLENCE, V28, P823, DOI 10.1007/s10896-013-9544-7; Iverson KM, 2013, J GEN INTERN MED, V28, P1288, DOI 10.1007/s11606-013-2534-x; Iverson KM, 2013, J WOMENS HEALTH, V22, P267, DOI 10.1089/jwh.2012.3755; Iverson KM, 2013, J TRAUMA STRESS, V26, P102, DOI 10.1002/jts.21781; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moffitt TE, 1997, PSYCHOL ASSESSMENT, V9, P47, DOI 10.1037/1040-3590.9.1.47; National Research Council, 2013, RET HOM IR AFGH ASS; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Plichta SB, 2004, J INTERPERS VIOLENCE, V19, P1296, DOI 10.1177/0886260504269685; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Sheridan DJ, 2007, TRAUMA VIOLENCE ABUS, V8, P281, DOI 10.1177/1524838007303504; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; Straus MA., 2007, ENCY DOMESTIC VIOLEN, V44, P190; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Thomas KA, 2014, PSYCHOL WOMEN QUART, V38, P124, DOI 10.1177/0361684313488354; Thompson RS, 2006, AM J PREV MED, V30, P447, DOI 10.1016/j.amepre.2006.01.016; US Department of Veterans Affairs, 2001, 2001 NAT SURV VET NS; US Preventive Services Task Force, 2013, SCREEN INT PARTN VIO; Varvaro F F, 1993, Orthop Nurs, V12, P37, DOI 10.1097/00006416-199301000-00009; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weathers F.W., 1993, ANN CONV INT SOC TRA; Widerstrom-Noga EG, 2009, J REHABIL RES DEV, V46, P1, DOI 10.1682/JRRD.2008.03.0038; World Health Organisation, 2013, GLOB REG EST VIOL WO	45	37	38	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7079	1537-1948		MED CARE	Med. Care	APR	2015	53	4		1			S112	S119		10.1097/MLR.0000000000000263			8	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	DS3BL	WOS:000380657800019	25767964				2022-02-06	
J	Dent, KA; Christie, KJ; Bye, N; Basrai, HS; Turbic, A; Habgood, M; Cate, HS; Turnley, AM				Dent, Krista A.; Christie, Kimberly J.; Bye, Nicole; Basrai, Harleen S.; Turbic, Alisa; Habgood, Mark; Cate, Holly S.; Turnley, Ann M.			Oligodendrocyte Birth and Death following Traumatic Brain Injury in Adult Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; WHITE-MATTER; PRECURSOR CELLS; AMYLOID-BETA; PROGENITORS; ASTROCYTES; EXPRESSION; AXONS; PROLIFERATION; REMYELINATION	Oligodendrocytes are responsible for producing and maintaining myelin throughout the CNS. One of the pathological features observed following traumatic brain injury (TBI) is the progressive demyelination and degeneration of axons within white matter tracts. While the effect of TBI on axonal health has been well documented, there is limited information regarding the response of oligodendrocytes within these areas. The aim of this study was to characterize the response of both mature oligodendrocytes and immature proliferative oligodendrocyte lineage cells across a 3 month timecourse following TBI. A computer-controlled cortical impact model was used to produce a focal lesion in the left motor cortex of adult mice. Immunohistochemical analyses were performed at 48 hours, 7 days, 2 weeks, 5 weeks and 3 months following injury to assess the prevalence of mature CC-1(+) oligodendrocyte cell death, immature Olig2(+) cell proliferation and longer term survival in the corpus callosum and external capsule. Decreased CC-1 immunoreactivity was observed in white matter adjacent to the site of injury from 2 days to 2 weeks post TBI, with ongoing mature oligodendrocyte apoptosis after this time. Conversely, proliferation of Olig2(+) cells was observed as early as 48 hours post TBI and significant numbers of these cells and their progeny survived and remained in the external capsule within the injured hemisphere until at least 3 months post injury. These findings demonstrate that immature oligodendrocyte lineage cells respond to TBI by replacing oligodendrocytes lost due to damage and that this process occurs for months after injury.	[Dent, Krista A.; Christie, Kimberly J.; Bye, Nicole; Basrai, Harleen S.; Turbic, Alisa; Cate, Holly S.; Turnley, Ann M.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia; [Habgood, Mark] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3052, Australia		Turnley, AM (corresponding author), Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic 3052, Australia.	turnley@unimelb.edu.au		Cate, Holly/0000-0001-6392-9640; Turbic, Alisa/0000-0002-9703-2484	National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia [GNT 1045125, 628344]; Stem Cells Australia (SCA)	This work was supported by National Health and Medical Research Council of Australia (NHMRC) (www.NHMRC.gov.au), Project grant #GNT 1045125 to AMT, Research Fellowship # 628344 to AMT, and Stem Cells Australia (SCA) (www.stemcellsaustralia.edu.au) to AMT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bradl M, 2010, ACTA NEUROPATHOL, V119, P37, DOI 10.1007/s00401-009-0601-5; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Caprariello AV, 2012, ANN NEUROL, V72, P395, DOI 10.1002/ana.23606; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; Conti AC, 1998, J NEUROSCI, V18, P5663; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Dimou L, 2008, J NEUROSCI, V28, P10434, DOI 10.1523/JNEUROSCI.2831-08.2008; Dong HX, 2003, J NEUROSCI, V23, P8682; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Ek CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012021; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; FOKSEANG J, 1995, DEV BIOL, V171, P1, DOI 10.1006/dbio.1995.1255; Foote AK, 2005, BRAIN, V128, P528, DOI 10.1093/brain/awh417; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; Horiuchi M, 2006, J BIOL CHEM, V281, P20095, DOI 10.1074/jbc.M603179200; Hughes EG, 2013, NAT NEUROSCI, V16, P668, DOI 10.1038/nn.3390; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jurewicz A, 2005, BRAIN, V128, P2675, DOI 10.1093/brain/awh627; Kang SH, 2010, NEURON, V68, P668, DOI 10.1016/j.neuron.2010.09.009; Keirstead HS, 1997, J NEUROPATH EXP NEUR, V56, P1191, DOI 10.1097/00005072-199711000-00003; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KIDD GJ, 1990, J NEUROSCI RES, V26, P409, DOI 10.1002/jnr.490260403; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 1999, EXP NEUROL, V160, P333, DOI 10.1006/exnr.1999.7224; Lindner M, 2008, NEUROPATH APPL NEURO, V34, P105, DOI 10.1111/j.1365-2990.2007.00879.x; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Mason JL, 2004, AM J PATHOL, V164, P1673, DOI 10.1016/S0002-9440(10)63726-1; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; McGavern DB, 1999, EXP NEUROL, V158, P171, DOI 10.1006/exnr.1999.7082; MCPHILEMY K, 1990, J NEUROCYTOL, V19, P494, DOI 10.1007/BF01257239; MCPHILEMY K, 1991, NEUROPATH APPL NEURO, V17, P275, DOI 10.1111/j.1365-2990.1991.tb00725.x; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Moore N, 2011, J ONCOL, V2011, DOI 10.1155/2011/396076; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Patel JR, 2011, FEBS LETT, V585, P3730, DOI 10.1016/j.febslet.2011.04.037; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Young KM, 2013, NEURON, V77, P873, DOI 10.1016/j.neuron.2013.01.006; Zhao JW, 2009, EUR J NEUROSCI, V29, P1853, DOI 10.1111/j.1460-9568.2009.06736.x; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	54	37	40	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2015	10	3							e0121541	10.1371/journal.pone.0121541			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CE6ZS	WOS:000351987300265	25798924	gold, Green Published			2022-02-06	
J	Zimmer, A; Marcinak, J; Hibyan, S; Webbe, F				Zimmer, Adam; Marcinak, Jaquelyn; Hibyan, Stuart; Webbe, Frank			Normative Values of Major SCAT2 and SCAT3 Components for a College Athlete Population	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						tests; assessment/diagnosis; sports	POSTURAL STABILITY; SPORT CONCUSSION; HIGH-SCHOOL; SYMPTOMS; INJURY	The Sports Concussion Assessment Tool-2 (SCAT2) is a posttrauma evaluative screener for concussion. Although a revised version (SCAT3) recently was released, the SCAT2 continues in use. Moreover, there have been no reports of normative values with college athletes with the SCAT2 or SCAT3. Similar to the SCAT3, the SCAT2 includes a 22-item self-report symptom scale, the Standardized Assessment of Concussion (SAC), and a hard surface-only version of the Balance Error Scoring System (BESS). The SCAT3 does not employ a total score and adds an optional gait component. The purpose of this study was to develop normative values for collegiate athletes on the SCAT2 and its subparts with respect to sex, collision risk by sport, and concussion history. In preseason, 477 college athletes (332 male, 145 female) completed the SCAT2. The average total score was 91.08 (SD=5.60). The average number of symptoms endorsed was 1.75. Average SAC and BESS scores were 27.17 (SD=2.01) and 25.64 (SD=4.07), respectively. Little or no difference was found in total and component scores due to sex, sport type, or concussion history. When baseline measurement is lacking, these data provide a good benchmark for interpreting SCAT2 and SCAT3 performance.	[Zimmer, Adam; Marcinak, Jaquelyn; Hibyan, Stuart; Webbe, Frank] Florida Inst Technol, Melbourne, FL 32901 USA		Webbe, F (corresponding author), Florida Inst Technol, 150 W Univ Blvd, Melbourne, FL 32901 USA.	Webbe@fit.edu		Webbe, Frank/0000-0002-4370-5698			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Crawford JR, 1998, CLIN NEUROPSYCHOL, V12, P482, DOI 10.1076/clin.12.4.482.7241; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Lovell MR, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P111, DOI 10.1007/0-387-32565-4_6; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Randolph C, 2001, J ATHL TRAINING, V36, P288; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832	26	37	37	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	MAR 4	2015	22	2					132	140		10.1080/23279095.2013.867265			9	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	CC5DR	WOS:000350379400008	25117270				2022-02-06	
J	Campos-Pires, R; Armstrong, SP; Sebastiani, A; Luh, C; Gruss, M; Radyushkin, K; Hirnet, T; Werner, C; Engelhard, K; Franks, NP; Thal, SC; Dickinson, R				Campos-Pires, Rita; Armstrong, Scott P.; Sebastiani, Anne; Luh, Clara; Gruss, Marco; Radyushkin, Konstantin; Hirnet, Tobias; Werner, Christian; Engelhard, Kristin; Franks, Nicholas P.; Thal, Serge C.; Dickinson, Robert			Xenon Improves Neurologic Outcome and Reduces Secondary Injury Following Trauma in an In Vivo Model of Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						brain injury; head trauma; inert gases; neuroprotection; xenon	D-ASPARTATE RECEPTOR; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; COMPETITIVE-INHIBITION; GLYCINE SITE; INTRACEREBRAL-HEMORRHAGE; INTRACRANIAL-PRESSURE; COGNITIVE DEFICITS; GAIT ABNORMALITIES; POTASSIUM CHANNELS	Objectives: To determine the neuroprotective efficacy of the inert gas xenon following traumatic brain injury and to determine whether application of xenon has a clinically relevant therapeutic time window. Design: Controlled animal study. Setting: University research laboratory. Subjects: Male C57BL/6N mice (n = 196). Interventions: Seventy-five percent xenon, 50% xenon, or 30% xenon, with 25% oxygen (balance nitrogen) treatment following mechanical brain lesion by controlled cortical impact. Measurements and Main Results: Outcome following trauma was measured using 1) functional neurologic outcome score, 2) histological measurement of contusion volume, and 3) analysis of locomotor function and gait. Our study shows that xenon treatment improves outcome following traumatic brain injury. Neurologic outcome scores were significantly (p < 0.05) better in xenon-treated groups in the early phase (24 hr) and up to 4 days after injury. Contusion volume was significantly (p < 0.05) reduced in the xenon-treated groups. Xenon treatment significantly (p < 0.05) reduced contusion volume when xenon was given 15 minutes after injury or when treatment was delayed 1 or 3 hours after injury. Neurologic outcome was significantly (p < 0.05) improved when xenon treatment was given 15 minutes or 1 hour after injury. Improvements in locomotor function (p < 0.05) were observed in the xenon-treated group, 1 month after trauma. Conclusions: These results show for the first time that xenon improves neurologic outcome and reduces contusion volume following traumatic brain injury in mice. In this model, xenon application has a therapeutic time window of up to at least 3 hours. These findings support the idea that xenon may be of benefit as a neuroprotective treatment in patients with brain trauma.	[Campos-Pires, Rita; Armstrong, Scott P.; Dickinson, Robert] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Anaesthet Pain Med & Intens Care Sect, London, England; [Sebastiani, Anne; Luh, Clara; Hirnet, Tobias; Werner, Christian; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anaesthesiol, Med Ctr, D-55122 Mainz, Germany; [Gruss, Marco] Klinikum Hanau, Dept Anaesthesiol, Hanau, Germany; [Radyushkin, Konstantin] Johannes Gutenberg Univ Mainz, Mouse Behav Outcome Unit, Focus Program Translat Neurosci, D-55122 Mainz, Germany; [Franks, Nicholas P.] Univ London Imperial Coll Sci Technol & Med, Dept Life Sci, London, England		Dickinson, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Anaesthet Pain Med & Intens Care Sect, London, England.	r.dickinson@imperial.ac.uk	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Franks, Nicholas/0000-0003-4874-4212	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_PC_12015, MC_PC_13064] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_PC_12015, MC_PC_13064] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1247958] Funding Source: researchfish		Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; Armstrong SP, 2012, ANESTHESIOLOGY, V117, P38, DOI 10.1097/ALN.0b013e31825ada2e; Arola OJ, 2013, CRIT CARE MED, V41, P2116, DOI 10.1097/CCM.0b013e31828a4337; Azzopardi D, 2013, ARCH DIS CHILD-FETAL, V98, pF437, DOI 10.1136/archdischild-2013-303786; Banks P, 2010, ANESTHESIOLOGY, V112, P614, DOI 10.1097/ALN.0b013e3181cea398; Bantel C, 2009, ANESTHESIOLOGY, V110, P986, DOI 10.1097/ALN.0b013e31819dadc7; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Baumert JH, 2009, J CARDIOTHOR VASC AN, V23, P614, DOI 10.1053/j.jvca.2009.01.028; Baumert JH, 2007, ANESTH ANALG, V105, P1200, DOI 10.1213/01.ane.0000284697.73471.9c; Bickler PE, 2012, ANESTHESIOLOGY, V117, P280, DOI 10.1097/ALN.0b013e318260a7b9; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Coburn M, 2008, CRIT CARE MED, V36, P588, DOI 10.1097/01.CCM.0B013E3181611F8A6; Coburn M, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-180; CULLEN SC, 1951, SCIENCE, V113, P580, DOI 10.1126/science.113.2942.580; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dickinson R, 2007, ANESTHESIOLOGY, V107, P756, DOI 10.1097/01.anes.0000287061.77674.71; Dickinson R, 2010, CRIT CARE, V14, DOI 10.1186/cc9051; Dingley J, 2006, STROKE, V37, P501, DOI 10.1161/01.STR.0000198867.31134.ac; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Fries M, 2008, CRIT CARE MED, V36, P2420, DOI 10.1097/CCM.0b013e3181802874; Harris K, 2013, ANESTHESIOLOGY, V119, P1137, DOI 10.1097/ALN.0b013e3182a2a265; Homi HM, 2003, ANESTHESIOLOGY, V99, P876, DOI 10.1097/00000542-200310000-00020; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Kawamata T, 1997, ACT NEUR S, V70, P191; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Limatola V, 2010, NEUROSCIENCE, V165, P874, DOI 10.1016/j.neuroscience.2009.10.063; Liu Y, 2013, BEHAV BRAIN RES, V257, P166, DOI 10.1016/j.bbr.2013.10.007; Ma D, 2002, BRIT J ANAESTH, V89, P739, DOI 10.1093/bja/aef258; Ma DQ, 2005, ANN NEUROL, V58, P182, DOI 10.1002/ana.20547; Martin D, 2004, HOSP MED, V65, P674, DOI 10.12968/hosp.2004.65.11.17047; Martin JL, 2007, BRIT J ANAESTH, V98, P236, DOI 10.1093/bja/ael340; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mio Y, 2009, ANESTH ANALG, V108, P858, DOI 10.1213/ane.0b013e318192a520; Mountney A, 2013, J NEUROSCI METH, V212, P1, DOI 10.1016/j.jneumeth.2012.08.025; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PITTINGER CB, 1953, ANESTHESIOLOGY, V14, P10, DOI 10.1097/00000542-195301000-00002; Preckel B, 2006, ANESTHESIOLOGY, V105, P187, DOI 10.1097/00000542-200607000-00029; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sheng SP, 2012, ANESTHESIOLOGY, V117, P1262, DOI 10.1097/ALN.0b013e3182746b81; Shu Y, 2010, ANESTHESIOLOGY, V113, P360, DOI 10.1097/ALN.0b013e3181d960d7; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Teig M, 2010, J NEUROSURG ANESTH, V22, P357, DOI 10.1097/ANA.0b013e3181f0dada; Thal SC, 2014, CRIT CARE MED, V42, P129, DOI 10.1097/CCM.0b013e3182a639fd; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wang XH, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-142; Warner DS, 2004, ANESTH ANALG, V99, P1208, DOI 10.1213/01.ANE.0000139930.04010.0D; Weber NC, 2006, EUR J PHARMACOL, V539, P1, DOI 10.1016/j.ejphar.2006.03.054; Weber NC, 2008, ANESTH ANALG, V107, P1807, DOI 10.1213/ane.Ob013e31818874bf; Wilhelm S, 2002, ANESTHESIOLOGY, V96, P1485, DOI 10.1097/00000542-200206000-00031; Williams G, 2010, J HEAD TRAUMA REHAB, V25, P366, DOI 10.1097/HTR.0b013e3181cd3600; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013; Yang T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037020	72	37	39	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2015	43	1					149	158		10.1097/CCM.0000000000000624			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AW6XN	WOS:000346409100039	25188549	Green Accepted			2022-02-06	
J	Katzenberger, RJ; Ganetzky, B; Wassarman, DA				Katzenberger, Rebeccah J.; Ganetzky, Barry; Wassarman, David A.			The gut reaction to traumatic brain injury	FLY			English	Article						bacteria; Drosophila; glucose; innate immune response; intestine; mortality; septate junction; TBI; tight junction; traumatic brain injury	INCREASED INTESTINAL PERMEABILITY; INNATE IMMUNE-RESPONSE; NF-KAPPA-B; INFLAMMATORY RESPONSE; BARRIER DYSFUNCTION; ORGAN DYSFUNCTION; DROSOPHILA MODEL; MUCOSA STRUCTURE; NERVOUS-SYSTEM; DANGER THEORY	Traumatic brain injury (TBI) is a complex disorder that affects millions of people worldwide. The complexity of TBI partly stems from the fact that injuries to the brain instigate non-neurological injuries to other organs such as the intestine. Additionally, genetic variation is thought to play a large role in determining the nature and severity of non-neurological injuries. We recently reported that TBI in flies, as in humans, increases permeability of the intestinal epithelial barrier resulting in hyperglycemia and a higher risk of death. Furthermore, we demonstrated that genetic variation in flies is also pertinent to the complexity of non-neurological injuries following TBI. The goals of this review are to place our findings in the context of what is known about TBI-induced intestinal permeability from studies of TBI patients and rodent TBI models and to draw attention to how studies of the fly TBI model can provide unique insights that may facilitate diagnosis and treatment of TBI.	[Katzenberger, Rebeccah J.; Ganetzky, Barry; Wassarman, David A.] Univ Wisconsin, Genet Lab, Madison, WI 53706 USA		Wassarman, DA (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.	dawassarman@wisc.edu					Al-Sadi R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085345; Alexiou GA, 2014, BRAIN INJURY, V28, P438, DOI 10.3109/02699052.2014.888769; Bahri S, 2010, DEVELOPMENT, V137, P2023, DOI 10.1242/dev.045088; Bansal V, 2010, J NEUROTRAUM, V27, P2255, DOI 10.1089/neu.2010.1372; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI [10.1089/neu.2008.0858, 10.1089/neu.2008-0858]; Barreau F, 2014, CURR OPIN MICROBIOL, V17, P91, DOI 10.1016/j.mib.2013.12.003; Berglund JJ, 2001, AM J PHYSIOL-GASTR L, V281, pG1487; Beynon AL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-40; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bischoff SC, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/s12876-014-0189-7; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bonnay F, 2013, P NATL ACAD SCI USA, V110, P2957, DOI 10.1073/pnas.1221910110; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Cao Y, 2013, P NATL ACAD SCI USA, V110, pE1752, DOI 10.1073/pnas.1306220110; Chen G, 2008, INFLAMM RES, V57, P57, DOI 10.1007/s00011-007-7101-7; Chinchore Y, 2012, P NATL ACAD SCI USA, V109, pE605, DOI 10.1073/pnas.1110666109; Chong SL, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/719476; Cunningham KE, 2012, ANN NY ACAD SCI, V1258, P34, DOI 10.1111/j.1749-6632.2012.06526.x; De-Souza DA, 2005, CRIT CARE MED, V33, P1125, DOI 10.1097/01.CCM.0000162680.52397.97; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Elkon B, 2014, PEDIATR CRIT CARE ME, V15, P623, DOI 10.1097/PCC.0000000000000170; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Feng D, 2007, J INT MED RES, V35, P644, DOI 10.1177/147323000703500509; Furness JB, 2014, ADV EXP MED BIOL, V817, P39, DOI 10.1007/978-1-4939-0897-4_3; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Guilhelmelli F, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00353; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Haron RH, 2011, MALAYS J MED SCI, V18, P69; Hernandez G, 2007, NEUROCRIT CARE, V7, P40, DOI 10.1007/s12028-007-0026-8; Hindle SJ, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00414; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Izumi Y, 2014, SEMIN CELL DEV BIOL, V36, P186, DOI 10.1016/j.semcdb.2014.09.009; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Katzenberger RJ, 2015, JOVE-J VIS EXP, DOI 10.3791/52905; Katzenberger RJ, 2015, ELIFE, V4, DOI 10.7554/eLife.04790; Katzenberger RJ, 2013, P NATL ACAD SCI USA, V110, pE4152, DOI 10.1073/pnas.1316895110; Kemp CD, 2008, AM SURGEON, V74, P866; Land WG, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00349; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Ley EJ, 2011, J TRAUMA, V70, P1141, DOI 10.1097/TA.0b013e3182146d66; Lin L, 2015, NAT REV DRUG DISCOV, V14, P543, DOI 10.1038/nrd4626; Lustenberger T, 2013, BRAIN INJURY, V27, P281, DOI 10.3109/02699052.2012.743178; Marchiando AM, 2010, J CELL BIOL, V189, P111, DOI 10.1083/jcb.200902153; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Narasimha M, 2008, J CELL SCI, V121, P747, DOI 10.1242/jcs.019422; Nelson KS, 2010, GENETICS, V185, P831, DOI 10.1534/genetics.110.114959; Petersen AJ, 2013, GENETICS, V194, P133, DOI 10.1534/genetics.113.150854; Petersen AJ, 2012, P NATL ACAD SCI USA, V109, pE656, DOI 10.1073/pnas.1110470109; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Pradeu T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00287; Prisco L, 2012, J NEUROSURG SCI, V56, P131; Pruitt D, 2015, J NEUROTRAU IN PRESS; Qing Q, 2015, J CELL MOL MED, V19, P1366, DOI 10.1111/jcmm.12523; Rera M, 2012, P NATL ACAD SCI USA, V109, P21528, DOI 10.1073/pnas.1215849110; Rera M, 2011, CELL METAB, V14, P623, DOI 10.1016/j.cmet.2011.09.013; Ringel Y, 2013, AM J PHYSIOL-GASTR L, V305, pG529, DOI 10.1152/ajpgi.00207.2012; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Salim A, 2009, AM SURGEON, V75, P25; Senga K, 2012, MOL BIOL CELL, V23, P2845, DOI 10.1091/mbc.E12-02-0097; Sequeira IR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099256; Soscia SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009505; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Stoecklein VM, 2012, J LEUKOCYTE BIOL, V92, P539, DOI 10.1189/jlb.0212072; Sun J, 2007, CYTOKINE, V40, P151, DOI 10.1016/j.cyto.2007.09.003; Suzuki T, 2013, CELL MOL LIFE SCI, V70, P631, DOI 10.1007/s00018-012-1070-x; Tan LH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003966; Verstrepen L, 2008, CELL MOL LIFE SCI, V65, P2964, DOI 10.1007/s00018-008-8064-8; Yu ZQ, 2008, DEV BIOL, V319, P56, DOI 10.1016/j.ydbio.2008.04.001; Yuan Q, 2014, NEUROCRIT CARE, V20, P69, DOI 10.1007/s12028-012-9730-0; Zhang X, 2015, JPEN-PARENTER ENTER, V39, P114, DOI 10.1177/0148607113501881; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	74	37	40	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1933-6934	1933-6942		FLY	Fly		2015	9	2					68	74		10.1080/19336934.2015.1085623			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	DF3ZP	WOS:000371287400003	26291482	Bronze, Green Published			2022-02-06	
J	Mychasiuk, R; Farran, A; Angoa-Perez, M; Briggs, D; Kuhn, D; Esser, MJ				Mychasiuk, Richelle; Farran, Allyson; Angoa-Perez, Mariana; Briggs, Denise; Kuhn, Donald; Esser, Michael J.			A Novel Model of Mild Traumatic Brain Injury for Juvenile Rats	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Neuroscience; Issue 94; Childhood; Concussion; Repetitive Brain Injury; Rodent; Translational Research		Despite growing evidence that childhood represents a major risk period for mild traumatic brain injury (mTBI) from sports-related concussions, motor vehicle accidents, and falls, a reliable animal model of mTBI had previously not been developed for this important aspect of development. The modified weight-drop technique employs a glancing impact to the head of a freely moving rodent transmitting acceleration, deceleration, and rotational forces upon the brain. When applied to juvenile rats, this modified weight-drop technique induced clinically relevant behavioural outcomes that were representative of post-concussion symptomology. The technique is a rapidly applied procedure with an extremely low mortality rate, rendering it ideal for high-throughput studies of therapeutics. In addition, because the procedure involves a mild injury to a closed head, it can easily be used for studies of repetitive brain injury. Owing to the simplistic nature of this technique, and the clinically relevant biomechanics of the injury pathophysiology, the modified weight-drop technique provides researchers with a reliable model of mTBI that can be used in a wide variety of behavioural, molecular, and genetic studies.	[Mychasiuk, Richelle; Farran, Allyson; Esser, Michael J.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 1N4, Canada; [Angoa-Perez, Mariana; Briggs, Denise; Kuhn, Donald] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48202 USA; [Angoa-Perez, Mariana; Briggs, Denise; Kuhn, Donald] John D Dingell VA Med Ctr, Detroit, MI USA		Mychasiuk, R (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 1N4, Canada.	r.mychasiuk@uleth.ca		Briggs, Denise/0000-0002-4824-3947	Department of Pediatrics at the University of Calgary; Alberta Children's Hospital Foundation (ACHF); Alberta Children's Hospital Research Institute (ACHRI); ACHF; Veterans AffairsUS Department of Veterans Affairs [IK6RX002419] Funding Source: NIH RePORTER	The authors would like to thank Irene Ma, Rose Tobais, and Jong Rho for their technical assistance. Funding was provided to MJE by the Department of Pediatrics at the University of Calgary, the Alberta Children's Hospital Foundation (ACHF) and the Alberta Children's Hospital Research Institute (ACHRI). The Postdoctoral fellowship for RM was provided by ACHF.	Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R., 2014, J NEUROTRAUMA, V31; Schallert T, 2002, PHARM CEREBRAL ISCHE; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang Z, 2010, METHODS MOL BIOL	10	37	39	0	7	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	DEC	2014		94							e51820	10.3791/51820			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB1AE	WOS:000349358000007	25548960	Green Published, Bronze			2022-02-06	
J	Nekludov, M; Mobarrez, F; Gryth, D; Bellander, BM; Wallen, H				Nekludov, Michael; Mobarrez, Fariborz; Gryth, Dan; Bellander, Bo-Michael; Wallen, Hakan			Formation of Microparticles in the Injured Brain of Patients with Severe Isolated Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						microparticles; traumatic brain injury; cerebrovenous; coagulopathy; neurosurgical ICU	PLATELET-DERIVED MICROPARTICLES; TISSUE FACTOR; INFLAMMATORY RESPONSE; CEREBROSPINAL-FLUID; COAGULATION; BLOOD; ACTIVATION; MICROVESICLES; COAGULOPATHY; HEMOSTASIS	The potential pathophysiological role of circulating microparticles (MPs) has been recognized in various conditions, such as cardiovascular and thrombotic diseases. Traumatic brain injury (TBI) has a complex pathophysiology that involves coagulopathy and inflammation. We investigated endothelial-, platelet-, and leukocyte-derived microparticles (EMPs, PMPs, and LMPs, respectively) in 16 patients with severe isolated TBI. Arterial and cerebrovenous samples were taken repeatedly, during 1-72 h after injury. Subpopulations of MPs, exposing tissue factor (TF) and P-selectin, were also studied. MP counts in cerebrovenous samples, irrespective of cellular origin, were higher in TBI cases, compared to healthy controls (peak levels of EMPs were approximately 7 times higher, PMPs 1.4 times higher, and LMPs 2 times higher, respectively; p<0.001 for all). MP counts declined sharply from high levels shortly after the trauma toward slightly elevated levels 72 h later. EMPs and PMPs exposing TF, as well as PMPs exposing P-selectin, showed a transcranial gradient with higher concentration in cerebrovenous, compared to arterial, samples. In contrast, LMPs exposing TF were higher in arterial samples, suggesting accumulation of LMPs in the brain. We conclude that the pattern of circulating MPs is altered after TBI. PMPs exposing P-selectin and EMPs exposing TF seem to be generated in the injured brain, whereas LMPs exposing TF are accumulated. The pathophysiological significance of these changes in MP pattern in TBI should be further investigated. Including MPs exposing brain-specific antigens in the assessment of brain injury would give further information of origin and likely give additional information of the size of the injury, given that the MP phenotypes investigated in the present study are not brain-specific markers.	[Nekludov, Michael; Gryth, Dan] Karolinska Inst, Karolinska Univ Hosp, Dept Physiol & Pharmacol, Sect Anesthesiol, Stockholm, Sweden; [Mobarrez, Fariborz; Wallen, Hakan] Karolinska Inst, Danderyds Hosp, Dept Clin Sci, Div Cardiovasc Med, Stockholm, Sweden; [Bellander, Bo-Michael] Karolinska Inst, Karolinska Univ Hosp, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden		Nekludov, M (corresponding author), Karolinska Univ Hosp Solna, Dept Anesthesiol, SE-17176 Stockholm, Sweden.	michael.nekludov@karolinska.se	Mobarrez, Fariborz/AAK-8929-2020	Mobarrez, Fariborz/0000-0002-7106-6248; Nekludov, Michael/0000-0001-9916-7086	Carnegie Foundation; Capio Foundation; Karolinska Institute fundKarolinska Institutet [245]	The authors thank Dr. Margareta Blomback for being such a powerful source of energy for our team. The authors thank the nursing personnel at NICU for all the assistance and everlasting helpfulness during the study. The authors thank the medical statistics expert, Eva Hagel, Karolinska Institute, for professionally performed analyses of our data. The authors also thank the Carnegie Foundation, the Capio Foundation, and Karolinska Institute fund 245 for financial support.	Biro E, 2003, J THROMB HAEMOST, V1, P2561, DOI 10.1046/j.1538-7836.2003.00456.x; Burnier L, 2009, THROMB HAEMOSTASIS, V101, P439, DOI 10.1160/TH08-08-0521; Dasgupta SK, 2006, TRANSL RES, V148, P19, DOI 10.1016/j.lab.2006.03.006; Esmon CT, 2005, BRIT J HAEMATOL, V131, P417, DOI 10.1111/j.1365-2141.2005.05753.x; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jy W, 2007, THROMB RES, V121, P319, DOI 10.1016/j.thromres.2007.04.014; Key NS, 2010, SEMIN THROMB HEMOST, V36, P865, DOI 10.1055/s-0030-1267040; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Langer F, 2013, BLOOD, V121, P2324, DOI 10.1182/blood-2012-10-460493; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Mause SF, 2010, CIRCULATION, V122, P495, DOI 10.1161/CIRCULATIONAHA.109.909473; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; Mobarrez F, 2013, SCHIZOPHR RES, V143, P192, DOI 10.1016/j.schres.2012.10.030; Mobarrez F, 2010, THROMB RES, V125, pE110, DOI 10.1016/j.thromres.2009.10.006; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; Owens AP, 2011, CIRC RES, V108, P1284, DOI 10.1161/CIRCRESAHA.110.233056; Sanborn MR, 2012, J NEUROSURG, V117, P579, DOI 10.3171/2012.6.JNS111163; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Shao HL, 2012, NAT MED, V18, P1835, DOI 10.1038/nm.2994; Skeppholm M, 2012, THROMB HAEMOSTASIS, V107, P1122, DOI 10.1160/TH11-11-0779; Soop A, 2013, SCAND J IMMUNOL, V78, P205, DOI 10.1111/sji.12076; Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a; Tilley RE, 2008, THROMB RES, V122, P604, DOI 10.1016/j.thromres.2007.12.023; Van der Zee PM, 2006, CLIN CHEM, V52, P657, DOI 10.1373/clinchem.2005.057414; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014; Vikerfors A, 2012, LUPUS, V21, P802, DOI 10.1177/0961203312437809; Zachau Anne C, 2012, J Med Case Rep, V6, P274, DOI 10.1186/1752-1947-6-274; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348	33	37	40	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1927	1933		10.1089/neu.2013.3168			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500005	24956150				2022-02-06	
J	Doherty, J; Sheehan, AE; Bradshaw, R; Fox, AN; Lu, TY; Freeman, MR				Doherty, Johnna; Sheehan, Amy E.; Bradshaw, Rachel; Fox, A. Nicole; Lu, Tsai-Yi; Freeman, Marc R.			PI3K Signaling and Stat92E Converge to Modulate Glial Responsiveness to Axonal Injury	PLOS BIOLOGY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; FIBRILLARY ACIDIC PROTEIN; CELL CORPSE ENGULFMENT; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; JAK/STAT PATHWAY; REACTIVE ASTROCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; COMPLEMENT RECEPTOR-3	Glial cells are exquisitely sensitive to neuronal injury but mechanisms by which glia establish competence to respond to injury, continuously gauge neuronal health, and rapidly activate reactive responses remain poorly defined. Here, we show glial PI3K signaling in the uninjured brain regulates baseline levels of Draper, a receptor essential for Drosophila glia to sense and respond to axonal injury. After injury, Draper levels are up-regulated through a Stat92E-modulated, injury-responsive enhancer element within the draper gene. Surprisingly, canonical JAK/STAT signaling does not regulate draper expression. Rather, we find injury-induced draper activation is downstream of the Draper/Src42a/Shark/Rac1 engulfment signaling pathway. Thus, PI3K signaling and Stat92E are critical in vivo regulators of glial responsiveness to axonal injury. We provide evidence for a positive auto-regulatory mechanism whereby signaling through the injury-responsive Draper receptor leads to Stat92E-dependent, transcriptional activation of the draper gene. We propose that Drosophila glia use this autoregulatory loop as a mechanism to adjust their reactive state following injury.	[Doherty, Johnna; Sheehan, Amy E.; Bradshaw, Rachel; Fox, A. Nicole; Lu, Tsai-Yi; Freeman, Marc R.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Worcester, MA 01605 USA		Doherty, J (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Worcester, MA 01605 USA.	marc.freeman@umassmed.edu		Freeman, Marc/0000-0003-3481-3715; Lu, Tsai-Yi/0000-0002-8818-6537	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS053538]; Howard Hughes Medical InstituteHoward Hughes Medical Institute; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053538] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (RO1 NS053538) and by the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson MA, 2014, NEUROSCI LETT, V565, P23, DOI 10.1016/j.neulet.2013.12.030; [Anonymous], 2010, NAT NEUROSCI, V13, P1441; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Awasaki T, 2006, NEURON, V50, P855, DOI 10.1016/j.neuron.2006.04.027; Bach EA, 2007, GENE EXPR PATTERNS, V7, P323, DOI 10.1016/j.modgep.2006.08.003; Baksa K, 2002, DEV BIOL, V243, P166, DOI 10.1006/dbio.2001.0539; Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013; Beemiller P, 2010, MOL BIOL CELL, V21, P470, DOI 10.1091/mbc.E08-05-0494; Betz A, 2008, P NATL ACAD SCI USA, V105, P13805, DOI 10.1073/pnas.0806291105; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Buchon N, 2009, CELL HOST MICROBE, V5, P200, DOI 10.1016/j.chom.2009.01.003; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Cohen G, 2006, GLIA, V53, P538, DOI 10.1002/glia.20304; Copf T, 2011, P NATL ACAD SCI USA, V108, P8059, DOI 10.1073/pnas.1012919108; Couto A, 2005, CURR BIOL, V15, P1535, DOI 10.1016/j.cub.2005.07.034; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Deng Yi Yu, 2011, Front Biosci (Schol Ed), V3, P884; Desai D, 2004, BIOCHEM BIOPH RES CO, V318, P642, DOI 10.1016/j.bbrc.2004.04.073; Doherty J, 2009, J NEUROSCI, V29, P4768, DOI 10.1523/JNEUROSCI.5951-08.2009; Dominguez E, 2008, J NEUROCHEM, V107, P50, DOI 10.1111/j.1471-4159.2008.05566.x; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Ekas LA, 2010, DEV BIOL, V344, P621, DOI 10.1016/j.ydbio.2010.05.497; Fancy SPJ, 2011, NAT NEUROSCI, V14, P1009, DOI 10.1038/nn.2855; Flaherty MS, 2010, DEV CELL, V18, P556, DOI 10.1016/j.devcel.2010.02.006; Freeman MR, 2003, NEURON, V38, P567, DOI 10.1016/S0896-6273(03)00289-7; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; Ghiglione C, 2002, DEVELOPMENT, V129, P5437, DOI 10.1242/dev.00116; Giaume C, 1996, TRENDS NEUROSCI, V19, P319, DOI 10.1016/0166-2236(96)10046-1; Gilbert MM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007083; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hasselblatt M, 2001, GLIA, V34, P18, DOI 10.1002/glia.1036; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Jones WD, 2007, NATURE, V445, P86, DOI 10.1038/nature05466; Kamen LA, 2007, MOL BIOL CELL, V18, P2463, DOI 10.1091/mbc.E07-01-0061; Karimi M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3; Kim LK, 2007, PLOS BIOL, V5, P2064, DOI 10.1371/journal.pbio.0050238; Kim MO, 2002, J NEUROCHEM, V81, P1361, DOI 10.1046/j.1471-4159.2002.00949.x; Lazarini F, 1996, J NEUROCHEM, V66, P459; Lee HK, 2009, J NEUROCHEM, V108, P776, DOI 10.1111/j.1471-4159.2008.05826.x; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Leverrier Y, 2003, J BIOL CHEM, V278, P38437, DOI 10.1074/jbc.M306649200; Logan MA, 2012, NAT NEUROSCI; Logan MA, 2007, NEURON GLIA BIOL, V3, P63, DOI [10.1017/S1740925X07000646, 10.1017/S1740925X0700049X]; Lovegrove B, 2006, CURR BIOL, V16, P2206, DOI 10.1016/j.cub.2006.09.029; Rivas ML, 2008, EMBO REP, V9, P1114, DOI 10.1038/embor.2008.170; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MacDonald JM, 2013, CELL DEATH DIFFER, V20, P1140, DOI 10.1038/cdd.2013.30; MacDonald JM, 2006, NEURON, V50, P869, DOI 10.1016/j.neuron.2006.04.028; Makki R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000441; Makranz C, 2004, NEUROBIOL DIS, V15, P279, DOI 10.1016/j.nbd.2003.11.007; Minakhina S, 2011, DEV BIOL, V352, P308, DOI 10.1016/j.ydbio.2011.01.035; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; Neniskyte U, 2011, J BIOL CHEM, V286, P39904, DOI 10.1074/jbc.M111.267583; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; Nyga R, 2005, BIOCHEM J, V390, P359, DOI 10.1042/BJ20041523; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Qin H, 2007, J IMMUNOL, V179, P5966, DOI 10.4049/jimmunol.179.9.5966; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Rogers J, 2007, INT REV NEUROBIOL, V82, P235, DOI 10.1016/S0074-7742(07)82012-5; Rogers SD, 2003, GLIA, V41, P180, DOI 10.1002/glia.10173; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; Schwaiger FW, 2000, EUR J NEUROSCI, V12, P1165, DOI 10.1046/j.1460-9568.2000.00005.x; Silver DL, 2005, DEVELOPMENT, V132, P3483, DOI 10.1242/dev.01910; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Sorrentino RP, 2004, GENETICS, V166, P1343, DOI 10.1534/genetics.166.3.1343; Sotillos S, 2013, DEVELOPMENT, V140, P1507, DOI 10.1242/dev.092320; Sotillos S, 2010, DEV BIOL, V340, P571, DOI 10.1016/j.ydbio.2010.02.015; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Vidal OM, 2010, J CELL SCI, V123, P3457, DOI 10.1242/jcs.066902; Wang LW, 2008, J CELL BIOL, V180, P721, DOI 10.1083/jcb.200711022; West DA, 2004, NEUROSCIENCE, V127, P333, DOI 10.1016/j.neuroscience.2004.05.022; Wu HH, 2009, NAT NEUROSCI, V12, P1534, DOI 10.1038/nn.2446; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8; Ziegenfuss JS, 2008, NATURE, V453, P935, DOI 10.1038/nature06901	87	37	38	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1545-7885			PLOS BIOL	PLoS. Biol.	NOV	2014	12	11							e1001985	10.1371/journal.pbio.1001985			16	Biochemistry & Molecular Biology; Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics	AU5DL	WOS:000345627300002	25369313	Green Published, Green Submitted, gold			2022-02-06	
J	Colantonio, A; Kim, H; Allen, S; Asbridge, M; Petgrave, J; Brochu, S				Colantonio, Angela; Kim, Hwan; Allen, Stefan; Asbridge, Mark; Petgrave, Josian; Brochu, Serge			Traumatic Brain Injury and Early Life Experiences Among Men and Women in a Prison Population	JOURNAL OF CORRECTIONAL HEALTH CARE			English	Article						traumatic brain injury; prison; sex differences; gender differences	VIOLENT CRIMINAL BEHAVIOR; SEXUAL-ABUSE; HEAD-INJURY; SUBSTANCE USE; HEALTH; PREVALENCE; REHABILITATION; TBI	This study examined the proportion of men and women reporting previous traumatic brain injury (TBI) in an Ontario (Canada) prison sample by demographic characteristics; adverse life experiences; and criminal, drug, and alcohol use history. Using data from The Cost of Substance Abuse in Canada study based on a random sample from four Ontario prisons, this study found 50.4% of males and 38% of females reporting previous TBI. More TBIs occurred before the first crime for women than for men. Women with TBI experienced more early physical and sexual abuse than those without TBI. Additionally, this study shows high prevalence of early life experiences among persons, particularly women, with a history of TBI. Prisoners and prison staff should be educated on TBI and best practice for rehabilitation of TBI.	[Colantonio, Angela; Petgrave, Josian] Univ Toronto, Toronto, ON, Canada; [Colantonio, Angela] Toronto Rehabil Inst UHN, Toronto, ON, Canada; [Kim, Hwan] Daegu Univ, Jillyang, Gyeongsan Gyeon, South Korea; [Allen, Stefan; Asbridge, Mark] Dalhousie Univ, Halifax, NS, Canada; [Brochu, Serge] Univ Montreal, Montreal, PQ, Canada		Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946] Funding Source: Medline		American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Brewer-Smyth K, 2004, BIOL PSYCHIAT, V55, P21, DOI 10.1016/S0006-3223(03)00705-4; Canadian Institute for Health Information, 2007, BURD NEUR DIS DIS IN; Chen A, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-76; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Colantonio A, 2007, BRAIN INJURY, V21, P1353, DOI 10.1080/02699050701785054; Colantonio Angela, 2010, Healthc Policy, V5, pe120; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Corrigan JD, 2007, BRAIN INJURY, V21, P343, DOI 10.1080/02699050701253103; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; Finkelstein E., 2006, INCIDENCE EC BURDEN; Glasser M, 2001, BRIT J PSYCHIAT, V179, P482, DOI 10.1192/bjp.179.6.482; Gomez J., 2006, INT GUIDELINES ESTIM; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Hawley CA, 2003, BRAIN INJURY, V17, P743, DOI 10.1080/0269905031000089341; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Jackson M., 2011, CORRECTIONS RES PAPE; Lemsky C., 2005, SUBSTANCE ABUSE BRAI; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; McDaniels-Wilson C, 2008, VIOLENCE AGAINST WOM, V14, P1090, DOI 10.1177/1077801208323160; Olson-Madden JH, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/174579; Perkes I, 2011, BRAIN INJURY, V25, P131, DOI 10.3109/02699052.2010.536193; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Shiroma Eric J, 2010, J Correct Health Care, V16, P273, DOI 10.1177/1078345810378253; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsukada M, 2012, BRAIN INJURY, V26, P774; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Yuhasz JE, 2013, J CORRECT HEALTH CAR, V19, P135, DOI 10.1177/1078345812474644	33	37	37	2	38	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1078-3458	1940-5200		J CORRECT HEALTH CAR	J. Correct. Health Care	OCT	2014	20	4					271	279		10.1177/1078345814541529			9	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	AQ3BL	WOS:000342663600002	25033995				2022-02-06	
J	Kesinger, MR; Nagy, LR; Sequeira, DJ; Charry, JD; Puyana, JC; Rubiano, AM				Kesinger, Matthew R.; Nagy, Lisa R.; Sequeira, Denisse J.; Charry, Jose D.; Puyana, Juan C.; Rubiano, Andres M.			A standardized trauma care protocol decreased in-hospital mortality of patients with severe traumatic brain injury at a teaching hospital in a middle-income country	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Quality improvement in LMIC; Trauma; Severe TBI; Outcomes	LIFE-SUPPORT PROGRAM; HEALTH-ORGANIZATIONS GUIDELINES; DAMAGE CONTROL RESUSCITATION; WORLD; CAPABILITIES; QUALITY	Introduction: Standardized trauma protocols (STP) have reduced morbidity and in-hospital mortality in mature trauma systems. Most hospitals in low-and middle-income countries (LMICs) have not implemented STPs, often because of financial and logistic limitations. We report the impact of an STP designed for the care of trauma patients in the emergency department (ED) at an LMIC hospital on patients with severe traumatic brain injury (STBI). Methods: We developed an STP based on generally accepted best practices and damage control resuscitation for a level I trauma centre in Colombia. Without a pre-existing trauma registry, we adapted an administrative electronic database to capture clinical information of adult patients with TBI, a head abbreviated injury score (AIS) >3, and who presented <12 h from injury. Demographics, mechanisms of injury, and injury severity were compared. Primary outcome was in-hospital mortality. Secondary outcomes were Glasgow Coma Score (GCS), length of hospital and ICU stay, and prevalence of ED interventions recommended in the STP. Logistic regression was used to control for potential confounders. Results: The pre-STP group was hospitalized between August 2010 and August 2011, the post-STP group between September 2011 and June 2012. There were 108 patients meeting inclusion criteria, 68 pre-STP implementation and 40 post-STP. The pre- and post-STP groups were similar in age (mean 37.1 vs. 38.6, p = 0.644), head AIS (median 4.5 vs. 4.0, p = 0.857), Injury Severity Scale (median 25 vs. 25, p = 0.757), and initial GCS (median 7 vs. 7, p = 0.384). Post-STP in-hospital mortality decreased (38% vs. 18%, p = 0.024), and discharge GCS increased (median 10 vs. 14, p = 0.034). After controlling for potential confounders, odds of in-hospital mortality post-STP compared to pre-STP were 0.248 (95% CI: 0.074-0.838, p = 0.025). Hospital and ICU stay did not significantly change. The use of many ED interventions increased post-STP, including bladder catheterization (49% vs. 73%, p = 0.015), hypertonic saline (38% vs. 63%, p = 0.014), arterial blood gas draws (25% vs. 43%, p = 0.059), and blood transfusions (3% vs. 18%, p = 0.008). Conclusions: An STP in an LMIC decreased in-hospital mortality, increased discharge GCS, and increased use of vital ED interventions for patients with STBI. An STP in an LMIC can be implemented and measured without a pre-existing trauma registry. (C) 2014 Elsevier Ltd. All rights reserved.	[Kesinger, Matthew R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; [Nagy, Lisa R.; Puyana, Juan C.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15260 USA; [Sequeira, Denisse J.] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Charry, Jose D.; Rubiano, Andres M.] Univ Surcolombiana, La Plata, Huila, Colombia		Kesinger, MR (corresponding author), Univ Pittsburgh, Dept Surg, 200 Lothrop St,Suite F1263-3, Pittsburgh, PA 15213 USA.	kesingermr2@upmc.edu; lisarnagy7@gmail.com; Des103@pitt.edu; danielcharry06@hotmail.com; puyajc@upmc.edu; rubianoam@gmail.com	RUBIANO, ANDRES M/K-6704-2012	RUBIANO, ANDRES M/0000-0001-8931-3254; Charry, Jose D./0000-0002-8789-7281	FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [R21 TW009332] Funding Source: Medline; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [R21TW009332] Funding Source: NIH RePORTER		Aboutanos MB, 2007, J TRAUMA, V62, P714, DOI 10.1097/TA.0b013e318031b56d; Aboutanos MB, 2010, WORLD J SURG, V34, P2735, DOI 10.1007/s00268-010-0716-9; ALI J, 1994, J TRAUMA, V36, P391, DOI 10.1097/00005373-199403000-00020; ALI J, 1993, J TRAUMA, V34, P890, DOI 10.1097/00005373-199306000-00022; ALI J, 1993, CAN J SURG, V36, P181; ALI J, 1993, J TRAUMA, V34, P8; *AM COLL SURG, 2004, ADV TRAUM LIF SUPP S; Arreola-Risa C, 2006, REV PANAM SALUD PUBL, V19, P94, DOI 10.1590/S1020-49892006000200004; Gerhardt RT, 2013, TRANSFUSION, V53, p9S, DOI 10.1111/trf.12030; Gosselin RA, 2009, B WORLD HEALTH ORGAN, V87, P246, DOI 10.2471/BLT.08.052290; Grote S, 2011, J NEUROTRAUM, V28, P527, DOI 10.1089/neu.2010.1433; Hanche-Olsen TP, 2012, WORLD J SURG, V36, P2371, DOI 10.1007/s00268-012-1659-0; Hashmi ZG, 2013, J TRAUMA ACUTE CARE, V75, P60, DOI 10.1097/TA.0b013e31829880a0; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Joshipura MK, 2003, INJURY, V34, P686, DOI 10.1016/S0020-1383(03)00163-3; Kesinger MR, 2014, WORLD J SURG, V38, P1869, DOI 10.1007/s00268-014-2534-y; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Mock C, 2006, WORLD J SURG, V30, P946, DOI 10.1007/s00268-005-0768-4; Mock C, 2012, WORLD J SURG, V36, P959, DOI 10.1007/s00268-012-1459-6; Ozgediz D, 2011, MT SINAI J MED, V78, P327, DOI 10.1002/msj.20253; Quansah R, 2008, CLIN ORTHOP RELAT R, V466, P2403, DOI 10.1007/s11999-008-0401-6; Son NT, 2007, INJURY, V38, P1014, DOI 10.1016/j.injury.2007.04.010; Trauma American College of Surgeons Trauma Committee, 2006, RES OPT CAR INJ PAT; van Olden GDJ, 2004, J TRAUMA, V57, P381, DOI 10.1097/01.TA.0000096645.13484.E6; World Health Organization, 2002, WORLD REPORT VIOLENC; World Health Organization, 2010, INJ VIOL FACTS	27	37	37	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2014	45	9					1350	1354		10.1016/j.injury.2014.04.037			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AN0NI	WOS:000340280900012	24861416				2022-02-06	
J	Pasquier, P; Dubost, C; Boutonnet, M; Chrisment, A; Villevieille, T; Batjom, E; Bordier, E; Ausset, S; Puidupin, M; Martinez, JY; Bay, C; Escarment, J; Pons, F; Lenoir, B; Merat, S				Pasquier, Pierre; Dubost, Clement; Boutonnet, Mathieu; Chrisment, Anne; Villevieille, Thierry; Batjom, Emmanuel; Bordier, Emmanuel; Ausset, Sylvain; Puidupin, Marc; Martinez, Jean-Yves; Bay, Christian; Escarment, Jacques; Pons, Francois; Lenoir, Bernard; Merat, Stephane			Predeployment training for forward medicalisation in a combat zone: The specific policy of the French Military Health Service	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Tactical Combat Casualty Care; French policy; Predeployment training; Forward medicalisation	CASUALTY CARE; CURRENT WAR; TRAUMA; BATTLEFIELD; OPERATIONS; DEPLOYMENT; PERSONNEL; INJURY; MEDICS; DEATH	Introduction: To improve the mortality rate on the battlefield, and especially the potentially survivable pre-Medical Treatment Facility deaths, Tactical Combat Casualty Care (TCCC) is now considered as a reference for management of combat casualty from the point of injury to the first medical treatment facility. TCCC comprises of a set of trauma management guidelines designed for use on the battlefield. The French Military Health Service also standardised a dedicated training programme, entitled "Sauvetage au Combat'' (SC) ("forward combat casualty care''), with the characteristic of forward medicalisation on the battlefield, the medical team being projected as close as possible to the casualty at the point of injury. The aim of our article is to describe the process and the result of the SC training. Materials and methods: Records from the French Military Health Service Academy - Ecole du Val-de-Grace administration, head of the SC teaching programme, defining its guidelines, and supporting its structure and its execution, were examined and analyzed, since the standardisation of the SC training programme in 2008. The total number of trainees was listed following the different courses (SC1, SC2, SC3). Results: At the end of 2013, every deployed combatant underwent SC1 courses (confidential data), 785 health-qualified combatants were graduated for SC2 courses and 672 Role 1 physician-nurse pairs for SC3 courses. Conclusion: The SC concept and programmes were defined in France in 2007 and are now completely integrated into the predeployment training of all combatants but also of French Military Health Service providers. Finally, SC teaching programmes enhance the importance of teamwork in forward combat medicalisation settings. (C) 2014 Elsevier Ltd. All rights reserved.	[Pasquier, Pierre; Dubost, Clement; Chrisment, Anne; Villevieille, Thierry; Batjom, Emmanuel; Bordier, Emmanuel; Merat, Stephane] Mil Teaching Hosp, Hop Instruct Arme Begin, Dept Anesthesiol, St Mande, France; [Pasquier, Pierre; Dubost, Clement; Chrisment, Anne; Villevieille, Thierry; Batjom, Emmanuel; Bordier, Emmanuel; Merat, Stephane] Mil Teaching Hosp, Hop Instruct Arme Begin, Intens Care Unit, St Mande, France; [Boutonnet, Mathieu; Ausset, Sylvain; Lenoir, Bernard] Mil Teaching Hosp, Hop Instruct Arme Percy, Dept Anesthesiol, Clamart, France; [Puidupin, Marc; Martinez, Jean-Yves; Escarment, Jacques] Mil Teaching Hosp, Hop Instruct Arme Percy, Intens Care Unit, Clamart, France; [Bay, Christian] French Mil Hlth Serv Acad, Ecole Val de Grace, Tact Care Training Dept, Paris, France; [Pons, Francois] French Mil Hlth Serv Acad, Ecole Val de Grace, Paris, France		Pasquier, P (corresponding author), Begin Mil Teaching Hosp, Intens Care Unit, 69 Ave Paris, F-94160 St Mande, France.	pasquier9606@me.com; clement.dubost@hotmail.fr; mathieuboutonnet@hotmail.com; anne.chrisment@hotmail.com; t-ville@orange.fr; ebtjm@free.fr; lbordier@club-internet.fr; sylvain.ausset@gmail.com; marc.puidupin@gmail.com; jyvesmartinez@yahoo.com; Christian.bay@sante.defense.gouv.fr; jacques.escarment@yahoo.fr; francois.pons@sante.defense.gouv.fr; Bernard.lenoir@sante.defense.gouv.fr; merat.stephane@wanadoo.fr	Ausset, Sylvain/M-7394-2019; Pasquier, Pierre/E-1489-2018	Ausset, Sylvain/0000-0001-8345-1058; Pasquier, Pierre/0000-0003-2337-7874; dubost, Clement/0000-0001-7539-6271; Boutonnet, Mathieu/0000-0002-7334-0132			Andersson SO, 2013, MIL MED, V178, P861, DOI 10.7205/MILMED-D-13-00048; Apodaca AN, 2013, SHOCK, V40, P5, DOI 10.1097/SHK.0b013e31829793d7; Battlefield Advanced Trauma Life Support (BATLS), 2004, J ROY ARMY MED CORPS, V150, P32; Benson M, 1996, Prehosp Disaster Med, V11, P117; Brooks AJ, 2005, EMERG MED J, V22, P263, DOI 10.1136/emj.2004.014308; Butler F, 2003, J TRAUMA, V54, pS2; Butler FK, 1996, MIL MED, V161, P3, DOI 10.1093/milmed/161.suppl_1.3; Butler FK, 2010, J TRAUMA, V69, pS10, DOI 10.1097/TA.0b013e3181e4220c; Butler FK, 2012, J TRAUMA ACUTE CARE, V73, pS395, DOI 10.1097/TA.0b013e3182754850; Champion HR, 2010, J TRAUMA, V68, P1139, DOI 10.1097/TA.0b013e3181d86a0d; Chapman PL, 2012, MIL MED, V177, P270, DOI 10.7205/MILMED-D-11-00305; Dubost C, 2013, J TRAUMA ACUTE CARE, V74, P1146, DOI 10.1097/TA.0b013e31828271a8; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Gerhardt RT, 2008, PREHOSP EMERG CARE, V12, P359, DOI 10.1080/10903120802101058; Gerhardt RT, 2013, TRANSFUSION, V53, p9S, DOI 10.1111/trf.12030; Gerhardt RT, 2011, J TRAUMA, V71, pS109, DOI 10.1097/TA.0b013e31822190a7; Gerhardt RT, 2009, ANN EMERG MED, V53, P169, DOI 10.1016/j.annemergmed.2008.04.013; Gerhardt RT, 2005, ANN EMERG MED, V46, pS45; Hoencampemail R, 2014, INJURY; Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Lairet JR, 2012, J TRAUMA ACUTE CARE, V73, pS38, DOI 10.1097/TA.0b013e3182606022; Lundberg L, 2008, J R Army Med Corps, V154, P34; Mabry RL, 2012, J TRAUMA ACUTE CARE, V73, pS32, DOI 10.1097/TA.0b013e3182606001; McLeod J, 2007, J R Army Med Corps, V153, P266; Midwinter MJ, 2011, J ROY ARMY MED CORPS, V157, pS299, DOI 10.1136/jramc-157-03s-08; Molde A, 2006, J R Army Med Corps, V152, P217; Nathens AB, 2004, LANCET, V363, P1794, DOI 10.1016/S0140-6736(04)16307-1; NATO, 2011, MED LESS LEARN NEWSL; Parsons IT, 2013, J R ARMY MED CORPS; Purim-Shem-Tov Yanina A, 2013, Mil Med, V178, pe362, DOI 10.7205/MILMED-D-12-00376; Ramasamy A, 2009, J R Army Med Corps, V155, P265; Savage E, 2011, CAN J SURG, V54, pS14, DOI 10.1503/cjs.025011; Singleton JAG, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003130; Sohn VY, 2007, J SURG RES, V138, P25, DOI 10.1016/j.jss.2006.09.006; Sohn Vance Y, 2007, J Surg Educ, V64, P199, DOI 10.1016/j.jsurg.2007.05.007; Tai N R M, 2009, J R Army Med Corps, V155, P253; Tien MHC, 2008, J AM COLL SURGEONS, V207, P174, DOI 10.1016/j.jamcollsurg.2008.01.065; Tyler JA, 2010, J AM COLL SURGEONS, V211, P658, DOI 10.1016/j.jamcollsurg.2010.07.009	39	37	44	1	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2014	45	9					1307	1311		10.1016/j.injury.2014.05.037			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AN0NI	WOS:000340280900005	24952973				2022-02-06	
J	Albrecht, JS; Liu, XG; Baumgarten, M; Langenberg, P; Rattinger, GB; Smith, GS; Gambert, SR; Gottlieb, SS; Zuckerman, IH				Albrecht, Jennifer S.; Liu, Xinggang; Baumgarten, Mona; Langenberg, Patricia; Rattinger, Gail B.; Smith, Gordon S.; Gambert, Steven R.; Gottlieb, Stephen S.; Zuckerman, Ilene H.			Benefits and Risks of Anticoagulation Resumption Following Traumatic Brain Injury	JAMA INTERNAL MEDICINE			English	Article							VENOUS THROMBOEMBOLISM PROPHYLAXIS; CLINICAL CLASSIFICATION SCHEMES; ATRIAL-FIBRILLATION; NATIONAL REGISTRY; HEMORRHAGE; WARFARIN; STROKE; THROMBOPROPHYLAXIS; VALIDATION; GUIDELINES	IMPORTANCE The increased risk of hemorrhage associated with anticoagulant therapy following traumatic brain injury creates a serious dilemma for medical management of older patients: Should anticoagulant therapy be resumed after traumatic brain injury, and if so, when? OBJECTIVE To estimate the risk of thrombotic and hemorrhagic events associated with warfarin therapy resumption following traumatic brain injury. DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of administrative claims data for Medicare beneficiaries aged at least 65 years hospitalized for traumatic brain injury during 2006 through 2009 who received warfarin in the month prior to injury (n = 10 782). INTERVENTION Warfarin use in each 30-day period following discharge after hospitalization for traumatic brain injury. MAIN OUTCOMES AND MEASURES The primary outcomes were hemorrhagic and thrombotic events following discharge after hospitalization for traumatic brain injury. Hemorrhagic events were defined on inpatient claims using International Classification of Diseases, Ninth Revision, Clinical Modification codes and included hemorrhagic stroke, upper gastrointestinal bleeding, adrenal hemorrhage, and other hemorrhage. Thrombotic events included ischemic stroke, pulmonary embolism, deep venous thrombosis, and myocardial infarction. A composite of hemorrhagic or ischemic stroke was a secondary outcome. RESULTS Medicare beneficiaries with traumatic brain injury were predominantly female (64%) and white (92%), with a mean (SD) age of 81.3 (7.3) years, and 82% had atrial fibrillation. Over the 12 months following hospital discharge, 55% received warfarin during 1 or more 30-day periods. We examined the lagged effect of warfarin use on outcomes in the following period. Warfarin use in the prior period was associated with decreased risk of thrombotic events (relative risk [RR], 0.77 [95% CI, 0.67-0.88]) and increased risk of hemorrhagic events (RR, 1.51 [95% CI, 1.29-1.78]). Warfarin use in the prior period was associated with decreased risk of hemorrhagic or ischemic stroke (RR, 0.83 [95% CI, 0.72-0.96]). CONCLUSIONS AND RELEVANCE Results from this study suggest that despite increased risk of hemorrhage, there is a net benefit for most patients receiving anticoagulation therapy, in terms of a reduction in risk of stroke, from warfarin therapy resumption following discharge after hospitalization for traumatic brain injury.	[Albrecht, Jennifer S.; Liu, Xinggang; Zuckerman, Ilene H.] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA; [Baumgarten, Mona; Langenberg, Patricia; Zuckerman, Ilene H.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Rattinger, Gail B.] Fairleigh Dickinson Univ, Sch Pharm, Div Pharm Practice, Florham Pk, NJ USA; [Smith, Gordon S.] Univ Maryland, Natl Study Ctr Trauma & Emergency Med Serv, Shock Trauma & Anesthesiol Res STAR Organized Res, Baltimore, MD 21201 USA; [Gambert, Steven R.; Gottlieb, Stephen S.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; [Zuckerman, Ilene H.] IMPAQ Int LLC, Columbia, MD 21044 USA		Zuckerman, IH (corresponding author), IMPAQ Int LLC, 10420 Little Patuxent Pkwy,Ste 300, Columbia, MD 21044 USA.	izuckerman@impaqint.com		Smith, Gordon/0000-0002-2911-3071; Albrecht, Jennifer/0000-0003-4838-2274	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 AG042768-01, T32AG000262-14]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000262, R21AG042768] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant R21 AG042768-01 (Zuckerman, principal investigator). Dr Albrecht is supported by National Institutes of Health grant T32AG000262-14.	Agarwal S, 2010, AM J CARDIOVASC DRUG, V10, P37, DOI 10.2165/11318870-000000000-00000; Ahmad O, 2009, INTERN MED J, V39, P752, DOI 10.1111/j.1445-5994.2008.01878.x; Allison PD, 1995, SURVIVAL ANAL USING; Arnason T, 2006, THROMB RES, V118, P253, DOI 10.1016/j.thromres.2005.06.015; Bjorck S, 2013, STROKE, V44, P3103, DOI 10.1161/STROKEAHA.113.002329; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS32, DOI 10.1089/neu.2007.9991; Carlile M, 2010, J TRAUMA, V68, P916, DOI 10.1097/TA.0b013e3181b16d2d; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Centers for Medicare and Medicaid Services Chronic Condition Data Warehouse, CONDITION CATEGORIES; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Faul M, 2010, TRAUMATIC BRAIN INJU; Gage BF, 2006, AM HEART J, V151, P713, DOI 10.1016/j.ahj.2005.04.017; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Jasuja GK, 2013, THROMB RES, V131, P31, DOI 10.1016/j.thromres.2012.10.010; Keeling D, 2011, BRIT J HAEMATOL, V154, P311, DOI 10.1111/j.1365-2141.2011.08753.x; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Liu X, J HEAD TRAUMA REHABI; Maletis GB, 2012, J BONE JOINT SURG AM, V94A, P714, DOI 10.2106/JBJS.J.01759; Marr A., 2004, CENTRAL NERVOUS SYST; Phelan HA, 2012, J NEUROTRAUM, V29, P1821, DOI 10.1089/neu.2012.2459; Pugh D, 2011, AGE AGEING, V40, P675, DOI 10.1093/ageing/afr097; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Salottolo K, 2011, J TRAUMA, V70, P19, DOI 10.1097/TA.0b013e318207c54d; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Singer DE, 2008, CHEST, V133, p546S, DOI 10.1378/chest.08-0678; Sniezek JE, 1995, GUIDELINES FOR SURVE; Wahl PM, 2010, PHARMACOEPIDEM DR S, V19, P596, DOI 10.1002/pds.1924; Witt DM, 2012, ARCH INTERN MED, V172, P1484, DOI 10.1001/archinternmed.2012.4261	38	37	37	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	AUG	2014	174	8					1244	1251		10.1001/jamainternmed.2014.2534			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AN2WP	WOS:000340447000011	24915005	Green Accepted, Bronze			2022-02-06	
J	Pandit, V; Patel, N; Rhee, P; Kulvatunyou, N; Aziz, H; Green, DJ; O'Keeffe, T; Zangbar, B; Tang, A; Gries, L; Friese, RS; Joseph, B				Pandit, Viraj; Patel, Nikita; Rhee, Peter; Kulvatunyou, Narong; Aziz, Hassan; Green, Donald J.; O'Keeffe, Terence; Zangbar, Bardiya; Tang, Andrew; Gries, Lynn; Friese, Randall S.; Joseph, Bellal			Effect of alcohol in traumatic brain injury: is it really protective?	JOURNAL OF SURGICAL RESEARCH			English	Article						Alcohol intoxication; Severe traumatic brain injury; Mortality; Complications; National trauma data bank	HEAD-INJURY; ETHANOL INTOXICATION; MORTALITY; CYTOKINES; SURVIVAL; MODERATE; RATS	Background: Studies have proposed a neuroprotective role for alcohol (ETOH) in traumatic brain injury (TBI). We hypothesized that ETOH intoxication is associated with mortality in patients with severe TBI. Methods: Version 7.2 of the National Trauma Data Bank (2007-2010) was queried for all patients with isolated blunt severe TBI (Head Abbreviated Injury Score >= 4) and blood ETOH levels recorded on admission. Primary outcome measure was mortality. Multivariate logistic regression analysis was performed to assess factors predicting mortality and in-hospital complications. Results: A total of 23,983 patients with severe TBI were evaluated of which 22.8% (n=5461) patients tested positive for ETOH intoxication. ETOH-positive patients were more likely to have in-hospital complications (P=0.001) and have a higher mortality rate (P=0.01). ETOH intoxication was an independent predictor for mortality (odds ratio: 1.2, 95% confidence interval: 1.1-2.1, P=0.01) and development of in-hospital complications (odds ratio: 1.3, 95% confidence interval: 1.1-2.8, P=0.009) in patients with isolated severe TBI. Conclusions: ETOH intoxication is an independent predictor for mortality in patients with severe TBI patients and is associated with higher complication rates. Our results from the National Trauma Data Standards differ from those previously reported. The proposed neuroprotective role of ETOH needs further clarification. (C) 2014 Elsevier Inc. All rights reserved.	[Pandit, Viraj; Patel, Nikita; Rhee, Peter; Kulvatunyou, Narong; Aziz, Hassan; Green, Donald J.; O'Keeffe, Terence; Zangbar, Bardiya; Tang, Andrew; Gries, Lynn; Friese, Randall S.; Joseph, Bellal] Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021; Zangbar, Bardiya/K-7147-2014	Aziz, Hassan/0000-0003-0406-1946; Zangbar, Bardiya/0000-0003-1215-1693			CDC, 2012, INJ PREV CONTR TRAUM; CDC, 2012, TRAUM BRAIN INJ US; Cebere A, 2003, NEUROCHEM RES, V28, P1193, DOI 10.1023/A:1024228412198; Centers for Disease Control, 2013, INJ PREV CONTR MOT V; Chen CM, 2012, J STUD ALCOHOL DRUGS, V73, P531, DOI 10.15288/jsad.2012.73.531; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; Goodman MD, 2013, J SURG RES, V184, P1053, DOI 10.1016/j.jss.2013.04.058; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greiffenstein P, 2007, ALCOHOL CLIN EXP RES, V31, P704, DOI 10.1111/j.1530-0277.2007.00355.x; Hadjibashi AA, 2012, J SURG RES, V173, P212, DOI 10.1016/j.jss.2011.05.029; Janis GC, 1998, ALCOHOL CLIN EXP RES, V22, P2055, DOI 10.1111/j.1530-0277.1998.tb05916.x; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Lustenberger T, 2011, J NEUROTRAUM, V28, P1699, DOI 10.1089/neu.2011.1866; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Martin TR, 1999, CHEST, V116, p2S, DOI 10.1378/chest.116.suppl_1.2S; Nelson Steve, 1992, ALCOHOL HEALTH RES W, V16, P73; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Shahin H, 2012, J TRAUMA, V14, P233; Shahin H, 2010, J TRAUMA, V69, P1176, DOI 10.1097/TA.0b013e3181edbd47; Shandro JR, 2009, J TRAUMA, V66, P1584, DOI 10.1097/TA.0b013e318182af96; Talving P, 2010, J TRAUMA, V68, P357, DOI 10.1097/TA.0b013e3181bb80bf; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699	26	37	37	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	AUG	2014	190	2					634	639		10.1016/j.jss.2014.04.039			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	AM4DD	WOS:000339801800038	24857283				2022-02-06	
J	Canty, AL; Fleming, J; Patterson, F; Green, HJ; Man, D; Shum, DHK				Canty, Allana L.; Fleming, Jennifer; Patterson, Freyr; Green, Heather J.; Man, David; Shum, David H. K.			Evaluation of a virtual reality prospective memory task for use with individuals with severe traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Prospective memory; Virtual reality; Brain injury; Ecological validity; Assessment	MULTIPLE; EVENT; PERFORMANCE; VALIDITY; DEFICITS; ADULTS; TIME	The current study aimed to evaluate the sensitivity, convergent validity and ecological validity of a newly developed virtual reality prospective memory (PM) task (i.e., the Virtual Reality Shopping Task; VRST) for use with individuals with traumatic brain injury (TBI). Thirty individuals with severe TBI and 24 uninjured adults matched on age, gender and education level were administered the VRST, a lexical decision PM task (LDPMT), an index of task-friendliness and a cognitive assessment battery. Significant others rated disruptions in the TBI participants' occupational activities, interpersonal relationships and independent living skills. The performance of the TBI group was significantly poorer than that of controls on event-based PM as measured by the LDPMT, and on time-and event-based PM as measured by the VRST. Performance on the VRST significantly predicted significant others' ratings of patients' occupational activities and independent living skills. The VRST was rated as significantly more reflective of an everyday activity, interesting and was afforded a higher recommendation than the LDPMT. For the TBI group, event and total PM performance on the VRST significantly correlated with performance on measures of mental flexibility and verbal fluency, and total PM performance correlated with verbal memory. These results provide preliminary but promising evidence of the sensitivity, as well as the convergent and ecological validity of the VRST.	[Canty, Allana L.; Green, Heather J.; Shum, David H. K.] Griffith Univ, Griffith Hlth Inst, Behav Basis Hlth Res Program, Nathan, Qld 4111, Australia; [Canty, Allana L.; Green, Heather J.; Shum, David H. K.] Griffith Univ, Sch Appl Psychol, Nathan, Qld 4111, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Sch Hlth & Rehabil Sci, Woolloongabba, Qld 4102, Australia; [Fleming, Jennifer] Univ Queensland, St Lucia, Qld, Australia; [Patterson, Freyr] Princess Alexandra Hosp, Occupat Therapy Dept, Woolloongabba, Qld 4102, Australia; [Man, David] Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China		Shum, DHK (corresponding author), Griffith Univ, Gold Coast Campus, Nathan, Qld 4222, Australia.	d.shum@griffith.edu.au	Shum, David/A-3914-2008; Fleming, Jennifer/AAH-5108-2020; Green, Heather/C-1169-2008	Shum, David/0000-0002-4810-9262; Green, Heather/0000-0003-4254-4076			Benton A., 1978, MULTILINGUAL APHASIA; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Burgess P.W., 1997, HAYLING BRIXTON TEST; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cohen J., 2013, STAT POWER ANAL BEHA; Craik FIM, 2006, MEM COGNITION, V34, P1236, DOI 10.3758/BF03193268; Einstein, 2007, PROSPECTIVE MEMORY O; Einstein GO, 2005, CURR DIR PSYCHOL SCI, V14, P286, DOI 10.1111/j.0963-7214.2005.00382.x; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS; HARRIS JE, 1982, HUM LEARN, V1, P123; Jansari A., 2004, S JOINT 27 C AUSTR S; Joyner KB, 2009, J PSYCHOEDUC ASSESS, V27, P452, DOI 10.1177/0734282909333945; Kinsella GJ, 2009, BRAIN IMPAIR, V10, P45, DOI 10.1375/brim.10.1.45; Klinger E, 2006, CYBERPSYCHOL BEHAV, V9, P342, DOI 10.1089/cpb.2006.9.342; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Knight RG, 2009, BRAIN IMPAIR, V10, P3, DOI 10.1375/brim.10.1.3; Lam YS, 2006, NEUROREHABILITATION, V21, P245; Levin H., 2002, HDB MEMORY DISORDERS, P381; Logie RH, 2011, MEM COGNITION, V39, P1561, DOI 10.3758/s13421-011-0120-1; Man DWK, 2011, NEUROPSYCHOL REHABIL, V21, P884, DOI 10.1080/09602011.2011.627270; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P350, DOI 10.1037/0278-7393.24.2.350; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McCauley SR, 2011, J CLIN EXP NEUROPSYC, V33, P639, DOI 10.1080/13803395.2010.547844; McDaniel MA., 1996, PROSPECTIVE MEMORY T, P1; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; McQueen, 2003, BRAIN IMPAIR, V4, P135, DOI [10.1375/brim.4.2.135.270, DOI 10.1375/BRIM.4.2.135.27024]; National Health and Medical Research Council (NH&MRC), 2007, NATL STAT ETH COND H; Potvin MJ, 2011, BRAIN INJURY, V25, P192, DOI 10.3109/02699052.2010.541896; Rand D, 2009, AM J OCCUP THER, V63, P535, DOI 10.5014/ajot.63.5.535; Rastle K., 2002, 358 534 NONWORDS ARC; Reitan R, 1985, HALSTEAD REITAN NEUR; Renison B, 2012, J INT NEUROPSYCH SOC, V18, P440, DOI 10.1017/S1355617711001883; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schmitter-Edgecombe M, 2009, NEUROPSYCHOLOGY, V23, P168, DOI 10.1037/a0014186; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D, 2011, NEUROPSYCHOLOGIA, V49, P2156, DOI 10.1016/j.neuropsychologia.2011.02.006; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Sweeney S, 2010, NEUROPSYCHOL REHABIL, V20, P239, DOI 10.1080/09602010903080531; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wilson B., 2005, CAMBRIDGE PROSPECTIV; Woods SP, 2009, J INT NEUROPSYCH SOC, V15, P42, DOI 10.1017/S1355617708090012; [No title captured]	49	37	39	0	24	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	APR	2014	24	2					238	265		10.1080/09602011.2014.881746			28	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	AI9BG	WOS:000337220800005	24559498	Green Accepted			2022-02-06	
J	Partridge, B				Partridge, Brad			Dazed and Confused: Sports Medicine, Conflicts of Interest, and Concussion Management	JOURNAL OF BIOETHICAL INQUIRY			English	Article						Conflict of interest; Sports medicine; Concussion; Sport; Ethics; Rugby league; Australian Rules football	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL; GUIDELINES; LOYALTIES; ZURICH; NEED	Professional sports with high rates of concussion have become increasingly concerned about the long-term effects of multiple head injuries. In this context, return-to-play decisions about concussion generate considerable ethical tensions for sports physicians. Team doctors clearly have an obligation to the welfare of their patient (the injured athlete) but they also have an obligation to their employer (the team), whose primary interest is typically success through winning. At times, a team's interest in winning may not accord with the welfare of an injured player, particularly when it comes to decisions about returning to play after injury. Australia's two most popular professional football codes-rugby league and Australian Rules football-have adopted guidelines that prohibit concussed players from continuing to play on the same day. I suggest that conflicts of interest between doctors, patients, and teams may present a substantial obstacle to the proper adherence of concussion guidelines. Concussion management guidelines implemented by a sport's governing body do not necessarily remove or resolve conflicts of interest in the doctor-patient-team triad. The instigation of a concussion exclusion rule appears to add a fourth party to this triad (the National Rugby League or the Australian Football League). In some instances, when conflicts of interest among stakeholders are ignored or insufficiently managed, they may facilitate attempts at circumventing concussion management guidelines to the detriment of player welfare.	Univ Queensland, UQCCR, Herston, Qld 4029, Australia		Partridge, B (corresponding author), Univ Queensland, UQCCR, Herston, Qld 4029, Australia.	b.partridge@uq.edu.au			Australia's National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; Australian Research Council (ARC)Australian Research Council	Brad Partridge receives funding from the Australia's National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC).	Anderson LC, 2005, J MED ETHICS, V31, P88, DOI 10.1136/jme.2002.000836; Anderson L, 2013, INT REV SOCIOL SPORT, V48, P238, DOI 10.1177/1012690211435031; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Australian Football League (AFL), 2013, MAN CONC AUSTR FOOTB; Australian Football League (AFL), 2011, MAN CONC AUSTR FOOTB; Badel P., 2012, DAILY TELEGRAPH; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Davis M., 2001, CONFLICT INTEREST PR; Davis M., 1982, BUS PROF ETHICS J, V1, P17, DOI [10.5840/bpej1982149, DOI 10.5840/BPEJ1982149]; Devitt BM, 2010, BRIT J SPORT MED, V44, P175, DOI 10.1136/bjsm.2009.068056; Dillon R., 2011, NEWCASTLE HERAL 0329, P56; Dunn WR, 2007, AM J SPORT MED, V35, P840, DOI 10.1177/0363546506295177; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Gardner A, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00141; Gilbert F, 2012, MED J AUSTRALIA, V196, P561, DOI 10.5694/mja11.11218; Kaye AH, 2012, MED J AUSTRALIA, V196, P547, DOI 10.5694/mja12.10539; Lane S., 2011, SYDNEY MORNING HERAL; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDermott Q., 2012, ABC; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mellifont D, 2012, J BIOETHIC INQ, V9, P369, DOI 10.1007/s11673-012-9386-7; MURRAY TH, 1986, SOC SCI MED, V23, P827, DOI 10.1016/0277-9536(86)90281-9; National Rugby League (NRL), 2012, MAN CONC RUGB LEAG; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Orchard J., 2012, BJSM BLOG       0315; Partridge B, 2011, AJOB NEUROSCI, V2, P62, DOI DOI 10.1080/21507740.2011.620066; Polsky S, 1998, J Contemp Health Law Policy, V14, P503; Price J, 2012, BRIT J SPORT MED, V46, P1000, DOI 10.1136/bjsports-2011-090687; Prichard G., 2012, SYDNEY MORNING HERAL; Thompson M., 2013, AFL MEDIA       0323; Webster A., 2012, COURIER MAIL    0518	34	37	37	0	36	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1176-7529	1872-4353		J BIOETHIC INQ	J. Bioethical Inq.	MAR	2014	11	1					65	74		10.1007/s11673-013-9491-2			10	Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences	AD4FB	WOS:000333202000011	24249203	Green Submitted			2022-02-06	
J	Silver, CH				Silver, Cheryl H.			Sources of data about children's executive functioning: Review and commentary	CHILD NEUROPSYCHOLOGY			English	Article						Child; Assessment; Executive function; Ecological validity; Parent report	BEHAVIOR RATING INVENTORY; PERFORMANCE-BASED MEASURES; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CROSS-INFORMANT CORRELATIONS; TRAUMATIC BRAIN-INJURY; FUNCTION DEFICITS; PARENT RATINGS; YOUNG-CHILDREN; VALIDITY; ADOLESCENTS	Accurate measurement of a child's executive functioning (EF) is important for diagnosis, description of functional impairment, and treatment planning. EF assessment typically consists of administration of a battery of performance-based tests involving abilities such as attention, inhibition, reasoning, planning, and mental flexibility. In recent years, observer (e.g., parent) rating scales have been added to the typical EF battery. However, research has revealed that performance-based tests and parent rating scales are not highly correlated. In other words, level of impairment indicated by one source of data often does not match level of impairment indicated by the other source of data. This disagreement places the clinician in a difficult situation when attempting to interpret evaluation results. The profession of pediatric neuropsychology needs to provide guidance about handling this disagreement. Using the current assessment tools, specific EF subdomains may need to be examined systematically to identify precisely where the disagreements lie. Perhaps the relative validity of the two data sources can be determined, and decisions can be made about what to emphasize and what/when to interpret cautiously. Alternatively, perhaps the goal should be to develop and/or refine measurement tools to increase agreement in order to improve accuracy and validity of test interpretation. At this time, the results of performance-based tests and rating scales of EF are being used together but are not being integrated. Evidence-based practice requires that more work be done to enhance the use of these two sources of data.	Univ Texas SW Med Ctr Dallas, Dept Rehabil Counseling, Dallas, TX 75390 USA		Silver, CH (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Rehabil Counseling, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	cheryl.silver@utsouthwestern.edu					Achenbach TM, 2006, CURR DIR PSYCHOL SCI, V15, P94, DOI 10.1111/j.0963-7214.2006.00414.x; ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Anderson P, 2000, NEW LEFT REV, P5; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson V, 2010, STUD NEUROPSYCHOL NE, P123; Archibald SJ, 1999, CHILD NEUROPSYCHOL, V5, P115, DOI 10.1076/chin.5.2.115.3167; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Barkley RA, 2010, ARCH CLIN NEUROPSYCH, V25, P157, DOI 10.1093/arclin/acq014; Baron I. S., 2004, NEUROPSYCHOLOGICAL E; BERNSTEIN JH, 1996, DEV SCORING SYSTEM R; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Bodnarchuk JL, 2004, J APPL DEV PSYCHOL, V25, P481, DOI 10.1016/j.appdev.2004.06.005; Cambridge Cognition, 1996, CAMBR NEUR TEST AUT; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Cripe L., 1996, ECOLOGICAL VALIDITY, P171; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; Delis DC., 2001, DELIS KAPLAN EXECUTI; Denckla MB, 2002, CHILD NEUROPSYCHOL, V8, P304, DOI 10.1076/chin.8.4.304.13512; Donders J, 2002, CHILD NEUROPSYCHOL, V8, P229, DOI 10.1076/chin.8.4.229.13508; Duhig AM, 2000, CLIN PSYCHOL-SCI PR, V7, P435, DOI 10.1093/clipsy/7.4.435; Emslie H., 2003, BEHAV ASSESSMENT DYS; Espy KA, 2004, CLIN NEUROPSYCHOL, V18, P411, DOI 10.1080/138540409052416; Espy KA, 2006, PSYCHOL ASSESSMENT, V18, P373, DOI 10.1037/1040-3590.18.4.373; Franzen M.D., 1996, ECOLOGICAL VALIDITY, P91; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA IP, 2000, BEHAV RATING INVENTO; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Glickman M., 2002, THESIS U TEXAS DALLA; Goulden LG, 2009, J PSYCHOEDUC ASSESS, V27, P439, DOI 10.1177/0734282909335574; Happe F, 2006, BRAIN COGNITION, V61, P25, DOI 10.1016/j.bandc.2006.03.004; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Joyner K. B., 2008, THESIS U TEXAS DALLA; Joyner KB, 2009, J PSYCHOEDUC ASSESS, V27, P452, DOI 10.1177/0734282909333945; Kemp, 1998, NEPSY DEV NEUROPSYCH; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; Kodituwakku PW, 2001, NEUROPSYCHOLOGIA, V39, P699, DOI 10.1016/S0028-3932(01)00002-1; KOLKO DJ, 1993, J CHILD PSYCHOL PSYC, V34, P991, DOI 10.1111/j.1469-7610.1993.tb01103.x; Korkman M., 2007, NEPSY 2; Krasnegor N.A., 1996, ATTENTION MEMORY EXE, P263; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Llorente AM., 2003, CHILDRENS COLOR TRAI; Long, 1996, ECOLOGICAL VALIDITY, P15; Mahone EM, 2009, J INT NEUROPSYCH SOC, V15, P31, DOI 10.1017/S1355617708090164; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Molho C. E., 1996, THESIS U TEXAS DALLA; Muller U, 2012, CLIN NEUROPSYCHOL, V26, P271, DOI 10.1080/13854046.2011.645558; Oberg E, 2011, CHILD NEUROPSYCHOL, V17, P521, DOI 10.1080/09297049.2011.555760; Parrish J, 2007, DEV MED CHILD NEUROL, V49, P412, DOI 10.1111/j.1469-8749.2007.00412.x; Rasmussen C, 2009, CHILD NEUROPSYCHOL, V15, P201, DOI 10.1080/09297040802385400; Reitan R. M., 1992, NEUROPSYCHOLOGICAL E; RICHTERS JE, 1992, PSYCHOL BULL, V112, P485, DOI 10.1037/0033-2909.112.3.485; RUFF R, 2001, ANN M NAT AC NEUR SA; Semrud-Clikeman M, 2010, J AUTISM DEV DISORD, V40, P1017, DOI 10.1007/s10803-010-0951-9; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Silver C. H., 1993, CHILDRENS EXECUTIVE; Smith SR, 2007, J PSYCHOEDUC ASSESS, V25, P139, DOI 10.1177/0734282906296233; Taylor HG, 2004, J INT NEUROPSYCH SOC, V10, P987, DOI 10.1017/S1355617704107078; Toplak ME, 2009, CHILD NEUROPSYCHOL, V15, P53, DOI 10.1080/09297040802070929; Treutler CM, 2003, J ABNORM CHILD PSYCH, V31, P13, DOI 10.1023/A:1021765114434; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Youngstrom E, 2000, J CONSULT CLIN PSYCH, V68, P1038, DOI 10.1037/0022-006X.68.6.1038	68	37	38	0	51	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	JAN 2	2014	20	1					1	13		10.1080/09297049.2012.727793			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	259FM	WOS:000327512800001	23030631				2022-02-06	
J	Cantor, J; Ashman, T; Dams-O'Connor, K; Dijkers, MP; Gordon, W; Spielman, L; Tsaousides, T; Allen, H; Nguyen, M; Oswald, J				Cantor, Joshua; Ashman, Teresa; Dams-O'Connor, Kristen; Dijkers, Marcel P.; Gordon, Wayne; Spielman, Lisa; Tsaousides, Theodore; Allen, Hafina; Michael Nguyen; Oswald, Jennifer			Evaluation of the Short-Term Executive Plus Intervention for Executive Dysfunction After Traumatic Brain Injury: A Randomized Controlled Trial With Minimization	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Brain injury; chronic; Cognition disorders; Cognitive therapy; Rehabilitation	PROBLEM-SOLVING DEFICITS; OF-THE-LITERATURE; COGNITIVE REHABILITATION; NEUROPSYCHOLOGIC REHABILITATION; VALIDATION; MANAGEMENT; INDIVIDUALS; ATTENTION; BEHAVIOR; REMEDIATION	Objective: To determine whether the Short-Term Executive Plus (STEP) cognitive rehabilitation program improves executive dysfunction after traumatic brain injury (TBI). Design: Randomized, waitlist controlled trial with minimization and blinded outcome assessment. Setting: Community. Participants: Participants with TBI and executive dysfunction (N=98; TBI severity 50% moderate/severe; mean time since injury +/- SD, 12 +/- 14y; mean age +/- SD, 45 +/- 14y; 62% women; 76% white). Intervention: STEP program: 12 weeks (9h/wk) of group training in problem solving and emotional regulation and individual sessions of attention and compensatory strategies training. Main Outcome Measures: Factor analysis was used to create a composite executive function measure using the Problem Solving Inventory, Frontal Systems Behavior Scale, Behavioral Assessment of the Dysexecutive Syndrome, and Self-Awareness of Deficits Interview. Emotional regulation was assessed with the Difficulties in Emotion Regulation Scale. The primary attention measure was the Attention Rating and Monitoring Scale. Secondary measures included neuropsychological measures of executive function, attention, and memory and measures of affective distress, self-efficacy, social participation, and quality of life. Results: Intention-to-treat mixed-effects analyses revealed significant treatment effects for the composite executive function measure (P =.008) and the Frontal Systems Behavior Scale (P=.049) and Problem Solving Inventory (P =.016). We found no between-group differences on the neuropsychological measures or on measures of attention, emotional regulation, self-awareness, affective distress, self-efficacy, participation, or quality of life. Conclusions: The STEP program is efficacious in improving self-reported post-TBI executive function and problem solving. Further research is needed to identify the roles of the different components of the intervention and its effectiveness with different TBI populations. Archives of Physical Medicine and Rehabilitation 2014;95:1-9 (c) 2014 by the American Congress of Rehabilitation Medicine	[Cantor, Joshua; Ashman, Teresa; Dams-O'Connor, Kristen; Dijkers, Marcel P.; Gordon, Wayne; Spielman, Lisa; Tsaousides, Theodore; Allen, Hafina; Michael Nguyen; Oswald, Jennifer] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA		Gordon, W (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, 3 East 101 St,Rm 118, New York, NY 10029 USA.	Wayne.gordon@mountsinai.org		Dijkers, Marcel/0000-0002-8362-5596	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001171] Funding Source: NIH RePORTER	Supported by the Centers for Disease Control and Prevention (grant no. 1R49CE001171-01).	Andrews F. M., 1976, SOCIAL INDICATORS WE; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Beck J.S., 2011, COGNITIVE BEHAV THER, V2nd ed; BECT AT, 1976, COGNITIVE THERAPY EM; Benson D.F., 1986, FRONTAL LOBES; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Braden C, 2010, BRAIN INJURY, V24, P1298, DOI 10.3109/02699052.2010.506859; Brandt J, 1998, HOPKINS VERBAL LEARN; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Bufkin JL, 2005, TRAUMA VIOLENCE ABUS, V6, P176, DOI 10.1177/1524838005275089; Canadian Academy of Psychosomatic Medicine, AID CAP EV ACE ADM; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Conners C. K., 2000, CONNERS CONTINUOUS P; D'Zurilla T. J., 1988, HDB COGNITIVE BEHAV; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Diggle P., 2002, ANAL LONGITUDINAL DA; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; First M., 1997, USER GUIDE STRUCTURE; Gagne R. M, 1965, CONDITIONS LEARNING; Golden CJ, 1978, STROOP COLOR WORD TE; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Grant M, 2012, NEUROPSYCHOL REHABIL, V22, P852, DOI 10.1080/09602011.2012.693455; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hamsher K., 1989, MULTILINGUAL APHASIA; Hawley LA, 2010, BRAIN INJURY, V24, P1292, DOI 10.3109/02699052.2010.506866; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HEPPNER PP, 1982, J COUNS PSYCHOL, V29, P66, DOI 10.1037/0022-0167.29.1.66; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria AR, 1963, RESTORATION FUNCTION; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Man DWK, 2006, NEUROREHABILITATION, V21, P205; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Palmese CA, 2000, BRAIN INJURY, V14, P535; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Raspelli S, 2011, STUD HEALTH TECHNOL, V167, P92, DOI 10.3233/978-1-60750-766-6-92; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; Reitan R, 1985, HALSTEAD REITAN NEUR; Renison B, 2012, J INT NEUROPSYCH SOC, V18, P440, DOI 10.1017/S1355617711001883; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1981, BRIT MED BULL, V37, P187, DOI 10.1093/oxfordjournals.bmb.a071699; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; Smith A., 1993, SYMBOL DIGIT MODALIT; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2001, ATTENTION PROCESS TR; Solberg MM, 2003, J MED SPEECH LANG PA, V11; Spielberger CD., 1970, STATE TRAIT ANXIETY; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Tennant A, 2007, DISABIL REHABIL, V29, P1583, DOI 10.1080/09638280701618828; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Walker AJ, 2010, BRAIN INJURY, V24, P517, DOI 10.3109/02699051003601721; Wechsler D., 1997, WAIS 3 WMS 3 TECHNIC; Wetzel L, 1991, SHORT CATEGORY BOOKL; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Woodcock R, 2001, TESTS COGNITIVE ABIL	77	37	37	2	37	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2014	95	1					1	9		10.1016/j.apmr.2013.08.005			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	289KI	WOS:000329681000001	23988395				2022-02-06	
J	Corrigan, F; Thornton, E; Roisman, LC; Leonard, AV; Vink, R; Blumbergs, PC; van den Heuvel, C; Cappai, R				Corrigan, Frances; Thornton, Emma; Roisman, Laila C.; Leonard, Anna V.; Vink, Robert; Blumbergs, Peter C.; van den Heuvel, Corinna; Cappai, Roberto			The neuroprotective activity of the amyloid precursor protein against traumatic brain injury is mediated via the heparin binding site in residues 96-110	JOURNAL OF NEUROCHEMISTRY			English	Article							NEURITE OUTGROWTH; GROWTH-FACTOR; ALZHEIMERS-DISEASE; FAMILY-MEMBERS; MICE; DOMAIN; FGF; SULFATE; APP; IMPACT	We have previously shown that following traumatic brain injury (TBI) the presence of the amyloid precursor protein (APP) may be neuroprotective. APP knockout mice have increased neuronal death and worse cognitive and motor outcomes following TBI, which is rescued by treatment with exogenous sAPP alpha (the secreted ectodomain of APP generated by alpha-secretase cleavage). Two neuroprotective regions were identified in sAPP alpha, the N and C-terminal domains D1 and D6a/E2 respectively. As both D1 and D6a/E2 contain heparin binding activity it was hypothesized that this is responsible for the neuroprotective activity. In this study, we focused on the heparin binding site, encompassed by residues 96-110 in D1, which has previously been shown to have neurotrophic properties. We found that treatment with APP96-110 rescued motor and cognitive deficits in APP-/- mice following focal TBI. APP96-110 also provided neuroprotection in Sprague-Dawley rats following diffuse TBI. Treatment with APP96-110 significantly improved functional outcome as well as preserve histological cellular morphology in APP-/- mice following focal controlled cortical impact injury. Furthermore, following administration of APP96-110 in rats after diffuse impact acceleration TBI, motor and cognitive outcomes were significantly improved and axonal injury reduced. These data define the heparin binding site in the D1 domain of sAPP alpha, represented by the sequence APP96-110, as the neuroprotective site to confer neuroprotection following TBI.	[Corrigan, Frances; Thornton, Emma; Leonard, Anna V.; Vink, Robert; van den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Discipline Anat & Pathol, Adelaide, SA, Australia; [Roisman, Laila C.; Cappai, Roberto] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia; [Roisman, Laila C.; Cappai, Roberto] Univ Melbourne, Mol Sci & BioTechnol Inst Bio21, Melbourne, Vic 3010, Australia; [Blumbergs, Peter C.] Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia		Cappai, R (corresponding author), Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.	r.cappai@unimelb.edu.au	Vink, Robert/S-5616-2019; Roisman, Laila C./P-9129-2019; Vink, Robert/J-7351-2012; Cappai, Roberto/B-3347-2010	Vink, Robert/0000-0002-4885-0667; Roisman, Laila C./0000-0001-8455-9327; Vink, Robert/0000-0002-4885-0667; , Corinna/0000-0003-0664-8935; Cappai, Roberto/0000-0002-9505-8496; Corrigan, Frances/0000-0001-6150-8893	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia	This study was funded in part by a grant from the National Health and Medical Research Council of Australia. We thank Prof. Hui Zheng for providing the APP knockout mice and Dr Mark Habgood (University of Melbourne), Dr Jenna Zeibell and Jim Manavis for expert technical assistance. We thank Dr Chi Pham (The University of Melbourne) for purifying the D1 domain. RC is a National Health and Medical Research Council Senior Research Fellow. No authors have a conflict of interest to declare.	Anliker B, 2006, NEURODEGENER DIS, V3, P239, DOI 10.1159/000095262; Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Corrigan F, 2012, J NEUROCHEM, V122, P208, DOI 10.1111/j.1471-4159.2012.07761.x; Corrigan F, 2012, BRAIN RES, V1451, P87, DOI 10.1016/j.brainres.2012.02.045; Corrigan F, 2012, NEUROSCI LETT, V515, P50, DOI 10.1016/j.neulet.2012.03.017; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Ford-Perriss M, 2002, GLYCOBIOLOGY, V12, P721, DOI 10.1093/glycob/cwf072; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Gakhar-Koppole N, 2008, EUR J NEUROSCI, V28, P871, DOI 10.1111/j.1460-9568.2008.06398.x; Gallagher J, 2007, DEV CELL, V13, P166, DOI 10.1016/j.devcel.2007.07.015; Gralle M, 2009, J BIOL CHEM, V284, P15016, DOI 10.1074/jbc.M808755200; GREENBERG SM, 1995, NEUROBIOL AGING, V16, P403, DOI 10.1016/0197-4580(94)00172-W; Heber S, 2000, J NEUROSCI, V20, P7951; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Itoh N, 2007, BIOL PHARM BULL, V30, P1819, DOI 10.1248/bpb.30.1819; Kaden D, 2008, J BIOL CHEM, V283, P7271, DOI 10.1074/jbc.M708046200; Koopmans G, 2003, PHYSIOL BEHAV, V79, P683, DOI 10.1016/S0031-9384(03)00171-9; Kwak YD, 2006, BIOCHEM BIOPH RES CO, V344, P431, DOI 10.1016/j.bbrc.2006.03.054; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lin XH, 1999, DEVELOPMENT, V126, P3715; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morimoto T, 1998, J NEUROSCI, V18, P9386; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; Paxinos G., 2007, MOUSE BRAIN STEREOTA; Raman R, 2005, CHEM BIOL, V12, P267, DOI 10.1016/j.chembiol.2004.11.020; Rapraeger AC, 2002, METHOD CELL BIOL, V69, P83, DOI 10.1016/S0091-679X(02)69009-0; Reinhard C, 2005, EMBO J, V24, P3996, DOI 10.1038/sj.emboj.7600860; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; SMALL DH, 1994, J NEUROSCI, V14, P2117; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Song HH, 2005, J BIOL CHEM, V280, P2116, DOI 10.1074/jbc.M410090200; Spillman D., 1994, CURR OPIN STRUC BIOL, V4, P667; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; Young-Pearse TL, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-15	43	37	37	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2014	128	1					196	204		10.1111/jnc.12391			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AA3FQ	WOS:000330978700011	23919582	Bronze, Green Published			2022-02-06	
J	Hunt, EJF; Wessely, S; Jones, N; Rona, RJ; Greenberg, N				Hunt, Elizabeth J. F.; Wessely, Simon; Jones, Norman; Rona, Roberto J.; Greenberg, Neil			The mental health of the UK Armed Forces: where facts meet fiction	EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY			English	Article						Military; combat; service personnel; veterans; reservists; post-traumatic stress disorder; delayed-onset PTSD; mild traumatic brain injury; Trauma Risk Management	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MILITARY PERSONNEL; PSYCHOLOGICAL SYMPTOMS; US SOLDIERS; LIFE EVENTS; ALCOHOL-USE; IRAQ; DEPLOYMENT; PTSD	A substantial amount of research has been conducted into the mental health of the UK military in recent years. This article summarises the results of the various studies and offers possible explanations for differences in findings between the UK and other allied nations. Post-traumatic stress disorder (PTSD) rates are perhaps surprisingly low amongst British forces, with prevalence rates of around 4% in personnel who have deployed, rising to 6% in combat troops, despite the high tempo of operations in recent years. The rates in personnel currently on operations are consistently lower than these. Explanations for the lower PTSD prevalence in British troops include variations in combat exposures, demographic differences, higher leader to enlisted soldier ratios, shorter operational tour lengths and differences in access to long-term health care between countries. Delayed-onset PTSD was recently found to be more common than previously supposed, accounting for nearly half of all PTSD cases; however, many of these had sub-syndromal PTSD predating the onset of the full disorder. Rates of common mental health disorders in UK troops are similar or higher to those of the general population, and overall operational deployments are not associated with an increase in mental health problems in UK regular forces. However, there does appear to be a correlation between both deployment and increased alcohol misuse and post-deployment violence in combat troops. Unlike for regular forces, there is an overall association between deployment and mental health problems in Reservists. There have been growing concerns regarding mild traumatic brain injury, though this appears to be low in British troops with an overall prevalence of 4.4% in comparison with 15% in the US military. The current strategies for detection and treatment of mental health problems in British forces are also described. The stance of the UK military is that psychological welfare of troops is primarily a chain of command responsibility, aided by medical advice when necessary, and to this end uses third location decompression, stress briefings, and Trauma Risk Management approaches. Outpatient treatment is provided by Field Mental Health Teams and military Departments of Community Mental Health, whilst inpatient care is given in specific NHS hospitals.	[Hunt, Elizabeth J. F.; Jones, Norman; Greenberg, Neil] Kings Coll London, ACDMH, Western Educ Ctr, London SE5 9RJ, England; [Wessely, Simon; Rona, Roberto J.] Kings Coll London, KCMHR, Western Educ Ctr, London SE5 9RJ, England		Hunt, EJF (corresponding author), Kings Coll London, ACDMH, Western Educ Ctr, London SE5 9RJ, England.	lizzie.hunt@gmail.com	Wessely, Simon C/A-8713-2008	Wessely, Simon Charles/0000-0002-6743-9929; greenberg, neil/0000-0003-4550-2971			American Psychiatric Association, 1980, DSM 3 DIAGN STAT MAN, V3rd; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.ajp.2007.06091491; Batzer WB, 2007, MIL MED, V172, P266, DOI 10.7205/MILMED.172.3.266; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; Brewin CR, 2012, PSYCHOL MED, V42, P2119, DOI 10.1017/S0033291712000189; Browne T, 2007, BRIT J PSYCHIAT, V190, P484, DOI 10.1192/bjp.bp.106.030544; Browne T, 2012, J TRAUMA STRESS, V25, P207, DOI 10.1002/jts.21678; Casper ST, 2008, MED HIST, V52, P327, DOI 10.1017/S0025727300002660; Cooke DJ, 2005, BRIT J PSYCHIAT, V186, P335, DOI 10.1192/bjp.186.4.335; Dandeker C, 2010, ARMED FORCES SOC, V36, P264, DOI 10.1177/0095327X09344068; Fear NT, 2008, AM J PREV MED, V35, P230, DOI 10.1016/j.amepre.2008.05.027; Fear NT, 2007, ADDICTION, V102, P1749, DOI 10.1111/j.1360-0443.2007.01978.x; Fear NT, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-797; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-6736(10)60672-1; Fear NT, 2009, INT J OCCUP ENV HEAL, V15, P291; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Frueh BC, 2007, AM J PUBLIC HEALTH, V97, P2143, DOI 10.2105/AJPH.2007.115436; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Goldberg DP, 1998, PSYCHOL MED, V28, P915, DOI 10.1017/S0033291798006874; Goodwin L., ARE COMMON IN PRESS; Goodwin L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078693; Goodwin L, 2012, J NERV MENT DIS, V200, P429, DOI 10.1097/NMD.0b013e31825322fe; Gould M, 2010, J ROY SOC MED, V103, P148, DOI 10.1258/jrsm.2010.090426; Gould M, 2008, PSYCHIATR BULL, V32, P99, DOI 10.1192/pb.bp.107.016337; Gray GC, 2006, PHILOS T R SOC B, V361, P553, DOI 10.1098/rstb.2006.1816; Greenberg N, 2008, Emerg Health Threats J, V1, pe10, DOI 10.3134/ehtj.08.010; Greenberg N, 2008, J R Army Med Corps, V154, P124; Greenberg N, 2008, J ROY SOC MED, V101, P78, DOI 10.1258/jrsm.2007.070024; Greenberg N, 2010, J TRAUMA STRESS, V23, P430, DOI 10.1002/jts.20538; Harvey SB, 2011, ANN EPIDEMIOL, V21, P666, DOI 10.1016/j.annepidem.2011.05.004; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hooper R, 2008, ADDICT BEHAV, V33, P1067, DOI 10.1016/j.addbeh.2008.03.010; Hosek J, 2011, DEPLOYMENT IRAQ AFGH; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Iversen A. C, 2009, ADV PSYCHIAT TREATME, V15, P100, DOI DOI 10.1192/APT.BP.107.004713; Iversen AC, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-31; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jones E, 2008, PSYCHOL MED, V38, P1419, DOI 10.1017/S003329170800278X; Jones E, 2004, SOC HIST MED, V17, P463, DOI 10.1093/shm/17.3.463; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Jones E, 2007, BMJ-BRIT MED J, V335, P1313, DOI 10.1136/bmj.39420.533461.25; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Jones M, 2006, OCCUP MED-OXFORD, V56, P322, DOI 10.1093/occmed/kql023; Jones N, 2003, OCCUP MED-OXFORD, V53, P469, DOI 10.1093/occmed/kqg093; Jones N, 2011, OCCUP MED-OXFORD, V61, P102, DOI 10.1093/occmed/kqq182; Jones N, 2011, J MENT HEALTH, V20, P136, DOI 10.3109/09638237.2010.541299; Jones N., OPERATIONAL IN PRESS; Jones N, 2012, PSYCHIATRY, V75, P49, DOI 10.1521/psyc.2012.75.1.49; Karasek R, 1998, J Occup Health Psychol, V3, P322, DOI 10.1037/1076-8998.3.4.322; Kessler RC, 2008, ANNU REV PUBL HEALTH, V29, P115, DOI 10.1146/annurev.publhealth.29.020907.090847; Killgore WDS, 2006, J PSYCHOSOM RES, V60, P379, DOI 10.1016/j.jpsychores.2006.02.012; Kok BC, 2012, J NERV MENT DIS, V200, P444, DOI 10.1097/NMD.0b013e3182532312; LeardMann CA, 2009, BMJ-BRIT MED J, V338, P1; LEE KA, 1995, AM J PSYCHIAT, V152, P516; Litz BT, 1997, AM J PSYCHIAT, V154, P178; MacManus D, 2012, PSYCHOL MED, V42, P1663, DOI 10.1017/S0033291711002327; Marx BP, 2012, J TRAUMA STRESS, V25, P457, DOI 10.1002/jts.21714; MCGEORGE T, 2006, OCCUPATIONAL HLTH RE, V122, P21; McManus S., 2009, ADULT PSYCHIAT MORBI; Mental Health in the Australian Defence Force, 2010, ADF MENT HLTH PREV W; Messenger K, 2012, J OCCUP ENVIRON MED, V54, P859, DOI 10.1097/JOM.0b013e31824e676b; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Morley Fletcher W., 1919, DIGITIZED INTERNET A, V1, P461; Mulligan K, 2012, J CONSULT CLIN PSYCH, V80, P331, DOI 10.1037/a0027664; Mulligan K, 2010, BRIT J PSYCHIAT, V197, P405, DOI 10.1192/bjp.bp.110.077263; Murrison A., 2010, FIGHTING FIT MENTAL; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pinder RJ, 2012, INT J SOC PSYCHIATR, V58, P433, DOI 10.1177/0020764011408534; Pook A, 2008, J R Army Med Corps, V154, P120; Rona R. J., 2007, BRIT MED J, V191, P506; Rona RJ, 2004, J MED SCREEN, V11, P148, DOI 10.1258/0969141041732193; Rona RJ, 2007, INT J EPIDEMIOL, V36, P319, DOI 10.1093/ije/dyl273; Rona RJ, 2012, J PSYCHIATR RES, V46, P1191, DOI 10.1016/j.jpsychires.2012.05.009; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P75, DOI 10.1097/HTR.0b013e31823029f6; Rona RJ, 2009, J TRAUMA STRESS, V22, P11, DOI 10.1002/jts.20383; Rona RJ, 2009, J PSYCHIATR RES, V43, P649, DOI 10.1016/j.jpsychires.2008.09.006; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Schnurr PP, 2004, J TRAUMA STRESS, V17, P85, DOI 10.1023/B:JOTS.0000022614.21794.f4; Schulte-Herbruggen O, 2012, DTSCH ARZTEBL INT, V109, P557, DOI 10.3238/arztebl.2012.0557; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Solomon Z, 2006, AM J PSYCHIAT, V163, P659, DOI 10.1176/appi.ajp.163.4.659; SOLOMON Z, 1989, SOC PSYCH PSYCH EPID, V24, P41, DOI 10.1007/BF01788199; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Sundin J, 2014, BRIT J PSYCHIAT, V204, P202, DOI 10.1192/bjp.bp.113.129569; Sundin J, 2010, INT ARCH OCC ENV HEA, V83, P653, DOI 10.1007/s00420-009-0504-8; Unwin C, 1999, LANCET, V353, P169, DOI 10.1016/S0140-6736(98)11338-7; Wilson J, 2009, AM J EPIDEMIOL, V169, P1362, DOI 10.1093/aje/kwp044; Wittchen HU, 2012, DTSCH ARZTEBL INT, V109, P559, DOI 10.3238/arztebl.2012.0559; Woodhead C, 2011, PSYCHOL MED, V41, P363, DOI 10.1017/S0033291710000759; Woodhead C., 2011, SOCIAL PSYCHIAT PSYC, V46, P559	93	37	37	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2000-8198	2000-8066		EUR J PSYCHOTRAUMATO	Eur. J. Psychotraumatol.		2014	5								23617	10.3402/ejpt.v5.23617			15	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Psychiatry	AO2GX	WOS:000341137400001	25206948	Green Published, gold			2022-02-06	
J	Kapapa, T; Rohrer, S; Struve, S; Petscher, M; Knig, R; Wirtz, CR; Woischneck, D				Kapapa, Thomas; Rohrer, Stefan; Struve, Sabine; Petscher, Matthias; Konig, Ralph; Wirtz, Christian Rainer; Woischneck, Dieter			Desmopressin Acetate in Intracranial Haemorrhage	NEUROLOGY RESEARCH INTERNATIONAL			English	Article							TRAUMATIC BRAIN-INJURY; PLATELET TRANSFUSION; THERAPY	Introduction. The secondary increase in the size of intracranial haematomas as a result of spontaneous haemorrhage or trauma is of particular relevance in the event of prior intake of platelet aggregation inhibitors. We describe the effect of desmopressin acetate as a means of temporarily stabilising the platelet function. Patients and Methods. The platelet function was analysed in 10 patients who had received single (N = 4) or multiple (N = 6) doses of acetylsalicylic acid and 3 patients (control group) who had not taken acetylsalicylic acid. All subjects had suffered intracranial haemorrhage. Analysis was performed before, half an hour and three hours after administration of desmopressin acetate. Statistical analysis was performed by applying a level of significance of P <= 0.05. Results. (1) Platelet function returned to normal 30 minutes after administration of desmopressin acetate. (2) The platelet function worsened again after three hours. (3) There were no complications related to electrolytes or fluid balance. Conclusion. Desmopressin acetate can stabilise the platelet function in neurosurgical patients who have received acetylsalicylic acid prior to surgery without causing transfusion-related side effects or a loss of time. The effect is, however, limited and influenced by the frequency of drug intake. Further controls are needed in neurosurgical patients.	[Kapapa, Thomas; Rohrer, Stefan; Konig, Ralph; Wirtz, Christian Rainer] Univ Klinikum Ulm, Neurochirurg Klin, Albert Einstein Allee 23, D-89081 Ulm, Germany; [Struve, Sabine] Klinikum Schwabing, Stadt Klinikum Munchen, Klin Hamatol Onkol Immunol Palliat Med Infekt & T, D-80804 Munich, Germany; [Petscher, Matthias] Klin Anasthesiol, Abt Klin Anasthesiol, D-89081 Ulm, Germany; [Woischneck, Dieter] Klinikum Landshut, Neurochirurg Klin, D-84034 Landshut, Germany		Kapapa, T (corresponding author), Univ Klinikum Ulm, Neurochirurg Klin, Albert Einstein Allee 23, D-89081 Ulm, Germany.	thomas.kapapa@uniklinik-ulm.de		Wirtz, Christian Rainer/0000-0001-8358-1813			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Arzneimittel F., 2011, FACHINFORMATION MINI; Baldi G, 2006, CEREBROVASC DIS, V22, P286, DOI 10.1159/000094604; Bassand JP, 2012, EUROPACE, V14, P312, DOI 10.1093/europace/eur263; Batchelor JS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000588; BECK KH, 1995, SEMIN THROMB HEMOST, V21, P32; BECK KH, 1994, BEITR INFUS, V32, P437; Bullock MR, 2006, NEUROSURGERY S3, V58, pS216; Federal Statistical Office of Germany, 2012, PRESCR THROMB AGGR I; Fintel DJ, 2012, VASC HEALTH RISK MAN, V8, P77, DOI 10.2147/VHRM.S26030; FLORDAL PA, 1993, BRIT J SURG, V80, P723, DOI 10.1002/bjs.1800800616; Guth M. C., 2012, ANASTH INTENSIVMED, V49, P528; I. F. K. C. Universitatsklinikum-Koln, 2012, AUFB FUNKT PFA 100; Karger R, 2012, ISRN HEMATOL, V2012; Kouides PA, 2009, BRIT J HAEMATOL, V145, P212, DOI 10.1111/j.1365-2141.2009.07610.x; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; LETHAGEN S, 1994, ANN HEMATOL, V69, P173, DOI 10.1007/BF02215950; Mannucci PM, 2007, NEW ENGL J MED, V356, P2301, DOI 10.1056/NEJMra067742; Raihan M Z, 2009, Mymensingh Med J, V18, P245; Reiter RA, 2003, BLOOD, V102, P4594, DOI 10.1182/blood-2002-11-3566; Saloheimo P, 2006, STROKE, V37, P129, DOI 10.1161/01.STR.0000196991.03618.31; Schebesch KM, 2008, ZBL NEUROCHIR, V69, P61, DOI 10.1055/s-2007-1004582; Schulman S, 2012, HEMATOL-AM SOC HEMAT, P517, DOI 10.1182/asheducation-2012.1.517; Schulz-Stubner S, 2002, EUR J ANAESTH, V19, P647, DOI 10.1017/S0265021502001060; SHERIDAN DP, 1994, CAN J SURG, V37, P33; Stanisic M, 2005, ACTA NEUROCHIR, V147, P1249, DOI 10.1007/s00701-005-0616-1; Taylor G, 2013, J TRAUMA ACUTE CARE, V74, P1367, DOI 10.1097/TA.0b013e31828cca61; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e	29	37	37	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-1852	2090-1860		NEUROL RES INT	Neurol. Res. Int.		2014	2014								298767	10.1155/2014/298767			7	Neurosciences	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V33EG	WOS:000215748100007	25610644	Green Published, gold, Green Submitted			2022-02-06	
J	Kurtz, P; Claassen, J; Helbok, R; Schmidt, JM; Fernandez, L; Presciutti, M; Stuart, RM; Connolly, ES; Lee, K; Badjatia, N; Mayer, SA				Kurtz, Pedro; Claassen, Jan; Helbok, Raimund; Schmidt, J. Michael; Fernandez, Luis; Presciutti, Mary; Stuart, R. Morgan; Connolly, E. Sander; Lee, Kiwon; Badjatia, Neeraj; Mayer, Stephan A.			Systemic glucose variability predicts cerebral metabolic distress and mortality after subarachnoid hemorrhage: a retrospective observational study	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; CRITICALLY-ILL PATIENTS; INTENSIVE INSULIN THERAPY; POSITRON-EMISSION-TOMOGRAPHY; HYPOGLYCEMIC NEURONAL DEATH; GLYCEMIC VARIABILITY; ESTIMATING EQUATIONS; LACTATE/PYRUVATE RATIO; TEMPERATURE MODULATION; CRITICAL ILLNESS	Introduction: Cerebral glucose metabolism and energy production are affected by serum glucose levels. Systemic glucose variability has been shown to be associated with poor outcome in critically ill patients. The objective of this study was to assess whether glucose variability is associated with cerebral metabolic distress and outcome after subarachnoid hemorrhage. Methods: A total of 28 consecutive comatose patients with subarachnoid hemorrhage, who underwent cerebral microdialysis and intracranial pressure monitoring, were studied. Metabolic distress was defined as lactate/pyruvate ratio (LPR) >40. The relationship between daily glucose variability, the development of cerebral metabolic distress and hospital outcome was analyzed using a multivariable general linear model with a logistic link function for dichotomized outcomes. Results: Daily serum glucose variability was expressed as the standard deviation (SD) of all serum glucose measurements. General linear models were used to relate this predictor variable to cerebral metabolic distress and mortality at hospital discharge. A total of 3,139 neuromonitoring hours and 181 days were analyzed. After adjustment for Glasgow Coma Scale (GCS) scores and brain glucose, SD was independently associated with higher risk of cerebral metabolic distress (adjusted odds ratio = 1.5 (1.1 to 2.1), P = 0.02). Increased variability was also independently associated with in hospital mortality after adjusting for age, Hunt Hess, daily GCS and symptomatic vasospasm (P = 0.03). Conclusions: Increased systemic glucose variability is associated with cerebral metabolic distress and increased hospital mortality. Therapeutic approaches that reduce glucose variability may impact on brain metabolism and outcome after subarachnoid hemorrhage.	[Kurtz, Pedro; Claassen, Jan; Helbok, Raimund; Schmidt, J. Michael; Fernandez, Luis; Presciutti, Mary; Stuart, R. Morgan; Connolly, E. Sander; Lee, Kiwon; Badjatia, Neeraj; Mayer, Stephan A.] Milstein Hosp 8 Ctr, Neurol Intens Care Unit, New York, NY 10032 USA		Claassen, J (corresponding author), Milstein Hosp 8 Ctr, Neurol Intens Care Unit, 177 Ft Washington Ave, New York, NY 10032 USA.	jc1439@mail.cumc.columbia.edu	Helbok, Raimund/AAA-8361-2021; Claassen, Jan/AAA-5451-2020; Badjatia, Neeraj/AAS-4855-2021	Schmidt, J. Michael/0000-0001-8141-2944; Badjatia, Neeraj/0000-0003-1509-9034	Department of Neurology/Neurosurgery, Columbia University Medical Center	We thank the attending physicians, fellows and nurses of the Division of Neurocritical Care, Department of Neurology/Neurosurgery, Columbia University Medical Center for their overall support of this project.	Ali NA, 2008, CRIT CARE MED, V36, P2316, DOI 10.1097/CCM.0b013e3181810378; Badjatia N, 2005, CRIT CARE MED, V33, P1603, DOI 10.1097/01.CCM.0000168054.60538.2B; Badjatia N, 2009, CRIT CARE MED, V37, P1893, DOI 10.1097/CCM.0b013e31819fffd3; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bagshaw SM, 2009, CRIT CARE, V13, DOI 10.1186/cc7921; Barletta JF, 2013, J CRIT CARE, V28, P798, DOI 10.1016/j.jcrc.2012.12.012; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Brunner R, 2012, CRIT CARE, V16, DOI 10.1186/cc11657; Dossett LA, 2008, AM SURGEON, V74, P679; Egi M, 2006, ANESTHESIOLOGY, V105, P244, DOI 10.1097/00000542-200608000-00006; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; Helbok R, 2010, NEUROCRIT CARE, V12, P317, DOI 10.1007/s12028-009-9327-4; Hermanides J, 2010, CRIT CARE MED, V38, P838, DOI 10.1097/CCM.0b013e3181cc4be9; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Krinsley JS, 2008, CRIT CARE MED, V36, P3008, DOI 10.1097/CCM.0b013e31818b38d2; Krinsley JS, 2013, CRIT CARE, V17, DOI 10.1186/cc12584; Krinsley JS, 2010, CRIT CARE MED, V38, P1206, DOI 10.1097/CCM.0b013e3181d3aba5; Krinsley James Stephen, 2009, J Diabetes Sci Technol, V3, P1292; Kruyt ND, 2009, STROKE, V40, pE424, DOI 10.1161/STROKEAHA.108.529974; Mackenzie IMJ, 2011, INTENS CARE MED, V37, P435, DOI 10.1007/s00134-010-2103-2; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Nagel A, 2009, J NEUROSURG, V111, P94, DOI 10.3171/2009.1.JNS08587; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Pan W, 2001, BIOMETRICS, V57, P529, DOI 10.1111/j.0006-341X.2001.00529.x; Pan W, 2001, BIOMETRICS, V57, P120, DOI 10.1111/j.0006-341X.2001.00120.x; Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2; PRENTICE RL, 1991, BIOMETRICS, V47, P825, DOI 10.2307/2532642; Ryan EA, 2004, DIABETES, V53, P955, DOI 10.2337/diabetes.53.4.955; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2004, STROKE, V35, P638, DOI 10.1161/01.STR.0000116101.66624.F1; Sarrafzadeh AS, 2010, J CEREBR BLOOD F MET, V30, P36, DOI 10.1038/jcbfm.2009.199; Schlenk F, 2008, INTENS CARE MED, V34, P1200, DOI 10.1007/s00134-008-1044-5; Schlenk F, 2008, CRIT CARE, V12, DOI 10.1186/cc6776; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Suh SW, 2007, GLIA, V55, P1280, DOI 10.1002/glia.20440; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2006, CURR OPIN CRIT CARE, V12, P119, DOI 10.1097/01.ccx.0000216577.57180.bd; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Zazulia AR, 2009, STROKE, V40, P1638, DOI 10.1161/STROKEAHA.108.536037	53	37	41	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2014	18	3							R89	10.1186/cc13857			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AO2OI	WOS:000341163800003	24887049	gold, Green Published			2022-02-06	
J	Magone, MT; Kwon, E; Shin, SY				Magone, M. Teresa; Kwon, Ellen; Shin, Soo Y.			Chronic visual dysfunction after blast-induced mild traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						accommodative insufficiency; blast-induced traumatic brain injury; combat-related traumatic brain injury; convergence insufficiency; dismounted injury; eyes; loss of consciousness; mild traumatic brain injury; near vision deficit; photophobia; traumatic brain injury; visual dysfunction	POSTTRAUMATIC-STRESS-DISORDER; POLYTRAUMA NETWORK SITE; DUAL SENSORY IMPAIRMENT; PERSISTENT; SYMPTOMS; VETERANS; MILITARY; SOLDIERS; PROGRAM; VISION	The purpose of this study was to investigate the long-term visual dysfunction in patients after blast-induced mild traumatic brain injury (mbTBI) using a retrospective case series of 31 patients with mbTBI (>12 mo prior) without eye injuries. Time since mbTBI was 50.5 +/- 19.8 mo. Age at the time of injury was 30.0 +/- 8.3 yr. Mean corrected visual acuity was 20/20. Of the patients, 71% (n = 22) experienced loss of consciousness; 68% (n = 15) of patients in this subgroup were dismounted during the blast injury. Overall, 68% (n = 21) of patients had visual complaints. The most common complaints were photophobia (55%) and difficulty with reading (32%). Of all patients, 25% were diagnosed with convergence insufficiency and 23% had accommodative insufficiency. Patients with more than one mbTBI had a higher rate of visual complaints (87.5%). Asymptomatic patients had a significantly longer time (62.5 +/- 6.2 mo) since the mbTBI than symptomatic patients (42.0 +/- 16.4 mo, p < 0.004). Long-term visual dysfunction after mbTBI is common even years after injury despite excellent distance visual acuity and is more frequent if more than one incidence of mbTBI occurred. We recommend obtaining a careful medical history, evaluation of symptoms, and binocular vision assessment during routine eye examinations in this prepresbyopic patient population.	[Magone, M. Teresa; Kwon, Ellen; Shin, Soo Y.] Dept Vet Affairs Med Ctr, Dept Surg, Eye Clin, Washington, DC 20422 USA		Magone, MT (corresponding author), Dept Vet Affairs Med Ctr, Dept Surg, Eye Clin, 50 Irving St NW, Washington, DC 20422 USA.	maria.magone@va.gov		Magone, M. Teresa/0000-0001-6370-6295			Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Armed Forces Health Surveillance Center, 2012, MED SURVEILL MON REP, V19, P19; BOHNEN N, 1991, J NEUROL, V238, P443, DOI 10.1007/BF00314651; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Coppola G, 2007, Cephalalgia, V27, P1427, DOI 10.1111/j.1468-2982.2007.01500.x; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desmoulin GT, 2009, J TRAUMA, V67, P1113, DOI 10.1097/TA.0b013e3181bb8e84; Digre KB, 2012, J NEURO-OPHTHALMOL, V32, P68, DOI 10.1097/WNO.0b013e3182474548; Du T, 2005, BRAIN INJURY, V19, P1125, DOI 10.1080/02699050500149817; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fraunfelder F, 2008, CLIN OCULAR TOXICOLO; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Galor A, 2012, AM J OPHTHALMOL, V154, P340, DOI 10.1016/j.ajo.2012.02.009; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; KENT P R, 1953, Mil Surg, V112, P202; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Military Health System Office of Strategic Communications, 2012, DOD NUMB TRAUM BRAIN; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schrupp LE, 2009, OPTOMETRY, V80, P642, DOI 10.1016/j.optm.2009.04.097; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Trachtman JN, 2010, OPTOMETRY, V81, P240, DOI 10.1016/j.optm.2009.07.017; Wick B., 2008, CLIN MANAGEMENT BINO; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wilkins AJ, 2004, EPILEPSIA S1, V45, P17; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Zollman FS, 2011, MANUAL OF TRAUMATIC BRAIN INJURY MANAGEMENT, P1; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	41	37	39	0	14	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2014	51	1					71	80		10.1682/JRRD.2013.01.0008			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	AF8GB	WOS:000334952600007	24805895	Bronze			2022-02-06	
J	Seifman, MA; Gomes, K; Nguyen, PN; Bailey, M; Rosenfeld, JV; Cooper, DJ; Morganti-Kossmann, MC				Seifman, Marc A.; Gomes, Keith; Nguyen, Phuong N.; Bailey, Michael; Rosenfeld, Jeffrey V.; Cooper, David J.; Morganti-Kossmann, Maria Cristina			Measurement of serum melatonin in intensive care unit patients: changes in traumatic brain injury, trauma, and medical conditions	FRONTIERS IN NEUROLOGY			English	Article						melatonin; TBI; trauma; intensive care unit; circadian		Melatonin is an endogenous hormone mainly produced by the pineal gland whose dysfunction leads to abnormal sleeping patterns. Changes in melatonin have been reported in acute traumatic brain injury (TBI); however, the impact of environmental conditions typical of the intensive care unit (ICU) has not been assessed. The aim of this study was to compare daily melatonin production in three patient populations treated at the ICU to differentiate the role of TBI versus ICU conditions. Forty-five patients were recruited and divided into severe TBI, trauma without TBI, medical conditions without trauma, and compared to healthy volunteers. Serum melatonin levels were measured at four daily intervals at 0400 h, 1000 h, 1600 h, and 2200 h for 7 days post-ICU admission by commercial enzyme linked immunosorbent assay. The geometric mean concentrations (95% confidence intervals) of melatonin in these groups showed no difference being 8.3 (6.3-11.0), 9.3 (70-12.3), and 8.9 (6.6-11.9) pg/mL, respectively, in TBI, trauma, and intensive care cohorts. All of these patient groups demonstrated decreased melatonin concentrations when compared to control patients. This study suggests that TBI as well as ICU conditions, may have a role in the dysfunction of melatonin. Monitoring and possibly substituting melatonin acutely in these settings may assist in ameliorating long-term sleep dysfunction in all of these groups, and possibly contribute to reducing secondary brain injury in severe TBI.	[Seifman, Marc A.; Gomes, Keith; Nguyen, Phuong N.] The Alfred, Natl Trauma Res Inst, Melbourne, Vic, Australia; [Seifman, Marc A.; Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Seifman, Marc A.; Gomes, Keith; Rosenfeld, Jeffrey V.] The Alfred, Dept Neurosurg, Melbourne, Vic, Australia; [Bailey, Michael; Cooper, David J.; Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Epidemiol, Melbourne, Vic 3004, Australia; [Bailey, Michael; Cooper, David J.; Morganti-Kossmann, Maria Cristina] Australian New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Cooper, David J.] The Alfred, Intens Care Unit, Melbourne, Vic, Australia; [Morganti-Kossmann, Maria Cristina] Univ Arizona, Dept Child Hlth, Barrow Neurol Inst, Phoenix, AZ USA		Morganti-Kossmann, MC (corresponding author), Monash Univ, Dept Epidemiol & Prevent Med, 99 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu	Cooper, D. James/G-7961-2013; Bailey, Michael J/A-4499-2012	Cooper, D. James/0000-0002-5872-9051; Bailey, Michael J/0000-0002-5551-1401; Morganti-Kossmann, Cristina/0000-0002-0807-2063			Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Barlow KM, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-271; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Brzezinski Amnon, 1997, New England Journal of Medicine, V336, P186; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Lewy A, 2006, CHRONOBIOL INT, V23, P403, DOI 10.1080/07420520500545862; Longoni B, 1998, LIFE SCI, V62, P853, DOI 10.1016/S0024-3205(98)00002-2; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rajaratnam SMW, 2009, SLEEP MED CLIN, V4, P179, DOI 10.1016/j.jsmc.2009.02.007; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; Rizzo V, 2002, J CHROMATOGR B, V774, P17, DOI 10.1016/S1570-0232(02)00168-X; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shilo L, 1999, AM J MED SCI, V317, P278, DOI 10.1097/00000441-199905000-00002; Shilo L, 2000, CHRONOBIOL INT, V17, P71, DOI 10.1081/CBI-100101033	25	37	38	0	0	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								237	10.3389/fneur.2014.00237			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QW	WOS:000209629300223	25477861	gold, Green Published			2022-02-06	
J	Spitz, G; Maller, JJ; Ng, A; O'Sullivan, R; Ferris, NJ; Ponsford, JL				Spitz, Gershon; Maller, Jerome J.; Ng, Amanda; O'Sullivan, Richard; Ferris, Nicholas J.; Ponsford, Jennie L.			Detecting Lesions after Traumatic Brain Injury Using Susceptibility Weighted Imaging: A Comparison with Fluid-Attenuated Inversion Recovery and Correlation with Clinical Outcome	JOURNAL OF NEUROTRAUMA			English	Article						cognition; magnetic resonance imaging; susceptibility-weighted imaging; traumatic brain injury	DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; WHITE-MATTER; MRI; CT; CHILDREN; STEM	The development and utilization of newer neuroimaging modalities provides the capability to more accurately detect the extent of pathology after TBI. The current study examined the ability of susceptibility-weighted imaging (SWI) to detect lesions after TBI as well as the relationship to subsequent clinical outcome. The performance of SWI was compared to that of fluid-attenuated inversion recovery (FLAIR). This study comprised 79 individuals with mild-to-severe TBI, 38 of whom completed neuropsychological tests of attention, working memory, processing speed, memory, and executive functions. SWI was found to quantify a greater lesion volume over the entire brain, specifically in frontal, central, limbic, subcortical gray, and parietal brain regions, than did FLAIR. Moreover, SWI was able to identify TBI-related lesions in almost one third of patients for whom FLAIR was unable to detect any lesions. Greater overall SWI volume, as well as frontal SWI volume, was found to relate to the severity of TBI. Conversely, no association was found between FLAIR lesion volume and injury severity. In addition, there was some evidence that higher lesion volume, for both SWI and FLAIR, were associated with poorer memory as well as processing speed impairment. This study suggests that SWI may provide additional sensitivity in the detection of lesions after TBI. Consequently, this imaging sequence may provide a more accurate representation of the severity of individuals' injuries and their subsequent neuropsychological outcomes.	[Spitz, Gershon; Ponsford, Jennie L.] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Spitz, Gershon; Ponsford, Jennie L.] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Maller, Jerome J.] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Maller, Jerome J.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [Ng, Amanda; Ferris, Nicholas J.] Monash Univ, Melbourne, Vic 3004, Australia; Monash Univ, Monash E Res Ctr, Melbourne, Vic 3004, Australia; [Ng, Amanda] Victorian Life Sci Computat Initiat, Life Sci Computat Ctr, Melbourne, Vic, Australia; [O'Sullivan, Richard] Epworth Med Fdn, Healthcare Imaging Serv, Melbourne, Vic, Australia		Spitz, G (corresponding author), Monash Univ, Sch Psychol & Psychiat, Bldg 17,Clayton Campus,Wellington Rd, Clayton, Vic 3800, Australia.	Gershon.Spitz@monash.edu	Spitz, Gershon/H-7755-2014; Maller, Jerome J/H-4963-2014	Spitz, Gershon/0000-0002-7810-1480; Maller, Jerome J/0000-0003-4685-1508			[Anonymous], 2008, AN SOFTW VERS 9 0 AN; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; BADDELEY A, 1994, DOORS PEOPLE; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Benton AL, 1994, MULTILINGUAL APHASIA; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burgess P.W., 1997, HAYLING BRIXTON TEST; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Coughhlan AK, 2007, BIRT MEMORY INFORM P; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Matsukawa H, 2011, ACTA NEUROCHIR, V153, P1687, DOI 10.1007/s00701-011-1002-9; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Mori S, 2005, MRI ATLAS HUMAN WHIT; OEHLER MC, 1995, AM J NEURORADIOL, V16, P1135; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reitan R, 1988, HALSTEAD REITAN NEUR; Rorden C, 2007, J COGNITIVE NEUROSCI, V19, P1081, DOI 10.1162/jocn.2007.19.7.1081; Rorden C, 2012, NEUROIMAGE, V61, P957, DOI 10.1016/j.neuroimage.2012.03.020; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith, 1973, SYMBOL DIGIT MODALIT; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Tong K., 2011, SUSCEPTIBILITY WEIGH; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; Wu Z, 2010, AM J NEURORADIOL, V31, P1302, DOI 10.3174/ajnr.A2022; Yao B, 2009, NEUROIMAGE, V44, P1259, DOI 10.1016/j.neuroimage.2008.10.029; [No title captured]	60	37	39	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2038	2050		10.1089/neu.2013.3021			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500005	23952803				2022-02-06	
J	Pretz, CR; Dams-O'Connor, K				Pretz, Christopher R.; Dams-O'Connor, Kristen			Longitudinal Description of the Glasgow Outcome Scale-Extended for Individuals in the Traumatic Brain Injury Model Systems National Database: A National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Longitudinal studies; Outcome assessment (health care); Rehabilitation	MULTICENTER; PREDICTORS	Objective: To comprehensively describe the temporal patterns of global outcome after traumatic brain injury (TBI) in the Traumatic Brain Injury Model Systems National Database (TBIMS NDB). Design: Longitudinal prospective cohort study. Setting: TBI Model Systems centers. Participants: Patients (N=3870) >= 16 years of age with moderate or severe TBI enrolled in the TBIMS NDB. Interventions: None. Main Outcome Measure: Glasgow Outcome Scale-Extended (GOS-E). Results: The trajectory of the GOS-E scores is best described with a model of quadratic change, in which scores initially increase and peak approximately 10 years after the first GOS-E assessment, and then decrease. Change occurs most rapidly in the initial and final years of the timeline. There was significant Variability in each growth parameter (P<.05). A reduced multilevel model was built, including all covariates (age at first GOS-E assessment, FIM, race, sex, rehabilitation length of stay) that related significantly to the growth parameters. An interactive tool was created to generate individual level trajectories based on various combinations of covariate values. Results provide an individual level account of the chronological progression of TBI outcomes, as measured by the GOS-E. Conclusions: Individual growth curve analysis is a statistically rigorous approach to describe temporal change with respect to the GOS-E at the individual level for participants within the TBIMS NDB. Results indicated that, for individuals in the TBIMS NDB as a group, functional status as measured by the GOS-E initially improves, plateaus, and then begins to decline. Factors such as age at first GOS-E assessment, race, FIM score at rehabilitation admission, and rehabilitation length of stay were found to influence baseline GOS-E scores, as well as the rate and extent of both improvement and decline over time. Additional research may be required to determine the generalizability of these findings and the usefulness of this tool for clinical applications. Archives of Physical Medicine and Rehabilitation 2013;94:2486-93 (C) 2013 by the American Congress of Rehabilitation Medicine	[Pretz, Christopher R.] Craig Hosp, Englewood, CO 80132 USA; [Pretz, Christopher R.] Traumat Brain Injury Natl Stat & Data Ctr, Englewood, CO 80132 USA; [Dams-O'Connor, Kristen] Mt Sinai Sch Med, New York, NY USA		Pretz, CR (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80132 USA.	cpretz@craighospital.org			Traumatic Brain Injury Model Systems National Data and Statistical Center; National Institute on Disability and Rehabilitation Research [H133A110006, H133A120084]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	Supported by the Traumatic Brain Injury Model Systems National Data and Statistical Center, National Institute on Disability and Rehabilitation Research (grant no. H133A110006); and the National Institute on Disability and Rehabilitation Research-funded Traumatic Brain Injury Model System Center at the Mount Sinai Medical Center (grant no. H133A120084).	Arango-Lasprilla JC, 2010, ARCH PHYS MED REHAB, V91, P1495, DOI 10.1016/j.apmr.2010.07.010; Ashman TA, 2006, MT SINAI J MED, V73, P999; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Connelly J, 2006, DISABIL REHABIL, V28, P629, DOI 10.1080/09638280500276513; Dijkers MP, 2004, SERVICES MAY NOT BE, pE12; Faul M, 2010, TRAUMATIC BRAIN INJU; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hox J.J., 2002, MULTILEVEL ANAL TECH; JENNETT B, 1975, LANCET, V1, P480; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Norman G, 2010, ADV HEALTH SCI EDUC, V15, P625, DOI 10.1007/s10459-010-9222-y; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; [No title captured]	23	37	37	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2013	94	12					2486	2493		10.1016/j.apmr.2013.06.021			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	264UD	WOS:000327905600023	23838239	Green Accepted			2022-02-06	
J	Liu, S; Zhang, LX; Wu, QF; Wu, Q; Wang, T				Liu, Su; Zhang, Lixia; Wu, Qinfeng; Wu, Qi; Wang, Tong			Chemokine CCL2 Induces Apoptosis in Cortex Following Traumatic Brain Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						CCL2; Traumatic brain injury; Apoptosis; Chemokine	MONOCYTE CHEMOATTRACTANT PROTEIN-1; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS; TISSUE LOSS; EXPRESSION; MCP-1; RAT; CCR2; ASTROCYTES; CYTOKINE	The chemokine C-C motif ligand 2 (CCL2) is an important mediator of neuroinflammation. Released in response to acute injury, ischemia, and neurodegenerative disease, CCL2 binds primarily to the G-protein-coupled chemokine C-C motif receptor 2 (CCR2) to recruit inflammatory cells to sites of tissue damage. Inflammation is thought to have both beneficial and deleterious consequences following traumatic brain injury (TBI), so we investigated CCL2-CCR2 signaling during the post-TBI period to assess possible neurodegenerative and protective actions. Local TBI in adult rat cortex was induced by Feeney's weight-drop method, and the expression of CCL2 and CCR2 in the tissue around the contusion site was measured by real-time quantitative PCR. Both CCL2 and CCR2 mRNA levels were increased markedly for at least 10 days after injury, peaking on day 3. The CCL2 protein was mainly co-localized with the astroglial marker glial fibrillary acidic protein and CCR2 protein with the neuronal nuclear marker NeuN as revealed by double immunofluorescence staining. A selective CCR2 antagonist, RS504393, reduced TUNEL staining, a marker of apoptosis, and improved performance in the Morris water maze 3 days post-TBI, suggesting that CCL2-CCR2 signaling has deleterious effects on neuronal survival and learning. Targeting the CCL2-CCR2 pathway may provide a novel therapeutic approach for the treatment of TBI.	[Liu, Su] Nanjing Med Univ, Nanjing 210029, Jiangsu, Peoples R China; [Zhang, Lixia; Wang, Tong] Nanjing Med Univ, Affiliated Hosp 1, Dept Rehabil Med, Nanjing 210029, Jiangsu, Peoples R China		Wang, T (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Rehabil Med, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	wangtong60621@163.com					Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Banisadr G, 2005, J COMP NEUROL, V492, P178, DOI 10.1002/cne.20729; Berman JW, 1996, J IMMUNOL, V156, P3017; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Che XM, 2001, BRAIN RES, V902, P171, DOI 10.1016/S0006-8993(01)02328-9; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Galasso JM, 2000, EXP NEUROL, V165, P295, DOI 10.1006/exnr.2000.7466; Galindo LT, 2011, NEUROL RES INT, V2011, DOI 10.1155/2011/564089; Ge SJ, 2009, J MOL NEUROSCI, V39, P269, DOI 10.1007/s12031-009-9197-4; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Lian H, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-47; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; McNair ND, 1999, NURS CLIN N AM, V34, P637; Muessel MJ, 2002, MOL BRAIN RES, V103, P12, DOI 10.1016/S0169-328X(02)00158-4; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Semple BD, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-67; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SOZZANI S, 1994, J IMMUNOL, V152, P3615; Tang XQ, 2013, J MOL NEUROSCI, V49, P140, DOI 10.1007/s12031-012-9912-4; Thau-Zuchman O, 2012, J MOL NEUROSCI, V47, P166, DOI 10.1007/s12031-012-9706-8; Umehara F, 1996, ACTA NEUROPATHOL, V91, P343, DOI 10.1007/s004010050435; Van der Voorn P, 1999, AM J PATHOL, V154, P45, DOI 10.1016/S0002-9440(10)65249-2; Wain JH, 2002, CLIN EXP IMMUNOL, V127, P436, DOI 10.1046/j.1365-2249.2002.01764.x; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2010, DISCOV MED, V10, P434; Zhang ZJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-136	36	37	41	0	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	NOV	2013	51	3					1021	1029		10.1007/s12031-013-0091-8			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	235IH	WOS:000325710500044	23934512				2022-02-06	
J	Empey, PE; de Mendizabal, NV; Bell, MJ; Bies, RR; Anderson, KB; Kochanek, PM; Adelson, PD; Poloyac, SM				Empey, Philip E.; de Mendizabal, Nieves Velez; Bell, Michael J.; Bies, Robert R.; Anderson, Kacey B.; Kochanek, Patrick M.; Adelson, P. David; Poloyac, Samuel M.		Pediat TBI Consortium Hypothermia	Therapeutic Hypothermia Decreases Phenytoin Elimination in Children with Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						children; drug metabolism; hypothermia; phenytoin; pharmacokinetics; traumatic brain injury	MODERATE HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; CARDIAC-ARREST; PHARMACOKINETICS; METABOLISM; PHARMACODYNAMICS; FOSPHENYTOIN; NEUROTRAUMA	Objective: Preclinical and clinical studies have suggested that therapeutic hypothermia, while decreasing neurologic injury, may also lead to drug toxicity that may limit its benefit. Cooling decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data suggest that drug levels are elevated. Fosphenytoin is metabolized by cytochrome P450 2C, has a narrow therapeutic range, and is a commonly used antiepileptic medication. The objective of this study was to evaluate the impact of therapeutic hypothermia on phenytoin levels and pharmacokinetics in children with severe traumatic brain injury. Design: Pharmacokinetic analysis of subjects participating in a multicenter randomized phase III study of therapeutic hypothermia for severe traumatic brain injury. Setting: ICU at the Children's Hospital of Pittsburgh. Patients: Nineteen children with severe traumatic brain injury. Interventions: None. Measurements and Main Results: A sum of 121 total and 114 free phenytoin levels were evaluated retrospectively in 10 hypothermia-treated and nine normothermia-treated children who were randomized to 48 hours of cooling to 32-33 degrees C followed by slow rewarming or controlled normothermia. Drug dosing, body temperatures, and demographics were collected during cooling, rewarming, and posttreatment periods (8 d). A trend toward elevated free phenytoin levels in the hypothermia group (p = 0.051) to a median of 2.2 mg/L during rewarming was observed and was not explained by dosing differences. Nonlinear mixed-effects modeling incorporating both free and total levels demonstrated that therapeutic hypothermia specifically decreased the time-variant component of the maximum velocity of phenytoin metabolism (V-max) 4.6-fold (11.6-2.53 mg/hr) and reduced the overall V-max by similar to 50%. Simulations showed that the increased risk for drug toxicity extends many days beyond the end of the cooling period. Conclusions: Therapeutic hypothermia significantly reduces phenytoin elimination in children with severe traumatic brain injury leading to increased drug levels for an extended period of time after cooling. Pharmacokinetic interactions between hypothermia and medications should be considered when caring for children receiving this therapy.	[Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA; [de Mendizabal, Nieves Velez; Bies, Robert R.] Indiana Univ, Sch Med, Div Clin Pharmacol, Indianapolis, IN USA; [de Mendizabal, Nieves Velez; Bies, Robert R.] Indiana Univ, Indiana Clin & Translat Sci Inst, Indianapolis, IN 46204 USA; [Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Anderson, Kacey B.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Child Hlth, Div Neurosurg Childrens Neurosci, Phoenix, AZ USA		Poloyac, SM (corresponding author), 3501 Terrace St,807 Salk Hall, Pittsburgh, PA 15261 USA.	poloyac@pitt.edu	Adelson, David/W-2083-2019; Empey, Philip/L-9604-2019; Kochanek, Patrick M/D-2371-2015	Empey, Philip/0000-0001-7474-2339; Kochanek, Patrick M/0000-0002-2627-913X	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Indiana CTSI; NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS); Laerdal Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Integra Life Sciences; Codman; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM073031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, U01NS052478] Funding Source: NIH RePORTER	Dr. Empey received grant support from the National Institutes of Health (NIH). Dr. Bell received grant support from NIH. Dr. Bies has received grant support from Indiana CTSI through a gift of Eli Lilly and Company. He has received payment for lectures from NIGMS and has received travel reimbursements from Indiana CTSI, Uppsala University, and NIAID/NIDA. Dr. Poloyac received grant support from NIH and support for travel from the American College of Clinical Pharmacy. Dr. Kochanek received grant support from the Laerdal Foundation and National Institutes of Health and disclosed having United States provisional patents (Method of Inducing EPR Following Cardiopulmonary Arrest and Small Molecule Inhibitors of RNA Binding MOTIF (RBM) Proteins for the Treatment of Acute Cellular Injury) and a CMU Invention Disclosure (Validation of a Multiplex Biomarker Panel for Detection of Abusive Head Trauma in Well-Appearing Children Carnegie Mellon University, Center for Technology Transfer and Enterprise Creation). Dr. Adelson received grant support from NIH, Integra Life Sciences, and Codman and consulted for Tramatec.	Adams BD, 2006, J EMERG MED, V30, P75, DOI 10.1016/j.jemermed.2005.01.034; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Anderson BJ, 2005, PAEDIAT PERINAT DRUG, V6, P133; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; BAUER LA, 1983, CLIN PHARMACOKINET, V8, P545, DOI 10.2165/00003088-198308060-00006; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BOUCHER BA, 1991, CLIN PHARMACOL THER, V50, P487, DOI 10.1038/clpt.1991.173; Boucher BA, 1996, PHARMACOTHERAPY, V16, P777; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Davis Parke, 2012, ANDA 084349 DILANTIN; de Haan TR, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-45; de Toledo JS, 2010, PEDIATR CRIT CARE ME, V11, P439, DOI 10.1097/PCC.0b013e3181c510e9; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Empey PE, 2012, CRIT CARE MED, V40, P1221, DOI 10.1097/CCM.0b013e31823779f9; Frend V, 2007, CLIN NEUROPHARMACOL, V30, P362, DOI 10.1097/WNF.0b013e318059ae1c; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hostler D, 2010, DRUG METAB DISPOS, V38, P781, DOI 10.1124/dmd.109.031377; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McKindley DS, 1997, J CLIN PHARMACOL, V37, P129, DOI 10.1002/j.1552-4604.1997.tb04771.x; OMARA NB, 1995, CRIT CARE MED, V23, P1418, DOI 10.1097/00003246-199508000-00017; Pfizer Pharmaceuticals, 2011, DIL PHEN SOD; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Stowe CD, 2000, J CLIN PHARMACOL, V40, P1452; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; von Winckelmann SL, 2008, PHARMACOTHERAPY, V28, P1391, DOI 10.1592/phco.28.11.1391; VOZEH S, 1981, J PHARMACOKINET BIOP, V9, P131, DOI 10.1007/BF01068078; Zhou JQ, 2011, DRUG METAB DISPOS, V39, P2209, DOI 10.1124/dmd.111.040642; Zhou JQ, 2011, EXPERT OPIN DRUG MET, V7, P803, DOI 10.1517/17425255.2011.574127	40	37	38	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2013	41	10					2379	2387		10.1097/CCM.0b013e318292316c			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225AP	WOS:000324935000034	23896831	Green Accepted			2022-02-06	
J	Goodman, MD; Makley, AT; Campion, EM; Friend, LAW; Lentsch, AB; Pritts, TA				Goodman, Michael D.; Makley, Amy T.; Campion, Eric M.; Friend, Lou Ann W.; Lentsch, Alex B.; Pritts, Timothy A.			Preinjury alcohol exposure attenuates the neuroinflammatory response to traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Alcohol; Inflammation; Neuroinflammation	NEURON-SPECIFIC ENOLASE; ETHANOL; MODEL; MORTALITY; INTOXICATION; MODERATE; FLUID; BINGE; RATS; MICE	Background: Traumatic brain injury (TBI) initiates a neuroinflammatory response that increases the risk of TBI-related mortality. Acute alcohol intoxication at the time of TBI is associated with improved survival. Ethanol is recognized as a systemic immunomodulator that may also impart neuroprotection. The effects of alcohol on TBI-induced neuroinflammation, however, are unknown. We hypothesized that ethanol treatment prior to TBI may provide neuroprotection by diminishing the neuroinflammatory response to injury. Materials and methods: Mice underwent gavage with ethanol (EtOH) or water (H2O) prior to TBI. Animals were subjected to blunt TBI or sham injury (Sham). Posttraumatic rapid righting reflex (RRR) and apnea times were assessed. Cerebral and serum samples were analyzed by ELISA for inflammatory cytokine levels. Serum neuron-specific enolase (NSE), a biomarker of injury severity, was also measured. Results: Neurologic recovery from TBI was more rapid in H2O-treated mice compared with EtOH-treated mice. However, EtOH/TBI mice had a 4-fold increase in RRR time compared with EtOH/Sham, whereas H2O/TBI mice had a 15-fold increase in RRR time compared with H2O/Sham. Ethanol intoxication at the time of TBI significantly increased posttraumatic apnea time. Preinjury EtOH treatment was associated with reduced levels of proinflammatory cytokines IL-6, KC, MCP-1, and MIP-1 alpha post TBI. NSE was significantly increased post injury in the H2O/TBI group compared with H2O/Sham but was not significantly reduced by EtOH pretreatment. Conclusions: Alcohol treatment prior to TBI reduces the local neuroinflammatory response to injury. The decreased neurologic and inflammatory impact of TBI in acutely intoxicated patients may be responsible for improved clinical outcomes. (C) 2013 Elsevier Inc. All rights reserved.	[Goodman, Michael D.; Makley, Amy T.; Campion, Eric M.; Friend, Lou Ann W.; Lentsch, Alex B.; Pritts, Timothy A.] Univ Cincinnati, Dept Surg, Coll Med, Inst Mil Med, Cincinnati, OH 45267 USA		Goodman, MD (corresponding author), Univ Cincinnati, Dept Surg, Mail Locat 0558,231 Albert Sabin Way, Cincinnati, OH 45267 USA.	md-goodman@hotmail.com		Pritts, Timothy/0000-0003-2495-3255	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM08478]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008478] Funding Source: NIH RePORTER	This work was supported in part by awards from NIH training grant T32 GM08478.	[Anonymous], 2001, TRAUM BRAIN INJ US R, V2004; Carson EJ, 1996, ALCOHOL CLIN EXP RES, V20, P132, DOI 10.1111/j.1530-0277.1996.tb01055.x; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Finkelstein E., 2006, INCIDENCE EC BURDEN; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greiffenstein P, 2007, ALCOHOL CLIN EXP RES, V31, P704, DOI 10.1111/j.1530-0277.2007.00355.x; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Livy DJ, 2003, ALCOHOL, V29, P165, DOI 10.1016/S0741-8329(03)00025-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Szabo G, 2009, ALCOHOL CLIN EXP RES, V33, P220, DOI 10.1111/j.1530-0277.2008.00842.x; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Vickery CD, 2008, ARCH PHYS MED REHAB, V89, P48, DOI 10.1016/j.apmr.2007.07.047; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	31	37	39	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2013	184	2					1053	1058		10.1016/j.jss.2013.04.058			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	215XE	WOS:000324243500055	23721933	Green Accepted			2022-02-06	
J	McGurk, SR; Mueser, KT; Cicerone, KD; Silverstein, SM; Myers, R; Bell, MD; Covell, NH; Drake, RE; Medalia, A; Bellack, AS; Essock, SM				McGurk, Susan R.; Mueser, Kim T.; Cicerone, Keith D.; Silverstein, Steven M.; Myers, Robert; Bell, Morris D.; Covell, Nancy H.; Drake, Robert E.; Medalia, Alice; Bellack, Alan S.; Essock, Susan M.			Mental Health System Funding of Cognitive Enhancement Interventions for Schizophrenia: Summary and Update of the New York Office of Mental Health Expert Panel and Stakeholder Meeting	PSYCHIATRIC REHABILITATION JOURNAL			English	Article						cognitive remediation; cognitive rehabilitation; severe mental illness; psychiatric rehabilitation; traumatic brain injury		Topic: A growing research literature indicates that cognitive enhancement (CE) interventions for people with schizophrenia can improve cognitive functioning and may benefit psychosocial functioning (e.g., competitive employment, quality of social relationships). Debate continues regarding the strength of evidence for CE and related policy implications, such as the appropriateness of funding CE services. Purpose: This paper summarizes and updates a meeting of experts and stakeholders convened in 2008 by the New York Office of Mental Health to review evidence on the impact of CE for people with schizophrenia and other serious mental illnesses, and addresses whether the evidence base for CE interventions is sufficient to warrant funding. Sources Used: Specific recommendations based on the extant literature are provided regarding the structure and components of CE programs that should be present in order to improve cognitive and psychosocial outcomes and therefore merit consideration of funding. Conclusions and Implications for Practice: These recommendations may serve as a starting point in developing standards for CE programs. Establishing evidence-based practice standards for implementing CE interventions for people with serious mental illnesses may facilitate dissemination of programs that have the greatest potential for improving individuals' functional outcomes while minimizing incremental costs associated with providing CE services. Important open questions include how the performance of CE programs should be monitored and which individuals might be expected to benefit from CE as evidenced by improved functioning in their everyday lives.	[McGurk, Susan R.; Mueser, Kim T.] Boston Univ, Ctr Psychiat Rehabil, Dept Occupat Therapy Psychol & Psychiat, Boston, MA 02215 USA; [Covell, Nancy H.] New York State Psychiat Inst & Hosp, Dept Mental Hlth Serv & Policy Res, New York, NY 10032 USA; [Cicerone, Keith D.] Univ Med & Dent, Robert Wood Johnson Med Sch Med, JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA; [Myers, Robert] Dartmouth Med Sch, Dartmouth Psychiat Res Ctr, Dept Psychiat & Community & Family Med, Dartmouth, NS, Canada; [Silverstein, Steven M.] Rutgers Univ Behav HealthCare, UMDNJ Univ Behav HealthCare, Violence Inst NJ, Div Schizophrenia Res, Piscataway, NJ USA; [Medalia, Alice] Columbia Univ, Ctr Med, Dept Psychiat, New York, NY USA; [Bellack, Alan S.] Univ Maryland, Sch Med, Bethesda, MD USA; [Bell, Morris D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; [Essock, Susan M.] Columbia Univ, Dept Psychiat, New York, NY USA; [Essock, Susan M.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA		McGurk, SR (corresponding author), Boston Univ, Ctr Psychiat Rehabil, 940 Commonwealth Ave West, Boston, MA 02215 USA.	mcgurk@bu.edu	Drake, Robert/AAS-3310-2020				Addington J, 2008, SCHIZOPHR RES, V99, P176, DOI 10.1016/j.schres.2007.07.004; Allen DN, 2007, SCHIZOPHR RES, V93, P325, DOI 10.1016/j.schres.2007.02.008; Bell M, 2003, ACTA PSYCHIAT SCAND, V108, P101, DOI 10.1034/j.1600-0447.2003.00090.x; Bell M, 2001, ARCH GEN PSYCHIAT, V58, P763, DOI 10.1001/archpsyc.58.8.763; Bell M, 2009, SCHIZOPHRENIA BULL, V35, P738, DOI 10.1093/schbul/sbm169; Bell MD, 2008, SCHIZOPHR RES, V105, P18, DOI 10.1016/j.schres.2008.06.026; Bell MD, 2005, J REHABIL RES DEV, V42, P829, DOI 10.1682/JRRD.2005.03.0061; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; Bracy O., 1995, COGREHAB SOFTWARE; Brenner HD, 1994, INTEGRATED PSYCHOL T; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cognitive Remediation Expert Working Group, 2012, CREW M SCHIZ INT RES; Couture SM, 2006, SCHIZOPHRENIA BULL, V32, pS44, DOI 10.1093/schbul/sbl029; Dickinson D, 2010, AM J PSYCHIAT, V167, P170, DOI 10.1176/appi.ajp.2009.09020264; Dixon LB, 2010, SCHIZOPHRENIA BULL, V36, P48, DOI 10.1093/schbul/sbp115; Drake RE., 2012, IPS SUPPORTED EMPLOY, DOI [10.1093/acprof:oso/9780199734016.001.0001, DOI 10.1093/ACPROF:OSO/9780199734016.001.0001]; Eack SM, 2009, PSYCHIAT SERV, V60, P1468, DOI 10.1176/appi.ps.60.11.1468; Fett AKJ, 2011, NEUROSCI BIOBEHAV R, V35, P573, DOI 10.1016/j.neubiorev.2010.07.001; Fisher M, 2013, ANNU REV CLIN PSYCHO, V9, P435, DOI 10.1146/annurev-clinpsy-032511-143134; Fisher M, 2009, AM J PSYCHIAT, V166, P805, DOI 10.1176/appi.ajp.2009.08050757; Fiszdon JM, 2006, SCHIZOPHR RES, V87, P261, DOI 10.1016/j.schres.2006.04.011; Green MF, 2004, SCHIZOPHR RES, V72, P1, DOI 10.1016/j.schres.2004.09.006; Green MF, 1996, AM J PSYCHIAT, V153, P321; Greig TC, 2007, SCHIZOPHR RES, V96, P156, DOI 10.1016/j.schres.2007.07.003; HEATON R, 1994, ARCH GEN PSYCHIAT, V51, P469; HEINRICHS DW, 1984, SCHIZOPHRENIA BULL, V10, P388, DOI 10.1093/schbul/10.3.388; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; Hoe M, 2012, PSYCHOL MED, V42, P2287, DOI 10.1017/S0033291712000578; Hogarty GE, 2004, ARCH GEN PSYCHIAT, V61, P866, DOI 10.1001/archpsyc.61.9.866; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; KESSLER RC, 1995, AM J PSYCHIAT, V152, P1026; Kidd SA, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/715176; Killackey E, 2008, BRIT J PSYCHIAT, V193, P114, DOI 10.1192/bjp.bp.107.043109; Krabbendam L, 2003, PSYCHOPHARMACOLOGY, V169, P376, DOI 10.1007/s00213-002-1326-5; Kurtz MM, 2008, J CONSULT CLIN PSYCH, V76, P491, DOI 10.1037/0022-006X.76.3.491; Kurtz MM, 2007, SCHIZOPHR RES, V89, P251, DOI 10.1016/j.schres.2006.09.001; Kurtz MM, 2012, SCHIZOPHRENIA BULL, V38, P1092, DOI 10.1093/schbul/sbr036; Kurtz MM, 2011, CLIN PSYCHOL REV, V31, P663, DOI 10.1016/j.cpr.2011.02.008; Kurtz MM, 2005, SCHIZOPHR RES, V74, P15, DOI 10.1016/j.schres.2004.07.005; Kurtz MM, 2001, NEUROPSYCHOL REV, V11, P197, DOI 10.1023/A:1012953108158; Liberman RP, 2007, J MENT HEALTH, V16, P595, DOI DOI 10.1080/09638230701494902; Lindenmayer JP, 2008, PSYCHIAT SERV, V59, P241, DOI 10.1176/appi.ps.59.3.241; Lindenmayer JP, 2013, SCHIZOPHRENIA BULL, V39, P507, DOI 10.1093/schbul/sbs120; MacCabe JH, 2013, JAMA PSYCHIAT, V70, P261, DOI 10.1001/2013.jamapsychiatry.43; McGurk SR, 2005, SCHIZOPHRENIA BULL, V31, P898, DOI 10.1093/schbul/sbi037; McGurk SR, 2004, SCHIZOPHR RES, V70, P147, DOI 10.1016/j.schres.2004.01.009; McGurk SR, 2003, PSYCHIAT SERV, V54, P1129, DOI 10.1176/appi.ps.54.8.1129; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; McGurk SR, 2007, AM J PSYCHIAT, V164, P437, DOI 10.1176/appi.ajp.164.3.437; McGurk SR, 2006, PSYCHIAT SERV, V57, P1421, DOI 10.1176/appi.ps.57.10.1421; McGurk SR, 2008, AM J PSYCHIATR REHAB, V11, P90, DOI 10.1080/15487760701853136; McGurk SR, 2009, SCHIZOPHRENIA BULL, V35, P319, DOI 10.1093/schbul/sbn182; Medalia A, 2005, SCHIZOPHRENIA BULL, V31, P942, DOI 10.1093/schbul/sbi045; Medalia A., 2009, COGNITIVE REMEDIATIO; Medalia A, 2011, SCHIZOPHRENIA BULL, V37, pS122, DOI 10.1093/schbul/sbr063; Medalia A, 2009, NEUROPSYCHOL REV, V19, P353, DOI 10.1007/s11065-009-9097-y; Mueser K. T., 1993, BEHAV THERAPIST, V16, P218; Mueser KT, 2012, PSYCHIATR REHABIL J, V35, P417, DOI 10.1037/h0094573; MUESER KT, 1991, PSYCHIAT RES, V37, P281, DOI 10.1016/0165-1781(91)90064-V; Mueser KT, 2001, SCHIZOPHRENIA BULL, V27, P281, DOI 10.1093/oxfordjournals.schbul.a006874; Nuechterlein KH, 2008, PSYCHIATR REHABIL J, V31, P340, DOI 10.2975/31.4.2008.340.349; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Patterson TL, 2001, SCHIZOPHR RES, V48, P351, DOI 10.1016/S0920-9964(00)00109-2; Penn DL, 1997, PSYCHOL BULL, V121, P114, DOI 10.1037/0033-2909.121.1.114; Pilling S, 2002, PSYCHOL MED, V32, P783, DOI 10.1017/S0033291702005640; Pitschel-Walz G, 2001, SCHIZOPHRENIA BULL, V27, P73, DOI 10.1093/oxfordjournals.schbul.a006861; Ritsner M, 2005, QUAL LIFE RES, V14, P1693, DOI 10.1007/s11136-005-2816-9; Roberts DL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/742106; Sartory G, 2005, SCHIZOPHR RES, V75, P219, DOI 10.1016/j.schres.2004.10.004; Sergi MJ, 2007, SCHIZOPHR RES, V90, P316, DOI 10.1016/j.schres.2006.09.028; Silverstein SM, 1998, PSYCHIAT QUART, V69, P95, DOI 10.1023/A:1024758402191; Silverstein SM, 2005, PSYCHOL MED, V35, P829, DOI 10.1017/S0033291704003356; Silverstein SM, 1998, PSYCHIAT QUART, V69, P169, DOI 10.1023/A:1022197109569; SILVERSTEIN SM, 1994, CONTINUUM, V1, P251; Silverstein SM, 2009, SCHIZOPHRENIA BULL, V35, P222, DOI 10.1093/schbul/sbm150; Bell MS, 2007, NY TIMES BK REV, P6; Smith TE, 1999, AM J PSYCHIAT, V156, P1817; Spaulding WD, 1999, SCHIZOPHRENIA BULL, V25, P275, DOI 10.1093/oxfordjournals.schbul.a033378; Spaulding WD, 1999, SCHIZOPHRENIA BULL, V25, P657, DOI 10.1093/oxfordjournals.schbul.a033409; Statucka M, 2013, PSYCHIAT RES, V206, P125, DOI 10.1016/j.psychres.2012.12.005; Twamley EW, 2012, J CLIN PSYCHIAT, V73, P1212, DOI 10.4088/JCP.12m07686; Twamley EW, 2003, SCHIZOPHRENIA BULL, V29, P359, DOI 10.1093/oxfordjournals.schbul.a007011; Vauth R, 2005, SCHIZOPHRENIA BULL, V31, P55, DOI 10.1093/schbul/sbi013; Velligan DI, 2008, SCHIZOPHR RES, V102, P312, DOI 10.1016/j.schres.2008.02.005; Wykes T, 1999, SCHIZOPHRENIA BULL, V25, P291, DOI 10.1093/oxfordjournals.schbul.a033379; Wykes T, 2005, COGNITIVE REMEDIATIO; Wykes T, 2008, SCHIZOPHRENIA BULL, V34, P523, DOI 10.1093/schbul/sbm114; Wykes T, 2011, SCHIZOPHRENIA BULL, V37, pS80, DOI 10.1093/schbul/sbr064; Wykes T, 2011, AM J PSYCHIAT, V168, P472, DOI 10.1176/appi.ajp.2010.10060855; Wykes T, 2009, SCHIZOPHR RES, V113, P252, DOI 10.1016/j.schres.2009.05.025; Zammit S, 2004, ARCH GEN PSYCHIAT, V61, P354, DOI 10.1001/archpsyc.61.4.354	94	37	40	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1095-158X	1559-3126		PSYCHIATR REHABIL J	Psychiatr. Rehabil. J.	SEP	2013	36	3					133	145		10.1037/prj0000020			13	Psychiatry; Rehabilitation	Social Science Citation Index (SSCI)	Psychiatry; Rehabilitation	V36SU	WOS:000209231800002	24059629				2022-02-06	
J	De Beaumont, L; Tremblay, S; Henry, LC; Poirier, J; Lassonde, M; Theoret, H				De Beaumont, Louis; Tremblay, Sebastien; Henry, Luke C.; Poirier, Judes; Lassonde, Maryse; Theoret, Hugo			Motor system alterations in retired former athletes: the role of aging and concussion history	BMC NEUROLOGY			English	Article						Motor learning; Retired athletes; Concussion; Motor cortex; Magnetic resonance spectroscopy	CHRONIC TRAUMATIC ENCEPHALOPATHY; MENTAL-STATE-EXAMINATION; METABOLITE CONCENTRATIONS; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; SPORTS CONCUSSION; LONG-TERM; BRAIN; NEUROTRANSMISSION; GLUTAMATE	Background: Retired athletes with a history of sports concussions experience cognitive and motor declines with aging, and the risk of severe neurodegenerative conditions is magnified in this population. The present study investigated the effects of aging on motor system metabolism and function in former university-level athletes who sustained their last concussion several decades prior to testing. Methods: To test the hypothesis that age and remote concussions induce functional as well as metabolic alterations of the motor system, we used proton magnetic resonance spectroscopy to detect metabolic abnormalities in the primary motor cortex and the serial reaction time task (SRTT) to evaluate motor learning. Results: Our results indicate that motor learning is significantly reduced in former concussed athletes relative to controls. In addition, glutamate/H2O ratio in M1 was disproportionately reduced in concussed athletes with advancing age and was found to strongly correlate with motor learning impairments. Conclusion: Findings from this study provide evidence that the acquisition of a repeated motor sequence is compromised in the aging concussed brain and that its physiological underpinnings could implicate disproportionate reductions of M1 glutamate concentrations with advancing age.	[De Beaumont, Louis; Tremblay, Sebastien; Henry, Luke C.; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Ctr Rech Neuropsychol & Cognit CERNEC, Montreal, PQ, Canada; [Lassonde, Maryse; Theoret, Hugo] CHU St Justine, Montreal, PQ, Canada; [De Beaumont, Louis; Poirier, Judes] Douglas Mental Hlth Univ Inst, Verdun, PQ H4H 1R3, Canada; [De Beaumont, Louis; Tremblay, Sebastien; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada		Theoret, H (corresponding author), Univ Montreal, Ctr Rech Neuropsychol & Cognit CERNEC, Montreal, PQ, Canada.	hugo.theoret@umontreal.ca		Theoret, Hugo/0000-0002-7458-8797; Tremblay, Sebastien/0000-0001-6251-9797	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Fonds de la recherche en sante du Quebec (FRSQ)Fonds de la Recherche en Sante du Quebec	We want to thank team physician Dr. Suzanne Leclerc for her help in recruiting athletes as well as providing concussion history information. This research was funded by grants from the Canadian Institute of Health Research (CIHR) awarded to ML and HT and by support from the Fonds de la recherche en sante du Quebec (FRSQ) awarded to HT and ML.	Abel EL, 2007, PERCEPT MOTOR SKILL, V104, P1251, DOI 10.2466/PMS.104.4.1251-1254; BENEDETTI MS, 1990, J NEUR TR S, V29, P259; BRAEKHUS A, 1995, J AM GERIATR SOC, V43, P656, DOI 10.1111/j.1532-5415.1995.tb07201.x; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Chantal S, 2004, BRAIN RES, V1003, P26, DOI 10.1016/j.brainres.2003.11.074; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; COBO M, 1992, NEUROBIOL AGING, V13, P705, DOI 10.1016/0197-4580(92)90093-D; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.ne.11.030188.000425; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Daselaar SM, 2003, NEUROBIOL AGING, V24, P1013, DOI 10.1016/S0197-4580(03)00030-7; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kaiser LG, 2005, NEUROBIOL AGING, V26, P665, DOI 10.1016/j.neurobiolaging.2004.07.001; Kelly JP, 1997, NEUROLOGY, V48, P581; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; MCENTEE WJ, 1993, PSYCHOPHARMACOLOGY, V111, P391, DOI 10.1007/BF02253527; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Minati L, 2010, J MED PHYS, V35, P154, DOI 10.4103/0971-6203.62128; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Perez MA, 2007, J NEUROSCI, V27, P1045, DOI 10.1523/JNEUROSCI.4128-06.2007; Petersen R C, 1997, Int Psychogeriatr, V9 Suppl 1, P65, DOI 10.1017/S1041610297004717; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Scarmeas N, 2002, NEUROLOGY, V59, P773, DOI 10.1212/WNL.59.5.773; Schmidt W J, 1992, J Neural Transm Suppl, V38, P65; Segovia G, 2001, MECH AGEING DEV, V122, P1, DOI 10.1016/S0047-6374(00)00225-6; Spencer DC, 2003, NEUROLOGY, V60, P1194, DOI 10.1212/01.WNL.0000052822.22994.86; Willingham DB, 2000, MEM COGNITION, V28, P366, DOI 10.3758/BF03198552; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	47	37	37	1	62	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	AUG 26	2013	13								109	10.1186/1471-2377-13-109			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	208YX	WOS:000323720100001	23972282	gold, Green Published			2022-02-06	
J	Kawai, N; Kawanishi, M; Kudomi, N; Maeda, Y; Yamamoto, Y; Nishiyama, Y; Tamiya, T				Kawai, Nobuyuki; Kawanishi, Masahiko; Kudomi, Nobuyuki; Maeda, Yukito; Yamamoto, Yuka; Nishiyama, Yoshihiro; Tamiya, Takashi			Detection of brain amyloid beta deposition in patients with neuropsychological impairment after traumatic brain injury: PET evaluation using Pittsburgh Compound-B	BRAIN INJURY			English	Article						Amyloid beta (beta); neuropsychological impairment; Pittsburgh Compound B; positron emission tomography; traumatic brain injury	POSITRON-EMISSION-TOMOGRAPHY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; HEAD-INJURY; SENILE PLAQUES; AXONAL INJURY; RISK-FACTOR; ACCUMULATION; ASSOCIATION; CEREBELLUM	Objective: Traumatic brain injury (TBI) is an epigenetic risk factor for Alzheimer's disease (AD) and amyloid beta (A beta) deposition is observed histopathologically in the traumatized brain. This study was conducted to detect cerebral Ab deposition using amyloid positron emission tomography (PET) in patients with neuropsychological impairment after TBI. Methods: Twelve patients with post-traumatic neuropsychological impairment (11 men and one woman, age range = 21-78 years) were examined using Pittsburgh Compound B (C-11-PIB) PET at the chronic stage after TBI (range 5-129 months). Results: C-11-PIB was positive in three patients and negative in the other nine patients. There was no correlation between C-11-PIB deposition and the severity of injury; initial CT findings; elapsed time from the injury; and neuropsychological test scores. Conclusions: The absence of A beta deposition in many patients with chronic neuropsychological impairment after TBI does not support the premise that A beta pathology progresses over time in the traumatized brain. Early and sequential C-11-PIB PET examination may clarify the time course of A beta deposition in the traumatized brain and the relationship between traumatic brain insult and subsequent neuropsychological impairment.	[Kawai, Nobuyuki; Kawanishi, Masahiko; Tamiya, Takashi] Kagawa Univ, Dept Neurol Surg, Fac Med, Kagawa 7610793, Japan; [Kudomi, Nobuyuki] Kagawa Univ, Dept Med Phys, Fac Med, Kagawa 7610793, Japan; [Maeda, Yukito] Kagawa Univ Hosp, Dept Clin Radiol, Kagawa, Japan; [Yamamoto, Yuka; Nishiyama, Yoshihiro] Kagawa Univ, Dept Radiol, Fac Med, Kagawa 7610793, Japan		Kawai, N (corresponding author), Kagawa Univ, Dept Neurol Surg, Fac Med, 1750-1 Miki Cho, Kagawa 7610793, Japan.	nobu@med.kagawa-u.ac.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; General Insurance Association of Japan	This work was supported in parts by grants from the Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science and the General Insurance Association of Japan. The authors report no conflicts of interests.	Bacskai BJ, 2007, ARCH NEUROL-CHICAGO, V64, P431, DOI 10.1001/archneur.64.3.431; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2008, BRAIN, V131, P1630, DOI 10.1093/brain/awn016; JOACHIM CL, 1989, AM J PATHOL, V135, P309; Kadir A, 2011, BRAIN, V134, P301, DOI 10.1093/brain/awq349; Kawai N, 2010, J NEUROTRAUM, V27, P2131, DOI 10.1089/neu.2010.1464; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Kraus J, 2000, HEAD INJURY, P1; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mormino EC, 2012, NEUROIMAGE, V59, P1152, DOI 10.1016/j.neuroimage.2011.07.098; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; YAMAGUCHI H, 1989, ACTA NEUROPATHOL, V77, P314, DOI 10.1007/BF00687584; Yaqub M, 2008, NEUROIMAGE, V42, P76, DOI 10.1016/j.neuroimage.2008.04.251	31	37	37	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2013	27	9					1026	1031		10.3109/02699052.2013.794963			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	180HZ	WOS:000321586100006	23662609				2022-02-06	
J	Bracchi-Ricard, V; Lambertsen, KL; Ricard, J; Nathanson, L; Karmally, S; Johnstone, J; Ellman, DG; Frydel, B; McTigue, DM; Bethea, JR				Bracchi-Ricard, Valerie; Lambertsen, Kate L.; Ricard, Jerome; Nathanson, Lubov; Karmally, Shaffiat; Johnstone, Joshua; Ellman, Ditte G.; Frydel, Beata; McTigue, Dana M.; Bethea, John R.			Inhibition of astroglial NF-kappaB enhances oligodendrogenesis following spinal cord injury	JOURNAL OF NEUROINFLAMMATION			English	Article						NF-kappaB; Spinal cord injury; Astrocyte; Oligodendrocyte; Microglia; CXCR4; TNFR2; Toll-like receptor	TUMOR-NECROSIS-FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CEREBRAL-ARTERY OCCLUSION; CHEMOKINE RECEPTOR CXCR4; IN-SITU HYBRIDIZATION; TRANSGENIC INHIBITION; FUNCTIONAL RECOVERY; EXPRESSION; INFLAMMATION; REMYELINATION	Background: Astrocytes are taking the center stage in neurotrauma and neurological diseases as they appear to play a dominant role in the inflammatory processes associated with these conditions. Previously, we reported that inhibiting NF-kappa B activation in astrocytes, using a transgenic mouse model (GFAP-I kappa B alpha-dn mice), results in improved functional recovery, increased white matter preservation and axonal sparing following spinal cord injury (SCI). In the present study, we sought to determine whether this improvement, due to inhibiting NF-kappa B activation in astrocytes, could be the result of enhanced oligodendrogenesis in our transgenic mice. Methods: To assess oligodendrogenesis in GFAP-I kappa B alpha-dn compared to wild-type (WT) littermate mice following SCI, we used bromodeoxyuridine labeling along with cell-specific immuno-histochemistry, confocal microscopy and quantitative cell counts. To further gain insight into the underlying molecular mechanisms leading to increased white matter, we performed a microarray analysis in naive and 3 days, 3 and 6 weeks following SCI in GFAP-I kappa B alpha-dn and WT littermate mice. Results: Inhibition of astroglial NF-kappa B in GFAP-I kappa B alpha-dn mice resulted in enhanced oligodendrogenesis 6 weeks following SCI and was associated with increased levels of myelin proteolipid protein compared to spinal cord injured WT mice. The microarray data showed a large number of differentially expressed genes involved in inflammatory and immune response between WT and transgenic mice. We did not find any difference in the number of microglia/leukocytes infiltrating the spinal cord but did find differences in their level of expression of toll-like receptor 4. We also found increased expression of the chemokine receptor CXCR4 on oligodendrocyte progenitor cells and mature oligodendrocytes in the transgenic mice. Finally TNF receptor 2 levels were significantly higher in the transgenic mice compared to WT following injury. Conclusions: These studies suggest that one of the beneficial roles of blocking NF-kappa B in astrocytes is to promote oligodendrogenesis through alteration of the inflammatory environment.	[Bracchi-Ricard, Valerie; Lambertsen, Kate L.; Ricard, Jerome; Karmally, Shaffiat; Johnstone, Joshua; Frydel, Beata; Bethea, John R.] Univ Miami, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Lambertsen, Kate L.; Ellman, Ditte G.] Univ Southern Denmark, Inst Mol Med, Dept Neurobiol Res, DK-5000 Odense C, Denmark; [Nathanson, Lubov] Univ Miami, Miller Sch Med, Dept Mol & Cellular Med, Miami, FL 33136 USA; [McTigue, Dana M.] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Dept Neurosci, Columbus, OH 43210 USA		Bethea, JR (corresponding author), Univ Miami, Miami Project Cure Paralysis, Miami, FL 33136 USA.	JBethea@miami.edu	Lambertsen, Kate L./I-8676-2014; Nathanson, Lubov/ABC-2642-2021	Lambertsen, Kate L./0000-0001-9276-4902; Ricard, Jerome/0000-0002-9019-4165; Nathanson, Lubov/0000-0003-1038-9083; , Ditte/0000-0001-6771-8672	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS051709-06]; Danish MRCDanish Medical Research Council; Carlsberg FoundationCarlsberg Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051709] Funding Source: NIH RePORTER	This work was supported by NIH grants NS051709-06 (JRB) and The Danish MRC and the Carlsberg Foundation (KLL). The authors acknowledge the technical assistance provided by technicians Karen Rich, Inge Holst Nielsen, Dorte Lyholmer and Louise Lykkemark.	Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Bajetto A, 2001, FRONT NEUROENDOCRIN, V22, P147, DOI 10.1006/frne.2001.0214; Banisadr G, 2011, NEUROBIOL DIS, V44, P19, DOI 10.1016/j.nbd.2011.05.019; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brambilla R, 2011, BRAIN, V134, P2736, DOI 10.1093/brain/awr199; Brambilla R, 2009, J NEUROCHEM, V110, P765, DOI 10.1111/j.1471-4159.2009.06190.x; Brambilla R, 2009, J IMMUNOL, V182, P2628, DOI 10.4049/jimmunol.0802954; Carbajal KS, 2011, GLIA, V59, P1813, DOI 10.1002/glia.21225; Chew LJ, 2011, J NEUROSCI, V31, P13921, DOI 10.1523/JNEUROSCI.3343-11.2011; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Clausen BH, 2005, NEUROSCIENCE, V132, P879, DOI 10.1016/j.neuroscience.2005.01.031; Cruz-Orengo L, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-170; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Dziembowska M, 2005, GLIA, V50, P258, DOI 10.1002/glia.20170; Farooque M, 2001, J NEUROTRAUM, V18, P105, DOI 10.1089/089771501750055811; Foote AK, 2005, BRAIN, V128, P528, DOI 10.1093/brain/awh417; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Glezer I, 2006, FASEB J, V20, P750, DOI 10.1096/fj.05-5234fje; Gottle P, 2010, ANN NEUROL, V68, P915, DOI 10.1002/ana.22214; Han YL, 2001, BRAIN RES, V888, P1, DOI 10.1016/S0006-8993(00)02924-3; Hayashi H, 2008, BIOCHEM BIOPH RES CO, V367, P584, DOI 10.1016/j.bbrc.2007.12.183; Khorooshi R, 2008, J IMMUNOL, V181, P7284, DOI 10.4049/jimmunol.181.10.7284; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kostianovsky AM, 2008, J IMMUNOL, V181, P5425, DOI 10.4049/jimmunol.181.8.5425; Kotter MR, 2006, J NEUROSCI, V26, P328, DOI 10.1523/JNEUROSCI.2615-05.2006; Kremer D, 2011, ANN NEUROL, V69, P602, DOI 10.1002/ana.22415; Lambertsen KL, 2007, NEUROSCIENCE, V144, P934, DOI 10.1016/j.neuroscience.2006.10.046; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Lambertsen KL, 2002, J CEREBR BLOOD F MET, V22, P785, DOI 10.1097/00004647-200207000-00004; Lambertsen KL, 2001, BRAIN RES PROTOC, V7, P175, DOI 10.1016/S1385-299X(01)00062-9; Li MZ, 2011, GLIA, V59, P108, DOI 10.1002/glia.21080; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; Mi S, 2007, NAT MED, V13, P1228, DOI 10.1038/nm1664; Moore CS, 2011, J NEUROSCI, V31, P6247, DOI 10.1523/JNEUROSCI.5474-10.2011; Moore CS, 2011, J NEUROSCI RES, V89, P13, DOI 10.1002/jnr.22482; Nash B, 2011, J NEUROSCI, V31, P13028, DOI 10.1523/JNEUROSCI.1449-11.2011; Nielsen HH, 2011, AM J PATHOL, V179, P2028, DOI 10.1016/j.ajpath.2011.06.006; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Opatz J, 2009, MOL CELL NEUROSCI, V40, P293, DOI 10.1016/j.mcn.2008.11.002; Patel JR, 2012, ACTA NEUROPATHOL, V124, P847, DOI 10.1007/s00401-012-1034-0; Patel JR, 2010, P NATL ACAD SCI USA, V107, P11062, DOI 10.1073/pnas.1006301107; Petty JM, 2007, J IMMUNOL, V178, P8148, DOI 10.4049/jimmunol.178.12.8148; Schonberg DL, 2007, J NEUROPATH EXP NEUR, V66, P1124, DOI 10.1097/nen.0b013e31815c2530; Smyth GK, 2005, BIOINFORMATICS, V21, P2067, DOI 10.1093/bioinformatics/bti270; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Smyth GK., 2004, STAT APPL GENET MOL, V3, pArticl, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Sohn J, 2006, J NEUROSCI, V26, P9722, DOI 10.1523/JNEUROSCI.1716-06.2006; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; Tripathi R, 2007, GLIA, V55, P698, DOI 10.1002/glia.20491; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Ubogu EE, 2006, TRENDS PHARMACOL SCI, V27, P48, DOI 10.1016/j.tips.2005.11.002; Wang LH, 2009, ONCOL REP, V22, P1333, DOI 10.3892/or_00000572; Wang YP, 2011, J NEUROSCI, V31, P6053, DOI 10.1523/JNEUROSCI.5524-09.2011; West MJ, 1996, J COMP NEUROL, V370, P11; Wu JF, 2010, GLIA, V58, P410, DOI 10.1002/glia.20932; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475	63	37	41	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JUL 23	2013	10								92	10.1186/1742-2094-10-92			16	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	201VO	WOS:000323171300001	23880092	Green Published, gold			2022-02-06	
J	Joseph, B; Aziz, H; Sadoun, M; Kulvatunyou, N; Tang, A; O'Keeffe, T; Wynne, J; Gries, L; Green, DJ; Friese, RS; Rhee, P				Joseph, Bellal; Aziz, Hassan; Sadoun, Moutamn; Kulvatunyou, Narong; Tang, Andrew; O'Keeffe, Terence; Wynne, Julie; Gries, Lynn; Green, Donald J.; Friese, Randall S.; Rhee, Peter			The acute care surgery model: Managing traumatic brain injury without an inpatient neurosurgical consultation	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	26th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 15-19, 2013	Scottsdale, AZ	Eastern Assoc Surg Trauma		Acute care surgery model; mild traumatic brain injury; neurosurgical consultation; intracranial hemorrhage	MINIMAL HEAD-INJURY; COMPUTED-TOMOGRAPHY; CT; MANAGEMENT; UTILITY	BACKGROUND: Neurosurgical services are a limited resource and effective use of them would improve the health care system. Acute care surgeons (ACS) are accustomed to treating mild traumatic brain injury (TBI) including those with minor radiographic intracranial injuries. We hypothesized that ACS safely manage mild TBI with intracranial hemorrhage (ICH) on head computed tomographic (CT) scan without neurosurgical consultation (NC). METHODS: We performed a retrospective analysis on all TBI patients with positive findings on head CT scan managed without NC during a 2-year period. Propensity scoring matched NC to no-NC patients on a 1: 2 ratio for Glasgow Coma Scale (GCS) score, head Abbreviated Injury Scale (h-AIS) score, neurological examination, age, Injury Severity Score (ISS), findings of initial head CT scan including type and size of ICH. RESULTS: A total of 270 patients with mild TBI and positive CT scan findings were included (90 with NC and 180 without NC). Sixty-three percent were male, and mean (SD) age was 39 (25) years. The median GCS was 15 (13-15), and the h-AIS score was 2 (1-3). In both groups, there was no neurosurgical intervention, in-hospital mortality, or 30-day readmission. In the no-NC group, 8% of the patients had postdischarge emergency department (ED) visits compared with 4% of the NC group (p = 0.5). All patients with postdischarge ED visits in both groups were discharged home from the ED. CONCLUSION: ACS can manage mild TBI with ICH without obtaining an inpatient NC. Further guidelines should be established to help identify which patients meet criteria to be safely managed without NC. (J Trauma Acute Care Surg. 2013; 75: 102-105. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Aziz, Hassan; Sadoun, Moutamn; Kulvatunyou, Narong; Tang, Andrew; O'Keeffe, Terence; Wynne, Julie; Gries, Lynn; Green, Donald J.; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021	Aziz, Hassan/0000-0003-0406-1946			Barker DE, 2006, AM SURGEON, V72, P1166; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Harbrecht BG, 2010, J TRAUMA, V68, P1367, DOI 10.1097/TA.0b013e3181d990da; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Huynh T, 2006, AM SURGEON, V72, P1162; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Levy AS, 2011, J TRAUMA, V71, P1199, DOI 10.1097/TA.0b013e31822067fc; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; RHODES M, 1993, J TRAUMA, V35, P384, DOI 10.1097/00005373-199309000-00009; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stippler M, 2012, EMERG MED J, V29, P528, DOI 10.1136/emermed-2011-200162; Tang AL, 2010, SCAND J SURG, V99, P61, DOI 10.1177/145749691009900202; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004; Valadka AB, 2010, J TRAUMA, V68, P1372; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092	21	37	37	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2013	75	1					102	105		10.1097/TA.0b013e3182946667			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	300EV	WOS:000330448100027	23778447				2022-02-06	
J	Schneider, KJ; Meeuwisse, WH; Kang, J; Schneider, GM; Emery, CA				Schneider, Kathryn J.; Meeuwisse, Willem H.; Kang, Jian; Schneider, Geoff M.; Emery, Carolyn A.			Preseason Reports of Neck Pain, Dizziness, and Headache as Risk Factors for Concussion in Male Youth Ice Hockey Players	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						dizziness; neck pain; headache; youth; risk factor; concussion	SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CERVICOGENIC HEADACHE; CEREBRAL CONCUSSION; INJURY; DISCOGRAPHY; MANAGEMENT; STATEMENT; FOOTBALL; CHILDREN	Objective: The objective of this study was to determine the risk of concussion in youth male hockey players with preseason reports of neck pain, headaches, and/or dizziness. Design: Secondary data analysis of pooled data from 2 prospective cohort studies. Setting: Ice hockey rinks in Alberta and Quebec, Canada. Participants: A total of 3832 male ice hockey players aged 11 to 14 years (280 teams) participated. Assessment of Risk Factors: Participants recorded baseline preseason symptoms of dizziness, neck pain, and headaches on the Sport Concussion Assessment Tool. Incidence rate ratios (IRR) were estimated using Poisson regression, adjusted for cluster by team, hours of exposure, and other covariates. Main Outcome Measures: Concussions that occurred during the season were recorded using a validated prospective injury surveillance system. Results: Preseason reports of neck pain and headache were risk factors for concussion (IRR = 1.67; 95% confidence interval [CI], 1.15-2.41 and IRR = 1.47; 95% CI, 1.01-2.13). Dizziness was a risk factor for concussion in the Pee Wee nonbody checking cohort (IRR = 3.11; 95% CI, 1.33-7.26). A combination of any 2 symptoms was a risk factor in the Pee Wee nonbody checking cohort (IRR = 3.65; 95% CI, 1.20-11.05) and the Bantam cohort (IRR = 2.40; 95% CI, 1.15-4.97). Conclusions: Male youth athletes reporting headache and neck pain at baseline were at an increased risk of concussion during the season. The risk associated with dizziness and any 2 of dizziness, neck pain, or headaches depended on age group and body checking. Clinical Relevance: Baseline testing may be of benefit to identify individuals with symptoms of dizziness, neck pain, and headaches who may be at a higher risk of concussion during the season.	[Schneider, Kathryn J.; Meeuwisse, Willem H.; Kang, Jian; Emery, Carolyn A.] Univ Calgary, Sport Injury Prevent Res Ctr, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Meeuwisse, Willem H.; Emery, Carolyn A.] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada; [Schneider, Geoff M.] Univ Calgary, Fac Med, Dept Med Sci, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst Child & Maternal, Calgary, AB T2N 1N4, Canada		Schneider, KJ (corresponding author), Univ Calgary, Sport Injury Prevent Res Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	kjschnei@ucalgary.ca	Emery, Carolyn/AAI-2761-2020	Schneider, Kathryn/0000-0002-5951-5899	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); MaxBell Foundation; Alberta Heritage Foundation for Medical Research Studentship Award; Alberta Heritage Foundation for Medical Research Population Health Investigator Award; Professorship in Pediatric Rehabilitation funded by the Children's Hospital Foundation through the Alberta Children's Hospital Research Institute for Child and Maternal Health; International Olympic Committee	Funding was provided by the Canadian Institutes of Health Research and MaxBell Foundation. Kathryn Schneider is funded by an Alberta Heritage Foundation for Medical Research Studentship Award. Carolyn Emery is funded by a Canadian Institutes of Health Research New Investigator Award, Alberta Heritage Foundation for Medical Research Population Health Investigator Award, and a Professorship in Pediatric Rehabilitation funded by the Children's Hospital Foundation through the Alberta Children's Hospital Research Institute for Child and Maternal Health. The Sport Injury Prevention Research Centre is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee.	Armstrong B, 2008, SPORTS MED, V38, P101, DOI 10.2165/00007256-200838020-00002; Balatsouras DG, 2007, INT J PEDIATR OTORHI, V71, P487, DOI 10.1016/j.ijporl.2006.11.024; Benson B, 2009, BRIT J SPORT MED, V43, pi99; Bogduk N, 2004, NEUROL CLIN, V22, P151, DOI 10.1016/S0733-8619(03)00100-2; BOGDUK N, 1986, J NEUROL NEUROSUR PS, V49, P775, DOI 10.1136/jnnp.49.7.775; BOGDUK N, 1988, SPINE, V13, P610; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Conicella E, 2008, HEADACHE, V48, P1005, DOI 10.1111/j.1526-4610.2007.01052.x; Cooper G, 2007, PAIN MED, V8, P344, DOI 10.1111/j.1526-4637.2006.00201.x; Dreyfuss P, 2009, PM&R, V1, P719, DOI 10.1016/j.pmrj.2009.05.014; El-Metwally A, 2004, PAIN, V110, P550, DOI 10.1016/j.pain.2004.03.021; Emery C, 2009, J SCI MED SPORT, V12, P180; Emery C, 2009, CLIN J SPORT MED, V19, P245; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Eviatar L, 1986, Pediatr Neurol, V2, P61, DOI 10.1016/0887-8994(86)90058-5; Falla DL, 2004, SPINE, V29, P2108, DOI 10.1097/01.brs.0000141170.89317.0e; Forsyth R, 1999, Pediatr Rev, V20, P39, DOI 10.1542/pir.20-2-39; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grubb SA, 2000, SPINE, V25, P1382, DOI 10.1097/00007632-200006010-00010; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Jull G, 1999, CEPHALALGIA, V19, P179, DOI 10.1046/j.1468-2982.1999.1903179.x; Jull G, 2004, MANUAL THER, V9, P89, DOI 10.1016/S1356-689X(03)00086-9; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Lewis DW, 2000, HEADACHE, V40, P200, DOI 10.1046/j.1526-4610.2000.00029.x; LORD SM, 1994, J NEUROL NEUROSUR PS, V57, P1187, DOI 10.1136/jnnp.57.10.1187; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pikus HJ, 1995, HEADACHE, V35, P621, DOI 10.1111/j.1526-4610.1995.hed3510621.x; Reid SA, 2005, MANUAL THER, V10, P4, DOI 10.1016/j.math.2004.03.006; Schellhas KP, 1996, SPINE, V21, P300, DOI 10.1097/00007632-199602010-00009; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Stata Corporation, 2008, STAT STAT SOFTW REL, V10, P1; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Weisleder P, 2001, J CHILD NEUROL, V16, P727, DOI 10.1177/088307380101601004	48	37	37	1	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2013	23	4					267	272		10.1097/JSM.0b013e318281f09f			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	299AM	WOS:000330366700004	23391986				2022-02-06	
J	Cabral, KP; Fraser, GL; Duprey, J; Gibbons, BA; Hayes, T; Florman, JE; Seder, DB				Cabral, Katherine P.; Fraser, Gilles L.; Duprey, Jennifer; Gibbons, Beth A.; Hayes, Timothy; Florman, Jeffrey E.; Seder, David B.			Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Intracerebral hemorrhage; Traumatic brain injury; Coagulopathy; Subarachnoid hemorrhage; Subdural hematoma; Oral anticoagulation therapy; Hematoma expansion	FRESH-FROZEN PLASMA; INTERNATIONAL NORMALIZED RATIO; ORAL ANTICOAGULANT REVERSAL; FACTOR-IX COMPLEX; INTRACEREBRAL HEMORRHAGE; RAPID REVERSAL; HEMATOMA GROWTH; TRAUMA PATIENTS; VITAMIN-K; MANAGEMENT	Prothrombin complex concentrates (PCCs) offer a means for the rapid reversal of warfarin, particularly in the setting of life-threatening bleeding. We evaluated the effectiveness and safety of a PCC-based protocol in patients with warfarin-associated intracerebral hemorrhage (ICH), subdural hematoma (SDH), or subarachnoid hemorrhage (SAH). This was a retrospective case-series review of patients treated with an institution-approved warfarin reversal protocol. Patients with intracranial hemorrhage and known warfarin use with an international normalized ratio (INR)>1.4 received fresh frozen plasma (FFP), vitamin K (phytonadione), and weight-based, 3-factor PCC (Profilnine (R) SD) dose based on the initial INR. Demographic and clinical information, the degree of and time to INR normalization, and adverse events were recorded. The thirty study patients included 19 with primary ICH, 7 with SDH, and 4 with SAH. The mean age was 72.8 (+/- 11) years, including 11 (37%) patients >= 80 years old. The median presenting INR was 2.3 (IQR 2-3.3) and post-treatment INR was 1.4 (IQR 1.3-1.5, Z score 6.4, p < 0.001). Median time from PCC administration to the first follow up INR was 95 (IQR 50-140) min. No patient's INR increased by more than 0.3 over 72 h. Nine patients (30%) underwent neurosurgical procedures after PCC administration and no procedure-related bleeding complication was noted. Adverse events included 3 instances of early hematoma expansion, one ischemic stroke in a patient with endocarditis on post-PCC day 1, one pulmonary embolism 5 weeks after PCC treatment, and one coronary in-stent thrombosis 60 days after PCC treatment. 6 patients died prior to hospital discharge of anticipated complications of their initial event, and none from identifiable thrombotic complications of PCC. A 3-factor PCC preparation (Profilnine (R) SD), administered with FFP and vitamin K to patients with acute warfarin-associated intracranial bleeding is a reasonable approach to urgent warfarin reversal. However, randomized, prospective trials are needed to verify the safety and clinical effectiveness of PCC administration in this population. (C) 2012 Elsevier B.V. All rights reserved:	[Cabral, Katherine P.] Albany Coll Pharm, Dept Pharm Practice, Albany, NY USA; [Fraser, Gilles L.] Maine Med Ctr, Dept Pharm, Portland, ME USA; [Fraser, Gilles L.; Duprey, Jennifer] Maine Med Ctr, Dept Crit Care Serv, Portland, ME USA; [Hayes, Timothy; Seder, David B.] Maine Med Ctr, Blood Bank, Portland, ME USA; [Florman, Jeffrey E.; Seder, David B.] Maine Med Ctr, Neurosci Inst, Portland, ME USA; [Gibbons, Beth A.; Florman, Jeffrey E.] Univ Vermont, Sch Med, Dept Surg, Burlington, VT 05405 USA		Seder, DB (corresponding author), Tufts Univ, Maine Med Ctr, Sch Med, 22 Bramhall St, Portland, ME 04102 USA.	dseder@cmamaine.com	Seder, David B./M-4829-2019	Seder, David/0000-0002-9717-1038; fraser, gilles/0000-0003-0841-7946			Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; Baggs JH, 2012, ANN PHARMACOTHER, V46, P51, DOI 10.1345/aph.1Q588; Bershad EM, 2010, NEUROCRIT CARE, V12, P403, DOI 10.1007/s12028-009-9310-0; Boulis NM, 1999, NEUROSURGERY, V45, P1113, DOI 10.1097/00006123-199911000-00020; Cartmill M, 2000, BRIT J NEUROSURG, V14, P458; Chapman SA, 2011, ANN PHARMACOTHER, V45, P869, DOI 10.1345/aph.1P605; Cucchiara B, 2008, STROKE, V39, P2993, DOI 10.1161/STROKEAHA.108.520668; Flaherty ML, 2008, NEUROLOGY, V71, P1084, DOI 10.1212/01.wnl.0000326895.58992.27; FREDRIKSSON K, 1992, STROKE, V23, P972, DOI 10.1161/01.STR.23.7.972; Goldstein JN, 2006, STROKE, V37, P151, DOI 10.1161/01.STR.0000195047.21562.23; Guest JF, 2010, CLIN THER, V32, P2478, DOI 10.1016/j.clinthera.2011.01.011; Holland L, 2009, TRANSFUSION, V49, P1171, DOI 10.1111/j.1537-2995.2008.02080.x; Huttner HB, 2006, STROKE, V37, P1465, DOI 10.1161/01.STR.0000221786.81354.d6; Kalina M, 2008, AM SURGEON, V74, P858; Kohler M, 1999, THROMB RES, V95, pS13, DOI 10.1016/S0049-3848(99)00079-1; Lankiewicz MW, 2006, J THROMB HAEMOST, V4, P967, DOI 10.1111/j.1538-7836.2006.01815.x; Lee SB, 2006, NEUROLOGY, V67, P1272, DOI 10.1212/01.wnl.0000238104.75563.2f; Lubetsky A, 2004, THROMB RES, V113, P371, DOI 10.1016/j.thromres.2004.04.004; Majeed A, 2012, THROMB RES, V129, P146, DOI 10.1016/j.thromres.2011.07.024; Makris M, 1997, THROMB HAEMOSTASIS, V77, P477; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Preston FE, 2002, BRIT J HAEMATOL, V116, P619, DOI 10.1046/j.0007-1048.2001.03295.x; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; Safaoui MN, 2009, AM J SURG, V197, P785, DOI 10.1016/j.amjsurg.2008.04.003; Schulman S, 2008, CHEST, V133, p257S, DOI 10.1378/chest.08-0674; Siddiq F, 2008, NEUROCRIT CARE, V8, P36, DOI 10.1007/s12028-007-9011-5; TABERNER DA, 1976, BRIT MED J, V2, P83, DOI 10.1136/bmj.2.6027.83; Vigue B, 2007, INTENS CARE MED, V33, P721, DOI 10.1007/s00134-007-0528-z	29	37	37	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	JUN	2013	115	6					770	774		10.1016/j.clineuro.2012.07.006			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	158GG	WOS:000319956900027	22835715				2022-02-06	
J	Monti, MM; Pickard, JD; Owen, AM				Monti, Martin M.; Pickard, John D.; Owen, Adrian M.			Visual cognition in disorders of consciousness: From V1 to top-down attention	HUMAN BRAIN MAPPING			English	Article						traumatic brain injury; minimally conscious state; consciousness; cognition; fMRI; vision	PERSISTENT VEGETATIVE STATE; HUMAN EXTRASTRIATE CORTEX; EVENT-RELATED FMRI; BEHAVIORAL-ASSESSMENT; MEDICAL ASPECTS; BRAIN ACTIVITY; AWARENESS; ROBUST; AREAS; OPTIMIZATION	What is it like to be at the lower boundaries of consciousness? Disorders of consciousness such as coma, the vegetative state, and the minimally conscious state are among the most mysterious and least understood conditions of the human brain. Particularly complicated is the assessment of residual cognitive functioning and awareness for diagnostic, rehabilitative, legal, and ethical purposes. In this article, we present a novel functional magnetic resonance imaging exploration of visual cognition in a patient with a severe disorder of consciousness. This battery of tests, first developed in healthy volunteers, assesses increasingly complex transformations of visual information along a known caudal to rostral gradient from occipital to temporal cortex. In the first five levels, the battery assesses (passive) processing of light, color, motion, coherent shapes, and object categories (i.e., faces, houses). At the final level, the battery assesses the ability to voluntarily deploy visual attention in order to focus on one of two competing stimuli. In the patient, this approach revealed appropriate brain activations, undistinguishable from those seen in healthy and aware volunteers. In addition, the ability of the patient to focus one of two competing stimuli, and switch between them on command, also suggests that he retained the ability to access, to some degree, his own visual representations. Hum Brain Mapp, 2013. (c) 2012 Wiley Periodicals, Inc.	[Monti, Martin M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA; [Monti, Martin M.; Owen, Adrian M.] MRC, Cognit & Brain Sci Unit, Cambridge, England; [Pickard, John D.] Univ Cambridge, Acad Neurosurg Unit, Cambridge CB2 1TN, England; [Owen, Adrian M.] Univ Western Ontario, Ctr Brain & Mind, London, ON, Canada		Monti, MM (corresponding author), Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.	monti@psych.ucla.edu	Williams, Jackie/B-3495-2015; Owen, Adrian M/B-4997-2015	Monti, Martin M/0000-0001-5511-3780	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [U.1055.01.002.00007.01, U.1055.01.002.00001.01]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [ICT Programme Project FP7-247919]; James S. McDonnell Foundation Scholar Award; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G9439390, G0001237] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390] Funding Source: researchfish	Contract grant sponsor: Medical Research Council; Contract grant numbers: U.1055.01.002.00007.01 and U.1055.01.002.00001.01; Contract grant sponsor: European Commission; Contract grant number: ICT Programme Project FP7-247919; Contract grant sponsor: James S. McDonnell Foundation Scholar Award.	Bekinschtein TA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00005; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Beauchamp MS, 1999, CEREB CORTEX, V9, P257, DOI 10.1093/cercor/9.3.257; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Bekinschtein TA, 2008, J NEUROL NEUROSUR PS, V79, P826, DOI 10.1136/jnnp.2007.132738; Bekinschtein TA, 2009, P NATL ACAD SCI USA, V106, P1672, DOI 10.1073/pnas.0809667106; Bernat JL, 2002, NEUROLOGY, V58, P337, DOI 10.1212/WNL.58.3.337; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Coleman MR, 2009, PROG BRAIN RES, V177, P231, DOI 10.1016/S0079-6123(09)17716-6; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; Elliott L, 2005, NEUROPSYCHOL REHABIL, V15, P480, DOI 10.1080/09602010443000506; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; Faugeras F, 2011, NEUROLOGY, V77, P264, DOI 10.1212/WNL.0b013e3182217ee8; Fins JJ, 2008, AM J BIOETHICS, V8, P3, DOI 10.1080/15265160802318113; Giacino JT, 2009, PROG BRAIN RES, V177, P33, DOI 10.1016/S0079-6123(09)17704-X; Giacino JT, 2006, ARCH PHYS MED REHAB, V87, pS67, DOI 10.1016/j.apmr.2006.07.272; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Giesbrecht B, 2004, CEREB CORTEX, V14, P521, DOI 10.1093/cercor/bhh014; Gill-Thwaites H, 2004, BRAIN INJURY, V18, P1255, DOI 10.1080/02699050410001719952; Hadjikhani N, 1998, NAT NEUROSCI, V1, P235, DOI 10.1038/681; Hampshire A, 2006, CEREB CORTEX, V16, P1679, DOI 10.1093/cercor/bhj116; Henson R, 2005, Q J EXP PSYCHOL-A, V58, P193, DOI 10.1080/02724980443000502; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; JENNETT B, 1972, LANCET, V1, P734; Kanwisher N, 1997, J NEUROSCI, V17, P4302; Kircher T, 2009, HUM BRAIN MAPP, V30, P4116, DOI 10.1002/hbm.20833; Kourtzi Z, 2000, J NEUROSCI, V20, P3310, DOI 10.1523/JNEUROSCI.20-09-03310.2000; Lamme VAF, 2010, COGN NEUROSCI-UK, V1, P204, DOI 10.1080/17588921003731586; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; McKeefry DJ, 1997, BRAIN, V120, P2229, DOI 10.1093/brain/120.12.2229; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; Monti MM, 2010, J PSYCHOPHYSIOL, V24, P76, DOI 10.1027/0269-8803/a000016; Monti MM, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3765; Monti MM, 2009, PROG BRAIN RES, V177, P249, DOI 10.1016/S0079-6123(09)17717-8; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Monti MM, 2009, ANN NY ACAD SCI, V1157, P81, DOI 10.1111/j.1749-6632.2008.04121.x; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Posner JB, 2007, PLUM POSNERS DIAGNOS; PUCE A, 1995, J NEUROPHYSIOL, V74, P1192, DOI 10.1152/jn.1995.74.3.1192; Qin PM, 2010, HUM BRAIN MAPP, V31, P1993, DOI 10.1002/hbm.20989; Qin PM, 2008, NEUROSCI LETT, V448, P24, DOI 10.1016/j.neulet.2008.10.029; Reinholz J, 2005, COGNITIVE BRAIN RES, V24, P702, DOI 10.1016/j.cogbrainres.2005.04.009; Rissman J, 2003, J COGNITIVE NEUROSCI, V15, P1160, DOI 10.1162/089892903322598120; Ropper AH, 2010, NEW ENGL J MED, V362, P648, DOI 10.1056/NEJMe0909667; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tong F, 1998, NEURON, V21, P753, DOI 10.1016/S0896-6273(00)80592-9; Tootell RBH, 1998, TRENDS COGN SCI, V2, P174, DOI 10.1016/S1364-6613(98)01171-1; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Woolrich MW, 2004, NEUROIMAGE, V21, P1732, DOI 10.1016/j.neuroimage.2003.12.023; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127	61	37	38	0	45	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	JUN	2013	34	6					1245	1253		10.1002/hbm.21507			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	129QA	WOS:000317855400001	22287214	Green Published			2022-02-06	
J	Caron, JG; Bloom, GA; Johnston, KM; Sabiston, CM				Caron, Jeffrey G.; Bloom, Gordon A.; Johnston, Karen M.; Sabiston, Catherine M.			Effects of Multiple Concussions on Retired National Hockey League Players	JOURNAL OF SPORT & EXERCISE PSYCHOLOGY			English	Article						concussions; hockey; depression; social support	SPORTS CONCUSSION; SOCIAL SUPPORT; INJURY; EXPERIENCES; PSYCHOLOGY; GENDER; RISK; PAIN; BODY	The purpose of this study was to understand the meanings and lived experiences of multiple concussions in professional hockey players using hermeneutic, idiographic, and inductive approaches within an interpretative phenomenological analysis. The interviewer was an athlete who had suffered multiple concussions, and the interviewees were five former National Hockey League athletes who had retired due to medically diagnosed concussions suffered during their careers. The men discussed the physical and psychological symptoms they experienced as a result of their concussions and how the symptoms affected their professional careers, personal relationships, and quality of life. The former professional athletes related these symptoms to the turmoil that is ever present in their lives. These findings are of interest to athletes, coaches, sport administrators, family members, sport psychology practitioners, and medical professionals, as they highlight the severity of short-and long-term effects of concussions.	[Caron, Jeffrey G.; Bloom, Gordon A.] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada; [Sabiston, Catherine M.] McGill Univ, Montreal, PQ, Canada; [Johnston, Karen M.; Sabiston, Catherine M.] Univ Toronto, Toronto, ON, Canada		Caron, JG (corresponding author), McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada.		Sabiston, Catherine/AAT-4924-2020	Sabiston, Catherine/0000-0002-8419-6666			Allen-Collinson J, 2009, QUAL RES SPORT EXERC, V1, P279, DOI 10.1080/19398440903192340; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Bernes K.B., 2009, J EXCELLENCE, P63; Bianco T, 2001, RES Q EXERCISE SPORT, V72, P376, DOI 10.1080/02701367.2001.10608974; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Brocki JM, 2006, PSYCHOL HEALTH, V21, P87, DOI 10.1080/14768320500230185; Chamberlain K, 2011, HEALTH PSYCHOL REV, V5, P48, DOI 10.1080/17437199.2010.520113; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Clifton, 2006, QUALITATIVE RES PSYC, V3, P102, DOI [DOI 10.1191/1478088706QP0620A, 10.1191/1478088706qp062oa, DOI 10.1191/1478088706QP062OA]; Clover J, 2010, CLIN SPORT MED, V29, P169, DOI 10.1016/j.csm.2009.09.008; COLBURN K, 1985, CAN J SOCIOL, V10, P153; Defrin R, 2009, PAIN, V145, P230, DOI 10.1016/j.pain.2009.06.028; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echlin PS, 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2F2010.9; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gulli C., 2011, MACLEANS MAG, V124, P56; Horton A. S., 2002, Medicine & Science in Sports & Exercise, V34, pS99, DOI 10.1097/00005768-200205001-00551; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Kontos AP, 2004, J APPL SPORT PSYCHOL, V16, P220, DOI 10.1080/10413200490485568; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; Melnick M. J., 1992, Journal of Physical Education, Recreation & Dance, V63, P32; Messner M. A., 1990, International Review for the Sociology of Sport, V25, P203, DOI 10.1177/101269029002500303; Mihovilovic Miro., 1968, INT REV SPORT SOCIOL, V3, P73, DOI [10.1177/101269026800300105, DOI 10.1177/101269026800300105]; Nolen-Hoeksema S, 2011, PERS INDIV DIFFER, V51, P704, DOI 10.1016/j.paid.2011.06.012; Ogilvie B. C., 1982, P 5 WORLD C SPORT PS, P176; Osborn M, 1998, BRIT J HEALTH PSYCH, V3, P65, DOI 10.1111/j.2044-8287.1998.tb00556.x; Quinn AM, 1999, J APPL SPORT PSYCHOL, V11, P210, DOI 10.1080/10413209908404201; Rees T., 2007, Social psychology in sport, P223; Rees T, 2000, SPORT PSYCHOL, V14, P327, DOI 10.1123/tsp.14.4.327; Safai P, 2003, SOCIOL SPORT J, V20, P127, DOI 10.1123/ssj.20.2.127; Smith J.A., 2009, INTERPRETATIVE PHENO; Smith J.A., 2004, QUALITATIVE RES PSYC, V1, P39, DOI DOI 10.1191/1478088704QP0040A; Smith M. D., 1996, CHILDREN YOUTH SPORT, P142; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tamminen KA, 2013, PSYCHOL SPORT EXERC, V14, P28, DOI 10.1016/j.psychsport.2012.07.002; Taylor Jim., 1994, J APPL SPORT PSYCHOL, V6, P1, DOI [10.1080/10413209408406462, DOI 10.1080/10413209408406462]; Weinstein MD, 1995, SEX ROLES, V33, P831, DOI 10.1007/BF01544782; WERTHNER P, 1986, INT J SPORT PSYCHOL, V17, P337; Wiese-Bjornstal DM, 1998, J APPL SPORT PSYCHOL, V10, P46, DOI 10.1080/10413209808406377; Willig C., 2001, INTRO QUALITATIVE RE; Yardley L., 2008, QUALITATIVE PSYCHOL, P235; YOUNG K, 1994, SOCIOL SPORT J, V11, P175, DOI 10.1123/ssj.11.2.175	48	37	37	5	73	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	0895-2779	1543-2904		J SPORT EXERCISE PSY	J. Sport Exerc. Psychol.	APR	2013	35	2					168	179		10.1123/jsep.35.2.168			12	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Psychology; Sport Sciences	127PF	WOS:000317710200005	23535975	Green Submitted			2022-02-06	
J	Miller, SC; Baktash, SH; Webb, TS; Whitehead, CR; Maynard, C; Wells, TS; Otte, CN; Gore, RK				Miller, Shannon C.; Baktash, Suzanne H.; Webb, Timothy S.; Whitehead, Casserly R.; Maynard, Charles; Wells, Timothy S.; Otte, Clifford N.; Gore, Russel K.			Risk for Addiction-Related Disorders Following Mild Traumatic Brain Injury in a Large Cohort of Active-Duty US Airmen	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							ALCOHOL-USE; SUBSTANCE-ABUSE; DRUG-USE; IRAQ; DEPRESSION; PATTERNS	Objective: Military personnel are at increased risk for traumatic brain injury (TBI) from combat and noncombat exposures. The sequelae of moderate to severe TBI are well described, but little is known regarding long-term performance decrements associated with mild TBI. Furthermore, while alcohol and drug use are well known to increase risk for TBI, little is known regarding the reverse pattern. The authors sought to assess possible associations between mild TBI and addiction-related disorders in active-duty U.S. military personnel. Method: A historical prospective study was conducted using electronically recorded demographic, medical, and military data for more than a half million active-duty U.S. Air Force service members. Cases were identified by ICD-9-CM codes considered by an expert panel to be indicative of mild TBI. Outcomes included ICD-9-CM diagnoses of selected addiction-related disorders. Cox proportional hazards modeling was used to calculate hazard ratios while controlling for varying lengths of follow-up and potential confounding variables. Results: Airmen with mild TBI were at increased risk for certain addiction-related disorders compared with a similarly injured non-mild TBI comparison group. Hazards for alcohol dependence, nicotine dependence, and nondependent abuse of drugs or alcohol were significantly elevated, with a consistent decrease over time. Conclusions: A novel finding of this study was the initial increased risk for addiction-related disorders that decreased with time, thus eroding war fighter performance in a military population. Moreover, these results suggest that mild TBI is distinguished from moderate to severe TBI in terms of timing of the risk, indicating that there is a need for screening and prevention of addiction-related disorders in mild TBI. Screening may be warranted in military troops as well as civilians at both short- and long-term milestones following mild TBI. (Am J Psychiatry 2013; 170:383-390)	[Whitehead, Casserly R.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Psychiat & Behav Neurosci, Ctr Treatment Res & Educ Addict Disorders, Cincinnati, OH USA; Univ Tennessee, Dept Elect Engn & Comp Sci, Knoxville, TN USA; USAF, Res Lab, Vulnerabil Anal Branch, AFMC Human Performance Wing 711, Wright Patterson AFB, OH 45433 USA; Infoscitex Corp, Waltham, MA USA; VA Puget Sound, Epidemiol Res & Informat Ctr, Seattle, WA USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA		Whitehead, CR (corresponding author), Vet Affairs Med Ctr, Cincinnati, OH 45267 USA.	casserly.whitehead.ctr@wpafb.af.mil	Otte, Clifford/AAB-9991-2022; Maynard, Charles/N-3906-2015; Gore, Russell/N-8988-2016	Maynard, Charles/0000-0002-1644-7814; Gore, Russell/0000-0002-8012-1579			American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Armed Forces Health Surveillance Center, 2007, MED SURVEILL MON REP, V14, P2; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Center for Substance Abuse Treatment, 2010, TREAT CLIENTS TRAUM, V9, P2; Collins R, 2012, TRAUMATIC BRAIN INJU, P223; Compton WM, 2011, P C BRIEF WASH DC MA; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Department of Defense, 2007, ACH VIS REP DEP DEF; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, AM J EPIDEMIOL, V168, P1095, DOI 10.1093/aje/kwn261; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; *PRACT MAN INF COR, 2006, INT CLASS DIS 9 REV, V1; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Schulte PA, 1996, AM J PUBLIC HEALTH, V86, P1281, DOI 10.2105/AJPH.86.9.1281; Singh JA, 2009, PREV CHRONIC DIS, V6; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wells TS, 2010, AM J PUBLIC HEALTH, V100, P90, DOI 10.2105/AJPH.2008.155432	37	37	39	0	21	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	APR	2013	170	4					383	390		10.1176/appi.ajp.2012.12010126			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	117AW	WOS:000316925500008	23429886				2022-02-06	
J	Spitz, G; Schonberger, M; Ponsford, J				Spitz, Gershon; Schoenberger, Michael; Ponsford, Jennie			The Relations Among Cognitive Impairment, Coping Style, and Emotional Adjustment Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety; brain injury; cognition; coping; depression; neuropsychology	CLOSED-HEAD-INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; SOCIAL SUPPORT; STRATEGIES; RECOVERY; REHABILITATION; APPRAISAL; SYMPTOMS	Objective: To examine the direct, mediated, and moderated associations among cognition, coping, and emotional adjustment following traumatic brain injury (TBI). Design: Cross-sectional, single-group design. Participants: Ninety-seven participants with mild to severe TBI recruited from their rehabilitation hospital and assessed on average 19 months postinjury. Measures: The BIRT Memory and Information Processing Battery, Doors Test from the Doors and People Test, Hayling Sentence Completion Test, Controlled Oral Word Association Test, Trail Making Test, Digit Span, Symbol Digit Modalities Test-Oral Version, Hospital Anxiety and Depression Scale, and the Coping Scale for Adults. Results: Poorer performance on measures of memory, executive functions, and attention and information processing was associated with greater levels of self-reported depression and anxiety. No mediated relation was found between cognition and emotional adjustment. However, the use of adaptive coping strategies was found to moderate the relation between the Hayling A-a measure of information processing speed-and self-reported depression. Conclusions: Greater impairments in cognition directly predicted higher levels of anxiety and depression following TBI. In addition, the results suggest that the use of adaptive coping strategies has a greater effect on levels of depression for individuals with poor information processing speed.	[Spitz, Gershon; Schoenberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Spitz, Gershon; Schoenberger, Michael; Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Clayton, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol & Psychotherapy, D-79106 Freiburg, Germany		Spitz, G (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus, Clayton, Vic 3800, Australia.	Gershon.Spitz@monash.edu	Spitz, Gershon/H-7755-2014	Spitz, Gershon/0000-0002-7810-1480			Aguinis H., 2004, REGRESSION ANAL CATE; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; BADDELEY A, 1994, DOORS PEOPLE; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Benton AL, 1994, MULTILINGUAL APHASIA; Blais MC, 2007, BRAIN INJURY, V21, P357, DOI 10.1080/02699050701311075; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BOMBARDIER CH, 1990, BEHAV RES THER, V28, P297, DOI 10.1016/0005-7967(90)90081-S; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Burgess P.W., 1997, HAYLING BRIXTON TEST; Castaneda AE, 2008, J AFFECT DISORDERS, V106, P1, DOI 10.1016/j.jad.2007.06.006; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Coughhlan AK, 2007, BIRT MEMORY INFORM P; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DESROSIERS G, 1987, INT J CLIN NEUROPSYC, V9, P162; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Folkman S., 1984, STRESS; Frydenberg E., 1996, COPING SCALE ADULTS; Frydenberg E, 2000, ANN M AM ED RES ASS; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Keiski MA, 2007, CLIN NEUROPSYCHOL, V21, P744, DOI 10.1080/13854040600775346; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kendall E, 2009, SOC SCI MED, V69, P947, DOI 10.1016/j.socscimed.2009.06.021; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; Novack TA, 2000, BRAIN INJURY, V14, P987; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Reitan R, 1988, HALSTEAD REITAN NEUR; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Smith, 1973, SYMBOL DIGIT MODALIT; Snaith R., 1994, HOSP ANXIETY DEPRESS; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Wechsler D., 1997, WECHSLER MEMORY SCAL; West S. G., 1991, MULTIPLE REGRESSION; Whelan-Goodinson R, 2008, J AFFECT DISORD; Wolters G, 2011, J HEAD TRAUMA REHAB, V26, P150, DOI 10.1097/HTR.0b013e3181e421dc; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; [No title captured]	55	37	38	0	48	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2013	28	2					116	125		10.1097/HTR.0b013e3182452f4f			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	105HU	WOS:000316058300005	22495104				2022-02-06	
J	Weinstein, E; Turner, M; Kuzma, BB; Feuer, H				Weinstein, Elizabeth; Turner, Michael; Kuzma, Benjamin B.; Feuer, Henry			Second impact syndrome in football: new imaging and insights into a rare and devastating condition Case report	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						brain concussion; cerebral concussion; trauma; postconcussion syndrome; brain injury; football	SPORTS; TRAUMA; EDEMA	Premature return to play for the concussed pediatric athlete may result in devastating neurological injury. Identification of at-risk patients and ideal management of the concussed athlete remain challenging for the pediatrician. The authors review a case of second impact syndrome in which neuroimaging was obtained between the first and second impacts, a circumstance which to their knowledge has not been previously reported. This case offers new insights into the underlying pathophysiology of this disease process and potential risk factors for its development. (http://thejns.org/doi/abs/10.3171/2012.11.PEDS12343)	[Weinstein, Elizabeth] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN USA; [Turner, Michael; Feuer, Henry] Indiana Univ Sch Med, Dept Neurol Surg, Goodman Campbell Brain & Spine, Indianapolis, IN USA; [Kuzma, Benjamin B.] Northwest Radiol Network, Indianapolis, IN USA		Turner, M (corresponding author), Indiana Univ, Dept Neurol Surg, Goodman Campbell Brain & Spine, 1801 North Senate Blvd,Suite 610, Indianapolis, IN 46202 USA.	mturner@goodmancampbell.com					BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Pellman Elliot J, 2006, Neurosurg Focus, V21, pE12; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538	11	37	37	0	22	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	MAR	2013	11	3					331	334		10.3171/2012.11.PEDS12343			4	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	094DV	WOS:000315244100016	23277914	Bronze			2022-02-06	
J	Badgeley, MA; McIlvain, NM; Yard, EE; Fields, SK; Comstock, RD				Badgeley, Marcus A.; McIlvain, Natalie M.; Yard, Ellen E.; Fields, Sarah K.; Comstock, R. Dawn			Epidemiology of 10,000 High School Football Injuries: Patterns of Injury by Position Played	JOURNAL OF PHYSICAL ACTIVITY & HEALTH			English	Article						surveillance; sports; concussion; knee	UNITED-STATES; SPORTS; PREVENTION; ATHLETICS	Background: With more than 1.1 million high school athletes playing annually during the 2005-06 to 2009-10 academic years, football is the most popular boys' sport in the United States. Methods: Using an internet-based data collection tool, RIO, certified athletic trainers (ATs) from 100 nationally representative US high schools reported athletic exposure and football injury data during the 2005-06 to 2009-10 academic years. Results: Participating ATs. reported 10,100 football injuries corresponding to an estimated 2,739,187 football-related injuries nationally. The injury rate was 4.08 per 1000 athlete-exposures (AEs) overall. Offensive lineman collectively (center, offensive guard, offensive tackle) sustained 18.3% of all injuries. Running backs (16.3%) sustained more injuries than any other position followed by linebackers (14.9%) and wide receivers (11.9%). The leading mechanism of injury was player-player contact (64.0%) followed by player-surface contact (13.4%). More specifically, injury occurred most commonly when players were being tackled (24.4%) and tackling (21.8%). Conclusions: Patterns of football injuries vary by position. Identifying such differences is important to drive development of evidence-based, targeted injury prevention efforts.	[Badgeley, Marcus A.; McIlvain, Natalie M.; Yard, Ellen E.; Comstock, R. Dawn] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH USA; [Fields, Sarah K.] Ohio State Univ, Dept Phys Act & Educ Serv, Columbus, OH 43210 USA		Badgeley, MA (corresponding author), Nationwide Childrens Hosp, Ctr Injury Res & Policy, Res Inst, Columbus, OH USA.			Badgeley, Marcus/0000-0001-8064-9050	NCIPC CDC HHS [R49/CE001172-01, R49/CE000674-01] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172, R49CE000674] Funding Source: NIH RePORTER		Adickes MS, 2004, SPORTS MED, V34, P201, DOI 10.2165/00007256-200434030-00005; Binkley HM, 2002, J ATHL TRAINING, V37, P329; Casa DJ, 2009, J ATHL TRAINING, V44, P332, DOI 10.4085/1062-6050-44.3.332; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; CULPEPPER MI, 1983, SOUTHERN MED J, V76, P873, DOI 10.1097/00007611-198307000-00014; DELEE JC, 1992, AM J SPORT MED, V20, P575, DOI 10.1177/036354659202000515; Dick R, 2007, J ATHL TRAINING, V42, P221; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Maughan RJ, 2010, SCAND J MED SCI SPOR, V20, P117, DOI 10.1111/j.1600-0838.2010.01221.x; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mueller FO., CATASTROPHIC SPORTS; National Federation of State High School Associations, 2009, 2009 10 HIGH SCH ATH; Peterson L, 2000, AM J SPORT MED, V28, pS51; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Ramirez M, 2006, AM J SPORT MED, V34, P1147, DOI 10.1177/0363546505284385; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Shirreffs SM, 2010, SCAND J MED SCI SPOR, V20, P90, DOI 10.1111/j.1600-0838.2010.01213.x; Sporting Goods Manufacturers Association, ORG SPORTS ATTR MILL; Stocker B D, 1997, J Ky Med Assoc, V95, P458; THOMPSON N, 1987, AM J SPORT MED, V15, P117, DOI 10.1177/036354658701500204; United States Census Bureau, CENS REG US; Weistroffer JK, 2011, AM J SPORT MED, V39, P632, DOI 10.1177/0363546510388901; Wham GS, 2010, J ATHL TRAINING, V45, P75, DOI 10.4085/1062-6050-45.1.75; Yard EE, 2010, J SAFETY RES, V41, P471, DOI 10.1016/j.jsr.2010.09.001	25	37	37	0	25	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1543-3080			J PHYS ACT HEALTH	J. Phys. Act. Health	FEB	2013	10	2					160	169		10.1123/jpah.10.2.160			10	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	098PD	WOS:000315560300004	22821941				2022-02-06	
J	Kalamatianos, T; Stavrinou, LC; Koutsarnakis, C; Psachoulia, C; Sakas, DE; Stranjalis, G				Kalamatianos, Theodosis; Stavrinou, Lampis C.; Koutsarnakis, Christos; Psachoulia, Christina; Sakas, Damianos E.; Stranjalis, George			PlGF and sVEGFR-1 in chronic subdural hematoma: implications for hematoma development	JOURNAL OF NEUROSURGERY			English	Article						chronic subdural hematoma; PlGF; sVEGFR-1; angiogenesis; vascular hemorrhagic disorder; traumatic brain injury	PLACENTA GROWTH-FACTOR; ENDOTHELIAL-CELLS; CEREBROSPINAL-FLUID; NATURAL-HISTORY; FINE-STRUCTURE; FACTOR VEGF; FACTOR-I; EXPRESSION; RECURRENCE; ANGIOGENESIS	Object. A considerable body of evidence indicates that inflammation and angiogenesis play a significant role in the development and progression of chronic subdural hematoma (CSDH). While various experimental and clinical studies have implicated placental growth factor (PlGF) in the processes that underpin pathological angiogenesis, no study has thus far investigated its expression in CSDH. The actions of PlGF and its related proangiogenic vascular endothelial growth factor (VEGF) are antagonized by a high-affinity soluble receptor, namely soluble VEGF receptor-1 (sVEGFR-1), and thus the ratio between sVEGFR-1 and angiogenic factors provides an index of angiogenic capacity. Methods. In the present study, using an automated electrochemiluminescence assay, levels of PlGF and sVEGFR-1 were quantified in serum and hematoma fluid obtained in 16 patients with CSDH. Results. Levels of PlGF and sVEGFR-1 were significantly higher in hematoma fluid than in serum (p < 0.0001). In serum, levels of sVEGFR-1 were higher than those of PlGF (p < 0.0001), whereas in hematoma fluid this difference was not apparent. Furthermore, the ratio of sVEGFR-1 to PlGF was significantly lower in hematoma fluid than in serum (p < 0.0001). Conclusions. Given previous evidence indicating a role for PlGF in promoting angiogenesis, inflammatory cell chemotaxis, and stimulation, as well as its ability to amplify VEGF-driven signaling under conditions favoring pathological angiogenesis, enhanced expression of PlGF in hematoma fluid suggests the involvement of this factor in the mechanisms of inflammation and angiogenesis in CSDH. Furthermore, a reduced ratio of sVEGFR-1 to PlGF in hematoma fluid is consistent with the proangiogenic capacity of CSDH. Future studies are warranted to clarify the precise role of PlGF and sVEGFR-1 in CSDH. (http://thejns.org/doi/abs/10.3171/2012.10.JNS12327)	[Kalamatianos, Theodosis; Stavrinou, Lampis C.; Koutsarnakis, Christos; Sakas, Damianos E.; Stranjalis, George] Hellen Ctr Neurosurg Res Prof Petros S Kokkalis, Athens 10675, Greece; [Kalamatianos, Theodosis; Stavrinou, Lampis C.; Koutsarnakis, Christos; Sakas, Damianos E.; Stranjalis, George] Univ Athens, Dept Neurosurg, Athens, Greece; [Psachoulia, Christina] Evangelismos Med Ctr, Dept Biochem, Athens, Greece		Kalamatianos, T (corresponding author), Hellen Ctr Neurosurg Res Prof Petros S Kokkalis, Poutarchou 3, Athens 10675, Greece.	theodosis.kalamatianos@kcl.ac.uk		Kalamatianos, Theodosis/0000-0003-4634-2965			Adini A, 2002, CANCER RES, V62, P2749; Ahmad S, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-15; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Bottomley MJ, 2000, CLIN EXP IMMUNOL, V119, P182, DOI 10.1046/j.1365-2249.2000.01097.x; Cai J, 2003, DIABETES, V52, P2959, DOI 10.2337/diabetes.52.12.2959; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524; Foidart JM, 2009, J REPROD IMMUNOL, V82, P106, DOI 10.1016/j.jri.2009.09.001; Foyouzi N, 2006, INT J GYNECOL OBSTET, V92, P32, DOI 10.1016/j.ijgo.2005.09.004; Frati A, 2004, J NEUROSURG, V100, P24, DOI 10.3171/jns.2004.100.1.0024; FRIEDE RL, 1978, AM J PATHOL, V92, P69; Fujisawa H, 2006, NEUROL MED-CHIR, V46, P333, DOI 10.2176/nmc.46.333; Funai M, 2011, J NEUROTRAUM, V28, P1127, DOI 10.1089/neu.2010.1498; Green CJ, 2001, CANCER RES, V61, P2696; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hohenstein A, 2005, J NEUROTRAUM, V22, P518, DOI 10.1089/neu.2005.22.518; Hong HJ, 2009, SURG NEUROL, V71, P161, DOI 10.1016/j.surneu.2008.01.023; Karumanchi SA, 2004, ENDOCRINOLOGY, V145, P4835, DOI 10.1210/en.2004-1028; Khaliq A, 1998, LAB INVEST, V78, P109; Kristof RA, 2008, J NEUROSURG, V108, P275, DOI 10.3171/JNS/2008/108/2/0275; Lee KS, 2004, BRAIN INJURY, V18, P351, DOI 10.1080/02699050310001645801; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; MARKWALDER TM, 1986, ACTA NEUROCHIR, V79, P100, DOI 10.1007/BF01407452; Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256; Nanko N, 2009, NEUROL MED-CHIR, V49, P379, DOI 10.2176/nmc.49.379; Odorisio T, 2002, J CELL SCI, V115, P2559; Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516; Pan PX, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-36; Pilarczyk K, 2008, ATHEROSCLEROSIS, V196, P333, DOI 10.1016/j.atherosclerosis.2006.10.038; Roeckl W, 1998, EXP CELL RES, V241, P161, DOI 10.1006/excr.1998.4039; Roncal C, 2010, CARDIOVASC RES, V86, P29, DOI 10.1093/cvr/cvp380; Santarius Thomas, 2010, Clin Neurosurg, V57, P112; SATO S, 1975, J NEUROSURG, V43, P569, DOI 10.3171/jns.1975.43.5.0569; SCHACHENMAYR W, 1978, AM J PATHOL, V92, P53; Schiettecatte J, 2010, CLIN BIOCHEM, V43, P768, DOI 10.1016/j.clinbiochem.2010.02.010; Schoenfeld Jonathan, 2004, Angiogenesis, V7, P143, DOI 10.1007/s10456-004-1677-0; Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423; Shono T, 2001, J CLIN NEUROSCI, V8, P411, DOI 10.1054/jocn.2000.0951; Suzuki K, 1999, J TRAUMA, V46, P532, DOI 10.1097/00005373-199903000-00040; Suzuki M, 1998, ACTA NEUROCHIR, V140, P51, DOI 10.1007/s007010050057; Weigel R, 2001, ACTA NEUROCHIR, V143, P811, DOI 10.1007/s007010170035; Weigel R, 2007, NEUROSURGERY, V61, P788, DOI 10.1227/01.NEU.0000298907.56012.E8; Wu FTH, 2010, J CELL MOL MED, V14, P528, DOI 10.1111/j.1582-4934.2009.00941.x; Yamamoto H, 2003, J NEUROSURG, V98, P1217, DOI 10.3171/jns.2003.98.6.1217; YAMASHIMA T, 1983, J NEUROSURG, V59, P298, DOI 10.3171/jns.1983.59.2.0298; Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172; Yoo SA, 2009, ARTHRITIS RHEUM-US, V60, P345, DOI 10.1002/art.24289; Ziche M, 1997, LAB INVEST, V76, P517	48	37	38	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2013	118	2					353	357		10.3171/2012.10.JNS12327			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	076DY	WOS:000313937900019	23140147				2022-02-06	
J	Lange, RT; Brickell, T; French, LM; Ivins, B; Bhagwat, A; Pancholi, S; Iverson, GL				Lange, Rael T.; Brickell, Tracey; French, Louis M.; Ivins, Brian; Bhagwat, Aditya; Pancholi, Sonal; Iverson, Grant L.			Risk Factors for Postconcussion Symptom Reporting after Traumatic Brain Injury in US Military Service Members	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; postconcussion symptoms; risk factors; service members	POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; POST-CONCUSSION SYNDROME; MENTAL-HEALTH PROBLEMS; GOOD OLD DAYS; COMPENSATION-SEEKING; EARLY INTERVENTION; TEST-PERFORMANCE; COMBAT VETERANS; POOR EFFORT	The purpose of this study was to identify factors that are predictive of, or associated with, postconcussion symptom reporting after traumatic brain injury (TBI) in the U.S. military. Participants were 125 U.S. military service members (age: M = 29.6 years, standard deviation [SD] = 8.9, range = 18-56 years) who sustained a TBI, divided into two groups based on symptom criteria for postconcussional disorder (PCD): PCD-Present (n = 65) and PCD-Absent (n = 60). Participants completed a neuropsychological evaluation at Walter Reed Army Medical Center (M = 9.4 months after injury, SD = 9.9; range: 1.1 to 44.8). Factors examined included demographic characteristics, injury-related variables, psychological testing, and effort testing. There were no significant group differences for age, sex, education, race, estimated premorbid intelligence, number of deployments, combat versus non-combat related injury, or mechanism of injury (p > 0.098 for all). There were significant main effects for severity of body injury, duration of loss of consciousness, duration of post-traumatic amnesia, intracranial abnormality, time tested post-injury, possible symptom exaggeration, poor effort, depression, and traumatic stress (p < 0.044 for all). PCD symptom reporting was most strongly associated with possible symptom exaggeration, poor effort, depression, and traumatic stress. PCD rarely occurred in the absence of depression, traumatic stress, possible symptom exaggeration, or poor effort (n = 7, 5.6%). Many factors unrelated to brain injury were influential in self-reported postconcussion symptoms in this sample. Clinicians cannot assume uncritically that endorsement of items on a postconcussion symptom checklist is indicative of residual effects from a brain injury.	[Lange, Rael T.; Brickell, Tracey; French, Louis M.; Ivins, Brian; Bhagwat, Aditya; Pancholi, Sonal; Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey; French, Louis M.; Bhagwat, Aditya] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Pancholi, Sonal] Ft Belvoir Community Hosp, Ft Belvoir, VA USA; [Brickell, Tracey; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA		Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Bethesda, MD 20852 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	Iverson, Grant/0000-0001-7348-9570; french, louis/0000-0002-9451-0604			Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant RA, 2003, BEHAV RES THER, V41, P489, DOI 10.1016/S0005-7967(02)00179-1; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Green P., 2003, J TRAUMA, V82; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson G. L., 2010, J INT SOC NEUROPSYCH, V16, P25; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kreutzer R.D, 2012, BRAIN INJURY MED PRI; Lange R. T., 2013, J NEUROTRAU IN PRESS; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morey, 1991, PERSONALITY ASSESSME; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; *PSYCH CORP, 2001, WECHSL TEST AD READ; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Shalev AY, 2012, ARCH GEN PSYCHIAT, V69, P166, DOI 10.1001/archgenpsychiatry.2011.127; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Smith DW, 1996, PSYCHOL ASSESSMENT, V8, P3, DOI 10.1037/1040-3590.8.1.3; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2007, J INT NEUROPSYCH SOC, V13, P196; Tsanadis J., 2007, INT NEUR SOC 35 ANN; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Weathers F. W., 1994, PTSD CHECKLIST CIVIL; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	89	37	37	0	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2013	30	4					237	246		10.1089/neu.2012.2685			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	093CM	WOS:000315169300001	23126461				2022-02-06	
J	Brennan, GP; Jimenez-Mateos, EM; McKiernan, RC; Engel, T; Tzivion, G; Henshall, DC				Brennan, Gary P.; Jimenez-Mateos, Eva M.; McKiernan, Ross C.; Engel, Tobias; Tzivion, Guri; Henshall, David C.			Transgenic Overexpression of 14-3-3 Zeta Protects Hippocampus against Endoplasmic Reticulum Stress and Status Epilepticus In Vivo	PLOS ONE			English	Article							TEMPORAL-LOBE EPILEPSY; INDUCED NEURONAL DEATH; EXPERIMENTALLY EVOKED SEIZURES; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; ER STRESS; MISFOLDED PROTEINS; CELL-DEATH; APOPTOSIS; MICE	14-3-3 proteins are ubiquitous molecular chaperones that are abundantly expressed in the brain where they regulate cell functions including metabolism, the cell cycle and apoptosis. Brain levels of several 14-3-3 isoforms are altered in diseases of the nervous system, including epilepsy. The 14-3-3 zeta (zeta) isoform has been linked to endoplasmic reticulum (ER) function in neurons, with reduced levels provoking ER stress and increasing vulnerability to excitotoxic injury. Here we report that transgenic overexpression of 14-3-3 zeta in mice results in selective changes to the unfolded protein response pathway in the hippocampus, including down-regulation of glucose-regulated proteins 78 and 94, activating transcription factors 4 and 6, and Xbp1 splicing. No differences were found between wild-type mice and transgenic mice for levels of other 14-3-3 isoforms or various other 14-3-3 binding proteins. 14-3-3 zeta overexpressing mice were potently protected against cell death caused by intracerebroventricular injection of the ER stressor tunicamycin. 14-3-3 zeta overexpressing mice were also potently protected against neuronal death caused by prolonged seizures. These studies demonstrate that increased 14-3-3 zeta levels protect against ER stress and seizure-damage despite down-regulation of the unfolded protein response. Delivery of 14-3-3 zeta may protect against pathologic changes resulting from prolonged or repeated seizures or where injuries provoke ER stress.	[Brennan, Gary P.; Jimenez-Mateos, Eva M.; McKiernan, Ross C.; Engel, Tobias; Henshall, David C.] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; [Tzivion, Guri] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA		Henshall, DC (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland.	dhenshall@rcsi.ie	Jimenez-Mateos, Eva/AAG-8072-2019; Brennan, Gary/K-4009-2019	Brennan, Gary/0000-0002-4262-0481; Engel, Tobias/0000-0001-9137-0637; Jimenez-Mateos, Eva/0000-0001-6417-6580; Henshall, David/0000-0001-6237-9632	Science Foundation IrelandScience Foundation IrelandEuropean Commission [08/IN.1/B1875, 08/RFP/1745]; Health Research Board award [HRA-POR/2011/41]	This study was funded by Science Foundation Ireland awards 08/IN.1/B1875 and 08/RFP/1745 and by Health Research Board award HRA-POR/2011/41. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berg D, 2003, NAT REV NEUROSCI, V4, P752, DOI 10.1038/nrn1197; Bronisz A, 2006, MOL BIOL CELL, V17, P3897, DOI 10.1091/mbc.E06-05-0470; Cheah PS, 2012, MOL PSYCHIATR, V17, P451, DOI 10.1038/mp.2011.158; Concannon CG, 2008, J NEUROCHEM, V105, P891, DOI 10.1111/j.1471-4159.2007.05187.x; Dunleavy M, 2010, AM J PATHOL, V176, P330, DOI 10.2353/ajpath.2010.090119; Engel T, 2012, FASEB J, V26, P1616, DOI 10.1096/fj.11-196089; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Engel T, 2010, J NEUROCHEM, V115, P92, DOI 10.1111/j.1471-4159.2010.06909.x; Engel T, 2010, FASEB J, V24, P853, DOI 10.1096/fj.09-145870; Fujikawa DG, 2006, STATUS EPILEPTICUS M, V36, P463; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2012, JASPERS BASIC MECH E, P262; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Jimenez-Mateos EM, 2012, NAT MED, V18, P1087, DOI 10.1038/nm.2834; Jimenez-Mateos EM, 2008, NEUROBIOL DIS, V32, P442, DOI 10.1016/j.nbd.2008.08.008; Kaneko K, 2006, MED HYPOTHESES, V67, P169, DOI 10.1016/j.mehy.2006.01.019; Kitao Y, 2001, J CLIN INVEST, V108, P1439, DOI 10.1172/JCI12978; Lin JH, 2007, ANN REV PATHOL; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu GL, 2012, NEUROL SCI; Liu GL, 2011, BRAIN RES BULL, V84, P94, DOI 10.1016/j.brainresbull.2010.10.004; Lukasiuk K, 2003, EUR J NEUROSCI, V17, P271, DOI 10.1046/j.1460-9568.2003.02461.x; MARTIN H, 1994, J NEUROCHEM, V63, P2259; Maruo K, 2003, BRAIN RES, V977, P294, DOI 10.1016/S0006-8993(03)02838-5; Miller-Delaney SFC, 2012, J NEUROSCI, V32, P1577, DOI 10.1523/JNEUROSCI.5180-11.2012; Murphy BM, 2010, CELL DEATH DIFFER, V17, P459, DOI 10.1038/cdd.2009.134; Murphy N, 2008, BIOMARKERS, V13, P377, DOI [10.1080/13547500802027971, 10.1080/13547500802027971 ]; Murphy N, 2008, J NEUROCHEM, V106, P978, DOI 10.1111/j.1471-4159.2008.05447.x; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Noh HS, 2006, J NEUROSCI RES, V84, P1829, DOI 10.1002/jnr.21057; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Olney J W, 1986, Adv Neurol, V44, P857; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Pozuelo-Rubio M, 2011, AUTOPHAGY, V7, P240, DOI 10.4161/auto.7.2.14286; Ramser EM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013462; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Schindler CK, 2006, J NEUROCHEM, V99, P561, DOI 10.1111/j.1471-4159.2006.04153.x; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Steinacker P, 2005, MOL CELL BIOL, V25, P1339, DOI 10.1128/MCB.25.4.1339-1346.2005; Stetler RA, 2008, J NEUROSCI, V28, P13038, DOI 10.1523/JNEUROSCI.4407-08.2008; Tanaka K, 2010, EPILEPSY RES, V88, P151, DOI 10.1016/j.eplepsyres.2009.10.012; Toyo-oka K, 2003, NAT GENET, V34, P274, DOI 10.1038/ng1169; Umahara T, 2004, ACTA NEUROPATHOL, V108, P279, DOI 10.1007/s00401-004-0885-4; Umahara T, 2011, BRAIN RES, V1410, P1, DOI 10.1016/j.brainres.2011.06.036; van der Brug MP, 2002, BRAIN RES, V956, P110, DOI 10.1016/S0006-8993(02)03487-X; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wang B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010409; WANG S, 1993, NEUROCHEM INT, V23, P575, DOI 10.1016/0197-0186(93)90106-F; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yacoubian TA, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.4; Yamamoto A, 2006, J NEUROPATH EXP NEUR, V65, P217, DOI 10.1097/01.jnen.0000202886.22082.2a	55	37	37	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2013	8	1							e54491	10.1371/journal.pone.0054491			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077JK	WOS:000314023600061	23359526	Green Published, gold, Green Submitted			2022-02-06	
J	Cheong, CU; Chang, CP; Chao, CM; Cheng, BC; Yang, CZ; Chio, CC				Cheong, Chong-Un; Chang, Ching-Ping; Chao, Chien-Ming; Cheng, Bor-Chih; Yang, Chung-Zhing; Chio, Chung-Ching			Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-alpha Contents and by Stimulating Newly Formed Neurogenesis	MEDIATORS OF INFLAMMATION			English	Article							NECROSIS-FACTOR-ALPHA; ADULT-RAT; HIPPOCAMPAL NEUROGENESIS; NEURONAL DIFFERENTIATION; CELL-PROLIFERATION; DENTATE GYRUS; EXPRESSION; DOUBLECORTIN; INFLAMMATION; CONTRIBUTES	It remains unclear whether etanercept penetrates directly into the contused brain and improves the outcomes of TBI by attenuating brain contents of TNF-alpha and/or stimulating newly formed neurogenesis. Rats that sustained TBI are immediately treated with etanercept. Acute neurological and motor injury is assessed in all rats the day prior to and 7 days after surgery. The numbers of the colocalizations of 5-bromodeoxyuridine and doublecortin specific markers in the contused brain injury that occurred during TBI were counted by immunofluorescence staining. Enzyme immunoassay for quantitative determination of TNF-alpha or etanercept in brain tissues is also performed. Seven days after systemic administration of etanercept, levels of etanercept can be detected in the contused brain tissues. In addition, neurological and motor deficits, cerebral contusion, and increased brain TNF-alpha contents caused by TBI can be attenuated by etanercept therapy. Furthermore, the increased numbers of the colocalizations of 5-bromodeoxyuridine and doublecortin specific markers in the contused brain tissues caused by TBI can be potentiated by etanercept therapy. These findings indicate that systemically administered etanercept may penetrate directly into the contused brain tissues and may improve outcomes of TBI by reducing brain contents of TNF-alpha and by stimulating newly formed neurogenesis.	[Cheong, Chong-Un; Chao, Chien-Ming] Chi Mei Med Ctr, Dept Intens Care Med, Tainan, Taiwan; [Chang, Ching-Ping; Cheng, Bor-Chih] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Chao, Chien-Ming; Cheng, Bor-Chih; Chio, Chung-Ching] Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan; [Yang, Chung-Zhing] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Biol & Drug Discovery, Taipei 110, Taiwan		Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan.	ccchio.ns@gmail.com	Bilfinger, Thomas V./J-6392-2019	Chang, Ching-Ping/0000-0003-0890-9414	National Science CouncilMinistry of Science and Technology, Taiwan [NSC90-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, NSC101-2314-B-218-001-MY3]; Department of Health, the Center of Excellence for Clinical Trial and Research in Neuroscience of the Republic of China [DOH99-TD-B-111-003]	This work was supported in part by the National Science Council (Grant nos. NSC90-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, and NSC101-2314-B-218-001-MY3) and the Department of Health, the Center of Excellence for Clinical Trial and Research in Neuroscience of the Republic of China (Grant no. DOH99-TD-B-111-003).	Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Campbell S, 2007, T I MET FINISH, V85, P6, DOI 10.1179/imf.2007.85.1.6; Chang MW, 2008, J NEUROSCI METH, V168, P186, DOI 10.1016/j.jneumeth.2007.09.013; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Francis J, 2004, AM J PHYSIOL-HEART C, V286, pH2264, DOI 10.1152/ajpheart.01072.2003; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Jiang Y, 2008, NEUROBIOL DIS, V32, P125, DOI 10.1016/j.nbd.2008.06.017; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; Liu YP, 2005, BRAIN RES, V1054, P152, DOI 10.1016/j.brainres.2005.06.085; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Oshima T, 2009, BRAIN RES, V1290, P102, DOI 10.1016/j.brainres.2009.07.022; Parent JM, 1997, J NEUROSCI, V17, P3727; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Wang Y, 1997, J NEUROSCI, V17, P4341; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	39	37	41	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2013	2013								620837	10.1155/2013/620837			9	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	141PJ	WOS:000318736800001	23710117	Green Published, gold			2022-02-06	
J	Golub, A; Bennett, AS				Golub, Andrew; Bennett, Alex S.			Prescription Opioid Initiation, Correlates, and Consequences Among a Sample of OEF/OIF Military Personnel	SUBSTANCE USE & MISUSE			English	Article						drug use disorder; minority; pain management; military personnel; veterans; reintegration; mental health	SUBSTANCE USE; DRUG-USERS; UNITED-STATES; BEHAVIOR; ABUSE; RECRUITMENT; DISORDERS; VETERANS; ALCOHOL; TRENDS	Prescription opioid (PO) misuse represents a major health risk for many service members and veterans. This paper examines the pathways to misuse among a sample of US veterans who recently returned from Iraq and Afghanistan to low-income, predominately minority sections of New York City. Recreational PO misuse was not common on deployment. Most PO misusers initiated use subsequent to PO use for pain management, an iatrogenic pathway. However, most PO users did not misuse them. Veterans that misused POs were more likely to have other reintegration problems including drug and alcohol use disorders, traumatic brain injury (TBI), unemployment, and homelessness.	[Golub, Andrew; Bennett, Alex S.] Natl Dev & Res Inst Inc, New York, NY USA		Golub, A (corresponding author), Natl Dev & Res Inst Inc, 47 Prospect Pkwy, Burlington, VT 05401 USA.	golub@ndri.org			National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA020178]; Peter F. McManus Charitable Trust; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA020178] Funding Source: NIH RePORTER	This research was supported by grants from the National Institute on Alcohol Abuse and Alcoholism (R01 AA020178) and from the Peter F. McManus Charitable Trust. Points of view expressed in this paper do not necessarily represent the official position of the U. S. Government, NIAAA, the McManus Trust or NDRI. The authors express their deep appreciation to the project interviewers-Mr. Gary Huggins (U. S. Marines, retired), Mr. Atiba Marson-Quinones (U. S. Navy Reserves), and Ms. Morgan Cooley (U. S. Army, retired)-to the data manager, Dr. Peter Vazan, and all of the veterans who participated in the study.	Abdul-Quader AS, 2006, AIDS BEHAV, V9, P403; Barrett F., 1996, GENDER WORK ORG, V3, P129, DOI DOI 10.1111/J.1468-0432.1996.TB00054.X; Bennett Alex S., 2012, ADDICTION SYNDROME H, P195; Bergen-Cico DK, 2011, WAR DRUGS ROLE MILIT; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bohnert ASB, 2010, DRUG ALCOHOL DEPEN, V110, P183, DOI 10.1016/j.drugalcdep.2010.03.010; Bray R. M., 2006, 2005 DEP DEFENSE SUR; Bray R.M., 2012, PAIN SYNDROMES RECRU, P3; Bray RM, 2007, ADDICTION, V102, P1092, DOI 10.1111/j.1360-0443.2007.01841.x; Bray RM, 2010, MIL MED, V175, P390, DOI 10.7205/MILMED-D-09-00132; CDCP, 2011, PRESCR PAINK OV US V; Courtwright D. T., 2001, DARK PARADISE HIST O; Ender M., 2009, AM SOLDIERS IRAQ MCS; Finley EP, 2011, FIELDS COMBAT UNDERS; Goebel JR, 2011, J PAIN SYMPTOM MANAG, V41, P848, DOI 10.1016/j.jpainsymman.2010.07.009; Golub A, 2004, J DRUG ISSUES, V34, P361, DOI 10.1177/002204260403400206; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Harocopos A, 2009, INT J DRUG POLICY, V20, P317, DOI 10.1016/j.drugpo.2008.06.003; Heckathorn D., 2012, RESPONDENT DRIVEN SA; Heckathorn DD, 2002, SOC PROBL, V49, P11, DOI 10.1525/sp.2002.49.1.11; Heckathorn DD, 1997, SOC PROBL, V44, P174, DOI 10.1525/sp.1997.44.2.03x0221m; Heckathorn DD, 2007, SOCIOL METHODOL, V37, P151, DOI 10.1111/j.1467-9531.2007.00188.x; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Holyfield Lori, 2011, VETERANS JOURNEYS HO; Iguchi MY, 2009, J URBAN HEALTH, V86, pS5, DOI 10.1007/s11524-009-9365-4; Institute of Medicine, 2012, SUBST US DIS US ARM; International Narcotics Control Board, 2009, REP INT NARC CONTR B; Jeffri J., 2003, CHANGING BEAT STUDY, VVol. 3, P48; Johnson CV, 2009, AM J PUBLIC HEALTH, V99, pS187, DOI 10.2105/AJPH.2007.127464; Karney B. R., 2008, INVISIBLE WOUNDS PRE; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lansky A, 2007, PUBLIC HEALTH REP, V122, P48, DOI 10.1177/00333549071220S108; Larance B, 2011, DRUG ALCOHOL REV, V30, P236, DOI 10.1111/j.1465-3362.2010.00283.x; Madaus JW, 2009, J POSTSECOND EDUC DI, V22, P10; Manchikanti L, 2008, PAIN PHYSICIAN, V11, pS63; Manchikanti Laxmaiah, 2007, Pain Physician, V10, P399; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; ONDCP, 2011, EP RESP AM PRESCR DR; Poehlman JA, 2011, MIL MED, V176, P397, DOI 10.7205/MILMED-D-10-00240; Rusch ML, 2009, J URBAN HEALTH, V86, P760, DOI 10.1007/s11524-009-9377-0; SAMHSA, 2010, 2009 NAT SURV DRUG U; Shahmanesh M, 2009, AM J PUBLIC HEALTH, V99, P1239, DOI 10.2105/AJPH.2008.149930; Skidmore WC, 2011, SOC WORK HEALTH CARE, V50, P85, DOI 10.1080/00981389.2010.522913; Strathdee SA., 2002, INT J DRUG POLICY, V13, P113, DOI [DOI 10.1016/S0955-3959(02)00010-5, 10.1016/S0955-3959(02)00010-5]; U.S. Army, 2010, ARM HLTH PROM RISK R; U.S. Army, 2012, ARM 2020 GEN HLTH DI; US Department of Defense, 2008, ENH POSTD HLTH ASS P; Wang JC, 2007, ADDICT BEHAV, V32, P924, DOI 10.1016/j.addbeh.2006.06.031; Warner M, 2011, NCHS DATA BRIEF; Wattana W, 2007, DRUG ALCOHOL DEPEN, V90, P228, DOI 10.1016/j.drugalcdep.2007.03.013; Wejnert C, 2008, SOCIOL METHOD RES, V37, P105, DOI 10.1177/0049124108318333; Wu Phipson C, 2010, J Opioid Manag, V6, P133; Zinberg, 1986, DRUG SET SETTING BAS	53	37	37	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1082-6084	1532-2491		SUBST USE MISUSE	Subst. Use Misuse		2013	48	10					811	820		10.3109/10826084.2013.796988			10	Substance Abuse; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Substance Abuse; Psychiatry; Psychology	186ES	WOS:000322025400003	23869455	Green Accepted			2022-02-06	
J	Planetta, PJ; Schulze, ET; Geary, EK; Corcos, DM; Goldman, JG; Little, DM; Vaillancourt, DE				Planetta, P. J.; Schulze, E. T.; Geary, E. K.; Corcos, D. M.; Goldman, J. G.; Little, D. M.; Vaillancourt, D. E.			Thalamic Projection Fiber Integrity in de novo Parkinson Disease	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							DIFFUSION TENSOR MRI; TRAUMATIC BRAIN-INJURY; WHITE-MATTER; INTRALAMINAR NUCLEI; CLINICAL-DIAGNOSIS; SUBSTANTIA-NIGRA; TRACTOGRAPHY; MICROSTRUCTURE; DEGENERATION; DYSFUNCTION	BACKGROUND AND PURPOSE Postmortem studies of advanced PD have revealed disease-related pathology in the thalamus with an apparent predilection for specific thalamic nuclei. In the present study, we used DTI to investigate in vivo the microstructural integrity of 6 thalamic regions in de novo patients with PD relative to healthy controls. MATERIALS AND METHODS: Forty subjects (20 with early stage untreated PD and 20 age- and sex-matched controls) were studied with a high-resolution DTI protocol at 3T to investigate the integrity of thalamic nuclei projection fibers. Two blinded, independent raters drew ROls in the following 6 thalamic regions: AN, VA, VL, DM, VPL/VPM, and PU. FA values were then calculated from the projection fibers in each region. RESULTS: FA values were reduced significantly in the fibers projecting from the AN, VA, and DM, but not the VPL/VPM and PU, in the PD group compared with the control group. In addition, there was a reduction in FA values that approached significance in the VL of patients with PD. These findings were consistent across both raters. CONCLUSIONS: The present study provides preliminary in vivo evidence of thalamic projection fiber degeneration in de novo PD and sheds light on the extent of disrupted thalamic circuitry as a result of the disease itself.	[Planetta, P. J.; Vaillancourt, D. E.] Univ Florida, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA; [Vaillancourt, D. E.] Univ Florida, Dept Radiol, Gainesville, FL 32611 USA; [Vaillancourt, D. E.] Univ Florida, Dept Biomed Engn, Gainesville, FL 32611 USA; [Schulze, E. T.; Geary, E. K.; Corcos, D. M.] Univ Illinois, Dept Neurol & Rehabil, Chicago, IL USA; [Corcos, D. M.] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA; [Corcos, D. M.] Univ Illinois, Dept Phys Therapy, Chicago, IL USA; [Corcos, D. M.] Univ Illinois, Dept Bioengn, Chicago, IL USA; [Corcos, D. M.; Goldman, J. G.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; [Little, D. M.] VISN 17 Ctr Excellence Res Returning War Vet, Dept Vet Affairs, Waco, TX USA; [Little, D. M.] Texas A&M Hlth Sci Ctr, Dept Psychiat & Behav Sci, Bryan, TX USA		Vaillancourt, DE (corresponding author), Univ Florida, Dept Appl Physiol & Kinesiol, POB 118205, Gainesville, FL 32611 USA.	vcourt@ufl.edu	Corcos, Daniel/AAX-9971-2021		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS-52318, R01-NS-58487, R01 N5058487-05]; Department of Defense/Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT 075675]; Michael J. Fox Foundation; Department of DefenseUnited States Department of Defense; Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058487, R01NS075012, R01NS052318] Funding Source: NIH RePORTER	This work was supported in part by grants from the Department of Defense/Congressionally Directed Medical Research Program (PT 075675) to D.M.L., Michael J. Fox Foundation (D.E.V.), and National Institutes of Health (R01-NS-52318 and R01NS-58487 to D.E.V.).; Daniel Corcos-RELATED: Grant: NIH;* Support for Travel to Meetings for the Study or Other Purposes: NIH.* Deborah Little RELATED: Grant: Department of Defense,* Department of Veterans Affairs.* David Vaillancourt-RELATED: Grant: Scaling and Sequencing Motor Output in Humans,* Comments: NIH R01 (I am PI); UNRELATED: Consultancy: I consult on a project at Northwestern University using diffusion imaging in Parkinson's disease. The project is unrelated to the current project; Grants/Grants Pending: NIH R01 N5058487-05, Comments: Role of Cortex and Cerebellum in Visually-Guided Motor Behavior.* (*Money paid to institution)	Arend I, 2008, PROG BRAIN RES, V171, P475, DOI 10.1016/S0079-6123(08)00669-9; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Blumenfeld H., 2002, NEUROANATOMY CLIN CA; Boska MD, 2007, NEUROBIOL DIS, V26, P590, DOI 10.1016/j.nbd.2007.02.010; Braak H, 2000, J NEUROL, V247, P3; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brooks D, 2009, BRAIN RES BULL, V78, P97, DOI 10.1016/j.brainresbull.2008.08.014; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Carrera E, 2006, NEUROLOGY, V66, P1817, DOI 10.1212/01.wnl.0000219679.95223.4c; Chan LL, 2007, J NEUROL NEUROSUR PS, V78, P1383, DOI 10.1136/jnnp.2007.121525; Chaudhuri KR, 2006, LANCET NEUROL, V5, P235, DOI 10.1016/S1474-4422(06)70373-8; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Du GW, 2011, MOVEMENT DISORD, V26, P1627, DOI 10.1002/mds.23643; Emre M, 2003, MOVEMENT DISORD, V18, pS63, DOI 10.1002/mds.10565; Gattellaro G, 2009, AM J NEURORADIOL, V30, P1222, DOI 10.3174/ajnr.A1556; Halliday GM, 2009, PARKINSONISM RELAT D, V15, pS152, DOI 10.1016/S1353-8020(09)70804-1; Henderson JM, 2000, ANN NEUROL, V47, P345, DOI 10.1002/1531-8249(200003)47:3<345::AID-ANA10>3.0.CO;2-V; Henderson JM, 2000, BRAIN, V123, P1410, DOI 10.1093/brain/123.7.1410; Hodaie M, 2007, NEUROSURGERY, V60, P17, DOI 10.1227/01.NEU.0000249209.11967.CB; Hughes AJ, 2001, NEUROLOGY, V57, pS34; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; JAHANSHAHI M, 1995, BRAIN, V118, P913, DOI 10.1093/brain/118.4.913; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Klein JC, 2010, NEUROIMAGE, V51, P555, DOI 10.1016/j.neuroimage.2010.02.062; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Kwon HG, 2011, NEURORADIOLOGY, V53, P787, DOI 10.1007/s00234-011-0878-7; Leh SE, 2008, INT J BIOMED IMAGING, V2008, DOI 10.1155/2008/789539; Li W, 2010, AM J NEURORADIOL, V31, P1861, DOI 10.3174/ajnr.A2195; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Mahlknecht P, 2010, NEURODEGENER DIS, V7, P300, DOI 10.1159/000314495; McKeown MJ, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-8; Metzger CD, 2010, FRONT NEUROANAT, V4, DOI 10.3389/fnana.2010.00138; Minati L, 2008, NMR BIOMED, V21, P2, DOI 10.1002/nbm.1143; Nicoletti G, 2010, NEUROLOGY, V74, P988, DOI 10.1212/WNL.0b013e3181d5a460; Nobili F, 2010, MOVEMENT DISORD, V25, P35, DOI 10.1002/mds.22899; Owen AM, 1998, BRAIN, V121, P949, DOI 10.1093/brain/121.5.949; Peran P, 2010, BRAIN, V133, P3423, DOI 10.1093/brain/awq212; Planetta PJ, 2011, NEURODEGENER DIS MAN, V1, P67, DOI 10.2217/NMT.10.6; Prodoehl J, 2010, MOVEMENT DISORD, V25, P2035, DOI 10.1002/mds.23360; Rub U, 2002, NEUROBIOL AGING, V23, P245, DOI 10.1016/S0197-4580(01)00269-X; Schmahmann JD, 2003, STROKE, V34, P2264, DOI 10.1161/01.STR.0000087786.38997.9E; Spraker MB, 2010, HUM BRAIN MAPP, V31, P1928, DOI 10.1002/hbm.20987; Vaillancourt DE, 2009, NEUROLOGY, V72, P1378, DOI 10.1212/01.wnl.0000340982.01727.6e; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; WIMBERGER DM, 1995, J COMPUT ASSIST TOMO, V19, P28, DOI 10.1097/00004728-199501000-00005; Yoshikawa K, 2004, J NEUROL NEUROSUR PS, V75, P481, DOI 10.1136/jnnp.2003.021873; Zhan W, 2012, MOVEMENT DISORD, V27, P90, DOI 10.1002/mds.23917; Zhang DY, 2010, CEREB CORTEX, V20, P1187, DOI 10.1093/cercor/bhp182; Zhou X, 1999, United States Patent, Patent No. [5 1999;864:233, 19995864233]	51	37	37	0	11	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2013	34	1					74	79		10.3174/ajnr.A3178			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	070WQ	WOS:000313545200014	22766668	Green Published, Green Accepted, hybrid			2022-02-06	
J	Schirmer, L; Merkler, D; Konig, FB; Bruck, W; Stadelmann, C				Schirmer, Lucas; Merkler, Doron; Koenig, Fatima B.; Brueck, Wolfgang; Stadelmann, Christine			Neuroaxonal Regeneration is More Pronounced in Early Multiple Sclerosis than in Traumatic Brain Injury Lesions	BRAIN PATHOLOGY			English	Article						axonal regeneration; GAP43; multiple sclerosis (MS); neuronal plasticity; traumatic brain injury (TBI)	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ANTEROGRADE AXONAL-TRANSPORT; SPINAL-CORD; MONOCLONAL-ANTIBODIES; HEAD-INJURY; DAMAGE; PROTEIN; PLASTICITY; PRECURSOR; MOTOR	The extent of irreversible neuroaxonal damage is the key determinant of permanent disability in traumatic and inflammatory conditions of the central nervous system (CNS). Structural damage is nevertheless in part compensated by neuroplastic events. However, it is unknown whether the same kinetics and mechanisms of neuroaxonal de- and regeneration take place in inflammatory and traumatic conditions. We analyzed neuroaxonal degeneration and plasticity in early multiple sclerosis (MS) lesions and traumatic brain injury (TBI). Neuroaxonal degeneration identified by the presence of SMI31+ chromatolytic neurons and SMI32+ axonal profiles were characteristic features of leukocortical TBI lesions. Axonal transport disturbances as determined by amyloid precursor protein (APP)+ spheroids were present in both TBI and MS lesions to a similar degree. Neurons expressing growth-associated protein 43 (GAP43) and synaptophysin (Syn) were found under both pathological conditions. However, axonal swellings immunopositive for GAP43 and Syn clearly prevailed in subcortical MS lesions, suggesting a higher regenerative potential in MS. In this context, GAP43+/APP+ axonal spheroid ratios correlated with macrophage infiltration in TBI and MS lesions, supporting the idea that phagocyte activation might promote neuroplastic events. Furthermore, axonal GAP43+ and Syn+ swellings correlated with prolonged survival after TBI, indicating a sustained regenerative response.	[Schirmer, Lucas; Merkler, Doron; Koenig, Fatima B.; Brueck, Wolfgang; Stadelmann, Christine] Univ Med Ctr Gottingen, Dept Neuropathol, Gottingen, Germany; [Schirmer, Lucas] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-8000 Munich, Germany; [Merkler, Doron] Univ Hosp Geneva, Div Clin Pathol, Geneva, Switzerland; [Merkler, Doron] Univ Geneva, Dept Pathol & Immunol, Geneva, Switzerland		Stadelmann, C (corresponding author), Inst Neuropathol, Robert Koch Str 40, D-37099 Gottingen, Germany.	cstadelmann@med.uni-goettingen.de	Merkler, Doron/N-9157-2016	Merkler, Doron/0000-0002-0247-2007; Schirmer, Lucas/0000-0001-7142-4116; Stadelmann, Christine/0000-0003-1766-5458	DFG transregional collaborative research center 43German Research Foundation (DFG); DFGGerman Research Foundation (DFG)European Commission [GRK 632]	This work was supported by the DFG transregional collaborative research center 43 "The brain as a target of inflammatory processes." LS was supported by the DFG (GRK 632 "Neuroplasticity").	Bar-Or A, 2011, CNS DRUGS, V25, P783, DOI 10.2165/11587820-000000000-00000; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Charcot JM, 1868, GAZ HOPITAUX, V141, P557; Charcot JM, 1868, GAZ HOPITAUX, V140, P566; Charcot JM, 1868, GAZETTE HOSP PARIS, V41, P554; CRAGG BG, 1970, BRAIN RES, V23, P1, DOI 10.1016/0006-8993(70)90345-8; DAHL D, 1989, ACTA NEUROPATHOL, V79, P154, DOI 10.1007/BF00294373; De Stefano N, 1998, BRAIN, V121, P1469, DOI 10.1093/brain/121.8.1469; Doinikow B, 1915, Z GESAMTE NEUROL PSY, V27, P151; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Frey D, 2000, J CELL BIOL, V149, P1443, DOI 10.1083/jcb.149.7.1443; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Kerschensteiner M, 2003, ANN NEUROL, V53, P292, DOI 10.1002/ana.10446; Kerschensteiner M, 2004, J EXP MED, V200, P1027, DOI 10.1084/jem.20040452; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kuhlmann T, 2002, BRAIN, V125, P2202, DOI 10.1093/brain/awf235; Li Y, 1998, STROKE, V29, P1972, DOI 10.1161/01.STR.29.9.1972; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Lucchinetti CF, 2011, NEW ENGL J MED, V365, P2188, DOI 10.1056/NEJMoa1100648; Mahad D, 2008, BRAIN, V131, P1722, DOI 10.1093/brain/awn105; Mahad DJ, 2009, BRAIN, V132, P1161, DOI 10.1093/brain/awp046; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Meeuwsen S, 2003, GLIA, V43, P243, DOI 10.1002/glia.10259; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; RADZUN HJ, 1991, LAB INVEST, V65, P306; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Rocca MA, 2010, NEUROLOGY, V74, P142, DOI 10.1212/WNL.0b013e3181c91a00; Schirmer L, 2011, BRAIN PATHOL, V21, P428, DOI 10.1111/j.1750-3639.2010.00466.x; Schirmer L, 2009, ANN NEUROL, V66, P698, DOI 10.1002/ana.21799; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Stadelmann C, 2002, BRAIN, V125, P75, DOI 10.1093/brain/awf015; Stadelmann C, 2011, CURR OPIN NEUROL, V24, P224, DOI 10.1097/WCO.0b013e328346056f; Stagi M, 2005, J NEUROSCI, V25, P352, DOI 10.1523/JNEUROSCI.3887-04.2005; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TETZLAFF W, 1989, J NEUROSCI, V9, P1303; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Vogt J, 2009, ANN NEUROL, V66, P310, DOI 10.1002/ana.21719; Wegner C, 2006, NEUROLOGY, V67, P960, DOI 10.1212/01.wnl.0000237551.26858.39; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069	50	37	37	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305			BRAIN PATHOL	Brain Pathol.	JAN	2013	23	1					2	12		10.1111/j.1750-3639.2012.00608.x			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	053CV	WOS:000312248600002	22612622	Green Published			2022-02-06	
J	Xing, GQ; Barry, ES; Benford, B; Grunberg, NE; Li, H; Watson, WD; Sharma, P				Xing, Guoqiang; Barry, Erin S.; Benford, Brandi; Grunberg, Neil E.; Li, He; Watson, William D.; Sharma, Pushpa			Impact of repeated stress on traumatic brain injury-induced mitochondrial electron transport chain expression and behavioral responses in rats	FRONTIERS IN NEUROLOGY			English	Article						oxidative phosphorylation; mitochondria; electron transport chain; behavior change; TBI; PTSD	ACOUSTIC STARTLE REFLEX; COMPLEX-I DEFICIENCY; HOUSEKEEPING PROTEINS; ALZHEIMERS-DISEASE; MATTER VOLUME; CYTOCHROME-C; WAR VETERANS; ANIMAL-MODEL; NICOTINE; DISORDER	A significant proportion of the military personnel returning from Iraq and Afghanistan conflicts have suffered from both mild traumatic brain injury (mTBI) and post-traumatic stress disorder. The mechanisms are unknown. We used a rat model of repeated stress and mTBI to examine brain activity and behavioral function. Adult male Sprague-Dawley rats were divided into four groups: Naive; 3 days repeated tail-shock stress; lateral fluid percussion mTBI; and repeated stress followed by mTBI (S-mTBI). Open field activity, sensorimotor responses, and acoustic startle responses (ASRs) were measured at various time points after mTBI. The protein expression of mitochondrial electron transport chain (ETC) complex subunits (CI-V) and pyruvate dehydrogenase (PDHE1 alpha 1) were determined in four brain regions at day 7-post mTBI. Compared to Naives, repeated stress decreased horizontal activity; repeated stress and mTBI both decreased vertical activity; and the mTBI and S-mTBI groups were impaired in sensorimotor and ASRs. Repeated stress significantly increased CI, CII, and CIII protein levels in the prefrontal cortex (PFC), but decreased PDH El al protein in the PFC and cerebellum, and decreased CIV protein in the hippocampus. The mTBI treatment decreased CV protein levels in the ipsilateral hippocampus. The S-mTBI treatment resulted in increased CII, CIII, CIV, and CV protein levels in the PFC, increased CI level in the cerebellum, and increased CIII and CV levels in the cerebral cortex, but decreased CI, CII, CIV, and PDHE1a1 protein levels in the hippocampus. Thus, repeated stress or mTBI alone differentially altered ETC expression in heterogeneous brain regions. Repeated stress followed by mTBI had synergistic effects on brain ETC expression, and resulted in more severe behavioral deficits. These results suggest that repeated stress could have contributed to the high incidence of long-term neurologic and neuropsychiatric morbidity in military personnel with or without mTBI.	[Xing, Guoqiang; Benford, Brandi; Sharma, Pushpa] Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Barry, Erin S.; Grunberg, Neil E.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA; [Li, He] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Watson, William D.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		Sharma, P (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gxing99@yahoo.com; pushpa.sharma@usuhs.edu	Xing, Guoqiang/ABA-8450-2020; Sharma, Pushpa/AAY-8756-2020	Barry, Erin/0000-0003-0788-7153	DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [W911NF 111005]; USAMRMCU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-10-1-0507]; Comprehensive National Neuroscience Program (CNNP) [W81XWH-10-2-0198]	This research was supported by DARPA award W911NF 111005 and USAMRMC award W81XWH-10-1-0507 (Pushpa Sharma), and by the Comprehensive National Neuroscience Program (CNNP) award W81XWH-10-2-0198 (William D. Watson). We would like to thank Dr. MM Jia for her contribution with the stress procedure, Mr. Kevin Cravedi for his excellent help in collecting behavioral data and Dr. Prasanth S. Ariyannur for dissecting the brain tissue.	ACRI JB, 1994, PSYCHOPHARMACOLOGY, V114, P369, DOI 10.1007/BF02244861; ACRI JB, 1991, PSYCHOPHARMACOLOGY, V104, P244, DOI 10.1007/BF02244186; Adam-Vizi V, 2005, ANTIOXID REDOX SIGN, V7, P1140, DOI 10.1089/ars.2005.7.1140; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; ASTONJONES G, 1994, J NEUROSCI, V14, P4467; BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Elliott BM, 2004, PHARMACOL BIOCHEM BE, V77, P21, DOI 10.1016/j.pbb.2003.09.016; Faraday MM, 1998, PHARMACOL BIOCHEM BE, V61, P281, DOI 10.1016/S0091-3057(98)00094-X; Faraday MM, 2003, PHARMACOL BIOCHEM BE, V74, P325, DOI 10.1016/S0091-3057(02)00999-1; Felmingham K, 2009, NEUROREPORT, V20, P1402, DOI 10.1097/WNR.0b013e3283300fbc; Ferguson RE, 2005, PROTEOMICS, V5, P566, DOI 10.1002/pmic.200400941; GRUNBERG NE, 1985, PHARMACOL BIOCHEM BE, V23, P851, DOI 10.1016/0091-3057(85)90081-4; Grunberg NE, 2011, REVISED NEUROLOGICAL; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hasegawa T, 2007, MED HYPOTHESES, V69, P1135, DOI 10.1016/j.mehy.2007.02.034; Hattori N, 2004, J NUCL MED, V45, P775; Hattori N, 2003, J NUCL MED, V44, P1709; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jia M, 2012, JOVE-J VIS EXP, DOI 10.3791/3361; Jiang XL, 2011, J PSYCHOPHARMACOL, V25, P287, DOI 10.1177/0269881109106911; Jiang XL, 2009, NEUROPSYCHOPHARMACOL, V34, P410, DOI 10.1038/npp.2008.71; Kim SH, 2000, CELL MOL LIFE SCI, V57, P1810, DOI 10.1007/PL00000661; Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255; Lannuzel A, 2003, NEUROSCIENCE, V121, P287, DOI 10.1016/S0306-4522(03)00441-X; Lazzeri C, 2009, INTERN EMERG MED, V4, P147, DOI 10.1007/s11739-008-0206-3; Li CSR, 2008, NEUROSCI BIOBEHAV R, V32, P581, DOI 10.1016/j.neubiorev.2007.10.003; Li RN, 2013, LIFE SCI, V92, P747, DOI 10.1016/j.lfs.2013.02.014; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Manczak M, 2005, J NEUROCHEM, V92, P494, DOI 10.1111/j.1471-4159.2004.02884.x; Manion ST, 2007, PHARMACOL BIOCHEM BE, V86, P559, DOI 10.1016/j.pbb.2007.01.019; Marti M, 2005, J NEUROSCI, V25, P9591, DOI 10.1523/JNEUROSCI.2546-05.2005; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matthews S, 2012, PSYCHOSOM MED, V74, P471, DOI 10.1097/PSY.0b013e31824f888f; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morse DE, 1997, PHARMACOL BIOCHEM BE, V56, P221, DOI 10.1016/S0091-3057(96)00214-6; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Nutt DJ, 2004, J CLIN PSYCHIAT, V65, P11; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pynoos RS, 1996, BIOL PSYCHIAT, V39, P129, DOI 10.1016/0006-3223(95)00088-7; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seematter G, 2004, CURR OPIN CLIN NUTR, V7, P169, DOI 10.1097/00075197-200403000-00011; SELIGMAN ME, 1967, J EXP PSYCHOL, V74, P1, DOI 10.1037/h0024514; SERVATIUS RJ, 1995, BIOL PSYCHIAT, V38, P539, DOI 10.1016/0006-3223(94)00369-E; Sharma Pushpa, 2012, Int J Crit Illn Inj Sci, V2, P172, DOI 10.4103/2229-5151.100931; Sharma Pushpa, 2009, J Emerg Trauma Shock, V2, P67, DOI 10.4103/0974-2700.50739; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Srinivasan S, 2012, FREE RADICAL BIO MED, V53, P1252, DOI 10.1016/j.freeradbiomed.2012.07.021; Su YA, 2008, INT J BIOL SCI, V4, P223; SWERDLOW NR, 1992, J PSYCHOPHARMACOL, V6, P176, DOI 10.1177/026988119200600210; Tretter L, 2004, NEUROCHEM RES, V29, P569, DOI 10.1023/B:NERE.0000014827.94562.4b; Tsolaki M, 2009, HELL J NUCL MED, V12, P41; Valenti D, 2011, BIOCHEM J, V435, P679, DOI 10.1042/BJ20101908; Villarreal G, 2002, BIOL PSYCHIAT, V52, P119, DOI 10.1016/S0006-3223(02)01359-8; Vlachos I, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001104; Xing G, 2013, POSTTRAUMATIC STRESS, P83; Xing GQ, 2012, NEUROSCI LETT, V525, P140, DOI 10.1016/j.neulet.2012.07.055; Xing GQ, 2012, EXP NEUROL, V234, P31, DOI 10.1016/j.expneurol.2011.12.007; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zelikowsky M, 2013, P NATL ACAD SCI USA, V110, P9938, DOI 10.1073/pnas.1301691110; Zhang J, 2011, PSYCHIAT RES-NEUROIM, V192, P84, DOI 10.1016/j.pscychresns.2010.09.001	71	37	37	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								196	10.3389/fneur.2013.00196			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QT	WOS:000209629000192	24376434	gold, Green Published			2022-02-06	
J	Donohue, MM; Cain, K; Zierath, D; Shibata, D; Tanzi, PM; Becker, KJ				Donohue, Megan M.; Cain, Kevin; Zierath, Dannielle; Shibata, Dean; Tanzi, Patricia M.; Becker, Kyra J.			Higher Plasma Fractalkine Is Associated With Better 6-Month Outcome From Ischemic Stroke	STROKE			English	Article						CX3CL1; fractalkine; inflammation; outcome; stroke	INTERCELLULAR-ADHESION MOLECULE-1; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MICROGLIAL ACTIVATION; SOLUBLE FRACTALKINE; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; RECEPTOR CX(3)CR1	Background and Purpose-Fractalkine (CX3CL1) is a unique chemokine that is constitutively expressed on neurons where it serves as an adhesion molecule for lymphocytes and monocytes. CX3CL1 may also be cleaved from the surface of these cells and enter the circulation to act as a traditional chemokine. CX3CL1 could thus influence the inflammatory response after stroke. We hypothesized that patients with higher plasma CX3CL1 after stroke would have a more robust inflammatory response and experience worse outcome. Methods-Plasma CX3CL1 concentrations were assessed in 85 patients who were part of a larger study evaluating immune responses after ischemic stroke; CX3CL1 values were available from Day 1 to Day 180 after stroke onset. CX3CL1 was correlated to measures of inflammation and its effect on outcome assessed. Results-At 1 day after stroke, CX3CL1 was lower in patients with severe strokes. At 180 days after stroke, CX3CL1 concentrations were lower in patients with poor outcome. The association of CX3CL1 and outcome at 180 days was independent of initial stroke severity. Plasma CX3CL1 at 180 days was inversely associated with systemic markers of inflammation, including white blood cell counts and high-sensitivity C-reactive protein. Conclusions-In contrast to our original hypothesis, lower concentrations of CX3CL1 are associated with worse stroke outcome. In light of recent studies suggesting an immunomodulatory and neuroprotective role for CX3CL1 in a variety of neurodegenerative diseases, a therapeutic role for CX3CL1 in stroke recovery should be considered. (Stroke. 2012; 43: 2300-2306.)	[Donohue, Megan M.; Zierath, Dannielle; Tanzi, Patricia M.; Becker, Kyra J.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA; [Cain, Kevin] Univ Washington, Sch Med, Dept Biostat, Seattle, WA USA; [Shibata, Dean] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA		Becker, KJ (corresponding author), Box 359775 HMC,325 9th Ave, Seattle, WA 98104 USA.	kjb@uw.edu	Becker, Kyra/L-1420-2019	Becker, Kyra/0000-0002-8310-4846	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049197]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049197] Funding Source: NIH RePORTER	This work was funded by National Institute of Neurological Disorders and Stroke R01NS049197.	Bachstetter AD, 2011, NEUROBIOL AGING, V32, P2030, DOI 10.1016/j.neurobiolaging.2009.11.022; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Blann A, 1999, BLOOD COAGUL FIBRIN, V10, P277, DOI 10.1097/00001721-199907000-00009; Chapman GA, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-15-j0004.2000; Cho SH, 2011, J BIOL CHEM, V286, P32713, DOI 10.1074/jbc.M111.254268; Cipriani R, 2011, J NEUROSCI, V31, P16327, DOI 10.1523/JNEUROSCI.3611-11.2011; Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93; Deiva K, 2004, EUR J NEUROSCI, V20, P3222, DOI 10.1111/j.1460-9568.2004.03800.x; Denes A, 2008, J CEREBR BLOOD F MET, V28, P1707, DOI 10.1038/jcbfm.2008.64; Duan RS, 2008, NEUROCHEM RES, V33, P1085, DOI 10.1007/s11064-007-9554-z; FASSBENDER K, 1995, STROKE, V26, P1361, DOI 10.1161/01.STR.26.8.1361; Fong SM, 1997, IMMUNOL RES, V16, P299, DOI 10.1007/BF02786396; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hatori K, 2002, J NEUROSCI RES, V69, P418, DOI 10.1002/jnr.10304; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Kasama T, 2008, FRONT BIOSCI-LANDMRK, V13, P2527, DOI 10.2741/2864; Kastenbauer S, 2003, J NEUROIMMUNOL, V137, P210, DOI 10.1016/S0165-5728(03)00085-7; Kim TS, 2008, NEUROSCI LETT, V436, P196, DOI 10.1016/j.neulet.2008.03.019; Krathwohl MD, 2004, STEM CELLS, V22, P109, DOI 10.1634/stemcells.22-1-109; Lauro C, 2010, NEUROPSYCHOPHARMACOL, V35, P1550, DOI 10.1038/npp.2010.26; Lee S, 2010, AM J PATHOL, V177, P2549, DOI 10.2353/ajpath.2010.100265; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Limatola C, 2005, J NEUROIMMUNOL, V166, P19, DOI 10.1016/j.jneuroim.2005.03.023; Lyden P, 1999, STROKE, V30, P2347, DOI 10.1161/01.STR.30.11.2347; Lyons A, 2009, J NEUROCHEM, V110, P1547, DOI 10.1111/j.1471-4159.2009.06253.x; Maggi L, 2011, FRONT CELL NEUROSCI, V5, DOI 10.3389/fncel.2011.00022; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1; Pabon MM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-9; Rancan M, 2004, J CEREBR BLOOD F MET, V24, P1110, DOI 10.1097/01.WCB.0000133470.91843.72; Ruitenberg MJ, 2008, J NEUROIMMUNOL, V205, P80, DOI 10.1016/j.jneuroim.2008.09.010; Shan S, 2011, NEUROBIOL AGING, V32, P443, DOI 10.1016/j.neurobiolaging.2009.03.004; Shyu KG, 1997, J NEUROL, V244, P90, DOI 10.1007/s004150050055; Sims JR, 2009, NEUROLOGY, V72, P2104, DOI 10.1212/WNL.0b013e3181aa5329; Simundic AM, 2004, CLIN INVEST MED, V27, P86; Soriano SG, 2002, J NEUROIMMUNOL, V125, P59, DOI 10.1016/S0165-5728(02)00033-4; Tanzi P, 2011, NEUROCRIT CARE, V14, P244, DOI 10.1007/s12028-010-9490-7; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Yajima N, 2005, ARTHRITIS RHEUM-US, V52, P1670, DOI 10.1002/art.21042; Zierath D, 2011, STROKE, V42, P3415, DOI 10.1161/STROKEAHA.111.627331; Zujovic V, 2000, GLIA, V29, P305, DOI 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.3.CO;2-M	42	37	38	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	SEP	2012	43	9					2300	+		10.1161/STROKEAHA.112.657411			9	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	000UX	WOS:000308416300021	22798324	Green Accepted, Bronze			2022-02-06	
J	Kim, J; Whyte, J; Patel, S; Europa, E; Slattery, J; Coslett, HB; Detre, JA				Kim, Junghoon; Whyte, John; Patel, Sunil; Europa, Eduardo; Slattery, John; Coslett, H. Branch; Detre, John A.			A Perfusion fMRI Study of the Neural Correlates of Sustained-Attention and Working-Memory Deficits in Chronic Traumatic Brain Injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury rehabilitation; cerebral blood flow; arterial spin-labeled fMRI; sustained attention; n-back working-memory task; go/no-go visual reaction time	POSITRON-EMISSION-TOMOGRAPHY; DIFFEOMORPHIC IMAGE REGISTRATION; DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; COGNITIVE REHABILITATION; INATTENTIVE BEHAVIOR; CORTEX; TASK; ACTIVATION	Background. Given that traumatic brain injury (TBI) results in chronic alteration of baseline cerebral perfusion, a perfusion functional MRI (fMRI) method that dissociates resting-and task-related cerebral blood flow (CBF) changes can be useful in noninvasively investigating the neural correlates of cognitive dysfunction and recovery in TBI. Objective. The authors used continuous arterial spin-labeled (ASL) perfusion fMRI to characterize CBF at rest and during sustained-attention and working-memory tasks. Methods. A total of 18 to 21 individuals with moderate to severe TBI and 14 to 18 demographically matched healthy controls completed 3 continuous 6-minute perfusion fMRI scans (resting, visual sustained attention, and 2-back working memory). Results. For both tasks, TBI participants showed worse behavioral performance than controls. Voxelwise neuroimaging analysis of the 2-back task found that group differences in task-induced CBF changes were localized to bilateral superior occipital cortices and the left superior temporal cortex. Whereas controls deactivated these areas during task performance, TBI participants tended to activate these same areas. These regions were among those found to be disproportionately hypoperfused at rest after TBI. For both tasks, the control and TBI groups showed different patterns of correlation between performance and task-related CBF changes. Conclusions. ASL perfusion fMRI demonstrated differences between individuals with TBI and healthy controls in resting perfusion and in task-evoked CBF changes as well as different patterns of performance-activation correlation. These results are consistent with the notion that sensory/attentional modulation deficits contribute to higher cognitive dysfunction in TBI.	[Kim, Junghoon; Whyte, John; Patel, Sunil; Europa, Eduardo; Slattery, John] Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Elkins Pk, PA 19027 USA; [Coslett, H. Branch; Detre, John A.] Univ Penn, Philadelphia, PA 19104 USA		Kim, J (corresponding author), Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	kimj@einstein.edu	Kim, Junghoon John/I-6702-2019	Kim, Junghoon John/0000-0001-5729-8993; Whyte, John/0000-0002-4381-1474	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD39621, R24HD050836, P30NS045839]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621, R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045839] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study is supported by the National Institutes of Health (grant numbers R24HD39621 [to JW], R24HD050836 [to JW; www.ncrrn.org], and P30NS045839 [to JAD]).	Aguirre GK, 1998, NEUROIMAGE, V8, P302, DOI 10.1006/nimg.1998.0367; Aguirre GK, 2002, NEUROIMAGE, V15, P488, DOI 10.1006/nimg.2001.0990; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Avants BB, 2006, MED IMAGE ANAL, V10, P397, DOI 10.1016/j.media.2005.03.005; Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Coull JT, 1998, NEUROPSYCHOLOGIA, V36, P1325, DOI 10.1016/S0028-3932(98)00035-9; Denys K, 2004, J NEUROSCI, V24, P2551, DOI 10.1523/JNEUROSCI.3569-03.2004; Detre JA, 2009, CURR OPIN NEUROL, V22, P348, DOI 10.1097/WCO.0b013e32832d9505; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Holmes AP, 1998, NEUROIMAGE, V7, pS754, DOI [10.1016/S1053-8119(18)31587-8, DOI 10.1016/S1053-8119(18)31587-8]; Jancke L, 1999, NEUROSCI LETT, V266, P125, DOI 10.1016/S0304-3940(99)00288-8; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim J, 2006, NEUROIMAGE, V31, P376, DOI 10.1016/j.neuroimage.2005.11.035; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Lawrence NS, 2003, J COGNITIVE NEUROSCI, V15, P1028, DOI 10.1162/089892903770007416; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Mai JK, 2004, ATLAS HUMAN BRAIN; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; Munoz-Cespedes JM, 2005, NEUROPSYCHOL REV, V15, P169, DOI 10.1007/s11065-005-9178-5; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Poghosyan V, 2008, NEURON, V58, P802, DOI 10.1016/j.neuron.2008.04.013; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; Schwartz MF, 2005, ARCH PHYS MED REHAB, V86, P1807, DOI 10.1016/j.apmr.2005.03.009; Slotnick SD, 2003, NEUROIMAGE, V19, P1602, DOI 10.1016/S1053-8119(03)00187-3; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Stamatakis EA, 2002, J NUCL MED, V43, P476; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Van Essen DC, 2001, VISION RES, V41, P1359, DOI 10.1016/S0042-6989(01)00045-1; Wang JJ, 2005, RADIOLOGY, V235, P218, DOI 10.1148/radiol.2351031663; Wang JJ, 2003, NEUROIMAGE, V19, P1449, DOI 10.1016/S1053-8119(03)00255-6; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; Wu WC, 2007, MAGN RESON MED, V58, P1020, DOI 10.1002/mrm.21403	56	37	39	0	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	SEP	2012	26	7					870	880		10.1177/1545968311434553			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	981MY	WOS:000306973700007	22357634	Green Accepted			2022-02-06	
J	Grujicic, A; LaBerge, M; Grujicic, M; Pandurangan, B; Runt, J; Tarter, J; Dillon, G				Grujicic, A.; LaBerge, M.; Grujicic, M.; Pandurangan, B.; Runt, J.; Tarter, J.; Dillon, G.			Potential Improvements in Shock-Mitigation Efficacy of a Polyurea-Augmented Advanced Combat Helmet	JOURNAL OF MATERIALS ENGINEERING AND PERFORMANCE			English	Article						Advanced Combat Helmet; internal lining/external coating; traumatic brain injury	TRAUMATIC BRAIN-INJURY; BLAST; AFGHANISTAN; CAPABILITY; MODEL; TBI	The design of the currently used Advanced Combat Helmet (ACH) has been optimized to attain maximum protection against ballistic impacts (fragments, shrapnel, etc.) and hard-surface collisions. However, the ability of the ACH to protect soldiers against blast loading appears not to be as effective. Polyurea, a micro-segregated elastomeric copolymer has shown superior shock-mitigation capabilities. In the present work, a combined Eulerian/Lagrangian transient non-linear dynamics computational fluid/solid interaction analysis is used to investigate potential shock-mitigation benefits which may result from different polyurea-based design augmentations of the ACH. Specific augmentations include replacement of the currently used suspension-pad material with polyurea and the introduction of a thin polyurea internal lining/external coating to the ACH shell. Effectiveness of different ACH designs was quantified by: (a) establishing the main forms of mild traumatic brain injury (mTBI); (b) identifying the key mechanical causes for these injuries; and (c) quantifying the extents of reductions in the magnitude of these mechanical causes. The results obtained show that while the ACH with a 2-mm-thick polyurea internal lining displays the best blast mitigation performance, it does not provide sufficient protection against mTBI.	[Grujicic, A.; LaBerge, M.] Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA; [Grujicic, M.; Pandurangan, B.] Clemson Univ, Dept Mech Engn, Clemson, SC 29634 USA; [Runt, J.] Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16082 USA; [Tarter, J.; Dillon, G.] Penn State Univ, Appl Res Labs, University Pk, PA 16082 USA		Grujicic, A (corresponding author), Clemson Univ, Dept Bioengn, Clemson, SC 29634 USA.	gmica@clemson.edu			Office of Naval Research (ONR) through Pennsylvania State UniversityOffice of Naval Research [4036-CU-ONR-1125]	The material presented in this paper is based on work supported by the Office of Naval Research (ONR) research contract entitled "Elastomeric Polymer-By-Design to Protect the Warfighter Against Traumatic Brain Injury by Diverting the Blast Induced Shock Waves from the Head'', Contract Number 4036-CU-ONR-1125 as funded through the Pennsylvania State University. The authors are indebted to Dr. Roshdy Barsoum of ONR for continuing support and interest in the present work and to Professors G. Settles and M. Hargather for stimulating discussions and friendship.	ABAQUS, 2010, ABAQUS VERS 6 10EF 1; Altair Engineering Inc, 2010, HYP HYPERWORKS 10 0; Amirkhizi AV, 2006, PHILOS MAG, V86, P5847, DOI 10.1080/14786430600833198; *ANSYS INC, 2007, ANSYS AUT 2D 3D VERS; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Christou GA, 2010, THESIS MIT; Cooper PW., 1996, EXPLOSIVES ENG; Cuitino A., 1992, ENG COMPUT-GERMANY, V9, P437, DOI DOI 10.1108/EB023876>; Davison L, 2008, FUNDAMENTALS SHOCKWA; Goel R., 2011, THESIS MIT; Grujicic M, 2010, MULTIDISCIP MODEL MA, V6, P335, DOI 10.1108/15736101011080097; Grujicic M, 2011, P I MECH ENG L-J MAT, V225, P182, DOI 10.1177/0954420711401959; Grujicic M, 2011, J MATER ENG PERFORM, V20, P877, DOI 10.1007/s11665-010-9724-z; Grujicic M, 2012, J MATER ENG PERFORM, V21, P2, DOI 10.1007/s11665-011-9875-6; Grujicic M, 2011, MAT SCI ENG A-STRUCT, V528, P3799, DOI 10.1016/j.msea.2011.01.081; Grujicic M, 2010, MAT SCI ENG A-STRUCT, V527, P7741, DOI 10.1016/j.msea.2010.08.042; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Grujicic M, 2009, MATER DESIGN, V30, P4273, DOI 10.1016/j.matdes.2009.04.028; Grujicic M, 2011, J MATER SCI, V46, P1767, DOI 10.1007/s10853-010-4998-y; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hyde D.W., 1988, USERS GUIDE MICROCOM; Moore DF, 2008, ANN NEUROL, V64, pS30; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Wallsten S. J., 2005, 0519 SOC SCI RES NET; Walsh S. M., 2005, ARLTR3700; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	28	37	38	0	43	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1059-9495	1544-1024		J MATER ENG PERFORM	J. Mater. Eng. Perform.	AUG	2012	21	8					1562	1579		10.1007/s11665-011-0065-3			18	Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Materials Science	975ZD	WOS:000306549400002					2022-02-06	
J	Oddy, M; Moir, JF; Fortescue, D; Chadwick, S				Oddy, Michael; Moir, Jane Frances; Fortescue, Deborah; Chadwick, Sarah			The prevalence of traumatic brain injury in the homeless community in a UK city	BRAIN INJURY			English	Article						Prevalence; homeless; traumatic brain injury	ADULTS; HOSTEL	Primary objective: The main aim of the study was to investigate the prevalence of traumatic brain injury in a sample of homeless individuals. Research design: The researchers employed a cross-sectional survey design and contacted 12 organizations providing services for homeless individuals across a city in the UK. Methods and procedures: The sample included 100 homeless participants (75 males and 25 females) who met the inclusion criteria. A matched control group (n = 100) of individuals who were not homeless was also recruited. A questionnaire was administered to all participants to elicit information relating to history of possible traumatic brain injury. Main outcomes and results: Results indicated that a significantly higher number of homeless participants (48%) reported a history of traumatic brain injury than control participants (21%). Of those homeless participants, 90% indicated they had sustained their first traumatic brain injury before they were homeless. Conclusions: These findings suggest that rates of traumatic brain injury are much higher among the homeless population than in the general population and that sustaining a traumatic brain injury may be a risk factor for homelessness.	[Oddy, Michael; Moir, Jane Frances; Chadwick, Sarah] Brain Injury Rehabil Trust, Slinfold RH13 0TP, W Sussex, England; [Oddy, Michael; Fortescue, Deborah] Disabil Trust Fdn, Burgess Hill, W Sussex, England		Oddy, M (corresponding author), Brain Injury Rehabil Trust, 5 Oaks Rd, Slinfold RH13 0TP, W Sussex, England.	michael.oddy@thedtgroup.org			Disabilities Trust Foundation, a constituent of The Disabilities Trust Group	The study was funded by The Disabilities Trust Foundation, a constituent of The Disabilities Trust Group. The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.	Backer Thomas Earl, 2007, J Prim Prev, V28, P375, DOI 10.1007/s10935-007-0100-1; Bremner AJ, 1996, BRIT J PSYCHIAT, V169, P434, DOI 10.1192/bjp.169.4.434; Gaultieri T, 1991, BRAIN INJURY, V5, P219; Gilchrist G, 2005, EUR J PUBLIC HEALTH, V15, P587, DOI 10.1093/eurpub/cki036; Gonzalez EA, 2001, J NERV MENT DIS, V189, P176, DOI 10.1097/00005053-200103000-00006; Highley JL, 2008, TRAUMATIC BRAIN INJU; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Oakes PM, 2008, J INTELLECT DISABILI, V12, P325, DOI 10.1177/1744629508100496; Rees S., 2009, MENTAL ILL HLTH ADUL; Silver JM, 1999, NEUROPSYCHIATRY AND MENTAL HEALTH SERVICES, P319; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Solliday-McRoy C, 2004, J NERV MENT DIS, V192, P471, DOI 10.1097/01.nmd.0000131962.30547.26; Spence S, 2004, J ROY SOC MED, V97, P375, DOI 10.1258/jrsm.97.8.375; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; [No title captured]	17	37	37	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2012	26	9					1058	1064		10.3109/02699052.2012.667595			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	971GI	WOS:000306191400002	22571822				2022-02-06	
J	Leibson, CL; Brown, AW; Long, KH; Ransom, JE; Mandrekar, J; Osler, TM; Malec, JF				Leibson, Cynthia L.; Brown, Allen W.; Long, Kirsten Hall; Ransom, Jeanine E.; Mandrekar, Jay; Osler, Turner M.; Malec, James F.			Medical Care Costs Associated with Traumatic Brain Injury over the Full Spectrum of Disease: A Controlled Population-Based Study	JOURNAL OF NEUROTRAUMA			English	Article						costs; head injury; outcome measures; traumatic brain injury	ROCHESTER EPIDEMIOLOGY PROJECT; UNITED-STATES; HEALTH-CARE; HEAD TRAUMA; FOLLOW-UP; HOSPITALIZATION; OUTCOMES; MILD; MORTALITY; SEVERITY	Data on traumatic brain injury (TBI) economic outcomes are limited. We used Rochester Epidemiology Project (REP) resources to estimate long-term medical costs for clinically-confirmed incident TBI across the full range of severity after controlling for pre-existing conditions and co-occurring injuries. All Olmsted County, Minnesota, residents with diagnoses indicative of potential TBI from 1985-2000 (n = 46,114) were identified, and a random sample (n = 7175) was selected for medical record review to confirm case status, and to characterize as definite (moderate/severe), probable (mild), or possible (symptomatic) TBI. For each case, we identified one age-and sex-matched non-TBI control registered in REP in the same year (-1 year) as case's TBI. Cases with co-occurring non-head injuries were assessed for non-head-injury severity and assigned similar non-head-injury-severity controls. The 1145 case/control pairs for 1988-2000 were followed until earliest death/emigration of either member for medical costs 12 months before and up to 6 years after baseline (i.e., injury date for cases and comparable dates for controls). Differences between case and control costs were stratified by TBI severity, as defined by evidence of brain injury; comparisons used Wilcoxon signed-rank plus multivariate modeling (adjusted for pre-baseline characteristics). From baseline until 6 years, each TBI category exhibited significant incremental costs. For definite and probable TBI, most incremental costs occurred within the first 6 months; significant long-term incremental medical costs were not apparent among 1-year survivors. By contrast, cost differences between possible TBI cases and controls were not as great within the first 6 months, but were substantial among 1-year survivors. Although mean incremental costs were highest for definite cases, probable and possible cases accounted for >90% of all TBI events and 66% of total incremental costs. Preventing probable and possible events might facilitate substantial reductions in TBI-associated medical care costs.	[Leibson, Cynthia L.] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Rochester, MN 55905 USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; [Ransom, Jeanine E.; Mandrekar, Jay] Mayo Clin, Dept Hlth Sci Res, Div Biomed Stat & Informat, Rochester, MN 55905 USA; [Long, Kirsten Hall] Long Hlth Econ Consulting, St Paul, MN USA; [Osler, Turner M.] Univ Vermont, Dept Surg, Coll Med, Burlington, VT 05405 USA; [Malec, James F.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA		Leibson, CL (corresponding author), Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, 200 1st St SW, Rochester, MN 55905 USA.	leibson@mayo.edu		Brown, Allen W./0000-0001-7228-3351	TBI Model System, National Institute on Disability and Rehabilitation Research [H133A020507, H133A070013]; National Research Service Award, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD-07447]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RO1 AG034676]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R56HD007447, R01HD007447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034676] Funding Source: NIH RePORTER	This research was supported by TBI Model System grants to the Mayo Clinic from the National Institute on Disability and Rehabilitation Research (H133A020507 and H133A070013), and a National Research Service Award from the National Institutes of Health (training grant no. HD-07447). The study was made possible by the Rochester Epidemiology Project (grant no. RO1 AG034676 from the National Institute on Aging). The authors thank Patricia K. Perkins and Nancy N. Diehl for invaluable and expert assistance in medical record abstraction and data collection and analysis.	ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Basu A, 2006, HEALTH ECON, V15, P1091, DOI 10.1002/hec.1099; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Birnbaum HG, 2009, PHARMACOECONOMICS, V27, P507, DOI 10.2165/00019053-200927060-00006; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Centers for Disease Control and Prevention. National Center for Health Statistics, 2005, BAR INJ DIAGN MATR C; Centers for Disease Control and Prevention. National Center for Health Statistics, 2009, ICD 9 CM OFF GUID CO; Centers for Disease Control and Prevention. National Center for Injury Prevention and Control, 2010, WHAT AR POT LONG TER; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Esposito D, 2009, AM J MANAG CARE, V15, P437; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Glance LG, 2009, ANN SURG, V249, P1032, DOI 10.1097/SLA.0b013e3181a38f28; H-ICDA, 1973, HOSP AD INT CLASS DI; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harwood H., 2002, UPDATING ESTIMATES E; Johns Hopkins Bloomberg School of Public Health, 2010, J HOPK ACG SYST; Johns Hopkins Bloomberg School of Public Health, 2002, UPD J HOPK ACG CAS M, V4, P1; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; King DA, 2010, BRIT J SPORT MED, V44, P1016, DOI 10.1136/bjsm.2009.064683; Leibson CL, 1996, NEUROLOGY, V46, P861; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Leibson CL, 2006, MOVEMENT DISORD, V21, P1864, DOI 10.1002/mds.21075; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Long KH, 2010, ALIMENT PHARM THER, V32, P261, DOI 10.1111/j.1365-2036.2010.04327.x; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Manning WG, 1981, HLTH EC HLTH EC, P103; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Melton LJ, 1997, NEW ENGL J MED, V337, P1466, DOI 10.1056/NEJM199711133372012; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Miller T. R., 1994, HEAD NECK INJURY, P211; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mullahy J, 1998, J HEALTH ECON, V17, P247, DOI 10.1016/S0167-6296(98)00030-7; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Shi JX, 2009, BRAIN INJURY, V23, P602, DOI 10.1080/02699050903014907; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Sosin DM, 1996, BRAIN INJURY, V10, P47; St Sauver JL, 2012, MAYO CLIN PROC, V87, P151, DOI 10.1016/j.mayocp.2011.11.009; Thompson JM, 2011, AM J PHYS MED REHAB, V90, P40, DOI 10.1097/PHM.0b013e3181fc7ff3; Thurman DJ, 2001, HEAD TRAUMA, P327; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 1989, INT CLASS DIS 9 REV; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; Vassallo JL, 2007, BRAIN INJURY, V21, P567, DOI 10.1080/02699050701426832; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Welch CA, 2009, PSYCHOSOMATICS, V50, P392, DOI 10.1176/appi.psy.50.4.392; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269	70	37	38	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2012	29	11					2038	2049		10.1089/neu.2010.1713			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	983CX	WOS:000307095800005	22414023	Green Published			2022-02-06	
J	Hu, ZH; Yu, DN; Almeida-Suhett, C; Tu, K; Marini, AM; Eiden, L; Braga, MF; Zhu, J; Li, Z				Hu, Zhonghua; Yu, Danni; Almeida-Suhett, Camila; Tu, Kang; Marini, Ann M.; Eiden, Lee; Braga, Maria F.; Zhu, Jun; Li, Zheng			Expression of miRNAs and Their Cooperative Regulation of the Pathophysiology in Traumatic Brain Injury	PLOS ONE			English	Article							GENE-EXPRESSION; MICRORNA; IMPACT; RAT; NEUROPROTECTION; MECHANISMS; GENOME; MEMORY	Traumatic brain injury (TBI) is a leading cause of injury-related death and disability worldwide. Effective treatment for TBI is limited and many TBI patients suffer from neuropsychiatric sequelae. The molecular and cellular mechanisms underlying the neuronal damage and impairment of mental abilities following TBI are largely unknown. Here we used the next generation sequencing platform to delineate miRNA transcriptome changes in the hippocampus at 24 hours and 7 days following TBI in the rat controlled cortical impact injury (CCI) model, and developed a bioinformatic analysis to identify cellular activities that are regulated by miRNAs differentially expressed in the CCI brains. The results of our study indicate that distinct sets of miRNAs are regulated at different post-traumatic times, and suggest that multiple miRNA species cooperatively regulate cellular pathways for the pathological changes and management of brain injury. The distinctive miRNAs expression profiles at different post-CCI times may be used as molecular signatures to assess TBI progression. In addition to known pathophysiological changes, our study identifies many other cellular pathways that are subjected to modification by differentially expressed miRNAs in TBI brains. These pathways can potentially be targeted for development of novel TBI treatment.	[Hu, Zhonghua; Li, Zheng] NIMH, Unit Synapse Dev & Plast, NIH, Bethesda, MD 20892 USA; [Eiden, Lee] NIMH, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA; [Tu, Kang; Zhu, Jun] NHLBI, Genet & Dev Biol Ctr, NIH, Bethesda, MD 20892 USA; [Yu, Danni] Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA; [Almeida-Suhett, Camila; Braga, Maria F.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Marini, Ann M.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Neurol, Bethesda, MD 20814 USA		Hu, ZH (corresponding author), NIMH, Unit Synapse Dev & Plast, NIH, Bethesda, MD 20892 USA.	lizheng2@mail.nih.gov	Hu, Zhonghua/J-1169-2016; Li, Zheng/I-8016-2014; Hu, Zhonghua/F-9493-2014; Almeida-Suhett, Camila/I-8045-2016	Hu, Zhonghua/0000-0002-0117-7081; Li, Zheng/0000-0002-2978-2531; Eiden, Lee/0000-0001-7524-944X; Almeida-Suhett, Camila/0000-0002-7588-9487	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [ZICHL006058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002882, ZIAMH002386] Funding Source: NIH RePORTER	Support for this work includes funding from the Intramural Research Program of the NIMH and Department of Defense in the Center for Neuroscience and Regenerative Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barr TL, 2011, BIOL RES NURS, V13, P140, DOI 10.1177/1099800410385671; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Faul M, 2010, TRAUMATIC BRAIN INJU; Fenelon K, 2011, P NATL ACAD SCI USA, V108, P4447, DOI 10.1073/pnas.1101219108; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Konopka W, 2010, J NEUROSCI, V30, P14835, DOI 10.1523/JNEUROSCI.3030-10.2010; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Ling KH, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-176; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Shao NY, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-409; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Smyth GK., 2004, STAT APPL GENET MOL, V3, pArticl, DOI [DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027]; Twigger SN, 2008, NAT GENET, V40, P523, DOI 10.1038/ng0508-523; Wu H, 2010, MOL CELL, V38, P67, DOI 10.1016/j.molcel.2010.02.021	35	37	39	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2012	7	6							e39357	10.1371/journal.pone.0039357			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	964XV	WOS:000305730900050	22761770	Green Submitted, Green Published, gold			2022-02-06	
J	Kasotakis, G; Michailidou, M; Bramos, A; Chang, YC; Velmahos, G; Alam, H; King, D; de Moya, MA				Kasotakis, George; Michailidou, Maria; Bramos, Athanosios; Chang, Yuchiao; Velmahos, George; Alam, Hasan; King, David; de Moya, Marc A.			Intraparenchymal vs Extracranial Ventricular Drain Intracranial Pressure Monitors in Traumatic Brain Injury: Less Is More?	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							SEVERE HEAD-INJURY; INTENSIVE-CARE; COMPLICATIONS; INTUBATION; MANAGEMENT; PROPHYLAXIS; EXPERIENCE; PLACEMENT; INFECTION; MANNITOL	BACKGROUND: Management of severe traumatic brain injury has centered on continuous intracranial pressure (ICP) monitoring with intraparenchymal ICP monitors (IPM) or extracranial ventricular drains (EVD). Our hypothesis was that neurologic outcomes are unaffected by the type of ICP monitoring device. STUDY DESIGN: We reviewed 377 adult patients with traumatic brain injury requiring ICP monitoring. Primary outcome was Glasgow Outcome Score (GOS) 1 month after injury. Secondary outcomes included mortality, monitoring-related complications, and length of ICU and hospital stay. RESULTS: There were 253 patients managed with an IPM and 124 with an EVD. There was no difference in GlasgowOutcome Score (2.7 +/- 1.3 vs 2.5 +/- 1.3, p = 0.45), mortality (30.9% vs 32.2%, p = 0.82), and hospital length of stay (LOS) (15.6 +/- 12.4 days vs 16.4 +/- 10.7 days, p = 0.57). Device-related complications (11.9% vs 31.1%, p < 0.001), duration of ICP monitoring (3.8 +/- 2.6 days vs 7.3 +/- 5.6 days, p < 0.001), and ICU LOS (7.6 +/- 5.6 days vs 9.5 +/- 6.2 days, p = 0.004) were longer in the EVD group. Age, opening ICP, and size of midline shift were independent predictors for neurologic outcomes and mortality, when type and severity of brain injury, as well as overall injury severity were controlled for. Duration of ICP monitoring and opening ICP were independent predictors for hospital LOS and the former predicted prolonged ICU stay. Device-related complications were affected by type of device. CONCLUSIONS: Use of EVDs in adult traumatic brain injury patients is associated with prolonged ICP monitoring, ICU LOS, and more frequent device-related complications. (J Am Coll Surg 2012;214:950-957. (C) 2012 by the American College of Surgeons)	[Kasotakis, George; Michailidou, Maria; Bramos, Athanosios; Chang, Yuchiao; Velmahos, George; Alam, Hasan; King, David; de Moya, Marc A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Div Trauma Emergency Surg & Surg Crit C, Boston, MA 02114 USA		de Moya, MA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Div Trauma Emergency Surg & Surg Crit C, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.			King, David/0000-0003-1028-1478; Kasotakis, George/0000-0002-7630-0742			BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Brain Trauma Foundation, 2007, GUID MAN SEV TRAUM B; Centers for Disease Control and Prevention NCfIPaC, 2007, TRAUM BRAIN INJ US; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLARK WC, 1989, NEUROSURGERY, V25, P20; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Devlin JW, 2010, CRIT CARE MED, V38, pS231, DOI 10.1097/CCM.0b013e3181de125a; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Faul M, 2010, TRAUMATIC BRAIN INJU; Flibotte JJ, 2004, NEUROCRIT CARE, V1, P61, DOI 10.1385/NCC:1:1:61; FRIEDMAN WA, 1980, J NEUROSURG, V53, P662, DOI 10.3171/jns.1980.53.5.0662; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GUILLAUME J, 1951, REV NEUROL, V84, P131; Guyot LL, 1998, ACT NEUR S, V71, P47; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; JENNETT B, 1975, LANCET, V1, P480; Khan SH, 1998, ACT NEUR S, V71, P50; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1978, J NEUROSURG, V48, P169, DOI 10.3171/jns.1978.48.2.0169; Marshall LF, 2004, J NEUROSURG, V100, P367, DOI 10.3171/jns.2004.100.3.0367; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; May Addison K, 2006, Surg Infect (Larchmt), V7, P409, DOI 10.1089/sur.2006.7.409; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; O'Neill BR, 2008, SURG NEUROL, V70, P268, DOI 10.1016/j.surneu.2007.05.007; PANG DL, 1994, J NEUROSURG, V80, P750, DOI 10.3171/jns.1994.80.4.0750; PARAMORE CG, 1994, ACTA NEUROCHIR, V127, P79, DOI 10.1007/BF01808552; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Prabhu VC, 1999, SURG NEUROL, V52, P226, DOI 10.1016/S0090-3019(99)00084-1; Saladino A, 2009, NEUROCRIT CARE, V10, P248, DOI 10.1007/s12028-008-9154-z; Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333; Schweickert WD, 2007, CHEST, V131, P1541, DOI 10.1378/chest.06-2065; Servadei F, 2002, ACT NEUR S, V81, P81; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHULTS WT, 1993, NEUROSURGERY, V33, P135; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Stoikes NF, 2008, SURG INFECT, V9, P503, DOI 10.1089/sur.2007.032; Sundbarg G, 1988, Br J Neurosurg, V2, P485, DOI 10.3109/02688698809029603; Vasilevskis EE, 2010, CHEST, V138, P1224, DOI 10.1378/chest.10-0466	52	37	38	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	JUN	2012	214	6					950	957		10.1016/j.jamcollsurg.2012.03.004			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	958NM	WOS:000305245800012	22541986				2022-02-06	
J	Wilde, EA; McCauley, SR; Barnes, A; Wu, TC; Chu, ZL; Hunter, JV; Bigler, ED				Wilde, Elisabeth A.; McCauley, Stephen R.; Barnes, Amanda; Wu, Trevor C.; Chu, Zili; Hunter, Jill V.; Bigler, Erin D.			Serial measurement of memory and diffusion tensor imaging changes within the first week following uncomplicated mild traumatic brain injury	BRAIN IMAGING AND BEHAVIOR			English	Article						Diffusion tensor imaging; Concussion; Mild traumatic brain injury; Semi-acute; Serial measurement; Memory	VERBAL WORKING-MEMORY; WHITE-MATTER INJURY; DSM-IV CRITERIA; POSTCONCUSSIONAL DISORDER; AXONAL INJURY; PRACTICAL SCALE; RISK-FACTORS; HEAD-INJURY; CONCUSSION; RECOVERY	Patients (n = 8) with uncomplicated mild traumatic brain injury (mTBI) underwent serial assessments (4) with diffusion tensor imaging (DTI) and neuropsychological testing within the first 8 days post-injury. Using a multi-case study design, we examined changes in brain parenchyma (via DTI-derived fractional anisotropy [FA], apparent diffusion coefficient [ADC], axial diffusivity [AD] and radial diffusivity [RD] in the left cingulum bundle) and in memory performance (via Hopkins Verbal Learning Test-Revised). Qualitative inspection of the results indicated that memory performance was transiently affected in most participants over the course of the week, with performance most negatively impacted on the second assessment (days 3-4 or 97-144 h post-injury), and then returning to within normal limits by 8 days post-injury. Alternatively, FA and other DTI metrics showed a more complex pattern, with the trajectory of some participants changing more prominently than others. For example, FA transiently increased in some participants over the study period, but the pattern was heterogeneous. Memory performance appeared to mirror changes in FA in certain cases, supporting a pathophysiological basis to memory impairment following mTBI. However, the pattern and the degree of symmetry between FA and memory performance was complex and did not always correspond. Serial imaging over the semi-acute recovery period may be important in reconciling conflicting findings in mTBI utilizing memory and/or DTI. Serial use of imaging modalities including DTI may aid understanding of underlying pathophysiological changes in the semi-acute post-injury period. Should a consistent pattern emerge that allows identification of patients at-risk for acute and/or persistent symptoms, such knowledge could guide development of therapeutic targets in mTBI and in understanding the most effective administration time window for these agents.	[Wilde, Elisabeth A.; McCauley, Stephen R.; Barnes, Amanda; Wu, Trevor C.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Barnes, Amanda; Wu, Trevor C.] Univ Texas Houston, Sch Med, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Chu, Zili; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [McCauley, Stephen R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Wu, Trevor C.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA		Wilde, EA (corresponding author), Baylor Coll Med, Phys Med & Rehabil Alliance, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu; mccauley@bcm.edu; afbarnes@bcm.edu; ctwu@bcm.edu; zchu@bcm.tmc.edu; jvhunter@texaschildrens.org; erinb@cortex.byu.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R03NS069943-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS069943] Funding Source: NIH RePORTER	This project was supported by grant number 1R03NS069943-01 from the National Institute of Neurological Disorders and Stroke. Portions of this study were presented at the 29th annual meeting of the National Neurotrauma Symposium, Ft. Lauderdale, Florida, June, 2011.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benedict RHB, 1998, J CLIN EXP NEUROPSYC, V20, P339, DOI 10.1076/jcen.20.3.339.822; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Faul M, 2010, TRAUMATIC BRAIN INJU; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kaneda M, 2008, NEUROSCI LETT, V436, P57, DOI 10.1016/j.neulet.2008.02.069; Ker K, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a865; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCauley SR, 2011, J NEUROTRAUM, V28, P503, DOI 10.1089/neu.2010.1555; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; TEASDALE G, 1974, LANCET, V2, P81; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020	58	37	37	3	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557			BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		319	328		10.1007/s11682-012-9174-3			10	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967LI	WOS:000305908900011	22684768				2022-02-06	
J	Kabadi, SV; Stoica, BA; Hanscom, M; Loane, DJ; Kharebava, G; Murray, MG; Cabatbat, RM; Faden, AI				Kabadi, Shruti V.; Stoica, Bogdan A.; Hanscom, Marie; Loane, David J.; Kharebava, Giorgi; Murray, Michael G., II; Cabatbat, Rainier M.; Faden, Alan I.			CR8, a Selective and Potent CDK Inhibitor, Provides Neuroprotection in Experimental Traumatic Brain Injury	NEUROTHERAPEUTICS			English	Article						Cell cycle; Traumatic brain injury; Cyclindependent kinases; Neurodegeneration; Neuroprotection; CR8	CONTROLLED CORTICAL IMPACT; CYCLIN-DEPENDENT KINASES; SPINAL-CORD-INJURY; MORRIS WATER MAZE; NEURONAL CELL-DEATH; ALZHEIMERS-DISEASE; DEGENERATING NEURONS; THERAPEUTIC TARGET; SPATIAL MEMORY; LEARNING-TASK	Traumatic brain injury (TBI) induces secondary injury mechanisms, including cell cycle activation (CCA), that leads to neuronal death and neurological dysfunction. We recently reported that delayed administration of roscovitine, a relatively selective cyclin-dependent kinase (CDK) inhibitor, inhibits CCA and attenuates neurodegeneration and functional deficits following controlled cortical impact (CCI) injury in mice. Here we evaluated the neuroprotective potential of CR8, a more potent second-generation roscovitine analog, using the mouse CCI model. Key CCA markers (cyclin A and B1) were significantly up-regulated in the injured cortex following TBI, and phosphorylation of CDK substrates was increased. Central administration of CR8 after TBI, at a dose 20 times less than previously required for roscovitine, attenuated CCA pathways and reduced post-traumatic apoptotic cell death at 24 h post-TBI. Central administration of CR8, at 3 h after TBI, significantly attenuated sensorimotor and cognitive deficits, decreased lesion volume, and improved neuronal survival in the cortex and dentate gyrus. Moreover, unlike roscovitine treatment in the same model, CR8 also attenuated post-traumatic neurodegeneration in the CA3 region of the hippocampus and thalamus at 21 days. Furthermore, delayed systemic administration of CR8, at a dose 10 times less than previously required for roscovitine, significantly improved cognitive performance after CCI. These findings further demonstrate the neuroprotective potential of cell cycle inhibitors following experimental TBI. Given the increased potency and efficacy of CR8 as compared to earlier purine analog types of CDK inhibitors, this drug should be considered as a candidate for future clinical trials of TBI.	[Kabadi, Shruti V.; Stoica, Bogdan A.; Hanscom, Marie; Loane, David J.; Kharebava, Giorgi; Murray, Michael G., II; Cabatbat, Rainier M.; Faden, Alan I.] Univ Maryland, Dept Anesthesiol, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Baltimore, MD 21201 USA		Stoica, BA (corresponding author), Univ Maryland, Dept Anesthesiol, Ctr Shock Trauma & Anesthesiol Res STAR, Sch Med, Baltimore, MD 21201 USA.	bstoica@anes.umm.edu	Loane, David/ABD-5177-2021; STOICA, BOGDAN/H-9782-2013	Loane, David/0000-0003-0393-3503; STOICA, BOGDAN/0000-0002-2501-6434; Hanscom, Marie/0000-0001-8308-135X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	We thank David Knipp, Stephanie Custer, and Titilola Akintola for expert technical assistance. This work was supported by a grant from the National Institutes of Health (grant No. R01 NS052568).	Arendt T, 2003, PROG NEUROBIOL, V71, P83, DOI 10.1016/j.pneurobio.2003.09.007; Bettayeb K, 2008, ONCOGENE, V27, P5797, DOI 10.1038/onc.2008.191; Bettayeb Karima, 2010, Genes Cancer, V1, P369, DOI 10.1177/1947601910369817; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Brunson KL, 2001, P NATL ACAD SCI USA, V98, P8856, DOI 10.1073/pnas.151224898; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Copani A, 1999, FASEB J, V13, P2225, DOI 10.1096/fasebj.13.15.2225; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gilbert PE, 2009, PROG NEURO-PSYCHOPH, V33, P774, DOI 10.1016/j.pnpbp.2009.03.037; Goldstein LB, 2003, ILAR J, V44, P125, DOI 10.1093/ilar.44.2.125; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Jerman T, 2006, LEARN MEMORY, V13, P458, DOI 10.1101/lm.246906; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kabadi SV, 2011, J NEUROTRAUMA   0906; Komina Oxane, 2011, J Exp Ther Oncol, V9, P27; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lee I, 2005, BEHAV NEUROSCI, V119, P145, DOI 10.1037/0735-7044.119.1.145; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LUNDBERG A, 1998, MOL CELL BIOL, V23, P1044; Maestre C, 2008, EMBO J, V27, P2736, DOI 10.1038/emboj.2008.195; MARTIN JH, 1996, NEUROANATOMY TEXT AT; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mitra J, 2004, ONCOGENE, V23, P3361, DOI 10.1038/sj.onc.1207446; Mori T, 1998, ACT NEUR S, V71, P120; Mosch B, 2007, J NEUROSCI, V27, P6859, DOI 10.1523/JNEUROSCI.0379-07.2007; Nauta WJH, 1986, FUNDAMENTAL NEUROANA; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Nutley BP, 2005, MOL CANCER THER, V4, P125; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; Vincent I, 1997, J NEUROSCI, V17, P3588; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wesierska-Gadek J, 2011, J CELL BIOCHEM, V112, P761, DOI 10.1002/jcb.23004	57	37	37	2	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	APR	2012	9	2					405	421		10.1007/s13311-011-0095-4			17	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	926EX	WOS:000302815200015	22167461	Bronze, Green Accepted, Green Published			2022-02-06	
J	Nawashiro, H; Wada, K; Nakai, K; Sato, S				Nawashiro, Hiroshi; Wada, Kojiro; Nakai, Kanji; Sato, Shunichi			Focal Increase in Cerebral Blood Flow After Treatment with Near-Infrared Light to the Forehead in a Patient in a Persistent Vegetative State	PHOTOMEDICINE AND LASER SURGERY			English	Article								Objective: This study aimed to quantify the cerebral blood flow (CBF) after bilateral, transcranial near-infrared light-emitting diode (LED) irradiation to the forehead in a patient in a persistent vegetative state following severe head injury. Background data: Positive behavioral improvement has been observed following transcranial near-infrared light therapy in humans with chronic traumatic brain injury and acute stroke. Methods: Single-photon emission computed tomography with N-isopropyl-[123I]p-iodoamphetamine (IMP-SPECT) was performed following a series of LED treatments. Results: IMP-SPECT showed unilateral, left anterior frontal lobe focal increase of 20%, compared to the pre-treatment value for regional CBF (rCBF) for this area, following 146 LED treatments over 73 days from an array of 23 x 850nm LEDs, 13mW each, held 5mm from the skin, 30 min per session, the power density 11.4mW/cm(2); the energy density 20.5 J/cm(2) at the skin. The patient showed some improvement in his neurological condition by moving his left arm/hand to reach the tracheostomy tube, post-LED therapy. Conclusions: Transcranial LED might increase rCBF with some improvement of neurological condition in severely head-injured patients. Further study is warranted.	[Nawashiro, Hiroshi; Wada, Kojiro] Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama 3598513, Japan; [Nakai, Kanji] Natl Def Med Coll, Dept Radiol, Tokorozawa, Saitama 3598513, Japan; [Sato, Shunichi] Natl Def Med Coll Res Inst, Div Biomed Informat Sci, Tokorozawa, Saitama, Japan		Nawashiro, H (corresponding author), Natl Def Med Coll, Dept Neurosurg, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	nawa1957@ndmc.ac.jp					Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Naeser M.A., 2011, PHOTOMED LA IN PRESS; PODREKA I, 1989, STROKE, V20, P183, DOI 10.1161/01.STR.20.2.183; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	7	37	39	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1549-5418	1557-8550		PHOTOMED LASER SURG	Photomed. Laser Surg.	APR	2012	30	4					231	233		10.1089/pho.2011.3044			3	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	925QN	WOS:000302776100007	22047598				2022-02-06	
J	Stein, DM; Lindell, AL; Murdock, KR; Kufera, JA; Menaker, J; Bochicchio, GV; Aarabi, B; Scalea, TM				Stein, Deborah M.; Lindell, Allison L.; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Bochicchio, Grant V.; Aarabi, Bizhan; Scalea, Thomas M.			Use of Serum Biomarkers To Predict Cerebral Hypoxia after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; clinical management of CNS injury; traumatic brain injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; INTRACTABLE INTRACRANIAL HYPERTENSION; MULITPLE COMPARTMENT SYNDROME; FIBRILLARY ACIDIC PROTEIN; GLASGOW OUTCOME SCALE; CARDIAC-ARREST; CEREBROSPINAL-FLUID; TISSUE OXYGEN; DECOMPRESSIVE CRANIECTOMY	The management of severe traumatic brain injury (TBI) focuses on prevention and treatment of secondary insults such as cerebral hypoxia (CH). There are a number of biomarkers that are thought to play a part in secondary injury following severe TBI. This study evaluates the association between S100 beta, neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP), detected in the serum of severe TBI patients and CH as measured by brain tissue oxygen partial pressure (Pbo(2)). Patients with severe TBI were prospectively enrolled. Pressure times time (PTD; mm Hg*h), measuring the depth and duration of CH, was calculated for 12-h periods for episodes of moderate (Pbo(2) < 20 mm Hg) and severe (Pbo(2) < 15 mm Hg) CH, and compared to serum levels of S100 beta, NSE, and GFAP drawn prior to periods of monitoring. An adjusted mixed model analysis was applied as was receiver operating characteristic (ROC) curve analysis. Of 76 patients enrolled, 24 had Pbo(2) monitoring. One hundred and thirty serum samples were matched with 12-h periods of monitoring. Significant associations were found in adjusted analyses between increasing serum levels of S100 beta (coefficient = 0.57, 0.56; p < 0.001), NSE (coefficient = 0.48, 0.52; p < 0.001), and GFAP (coefficient = 0.29, 0.30; p = 0.003 and 0.002), and increasing PTD of moderate (Pbo(2) < 20mm Hg) and severe (Pbo(2) < 15 mm Hg) CH. AUCs for the prediction of moderate and severe CH were 0.62 and 0.66 for S100 beta, 0.55 and 0.71 for NSE, and 0.50 and 0.62 for GFAP, respectively. Specificities were between 76% and 90% for S100 beta and NSE. S100 beta, NSE, and GFAP demonstrate promise as candidate serum markers of impending CH. The fact that these biomarker elevations occur prior to the onset of clinical manifestations suggests that we may be able to predict imminent events following TBI. Given the morbidity of CH, early intervention and prevention may have a significant impact on outcomes and help guide decisions about the timing of interventions.	[Stein, Deborah M.] Univ Maryland, Med Ctr, Div Crit Care,Sch Med, R Adams Cowley Shock Trauma Ctr,Program Trauma, Baltimore, MD 21201 USA; [Stein, Deborah M.; Lindell, Allison L.; Murdock, Karen R.; Kufera, Joseph A.; Menaker, Jay; Bochicchio, Grant V.; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, Baltimore, MD 21201 USA		Stein, DM (corresponding author), Univ Maryland, Med Ctr, Div Crit Care,Sch Med, R Adams Cowley Shock Trauma Ctr,Program Trauma, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963	 [W81XWH-07-2-0118]	This study was supported by W81XWH-07-2-0118. The authors would like to thank Dr. Hegang Chen for his statistical assistance with this study.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Association for the Advancement of Automotive Medicine, 2005, ABBR INJ SCAL; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; Astudillo R, 1996, EUR J CARDIO-THORAC, V10; Bardt TF, 1998, ACT NEUR S, V71, P153; Basile AM, 2001, EUR NEUROL, V45, P151, DOI 10.1159/000052114; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bridges E, 2010, AACN ADV CRIT CARE, V21, P260, DOI 10.1097/NCI.0b013e3181e67385; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; Cunningham RT, 1996, EUR J CLIN INVEST, V26, P298, DOI 10.1046/j.1365-2362.1996.129282.x; CUNNINGHAM RT, 1991, EUR J CLIN INVEST, V21, P497, DOI 10.1111/j.1365-2362.1991.tb01401.x; DAUBERSCHMIDT R, 1991, MOL CHEM NEUROPATHOL, V14, P237, DOI 10.1007/BF03159939; Dings J, 1998, NEUROL RES, V20, pS71; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Figaji AA, 2009, CHILD NERV SYST, V25, P1335, DOI 10.1007/s00381-009-0821-y; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Gracias VH, 2007, J TRAUMA, V62, P656; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb; KENNEDY CS, 2004, CLIN PEDIAT EMERG ME, V5, P224; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kirchhoff C, 2008, EUR J MED RES, V13, P511; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Kraus J, 1996, NEUROTRAUMA, P13; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Reisinger J, 2007, EUR HEART J, V28, P52, DOI 10.1093/eurheartj/ehl316; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Scalea TM, 2007, J TRAUMA, V62, P647, DOI 10.1097/TA.0b013e31802ee542; SELLMAN M, 1992, SCAND J THORAC CARD, V26, P39, DOI 10.3109/14017439209099051; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stroick M, 2006, CURR MED CHEM, V13, P3053, DOI 10.2174/092986706778521751; Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	69	37	38	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1140	1149		10.1089/neu.2011.2149			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100014	22360297				2022-02-06	
J	Baker, TA; Romero, J; Bach, HH; Strom, JA; Gamelli, RL; Majetschak, M				Baker, Todd A.; Romero, Jacqueline; Bach, Harold H.; Strom, Joel A.; Gamelli, Richard L.; Majetschak, Matthias			Systemic release of cytokines and heat shock proteins in porcine models of polytrauma and hemorrhage	CRITICAL CARE MEDICINE			English	Article						biomarker; inflammation; injury severity; mortality; resuscitation; shock	NECROSIS-FACTOR-ALPHA; MULTIPLE ORGAN FAILURE; INFLAMMATORY GENE-TRANSCRIPTION; SEVERELY INJURED PATIENTS; TRAUMATIC BRAIN-INJURY; SEVERE BLUNT TRAUMA; HLA-DR EXPRESSION; EXOGENOUS UBIQUITIN; RESPONSE SYNDROME; IMMUNE-RESPONSE	Objective: To define systemic release kinetics of a panel of cytokines and heat shock proteins in porcine polytrauma/hemorrhage models and to evaluate whether they could be useful as early trauma biomarkers. Design: Prospective observational study. Setting: Research laboratory. Subjects: Twenty-one Yorkshire pigs. Interventions: None. Measurements and Main Results: Pigs underwent polytrauma (femur fractures/lung contusion, P), hemorrhage (mean arterial pressure 25-30 mm Hg, H), polytrauma plus hemorrhage (P/H), or sham procedure (S). Plasma was obtained at baseline, in 5- to 15-min intervals during a 60-min shock period without intervention, and in 60- to 120-min intervals during fluid resuscitation for up to 300 min. Plasma was assayed for interleukin-10, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-12/interleukin-23p40, interleukin-13, interleukin-17, interleukin-18, interferon gamma, transforming growth factor-beta, tumor necrosis factor-alpha, heat shock protein 40, heat shock protein 70, and heat shock protein 90 by enzyme-linked immunosorbent assay. All animals after S, P, and H survived (n = 5/group). Three of six animals after P/H died. Interleukin-10 increased during shock after P and this increase was attenuated after H. Tumor necrosis factor-alpha increased during the shock period after P, H, and also after S. P/H abolished the systemic interleukin-10 and tumor necrosis factor-alpha release and resulted in 20% to 30% increased levels of interleukin-6 during shock. As fluid resuscitation was initiated, tumor necrosis factor-alpha and interleukin-10 levels decreased after P, H, and P/H; heat shock protein 70 increased after P; and interleukin-6 levels remained elevated after P/H and also increased after P and S. Conclusions: Differential regulation of the systemic cytokine release after polytrauma and/or hemorrhage, in combination with the effects of resuscitation, can explain the variability and inconsistent association of systemic cytokine/heat shock protein levels with clinical variables in trauma patients. Insults of major severity (P/H) partially suppress the systemic inflammatory response. The plasma concentrations of the measured cytokines/heat shock proteins do not reflect injury severity or physiological changes in porcine trauma models and are unlikely to be able to serve as useful trauma biomarkers in patients. (Crit Care Med 2012; 40: 876-885)	[Baker, Todd A.; Romero, Jacqueline; Bach, Harold H.; Gamelli, Richard L.; Majetschak, Matthias] Loyola Univ Chicago, Stritch Sch Med, Burn & Shock Trauma Inst, Dept Surg, Maywood, IL 60153 USA; [Majetschak, Matthias] Loyola Univ Chicago, Stritch Sch Med, Dept Mol Pharmacol & Therapeut, Maywood, IL USA; [Strom, Joel A.] Univ Florida, Coll Med Jacksonville, Div Cardiol, Jacksonville, FL USA		Majetschak, M (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Burn & Shock Trauma Inst, Dept Surg, Maywood, IL 60153 USA.	mmajetschak@lumc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM008750]; U.S. Department of the Army [W81XWH-05-1-0585]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008750] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health T32 GM008750 and the U.S. Department of the Army under Award Number W81XWH-05-1-0585. The U.S. Army Medical Research Acquisition Activity, (Fort Detrick, MD) is the awarding and administering acquisition office. Information contained in this article does not necessarily reflect the position or the policy of the government, and no official endorsement is inferred.	ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; Adib-Conquy M, 2007, FEBS LETT, V581, P3723, DOI 10.1016/j.febslet.2007.03.074; Angele MK, 2008, CRIT CARE, V12, DOI 10.1186/cc6919; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Block EFJ, 2004, J TRAUMA, V56, P999; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; Cerovic O, 2003, INTENS CARE MED, V29, P1300, DOI 10.1007/s00134-003-1753-8; CINAT M, 1995, J TRAUMA, V39, P112, DOI 10.1097/00005373-199507000-00015; De AK, 2000, J IMMUNOL, V165, P3951, DOI 10.4049/jimmunol.165.7.3951; Ditschkowski M, 1999, ANN SURG, V229, P246, DOI 10.1097/00000658-199902000-00013; Ditschkowski M, 1999, EUR J SURG, V165, P1129, DOI 10.1080/110241599750007630; Dudkiewicz M, 2008, CRIT CARE MED, V36, P2838, DOI 10.1097/CCM.0b013e318186f6b3; Earle SA, 2005, SURGERY, V138, P431, DOI 10.1016/j.surg.2005.06.026; Ertel W, 1998, UNFALLCHIRURG, V101, P520, DOI 10.1007/s001130050304; Flohe S, 2004, INTENS CARE MED, V30, P96, DOI 10.1007/s00134-003-2041-3; Flohe SB, 2008, INNATE IMMUN-LONDON, V14, P333, DOI 10.1177/1753425908100016; Frangen TM, 2008, SHOCK, V29, P462, DOI 10.1097/SHK.0b013e3181598a9d; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; GRYGLEWSKI A, 1985, ARCH IMMUNOL THER EX, V33, P489; Hensler T, 2000, INFLAMM RES, V49, P524, DOI 10.1007/s000110050626; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Jastrow KM, 2009, J AM COLL SURGEONS, V209, P320, DOI 10.1016/j.jamcollsurg.2009.05.002; Kamada H, 2000, CANCER RES, V60, P6416; KAMPSCHMIDT RF, 1980, P SOC EXP BIOL MED, V164, P537; Kawasaki T, 2009, AM J PHYSIOL-CELL PH, V296, pC124, DOI 10.1152/ajpcell.00447.2008; Keel M, 1996, J TRAUMA, V41, P430, DOI 10.1097/00005373-199609000-00008; Liener UC, 2002, SHOCK, V17, P169, DOI 10.1097/00024382-200203000-00002; Liu Jing-Qu, 2004, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V16, P70; Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e; Majetschak M, 2000, UNFALLCHIRURG, V103, P903, DOI 10.1007/s001130050639; Majetschak M, 1999, ANN SURG, V230, P207, DOI 10.1097/00000658-199908000-00011; Majetschak M, 1997, J TRAUMA, V43, P880, DOI 10.1097/00005373-199712000-00002; Majetschak M, 1999, CRIT CARE MED, V27, P313, DOI 10.1097/00003246-199902000-00037; Majetschak M, 2000, CRIT CARE MED, V28, P1847, DOI 10.1097/00003246-200006000-00027; Majetschak M, 2005, CLIN DIAGN LAB IMMUN, V12, P296, DOI 10.1128/CDLI.12.2.296-303.2005; Majetschak M, 2004, J TRAUMA, V56, P991, DOI 10.1097/01.TA.0000127770.29009.5A; MANIKIS P, 1995, AM J EMERG MED, V13, P619, DOI 10.1016/0735-6757(95)90043-8; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; Moomey CB, 1999, CRIT CARE MED, V27, P154, DOI 10.1097/00003246-199901000-00044; Namas R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008406; Pespeni M, 2005, J SURG RES, V126, P41, DOI 10.1016/j.jss.2005.01.012; Pittet JF, 2002, J TRAUMA, V52, P611, DOI 10.1097/00005373-200204000-00001; Proctor KG, 2008, AM J PHYSIOL-REG I, V294, pR1822, DOI 10.1152/ajpregu.90301.2008; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Roetman B, 2008, J INTERF CYTOK RES, V28, P741, DOI 10.1089/jir.2008.0029; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; Schmitz D, 2010, INFLAMM RES, V59, P141, DOI 10.1007/s00011-009-0081-z; Spielmann S, 2001, ACTA ANAESTH SCAND, V45, P364, DOI 10.1034/j.1399-6576.2001.045003364.x; SVOBODA P, 1994, J TRAUMA, V36, P336, DOI 10.1097/00005373-199403000-00009; Watters JM, 2006, J TRAUMA, V61, P300, DOI 10.1097/01.ta.0000224211.36154.44; Wheeler Derek S, 2005, Pediatr Crit Care Med, V6, P308, DOI 10.1097/01.PCC.0000161075.97355.2E; Yadav K, 2009, RESUSCITATION, V80, P83, DOI 10.1016/j.resuscitation.2008.09.012; Ziegler TR, 2005, INTENS CARE MED, V31, P1079, DOI 10.1007/s00134-005-2690-5	57	37	37	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2012	40	3					876	885		10.1097/CCM.0b013e318232e314			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895YO	WOS:000300532800023	21983369	Green Accepted			2022-02-06	
J	Rosen, RC; Marx, BP; Maserejian, NN; Holowka, DW; Gates, MA; Sleeper, LA; Vasterling, JJ; Kang, HK; Keane, TM				Rosen, Raymond C.; Marx, Brian P.; Maserejian, Nancy N.; Holowka, Darren W.; Gates, Margaret A.; Sleeper, Lynn A.; Vasterling, Jennifer J.; Kang, Han K.; Keane, Terence M.			Project VALOR: design and methods of a longitudinal registry of post-traumatic stress disorder (PTSD) in combat-exposed Veterans in the Afghanistan and Iraqi military theaters of operations	INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH			English	Article						post-traumatic stress disorder (PTSD); study design; disease registry; combat-exposed Veterans; psychosocial outcomes	STRUCTURED CLINICAL INTERVIEW; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; WAR VETERANS; DEPLOYMENT; SYMPTOMS; THERAPY; ASSOCIATION; VALIDATION; PREDICTORS	Few studies have investigated the natural history of post-traumatic stress disorder (PTSD). Project VALOR (Veterans' After-discharge Longitudinal Registry) was designed as a longitudinal patient registry assessing the course of combat-related PTSD among 1600 male and female Veterans who served in Operation Enduring Freedom (OEF) in Afghanistan or Operation Iraqi Freedom (OIF). Aims of the study include investigating patterns and predictors of progression or remission of PTSD and treatment utilization. The study design was based on recommendations from the Agency for Healthcare Quality and Research for longitudinal disease registries and used a pre-specified theoretical model to select the measurement domains for data collection and interpretation of forthcoming results. The registry will include 1200 male and female Veterans with a recent diagnosis of PTSD in the Department of Veteran Affairs (VA) electronic medical record and a comparison group of 400 Veterans without a medical record-based PTSD diagnosis, to also allow for case-control analyses. Data are collected from administrative databases, electronic medical records, a self-administered questionnaire, and a semi-structured diagnostic telephone interview. Project VALOR is a unique and timely registry study that will evaluate the clinical course of PTSD, psychosocial correlates, and health outcomes in a carefully selected cohort of returning OEF/OIF Veterans. Copyright (C) 2011 John Wiley & Sons, Ltd.	[Rosen, Raymond C.; Maserejian, Nancy N.; Gates, Margaret A.; Sleeper, Lynn A.] New England Res Inst Inc, Watertown, MA 02472 USA; [Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Keane, Terence M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA; [Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Keane, Terence M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Kang, Han K.] Environm Epidemiol Serv, Dept Vet Affairs, Washington, DC USA		Rosen, RC (corresponding author), New England Res Inst Inc, 9 Galen St, Watertown, MA 02472 USA.	rrosen@neriscience.com	Marx, Brian/AAK-5072-2020; Keane, Terence/I-8253-2014	Gates Kuliszewski, Margaret/0000-0002-2111-6227; Keane, Terence/0000-0002-0482-3149	US Department of DefenseUnited States Department of Defense [W81XWH-08-2-0102, W81XWH-08-2-0100]	This work was funded by the US Department of Defense Awards W81XWH-08-2-0102 and W81XWH-08-2-0100.	Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Conway PH, 2009, NEW ENGL J MED, V361, P328, DOI 10.1056/NEJMp0905631; Dreyer NA, 2009, JAMA-J AM MED ASSOC, V302, P790, DOI 10.1001/jama.2009.1092; Forbes D, 2004, J TRAUMA STRESS, V17, P249, DOI 10.1023/B:JOTS.0000029268.22161.bd; Friedman MJ, 2007, J CLIN PSYCHIAT, V68, P711, DOI 10.4088/JCP.v68n0508; Gliklich RE, 2010, AHRQ PUBLICATION; Gray MJ, 2004, ASSESSMENT, V11, P330, DOI 10.1177/1073191104269954; Hawthorne G, 2006, SOC PSYCH PSYCH EPID, V41, P164, DOI 10.1007/s00127-005-0986-y; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kessler RC, 2003, J OCCUP ENVIRON MED, V45, P156, DOI 10.1097/01.jom.0000052967.43131.51; Kessler RC, 2008, INT J METH PSYCH RES, V17, pS6, DOI 10.1002/mpr.269; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Kubzansky LD, 2007, ARCH GEN PSYCHIAT, V64, P109, DOI 10.1001/archpsyc.64.1.109; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Marx BP, 2009, S ANN M INT SOC TRAU; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Reid MC, 1999, ARCH INTERN MED, V159, P1681, DOI 10.1001/archinte.159.15.1681; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schnurr P P, 1999, Semin Clin Neuropsychiatry, V4, P295; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Schnurr PP, 2003, ARCH GEN PSYCHIAT, V60, P481, DOI 10.1001/archpsyc.60.5.481; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Scott CK, 2006, J TRAUMA STRESS, V19, P757, DOI 10.1002/jts.20186; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sheehan DV, 1998, J CLIN PSYCHIAT S20, V59, P4; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Vasterling JJ, 2008, J REHABIL RES DEV, V45, P347, DOI 10.1682/JRRD.2007.05.0077; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Wolfe J, 1999, J CONSULT CLIN PSYCH, V67, P520, DOI 10.1037/0022-006X.67.4.520	44	37	37	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1049-8931	1557-0657		INT J METH PSYCH RES	Int. J. Methods Psychiatr. Res.	MAR	2012	21	1					5	16		10.1002/mpr.355			12	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	907QI	WOS:000301432000004	22095917	Green Published			2022-02-06	
J	Thau-Zuchman, O; Shohami, E; Alexandrovich, AG; Trembovler, V; Leker, RR				Thau-Zuchman, Orli; Shohami, Esther; Alexandrovich, Alexander G.; Trembovler, Victoria; Leker, Ronen R.			The Anti-Inflammatory Drug Carprofen Improves Long-Term Outcome and Induces Gliogenesis after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						angiogenesis; neurogenesis; neuroprotection; vascular endothelial growth factor; traumatic brain injury	CLOSED-HEAD INJURY; ENDOTHELIAL GROWTH-FACTOR; NEUROTROPHIC FACTORS; CEREBRAL-ISCHEMIA; CELL-DEATH; STEM-CELLS; CYCLOOXYGENASE-2; MICE; NEUROGENESIS; ACTIVATION	Traumatic brain injury (TBI) initiates acute and chronic inflammatory processes involving cyclooxygenase-2 (COX-2), which may have detrimental effects on outcome and especially on brain regeneration. Therefore we aimed to study whether carprofen, a COX-2 inhibitor, would improve outcome and increase neurogenesis after TBI. TBI was induced in Sabra mice that were then treated with vehicle or carprofen for 7 days. Functional outcome was evaluated with the Neurological Severity Score (NSS).Cytokine levels were assessed 4 h post-TBI and water content was measured 24 h post TBI. Mice were given BrdU to label newborn cells for 10 days. The animals were killed 90 days post-TBI and the lesion size as well as newborn cell fate were assessed. Carprofen significantly reduced lesion size (p=0.002), decreased water content in the lesioned cortex (p=0.03), reduced the number of microglia in the lesioned cortex (p<0.0001), and lowered the levels of proinflammatory cytokines (IL-1 beta, p=0.03; IL-6, p=0.02). Carprofen led to significantly larger improvements in functional outcome (p <= 0.008) which were durable over 90 days. Carprofen also induced a threefold increase in the proliferation of new cells in the pen-lesion area ( p <= 0.002), but newborn cells differentiated mainly into glia in both groups. Carprofen is neuroprotective and induces cell proliferation and gliogenesis after TBI. Treatment with carprofen is consistently associated with better functional outcome. Our results imply that anti-inflammatory drugs may represent novel therapeutic options for TBI.	[Thau-Zuchman, Orli; Leker, Ronen R.] Hadassah Hebrew Univ, Med Ctr, Dept Neurol, Jerusalem, Israel; [Thau-Zuchman, Orli; Leker, Ronen R.] Hadassah Hebrew Univ, Med Ctr, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Jerusalem, Israel; [Thau-Zuchman, Orli; Shohami, Esther; Alexandrovich, Alexander G.; Trembovler, Victoria] Hebrew Univ Jerusalem, Sch Pharm, Inst Drug Res IDR, IL-91905 Jerusalem, Israel		Leker, RR (corresponding author), Hadassah Univ Hosp, Dept Neurol, POB 12000, IL-91120 Jerusalem, Israel.	leker@cc.huji.ac.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334; Thau-Zuchman, Orli/0000-0003-0403-7962	Sol Irwin Juni Trust; Peritz and Chantal Scheinberg Cerebrovascular Research Fund; United States Agency for International DevelopmentUnited States Agency for International Development (USAID)	This study was supported by the Sol Irwin Juni Trust Fund and by the Peritz and Chantal Scheinberg Cerebrovascular Research Fund. E. Shohami is the incumbent of the Dr. Leon and Dr. Mina Deutsch Chair in Psychopharmacology at The Hebrew University, and a member of the Brettler Center for Research in Molecular Pharmacology and Therapeutics, The Hebrew University. This research was also supported in part by a grant from the United States Agency for International Development's American Schools and the Hospitals Abroad (ASHA) Program for the procurement of the confocal microscope.	Ben-Hur T, 2008, J NEUROL SCI, V265, P102, DOI 10.1016/j.jns.2007.05.007; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Cacci E, 2008, GLIA, V56, P412, DOI 10.1002/glia.20616; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hakan T, 2010, NEUROL RES, V32, P629, DOI 10.1179/016164109X12464612122731; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Kelsen J, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-31; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kluska MM, 2005, NEUROSCIENCE, V135, P723, DOI 10.1016/j.neuroscience.2005.06.082; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morgan SC, 2004, J NEUROCHEM, V90, P89, DOI 10.1111/j.1471-4159.2004.02461.x; Sasaki T, 2003, J NEUROSCI RES, V72, P461, DOI 10.1002/jnr.10595; Schwartz M, 2000, ANN NY ACAD SCI, V917, P341; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tonchev AB, 2007, NEUROSCIENCE, V144, P1425, DOI 10.1016/j.neuroscience.2006.10.052; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang Feng, 2009, P187, DOI 10.1007/978-1-60327-185-1_15	32	37	37	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					375	384		10.1089/neu.2010.1673			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300016	21561314				2022-02-06	
J	Thomas, TC; Hinzman, JM; Gerhardt, GA; Lifshitz, J				Thomas, Theresa Currier; Hinzman, Jason M.; Gerhardt, Greg A.; Lifshitz, Jonathan			Hypersensitive Glutamate Signaling Correlates with the Development of Late-Onset Behavioral Morbidity in Diffuse Brain-Injured Circuitry	JOURNAL OF NEUROTRAUMA			English	Article						amperometry; brain trauma; fluid percussion glutamate; thalamocortical system	AGE-RELATED-CHANGES; FLUID-PERCUSSION; EXTRACELLULAR GLUTAMATE; MULTISITE MICROELECTRODES; NEURONAL INJURY; AXONAL INJURY; RAT-BRAIN; EXPRESSION; POTASSIUM; CORTEX	In diffuse brain-injured rats, robust sensory sensitivity to manual whisker stimulation develops over 1 month post-injury, comparable to agitation expressed by brain-injured individuals with overstimulation. In the rat, whisker somatosensation relies on thalamocortical glutamatergic relays between the ventral posterior medial (VPM) thalamus and barrel fields of somatosensory cortex (S1BF). Using novel glutamate-selective microelectrode arrays coupled to amperometry, we test the hypothesis that disrupted glutamatergic neurotransmission underlies the whisker sensory sensitivity associated with diffuse brain injury. We report hypersensitive glutamate neurotransmission that parallels and correlates with the development of post-traumatic sensory sensitivity. Hypersensitivity is demonstrated by significant 110% increases in VPM extracellular glutamate levels, and 100% increase in potassium-evoked glutamate release in the VPM and S1BF, with no change in glutamate clearance. Further, evoked glutamate release showed 50% greater sensitivity to a calcium channel antagonist in brain-injured over uninjured VPM. In conjunction with no changes in glutamate transporter gene expression and exogenous glutamate clearance efficiency, these data support a presynaptic origin for enduring post-traumatic circuit alterations. In the anatomically-distinct whisker circuit, the injury-induced functional alterations correlate with the development of late-onset behavioral morbidity. Effective therapies to modulate presynaptic glutamate function in diffuse-injured circuits may translate into improvements in essential brain function and behavioral performance in other brain-injured circuits in rodents and in humans.	[Thomas, Theresa Currier; Hinzman, Jason M.; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Coll Med, Lexington, KY 40536 USA; [Thomas, Theresa Currier; Hinzman, Jason M.; Gerhardt, Greg A.; Lifshitz, Jonathan] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; [Hinzman, Jason M.; Gerhardt, Greg A.] Univ Kentucky, Ctr Microelectrode Technol, Coll Med, Lexington, KY 40536 USA; [Hinzman, Jason M.; Gerhardt, Greg A.] Univ Kentucky, Morris K Udall Parkinsons Dis Res Ctr Excellence, Coll Med, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Univ Kentucky, Dept Phys Med & Rehabil, Coll Med, Lexington, KY 40536 USA		Lifshitz, J (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Coll Med, Biomed & Biol Sci Res Bldg,B463 741 S Limestone S, Lexington, KY 40536 USA.	JLifshitz@uky.edu	Thomas, Theresa Currier/K-1979-2019	Thomas, Theresa Currier/0000-0002-9619-7666	Kentucky Spinal Cord and Head Injury Research Trust [7-11, R01 NS065052, T32 AG000242, P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, P30NS051220, R03NS077098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000242] Funding Source: NIH RePORTER	The authors would like to sincerely thank Francois Pomerleau and Peter Huettl for their help with installing and maintenance of the FAST system, Amanda Lisembee, Katelyn McNamara, Kelley Hall, Tuoxin Cao, and Shima Dowla for technical assistance with the experiments, Richard Rogers, Ph.D. and Gerlinda Hermann, Ph.D. for instruction on the fabrication of double-barrel micropipettes, and George M. Smith, Ph.D. and Pooja Talauliker, Ph.D. for critical feedback on the manuscript. This work was supported by the Kentucky Spinal Cord and Head Injury Research Trust grant #7-11 to Jonathan Lifshitz, R01 NS065052 to Jonathan Lifshitz, T32 AG000242 to Greg A. Gerhardt in support of Theresa C. Thomas, U.K. College of Medicine, and P30 NS051220 to Edward D. Hall, Ph.D.	Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Burmeister JJ, 2004, P ANN INT IEEE EMBS, V26, P5348; Burmeister JJ, 2002, J NEUROSCI METH, V119, P163, DOI 10.1016/S0165-0270(02)00172-3; Burmeister JJ, 2001, ANAL CHEM, V73, P1037, DOI 10.1021/ac0010429; Burmeister JJ, 2000, ANAL CHEM, V72, P187, DOI 10.1021/ac9907991; Cai X, 2007, J NEUROSCI, V27, P59, DOI 10.1523/JNEUROSCI.4502-06.2007; CASS WA, 1992, J NEUROCHEM, V59, P259, DOI 10.1111/j.1471-4159.1992.tb08899.x; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Conti AC, 1998, J NEUROSCI, V18, P5663; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Day BK, 2006, J NEUROCHEM, V96, P1626, DOI 10.1111/j.1471-4159.2006.03673.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Emery DL, 2000, J COMP NEUROL, V424, P521; ERB DE, 1991, EXP BRAIN RES, V83, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Formisano R, 2009, J HEADACHE PAIN, V10, P145, DOI 10.1007/s10194-009-0108-4; FRIEDEMANN MN, 1992, NEUROBIOL AGING, V13, P325, DOI 10.1016/0197-4580(92)90046-Z; GERHARDT G, 1985, J PHARMACOL EXP THER, V235, P259; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hascup ER, 2010, J NEUROCHEM, V115, P1608, DOI 10.1111/j.1471-4159.2010.07066.x; Hascup K. N., 2006, ELECTROCHEMICAL METH, P407; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Homola A, 2006, NEUROSCI LETT, V404, P137, DOI 10.1016/j.neulet.2006.05.028; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kidd FL, 1999, NATURE, V400, P569, DOI 10.1038/23040; LAND PW, 1995, J COMP NEUROL, V355, P573, DOI 10.1002/cne.903550407; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Latour I, 2003, GLIA, V41, P347, DOI 10.1002/glia.10162; Lifshitz J., 2011, BRAIN STRUCT FUNCT; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCCANN MJ, 1990, J PHYSIOL-LONDON, V428, P95, DOI 10.1113/jphysiol.1990.sp018202; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; McNamara KCS, 2010, J NEUROTRAUM, V27, P695, DOI 10.1089/neu.2009.1237; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MOUSSY F, 1994, ANAL CHEM, V66, P674, DOI 10.1021/ac00077a015; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; Nickell J, 2005, J NEURAL TRANSM, V112, P87, DOI 10.1007/s00702-004-0151-x; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Paxinos G., 2007, RAT BRAIN IN STEREOT; Pomerleau F, 2003, ANN NY ACAD SCI, V1003, P454, DOI 10.1196/annals.1300.051; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Quintero JE, 2007, EXP NEUROL, V208, P238, DOI 10.1016/j.expneurol.2007.08.002; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheid R, 2010, DTSCH ARZTEBL INT, V107, P199, DOI 10.3238/arztebl.2010.0199; Schubert D, 2007, BRAIN STRUCT FUNCT, V212, P107, DOI 10.1007/s00429-007-0147-z; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Thomas TC, 2009, NEUROPSYCHOPHARMACOL, V34, P436, DOI 10.1038/npp.2008.74; Ueda Y, 2001, J NEUROCHEM, V76, P892, DOI 10.1046/j.1471-4159.2001.00087.x; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; Van Landeghem FKH, 2006, J NEUROTRAUM, V23, P1518, DOI 10.1089/neu.2006.23.1518; Waite P, 1995, RAT NERVOUS SYSTEM; Watt AJ, 2000, NEURON, V26, P659, DOI 10.1016/S0896-6273(00)81202-7; Wiley JL, 1996, BRAIN RES, V716, P47, DOI 10.1016/0006-8993(96)00045-5; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; Yamaki T, 1998, BRAIN RES PROTOC, V3, P100, DOI 10.1016/S1385-299X(98)00030-0; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; [No title captured]	72	37	37	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					187	200		10.1089/neu.2011.2091			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300001	21939393	Green Published			2022-02-06	
J	Kleffelgaard, I; Roe, C; Soberg, HL; Bergland, A				Kleffelgaard, Ingerid; Roe, Cecilie; Soberg, Helene L.; Bergland, Astrid			Associations among self-reported balance problems, post-concussion symptoms and performance-based tests: a longitudinal follow-up study	DISABILITY AND REHABILITATION			English	Article						Balance problems; mild traumatic brain injury; post-concussion symptoms	TRAUMATIC BRAIN-INJURY; MOBILITY ASSESSMENT-TOOL; DYNAMIC GAIT INDEX; MILD HEAD-INJURY; WALKING SPEED; INTERRATER RELIABILITY; VESTIBULAR DISORDERS; CONCURRENT VALIDITY; DIZZINESS; PEOPLE	Purpose: The main objectives of this study were to describe long-term self-reported balance problems and to explore their associations with post-concussion symptoms and performance-based tests. Method: Prospective study of patients with mild traumatic brain injury (MTBI). Self-reported balance problems and post-concussion symptoms were measured with the Rivermead Post-concussion Symptoms Questionnaire at 1 and 4 years after injury. Performance-based tests were performed 4 years after injury and included posturography, the Dynamic Gait Index (DGI), walking speed tests, and the six-minute walk test. Results: Self-reported balance problems were reported in 31% of patients 4 years after injury and correlated significantly with post-concussion symptoms. The correlations with performance-based tests varied from rho = 0.18 to rho = 0.70 and were strongest for the maximum walking speed test (rho = 0.70) and a dual-task test (rho = 0.43). The DGI had a considerable ceiling effect. Conclusions: Balance problems were long-term consequences of MTBI in one third of this study sample. Self-reported balance problems correlated with post-concussion symptoms and some of the performance-based tests. Future research needs to develop and evaluate appropriate rehabilitation strategies that also address the balance problems.	[Kleffelgaard, Ingerid; Roe, Cecilie; Soberg, Helene L.] Oslo Univ Hosp HF, Dept Phys Med & Rehabil, N-0407 Oslo, Norway; [Bergland, Astrid] Oslo Univ Coll, Dept Physiotherapy, Oslo, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway		Kleffelgaard, I (corresponding author), Oslo Univ Hosp HF, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	ingerid.kleffelgard@oslo-universitetssykehus.no					Aiken L. S., 2013, APPL MULTIPLE REGRES, DOI 10.4324/9780203774441; Allison L., 1999, NEUROLOGY REPORT, V23, P13, DOI DOI 10.1097/01253086-199923010-00010; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bohannon RW, 1997, AGE AGEING, V26, P15, DOI 10.1093/ageing/26.1.15; Brauer SG, 2004, HUM MOVEMENT SCI, V23, P489, DOI 10.1016/j.humov.2004.08.020; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; Enright Paul L, 2003, Respir Care, V48, P783; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Finch E, 2002, PHYS REHABILITATION; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; Marchetti GF, 2008, PHYS THER, V88, P640, DOI 10.2522/ptj.20070130; Maskell F, 2006, BRAIN INJURY, V20, P293, DOI 10.1080/02699050500488041; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; McCulloch Karen, 2007, J Neurol Phys Ther, V31, P104; Moseley AM, 2004, J HEAD TRAUMA REHAB, V19, P341, DOI 10.1097/00001199-200407000-00008; Quinn B, 2000, BRAIN INJURY, V14, P1063; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Shumway-Cook A, 2001, MOTOR CONTROL THEORY, P405; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Stratford P., 1995, PHYSIOTHER CAN, V47, P258, DOI DOI 10.3138/PTC.47.4.258; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; Van Loo MA, 2004, BRAIN INJURY, V18, P1041, DOI 10.1080/02699050410001672314; Whitney Susan, 2003, Physiother Res Int, V8, P178, DOI 10.1002/pri.288; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams G, 2005, BRAIN INJURY, V19, P925, DOI 10.1080/02699050500058687; Williams GP, 2006, PHYS THER, V86, P395, DOI 10.1093/ptj/86.3.395; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711; Wrisley DM, 2003, ARCH PHYS MED REHAB, V84, P1528, DOI 10.1016/S0003-9993(03)00274-0	41	37	39	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2012	34	9					788	794		10.3109/09638288.2011.619624			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	909TG	WOS:000301587200012	22149161				2022-02-06	
J	Moreau, OK; Yollin, E; Merlen, E; Daveluy, W; Rousseaux, M				Moreau, Odile Kozlowski; Yollin, Edwige; Merlen, Emilie; Daveluy, Walter; Rousseaux, Marc			Lasting Pituitary Hormone Deficiency after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						activities of daily living; cognitive disorders; pituitary deficiency; sequelae; traumatic brain injury	POSTTRAUMATIC DIABETES-INSIPIDUS; GROWTH-FACTOR-I; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; GH DEFICIENCY; ANTERIOR LOBE; HEAD-INJURY; ACUTE-PHASE; LONG-TERM; HIGH-RISK	Pituitary deficiencies have been reported after traumatic brain injury (TBI) and may contribute to lasting cognitive disorders in this context. In a population of TBI patients with persistent cognitive and/or behavioral disorders, we sought to determine the prevalence of lasting pituitary deficiency and relationships with TBI severity, cognitive disorders, and impairments in activities of daily living (ADL). Fifty-five patients were included (mean age 36.1 years; 46 men) at least 1 year after TBI. They underwent a comprehensive evaluation of pituitary function (basic tests and stimulation), initial TBI severity, and long-term outcomes (cognitive performance, Glasgow Outcome Scale score, impact on ADL, and quality of life [QoL]). We used chi-squared and Mann-Whitney tests to probe for significant (p <= 0.05) relationships between pituitary disorders and other parameters. Thirty-eight (69%) patients had at least one pituitary hormone deficiency. Growth hormone deficiency was more prevalent (severe: 40.0%; partial: 23.6%) than corticotropin (27.3%) or thyrotropin (21.8%) deficiencies. Other deficiencies were rare. Growth hormone deficiency was associated with attention and verbal memory disorders and reduced involvement in ADL. We did not find any relationship between pituitary deficiency and the TBI's initial severity. In a multivariate analysis, the TBI severity was introduced as a first factor, and pituitary deficits as a secondary factor for explaining the late outcome (ADL and QoL). In conclusion, TBI patients with cognitive sequelae must undergo pituitary screening because growth hormone, corticotropin, and thyrotropin deficits are particularly common and can adversely affect ADL and reduce QoL.	[Yollin, Edwige; Merlen, Emilie] CHRU, Huriez Hosp, Endocrinol Unit, Lille, France		Moreau, OK (corresponding author), CHRU Univ Lille Nord de France, Swynghedauw Hosp, Neurol Rehabil Unit, Lille, France.	odile.moreau@chru-lille.fr					Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Berg C, 2010, EXP CLIN ENDOCR DIAB, V118, P139, DOI 10.1055/s-0029-1225611; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Brooks N., 1994, EVALUATION TRAUMATIC, V1994, P1; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Colao A, 2009, J CLIN ENDOCR METAB, V94, P4414, DOI 10.1210/jc.2009-1134; DANIEL PM, 1959, LANCET, V2, P927; Ellison DH, 2007, NEW ENGL J MED, V356, P2064, DOI 10.1056/NEJMcp066837; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Ghigo E, 2008, GROWTH HORM IGF RES, V18, P1, DOI 10.1016/j.ghir.2007.07.004; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; HOECK HC, 1995, EUR J ENDOCRINOL, V133, P305, DOI 10.1530/eje.0.1330305; JENNETT B, 1975, LANCET, V1, P480; Jeong JH, 2010, J NEUROSURG, V113, P532, DOI 10.3171/2009.10.JNS091152; KAWAI K, 1995, J NEUROSURG, V83, P368, DOI 10.3171/jns.1995.83.2.0368; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MASSOL J, 1987, NEURORADIOLOGY, V29, P299, DOI 10.1007/BF00451773; Mathe JF, 2005, ANN FR ANESTH, V24, P688, DOI 10.1016/j.annfar.2005.03.029; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Park KD, 2010, BRAIN INJURY, V24, P1330, DOI 10.3109/02699052.2010.506863; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider HJ, 2003, EUR J ENDOCRINOL, V149, P377, DOI 10.1530/eje.0.1490377; SHEEHAN HL, 1961, ACTA ENDOCRINOL-COP, V37, P479, DOI 10.1530/acta.0.0370479; STABLER B, 1992, CLIN ENDOCRINOL, V36, P467, DOI 10.1111/j.1365-2265.1992.tb02247.x; Tandon A, 2009, ACTA NEUROCHIR, V151, P1411, DOI 10.1007/s00701-009-0444-9; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Truelle JL, 2008, ACTA NEUROCHIR SUPPL, V101, P125; van Dam PS, 2004, EUR J PHARMACOL, V490, P87, DOI 10.1016/j.ejphar.2004.02.047; van Dam PS, 2000, GROWTH HORM IGF RES, V10, P69, DOI 10.1016/S1096-6374(00)80013-1; Van der Linden M., 2004, VALUATION TROUBLES M; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; Wechsler R., 1989, ECHELLE INTELLIGENCE; Zimmermann P., 1994, TEST ATTENTIONAL PER; [No title captured]	56	37	37	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					81	89		10.1089/neu.2011.2048			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300009	21992034				2022-02-06	
J	Fathi, AR; Pluta, RM; Bakhtian, KD; Qi, M; Lonser, RR				Fathi, Ali Reza; Pluta, Ryszard M.; Bakhtian, Kamran D.; Qi, Meng; Lonser, Russell R.			Reversal of cerebral vasospasm via intravenous sodium nitrite after subarachnoid hemorrhage in primates Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						nitric oxide; sodium nitrite; subarachnoid hemorrhage; vasospasm; traumatic brain injury	TRANSLUMINAL BALLOON ANGIOPLASTY; INTRAARTERIAL PAPAVERINE; OXIDE SYNTHASE; ENDOGENOUS INHIBITOR; DOUBLE-BLIND; MODEL; TRIAL; DEOXYHEMOGLOBIN; NITROPRUSSIDE; ASSOCIATION	Object. Subarachnoid hemorrhage (SAH)-induced vasospasm is a significant underlying cause of aneurysm rupture-related morbidity and death. While long-term intravenous infusion of sodium nitrite (NaNO(2)) can prevent cerebral vasospasm after SAH, it is not known if the intravenous administration of this compound can reverse established SAH-induced vasospasm. To determine if the intravenous infusion of NaNO(2) can reverse established vasospasm, the authors infused primates with the compound after SAH-induced vasospasm was established, Methods. Subarachnoid hemorrhage-induced vasospasm was created in 14 cynomolgus macaques via subarachnoid implantation of a 5-ml blood clot. On Day 7 after clot implantation, animals were randomized to either control (saline infusion, 5 monkeys) or treatment groups (intravenous NaNO(2) infusion at 300 mu g/kg/hr for 3 hours 1.7 monkeys) or 8 hours [2 monkeys]). Arteriographic vessel diameter was blindly analyzed to determine the degree of vasospasm before, during, and after treatment. Nitric oxide metabolites (nitrite, nitrate, and S-nitrosothiols) were measured in whole blood and CSF. Results. Moderate-to-severe vasospasm was present in all animals before treatment (control, 36.2% +/- 8.8% [mean +/- SD]; treatment, 45.5% +/- 12.5%; p = 0.9). While saline infusion did not reduce vasospasm, NaNO(2) infusion significantly reduced the degree of vasospasm (26.9% +/- 7.6%; p = 0.008). Reversal of the vasospasm lasted more than 2 hours after cessation of the infusion and could be maintained with a prolonged infusion. Nitrite (peak value, 3.7 +/- 2.1 mu mol/L), nitrate (18.2 +/- 5.3 mu mol/L), and S-nitrosothiols (33.4 +/- 11.4 mu mol/L) increased significantly in whole blood, and nitrite increased significantly in CSF. Conclusions. These findings indicate that the intravenous infusion of NaNO(2) can reverse SAH-induced vasospasm in primates. Further, these findings indicate that a similar treatment paradigm could be useful in reversing cerebral vasospasm after aneurysmal SAH. (DOI: 10.3171/2011.7.JNS11390)	[Fathi, Ali Reza; Pluta, Ryszard M.; Bakhtian, Kamran D.; Qi, Meng; Lonser, Russell R.] Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; [Fathi, Ali Reza] Kantonsspital Aarau AG, Dept Neurosurg, Aarau, Switzerland; [Qi, Meng] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing, Jiangsu, Peoples R China		Lonser, RR (corresponding author), Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bldg 10,Room 3D20, Bethesda, MD 20892 USA.	lonserr@ninds.nih.gov	QI, Meng/F-2802-2012		National Institute of Neurological Disorders and Stroke at the NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBSKP3-123454]; China Scholarship CouncilChina Scholarship Council [2008619102]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003054] Funding Source: NIH RePORTER	This research was supported by the Intramural Research Program of the National Institute of Neurological Disorders and Stroke at the NIH. Dr. Fathi was supported by a grant from the Swiss National Science Foundation (PBSKP3-123454). Dr. Qi was supported by a scholarship from the China Scholarship Council (Scholarship No. 2008619102).	AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Cross DT, 1998, AM J NEURORADIOL, V19, P1319; Crowley RW, 2011, STROKE, V42, P919, DOI 10.1161/STROKEAHA.110.597005; Dejam A, 2007, CIRCULATION, V116, P1821, DOI 10.1161/CIRCULATIONAHA.107.712133; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; ESPINOSA F, 1984, J NEUROSURG, V60, P1167, DOI 10.3171/jns.1984.60.6.1167; Frontera JA, 2010, NEUROSURGERY, V66, P35, DOI 10.1227/01.NEU.0000359530.04529.07; Giller CA, 1998, NEUROSURGERY, V42, P1076, DOI 10.1097/00006123-199805000-00077; Hoh BL, 2005, NEUROSURG CLIN N AM, V16, P501, DOI 10.1016/j.nec.2005.04.004; Jung CS, 2007, J NEUROSURG, V107, P945, DOI 10.3171/JNS-07/11/0945; Jung CS, 2004, J NEUROSURG, V101, P836, DOI 10.3171/jns.2004.101.5.0836; KASSELL NF, 1984, STROKE, V15, P566, DOI 10.1161/01.STR.15.3.566; Keefer LK, 2003, ANNU REV PHARMACOL, V43, P585, DOI 10.1146/annurev.pharmtox.43.100901.135831; MacArthur PH, 2007, J CHROMATOGR B, V851, P93, DOI 10.1016/j.jchromb.2006.12.012; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; Park KW, 2002, CAN J ANAESTH, V49, P427, DOI 10.1007/BF03017335; Pluta RM, 2005, JAMA-J AM MED ASSOC, V293, P1477, DOI 10.1001/jama.293.12.1477; Pluta RM, 1996, J NEUROSURG, V84, P648, DOI 10.3171/jns.1996.84.4.0648; Pluta RM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014504; Polin RS, 2000, J NEUROSURG, V92, P284, DOI 10.3171/jns.2000.92.2.0284; Polin RS, 1998, NEUROSURGERY, V42, P1256, DOI 10.1097/00006123-199806000-00031; Raabe A, 2002, NEUROSURGERY, V50, P1006, DOI 10.1097/00006123-200205000-00013; Reinert M, 2004, NEUROL RES, V26, P435, DOI 10.1179/016164104225015976; Rejdak K, 2004, J NEUROL SCI, V219, P71, DOI 10.1016/j.jns.2003.12.011; Thomas JE, 1999, STROKE, V30, P1409, DOI 10.1161/01.STR.30.7.1409; Tierney TS, 2006, NEUROSURGERY, V58, P952, DOI 10.1227/01.NEU.0000210182.48546.8F; Vajkoczy P, 2001, STROKE, V32, P498, DOI 10.1161/01.STR.32.2.498; Vellimana AK, 2011, STROKE, V42, P776, DOI 10.1161/STROKEAHA.110.607200; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; Zwienenberg-Lee M, 2008, STROKE, V39, P1759, DOI 10.1161/STROKEAHA.107.502666	32	37	39	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	2011	115	6					1213	1220		10.3171/2011.7.JNS11390			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	853UH	WOS:000297450700025	21888479	Green Accepted			2022-02-06	
J	Hellstrom, M; Pollett, MA; Harvey, AR				Hellstroem, Mats; Pollett, Margaret A.; Harvey, Alan R.			Post-Injury Delivery of rAAV2-CNTF Combined with Short-Term Pharmacotherapy Is Neuroprotective and Promotes Extensive Axonal Regeneration after Optic Nerve Trauma	JOURNAL OF NEUROTRAUMA			English	Article						cAMP; ciliary neurotrophic factor; growth factors; neural injury; RGC; therapeutic approaches for the treatment of CNS injury; viral-mediated transfection	RETINAL GANGLION-CELLS; CILIARY NEUROTROPHIC FACTOR; RECOMBINANT ADENOASSOCIATED VIRUS; SPINAL-CORD-INJURY; LEBERS CONGENITAL AMAUROSIS; OCULAR GENE-TRANSFER; IN-VIVO; VIRAL VECTORS; AAV SEROTYPES; INTRAVITREAL INJECTION	Recombinant adeno-associated viral (rAAV) vectors expressing neurotrophic genes reduce neuronal death and promote axonal regeneration in central nervous system (CNS) injury models. Currently, however, use of rAAV to treat clinical neurotrauma is problematic because there is a delay in the onset of transgene expression. Using the adult rat retina and optic nerve (ON), we have tested whether rAAV gene therapy administered at the time of injury combined with short-term pharmacotherapy has synergistic effects that enhance neuronal survival and regeneration. The ON was transected and a 1.5 cm segment of autologous peripheral nerve (PN) was grafted onto the cut end. At this time, bicistronic rAAV2 encoding ciliary neurotrophic factor (CNTF) and green fluorescent protein (rAAV2-CNTF-GFP) was injected into the injured eye. To provide interim support for axotomized retinal ganglion cells (RGCs) during vector integration and therapeutic transgene expression, rCNTF protein and a cyclic adenosine monophosphate (cAMP) analogue (CPT-cAMP) were injected intravitreally 3 and 10 days postoperatively. For comparison, another rAAV2-CNTF-GFP group received two intravitreal saline injections 3 and 10 days after the PN-ON surgery. A further PN graft group received only postoperative intravitreal injections of rCNTF plus CPT-cAMP. After 4 weeks, regenerating RGCs were retrogradely labelled by applying fluorogold to the distal end of each PN graft. Compared to saline-injected animals, both RGC survival and axonal regrowth were significantly higher in the rCNTF and CPT-cAMP injected rAAV2-CNTF-GFP group; approximately one third of the RGC population survived axotomy, and 27% of these regrew an axon. These values were also higher than those obtained in rats that received only rCNTF plus CPT-cAMP injections. Therefore, we show for the first time that rAAV-mediated gene delivery at the time of, or just after, neurotrauma is most successful when combined with temporary post-injury trophic support, and is potentially a viable treatment strategy for patients after acute CNS injury.	[Hellstroem, Mats; Pollett, Margaret A.; Harvey, Alan R.] Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009, Australia		Harvey, AR (corresponding author), Univ Western Australia, Sch Anat & Human Biol, M309,35 Stirling Highway, Crawley, WA 6009, Australia.	alan.harvey@uwa.edu.au	Harvey, Alan R/A-4911-2008	, Alan/0000-0002-2590-831X	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; Western Australia Neurotrauma Research Program; International Postgraduate Research ScholarshipAustralian Government; University of Western Australia	This study was funded by the National Health and Medical Research Council (NHMRC) and Western Australia Neurotrauma Research Program. M. H. was supported by an International Postgraduate Research Scholarship and a University of Western Australia Completion Scholarship.	AGUAYO AJ, 1991, PHILOS T R SOC B, V331, P337, DOI 10.1098/rstb.1991.0025; Airavaara M, 2010, EXP NEUROL, V225, P104, DOI 10.1016/j.expneurol.2010.05.020; Alcala-Barraza SR, 2010, J DRUG TARGET, V18, P179, DOI 10.3109/10611860903318134; Allocca M, 2008, J CLIN INVEST, V118, P1955, DOI 10.1172/JCI34316; Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075; Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Benowitz L, 2008, EXP NEUROL, V209, P389, DOI 10.1016/j.expneurol.2007.05.025; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bjorklund T, 2010, MOVEMENT DISORD, V25, pS161, DOI 10.1002/mds.22785; Blits B, 2010, J NEUROSCI METH, V185, P257, DOI 10.1016/j.jneumeth.2009.10.009; Burger C, 2005, HUM GENE THER, V16, P781, DOI 10.1089/hum.2005.16.781; Cen LP, 2007, INVEST OPHTH VIS SCI, V48, P4257, DOI 10.1167/iovs.06-0791; Chen J, 2007, BRAIN, V130, P954, DOI 10.1093/brain/awm049; Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002; Cui Q, 2006, MOL NEUROBIOL, V33, P155, DOI 10.1385/MN:33:2:155; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Cui Q, 2000, NEUROREPORT, V11, P3999, DOI 10.1097/00001756-200012180-00019; Cui Q, 2009, NEUROSCIENCE, V158, P1039, DOI 10.1016/j.neuroscience.2008.07.036; Danias J, 2002, INVEST OPHTH VIS SCI, V43, P587; DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206; Fiandaca MS, 2010, CURR OPIN MOL THER, V12, P519; Filbin MT, 2006, NAT NEUROSCI, V9, P715, DOI 10.1038/nn0606-715; Fisher KJ, 1996, J VIROL, V70, P520, DOI 10.1128/JVI.70.1.520-532.1996; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Gellrich NC, 2002, BRIT J OPHTHALMOL, V86, P233, DOI 10.1136/bjo.86.2.233; Gogel S, 2011, GENE THER, V18, P1, DOI 10.1038/gt.2010.130; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168; Hellstrom M, 2011, MOL CELL NEUROSCI, V46, P507, DOI 10.1016/j.mcn.2010.12.003; Hellstrom M, 2011, CURR GENE THER, V11, P116, DOI 10.2174/156652311794940746; Hellstrom M, 2009, GENE THER, V16, P521, DOI 10.1038/gt.2008.178; Hermening S, 2006, J VIROL METHODS, V136, P30, DOI 10.1016/j.jviromet.2006.03.031; Hermens WTJMC, 1998, PROG NEUROBIOL, V55, P399, DOI 10.1016/S0301-0082(98)00007-0; Hu Y, 2007, MOL CELL NEUROSCI, V34, P88, DOI 10.1016/j.mcn.2006.10.005; Jain KK, 2009, MOL BIOTECHNOL, V42, P367, DOI 10.1007/s12033-009-9166-8; Kim HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004987; Kong FS, 2010, EXP EYE RES, V90, P546, DOI 10.1016/j.exer.2010.01.011; Kurimoto T, 2010, J NEUROSCI, V30, P15654, DOI 10.1523/JNEUROSCI.4340-10.2010; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126; Leibinger M, 2009, J NEUROSCI, V29, P14334, DOI 10.1523/JNEUROSCI.2770-09.2009; Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252; Lu P, 2008, EXP NEUROL, V209, P313, DOI 10.1016/j.expneurol.2007.08.004; Ma YP, 2010, CELL MOL BIOENG, V3, P3, DOI 10.1007/s12195-010-0114-2; Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315; Malik JMI, 2005, MOL THER, V11, P373, DOI 10.1016/j.ymthe.2004.11.014; Manfredsson FP, 2009, CURR GENE THER, V9, P375, DOI 10.2174/156652309789753400; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; Mason MRJ, 2010, MOL THER, V18, P715, DOI 10.1038/mt.2010.19; McCarty DM, 2001, GENE THER, V8, P1248, DOI 10.1038/sj.gt.3301514; Muller A, 2009, MOL CELL NEUROSCI, V41, P233, DOI 10.1016/j.mcn.2009.03.002; Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267; Natkunarajah M, 2008, GENE THER, V15, P463, DOI 10.1038/sj.gt.3303074; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Park KK, 2009, MOL CELL NEUROSCI, V41, P313, DOI 10.1016/j.mcn.2009.04.002; Planchamp V, 2008, BRAIN, V131, P2606, DOI 10.1093/brain/awn196; Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; Rahim AA, 2009, GENE THER, V16, P509, DOI 10.1038/gt.2008.186; Ruitenberg MJ, 2004, NEUROBIOL DIS, V15, P394, DOI 10.1016/j.nbd.2003.11.018; Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; Shen F, 2008, GENE THER, V15, P30, DOI 10.1038/sj.gt.3303048; Simonato M, 2010, EPILEPSIA, V51, P48, DOI 10.1111/j.1528-1167.2010.02609.x; Sweigard JH, 2010, INVEST OPHTH VIS SCI, V51, P2219, DOI 10.1167/iovs.09-4367; Thomas CE, 2000, P NATL ACAD SCI USA, V97, P7482, DOI 10.1073/pnas.120474397; van Adel BA, 2005, J NEUROBIOL, V63, P215, DOI 10.1002/neu.20117; Von Seggern DJ, 2003, MOL THER, V7, P27, DOI 10.1016/S1525-0016(02)00030-8; Wang Z, 2003, GENE THER, V10, P2105, DOI 10.1038/sj.gt.3302133; Yanez-Munoz RJ, 2006, NAT MED, V12, P348, DOI 10.1038/nm1365; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yin YQ, 2009, P NATL ACAD SCI USA, V106, P19587, DOI 10.1073/pnas.0907085106; Yokoi K, 2007, INVEST OPHTH VIS SCI, V48, P3324, DOI 10.1167/iovs.06-1306; Zhu W, 2008, STROKE, V39, P1254, DOI 10.1161/STROKEAHA.107.500801; Zhu W, 2009, J CEREBR BLOOD F MET, V29, P1528, DOI 10.1038/jcbfm.2009.75; Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76	77	37	39	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2011	28	12					2475	2483		10.1089/neu.2011.1928			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	865DS	WOS:000298291600007	21861632				2022-02-06	
J	Farias, SE; Heidenreich, KA; Wohlauer, MV; Murphy, RC; Moore, EE				Farias, Santiago E.; Heidenreich, Kim A.; Wohlauer, Max V.; Murphy, Robert C.; Moore, Ernest E.			Lipid Mediators in Cerebral Spinal Fluid of Traumatic Brain Injured Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Free fatty acids; Lipid mediators; Eicosanoids; Mass spectrometry	CORD NEURONS; IN-VIVO; ACID; PHOSPHOLIPIDS; INFLAMMATION; EICOSANOIDS; ACTIVATION; BLOOD; RAT	Background: Enzymatic and nonenzymatic oxidation of polyunsaturated fatty acids leads to the formation of biologically active products known as lipid mediators. In the brain, lipid mediators play an important role in supporting homeostasis and normal function. Thus, levels of these metabolites in normal and pathologic conditions in the brain are particularly relevant in understanding the transition to disease. Methods: In this study, liquid chromatography tandem mass spectrometry was used to analyze lipid mediators in cerebrospinal fluid (CSF) of controls and traumatic brain injured (TBI) patients. Results: Our results showed that the levels of arachidonic acid (AA), docosahexaenoic acid (DHA), 5- and 12-eicosatetraenoic acid (HETE) were significantly increased in the CSF of TBI patients. The magnitude of increase was 10-fold for AA, DHA, and 5-HETE and 17-fold for 12-HETE. Prostaglandins and leukotrienes were not detected in CSF of either control or brain injured patients. Furthermore, this study found that isoprostanes and thromboxanes are present in CSF of brain injured patients. Conclusions: This study clearly shows that certain lipid mediators accumulate in the CSF of TBI patient. This study also suggests the potential use of DHA, AA, 5- and 12-HETE as biochemical markers of brain injury and to monitor the impact of interventions.	[Wohlauer, Max V.; Moore, Ernest E.] Univ Colorado, Dept Surg, Denver Hlth Med Ctr, UCD, Denver, CO 80202 USA; [Farias, Santiago E.; Heidenreich, Kim A.; Murphy, Robert C.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO USA		Moore, EE (corresponding author), Univ Colorado, Dept Surg, Denver Hlth Med Ctr, UCD, Denver, CO 80202 USA.	ernest.moore@dhha.org	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL025785, P50GM4922, T32GM008315]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL025785, R01HL025785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008315] Funding Source: NIH RePORTER	Supported by grants from National Institutes of Health (HL025785, P50GM4922, and T32GM008315).	Axelsen PH, 2010, J LIPID RES, V51, P660, DOI [10.1194/jlr.d001750, 10.1194/jlr.D001750]; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; CAZEVIEILLE C, 1994, NEUROCHEM INT, V24, P395, DOI 10.1016/0197-0186(94)90118-X; Cowley TR, 2008, EUR J NEUROSCI, V27, P2999, DOI 10.1111/j.1460-9568.2008.06251.x; Farias SE, 2008, J LIPID RES, V49, P1990, DOI 10.1194/jlr.M800200-JLR200; Farooqui AA, 2006, NEUROSCIENTIST, V12, P245, DOI 10.1177/1073858405285923; Garrido R, 2001, J NEUROCHEM, V76, P1395, DOI 10.1046/j.1471-4159.2001.00135.x; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; LANGOIS JA, 2006, TRAUMATIC BRAIN INJU; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Rapoport SI, 1999, NEUROCHEM RES, V24, P1403, DOI 10.1023/A:1022584707352; Saitoh M, 2003, BRAIN RES, V991, P187, DOI 10.1016/j.brainres.2003.08.039; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; SUN GY, 1989, ANN NY ACAD SCI, V559, P37; TEASDALE G, 1974, LANCET, V2, P81; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2	19	37	38	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1211	1218		10.1097/TA.0b013e3182092c62			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	849IG	WOS:000297118600027	21427623				2022-02-06	
J	O'Kane, JW; Levy, MR; Pietila, KE; Caine, DJ; Schiff, MA				O'Kane, John W.; Levy, Marni R.; Pietila, Kristin E.; Caine, Dennis J.; Schiff, Melissa A.			Survey of Injuries in Seattle Area Levels 4 to 10 Female Club Gymnasts	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						gymnastics; youth; injury; concussion; risk factors	EPIDEMIOLOGY; ELITE	Objective: To evaluate incidence, distribution, and contributing factors of injury in club gymnastics. Design: Cross-sectional survey. Setting: Five randomly selected gymnastics clubs near Seattle, WA. Participants: Ninety-six club gymnasts from competitive levels 4 to 10. Interventions: The participants completed a questionnaire regarding demographics, injuries and contributing factors, and exposure time in the last competitive season. Main Outcome Measures: Acute and overuse injury incidence rates stratified by practice and competition, age categories, and level using relative risks and 95% confidence intervals (CIs). Chi-square testing was used to compare demographic-specific and gymnastic-specific variables between injured and uninjured. Multivariate regression modeling was used to assess independent risk factors for risk of acute and overuse injuries. Results: Acute injury rate was 1.3 per 1000 hours and in univariate, but not multivariate analysis, it was 3.6-fold greater (95% CI, 1.6-9.1) among 10 to 12 year olds and 3.1-fold greater (95% Cl, 1.3-8.0) among 13 to 17 year olds compared with 7 to 9 year olds. The most common acutely injured body parts were foot (21.0%), ankle (19.3%), knee (14.0%), and wrist (8.8%). The majority of injuries occurred in practice, but the meet injury rate was higher. Most injuries occurred on floor exercise (32.1%), beam (20.7%), and bars (17.0). Injury was most common during landing. The overuse injury rate was 1.8 per 1000 hours. During their gymnastics careers, concussions occurred in 30.2% and stress fractures affecting mostly low back and foot occurred in 16.7% of the gymnasts. Conclusions: Gymnasts are at similar risk of acute and overuse injuries, and acute injury rates were greater among older gymnasts. However, this predictor did not remain significant in multivariate analysis. Concussions and stress fractures are common. Gymnastics injury prevention studies should focus on older gymnasts, concussion education, and landing after a skill.	[O'Kane, John W.] UW Sports Med Clin, Bank Amer Arena, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Levy, Marni R.; Schiff, Melissa A.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Pietila, Kristin E.; Schiff, Melissa A.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA; [Caine, Dennis J.] Univ N Dakota, Dept Phys Educ Exercise Sci & Wellness, Grand Forks, ND 58201 USA		O'Kane, JW (corresponding author), UW Sports Med Clin, Bank Amer Arena, Dept Orthopaed & Sports Med, 3950 Montlake Blvd,Room 148,Box 354060, Seattle, WA 98195 USA.	jokane@u.washington.edu					BACKX FJG, 1991, AM J SPORT MED, V19, P124, DOI 10.1177/036354659101900206; Bak K., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P148; CAINE D, 1989, AM J SPORT MED, V17, P811, DOI 10.1177/036354658901700616; Caine D, 2005, MED SPORT SCI, V48, P18, DOI 10.1159/000084282; Caine D, 2003, PHYS THER SPORT, V4, P10, DOI 10.1016/S1466-853X(02)00070-6; Caine DJ, 2006, BRIT J SPORT MED, V40, P91; DIXON M, 1993, MED SCI SPORT EXER, V25, P1322; Harringe ML, 2007, SCAND J MED SCI SPOR, V17, P115, DOI 10.1111/j.1600-0838.2006.00546.x; Kolt GS, 1999, BRIT J SPORT MED, V33, P312, DOI 10.1136/bjsm.33.5.312; Kolt GS, 2004, PERCEPT MOTOR SKILL, V99, P195, DOI 10.2466/PMS.99.5.195-207; LINDNER KJ, 1990, CAN J SPORT SCI, V15, P254; Lindner KJ., 1993, J HUM MOV STUD, V25, P69; Marshall SW, 2007, J ATHL TRAINING, V42, P234; Martens R., 1990, COMPETITIVE ANXIETY; Singh S, 2008, PEDIATRICS, V121, pE954, DOI 10.1542/peds.2007-0767; US Centers for Disease Control and Prevention, CDC GROWTH CHARTS US	16	37	39	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2011	21	6					486	492		10.1097/JSM.0b013e31822e89a8			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	849PK	WOS:000297137400004	21959798				2022-02-06	
J	Caterino, JM; Raubenolt, A; Cudnik, MT				Caterino, Jeffrey M.; Raubenolt, Amy; Cudnik, Michael T.			Modification of Glasgow Coma Scale Criteria for Injured Elders	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY, 2010	Phoenix, AZ	Soc Acad Emergency Med			TRAUMATIC BRAIN-INJURY; MISSING DATA; MULTIPLE IMPUTATION; INCREASED MORTALITY; ADVANCED STATISTICS; NONTRAUMA CENTERS; CLINICAL-RESEARCH; GERIATRIC TRAUMA; OLDER-ADULTS; OUTCOMES	Objectives: An abnormal field Glasgow Coma Scale (GCS) score of <= 13 has been used in our emergency medical services (EMS) system to prompt transport to a trauma center. For elders, Ohio has recently adopted a GCS of <= 14 to prompt EMS transport to a trauma center, as older patients respond differently to trauma and may benefit from a different GCS threshold. This study sought to determine if a field GCS of 14 is an appropriate cutoff to initiate transport to a trauma center among injured elders. Methods: This was a retrospective, observational statewide analysis of injured patients 16 years old captured by the Ohio Trauma Registry from 2002 to 2007. Outcomes studied included mortality, traumatic brain injury (TBI), neurosurgical intervention, and endotracheal intubation (ETI). Multiple imputation was performed to account for missing data. Age-stratified sensitivity and specificity for proposed GCS cutoffs of 13 and 14 were calculated. A series of multivariate logistic regression models was then constructed using each outcome as a dependent variable. Independent variables included age, GCS score, sex, blood pressure, injury type, nontrauma center, race, ethnicity, and Injury Severity Score (ISS). Two separate analyses were performed. For each age group, odds ratios (ORs) of each outcome were calculated both for the decrease in GCS from 15 to 14 and for the decrease from 14 to 13. The group of elders with GCS 14 was then compared to adults with GCS 13. Results: A total of 52,412 study patients were identified. For a GCS cutoff of 13, sensitivity among elders for each outcome was >20% less than sensitivity for adults, and specificity was 5% to 10% greater. Increasing the GCS cutoff for elders to 14 resulted in improved sensitivity for all outcomes (approximately 10%), with a decline in specificity to values near that of adults with GCS 13. In the multivariate models for elders, mortality increased with a decrease in GCS both from 15 to 14 (OR = 1.40, 95% confidence interval [CI] = 1.07 to 1.83) and from GCS 14 to 13 (OR = 2.34, 95% CI = 1.57 to 3.52). In adults, mortality did not increase with the drop from GCS 15 to 14 (OR = 1.22, 95% CI = 0.88 to 1.71) or from GCS 14 to 13 (OR = 1.45, 95% CI = 0.91 to 2.30). When comparing elders with GCS 14 to adults with GCS 13, elders had greater odds of mortality (OR = 4.68, 95% CI = 2.90 to 7.54) and TBI (OR = 1.84, 95% CI = 1.45 to 2.34). Conclusions: Changing the EMS trauma triage cutoff for elders from GCS 13 to GCS 14 results in improved sensitivity for clinically relevant outcomes. In injured elders, the decline in GCS from 15 to 14 is associated with increased mortality, a finding not observed in younger adults. Elders with GCS 14 have greater odds of mortality and TBI than adults with GCS 13. These results support recent changes in EMS trauma triage guidelines for elders adopted in Ohio. ACADEMIC EMERGENCY MEDICINE 2011; 18: 1014-1021 (C) 2011 by the Society for Academic Emergency Medicine	[Caterino, Jeffrey M.; Raubenolt, Amy; Cudnik, Michael T.] Ohio State Univ, Dept Emergency Med, Columbus, OH 43210 USA; [Raubenolt, Amy] Michigan State Univ, Dept Emergency Med, Kalamazoo, MI USA		Caterino, JM (corresponding author), Ohio State Univ, Dept Emergency Med, Columbus, OH 43210 USA.	jeffrey.caterino@osumc.edu					American College of Surgeons, 2004, ATLS ADV TRAUM LIF S, V7th ed; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Caterino JM, 2010, AM J EMERG MED, V28, P151, DOI 10.1016/j.ajem.2008.10.027; Chiara Osvaldo, 2003, Curr Opin Crit Care, V9, P510, DOI 10.1097/00075198-200312000-00008; CLARK DE, NATL TRAUMA DATA BAN; Demetriades D, 2001, J TRAUMA, V51, P754, DOI 10.1097/00005373-200110000-00022; Demissie S, 2003, STAT MED, V22, P545, DOI 10.1002/sim.1340; Durham R, 2006, ANN SURG, V243, P775, DOI 10.1097/01.sla.0000219644.52926.f1; *E PRACT MAN GUID, PRACT MAN GUID GER T; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2006, ACAD EMERG MED, V13, P968, DOI 10.1197/j.aem.2006.05.019; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Haukoos JS, 2007, ACAD EMERG MED, V14, P662, DOI 10.1197/j.aem.2006.11.037; Kerby JD, 2007, J TRAUMA, V63, P1026, DOI 10.1097/TA.0b013e318157d9e8; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; Ma MHM, 1999, J TRAUMA, V46, P168; Meldon SW, 2002, J TRAUMA, V52, P79, DOI 10.1097/00005373-200201000-00014; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; Newgard CD, 2007, ACAD EMERG MED, V14, P669, DOI 10.1197/j.aem.2006.11.038; *OH DEP PUBL SAF, OH TRAUM REG DAT EL; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; PELLICANE JV, 1992, J TRAUMA, V33, P440, DOI 10.1097/00005373-199209000-00018; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Phillips S, 1996, J TRAUMA, V40, P278, DOI 10.1097/00005373-199602000-00018; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Scheetz Linda J, 2003, J Emerg Nurs, V29, P109, DOI 10.1067/men.2003.59; SMITH JS, 1990, J TRAUMA, V30, P1533, DOI 10.1097/00005373-199012000-00017; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Tornetta P, 1999, J TRAUMA, V46, P702, DOI 10.1097/00005373-199904000-00024; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; ZIMMERGEMBECK MJ, 1995, J TRAUMA, V39, P922, DOI 10.1097/00005373-199511000-00017; OHIO TRAUMA REGISTRY	39	37	37	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	OCT	2011	18	10					1014	1021		10.1111/j.1553-2712.2011.01164.x			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	835QE	WOS:000296050100001	21951715	Bronze			2022-02-06	
J	Chelly, H; Chaari, A; Daoud, E; Dammak, H; Medhioub, F; Mnif, J; Ben Hamida, C; Bahloul, M; Bouaziz, M				Chelly, Hedi; Chaari, Anis; Daoud, Emna; Dammak, Hssan; Medhioub, Fatma; Mnif, Jameleddine; Ben Hamida, Chokri; Bahloul, Mabrouk; Bouaziz, Mounir			Diffuse Axonal Injury in Patients With Head Injuries: An Epidemiologic and Prognosis Study of 124 Cases	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head trauma; Diffuse axonal injury; Brain magnetic resonance imaging; Cerebral computed tomography; Prognosis	TRAUMATIC BRAIN-INJURY; PRACTICAL SCALE; SEVERITY SCORE; COMA; CONSCIOUSNESS; TOMOGRAPHY; DIAGNOSIS; CT	Background: Diffuse axonal injury (DAI) is usually associated to severe trauma. Recent imaging advances made its diagnosis easier. Its prognosis impact is not yet well established. The aim of this article is to describe the epidemiologic, clinical, and radiologic features of posttraumatic DAI and to study its prognosis impact on mortality and outcome according to Glasgow Outcome Scale. Methods: This is a retrospective study over a 4-year period (2004-2007) of 124 patients admitted for head trauma. Demographic, clinical, biological, and radiologic findings were recorded at admission and during intensive care unit stay. Results: Mean age (+/- standard deviation) was 28 years +/- 15.8 years. Cranial computed tomography scan was sufficient enough to diagnose DAI in 31 patients. Magnetic resonance imaging was performed in 105 patients with a delay of 7.7 days +/- 8.6 days. Most patients were classified as stage II (49.5%) or stage III (44.8%) according to Gentry's classification. In a multivariate analysis, factors associated with higher mortality were dysautonomia (p = 0.018; odds ratio [OR] = 4.17), hyperglycemia >= 8 mmol/L (p = 0.001; OR = 3.84) on intensive care unit admission, and subdural hematoma (p = 0.031; OR = 3.99), whereas factors associated to poor outcome according to Glasgow Outcome Scale score were Glasgow Coma Scale score < 8 (p = 0.032, OR = 3.55), secondary systemic injuries score >= 3 (p = 0.034, OR = 2.83), hyperglycemia >= 8 mmol/L (p = 0.002, OR = 5.55), and DAI count >= 6 (p = 0.035, OR = 3.33). In patients with pure DAI, the absence of consciousness recovery was the unique independent factor of mortality (p < 0.001, OR = 116.4), whereas only transfusion need was an independent factor of poor outcome (p = 0.017, OR = 4.44). Conclusion: Dysautonomia, hyperglycemia, and subdural hematoma are the main factors associated to higher mortality when DAIs are diagnosed, whereas a DAI count >= 6 is associated to poor outcome. Magnetic resonance imaging classification did not have a prognosis value even in patients with pure DAI.	[Chelly, Hedi; Chaari, Anis; Dammak, Hssan; Medhioub, Fatma; Ben Hamida, Chokri; Bahloul, Mabrouk; Bouaziz, Mounir] CHU Habib Bourguiba, Serv Reanimat Med, Sfax, Tunisia; [Daoud, Emna] CHU Hedi Chaker, Serv Radiol, Sfax, Tunisia; [Mnif, Jameleddine] CHU Habib Bourguiba, Serv Radiol, Sfax, Tunisia		Chaari, A (corresponding author), CHU Habib Bourguiba, Serv Reanimat Med, Sfax, Tunisia.	anischaari2004@yahoo.fr		Bahloul, Mabrouk/0000-0002-6488-8294			ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Bardenheuer M, 2000, UNFALLCHIRURG, V103, P355, DOI 10.1007/s001130050550; DUROCHER A, 1988, INTENS CARE MED, V14, P39, DOI 10.1007/BF00254120; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Eum SW, 1998, J KOREAN NEUROSURG S, V27, P1668; Fiser SM, 1998, AM SURGEON, V64, P1088; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1994, RADIOLOGY, V191, P1; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; JENNETT B, 1975, LANCET, V1, P480; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Park SJ, 2009, J KOREAN NEUROSURG S, V46, P205, DOI 10.3340/jkns.2009.46.3.205; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; SKLAR EML, 1992, RADIOL CLIN N AM, V30, P353; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Vyrostek Sara B., 2004, Morbidity and Mortality Weekly Report, V53, P1; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215; TUNISIAN NATL GUARD	40	37	39	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2011	71	4					838	846		10.1097/TA.0b013e3182127baa			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	833ZT	WOS:000295925700018	21460740				2022-02-06	
J	Mortberg, E; Zetterberg, H; Nordmark, J; Blennow, K; Catry, C; Decraemer, H; Vanmechelen, E; Rubertsson, S				Mortberg, E.; Zetterberg, H.; Nordmark, J.; Blennow, K.; Catry, C.; Decraemer, H.; Vanmechelen, E.; Rubertsson, S.			Plasma tau protein in comatose patients after cardiac arrest treated with therapeutic hypothermia	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							NEURON-SPECIFIC ENOLASE; AMERICAN-HEART-ASSOCIATION; TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; SERUM CLEAVED-TAU; S-100B; DAMAGE; RESUSCITATION; BIOMARKER; CARE	Background: Neurological outcome after cardiac arrest (CA) is difficult to predict in the acute phase. In this pilot study, we assessed blood levels of tau protein as a prognostic marker for the neurological outcome after 6 months in patients treated with hypothermia after resuscitation from CA. Methods: 22 unconscious patients resuscitated after CA were treated with mild hypothermia (32-34 degrees C) for 26 h. Blood samples were collected at 2, 6, 12, 24, 48, and 96 h after CA, and the concentration of tau protein was analyzed. Neurological outcome was assessed with the Glasgow-Pittsburgh cerebral performance category (CPC) scale at intensive care unit (ICU) discharge and after 6 months. The higher of the two CPC scores was used. Results: At ICU discharge, 21/22 patients were alive, of whom 10 had a good (CPC 1-2) outcome. After 6 months, 15/22 patients were alive, of whom 14 had a good outcome. Tau protein levels were higher among those with a poor outcome at 48 h and 96 h. At 96 h sampling, tau concentration predicted a poor outcome (CPC 3-5) with a sensitivity of 71% and a specificity of 93%. Conclusions: Although in a pilot study, a late increase in plasma tau protein seems to be associated with a worse outcome after hypothermia treatment after CA, although more studies are needed.	[Mortberg, E.; Nordmark, J.; Rubertsson, S.] Uppsala Univ, Univ Uppsala Hosp, Dept Surg Sci Anaesthesia & Intens Care, Uppsala, Sweden; [Zetterberg, H.; Blennow, K.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Catry, C.; Decraemer, H.; Vanmechelen, E.] Innogenet, Ghent, Belgium		Mortberg, E (corresponding author), Univ Uppsala Hosp, Dept Surg Sci, SE-75185 Uppsala, Sweden.	erik.mortberg@surgsci.uu.se	Vanmechelen, Eugeen/AAA-8005-2019	Vanmechelen, Eugeen/0000-0002-9466-5366			Al Thenayan E, 2008, NEUROLOGY, V71, P1535, DOI 10.1212/01.wnl.0000334205.81148.31; Aune S, 2011, RESUSCITATION, V82, P431, DOI 10.1016/j.resuscitation.2010.11.021; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Bitsch A, 2002, EUR NEUROL, V47, P45, DOI 10.1159/000047946; Cummins RO, 1997, RESUSCITATION, V34, P151, DOI 10.1016/S0300-9572(97)01112-X; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Hansson O, 2010, NEUROBIOL AGING, V31, P357, DOI 10.1016/j.neurobiolaging.2008.03.027; Herlitz J, 2008, NATIONELLT REGISTER; Holzer M, 2002, NEW ENGL J MED, V346, P549; JENNETT B, 1975, LANCET, V1, P480; Lachno DR, 2009, J NUTR HEALTH AGING, V13, P220, DOI 10.1007/s12603-009-0062-5; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; MERCKEN M, 1992, J NEUROCHEM, V58, P548, DOI 10.1111/j.1471-4159.1992.tb09754.x; Mortberg E, 2011, RESUSCITATION, V82, P26, DOI 10.1016/j.resuscitation.2010.10.011; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Nolan JP, 2007, ANAESTHESIA, V62, P1207, DOI 10.1111/j.1365-2044.2007.05232.x; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Okumus N, 2008, PEDIATR NEUROL, V39, P245, DOI 10.1016/j.pediatrneurol.2008.07.004; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Rundgren M, 2006, INTENS CARE MED, V32, P836, DOI 10.1007/s00134-006-0178-6; Rundgren M, 2010, CRIT CARE MED, V38, P1838, DOI 10.1097/CCM.0b013e3181eaa1e7; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Shinozaki K, 2009, RESUSCITATION, V80, P870, DOI 10.1016/j.resuscitation.2009.05.005; Stern P, 2007, TUMOR BIOL, V28, P84, DOI 10.1159/000098441; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Tiainen M, 2005, CRIT CARE MED, V33, P1736, DOI 10.1097/01.CCM.0000171536.63641.D9; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Vanmechelen E, 2000, NEUROSCI LETT, V285, P49, DOI 10.1016/S0304-3940(00)01036-3; Wennervirta JE, 2009, CRIT CARE MED, V37, P2427, DOI 10.1097/CCM.0b013e3181a0ff84; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; Young GB, 2009, NEW ENGL J MED, V361, P605, DOI 10.1056/NEJMcp0903466	37	37	38	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2011	55	9					1132	1138		10.1111/j.1399-6576.2011.02505.x			7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	823DM	WOS:000295102500014	22092212				2022-02-06	
J	Zayas, JO; Feliciano, YZ; Hadley, CR; Gomez, AA; Vidal, JA				Zayas, Julio O.; Feliciano, Yara Z.; Hadley, Celene R.; Gomez, Angel A.; Vidal, Jorge A.			Temporal Bone Trauma and the Role of Multidetector CT in the Emergency Department	RADIOGRAPHICS			English	Article							RESOLUTION COMPUTED-TOMOGRAPHY; FACIAL PARALYSIS; MIDDLE-EAR; FRACTURES; COMPLICATIONS; INJURIES; MANAGEMENT; CLASSIFICATION	The temporal bone anatomy is complex, with many critical structures in close association with one another. The temporal bone region comprises cranial nerves V, VI, VII, and VIII; vascular structures such as the internal carotid and middle meningeal arteries; sigmoid sinus; jugular bulb; and sensorineural and membranous structures of the inner ear. Most temporal bone fractures are a result of high-energy blunt head trauma. Multidetector computed tomography (CT) plays a fundamental role in the initial evaluation of patients with polytrauma in the emergency department. Multidetector CT may help identify important structural injuries that may have devastating complications such as sensorineural hearing loss, conductive hearing loss, dizziness and balance dysfunction, perilymphatic fistulas, cerebrospinal fluid leaks, facial nerve paralysis, and vascular injury. Although classifying temporal bone fractures helps physicians understand and predict trauma-associated complications and guide treatment, identifying injury to critical structures is more important for guiding management and determining prognosis than is simply classifying temporal bone fractures into a general category. Many temporal bone fractures and complications may be readily identified and characterized at routine cervical, maxillofacial, and head multidetector CT performed in patients with polytrauma, without the need for dedicated temporal bone multidetector CT. Dedicated temporal bone multidetector CT should be considered when there is a high degree of suspicion for temporal bone fractures and no fractures are identified at head, cervical, or maxillofacial CT. (C) RSNA, 2011 . radiographics.rsna.org	[Zayas, Julio O.; Feliciano, Yara Z.; Hadley, Celene R.; Gomez, Angel A.; Vidal, Jorge A.] Univ Puerto Rico, Dept Radiol Sci, Diagnost Radiol Sect, Puerto Rico Med Ctr, San Juan, PR 00936 USA		Zayas, JO (corresponding author), Univ Puerto Rico, Dept Radiol Sci, Diagnost Radiol Sect, Puerto Rico Med Ctr, Med Sci Campus,Ave Americo Miranda,POB 5067, San Juan, PR 00936 USA.	julio.zayas@upr.edu					AVRAHAMI E, 1988, NEURORADIOLOGY, V30, P166, DOI 10.1007/BF00395619; BELLUCCI RJ, 1983, OTOLARYNG CLIN N AM, V16, P633; Brodie HA, 1997, AM J OTOL, V18, P188; CANNON CR, 1983, ARCH OTOLARYNGOL, V109, P285; Dahiya R, 1999, J TRAUMA, V47, P1079, DOI 10.1097/00005373-199912000-00014; FISCH U, 1974, LARYNGOSCOPE, V84, P2141, DOI 10.1288/00005537-197412000-00005; FISCH U, 1980, J LARYNGOL OTOL, V94, P129, DOI 10.1017/S0022215100088575; GEAN AD, 1994, IMAGING HEAD TRAUMA, P51; GHORAYEB BY, 1992, LARYNGOSCOPE, V102, P129; GRIFFIN JE, 1979, LARYNGOSCOPE, V89, P1432, DOI 10.1002/lary.5540890908; GURDJIAN ES, 1946, SURG GYNECOL OBSTET, V83, P219; HARKER LA, 1974, OTOLARYNG CLIN N AM, V7, P425; HASSO AN, 1988, OTOLARYNG CLIN N AM, V21, P295; Hough JV, 1980, OTOLARYNGOLOGY, V2, P1656; HOUGH JVD, 1968, LARYNGOSCOPE, V78, P899, DOI 10.1288/00005537-196806000-00003; Ishman SL, 2004, LARYNGOSCOPE, V114, P1734, DOI 10.1097/00005537-200410000-00011; Kerman M, 2002, NEUROSURG QUART, V12, P23, DOI 10.1097/00013414-200203000-00003; Kollias SS, 2004, MED RAD DIA IMG, P49; LAMBERT PR, 1984, LARYNGOSCOPE, V94, P1022; Lancaster JL, 1999, J ROY COLL SURG EDIN, V44, P87; Little SC, 2006, ARCH OTOLARYNGOL, V132, P1300, DOI 10.1001/archotol.132.12.1300; MCGOVERN FH, 1968, ARCH OTOLARYNGOL, V88, P536; McHugh HE, 1959, ANN OTOL, V68, P855; Meriot P, 1997, RADIOGRAPHICS, V17, P1445, DOI 10.1148/radiographics.17.6.9397457; Nosan DK, 1997, OTOLARYNG HEAD NECK, V117, P67, DOI 10.1016/S0194-5998(97)70209-2; Patay Z, 1995, RIV NEURORADIOL, V8, P855, DOI 10.1177/197140099500800611; Resnick DK, 1997, NEUROSURGERY, V40, P1177, DOI 10.1097/00006123-199706000-00012; SCHUBIGER O, 1986, NEURORADIOLOGY, V28, P93, DOI 10.1007/BF00327878; Swartz J. D., 1995, HEAD NECK IMAGING, P1425; SWARTZ JD, 1983, RADIOLOGY, V148, P449, DOI 10.1148/radiology.148.2.6867341; Swartz JD, 1997, IMAGING TEMPORAL BON, P318; TRAVIS LW, 1977, J TRAUMA, V17, P761, DOI 10.1097/00005373-197710000-00003; Ulrich K, 1926, ACTA OTO-LARYNGOL, V6, P1; Yanagihara N, 1997, Ear Nose Throat J, V76, P79; Yanagihara N, 1997, ENT-EAR NOSE THROAT, V76, P83	35	37	45	1	6	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0271-5333			RADIOGRAPHICS	Radiographics	OCT	2011	31	6			SI		1741	1755		10.1148/rg.316115506			15	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	834SU	WOS:000295985200018	21997992	Bronze			2022-02-06	
J	Scher, AI; Wu, H; Tsao, JW; Blom, HJ; Feit, P; Nevin, RL; Schwab, KA				Scher, Ann I.; Wu, Holly; Tsao, Jack W.; Blom, Henk J.; Feit, Preethy; Nevin, Remington L.; Schwab, Karen A.			MTHFR C677T Genotype As a Risk Factor for Epilepsy Including Post-Traumatic Epilepsy in a Representative Military Cohort	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; epilepsy; folate; head injury; homocysteine; migraine; MTHFR C677T; post-traumatic seizure; traumatic brain injury	METHYLENETETRAHYDROFOLATE REDUCTASE GENE; ANTIEPILEPTIC DRUGS; HOMOCYSTEINE; MUTATION; POLYMORPHISMS; ASSOCIATION; MIGRAINE; METAANALYSIS; SEIZURES; DISEASE	The well-studied C677T variant in the methylenetetrahydrofolate reductase (MTHFR) enzyme is a biologically plausible genetic risk factor for seizures or epilepsy. First, plasma/serum levels of homocysteine, a pro-convulsant, are moderately elevated in individuals with the homozygote TT genotype. Furthermore, the TT genotype has been previously linked with migraine with aura-a comorbid condition-and with alcohol withdrawal seizures. Finally, several small studies have suggested that the TT genotype may be overrepresented in epilepsy patients. In this study, we consider whether the MTHFR C677T or A1298C variants are associated with risk of epilepsy including post-traumatic epilepsy (PTE) in a representative military cohort. Study subjects were selected from the cohort of military personnel on active duty during the years 2003 through 2007 who had archived serum samples at the DoD Serum Repository, essentially all active duty personnel during this time frame. We randomly selected 800 epilepsy patients and 800 matched controls based on ICD-9-CM diagnostic codes. We were able to isolate sufficient genetic material from the archived sera to genotype approximately 85% of our study subjects. The odds of epilepsy were increased in subjects with the TT versus CC genotype (crude OR=1.52 [1.04-2.22], p=0.031; adjusted OR=1.57 [1.07-2.32], p=0.023). In our sensitivity analysis, risk was most evident for patients with repeated rather than single medical encounters for epilepsy (crude OR=1.85 [1.14-2.97], p=0.011, adjusted OR=1.95 [1.19-3.19], p=0.008), and particularly for PTE (crude OR=3.14 [1.41-6.99], p=0.005; adjusted OR=2.55 [1.12-5.80], p=0.026). Our early results suggest a role for the common MTHFR C677T variant as a predisposing factors for epilepsy including PTE. Further exploration of baseline homocysteine and folate levels as predictors of seizure risk following traumatic brain injury is warranted.	[Scher, Ann I.; Wu, Holly; Feit, Preethy] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Tsao, Jack W.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Blom, Henk J.] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Dept Clin Chem, Metab Unit, Amsterdam, Netherlands; [Nevin, Remington L.] Bayne Jones Army Community Hosp, Dept Prevent Med, Ft Polk, LA USA; [Schwab, Karen A.] Def & Vet Brain Injury Ctr, Washington, DC USA		Scher, AI (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA.	ascher@usuhs.mil		Nevin, Remington/0000-0002-0534-1889; Scher, Ann/0000-0003-4599-9834; Blom, Henk/0000-0001-5202-9241	Henry Jackson Foundation for Military Medicine; Uniformed Services University	Funding for this study was provided by the Comprehensive Neuroscience Program of the Henry Jackson Foundation for Military Medicine, and the Intramural Research Program of the Uniformed Services University.	Apeland T, 2003, CLIN CHEM, V49, P1005, DOI 10.1373/49.6.1005; Bigal ME, 2003, EPILEPSY BEHAV, V4, pS13, DOI 10.1016/j.yebeh.2003.07.003; Bleich S, 2004, PROG NEURO-PSYCHOPH, V28, P453, DOI 10.1016/j.pnpbp.2003.11.019; Botto LD, 2000, AM J EPIDEMIOL, V151, P862; Caccamo D, 2004, NEUROMOL MED, V6, P117, DOI 10.1385/NMM:6:2-3:117; Cavalleri GL, 2007, LANCET NEUROL, V6, P970, DOI 10.1016/S1474-4422(07)70247-8; Cronin S, 2005, STROKE, V36, P1581, DOI 10.1161/01.STR.0000169946.31639.af; de Bree A, 2003, AM J CLIN NUTR, V77, P687, DOI 10.1093/ajcn/77.3.687; DEAN JC, 2007, SEIZURE, V17, P269; Dean JCS, 1999, CLIN GENET, V56, P216, DOI 10.1034/j.1399-0004.1999.560306.x; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1422, DOI 10.1001/archneur.57.10.1422; Esfahani ST, 2003, J AM DIET ASSOC, V103, P200, DOI 10.1053/jada.2003.50030; Greenberg DA, 2007, CURR NEUROL NEUROSCI, V7, P320, DOI 10.1007/s11910-007-0049-8; Helbig I, 2008, LANCET NEUROL, V7, P231, DOI 10.1016/S1474-4422(08)70039-5; Hillemacher T, 2007, J NEURAL TRANSM, V114, P151, DOI 10.1007/s00702-006-0541-3; Jette N, 2010, EPILEPSIA, V51, P62, DOI 10.1111/j.1528-1167.2009.02201.x; Kini U, 2007, EUR J MED GENET, V50, P411, DOI 10.1016/j.ejmg.2007.08.002; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; KUBOVA H, 1995, EPILEPSIA, V36, P750, DOI 10.1111/j.1528-1157.1995.tb01611.x; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lewis SJ, 2005, BMJ-BRIT MED J, V331, P1053, DOI 10.1136/bmj.38611.658947.55; Lievers KJA, 2003, ANN CLIN BIOCHEM, V40, P46, DOI 10.1258/000456303321016169; Ludvigsson P, 2006, ANN NEUROL, V59, P210, DOI 10.1002/ana.20745; Lutz UC, 2006, ALCOHOL CLIN EXP RES, V30, P1966, DOI 10.1111/j.1530-0277.2006.00242.x; Mares P, 2002, EPILEPSIA, V43, P61, DOI 10.1046/j.1528-1157.43.s.5.21.x; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Ono H, 2000, J INHERIT METAB DIS, V23, P525, DOI 10.1023/A:1005680701884; OTTMAN R, 1994, NEUROLOGY, V44, P2105, DOI 10.1212/WNL.44.11.2105; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; Rubino E, 2007, CEPHALALGIA, V29, P807; Schneider JA, 1998, AM J HUM GENET, V62, P1258, DOI 10.1086/301836; Schurks M, 2010, HEADACHE, V50, P588, DOI 10.1111/j.1526-4610.2009.01570.x; Silverberg MJ, 2003, MIL MED, V168, P160, DOI 10.1093/milmed/168.2.160; Sniezawska A, 2011, SEIZURE-EUR J EPILEP, V20, P533, DOI 10.1016/j.seizure.2011.04.001; Tan NCK, 2004, EPILEPSIA, V45, P1429, DOI 10.1111/j.0013-9580.2004.22904.x; Tan NCK, 2010, EPILEPSIA, V51, P686, DOI 10.1111/j.1528-1167.2009.02423.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Yoo JH, 1999, METABOLISM, V48, P1047, DOI 10.1016/S0026-0495(99)90204-4	38	37	40	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1739	1745		10.1089/neu.2011.1982			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000007	21787169				2022-02-06	
J	Haider, AH; Crompton, JG; Oyetunji, T; Risucci, D; DiRusso, S; Basdag, H; Villegas, CV; Syed, ZU; Haut, ER; Efron, DT				Haider, Adil H.; Crompton, Joseph G.; Oyetunji, Tolulope; Risucci, Donald; DiRusso, Stephen; Basdag, Hatice; Villegas, Cassandra V.; Syed, Zain U.; Haut, Elliott R.; Efron, David T.			Mechanism of injury predicts case fatality and functional outcomes in pediatric trauma patients: the case for its use in trauma outcomes studies	JOURNAL OF PEDIATRIC SURGERY			English	Article						Pediatric trauma; Functional outcomes; Mechanism of injury	SEVERITY SCORE; BRAIN-INJURY; MORTALITY; RACE; DISCHARGE; FALL	Background/Purpose: The mechanism of injury (MOI) may serve as a useful adjunct to injury scoring systems in pediatric trauma outcomes research. The objective is to determine the independent effect of MOI on case fatality and functional outcomes in pediatric trauma patients. Methods: Retrospective review of pediatric patients ages 2 to 18 years in the National Trauma Data Bank from 2002 through 2006 was done. Mechanism of injury was classified by the International Classification of Diseases, Ninth Revision, E codes. The main outcome measures were mortality, discharge disposition (home vs rehabilitation setting), and functional impairment at hospital discharge. Multiple logistic regression was used to adjust for injury severity (using the Injury Severity Score and the presence of shock upon admission in the emergency department), age, sex, and severe head or extremity injury. Results: Thirty-five thousand ninety-seven pediatric patients in the National Trauma Data Bank met inclusion criteria. Each MOI had differences in the adjusted odds of death or functional disabilities as compared with the reference group (fall). The MOI with the greatest risk of death was gunshot wounds (odds ratio [OR], 3.52; 95% confidence interval [CI], 2.23-5.54 95). Pediatric pedestrians struck by a motor vehicle have the highest risk of locomotion (OR, 3.30; 95% CI, 2.89-3.77) and expression (OR, 1.65; 95% CI, 1.22-2.23) disabilities. Conclusion: Mechanism of injury is a significant predictor of clinical and functional outcomes at discharge for equivalently injured patients. These findings have implications for injury prevention, staging, and prognosis of traumatic injury and posttreatment planning. (C) 2011 Published by Elsevier Inc.	[Haider, Adil H.; Basdag, Hatice; Villegas, Cassandra V.; Syed, Zain U.; Haut, Elliott R.; Efron, David T.] Johns Hopkins Univ, Sch Med, Dept Surg, Ctr Trials & Outcomes Res, Baltimore, MD 21287 USA; [Crompton, Joseph G.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA; [Oyetunji, Tolulope] Howard Univ, Coll Med, Dept Surg, Washington, DC 20059 USA; [Risucci, Donald] New York Med Coll, Dept Surg, Valhalla, NY 10595 USA; [DiRusso, Stephen] St Barnabas Hosp Med Ctr, Bronx, NY 10457 USA		Haider, AH (corresponding author), Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21212 USA.	ahaider1@jhmi.edu	Haut, Elliott R./J-3948-2019	Haut, Elliott/0000-0001-7075-771X; Oyetunji, Tolulope/0000-0003-3039-7195	National Institutes of Health/NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112-01]; American College of Surgeons C. James Carrico; Johns Hopkins Dean's Research Fellowship for Medical Students; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112] Funding Source: NIH RePORTER	National Institutes of Health/NIGMS K23GM093112-01 and American College of Surgeons C. James Carrico Fellowship for the study of Trauma and Critical Care (Dr Haider) and Johns Hopkins Dean's Research Fellowship for Medical Students (Ms Villegas).	Arthurs ZM, 2009, J VASC SURG, V49, P988, DOI 10.1016/j.jvs.2008.11.052; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bergeron E, 2006, J TRAUMA, V60, P268, DOI 10.1097/01.ta.0000197651.00482.c5; Burd RS, 2007, J TRAUMA, V62, P1004, DOI 10.1097/01.ta.0000221555.01704.c9; *CENS BUR US, 2006 2008 AM COMM SU; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Choo B, 2006, BURNS, V32, P20, DOI 10.1016/j.burns.2005.04.033; *COMM INJ SCAL, 1998, ABBR INJ SCAL 1998 R; Furnival RA, 1999, PEDIATR EMERG CARE, V15, P215, DOI 10.1097/00006565-199906000-00013; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2007, ARCH SURG-CHICAGO, V142, P875, DOI 10.1001/archsurg.142.9.875; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Haider AH, 2009, J SURG RES, V153, P138, DOI 10.1016/j.jss.2008.04.011; KNOPP R, 1988, ANN EMERG MED, V17, P895, DOI 10.1016/S0196-0644(88)80666-8; Love PF, 2009, J TRAUMA, V67, pS12, DOI 10.1097/TA.0b013e3181ac7f22; Maybury RS, 2010, SURGERY, V148, P202, DOI 10.1016/j.surg.2010.05.010; Moore Lynne, 2009, J Emerg Trauma Shock, V2, P73, DOI 10.4103/0974-2700.44774; Narci A, 2009, PEDIATR SURG INT, V25, P25, DOI 10.1007/s00383-008-2287-5; OSBERG JS, 1992, AM J PUBLIC HEALTH, V82, P422, DOI 10.2105/AJPH.82.3.422; Ott R, 2000, J TRAUMA, V49, P729, DOI 10.1097/00005373-200010000-00023; Oyetunji T, 2010, J SURG RES, V159, P627, DOI 10.1016/j.jss.2009.08.026; POLLOCK DA, 1989, JAMA-J AM MED ASSOC, V262, P2280, DOI 10.1001/jama.262.16.2280; Stallion A, 2007, J TRAUMA, V62, P1262; *STAT U NEW YORK B, 1997, GUID UN DAT SET MED; Sullivan T, 2003, J TRAUMA, V55, P1083, DOI 10.1097/01.TA.0000102175.58306.2A; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tyroch AH, 2000, ARCH SURG-CHICAGO, V135, P1173, DOI 10.1001/archsurg.135.10.1173; WESSON D, 2006, PEDIAT TRAUMA PATHOP, P43	28	37	37	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	AUG	2011	46	8					1557	1563		10.1016/j.jpedsurg.2011.04.055			7	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Surgery	808BZ	WOS:000293950100024	21843724				2022-02-06	
J	Baldwin, K; Hosalkar, HS; Donegan, DJ; Rendon, N; Ramsey, M; Keenan, MAE				Baldwin, Keith; Hosalkar, Harish S.; Donegan, Derek J.; Rendon, Norma; Ramsey, Matthew; Keenan, Mary Ann E.			Surgical Resection of Heterotopic Bone About the Elbow: An Institutional Experience With Traumatic and Neurologic Etiologies	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						Heterotopic ossification; brain injury; trauma; elbow	OSSIFICATION	Purpose We evaluated the outcomes of patients with elbow heterotopic ossification (HO) who underwent surgical intervention. Our goal was to elucidate differences in outcome of surgical treatment between those patients with traumatic brain injury, direct elbow trauma, or combined etiologies. In addition, we used regression analysis to adjust for confounding factors (such as age, gender, preoperative range of motion [ROM], location of HO, chronicity of HO [ie, time from HO formation to surgery], and whether motor control was spastic or normal) on the relationship between surgical outcome and etiology. Methods We reviewed 60 patients (64 elbows) surgically treated for heterotopic ossification. A total of 42 patients had trauma as the primary etiology, 15 had traumatic brain injury, and 7 had combined etiologies. All had pain or functional limitations at presentation. All patients had surgical resection of their HO. Functional and ROM outcomes were recorded. Results Mean preoperative arc of motion for the entire cohort was 57 degrees (range, 0 degrees to 15 degrees). Mean postoperative arc for the entire cohort was 106 degrees (range, 0 degrees to 145 degrees) at a mean follow-up of 44 months (range, 21-72 mo), demonstrating a significant gain. Average gain, in arc of motion was 49 degrees (range, 10 degrees to 140 degrees). Gains in motion were not significantly different in any individual etiologic group. A total of 6% of cases were complicated by infection, 13% of cases had recurrence of HO, and 11% of cases required repeat surgery for infection or recurrence. Preoperative ROM was an important independent predictor of final range achieved and gain in ROM after surgical intervention. Recurrence rates were higher in patients with neurologic involvement. Postoperative stiffness was related to preoperative stiffness, delay of surgery longer than 12 months, and anterior location of the HO. Conclusions Surgical excision of heterotopic bone about the elbow results in significant gains in ROM regardless of etiology. The likelihood of recurrence is higher in patients with central nervous system injuries than in patients with purely localized trauma. (J Hand Surg 2011;36A: 798-803. Copyright (C) 2011 by the American Society for Surgery of the Hand. All rights reserved.)	Univ Penn, Dept Orthopaed Surg, Sch Med, Philadelphia, PA 19104 USA; Thomas Jefferson Univ Hosp, Dept Orthopaed Surg, Rothman Inst, Sch Med, Philadelphia, PA 19107 USA; Rady Childrens Hosp, San Diego, CA USA		Keenan, MAE (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 2 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	maryann.keenan@uphs.upenn.edu	Keenan, Mary Ann/ABB-1551-2020				FIGGIE MP, 1989, J BONE JOINT SURG AM, V71A, P513, DOI 10.2106/00004623-198971040-00006; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P38; HASTINGS H, 1994, HAND CLIN, V10, P417; Heirweg S, 2003, Acta Orthop Belg, V69, P18; JUPITER J, 2006, STIFF ELBOW, P9; Jupiter JB, 1998, J BONE JOINT SURG AM, V80A, P248, DOI 10.2106/00004623-199802000-00012; Jupiter Jesse B, 2003, Instr Course Lect, V52, P93; Lazarus MD, 1999, NEUROREHABILITATION, V12, P145; McAuliffe JA, 1997, J BONE JOINT SURG AM, V79A, P749, DOI 10.2106/00004623-199705000-00015; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; ORZEL JA, 1985, J NUCL MED, V26, P125; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120, DOI 10.1302/0301-620X.63B1.7204466; STANLEY D, 1998, SURG ELBOW, P228; Thompson H C 3rd, 1967, Clin Orthop Relat Res, V50, P129; Viola RW, 1999, J HAND SURG-AM, V24A, P370; Viola RW, 2000, CLIN ORTHOP RELAT R, P65	16	37	40	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0363-5023			J HAND SURG-AM	J. Hand Surg.-Am. Vol.	MAY	2011	36A	5					798	803		10.1016/j.jhsa.2011.01.015			6	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	758SC	WOS:000290185700005	21458925				2022-02-06	
J	Dalla Libera, AL; Regner, A; De Paoli, J; Centenaro, L; Martins, TT; Simon, D				Dalla Libera, Andre Luiz; Regner, Andrea; De Paoli, Juliana; Centenaro, Leonara; Martins, Tatiane Tolazzi; Simon, Daniel			IL-6 polymorphism associated with fatal outcome in patients with severe traumatic brain injury	BRAIN INJURY			English	Article						Interleukin-6; traumatic brain injury; genetic polymorphism; neuroinflammation	HEAD-INJURY; MAJOR TRAUMA; INTERLEUKIN-6; DISEASE; EXPRESSION; HAPLOTYPES; GENOTYPE; HUMANS; GENDER; GENE	Objective: The aim of this study was to test whether a functional polymorphism (-174C/G) located in the promoter region of the interleukin-6 (IL-6) gene is associated with primary short-term outcome (death or Intensive Care Unit discharge) in patients with severe traumatic brain injury (TBI). Methods: The study group consisted of 77 male patients who suffered severe TBI. The -174C/G IL-6 polymorphism was analysed by polymerase chain reaction (PCR) followed by restriction digestion. Results: Severe TBI was associated with a 44% mortality rate. The GG genotype was significantly more frequent in the survivor group than in non-surviving patients (67% vs 41%; p = 0.038); similarly, the IL-6 -174G allele was more frequent in the survivor group than in non-surviving patients (81% vs 65%; p = 0.031). Conclusion: The findings indicate that genetic variation regarding inflammatory response has significant impact on the short-term outcome for patients after acute severe TBI.	[Dalla Libera, Andre Luiz; Regner, Andrea; Simon, Daniel] Univ Luterana Brasil ULBRA, Programa Posgrad Genit & Toxicol Aplicada, Canoas, Brazil; [Regner, Andrea; De Paoli, Juliana; Simon, Daniel] Univ Luterana Brasil, Programa Posgrad Diagnost Genet & Mol, Canoas, Brazil; [Regner, Andrea; Centenaro, Leonara; Martins, Tatiane Tolazzi] Univ Luterana Brasil, Curso Med, Canoas, Brazil		Simon, D (corresponding author), Univ Luterana Brasil, PPG Diagnost Genet & Mol, Av Farroupilha 8001,Predio 22,5 Andar, BR-92425900 Canoas, RS, Brazil.	daniel.simon@ulbra.br	Regner, Andrea/M-2596-2014; Simon, Daniel/A-9087-2011	Regner, Andrea/0000-0002-6657-7991; Simon, Daniel/0000-0003-1122-8468	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [484391/2007-0, 568691/2008-3]	The authors report no conflicts of interest. The present study received financial support from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; research grants 484391/2007-0 and 568691/2008-3).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Harding DR, 2004, PEDIATRICS, V114, P941, DOI 10.1542/peds.2003-0494-F; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015, DOI 10.1152/ajpheart.2000.279.3.H1015; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kraus J, 1996, NEUROTRAUMA, P13; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McDaniel DO, 2007, J TRAUMA, V63, P147, DOI 10.1097/TA.0b013e31806bf0ab; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Noe E, 2010, BRAIN INJURY, V24, P886, DOI 10.3109/02699051003724952; Opdal SH, 2007, HUM IMMUNOL, V68, P541, DOI 10.1016/j.humimm.2007.02.008; Rivera-Chavez FA, 2003, SHOCK, V20, P218, DOI 10.1097/00024382-200309000-00004; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sperry JL, 2008, J TRAUMA, V64, P572, DOI 10.1097/TA.0b013e3181650fdf; Terry CF, 2000, J BIOL CHEM, V275, P18138, DOI 10.1074/jbc.M000379200; Thorns V, 2002, J NEUROIMMUNOL, V127, P22, DOI 10.1016/S0165-5728(02)00072-3; Tsukamoto K, 1998, J HUM GENET, V43, P71, DOI 10.1007/s100380050042; Vasilescu A, 2003, GENES IMMUN, V4, P441, DOI 10.1038/sj.gene.6363983; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; Wilson M, 2007, BRIT J ANAESTH, V99, P43, DOI 10.1093/bja/aem142; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	33	37	37	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2011	25	4					365	369		10.3109/02699052.2011.556107			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	739RL	WOS:000288735600005	21314275				2022-02-06	
J	Pedrero-Perez, EJ; de Leon, JMRS; Lozoya-Delgado, P; Llanero-Luque, M; Rojo-Mota, G; Puerta-Garcia, C				Pedrero-Perez, Eduardo J.; de Leon, Jose M. Ruiz-Sanchez; Lozoya-Delgado, Paz; Llanero-Luque, Marcos; Rojo-Mota, Gloria; Puerta-Garcia, Carmen			Prefrontal symptoms assessment: psychometric properties and normative data of the Dysexecutive Questionnaire (DEX) in a sample from the Spanish population	REVISTA DE NEUROLOGIA			Spanish	Article						DEX; Dysexecutive Questionnaire; Dysexecutive syndrome; Prefrontal cortex	FRONTAL-SUBCORTICAL CIRCUITS; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTIONS; ECOLOGICAL VALIDITY; ALZHEIMERS-DISEASE; PARALLEL ANALYSIS; CORTEX; BEHAVIOR; NEUROPSYCHOLOGY; ATTENTION	Introduction. Research on the deficits derived from alterations in the prefrontal circuits has been conducted almost exclusively from a categorical perspective, which differentiates normal from pathological functioning. The functioning of the prefrontal cortex, however, can be seen as a continuous dimension. The Dysexecutive Questionnaire (DEX) was created with the intention of being useful as a qualitative measure of the symptoms of 'dysexecutive syndrome' in day-today life. Aim. To explore the psychometric properties of the self-reported DEX in a broad sample of the non-clinical population with a view to providing interpretations that can be of use in clinical practice. Subjects and methods. The Spanish version of the DEX was administered to 1013 non-clinical individuals living in Madrid, Saragossa, Asturias, Navarre and Seville (380 males and 633 females). Results. The factorial study conducted in parallel reveals the existence of two factors with adequate consistency and internal validity indices: items that explore difficulties in beginning, maintaining and organising behaviour (disorganisation/apathy) and items related with the interruption of behaviour in situations where it is inappropriate (disinhibition/impulsivity). The distribution according to age matches the developmental premises. The following cut-off points are proposed: < 10, optimal functioning; 10-18, sub-optimal functioning within normality; 19-28, moderately dysexecutive functioning that requires identification of the possible causes, and > 28, important degree of dysexecutive disorder that would include severe pathologies. Conclusions. The DEX may be useful as an instrument for detecting subjects with demonstrable brain disorders and those with deficient executive functioning without the presence of any known or identifiable pathology.	[Pedrero-Perez, Eduardo J.; Rojo-Mota, Gloria; Puerta-Garcia, Carmen] Ctr Atenc Drogodependientes CAD 4, Inst Adicc, E-28027 Madrid, Spain; [de Leon, Jose M. Ruiz-Sanchez; Lozoya-Delgado, Paz] Univ Complutense Madrid, Dept Psicol Basica 2, E-28040 Madrid, Spain; [Llanero-Luque, Marcos] Hosp Moraleja, Serv Neurol, Madrid, Spain		Pedrero-Perez, EJ (corresponding author), Ctr Atenc Drogodependientes CAD 4, Inst Adicc, Alcala 527, E-28027 Madrid, Spain.	ejpedrero@yahoo.es	Rojo-Mota, Gloria/P-3916-2016; Pedrero-Perez, Eduardo Jose/P-8127-2015; Ruiz-Sanchez de Leon, Jose M./J-2593-2015	Rojo-Mota, Gloria/0000-0003-0358-1181; Pedrero-Perez, Eduardo Jose/0000-0002-3940-5609; Ruiz-Sanchez de Leon, Jose M./0000-0003-2834-0827			Alderman N, 2001, NEUROPSYCHOL REHABIL, V11, P529, DOI 10.1080/09602010042000231; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Amieva H, 2003, BRAIN COGNITION, V53, P129, DOI 10.1016/S0278-2626(03)00094-0; Arnsten AFT, 2009, NAT REV NEUROSCI, V10, P410, DOI 10.1038/nrn2648; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; Bodenburg S, 2008, J NERV MENT DIS, V196, P75, DOI 10.1097/NMD.0b013e31815faa2b; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess P., 1997, METHODOLOGY FRONTAL, P81; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Caspi A, 2003, J PERS, V71, P495, DOI 10.1111/1467-6494.7104001; Cederlund M, 2010, RES DEV DISABIL, V31, P287, DOI 10.1016/j.ridd.2009.09.006; Chan RCK, 2008, J NEUROL NEUROSUR PS, V79, P86, DOI 10.1136/jnnp.2007.117184; Chan RCK, 2002, CLIN REHABIL, V16, P900, DOI 10.1191/0269215502cr574oa; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chaytor N, 2007, BRAIN INJURY, V21, P615, DOI 10.1080/02699050701426949; Cullen B, 2005, INT J GERIATR PSYCH, V20, P686, DOI 10.1002/gps.1344; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Duncan J, 2001, NAT REV NEUROSCI, V2, P820, DOI 10.1038/35097575; Espinosa A, 2009, J INT NEUROPSYCH SOC, V15, P751, DOI 10.1017/S135561770999035X; Garcia-Molina A, 2008, REV NEUROLOGIA, V46, P175, DOI 10.33588/rn.4603.2007196; Garcia-Molina A, 2009, REV NEUROLOGIA, V48, P435, DOI 10.33588/rn.4808.2008265; Gerstorf D, 2008, AGING NEUROPSYCHOL C, V15, P424, DOI 10.1080/13825580701640374; Goldenberg G, 2007, CORTEX, V43, P424, DOI 10.1016/S0010-9452(08)70467-2; Greenop KR, 2010, ALZHEIMER DIS ASS DI; Greenwood PM, 2000, J INT NEUROPSYCH SOC, V6, P705, DOI 10.1017/S1355617700666092; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hayton JC, 2004, ORGAN RES METHODS, V7, P191, DOI 10.1177/1094428104263675; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Hulette CM, 1998, J NEUROPATH EXP NEUR, V57, P1168, DOI 10.1097/00005072-199812000-00009; Iqbal N, 2009, EPILEPSY BEHAV, V14, P516, DOI 10.1016/j.yebeh.2008.12.025; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Llanero-Luque M, 2008, REV NEUROLOGIA, V47, P457, DOI 10.33588/rn.4709.2008257; Mathias JL, 2003, APPL NEUROPSYCHOL, V10, P57, DOI 10.1207/S15324826AN1002_01; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Mooney B, 2006, APPL NEUROPSYCHOL, V13, P12, DOI 10.1207/s15324826an1301_2; Murphy ME, 2010, EVERYDAY EXECUTIVE F; O'Connor BP, 2000, BEHAV RES METH INS C, V32, P396, DOI 10.3758/BF03200807; Perez EJP, 2009, ADICCIONES, V21, P155, DOI 10.20882/adicciones.243; Pedrero-Perez E.J., 2010, PERSONALITY TRAITS T, P1; RINDFUSS RR, 1991, DEMOGRAPHY, V28, P493, DOI 10.2307/2061419; de Leon JMS, 2010, ADICCIONES, V22, P233, DOI 10.20882/adicciones.184; de Leon JMRS, 2010, REV NEUROLOGIA, V51, P650, DOI 10.33588/rn.5111.2010270; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Tirapu-Ustarroz J, 2008, REV NEUROLOGIA, V46, P684, DOI 10.33588/rn.4611.2008119; Tirapu-Ustarroz J, 2008, REV NEUROLOGIA, V46, P742, DOI 10.33588/rn.4612.2008252; Verdejo-Garcia A, 2010, PSICOTHEMA, V22, P227; Walley RM, 2005, J INTELL DISABIL RES, V49, P613, DOI 10.1111/j.1365-2788.2005.00717.x; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014	51	37	38	3	13	REVISTA DE NEUROLOGIA	BARCELONA	C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN	0210-0010	1576-6578		REV NEUROLOGIA	Rev. Neurologia	APR 1	2011	52	7					394	404		10.33588/rn.5207.2010731			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	972EP	WOS:000306260300002	21425108				2022-02-06	
J	Hanten, G; Cook, L; Orsten, K; Chapman, SB; Li, XQ; Wilde, EA; Schnelle, KP; Levin, HS				Hanten, Gerri; Cook, Lori; Orsten, Kimberley; Chapman, Sandra B.; Li, Xiaoqi; Wilde, Elisabeth A.; Schnelle, Kathleen P.; Levin, Harvey S.			Effects of traumatic brain injury on a virtual reality social problem solving task and relations to cortical thickness in adolescence	NEUROPSYCHOLOGIA			English	Article						TBI; Adolescents; Virtual reality; Social problem solving; Brain structure	HUMAN ORBITOFRONTAL CORTEX; TEMPORAL-LOBE ACTIVATIONS; ENVIRONMENT TECHNOLOGY; CEREBRAL-CORTEX; CHILDREN; MEMORY; MODERATE; OUTCOMES; SKILLS; MRI	Social problem solving was assessed in 28 youth ages 12-19 years (15 with moderate to severe traumatic brain injury (TBI), 13 uninjured) using a naturalistic, computerized virtual reality (VR) version of the Interpersonal Negotiations Strategy interview (Yeates, Schultz, & Selman, 1991). In each scenario, processing load condition was varied in terms of number of characters and amount of information. Adolescents viewed animated scenarios depicting social conflict in a virtual microworld environment from an avatar's viewpoint, and were questioned on four problem solving steps: defining the problem, generating solutions, selecting solutions, and evaluating the likely outcome. Scoring was based on a developmental scale in which responses were judged as impulsive, unilateral, reciprocal, or collaborative, in order of increasing score. Adolescents with TBI were significantly impaired on the summary VR-Social Problem Solving (VR-SPS) score in Condition A (2 speakers, no irrelevant information), p = 0.005: in Condition B (2 speakers + irrelevant information), p = 0.035; and Condition C (4 speakers + irrelevant information), p = 0.008. Effect sizes (Cohen's D) were large (A = 1.40, B = 0.96, C = 1.23). Significant group differences were strongest and most consistent for defining the problems and evaluating outcomes. The relation of task performance to cortical thickness of specific brain regions was also explored, with significant relations found with orbitofrontal regions, the frontal pole, the cuneus, and the temporal pole. Results are discussed in the context of specific cognitive and neural mechanisms underlying social problem solving deficits after childhood TBI. (C) 2010 Elsevier Ltd. All rights reserved.	[Hanten, Gerri; Orsten, Kimberley; Li, Xiaoqi; Wilde, Elisabeth A.; Schnelle, Kathleen P.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Cook, Lori; Chapman, Sandra B.] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75235 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA		Hanten, G (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grant number R01NS021889 from the National Institute of Neurological Disorders and Stroke. The authors would also like to thank Alyssa Ibarra for her assistance with the task sentence structure analysis.	Adolphs R, 2001, NEUROPSYCHOLOGY, V15, P396, DOI 10.1037//0894-4105.15.3.396; [Anonymous], 2007, INT J VIRTUAL REALIT; Babu S., 2007, IEEE VIRT REAL C CHA; BEARDSLEE WR, 1987, DEV PSYCHOL, V23, P807, DOI 10.1037/0012-1649.23.6.807; Bechara A, 2005, NAT NEUROSCI, V8, P1458, DOI 10.1038/nn1584; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Biocca F, 2003, PRESENCE-VIRTUAL AUG, V12, P456, DOI 10.1162/105474603322761270; Blascovich J, 2002, PSYCHOL INQ, V13, P103, DOI 10.1207/S15327965PLI1302_01; Bray S, 2010, J NEUROPHYSIOL, V103, P2506, DOI 10.1152/jn.01030.2009; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Cho S, 2010, CEREB CORTEX, V20, P524, DOI 10.1093/cercor/bhp121; Crockford DN, 2005, BIOL PSYCHIAT, V58, P787, DOI 10.1016/j.biopsych.2005.04.037; Cromby J.J., 1996, P 1 EUR C DIS VIRT R; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DESPOSITO M, 2008, MENTAL PROCESSES HUM, P7; DODGE KA, 1985, CHILDRENS PEER RELAT, P3; Dolan RS, 2000, NEUROIMAGE, V11, P203, DOI 10.1006/nimg.2000.0538; Dotsch R, 2008, J EXP SOC PSYCHOL, V44, P1194, DOI 10.1016/j.jesp.2008.03.003; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Freeman D, 2008, BRIT J PSYCHIAT, V192, P258, DOI 10.1192/bjp.bp.107.044677; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Haldane M, 2008, J PSYCHOPHARMACOL, V22, P138, DOI 10.1177/0269881107082955; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Heeter C., 1992, PRESENCE TELEOPERATO, V1, P262, DOI [10.1162/pres.1992.1.2.262, DOI 10.1162/PRES.1992.1.2.262]; JACOBY S, 2006, 6 INT C DIS VIRT REA; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson MH, 2005, DEV PSYCHOBIOL, V46, P287, DOI 10.1002/dev.20057; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kohlberg L., 1969, HDB SOCIALIZATION TH; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; LAVIOLA JJ, 2008, ADV INFORM KNOWLEDGE, P225; LEE KH, 2009, SOCIAL COGNITION AFF; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; LIVATINO S, 2007, HDB EVALUATION STUDI, P2007; LLOYD J, 2006, P 6 INT C DIS VIRT R; Loomis JM, 1999, BEHAV RES METH INS C, V31, P557, DOI 10.3758/BF03200735; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Mitchell P, 2007, J AUTISM DEV DISORD, V37, P589, DOI 10.1007/s10803-006-0189-8; Moore K, 2002, CYBERPSYCHOL BEHAV, V5, P197, DOI 10.1089/109493102760147178; MORRIS RG, 2006, P 6 INT C DIS VIRT R; Morrison RG, 2004, J COGNITIVE NEUROSCI, V16, P260, DOI 10.1162/089892904322984553; O'Doherty JP, 2007, ANN NY ACAD SCI, V1121, P254, DOI 10.1196/annals.1401.036; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Parsons S, 2004, J AUTISM DEV DISORD, V34, P449, DOI 10.1023/B:JADD.0000037421.98517.8d; Parsons S, 2002, J INTELL DISABIL RES, V46, P430, DOI 10.1046/j.1365-2788.2002.00425.x; Parsons S, 2006, COMPUT EDUC, V47, P186, DOI 10.1016/j.compedu.2004.10.003; Rankin KP, 2006, BRAIN, V129, P2945, DOI 10.1093/brain/awl254; Reinkensmeyer DJ, 2007, 2007 VIRTUAL REHABILITATION, P42; Riva G, 2007, CYBERPSYCHOL BEHAV, V10, P45, DOI 10.1089/cpb.2006.9993; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Royet JP, 2000, J NEUROSCI, V20, P7752; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; Schilbach L, 2006, NEUROPSYCHOLOGIA, V44, P718, DOI 10.1016/j.neuropsychologia.2005.07.017; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Semel E., 2003, CLIN EVALUATION LANG; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Stewart L, 2001, NEUROPSYCHOLOGIA, V39, P1, DOI 10.1016/S0028-3932(00)00084-1; TEASDALE G, 1974, LANCET, V2, P81; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Trenholme David, 2008, Virtual Reality, V12, P181, DOI 10.1007/s10055-008-0092-z; Tsujimoto S, 2010, NAT NEUROSCI, V13, P120, DOI 10.1038/nn.2453; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Virvou M, 2008, COMPUT EDUC, V50, P154, DOI 10.1016/j.compedu.2006.04.004; Waltz JA, 1999, PSYCHOL SCI, V10, P119, DOI 10.1111/1467-9280.00118; Wechsler D., 2011, WECHSLER ABBREVIATED; Weiderholt J.L., 2001, GRAY ORAL READING TE, V4th; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 1991, MERRILL PALMER QUART, V37, P369; YEATES KO, 1990, CLIN PSYCHOL REV, V10, P567, DOI 10.1016/0272-7358(90)90097-T	84	37	39	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	FEB	2011	49	3					486	497		10.1016/j.neuropsychologia.2010.12.007			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	728YH	WOS:000287909900021	21147137	Green Accepted			2022-02-06	
J	Shum, D; Fleming, J; Gill, H; Gullo, MJ; Strong, J				Shum, David; Fleming, Jennifer; Gill, Hannah; Gullo, Matthew J.; Strong, Jenny			A RANDOMIZED CONTROLLED TRIAL OF PROSPECTIVE MEMORY REHABILITATION IN ADULTS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						brain injuries; memory; rehabilitation; awareness	CLOSED-HEAD INJURY; COMPREHENSIVE ASSESSMENT; EXECUTIVE FUNCTIONS; SELF-AWARENESS; PERFORMANCE; REMEDIATION; EVENT; CAPM	Objective: To examine the efficacy of compensatory prospective memory training, preceded by self-awareness training for adults with traumatic brain injury. Design: Randomized controlled trial with 4 intervention groups: (i) self-awareness plus compensatory prospective memory training; (h) self-awareness training plus active control; (iii) active control plus compensatory prospective memory training; and (iv) active control only. Subjects: Forty-five rehabilitation patients with moderate severe traumatic brain injury living in the community. Methods: Four groups of participants completed an 8-session individual intervention programme with pre- and post-assessment by a blind assessor on a standardized test of prospective memory, actual strategy use, relatives' ratings of prospective memory failure, and level of psychosocial reintegration. Results: Larger changes in prospective memory test score and strategy use were found in groups with compensatory prospective memory training compared with those groups without. Conclusion: The results provide evidence that prospective memory can be improved in patients with traumatic brain injury using a compensatory approach in a relatively short duration and low intensity intervention.	[Shum, David; Gullo, Matthew J.] Griffith Univ, Sch Psychol, Brisbane, Qld 4122, Australia; [Shum, David; Gullo, Matthew J.] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4122, Australia; [Fleming, Jennifer; Gill, Hannah; Strong, Jenny] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; [Fleming, Jennifer] Queensland Hlth, Metro S Hlth Dist, Ctr Functioning & Hlth Res, Brisbane, Qld, Australia		Shum, D (corresponding author), Griffith Univ, Sch Psychol, Mt Gravatt Campus,176 Messines Ridge Rd, Brisbane, Qld 4122, Australia.	D.Shum@griffith.edu.au	Fleming, Jennifer M/B-4436-2011; Strong, Jenny/F-1211-2010; Gullo, Matthew/C-3850-2008; Shum, David/A-3914-2008; Gullo, Hannah/C-5011-2008	Strong, Jenny/0000-0002-9367-8755; Gullo, Matthew/0000-0003-3657-5191; Shum, David/0000-0002-4810-9262; GULLO, Hannah/0000-0003-4238-4033	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [277002]	This project was funded by a National Health and Medical Research Council Project Grant (no: 277002). The authors would like to thank Nadine Roche and the Occupational Therapy staff at the Princess Alexandra Hospital. We thank Professor John O'Gorman for his insightful and useful comments on various versions of this manuscript and Professor Barbara Wilson for making the CAMPROMPT available for the research before it was published.	Baddeley A. D., 1990, AUTOBIOGRAPHICAL MEM; Chau LT, 2007, NEUROPSYCHOL REHABIL, V17, P707, DOI 10.1080/09602010600923926; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; Einstein, 2007, PROSPECTIVE MEMORY O; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; Fleming J, 2009, BRAIN IMPAIR, V10, P34, DOI 10.1375/brim.10.1.34; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Grieve J., 2008, NEUROPSYCHOLOGY OCCU; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; Levine B., 2002, PRINCIPLES FRONTAL L, P51; Martin M, 2003, INT J PSYCHOL, V38, P195, DOI 10.1080/00207590344000123; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Neulinger K., 2002, BRAIN IMPAIR, V3, P1, DOI [10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Schmitter-Edgecombe M, 2004, BRAIN INJURY, V18, P997, DOI 10.1080/02699050410001719934; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wechsler D., 1989, WECHSLER ABBREVIATED; Wilson B., 2005, CAMBRIDGE PROSPECTIV; WILSON BA, 2002, HDB MEMORY DISORDERS, P617	35	37	38	0	20	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	FEB	2011	43	3					216	223		10.2340/16501977-0647			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	721WL	WOS:000287388400006	21305237	Green Published, Green Submitted, gold			2022-02-06	
J	Terrio, HP; Nelson, LA; Betthauser, LM; Harwood, JE; Brenner, LA				Terrio, Heidi P.; Nelson, Lonnie A.; Betthauser, Lisa M.; Harwood, Jeri E.; Brenner, Lisa A.			Postdeployment Traumatic Brain Injury Screening Questions: Sensitivity, Specificity, and Predictive Values in Returning Soldiers	REHABILITATION PSYCHOLOGY			English	Article						concussion; military; postdeployment; screening; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; IRAQ; IDENTIFICATION; RELIABILITY; AFGHANISTAN; DEPRESSION; DEPLOYMENT; VALIDITY; TBI	Objective: To evaluate the sensitivity, specificity, and predictive values of Post-Deployment Health Assessment traumatic brain injury (TBI) screening questions employed by the Department of Defense (DOD). Participants: Complete data was obtained from 3,072 soldiers upon return from a 15-month deployment to Iraq. Method: Comparisons were made between responses to the DOD four-item screener and a brief structured clinical interview for likely deployment-related TBI history. The interview process was facilitated using responses to the Warrior Administered Retrospective Casualty Assessment Tool (WARCAT). Results: The sensitivity and specificity of the DOD screening tool (positive response to all four items) in comparison to the clinician-confirmed diagnosis was 60% and 96%, respectively. The sensitivity increased to 80%, with a slight decrease in specificity to 93%, for positive TBI screening when affirmative responses to questions 1 and 2 only were included. Conclusions: Affirmative responses to questions 1 and 2 of the DOD TBI screening tool demonstrated higher sensitivity for clinician-diagnosed deployment-related TBI. These two items perform better than positive responses to all four questions; the criteria presently being used for documentation and referral of a deployment-related TBI. These findings support further exploration of TBI screening and assessment procedures.	[Terrio, Heidi P.] Evans Army Community Hosp, Def & Vet Brain Injury Ctr, Dept Deployment Hlth, Ft Carson, CO USA; [Betthauser, Lisa M.] Univ Colorado Denver, Mental Illness Res Educ & Clin Ctr, Denver VA Med Ctr, Denver, CO USA; [Harwood, Jeri E.] Univ Colorado Denver, Dept Pediat, Sch Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Dept Vet Affairs, Mental Illness Res Educ & Clin Ctr, Sch Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Dept Psychiat, Sch Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Dept Neurol, Sch Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Dept Phys Med & Rehabil, Sch Med, Denver, CO USA		Terrio, HP (corresponding author), USA, Western Reg Med Command, Bldg 2006,Liggett Ave,Room 317,Mail Stop 109,Box, Jblm, WA 98433 USA.	heidi.terrio@amedd.army.mil	Brenner, Lisa A./AAG-2442-2019				Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; *DEP DEF, 2009, 649002E DEP DEF; Department of Defense, 2006, 649003 DEP DEF; Deployment Health Clinical Center, 2010, POSTD HLTH ASS PDHA; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; *EV ARM COMM HOSP, 2010, SOLD READ PROC INJ E; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; *IBM, SPSS VERS 15 0 COMP; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kroenke K, 2003, MED CARE, V41, P1284, DOI 10.1097/01.MLR.0000093487.78664.3C; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; OLSONMADDEN J, 2010, ASSESSMENT DIA UNPUB; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; *SPSS, PASW VERS 18 0 COMP; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Van Dyke SA, 2010, MIL MED, V175, P947, DOI 10.7205/MILMED-D-10-00337; Wright KM, 2008, MIL MED, V173, P411, DOI 10.7205/MILMED.173.5.411	32	37	37	0	2	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2011	56	1					26	31		10.1037/a0022685			6	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	735LZ	WOS:000288417400003	21401283				2022-02-06	
J	Levin, HS; Wilde, EA; Hanten, G; Li, XQ; Chu, ZD; Vasquez, AC; Cook, L; Yallampalli, R; Hunter, JV				Levin, Harvey S.; Wilde, Elisabeth A.; Hanten, Gerri; Li, Xiaoqi; Chu, Zili David; Vasquez, Ana C.; Cook, Lori; Yallampalli, Ragini; Hunter, Jill V.			Mental State Attributions and Diffusion Tensor Imaging After Traumatic Brain Injury in Children	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							LONG-TERM OUTCOMES; WORKING-MEMORY; SOCIAL BRAIN; HEAD-INJURY; MIND; ADOLESCENTS; PERCEPTION; SKILLS	We studied social cognition in 49 children 3 months after moderate to severe traumatic brain injury (TBI) and in 39 children with orthopedic injury (OI). Children underwent diffusion tensor imaging (DTI) and a mental attribution task showing two triangles. Mental state attributions increased when one triangle reacted to intentions of the other, but less so in the TBI than the OI group. DTI identified injury to white matter microstructure in the TBI group, but the relation of DTI to mental attributions did not differ between groups. Moderate to severe TBI produces white matter disconnections that may affect social cognitive networks.	[Levin, Harvey S.; Wilde, Elisabeth A.; Hanten, Gerri; Li, Xiaoqi; Vasquez, Ana C.; Yallampalli, Ragini] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Chu, Zili David; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Cook, Lori] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75230 USA; [Chu, Zili David; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA		Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS021889-25, R01 NS021889-27, R01 NS021889-26A1, R01 NS021889] Funding Source: Medline		Abell F, 2000, COGNITIVE DEV, V15, P1, DOI 10.1016/S0885-2014(00)00014-9; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671; Castelli F, 2000, NEUROIMAGE, V12, P314, DOI 10.1006/nimg.2000.0612; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Ciccetti D., 1984, VINELAND ADAPTIVE BE; De Lange FP, 2008, CURR BIOL, V18, P454, DOI 10.1016/j.cub.2008.02.057; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gobbini MI, 2007, J COGNITIVE NEUROSCI, V19, P1803, DOI 10.1162/jocn.2007.19.11.1803; Hanten G, 2009, TOP LANG DISORD, V29, P236, DOI 10.1097/TLD.0b013e3181b531f0; Heider F, 1944, AM J PSYCHOL, V57, P243, DOI 10.2307/1416950; Hoogenraad F., 2002, MULTICENTER EVALUATI; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lombardo MV, 2010, J COGNITIVE NEUROSCI, V22, P1623, DOI 10.1162/jocn.2009.21287; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pelphrey KA, 2008, ANN NY ACAD SCI, V1145, P283, DOI 10.1196/annals.1416.007; Reynolds C. R., 1998, BEHAV ASSESSMENT SYS; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2009, J CLIN EXP NEUROPSYC, V31, P205, DOI 10.1080/13803390802098118; WOODCOCK RW, 2001, WOODCOCKJOHNSON TEST; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535	40	37	37	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2011	36	3					273	287	PII 935838800	10.1080/87565641.2010.549885			15	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	746LB	WOS:000289247200001	21462007	Green Accepted			2022-02-06	
J	Shear, DA; Tate, CC; Tate, MC; Archer, DR; LaPlaca, MC; Stein, DG; Dunbar, GL				Shear, Deborah A.; Tate, Ciara C.; Tate, Matthew C.; Archer, David R.; LaPlaca, Michelle C.; Stein, Donald G.; Dunbar, Gary L.			Stem cell survival and functional outcome after traumatic brain injury is dependent on transplant timing and location	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Neural stem cells; traumatic brain injury; motor recovery; spatial learning and memory; stem cell survival and migration; CNS repair	CHONDROITIN SULFATE PROTEOGLYCAN; SPINAL-CORD-INJURY; NG2-POSITIVE CELLS; NG2; RECOVERY; DEFICITS; MODEL; MOTOR; RAT	Purpose: Recent work indicates that transplanted neural stem cells (NSCs) can survive, migrate to the injury site, and facilitate recovery from traumatic brain injury (TBI). The present study manipulated timing and location of NSC transplants following controlled cortical impact injury (CCI) in mice to determine optimal transplant conditions. Methods: In Experiment 1 (timing), NSCs (E14.5 mouse) were injected into the host striatum, ipsilateral to the injury, at 2, 7, or 14 days. In Experiment 2 (location), NSCs or vehicle were injected into the mouse striatum (7 days post-CCI) either ipsilateral or contralateral to the injury and cognitive and motor abilities were assessed from weeks 1-8 post-transplant. Histological measures of NSC survival, migration, and differentiation were taken at 6 and 8 weeks post-transplant. Results: The results demonstrate that: (1) 2-7 days post-injury is the optimal time-range for delivering NSCs; (2) time of transplantation does not affect short-term phenotypic differentiation; (3) transplant location affects survival, migration, phenotype, and functional efficacy; and (4) NSC-mediated functional recovery is not contingent upon NSC migration or phenotypic differentiation. Conclusions: These findings provide further support for the idea that mechanisms other than the replacement of damaged neurons or glia, such as NSC-induced increases in protective neurotrophic factors, may be responsible for the functional recovery observed in this model of TBI.	[Shear, Deborah A.; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; [Tate, Ciara C.; LaPlaca, Michelle C.] Emory Univ, Dept Biomed Engn, Georgia Inst Technol, Atlanta, GA 30322 USA; [Tate, Matthew C.] Emory Univ, Sch Med, Atlanta, GA USA; [Archer, David R.] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA; [Stein, Donald G.] Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; [Shear, Deborah A.; Dunbar, Gary L.] Field Neurosci Inst, Saginaw, MI USA; [Shear, Deborah A.; Dunbar, Gary L.] Cent Michigan Univ, Dept Psychol, Neurosci Program, Mt Pleasant, MI 48859 USA		Shear, DA (corresponding author), Walter Reed Army Inst Res, MRMC UWI C, Bldng 503-2 W14, Silver Spring, MD 20910 USA.	Deborah.Shear@AMEDD.ARMY.MIL	Stein, Donald/AAJ-5139-2020; Shear, Deborah/B-3607-2011		John G. Kulhavi Professorship	This work was supported by a generous research gift from Field Neurosciences Institute, Saginaw MI (to DGS) and a John G. Kulhavi Professorship (to GLD).	Chittajallu R, 2004, J PHYSIOL-LONDON, V561, P109, DOI 10.1113/jphysiol.2004.074252; Dey ND, 2010, BEHAV BRAIN RES, V214, P193, DOI 10.1016/j.bbr.2010.05.023; Dunbar Gary L, 2006, Behav Cogn Neurosci Rev, V5, P63, DOI 10.1177/1534582306289367; Horner PJ, 2002, J NEUROCYTOL, V31, P469, DOI 10.1023/A:1025739630398; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Levine JM, 1996, PERSPECT DEV NEUROBI, V3, P245; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Nakahira E, 2006, DEV BIOL, V291, P123, DOI 10.1016/j.ydbio.2005.12.010; Polito A, 2005, J ANAT, V207, P707, DOI 10.1111/j.1469-7580.2005.00454.x; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Rossignol J, 2011, BEHAV BRAIN RES, V217, P369, DOI 10.1016/j.bbr.2010.11.006; Shear DA, 2000, NEUROREPORT, V11, P1833, DOI 10.1097/00001756-200006260-00007; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; STALLCUP WB, 1981, DEV BIOL, V83, P154, DOI 10.1016/S0012-1606(81)80018-8; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Trotter J, 2005, J NEUROL SCI, V233, P37, DOI 10.1016/j.jns.2005.03.024; Wu D, 2005, J NEUROCYTOL, V34, P459, DOI 10.1007/s11068-006-8998-4; [No title captured]	23	37	46	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2011	29	4					215	225		10.3233/RNN-2011-0593			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	814VR	WOS:000294485800001	21697596				2022-02-06	
J	Struchen, MA; Pappadis, MR; Sander, AM; Burrows, CS; Myszka, KA				Struchen, Margaret A.; Pappadis, Monique R.; Sander, Angelle M.; Burrows, Christina S.; Myszka, Katherine A.			Examining the Contribution of Social Communication Abilities and Affective/Behavioral Functioning to Social Integration Outcomes for Adults With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						craniocerebral trauma; social communication; social integration; traumatic brain injury	CLOSED-HEAD-INJURY; COMMUNITY INTEGRATION; FOLLOW-UP; CLINICAL TOOL; QUESTIONNAIRE; COMPETENCE; SKILLS; REHABILITATION; PERSPECTIVES; PERCEPTIONS	Objective: To evaluate the contribution of social communication abilities and affective/behavioral functioning to social integration outcomes for persons with traumatic brain injury (TBI). Design: Prospective cohort study. Participants: A total of 184 adults with TBI (72.8% men) evaluated at least 6 months postdischarge from acute care or inpatient rehabilitation hospitals and after living at least 3 months in the community postdischarge (Mean = 7.84 months postinjury). Measures: La Trobe Communication Questionnaire (LCQ), Assessment of Interpersonal Problem-Solving Skills (AIPSS), Affective Behavioral subscale From the Problem Checklist of the Head Injury Family Interview (AB-HIFI), Craig Handicap Assessment and Reporting Technique-Short Form Social Integration subscale (CHART-SF-SI), Community Integration Questionnaire Social Integration subscale (CIQ-SI). Results: Social communication measures (LCQ, AIPSS) and self-reported behavioral functioning (AB-HIFI) contributed significantly to concurrently measured social integration outcomes after controlling for demographic and injury-related variables. Separate hierarchical multiple regression analyses revealed that social communication and behavioral variables accounted for 11.3% of variance in CIQ-SI and 16.3% of variance in CHART-SF-SI. Conclusions: Social communication abilities and affective/ behavioral functioning make a substantial contribution to social integration outcomes after TBI. The implications of such evidence for clinical assessment and intervention are discussed.	[Struchen, Margaret A.; Sander, Angelle M.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Struchen, Margaret A.; Pappadis, Monique R.; Sander, Angelle M.; Burrows, Christina S.] TIRR Mem Hermann Hosp, Brain Injury Res Ctr, Houston, TX USA; [Pappadis, Monique R.] Univ Houston, Grad Coll Social Work, Houston, TX USA; [Burrows, Christina S.; Myszka, Katherine A.] Univ Houston, Dept Psychol, Houston, TX USA; [Sander, Angelle M.] Harris Cty Hosp Dist, Dept Phys Med & Rehabil, Quentin Mease Community Hosp, Houston, TX USA		Struchen, MA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1 Baylor Plaza, Houston, TX 77030 USA.	struchen@bcm.edu	Pappadis, Monique/Q-8639-2016	Pappadis, Monique/0000-0003-4742-4380; O'Brien, Katherine/0000-0002-1416-4124	National Institute on Disability and Rehabilitation Research, US Department of EducationUS Department of Education [H133B031117, H133B090023, H133A070043]	This work was supported by grants from the National Institute on Disability and Rehabilitation Research, US Department of Education (grant H133B031117, Rehabilitation Research and Training Center on Community Integration of Persons with Traumatic Brain Injury; H133B090023, Rehabilitation Research and Training Center on Developing Strategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury; and H133A070043, Texas Traumatic Brain Injury Model System of TIRR).	BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BOWERS D, 1991, BRAIN, V114, P2593, DOI 10.1093/brain/114.6.2593; Bowers D., 1991, FLORIDA AFFECT BATTE; Brooks DN, 1979, REHABILITATION HEAD, P107; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BRUININKS RH, 1992, RES DEV DISABIL, V13, P463, DOI 10.1016/0891-4222(92)90003-O; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; *CRAIG HOSP RES DE, 1999, CRAIG HAND ASS REP T; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Damico J. S., 1985, COMMUNICATION SKILLS, P165; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DONAHOE CP, 1990, PSYCHIATRY, V53, P329; Donahoe CP, 1996, SOCIAL INDEPENDENT L; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Gage M, 1997, AM J OCCUP THER, V51, P96, DOI 10.5014/ajot.51.2.96; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hoofien D, 2001, BRAIN INJURY, V15, P189; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KARPMAN T, 1985, J APPL REHABILITATIO, V0017, P00028; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; MARSH NV, 1999, BRAIN DAM B, P175; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCFALL RM, 1982, BEHAV ASSESS, V4, P1; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Mooney GF, 1988, COGNITIVE REHABI SEP, P14; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P18; PRUTTING CA, 1982, J SPEECH HEAR DISORD, V47, P123, DOI 10.1044/jshd.4702.123; SALZBERG CL, 1981, MENT RETARD, V19, P127; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sander AM, 2010, J HEAD TRAUMA REHAB, V25, P121, DOI 10.1097/HTR.0b013e3181cd1635; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Sherron P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [DOI 10.1097/00001199-199109000-00004, https://doi.org/10.1097/00001199-199109000-00004]; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; *SPSS INC, 2009, PASW STAT 18 REL VER; Struchen M. A., 2005, REHABILITATION TRAUM, P88; Struchen MA, 2003, J INT NEUROPSYCH SOC, V9, P255; Struchen MA, 2002, ASSESSMENT INTERPERS; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Whiteneck GG, 1992, GUIDE USE CHART CRAI; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205	68	37	37	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2011	26	1					30	42		10.1097/HTR.0b013e3182048f7c			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	703GA	WOS:000285965200004	21209561				2022-02-06	
J	Chang, YJ; Wang, TY				Chang, Yao-Jen; Wang, Tsen-Yung			Comparing picture and video prompting in autonomous indoor wayfinding for individuals with cognitive impairments	PERSONAL AND UBIQUITOUS COMPUTING			English	Article						Cognitive impairments; Ubiquitous computing; User interface; Bluetooth	DAILY LIVING SKILLS; SYSTEMS; PEOPLE; TECHNOLOGY; ADULTS	A challenge to individuals with cognitive impairments in wayfinding is how to remain oriented, recall routines, and travel in unfamiliar areas in a way relying on limited cognitive capacity. According to psychological model of spatial navigation and the requirements of rehabilitation professionals, a novel wayfinding system is presented with an aim to increase workplace and life independence for people with traumatic brain injury, cerebral palsy, intellectual and developmental disabilities, schizophrenia, Down syndromes, and Alzheimer's disease. An architecture is proposed based on Bluetooth tags and scanning PDAs. A prototype is built and tested in field experiments with real patients. Two modalities, video and picture prompts, were compared by 20 subjects with cognitive impairments. The experimental results show the computer-human interface is friendly and the capabilities of wayfinding are reliable. Video prompts performed better by 25-28% than picture prompts at the price of users feeling slightly more rushed.	[Chang, Yao-Jen] Chung Yuan Christian Univ, Dept Elect Engn, Chungli 320, Taiwan; [Wang, Tsen-Yung] Natl Yang Ming Univ, Inst Hlth & Welf Policy, Taipei 112, Taiwan		Chang, YJ (corresponding author), Chung Yuan Christian Univ, Dept Elect Engn, Chungli 320, Taiwan.	yjchang@cycu.edu.tw; tywang@ym.edu.tw			National Science CouncilMinistry of Science and Technology, Taiwan [NSC 95-2627-E-008-002-, NSC 96-2627-E-008-001-, NSC 97-2627-E-008-001-]	The work presented in this paper has been funded by the National Science Council under grant numbers NSC 95-2627-E-008-002-, NSC 96-2627-E-008-001-, and NSC 97-2627-E-008-001-. Thanks for all the participating job coaches who have served the mentally impaired heartily and truthfully. Thanks for all the participating individuals with cognitive impairments, who have shown us deeper values of life. We thank the anonymous reviewers for their comments and suggestions which greatly improve the presentation of the paper. We also would like to extend our special thanks to a reviewer who suggests the idea of adaptive video framerate in the future work.	Allen GL, 1999, WAYFINDING BEHAVIOR, P46; BAUCHET J, 2005, P 3 INT C SMART HOM, P3; Baus J., 2001, COGN PROCESS, V2, P323; Baus J, 2007, 2007 INTERNATIONAL CONFERENCE ON INTELLIGENT USER INTERFACES, P302; Bluetooth SIG, 2004, BLUET SPEC V2 0; Boger J, 2005, 19TH INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE (IJCAI-05), P1293; BOHONOS S, 2007, P 1 ACM SIGMOBILE IN, P83; BOND GR, 1996, SUPPORTED EMPLOYMENT; BOND GR, 1992, VOCATIONAL REHABILIT; Cannella HI, 2005, RES DEV DISABIL, V26, P1, DOI 10.1016/j.ridd.2004.01.006; Cannella-Malone H, 2006, EDUC TRAIN DEV DISAB, V41, P344; Carmien S., 2005, ACM Transactions on Computer-Human Interaction, V12, P233, DOI 10.1145/1067860.1067865; Chan Y K, 2008, Progress In Electromagnetics Research B, V2, P27, DOI 10.2528/PIERB07110101; Chang YJ, 2008, 2008 3RD INTERNATIONAL SYMPOSIUM ON WIRELESS PERVASIVE COMPUTING, VOLS 1-2, P622; Chang YJ, 2009, IEEE WIREL COMMUN, V16, P34, DOI 10.1109/MWC.2009.5109462; Chang YJ, 2008, 2008 2ND INTERNATIONAL CONFERENCE ON PERVASIVE COMPUTING TECHNOLOGIES FOR HEALTHCARE, P101; Chang YJ, 2007, ASSETS'07: PROCEEDINGS OF THE NINTH INTERNATIONAL ACM SIGACCESS CONFERENCE ON COMPUTERS AND ACCESSIBILITY, P231; Cihak DF, 2008, EDUC TRAIN DEV DISAB, V43, P102; Cihak DF, 2007, RES DEV DISABIL, V28, P397, DOI 10.1016/j.ridd.2006.05.003; Cook A. M., 2008, ASSISTIVE TECHNOLOGY; Dijkstra E. W, 1959, NUMER MATH, V1, P269, DOI [DOI 10.1007/BF01386390, 10.1007/BF01386390]; Dutton GN, 2003, EYE, V17, P289, DOI 10.1038/sj.eye.6700344; FATIHA L, 2005, P 3 INT C SMART HOM, P245; GENTRY T, 2007, BRAIN INJURY     DEC, P19; Giroux S., 2005, P 3 INT C SMART HOM; Golledge R.G., 1999, WAYFINDING BEHAV COG; Goodman J, 2005, BEHAV INFORM TECHNOL, V24, P3, DOI 10.1080/01449290512331319021; Goodwin Simon, 1997, COMP MENTAL HLTH POL; Gu YY, 2009, IEEE COMMUN SURV TUT, V11, P13, DOI 10.1109/SURV.2009.090103; Hazas M, 2006, IEEE T MOBILE COMPUT, V5, P536, DOI 10.1109/TMC.2006.57; KRAY C, 2002, P SPAT COGN 2002 TUT; Liao L, 2007, ARTIF INTELL, V171, P311, DOI 10.1016/j.artint.2007.01.006; Liu AL, 2008, DISABIL REHABIL-ASSI, V3, P69, DOI 10.1080/17483100701500173; Liu H, 2007, IEEE T SYST MAN CY C, V37, P1067, DOI 10.1109/TSMCC.2007.905750; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Ni LM, 2004, WIREL NETW, V10, P701, DOI 10.1023/B:WINE.0000044029.06344.dd; Nothegger C., 2004, SPAT COGN COMPUT, V4, P113, DOI [10.1207/s15427633scc0402_1, DOI 10.1207/S15427633SCC0402_1]; O'Connell ME, 2003, NEUROREHABILITATION, V18, P9; Passini, 1996, DESIGN STUDIES, V17, P319, DOI DOI 10.1016/0142-694X(96)00001-4; Pigot H, 2003, ADV COMP BIOENG, V7, P507; Raubal M., 2001, COGNITIVE PROCESSING, V2, P363, DOI DOI 10.1007/S00779-008-0207-2; ROSS DA, 2005, P 28 RESNA C JUN; Sohlberg MM, 2007, BRAIN INJURY, V21, P531, DOI 10.1080/02699050701311000; Sohlberg MM, 2003, BRAIN INJURY, V17, P609, DOI 10.1080/0269905031000070189; Sutcliffe A, 2003, INTERACT COMPUT, V15, P577, DOI 10.1016/S0953-5438(03)00051-1; Van Laarhoven T, 2006, EDUC TRAIN DEV DISAB, V41, P365; WAHLSTER W, 2001, P INT WORKSH INF PRE, P5; [No title captured]; [No title captured], DOI DOI 10.1145/1054972.1055043	49	37	37	0	15	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1617-4909	1617-4917		PERS UBIQUIT COMPUT	Pers. Ubiquitous Comput.	DEC	2010	14	8					737	747		10.1007/s00779-010-0285-9			11	Computer Science, Information Systems; Telecommunications	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Computer Science; Telecommunications	679DL	WOS:000284139500007					2022-02-06	
J	Reed, N; Taha, T; Keightley, M; Duggan, C; McAuliffe, J; Cubos, J; Baker, J; Faught, B; McPherson, M; Montelpare, W				Reed, N.; Taha, T.; Keightley, M.; Duggan, C.; McAuliffe, J.; Cubos, J.; Baker, J.; Faught, B.; McPherson, M.; Montelpare, W.			Measurement of Head Impacts in Youth Ice Hockey Players	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						concussion; head acceleration; youth athletes; ice hockey	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CHILDREN; RATES; ACCELERATION; MAGNITUDE; STATEMENT	Despite growing interest in the biomechanical mechanisms of sports-related concussion, ice hockey and the youth sport population has not been studied extensively. The purpose of this pilot study was: 1) to describe the biomechanical measures of head impacts in youth minor ice hockey players; and, 2) to investigate the influence of player and game characteristics on the number and magnitude of head impacts. Data was collected from 13 players from a single competitive Bantam boy's (ages 13-14 years) AAA ice hockey team using telemetric accelerometers implanted within the players' helmets at 27 ice hockey games. The average linear acceleration, rotational acceleration, Gadd Severity Index and Head Injury Criterion of head impacts were recorded. A significantly higher number of head impacts per player per game were found for wingers when compared to centre and defense player positions (df = 355, t = 3.087, p = 0.00218) and for tournament games when compared to regular season and playoff games (df = 355, t = 2.641, p = 0.086). A significant difference in rotational acceleration according to player position (F-2,F-1812 = 4.9551, p = 0.0071) was found. This study is an initial step towards a greater understanding of head impacts in youth ice hockey.	[Reed, N.; Taha, T.] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON M5G 1V7, Canada; [McAuliffe, J.] Nipissing Univ, Dept Phys & Hlth Educ, N Bay, ON, Canada; [Cubos, J.; Baker, J.] York Univ, Sch Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada; [Faught, B.] Brock Univ, Fac Appl Hlth Sci, St Catharines, ON L2S 3A1, Canada; [McPherson, M.; Montelpare, W.] Lakehead Univ, Sch Kinesiol, Thunder Bay, ON P7B 5E1, Canada		Reed, N (corresponding author), Univ Toronto, Fac Phys Educ & Hlth, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	nick.reed@utoronto.ca	Baker, Joseph/J-6164-2014	Baker, Joseph/0000-0002-5686-1737	Ontario Neurotrauma Foundation	The authors would like to thank the Ontario Neurotrauma Foundation who provided funding for this project. Additionally, special thanks must be given to our participant hockey team, the Greater Toronto Hockey League, the Ontario Hockey Federation and the Ontario Hockey Research Group for all their cooperation and support.	BARNSLEY R, 1988, RESTOR NEUROL NEUROS, V20, P167; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Chu, 2006, J BIOMECH, V39, DOI https://doi.org/10.1016/s0021-9290(06)83518-9; CHU JJ, 2006, J BIOMECH, V39, pS153; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Crawley M. J, 2007, R BOOK, P449; Crisco JJ, 1997, MED SCI SPORT EXER, V29, P26, DOI 10.1097/00005768-199701000-00005; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gadd C. W, 1966, SAE TECHNICAL PAPER, DOI 10.4271/660793; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harriss DJ, 2009, INT J SPORTS MED, V30, P701, DOI 10.1055/s-0029-1237378; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; LEHR E, 1990, COMMUNITY INTEGRATIO; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MIHALIK J, 2008, J SPORTS ENG TECHNOL, V222, P45; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; Wattie N, 2007, PEDIATRICS, V120, P142, DOI 10.1542/peds.2006-2672; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	53	37	37	1	14	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	NOV	2010	31	11					826	833		10.1055/s-0030-1263103			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	675PN	WOS:000283842800011	20830655				2022-02-06	
J	Seo, TB; Kim, BK; Ko, IG; Kim, DH; Shin, MS; Kim, CJ; Yoon, JH; Kim, H				Seo, Tae-Beom; Kim, Bo-Kyun; Ko, Il-Gyu; Kim, Dong-Hyun; Shin, Mal-Soon; Kim, Chang-Ju; Yoon, Jin-Hwan; Kim, Hong			Effect of treadmill exercise on Purkinje cell loss and astrocytic reaction in the cerebellum after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Cerebellum; Traumatic brain injury; Purkinje cells; Reactive astrocytes; Treadmill exercise	LATERAL FLUID PERCUSSION; CORTICAL IMPACT INJURY; SYNAPTIC PLASTICITY; COGNITIVE FUNCTION; TIME-COURSE; RATS; DEGENERATION; EXCITOTOXICITY; VULNERABILITY; EXPRESSION	The cerebellum is one of the brain areas, which is selectively vulnerable to forebrain traumatic brain injuries (TBI). Physical exercise in animals is known to promote cell survival and functional recovery after brain injuries. However, the detailed pathologic and functional alterations by exercise following an indirect cerebellar injury induced by a TBI are largely unknown. We determined the effects of treadmill exercise on survival of Purkinje neurons and on a population of reactive astrocytes in the gyrus of lobules VIII and IX of the cerebellum after TBI. The rats were divided into four groups: the sham-operation group, the sham-operation with exercise group, the TBI-induction group, and the TBI-induction with exercise group. Cell biological changes of Purkinje neurons following indirect cerebellar injury were analyzed by immunohistochemistry. TBI-induced loss of calbindin-stained Purkinje neurons in the posterior region of the cerebellum and TBI also increased formation of reactive astroyctes in both the granular and molecular layers of the cerebellar posterior region. Treadmill exercise for 10 days after TBI increased the number of calbindin-stained Purkinje neurons and suppressed formation of reactive astroyctes. The present study provides the possibility that treadmill exercise may be an important mediator to enhance survival of Purkinje neurons in TBI-induced indirect cerebellar injury. (C) 2010 Elsevier Ireland Ltd. All rights reserved.	[Kim, Hong] Daegu Haany Univ, Dept Oriental Sports Med, Gyongsan 712715, Gyeongsangbuk D, South Korea; [Seo, Tae-Beom; Kim, Bo-Kyun; Ko, Il-Gyu; Kim, Dong-Hyun; Shin, Mal-Soon; Kim, Chang-Ju] Kyung Hee Univ, Coll Med, Dept Physiol, Seoul 130701, South Korea; [Yoon, Jin-Hwan] Hannam Univ, Dept Sports Sci, Taejon 306791, South Korea		Kim, H (corresponding author), Daegu Haany Univ, Dept Oriental Sports Med, Gyongsan 712715, Gyeongsangbuk D, South Korea.	joshua@dhu.ac.kr	Kim, Dong-Hyun/AAH-3043-2020; Kim, Chang Ju/M-4216-2017	Kim, Chang Ju/0000-0003-4749-5795; Jin-Hwan, yoon/0000-0001-9026-6416	Daegu Haany University Ky.lin Foundation	This research was supported by a grant from Daegu Haany University Ky.lin Foundation in 2008.	Ai JL, 2007, EXP BRAIN RES, V177, P95, DOI 10.1007/s00221-006-0654-9; Ai JL, 2002, NEUROSCI LETT, V332, P155, DOI 10.1016/S0304-3940(02)00945-X; BEDFORD TG, 1979, J APPL PHYSIOL, V47, P1278, DOI 10.1152/jappl.1979.47.6.1278; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; BRORSON JR, 1994, J NEUROSCI, V14, P187; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Jang MH, 2002, NEUROSCI LETT, V322, P29, DOI 10.1016/S0304-3940(02)00076-9; Klintsova AY, 2004, BRAIN RES, V1028, P92, DOI 10.1016/j.brainres.2004.09.003; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; OHearn E, 1997, J NEUROSCI, V17, P8828; Park E, 2007, PROG BRAIN RES, V161, P327, DOI 10.1016/S0079-6123(06)61023-6; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Strahlendorf JC, 1996, BRAIN RES, V729, P197, DOI 10.1016/0006-8993(96)00367-8; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Viscomi MT, 2009, CEREBELLUM, V8, P184, DOI 10.1007/s12311-009-0107-7	39	37	38	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 13	2010	481	3					178	182		10.1016/j.neulet.2010.06.087			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	642NB	WOS:000281220600010	20603186				2022-02-06	
J	de Groot, YJ; Jansen, NE; Bakker, J; Kuiper, MA; Aerdts, S; Maas, AIR; Wijdicks, EFM; van Leiden, HA; Hoitsma, AJ; Kremer, BHPH; Kompanje, EJO				de Groot, Yorick J.; Jansen, Nichon E.; Bakker, Jan; Kuiper, Michael A.; Aerdts, Stan; Maas, Andrew I. R.; Wijdicks, Eelco F. M.; van Leiden, Hendrik A.; Hoitsma, Andries J.; Kremer, Berry H. P. H.; Kompanje, Erwin J. O.			Imminent brain death: point of departure for potential heart-beating organ donor recognition	INTENSIVE CARE MEDICINE			English	Article						Brain death; Critical care organisation; Neurotrauma; Transplantation; Stroke; Emergency medicine	SCORE COMA SCALE; CARE; DONATION; VALIDATION; CONSCIOUSNESS; PERFORMANCE; WITHDRAWAL; CONSENT; AUDIT; TIME	There is, in European countries that conduct medical chart review of intensive care unit (ICU) deaths, no consensus on uniform criteria for defining a potential organ donor. Although the term is increasingly being used in recent literature, it is seldom defined in detail. We searched for criteria for determination of imminent brain death, which can be seen as a precursor for organ donation. We organized meetings with representatives from the field of clinical neurology, neurotraumatology, intensive care medicine, transplantation medicine, clinical intensive care ethics, and organ procurement management. During these meetings, all possible criteria were discussed to identify a patient with a reasonable probability to become brain dead (imminent brain death). We focused on the practical usefulness of two validated coma scales (Glasgow Coma Scale and the FOUR Score), brain stem reflexes and respiration to define imminent brain death. Further we discussed criteria to determine irreversibility and futility in acute neurological conditions. A patient who fulfills the definition of imminent brain death is a mechanically ventilated deeply comatose patient, admitted to an ICU, with irreversible catastrophic brain damage of known origin. A condition of imminent brain death requires either a Glasgow Coma Score of 3 and the progressive absence of at least three out of six brain stem reflexes or a FOUR score of E0M0B0R0. The definition of imminent brain death can be used as a point of departure for potential heart-beating organ donor recognition on the intensive care unit or retrospective medical chart analysis.	[de Groot, Yorick J.; Bakker, Jan; Kompanje, Erwin J. O.] Erasmus MC Univ, Dept Intens Care, Med Ctr, NL-3000 CA Rotterdam, Netherlands; [Jansen, Nichon E.; van Leiden, Hendrik A.] Dutch Transplant Fdn, Leiden, Netherlands; [Kuiper, Michael A.] Med Ctr Leeuwarden, Dept Intens Care, Leeuwarden, Netherlands; [Aerdts, Stan] Isala Clin, Dept Intens Care, Zwolle, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Wijdicks, Eelco F. M.] Mayo Clin, Div Crit Care Neurol, Rochester, MN USA; [Kremer, Berry H. P. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Hoitsma, Andries J.] Radboud Univ Nijmegen Med Ctr, Dept Nephrol, Nijmegen, Netherlands		Kompanje, EJO (corresponding author), Erasmus MC Univ, Dept Intens Care, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands.	e.j.o.kompanje@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Hoitsma, A.J./L-4382-2015; Jansen, Nichon/ABF-8095-2021; Bakker, Jan/A-4011-2009; Kuiper, Michael/AAG-9878-2019	Maas, Andrew IR/0000-0003-1612-1264; Jansen, Nichon/0000-0003-2952-3799; Bakker, Jan/0000-0003-2236-7391; Kuiper, Michael/0000-0001-6201-7332			[Anonymous], 1968, JAMA, V205, P337; Barber K, 2006, BMJ-BRIT MED J, V332, P1124, DOI 10.1136/bmj.38804.658183.55; Chan JD, 2004, CHEST, V126, P286, DOI 10.1378/chest.126.1.286; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; *EUROTR INT FDN, 2008, ANN REP EUROTR INT F; Gortmaker SL, 1996, CRIT CARE MED, V24, P432, DOI 10.1097/00003246-199603000-00012; *HLTH RES SERV ADM, 2007, ANN REP US ORG PROC; Hoffenberg R, 1997, LANCET, V350, P1320, DOI 10.1016/S0140-6736(97)02306-4; Iyer VN, 2009, MAYO CLIN PROC, V84, P694, DOI 10.1016/S0025-6196(11)60519-3; Kompanje EJO, 2006, INTENS CARE MED, V32, P217, DOI 10.1007/s00134-005-0001-9; LOVEGROVE C, 2006, NAT CLIN PRACT NEURO, V2, P4; Lytle FT, 2009, AM J TRANSPLANT, V9, P1446, DOI 10.1111/j.1600-6143.2009.02575.x; Margarida A, 2009, GUIDE RECOMMENDATION; Molina A, 2008, J MED ETHICS, V34, P688, DOI 10.1136/jme.2007.022921; MOLLARET P., 1959, REV NEUROL [PARIS], V101, P3; MURPHY C, 2008, POTENTIAL DONOR AUDI; Opdam HI, 2004, INTENS CARE MED, V30, P1390, DOI 10.1007/s00134-004-2185-9; RIKER RR, 1995, TRANSPLANTATION, V59, P880; Robertson JA, 1999, HASTINGS CENT REP, V29, P6, DOI 10.2307/3527865; Rodrigue JR, 2006, AM J TRANSPLANT, V6, P190, DOI 10.1111/j.1600-6143.2005.01130.x; Roels L, 2007, AM J TRANSPLANT, V7, P1439, DOI 10.1111/j.1600-6143.2007.01831.x; Rosenberg RN, 2009, JAMA-J AM MED ASSOC, V301, P1172, DOI 10.1001/jama.2009.224; Shafer TJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b701; Siminoff LA, 2004, SOC SCI MED, V59, P2325, DOI 10.1016/j.socscimed.2004.03.029; Siminoff LA, 2001, JAMA-J AM MED ASSOC, V286, P71, DOI 10.1001/jama.286.1.71; Simpkin AL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b991; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Stead LG, 2009, NEUROCRIT CARE, V10, P50, DOI 10.1007/s12028-008-9145-0; TEASDALE G, 1974, LANCET, V2, P81; Tuttle-Newhall JE, 2009, AM J TRANSPLANT, V9, P879, DOI 10.1111/j.1600-6143.2009.02565.x; WERTHEIMER P, 1959, PRESSE MED, V67, P87; Wijdicks EFM, 2008, NEUROLOGY, V70, P1234, DOI 10.1212/01.wnl.0000289762.50376.b6; Wijdicks Eelco F M, 2006, Rev Neurol Dis, V3, P109; Wijdicks EF, 2008, COMATOSE PATIENT; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wijdicks EFM, 2001, J NEUROL NEUROSUR PS, V70, P127, DOI 10.1136/jnnp.70.1.127; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435; Wood KE, 2004, NEW ENGL J MED, V351, P2730, DOI 10.1056/NEJMra013103; Wood KE, 2007, CURR OPIN ANESTHESIO, V20, P97, DOI 10.1097/ACO.0b013e3280895ac8; 2007, TRANSPLANT ACTIVITY	40	37	40	0	4	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2010	36	9					1488	1494		10.1007/s00134-010-1848-y			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	638PV	WOS:000280908000006	20232039	Green Published, hybrid			2022-02-06	
J	Eberle, BM; Schnuriger, B; Inaba, K; Gruen, JP; Demetriades, D; Belzberg, H				Eberle, Barbara M.; Schnueriger, Beat; Inaba, Kenji; Gruen, J. Peter; Demetriades, Demetrios; Belzberg, Howard			Decompressive craniectomy: Surgical control of traumatic intracranial hypertension may improve outcome	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Decompressive craniectomy; Severe traumatic brain injury; Intractable intracranial hypertension; Glasgow outcome score	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURIES; BRAIN-INJURY; MANAGEMENT; EXPERIENCE; IMPACT; EDEMA	Introduction: The purpose of this study was to assess the role of decompressive craniectomy (DC) in patients with post-traumatic intractable intracranial hypertension (ICH) in the absence of an evacuable intracerebral haemorrhage. Methods: Retrospective study at LAC+USC Medical Centre including patients who underwent DC for post-traumatic malignant brain swelling or ICH without space occupying haemorrhage, during the period 01/2004 to 12/2008. The analysis included the effect of DC on intracranial pressure (ICP) and timing of DC on functional outcomes and survival. Results: Of 106 patients who underwent DC, 43 patients met inclusion criteria. Of those, 34 were operated within the first 24 h from admission. DC decreased the ICP significantly from 37.8 +/- 12.1 mmHg to 12.7 +/- 8.2 mmHg in survivors and from 52.8 +/- 13.0 to 32.0 +/- 17.3 mmHg in non-survivors. Overall 25.6% died (11 of 43), and 32.5% (14 of 43) remained in vegetative state or were severely disabled. Favourable outcome (Glasgow Outcome Scale 4 and 5) was observed in 41.9% (18 of 43). No tendency towards either increased or decreased incidence in favourable outcome was found relative to the time from admission to DC. Six of the 18 patients (33.3%) with favourable outcome were operated on within the first 6 h. Conclusions: DC lowers ICP and raises CPP to high normal levels in survivors compared to non-survivors. The timing of DC showed no clear trend, for either good neurological outcome or death. Overall, the survival rate of 74.4% is promising and 41.9% had favourable neurological outcome. (C) 2010 Elsevier Ltd. All rights reserved.	[Eberle, Barbara M.; Schnueriger, Beat; Inaba, Kenji; Demetriades, Demetrios; Belzberg, Howard] LAC USC Med Ctr, Dept Surg, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA USA; [Gruen, J. Peter] LAC USC Med Ctr, Dept Neurosurg, Los Angeles, CA USA		Belzberg, H (corresponding author), Univ So Calif, Keck Sch Med, Los Angeles Cty Gen Hosp, LAC USC Med Ctr,Crit Care Serv, 1200 N State St,C5L100, Los Angeles, CA 90033 USA.	belzberg@usc.edu	INABA, KENJI/AAC-8532-2020				Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cannon ML, 2001, J NEUROSURG, V95, P1053, DOI 10.3171/jns.2001.95.6.1053; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Davella D, 2000, J Neurosurg Sci, V44, P19; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Farin A, 2004, ACT NEUR S, V89, P101; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	31	37	40	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2010	41	9					894	898		10.1016/j.injury.2010.02.023			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	634SL	WOS:000280605500003	21574279				2022-02-06	
J	O'Donnell, ML; Creamer, M; Holmes, ACN; Ellen, S; McFarlane, AC; Judson, R; Silove, D; Bryant, RA				O'Donnell, Meaghan L.; Creamer, Mark; Holmes, Alexander C. N.; Ellen, Steven; McFarlane, Alexander C.; Judson, Rodney; Silove, Derrick; Bryant, Richard A.			Posttraumatic Stress Disorder After Injury: Does Admission to Intensive Care Unit Increase Risk?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Injury; Posttraumatic stress disorder; Intensive care unit	QUALITY-OF-LIFE; MENTAL-HEALTH; TRAUMA; DELIRIUM; SLEEP; PREVALENCE; VALIDATION; DELUSIONS; SURVIVORS; SYMPTOMS	Background: This study aimed to index the prevalence of posttraumatic stress disorder (PTSD) after injury requiring intensive care unit (ICU) admission to investigate whether an ICU admission after injury increases risk for PTSD and to identify predictors of PTSD after ICU admission. Methods: A two-group (those admitted to the ICU vs. those not admitted to ICU), prospective, cohort study of 829 randomly selected injury patients from five major trauma hospitals across Australia. We collected information on factors that may increase risk for PTSD including demographic variables (gender, age, income, education, and marital status), preinjury mental health status (prior trauma, psychiatric history, and prior social support), and injury characteristics (mild traumatic brain injury, injury severity, length of hospital admission, discharge destination, pain, and perceived threat). PTSD was measured at 12 months by structured clinical interview. Results: ICU patients were significantly more likely to have PTSD at 12 months than trauma controls (17% vs. 7%). Stepwise logistic regressions showed that an ICU admission significantly contributed to the development of PTSD after controlling for demographic, preinjury mental health status, and injury characteristic variables. Conclusions: Injury patients are three times more likely to develop later PTSD if they have an ICU admission. Given we controlled for many risk variables, it seems that an ICU admission itself may contribute to the development of PTSD. Mental health services such as screening and early intervention may be particularly useful for this population.	[O'Donnell, Meaghan L.; Creamer, Mark] Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, E Melnourne, Vic, Australia; [O'Donnell, Meaghan L.; Creamer, Mark; Holmes, Alexander C. N.] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia; [O'Donnell, Meaghan L.] Natl Trauma Res Inst, Prahran, Vic, Australia; [Ellen, Steven] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Dept Psychiat, Prahran, Vic 3181, Australia; [McFarlane, Alexander C.] Univ Adelaide, Dept Psychiat, Ctr Vet & Mil Hlth, Adelaide, SA, Australia; [Judson, Rodney] Royal Melbourne Hosp, Trauma Serv, Div Surg Perioperat & Imaging, Melbourne, Vic, Australia; [Silove, Derrick] Univ New S Wales, Psychiat Res & Teaching Unit, Dept Psychiat, Liverpool, NSW, Australia; [Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia		O'Donnell, ML (corresponding author), Australian Ctr Posttraumat Mental Hlth, Dept Psychiat, Level 1,340 Albert St, Melbourne, Vic 3002, Australia.	mod@unimelb.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X; O'Donnell, Meaghan/0000-0003-4349-0022	NHMRCNational Health and Medical Research Council of Australia [300304]; Victorian Trauma Foundation [V-11]; National Health and Medical Research Council Australian Clinical ResearchNational Health and Medical Research Council of Australia [359284]	Supported by an NHMRC Program grant 300304, a Victorian Trauma Foundation grant V-11, and a National Health and Medical Research Council Australian Clinical Research Fellowship 359284.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERRY J, 2006, HOSP SEPARATIONS DUE; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; DiMartini A, 2007, PSYCHOSOMATICS, V48, P436, DOI 10.1176/appi.psy.48.5.436; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Girard TD, 2008, CRIT CARE, V12, DOI 10.1186/cc6149; Griffiths J, 2007, INTENS CARE MED, V33, P1506, DOI 10.1007/s00134-007-0730-z; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Jackson JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5707; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; Mellman TA, 2002, AM J PSYCHIAT, V159, P1696, DOI 10.1176/appi.ajp.159.10.1696; Mistraletti G, 2008, MINERVA ANESTESIOL, V74, P329; O'Donnell ML, 2008, CLIN PSYCHOL REV, V28, P387, DOI 10.1016/j.cpr.2007.07.008; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; O'Donnell ML, 2009, J TRAUMA, V66, P470, DOI 10.1097/TA.0b013e31815d965e; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; Schelling G, 2003, CRIT CARE MED, V31, P1971, DOI 10.1097/01.CCM.0000069512.10544.40; SCHUSTER TL, 1990, AM J COMMUN PSYCHOL, V18, P423, DOI 10.1007/BF00938116; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Sessler CN, 2008, CHEST, V133, P552, DOI 10.1378/chest.07-2026; Shalev AY, 2002, BIOL PSYCHIAT, V51, P532, DOI 10.1016/S0006-3223(02)01335-5; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Talwar Arunabh, 2008, Indian J Chest Dis Allied Sci, V50, P151; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; World Health Organization, 1997, COMP INT DIAGN INT C; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2002, ARCH SURG-CHICAGO, V137, P200, DOI 10.1001/archsurg.137.2.200; 2006, NATL CTR INJURY PREV	43	37	38	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2010	69	3					627	632		10.1097/TA.0b013e3181bc0923			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	649HX	WOS:000281760800035	20118816				2022-02-06	
J	Stojsih, S; Boitano, M; Wilhelm, M; Bir, C				Stojsih, S.; Boitano, M.; Wilhelm, M.; Bir, C.			A prospective study of punch biomechanics and cognitive function for amateur boxers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							HEAD-INJURIES; FOOTBALL; ACCELERATION; CONCUSSION; IMPACTS	Objective To evaluate several biomechanical factors of the head during a sparring session and their link to cognitive function. Design Instrumented Boxing Headgear (IBH) was used for data collection during four 2 min sparring sessions. Neurocognitive assessment was measured using the ImPACT (c) Concussion management software. A baseline neurocognitive test was obtained from each athlete prior to sparring; two additional tests were obtained and compared with the baseline. Setting Male and female amateur boxers. Participants Data were collected from 30 male and 30 female amateur boxers. Main outcome measurements Head accelerations (translational and rotational), injury severity indexes (Head Injury Criteria (HIC) and Gadd Severity Index (051)) and cognitive function scores. Results Peak translational and rotational acceleration values were 191 g and 17 156 rad/s(2), respectively, for males and 184 g and 13 113 rad/s(2), respectively, for females. The peak HIC and GSI values for males were 1652 and 2292, respectively, and for females 1079 and 1487, respectively. There was no significant difference in the neurocognitive scores between genders. A decrease was exhibited in the delayed memory postbout scores. All other scores either increased or did not significantly decrease when compared with the baseline. Conclusions The majority of impacts experienced by both genders were under the threshold for mild head injury. There was a statistically significant difference between peak translational and rotational acceleration, HIC and GSI when comparing genders. When analysing cognitive functions, there was no statistical difference between genders.	[Stojsih, S.; Wilhelm, M.; Bir, C.] Wayne State Univ, Detroit, MI 48201 USA; [Boitano, M.] McMaster Univ, Hamilton, ON, Canada		Bir, C (corresponding author), Wayne State Univ, 818 W Hancock, Detroit, MI 48201 USA.	cbir@wayne.edu		Bir, Cynthia/0000-0002-0777-0951	National Operating Committee on Standards for Athletic Equipment	The National Operating Committee on Standards for Athletic Equipment provided funding for this research project. Impact Boxing Headgear was developed for this study by Simbex, and the IBH data were postprocessed by J Beckwith of Simbex. K Paden assisted in the postprocessing of the neurocognitive data. Boxers from USA boxing, U of M, the Armed Forces, Ramos Boxing Gym, Zarzamora Street Gym, Windsor Boxing Club and Border City Boxing Gym volunteered their time to participate in the study. E Hanlon, C Schreiner, R Bolander and 0 Pinto Neto assisted in data collection for the study. Statistical analysis was completed by B Ozkan, from Wayne State University.; Funding The National Operating Committee on Standards for Athletic Equipment provided funding for this research project.	ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Backaitis S.H., 1981, HEAD NECK INJURY CRI, P175; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Cross KM, 2003, CLIN SPORT MED, V22, P639, DOI 10.1016/S0278-5919(02)00099-6; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; EPPINGER RH, 1981, HEAD NECK INJURY CRI, P204; HEILBRONNER RL, 1991, AM J SPORT MED, V19, P376, DOI 10.1177/036354659101900409; Holbourn AHS, 1943, LANCET, V2, P438; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; MCELHANEY JH, 1976, HDB HUMAN TOLERANCE, P288; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Smith MS, 2000, J SPORT SCI, V18, P445, DOI 10.1080/02640410050074377; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Zazryn T, 2006, BRIT J SPORT MED, V40, P670, DOI 10.1136/bjsm.2006.025924; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	25	37	37	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2010	44	10					725	730		10.1136/bjsm.2008.052845			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	635MC	WOS:000280658800010	19019907				2022-02-06	
J	Walker, RL; Clark, ME; Sanders, SH				Walker, Robyn L.; Clark, Michael E.; Sanders, Steven H.			The "Postdeployment Multi-Symptom Disorder": An Emerging Syndrome in Need of a New Treatment Paradigm	PSYCHOLOGICAL SERVICES			English	Article						chronic pain; postconcussive syndrome; posttraumatic stress disorder; treatment	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; OPERATIONS ENDURING FREEDOM; CHRONIC PAIN; VETERANS; WAR; POLYTRAUMA; SOLDIERS; BLAST; CARE	Many veterans of Operation Enduring Freedom and Operation Iraqi Freedom have incurred blast related injuries during deployment. One of the most common blast related injuries is mild traumatic brain injury, with the long-term consequences known as postconcussive Syndrome (PCS). Because of frequent combat related injuries and lengthy deployments, many OEF/OIF returnees also report ongoing pain problems and symptoms of posttraumatic stress disorder (PTSD). A substantial percentage of these returning service members present to Department of Veterans Affairs facilities with multiple comorbid symptoms of PCS, pain, and PTSD, which we have termed "Post-deployment Multi-Symptom Disorder." Despite the recent clinical literature suggesting that this clinical triad of symptoms appears to be a common phenomenon that may be resistant to current treatments, there has been no guidance toward how to best manage these problems. This article introduces the conceptualization of this new "disorder" comprised of the clinical triad of PCS, pain, and PTSD symptoms, and proposes an integrated treatment model based on the current empirically supported treatments for each of these conditions.	[Walker, Robyn L.; Clark, Michael E.; Sanders, Steven H.] James A Haley Vet Affairs Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL USA; [Clark, Michael E.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA		Walker, RL (corresponding author), Chron Pain Rehabil Program 2CW, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Robyn.Walker2@va.gov					American Psychiatric Association, 2004, PRACT GUID TREATM PA; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; [Anonymous], 2009, VA DOD CLIN PRACT GU; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Baker DG, 1997, ARCH INTERN MED, V157, P2076, DOI 10.1001/archinte.157.18.2076; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Benedek DM, 2009, GUIDELINE WATCH PRAC; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Clark ME, 2004, PAIN MED, V5, P333, DOI 10.1111/j.1526-4637.2004.04059.x; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; Commission on Accreditation of Rehabilitation Facilities. (CARF), 2009, MED REH STAND MAN; Foa E.B., 2008, EFFECTIVE TREATMENTS; Gallagher R, 2006, J AM MED DIR ASSOC, V7, P432, DOI 10.1016/j.jamda.2006.04.010; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; HICKLING EJ, 1992, J ANXIETY DISORD, V6, P285, DOI 10.1016/0887-6185(92)90040-E; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Institute of Medicine, 2007, TREATM PTSD ASS EV; Kalra R, 2008, FED PRACT, V25, P36; Kang HK, 2005, NEW ENGL J MED, V352, P1289, DOI 10.1056/NEJMp058024; Keane TM., 2002, ANXIETY ITS DISORDER, V2, P418; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Marlatt GA, 1996, ADDICT BEHAV, V21, P779, DOI 10.1016/0306-4603(96)00042-1; McLean SA, 2005, PSYCHOSOM MED, V67, P783, DOI 10.1097/01.psy.0000181276.49204.bb; Merskey H., 1994, IASP TASK FORCE TAXO, P209; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MUSE M, 1986, PAIN, V25, P389, DOI 10.1016/0304-3959(86)90243-5; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Otis J. D., 2008, S COND VISN 21 POST; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Otis JD, 2009, PAIN MED, V10, P1300, DOI 10.1111/j.1526-4637.2009.00715.x; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sanders Steven H, 2005, Pain Pract, V5, P303, DOI 10.1111/j.1533-2500.2005.00033.x; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Turk D. C., INTERDISCIP IN PRESS; Veterans Health Administration, 2003, NAT PAIN MAN STRAT; Veterans Health Administration, 2006, VHA HDB 2A, P1; Veterans Health Administration Department of Defense, 2007, VA DOD CLIN PRACT GU; Veterans Health Administration Department of Defense, 2003, VA DOD CLIN PRACT GU; Veterans Health Administration Department of Defense, 2004, VA DOD CLIN PRACT GU; Warden DL, 2005, J NEUROTRAUM, V22, P1178; World Health Organization, 1994, WHO AN PAIN MAN LADD	62	37	37	0	5	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1541-1559	1939-148X		PSYCHOL SERV	Psychol. Serv.	AUG	2010	7	3					136	147		10.1037/a0019684			12	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	789QG	WOS:000292529800005					2022-02-06	
J	Goldshmit, Y; Bourne, JA				Goldshmit, Yona; Bourne, James A.			Upregulation of EphA4 on Astrocytes Potentially Mediates Astrocytic Gliosis after Cortical Lesion in the Marmoset Monkey	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; brain injury; EphA4; glial fibrillary acidic protein	CENTRAL-NERVOUS-SYSTEM; RECEPTOR TYROSINE KINASES; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; GENE-EXPRESSION; VISUAL-CORTEX; NITRIC-OXIDE; HUMAN BRAIN; GROWTH; REGENERATION	Glial scar formation occurs in response to brain injury in mammalian models and inhibits axonal growth. Identification of molecules that may mediate reactivity of astrocytes has become a leading therapeutic goal in the field of neurotrauma. In adult rodent brain and spinal cord, many of the Eph receptors and their ephrin ligands have been demonstrated to be upregulated on reactive astrocytes at the injury site; however, little is known about the expression of these molecules in nonhuman primate injury models. This study examines the role of the tyrosine kinase EphA4 receptor, which predominantly binds most ephrin ligands, after injury in marmoset monkey brain. Following lesioning of the primary visual cortex (V1) in the adult marmoset, EphA4 is strongly upregulated on reactive astrocytes around the lesion site, which secrete extracellular matrix molecules such as chondroitin sulfate proteoglycans, which are known for their inhibitory effect on axonal growth and regeneration. This astrocyte reactivity was also associated with neuronal death in the area adjacent to the lesion site. EphA4 activation induced by clustered ephrin A5-Fc-mediated astrocyte proliferation and glial fibrillary acidic protein expression in vitro, as demonstrated by closure of scratched wound and MTT assays, occurs via two potential signaling pathways, the mitogen-activated protein kinase and Rho pathways. These results in a nonhuman primate model highlight the importance of developing pharmacotherapeutic approaches to block these molecules following brain injury.	[Goldshmit, Yona; Bourne, James A.] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic 3800, Australia		Goldshmit, Y (corresponding author), Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic 3800, Australia.	yona.goldshmit@med.monash.edu.au	Bourne, James/B-5265-2018	Bourne, James/0000-0002-0902-3108	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [491022, 433620]; Australian Regenerative Medicine Institute	The authors thank Prof. Marcello Rosa (Monash University) for providing brain tissue, which was collected as part of experiments funded by National Health and Medical Research Council (NHMRC) Project Grant 491022. Also, the authors would like to thank Dr. Samuel McLenachan for revision of earlier versions of this manuscript. This work was supported by the Australian Regenerative Medicine Institute; an NHMRC Project Grant 433620 (J.A.B.); a VNI Fellowship to Y.G.; and an R.D. Wright Fellowship (NHMRC) to J.A.B.	Bourne JA, 2006, CEREB CORTEX, V16, P405, DOI 10.1093/cercor/bhi119; Bowden TA, 2009, STRUCTURE, V17, P1386, DOI 10.1016/j.str.2009.07.018; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bundesen LQ, 2003, J NEUROSCI, V23, P7789; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Donoghue MJ, 1999, J NEUROSCI, V19, P5967, DOI 10.1523/JNEUROSCI.19-14-05967.1999; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Fukai J, 2008, MOL CANCER THER, V7, P2768, DOI 10.1158/1535-7163.MCT-07-2263; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Goldshmit Y, 2006, J COMP NEUROL, V497, P864, DOI 10.1002/cne.21029; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Herrmann JE, 2010, EXP NEUROL, V223, P582, DOI 10.1016/j.expneurol.2010.02.005; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; Kullander K, 2001, GENE DEV, V15, P877, DOI 10.1101/gad.868901; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Liebl DJ, 2003, J NEUROSCI RES, V71, P7, DOI 10.1002/jnr.10457; Lim JH, 2007, BRAIN RES, V1164, P1, DOI 10.1016/j.brainres.2007.06.020; Lin R, 2008, J NEUROCHEM, V104, P400, DOI 10.1111/j.1471-4159.2007.05066.x; Lyckman AW, 2001, J NEUROSCI, V21, P7684, DOI 10.1523/JNEUROSCI.21-19-07684.2001; Martone ME, 1997, BRAIN RES, V771, P238, DOI 10.1016/S0006-8993(97)00792-0; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Miranda JD, 1999, EXP NEUROL, V156, P218, DOI 10.1006/exnr.1998.7012; Moreno-Flores MT, 1999, NEUROSCIENCE, V91, P193, DOI 10.1016/S0306-4522(98)00568-5; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Puschmann TB, 2010, J NEUROCHEM, V113, P881, DOI 10.1111/j.1471-4159.2010.06655.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Salgado D, 2008, BIOINFORMATICS, V24, P447, DOI 10.1093/bioinformatics/btm599; Sestan N, 2001, CURR BIOL, V11, P39, DOI 10.1016/S0960-9822(00)00043-9; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; Sobel RA, 2005, BRAIN PATHOL, V15, P35; Symonds ACE, 2007, EUR J NEUROSCI, V25, P744, DOI 10.1111/j.1460-9568.2007.05321.x; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang M, 2005, J NEUROCHEM, V95, P630, DOI 10.1111/j.1471-4159.2005.03408.x; Wang Y, 2003, MOL BRAIN RES, V120, P79, DOI 10.1016/j.molbrainres.2003.10.005; Willson CA, 2002, CELL TRANSPLANT, V11, P229; Xiao DQ, 2006, BRAIN RES, V1067, P67, DOI 10.1016/j.brainres.2005.10.073; Zhao ML, 1998, BRAIN RES, V813, P402, DOI 10.1016/S0006-8993(98)01023-3	47	37	39	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1321	1332		10.1089/neu.2010.1294			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100016	20486805				2022-02-06	
J	Malec, JF; Brown, AW; Moessner, AM; Stump, TE; Monahan, P				Malec, James F.; Brown, Allen W.; Moessner, Anne M.; Stump, Timothy E.; Monahan, Patrick			A Preliminary Model for Posttraumatic Brain Injury Depression	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Rehabilitation	IMPAIRED SELF-AWARENESS; CLOSED-HEAD-INJURY; MOOD DISORDERS; INDIVIDUALS; INVENTORY; SEQUELAE; PERSONALITY; SEVERITY; SCALE	Malec JF, Brown AW, Moessner AM, Stump TE, Monahan P. A preliminary model for posttraumatic brain injury depression. Arch Phys Med Rehabil 2010;91:1087-97. Objective: To develop, based on previous research, and evaluate a model for depression after traumatic brain injury (TBI). Design: Cross-sectional structural equation modeling (SEM) of data from consecutively recruited patients. Setting: Acute hospital and inpatient rehabilitation units. Participants: Adult patients (N=158) after hospital admission for moderate to severe TBI. Interventions: Not applicable. Main Outcome Measures: External appraisal of ability in participants was measured by the Mayo-Portland Adaptability Inventory (MPAI-4) Ability Index completed by a TBI clinical nurse specialist. Patient self-appraisal of post-TBI ability and depression were measured by the Awareness Questionnaire and Beck Depression Inventory-II. Functional outcome 1 year after injury was assessed with the MPAI-4 Participation Index. Results: Successive SEM resulted in a parsimonious model with excellent fit. Consistent with prior research, a moderately strong association between self-appraisal of post-TBI ability and depression was found. Injury severity, as measured by the duration of posttraumatic amnesia (PTA), was not significantly associated with post-TBI depression. The 1-year functional outcome was associated with depression and TBI severity. Conclusions: The strong association between self-appraisal of post-TBI ability and depression is consistent with the cognitive-behavioral model of depression and recommends consideration and further study of cognitive-behavioral therapy for post-TBI depression. The lack of association between TBI severity and depression may represent the indirect and proxy nature of current measures of TBI severity such as PTA. Emerging neuroimaging techniques (eg, diffusion tensor imaging, magnetic resonance imaging spectroscopy) may provide the more direct measures of disruption of brain function after TBI that are needed to advance this line of research.	[Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN 46077 USA; [Malec, James F.] Indiana Univ, Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Stump, Timothy E.; Monahan, Patrick] Indiana Univ, Sch Med, Div Biostat, Indianapolis, IN USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Moessner, Anne M.] Mayo Clin, Dept Nursing, Rochester, MN USA		Malec, JF (corresponding author), Rehabil Hosp Indiana, 4141 Shore Dr, Indianapolis, IN 46077 USA.	jmalec@rhin.com		Brown, Allen W./0000-0001-7228-3351	National Institute for Disability and Rehabilitation Research [H133A020507]	Supported by the National Institute for Disability and Rehabilitation Research (FBI Model System grant no. H133A020507).	Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Beck A.T., 1967, DEPRESSION CAUSES TR; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malec JF., MANUAL MAYO PORTLAND; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Muthen L.K., 2012, MPLUS USERS GUIDE, V7; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PHATAK VS, 2007, 35 ANN M INT NEUR SO; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Wallace CA, 2000, BRAIN INJURY, V14, P549; [No title captured]	55	37	37	1	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2010	91	7					1087	1097		10.1016/j.apmr.2010.04.002			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	625PM	WOS:000279907400013	20599048				2022-02-06	
J	Reid, WM; Rolfe, A; Register, D; Levasseur, JE; Churn, SB; Sun, D				Reid, Wendy Murdock; Rolfe, Andrew; Register, David; Levasseur, Joseph E.; Churn, Severn B.; Sun, Dong			Strain-Related Differences after Experimental Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						epilepsy; Fischer 344 rat; fluid percussion injury; Sprague-Dawley rat; strain	KINASE-II ACTIVITY; SPRAGUE-DAWLEY RATS; STATUS EPILEPTICUS; FLUID PERCUSSION; PILOCARPINE MODEL; FLUORO-JADE; SPINAL-CORD; SEIZURES; RECOVERY; VULNERABILITY	The present study directly compares the effects of experimental brain injury in two commonly used rat strains: Fisher 344 and Sprague-Dawley. We previously found that Fisher rats have a higher mortality rate and more frequent seizure attacks at the same injury level than Sprague-Dawley rats. Although strain differences in rats are commonly accepted as contributing to variability among studies, there is a paucity of literature addressing strain influence in experimental neurotrauma. Therefore this study compares outcome measures in two rat strains following lateral fluid percussion injury. Fisher 344 and Sprague-Dawley rats were monitored for changes in physiological measurements, intracranial pressure, and electroencephalographic activity. We further analyzed neuronal degeneration and cell death in the injured brain using Fluoro-Jade-B (FJB) histochemistry and caspase-3 immunostaining. Behavioral studies using the beam walk and Morris water maze were conducted to characterize strain differences in both motor and cognitive functional recovery following injury. We found that Fisher rats had significantly higher intracranial pressure, prolonged seizure activity, increased FJB-positive staining in the injured cortex and thalamus, and increased caspase-3 expression than Sprague-Dawley rats. On average, Fisher rats displayed a greater amount of total recording time in seizure activity and had longer ictal durations. The Fisher rats also had increased motor deficits, correlating with the above results. In spite of these results, Fisher rats performed better on cognitive tests following injury. The results demonstrate that different rat strains respond to injury differently, and thus in preclinical neurotrauma studies strain influence is an important consideration when evaluating outcomes.	[Reid, Wendy Murdock; Rolfe, Andrew; Levasseur, Joseph E.; Sun, Dong] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Register, David; Churn, Severn B.] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA		Reid, WM (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980631,Med Coll Virginia Campus, Richmond, VA 23298 USA.	murdockwm@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055086]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055086] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health grant no. NS055086 (to D.S.).	Alahmed S, 2008, NEUROSCIENCE, V157, P677, DOI 10.1016/j.neuroscience.2008.08.072; Anderson KJ, 2003, J NEUROTRAUM, V20, P1223, DOI 10.1089/089771503770802899; Churn SB, 2000, BRAIN RES, V875, P66, DOI 10.1016/S0006-8993(00)02623-8; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Clausen F, 2005, ACTA NEUROCHIR, V147, P775, DOI 10.1007/s00701-005-0550-2; DeLorenzo Robert J, 2006, Adv Neurol, V97, P187; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Feeney D M, 1987, Brain Inj, V1, P27, DOI 10.3109/02699058709034441; Fujikawa TG, 2000, EPILEPSIA, V41, P981, DOI 10.1111/j.1528-1157.2000.tb00283.x; GOLDEN GT, 1995, EPILEPSY RES, V20, P151, DOI 10.1016/0920-1211(94)00079-C; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; Hort J, 2000, BEHAV BRAIN RES, V112, P77, DOI 10.1016/S0166-4328(00)00163-7; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; IWASAKI H, 1995, INT J EXP PATHOL, V76, P171; Jiao XL, 2003, PROG NEURO-PSYCHOPH, V27, P913, DOI 10.1016/S0278-5846(03)00150-7; Kearns DN, 2006, BEHAV BRAIN RES, V169, P193, DOI 10.1016/j.bbr.2006.01.005; Kochan LD, 2000, NEUROSCIENCE, V95, P735; Kurz JE, 2005, BRAIN RES, V1048, P153, DOI 10.1016/j.brainres.2005.04.062; Lei YL, 2009, LIFE SCI, V85, P794, DOI 10.1016/j.lfs.2009.10.010; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Mazarati A, 2002, EPILEPSIA, V43, P74, DOI 10.1046/j.1528-1157.43.s.5.25.x; Paulson PE, 2005, EXP NEUROL, V196, P413, DOI 10.1016/j.expneurol.2005.08.015; SCHALLERT T, 1986, BRAIN RES, V379, P104, DOI 10.1016/0006-8993(86)90261-1; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Singleton MW, 2005, EPILEPSIA, V46, P1389, DOI 10.1111/j.1528-1167.2005.19205.x; Singleton MW, 2005, DEV BRAIN RES, V156, P67, DOI 10.1016/j.devbrainres.2005.02.001; Statler KD, 2008, EPILEPSY RES, V78, P232, DOI 10.1016/j.eplepsyres.2007.11.001; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Uchida S, 2008, EUR J NEUROSCI, V27, P2250, DOI 10.1111/j.1460-9568.2008.06218.x; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Walberer M, 2006, LAB ANIM-UK, V40, P1, DOI 10.1258/002367706775404426; Wasterlain CG, 2002, PROG BRAIN RES, V135, P335; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; Xu B, 2004, EUR J NEUROSCI, V20, P403, DOI 10.1111/j.1460-9568.2004.03489.x	37	37	37	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1243	1253		10.1089/neu.2010.1270			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100009	20392137	Green Published			2022-02-06	
J	Rousseaux, M; Verigneaux, C; Kozlowski, O				Rousseaux, M.; Verigneaux, C.; Kozlowski, O.			An analysis of communication in conversation after severe traumatic brain injury	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						behaviour; non-verbal communication; traumatic brain injury; verbal communication	CLOSED-HEAD-INJURY; PRAGMATIC LANGUAGE-SKILLS; SOCIAL COMMUNICATION; PERCEPTION DEFICITS; EMOTION PERCEPTION; DYSARTHRIA; NEUROPRAGMATICS; RECOGNITION; LISTENER; ABILITY	Background and objective: Communication disorders have been reported following severe traumatic brain injury. However, we have little information about patient behaviour during dyadic interaction. Here, we analyzed conversation at the rehabilitation and chronic phase post traumatic brain injury (TBI), to define the main mechanisms of verbal and non-verbal communication disorders and relationship with other cognitive difficulties. Methods: Sixteen patients were evaluated at the rehabilitation phase (2-12 months) and 18 at the chronic phase (after 2 years) following severe TBI. They were compared with equivalent groups of matching (gender, age, education level) control subjects. We used the Lille Communication Test, which comprises three parts: participation to communication (greeting, attention, engagement), verbal communication (verbal comprehension, speech outflow, intelligibility, word production, syntax, verbal pragmatics, verbal feedback) and non-verbal communication (understanding gestures, affective expressivity, producing gestures, pragmatics, non-verbal feedback). We also investigated executive functions (Stroop test, trail-making test, categorical evocation), language (Montreal-Toulouse protocol) and behaviour (Neurobehavioural Rating Scale). Verbal communication disorders were relatively equivalent at the rehabilitation and chronic phases. Results: Patients were impaired (P < 0.01) in their participation to communication, especially in greeting behaviour. Verbal communication was mostly affected by difficulties in producing fluent and intelligible language and using pragmatics (responding to open questions, presenting new information and introducing new themes, organizing discourse and adapting to interlocutor knowledge). Non-verbal communication was impaired by difficulties in using pragmatics (mostly adapted prosody). Participation and verbal communication correlated with the executive functions, language and behavioural assessment. Conclusions: Disorders of social communication justify systematic assessment in patients with TBI.	[Rousseaux, M.; Verigneaux, C.; Kozlowski, O.] CHRU, Hop Swynghedauw, Serv Reeduc Neurol, F-59037 Lille, France; [Rousseaux, M.; Verigneaux, C.] Univ Lille 2, Inst Orthophonie, Lille, France		Rousseaux, M (corresponding author), CHRU, Hop Swynghedauw, Serv Reeduc Neurol, F-59037 Lille, France.	marc.rousseaux@chru-lille.fr			AllerganAbbVieAllergan; IPSENIpsen; MERZ	Dr Marc Rousseaux received honoraria for lecturing and serving in the scientific advisory board from Allergan, IPSEN and MERZ.	Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Aubert S., 2004, Annales de Readaptation et de Medecine Physique, V47, P135, DOI 10.1016/j.annrmp.2004.02.001; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Borgaro SR, 2004, BRAIN INJURY, V18, P33, DOI 10.1080/0269905031000110562; Bornhofen C, 2008, J INT NEUROPSYCH SOC, V14, P511, DOI 10.1017/S1355617708080703; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Cools C, 1998, INT J REHABIL RES, V21, P323, DOI 10.1097/00004356-199809000-00007; D'Innocenzo J, 2006, CLIN LINGUIST PHONET, V20, P659, DOI 10.1080/02699200500224272; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Davis G.A., 1981, LANGUAGE INTERVENTIO, P169; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Drummond SS, 2004, BRAIN INJURY, V18, P41, DOI 10.1080/0269905031000149461; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Friedland D, 1998, BRAIN INJURY, V12, P1, DOI 10.1080/026990598122818; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Guo YE, 2008, BRAIN INJURY, V22, P83, DOI 10.1080/02699050701824150; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P369, DOI 10.1080/026990598122502; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Lefeuvre M, 2001, TLC TEST LILLOIS COM; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; MCDONALD S, 1995, BRAIN INJURY, V9, P255, DOI 10.3109/02699059509008197; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Nespoulous J.-L., 1992, PROTOCOLE MONTREAL T; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; Wenke RJ, 2008, BRAIN INJURY, V22, P339, DOI 10.1080/02699050801960987	32	37	38	0	20	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1351-5101			EUR J NEUROL	Eur. J. Neurol.	JUL	2010	17	7					922	929		10.1111/j.1468-1331.2009.02945.x			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	613YQ	WOS:000279021700007	20100227				2022-02-06	
J	Arnold, JD; Dart, BW; Barker, DE; Maxwell, RA; Burkholder, HC; Mejia, VA; Smith, PW; Longley, JM				Arnold, Joshua D.; Dart, Benjamin W.; Barker, Donald E.; Maxwell, Robert A.; Burkholder, Hans C.; Mejia, Vicente A.; Smith, Philip W.; Longley, Joy M.			Unfractionated Heparin Three Times a Day versus Enoxaparin in the Prevention of Deep Vein Thrombosis in Trauma Patients	AMERICAN SURGEON			English	Article; Proceedings Paper	Southeastern Surgical Congress 2010	FEB 20-23, 2010	Savannah, GA				MOLECULAR-WEIGHT HEPARIN; FATAL PULMONARY-EMBOLISM; LOW-DOSE HEPARIN; VENOUS THROMBOEMBOLISM; POSTTHROMBOTIC SYNDROME; MULTICENTER TRIAL; SURGICAL-PATIENTS; RISK; ANTICOAGULANT; MANAGEMENT	Venous thromboembolic disease is a significant source of morbidity and mortality in hospitalized trauma patients. Multiple drugs and dosing regimens have been suggested for pharmacoprophylaxis. In this study, we compared efficacy, complications, and cost of unfractionated heparin administered subcutaneously three times a day with standard-dosed enoxaparin for prophylaxis of deep venous thrombosis (DVT) in adult trauma patients over 1 year. Patients admitted for greater than 72 hours who received pharmacoprophylaxis as part of a comprehensive DVT protocol were included. A change was made in the protocol from enoxaparin (30 mg twice a day or 40 mg per day) to heparin (5000 U three times a day) at midyear. Surveillance lower extremity venous ultrasound was performed according to established institutional guidelines. Data, including demographics, associated injuries, complications, and cost, were collected and analyzed. Four hundred seventy-six patients met inclusion criteria. Two hundred thirty-seven (49.8%) patients received enoxaparin and 239 (50.2%) received heparin. Proximal lower extremity DVTs were detected in 16 (6.75%) patients in the enoxaparin group and 17 (7.11%) in the heparin group (P = 0.999). Risk factors for DVT in these patients included spinal cord injury (P = 0.001) and closed head injury (P = 0.031). There was no difference between the incidence of pulmonary emboli and bleeding. There was an estimated yearly pharmacy cost savings of $135,606. In trauma patients, subcutaneous heparin dosed three times a day may be as effective as standard-dosed enoxaparin for prophylaxis of venous thromboembolism without increased complications. Heparin three times a day for venous thromboembolism prophylaxis was associated with significant pharmaceutical cost savings.	[Arnold, Joshua D.; Dart, Benjamin W.; Barker, Donald E.; Maxwell, Robert A.; Burkholder, Hans C.; Mejia, Vicente A.; Smith, Philip W.; Longley, Joy M.] Univ Tennessee, Coll Med, Dept Surg, Chattanooga, TN USA		Arnold, JD (corresponding author), 979 E 3rd St,Suite B401, Chattanooga, TN 37403 USA.	arnoljd5@hotmail.com					Anderson Jr FA, 2005, BLOOD, V106, P910, DOI 10.1182/blood.V106.11.910.910; ANDERSSON LO, 1976, THROMB RES, V9, P575, DOI 10.1016/0049-3848(76)90105-5; Bara L, 1988, Acta Chir Scand Suppl, V543, P65; BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; BJORNSSON TD, 1982, CLIN PHARMACOL THER, V31, P104, DOI 10.1038/clpt.1982.16; BRADBROOK ID, 1987, BRIT J CLIN PHARMACO, V23, P667, DOI 10.1111/j.1365-2125.1987.tb03100.x; CLAGETT GP, 1988, ANN SURG, V208, P227, DOI 10.1097/00000658-198808000-00016; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Cushman M, 2004, AM J MED, V117, P19, DOI 10.1016/j.amjmed.2004.01.018; DEITELZWEIG S, 2009, J THROMB THROMB 1001; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Haas S, 2005, THROMB HAEMOSTASIS, V94, P814, DOI 10.1160/TH02-10-0189; Hansson PO, 2000, ARCH INTERN MED, V160, P769, DOI 10.1001/archinte.160.6.769; Harenberg J, 1996, HAEMOSTASIS, V26, P127; HARENBERG J, 1990, SEMIN THROMB HEMOST, V16, P12; Heit JA, 2000, ARCH INTERN MED, V160, P761, DOI 10.1001/archinte.160.6.761; HIRSH J, 1976, CIRCULATION, V53, P691, DOI 10.1161/01.CIR.53.4.691; Hirsh J, 2008, CHEST, V133, p141S, DOI 10.1378/chest.08-0689; Johanson NA, 2009, J BONE JOINT SURG AM, V91A, P1756, DOI 10.2106/JBJS.I.00511; JOHNSON EA, 1976, CARBOHYD RES, V51, P119, DOI 10.1016/S0008-6215(00)84041-0; *JOINT COMM CTR ME, SPEC MAN NAT HOSP IM; Kahn SR, 2002, BLOOD REV, V16, P155, DOI 10.1016/S0268-960X(02)00008-5; Kleber FX, 2003, AM HEART J, V145, P614, DOI 10.1067/mhj.2003.189; Lechler E, 1996, HAEMOSTASIS, V26, P49; MacDougall DA, 2006, AM J HEALTH-SYST PH, V63, pS5, DOI 10.2146/ajhp060388; Merli G, 2003, J TRAUMA, V54, P1116, DOI 10.1097/01.TA.0000066385.10596.71; OLSSON P, 1963, ACTA MED SCAND, V173, P619; Passman MA, 2010, AM J SURG, V199, pS21, DOI 10.1016/j.amjsurg.2009.10.005; Prandoni P, 2009, BRIT J HAEMATOL, V145, P286, DOI 10.1111/j.1365-2141.2009.07601.x; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Spinal Cord Injury Thromboprophylaxis Investigators, 2003, J TRAUMA, V54, P1125; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Velmahos GC, 2006, AM SURGEON, V72, P757; Wakefield TW, 2008, CURR PROB SURG, V45, P844, DOI 10.1067/j.cpsurg.2008.08.002; WOLF H, 1991, SEMIN THROMB HEMOST, V17, P343, DOI 10.1055/s-2007-1002632	38	37	40	0	8	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JUN	2010	76	6					563	570					8	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	602YG	WOS:000278174400002	20583509				2022-02-06	
J	Colantonio, A; Mar, W; Escobar, M; Yoshida, K; Velikonja, D; Rizoli, S; Cusimano, M; Cullen, N				Colantonio, Angela; Mar, Wanna; Escobar, Michael; Yoshida, Karen; Velikonja, Diana; Rizoli, Sandro; Cusimano, Michael; Cullen, Nora			Women's Health Outcomes After Traumatic Brain Injury	JOURNAL OF WOMENS HEALTH			English	Article							LONG-TERM; HYPOPITUITARISM; VALIDITY; RISK	Background: Traumatic brain injury (TBI) is a major public health problem, yet little is known about how this injury may affect long-term outcomes unique to women. This research examined the health outcomes relevant to premenopausal women 5-12 years after injury. Methods: This was a retrospective cohort study at eight participating acute care= rehabilitation facilities. Participants were consecutive eligible women with moderate to severe TBI. A follow-up interview assessed menstrual functioning, fertility, and pregnancy experiences before and after injury as well as cervical cancer screening. Demographic variables, self-rated general and mental health, and functional limitations were also collected. Injury-related information was abstracted from health records. Female control participants recruited were matched on age, education, and geographic location. Results: Of the 104 women with TBI (W-TBI), 46% experienced amenorrhea with duration of up to 60 months. Cycles became irregular for 68% of W-TBI after the injury. These findings were significantly different from those of controls. Among W-TBI, menstrual disturbances were associated with injury severity. No differences were shown between W-TBI and controls with respect to fertility, although significantly fewer W-TBI had one or more live births, and they reported more difficulties in the postpartum period than controls. W-TBI were less likely to have regular Pap smears and reported lower mental health, self-rated health, and function. Conclusions: These findings inform prognosis after TBI for women and provide evidence for long-term monitoring of health outcomes and increased support after childbirth. More research is needed in this area, particularly with respect to the neuroendocrine system.	[Colantonio, Angela] Univ Toronto, Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; [Velikonja, Diana] McMaster Univ, Hamilton, ON, Canada; [Rizoli, Sandro] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Cusimano, Michael] St Michaels Hosp, Toronto, ON M5B 1W8, Canada		Colantonio, A (corresponding author), Univ Toronto, Toronto Rehabil Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Cusimano, Michael/X-4059-2019	Cullen, Nora/0000-0001-6359-9418; Escobar, Michael/0000-0001-9055-4709; Cusimano, Michael/0000-0002-9989-0650; Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR) [200903MOP]; The Toronto Rehabilitation Institute; Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario	We thank our collaborators and the administrative staff who provided support at the participating sites. We also thank the Institute for Social Research at York University for their assistance with recruiting controls, the interviewers for their assistance with data collection, and Junlang Yin for performing the statistical analyses. The study received ethics approval from the University of Toronto and from the research ethics boards of the eight participating centers: Toronto Rehabilitation Institute, Sunnybrook Health Sciences Centre, St. Michael's Hospital, Bridgepoint Health, Hamilton General Hospital, Chedoke Hospital, Thunder Bay Regional Health Sciences Centre, Brain Injury Services of Northern Ontario. We also sincerely thank the participants in this research study and Alice Bellavance. Funding for the study was obtained from the Canadian Institutes for Health Research grant 200903MOP, The Toronto Rehabilitation Institute, and a grant from the Ministry of Health and Long Term Care to the Toronto Rehabilitation Institute. This report was presented at the American Congress of Rehabilitation Medicine Annual Meeting, October 2009, where it received a best paper award (first place).	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Altman BM., 2008, DISABILITY HLTH US 2; [Anonymous], 2007, NEUR DIS PUBL HLTH C; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; *CAN I HLTH INF, 2006, BRAIN INJ CAN DEC CH; *CAN PAR ASS, 2008, SCI FACTS; Canadian Institute for Health Information, 2007, BURD NEUR DIS DIS IN; Caplan LS, 2003, CANCER EPIDEM BIOMAR, V12, P1182; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; FILLENBAUM G, 1975, MULTIDIMENSIONAL FUN; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; GROSSMAN WF, 1994, J REPROD MED, V39, P738; Jackson AB, 1999, ARCH PHYS MED REHAB, V80, P1420, DOI 10.1016/S0003-9993(99)90253-8; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Mild Traumatic Brain Injury Committee of the Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHABI, V8, P86; Mukherjee D, 2003, WOMEN THER, V26, P3, DOI 10.1300/J015v26n01_01; *NAT I CAN CAN CAN, 2008, CAN CANC STAT 2008; Public Health Agency of Canada, 2007, HIV AIDS EP UPD NOV; RIDDELL L, 2003, WERE WOMEN TOO IDENT; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; SANDER AM, 2006, BRAIN INJURY MED, P1117; SIPKSI ML, 1991, J AM PARAPLEGIC SOC, V14, P122; Sipski M L, 2001, Phys Med Rehabil Clin N Am, V12, P79; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Solomon CG, 2002, J CLIN ENDOCR METAB, V87, P2013, DOI 10.1210/jc.87.5.2013; *STAT CAN, 2002, JOINT CAN US SURV HL; Stein K, 1999, BRIT MED J, V318, P641, DOI 10.1136/bmj.318.7184.641; TADMAN N, 2005, WOMEN TRAUMATIC BRAI; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomeo CA, 1999, EPIDEMIOLOGY, V10, P774, DOI 10.1097/00001648-199911000-00022; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; Ware J.E., 1993, SF 36 HLTH SURVEY MA	39	37	38	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	JUN	2010	19	6					1109	1116		10.1089/jwh.2009.1740			8	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	610YB	WOS:000278775400007	20469963	Green Submitted			2022-02-06	
J	Lakshmanan, R; Loo, JA; Drake, T; Leblanc, J; Ytterberg, AJ; McArthur, DL; Etchepare, M; Vespa, PM				Lakshmanan, R.; Loo, J. A.; Drake, T.; Leblanc, J.; Ytterberg, A. J.; McArthur, D. L.; Etchepare, M.; Vespa, P. M.			Metabolic Crisis After Traumatic Brain Injury is Associated with a Novel Microdialysis Proteome	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Microdialysis; Proteomics; Metabolic crisis; Biomarkers	BIOMARKERS; PROTEINS; PRESSURE; DAMAGE; SERUM; TAU	To examine if the metabolic distress after traumatic brain injury (TBI) is associated with a unique proteome. Patients with severe TBI prospectively underwent cerebral microdialysis for the initial 96 h after injury. Hourly sampling of metabolism was performed and patients were categorized as having normal or abnormal metabolism as evidenced by the lactate/pyruvate ratio (LPR) threshold of 40. The microdialysate was frozen for proteomic batch processing retrospectively. We employed two different routes of proteomic techniques utilizing mass spectrometry (MS) and categorized as diagnostic and biomarker identification approaches. The diagnostic approach was aimed at finding a signature of MS peaks which can differentiate these two groups. We did this by enriching for intact peptides followed by MALDI-MS analysis. For the biomarker identification approach, we applied classical bottom-up (trypsin digestion followed by LC-MS/MS) proteomic methodologies. Five patients were studied, 3 of whom had abnormal metabolism and 2 who had normal metabolism. By comparison, the abnormal group had higher LPR (1609 +/- A 3691 vs. 15.5 +/- A 6.8, P < 0.001), higher glutamate (157 +/- A 84 vs. 1.8 +/- A 1.4 mu M, P < 0.001), and lower glucose (0.27 +/- A 0.35 vs. 1.8 +/- A 1.1 mmol/l, P < 0.001). The abnormal group demonstrated 13 unique proteins as compared with the normal group in the microdialysate. These proteins consisted of cytoarchitectural proteins, as well as blood breakdown proteins, and a few mitochondrial proteins. A unique as yet to be characterized peptide was found at m/z (mass/charge) 4733.5, which may represent a novel biomarker of metabolic distress. Metabolic distress after TBI is associated with a differential proteome that indicates cellular destruction during the acute phase of illness. This suggests that metabolic distress has immediate cellular consequences after TBI.	[McArthur, D. L.; Etchepare, M.; Vespa, P. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg & Neurol, Ronald Reagan UCLA Med Ctr, Los Angeles, CA 90095 USA; [Drake, T.; Leblanc, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Lakshmanan, R.; Loo, J. A.; Ytterberg, A. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Chem & Biochem, Los Angeles, CA 90095 USA		Vespa, PM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg & Neurol, Ronald Reagan UCLA Med Ctr, 757 Westwood Blvd,RR 6236A, Los Angeles, CA 90095 USA.	PVespa@mednet.ucla.edu	Ytterberg, Anders/E-1773-2016; McArthur, David/E-6442-2013	Ytterberg, Anders/0000-0002-1485-2314; McArthur, David/0000-0003-3385-1314	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS058489] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER		Afinowi R, 2009, J NEUROSCI METH, V181, P95, DOI 10.1016/j.jneumeth.2009.02.021; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.3.CO;2-W; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Larsen MR, 2001, PROTEOMICS, V1, P223; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Maurer Martin H, 2003, Proteome Sci, V1, P7, DOI 10.1186/1477-5956-1-7; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Yang XY, 2009, BRAIN INJURY, V23, P830, DOI 10.1080/02699050903196670; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zuberovic A, 2009, ELECTROPHORESIS, V30, P1836, DOI 10.1002/elps.200800714	22	37	38	1	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2010	12	3					324	336		10.1007/s12028-010-9342-5			13	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	590RJ	WOS:000277244700003	20225002	Green Accepted			2022-02-06	
J	Tran, ND; Kim, S; Vincent, HK; Rodriguez, A; Hinton, DR; Bullock, MR; Young, HF				Tran, Nam D.; Kim, Stefan; Vincent, Heather K.; Rodriguez, Anthony; Hinton, David R.; Bullock, M. Ross; Young, Harold F.			Aquaporin-1-mediated cerebral edema following traumatic brain injury: effects of acidosis and corticosteroid administration Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						aquaporin-1; traumatic brain injury; cerebral cortex; edema	FLUID-PERCUSSION INJURY; AQUAPORIN-4 MESSENGER-RNA; SPINAL-CORD-INJURY; WATER CHANNEL; INTRACRANIAL HYPERTENSION; NEUROBEHAVIORAL FUNCTION; PREFERENTIAL EXPRESSION; CO2 PERMEABILITY; GROWTH-FACTOR; UP-REGULATION	Object. Dysregulation of water homeostasis induces cerebral edema. Edema is a major cause of morbidity and mortality following traumatic brain injury (TBI). Aquaporin-1 (AQP-1), a water channel found in the brain, can function as a transporter for CO2 across the cellular membrane. Additionally, AQP-1's promoter contains a glucocorticoid response element. Thus, AQP-1 may be involved with edema-related brain injury and might be modulated by external conditions such as the pH and the presence of steroids. In this study, the authors investigated the hypotheses that: 1) AQP-1 participates in brain water homeostasis following TBI; 2) secondary injury (for example, acidosis) alters the expression of AQP-1 and exacerbates cerebral edema; and 3) corticosteroids augment brain AQP-1 expression and differentially affect cerebral edema under nonacidotic and acidotic conditions. Methods. Anesthetized Sprague-Dawley rats were subjected to moderate to severe TBI (2.5-3.5 atm) or surgery without injury, and they were randomized to receive a 3-mg/kg bolus of intravenous dexamethasone within 10 minutes after injury or surgery, a 3-mg/kg bolus of dexamethasone followed by 1-mg/kg maintenance doses every 8 hours for 24 hours, or saline boluses at similar time intervals. A second group of animals was subjected to respiratory acidosis with target arterial blood pH 6.8-7.2 for 1 hour following the surgery or injury. To evaluate selective blockage of AQP-1, some animals received a single intraperitoneal dose of HgCl2 (0.3-30.0 mmol/L) within 30 minutes of injury or surgery. At 4 or 24 hours postinjury, animals were killed and their brains were harvested for mRNA, protein, or water content analyses. Results. The authors demonstrated elevated cerebral edema levels at 4 and 24 hours following TBI. Dexamethasone administration within 1 hour of TBI attenuated the cerebral edema under nonacidotic conditions but worsened it under acidotic conditions. Selective blockage of AQP-1 channels with HgCl2 attenuated the edematous effects of corticosteroids and acidosis. Reverse transcriptase polymerase chain reaction and immunohistochemical analyses demonstrated a paucity of AQP-1 in the cerebral cortices of the uninjured animals. In contrast, AQP-1 mRNA and protein levels were higher in the cerebral cortices of animals that sustained a TBI. Conclusions. These findings implicate an important, modifiable role for AQP-1 in water homeostasis within the CNS following TBI. (DOI: 10.3171/2009.8.JNS081704)	[Tran, Nam D.; Young, Harold F.] Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; [Kim, Stefan] Lahey Clin Fdn, Dept Neurosurg, Burlington, MA USA; [Vincent, Heather K.] Univ Florida, Dept Orthoped & Rehabil, Gainesville, FL USA; [Rodriguez, Anthony; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; [Bullock, M. Ross] Univ Miami, Dept Neurosurg, Coral Gables, FL 33124 USA		Tran, ND (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Neurosurg, 12902 Magnolia Dr, Tampa, FL 33612 USA.	namdtran@alumni.usc.edu	Vincent, Heather/ABH-4566-2020				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Amlal H, 2004, AM J PHYSIOL-CELL PH, V286, pC1019, DOI 10.1152/ajpcell.00394.2003; Anderson RE, 2000, BRAIN RES, V856, P220, DOI 10.1016/S0006-8993(99)02435-X; Badaut J, 2003, ACTA NEUROCHIR SUPPL, V86, P495; Badaut J, 2004, NEUROSCIENCE, V128, P27, DOI 10.1016/j.neuroscience.2004.05.042; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Blank ME, 2003, J PHYSIOL-LONDON, V550, P419, DOI 10.1113/jphysiol.2003.040113; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; Fedorovich SV, 2003, NEUROCHEM RES, V28, P715, DOI 10.1023/A:1022809716834; Feldmann H, 1979, Acta Neurochir Suppl (Wien), V28, P74; Gao HW, 2006, GLIA, V53, P783, DOI 10.1002/glia.20336; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2003, ACT NEUR S, V86, P7; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MOON C, 1997, AM J PHYSIOL-CELL PH, V273, pC1562; Morishima T, 2008, NEUROSCI RES, V61, P18, DOI 10.1016/j.neures.2008.01.005; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Nesic O, 2008, J NEUROCHEM, V105, P628, DOI 10.1111/j.1471-4159.2007.05177.x; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Oshio K, 2005, NEUROSURGERY, V56, P375, DOI 10.1227/01.NEU.0000148904.57841.6B; Oshio K, 2006, BIOCHEM BIOPH RES CO, V341, P1022, DOI 10.1016/j.bbrc.2006.01.062; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Park CO, 1998, YONSEI MED J, V39, P395, DOI 10.3349/ymj.1998.39.5.395; Perez E, 2007, BRAIN RES, V1128, P164, DOI 10.1016/j.brainres.2006.09.109; Plesnila N, 1999, J NEUROTRAUM, V16, P831, DOI 10.1089/neu.1999.16.831; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Rhodes Jonathan K J, 2003, Curr Opin Crit Care, V9, P86; Ringel F, 2006, NEUROSCI LETT, V398, P306, DOI 10.1016/j.neulet.2006.01.012; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shields SD, 2007, PAIN, V131, P8, DOI 10.1016/j.pain.2006.11.018; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Solenov EI, 2002, J NEUROSCI METH, V113, P85, DOI 10.1016/S0165-0270(01)00481-2; Stoenoiu MS, 2003, J AM SOC NEPHROL, V14, P555, DOI 10.1097/01.ASN.0000053420.37216.9E; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Suzuki R, 2006, ACTA NEUROCHIR SUPPL, V96, P398; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V292, P771, DOI 10.1006/bbrc.2002.6709; Valadka AB, 2007, NEUROSURGERY, V61, P203, DOI 10.1227/01.NEU.0000255497.26440.01; Venero JL, 1999, NEUROSCIENCE, V94, P239, DOI 10.1016/S0306-4522(99)00182-7; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Vornov JJ, 1996, J NEUROCHEM, V67, P2379; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	71	37	37	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2010	112	5					1095	1104		10.3171/2009.8.JNS081704			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	591BW	WOS:000277273600028	19731985				2022-02-06	
J	Di Pietro, V; Amin, D; Pernagallo, S; Lazzarino, G; Tavazzi, B; Vagnozzi, R; Pringle, A; Belli, A				Di Pietro, Valentina; Amin, Daven; Pernagallo, Salvatore; Lazzarino, Giuseppe; Tavazzi, Barbara; Vagnozzi, Roberto; Pringle, Ashley; Belli, Antonio			Transcriptomics of Traumatic Brain Injury: Gene Expression and Molecular Pathways of Different Grades of Insult in a Rat Organotypic Hippocampal Culture Model	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; gene expression; IL-1; diffuse axonal injury; transcriptomics	TEMPORAL WINDOW; HEAD-INJURY; VULNERABILITY; INFLAMMATION; MICRODIALYSIS; INTERLEUKIN-1; CONCUSSIONS; MANAGEMENT; INHIBITORS; SEIZURE	Traumatic brain injury (TBI) is the one of the most common forms of head trauma, and it remains a leading cause of death and disability. It is known that the initial mechanical axonal injury triggers a complex cascade of neuroinflammatory and metabolic events, the understanding of which is essential for clinical, translational, and pharmacological research. These can occur even in mild TBI, and are associated with several post-concussion manifestations, including transiently heightened vulnerability to a second insult. Recent studies have challenged the tenet that ischemia is the ultimate modality of tissue damage following TBI, as metabolic dysfunction can develop in the presence of normal perfusion and before intracranial hypertension. In order to elucidate the cellular and molecular changes occurring in TBI as a direct result of neuronal injury and in the absence of ischemic damage, we performed a microarray analysis of expressed genes and molecular interaction pathways for different levels of severity of trauma using an in-vitro model. A stretch injury, equivalent to human diffuse axonal injury, was delivered to rat organotypic hippocampal slice cultures, and mRNA levels following a 10% (mild) and 50% (severe) stretch were compared with controls at 24 h. More genes were differentially expressed following 10% stretch than 50% stretch, indicating the early activation of complex cellular mechanisms. The data revealed remarkable differential gene expression following mTBI, even in the absence of cell damage. Pathway analysis revealed that molecular interactions in both levels of injury were similar, with IL-1 beta playing a central role. Additional pathways of neurodegeneration involving RhoA (ras homolog gene family, member A) were found in 50% stretch.	[Di Pietro, Valentina; Amin, Daven; Pringle, Ashley; Belli, Antonio] Univ Southampton, Sch Med, Div Clin Neurosci, Southampton SO16 6YD, Hants, England; [Pernagallo, Salvatore] Univ Edinburgh, Sch Chem, Edinburgh, Midlothian, Scotland; [Lazzarino, Giuseppe] Univ Catania, Div Biochem & Mol Biol, Catania, Italy; [Tavazzi, Barbara] Catholic Univ Rome Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy		Belli, A (corresponding author), Univ Southampton, Div Clin Neurosci, Southampton Gen Hosp, S Acad Block MP806, Southampton SO16 6YD, Hants, England.	a.belli@soton.ac.uk	Pernagallo, Salvatore/K-3003-2017; Belli, Antonio/I-3799-2015; Pernagallo, Salvatore/B-4739-2009; Pernagallo, Salvatore/P-3224-2019; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Pernagallo, Salvatore/0000-0002-0259-9008; Belli, Antonio/0000-0002-3211-9933; Pernagallo, Salvatore/0000-0002-0259-9008; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279; Pringle, Ashley/0000-0003-2421-4380	Italian Ministry of University and Scientific ResearchMinistry of Education, Universities and Research (MIUR) [2007JBHZ5F-COFIN]	We wish to thank the Wessex Neurological Centre Trust for funding this study and for their continuing support for our research. We also wish to thank the Italian Ministry of University and Scientific Research for funding Dr. Tavazzi's work (research grant PRIN 2007JBHZ5F-COFIN 2007). We are also grateful to Prof. Mark Bradley of the School of Chemistry, University of Edinburgh, for his support.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Berry M, 1982, Bibl Anat, P1; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Domeniconi M, 2005, J NEUROL SCI, V233, P43, DOI 10.1016/j.jns.2005.03.023; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; FAN L, 1995, MOL BRAIN RES, V30, P125; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Jay G W, 1996, J Insur Med, V27, P262; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; Jimenez-Mateos EM, 2008, NEUROBIOL DIS, V32, P442, DOI 10.1016/j.nbd.2008.08.008; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kerrien S, 2007, NUCLEIC ACIDS RES, V35, pD561, DOI 10.1093/nar/gkl958; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Luo Z, 2001, NEUROBIOL DIS, V8, P183, DOI 10.1006/nbdi.2001.0387; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Roopra A, 2001, Mol Interv, V1, P219; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Saavedra A, 2007, NEUROBIOL DIS, V25, P92, DOI 10.1016/j.nbd.2006.08.019; SAUGSTAD JA, 2007, SOC NEUR ABSTR, V116, P111; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; TEASDALE G, 1974, LANCET, V2, P81; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	37	37	37	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					349	359		10.1089/neu.2009.1095			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800008	19903084				2022-02-06	
J	Diedler, J; Sykora, M; Hahn, P; Heerlein, K; Scholzke, MN; Kellert, L; Bosel, J; Poli, S; Steiner, T				Diedler, Jennifer; Sykora, Marek; Hahn, Philipp; Heerlein, Kristin; Schoelzke, Marion N.; Kellert, Lars; Boesel, Julian; Poli, Sven; Steiner, Thorsten			Low hemoglobin is associated with poor functional outcome after non-traumatic, supratentorial intracerebral hemorrhage	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL-BLOOD-FLOW; CRITICALLY-ILL; ANEMIC HYPOXIA; TRANSFUSION; HEMODILUTION; METABOLISM; OXYGENATION; ISCHEMIA	Introduction: The impact of anemia on functional outcome and mortality in patients suffering from non-traumatic intracerebral hemorrhage (ICH) has not been investigated. Here, we assessed the relationship between hemoglobin (HB) levels and clinical outcome after ICH. Methods: One hundred and ninety six patients suffering from supratentorial, non-traumatic ICH were extracted from our local stroke database (June 2004 to June 2006). Clinical and radiologic computed tomography data, HB levels on admission, mean HB values and nadir during hospital stay were recorded. Outcome was assessed at discharge and 3 months using the modified Rankin score (mRS). Results: Forty six (23.5%) patients achieved a favorable functional outcome (mRS <= 3) and 150 (76.5%) had poor outcome (mRS 4 - 6) at discharge. Patients with poor functional outcome had a lower mean HB (12.3 versus 13.7 g/dl, P < 0.001) and nadir HB (11.5 versus 13.0 g/dl, P < 0.001). Ten patients (5.1%) received red blood cell (RBC) transfusions. In a multivariate logistic regression model, the mean HB was an independent predictor for poor functional outcome at three months (odds ratio (OR) 0.73, 95% confidence interval (CI) 0.58-0.92, P = 0.007), along with National Institute of Health Stroke Scale (NIHSS) at admission (OR 1.17, 95% CI 1.11 - 1.24, P < 0.001), and age (OR 1.08, 95% CI 1.04 - 1.12, P < 0.001). Conclusions: We report an association between low HB and poor outcome in patients with non-traumatic, supratentorial ICH. While a causal relationship could not be proven, previous experimental studies and studies in brain injured patients provide evidence for detrimental effects of anemia on brain metabolism. However, the potential risk of anemia must be balanced against the risk of harm from red blood cell infusion.	[Diedler, Jennifer; Sykora, Marek; Hahn, Philipp; Heerlein, Kristin; Schoelzke, Marion N.; Kellert, Lars; Boesel, Julian; Poli, Sven; Steiner, Thorsten] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Sykora, Marek] Comenius Univ, Dept Neurol, Bratislava 81369, Slovakia		Diedler, J (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	jennifer.diedler@med.uni-heidelberg.de	Steiner, Thorsten/L-2868-2018; Steiner, Thorsten/A-7391-2014	Steiner, Thorsten/0000-0002-5080-8222; 			Beutler E, 2006, BLOOD, V107, P1747, DOI 10.1182/blood-2005-07-3046; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Diringer MN, 2001, CRIT CARE MED, V29, P635, DOI 10.1097/00003246-200103000-00031; Gujjar AR, 1998, NEUROLOGY, V51, P447, DOI 10.1212/WNL.51.2.447; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Huan WY, 2009, J CLIN NEUROSCI, V16, P645, DOI 10.1016/j.jocn.2008.08.014; Kim-Han JS, 2006, STROKE, V37, P2457, DOI 10.1161/01.STR.0000240674.99945.4e; Kramer AH, 2008, CRIT CARE MED, V36, P2070, DOI 10.1097/CCM.0b013e31817c1095; Kramer AH, 2009, NEUROCRIT CARE, V10, P157, DOI 10.1007/s12028-008-9171-y; Kumar MA, 2009, CRIT CARE MED, V37, P1442, DOI 10.1097/CCM.0b013e31819ced3a; Kuwata N, 1995, NEUROSURG REV, V18, P237, DOI 10.1007/BF00383874; Lee EJ, 1999, J NEUROL SCI, V164, P117, DOI 10.1016/S0022-510X(99)00068-4; Lee EJ, 2001, J NEUROL SCI, V190, P3, DOI 10.1016/S0022-510X(01)00567-6; Miller CM, 2007, NEUROCRIT CARE, V6, P22, DOI 10.1385/NCC:6:1:22; Naidech AM, 2007, CRIT CARE MED, V35, P2383, DOI 10.1097/01.CCM.0000284516.17580.2C; Nybo M, 2007, EUR J NEUROL, V14, P477, DOI 10.1111/j.1468-1331.2006.01591.x; Powers WJ, 2001, NEUROLOGY, V57, P18, DOI 10.1212/WNL.57.1.18; Reasoner DK, 1996, ANESTH ANALG, V82, P61, DOI 10.1097/00000539-199601000-00011; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Steiner T, 2006, NEUROSURGERY, V59, P767, DOI 10.1227/01.NEU.0000232837.34992.32; TODD MM, 1994, J NEUROTRAUM, V11, P149, DOI 10.1089/neu.1994.11.149; Tomiyama Y, 1999, AM J PHYSIOL-HEART C, V276, pH1190, DOI 10.1152/ajpheart.1999.276.4.H1190; Tseng MY, 2008, BRIT J NEUROSURG, V22, P257, DOI 10.1080/02688690701832100; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; van Bommel J, 2002, ANESTHESIOLOGY, V97, P660, DOI 10.1097/00000542-200209000-00021; Vespa PM, 2006, CURR OPIN CRIT CARE, V12, P119, DOI 10.1097/01.ccx.0000216577.57180.bd; Vespa PM, 2009, STROKE, V40, P1547, DOI 10.1161/STROKEAHA.108.542803; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; WADE JPH, 1987, STROKE, V18, P68, DOI 10.1161/01.STR.18.1.68; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; Zazulia AR, 2009, STROKE, V40, P1638, DOI 10.1161/STROKEAHA.108.536037; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	36	37	38	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2010	14	2							R63	10.1186/cc8961			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611LO	WOS:000278816800038	20398266	Green Published, gold			2022-02-06	
S	French, LM		Barchas, JD; Difede, J		French, Louis M.			Military traumatic brain injury: an examination of important differences	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	military TBI; mild TBI; blast injury; war trauma	POSTTRAUMATIC-STRESS-DISORDER; SERVICE MEMBERS; MENTAL-HEALTH; IRAQI FREEDOM; COMBAT DUTY; BLAST; US; REHABILITATION; POLYTRAUMA; AFGHANISTAN	Traumatic brain injury, especially mild traumatic brain injury, is a common consequence of modern warfare. In the current conflicts in Iraq and Afghanistan, much attention has been devoted to blast as a "new" mechanism of brain injury. While the evidence for primary blast effects upon the central nervous system is limited and controversial, there are a number of aspects of blast-induced brain injury that may be different. These include high rates of sensory impairment, pain issues, and polytrauma. In addition, the emotional context in which the injury occurred must also be considered in understanding the clinical presentation of these patients. Successful treatment of these individuals must use a multidisciplinary approach focused on the varied conditions that occur in those injured.	[French, Louis M.] Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Washington, DC 20307 USA; [French, Louis M.] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [French, Louis M.] Natl Naval Med Ctr, Washington, DC USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA		French, LM (corresponding author), Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, MATC Bldg 2A,Room 203,6900 Georgia Ave NW, Washington, DC 20307 USA.	louis.french@us.army.mil	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Capella-McDonnall NE, 2005, INT J GERIATR PSYCH, V20, P855, DOI 10.1002/gps.1368; CAREY ME, 1982, ACTA CHIR SCAND, P351; CARROLL LJ, 2004, J REHABIL MED, V84, pS84; Chambers LW, 2005, ARCH SURG-CHICAGO, V140, P26, DOI 10.1001/archsurg.140.1.26; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chia EM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1465, DOI 10.1001/archopht.124.10.1465; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; FRENCH LM, 2008, J SPEC OPER MED, V8, P77; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Helfer TM, 2010, AM J PREV MED, V38, pS71, DOI 10.1016/j.amepre.2009.10.025; Hilber D, 2010, AM J PREV MED, V38, pS78, DOI 10.1016/j.amepre.2009.10.015; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Lanska DJ, 2009, ANN NEUROL, V66, P444, DOI 10.1002/ana.21822; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lieberman HR, 2005, AVIAT SPACE ENVIR MD, V76, pC7; Lieberman HR, 2005, BIOL PSYCHIAT, V57, P422, DOI 10.1016/j.biopsych.2004.11.014; Luria A.R., 1976, WORKING BRAIN INTRO; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Martin E.M, 2008, J TRAUMA NURS, V15, P100; Martin Elisabeth Moy, 2008, J Trauma Nurs, V15, P94, DOI 10.1097/01.JTN.0000337149.29549.28; McDonald I, 2007, BRAIN, V130, P288, DOI 10.1093/brain/awl335; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Messinger SD, 2009, DISABIL REHABIL, V31, P2130, DOI [10.3109/09638280902943223a, 10.3109/09638280902943223]; Mott FW, 1916, LANCET, V1, P545; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Packard RC, 2008, CURR PAIN HEADACHE R, V12, P67, DOI 10.1007/s11916-008-0013-6; Pasquina PF, 2008, J REHABIL RES DEV, V45, P953, DOI 10.1682/JRRD.2007.10.0163; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Polusny MA, 2009, MIL MED, V174, P353, DOI 10.7205/MILMED-D-01-1608; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; SEMMES J, 1954, AM J PSYCHOL, V67, P220, DOI 10.2307/1418625; Shafi S, 2005, J TRAUMA, V59, P830, DOI 10.1097/01.ta.0000188147.36232.c0; Stansbury LG, 2008, J ORTHOP TRAUMA, V22, P43, DOI 10.1097/BOT.0b013e31815b35aa; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; WARDEN DL, 2005, TXB TRAUMATIC BRAIN, P231; Weichel EA, 2009, J HEAD TRAUMA REHAB, V24, P41, DOI 10.1097/HTR.0b013e3181956ffd; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943; [No title captured]	70	37	37	0	8	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						38	45		10.1111/j.1749-6632.2010.05696.x			8	Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000006	20955324				2022-02-06	
J	Tay, SY; Ang, BT; Lau, XY; Meyyappan, A; Collinson, SL				Tay, Sze Yan; Ang, Beng Ti; Lau, Xin Yin; Meyyappan, Amutha; Collinson, Simon Lowes			Chronic Impairment of Prospective Memory after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive functioning; mild traumatic brain injury; prospective memory	CLOSED-HEAD INJURY; COMPLEX INTENTIONS; UNITED-STATES; MODERATE; REALIZATION; PERFORMANCE; SYMPTOMS; DISEASE; EVENT; TIME	Prospective memory (PM), the ability to recall future intentions, is crucial for independent living. Impairment of PM is a common complaint following head injury and is a significant impediment to good recovery, yet no studies have explored PM in mild traumatic brain injury (mTBI). In this study, prospective memory was examined in 31 mTBI patients and matched controls within a month of injury and 3 months after. mTBI patients performed more poorly than controls on the MIST task (Raskin, 2004) within the first month following injury, indicating that PM impairment is part of the acute cognitive sequelae of mTBI. These problems persisted beyond 3 months post-injury, suggesting that PM may be a sensitive indicator of cerebral compromise in mild brain injuries.	[Tay, Sze Yan; Meyyappan, Amutha; Collinson, Simon Lowes] Natl Univ Singapore, Dept Psychol, Fac Arts & Social Sci, Singapore 117570, Singapore; [Tay, Sze Yan] Singapore Gen Hosp, Dept Neurol, Brain Ctr, Singapore 0316, Singapore; [Ang, Beng Ti] Natl Inst Neurosci, Dept Neurosurg, Singapore, Singapore; [Lau, Xin Yin] Macquarie Univ, Dept Psychol, Ctr Emot Hlth, Sydney, NSW 2109, Australia		Tay, SY (corresponding author), Natl Univ Singapore, Dept Psychol, Fac Arts & Social Sci, Block AS4,02-07,9 Arts Link, Singapore 117570, Singapore.	tay.sze.yan@sgh.com.sg		Collinson, Simon Lowes/0000-0001-9232-9732			Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Brown G, 1996, BECKS DEPRESSION INV; Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; CURRY LM, 1991, PHILADELPHIA HEAD IN; DIETER JNI, 1999, WHIPLASH RELATED HEA, P879; Einstein, 2008, PROSPECTIVE MEMORY C, P283; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Heng K. W. J., 2007, SMJ Singapore Medical Journal, V48, P1107; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jennett B, 1981, MANAGEMENT HEAD INJU; Jones S, 2006, NEUROPSYCHOLOGY, V20, P144, DOI 10.1037/0894-4105.20.2.144; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Karantzoulis S, 2009, J INT NEUROPSYCH SOC, V15, P407, DOI 10.1017/S1355617709090596; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2005, J NEUROL NEUROSUR PS, V76, P1501, DOI 10.1136/jnnp.2004.051268; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Kliegel M, 2003, INT J PSYCHOL, V38, P193, DOI 10.1080/00207590344000114; Kliegel M., 2008, PROSPECTIVE MEMORY C, P235; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McDaniel MA., 1996, PROSPECTIVE MEMORY T, P1; McHugh T, 2006, BRAIN COGNITION, V60, P209; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; PERINI S, 1984, NEUROL CLIN, V2, P719, DOI 10.1016/S0733-8619(18)31071-5; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Raskin SA, 2009, BRAIN IMPAIR, V10, P23, DOI 10.1375/brim.10.1.23; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Stein S. C., 1996, NEUROTRAUMA, P31; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Thurman DJ, 2001, HEAD TRAUMA, P327; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Umile EM, 1998, BRAIN INJURY, V12, P577; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; WRIGHTON P, 1999, MILD HEAD INJURY GUI	52	37	37	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					77	83		10.1089/neu.2009.1074			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200006	19698071				2022-02-06	
J	Yu, Z; Morrison, B				Yu, Zhe; Morrison, Barclay, III			Experimental Mild Traumatic Brain Injury Induces Functional Alteration of the Developing Hippocampus	JOURNAL OF NEUROPHYSIOLOGY			English	Article							PAIRED-PULSE FACILITATION; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; IN-VITRO; SLICE CULTURES; ORGANOTYPIC CULTURES; CA1 AREA; POSTNATAL ONTOGENESIS; SYNAPTIC-TRANSMISSION	Yu Z, Morrison B. Experimental mild traumatic brain injury induces functional alteration of the developing hippocampus. J Neurophysiol 103: 499-510, 2010. First published November 18, 2009; doi: 10.1152/jn.00775.2009. It is estimated that similar to 1.5 million Americans suffer a traumatic brain injury (TBI) every year, of which similar to 80% are considered mild injuries. Because symptoms caused by mild TBI last less than half an hour by definition and apparently resolve without treatment, the study of mild TBI is often neglected resulting in a significant knowledge gap for this wide-spread problem. In this work, we studied functional (electrophysiological) alterations of the neonatal/juvenile hippocampus after experimental mild TBI. Our previous work reported significant cell death after in vitro injury >10% biaxial deformation. Here we report that biaxial deformation as low as 5% affected neuronal function during the first week after in vitro mild injury of hippocampal slice cultures. These results suggest that even very mild mechanical events may lead to a quantifiable neuronal network dysfunction. Furthermore, our results highlight that safe limits of mechanical deformation or tolerance criteria may be specific to a particular outcome measure and that neuronal function is a more sensitive measure of injury than cell death. In addition, the age of the tissue at injury was found to be an important factor affecting posttraumatic deficits in electrophysiological function, indicating a relationship between developmental status and vulnerability to mild injury. Our findings suggest that mild pediatric TBI could result in functional deficits that are more serious than currently appreciated.	[Yu, Zhe; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA		Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 1210 Amsterdam Ave,351 Engn Terrace, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008; Yu, Zhe/K-6180-2013	Morrison, Barclay/0000-0001-7676-0864; Yu, Zhe/0000-0002-1401-2294	Southern Consortium for Injury Biomechanics; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 052794]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS052794] Funding Source: NIH RePORTER	This work was supported by the Southern Consortium for Injury Biomechanics and National Institute of Neurological Disorders and Stroke Grant R21 052794.	Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI [DOI 10.1117/1.3589100, DOI 10.1201/9781420005615.AX4]; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Amaral D G, 1993, Curr Opin Neurobiol, V3, P225, DOI 10.1016/0959-4388(93)90214-J; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Beaulieu CL, 2002, SURG CLIN N AM, V82, P393, DOI 10.1016/S0039-6109(02)00009-9; Bishop Naomi B, 2006, Curr Probl Pediatr Adolesc Health Care, V36, P318, DOI 10.1016/j.cppeds.2006.05.004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BOLSHAKOV VY, 1995, SCIENCE, V269, P1730, DOI 10.1126/science.7569903; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BUCHS PA, 1993, DEV BRAIN RES, V71, P81, DOI 10.1016/0165-3806(93)90108-M; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Buzsaki G, 2004, NAT NEUROSCI, V7, P446, DOI 10.1038/nn1233; Cao R, 2006, NEUROSCI LETT, V401, P136, DOI 10.1016/j.neulet.2006.03.005; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Collin C, 1997, J NEUROPHYSIOL, V77, P1614, DOI 10.1152/jn.1997.77.3.1614; Cronin AF, 2001, AM J OCCUP THER, V55, P377, DOI 10.5014/ajot.55.4.377; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fiala JC, 2003, J COMP NEUROL, V465, P90, DOI 10.1002/cne.10825; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GAHWILER BH, 1984, NEUROSCIENCE, V11, P751, DOI 10.1016/0306-4522(84)90192-1; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Goldsmith W, 2001, CRIT REV BIOMED ENG, V29, P441, DOI 10.1615/CritRevBiomedEng.v29.i56.10; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graudejus O, 2009, J ELECTROCHEM SOC, V156, pP85, DOI 10.1149/1.3115465; Huang FS, 2007, EUR J NEUROSCI, V25, P3253, DOI 10.1111/j.1460-9568.2007.05539.x; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; KIERNAN JA, 1971, EXP NEUROL, V32, P111, DOI 10.1016/0014-4886(71)90169-5; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mori-Kawakami F, 2003, J PHYSIOL-LONDON, V553, P37, DOI 10.1113/jphysiol.2003.045948; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison Barclay 3rd, 2003, Stapp Car Crash J, V47, P93; MULLER D, 1993, DEV BRAIN RES, V71, P93, DOI 10.1016/0165-3806(93)90109-N; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; *NAT CTR INJ PREV, 2005, TRAUM BRAIN INJ US A; Pena F, 2002, NEUROPHARMACOLOGY, V42, P807, DOI 10.1016/S0028-3908(02)00024-2; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; POKORNY J, 1981, BRAIN RES BULL, V7, P113, DOI 10.1016/0361-9230(81)90075-7; POKORNY J, 1981, BRAIN RES BULL, V7, P121, DOI 10.1016/0361-9230(81)90076-9; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; RAPHAELY RC, 1980, PEDIATR CLIN N AM, V27, P715; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; Sanchez JC, 2006, EXP NEUROL, V198, P31, DOI 10.1016/j.expneurol.2005.10.031; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; SHARONOVA I N, 1982, Byulleten' Eksperimental'noi Biologii i Meditsiny, V93, P14; Shimono K, 2002, J NEUROSCI METH, V120, P193, DOI 10.1016/S0165-0270(02)00202-9; Sirvio J, 1996, NEUROSCIENCE, V74, P1025, DOI 10.1016/0306-4522(96)00170-4; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; Thomson AM, 2000, TRENDS NEUROSCI, V23, P305, DOI 10.1016/S0166-2236(00)01580-0; Villablanca JR, 1998, DEV BRAIN RES, V105, P309, DOI 10.1016/S0165-3806(97)00187-9; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wirth C, 2004, J NEUROPHYSIOL, V91, P1635, DOI 10.1152/jn.00950.2003; WU LG, 1994, J NEUROSCI, V14, P645; Xiang ZM, 2000, J NEUROSCI METH, V98, P145, DOI 10.1016/S0165-0270(00)00197-7; Yu Z, 2007, NANO LETT, V7, P2188, DOI 10.1021/nl070291a; Yu Z, 2009, J NEUROTRAUM, V26, P1135, DOI 10.1089/neu.2008.0810	86	37	38	0	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	JAN	2010	103	1					499	510		10.1152/jn.00775.2009			12	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	542VD	WOS:000273526000047	19923245	Green Published			2022-02-06	
J	Jacobsson, LJ; Westerberg, M; Soderberg, S; Lexell, J				Jacobsson, L. J.; Westerberg, M.; Soderberg, S.; Lexell, J.			Functioning and disability 6-15 years after traumatic brain injuries in northern Sweden	ACTA NEUROLOGICA SCANDINAVICA			English	Article						disability evaluation; Glasgow Outcome Scale; outcome; recovery of function; traumatic brain injury; questionnaires	COMMUNITY INTEGRATION QUESTIONNAIRE; FOLLOW-UP; PRACTICAL SCALE; REHABILITATION; ADULTS; COMA; ADJUSTMENT; MODERATE; LIFE	Objectives - To assess long-term functioning and disability after traumatic brain injury (TBI). Material and methods - Individuals (n = 88) in Norrbotten, northern Sweden, who had been transferred for neurosurgical care were assessed with internationally established TBI outcome measures 6-15 years post-injury. Results - There was an improvement in overall outcome from discharge from inpatient rehabilitation to follow-up. Many individuals had a high degree of motor and cognitive functioning, which enabled them to live independently in their own home without assistance, but there remained a disability related to community reintegration and social participation. This affected their productivity and to some degree their marital stability. The remaining disability and reduced productivity were related to the age at injury and the injury severity. Conclusions Our data showed that individuals with a TBI can achieve and maintain a high degree of functioning many years after the injury. Increasing age and a greater injury severity contributed to their long-term disability.	[Jacobsson, L. J.] Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden; [Jacobsson, L. J.; Soderberg, S.; Lexell, J.] Lulea Univ Technol, Dept Hlth Sci, S-95187 Lulea, Sweden; [Westerberg, M.] Lulea Univ Technol, Dept Business Adm & Social Sci, S-95187 Lulea, Sweden; [Lexell, J.] Univ Lund Hosp, Dept Rehabil Med, S-22185 Lund, Sweden; [Lexell, J.] Lund Univ, Dept Clin Sci, Div Rehabil Med, Lund, Sweden		Jacobsson, LJ (corresponding author), Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden.	lars.jacobsson@nll.se	Westerberg, Mats/C-3300-2012	Westerberg, Mats/0000-0001-5464-9292; Jacobsson, Lars/0000-0002-1127-1178; Lexell, Jan/0000-0001-5294-3332	Norrbacka-Eugenia Foundation; Cancer and Traffic Injury Fund; Norrbotten County Council; Swedish Association	This study was supported by grants from the Norrbacka-Eugenia Foundation, the Cancer and Traffic Injury Fund, Norrbotten County Council, the Swedish Association of Brain Injured and their Families and Skane county councils research and development foundation.	Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Emanuelson I, 1996, CHILD NERV SYST, V12, P460, DOI 10.1007/BF00261625; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grimby G, 1996, SCAND J REHABIL MED, V28, P51; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; JENNETT B, 1975, LANCET, V1, P480; Jonsson CA, 2004, BRAIN INJURY, V18, P921, DOI 10.1080/02699050410001671900; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; KIM JA, 1997, OCCUPATIONAL THERAPY, V4, P178; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Salter K, 2008, BRAIN INJURY, V22, P820, DOI 10.1080/02699050802425428; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Sorbo AK, 2009, INT J REHABIL RES, V32, P139, DOI 10.1097/MRR.0b013e328325a5d1; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	33	37	37	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	DEC	2009	120	6					389	395		10.1111/j.1600-0404.2009.01238.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	519IH	WOS:000271758800003	19922583				2022-02-06	
J	Calogeropoulou, T; Avlonitis, N; Minas, V; Alexi, X; Pantzou, A; Charalampopoulos, I; Zervou, M; Vergou, V; Katsanou, ES; Lazaridis, I; Alexis, MN; Gravanis, A				Calogeropoulou, Theodora; Avlonitis, Nicolaos; Minas, Vassilios; Alexi, Xanthippi; Pantzou, Athanasia; Charalampopoulos, Ioannis; Zervou, Maria; Vergou, Varvara; Katsanou, Efrosini S.; Lazaridis, Iakovos; Alexis, Michael N.; Gravanis, Achille			Novel Dehydroepiandrosterone Derivatives with Antiapoptotic, Neuroprotective Activity	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; ESTROGEN-RECEPTOR-BETA; PROSTATE-CANCER CELLS; NERVOUS-SYSTEM; NEUROACTIVE STEROIDS; GABA(A) RECEPTORS; IN-VITRO; HIPPOCAMPAL-NEURONS; PROTEIN EXPRESSION	DHEA analogues with modifications at positions C3 or 07 were synthesized and evaluated for neuroprotective activity against the neural-crest-derived PC12 cell model of serum deprivation-induced apoptosis. The most potent compounds were the spiro-epoxy derivatives 17 beta-spiro[5-androstene-17, 2'-oxiran]-3 beta-ol (20), (20S)-3 beta,21-dihydroxy-17 beta,20-epoxy-5-pregnene (23), and (20R)-3 beta,21-dihydroxy-17 alpha,20-epoxy-5-pregnene (27) with IG(50) values of 0.19 +/- 0.01, 99.0 +/- 4.6, and 6.4 +/- 0.3 nM, respectively. Analogues 20, 23, and 27, up to the micromolar range of concentrations, were unable to activate estrogen receptor alpha and beta (ER alpha and ER beta) or to interfere with ER-dependent gene expression significantly. In addition, they were unable to stimulate the growth of Ishikawa, MCF-7, and LNCaP cells. Our results suggest that the spiro-epoxyneurosteroid derivatives 20, 23, and 27 may prove to be lead molecules for the synthesis of novel neuroprotective agents.	[Calogeropoulou, Theodora; Avlonitis, Nicolaos; Pantzou, Athanasia; Zervou, Maria] Natl Hellen Res Fdn, Inst Organ & Pharmaceut Chem, Athens 11635, Greece; [Alexi, Xanthippi; Katsanou, Efrosini S.; Alexis, Michael N.] Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens 11635, Greece; [Minas, Vassilios; Charalampopoulos, Ioannis; Vergou, Varvara; Lazaridis, Iakovos; Gravanis, Achille] Univ Crete, Sch Med, Dept Pharmacol, Iraklion 71110, Greece		Calogeropoulou, T (corresponding author), Natl Hellen Res Fdn, Inst Organ & Pharmaceut Chem, 48 Vassileos Constantinou Ave, Athens 11635, Greece.	tcalog@eie.gr	Katsanou, Efrosini/AAU-1502-2020; Charalampopoulos, Ioannis/I-6319-2012; Avlonitis, Nicolaos/A-5161-2009; Avlonitis, Nicolaos/T-6053-2019	Katsanou, Efrosini/0000-0002-6381-1332; Charalampopoulos, Ioannis/0000-0003-3415-7332; Alexis, Michael N/0000-0002-4243-7628; Zervou, Maria/0000-0001-5963-4954; Lazaridis, Iakovos/0000-0002-4578-2347	Greek General Secretariat for Research and TechnologyGreek Ministry of Development-GSRT [PENED 2001 ED258]; Bionature EA Ltd.; EmergoMed Co	This work was Supported in part by the Greek General Secretariat for Research and Technology (Programme PENED 2001 ED258) and a grant from Bionature EA Ltd. and EmergoMed Co.	Barger SW, 2000, J NEUROSCI RES, V62, P503, DOI 10.1002/1097-4547(20001115)62:4<503::AID-JNR4>3.0.CO;2-A; Bastianetto S, 1999, MOL BRAIN RES, V66, P35, DOI 10.1016/S0169-328X(99)00002-9; Baulieu EE, 1998, P NATL ACAD SCI USA, V95, P4089, DOI 10.1073/pnas.95.8.4089; Belanger N, 2003, ENDOCRINE, V21, P97, DOI 10.1385/ENDO:21:1:97; Belanger N, 2006, NEUROBIOL AGING, V27, P1684, DOI 10.1016/j.neurobiolaging.2005.09.028; Bhacca NS, 1996, J CHEM CRYSTALLOGR, V26, P483, DOI 10.1007/BF01668309; BOLOGA L, 1987, J NEUROSCI RES, V17, P225, DOI 10.1002/jnr.490170305; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Cardounel A, 1999, P SOC EXP BIOL MED, V222, P145, DOI 10.1046/j.1525-1373.1999.d01-124.x; Charalampopoulos I, 2006, FASEB J, V20, P577, DOI 10.1096/fj.05-5078fje; Charalampopoulos I, 2005, ENDOCRINOLOGY, V146, P3309, DOI 10.1210/en.2005-0263; Charalampopoulos I, 2008, TRENDS ENDOCRIN MET, V19, P300, DOI 10.1016/j.tem.2008.07.004; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Chavez-Delgado ME, 2005, J BIOMED MATER RES B, V74B, P589, DOI 10.1002/jbm.b.30243; Chen WY, 2006, ARCH INTERN MED, V166, P1027, DOI 10.1001/archinte.166.9.1027; Chu GH, 1998, STEROIDS, V63, P214, DOI 10.1016/S0039-128X(98)00006-3; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Compagnone NA, 2008, J STEROID BIOCHEM, V109, P307, DOI 10.1016/j.jsbmb.2008.03.022; COREY EJ, 1972, J AM CHEM SOC, V94, P6190, DOI 10.1021/ja00772a043; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Fiore C, 2004, J NEUROSCI RES, V75, P391, DOI 10.1002/jnr.10821; Fokialakis N, 2004, CHEM BIOL, V11, P397, DOI 10.1016/j.chembiol.2004.02.014; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; GAL GS, 1970, Patent No. 3492292; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; GILL JC, 1986, J MED CHEM, V29, P1537, DOI 10.1021/jm00158a039; GRAVANIS A, 2008, Patent No. 2008155534; Gritzapis AD, 2003, BREAST CANCER RES TR, V80, P1, DOI 10.1023/A:1024462416640; Gubba EM, 2004, MOL BRAIN RES, V127, P48, DOI 10.1016/j.molbrainres.2004.05.004; Guerini V, 2005, CANCER RES, V65, P5445, DOI 10.1158/0008-5472.CAN-04-1941; HANESSIAN S, 1975, CAN J CHEM, V53, P2975, DOI 10.1139/v75-419; HART TW, 1979, J CHEM SOC CHEM COMM, P156, DOI 10.1039/c39790000156; He DN, 2007, PROSTATE, V67, P1318, DOI 10.1002/pros.20615; Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Hogenkamp DJ, 1997, J MED CHEM, V40, P61, DOI 10.1021/jm960021x; Johnson SM, 2007, ENDOCR-RELAT CANCER, V14, P337, DOI 10.1677/ERC-06-0085; Kasiotis KM, 2006, STEROIDS, V71, P249, DOI 10.1016/j.steroids.2005.10.004; Katsanou ES, 2007, J STEROID BIOCHEM, V104, P228, DOI 10.1016/j.jsbmb.2007.03.028; Keller EA, 2004, DEV BRAIN RES, V153, P13, DOI 10.1016/j.devbrainres.2004.07.009; Kimonides VG, 1998, P NATL ACAD SCI USA, V95, P1852, DOI 10.1073/pnas.95.4.1852; KRATNIC S, 2006, TRENDS NEUROSCI, V28, P670; Kulkarni S. K., 1995, Drugs of Today, V31, P433; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Lapchak PA, 2004, BRAIN RES, V997, P152, DOI 10.1016/j.brainres.2003.10.047; Lapchak PA, 2000, STROKE, V31, P1953, DOI 10.1161/01.STR.31.8.1953; Lazennec G, 1999, MOL ENDOCRINOL, V13, P969, DOI 10.1210/me.13.6.969; Le Goascogne C, 2000, GLIA, V29, P14, DOI 10.1002/(SICI)1098-1136(20000101)29:1<14::AID-GLIA2>3.3.CO;2-E; Leskiewicz M, 2008, J NEUROSCI RES, V86, P1361, DOI 10.1002/jnr.21591; Loria RM, 1996, J ENDOCRINOL, V150, pS209; LUCHE JL, 1978, J AM CHEM SOC, V100, P2226, DOI 10.1021/ja00475a040; Maggiolini M, 2004, J MOL ENDOCRINOL, V32, P777, DOI 10.1677/jme.0.0320777; Maksay G, 2007, BRIT J PHARMACOL, V151, P1078, DOI 10.1038/sj.bjp.0707316; Marx CE, 2000, BRAIN RES, V871, P104, DOI 10.1016/S0006-8993(00)02452-5; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McLachlan JA, 1996, J IMMUNOL, V156, P328; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Nettles KW, 2008, NAT CHEM BIOL, V4, P241, DOI 10.1038/nchembio.76; Ngatcha BT, 2005, J MED CHEM, V48, P5257, DOI 10.1021/jm058179h; Ngatcha BT, 1999, SYNTHETIC COMMUN, V29, P1065, DOI 10.1080/00397919908086075; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; PARKER KA, 1977, Patent No. 4059575; Pathirathna S, 2005, PAIN, V114, P429, DOI 10.1016/j.pain.2005.01.009; Patte-Mensah C, 2004, J COMP NEUROL, V477, P286, DOI 10.1002/cne.20251; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; PLUMB JA, 1989, CANCER RES, V49, P4435; Pomata PE, 2000, DEV BRAIN RES, V120, P83, DOI 10.1016/S0165-3806(99)00181-9; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; Sapolsky R.M, 1992, STRESS AGING BRAIN M; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Schumacher M, 2003, PROG NEUROBIOL, V71, P3, DOI 10.1016/j.pneurobio.2003.09.004; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Skretas G, 2007, J AM CHEM SOC, V129, P8443, DOI 10.1021/ja067754j; Souli C, 2005, J MED CHEM, V48, P5203, DOI 10.1021/jm050271q; Straub RH, 2002, EUR J ENDOCRINOL, V146, P365, DOI 10.1530/eje.0.1460365; Suzuki M, 2004, P NATL ACAD SCI USA, V101, P3202, DOI 10.1073/pnas.0307325101; Takahashi Y, 2006, MOL CARCINOGEN, V45, P18, DOI 10.1002/mc.20153; TAKANO S, 1983, J CHEM SOC CHEM COMM, P760, DOI 10.1039/c39830000760; Todorovic SM, 2004, MOL PHARMACOL, V66, P1223, DOI 10.1124/mol.104.002402; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Vihko P, 2006, MOL CELL ENDOCRINOL, V248, P141, DOI 10.1016/j.mce.2005.12.005; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wittmann BM, 2007, CANCER RES, V67, P9549, DOI 10.1158/0008-5472.CAN-07-1590; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x; Xilouri M, 2007, NEUROCHEM INT, V50, P660, DOI 10.1016/j.neuint.2006.12.010	93	37	39	0	8	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	NOV 12	2009	52	21					6569	6587		10.1021/jm900468p			19	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Pharmacology & Pharmacy	514WW	WOS:000271427900013	19845386				2022-02-06	
J	Shulga, A; Blaesse, A; Kysenius, K; Huttunen, HJ; Tanhuanpaa, K; Saarma, M; Rivera, C				Shulga, Anastasia; Blaesse, Anne; Kysenius, Kai; Huttunen, Henri J.; Tanhuanpaa, Kimmo; Saarma, Mart; Rivera, Claudio			Thyroxin regulates BDNF expression to promote survival of injured neurons	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						BDNF; Thyroxin; KCC2; Trophic support; Axotomy; Time-lapse microscopy		A growing amount of evidence indicates that neuronal trauma can induce a recapitulation of developmental-like mechanisms for neuronal survival and regeneration. Concurringly, ontogenic dependency of central neurons for brain-derived neurotrophic factor (BDNF) is lost during maturation but is re-acquired after injury. Here we show in organotypic hippocampal slices that thyroxin, the thyroid hormone essential for normal CNS development, induces up-regulation of BDNF upon injury. This change in the effect of thyroxin is crucial to promote survival and regeneration of damaged central neurons. In addition, the effect of thyroxin on the expression of the K-Cl cotransporter (KCC2), a marker of neuronal maturation, is changed from down to up-regulation. Notably, previous results in humans have shown that during the first few days after traumatic brain injury or spinal cord injury, thyroid hormone levels are often diminished. Our data suggest that maintaining normal levels of thyroxin during the early post-traumatic phase of CNS injury could have a therapeutically positive effect. (C) 2009 Elsevier Inc. All rights reserved.	[Shulga, Anastasia; Blaesse, Anne; Tanhuanpaa, Kimmo; Saarma, Mart; Rivera, Claudio] Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland; [Kysenius, Kai; Huttunen, Henri J.] Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland		Rivera, C (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Viikinkaari 9, FIN-00014 Helsinki, Finland.	Claudio.rivera@helsinki.fi	Rivera, Claudio/ABE-2499-2021; Kysenius, Kai/U-6388-2019	Rivera, Claudio/0000-0003-2462-6561; Kysenius, Kai/0000-0003-1038-2850; Huttunen, Henri/0000-0002-9867-4438; Shulga, Anastasia/0000-0003-0262-3570	Academy of FinlandAcademy of FinlandEuropean Commission; University of Helsinki, Biocentrum Helsinki; Sigrid Juselius FoundationSigrid Juselius Foundation; Helsinki Biomedical Graduate School	We thank Pavel Uvarov for providing expertise for real-time PCR and Miika Palviainen and Marjo Heikura for excellent technical assistance. This work was supported by grants from the Academy of Finland, from the University of Helsinki, Biocentrum Helsinki and from the Sigrid Juselius Foundation and Helsinki Biomedical Graduate School.	Aguado F, 2003, DEVELOPMENT, V130, P1267, DOI 10.1242/dev.00351; Barakat-Walter I, 1999, J NEUROBIOL, V40, P541, DOI 10.1002/(SICI)1097-4695(19990915)40:4<541::AID-NEU10>3.0.CO;2-Q; Barakat-Walter I, 2007, J NEUROTRAUM, V24, P567, DOI 10.1089/neu.2006.0104; BAUMAN WA, 2000, PHYS MED REH CLIN N, V1, P109; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bernal J, 2005, VITAM HORM, V71, P95, DOI 10.1016/S0083-6729(05)71004-9; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BUGARESTI JM, 1992, PARAPLEGIA, V30, P401, DOI 10.1038/sc.1992.90; Burton A, 2005, LANCET NEUROL, V4, P18, DOI 10.1016/S1474-4422(04)00958-5; Calza L, 2005, BRAIN RES REV, V48, P339, DOI 10.1016/j.brainresrev.2004.12.022; Calza L, 2002, P NATL ACAD SCI USA, V99, P3258, DOI 10.1073/pnas.052704499; Camboni D, 2003, NEUROSCI LETT, V350, P141, DOI 10.1016/S0304-3940(03)00880-2; Carmona MA, 2006, CEREB CORTEX, V16, P47, DOI 10.1093/cercor/bhi083; Cernak I, 1999, BRAIN INJURY, V13, P1005; Chong JSWLV, 2000, INT J CLIN PRACT, V54, P621; Conner JM, 1997, J NEUROSCI, V17, P2295; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; D'Intino G, 2006, NEUROL RES, V28, P513, DOI 10.1179/016164106X116773; De Groot LJ, 1999, J CLIN ENDOCR METAB, V84, P151, DOI 10.1210/jc.84.1.151; FACKTOR MA, 1993, RESUSCITATION, V26, P141, DOI 10.1016/0300-9572(93)90174-O; Fernandez M, 2004, P NATL ACAD SCI USA, V101, P16363, DOI 10.1073/pnas.0407262101; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Friauf E, 2008, EUR J NEUROSCI, V28, P2371, DOI 10.1111/j.1460-9568.2008.06528.x; GENUTH SM, 2004, PHYSIOLOGY; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; JABBARI B, 1980, EPILEPSIA, V21, P91, DOI 10.1111/j.1528-1157.1980.tb04048.x; Kilby MD, 2003, CLIN ENDOCRINOL, V59, P280, DOI 10.1046/j.1365-2265.2003.01804.x; Koibuchi N, 2001, THYROID, V11, P205, DOI 10.1089/105072501750159534; KORCZYN AD, 1976, EPILEPSIA, V17, P33, DOI 10.1111/j.1528-1157.1976.tb03378.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; Lipska BK, 2001, EUR J NEUROSCI, V14, P135, DOI 10.1046/j.1460-9568.2001.01633.x; Ludwig A, 2003, EUR J NEUROSCI, V18, P3199, DOI 10.1111/j.1460-9568.2003.03069.x; Luesse HG, 1998, EXP BRAIN RES, V119, P1, DOI 10.1007/s002210050313; Mamounas LA, 2000, J NEUROSCI, V20, P771, DOI 10.1523/JNEUROSCI.20-02-00771.2000; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oble DA, 2004, EXP NEUROL, V189, P105, DOI 10.1016/j.expneurol.2004.05.024; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Rivera C, 2004, J NEUROSCI, V24, P4683, DOI 10.1523/JNEUROSCI.5265-03.2004; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; RIVERA C, 2005, J PHYSL, P27; Schenker M, 2003, EXP NEUROL, V184, P225, DOI 10.1016/S0014-4886(03)00255-3; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; SU YH, 1993, EPILEPSIA, V34, P488, DOI 10.1111/j.1528-1157.1993.tb02589.x; TATOR CH, 1983, J NEUROSURG, V58, P406, DOI 10.3171/jns.1983.58.3.0406; TATOR CH, 1980, J NEUROSURG, V53, P381, DOI 10.3171/jns.1980.53.3.0381; TATOR CH, 1982, SURG NEUROL, V18, P64, DOI 10.1016/0090-3019(82)90021-0; Tatsumi K, 2005, NEUROCHEM INT, V46, P381, DOI 10.1016/j.neuint.2004.12.007; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; Tenedieva V. D., 2000, V76, P385; Tentes I, 2003, IN VIVO, V17, P601; Tornberg J, 2005, EUR J NEUROSCI, V21, P1327, DOI 10.1111/j.1460-9568.2005.03959.x; Toyoda H, 2003, J NEUROPHYSIOL, V89, P1353, DOI 10.1152/jn.00721.2002; Uvarov P, 2005, J NEUROCHEM, V95, P1144, DOI 10.1111/j.1471-4159.2005.03434.x; Voria I, 2006, EXP NEUROL, V197, P258, DOI 10.1016/j.expneurol.2005.10.001; Willems E, 2006, INT J DEV BIOL, V50, P627, DOI 10.1387/ijdb.052130ew; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015; ZHOU M, 2003, SICHUAN DAXUE XUEBAO, V4, P713	62	37	39	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	NOV	2009	42	4					408	418		10.1016/j.mcn.2009.09.002			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	524CI	WOS:000272121000015	19765661				2022-02-06	
J	Castellani, C; Bimbashi, P; Ruttenstock, E; Sacherer, P; Stojakovic, T; Weinberg, AM				Castellani, C.; Bimbashi, P.; Ruttenstock, E.; Sacherer, P.; Stojakovic, T.; Weinberg, A-M			Neuroprotein s-100B-a useful parameter in paediatric patients with mild traumatic brain injury?	ACTA PAEDIATRICA			English	Article						Children; Mild traumatic brain injury; Neuroprotein; Neurotrauma; S-100	MINOR HEAD-INJURY; GLASGOW COMA SCALE; PROTEIN MEASUREMENTS; COMPUTED-TOMOGRAPHY; SERUM S100B; MANAGEMENT; DAMAGE	Aims: To examine the correlation of S-100B to cranial computerized tomography (CCT) scan results in children after mild traumatic brain injury (MTBI). Methods: One hundred and nine paediatric patients (0-18 years) with MTBI were included in this prospective single-centre study. Serum was collected within 6 h of trauma for determination of serum S-100B. The upper reference of S-100B was set to 0.16 mu g/L. A CCT scan was performed in all patients and the results were correlated to the S-100B values. Results: Computerized tomography was abnormal in 36 patients showing intracerebral haemorrhages and/or skull fractures. Serum S-100B level was significantly higher in patients with a pathological condition as shown in CT scan results (p = 0.003). There were no false negative, but 42 false positive test results for S-100B. This resulted in a sensitivity of 1.00, specificity of 0.42, positive predictive value of 0.46 and negative predictive value of 1.00. An area under the receiver operating curve of 0.68 was calculated. Conclusion: S-100B is a valuable tool to rule out patients with pathological CCT findings in a collective of paediatric patients with MTBI. Elevations of S-100B do not necessarily lead to a pathological finding in the CT scan, but values below the cut-off safely rule out the evidence of intracranial lesions.	[Castellani, C.; Bimbashi, P.; Ruttenstock, E.; Sacherer, P.; Weinberg, A-M] Med Univ Graz, Dept Pediat Surg, A-8036 Graz, Austria; [Stojakovic, T.] Med Univ Graz, Dept Med & Chem Diagnost, A-8036 Graz, Austria		Weinberg, AM (corresponding author), Med Univ Graz, Dept Pediat Surg, Auenbruggerpl 34, A-8036 Graz, Austria.	annelie.weinberg@t-online.de					Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Castellani C, 2008, CLIN CHEM LAB MED, V46, P1296, DOI 10.1515/CCLM.2008.262; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Eide PK, 2003, ACTA NEUROCHIR, V145, P171, DOI 10.1007/s00701-002-1062-y; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; *ROCH DIAGN CORP, 2007, ROCH D EL R S100 PRO; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Stein SC, 1996, NEUROSURG QUART, V6, P108, DOI 10.1097/00013414-199606000-00004; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Vos PE, 2002, SHOCK, V18, P481, DOI 10.1097/00024382-200211000-00017	26	37	40	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0803-5253	1651-2227		ACTA PAEDIATR	Acta Paediatr.	OCT	2009	98	10					1607	1612		10.1111/j.1651-2227.2009.01423.x			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	490HP	WOS:000269491100016	19843022				2022-02-06	
J	Kreutziger, J; Schlaepfer, J; Wenzel, V; Constantinescu, MA				Kreutziger, Janett; Schlaepfer, Jessica; Wenzel, Volker; Constantinescu, Mihai Adrian			The Role of Admission Blood Glucose in Outcome Prediction of Surviving Patients With Multiple Injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Multiple trauma; Blood glucose; Hyperglycemia; Outcome	INTENSIVE INSULIN THERAPY; TRAUMA-REGISTRY; BASE DEFICIT; BRAIN-INJURY; HYPERGLYCEMIA; MORTALITY; MORBIDITY; RISK; CARE	Background: Recent literature demonstrates hyperglycemia to be common in patients with trauma and associated with poor outcome in patients wit traumatic brain injury and critically ill patients. The goal of this study was to analyze the impact of admission blood glucose on the outcome of surviving patients with multiple injuries. Methods: Patients' charts (age > 16) admitted to the emergency room of the University Hospital of Berne, Switzerland, between January 1, 2002, and December 31, 2004, with an Injury Severity Score 2:17 and more than one severely injured organ system were reviewed retrospectively. Outcome measurements included morbidity, intensive care unit, and hospital length of stay. Results: The inclusion criteria were met by 555 patients, of which 108 (19.5%) patients died. After multiple regression analysis, admission blood glucose proved to be an independent predictor of posttraumatic morbidity (p < 0.0001), intensive care unit, and hospital length of stay (p < 0.0001), despite intensified insulin therapy on the intensive care unit. Conclusions: In this population of patients with multiple injuries, hyperglycemia on admission was strongly associated with increased morbidity, especially infections, prolonged intensive care unit, and hospital length of stay independent of injury severity, gender, age, and various biochemical parameters.	[Kreutziger, Janett; Wenzel, Volker] Innsbruck Med Univ, Dept Anesthesiol & Crit Care Med, Innsbruck, Austria; [Schlaepfer, Jessica] Spital Interlaken, Dept Surg, Unterseen, Switzerland; [Constantinescu, Mihai Adrian] Univ Hosp Bern, Inselspital, Dept Plast Reconstruct & Hand Surg, CH-3010 Bern, Switzerland		Kreutziger, J (corresponding author), Innsbruck Med Univ, Dept Anesthesiol & Crit Care Med, Innsbruck, Austria.	janett.kreutziger@uki.at	Constantinescu, Mihai A./AAC-6061-2020; Kreutziger, Janett/AAU-4102-2021	Kreutziger, Janett/0000-0001-5363-8858			*ASS ADV AUT MED, ABBR INJ SCAL 1990; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bennett-Guerrero E, 1999, ANESTH ANALG, V89, P514, DOI 10.1097/00000539-199908000-00050; Bochicchio GV, 2005, AM SURGEON, V71, P171; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Christiansen C, 2004, INTENS CARE MED, V30, P1685, DOI 10.1007/s00134-004-2325-2; FitzSullivan E, 2005, AM J SURG, V190, P941, DOI 10.1016/j.amjusrg.2005.08.024; Fynn-Thompson Francis, 2004, Semin Thorac Cardiovasc Surg, V16, P77, DOI 10.1053/j.semtcvs.2004.01.004; Gore DC, 2001, J TRAUMA, V51, P540, DOI 10.1097/00005373-200109000-00021; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kreutziger J, 2009, INTENS CARE MED, V35, P1234, DOI 10.1007/s00134-009-1446-z; Krinsley JS, 2008, CRIT CARE MED, V36, P3008, DOI 10.1097/CCM.0b013e31818b38d2; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LORENZ RA, 2005, AORN J, V81, P147; LORENZ RA, 2005, AORN J, V81, P151; Lorenz Rebecca Ann, 2005, AORN J, V81, P126; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Marette A, 2002, CURR OPIN CLIN NUTR, V5, P377, DOI 10.1097/00075197-200207000-00005; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Rixen D, 2000, J TRAUMA, V49, P392, DOI 10.1097/00005373-200009000-00003; Rixen D, 2001, SHOCK, V15, P83, DOI 10.1097/00024382-200115020-00001; SALZANO L, 61 ANN M AAST 2002 O; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Thorell A, 1999, Curr Opin Clin Nutr Metab Care, V2, P69, DOI 10.1097/00075197-199901000-00012; Turina M, 2005, CRIT CARE MED, V33, P1624, DOI 10.1097/01.CCM.0000170106.61978.D8; Turina M, 2006, ANN SURG, V243, P845, DOI 10.1097/01.sla.0000220041.68156.67; Van den Berghe G, 2004, J CLIN INVEST, V114, P1187, DOI 10.1172/JCI200423506; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WOLFE RR, 1987, NEW ENGL J MED, V317, P403, DOI 10.1056/NEJM198708133170702; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf	41	37	37	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2009	67	4					704	708		10.1097/TA.0b013e3181b22e37			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	506BE	WOS:000270747000005	19820574				2022-02-06	
J	Park, SK; Chun, HJ; Kim, DW; Im, TH; Hong, HJ; Yi, HJ				Park, Sang-Kyu; Chun, Hyoung-Joon; Kim, Dong-Won; Im, Tai-Ho; Hong, Hyun-Jong; Yi, Hyeong-Joong			Acute Physiology and Chronic Health Evaluation II and Simplified Acute Physiology Score II in Predicting Hospital Mortality of Neurosurgical Intensive Care Unit Patients	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						APACHE; Intensive Care Units; Mortality; Simplified Acute Physiologic Score; Subarachnoid Hemorrhage; Brain Injuries	APACHE-II; SAPS-II; SEVERITY; MULTICENTER; SURVIVAL; PROGNOSIS; ABILITY; COST; BIAS	We study the predictive power of Acute Physiology and Chronic Health Evaluation II (APACHE II) and Simplified Acute Physiology Score II (SAPS II) in neurosurgical intensive care unit (ICU) patients. Retrospective investigation was conducted on 672 consecutive ICU patients during the last 2 yr. Data were collected during the first 24 hours of admission and analyzed to calculate predicted mortality. Mortality predicted by two systems was compared and, multivariate analyses were then performed for subarachnoid hemorrhage (SAH) and traumatic brain injury (TBI) patients. Observed mortality was 24.8% whereas predicted mortalities were 37.7% and 38.4%, according to APACHE II and SAPS II. Calibration curve was close to the line of perfect prediction. SAPS II was not statistically significant according to a Lemeshow-Hosmer test, but slightly favored by area under the curve (AUC). In SAH patients, SAPS II was an independent predictor for mortality. In TBI patients, both systems had independent prognostic implications. Scoring systems are useful in predicting mortality and measuring performance in neurosurgical ICU setting. TBI patients are more affected by systemic insults than SAH patients, and this discrepancy of predicting mortality in each neurosurgical disease prompts us to develop a more specific scoring system targeted to cerebral dysfunction.	[Chun, Hyoung-Joon; Hong, Hyun-Jong; Yi, Hyeong-Joong] Hanyang Univ, Med Ctr, Dept Neurosurg, Seoul 133792, South Korea; [Kim, Dong-Won] Hanyang Univ, Med Ctr, Dept Anesthesia & Pain Med, Seoul 133792, South Korea; [Im, Tai-Ho] Hanyang Univ, Med Ctr, Dept Emergency Med, Seoul 133792, South Korea; [Park, Sang-Kyu] Ajou Univ Hosp, Dept Neurosurg, Suwon, South Korea		Yi, HJ (corresponding author), Hanyang Univ, Med Ctr, Dept Neurosurg, 17 Haengdang Dong, Seoul 133792, South Korea.	hjyi8499@hanyang.ac.kr	Yi, Hyeong-Joong/AAR-2685-2020				Blot F, 1997, EUR J CANCER, V33, P1031, DOI 10.1016/S0959-8049(97)00042-7; BROWN MC, 1995, CRIT CARE MED, V23, P848, DOI 10.1097/00003246-199505000-00012; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; CHU DY, 1993, CRIT CARE CLIN, V9, P89, DOI 10.1016/S0749-0704(18)30209-4; Claassen J, 2004, CRIT CARE MED, V32, P832, DOI 10.1097/01.CCM.0000114830.48833.8A; COWEN JS, 1994, CRIT CARE CLIN, V10, P53, DOI 10.1016/S0749-0704(18)30144-1; ElSolh AA, 1996, CHEST, V110, P1299, DOI 10.1378/chest.110.5.1299; Goldhill DR, 1998, CRIT CARE MED, V26, P1337, DOI 10.1097/00003246-199808000-00017; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEADLEY J, 1992, CANCER-AM CANCER SOC, V70, P497, DOI 10.1002/1097-0142(19920715)70:2<497::AID-CNCR2820700220>3.0.CO;2-H; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LEMESHOW S, 1985, CRIT CARE MED, V13, P519, DOI 10.1097/00003246-198507000-00001; MOREAU R, 1989, CRIT CARE MED, V17, P409, DOI 10.1097/00003246-198905000-00006; Murthy J M, 2001, Neurol India, V49 Suppl 1, pS91; Pierpont GL, 1999, CLIN CARDIOL, V22, P366, DOI 10.1002/clc.4960220514; PITTET D, 1993, INTENS CARE MED, V19, P265, DOI 10.1007/BF01690546; RAPOPORT J, 1994, CRIT CARE MED, V22, P1385, DOI 10.1097/00003246-199409000-00006; ROWAN KM, 1994, CRIT CARE MED, V22, P1392, DOI 10.1097/00003246-199409000-00007; SARMIENTO J, 1991, CRIT CARE MED, V19, P867, DOI 10.1097/00003246-199107000-00007; Schuiling WJ, 2005, NEUROSURGERY, V57, P230, DOI 10.1227/01.NEU.0000166536.42876.9C; Schuster HP, 1997, INTENS CARE MED, V23, P1056, DOI 10.1007/s001340050456; SMITH RL, 1989, CHEST, V96, P857, DOI 10.1378/chest.96.4.857; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Tunnell RD, 1998, ANAESTHESIA, V53, P1045, DOI 10.1046/j.1365-2044.1998.00566.x; VASSAR MJ, 1992, J TRAUMA, V32, P490, DOI 10.1097/00005373-199204000-00014; Yi HJ, 2006, NEUROSURGERY, V59, P838, DOI 10.1227/01.NEU.0000232976.22414.D9; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1432, DOI 10.1097/00003246-199310000-00009; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010	31	37	41	0	6	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	JUN	2009	24	3					420	426		10.3346/jkms.2009.24.3.420			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	462IA	WOS:000267343400010	19543503	Green Submitted, gold, Green Published			2022-02-06	
J	Bigford, GE; Alonso, OF; Dietrich, WD; Keane, RW				Bigford, Gregory E.; Alonso, Ofelia F.; Dietrich, W. Dalton; Keane, Robert W.			A Novel Protein Complex in Membrane Rafts Linking the NR2B Glutamate Receptor and Autophagy Is Disrupted following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						autophagy; excitotoxicity; membrane rafts; traumatic brain injury	EXCITATORY AMINO-ACIDS; LIPID RAFTS; NMDA RECEPTORS; CELL-DEATH; KINASE-II; POSTSYNAPTIC DENSITY-95; SIGNALING PATHWAYS; UP-REGULATION; RAT-BRAIN; IN-VITRO	Hyperactivation of N-methyl-D-aspartate receptors (NRs) is associated with neuronal cell death induced by traumatic brain injury (TBI) and many neurodegenerative conditions. NR signaling efficiency is dependent on receptor localization in membrane raft microdomains. Recently, excitotoxicity has been linked to autophagy, but mechanisms governing signal transduction remain unclear. Here we have identified protein interactions between NR2B signaling intermediates and the autophagic protein Beclin-1 in membrane rafts of the normal rat cerebral cortex. Moderate TBI induced rapid recruitment and association of NR2B and pCaMKII to membrane rafts, and translocation of Beclin-1 out of membrane microdomains. Furthermore, TBI caused significant increases in expression of key autophagic proteins and morphological hallmarks of autophagy that were significantly attenuated by treatment with the NR2B antagonist Ro 25-6981. Thus, stimulation of autophagy by NR2B signaling may be regulated by redistribution of Beclin-1 in membrane rafts after TBI.	[Bigford, Gregory E.; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Alonso, Ofelia F.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Neurol Surg & Miami Project Cure Paralysis, Miami, FL 33136 USA		Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.	rkeane@miami.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS42133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER	We thank Ana Gomez for help with transmission electron microscopy and Doris Nonner for preparation of rat primary neuronal cultures. This work was supported by the NIH/NINDS ( grants NS30291 and NS42133).	Aarts MM, 2004, CURR MOL MED, V4, P137, DOI 10.2174/1566524043479202; Abulrob A, 2005, J NEUROCHEM, V92, P1477, DOI 10.1111/j.1471-4159.2005.03001.x; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Barria A, 2005, NEURON, V48, P289, DOI 10.1016/j.neuron.2005.08.034; Besshoh S, 2005, J NEUROCHEM, V93, P186, DOI 10.1111/j.1471-4159.2004.03009.x; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Davis AR, 2007, J NEUROTRAUM, V24, P823, DOI 10.1089/neu.2006.0227; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dong YN, 2004, J NEUROSCI, V24, P11035, DOI 10.1523/JNEUROSCI.3722-04.2004; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Frank C, 2004, FEBS LETT, V566, P25, DOI 10.1016/j.febslet.2004.03.113; Gardoni F, 2006, EUR J NEUROSCI, V24, P2694, DOI 10.1111/j.1460-9568.2006.05140.x; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Grant SGN, 2003, BIOESSAYS, V25, P1229, DOI 10.1002/bies.10381; Guirland C, 2004, NEURON, V42, P51, DOI 10.1016/S0896-6273(04)00157-6; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hering H, 2003, J NEUROSCI, V23, P3262; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOLLMANN M, 1994, RENAL PHYSIOL BIOCH, V17, P182; Hu BR, 1998, J NEUROSCI, V18, P625; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lan JY, 2001, J NEUROSCI, V21, P6058, DOI 10.1523/JNEUROSCI.21-16-06058.2001; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Lei ZG, 2006, NEUROSCI LETT, V407, P224, DOI 10.1016/j.neulet.2006.06.019; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LISMAN JE, 2001, J PHYSL, V532, P59; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu LD, 2004, SCIENCE, V304, P1021, DOI 10.1126/science.1096615; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Luo S, 2007, CELL DEATH DIFFER, V14, P1247, DOI 10.1038/sj.cdd.4402149; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Meng FJ, 2004, ACTA PHARMACOL SIN, V25, P176; Meng FJ, 2003, BRAIN RES, V967, P161, DOI 10.1016/S0006-8993(02)04267-1; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Mutel V, 1998, J NEUROCHEM, V70, P2147; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Suzuki T, 2001, MOL BRAIN RES, V89, P20, DOI 10.1016/S0169-328X(01)00051-1; Takacs-Vellai K, 2005, CURR BIOL, V15, P1513, DOI 10.1016/j.cub.2005.07.035; Takadera T, 2004, BRAIN RES, V1020, P196, DOI 10.1016/j.brainres.2004.06.035; ULRICHBAYER K, 2006, J NEUROSCI, V26, P1164; ULRICHBAYER K, 2001, LETT NAT, V411, P801; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; Wong W, 2004, J BIOL CHEM, V279, P444, DOI 10.1074/jbc.M304675200; Wu LJ, 2005, J NEUROSCI, V25, P11107, DOI 10.1523/JNEUROSCI.1678-05.2005; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Zhang SJ, 2007, NEURON, V53, P549, DOI 10.1016/j.neuron.2007.01.025	84	37	38	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					703	720		10.1089/neu.2008.0783			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500006	19335206	Green Published			2022-02-06	
J	Kim, KH				Kim, Kyu-Hong			Predictors for Functional Recovery and Mortality of Surgically Treated Traumatic Acute Subdural Hematomas in 256 Patients	JOURNAL OF KOREAN NEUROSURGICAL SOCIETY			English	Article						Acute subdural hematoma; Functional recovery; Mortality	SEVERE HEAD-INJURY; PROGNOSTIC-FACTORS; MORBIDITY; COMA	Objective : The purpose of this study was to investigate the reliable factors influencing the surgical outcome of the patients with traumatic acute subdural hematoma (ASOH) and to improve the functional outcome of these patients. Methods : A total of 256 consecutive patients who underwent surgical intervention for traumatic ASDH between March 1998 and March 2008 were reviewed. We evaluated the influence of perioperative variables on functional recovery and mortality using multivariate logistic regression analysis. Results : Functional recovery was achieved in 42.2% of patients and the overall mortality was 39.8%. Age (OR=4.91, P=0.002), mechanism of injury (OR=3.66, p=0.003), pupillary abnormality (OR=3.73, p=0.003), GCS score on admission (OR=5.64, p=0.000), and intraoperative acute brain swelling (ABS) (OR=3.71, p=0.009) were independent predictors for functional recovery. And preoperative pupillary abnormality (OR=2.60, P=0.023), GCS score (OR=4.66, p=0.000), and intraoperative ABS (OR=4.16, p=0.001) were independent predictors for mortality. Midline shift, thickness and volume of hematoma, type of surgery, and time to surgery showed no independent association with functional recovery, although these variables were correlated with functional recovery in univariate analyses. Conclusion : Functional recovery was more likely to be achieved in patients who were under 40 years of age, victims of motor vehicle collision and having preoperative reactive pupils, higher GCS score and the absence of ABS during surgery. These results would be helpful for neurosurgeon to improve outcomes from traumatic acute subdural hematomas.	Sungkyunkwan Univ, Dept Neurosurg, Masan Samsung Hosp, Sch Med, Masan 630723, South Korea		Kim, KH (corresponding author), Sungkyunkwan Univ, Dept Neurosurg, Masan Samsung Hosp, Sch Med, 50 Hapseong 2 Dong, Masan 630723, South Korea.	unikkh@unitel.co.kr					BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Cooper P R, 1976, Surg Neurol, V5, P25; Cruz J, 2001, NEUROSURGERY, V49, P864; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; D'Amato L, 2007, J Neurosurg Sci, V51, P107; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JANG HS, 1996, J KOREAN NEUROSURG S, V25, P111; JENNETT B, 1975, LANCET, V1, P480; KLUN B, 1984, ACTA NEUROCHIR, V71, P171, DOI 10.1007/BF01401312; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; PIOTROWSKI WP, 1995, UNFALLCHIRURG, V98, P432; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; RICHARDS T, 1974, SURGERY, V75, P253; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944; STENING WA, 1986, AUST NZ J SURG, V56, P549, DOI 10.1111/j.1445-2197.1986.tb07098.x; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; TEASDALE G, 1974, LANCET, V2, P81; Tian HL, 2008, CHINESE MED J-PEKING, V121, P1080, DOI 10.1097/00029330-200806020-00007; TOKUTOMI T, 1992, RECENT ADV NEUROTRAU, P367; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552	40	37	37	0	4	KOREAN NEUROSURGICAL SOC	SEOUL	BLDG B, #402, 27, CHILPAE-RO, JUNG-GU, SEOUL, 04511, SOUTH KOREA	2005-3711	1598-7876		J KOREAN NEUROSURG S	J. Korean. Neurosurg. Soc.	MAR	2009	45	3					143	150		10.3340/jkns.2009.45.3.143			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	430PD	WOS:000265000100002	19352475	gold, Green Published			2022-02-06	
J	Wachter, D; Gundling, K; Oertel, MF; Stracke, H; Boker, DK				Wachter, Dorothee; Guendling, Katja; Oertel, Matthias F.; Stracke, Hilmar; Boeker, Dieter-Karsten			Pituitary insufficiency after traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						CT scan; Hypopituitarism; Intracranial hemorrhage; Quality of life; Traumatic brain injury	GROWTH-HORMONE DEFICIENCY; SUBARACHNOID HEMORRHAGE; GH DEFICIENCY; HEAD TRAUMA; HIGH-RISK; HYPOPITUITARISM; DYSFUNCTION; PREVALENCE; TBI; DIAGNOSIS	After traumatic brain injury (TBI), patients present with psychological disorders that may be explained by post-traumatic pituitary insufficiency (PI). The goal of this study was to determine the relationship between hypopituitarism, neuropsychological changes and findings on CT scans after TBI. Hospital charts of 55 TBI patients were screened for age, Glasgow Coma Scale (GSC) score, hypoxia or hypotension. The first two CT scans were analyzed for hemorrhagic lesions. Basal levels of the following hormones were recorded: cortisol, prolactin, estradiol, testosterone, insulin-like growth factor 1 and free thyroxine. Hormonal stimulation tests were performed either if the basal hormone screening revealed an abnormality or if the patient answered "yes" to at least one question in the non-evaluated neuropsychological questionnaire. Overall, 14 out of 55 patients (25.4%) presented with PI; one of them with two hormonal deficits. Growth hormone deficit, hypothyroidism and hypocortisolism were found in one, one and two patients, respectively. Neuropsychological complaints were present in 67% of the patients and were associated with intracerebral hemorrhagic lesions and not PI. Neuropsychological complaints after TBI are more frequent than PI. Brain tissue damage is most important than PI in the development of psychological changes after TBI. (C) 2008 Published by Elsevier Ltd.	[Wachter, Dorothee; Guendling, Katja; Oertel, Matthias F.; Boeker, Dieter-Karsten] Univ Hosp, Dept Neurosurg, D-35385 Giessen, Germany; [Stracke, Hilmar] Univ Hosp, Dept Endocrinol, D-35385 Giessen, Germany		Oertel, MF (corresponding author), Univ Hosp, Dept Neurosurg, Klin Str 29, D-35385 Giessen, Germany.	matthias.oertel@neuro.med.uni-giessen.de	Mielke, Dorothee/AAU-6776-2021				Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Aimaretti G, 1998, J ENDOCRINOL INVEST, V21, P506, DOI 10.1007/BF03347336; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; CONSENSUS G, 1998, J CLIN ENDOCR METAB, V83, P379; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; DANIEL PM, 1959, LANCET, V2, P927; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kreutzer J, 2001, J CLIN ENDOCR METAB, V86, P4072, DOI 10.1210/jc.86.9.4072; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lippert-Gruener M, 2007, BRAIN INJURY, V21, P1001, DOI 10.1080/02699050701468933; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mulligan T, 2006, INT J CLIN PRACT, V60, P762, DOI 10.1111/j.1742-1241.2006.00992.x; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Popovic V, 2005, FRONT HORM RES, V33, P33, DOI 10.1159/000088399; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Salehi F, 2007, BRAIN INJURY, V21, P651, DOI 10.1080/02699050701426956; Schneider HJ, 2007, J ENDOCRINOL INVEST, V30, pRC9, DOI 10.1007/BF03346291; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Yehuda R, 1999, Semin Clin Neuropsychiatry, V4, P256	39	37	40	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	FEB	2009	16	2					202	208		10.1016/j.jocn.2008.01.009			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	418XA	WOS:000264181900005	19097906				2022-02-06	
J	Bottari, C; Dassa, C; Rainville, C; Dutil, E				Bottari, Carolina; Dassa, Clement; Rainville, Constant; Dutil, Elisabeth			The factorial validity and internal consistency of the Instrumental Activities of Daily Living Profile in individuals with a traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain injuries; Activities of daily living; Factor analysis; Executive functions; Ecological assessments	EXPLORATORY FACTOR-ANALYSIS; FRONTAL-LOBE DAMAGE; WORKING-MEMORY; COGNITIVE NEUROPSYCHOLOGY; PERFORMING ACTIVITIES; NATURALISTIC ACTION; EXECUTIVE DEFICITS; EVERYDAY ACTION; REHABILITATION; IMPAIRMENTS	The objective of the study was to investigate the factorial validity and internal consistency of the Instrumental Activities of Daily Living (IADL) Profile. A group of 96 patients aged 16 to 65 years, with moderate to severe traumatic brain injuries, was recruited from 12 rehabilitation hospitals in Quebec. The IADL Profile was administered by an occupational therapist in each subject's home and community environment. Principal axis factoring and confirmatory factor analysis provide preliminary support for six correlated factors (F): (F1) going to grocery store/shopping for groceries, (F2) having a meal with guests/cleaning up, (F3) putting on outdoor clothing, (F4) obtaining information, (F5) making a budget, (F6) preparing a hot meal for guests. Total explained variance was 73.6%. Cronbach's alpha analysis revealed high to very high internal consistency for all scales ranging from .81 to .98; internal consistency of the total scale was very high (0.95). The findings suggest that the IADL Profile is a promising means of documenting both IADL independence and the repercussions of executive function deficits on everyday tasks in real-world environments.	[Bottari, Carolina; Dassa, Clement; Dutil, Elisabeth] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada; [Bottari, Carolina; Rainville, Constant; Dutil, Elisabeth] Ctr Interdisciplinary Res Rehabil Greater Montrea, Montreal, PQ, Canada; [Dassa, Clement] Grp Rech Interdisciplinaire Sante, Montreal, PQ, Canada; [Rainville, Constant] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Rainville, Constant] Inst Univ Geriatr Montreal, Montreal, PQ, Canada		Bottari, C (corresponding author), Montreal Neurol Inst, Room 276,3801 Univ, Montreal, PQ H3A 2B4, Canada.	carolina.bottari@umontreal.ca					Ashley MJ, 2001, BRAIN INJURY, V15, P435, DOI 10.1080/02699050010005896; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; BAUM C, 1993, AM J OCCUP THER, V47, P431, DOI 10.5014/ajot.47.5.431; Bentler P. M., 1995, EQS STRUCTURAL EQUAT; Boomsma A., 2001, FESTSCHRIFT HONOR K, P139; BOTTARI C, 2007, THESIS U MONTREAL MO; BOTTARI C, 2004, PROFIL ACTIVITES INS; BOTTARI C, 2007, CANADIAN J OCCUPAT S; Bottari C., 2006, AUST OCCUP THER J, V53, P98, DOI DOI 10.1111/J.1440-1630.2006.00547.X; Bottari C, 2007, J HEAD TRAUMA REHAB, V22, P26, DOI 10.1097/00001199-200701000-00003; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Comrey A., 1992, 1 COURSE FACTOR ANAL; Cooper B., 1996, CAN J OCCUP THER, V63, P9, DOI [10.1177/000841749606300103, DOI 10.1177/000841749606300103]; Costello A., 2005, PAN PACIFIC MANAGEME, V10, P1, DOI DOI 10.7275/JYJ1-4868; Crepeau F, 1997, NEUROPSYCHOL REHABIL, V7, P147, DOI 10.1080/713755525; Cripe L., 1996, ECOLOGICAL VALIDITY, P171; Crocker L., 1986, INTRO CLASSICAL MODE; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DUTIL E, 1990, Occupational Therapy in Health Care, V7, P7, DOI 10.1080/J003v07n01_03; DUTIL E, 1994, P COMB ANN C EXP AM; Dutil E., 2005, ADL PROFILE DESCRIPT, V1; DUTIL E, 1991, CANADIAN J OCCUPATIO, V59, P40; Dutil E., 1995, EXPERIENCES ERGOTHER, P52; Fischer Helene, 2001, BMC Physiology, V1, P1, DOI 10.1186/1472-6793-1-1; Forde EME, 2000, BRAIN COGNITION, V44, P214, DOI 10.1006/brcg.2000.1229; Forde EME, 2002, NEUROCASE, V8, P59, DOI 10.1093/neucas/8.1.59; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Gerbing DW, 1996, STRUCT EQU MODELING, V3, P62, DOI 10.1080/10705519609540030; Gitlin LN, 2001, GERONTOLOGIST, V41, P4, DOI 10.1093/geront/41.1.4; Gitlin LN, 2003, GERONTOLOGIST, V43, P628, DOI 10.1093/geront/43.5.628; Godbout L, 2005, BRAIN INJURY, V19, P337, DOI 10.1080/02699050400005093; Godbout L, 1995, NEUROPSYCHOLOGIA, V33, P1671, DOI 10.1016/0028-3932(95)00047-X; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hogarty KY, 2005, EDUC PSYCHOL MEAS, V65, P202, DOI 10.1177/0013164404267287; Hoppes S, 2003, AM J OCCUP THER, V57, P396, DOI 10.5014/ajot.57.4.396; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Humphreys GW, 2001, NAT NEUROSCI, V4, P84, DOI 10.1038/82940; Humphreys GW, 1998, COGN NEUROPSYCHOL, V15, P771; HUMPHREYS GW, 2001, HDB COGNITIVE NEUROP, P565; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; KAISER HF, 1974, PSYCHOMETRIKA, V39, P31, DOI 10.1007/BF02291575; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KIELHOFNER G., 1995, MODEL HUMAN OCCUPATI; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Le Thiec F., 1999, Annales de Readaptation et de Medecine Physique, V42, P1, DOI 10.1016/S0168-6054(99)80030-0; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak, 1989, ASSESSMENT BEHAV CON, V7, P113; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; LYSACK CL, 2000, AM J OCCUPATIONAL TH, V55, P433; MacNeill SE, 1997, ARCH PHYS MED REHAB, V78, P755, DOI 10.1016/S0003-9993(97)90085-X; MacNeill SE, 2000, REHABIL PSYCHOL, V45, P356, DOI 10.1037/0090-5550.45.4.356; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; NEISTADT ME, 1992, OCCUPATIONAL THERAPY, V12, P431; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pedhazur E. J., 1991, MEASUREMENTS DESIGN; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rempfer MV, 2003, PSYCHIAT RES, V117, P103, DOI 10.1016/S0165-1781(02)00318-9; ROGERS JC, 1982, AM J OCCUP THER, V36, P709, DOI 10.5014/ajot.36.11.709; Rousseau J., 1994, CANADIAN J OCCUPATIO, V61, P149, DOI DOI 10.1177/000841749406100304; ROUSSEAU J, 1994, CANADIAN J OCCUPATIO, V61, P159, DOI DOI 10.1177/000841749406100305; Sbordone RJ, 1999, STUD NEUROPSYCHOL DE, P227; Schermelleh-Engel K., 2003, METHODS PSYCHOL RES, V8, P23; Schwartz MF, 2006, COGN NEUROPSYCHOL, V23, P202, DOI 10.1080/02643290500202623; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sirigu A, 1996, CORTEX, V32, P297, DOI 10.1016/S0010-9452(96)80052-9; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; [No title captured]	85	37	37	0	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	2					177	207	PII 901753073	10.1080/09602010802188435			31	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	412HQ	WOS:000263716300002	18720231				2022-02-06	
J	Tellier, A; Marshall, SC; Wilson, KG; Smith, A; Perugini, M; Stiell, IG				Tellier, Andree; Marshall, Shawn C.; Wilson, Keith G.; Smith, Andra; Perugini, Mary; Stiell, Ian Gilmour			The heterogeneity of mild traumatic brain injury: Where do we stand?	BRAIN INJURY			English	Article						Glasgow Coma Scale; mild brain injury; outcome; traumatic brain injury	MINOR HEAD-INJURY; LIFE SATISFACTION; FOLLOW-UP; COMPLAINTS; SYMPTOMS; CONSCIOUSNESS; DISABILITY; SUPPORT; COMA	Primary objective: To explore the heterogeneity of mild traumatic brain injury (mTBI). Methods and procedures: Hospital-based prospective follow-up study of 125 patients with mTBI sub-divided into 'severity' sub-groups on the basis of GCS scores (GCS of 15 = mild sub-group; GCS of 13-14 = moderate sub-group). Post-traumatic amnesia (PTA) duration (30 minutes used as a cut-off) was also used to define group membership for secondary analyses. The follow-up assessment consisted of a brief neuropsychological battery as well as measures of neurobehavioural functioning, community integration and post-concussive symptomatology. CT scanning was also obtained when clinically relevant. Main outcomes and results: The two mTBI sub-groups, as defined by GCS scores, did not differ with respect to post-concussive symptomatology, neurobehavioural symptoms, neuropsychological performance or CT scan abnormalities. In contrast, when group membership was redefined on the basis of PTA, the two sub-groups differed significantly with respect to intracranial abnormalities and report of aggressive or disinhibited behaviours at the 6-month mark. Conclusions: While the notion of heterogeneity in mTBI was not supported when severity was based on GCS scores, there was partial support when PTA duration was used as a measure of severity.	[Tellier, Andree] Univ Ottawa, Dept Psychol, Neuropsychol Serv, Ottawa Hosp, Ottawa, ON K1Y 4E9, Canada; [Marshall, Shawn C.] Univ Ottawa, Rehabil Ctr, Dept Med, Ottawa Hosp, Ottawa, ON K1Y 4E9, Canada; [Wilson, Keith G.; Perugini, Mary] Univ Ottawa, Rehabil Ctr, Dept Psychol, Ottawa Hosp, Ottawa, ON K1Y 4E9, Canada; [Stiell, Ian Gilmour] Univ Ottawa, Loeb Res Inst, Clin Epidemiol Unit, Ottawa, ON K1Y 4E9, Canada; [Smith, Andra] Univ Ottawa, Sch Psychol, Ottawa, ON K1Y 4E9, Canada		Tellier, A (corresponding author), Univ Ottawa, Dept Psychol, Neuropsychol Serv, Ottawa Hosp, Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	atellier@ottawahospital.on.ca		Stiell, Ian/0000-0002-2583-6408	Ontario Neurotrauma Foundation	This research was supported by funding from the Ontario Neurotrauma Foundation.	Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; AMMONS RB, 1962, PSYCHOL REP, V11, P111, DOI 10.1177/003329416201100106; Bailey B. N., 1989, TXB HEAD INJURY, P308; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P15, DOI 10.1080/16501960410023688; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Finlayson MAJ, 2004, STUD NEUROPSYCHOL DE, P417; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Golden CJ, 1978, STROOP COLOR WORD TE; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; IVERSON GL, 1998, 21 ITEM TEST RES MAN; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy RE, 2006, J HEAD TRAUMA REHAB, V21, P260, DOI 10.1097/00001199-200605000-00006; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2000, BRAIN INJURY, V14, P219; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Raskin SA, 1997, BRAIN INJURY, V11, P587, DOI 10.1080/026990597123287; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1977, LANCET, V1, P1; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stalnacke BM, 2007, J REHABIL MED, V39, P405, DOI 10.2340/16501977-0057; TEASDALE G, 1974, LANCET, V2, P81; Tellier A, 1999, BRAIN INJURY, V13, P463; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1989, MILD HEAD INJURY, P245	56	37	37	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					879	887	PII 915242992	10.1080/02699050903200555			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300004	20100124				2022-02-06	
J	Vallat-Azouvi, C; Pradat-Diehl, P; Azouvi, P				Vallat-Azouvi, Claire; Pradat-Diehl, Pascale; Azouvi, Philippe			Rehabilitation of the central executive of working memory after severe traumatic brain injury: Two single-case studies	BRAIN INJURY			English	Article						Cognitive rehabilitation; executive functioning; attention; traumatic brain injury	DUAL-TASK PERFORMANCE; DIVIDED ATTENTION; SELECTIVE IMPAIRMENT; DEFICITS; COMPONENT; CHILDREN; LOAD	Background/objective: A deficit of the central executive of working memory is a frequent finding in patients with severe traumatic brain injury (TBI). The objective of the present study was to assess the efficacy of a rehabilitation programme of the central executive after severe TBI. Method: An experimental single-case design was used in two patients with remote severe TBI suffering from an isolated central executive deficit. Outcome was assessed with specific working memory tests (spans, Brown Peterson, n-back), non-specific cognitive tasks requiring working memory (dual-task, arithmetic solving problem), an ecological questionnaire to assess generalization to everyday life and non-target tasks not requiring working memory, to assess the specificity of the therapy. Results: Performance was stable on two baseline sessions before therapy. For both patients, an improvement was found for target measures, mainly for central executive tasks, and for the questionnaire on attention failures in everyday life. In opposition, no change was found for non-target measures. Discussion: Improvement was not seemingly related to spontaneous recovery, nor to re-test effects. This study suggests that specific cognitive training may improve the central executive of working memory in patients with remote severe TBI.	[Azouvi, Philippe] Hop Raymond Poincare, Serv Med Phys & Readapt, AP HP, F-92380 Garches, France; [Vallat-Azouvi, Claire] Hop Raymond Poincare, UGECAM Antenne UEROS, F-92380 Garches, France; [Vallat-Azouvi, Claire; Pradat-Diehl, Pascale; Azouvi, Philippe] INSERM, U731, Paris, France; [Vallat-Azouvi, Claire; Pradat-Diehl, Pascale; Azouvi, Philippe] UPMC, Fac Med, Lab Physiol & Physiopathol Motricite, Paris, France; [Pradat-Diehl, Pascale] Hop La Pitie Salpetriere, AP HP, Serv Med Phys & Readapt, Paris, France; [Azouvi, Philippe] Univ Versailles St Quentin, Versailles, France		Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readapt, AP HP, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr					Allain P, 2001, BRAIN COGNITION, V45, P21, DOI 10.1006/brcg.2000.1249; Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A., 2002, PRINCIPLES FRONTAL L, P246, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0016; Baddeley A.D., 1986, WORKING MEMORY; BROOKS D N, 1975, Cortex, V11, P329; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Bublak P, 2000, J CLIN EXP NEUROPSYC, V22, P176, DOI 10.1076/1380-3395(200004)22:2;1-1;FT176; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; Duval J, 2008, NEUROPSYCHOL REHABIL, V18, P430, DOI 10.1080/09602010701573950; Klingberg T, 2002, J CLIN EXP NEUROPSYC, V24, P781, DOI 10.1076/jcen.24.6.781.8395; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Le Gall C., 2007, Annales de Readaptation et de Medecine Physique, V50, P5, DOI 10.1016/j.annrmp.2006.06.007; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Taylor E., 1959, PSYCHOL APPRAISAL CH; Vallat C, 2005, BRAIN INJURY, V19, P1157, DOI 10.1080/02699050500110595; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; WECHSLER D, 1997, WAIS 3 MANUEL ECHELL; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767; WILSON B, 1987, REHABILITATION MEMOR; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110; ZIMMERMANN P, 1992, BATTERIE TESTS NEURO; Zimmermann P, 1995, TEST ATTENTIONAL PER	52	37	39	1	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	6					585	594	PII 911809129	10.1080/02699050902970711			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800012	19484632				2022-02-06	
J	Yang, CC; Hua, MS; Tu, YK; Huang, SJ				Yang, Chi-Cheng; Hua, Mau-Sun; Tu, Yong-Kwang; Huang, Sheng-Jean			Early clinical characteristics of patients with persistent post-concussion symptoms: A prospective study	BRAIN INJURY			English	Article						Persistent post-concussion symptoms; early predictors; prospective study	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; COMA SCALE SCORE; QUALITY-OF-LIFE; POSTCONCUSSION SYMPTOMS; DIAGNOSTIC-CRITERIA; MODERATE; MANAGEMENT; DISABILITY; PREDICTION	Primary objective: To identify the early clinical features of patients with mild traumatic brain injury (mTBI) that are predictive of the presence of persistent post-concussion symptoms (PPCS). Research design: A prospective study was conducted at a level I trauma centre. Methods and procedures: One hundred and eighty mTBI patients participated in this study. The post-concussion symptoms (PCS) were evaluated with a PCS checklist. All patients were examined at 1, 2 and 8 weeks post-injury. The chi-square test was used to evaluate the associations of each PCS and the logistic regression was used to identify potential predictors of mTBI patients who might suffer from PPCS. Main outcomes and results: Less than one-tenth of the mTBI patients examined complained of PPCS at 2 months after head trauma. Patients with PPCS are more likely to suffer from intracranial lesions. Moreover, clinical symptoms at 1 and 2 weeks post-injury, especially physical ones including headache, dizziness and fatigue, were reported significantly more often by patients with PPCS. Conclusions: This study showed that early clinical symptoms and intracranial lesions may be strongly associated with the presence of PPCS. Thus, those specific characteristics may be used as early indicators of long-term difficulties.	[Huang, Sheng-Jean] Natl Taiwan Univ Hosp, Yun Lin Branch, Dept Neurosurg, Taipei 100, Taiwan; [Huang, Sheng-Jean] Natl Taiwan Univ, Dept Surg, Taipei, Taiwan; [Yang, Chi-Cheng; Tu, Yong-Kwang; Huang, Sheng-Jean] Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan; [Yang, Chi-Cheng; Hua, Mau-Sun] Natl Taiwan Univ, Dept Psychol, Taipei, Taiwan		Huang, SJ (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, 7 Chung San S Rd, Taipei 100, Taiwan.	d92227007@ntu.edu.tw		Tu, Yong-kwang/0000-0003-2113-1176			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chi H. T., 2005, CLASSIFICATION MED R; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Department of Health, 2005, HLTH NAT HLTH INS AN; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eslinger PJ, 2007, BRAIN INJURY MED PRI, P779; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Granacher Jr RP, 2003, TRAUMATIC BRAIN INJU, P25; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; HSIANG JN, 2005, LONG TERM EFFECTS ME, V15, P153; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson G.L., 2007, BRAIN INJURY MED PRI, P333; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kraus J, 1996, NEUROTRAUMA, P13; LEE LH, 1992, CHIN MED J TAPIEI, V50, P219; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MCCREA MA, 2007, MILD TRAUMATIC BRAIN, P153; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Tellier A, 1999, BRAIN INJURY, V13, P463; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Uchino Y, 2001, ACTA NEUROCHIR, V143, P1031, DOI 10.1007/s007010170008; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Von Wild K, 2001, BRAIN INJURY, V15, P273; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1992, ICD 10 CLASSIFICATIO; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	56	37	38	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	4					299	306	PII 909975018	10.1080/02699050902788543			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	425MY	WOS:000264643000004	19330593				2022-02-06	
J	Shores, EA; Lammel, A; Hullick, C; Sheedy, J; Flynn, M; Levick, W; Batchelor, J				Shores, E. A.; Lammel, A.; Hullick, C.; Sheedy, J.; Flynn, M.; Levick, W.; Batchelor, J.			The diagnostic accuracy of the Revised Westmead PTA Scale as an adjunct to the Glasgow Coma Scale in the early identification of cognitive impairment in patients with mild traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							BLUNT HEAD-INJURY; POSTTRAUMATIC AMNESIA; PRACTICAL SCALE; CONSCIOUSNESS; DURATION	Background: Assessment of patients with mild traumatic brain injury (mTBI) is predominantly done using the Glasgow Coma Scale (GCS). While the GCS is universally accepted for assessment of severity of traumatic brain injury, it may not be appropriate to rely on the GCS alone when assessing patients with mTBI in prehospital settings and emergency departments. Objective: To determine whether administering the Revised Westmead Post-traumatic Amnesia (PTA) Scale (R-WPTAS) in addition to the GCS would increase diagnostic accuracy in the early identification of cognitive impairment in patients with mTBI. Methods: Data were collected from 82 consecutive participants with mTBI who presented to the emergency department of a level 1 trauma centre in Australia. A matched sample of 88 control participants who attended the emergency department for reasons other than head trauma was also assessed. All patients were assessed using the GCS, R-WPTAS and a battery of neuropsychological tests. Results: Patients with mTBI scored poorly compared with control patients on all measures. The R-WPTAS showed greater concurrent validity with the neuropsychological measures than the GCS and significantly increased prediction of group membership of patients with mTBI with cognitive impairment. Conclusions: The R-WPTAS significantly improves diagnostic accuracy in identifying patients with mTBI who may be in PTA. Administration takes less than 1 min, and since early identification of a patient's cognitive status facilitates management decisions, it is recommended for routine use whenever the GCS is used.	[Shores, E. A.; Lammel, A.; Batchelor, J.] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Hullick, C.; Levick, W.] John Hunter Hosp, Div Emergency Med, New Lambton, Australia; [Sheedy, J.] St Vincents Hosp, Trauma Serv, Sydney, NSW 2010, Australia; [Flynn, M.] Ambulance Serv NSW, Sydney, NSW, Australia		Shores, EA (corresponding author), Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia.	ashores@psy.mq.edu.au	Hullick, Carolyn/AAA-3334-2020; hullick, Carolyn/H-7116-2019	Hullick, Carolyn/0000-0002-6157-8880; hullick, Carolyn/0000-0002-6157-8880; Batchelor, Jennifer/0000-0003-4438-4993; Shores, Edwin A/0000-0003-1553-5131	Ambulance Service of New South Wales' Hamilton station; Rehabilitation Grant from the Motor Accident Authority of New South Wales [04/239]; Collaborative Research Grant from Macquarie University, Sydney, Australia [A006079]	The authors thank the clinical staff at the John Hunter Hospital Emergency Department and the paramedics and ambulance officers of the Ambulance Service of New South Wales' Hamilton station for their support in having made this study possible.; This study was funded by a Rehabilitation Grant from the Motor Accident Authority of New South Wales (Grant Ref: 04/239) and a Collaborative Research Grant from Macquarie University, Sydney, Australia (Grant Ref: A006079). The funding sources had no role in the study design, data collection and analysis, interpretation of the data, writing or any decision to submit to the Journal of Neurology, Neurosurgery and Psychiatry.	Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; DEVILLY GJ, 2005, CLIN TOOLS SOFTWARE; GEFFEN G, 1994, AUST OCCUP THER J, V41, P31, DOI DOI 10.1111/J.1440-1630.1994.TB01809.X; Greenwood R, 1997, LANCET, V349, P1041, DOI 10.1016/S0140-6736(05)62288-X; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Laureys S, 2005, LANCET NEUROL, V4, P789, DOI 10.1016/S1474-4422(05)70230-1; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; LOVELL MR, 2004, IMPACT TRAUMA; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; *MEDCALC WIND, 2009, V 9 2 0 1; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Richardson W. S., 2000, EVIDENCE BASED MED P, V2nd; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; SHORES A, 1990, AUST NZ J PSYCHIAT, V24, P133, DOI 10.3109/00048679009062895; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198	26	37	37	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2008	79	10					1100	1106		10.1136/jnnp.2007.132571			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	348XG	WOS:000259242800004	18223020				2022-02-06	
J	Newsome, MR; Scheibel, RS; Troyanskaya, M; Hanten, G; Lin, X; Vasquez, C; Li, X; Wilde, EA; Levin, HS; Steinberg, JL; Chu, Z; Lu, H; Lane, S; Hunter, JV; Zientz, J				Newsome, Mary R.; Scheibel, Randall S.; Troyanskaya, Maya; Hanten, Gerri; Lin, Xiaodi; Vasquez, Carmen; Li, Xiaoqi; Wilde, Elisabeth A.; Levin, Harvey S.; Steinberg, Joel L.; Chu, Z.; Lu, Hanzhang; Lane, Summer; Hunter, Jill V.; Zientz, Jennifer			Effects of traumatic brain injury on working memory-related brain activation in adolescents	NEUROPSYCHOLOGY			English	Article						fMRI; traumatic brain injury; adolescents; working memory	PREFRONTAL CORTEX; FUNCTIONAL MRI; FMRI; MAINTENANCE; RETRIEVAL; CHILDREN; CHILDHOOD; REVEALS	Eight adolescents (ages 13-18 years) who sustained traumatic brain injury (TBI) and eight gender- and age-matched typically developing (TD) adolescents underwent event-related functional MRI (fMRI) while performing a Sternberg letter recognition task. Encoding, maintenance, and retrieval were examined with memory loads of one or four items during imaging. Both groups performed above a 70% accuracy criterion and did not differ in performance. TD, adolescents showed greater increase in frontal and parietal activation during high-load relative to low-load maintenance than the TBI group. The TBI patients showed greater increase in activation during high-load relative to low-load encoding and retrieval than the TD group. Results from this preliminary study suggest that the capability to differentially allocate neural resources according to memory load is disrupted by TBI for the maintenance subcomponent of working memory. The overrecruitment of frontal and extrafrontal regions during encoding and retrieval following TBI may represent a compensatory process.	[Newsome, Mary R.; Scheibel, Randall S.; Troyanskaya, Maya; Hanten, Gerri; Lin, Xiaodi; Vasquez, Carmen; Li, Xiaoqi; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Steinberg, Joel L.] Univ Texas Houston, Sch Med, Dept Psychiat & Behav Sci, Houston, TX USA; [Chu, Z.; Hunter, Jill V.] Texas Childrens Hosp, Baylor Coll Med & Diagnost Imaging, Houston, TX 77030 USA; [Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Lane, Summer; Zientz, Jennifer] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75230 USA		Newsome, MR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mnewsome@bcm.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS021889, NS042772] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS042772] Funding Source: NIH RePORTER		Baddeley A.D., 1986, WORKING MEMORY; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cabeza R, 2002, NEUROIMAGE, V16, P317, DOI 10.1006/nimg.2002.1063; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Gazzaley Adam, 2004, Cognitive Affective & Behavioral Neuroscience, V4, P580, DOI 10.3758/CABN.4.4.580; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; Karlsgodt KH, 2005, NEUROIMAGE, V25, P1224, DOI 10.1016/j.neuroimage.2005.01.038; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; MILLER, 2001, ANN REV NEUROSCIENCE, V24, P167; Narayanan NS, 2005, NEUROPSYCHOLOGY, V19, P223, DOI 10.1037/0894-4105.19.2.223; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Olesen PJ, 2003, COGNITIVE BRAIN RES, V18, P48, DOI 10.1016/j.cogbrainres.2003.09.003; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Swanson HL, 1999, J EXP CHILD PSYCHOL, V72, P1, DOI 10.1006/jecp.1998.2477; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Veltman DJ, 2003, NEUROIMAGE, V18, P247, DOI 10.1016/S1053-8119(02)00049-6; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Woodward TS, 2006, NEUROSCIENCE, V139, P317, DOI 10.1016/j.neuroscience.2005.05.043	30	37	38	1	9	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	2008	22	4					419	425		10.1037/0894-4105.22.4.419			7	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	319NS	WOS:000257171300001	18590353				2022-02-06	
J	von Baumgarten, L; Trabold, R; Thal, S; Back, T; Plesnila, N				von Baumgarten, Louisa; Trabold, Raimund; Thal, Serge; Back, Tobias; Plesnila, Nikolaus			Role of cortical spreading depressions for secondary brain damage after traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cortical spreading depression; intracranial pressure; mice; regional cerebral blood flow; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; PERIINFARCT DEPOLARIZATIONS; RAT-BRAIN; INTRACRANIAL-PRESSURE; ARTERY OCCLUSION; GENE-EXPRESSION; BLOOD-FLOW; GLUCOSE; CORTEX; MICRODIALYSIS	In recent years, several studies have unequivocally shown the occurrence of cortical spreading depressions (CSDs) after stroke and traumatic brain injury (TBI) in humans. The fundamental question, however, is whether CSDs cause or result from secondary brain damage. The aim of the current study was, therefore, to investigate the role of CSDs for secondary brain damage in an experimental model of TBI. C57/BL6 mice were traumatized by controlled cortical impact. Immediately after trauma, each animal showed one heterogeneous direct current (DC) potential shift accompanied by a profound depression of electroencephalogram (EEG) amplitude, and a temporary decrease of ipsi- and contralateral regional cerebral blood flow (rCBF) suggesting bilateral CSDs. Within the next 3 h after TBI, CSDs occurred at a low frequency (0.38 CSD/h per animal, n = 7) and were accompanied by rCBF changes confined to the ipsilateral hemisphere. No significant relationship between the number of SDs and lesion size or intracranial pressure (ICP) could be detected. Even increasing the number of posttraumatic CSDs by application of KCl by more than six times did not increase ICP or contusion volume. We therefore conclude that CSDs may not contribute to posttraumatic secondary brain damage in the normally perfused and oxygenated brain.	[von Baumgarten, Louisa; Trabold, Raimund; Plesnila, Nikolaus] Univ Munich, Inst Surg Res, Med Ctr Grosshadern, D-8000 Munich, Germany; [von Baumgarten, Louisa; Trabold, Raimund; Thal, Serge; Plesnila, Nikolaus] Univ Munich, Med Ctr Grosshadern, Dept Neurosurg, Lab Expt Neurosurg, D-8000 Munich, Germany; [Back, Tobias] Saxon Hosp Arnsdorf, Dept Neurol, Arnsdorf, Germany		Plesnila, N (corresponding author), Klinikum Univ Munchen Grosshadern, Marchioninistr 15, D-81366 Munich, Germany.	plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019; von Baumgarten, Louisa/A-4636-2016; Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729			Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Horiguchi T, 2005, BRAIN RES, V1039, P84, DOI 10.1016/j.brainres.2005.01.047; Jander S, 2001, J CEREBR BLOOD F MET, V21, P218, DOI 10.1097/00004647-200103000-00005; Kitahara Y, 2001, J NEUROSURG ANESTH, V13, P26, DOI 10.1097/00008506-200101000-00005; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; Lauritzen M, 2001, CEPHALALGIA, V21, P757, DOI 10.1046/j.1468-2982.2001.00244.x; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MIES G, 1984, EXP NEUROL, V84, P249, DOI 10.1016/0014-4886(84)90222-X; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MILNER PM, 1958, ELECTROEN CLIN NEURO, V10, P705, DOI 10.1016/0013-4694(58)90073-7; Mun-Bryce S, 2001, BRAIN RES, V888, P248, DOI 10.1016/S0006-8993(00)03068-7; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NEDERGAARD M, 1986, J CEREBR BLOOD F MET, V6, P607, DOI 10.1038/jcbfm.1986.108; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Ohta K, 2001, STROKE, V32, P535, DOI 10.1161/01.STR.32.2.535; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; SAITO R, 1995, BRAIN RES, V699, P109, DOI 10.1016/0006-8993(95)00898-Z; Selman WR, 2004, BRAIN RES, V999, P167, DOI 10.1016/j.brainres.2003.11.016; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Umegaki M, 2005, J NEUROSCI, V25, P1387, DOI 10.1523/JNEUROSCI.4182-04.2005; Urbach A, 2006, EUR J NEUROSCI, V24, P841, DOI 10.1111/j.1460-9568.2006.04862.x; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; ZORNOW MH, 1992, ANESTH ANALG, V75, P232; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	40	37	37	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2008	28	7					1353	1360		10.1038/jcbfm.2008.30			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	318DZ	WOS:000257073100008	18414497	Bronze			2022-02-06	
J	Flores, AH; Haileyesus, T; Greenspan, AI				Flores, Adrian H.; Haileyesus, Tadesse; Greenspan, Arlene I.			National estimates of outdoor recreational injuries treated in emergency departments, United States, 2004-2005	WILDERNESS & ENVIRONMENTAL MEDICINE			English	Article						outdoor; recreation; injury; prevention; wilderness	WILDERNESS; SAFETY; RISK	Objective.-To provide national estimates of nonfatal outdoor recreational injuries treated in US emergency departments (EDs). Methods.-Outdoor recreational injuries from January 2004 through December 2005 were identified using the National Electronic Injury Surveillance System-All Injury Program, a nationally representative sample of ED visits. National estimates of outdoor recreational injuries were calculated, and activities leading to injury, demographic characteristics, principal diagnoses, and primary body parts affected were described. Results.-From January 2004 through December 2005, an estimated 212 708 (95% CI = 113 808-311 608) persons were treated each year in US EDs for outdoor recreational injuries. The annual rate of injuries was 72.1 per 100 000 population (95% CI = 38.6-105.6). Males accounted for 68.2% of the injuries. The lower limb (27%), upper limb (25%), and head and neck region (23.3%) were the most commonly injured body regions. Fractures (27.4%) and sprains or strains (23.9%) were the most common diagnoses. Traumatic brain injuries were diagnosed in 6.5% of injuries, and 5% of injuries resulted in hospitalization or transfer to another hospital. Conclusions.-The results of this study provide a starting point for further research into the epidemiology of outdoor and wilderness injury. The results reinforce many common perceptions about the nature of these injuries while highlighting the potential severity and long-term consequences of the injuries. The general recommendations of proper planning, preparation, and problem anticipation for outdoor and wilderness injury prevention should be followed to reduce both the number and severity of injuries.	[Flores, Adrian H.; Greenspan, Arlene I.] Ctr Dis Control & Prevent, Div Unintent Injuiry Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; [Haileyesus, Tadesse] Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA		Greenspan, AI (corresponding author), Ctr Dis Control & Prevent, Div Unintent Injuiry Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,Mailstop K-63, Atlanta, GA 30341 USA.	agreenspan@cdc.gov					AUERBACH PS, 2001, WILDERNESS MED; Boulware DR, 2003, AM J MED, V114, P288, DOI 10.1016/S0002-9343(02)01494-8; Bowker J. M., 2006, Journal of Agricultural and Applied Economics, V38, P317; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; Ela GK, 2004, WILD ENVIRON MED, V15, P11, DOI 10.1580/1080-6032(2004)015[0011:EOWSAR]2.0.CO;2; Federiuk CS, 2002, WILD ENVIRON MED, V13, P245, DOI 10.1580/1080-6032(2002)013[0245:SSASII]2.0.CO;2; GENTILE DA, 1992, ANN EMERG MED, V21, P853, DOI 10.1016/S0196-0644(05)81034-0; Gerdes EM, 2006, J TRAUMA, V61, P1517, DOI 10.1097/01.ta.0000209402.40864.b2; Gerson LW, 2004, INJURY PREV, V10, P134, DOI 10.1136/ip.2004.005256; Hargarten S, 1999, WILD ENVIRON MED, V10, P2, DOI 10.1580/1080-6032(1999)010[0002:ICRAWM]2.3.CO;2; Kronisch RL, 2002, SPORTS MED, V32, P523, DOI 10.2165/00007256-200232080-00004; Montalvo R, 1998, WESTERN J MED, V168, P248; *NAT SPORT GOODS A, 10 YEAR HIST SEL SPO; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; *OUTD IND FDN, OUTD RECR PART STUD; PATON BC, 1992, J WILDERNESS MED, V3, P128, DOI 10.1580/0953-9859-3.2.128; Powell C, 2007, WILD ENVIRON MED, V18, P10, DOI 10.1580/1080-6032(2007)18[10:TPORAR]2.0.CO;2; Russell MF, 2004, EMERG MED CLIN N AM, V22, P561, DOI 10.1016/j.emc.2004.01.013; Schonfeld L, 2000, J GERIATR PSYCH NEUR, V13, P124, DOI 10.1177/089198870001300305; Schroeder T, 2001, NATL ELECT INJURY SU; Sholl JM, 2004, EMERG MED CLIN N AM, V22, P265, DOI 10.1016/j.emc.2004.01.001; Shults RA, 2005, PEDIATRICS, V116, pE608, DOI 10.1542/peds.2005-0937; Stephens BD, 2005, WILD ENVIRON MED, V16, P192, DOI 10.1580/1080-6032(2005)16[192:RIIWSN]2.0.CO;2; *US BUR CENS, 2004, CENS POP; *US CONS PROD SAF, WHICH HELM WHIC ACT; *US CONS PROD SAF, 1999, SKI HELM EV POT HEAD; *US DEP AGR FOR SE, AM PART OUTD RECR RE	27	37	37	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1080-6032	1545-1534		WILD ENVIRON MED	Wildern. Environ. Med.	SUM	2008	19	2					91	98		10.1580/07-WEME-OR-152.1			8	Public, Environmental & Occupational Health; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Sport Sciences	310DR	WOS:000256509600003	18513117	Green Submitted, Bronze			2022-02-06	
J	Ashman, TA; Cantor, JB; Gordon, WA; Sacks, A; Spielman, L; Egan, M; Hibbard, MR				Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Sacks, Amanda; Spielman, Lisa; Egan, Matthew; Hibbard, Mary R.			A comparison of cognitive functioning in older adults with and without traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aging; APOE epsilon 4; cognitive functioning; older adult; traumatic brain injury	HEAD-INJURY; ALZHEIMERS-DISEASE; MODERATE; MILD; REHABILITATION; ASSOCIATION; DECLINE; RISK; AGE; EPIDEMIOLOGY	Objective: Cognitive impairments are common sequelae of traumatic brain injury (TBI) and are often associated with the natural process of aging. Few studies have examined the effect of both age and TBI on cognitive functioning. The purpose of this study was to compare cognitive functioning between older adults who sustained a TBI to an age-matched group of individuals without a brain injury and to determine whether the presence or absence of a genetic marker apolipoprotein 8 (APOE epsilon 4 allele) accounts for additional cognitive decline in both groups examined. Methods and procedures: Cognitive performance was measured by 11 neuropsychological tests, in 54 adults with TBI aged 55 and older and 40 age-matched control participants. All participants were reexamined 2 to 5 years later. Setting: Community volunteer-based sample examined at a large, urban medical center. Main outcome measure(s): California Verbal Learning Test; Wechsler Memory Scale-III (Logical Memory I & II; Visual Reproduction I & II); Grooved Pegboard; Woodcock-Johnson Test of Cognitive Ability (Visual Matching and Cross-out); Wisconsin Card Sorting Test; Trail Making Test A & B; Conners' Continuous Performance Task; Wechsler Adult Intelligence Scale-III (Vocabulary); Controlled Oral Word Association Test; and Boston Naming Test. Results: Participants with TBI had lower scores on tests of attention and verbal memory than did participants with no disability. Neither group exhibited a significant decline in cognitive function over time. The presence of the APOE epsilon 4 allele did not account for additional decline in cognitive function in either group. Conclusion(s): The findings suggest that older adults with TBI may not be at increased risk for cognitive decline over short time periods (2 to 5 years) even if they are carriers of the APOE epsilon 4 allele.	[Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Sacks, Amanda; Spielman, Lisa; Egan, Matthew; Hibbard, Mary R.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Ashman, TA (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013				ADEKOYA N, 1998, MMWR SURVEILL SUMM, V51, P1; AharonPeretz J, 1997, BRAIN INJURY, V11, P871; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Blacker D, 2007, ARCH NEUROL-CHICAGO, V64, P862, DOI 10.1001/archneur.64.6.862; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Centers for Disease Control and Prevention, 2002, CDC INJ RES AG; Chai Chen K, 2007, Am J Alzheimers Dis Other Demen, V22, P37, DOI 10.1177/1533317506295655; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; CHIANG MF, 1949, ACTA NEUROCHIR WIEN, V145, P653; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; CORKIN S, 1989, J NEUROSCI, V9, P3876; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1993, NEUROPSYCHOLOGY, V7, P193, DOI DOI 10.1037/0894-4105.7.2.193; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; Delis D.C., 2000, CALIFORNIA VERBAL LE; Flanagan JL, 1997, J COMMUN DISORD, V30, P33, DOI 10.1016/S0021-9924(96)00039-1; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Goodglass H, 1998, BRAIN LANG, V64, P1, DOI 10.1006/brln.1998.1950; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Hamsher K., 1989, MULTILINGUAL APHASIA; HAUT MC, 1992, NEUROPSYCHOLOGY, P51; HEATON RK, 1993, CARD SORTING TEST WC; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Katzman R, 1996, NEUROLOGY, V46, P889; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KERR C, 1995, BRAIN INJURY, V9, P777, DOI 10.3109/02699059509008234; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Mauri M, 2006, FUNCT NEUROL, V21, P223; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McArdle JJ, 2002, DEV PSYCHOL, V38, P115, DOI 10.1037//0012-1649.38.1.115; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; MILLIS SR, 1995, BRAIN INJURY, V9, P509, DOI 10.3109/02699059509008210; Millis SR, 2003, AM J PHYS MED REHAB, V82, pS32, DOI 10.1097/01.PHM.0000087007.19214.32; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rasmusson DX, 1996, BRAIN COGNITION, V31, P133, DOI 10.1006/brcg.1996.0038; Reitan R, 1985, HALSTEAD REITAN NEUR; *RES TRAIN CTR COM, 1998, BRAIN INJ QUEST; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Swan GE, 2005, J GERIATR PSYCH NEUR, V18, P196, DOI 10.1177/0891988705281864; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tulsky D., 1997, WAIS 3 WMS 3 TECHNIC; TULSKY DS, 1997, WMS 3 ADM SCORING MA; TUPPER DE, 1990, J LEARN DISABIL, V23, P306, DOI 10.1177/002221949002300510; US Census Bureau, 2005, INT STAT POP PROJ; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; vanDuijn CM, 1996, J NEUROL NEUROSUR PS, V60, P478, DOI 10.1136/jnnp.60.5.478; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Walker A E, 1972, Scand J Rehabil Med, V4, P5; Wechsler D, 1997, WAIS 3 WMS 3 TECHN M; WOODCOCK RW, 2001, W JOHNSON 3 TEST COG; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	81	37	40	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2008	23	3					139	148		10.1097/01.HTR.0000319930.69343.64			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	309XN	WOS:000256493600002	18520426				2022-02-06	
J	Fillpovic, R; Zecevic, N				Fillpovic, Radmila; Zecevic, Nada			Neuroprotective role of minocycline in co-cultures of human fetal neurons and microglia	EXPERIMENTAL NEUROLOGY			English	Article						LPS; ameboid microglia; neuroprotection; Bcl-2; bax; TLR4	CENTRAL-NERVOUS-SYSTEM; TOLL-LIKE RECEPTORS; SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; MULTIPLE-SCLEROSIS; MOLECULAR-MECHANISMS; PROTEIN-KINASES; INNATE IMMUNITY; MOUSE MODEL	Bacterial infections during pregnancy often result in premature birth and neonatal white matter damage. During these infections, microglia, the resident immune cells of the CNS, undergo activation and contribute to further neuronal damage of the CNS. Minocycline, a second-generation tetracycline antibiotic, inhibits microglial activation and protects neurons in rodents but data about its effects on human cells are limited. We studied the mechanism of the neuroprotective effect of minocycline in either purified cell cultures or co-cultures of microglia and neurons from human fetal brain during inflammation induced by lipopolysaccharide (LPS). In neuron/microglial co-cultures, minocycline treatment prevented activation and proliferation of microglia and protected neurons as demonstrated by decreased neuronal cell death and a shift of Bcl-2 family proteins toward anti-apoptotic ratio. Notably, neither minocycline nor LPS had an effect on neurons in purified neuronal cultures. The ability of minocycline to regulate activation of human fetal microglia might be relevant in therapies used towards treating neonatal CNS infections. (C) 2008 Elsevier Inc. All rights reserved.	[Fillpovic, Radmila; Zecevic, Nada] Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA		Fillpovic, R (corresponding author), Univ Connecticut, Dept Physiol & Neurobiol, 75 N Eagleville Rd,U-3156, Storrs, CT 06269 USA.	radmila.filipovic@uconn.edu; nzecevic@neuron.uchc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041489] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041489] Funding Source: NIH RePORTER		Ackman JB, 2006, J NEUROSCI, V26, P11413, DOI 10.1523/JNEUROSCI.3340-06.2006; Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Andjelkovic AV, 1998, BRAIN RES, V814, P13, DOI 10.1016/S0006-8993(98)00830-0; Back SA, 2004, SEMIN PERINATOL, V28, P405, DOI 10.1053/j.semperi.2004.10.010; BARZA M, 1975, ANTIMICROB AGENTS CH, V8, P713, DOI 10.1128/AAC.8.6.713; Bonelli RM, 2003, J PSYCHOPHARMACOL, V17, P461, DOI 10.1177/0269881103174008; Brosnan CF, 1996, BRAIN PATHOL, V6, P243, DOI 10.1111/j.1750-3639.1996.tb00853.x; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Bsibsi M, 2006, GLIA, V53, P688, DOI 10.1002/glia.20328; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Chechneva O, 2006, NEUROBIOL DIS, V23, P247, DOI 10.1016/j.nbd.2006.02.015; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; CHOI BH, 1981, J COMP NEUROL, V196, P683, DOI 10.1002/cne.901960412; Chu CT, 2004, EUR J BIOCHEM, V271, P2060, DOI 10.1111/j.1432-1033.2004.04132.x; Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001; Dammann O, 2001, EARLY HUM DEV, V64, P79, DOI 10.1016/S0378-3782(01)00183-9; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Familian A, 2006, GLIA, V53, P233, DOI 10.1002/glia.20268; Fan LW, 2005, NEUROSCIENCE, V133, P159, DOI 10.1016/j.neuroscience.2005.02.016; Ferrer I, 2003, BRAIN PATHOL, V13, P62; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Filipovic R, 2002, J NEUROIMMUNOL, V127, P1, DOI 10.1016/S0165-5728(02)00070-X; Filipovic R, 2008, GLIA, V56, P1, DOI 10.1002/glia.20582; HASSAN NF, 1991, NEUROSCIENCE, V41, P149, DOI 10.1016/0306-4522(91)90205-3; HETZMAN M, 2004, EUR J BIOCHEM, V271, P2050; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320; Kaftan H, 1998, SEMIN PERINATOL, V22, P15, DOI 10.1016/S0146-0005(98)80004-9; Karlsson M, 1996, ANTIMICROB AGENTS CH, V40, P1104, DOI 10.1128/AAC.40.5.1104; Kerfoot SM, 2004, J IMMUNOL, V173, P7070, DOI 10.4049/jimmunol.173.11.7070; Kerkovich DM, 1999, INT J DEV NEUROSCI, V17, P347, DOI 10.1016/S0736-5748(99)00036-2; Kloppenburg M, 1996, ANTIMICROB AGENTS CH, V40, P934, DOI 10.1128/AAC.40.4.934; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lai AY, 2006, GLIA, V53, P809, DOI 10.1002/glia.20335; Lauro GM, 1995, INT J DEV NEUROSCI, V13, P739, DOI 10.1016/0736-5748(95)00059-3; Lee SM, 2004, J NEUROCHEM, V91, P568, DOI 10.1111/j.1471-4159.2004.02780.x; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Leviton A, 2005, ANN NEUROL, V58, P821, DOI 10.1002/ana.20662; Li WW, 2005, J NEUROIMMUNOL, V158, P58, DOI 10.1016/j.jneuroim.2004.08.011; Lott Judy Wright, 2003, Crit Care Nurs Clin North Am, V15, P35; Maier K, 2007, NEUROBIOL DIS, V25, P514, DOI 10.1016/j.nbd.2006.10.022; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Metz LM, 2004, ANN NEUROL, V55, P756, DOI 10.1002/ana.20111; Monier A, 2006, J COMP NEUROL, V499, P565, DOI 10.1002/cne.21123; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x; Nikodemova M, 2007, J BIOL CHEM, V282, P15208, DOI 10.1074/jbc.M611907200; Noseworthy JH, 1999, CURR OPIN NEUROL, V12, P279, DOI 10.1097/00019052-199906000-00007; Penfield W., 1932, CYTOLOGY CELLULAR PA, V2, P482; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Ravina BM, 2003, NEUROLOGY, V60, P1234, DOI 10.1212/01.WNL.0000058760.13152.1A; Rezaie P, 2005, CEREB CORTEX, V15, P938, DOI 10.1093/cercor/bhh194; Rezaie P, 2003, NEUROEMBRYOLOGY, V2, P18, DOI DOI 10.1159/000068498; Romero R, 1998, AM J OBSTET GYNECOL, V179, P186, DOI 10.1016/S0002-9378(98)70271-6; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P817, DOI 10.1016/0002-9378(89)90409-2; Schwartz ML, 2004, SEMIN PERINATOL, V28, P379, DOI 10.1053/j.semperi.2004.10.009; Shankaran M, 2007, J NEUROSCI RES, V85, P2374, DOI 10.1002/jnr.21389; Slevin M, 2000, NEUROREPORT, V11, P2759, DOI 10.1097/00001756-200008210-00030; Song Y, 2004, NEUROREPORT, V15, P2181, DOI 10.1097/00001756-200410050-00007; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Suk K, 2004, NEUROSCI LETT, V366, P167, DOI 10.1016/j.neulet.2004.05.038; Tanaka J, 1996, EXP NEUROL, V137, P367, DOI 10.1006/exnr.1996.0038; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tsuji M, 2004, EXP NEUROL, V189, P58, DOI 10.1016/j.expneurol.2004.01.011; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zecevic N, 1998, DEV BRAIN RES, V105, P97, DOI 10.1016/S0165-3806(97)00176-4; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426	82	37	37	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2008	211	1					41	51		10.1016/j.expneurol.2007.12.024			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	298ZM	WOS:000255725600007	18359018				2022-02-06	
J	Schubert, GA; Poli, S; Mendelowitsch, A; Schilling, L; Thome, C				Schubert, Gerrit Alexander; Poli, Sven; Mendelowitsch, Aminadav; Schilling, Lothar; Thome, Claudius			Hypothermia reduces early hypoperfusion and metabolic alterations during the acute phase of massive subarachnoid hemorrhage: A Laser-Doppler-flowmetry and microdialysis study in rats	JOURNAL OF NEUROTRAUMA			English	Article						CBF autoregulation; hypothermia; metabolism; microdialysis; subarachnoid hemorrhage	CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL MICRODIALYSIS; MILD HYPOTHERMIA; ACUTE VASOCONSTRICTION; BEDSIDE MICRODIALYSIS; MODERATE HYPOTHERMIA; ENERGY-METABOLISM; AMINO-ACIDS; IN-VIVO	Morbidity and mortality of subarachnoid hemorrhage (SAH) are correlated with the severity of the patient's acute neurological deficit. This initial presentation has been attributed to cerebral hypoperfusion in the acute phase, and we investigated the impact of moderate hypothermia on the early changes in perfusion and metabolism following massive experimental SAH. SAH was induced in 61 anesthetized rats by rapid injection of 0.5 mL of arterial blood into the cisterna magna. In normothermia (NT), animals were kept at 37 degrees C, while in the primary hypothermia (pHT) group, temperature was lowered to 32 degrees C prior to SAH, and in the secondary hypothermia (sHT) group, cooling was started immediately after SAH. From 30 min prior to 180 min after SAH, Laser-Doppler-flowmetry (LDF) probes allowed online recording of cerebral blood flow (CBF) while parenchymal dialysate was collected by microdialysis probes within the frontoparietal cortex. In NT, the acute phase was characterized by impaired autoregulation and prolonged hypoperfusion. In pHT and sHT, autoregulation was preserved and acute hypoperfusion rapidly improved. SAH also caused a highly significant reduction in glucose in NT only. pHT significantly reduced accumulation of lactate, glutamate, and aspartate. Comparable trends were present for histidine, GABA, and taurine, while glutamine consumption was ameliorated. Early perfusion deficits caused by acute hypoperfusion and disruption of cerebral autoregulation can be ameliorated by hypothermia. Also, the acute phase of experimental SAH is characterized by glucose depletion, lactate accumulation, and release of excitatory amino acids, which can be influenced favorably by hypothermia.	[Schubert, Gerrit Alexander; Poli, Sven; Thome, Claudius] Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany; [Mendelowitsch, Aminadav] Cranio Facial Ctr Hirslanden, Neurosurg Clin, Aarau, Switzerland; [Schilling, Lothar] Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg Res, D-68167 Mannheim, Germany		Schubert, GA (corresponding author), Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	gerrit.schubert@nch.ma.uni-heidelberg.de	Schubert, Gerrit Alexander/Q-9192-2017	Schubert, Gerrit Alexander/0000-0001-9135-6042			Baldwin ME, 2004, STROKE, V35, P2506, DOI 10.1161/01.STR.0000144654.79393.cf; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; BEDERSON JB, 1995, STROKE, V26, P1086, DOI 10.1161/01.STR.26.6.1086; Cambj-Sapunar L, 2003, STROKE, V34, P1269, DOI 10.1161/01.STR.0000065829.45234.69; De Micheli E, 2000, ADV EXP MED BIOL, V483, P595; DELGADO TJ, 1985, STROKE, V16, P595, DOI 10.1161/01.STR.16.4.595; Eddy VA, 2000, SURG CLIN N AM, V80, P845, DOI 10.1016/S0039-6109(05)70099-2; El Idrissi A, 2003, ADV EXP MED BIOL, V526, P515; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Fujisawa H, 1999, J NEUROTRAUM, V16, P1083, DOI 10.1089/neu.1999.16.1083; Hutchinson PJ, 2002, J NEUROL NEUROSUR PS, V72, P99, DOI 10.1136/jnnp.72.1.99; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; JAKOBSEN J, 1992, ACTA NEUROL SCAND, V86, P1, DOI 10.1111/j.1600-0404.1992.tb08044.x; Karibe H, 2000, NEUROSURGERY, V47, P594, DOI 10.1097/00006123-200009000-00012; Khan SNH, 2000, NEUROCHEM RES, V25, P217, DOI 10.1023/A:1007519419342; Kollmar R, 2002, ANESTHESIOLOGY, V97, P868, DOI 10.1097/00000542-200210000-00018; Lynch JR, 2005, STROKE, V36, P2024, DOI 10.1161/01.STR.0000177879.11607.10; Morgan ME, 1996, J PHARMACOL EXP THER, V277, P1167; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; OKAMOTO K, 1983, BRAIN RES, V260, P249, DOI 10.1016/0006-8993(83)90678-9; Piepgras A, 2001, NEUROSURGERY, V48, P1128, DOI 10.1097/00006123-200105000-00033; Preisman S, 2005, BRIT J ANAESTH, V95, P207, DOI 10.1093/bja/aei147; PROUST F, 1995, STROKE, V26, P1553, DOI 10.1161/01.STR.26.9.1553; Ratsep T, 2001, J NEUROSURG, V95, P393, DOI 10.3171/jns.2001.95.3.0393; ROSENSTEIN J, 1984, NEUROSURGERY, V15, P519, DOI 10.1227/00006123-198410000-00008; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; Scheller D, 2000, NEUROCHEM RES, V25, P801, DOI 10.1023/A:1007513423270; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Sehba FA, 1999, STROKE, V30, P1955, DOI 10.1161/01.STR.30.9.1955; Shuaib A, 1996, ACT NEUR S, V67, P53; Thome C, 2005, NEUROL RES, V27, P229, DOI 10.1179/016164105X25252; Thome C, 2001, ACTA NEUROCHIR SUPPL, V77, P255; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Ueda Y, 2003, J NEUROSURG, V99, P899, DOI 10.3171/jns.2003.99.5.0899; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Vajkoczy P, 2005, J NEUROSURG, V103, P9, DOI 10.3171/jns.2005.103.1.0009; VERHAEGEN MJJ, 1993, STROKE, V24, P407, DOI 10.1161/01.STR.24.3.407; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919; Yamaguchi S, 2000, NEUROL RES, V22, P657; Zuccarello M, 2001, ACTA NEUROCHIR SUPPL, V77, P61	42	37	38	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2008	25	5					539	548		10.1089/neu.2007.0500			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	303PY	WOS:000256054100010	18352824				2022-02-06	
J	Adembri, C; Massagrande, A; Tani, A; Miranda, M; Margheri, M; De Gaudio, R; Pellegrini-Giampietro, DE				Adembri, Chiara; Massagrande, Alessandra; Tani, Alessia; Miranda, Marco; Margheri, Martina; De Gaudio, Raffaele; Pellegrini-Giampietro, Domenico E.			Carbamylated erythropoietin is neuroprotective in an experimental model of traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						erythropoietin; carbamylated erythropoietin; neuro-protection; organotypic hippocampal slices; propidium iodide; traumatic brain injury		Objective: The well-documented neuroprotective effects of recombinant human erythropoietin (rhEPO) are commonly associated with untoward erythrocyte-stimulating effects (polycythemia), with subsequent risk of thromboembolic complications. A carbamylated-rhEPO (CEPO) derivative, which is neuroprotective but lacks hematopoietic activity, has been recently developed. In this study, we evaluated the neuroprotective capability of CEPO in an in vitro model of cerebral trauma in which rhEPO was previously shown to reduce posttraumatic cell death. Design: Prospective, controlled experiment. Setting: Animal, basic science laboratory. Subjects: Wistar rats, 8 days old. Interventions: Organotypic hippocampal slices, obtained from rat brains, were subjected to a well-characterized model of mechanical injury followed by addition of 10 IU/mL rhEPO, 10-100 IU/mL CEPO, or vehicle (injured control) to the incubation medium at different times to assess the temporal window of therapeutic neuroprotection. Measurements and Main Results, Posttraumatic cell death was quantified at 12, 24, or 48 hrs after injury by measuring propidium iodide fluorescence in the selectively vulnerable CA1 hippocampal area. Posttraumatic injury, observed in injured, vehicle-treated hippocampal slices, was significantly attenuated by addition of either 10 IU/mL rhEPO or 10 IU/mL CEPO. The neuroprotective efficacy of 10 IU/mL rhEPO or CEPO remained intact even when administration was delayed 1 hr after trauma. Qualitative microscopy in semithin sections showed that both rhEPO and CEPO exerted a marked pyramidal neuron-sparing effect. Conclusion: Our study shows that 10 IU/mL CEPO exerts neuroprotective effects comparable with those of rhEPO in an in vitro model of mechanical cerebral trauma. Because CEPO lacks hematopoietic effects and seems to possess a prolonged therapeutic time window, this erythropoietin derivative may represent an exciting new pharmacologic tool in treating patients with mechanical injury to the brain.	[Adembri, Chiara; Massagrande, Alessandra; Miranda, Marco; De Gaudio, Raffaele] Univ Florence, Sect Anesthesiol & Intens Care, Dept Crit Care Med, Florence, Italy; [Tani, Alessia; Margheri, Martina] Univ Florence, Dept Anat Histol & Forens Med, Florence, Italy; [Pellegrini-Giampietro, Domenico E.] Univ Florence, Dept Preclin & Clin Pharmacol, Florence, Italy		Adembri, C (corresponding author), Univ Florence, Sect Anesthesiol & Intens Care, Dept Crit Care Med, Florence, Italy.	chiara.adembri@unifi.it		Pellegrini-Giampietro, Domenico E./0000-0002-3920-2297			Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Montero M, 2007, EXP NEUROL, V204, P106, DOI 10.1016/j.expneurol.2006.09.026; Sundstrom L, 2005, DRUG DISCOV TODAY, V10, P993, DOI 10.1016/S1359-6446(05)03502-6; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285	10	37	40	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2008	36	3					975	978		10.1097/CCM.0B013E3181644343			4	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	266QD	WOS:000253450500044	18176311				2022-02-06	
J	Naunheim, RS; Matero, D; Fucetola, R				Naunheim, Rosanne S.; Matero, David; Fucetola, Robert			Assessment of patients with mild concussion in the emergency department	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	23rd Annual National-Neurotrauma-Society Symposium	NOV 10-11, 2005	Washington, DC	Natl Neurotrauma Soc		concussion; head injury; neurocognitive testing	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; POSTCONCUSSION SYNDROME; NEUROPSYCHOLOGICAL ASSESSMENT; SPORTS CONCUSSION; IMPACT; SPECIFICITY; SENSITIVITY; SYMPTOMS; HEALTH	Objectives: (1) to test the validity of the Standardized Assessment of Concussion (SAC) in characterizing the early evolution of concussion-related symptoms and mental status changes in the emergency department (ED) setting and (2) to compare it to the Conner's Continuous Performance Test 2nd Edition (CPT-II). Design: Prospective within-subject (repeated measures) design. Participants: Sixty-two persons with concussion (Glasgow Coma Scale = 15) and negative head computed tomographic scan results were examined on arrival in the ED and 3 and 6 hours later. Setting: A large urban, tertiary medical center ED. Main Outcome Measures: SAC; CPT-II; Post-Concussion Symptom Scale-Revised (PCS-R). Results: SAC and CPT-II scores improved significantly over the time course in the ED. Symptoms did not correlate with improvement, with many subjects complaining of headache or nausea after their scores improved. The average initial score on the SAC was 21 +/- 5.4/30. Conclusion: The SAC appears sensitive to the acute changes following concussion. It may be a useful tool for clinicians in detecting mental status changes after a concussion, when Glasgow Coma Scale and radiologic findings are normal.	[Naunheim, Rosanne S.] Washington Univ, Sch Med, Div Emergency Med, St Louis, MO 63110 USA; [Fucetola, Robert] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Matero, David] Univ Colorado, Hlth Sci Ctr, Div Emergency Med, Denver, CO USA		Naunheim, RS (corresponding author), Washington Univ, Sch Med, Div Emergency Med, 660 So Euclid,Box 8072, St Louis, MO 63110 USA.						Amenta F, 2002, J NEUROL SCI, V203, P147, DOI 10.1016/S0022-510X(02)00281-2; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; Conners C, 2002, MANUAL CONNERS CONTI; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Epstein JN, 2001, J CLIN EXP NEUROPSYC, V23, P362, DOI 10.1076/jcen.23.3.362.1186; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Iverson GL, 2004, PSYCHOL REP, V95, P1241, DOI 10.2466/pr0.95.3f.1241-1247; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; RUTHERFORD WH, 1977, LANCET, V1, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Tinius TP, 2003, ARCH CLIN NEUROPSYCH, V18, P199, DOI 10.1016/S0887-6177(01)00196-2; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514	31	37	37	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2008	23	2					116	122		10.1097/01.HTR.0000314530.30401.70			7	Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	280KW	WOS:000254426700006	18362765				2022-02-06	
J	Di Giorgio, AM; Hou, YJ; Zhao, XR; Zhang, B; Lyeth, BG; Russell, MJ				Di Giorgio, Anthony M.; Hou, Yongjin; Zhao, Xueren; Zhang, Bin; Lyeth, Bruce G.; Russell, Michael J.			Dimethyl sulfoxide provides neuroprotection in a traumatic brain injury model	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						DMSO; curcumin; traumatic brain injury; antioxidant; neuroprotection	ACUTE NEURONAL DEGENERATION; FOCAL CEREBRAL-ISCHEMIA; FLUORO-JADE; OXIDATIVE STRESS; BEHAVIORAL DEFICITS; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; SPINAL-CORD; CURCUMIN; RAT	Purpose: The objective of this study was to evaluate the neuroprotective potential of the antioxidant, curcumin compared to alpha-tocopherol in a rat model of traumatic brain injury (TBI). Methods: Male Sprague-Dawley rats were administered curcumin (3, 30, 300 mg/kg), alpha-tocopherol (100 mg/kg), DMSO vehicle, or saline, 30 min prior to and 30 and 90 min after moderate lateral fluid percussion TBI. Rats were euthanized at 24 hours after injury and coronal brain sections were stained with Fluoro-Jade to identify degenerating neurons. Degenerating neurons in the CA2-3 sector of the dorsal hippocampus were quantified in 10 sections spaced 300 mu m apart in each rat. Results: One way ANOVA revealed a significant difference (p = 0.01) between groups. The curcumin, alpha-tocopherol, and DMSO groups had significantly reduced numbers of degenerating neurons compared to the saline-treated group. No significant differences were observed between any of the drug treatment groups or the DMSO group. Conclusions: Since protection in the DMSO vehicle group was equal to that of the experimental groups, no conclusions about neuroprotection regarding alpha-tocopherol or curcumin can be made from this study. The results suggest that DMSO may be acting as an overriding neuroprotectant in this experiment. We conclude that DMSO is a viable neuroprotective agent against secondary cell death in TBI.	[Zhao, Xueren; Zhang, Bin; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Di Giorgio, Anthony M.; Hou, Yongjin; Russell, Michael J.] AAaken Labs, Davis, CA USA; [Zhang, Bin] Shandong Univ, Sch Med, Dept Pharmacol, Jinan 250100, Shandong, Peoples R China		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 45136]; Aaken Laboratories; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045136] Funding Source: NIH RePORTER	This research was supported in part by NIH NS 45136 ( BGL) and Aaken Laboratories ( MJR).	Bardutzky J, 2005, J CEREBR BLOOD F MET, V25, P968, DOI 10.1038/sj.jcbfm.9600095; BROMONT C, 1989, STROKE, V20, P918, DOI 10.1161/01.STR.20.7.918; Butterfield DA, 2002, J NUTR BIOCHEM, V13, P444, DOI 10.1016/S0955-2863(02)00205-X; CLEMENS JA, 1991, STROKE, V22, P1048, DOI 10.1161/01.STR.22.8.1048; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; Cuzzocrea S, 2000, J PINEAL RES, V29, P217, DOI 10.1034/j.1600-0633.2002.290404.x; DELATORRE JC, 1991, CAN J PHYSIOL PHARM, V69, P191, DOI 10.1139/y91-028; DIKSHIT M, 1995, INDIAN J MED RES, V101, P31; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; Ghoneim AI, 2002, PHARMACOL RES, V46, P273, DOI 10.1016/S1043-6618(02)00123-8; HALL ED, 1992, J NEUROTRAUM, V9, pS165; Hulsmann S, 1999, NEUROSCI LETT, V261, P1, DOI 10.1016/S0304-3940(98)00999-9; Ikeda K, 2003, TOXICOLOGY, V189, P55, DOI 10.1016/S0300-483X(03)00152-5; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kiziltepe U, 2004, J VASC SURG, V40, P138, DOI 10.1016/j.jvs.2004.03.032; Langlois J. A., 2006, TRAUMATIC BRAIN INJU, P1; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; LITTLE JR, 1983, ANN NY ACAD SCI, V411, P269, DOI 10.1111/j.1749-6632.1983.tb47308.x; LITTLE JR, 1981, NEUROSURGERY, V9, P34, DOI 10.1227/00006123-198107000-00006; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIR M, 1996, DMSO MANY USES MUCH, P230; Osakada F, 2003, EUR J PHARMACOL, V465, P15, DOI 10.1016/S0014-2999(03)01495-X; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Perez-Pasten R, 2006, TOXICOL LETT, V161, P167, DOI 10.1016/j.toxlet.2005.09.001; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rajakrishnan V, 1999, PHYTOTHER RES, V13, P571, DOI 10.1002/(SICI)1099-1573(199911)13:7&lt;571::AID-PTR494&gt;3.0.CO;2-7; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; REPINE JE, 1981, P NATL ACAD SCI-BIOL, V78, P1001, DOI 10.1073/pnas.78.2.1001; SABEL BA, 1985, EXP NEUROL, V88, P95, DOI 10.1016/0014-4886(85)90116-5; SABEL BA, 1982, PHYSIOL BEHAV, V28, P1017, DOI 10.1016/0031-9384(82)90169-X; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SAWADA M, 1975, ANN NY ACAD SCI, V243, P337, DOI 10.1111/j.1749-6632.1975.tb25375.x; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SHARMA OP, 1976, BIOCHEM PHARMACOL, V25, P1811, DOI 10.1016/0006-2952(76)90421-4; Shoskes DA, 1998, TRANSPLANTATION, V66, P147, DOI 10.1097/00007890-199807270-00001; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Simonyi A, 2005, MOL NEUROBIOL, V31, P135, DOI 10.1385/MN:31:1-3:135; SREEJAYAN, 1994, J PHARM PHARMACOL, V46, P1013, DOI 10.1111/j.2042-7158.1994.tb03258.x; SRIMAL RC, 1973, J PHARM PHARMACOL, V25, P447, DOI 10.1111/j.2042-7158.1973.tb09131.x; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; TORRE JCDL, 1976, STROKE, V7, P577, DOI 10.1161/01.STR.7.6.577; Wang Q, 2005, J NEUROSCI RES, V82, P138, DOI 10.1002/jnr.20610; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	53	37	37	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2008	26	6					501	507					7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	390KO	WOS:000262162900007	19096138				2022-02-06	
J	Gagnon, I; Swaine, B; Champagne, F; Lefebvre, H				Gagnon, Isabelle; Swaine, Bonnie; Champagne, Francois; Lefebvre, Helene			Perspectives of adolescents and their parents regarding service needs following a mild traumatic brain injury	BRAIN INJURY			English	Article; Proceedings Paper	Conference of the International-Society-for-Adolescent-Psychology-and-Psychiatry	JUL 04-07, 2007	Montreal, CANADA	Int Soc Adolescent Psychol & Psychiat		adolescent; traumatic brain injury; health service needs; needs assessment	CHILDREN; SUPPORT; INFORMATION; MANAGEMENT; TEENAGERS; CANCER; RECOMMENDATIONS; PERCEPTIONS; PREVENTION; ISSUES	Primary objective: Various guidelines have been developed to implement coherent and uniform management of persons with a mild traumatic brain injury (mTBI), but those have typically been developed for adults or children and may not address or meet the specific needs of adolescents. The purpose of this study was to explore the specific service needs of adolescents (12-18 years) after a mTBI. Study design: Qualitative phenomenological study. Methods and procedures: Individual semi-structured interviews were conducted with 15 adolescents and their parents who had received different levels of care from paediatric trauma centres within the previous 12 months. Main outcomes and results: All adolescents and parents expressed the need to receive information about the injury, its expected recovery and when to return to activities. Many adolescents reported wanting to be seen rapidly, by professionals who genuinely care about them and who acknowledge that they have specific needs that differ from those of younger children. Parents and, to a lesser degree, adolescents think that enhanced communication between the healthcare and school systems would be beneficial following a mTBI to assist in returning to demanding academic activities. Conclusions: Professionals involved in the management of adolescents with mTBI should be aware of their needs in order to provide optimal and developmentally appropriate services.	[Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Phys Therapy Dept, Montreal, PQ H3H 1P3, Canada; [Gagnon, Isabelle; Champagne, Francois] Univ Montreal, Fac Med, Dept Adm Sante, Montreal, PQ H3C 3J7, Canada; [Swaine, Bonnie] Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; [Swaine, Bonnie; Lefebvre, Helene] Ctr Rech Interdisciplinaire & Readaptat Montreal, Montreal, PQ, Canada; [Lefebvre, Helene] Univ Montreal, Fac Sci Infirmieres, Montreal, PQ, Canada		Gagnon, I (corresponding author), McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Phys Therapy Dept, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.	isabelle.gagnon6@sympatico.ca		Gagnon, Isabelle/0000-0003-2043-1644			ACKARD DM, 2002, J AM ACAD CHILD ADOL, V41, P393; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Beresford BA, 2003, J ADOLESCENT HEALTH, V33, P172, DOI 10.1016/S1054-139X(03)00047-8; Bergman DA, 1999, PEDIATRICS, V104, P1407; Blum RW, 2002, PEDIATRICS, V110, P1301; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brooks BM, 2003, DISABIL REHABIL, V25, P51, DOI 10.1080/09638280210151987; *CAN PED SOC, 2006, PEDIAT CHILD HLTH, V11, P420; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chedekel DS, 2001, J BURN CARE REHABIL, V22, P301, DOI 10.1097/00004630-200107000-00012; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Dunsmore J, 1995, J PSYCHOSOC ONCOL, V13, P39; Esmond G, 2000, Nurs Stand, V14, P47; GAGNON I, 2007, IDENTIFYING SPECIFIC; Giorgi A., 1986, PHENOMENOLOGY PEDAGO, V4, P22; Greenspan AI, 2000, BRAIN INJURY, V14, P417; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; HARRIS JR, 1994, J COGNITIVE REHABILI, V12, P4; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hollis R, 2001, LANCET ONCOL, V2, P43, DOI 10.1016/S1470-2045(00)00195-9; Irwin CE, 2002, J ADOLESCENT HEALTH, V31, P91, DOI 10.1016/S1054-139X(02)00489-5; Ishibashi A, 2001, CANCER NURS, V24, P61, DOI 10.1097/00002820-200102000-00010; Jacobson LD, 2000, FAM PRACT, V17, P156, DOI 10.1093/fampra/17.2.156; Kari J A, 1999, Nurs Stand, V13, P49; Kelly Daniel, 2003, Eur J Oncol Nurs, V7, P53, DOI 10.1054/ejon.2002.0204; Kelly JP, 1997, NEUROLOGY, V48, P581; KING RB, 1980, ADOLESCENT REHABILIT; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Ministere de la sante et des services sociaux du Quebec & Societe d'assurance automobile du Quebec, 2005, OR MIN TRAUM CRAN LE; Neumark-Sztainer D, 2000, AM J HEALTH PROMOT, V14, P232, DOI 10.4278/0890-1171-14.4.232; Nuttall P, 1992, Issues Compr Pediatr Nurs, V15, P199, DOI 10.3109/01460869209078252; Patton MQ., 2015, QUALITATIVE RES EVAL, V4; PELCHAT D, 1997, RAPP RECH CQRS; Petersen DJ, 2001, NEEDS ASSESSMENT PUB; Potter R., 2002, PSYCHIAT B, V26, P377; Rahi JS, 2004, PEDIATRICS, V114, pE477, DOI 10.1542/peds.2004-0240; Ramritu PL, 1999, INT J NURS STUD, V36, P209, DOI 10.1016/S0020-7489(99)00016-4; Rosenzweig-Lipson S, 2000, FASEB J, V14, pA1321; Rossi P. H., 2004, EVALUATION SYSTEMATI; *ROY COLL PEDIAT C, 2003, CR114 ROY COLL PSYCH; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Sherwin ED, 2000, BRAIN INJURY, V14, P267; Strauss A., 1998, BASICS QUALITATIVE R, V2nd Edition; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Symon AG, 2003, MIDWIFERY, V19, P140, DOI 10.1016/S0266-6138(03)00004-4; VANDERMAREN JM, METHODES RECHERCHE E; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Whelan J, 2003, EUR J CANCER, V39, P2573, DOI 10.1016/j.ejca.2003.09.014; [No title captured]	55	37	37	0	18	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					161	173		10.1080/02699050701867381			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600007	18240045				2022-02-06	
J	Knight, C; Alderman, N; Johnson, C; Green, S; Birkett-Swan, L; Yorstan, G				Knight, Caroline; Alderman, Nick; Johnson, Chrissie; Green, Sharon; Birkett-Swan, Louise; Yorstan, Graeme			The St Andrew's Sexual Behaviour Assessment (SASBA): Development of a standardised recording instrument for the measurement and assessment of challenging sexual behaviour in people with progressive and acquired neurological impairment	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						sexual; behaviour; assessment; neurological; impairment	NEUROBEHAVIORAL REHABILITATION SERVICE; TRAUMATIC BRAIN-INJURY; AGGRESSIVE-BEHAVIOR; OVERT AGGRESSION; OAS-MNR; DEMENTIA; MANAGEMENT; REDUCTION; ISSUES; SCALE	Inappropriate sexual behaviour (ISB) as a sequela of neurological impairment is often overlooked in comparison to other challenging behaviours such as agitation and aggression, yet the impact on patients and carers can be equally significant and pervasive. Inconsistencies in terminology and lack of standardised measurement tools for ISB limit the degree to which such behaviour can be objectively and consistently identified, reported and managed within and between services. This paper proposes a new ISB scale, the St Andrew's Sexual Behaviour Assessment (SASBA) based on the Overt Aggression Scale - Modified for Neurorehabilitation (OAS-MNR: Alderman, Knight, Morgan, 1997). The validity and reliability of the SASBA for use with people who have both progressive neurological conditions and acquired brain injury admitted to in-patient services is explored. This scale allows continuous observations of four categories of ISB, each of which has four levels of severity, that were developed with reference to relevant literature (Johnson, Knight, Alderman, 2006). Statistical properties of the scale were obtained using written descriptions and video enactments of ISB generated by clinicians. Results indicate strong construct and content validity, and good inter-rater and test-retest reliability. Some preliminary field data are presented with 924 incidents of challenging behaviour captured by the OAS-MNR and SASBA over a 10-week period for 36 patients; 16.34% of incidents were sexual behaviour. Clinical uses of the scale and perceived concerns or benefits for staff are discussed.	[Knight, Caroline; Alderman, Nick; Johnson, Chrissie; Green, Sharon; Birkett-Swan, Louise; Yorstan, Graeme] St Andrews Healthcare, Northampton NN1 5DG, England		Knight, C (corresponding author), St Andrews Healthcare, Billing Rd, Northampton NN1 5DG, England.	cknight@standrew.co.uk		Yorston, Graeme/0000-0001-7045-9202; Alderman, Nick/0000-0002-8523-4142			Alagiakrishnan K, 2005, POSTGRAD MED J, V81, P463, DOI 10.1136/pgmj.2004.028043; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Alderman N, 2001, BRAIN DAM B, P175; Alderman N, 2002, BRAIN INJURY, V16, P469, DOI 10.1080/02699050110118458; Alderman N, 1999, NEUROPSYCHOL REHABIL, V9, P385, DOI 10.1080/096020199389455; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Alderman N, 2007, BRAIN INJURY, V21, P891, DOI 10.1080/02699050701543560; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Bezeau SC, 2004, BRAIN INJURY, V18, P299, DOI 10.1080/02699050310001617398; Braun UK, 2004, GERIATRICS, V59, P32; Britton KR, 1998, BRAIN INJURY, V12, P703, DOI 10.1080/026990598122269; BURNS A, 1990, BRIT J PSYCHIAT, V157, P86, DOI 10.1192/bjp.157.1.86; COHENMANSFIELD J, 1989, J GERONTOL, V44, pM77, DOI 10.1093/geronj/44.3.M77; Cubit K, 2007, AUSTRALAS J AGEING, V26, P64, DOI 10.1111/j.1741-6612.2007.00217.x; Devanand D P, 1992, Int Psychogeriatr, V4 Suppl 2, P161; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Gwet K., 2001, STAT TABLES INTER RA; Haboubi NHJ, 2003, DISABIL REHABIL, V25, P291, DOI 10.1080/0963828021000031188; Harris L, 1998, SEX DISABIL, V16, P205, DOI 10.1023/A:1023099109976; Hashmi F. H., 2000, CLIN GERIATRICS, V8, P61; Howell DC., 1997, STAT METHODS PSYCHOL, V4th ed; HUGHES GV, 2005, J SEX AGGRESS, V11, P95, DOI DOI 10.1080/13552600410001731803; Johnson C, 2006, BRAIN INJURY, V20, P687, DOI 10.1080/02699050600744137; Jones NT, 2007, J SEX AGGRESS, V13, P51; KAY SR, 1988, J NERV MENT DIS, V176, P539, DOI 10.1097/00005053-198809000-00007; Kelly G, 2006, BRAIN INJURY, V20, P307, DOI 10.1080/02699050500488074; LANDIS JR, 1977, BIOMETRICS, V33, P174; Lawrie Barbara, 2004, Rehabil Nurs, V29, P9; MAYERS KS, 1994, SEX DISABIL, V12, P207, DOI 10.1007/BF02547907; Nagaratnam N, 2002, ARCH GERONTOL GERIAT, V35, P195, DOI 10.1016/S0167-4943(02)00026-2; Philo S W, 1996, J Gerontol Nurs, V22, P17; Ryden M B, 1988, Alzheimer Dis Assoc Disord, V2, P342, DOI 10.1097/00002093-198802040-00003; RYDEN MB, 1991, RES NURS HEALTH, V14, P87, DOI 10.1002/nur.4770140203; Simpson G, 2001, J HEAD TRAUMA REHAB, V16, P556, DOI 10.1097/00001199-200112000-00004; Simpson G, 1999, J HEAD TRAUMA REHAB, V14, P567, DOI 10.1097/00001199-199912000-00005; Swan L, 2004, BRAIN INJURY, V18, P143, DOI 10.1080/02699050310001596923; Tsai SJ, 1999, ALZ DIS ASSOC DIS, V13, P60, DOI 10.1097/00002093-199903000-00009; Voyer Philippe, 2005, BMC Geriatr, V5, P13, DOI 10.1186/1471-2318-5-13; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; ZENCIUS A, 1990, Brain Injury, V4, P175, DOI 10.3109/02699059009026163; ZUIDEMA S, 2004, J GERIATR PSYCHIAT, V20, P41	43	37	37	0	13	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	2					129	159		10.1080/09602010701822381			31	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	276HD	WOS:000254131000001	18350412				2022-02-06	
J	Pekkala, S; Albert, ML; Spiro, A; Erkinjuntti, T				Pekkala, S.; Albert, M. L.; Spiro, A., III; Erkinjuntti, T.			Perseveration in Alzheimer's disease	DEMENTIA AND GERIATRIC COGNITIVE DISORDERS			English	Article						recurrent perseveration; stuck-in-set perseveration; continuous perseveration; semantic verbal fluency task; Alzheimer's disease	TRAUMATIC BRAIN INJURY; HUNTINGTONS-DISEASE; VASCULAR DEMENTIA; CATEGORY FLUENCY; WORKING-MEMORY; VERBAL FLUENCY; FRONTAL LOBES; APHASIA; VARIETIES; RETRIEVAL	Background/Aims and Methods: Perseveration is common in Alzheimer's disease (AD). We document the type and quantitative burden of perseveration as cognitive decline progresses from normal aging (n = 30) through mild AD (n = 20) to moderate AD (n = 20) by administering a semantic verbal fluency task. Results: We found perseveration to increase significantly with increasing severity of AD and different types of perseveration that distinguish the subject groups in a statistically significant manner. Recurrent and continuous perseverations appear early in AD. As the disease progresses in severity into moderate stage, the number of recurrent and continuous perseverations increases, and stuck-in-set perseverations emerge. Conclusion: The different types of perseveration are likely to reflect the progressive deterioration of different brain regions in AD. Copyright (C) 2007 S. Karger AG, Basel.	[Pekkala, S.; Albert, M. L.] VA Boston Healthcare Syst, Language Aging Brain Lab, Med Res Serv, Boston, MA 02130 USA; [Pekkala, S.] Univ Helsinki, Dept Speech Sci, Helsinki, Finland; [Erkinjuntti, T.] Univ Helsinki, Dept Neurol, Helsinki, Finland; [Spiro, A., III] VA Boston Healthcare Syst, Normat Aging Study, Boston, MA 02130 USA; [Albert, M. L.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Spiro, A., III] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA		Pekkala, S (corresponding author), VA Boston Healthcare Syst, Language Aging Brain Lab, Med Res Serv, 12D,Room 91,150 S Huntington Ave, Boston, MA 02130 USA.	seija.pekkala@helsinki.fi		Pekkala, Seija/0000-0003-2849-974X; Spiro III, Avron/0000-0003-4080-8621	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG014345] Funding Source: NIH RePORTER		ALBERT ML, 1986, CORTEX, V22, P103, DOI 10.1016/S0010-9452(86)80035-1; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; Azuma T, 2004, NEUROPSYCHOLOGY, V18, P69, DOI 10.1037/0894-4105.18.1.69; BARR WB, 1989, J COMMUN DISORD, V22, P327, DOI 10.1016/0021-9924(89)90009-9; BAYLES KA, 1993, J CLIN EXP NEUROPSYC, V15, P547, DOI 10.1080/01688639308402578; Beatty WW, 1997, AGING NEUROPSYCHOL C, V4, P273, DOI 10.1080/13825589708256652; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Demery JA, 2002, J CLIN EXP NEUROPSYC, V24, P818, DOI 10.1076/jcen.24.6.818.8400; Foldi NS, 2003, AGING NEUROPSYCHOL C, V10, P268, DOI 10.1076/anec.10.4.268.28970; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDBERG E, 1986, J CLIN EXP NEUROPSYC, V8, P710, DOI 10.1080/01688638608405191; Goldberg E., 2001, EXECUTIVE BRAIN FRON; HELMESTABROOKS N, 1994, BRAIN LANG, V47, P457; HOTZ G, 1995, BRAIN INJURY, V9, P151, DOI 10.3109/02699059509008188; HUDSON AJ, 1968, BRAIN, V91, P571, DOI 10.1093/brain/91.3.571; Lamar M, 1997, NEUROPSYCHOLOGY, V11, P523, DOI 10.1037/0894-4105.11.4.523; LURIA AR, 1965, BRAIN, V88, P1, DOI 10.1093/brain/88.1.1; Marczinski CA, 2006, BRAIN LANG, V97, P258, DOI 10.1016/j.bandl.2005.11.001; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Paulesu E, 1997, NEUROREPORT, V8, P2011, DOI 10.1097/00001756-199705260-00042; Possin KL, 2005, J CLIN EXP NEUROPSYC, V27, P953, DOI 10.1080/13803390490919092; Ramage A, 1999, BRAIN LANG, V66, P329, DOI 10.1006/brln.1999.2032; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; Rosen VM, 1997, J EXP PSYCHOL GEN, V126, P211, DOI 10.1037/0096-3445.126.3.211; ROSSER A, 1994, J NEUROL NEUROSUR PS, V57, P1389, DOI 10.1136/jnnp.57.11.1389; SANDSON J, 1984, NEUROPSYCHOLOGIA, V22, P715, DOI 10.1016/0028-3932(84)90098-8; SANDSON J, 1987, NEUROLOGY, V37, P1736, DOI 10.1212/WNL.37.11.1736; SHINDLER AG, 1984, BRAIN LANG, V23, P148, DOI 10.1016/0093-934X(84)90013-0; Suhr JA, 1998, ARCH CLIN NEUROPSYCH, V13, P447, DOI 10.1016/S0887-6177(97)00040-1; Traykov L, 2005, J NEUROL SCI, V229, P75, DOI 10.1016/j.jns.2004.11.006; TROSTER AI, 1989, BRAIN LANG, V37, P500, DOI 10.1016/0093-934X(89)90032-1; VILKKI J, 1989, BRAIN LANG, V36, P543, DOI 10.1016/0093-934X(89)90085-0; [No title captured]; [No title captured]; [No title captured]	37	37	37	0	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1420-8008	1421-9824		DEMENT GERIATR COGN	Dement. Geriatr. Cogn. Disord.		2008	25	2					109	114		10.1159/000112476			6	Geriatrics & Gerontology; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry	254MW	WOS:000252591700003	18075249				2022-02-06	
J	Ruocco, AC; Swirsky-Sacchetti, T; Chute, DL; Mandel, S; Platek, SM; Zillmer, EA				Ruocco, Anthony C.; Swirsky-Sacchetti, Thomas; Chute, Douglas L.; Mandel, Steven; Platek, Steven M.; Zillmer, Eric A.			Distinguishing between neuropsychological malingering and exaggerated psychiatric symptoms in a neuropsychological setting	CLINICAL NEUROPSYCHOLOGIST			English	Article						malingering; neuropsychology; personality; symptom validity	CLINICAL MULTIAXIAL INVENTORY; PERSONAL-INJURY LITIGANTS; MMPI-2 VALIDITY SCALES; CLOSED-HEAD INJURY; FAKE BAD SCALE; NEUROCOGNITIVE DYSFUNCTION; DISORDER SYMPTOMATOLOGY; COGNITIVELY INTACT; MODIFIER INDEXES; NORMATIVE DATA	It is unclear whether symptom validity test (SVT) failure in neuropsychological and psychiatric domains overlaps. Records of 105 patients referred for neuropsychological evaluation, who completed the Test of Memory Malingering (TOMM), Reliable Digit Span (RDS), and Millon Clinical Multiaxial Inventory-III (MCMI-III), were examined. TOMM and RDS scores were uncorrelated with MCMI-III symptom validity indices and factor analysis revealed two distinct factors for neuropsychological and psychiatric SVTs. Only 3.5% of the sample failed SVTs in both domains, 22.6% solely failed the neuropsychological SVT, and 6.1% solely failed the psychiatric SVT. The results support a dissociation between neuropsychological malingering and exaggeration of psychiatric symptoms in a neuropsychological setting.	[Ruocco, Anthony C.; Chute, Douglas L.; Platek, Steven M.; Zillmer, Eric A.] Drexel Univ, Dept Psychol, Neuropsychol Program, Philadelphia, PA 19102 USA; [Swirsky-Sacchetti, Thomas; Mandel, Steven] Thomas Jefferson Univ, Jefferson Med Coll, Dept Neurol, Philadelphia, PA 19107 USA		Ruocco, AC (corresponding author), Drexel Univ, Dept Psychol, Neuropsychol Program, 245 N 15th St,Mail Stop 626, Philadelphia, PA 19102 USA.	acr32@drexel.edu	Ruocco, Anthony C./B-4915-2010; Ruocco, Anthony Charles/AAM-4794-2021	Ruocco, Anthony C./0000-0002-1942-7181; 			Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bagby R. M., 1991, PSYCHOL ASSESSMENT J, V3, P496, DOI DOI 10.1037/1040-3590.3.3.496; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Blais MA, 1995, J CLIN PSYCHOL, V51, P783, DOI 10.1002/1097-4679(199511)51:6<783::AID-JCLP2270510609>3.0.CO;2-8; BOONE KB, 1995, J CLIN PSYCHOL, V51, P457, DOI 10.1002/1097-4679(199505)51:3<457::AID-JCLP2270510322>3.0.CO;2-7; Bunce SC, 2005, PROC SPIE, V5769, P24, DOI 10.1117/12.600601; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher J.N., 1989, MMPI 2 MINNESOTA MUL; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Choca J.P., 2004, INTERPRETIVE GUIDE M, V3rd; Daubert SD, 2000, PSYCHOL ASSESSMENT, V12, P418, DOI 10.1037/1040-3590.12.4.418; FALSSTEWART W, 1995, J PERS ASSESS, V64, P540, DOI 10.1207/s15327752jpa6403_11; GRAHAM JR, 2000, MMPI 2 ASSESSING PER; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCaffrey R.J., 2003, J FORENSIC NEUROPSYC, V3, P45, DOI [https://doi.org/10.1300/J151v03n03_03, DOI 10.1300/J151V03N03_03]; MCNEIL K, 1990, J CLIN PSYCHOL, V46, P755, DOI 10.1002/1097-4679(199011)46:6<755::AID-JCLP2270460609>3.0.CO;2-J; Millon, 1997, MANUAL MILLON CLIN M; Millon, 1983, MILLON CLIN MULTIAXI; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Morgan CD, 2002, J PERS ASSESS, V78, P288, DOI 10.1207/S15327752JPA7802_05; Nunez JM, 2005, NEUROIMAGE, V25, P267, DOI 10.1016/j.neuroimage.2004.10.041; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; RETZLAFF PD, 1991, J PERS ASSESS, V55, P219; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Ruocco AC, 2003, ARCH CLIN NEUROPSYCH, V18, P737; RUOCCO AC, 2006, UNPUB ASSESSING PERS; Ruocco AC, 2007, J NEUROPSYCH CLIN N, V19, P27, DOI 10.1176/appi.neuropsych.19.1.27; Schoenberg MR, 2004, J PERS ASSESS, V82, P273, DOI 10.1207/s15327752jpa8203_03; Schoenberg MR, 2003, PSYCHOL ASSESSMENT, V15, P198, DOI 10.1037/1040-3590.15.2.198; Slick D., 1997, VSVT VICTORIA SYMPTO; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; SMITH D, 1988, J CLIN PSYCHOL, V44, P165, DOI 10.1002/1097-4679(198803)44:2<165::AID-JCLP2270440212>3.0.CO;2-E; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; VANGORP WG, 1986, J CLIN PSYCHOL, V42, P742, DOI 10.1002/1097-4679(198609)42:5<742::AID-JCLP2270420510>3.0.CO;2-3; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; Wise EA, 2002, PSYCHOL REP, V90, P760, DOI 10.2466/PR0.90.3.760-766; Zago S, 2004, CORTEX, V40, P519, DOI 10.1016/S0010-9452(08)70144-8; [No title captured]	55	37	37	0	22	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	3					547	564		10.1080/13854040701336444			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	298LU	WOS:000255690000193	17853126				2022-02-06	
J	Wenke, RJ; Theodoros, D; Cornwell, P				Wenke, Rachel J.; Theodoros, Deborah; Cornwell, Petrea			The short- and long-term effectiveness of the LSVT (R) for dysarthria following TBI and stroke	BRAIN INJURY			English	Article						dysarthria; TBI; stroke; treatment	INTENSIVE VOICE TREATMENT; TRAUMATIC BRAIN-INJURY; HYPOKINETIC-SPASTIC DYSARTHRIA; SOUND PRESSURE LEVEL; PARKINSON-DISEASE; SPEECH TREATMENT; PRINCIPLED APPROACH; SPEAKING RATE; INTELLIGIBILITY; INDIVIDUALS	Objectives: To examine the effectiveness of Lee Silverman Voice Treatment (LSVT (R)) for the treatment of 10 individuals with dysarthria following TBI and stroke. Research design: ABAA experimental research design. Methods: Participants received 4 weeks of the standard LSVT (R) programme. To measure the effects of intervention, participants were assessed using perceptual and acoustic speech measures and everyday communication outcome measures prior to, immediately post and 6 months post-treatment. Results: Following treatment, participants demonstrated statistically and clinically significant improvements to several acoustic and perceptual parameters. This included increased vocal loudness in sustained phonation and connected speech, increased vocal frequency range and improved word and sentence intelligibility. Improved ratings of communication initiation and participation and well-being were also found on the AusTOMs and items on participant questionnaires post-LSVT (R). The majority of treatment effects were maintained 6 months following treatment. Conclusions: LSVT (R) has the potential to be a viable treatment option for individuals with dysarthria featuring respiratory-phonatory impairments following TBI and stroke.	[Wenke, Rachel J.; Theodoros, Deborah; Cornwell, Petrea] Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia; [Cornwell, Petrea] Princess Alexandra Hosp, Speech Pathol Dept, Brisbane, Qld 4102, Australia		Wenke, RJ (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia.	r.wenke@uq.edu.au	Theodoros, Deborah/F-1362-2010; Cornwell, Petrea/AAE-5547-2019				ARBOIX A, 1990, STROKE, V21, P842, DOI 10.1161/01.STR.21.6.842; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Ballard KJ, 2001, J COMMUN DISORD, V34, P3, DOI 10.1016/S0021-9924(00)00038-1; Beukelman D.R., 1984, ASSESSMENT INTELLIGI; BINDER LM, 1987, REHABIL PSYCHOL, P65; Cahill LM, 2004, J HEAD TRAUMA REHAB, V19, P241, DOI 10.1097/00001199-200405000-00005; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; COUNTRYMAN S, 1994, J MED LANGUAGE PATHO, V3, P211; De Bodt MS, 2002, J COMMUN DISORD, V35, P283, DOI 10.1016/S0021-9924(02)00065-5; DEPIJPER JR, 2007, SEMITONE CONVERSIONS; Dromey C, 1998, J SPEECH LANG HEAR R, V41, P1003, DOI 10.1044/jslhr.4105.1003; Dromey C, 2000, J MED SPEECH-LANG PA, V8, P155; Duffy, 2005, MOTOR SPEECH DISORDE; Eadie TL, 2006, AM J SPEECH-LANG PAT, V15, P307, DOI 10.1044/1058-0360(2006/030); El Sharkawi A, 2002, J NEUROL NEUROSUR PS, V72, P31; ENGEN T, 1972, WOODWORTH SCHLOSBERG, P478; Fairbanks G., 1960, VOICE ARTICULATION D; Fox C.M., 1997, AM J SPEECH-LANG PAT, V6, P85; Fox Cynthia M., 2006, Seminars in Speech and Language, V27, P283, DOI 10.1055/s-2006-955118; Hokkanen LSK, 2006, EUR J NEUROL, V13, P161, DOI 10.1111/j.1468-1331.2006.01157.x; Huber JE, 2006, J SPEECH LANG HEAR R, V49, P1368, DOI 10.1044/1092-4388(2006/098); KEATLEY A, 1994, EUR J DISORDER COMM, V29, P183; Kent R. D., 1996, AM J SPEECH LANGUAGE, V5, P7, DOI [10.1044/1058-0360.0503.07, DOI 10.1044/1058-0360.0503.07]; KENT RD, 1987, J SPEECH HEAR DISORD, V52, P367, DOI 10.1044/jshd.5204.367; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Knock TR, 2000, APHASIOLOGY, V14, P653, DOI 10.1080/026870300401379; LEFFORGE A, 2005, EAGLE FEATHER, V2, P1; MAAS E, IN PRESS AM J SPEECH; MCHENRY MA, 1994, J MED SPEECH-LANG PA, V2, P59; MILENKOVIC P, 2002, TF32 COMPUTER SOFTWA; Palmer R, 2007, INT J LANG COMM DIS, V42, P61, DOI 10.1080/13682820601173296; Perry A, 2004, INT J QUAL HEALTH C, V16, P285, DOI 10.1093/intqhc/mzh059; Prigatano GP, 2005, ACT NEUR S, V93, P39; Ramig L. O., 1994, J MED SPEECH-LANG PA, V2, P191; Ramig L.O., 1992, INTELLIGIBILITY SPEE, P119, DOI DOI 10.1075/SSPCL.1.05RAM; Ramig LO, 1996, NEUROLOGY, V47, P1496, DOI 10.1212/WNL.47.6.1496; Ramig LO, 2001, J NEUROL NEUROSUR PS, V71, P493, DOI 10.1136/jnnp.71.4.493; RAMIG LO, 1995, J SPEECH HEAR RES, V38, P1232, DOI 10.1044/jshr.3806.1232; Ramig LO, 1995, LEE SILVERMAN VOICE; Robertson S, 2001, INT J LANG COMM DIS, V36, P292, DOI 10.3109/13682820109177900; RUSSELL NK, 1988, J SPEECH HEAR RES, V31, P146, DOI 10.1044/jshr.3102.146; Saldert C, 2007, CLIN LINGUIST PHONET, V21, P637, DOI 10.1080/02699200701431056; Sapir S, 2003, AM J SPEECH-LANG PAT, V12, P387, DOI 10.1044/1058-0360(2003/085); Sapir S, 2001, J MED SPEECH-LANG PA, V9, P141; SAPIR S, J SPEECH LANGUAGE HE, V50, P899; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Schmidt R. A., 1999, MOTOR CONTROL LEARNI; SCHMIDT RA, 1992, PSYCHOL SCI, V3, P207, DOI 10.1111/j.1467-9280.1992.tb00029.x; SCHMIDT RA, 1991, MOTOR LEARNING HUMAN; Sellars C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002088.pub2; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; SMITH ME, 1995, J VOICE, V9, P453, DOI 10.1016/S0892-1997(05)80210-3; Solomon NP, 2004, J MED SPEECH-LANG PA, V12, P213; Solomon NP, 2001, AM J SPEECH-LANG PAT, V10, P51, DOI 10.1044/1058-0360(2001/008); Solomon NP, 2000, J VOICE, V14, P331; Spencer KA., 2002, 3 AC NEUR COMM DIS S; SPIELMAN J, 2000, AM SPEECH LANG HEAR; Stevens S. S., 1975, PSYCHOPHYSICS; TANNER DC, 2003, PSYCHOL NEUROGENIC C; Tasko SM, 2004, J SPEECH LANG HEAR R, V47, P85, DOI 10.1044/1092-4388(2004/008); Theodoros DG, 2001, TRAUMATIC BRAIN INJU, P155; Tjaden K, 2004, J SPEECH LANG HEAR R, V47, P766, DOI 10.1044/1092-4388(2004/058); Wang YT, 2005, J COMMUN DISORD, V38, P231, DOI 10.1016/j.jcomdis.2004.12.001; Ward EC, 2000, J MED SPEECH-LANG PA, V8, P331; WARLOW CP, 1996, STROKE PRACTICAL GUI; Weismer G, 2002, J SPEECH LANG HEAR R, V45, P421, DOI 10.1044/1092-4388(2002/033); Weismer G., 1992, INTELLIGIBILITY SPEE, P68; Whitehill TL, 2002, J SPEECH LANG HEAR R, V45, P80, DOI 10.1044/1092-4388(2002/006); Williams LS, 2006, STROKE, V37, P2081, DOI 10.1161/01.STR.0000230583.10311.9f; Wohlert AB, 2000, J SPEECH LANG HEAR R, V43, P1229, DOI 10.1044/jslhr.4305.1229; Wood RL, 2001, BRAIN DAM B, P3; Yorkston KM., 1999, MANAGEMENT MOTOR SPE; YORKSTON KM, 2005, PRACTICE GUIDELINES; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	74	37	38	1	42	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	4					339	352		10.1080/02699050801960987			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	279HS	WOS:000254346900007	18365848				2022-02-06	
J	Cullen, DK; Stabenfeldt, SE; Simon, CM; Tate, CC; LaPlaca, MC				Cullen, D. Kacy; Stabenfeldt, Sarah E.; Simon, Crystal M.; Tate, Ciara C.; LaPlaca, Michelle C.			In vitro neural injury model for optimization of tissue-engineered constructs	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						transplantation; apoptosis; laminin; neural stem cells	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; SPINAL-CORD-INJURY; STEM-CELLS; HIPPOCAMPAL-NEURONS; PRIMARY CULTURES; GLIAL SCAR; RAT; ASTROCYTES	Stem cell transplantation is a promising approach for the treatment of traumatic brain injury, although the therapeutic benefits are limited by a high degree of donor cell death. Tissue engineering is a strategy to improve donor cell survival by providing structural and adhesive support. However, optimization prior to clinical implementation requires expensive and time-consuming in vivo studies. Accordingly, we have developed a three-dimensional (3-D) in vitro model of the injured host-transplant interface that can be used as a test bed for high-throughput evaluation of tissue-engineered strategies. The neuronal-astrocytic cocultures in 3-D were subjected to mechanical loading (inducing cell death and specific astrogliotic alterations) or to treatment with transforming growth factor-beta 1 (TGF-beta l), inducing astrogliosis without affecting viability. Neural stem cells (NSCs) were then delivered to the cocultures. A sharp increase in the number of TUNEL+ donor cells was observed in the injured cocultures compared to that in the TGF-beta 1-treated and control cocultures, suggesting that factors related to mechanical injury, but not strictly astrogliosis, were detrimental to donor cell survival. We then utilized the mechanically injured cocultures to evaluate a methylcellulose-laminin (MC-LN) scaffold designed to reduce apoptosis. When NSCs were codelivered with MC alone or MC-LN to the injured cocultures, the number of caspase(+) donor cells significantly decreased compared to that with vehicle delivery (medium). Collectively, these results demonstrate the utility of an in vitro model as a preanimal test bed and support further investigation of a tissue-engineering approach for chaperoned NSC delivery targeted to improve donor cell survival in neural transplantation. (C) 2007 Wiley-Liss, Inc.	[Cullen, D. Kacy; Stabenfeldt, Sarah E.; Simon, Crystal M.; Tate, Ciara C.; LaPlaca, Michelle C.] Emory Univ, Georgia Inst Technol, Dept Biomed Engn Inst Bioengn & Biosci, Lab Neuroengn, Atlanta, GA 30322 USA		LaPlaca, MC (corresponding author), GT Emory Coulter Dept BME, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS054527] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1F32 NS 054527] Funding Source: Medline		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Asher RA, 2000, J NEUROSCI, V20, P2427; Bakshi A, 2005, BRAIN RES, V1065, P8, DOI 10.1016/j.brainres.2005.09.059; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Braitenberg V, 2001, J COMPUT NEUROSCI, V10, P71, DOI 10.1023/A:1008920127052; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Conti AC, 1998, J NEUROSCI, V18, P5663; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Evans MS, 1998, J NEUROSCI METH, V79, P37, DOI 10.1016/S0165-0270(97)00159-3; Faijerson J, 2006, J NEUROSCI RES, V84, P1415, DOI 10.1002/jnr.21044; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FERREIRA A, 1987, DEV BRAIN RES, V34, P9, DOI 10.1016/0165-3806(87)90191-X; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GABBOTT PLA, 1987, NEUROSCIENCE, V21, P833, DOI 10.1016/0306-4522(87)90040-6; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gary DS, 2003, J NEUROCHEM, V84, P878, DOI 10.1046/j.1471-4159.2003.01579.x; Gary DS, 2001, J NEUROCHEM, V76, P1485, DOI 10.1046/j.1471-4159.2001.00173.x; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Irvin DK, 2003, DEV NEUROSCI-BASEL, V25, P162, DOI 10.1159/000072265; Kanelos SK, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199812000-00003; Kobayashi K, 1999, MACROMOLECULES, V32, P7070, DOI 10.1021/ma990242n; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; KOLLER H, 1990, SYNAPSE, V5, P59, DOI 10.1002/syn.890050105; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Leone DP, 2005, J CELL SCI, V118, P2589, DOI 10.1242/jcs.02396; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; MCINTOSH TK, 1999, SECONDARY BRAIN INJU; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Micci MA, 2005, NEUROGASTROENT MOTIL, V17, P557, DOI 10.1111/j.1365-2982.2005.00702.x; Mondal D, 2004, CANCER INVEST, V22, P925, DOI 10.1081/CNV-200039679; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; NUNEZ J, 1988, TRENDS NEUROSCI, V11, P477, DOI 10.1016/0166-2236(88)90004-5; PASSAQUIN AC, 1994, INT J DEV NEUROSCI, V12, P363, DOI 10.1016/0736-5748(94)90086-8; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; PIZZI M, 1995, MOL BRAIN RES, V34, P38, DOI 10.1016/0169-328X(95)00129-G; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rao MS, 1999, ANAT RECORD, V257, P137; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; SANTAOLALLA J, 1995, J NEUROSCI RES, V42, P172, DOI 10.1002/jnr.490420204; Schmeichel KL, 2003, J CELL SCI, V116, P2377, DOI 10.1242/jcs.00503; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH GM, 1990, DEV BIOL, V138, P377, DOI 10.1016/0012-1606(90)90204-V; Stabenfeldt SE, 2006, J BIOMED MATER RES A, V77A, P718, DOI 10.1002/jbm.a.30638; Steinschneider R, 1996, DEV BRAIN RES, V95, P15, DOI 10.1016/0165-3806(96)00052-1; Tate MC, 2004, MOL CELL NEUROSCI, V27, P22, DOI 10.1016/j.mcn.2004.05.001; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Whittemore SR, 1999, J NEUROTRAUM, V16, P667, DOI 10.1089/neu.1999.16.667; Yamada KM, 2003, BRAZ J MED BIOL RES, V36, P959, DOI 10.1590/S0100-879X2003000800001	70	37	38	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC	2007	85	16					3642	3651		10.1002/jnr.21434			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	243EP	WOS:000251778200015	17671988				2022-02-06	
J	Corral, L; Ventura, JL; Herrero, JI; Monfort, JL; Juncadella, M; Gabarrs, A; Bartolome, C; Javierre, CF; Garcia-Huete, L				Corral, Luisa; Luis Ventura, Jose; Ignacio Herrero, Jose; Luis Monfort, Jose; Juncadella, Montserrat; Gabarrs, Andreu; Bartolome, Carlos; Javierre, Casimiro F.; Garcia-Huete, Lucia			Improvement in GOS and GOSE scores 6 and 12 months after severe traumatic brain injury	BRAIN INJURY			English	Article						severe traumatic brain injury; Glasgow outcome scale; Glasgow coma scale; timing; prognosis	GLASGOW-OUTCOME-SCALE; SEVERE HEAD-INJURY; YOUNG-PEOPLE; FOLLOW-UP; DISABILITY; ADULTS; DAMAGE; CARE	Primary objective: To assess improvements in Glasgow Outcome Scale (GOS) and GOS extended (GOSE) scores between 6 months and 1 year following severe traumatic brain injury (TBI). Methods and procedures: One studied 214 adult patients with severe TBI with Glasgow Coma Scale (GCS) < 9 admitted to Intensive Care Unit (ICU). GOS scores were obtained 6 and 12 months after injury in 195 subjects. Patients were predominantly male (84%) and median age was 35 years. Main outcomes and results: Outcome (GOS and GOSE at 6 months and I year) was better in the high GCS score at admission (6-8) group than in the low score group (3-5). The improvement in GOS scores between 6 months and 1 year was greater in the high GCS score at admission group than in the low score group. At 6 months, 75 patients had died and 120 survived. None died between the 6-12-month assessments; at 12 months, 36% had improved GOS score. Conclusions: GOS scores improved between 6-12 months after severe TBI in 36% of survivors and it is concluded that the expectancy of improvement is incomplete at 6 months. This improvement was greater in patients with better GCS scores (6-8) at admission than in those with worse GCS scores (3-5).	[Corral, Luisa; Luis Ventura, Jose; Ignacio Herrero, Jose] Bellvitge Univ Hosp, Intens Care Unit, Barcelona 08907, Spain; [Luis Monfort, Jose] Bellvitge Univ Hosp, Dept Neuroradiol, Barcelona 08907, Spain; [Juncadella, Montserrat] Bellvitge Univ Hosp, Dept Neuropsychol, Barcelona 08907, Spain; [Gabarrs, Andreu] Bellvitge Univ Hosp, Dept Neurosurg, Barcelona 08907, Spain; [Bartolome, Carlos; Garcia-Huete, Lucia] Bellvitge Univ Hosp, Dept Anaesthesiol, Barcelona 08907, Spain; [Javierre, Casimiro F.] Univ Barcelona, Dept Physiol Sci 2, Barcelona, Spain		Corral, L (corresponding author), Bellvitge Univ Hosp, Intens Care Unit, Feixa Llarga S-N,Hosp Llobregat, Barcelona 08907, Spain.	301301ca@comb.es		Corral, Luisa/0000-0002-2888-7833			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Avesani R, 2005, BRAIN INJURY, V19, P933, DOI 10.1080/02699050400002371; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Currens JAB, 2000, INJURY, V31, P93, DOI 10.1016/S0020-1383(99)00244-2; de Guise E, 2005, CAN J NEUROL SCI, V32, P186, DOI 10.1017/S0317167100003954; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hoffmann B, 2002, ACT NEUR S, V79, P33; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; LANGLOIS JA, 2003, SURVEILLANCE SUMMARI, V27, P1; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Orient-Lopez F, 2004, REV NEUROLOGIA, V39, P901, DOI 10.33588/rn.3910.2004302; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Woischneck D, 1998, ACT NEUR S, V71, P138	34	37	40	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2007	21	12					1225	1231		10.1080/02699050701727460			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	249HP	WOS:000252219200002	18236198				2022-02-06	
J	Bell, JD; Ai, JL; Chen, YH; Baker, AJ				Bell, Joshua D.; Ai, Jinglu; Chen, Yonghong; Baker, Andrew J.			Mild in vitro trauma induces rapid Glur2 endocytosis, robustly augments calcium permeability and enhances susceptibility to secondary excitotoxic insult in cultured Purkinje cells	BRAIN			English	Article						GluR2; AMPA; stretch; traumatic brain injury; cerebellum; Purkinje cells; calcium; endocytosis	GLUTAMATE-OPERATED CHANNELS; OXYGEN-GLUCOSE DEPRIVATION; EXCITATORY AMINO-ACIDS; AMPA-RECEPTOR CHANNELS; STRETCH-INDUCED INJURY; BRAIN-INJURY; MECHANICAL STRETCH; DEPENDENT NEURODEGENERATION; QUANTITATIVE-DETERMINATION; MOLECULAR-MECHANISMS	Mild brain trauma results in a wide range of neurological symptoms that are not easily explained by the primary pathology. Purkinje neurons of the cerebellum are selectively vulnerable to brain trauma, including indirect remote trauma to the forebrain. This vulnerability manifests itself as a selective and delayed cell loss, for which the underlying mechanisms are poorly understood. Alterations to the surface expression of calcium impermeable AMPA receptors (GluR2-containing) may mediate post-traumatic calcium overload, and initiate biochemical cascades that ultimately cause progressive cell death. Our current study examined this hypothesis using an in vitro model of mild Purkinje trauma, delivered by an elastic stretch at 2.5-2.9 pounds per square inch (psi). This mild trauma alone did not increase cell loss as measured by propidium iodide (PI) uptake (at 20 h) compared to uninjured controls. However, there was a marked increase in cell loss, when cells following mild trauma, were exposed to 10 mu M AMPA for 1 h compared to either mild trauma or AMPA exposure alone. Mild injury rendered Purkinje neurons significantly more permeable to AMPA-stimulated (4 mu M) calcium influx at 15 min post-injury, including a sustained calcium plateau. This effect was eliminated by inhibiting protein kinase C-dependent GluR2 endocytosis with 2 mu M Go6976 or blocking the calcium pore of GluR1/3 containing AMPARs with 500 nM 1-naphthylacetyl spermine (Naspm). Nifedipine (2 mM) eliminated the calcium plateau following mild injury but not the initial spike of Ca2+ increase. These results suggest that mild injuries resulted in a rapid AMPA receptor subtype switch (GluR2 was replaced by GluR1/3), which in turn resulted in an enhanced Ca2+ permeability. We further confirmed this by immunocytochemistry. Dendritic GluR2 co-localization with the pre-synaptic marker synaptophysin was markedly down-regulated at 15 min following mild stretch (P < 0.01), indicative of a rapid decrease in the synaptic expression of receptors containing this subunit. Carboxyfluorescence (CBF) assays revealed that mild stretch did not alter membrane integrity. Finally, we demonstrated that the combination of 500 nM Naspm and 5 nM Go6976 conferred a powerful neuroprotective effect on Purkinje cells by effectively eliminating the effects of mild stretch combined with AMPA in 95% of cells. These results represent a newly described mechanism rendering neurons susceptible to secondary injuries following trauma. Prevention of GluR2 endocytosis may be critical in the development of pharmacotherapies aimed at mild, seemingly inconsequential trauma, to avoid ensuing secondary damage.	Univ Toronto, St Michaels Hosp, Cara Phelan Ctr Trauma Res, Traumat Brain Injury Lab, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON, Canada		Baker, AJ (corresponding author), Univ Toronto, St Michaels Hosp, Cara Phelan Ctr Trauma Res, Traumat Brain Injury Lab, 100 Coll St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca		AI, JINGLU/0000-0001-7414-0207			Ai JL, 2007, EXP BRAIN RES, V177, P95, DOI 10.1007/s00221-006-0654-9; Ai JL, 2006, EXP BRAIN RES, V169, P126, DOI 10.1007/s00221-005-0314-5; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BARTOLETTI DC, 1989, FEBS LETT, V256, P4, DOI 10.1016/0014-5793(89)81707-7; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; BRORSON JR, 1994, J NEUROSCI, V14, P187; BRORSON JR, 1992, MOL PHARMACOL, V41, P603; BRORSON JR, 1995, J NEUROSCI, V15, P4515; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; David JC, 1996, J NEUROSCI, V16, P200; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gift EA, 2000, CYTOMETRY, V39, P243; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Groc L, 2006, CELL TISSUE RES, V326, P423, DOI 10.1007/s00441-006-0254-9; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; JOELS M, 1989, P NATL ACAD SCI USA, V86, P3404, DOI 10.1073/pnas.86.9.3404; Joyal CC, 1996, BRAIN RES, V739, P1, DOI 10.1016/S0006-8993(96)00333-2; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Lalonde R, 2003, CEREBELLUM, V2, P300, DOI 10.1080/14734220310017456; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Leggio MG, 2000, P NATL ACAD SCI USA, V97, P2320, DOI 10.1073/pnas.040554297; LINDEN DJ, 1993, NEURON, V11, P1093, DOI 10.1016/0896-6273(93)90222-D; Liu BS, 2006, J NEUROSCI, V26, P5309, DOI 10.1523/JNEUROSCI.0567-06.2006; Liu SQJ, 2000, NATURE, V405, P454, DOI 10.1038/35013064; LLANO I, 1988, P NATL ACAD SCI USA, V85, P3221, DOI 10.1073/pnas.85.9.3221; LUCHTER S, 1995, J NEUROTRAUM, V12, P517, DOI 10.1089/neu.1995.12.517; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Manni E, 2004, NAT REV NEUROSCI, V5, P241, DOI 10.1038/nrn1347; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; Middleton FA, 1998, TRENDS NEUROSCI, V21, P367, DOI 10.1016/S0166-2236(98)01330-7; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; Momiyama A, 2003, J PHYSIOL-LONDON, V549, P75, DOI 10.1113/jphysiol.2002.033472; Momiyama A, 1996, J PHYSIOL-LONDON, V494, P479, DOI 10.1113/jphysiol.1996.sp021507; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; Ogoshi F, 2003, J NEUROSCI, V23, P10521; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Petrosini L, 1998, PROG NEUROBIOL, V56, P191, DOI 10.1016/S0301-0082(98)00036-7; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Sattler R, 1997, J CEREBR BLOOD F MET, V17, P455, DOI 10.1097/00004647-199704000-00011; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SORIMACHI M, 1993, J NEUROCHEM, V60, P1236, DOI 10.1111/j.1471-4159.1993.tb03282.x; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Tanaka J, 2005, J NEUROSCI, V25, P799, DOI 10.1523/JNEUROSCI.4256-04.2005; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Tempia F, 1996, J NEUROSCI, V16, P456; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; Yuzaki M, 1996, J NEUROSCI, V16, P4651; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	76	37	42	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2007	130		10				2528	2542		10.1093/brain/awm164			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	218UC	WOS:000250039500007	17664176	hybrid			2022-02-06	
J	Kirov, I; Fleysher, L; Babb, JS; Silver, JM; Grossman, RI; Gonen, O				Kirov, Ivan; Fleysher, Lazar; Babb, James S.; Silver, Jonathan M.; Grossman, Robert I.; Gonen, Oded			Characterizing 'mild' in traumatic brain injury with proton MR spectroscopy in the thalamus: Initial findings	BRAIN INJURY			English	Article						mild traumatic brain injury (mTBI); 3D proton MR spectroscopy ((1)H-MRS); thalamus; N-acetylaspartate (NAA); metabolic imaging	MAGNETIC-RESONANCE-SPECTROSCOPY; HEAD-INJURY; AXONAL INJURY; MISERABLE MINORITY; MAJOR DEPRESSION; UNITED-STATES; SEVERITY; DISORDER; ATROPHY; HUMANS	Objective: Although most mild traumatic brain injury ( mTBI) patients suffer any of several post- concussion symptoms suggestive of thalamic involvement, they rarely present with any MRI- visible pathology. The aim here, therefore, is to characterize their thalamic metabolite levels with proton MR spectroscopy ((1)H- MRS) compared with healthy controls. Methods: T(1)- weighted MRI and multi- voxel (1)H- MRS were acquired at 3 Tesla from 20 mTBI ( Glasgow Coma Scale score of 15 - 13) patients, 19 - 59 years old, 0 - 7 years post- injury; and from 17 age and gender matched healthy controls. Mixed model regression was used to compare patients and controls with respect to the mean absolute N- acetylaspartate ( NAA), choline ( Cho) and creatine ( Cr) levels within each thalamus. Results: The mTBI- induced thalamic metabolite concentration changes were under +/- 13.0% for NAA, +/- 13.5% for Cr and +/- 18.8% for Cho relative to their corresponding concentrations in the controls: NAA: 10.08 +/- 0.30 ( mean +/- standard error), Cr: 5.62 +/- 0.18 and Cho: 2.08 +/- 0.09mM. These limits represent the minimal detectable differences between the two cohorts. Conclusion: The change in metabolic levels in the thalamus of patients who sustained clinically defined mTBI could be an instrumental characteristic of 'mildness'. (1)H- MRS could, therefore, serve as an objective laboratory indicator for differentiating 'mild' from more severe categories of head- trauma, regardless of the presence or lack of current clinical symptoms.	NYU, Sch Med, Dept Radiol, New York, NY 10016 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA		Gonen, O (corresponding author), NYU, Sch Med, Dept Radiol, 650 1st Ave, New York, NY 10016 USA.	oded.gonen@med.nyu.edu	Kirov, Ivan/I-2792-2019	Kirov, Ivan/0000-0001-5641-8578; Gonen, Oded/0000-0002-3148-2028; Babb, James/0000-0003-1798-1186	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB001015] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39135] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Cihangiroglu M, 2002, NEUROL RES, V24, P7, DOI 10.1179/016164102101199440; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Goelman G, 2006, MAGN RESON MED, V56, P34, DOI 10.1002/mrm.20942; Gonen O, 1998, MAGN RESON MED, V39, P34, DOI 10.1002/mrm.1910390108; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kreis R, 1997, PROG NUCL MAG RES SP, V31, P155, DOI 10.1016/S0079-6565(97)00014-9; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Soher BJ, 1998, MAGNET RESON MED, V40, P822, DOI 10.1002/mrm.1910400607; Son BC, 2000, ACT NEUR S, V76, P13; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE G, 1974, LANCET, V2, P81; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	46	37	39	0	7	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2007	21	11					1147	1154		10.1080/02699050701630383			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	222WX	WOS:000250329900006	17882630				2022-02-06	
J	Ganesalingam, K; Yeates, KO; Sanson, A; Anderson, V				Ganesalingam, Kalaichelvi; Yeates, Keith Owen; Sanson, Ann; Anderson, Vicki			Social problem-solving skills following childhood traumatic brain injury and its association with self-regulation and social and behavioural functioning	JOURNAL OF NEUROPSYCHOLOGY			English	Article							RATING-SCALE; HEAD-INJURY; ATTENTION; COMPETENCE; CHILDREN; RECOVERY; OUTCOMES; DELAY; TERM	This study examines social problem-solving skills following childhood traumatic brain injury (TBI) and its association with self-regulation, and social and behavioural functioning. Participants included 65 children with moderate to severe TBI and 65 children without TBI, all between 6 and 11 years of age. Social problem-solving, self-regulation, and social and behavioural functioning were assessed 2-5 years following injury. Children were administered a newly developed semi-structured task to assess their solutions to hypothetical situations involving social problems or dilemmas. When compared with uninjured children, those with TBI suggested avoidant and aggressive solutions more often and assertive solutions less often in response to the hypothetical situations. Children's self-regulatory skills, as measured by the Matching Familiar Figures Test (MFFT), Test of Everyday Attention for Children (TEA-Ch) and the Delay of Gratification Task (DGT), collectively accounted for significant variance in their solutions to social problems, such that better self-regulation predicted more assertive solutions and fewer aggressive solutions. Assertive solutions were positively related to parent- and teacher-rated social and behavioural outcomes, whereas aggressive solutions were negatively related to the outcomes. The difficulties in social problem-solving skills demonstrated by children with TBI may help account for their poor social and behavioural functioning.	[Ganesalingam, Kalaichelvi] Columbus Childrens Hosp, Childrens Res Inst, Columbus, OH 43205 USA; [Ganesalingam, Kalaichelvi; Sanson, Ann; Anderson, Vicki] Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Anderson, Vicki] Murdoch Childrens Res Ctr, Melbourne, Vic, Australia		Ganesalingam, K (corresponding author), Columbus Childrens Hosp, Childrens Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	GanesaKa@chi.osu.edu	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Sanson, Ann/0000-0003-4910-3310			Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; *AUSTR BUR STAT, 2001, POP AUSTR NZ COMP; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Daniel A., 1983, POWER PRIVILEGE PRES; Davis P, 1997, NZ SOCIOECONOMIC IND; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DODGE KA, 1986, MINN SYM CHILD PSYCH, V18, P77; EYBERG SM, 1983, J CLIN CHILD PSYCHOL, V12, P347, DOI 10.1207/s15374424jccp1203_19; FUNDERBURK BW, 1989, BEHAV ASSESS, V11, P297; Gresham FM., 1990, SOCIAL SKILLS RATING; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; MANLY T, 1999, TEST EVEYDAY ATTENTI; Mariani MA, 1997, DEV NEUROPSYCHOL, V13, P111, DOI 10.1080/87565649709540671; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MISCHEL W, 1970, J PERS SOC PSYCHOL, V16, P329, DOI 10.1037/h0029815; *NAT HLTH INF MAN, 2001, NAT HLTH PLAN AUSTR; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; RUBIN KH, 1984, J CONSULT CLIN PSYCH, V52, P17, DOI 10.1037/0022-006X.52.1.17; RUBIN KH, 1992, HDB SOCIAL DEV; Sethi A, 2000, DEV PSYCHOL, V36, P767, DOI 10.1037//0012-1649.36.6.767; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; Shields A., 1998, EMOTION REGULATION C; SHIELDS AM, 1994, DEV PSYCHOPATHOL, V6, P57, DOI 10.1017/S0954579400005885; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; YEATES KO, 1991, MERRILL PALMER QUART, V37, P369; YEATES KO, 1990, CLIN PSYCHOL REV, V10, P567, DOI 10.1016/0272-7358(90)90097-T	33	37	37	1	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	SEP	2007	1		2				149	170		10.1348/174866407X185300			22	Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	V06HD	WOS:000207183800002	19331015				2022-02-06	
J	Beebe, DW; Krivitzky, L; Wells, CT; Wade, SL; Taylor, HG; Yeates, KO				Beebe, Dean W.; Krivitzky, Lauren; Wells, Carolyn T.; Wade, Shari L.; Taylor, H. Gerry; Yeates, Keith Owen			Brief report: Parental report of sleep behaviors following moderate or severe pediatric traumatic brain injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article; Proceedings Paper	33rd Annual Meeting of the International-Neuropsychological-Society	FEB 03, 2005	St Louis, MO	Int Neuropsychol Soc		brain injury; children; longitudinal; orthopedic injury; pediatrics; sleep	SHORT-TERM; CHILDREN; DISTURBANCES; ADOLESCENTS; OUTCOMES; SYMPTOMS	Objective Determine the effect of moderate and severe traumatic brain injuries (TBI) on the sleep of school-aged children. Methods A concurrent cohort-prospective design compared children aged 6-12 years who sustained moderate TBI (baseline n = 56), severe TBI (n = 53), or only orthopedic injuries (n = 80). Retrospective parental report of pre-injury sleep was collected about 3 weeks post-injury. Post-injury assessments occurred prospectively a mean of 6, 12, and 48 months later. Results Growth curve analyses compared the groups over time. The moderate TBI group had worse pre-injury sleep than the other groups. The moderate TBI and orthopedic injury groups displayed a small decline in sleep problems from pre- to post-injury. Children with severe TBI displayed increased post-injury sleep problems. Conclusions Children who sustain severe TBI are at elevated risk for post-injury sleep problems. Because sleep problems may result in daytime impairments and family distress, additional clinical and research attention is warranted.	Cincinnati Childrens Hosp Med Ctr, Div Psychol MLC 3015, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; Childrens Natl Med Ctr, Washington, DC 20010 USA; Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Ohio State Univ, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH 43205 USA		Beebe, DW (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Psychol MLC 3015, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	dean.beebe@cchmc.org	Sanguansri, Luz/B-6630-2011; Yeates, Keith/AAJ-4223-2020	Sanguansri, Luz/0000-0003-1908-7604; Yeates, Keith/0000-0001-7680-2892	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER		Achenbach TM, 1991, MANUAL CHILD BEHAV C; Blunden SL, 2006, SLEEP MED REV, V10, P109, DOI 10.1016/j.smrv.2005.11.003; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; Gregory AM, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200208000-00015; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; MINDELL JA, 2003, CLIN GUIDE PEDIAT SL; NAKAYAMA DK, 1990, J TRAUMA, V30, P1390, DOI 10.1097/00005373-199011000-00012; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Singer J, 2003, APPL LONGITUDINAL DA APPL LONGITUDINAL DA, DOI [10.1093/acprof:oso/ 9780195152968.003.0001, DOI 10.1093/ACPROF:OSO/9780195152968.003.0001]; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; Wiggs L, 2000, SLEEP MED REV, V4, P299, DOI 10.1053/smrv.1999.0094; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	21	37	37	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	AUG	2007	32	7					845	850		10.1093/jpepsy/jsm003			6	Psychology, Developmental	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology	193JT	WOS:000248271000010	17442693	Green Accepted, Green Published, Bronze			2022-02-06	
J	Hoane, MR; Pierce, JL; Holland, MA; Birky, ND; Dang, T; Vitek, MP; McKenna, SE				Hoane, Michael R.; Pierce, Jeremy L.; Holland, Michael A.; Birky, Nicholas D.; Dang, Tan; Vitek, Michael P.; McKenna, Suzanne E.			The novel apolipoprotein E-based peptide COG1410 improves sensorimotor performance and reduces injury magnitude following cortical contusion injury	JOURNAL OF NEUROTRAUMA			English	Article						apoE; behavioral recovery; GFAP; neuroprotection; recovery of function; TBI; trauma	TRAUMATIC BRAIN-INJURY; APOE GENOTYPE; MURINE MODEL; NEUROPROTECTION; INFLAMMATION; ACTIVATION; DISABILITY; EXPRESSION; THERAPY; DISEASE	It has previously been shown that small peptide molecules derived from the apolipoprotein E ( ApoE) receptor binding region are anti-inflammatory in nature and can improve outcome following head injury. The present study evaluated the preclinical efficacy of COG1410, a small molecule ApoE-mimetic peptide (1410 daltons), following cortical contusion injury (CCI). Animals were prepared with a unilateral CCI of the sensorimotor cortex (SMC) or sham procedure. Thirty mins post-CCI the animals received i.v. infusions of 0.8 mg/kg COG1410, 0.4 mg/kg COG1410, or vehicle. Starting on day 2, the animals were tested on a battery of behavioral measures to assess sensorimotor (vibrissae-forelimb placing and forelimb use-asymmetry), and motor (tapered balance beam) performance. Administration of the 0.8 mg/kg dose of COG1410 significantly improved recovery on the vibrissae-forelimb and limb asymmetry tests. However, no facilitation was observed on the tapered beam. The low dose (0.4 mg/kg) of COG1410 did not show any significant differences compared to vehicle. Lesion analysis revealed that the 0.8 mg/kg dose of COG1410 significantly reduced the size of the injury cavity compared to the 0.4 mg/kg dose and vehicle. The 0.8 mg/kg dose also reduced the number of glial fibrillary acid protein (GFAP(+)) reactive cells in the injured cortex. These results suggest that a single dose of COG1410 facilitates behavioral recovery and provides neuroprotection in a dose and task-dependent manner. Thus, the continued clinical development of ApoE based therapeutics is warranted and could represent a novel strategy for the treatment of traumatic brain injuries.	So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA; Cognosci Inc, Res Triangle Pk, NC USA; Duke Univ, Med Ctr, Div Neurol, Dept Med, Durham, NC USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC USA		Hoane, MR (corresponding author), So Illinois Univ, Dept Psychol, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Life Sci 2,MC 6502, Carbondale, IL 62901 USA.	mhoane@siu.edu		Hoane, Michael/0000-0001-7779-2657; Vitek, Michael/0000-0001-8140-8048	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS048689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG020473] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R44AG020473] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS048689] Funding Source: Medline		Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Becerra GD, 2007, BEHAV BRAIN RES, V179, P118, DOI 10.1016/j.bbr.2007.01.024; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gay EA, 2006, J PHARMACOL EXP THER, V316, P835, DOI 10.1124/jpet.105.095505; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Schallert T, 2005, BEHAV LAB RAT, P129; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Zareparsi S, 2002, AM J MED GENET, V107, P156, DOI 10.1002/ajmg.10111	43	37	39	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1108	1118		10.1089/neu.2006.0254			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200003	17610351				2022-02-06	
J	Dore-Duffy, P; Wang, XQ; Mehedi, A; Kreipke, CW; Rafols, JA				Dore-Duffy, Paula; Wang, Xueqain; Mehedi, Afroza; Kreipke, Christian W.; Rafols, Jose A.			Differential expression of capillary VEGF isoforms following traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						brain trauma; angiogenesis; pericytes	ENDOTHELIAL GROWTH-FACTOR; VESSEL FORMATION; TUMOR-GROWTH; ANGIOGENESIS; HEPARIN; RECEPTORS; VEGF(121); BINDING; CELLS; PERICYTES	Objectives: While it is known that angiogenesis occurs after trauma, we sought to characterize the expression of vascular endothelial growth factor (VEGF) subtypes, vascular endothelial growth factor receptor 2 (VEGFR2) and angiopoietin within capillaries of animals subjected to traumatic brain injury (TBI). Further, we sought to characterize pericyte cell death in isolated capillaries. Methods: We used Marmarou's acceleration impact model to induce head trauma and measured VEGF, VEGFR2 and angiopoietin levels in isolated capillaries. TUNEL was used to determine pericyte cell death. Results: The VEGF response was restricted to the VEGF120 isoform. No increase in transcripts for VEGF164 and VEGF188 was observed. VEGFR2 was marginally increased and angiopoietin was increased. A subset of pericytes were TUNEL-positive. Discussion: These results show a distinct expression pattern of angiogenic factors following injury and suggest that pericyte involvement in adaptive angiogenesis may be altered following TBI.	Wayne State Univ, Sch Med, Div Neuroimmunol, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA		Dore-Duffy, P (corresponding author), Wayne State Univ, Sch Med, Div Neuroimmunol, Dept Neurol, 540 E Canfield, Detroit, MI 48201 USA.	pdduffy@med.wayne.edu					Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Ashikari- Hada S, 2005, J BIOL CHEM, V280, P31508, DOI 10.1074/jbc.M414581200; BALLAUN C, 1995, J INVEST DERMATOL, V104, P7, DOI 10.1111/1523-1747.ep12613450; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bates DO, 2002, CANCER RES, V62, P4123; Beckman JD, 2006, ENDOCRINE, V29, P467, DOI 10.1385/ENDO:29:3:467; Benelli R, 2006, CURR PHARM DESIGN, V12, P3101, DOI 10.2174/138161206777947461; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; BREIER G, 1992, DEVELOPMENT, V114, P521; Brkovic A, 2007, J CELL BIOCHEM, V100, P727, DOI 10.1002/jcb.21124; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Cheung CY, 1999, J SOC GYNECOL INVEST, V6, P179, DOI 10.1016/S1071-5576(99)00016-7; Cheung CY, 1998, GROWTH FACTORS, V16, P11, DOI 10.3109/08977199809017488; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; DIAZFLORES L, 1994, ANAT REC, V238, P68, DOI 10.1002/ar.1092380109; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272; Dore-Duffy Paula, 2003, Methods Mol Med, V89, P375; DOREDUFFY P, 1994, J CEREBR BLOOD F MET, V14, P837, DOI 10.1038/jcbfm.1994.105; Ehrbar M, 2004, CIRC RES, V94, P1124, DOI 10.1161/01.RES.0000126411.29641.08; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Galambos C, 2002, AM J RESP CELL MOL, V27, P194, DOI 10.1165/ajrcmb.27.2.4703; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Goerges AL, 2003, J BIOL CHEM, V278, P19518, DOI 10.1074/jbc.M211208200; Gowdak LHW, 2000, CIRCULATION, V102, P565; Hamik A, 2006, ARTERIOSCL THROM VAS, V26, P1936, DOI 10.1161/01.ATV.0000232542.42968.e3; HAVASHI T, 2006, CURR NEUROVASC RES, V3, P119; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; LaManna JC, 2004, J EXP BIOL, V207, P3163, DOI 10.1242/jeb.00976; Lim M, 2006, CURR NEUROVASC RES, V3, P237, DOI 10.2174/156720206778018730; LOBB RR, 1985, INT J CANCER, V36, P473, DOI 10.1002/ijc.2910360410; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; MAJONE TE, 1995, J BIOL CHEM, V270, P15059; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; Mohamedali KA, 2006, CANCER RES, V66, P10919, DOI 10.1158/0008-5472.CAN-06-0459; MOHANRAJ D, 1995, BIOCHEM BIOPH RES CO, V215, P750, DOI 10.1006/bbrc.1995.2527; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Pichiule P, 2003, ADV EXP MED BIOL, V530, P611; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Ramsauer M, 2002, FASEB J, V16, P1274, DOI 10.1096/fj.01-0814fje; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Sakurai S, 2002, INVEST OPHTH VIS SCI, V43, P2774; SEIP WF, 1980, J CLIN MICROBIOL, V11, P226, DOI 10.1128/JCM.11.3.226-233.1980; Shimizu T, 2007, J REPROD DEVELOP, V53, P105, DOI 10.1262/jrd.18088; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; SOBEL AT, 1977, J IMMUNOL, V119, P1230; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Tian Xuejun, 1999, Zhonghua Zhongliu Zazhi, V21, P93; Tober KL, 1998, BIOCHEM BIOPH RES CO, V247, P644, DOI 10.1006/bbrc.1998.8787; Wakui S, 2006, LAB INVEST, V86, P1172, DOI 10.1038/labinvest.3700476; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Zhang HT, 2000, BRIT J CANCER, V83, P63	59	37	38	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2007	29	4					395	403		10.1179/016164107X204729			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	192PM	WOS:000248214200010	17626736				2022-02-06	
J	Czigner, A; Mihaly, A; Farkas, O; Buki, A; Krisztin-Peva, B; Dobo, E; Barzo, P				Czigner, A.; Mihaly, A.; Farkas, O.; Buki, A.; Krisztin-Peva, B.; Dobo, E.; Barzo, P.			Kinetics of the cellular immune response following closed head injury	ACTA NEUROCHIRURGICA			English	Article						closed head injury; lymphocytes; microglia; inflammation; rat	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC AXONAL INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; BRAIN INJURY; SPINAL-CORD; INFLAMMATORY RESPONSE; CNS; RAT; MICROGLIA; DAMAGE	Background. The contribution of brain edema to brain swelling in cases of traumatic brain injury (TBI) remains a critical problem. We believe that inflammatory reactions may play a fundamental role in brain swelling following a head injury. Although possible roles of microglia activation and the release of mediators have been suggested, direct evidence of cellular immune reactivity in diffuse brain injury following closed head trauma is lacking. Accordingly, the objective of this study was to assess the temporal pattern of microglia activation and lymphocyte migration in an experimental model of TBI. Method. An impact acceleration TBI model was utilized to induce diffuse brain damage in adult Wistar rats. The animals were separated into three groups: unoperated controls, sham-operated controls and trauma group. At various times after TBI induction (5min-24h), rats were perfused transcardially. Sagittal brain sections were analyzed with immunohistochemical markers of CD3 to reveal the presence of T-lymphocytes, and by immunochemistry for the detection of CD11b to reveal microglia activation within the brain parenchyma. Findings. In the control groups, scattered T-cells were found in the brain parenchyma. In the trauma group, TBI induced microglia activation and a transient biphasic T-cell infiltration of the brain parenchyma in all regions was found, beginning as early as 30min post injury and reaching its maximum values at 45min and 3h after trauma induction. Conclusion. These results lead us to suggest that the acute response to severe head trauma with early edema formation is likely to be associated with inflammatory events which might be triggered by activated microglia and infiltrating lymphocytes. It is difficult to overestimate the clinical significance of these observations, as the early and targeted treatment of patients with severe head injuries with immunosuppressive medication may result in a far more favorable outcome.	Univ Szeged, Dept Neurosurg, Fac Med, H-6725 Szeged, Hungary; Univ Szeged, Dept Anat, Fac Med, H-6725 Szeged, Hungary; Univ Pecs, Fac Med, Dept Neurosurg, H-7622 Pecs, Hungary		Barzo, P (corresponding author), Univ Szeged, Dept Neurosurg, Fac Med, Semmelweis 6, H-6725 Szeged, Hungary.	pbarzo@yahoo.com	Buki, Andras/B-1960-2010; Mihaly, Andras/K-5096-2012	Mihaly, Andras/0000-0002-6802-0169			Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Becher B, 2000, GLIA, V29, P293; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 2000, J NEUROSCI, V20, P2825; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; HART MN, 1995, TRENDS NEUROSCI, V18, P475, DOI 10.1016/0166-2236(95)92767-K; HICKEY WF, 1987, P NATL ACAD SCI USA, V84, P2082, DOI 10.1073/pnas.84.7.2082; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; HICKEY WF, 1985, CELL IMMUNOL, V91, P528, DOI 10.1016/0008-8749(85)90251-5; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Horvath KM, 2000, EUR J PHARMACOL, V405, P33, DOI 10.1016/S0014-2999(00)00539-2; Juurlink BHJ, 2000, BRAIN PATHOL, V10, P93; Kalla R, 2001, J COMP NEUROL, V436, P182; KIDA S, 1995, NEUROPATH APPL NEURO, V21, P181, DOI 10.1111/j.1365-2990.1995.tb01048.x; KIDA SY, 1993, ACTA NEUROPATHOL, V85, P646, DOI 10.1007/BF00334675; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; LASSMANN H, 1986, PROGR NEUROPATHOLOGY, V6, P33; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Ling CY, 2006, J NEUROSCI, V26, P731, DOI 10.1523/JNEUROSCI.3502-05.2006; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; PATERSON PY, 1982, CLIN IMMUNOL REV, V1, P581; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Streit W. J., 2005, NEUROGLIA, P60; TRAUGOTT U, 1985, CELL IMMUNOL, V91, P240, DOI 10.1016/0008-8749(85)90047-4; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; Weller RO, 1996, BRAIN PATHOL, V6, P275, DOI 10.1111/j.1750-3639.1996.tb00855.x	42	37	38	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2007	149	3					281	289		10.1007/s00701-006-1095-8			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	143TK	WOS:000244747800023	17288002				2022-02-06	
J	Francisco, GE; Walker, WC; Zasler, ND; Bouffard, MH				Francisco, Gerard E.; Walker, William C.; Zasler, Nathan D.; Bouffard, Mark H.			Pharmacological management of neurobehavioural sequelae of traumatic brain injury: A survey of current physiatric practice	BRAIN INJURY			English	Article						brain injuries; drug therapy; survey	AGITATION; MEMORY	Objective: To describe pharmacological preference for the treatment of neurobehavioural sequela of traumatic brain injury (TBI). Design: Survey. Participants: TBI physiatrists were divided into specialists ( completed a TBI fellowship or commit > 70% of clinical practice time to TBI) and non-specialists. Outcome measures: Participants were asked to list the drugs most frequently prescribed for each of 15 neurobehavioural symptoms commonly encountered during TBI rehabilitation and enumerate neurobehavioural symptom for which they prescribed each listed drug or drug class. Results: There was no clear consensus on drug of choice for each target symptom. There were differences in drug choice patterns between specialists and non-specialists, especially for agitation. Conclusion: There is limited uniformity in drug selection for various TBI neurobehavioural sequela. Potential explanations include the availability of various medications with similar clinical effect, the variability of clinical presentation and severity of neurobehavioural symptoms and the lack of clinical practice guidelines.	Inst Rehabil & Res, Houston, TX 77030 USA; Univ Texas, Baylor Coll Med, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Concuss Care Ctr Virginia, Glen Allen, VA USA		Francisco, GE (corresponding author), Inst Rehabil & Res, 1333 Moursund St, Houston, TX 77030 USA.	gerard.e.francisco@uth.tmc.edu	Walker, William C/N-3162-2014				Beers SR, 2005, J HEAD TRAUMA REHAB, V20, P450, DOI 10.1097/00001199-200509000-00006; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P917; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; FLEMINGER S, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003299; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Giacino JT, 2003, J HEAD TRAUMA REHAB, V18, P4, DOI 10.1097/00001199-200301000-00003; Levy M, 2005, NEUROREHABILITATION, V20, P279; MALKMUS D, 1980, REHAPILITATION HEAD; MEYTHELER JM, 2006, HEAD TRAUMA REHABILI, V21, P416; MEYTHELER JM, 1992, ARCH PHYS MED REHAB, V10, P917; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ripley DL, 2006, J HEAD TRAUMA REHAB, V21, P85, DOI 10.1097/00001199-200601000-00010; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SPEECH TJ, 2003, J HEAD TRAUMA REHAB, V18, P4; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	15	37	37	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	10					1007	1014		10.1080/02699050701559558			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600002	17891562				2022-02-06	
S	Klein, TW; Newton, CA		Shurin, MR; Smolkin, YS		Klein, Thomas W.; Newton, Catherine A.			Therapeutic potential of cannabinoid-based drugs	IMMUNE-MEDIATED DISEASES: FROM THEORY TO THERAPY	Advances in Experimental Medicine and Biology		English	Article; Proceedings Paper	1st International Congress on Immune-Mediated Diseases	OCT 03-08, 2005	Moscow, RUSSIA				CLOSED-HEAD INJURY; MULTIPLE-SCLEROSIS CAMS; CB2 RECEPTOR; DOUBLE-BLIND; ENDOGENOUS CANNABINOIDS; DEXANABINOL HU-211; NEUROPATHIC PAIN; AJULEMIC ACID; BRAIN-INJURY; DELTA-9-TETRAHYDROCANNABINOL	Cannabinoid-based drugs modeled on cannabinoids originally isolated from marijuana are now known to significantly impact the functioning of the endocannabinoid system of mammals. This system operates not only in the brain but also in organs and tissues in the periphery including the immune system. Natural and synthetic cannabinoids are tricyclic terpenes, whereas the endogenous physiological ligands are eicosanoids. Several receptors for these compounds have been extensively described, CB1, and CB2, and are G protein-coupled receptors; however, cannabinoid-based drugs are also demonstrated to function independently of these receptors. Cannabinoids regulate many physiological functions and their impact on immunity is generally antiinflammatory as powerful modulators of the cytokine cascade. This anti-inflammatory potency has led to the testing of these drugs in chronic inflammatory laboratory paradigms and even in some human diseases. Psychoactive and noripsychoactive cannabinoid-based drugs such as Delta(9)-tetrahydrocannabinol, cannabidiol, HU-211, and ajulemic acid have been tested and found moderately effective in clinical trials of multiple sclerosis, traumatic brain injury, arthritis, and neuropathic pain. Furthermore, although clinical trials are not yet reported, preclinical data with cannabinoid-based drugs suggest efficacy in other inflammatory diseases such as inflammatory bowel disease, Alzheimer's disease, atherosclerosis, and osteoporosis.	Univ S Florida, Dept Mol Med, Tampa, FL 33620 USA		Klein, TW (corresponding author), Univ S Florida, Dept Mol Med, Tampa, FL 33620 USA.	tklein@health.usf.edu					ANDAY JK, 2005, PHARM RES, V20, P20; Arevalo-Martin A, 2003, J NEUROSCI, V23, P2511; Baker D, 2006, TRENDS PHARMACOL SCI, V27, P1, DOI 10.1016/j.tips.2005.11.003; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Baldwin GC, 1997, AM J RESP CRIT CARE, V156, P1606, DOI 10.1164/ajrccm.156.5.9704146; Blake DR, 2006, RHEUMATOLOGY, V45, P50, DOI 10.1093/rheumatology/kei183; Breivogel CS, 2001, MOL PHARMACOL, V60, P155, DOI 10.1124/mol.60.1.155; Burstein SH, 1998, LIFE SCI, V63, P161, DOI 10.1016/S0024-3205(98)00256-2; Cabral GA, 1998, J NEUROIMMUNOL, V83, P116, DOI 10.1016/S0165-5728(97)00227-0; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Chang YH, 2001, J CELL BIOCHEM, V81, P715, DOI 10.1002/jcb.1103; Croxford JL, 2003, J CLIN INVEST, V111, P1231, DOI 10.1172/JCI200317652; Dajani EZ, 1999, J PHARMACOL EXP THER, V291, P31; Derocq JM, 2000, J BIOL CHEM, V275, P15621, DOI 10.1074/jbc.275.21.15621; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Di Marzo V, 2006, GUT, V55, P1373, DOI 10.1136/gut.2005.090472; Ehrhard FK, 2002, BRILLS TIBET STU LIB, V2, P29; Elmes SJR, 2005, PAIN, V118, P327, DOI 10.1016/j.pain.2005.09.005; Eubanks LM, 2006, MOL PHARMACEUT, V3, P773, DOI 10.1021/mp060066m; FISCHERSTENGER K, 1993, J PHARMACOL EXP THER, V267, P1558; Fowler CJ, 2005, PHARMACOL BIOCHEM BE, V81, P248, DOI 10.1016/j.pbb.2005.01.023; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898; Hohmann AG, 2006, AAPS J, V8, pE693, DOI 10.1208/aapsj080479; Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030; Ibrahim MM, 2003, P NATL ACAD SCI USA, V100, P10529, DOI 10.1073/pnas.1834309100; Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255; Iskedjian M, 2007, CURR MED RES OPIN, V23, P17, DOI 10.1185/030079906X158066; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370; Karst M, 2003, JAMA-J AM MED ASSOC, V290, P1757, DOI 10.1001/jama.290.13.1757; Kishimoto S, 2004, J BIOCHEM, V135, P517, DOI 10.1093/jb/mvh063; Klein RG, 2000, EVOL ANTHROPOL, V9, P17, DOI 10.1002/(SICI)1520-6505(2000)9:1<17::AID-EVAN3>3.0.CO;2-A; Klein TW, 2006, J NEUROIMMUNE PHARM, V1, P50, DOI 10.1007/s11481-005-9007-x; KLEIN TW, 1993, J PHARMACOL EXP THER, V267, P635; Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101; Klein TW, 2005, NAT REV IMMUNOL, V5, P400, DOI 10.1038/nri1602; Klein TW, 1998, IMMUNOL TODAY, V19, P373, DOI 10.1016/S0167-5699(98)01300-0; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Liu JL, 2003, MOL PHARMACOL, V63, P983, DOI 10.1124/mol.63.5.983; Lu TY, 2006, EUR J PHARMACOL, V532, P170, DOI 10.1016/j.ejphar.2005.12.040; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MACKENZIE IRA, 1995, NEUROBIOL AGING, V16, P797, DOI 10.1016/0197-4580(95)00092-S; Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; MASSA F, 2005, J MOL MED, V26, P26; Mathison R, 2004, BRIT J PHARMACOL, V142, P1247, DOI 10.1038/sj.bjp.0705889; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Milton NGN, 2002, NEUROSCI LETT, V332, P127, DOI 10.1016/S0304-3940(02)00936-9; Mitchell VA, 2005, NEUROSCI LETT, V382, P231, DOI 10.1016/j.neulet.2005.03.019; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NAHAS GG, 1974, SCIENCE, V183, P419, DOI 10.1126/science.183.4123.419; NEWTON CA, 1994, INFECT IMMUN, V62, P4015, DOI 10.1128/IAI.62.9.4015-4020.1994; Nogid A, 2006, CLIN THER, V28, P1764, DOI 10.1016/j.clinthera.2006.11.020; Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103; Offertaler L, 2003, MOL PHARMACOL, V63, P699, DOI 10.1124/mol.63.3.699; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Pacifici R, 2003, JAMA-J AM MED ASSOC, V289, P1929, DOI 10.1001/jama.289.15.1929-b; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pertwee RG, 2005, AAPS J, V7, pE625, DOI 10.1208/aapsj070364; Pinto L, 2002, GASTROENTEROLOGY, V123, P227, DOI 10.1053/gast.2002.34242; Porter AC, 2002, J PHARMACOL EXP THER, V301, P1020, DOI 10.1124/jpet.301.3.1020; Pryce G, 2003, BRAIN, V126, P2191, DOI 10.1093/brain/awg224; PRYCE G, 2007, BRIT J PHARMACOL, V15, P15; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rog DJ, 2005, NEUROLOGY, V65, P812, DOI 10.1212/01.wnl.0000176753.45410.8b; Rousseaux C, 2007, NAT MED, V13, P35, DOI 10.1038/nm1521; Salim K, 2005, NEUROPHARMACOLOGY, V48, P1164, DOI 10.1016/j.neuropharm.2005.02.010; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Smith SR, 2000, J PHARMACOL EXP THER, V293, P136; Steffens S, 2005, NATURE, V434, P782, DOI 10.1038/nature03389; Sumariwalla PF, 2004, ARTHRITIS RHEUM-US, V50, P985, DOI 10.1002/art.20050; Sun Y, 2006, BIOCHEM SOC T, V34, P1095, DOI 10.1042/BST0341095; Svendsen KB, 2004, BMJ-BRIT MED J, V329, P253, DOI 10.1136/bmj.38149.566979.AE; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tomida I, 2004, BRIT J OPHTHALMOL, V88, P708, DOI 10.1136/bjo.2003.032250; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; Vaney C, 2004, MULT SCLER, V10, P417, DOI 10.1191/1352458504ms1048oa; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; Wade DT, 2004, MULT SCLER, V10, P434, DOI 10.1191/1352458504ms1082oa; Wagner JA, 1998, J MOL MED-JMM, V76, P824, DOI 10.1007/s001090050287; Wang Y, 2001, ANAL BIOCHEM, V294, P73, DOI 10.1006/abio.2001.5015; WIRGUIN I, 1994, IMMUNOPHARMACOLOGY, V28, P209, DOI 10.1016/0162-3109(94)90056-6; Wright K, 2005, GASTROENTEROLOGY, V129, P437, DOI 10.1053/j.gastro.2005.05.026; Yuan M, 2002, J NEUROIMMUNOL, V133, P124, DOI 10.1016/S0165-5728(02)00370-3; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1; Zajicek JP, 2005, J NEUROL NEUROSUR PS, V76, P1664, DOI 10.1136/jnnp.2005.070136; Zhu LX, 2000, J IMMUNOL, V165, P373, DOI 10.4049/jimmunol.165.1.373; ZHU WG, 1994, J PHARMACOL EXP THER, V270, P1334; Zurier RB, 2003, BIOCHEM PHARMACOL, V65, P649, DOI 10.1016/S0006-2952(02)01604-0; Zurier RB, 1998, ARTHRITIS RHEUM-US, V41, P163, DOI 10.1002/1529-0131(199801)41:1<163::AID-ART20>3.3.CO;2-0; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	99	37	37	0	19	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0065-2598	2214-8019	978-0-387-72004-3	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2007	601						395	413					19	Immunology; Medicine, Research & Experimental	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	BGN45	WOS:000248597900043	17713029				2022-02-06	
J	Mandalis, A; Kinsella, G; Ong, B; Anderson, V				Mandalis, Anna; Kinsella, Glynda; Ong, Ben; Anderson, Vicki			Working memory and new learning following pediatric traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; PREFRONTAL CORTEX; TASK-PERFORMANCE; YOUNG-CHILDREN; FUNCTIONAL MRI; ADOLESCENTS; ATTENTION; RECOVERY; ABILITIES; DISEASE	Working memory (WM), the ability to monitor, process and maintain task relevant information on-line to respond to immediate environmental demands, is controlled by frontal systems (D'Esposito et al., 2006), which are particularly vulnerable to damage from a traumatic brain injury (TBI). This study employed the adult-based Working Memory model of Baddeley and Hitch (1974) to examine the relationship between working memory function and new verbal learning in children with TBI. A cross-sectional sample of 36 school-aged children with a moderate to severe TBI was compared to age-matched healthy Controls on a series of tasks assessing working memory subsystems: the Phonological Loop (PL) and Central Executive (CE). The TBI group performed significantly more poorly than Controls on the PL measure and the majority of CE tasks. On new learning tasks, the TBI group consistently produced fewer words than Controls across the learning and delayed recall phases. Results revealed impaired PL function related to poor encoding and acquisition on a new verbal learning task in the TBI group. CE retrieval deficits in the TBI group contributed to general memory dysfunction in acquisition, retrieval and recognition memory. These results suggest that the nature of learning and memory deficits in children with TBI is related to working memory impairment.	Murdoch Childrens Res Inst, Murdoch, WA, Australia; Royal Childrens Hosp, Dept Psychol, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia		Mandalis, A (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	anna.mandalis@childneuropsychology.com.au	Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; ANDERSON V, 1995, NEUROPSYCHOLOGICAL A; Anderson VA, 2000, BRAIN INJURY, V14, P679; Baddeley A, 2001, J EXP PSYCHOL GEN, V130, P641, DOI 10.1037//0096-3445.130.4.641; Baddeley A, 1996, P NATL ACAD SCI USA, V93, P13468, DOI 10.1073/pnas.93.24.13468; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A.D., 1986, WORKING MEMORY; BADDELEY AD, 2001, FRONTAL LOBES, P246; Beddeley AD., 1974, PSYCHOL LEARN MOTIV, V8, P47, DOI [DOI 10.1016/S0079-7421(08)60452-1, 10.1016/S0079-7421(08)60452-1]; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Collette F, 2002, NEUROSCI BIOBEHAV R, V26, P105, DOI 10.1016/S0149-7634(01)00063-X; D'Esposito M, 2006, J INT NEUROPSYCH SOC, V12, P248, DOI 10.1017/S1355617706060322; D'Esposito M, 1998, NEUROIMAGE, V8, P274, DOI 10.1006/nimg.1998.0364; DALRYMPLEALFORD JC, 1994, J NEUROL NEUROSUR PS, V57, P360, DOI 10.1136/jnnp.57.3.360; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Garth J, 1997, Pediatr Rehabil, V1, P99; GATHERCOLE SE, 1993, DEV PSYCHOL, V29, P770, DOI 10.1037/0012-1649.29.4.770; Gathercole SE, 2005, J CHILD PSYCHOL PSYC, V46, P598, DOI 10.1111/j.1469-7610.2004.00379.x; HALPERIN JM, 1989, J CLIN EXP NEUROPSYC, V11, P518, DOI 10.1080/01688638908400910; HITCH GJ, 1983, PHILOS T ROY SOC B, V302, P325, DOI 10.1098/rstb.1983.0058; HITCH GJ, 1988, MEM COGNITION, V16, P120, DOI 10.3758/BF03213479; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Jarrold C, 2004, J MEM LANG, V50, P134, DOI 10.1016/j.jml.2003.10.004; Jarrold C, 2001, Downs Syndr Res Pract, V7, P17, DOI 10.3104/reviews.110; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; LEZAK M, 2004, NEUROPSYCHOLOGY ASSE; Logie RH, 2004, NEUROPSYCHOLOGY, V18, P504, DOI 10.1037/0894-4105.18.3.504; Loose R, 2003, HUM BRAIN MAPP, V18, P249, DOI 10.1002/hbm.10082; MAROSSZEKY NEV, 1993, CLIN NEUROPSYCHOL, V7, P85, DOI 10.1080/13854049308401890; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rowe JB, 2001, NEUROPSYCHOLOGIA, V39, P315, DOI 10.1016/S0028-3932(00)00109-3; Shah, 1999, MODELS WORKING MEMOR, DOI DOI 10.1017/CBO9781139174909.005; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; [No title captured]	52	37	37	0	10	LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS	PHILADELPHIA	325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2007	32	2					683	701		10.1080/87565640701376045			19	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	212NJ	WOS:000249603000005	17931125				2022-02-06	
J	Niechwiej-Szwedo, E; Inness, EL; Howe, JA; Jaglal, S; McIlroy, WE; Verrier, MC				Niechwiej-Szwedo, E.; Inness, E. L.; Howe, J. A.; Jaglal, S.; McIlroy, W. E.; Verrier, M. C.			Changes in gait variability during different challenges to mobility in patients with traumatic brain injury	GAIT & POSTURE			English	Article						traumatic brain injury; gait; variability; dynamic stability	STRIDE VARIABILITY; OLDER ADULTS; HEAD-INJURY; WALKING; DISEASE; BALANCE; LENGTH; FALLS	Postural stability may be compromised in patients who have sustained a traumatic brain injury (TBI). The purpose of the present study was to examine dynamic stability during gait by measuring spatial and temporal variability of foot placement, and to determine the effect of increased difficulty of the walking task on gait variability in patients with TBI. It was hypothesized that patients with TBI will show increased variability in step time, step length, and step width in comparison to healthy controls and that such differences would be accentuated by increased task difficulty. Participants (patients: n = 20, controls: n = 20) were asked to walk across a pressure sensitive mat at their preferred pace (PW), as fast as possible (FW), and with their eyes closed (EC). In accordance with the hypotheses, patients had significantly greater variability in step time and step length in comparison to healthy controls, and when the complexity of the gait task increased (FW and EC tasks). Although step width variability showed no significant difference between the groups, both control and patient groups had increased step width variability in the EC task. It is proposed that such increases in variability reflect greater challenges to maintaining dynamic stability during gait among individuals with TBI and when performing more difficult tasks. (C) 2006 Elsevier B.V. All rights reserved.	Univ Toronto, Grad Dept Rehabil Sci, Restorat Motor Control Lab, Toronto, ON M5G 1V7, Canada; Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada; Toronto Rehabil Inst, Restorat Motor Control Lab, Toronto, ON, Canada		Verrier, MC (corresponding author), Univ Toronto, Grad Dept Rehabil Sci, Restorat Motor Control Lab, 500 Univ Ave, Toronto, ON M5G 1V7, Canada.	m.verrier@utoronto.ca		Jaglal, Susan/0000-0002-2930-1443; Inness, Elizabeth L./0000-0002-9217-4619			Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; [Anonymous], 1995, GAIT POSTURE; BASFORD JR, 2003, ARCH PHYS MED REHAB, V84, P249; Bilney B, 2003, GAIT POSTURE, V17, P68, DOI 10.1016/S0966-6362(02)00053-X; Danion F, 2003, GAIT POSTURE, V18, P69, DOI 10.1016/S0966-6362(03)00030-4; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Hausdorff JM, 2003, EXP BRAIN RES, V149, P187, DOI 10.1007/s00221-002-1354-8; HEITMANN DK, 1989, PHYS THER, V69, P923, DOI 10.1093/ptj/69.11.923; INNESS EL, 2004, ARCH PHYS MED REHAB, V85, pE11; Langlois JA, 1997, AM J PUBLIC HEALTH, V87, P393, DOI 10.2105/AJPH.87.3.393; MacKay-Lyons M, 1998, PHYS THER, V78, P1083, DOI 10.1093/ptj/78.10.1083; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Nakamura T, 1996, GERONTOLOGY, V42, P108, DOI 10.1159/000213780; Patla AE, 1998, ECOL PSYCHOL, V10, P287, DOI 10.1207/s15326969eco103&4_7; TOWNSEND MA, 1985, J BIOMECH, V18, P21, DOI 10.1016/0021-9290(85)90042-9; van Emmerik REA, 2002, EXERC SPORT SCI REV, V30, P177, DOI 10.1097/00003677-200210000-00007; WINTER DA, 1992, PHYS THER, V72, P45, DOI 10.1093/ptj/72.1.45; Zar J.H., 1999, BIOSTAT ANAL, V4th	20	37	37	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362			GAIT POSTURE	Gait Posture	JAN	2007	25	1					70	77		10.1016/j.gaitpost.2006.01.002			8	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Orthopedics; Sport Sciences	127RS	WOS:000243604600010	16490355				2022-02-06	
J	Tate, CC; Tate, MC; LaPlaca, MC				Tate, Ciara C.; Tate, Matthew C.; LaPlaca, Michelle C.			Fibronectin and laminin increase in the mouse brain after controlled cortical impact injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; fibronectin; laminin; mouse; traumatic brain injury	EXTRACELLULAR-MATRIX PROTEINS; FOCAL CEREBRAL-ISCHEMIA; PLASMA FIBRONECTIN; GROWTH-FACTOR; BASAL LAMINA; INTEGRIN; RAT; EXPRESSION; BARRIER; TRAUMA	The complex environment of the traumatically injured brain exhibits aspects of inhibition and ongoing cell death together with attempts at repair and regeneration. Elucidating these events and exploiting those factors involved in endogenous repair and regeneration may aid in developing more effective treatments for traumatic brain injury. Two extracellular matrix proteins critical to neural development-fibronectin and laminin-may also play a protective or reparative role in the injury response. While both of these proteins have been found to increase following human brain injury, the presence of these proteins has not been studied in a clinically-relevant animal model of blunt head trauma. In this study, we examined the spatiotemporal profile of both fibronectin and laminin in the mouse brain following controlled cortical impact injury. Fibronectin and laminin reactivity was localized to the injury penumbra up to 14 days post-injury and was significantly higher than uninjured controls at 3 days post-injury. Upon examining the spatial relationship of fibronectin and laminin to support cells, we found macrophages/activated microglia prominently present in the fibronectin-rich tissue, consistent with a role for fibronectin in facilitating debris clearing. Furthermore, reactive astrocyte processes were found sheathing laminin positive vasculature, suggesting that laminin may play a role in repairing the blood-brain barrier. These and other hypothesized reparative roles for fibronectin and laminin after traumatic brain injury are discussed.	Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Lab Neuroengn, Atlanta, GA 30322 USA		LaPlaca, MC (corresponding author), Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Lab Neuroengn, 313 Ferst Dr, Atlanta, GA 30322 USA.	michelle.laplaca@bme.gatech.edu					Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bi XN, 2001, J COMP NEUROL, V435, P184, DOI 10.1002/cne.1201; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EGAN RA, 1991, BRAIN RES, V568, P330, DOI 10.1016/0006-8993(91)91421-V; Einheber S, 1996, J COMP NEUROL, V370, P105; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Freire E, 2004, J CELL SCI, V117, P4067, DOI 10.1242/jcs.01276; Fukai F, 1998, EXP CELL RES, V242, P92, DOI 10.1006/excr.1998.4076; Gibson RM, 2005, MOL CELL NEUROSCI, V28, P588, DOI 10.1016/j.mcn.2004.11.004; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRANT DS, 1990, ANN NY ACAD SCI, V588, P61, DOI 10.1111/j.1749-6632.1990.tb13197.x; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hou SP, 2005, J NEUROSCI METH, V148, P60, DOI 10.1016/j.jneumeth.2005.04.016; Kakinuma Y, 1998, NAT MED, V4, P1078, DOI 10.1038/2070; Langlios JA, 2004, TRAUMATIC BRAIN INJU; Lariviere B, 2003, WOUND REPAIR REGEN, V11, P79, DOI 10.1046/j.1524-475X.2003.11112.x; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Maenpaa A, 1997, ACTA NEUROPATHOL, V94, P216, DOI 10.1007/s004010050696; MARTIN DE, 1988, ARCH DERMATOL, V124, P226, DOI 10.1001/archderm.124.2.226; MIZUTANI K, 1987, ACTA HISTOCHEM CYTOC, V20, P87, DOI 10.1267/ahc.20.87; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Properzi F, 2003, BIOCHEM SOC T, V31, P335, DOI 10.1042/BST0310335; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SUZUKI M, 1990, ACTA NEUROPATHOL, V80, P355, DOI 10.1007/BF00307687; Szabo A, 2004, NEUROPATH APPL NEURO, V30, P169, DOI 10.1046/j.0305-1846.2003.00524.x; Tsuru A, 1996, EARLY HUM DEV, V45, P93, DOI 10.1016/0378-3782(95)01724-0; Yanaka K, 1996, J NEUROSURG, V85, P125, DOI 10.3171/jns.1996.85.1.0125; Yanaka K, 1997, J CEREBR BLOOD F MET, V17, P605; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	33	37	41	1	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					226	230		10.1089/neu.2006.0043			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100022	17263686				2022-02-06	
J	Winocur, G; Palmer, H; Dawson, D; Binns, MA; Bridges, K; Stuss, DT				Winocur, Gordon; Palmer, Heather; Dawson, Deirdre; Binns, Malcolm A.; Bridges, Kristen; Stuss, Donald T.			Cognitive rehabilitation in the elderly: An evaluation of psychosocial factors	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						neuropsychology; aging; frontal lobe; quality of life; cognition; memory	TRAUMATIC BRAIN-INJURY; PHYSICAL-ACTIVITY; LEISURE ACTIVITY; OLDER; PEOPLE; HEALTH; RISK; LIFE; PARTICIPATION; EXERCISE	In this study, we report changes in psychosocial function in two groups of older adults that participated in the experimental trial of our cognitive rehabilitation program. The results, based on tests that measured a range of psychosocial attributes, showed that, following training, participants improved in terms of overall well-being, as well as in specific areas that included perceived happiness, coping strategies, and quality of life. An important finding was that improvements were also observed in long-term follow-up testing. Both groups benefited from training, but the effect was greater in the group that received training before undergoing a control procedure. The results, which show that the benefits of our rehabilitation program extend into the psychosocial domain, underscore the potentially important relationship between psychosocial factors and cognitive performance in older adults.	Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Psychol, Toronto, ON, Canada; Univ Toronto, Dept Med Psychiat, Toronto, ON, Canada; Trent Univ, Dept Psychol, Peterborough, ON, Canada; Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Univ Toronto, Dept Med Occupat Sci & Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Dept Med Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada		Winocur, G (corresponding author), Rotman Res Inst, 3560 Bathrust St, Toronto, ON M6A 2E1, Canada.	gwinocur@rotman-baycrest.on.ca	Binns, Malcolm/AAQ-9195-2020; Dawson, Deirdre R/I-8882-2014	Binns, Malcolm/0000-0001-9998-6612; Dawson, Deirdre R/0000-0001-7517-6121			Albert MS, 1995, PSYCHOL AGING, V10, P578, DOI 10.1037/0882-7974.10.4.578; Arbuckle TY, 1986, PSYCHOL AGING, V1, P55, DOI 10.1037/0882-7974.1.1.55; Arbuckle TY, 1998, PSYCHOL AGING, V13, P663, DOI 10.1037/0882-7974.13.4.663; Bailis DS, 2002, J GERONTOL B-PSYCHOL, V57, pP531, DOI 10.1093/geronb/57.6.P531; Baltes P.B., 1982, AGING COGNITIVE PROC, V8, P353, DOI [10.1007/978-1-4684-4178-9_19, DOI 10.1007/978-1-4684-4178-9_19]; BenYishay Y, 1996, NEUROPSYCHOL REHABIL, V6, P327, DOI 10.1080/713755514; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Churchill JD, 2002, NEUROBIOL AGING, V23, P941, DOI 10.1016/S0197-4580(02)00028-3; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Colcombe SJ, 2003, J GERONTOL A-BIOL, V58, P176; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Coulson I, 2001, ARCH GERONTOL GERIAT, V33, P273, DOI 10.1016/S0167-4943(01)00190-X; Dawson D., 1999, COGNITIVE NEUROREHAB, P94; EMERY CF, 1995, GERONTOLOGIST, V35, P378, DOI 10.1093/geront/35.3.378; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P992, DOI 10.1037/0022-3514.50.5.992; Greenwood CE, 1999, MATURE MED, V2; Hertzog C, 1999, PSYCHOL AGING, V14, P528, DOI 10.1037/0882-7974.14.3.528; Hultsch DavidF., 1998, MEMORY CHANGE AGED; Jennings JM, 2003, EDUC GERONTOL, V29, P71, DOI 10.1080/713844231; KOZMA A, 1980, J GERONTOL, V35, P906, DOI 10.1093/geronj/35.6.906; Kramer AF, 2004, J GERONTOL A-BIOL, V59, P940; KRPAN KK, IN PRESS J INT NEURO; Laurin D, 2001, ARCH NEUROL-CHICAGO, V58, P498, DOI 10.1001/archneur.58.3.498; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Menec VH, 1997, J AGING HEALTH, V9, P105, DOI 10.1177/089826439700900106; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NOSEK MA, 1992, REHABIL COUNS BULL, V36, P21; PRIGATANO GP, 1986, NEUROPSYCHOLOGICAL R, P29; Pushkar D, 1997, PSYCHOL AGING, V12, P600, DOI 10.1037/0882-7974.12.4.600; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; Rejeski WJ, 2001, J GERONTOL A-BIOL, V56, P23, DOI 10.1093/gerona/56.suppl_2.23; Rodin J, 1985, Annu Rev Gerontol Geriatr, V5, P3; RODIN J, 1992, J GERONTOL, V47, pP373, DOI 10.1093/geronj/47.6.P373; Rose, 1982, CLIN GERONTOLOGIST, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; Ruff RM, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P99; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; Stuss DT, 2007, J INT NEUROPSYCH SOC, V13, P120, DOI 10.1017/S1355617707070154; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Wilson RS, 2003, CURR DIR PSYCHOL SCI, V12, P87, DOI 10.1111/1467-8721.01236; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742; WILSON RS, 1987, REHABILITATION MEMOR; WINOCUR G, 1990, CAN J PSYCHOL, V44, P435, DOI 10.1037/h0084270; WINOCUR G, 1987, CAN J PSYCHOL, V41, P257, DOI 10.1037/h0084156; Winocur G, 2007, J INT NEUROPSYCH SOC, V13, P166, DOI 10.1017/S1355617707070191	48	37	42	0	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2007	13	1					153	165		10.1017/S135561770707018X			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	127PO	WOS:000243599000017	17166314				2022-02-06	
J	Kukacka, J; Vajtr, D; Huska, D; Prusa, R; Houstava, L; Samal, F; Diopan, V; Kotaska, K; Kizek, R				Kukacka, Jiri; Vajtr, David; Huska, Dalibor; Prusa, Richard; Houstava, Ladislav; Samal, Filip; Diopan, Vaclav; Kotaska, Karel; Kizek, Rene			Blood metallothionein, neuron specific enolase, and protein S100B in patients with traumatic brain injury	NEUROENDOCRINOLOGY LETTERS			English	Article; Proceedings Paper	11th Interdisciplinary Slovak-Czech Toxicological Conference	JUN 05-07, 2006	Trencianske Teplice, SLOVAKIA	Slovak Acad Sci, Inst Expt Pharmaccol, Slovak Toxicol Soc, Czech Soc Expt & Clin Pharmacol, Czech Med Assoc JE Purkyne, Slovak Assoc Lab Anim Sci		metallothionein; contusion; diffuse axonal injury; Glasgow Coma Score; neuron specific enolase; S100B protein; oxidative stress; Brdicka reaction; differential pulse voltammetry	SEVERE HEAD-INJURY; PATHOLOGY; RELEASE	OBJECTIVES: The aim of this study was to evaluate the correlation of neuron specific enolase (NSE), protein S100B and time-profile of Glasgow Coma Score (GCS) development with metallothionein (MT) blood levels in patients with traumatic brain injury (TBI) during 10 days of hospitalization. Patients were divided into 2 groups with respect to NSE and S100B levels-with (group 1) and without (group II) GCS improvement. METHODS: Serum NSE and S100B concentrations were measured by immunochemical methods; serum metallothionein concentration by electrochemical technique. Cortical biopsies were investigated immunohistochemically and by electron microscope. A cDNA microarray containing 700 gene probes was used to study the changes in gene expression in the ipsilateral cortex. RESULTS: Values of MT in the blood of group I showed a non-significant decrease compared to group II during 1-3 days after admission. There was an increase of MT during 4-8 days in comparison with values of 1-3 days. The highest value of MT during hospitalization was found in a patient with diffuse axonal injury (group 11). The data of cDNA microarray suggested an increase in expression of gene transcripts for oxygen free radical scavenger proteins corresponding with the increase of MT during 4-8 days in both groups. CONCLUSIONS: The experimental data indicate that monitoring the content of MT in patients with trauma brain injury would be a suitable approach to evaluate the degree of injury or duration of prolonging unconsciousness, particularly in diagnosis of diffuse axonal injury.	Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Sch Med 2, CZ-15006 Prague 5, Czech Republic; Univ Hosp Motol, CZ-15006 Prague, Czech Republic; Charles Univ Prague, Inst Forens Med & Toxicol, Sch Med 1, CZ-15006 Prague 5, Czech Republic; Charles Univ Prague, Clin Neurosurg, Med Sch 3, CZ-15006 Prague 5, Czech Republic; Univ Hosp Kralovske Vinohrady, Prague, Czech Republic; Mendel Univ Agr & Forestry Brno, Dept Chem & Biochem, Fac Agron, Brno, Czech Republic		Kukacka, J (corresponding author), Charles Univ Prague, Dept Clin Biochem & Pathobiochem, Sch Med 2, Uvalu 84, CZ-15006 Prague 5, Czech Republic.	jiri.kukacka@lf2.cuni.cz	Huska, Dalibor/J-9493-2018; Huska, Dalibor/M-8285-2019; Kizek, Rene/D-7748-2012; Kukacka, Jiri/C-4770-2013; Kotaska, Karel/A-3830-2008	Huska, Dalibor/0000-0003-3852-8751; Kizek, Rene/0000-0002-0467-6169			Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; ILARIA R, 1985, J NEUROSCI METH, V15, P165, DOI 10.1016/0165-0270(85)90053-6; Kukacka J, 2006, FASEB J, V20, pA75; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 2006, J NEUROSCI RES, V83, P974, DOI 10.1002/jnr.20790; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2006, FEBS J, V273, P1857, DOI 10.1111/j.1742-4658.2006.05207.x; Petrlova J, 2006, ELECTROCHIM ACTA, V51, P5112, DOI 10.1016/j.electacta.2006.03.078; Prusa R, 2006, CLIN CHEM, V52, pA175; Prusa R, 2004, MOL BIOL CELL, V15, p249A; Vajtr D, 2006, Soud Lek, V51, P36; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 2002, J CLIN NEUROSCI, V9, P51, DOI 10.1054/jocn.2001.0904; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	18	37	41	0	4	MAGHIRA & MAAS PUBLICATIONS	STOCKHOLM	PO BOX 26132, S-100 41 STOCKHOLM, SWEDEN	0172-780X			NEUROENDOCRINOL LETT	Neuroendocrinol. Lett.	DEC	2006	27			2			116	120					5	Endocrinology & Metabolism; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	153NQ	WOS:000245442600028	17159794				2022-02-06	
J	Bhambhani, Y; Maikala, R; Farag, M; Rowland, G				Bhambhani, Yagesh; Maikala, Ram; Farag, Mamdouh; Rowland, Gary			Reliability of near-infrared spectroscopy measures of cerebral oxygenation and blood volume during handgrip exercise in nondisabled and traumatic brain-injured subjects	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						Bland-Altman analysis; blood volume; cerebral oxygenation; handgrip contractions; intraclass correlations; motor function; near infrared spectroscopy; rehabilitation; testretest reliability; traumatic brain injury	SEVERE HEAD-INJURY; FUNCTIONAL MRI; ACTIVATION; FLOW; NIRS; REPRODUCIBILITY; MONITOR; HUMANS; SIGNAL; AREAS	We compared the test-retest reliability of nedrinfrared spectroscopy (NIRS) measures of cerebral oxygenation and blood volume during a rhythmic handgrip exercise in 13 nondisabled subjects and 25 subjects with moderate to severe traumatic brain injury (TBI). Subjects with TBI (average Glasgow Coma Scale score = 4.2, average time since injury = 21 mo) had completed an acute brain injury rehabilitation program. After 2 min of rest, each subject performed 60 s of maximal rhythmic handgrip contractions with the right hand in two trials 24 to 48 h apart. We used NIRS to measure cerebral oxygenation and blood volume responses from the left prefrontal lobe. Both groups' cerebral oxygenation and blood volume increased during handgrip contractions. The change in cerebral oxygenation was significantly lower in subjects with TBI compared with nondisabled subjects. Intraclass correlations between the two trials for cerebral oxygenation and blood volume were 0.83 and 0.80, respectively, in nondisabled subjects and 0.70 and 0.64, respectively, in subjects with TBI. The findings indicate that NIRS is a reliable noninvasive technique for evaluating cerebral oxygenation and ' blood volume changes during motor function. NIRS can be useful in monitoring recovery of cerebral oxygenation during rehabilitation of patients with TBI.	Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2G4, Canada; Alberta Hosp Ponoka, Brain Injury Rehabil Program, Ponoka, AB, Canada		Bhambhani, Y (corresponding author), Univ Alberta, Fac Rehabil Med, Corbett Hall,Room 373, Edmonton, AB T6G 2G4, Canada.	yagesh.bhambhani@ualberta.ca					ADELSON PD, 1988, ACTA NEUROCHIR S, V71, P250; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Cheng OSK, 2002, ACTA NEUROCHIR SUPPL, V81, P135; Colier WNJM, 1999, EXP BRAIN RES, V129, P457, DOI 10.1007/s002210050913; Fallgatter AJ, 1998, EUR ARCH PSY CLIN N, V248, P245, DOI 10.1007/s004060050045; Fujiwara N, 2004, NEUROIMAGE, V21, P1464, DOI 10.1016/j.neuroimage.2003.10.042; Giller CA, 2000, J APPL PHYSIOL, V88, P2205, DOI 10.1152/jappl.2000.88.6.2205; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Hirth C, 1997, ADV EXP MED BIOL, V411, P461; Houtman S, 1999, CLIN PHYSIOL, V19, P169; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1997, ACT NEUR S, V70, P112; Kastrup A, 1999, J CEREBR BLOOD F MET, V19, P1066, DOI 10.1097/00004647-199910000-00002; KAWASHIMA R, 1993, BRAIN RES, V623, P33, DOI 10.1016/0006-8993(93)90006-9; Keppel G., 1973, DESIGN ANAL RES HDB; Kleinschmidt A, 1996, J CEREBR BLOOD F MET, V16, P817, DOI 10.1097/00004647-199609000-00006; Koike A, 2004, CHEST, V125, P182, DOI 10.1378/chest.125.1.182; Kurihara K, 2003, CLIN PHYSIOL FUNCT I, V23, P177, DOI 10.1046/j.1475-097X.2003.00488.x; Mehagnoul-Schipper DJ, 2002, HUM BRAIN MAPP, V16, P14, DOI 10.1002/hbm.10026; Mehagnoul-Schipper DJ, 2001, CLIN PHYSIOL, V21, P77, DOI 10.1046/j.1365-2281.2001.00290.x; Obrig H, 1997, ADV EXP MED BIOL, V413, P113; Obrig H, 1996, J APPL PHYSIOL, V81, P1174, DOI 10.1152/jappl.1996.81.3.1174; Pollard V, 1996, ANESTH ANALG, V82, P269, DOI 10.1097/00000539-199602000-00010; RODRIGUEZ G, 1988, J CEREBR BLOOD F MET, V8, P783, DOI 10.1038/jcbfm.1988.133; Roth R, 1996, NEUROREPORT, V7, P1280, DOI 10.1097/00001756-199605170-00012; Saitou H, 2000, ARCH PHYS MED REHAB, V81, P1348, DOI 10.1053/apmr.2000.9400; Sakatani K, 2003, ACT NEUR S, V87, P59; Schroeter ML, 2006, NEUROIMAGE, V30, P349, DOI 10.1016/j.neuroimage.2005.09.048; Simonson SG, 1996, CRIT CARE CLIN, V12, P1019, DOI 10.1016/S0749-0704(05)70290-6; Totaro R, 1998, CLIN SCI, V95, P497, DOI 10.1042/CS19980122; UZUNER N, 2000, EUR J ULTRASOUND, V11, P1147; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; VILLRINGER A, 1993, NEUROSCI LETT, V154, P101, DOI 10.1016/0304-3940(93)90181-J; Watanabe A, 2003, J NEUROPSYCH CLIN N, V15, P442, DOI 10.1176/appi.neuropsych.15.4.442	36	37	37	0	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	NOV-DEC	2006	43	7					845	856		10.1682/JRRD.2005.09.0151			12	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	156FO	WOS:000245633700007	17436171	Bronze			2022-02-06	
J	Levchakov, A; Linder-Ganz, E; Raghupathi, R; Margulies, SS; Gefen, A				Levchakov, Anna; Linder-Ganz, Eran; Raghupathi, Ramesh; Margulies, Susan S.; Gefen, Amit			Computational studies of strain exposures in neonate and mature rat brains during closed head impact	JOURNAL OF NEUROTRAUMA			English	Article						finite element model; strain and stress distributions; tissue mechanical properties; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION MODEL; AXONAL INJURY; AGE; RESPONSES	Traumatic brain injury (TBI) is the most common cause of death in childhood, and the majority of fatal cases are due to motor vehicle accidents, falls, sport-related accidents, and child abuse. Rodents and particularly rats became a commonly used animal model of TBI in childhood as well as in adults, and different techniques are described in the literature to induce the brain injury. However, findings reported in the last decade regarding the increased stiffness of brain tissue in young animals, including rats, are not considered in experimental designs of TBI studies, and this may seriously bias the results when TBI effects are compared across different animal ages. In this study, we determined the strain and stress distributions in neonatal (post-natal-day [PND] 13-17) and mature (PND 43 and 90) rat brains during a closed head injury, using age-specific finite element (FE) models. The FE simulations indicated that for identical cortical displacements, the neonatal brain may be exposed to larger peak stress magnitudes compared with a mature brain due to stiffer tissue properties in the neonate, as well as larger strain magnitudes due to its smaller size. The brain volume subjected to a certain strain level was greater in the neonate brain compared with the adult models for all indentation depths greater than 1 mm. In conclusion, our present findings allow better design of closed head impact experiments which involve an age factor. Additionally, the larger peak stresses and larger strain volumetric exposures observed in the neonatal brain support the hypothesis that the smaller size and stiffer tissue of the infant brain makes it more susceptible to TBI.	Tel Aviv Univ, Fac Engn, Dept Biomed Engn, IL-69978 Tel Aviv, Israel; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA USA; Univ Penn, Sch Engn & Appl Sci, Dept Bioengn, Philadelphia, PA 19104 USA		Gefen, A (corresponding author), Tel Aviv Univ, Fac Engn, Dept Biomed Engn, Ramat Aviv Campus, IL-69978 Tel Aviv, Israel.	gefen@eng.tau.ac.il	Gefen, Amit/M-4720-2015; Raghupathi, Ramesh/AAX-5538-2021	Gefen, Amit/0000-0002-0223-7218; Linder-Ganz, Eran/0000-0001-6309-3505	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS-41562] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041562] Funding Source: NIH RePORTER		Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; Bandak F, 1994, 38 STAPP CAR CRASH C; BRUCE D, 1990, HEAD INJURIES PEDIAT; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; DEJEAMMES M, 1984, SAE T, P427; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296, DOI 10.1152/physrev.1945.25.2.296; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobbing J., 1981, SCI F PAEDIATRICS, P744; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fisher M D, 1997, Crit Care Nurs Q, V20, P36; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Griesbach G. S., 2000, Journal of Neurotrauma, V17, P986; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOHAN D, 1979, J BIOMECH ENG-T ASME, V101, P250, DOI 10.1115/1.3426254; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Ommaya AK, 1967, 11 STAPP CAR CRASH C; PASCUCCI RC, 1998, CARE MED, V14, P185; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pena A, 2005, ACT NEUR S, V95, P333; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; PRANGE MT, 2001, SUMM BIOENG C ASME B; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; RUAN JS, 1993, SAE T; STURTZ G, 1980, SAE T, P513; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; ZHOU C, 1994, SAE T; ZHOU C, 1995, SAE T	48	37	37	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1570	1580		10.1089/neu.2006.23.1570			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500016	17020491				2022-02-06	
J	Lin, HW; Basu, A; Druckman, C; Cicchese, M; Krady, JK; Levison, SW				Lin, Hsiao-Wen; Basu, Anirban; Druckman, Charles; Cicchese, Michael; Krady, J. Kyle; Levison, Steven W.			Astrogliosis is delayed in type 1 interleukin-1 receptor-null mice following a penetrating brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article							CHONDROITIN-SULFATE PROTEOGLYCAN; CENTRAL-NERVOUS-SYSTEM; FACTOR MESSENGER-RNA; GROWTH-FACTOR; CONVERTING-ENZYME; RAT-BRAIN; ACTIVATED RECEPTOR-1; CYTOKINE REGULATION; CEREBRAL-ISCHEMIA; GENE-EXPRESSION	The cytokines IL-1 alpha and IL-1 beta are induced rapidly after insults to the CNS, and their subsequent signaling through the type 1 IL-1 receptor (IL-1R1) has been regarded as essential for a normal astroglial and microglial/macrophage response. To determine whether abrogating signaling through the IL-1R1 will alter the cardinal astrocytic responses to injury, we analyzed molecules characteristic of activated astrocytes in response to a penetrating stab wound in wild type mice and mice with a targeted deletion of IL-1R1. Here we show that after a stab wound injury, glial fibrillary acidic protein (GFAP) induction on a per cell basis is delayed in the IL-1R1-null mice compared to wild type counterparts. However, the induction of chondroitin sulfate proteoglycans, tenascin, S-100B as well as glutamate transporter proteins, GLAST and GLT-1, and glutamine synthetase are independent of IL-1R1 signaling. Cumulatively, our studies on gliosis in the IL-1R1-null mice indicate that abrogating IL-1R1 signaling delays some responses of astroglial activation; however, many of the important neuroprotective adaptations of astrocytes to brain trauma are preserved. These data recommend the continued development of therapeutics to abrogate IL-1R1 signaling to treat traumatic brain injuries. However, astroglial scar related proteins were induced irrespective of blocking IL-1R1 signaling and thus, other therapeutic strategies will be required to inhibit glial scarring.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA; Natl Brain Res Ctr, Gurgaon 122050, India; Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA		Levison, SW (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, 185 S Orange Ave, Newark, NJ 07103 USA.	linh3@umdnj.edu; anirban@nbrc.res.in; chuckdruck@hotmail.com; michael_cicchese@yahoo.com; jkk7@psu.edu; steve.levison@umdnj.edu	BASU, ANIRBAN/C-1166-2009; Levison, Steven W./Q-6903-2019	Levison, Steven W./0000-0002-1264-7309; Basu, Anirban/0000-0002-5200-2054			Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; ALOISI F, 1992, J IMMUNOL, V149, P2358; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; Basu A, 2005, J CEREBR BLOOD F MET, V25, P17, DOI 10.1038/sj.jcbfm.9600002; Basu A, 2002, GLIA, V40, P109, DOI 10.1002/glia.10118; Basu A, 2002, J NEUROSCI, V22, P6071; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; BAUER J, 1993, J NEUROIMMUNOL, V48, P13, DOI 10.1016/0165-5728(93)90053-2; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Colognato R, 2003, BLOOD, V102, P2645, DOI 10.1182/blood-2002-08-2497; DACUNHA A, 1992, J NEUROIMMUNOL, V36, P157; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; DECKERTSCHLUTER M, 1992, J NEUROL SCI, V113, P50, DOI 10.1016/0022-510X(92)90264-L; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; DOU CL, 1994, J NEUROSCI, V14, P7616; Eng DL, 1997, BRAIN RES, V778, P215, DOI 10.1016/S0006-8993(97)01093-7; Engel U, 1996, GLIA, V16, P16, DOI 10.1002/(SICI)1098-1136(199601)16:1<16::AID-GLIA3>3.3.CO;2-I; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedman WJ, 1996, J BIOL CHEM, V271, P31115, DOI 10.1074/jbc.271.49.31115; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HARTUNG HP, 1989, BRAIN RES, V489, P113, DOI 10.1016/0006-8993(89)90013-9; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; HENDERSON CE, 1994, NEURAL CELL CULTURE; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; HOFMAN FM, 1986, J IMMUNOL, V136, P3239; Krum JM, 2002, EXP NEUROL, V174, P137, DOI 10.1006/exnr.2002.7867; Kuhlow CJ, 2003, GLIA, V44, P76, DOI 10.1002/glia.10273; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; Lee MT, 1996, AM J HEMATOL, V51, P307, DOI 10.1002/(SICI)1096-8652(199604)51:4<307::AID-AJH10>3.0.CO;2-B; Legos JJ, 2000, NEUROSCI LETT, V282, P189, DOI 10.1016/S0304-3940(00)00907-1; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levison SW, 1996, EXP NEUROL, V141, P256, DOI 10.1006/exnr.1996.0160; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; McGuinness MC, 1997, J NEUROIMMUNOL, V75, P174, DOI 10.1016/S0165-5728(97)00020-9; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; Nawashiro H, 2000, J CEREBR BLOOD F MET, V20, P1040, DOI 10.1097/00004647-200007000-00003; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; NORRIS JG, 1994, J IMMUNOL, V152, P841; OCALLAGHAN JP, 1991, NEUROTOXICOL TERATOL, V13, P275, DOI 10.1016/0892-0362(91)90073-6; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; Pacoste C., 2001, INT J STRUCT STAB DY, V1, P1; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Shinohara T, 2002, CYTOKINE, V19, P66, DOI 10.1006/cyto.2002.1946; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; STALLCUP WB, 1981, DEV BIOL, V83, P154, DOI 10.1016/S0012-1606(81)80018-8; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; YAMADA T, 1994, BRAIN RES, V637, P308, DOI 10.1016/0006-8993(94)91250-5; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676	79	37	38	1	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUN 30	2006	3								15	10.1186/1742-2094-3-15			11	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	174UV	WOS:000246969200001	16808851	gold, Green Published			2022-02-06	
J	Huang, SJ; Chang, L; Han, YY; Lee, YC; Tu, YK				Huang, Sheng-Jean; Chang, Lin; Han, Yin-Yi; Lee, Yuan-Chi; Tu, Yong-Kwang			Efficacy and safety of hypertonic saline solutions in the treatment of severe head injury	SURGICAL NEUROLOGY			English	Article						severe head injury; intracranial pressure; hypertonic saline; cerebral blood flow	ELEVATED INTRACRANIAL-PRESSURE; LACTATED RINGERS SOLUTION; MALIGNANT CEREBRAL EDEMA; TRAUMATIC BRAIN-INJURY; HEMORRHAGIC-SHOCK; INTRACEREBRAL HEMORRHAGE; WATER-CONTENT; BLOOD-FLOW; RESUSCITATION; MANNITOL	Background: The present study was undertaken to evaluate the efficacy and safety of hypertonic saline (HS) in the treatment of intracranial hypertension after severe head injury. Methods: This prospective, observational study was performed in an 11-bed neurosurgery intensive care unit of a teaching hospital. From February 2002 to September 2004, 18 severely head-injured patients with elevated intracranial pressure (ICP) and Glasgow Coma Scale scores of 5 to 8 (mean, 5.9 +/- 1.2) were admitted to the unit and treated according to a standard protocol. One dose per day of 3% saline was administered by rapid infusion (300 mL/20 min) when ICP values exceeded 20 min Hg. After infusion, cerebral blood flow, ICP, blood pressure, end-tidal carbon dioxide, and heart rate were monitored continuously for 60 minutes and recorded. Serum osmolarity, sodium, potassium, chloride, arterial carbon dioxide pressure, arterial oxygen pressure, hemoglobin, lactic acid, and pH were measured immediately before infusion (zero time) and 20 and 60 minutes after infusion. Mean arterial pressure, cerebral perfusion pressure (CPP), mean flow velocity (MFV), and pulsatility index (PI) were also recorded and analyzed. Results: Intracranial pressure fell immediately after initiation of infusion with further significant decreases observed at 20 and 60 minutes (30.4 +/- 8.5, 24.3 +/- 7.4, and 23.8 +/- 8.3 mm Hg, respectively; P < .01). At these respective times CPP increased significantly (78.7 +/- 8.7. 83.2 +/- 7.8, and 87.2 +/- 12.8 min Hg), PI dropped rapidly (1.51 +/- 0.42, 1.38 +/- 0.32, and 1.34 +/- 0.33) and MFV increased (66.26 +/- 25.91, 71.92 +/- 28.13, and 68.74 +/- 28.44). Serum sodium increased from 141.3 +/- 7.2 to 146.3 +/- 7.2 mmol/L after 20 minutes and returned to 144.3 +/- 7.36 mmol/L at 60 minutes. Potassium concentrations decreased significantly from 3.9 +/- 0.39 to 3.55 +/- 0.35 mmoUL after 20 minutes (P < .01). Lactic acid values at 0, 20, and 60 minutes were 1.6 +/- 0.5, 1.47 +/- 0.48, and 1.38 +/- 0.53 mmol/L, respectively (P < .01). Conclusion: Rapid infusion of single dose daily of HS is a safe alternative for the treatment of elevated ICP in severe head injury. Further evaluations of long-term consequences and complications and of maximal tolerance to this treatment are required. (c) 2006 Elsevier Inc. All rights reserved.	Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Traumatol, Taipei 100, Taiwan		Tu, YK (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei 100, Taiwan.	yktu@ha.mc.ntu.edu.tw		HAN, YIN-YI/0000-0001-8831-7835; Tu, Yong-kwang/0000-0003-2113-1176			ANISH B, 2004, CURR OPIN CRIT CARE, V10, P126; Bacher A, 1998, CRIT CARE MED, V26, P108, DOI 10.1097/00003246-199801000-00024; BINGAMAN WE, 1995, NEUROL CLIN, V13, P479, DOI 10.1016/S0733-8619(18)30031-8; BLECK TP, 1995, MAYO CLIN PROC, V70, P195, DOI 10.4065/70.2.195; CARDEN DL, 1989, RESUSCITATION, V17, P153, DOI 10.1016/0300-9572(89)90067-1; DAVIS JW, 1994, J TRAUMA, V36, P168, DOI 10.1097/00005373-199402000-00002; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; DUCEY JP, 1990, CRIT CARE MED, V18, P744, DOI 10.1097/00003246-199007000-00013; FENSTERMACHER JD, 1966, AM J PHYSIOL, V211, P341, DOI 10.1152/ajplegacy.1966.211.2.341; FRASER PA, 1990, J PHYSIOL-LONDON, V423, P343, DOI 10.1113/jphysiol.1990.sp018026; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GOULIN GD, 1994, ANESTH ANALG, V79, P1036; GUNNAR W, 1988, SURGERY, V103, P398; Hariri R J, 1994, Neurosurg Clin N Am, V5, P687; Hartl R, 1997, ACT NEUR S, V70, P126; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; HUANG SJ, 2005, CRIT CARE MED, V31, pY2559; JOSE IS, 2004, CLEVE CLIN J MED S1, V71, pS9; Kempski O, 2005, CRIT CARE MED, V33, P259, DOI 10.1097/01.CCM.0000151046.70094.4C; Kempski O, 1997, J TRAUMA, V42, pS38, DOI 10.1097/00005373-199705001-00007; Kempski O, 1996, ACT NEUR S, V66, P114; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; Laureno R, 1997, ANN INTERN MED, V126, P57, DOI 10.7326/0003-4819-126-1-199701010-00008; Maeda T, 2003, ACT NEUR S, V86, P329; Marion DW, 1997, CONT NEUROSURG, V19, P1; MATTEUCCI MJ, 1993, J TRAUMA, V34, P1, DOI 10.1097/00005373-199301000-00001; MOSS GS, 1988, AM J SURG, V155, P425, DOI 10.1016/S0002-9610(88)80106-5; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PRIEN T, 1993, ZBL CHIR, V118, P257; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 1998, J NEUROSURG ANESTH, V10, P188, DOI 10.1097/00008506-199807000-00010; Rabinovici R, 1996, J SURG RES, V60, P176, DOI 10.1006/jsre.1996.0028; RAPOPORT SI, 1979, BRAIN RES, V172, P354, DOI 10.1016/0006-8993(79)90546-8; REED RL, 1991, J TRAUMA, V31, P8, DOI 10.1097/00005373-199101000-00002; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; Schwarz S, 2002, STROKE, V33, P136, DOI 10.1161/hs0102.100877; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TEASDALE G, 1974, LANCET, V2, P81; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; Tollofsrud S, 1998, ACTA ANAESTH SCAND, V42, P145, DOI 10.1111/j.1399-6576.1998.tb05100.x; Tollofsrud S, 1998, ACTA ANAESTH SCAND, V42, P154, DOI 10.1111/j.1399-6576.1998.tb05101.x; Toung TJK, 2005, CRIT CARE MED, V33, P203, DOI 10.1097/01.CCM.0000150659.15558.23; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	56	37	44	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	2006	65	6					539	546		10.1016/j.surneu.2005.11.019			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	052NI	WOS:000238240000005	16720165				2022-02-06	
J	Klonoff, PS; Watt, LM; Dawson, LK; Henderson, SW; Gehrels, JA; Wethe, JV				Klonoff, Pamela S.; Watt, Lisa M.; Dawson, Lauren K.; Henderson, Steven W.; Gehrels, Jo-Ann; Wethe, Jennifer Voreis			Psychosocial outcomes 1-7 years after comprehensive milieu-oriented neurorehabilitation: The role of pre-injury status	BRAIN INJURY			English	Article						outcome; neurorehabilitation; brain injury; work; driving	TRAUMATIC BRAIN-INJURY; 11 YEARS POSTDISCHARGE; TERM-FOLLOW-UP; COMMUNITY INTEGRATION; REHABILITATION; PREDICTORS; EMPLOYMENT; VARIABLES; RETURN; SEVERITY	Primary objective: To explore pre-injury variables related to post-discharge psychosocial status and identify factors related to work and driving outcomes. Methods and procedures: Ninety-three brain-injured patients attended a holistic milieu-oriented neurorehabilitation program and were contacted 1-7 years post-discharge. Experimental interventions: Questionnaire data addressing pre-injury and post-injury work, driving, income, marital status and living situation. Main outcomes and results: 74.3% were involved in competitive work and/or school with 86.0% productive at follow-up. Post-injury income decreased significantly compared with pre-injury levels. Pre-injury relationship status did not differ significantly from post-injury; 81.1% remaining in a stable relationship or married at follow-up. Pre-injury and post-injury accident rates were related; 73.1% drove at follow-up. Higher education, non-right hemispheric injury, shorter treatment length and return to work related to driving. Younger age, higher education, non-right hemispheric injury and driving post-injury related to positive work status. Conclusions: Pre-injury psychosocial data provide an important context for understanding post-discharge outcome after brain injury. Holistic milieu-oriented rehabilitation facilitates long-term successful work, driving and relationship stability.	Barrow Neurol Inst, Ctr Trasit Neurorehabil, Catholic Healthcare W, Phoenix, AZ 85013 USA		Klonoff, PS (corresponding author), Barrow Neurol Inst, St Josephs Hosp & Med Ctr, CTN,222 W Thomas Rd,Suite 401, Phoenix, AZ 85013 USA.	pamela.klonoff@chw.edu					Ashley MJ, 1997, BRAIN INJURY, V11, P677; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Hartman-Maeir A, 2003, DISABIL REHABIL, V25, P35, DOI 10.1080/0963828021000007897; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Klonoff PS, 2000, ARCH PHYS MED REHAB, V81, P1535, DOI 10.1053/apmr.2000.9177; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Novack TA, 2000, BRAIN INJURY, V14, P987; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; SUNDET K, 1995, SCAND J PSYCHOL, V36, P47, DOI 10.1111/j.1467-9450.1995.tb00967.x; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	35	37	37	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2006	20	6					601	612		10.1080/02699050600744301			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100005	16754285				2022-02-06	
J	Stevens, ST; Lassonde, M; de Beaumont, L; Keenan, JP				Stevens, S. T.; Lassonde, M.; de Beaumont, L.; Keenan, J. P.			The effect of visors on head and facial injury in National Hockey League players	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						concussions; head injuries; ice hockey; National Hockey League (NHL); face visor; visor	ICE-HOCKEY; CONCUSSIONS; NECK	There has been an increase in the number of concussions sustained by players in the National Hockey League (NHL). White wearing a helmet is now required by the NHL, the face visor-remains optional. It is unknown to what degree face visors influence concussion, other head injury and eye-injury rates at the professional level. Data from the 2001-2002 NHL season were examined. It was found that wearing a face visor did not significantly influence the prevalence of concussion. Visor protection did, however, minimise eye-injuries and other, non-concussion head injuries. These data suggest that, white a visor may prevent some head and eye-injuries, other measures may be necessary to reduce the number of concussions. (c) 2006 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	Montclair State Univ, Cognit Neuroimaging Lab, Montclair, NJ 07043 USA; Univ Montreal, Ctr Rech Neuropsychol & Cognit, Montreal, PQ, Canada		Keenan, JP (corresponding author), Montclair State Univ, Cognit Neuroimaging Lab, 219 Dickson Hall, Montclair, NJ 07043 USA.	keenanj@mail.montclair.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barth JT, 2001, J ATHL TRAINING, V36, P253; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Deady B, 1996, J Emerg Med, V14, P645, DOI 10.1016/S0736-4679(96)00134-5; DIAMOND D, 2003, TOTAL NHL; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FISCHLER S, 1996, GREAT BOOK HOCKEY; Ing E, 2002, CAN J OPHTHALMOL, V37, P161, DOI 10.1016/S0008-4182(02)80058-8; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Menard S.W., 1995, APPL LOGISTIC REGRES; PASHBY T, 1987, CAN J OPHTHALMOL, V22, P293; Pashby T J, 1979, Am J Sports Med, V7, P254, DOI 10.1177/036354657900700410; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; Voyer D., 1998, Journal of Sport Behavior, V21, P456; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; 2003, HOCKEY REGISTER 2003; 2004, HOCKEY NEWS, V57, P4	22	37	37	0	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	JUN	2006	9	3					238	242		10.1016/j.jsams.2006.03.025			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	061TE	WOS:000238894700008	16716662				2022-02-06	
J	Basso, D; Lotze, M; Vitale, L; Ferreri, F; Bisiacchi, P; Belardinelli, MO; Rossini, PM; Birbaumer, N				Basso, D; Lotze, M; Vitale, L; Ferreri, F; Bisiacchi, P; Belardinelli, MO; Rossini, PM; Birbaumer, N			The role of prefrontal cortex in visuo-spatial planning: a repetitive TMS study	EXPERIMENTAL BRAIN RESEARCH			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; HUMAN CORTICOSPINAL EXCITABILITY; RTMS; SAFETY; MODEL	The visuo-spatial planning process is based on an "opportunistic" combination of heuristics and strategies, carried out in small units during the execution of plans. In order to investigate the functional role of the prefrontal cortex in heuristic switching, 42 healthy controls performed a labyrinth crossing task (the Maps Test). During this computerized version of the Travelling Salesperson Problem, subjects had to decide which order of locations optimizes total travel time and distance. This task was performed with and without 1 Hz repetitive transcranial magnetic stimulation (rTMS), which exerts an inhibitory action on the targeted area, applied during the task over bilateral frontal sites (active stimulation) and parieto-occipital site (sham stimulation). Only repetitive bilateral rTMS over F3 and F4 significantly decreased the number of strategies with changes of heuristics, and increased the number of movements required to solve the task. This behaviour contrasts with the performance of healthy subjects in the planning task, but is consistent with the performance of frontal traumatic brain injury patients. The results indicate that, in a visuo-spatial problem-solving task, the prefrontal cortex is involved in the switching between heuristics during the execution of a plan.	Interuniv Ctr Res Cognit Proc Nat & Artificial Sy, ECONA, I-00185 Rome, Italy; Inst Med Psychol & Verhaltensneurobiol, Tubingen, Germany; Univ Roma La Sapienza, Dept Psychol, Rome, Italy; Neurol, Rome, Italy; Univ Padua, Dept Gen Psychol, Padua, Italy; IRCCS, Ctr S Giovanni di Dio Fatebenefratelli, Brescia, Italy		Basso, D (corresponding author), Interuniv Ctr Res Cognit Proc Nat & Artificial Sy, ECONA, Via Marsi,78,Stanza 16,2 Piano, I-00185 Rome, Italy.	demis.basso@uniroma1.it	Rossini, Paolo M./D-4994-2013; Olivetti, Marta/T-4540-2017; Basso, Demis/Q-4782-2017; Lotze, Martin/D-2964-2012; BISIACCHI, PATRIZIA/B-8976-2008	Rossini, Paolo M./0000-0003-2665-534X; Olivetti, Marta/0000-0003-3169-3359; Basso, Demis/0000-0002-4595-3513; Lotze, Martin/0000-0003-4519-4956; BISIACCHI, PATRIZIA/0000-0003-2760-8000; Ferreri, Florinda/0000-0002-7938-905X; Birbaumer, Niels/0000-0002-6786-5127			Basso D, 2001, BRAIN COGNITION, V46, P38, DOI 10.1016/S0278-2626(01)80029-4; BASSO D, 2005, THESIS U ROME DEP PS; BISIACCHI PS, 2002, IAPS B PEOPLE ENV ST, V21, P1; Boroojerdi B, 2001, NEUROLOGY, V56, P526, DOI 10.1212/WNL.56.4.526; CADWALLADER M, 1975, ECON GEOGR, V51, P339, DOI 10.2307/142918; Chen R, 1997, ELECTROMYOGR MOTOR C, V105, P415, DOI 10.1016/S0924-980X(97)00036-2; Cisek P., 2005, COGN PROCESS, V6, P15, DOI DOI 10.1007/S10339-004-0046-7; Cohen G., 1989, MEMORY REAL WORLD; Dehaene S, 1991, CEREB CORTEX, V1, P62, DOI 10.1093/cercor/1.1.62; Fitzgerald PB, 2002, CLIN NEUROPHYSIOL, V113, P1136, DOI 10.1016/S1388-2457(02)00145-1; Graham SM, 2000, MEM COGNITION, V28, P1191, DOI 10.3758/BF03211820; HAYES-ROTH B, 1979, Cognitive Science, V3, P275, DOI 10.1207/s15516709cog0304_1; HIRTLE SC, 1992, GEOFORUM, V23, P227, DOI 10.1016/0016-7185(92)90019-Z; Karim AA, 2003, SUPPL CLIN NEUROPHYS, V56, P331; Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545; Leocani L, 2000, BRAIN, V123, P1161, DOI 10.1093/brain/123.6.1161; MacGregor JN, 2004, MEM COGNITION, V32, P260, DOI 10.3758/BF03196857; McKeefry DJ, 1997, NEUROIMAGE, V5, P1, DOI 10.1006/nimg.1996.0246; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MORRIS RG, 1993, NEUROPSYCHOLOGIA, V31, P1367, DOI 10.1016/0028-3932(93)90104-8; Phillips LH, 2001, Q J EXP PSYCHOL-A, V54, P579, DOI 10.1080/02724980042000237; Rossi S, 2000, CEREB CORTEX, V10, P802, DOI 10.1093/cercor/10.8.802; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Vandenberghe R, 1996, NATURE, V383, P254, DOI 10.1038/383254a0; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8	27	37	37	0	7	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	MAY	2006	171	3					411	415		10.1007/s00221-006-0457-z			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	044HC	WOS:000237662000012	16710684				2022-02-06	
J	Engberg, AW; Liebach, A; Nordenbo, A				Engberg, AW; Liebach, A; Nordenbo, A			Centralized rehabilitation after severe traumatic brain injury - a population-based study	ACTA NEUROLOGICA SCANDINAVICA			English	Article						centralized; population-based; rehabilitation; severe traumatic brain injury	SEVERE HEAD-INJURY; STROKE UNIT; SCALE	Objectives - To present results from the first 3 years of centralized subacute rehabilitation after very severe traumatic brain injury (TBI), and to compare results of centralized versus decentralized rehabilitation. Material and methods - Prospectively, the most severely injured group of adults from an uptake area of 2.4 million in Denmark were included at admission to a regional brain injury unit (BIU), on average 19 days after injury. Patients in the retrospective study used for comparison were randomly chosen from the national hospital register. Results and conclusions - Out of 117 patients in the prospective study, six died, and 92 (1.27 per 100,000 population per year) survived after a post-traumatic amnesia (PTA) period of at least 28 days. All 19 patients with PTA 7-27 days and 48% of survivors with PTA at least 4 weeks were discharged directly home. The incidence of patients vegetative at 1 month post-trauma was 0.29, and at 1 year 0.055 per 100,000 population. By comparison of 39 patients from the centralized unit injured in 2000-2003 with 21 patients injured in 1982, 1987 or 1992 and with similar PTA- and age distributions and male/female ratio, Glasgow Outcome Scale score at discharge was significantly better for the former group.	Univ Copenhagen, Hvidovre Hosp, Dept Neurol Rehabil 354, Brain Injury Unit, DK-2650 Hvidovre, Denmark		Engberg, AW (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Neurol Rehabil 354, Brain Injury Unit, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.	aae@dadlnet.dk					AFFOLTER F, 1980, INT REHABIL MED, V3, P3; *AM ASS ADV AUT ME, 1990, ABBR INJ SCAL PLAIN; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; AZOUVI P, 1996, BRAIN INJURY, V10, P849; COOMBES K, 1996, ERNAHRUNGSSONDE ESSE, P137; DAVIES PM, 1994, STARTING AGAIN EARLY; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; GREENBLATT R, 1961, JAMA-J AM MED ASSOC, V178, P101, DOI 10.1001/jama.1961.03040410001001; HARRADINE PG, 2004, MED J AUSTRALIA, V3, P130; HOLLAND AD, 1984, LANGUAGE DISORDERS A, P245; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jennett B., 2002, VEGETATIVE STATE; JORGENSEN HS, 1995, STROKE, V26, P1178, DOI 10.1161/01.STR.26.7.1178; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LINN S, 1995, INJURY SEVERITY SCOR, V5, P440; LIPP B, 1996, WEGE ANFANG FRUHREHA; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; ODDY M, 1984, CLOSED HEAD INJURY P, P108; SAZBON I, 1990, J NEUROSURG, V73, P479; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; *SUND NAT BOARD HL, 1997, BEH TRAUM HJERN TILG; [No title captured]	25	37	37	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	MAR	2006	113	3					178	184		10.1111/j.1600-0404.2005.00570.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	006SP	WOS:000234917700006	16441248				2022-02-06	
J	Sheldon, AL; Gonzalez, MI; Robinson, MB				Sheldon, AL; Gonzalez, MI; Robinson, MB			A carboxyl-terminal determinant of the neuronal glutamate transporter, EAAC1, is required for platelet-derived growth factor-dependent trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; PROTEIN-KINASE-C; PERINUCLEAR STORAGE COMPARTMENT; TRAUMATIC BRAIN-INJURY; GABA SYNTHESIS; AMINO; ACTIVATION; SUBTYPE; GLUT4; EXCITOTOXICITY	The neuronal glutamate transporter, EAAC1 ( excitatory amino acid carrier 1), undergoes rapid regulation after treatment with platelet-derived growth factor (PDGF) or phorbol ester in C6 glioma cells and neurons. A large intracellular pool of EAAC1 exists, from which transporters are redistributed to the cell surface in response to these signals. Here we show that PDGF had no effect on subcellular localization of the glial glutamate transporter, GLT-1, after transfection into C6 glioma cells. Chimeras consisting of domains from EAAC1 or GLT-1 were used to investigate structural motifs involved in PDGF-dependent redistribution of EAAC1. PDGF did not induce trafficking of an EAAC1 chimera containing the carboxyl- terminal domain of GLT-1; however, it did induce trafficking of a GLT-1 chimera containing the carboxyl- terminal domain of EAAC1. A truncated mutant of EAAC1 lacking 10 carboxyl-terminal amino acids was responsive to PDGF, whereas a mutant lacking 20 residues was not. Alanine substitution mutagenesis in this region revealed a short motif, (YVN504)-Y-502, necessary for regulated trafficking. This motif was also involved in protein kinase C-dependent trafficking, as mutant transporters exhibited an attenuated response to phorbol ester. Interestingly, the presence of YVN in the homologous region of a nonresponsive chimera was not sufficient to confer regulated trafficking; however, the presence of a 12-amino acid motif starting at this Tyr residue was sufficient to confer responsiveness to PDGF. These studies identify a novel motif within the carboxyl terminus of EAAC1 which is required for regulated trafficking. The possibility that this motif targets EAAC1 to an intracellular, "regulated pool" is discussed.	Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Neurosci, Philadelphia, PA 19104 USA		Robinson, MB (corresponding author), Dept Pediat, 502N Abramson Pediat Res Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@pharm.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R13HD029679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039011, R01NS029868] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30-HD29679] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5-T32-GM07517] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1-F31-MH1071008-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29868, NS39011] Funding Source: Medline		BECKMANN ML, 2005, NEUROPHARMACOL C, V15; Cheng CL, 2002, J NEUROSCI, V22, P10643; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Conti F, 1998, CEREB CORTEX, V8, P108, DOI 10.1093/cercor/8.2.108; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Diamond JS, 2001, J NEUROSCI, V21, P8328, DOI 10.1523/JNEUROSCI.21-21-08328.2001; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; He Y, 2000, J COMP NEUROL, V418, P255; Kalandadze A, 2002, J BIOL CHEM, V277, P45741, DOI 10.1074/jbc.M203771200; Levenson J, 2002, NAT NEUROSCI, V5, P155, DOI 10.1038/nn791; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Mathews GC, 2003, J NEUROSCI, V23, P2040; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Palacios S, 2001, J BIOL CHEM, V276, P3371, DOI 10.1074/jbc.M006739200; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Tsvetkov E, 2004, NEURON, V41, P139, DOI 10.1016/S0896-6273(03)00800-6; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	32	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4876	4886		10.1074/jbc.M504983200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	WOS:000235426200038	16368696	hybrid			2022-02-06	
J	Hewitt, J; Evans, JJ; Dritschel, B				Hewitt, J.; Evans, J. J.; Dritschel, B.			Theory driven rehabilitation of executive functioning: Improving planning skills in people with traumatic brain injury through the use of an autobiographical episodic memory cueing procedure	NEUROPSYCHOLOGIA			English	Article						traumatic brain injury; rehabilitation; executive dysfunction; planning; problem solving	AMNESIA	Traumatic brain injury (TBI) frequently leads to the development of a 'dysexecutive syndrome'. The associated difficulties with problem solving (including specific impairments in planning, initiation/plan-implementation and self-monitoring) represent a major challenge to functional recovery and adaptation following brain injury and serve as an important target for rehabilitation. Previous research suggests that one reason people with TBI are poor at everyday planning is that they fail to spontaneously use specific autobiographical memories to support planning in unstructured situations. In this study, we examined whether a self-instructional technique involving self-cueing to recall specific autobiographical experiences would improve performance on a planning task. Two groups of 15 participants who had suffered a closed traumatic brain injury carried out the Everyday Descriptions Task (Dritschel, B. (1991). The role of autobiographical memory in describing how to perform everyday activities. In Paper presented at the European Cognitive Society Conference.), in which they were asked to describe how they would plan eight common unstructured activities, i.e. activities that could be solved in a variety of ways. Group 1 was then asked to describe how to plan a second set of eight unstructured activities. Prior to completing their second set of eight activities, Group 2 underwent training in a procedure aimed at prompting the retrieval of specific memories to support planning. The results suggested that the intervention was effective at increasing the number of specific memories recalled, with a corresponding increase in the effectiveness of the plan and number of relevant steps in the plan. Potential applications of the technique are discussed. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland; Univ St Andrews, St Andrews KY16 9AJ, Fife, Scotland		Evans, JJ (corresponding author), Gartnavel Royal Hosp, Sch Psychol Med, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	jonathan.evans@clinmed.gla.ac.uk		Dritschel, Barbara/0000-0002-0909-6323			BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; Baddeley A. D., 1990, AUTOBIOGRAPHICAL MEM; BADDELEY AD, 1986, AUTOBIOGRAPHICAL MEM; Barsalou L. W., 1988, REMEMBERING RECONSID; Burgess P.W., 1997, HAYLING BRIXTON TEST; BURGESS PW, 1996, COGNITIVE MODELS MEM; Burgess PW., 1996, BEHAV ASSESSMENT DYS; Cohen J., 2013, STAT POWER ANAL BEHA; CONWAY MA, 1987, MEM COGNITION, V15, P119, DOI 10.3758/BF03197023; CONWAY MA, 1993, THEORIES REMEMBERING; DECOSTELLO AL, 1989, CORTEX, V29, P105; DRITSCHEL B, 1991, EUR COGN SOC C; Dritschel BH, 1998, BRAIN INJURY, V12, P875; EVANS J, 1992, PSYCHOL MED, V22, P399, DOI 10.1017/S0033291700030348; EVANS JJ, 2001, NEUROBEHAVIORAL DISA; GOODARD L, 1996, J ABNORM PSYCHOL, V36, P449; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; MARX EM, 1992, J ABNORM PSYCHOL, V101, P78, DOI 10.1037/0021-843X.101.1.78; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; ROSS BH, 1984, COGNITIVE PSYCHOL, V16, P371, DOI 10.1016/0010-0285(84)90014-8; Seifert C. M., 1994, ANALOGY METAPHOR REM, P95; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1998, PREFRONTAL CORTEX EX; WILLIAMS JMG, 1996, STUDIES AUTOBIOGRAPH, P271; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO	28	37	38	0	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	8					1468	1474		10.1016/j.neuropsychologia.2005.11.016			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	049JG	WOS:000238011700021	16384587				2022-02-06	
J	Shields, BJ; Smith, GA				Shields, BJ; Smith, GA			Cheerleading-related injuries to children 5 to 18 years of age: United States, 1990-2002	PEDIATRICS			English	Article							HIGH-SCHOOL; FREQUENCY	OBJECTIVE. To describe the epidemiology of cheerleading-related injuries among children in the United States. DESIGN. A retrospective analysis of data for children 5 to 18 years old from the National Electronic Injury Surveillance System (NEISS) of the US Consumer Product Safety Commission, 1990-2002. METHODS. Sample weights provided by the NEISS were used to make national estimates of cheerleading-related injuries. Injury rates were calculated for the most frequently occurring types of injury using cheerleading participation data. RESULTS. An estimated 208 800 children (95% confidence interval [CI]: 166 620 250 980) 5 to 18 years of age were treated in US hospital emergency departments for cheerleading-related injuries during the 13-year period of 1990-2002. The number of injuries increased by 110% from 10 900 in 1990 to 22 900 in 2002, with an average of 16 100 (95% CI: 12 848-19 352) injuries per year (P < .01). The average age of injured children was 14.4 years (median: 15.0 years); 97% were female; and 85% of injuries occurred to children 12 to 17 years old. The number of injuries per 1000 participants per year was greater for 12- to 17-year-olds (8.1) than for 6- to 11-year-olds (1.2) for all cheerleading-related injuries combined (P <. 01; relative risk [RR]: 6.49; 95% CI: 6.40-6.58), as well as for injuries grouped by body part injured and type of injury. The body parts injured were lower extremity (37.2%), upper extremity (26.4%), head/neck (18.8%), trunk (16.8%), and other (0.8%). Injury diagnoses were strains/sprains (52.4%), soft tissue injuries (18.4%), fractures/dislocations (16.4%), lacerations/avulsions (3.8%), concussions/closed head injuries (3.5%), and other (5.5%). Children in the 12- to 18-year age group were more likely to sustain strains or sprains to the lower extremity than 5- to 11-year-olds (P < .01; RR: 1.62; 95% CI: 1.50-1.88). The majority of patients with cheerleading-related injuries was treated and released from the emergency department (98.7%). Patients sustaining fractures or dislocations were more likely to be admitted to the hospital than those sustaining other types of injury ( P < .01; RR: 5.30; 95% CI: 3.29-6.43). CONCLUSIONS. To our knowledge, this study is the first to report numbers, rates, and trends of cheerleading-related injuries to children using a nationally representative sample. Cheerleading is an important source of injury to girls. The number of cheerleading-related injuries more than doubled during the 13-year study period. A set of uniform rules and regulations directed at increasing the safety of cheerleading, that are universally enforced, should be implemented. Mandatory completion of a safety training and certification program should be required of all cheerleading coaches. Establishment of a national database for cheerleading-related injuries would facilitate the development and evaluation of injury-prevention strategies based on epidemiologic evidence.	Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Pediat, Columbus, OH 43210 USA		Shields, BJ (corresponding author), Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	shieldsb@pediatrics.ohio-state.edu					*AM ASS CHEERL COA, AM ASS CHEERL COACHE; American Sports Data Inc, 2004, SUP SPORTS PART, VII; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Axe M J, 1991, Del Med J, V63, P359; Boden BP, 2003, AM J SPORT MED, V31, P881, DOI 10.1177/03635465030310062501; CANTU RC, 1994, CLIN J SPORT MED, V4, P75; *CHIC IL, 2003, SPSS WIND COMP PROGR; Davis Y, 1996, J SAFETY RES, V27, P83, DOI 10.1016/0022-4375(96)00002-3; Fort GG, 1999, AM J EMERG MED, V17, P432, DOI 10.1016/S0735-6757(99)90107-9; Hage P, 1981, Phys Sportsmed, V9, P140, DOI 10.1080/00913847.1981.11711019; HAGE P, 1983, PHYSICIAN SPORTSMED, V11, P25; HOPKINS RS, 1989, AM J PREV MED, V5, P104, DOI 10.1016/S0749-3797(18)31112-7; Hutchinson MR, 1997, PHYSICIAN SPORTSMED, V25, P83, DOI 10.3810/psm.1997.09.1508; Jacobson BH, 2005, BRIT J SPORT MED, V39, P237, DOI 10.1136/bjsm.2004.014605; Jacobson BH, 2004, J ORTHOP SPORT PHYS, V34, P261, DOI 10.2519/jospt.2004.34.5.261; KESSLER E, 1999, NEIS SAMPLE DESIGN I; *LUCK, 2002, PEDIATR CLIN N AM, V49, P753; Luckstead EF, 2002, PEDIATR CLIN N AM, V49, P753, DOI 10.1016/S0031-3955(02)00017-2; Luckstead EF, 2002, PEDIATR CLIN N AM, V49, P581, DOI 10.1016/S0031-3955(02)00006-8; McDonald A K, 1996, Inj Prev, V2, P77, DOI 10.1136/ip.2.1.77; McGeehan J, 2004, PEDIATRICS, V114, P124, DOI 10.1542/peds.114.1.124; MCNEILL AM, 1995, ANN EMERG MED, V26, P187, DOI 10.1016/S0196-0644(95)70150-8; Mueller FO, 2001, J ATHL TRAINING, V36, P312; MUELLER FO, 2003, SPECIAL SECTIONS CHE; NINEMIRE V, 2005, HUSKERS CHEERLEADERS; Ortega HW, 2004, CLIN PEDIATR, V43, P251, DOI 10.1177/000992280404300306; ROENIGK A, 2002, AM CHEERLEADER, V8, P159; ROENIGK A, 2002, AM CHEERLEADER, V8, P46; Schroeder T., 2001, NEISS SAMPLE DESIGN; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; SHIELDS RW, 1986, ARCH PHYS MED REHAB, V67, P824; Simon TD, 2004, ACAD EMERG MED, V11, P1042, DOI 10.1197/j.aem.2004.04.013; Sinha AK, 1999, CLIN J SPORT MED, V9, P199, DOI 10.1097/00042752-199910000-00003; Smith GA, 1998, PEDIATRICS, V101, P406, DOI 10.1542/peds.101.3.406; Smith GA, 1998, ARCH PEDIAT ADOL MED, V152, P694; Weiss H B, 1996, Inj Prev, V2, P166, DOI 10.1136/ip.2.2.166; Weiss H B, 1996, Inj Prev, V2, P61, DOI 10.1136/ip.2.1.61; *WORLD CHEERL ASS, OP CHALL SER DIV 200; Xiang HY, 2005, J TRAUMA, V58, P112, DOI 10.1097/01.TA.0000151270.26634.DD; UNL RIGHTS ALLOW STU	40	37	39	4	23	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2006	117	1					122	129		10.1542/peds.2005-1139			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	999QV	WOS:000234406100017	16396869	Bronze			2022-02-06	
J	Avesani, R; Salvi, L; Rigoli, G; Gambini, MG				Avesani, R; Salvi, L; Rigoli, G; Gambini, MG			Reintegration after severe brain injury: A retrospective study	BRAIN INJURY			English	Article							FINNISH PATIENTS 5; ACUTE PREDICTORS; RETURN; WORK; REHABILITATION; EMPLOYMENT; REEMPLOYMENT; PROGRAM	Primary objective: The evaluation of school and work reintegration of patients following severe brain injury and of the relationship between the most common (early and late) prognostic indicators and reintegration itself. Research design: A retrospective study on a population of 353 patients consecutively admitted to an intensive rehabilitation unit (S. Cuore Hospital, Negrar, Italy) from 1991-1999. Methods and procedures: Evaluation of school and work outcome in this population up to December 2001 (follow-up from 2-10 years post-trauma). Data collection was made using the EBIS (European Brain Injury Society) protocol. Results: In December 2001, 53% of those previously working had returned to competitive work; 76.5% of students were continuing with their studies or had progressed into work. There was a significant difference between employed and non-employed groups in terms of GCS, post-traumatic amnesia (PTA), in-patient rehabilitation length of stay (LOS) and GOS at 6 and at 12 months post-injury. Conclusions: The data confirm the predictive value of the indices used regarding work reintegration in TBI patients. Nevertheless, prolonged and intensive rehabilitation programmes can lead to high re-employment rates in patients whose initial prognosis seemed very poor.	Don Calabria Hosp, Rehabil Serv, I-37024 Verona, Italy		Salvi, L (corresponding author), Don Calabria Hosp, Rehabil Serv, Via Don Sempreboni 5, I-37024 Verona, Italy.	lukesalvi@libero.it		Gambini, Maria Grazia/0000-0002-6211-2169			Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Avesani R, 2002, ACT NEUR S, V79, P45; BROOKS DN, 1995, DOCUMENT EUROPEEN EV; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PITIDIS A, 1998, C MEAS BURD INJ ECOS; PITIDIS A, 1997, HLTH ORG, V3, P102; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011; 2003, OFFICIAL GAZETT 0312	21	37	38	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2005	19	11					933	939		10.1080/02699050400002371			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	983YY	WOS:000233269500008	16299934				2022-02-06	
J	Chen, WH; Tzeng, SF				Chen, WH; Tzeng, SF			Pituitary adenylate cyclase-activating polypeptide prevents cell death in the spinal cord with traumatic injury	NEUROSCIENCE LETTERS			English	Article						pituitary adenylyl cyclase-activating polypeptide; spinal cord injury; neuroprotection	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; CEREBELLAR GRANULE CELLS; NEUROTROPHIC FACTOR; GENE-TRANSFER; CYCLIC-AMP; RAT-BRAIN; REGENERATION; PACAP; RECEPTOR; EXPRESSION	Pituitary adenylyl cyclase-activating polypeptide (PACAP) is a potent factor in the regulation of neurotransmission, neuroprotection, neurogenesis and anti-inflammation. We here examined the neuroprotective effect of PACAP on injury to the spinal cord tissue of adult rats, induced by dropping a 10 g NYU impactor from the height of 25 mm (moderate injury) or 50 mm (severe injury). PACAP was found to effectively attenuate cell apoptosis in the spinal cord with moderate injury. However, treatment with PACAP had a lesser effect on decreasing DNA fragmentation in the lesion center of the spinal cord with severe contusion injury. Yet, greater extended neural fibers and motor neurons were observed in the rostral and caudal regions of the PACAP-treated spinal cord when compared to that seen in the PBS-treated control. Our findings indicate the beneficial effect of PACAP for the treatment of spinal cord injury (SCI). (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Natl Cheng Kung Univ, Dept Life Sci, Tainan 70101, Taiwan		Tzeng, SF (corresponding author), Natl Cheng Kung Univ, Dept Life Sci, 1 Ta Hsueh Rd, Tainan 70101, Taiwan.	stzeng@mail.ncku.eud.tw					Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Chang JY, 1997, NEUROCHEM INT, V31, P161, DOI 10.1016/S0197-0186(96)00145-3; Cheng H, 2002, J NEUROSCI RES, V69, P397, DOI 10.1002/jnr.10303; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; DiCicco-Bloom E, 2000, DEV BIOL, V219, P197, DOI 10.1006/dbio.2000.9604; HARMAR T, 1994, TRENDS PHARMACOL SCI, V15, P97, DOI 10.1016/0165-6147(94)90042-6; Hendriks WTJ, 2004, PROG BRAIN RES, V146, P451; Horner P, 2002, ARCH NEUROL-CHICAGO, V59, P1717, DOI 10.1001/archneur.59.11.1717; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kong LY, 1999, NEUROSCIENCE, V91, P493, DOI 10.1016/S0306-4522(98)00606-X; Lee M, 2001, J NEUROSCI, V21, P3849, DOI 10.1523/JNEUROSCI.21-11-03849.2001; Lindholm D, 1998, ANN NY ACAD SCI, V865, P189, DOI 10.1111/j.1749-6632.1998.tb11178.x; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; PINCUS DW, 1990, BRAIN RES, V514, P355, DOI 10.1016/0006-8993(90)91433-H; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084; Tai MH, 2003, EXP NEUROL, V183, P508, DOI 10.1016/S0014-4886(03)00130-4; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 2003, J NEUROSCI RES, V72, P303, DOI 10.1002/jnr.10530; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; Waschek JA, 1996, ANN NY ACAD SCI, V805, P290; YOUNG W, 1993, ADV NEUROL, V59, P249	25	37	39	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 12	2005	384	1-2					117	121		10.1016/j.neulet.2005.04.070			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	943MF	WOS:000230357400023	15913892				2022-02-06	
J	Straume-Naesheim, TM; Andersen, TE; Bahr, R				Straume-Naesheim, TM; Andersen, TE; Bahr, R			Reproducibility of computer based neuropsychological testing among Norwegian elite football players	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL SOCCER PLAYERS; TRAUMATIC BRAIN-INJURY; TEST-PERFORMANCE; COGNITIVE IMPAIRMENT; HEAD-INJURIES; CONCUSSIONS; SCORES; IMPACT	Background: Head injuries account for 4-22% of all football injuries. The rate of brain injuries is difficult to assess, due to the problem of defining and grading concussion. Thus computerised testing programs for cognitive function have been developed. Objective: To assess the reliability of a computerised neuropsychological test battery (CogSport) among Norwegian professional football players. Methods: Norwegian professional football league players (90.3% participation) performed two consecutive baseline Cogsport tests before the 2004 season. CogSport consists of seven different subtasks: simple reaction time (SRT), choice reaction time (ChRT), congruent reaction time (CgRT), monitoring (MON), one-back (OBK), matching (Match) and learning (Learn). Results: There was a small but significant improvement from repeated testing for the reaction time measurements of all seven subtasks (SRT: 0.7%, ChRT: 0.4%, CgRT: 1.2%, MON: 1.3%, OBK: 2.7%, Match: 2.0%, Learn: 1.1%). The coefficient of variation (CV) ranged from 1.0% to 2.7%; corresponding intraclass correlation coefficients ranged from 0.45 (0.34 to 0.55) to 0.79 (0.74 to 0.84). The standard deviation data showed higher CVs, ranging from 3.7% (Learn) to 14.2% (SRT). Thus, the variance decreased wit increasing complexity of the task. The accuracy data displayed uniformly high CV (10.4-12.2) and corresponding low intraclass correlation coefficient (0.14 (0.01 to 0.26) to 0.31 (0.19 to 0.42)). Conclusion: The reproducibility for the mean reaction time measures was excellent, but less good for measures of accuracy and consistency. Consecutive testing revealed a slight learning effect from test 1 to test 2, and double baseline testing is recommended to minimise this effect.	Oslo Sports Trauma & Res Ctr, Oslo, Norway; Norwegian Univ Sport & Phys Educ, Oslo, Norway		Straume-Naesheim, TM (corresponding author), Oslo Sports Trauma & Res Ctr, Oslo, Norway.	truls.straume-nesheim@nih.no	Bahr, Roald/B-6964-2014	Bahr, Roald/0000-0001-5725-4237; Andersen, Thor Einar/0000-0003-4172-4518			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BENESTAD HB, 2004, FORSKNINGSMETODE MED, P83; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLIE A, 2005, SPORTS NEUROPSYCHOLO; COLLIE A, 2004, BRIT J SPORT MED, V38, P254; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; ERLANGER DM, 2001, BRIT J SPORT MED, V35, P367; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; L?ders H., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MACCIOCCHI SN, 1990, J CLIN PSYCHOL, V46, P628, DOI 10.1002/1097-4679(199009)46:5<628::AID-JCLP2270460514>3.0.CO;2-V; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; MULLER R, 1994, STAT MED, V13, P2465, DOI 10.1002/sim.4780132310; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sale DG, 1990, PHYSL TESTING HIGH P PHYSL TESTING HIGH P, P21; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Westerman R., 2001, ADF HLTH, V2, P29	34	37	37	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I64	I69		10.1136/bjsm.2005.019620			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	954KI	WOS:000231153600009	16046358	Green Published, Bronze			2022-02-06	
J	Pannu, R; Singh, AK; Singh, I				Pannu, R; Singh, AK; Singh, I			A novel role of lactosylceramide in the regulation of tumor necrosis factor alpha-mediated proliferation of rat primary astrocytes - Implications for astrogliosis following neurotrauma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; LIPID RAFTS; REACTIVE ASTROCYTES; ERK/MAP KINASE; MESSENGER-RNA; CELL-LINE; TNF-ALPHA; EXPRESSION	The present study describes the role of glycosphingolipids in neuroinflammatory disease and investigates tumor necrosis factor alpha (TNF alpha)-induced astrogliosis following spinal cord injury. Astrogliosis is the hallmark of neuroinflammation and is characterized by proliferation of astrocytes and increased glial fibrillary acidic protein (GFAP) gene expression. In primary astrocytes, TNF alpha stimulation increased the intracellular levels of lactosylceramide (LacCer) and induced GFAP expression and astrocyte proliferation. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol.HCl (PDMP), a glucosylceramide synthase and LacCer synthase (GalT-2) inhibitor, inhibited astrocyte proliferation and GFAP expression, which were reversed by exogenous supplementation of LacCer but not by other glycosphingolipids. TNF alpha caused a rapid increase in the activity of GalT-2 and synthesis of LacCer. Silencing of GalT-2 gene using antisense oligonucleotides also attenuated the proliferation of astrocytes and GFAP expression. The PDMP and antisense-mediated inhibition of proliferation and GFAP expression was well correlated with decreased Ras/ERK1/2 pathway activation. Furthermore, TNF alpha-mediated astrocyte proliferation and GFAP expression was also inhibited by LY294002, a phosphatidylinositol 3-kinase inhibitor, which was reversed by exogenous LacCer. LY294002 also inhibited TNF alpha-induced GalT-2 activation and LacCer synthesis, suggesting a phosphatidylinositol 3-kinase-mediated regulation of GalT-2. In vivo, PDMP treatment attenuated chronic ERK1/2 activation and spinal cord injury (SCI)-induced astrocyte proliferation with improved functional recovery post-SCI. Therefore, the in vivo studies support the conclusions drawn from cell culture studies and provide evidence for the role of LacCer in TNF alpha-induced astrogliosis in a rat model of SCI. To our knowledge, this is the first report demonstrating the role of LacCer in the regulation of TNF alpha-induced proliferation and reactivity of primary astrocytes.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Dept Pediat, Charleston, SC USA; Ralph H Johnson Vet Affairs Med Ctr, Dept Pathol, Charleston, SC USA		Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 316 Clin Sci Bldg,96 Jonathan Lucas St, Charleston, SC 29425 USA.	singhi@musc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-34741, NS-40144, NS-22576, NS-37766] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034741, R01NS022576, R01NS040144, R01NS037766, R37NS022576] Funding Source: NIH RePORTER		Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BARNA BP, 1990, J NEUROIMMUNOL, V30, P239, DOI 10.1016/0165-5728(90)90108-Y; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BETHEA JR, 1990, J NEUROIMMUNOL, V30, P1, DOI 10.1016/0165-5728(90)90047-Q; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; ENG LF, 1992, PROG BRAIN RES, V94, P353; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fern R, 2001, Prog Brain Res, V132, P405; FICHARD A, 1991, DEV BIOL, V148, P1, DOI 10.1016/0012-1606(91)90312-Q; Giri S, 2002, FASEB J, V16, DOI 10.1096/fj.01-0798com; Gong NL, 2004, P NATL ACAD SCI USA, V101, P6490, DOI 10.1073/pnas.0308684101; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Houle JD, 2003, EXP NEUROL, V182, P247, DOI 10.1016/S0014-4886(03)00029-3; Iwabuchi K, 2002, BLOOD, V100, P1454, DOI 10.1182/blood.V100.4.1454.h81602001454_1454_1464; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LACHMAN LB, 1987, J IMMUNOL, V138, P2913; Mandell JW, 1999, NEUROREPORT, V10, P3567, DOI 10.1097/00001756-199911260-00019; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Moon LDF, 2000, EXP NEUROL, V161, P49, DOI 10.1006/exnr.1999.7230; MUCKE L, 1993, FASEB J, V7, P1226, DOI 10.1096/fasebj.7.13.8405808; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pannu R, 2004, J NEUROSCI, V24, P5942, DOI 10.1523/JNEUROSCI.1271-04.2004; Parkin ET, 2001, BIOCHEM J, V358, P209, DOI 10.1042/0264-6021:3580209; Pebay A, 2001, EUR J NEUROSCI, V13, P2067, DOI 10.1046/j.0953-816x.2001.01585.x; Pettus BJ, 2003, FASEB J, V17, P1411, DOI 10.1096/fj.02-1038com; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 2003, TRENDS PHARMACOL SCI, V24, P13, DOI 10.1016/S0165-6147(02)00006-8; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; Rabchevsky AG, 2001, ARCH NEUROL-CHICAGO, V58, P721, DOI 10.1001/archneur.58.5.721; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Steeves JD, 1998, ANN NY ACAD SCI, V860, P412, DOI 10.1111/j.1749-6632.1998.tb09065.x; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tatagiba M, 1997, NEUROSURGERY, V40, P541, DOI 10.1097/00006123-199703000-00023; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Won JS, 2004, J NEUROCHEM, V88, P583, DOI 10.1046/j.1471-4159.2003.02165.x; Won JS, 2001, BRAIN RES, V903, P207, DOI 10.1016/S0006-8993(01)02452-0; YAJIMA K, 1979, LAB INVEST, V41, P385; Yan P, 2001, J NEUROTRAUM, V18, P563, DOI 10.1089/089771501300227369; Yanase H, 2001, PIGM CELL RES, V14, P103, DOI 10.1034/j.1600-0749.2001.140205.x; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang L, 2000, NEUROREPORT, V11, P409, DOI 10.1097/00001756-200002070-00037	50	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 8	2005	280	14					13742	13751		10.1074/jbc.M411959200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912QW	WOS:000228095500070	15668227	hybrid			2022-02-06	
J	Mauler, F; Horvath, E				Mauler, F; Horvath, E			Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						5-HT1A; middle cerebral artery occlusion; neuroprotection; repinotan hydrochloride; subdural hematoma; traumatic brain injury	BAY X 3702; CEREBRAL-ARTERY OCCLUSION; THERAPEUTIC TIME WINDOW; ACUTE SUBDURAL-HEMATOMA; IN-VIVO; GLUTAMATE RELEASE; CULTURED NEURONS; RAT HIPPOCAMPUS; TRANSIENT; ISCHEMIA	Repinotan is a highly potent 5-HT1A receptor agonist with strong neuroprotective efficacy in animal models of middle cerebral artery occlusion and traumatic brain injury. In this study, we characterized the time window for neuroprotective effects of repinotan in animal models. In the permanent middle cerebral artery occlusion model, repinotan showed neuroprotective efficacy when administered as a triple bolus injection (0.3-100 mu g/kg) or an intravenous infusion (0.3-100 mu g/ kg per hour). A 73% reduction in infarct volume was observed with a 3 mu g/kg intravenous bolus, and a 65% reduction was observed with a 3 and 10 mu g/kg per hour intravenous infusion. When delayed until 5 hours after occlusion, repinotan (10 mu g/kg per hour) reduced infarct volume by 43%. In the transient middle cerebral artery occlusion model, repinotan (10 mu g/kg per hour) administered immediately after occlusion reduced infarct volume by 97%, and a delay to 5 hours reduced infarct volume by 81%. In the acute subdural hematoma model, repinotan (3 and 10 mu g/kg per hour) reduced infarct volume by 65%. In this model, repinotan (3 mu g/kg per hour) administered 5 hours after occlusion reduced infarct volume by 54%. The favorable neuroprotective efficacy, broad doseresponse curve, and prolonged therapeutic window observed in all models strongly suggest that repinotan is a promising candidate for treating acute ischemic stroke in humans.	Bayer Hlth Care, Global Drug Safety, PH R EU CNS, D-42096 Wuppertal, Germany		Mauler, F (corresponding author), Bayer Hlth Care, Global Drug Safety, PH R EU CNS, Aprather Weg 18A, D-42096 Wuppertal, Germany.	frank.mauler@bayerhealthcare.com					Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Ahlemeyer B, 1999, EUR J PHARMACOL, V370, P211, DOI 10.1016/S0014-2999(99)00136-3; Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Boxer PA, 1997, DRUG DISCOV TODAY, V2, P219, DOI 10.1016/S1359-6446(97)01045-3; Casanovas JM, 2000, N-S ARCH PHARMACOL, V362, P248, DOI 10.1007/s002100000291; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dong JM, 1998, J PHARMACOL EXP THER, V286, P1239; Furuichi Y, 2003, BRAIN RES, V965, P137, DOI 10.1016/S0006-8993(02)04151-3; GERLACH I, 1998, J NEUROTRAUM, V15, P870; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Horikawa N, 2001, BIOL PHARM BULL, V24, P767, DOI 10.1248/bpb.24.767; Horvath E., 1997, Society for Neuroscience Abstracts, V23, P1923; HORVATH E, 1997, J NEUROTRAUM, V14, P800; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Kukley M, 2001, NEUROSCIENCE, V107, P405, DOI 10.1016/S0306-4522(01)00369-4; LEES KR, 1997, NEUROLOGY S4, V49, P66; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Matsuyama S, 1996, BRAIN RES, V728, P175, DOI 10.1016/0006-8993(96)00395-2; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; Mauler F, 2003, CNS DRUG REV, V9, P343; Mauler F, 2003, BRAIN RES, V989, P99, DOI 10.1016/S0006-8993(03)03376-6; Mauler F, 2002, J PHARMACOL EXP THER, V302, P359, DOI 10.1124/jpet.302.1.359; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Mohr J.P., 1986, STROKE PATHOPHYSIOLO, P377; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; Paxinos G, 1996, RAT BRAIN STEREOTAXI; RAITERI M, 1991, J PHARMACOL EXP THER, V257, P1184; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Schaper C, 2000, BRAIN RES, V883, P41, DOI 10.1016/S0006-8993(00)02876-6; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; SHIMIZU H, 1993, BRAIN RES, V605, P33, DOI 10.1016/0006-8993(93)91353-T; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; TAKAGI K, 1993, J CEREBR BLOOD F MET, V13, P575, DOI 10.1038/jcbfm.1993.75; Takahashi M, 1998, J PHARMACOL EXP THER, V287, P559; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; WAHL F, 1994, J NEUROCHEM, V63, P1003; Wardlaw JM., 2003, THROMBOLYSIS ACUTE I; Yenari MA, 1998, CLIN NEUROPHARMACOL, V21, P28; ZHAO Q, 1995, TRANSIENT MIDDLE CER	51	37	37	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2005	25	4					451	459		10.1038/sj.jcbfm.9600038			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	915CH	WOS:000228274700005	15674237	Bronze			2022-02-06	
J	Bhambhani, Y; Rowland, G; Farag, M				Bhambhani, Y; Rowland, G; Farag, M			Effects of circuit training on body composition and peak cardiorespiratory responses in patients with moderate to severe traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						aerobic exercise; body composition; brain injuries; rehabilitation	METABOLIC-RATE; EXERCISE; RELIABILITY; DEPRESSION; HUMANS	Objective: To examine the time course of the changes in body composition and peak cardiorespiratory fitness resulting from routine brain injury rehabilitation program (BIRP) activities and circuit training in patients with moderate to severe traumatic brain injury (TBI). Design: Time-series design spanning 18 weeks. Trials T1 and T2 were completed in weeks 1 and 2, respectively, to establish reliability of the measurements, followed by trial 3 (T3) 4 weeks later to evaluate changes resulting from the BIRP. Setting: A BIRP in a community rehabilitation hospital. Setting: A BIRP in a community rehabilitation hospital. Participants: Fourteen inpatients with moderate to severe acquired TBI (Glasgow Coma Scale score, 4.6+/-1.4; time since injury, 17.2+/-17mo). Interventions: Twelve-week circuit-training program designed to enhance muscular strength and endurance and aerobic fitness. Subjects were tested midway (T4) through the program and at the end (T5) of 12 weeks. The patients completed an average of 32 supervised sessions, each lasting 1 hour. Main Outcome Measures: Changes in body composition and peak cardiorespiratory responses. Results: No significant changes were observed in the body mass or percentage body fat during the study. The peak values of power output, oxygen uptake, and ventilation rate increased significantly as a result of training, with no concomitant increases in peak heart rate or blood lactate (T5>T3, T2, T1; P<.05). No significant changes were evident midway through training. Conclusions: In a heterogeneous sample of patients with moderate to severe TBI, (1) body composition and peak cardiorespiratory responses remained fairly stable during 6 weeks of BIRP activities, (2) improvements in peak cardiorespiratory fitness required more than 6 weeks of circuit training, and (3) a 12-week course of circuit training without controlling caloric intake was not effective in reducing body weight or percentage body fat.	Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2G4, Canada; Alberta Hosp Ponoka, Brain Injury Rehabil Provincial Program, Ponoka, AB, Canada		Bhambhani, Y (corresponding author), Univ Alberta, Fac Rehabil Med, Rm 373,Corbett Hall, Edmonton, AB T6G 2G4, Canada.	yagesh.bhambhani@ualberta.ca					American College of Sports Medicine, 2001, GUID EX TEST PRESCR; [Anonymous], 1990, Med Sci Sports Exerc, V22, P265; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Bhambhani Y, 1985, Can J Appl Sport Sci, V10, P44; Bhambhani Y, 2003, ARCH PHYS MED REHAB, V84, P1629, DOI 10.1053/S0003-9993(03)00343-5; Bode RK, 2002, ARCH PHYS MED REHAB, V83, P100, DOI 10.1053/apmr.2002.26073; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Dulloo AG, 1998, AM J CLIN NUTR, V68, P599, DOI 10.1093/ajcn/68.3.599; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Greenleaf J E, 1982, Exerc Sport Sci Rev, V10, P84; Henson Martha B., 1993, Brain Injury, V7, P169, DOI 10.3109/02699059309008170; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; McArdle WD., 2001, EXERCISE PHYSL ENERG; MCLEAN KP, 2002, ACSM RESOURCES CLIN, P98; NEUFER PD, 1989, SPORTS MED, V8, P302, DOI 10.2165/00007256-198908050-00004; NOVACK TA, 1988, REHABIL COUNS BULL, V31, P313; Pepe JL, 1999, J HEAD TRAUMA REHAB, V14, P462, DOI 10.1097/00001199-199910000-00007; Pinnington H, 2001, J SCI MED SPORT, V4, P129, DOI 10.1016/S1440-2440(01)80014-1; Raggueneau J L, 1979, Anesth Analg (Paris), V36, P439; RAURICH JM, 1994, JPEN-PARENTER ENTER, V18, P521, DOI 10.1177/0148607194018006521; SALTIN B, 1968, CIRCULATION       S7, V38, P1, DOI DOI 10.1161/01.CIR.38.6.1104; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Topp Robert, 2002, AACN Clin Issues, V13, P263, DOI 10.1097/00044067-200205000-00011; *US DHHS, 1996, PHYS ACT HLTH REP SU; VITALE AE, 1995, PERCEPT MOTOR SKILL, V80, P57, DOI 10.2466/pms.1995.80.1.57; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; Wiercisiewski DR, 1998, J HEAD TRAUMA REHAB, V13, P28, DOI 10.1097/00001199-199802000-00006; Wolman RL, 1994, CLIN REHABIL, V8, P253; Young B, 1991, Neurosurg Clin N Am, V2, P301	37	37	39	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2005	86	2					268	276		10.1016/j.apmr.2004.04.022			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	894UY	WOS:000226818300013	15706553				2022-02-06	
J	Trentz, OA; Handschin, AE; Bestmann, L; Hoerstrup, SP; Trentz, OL; Platz, A				Trentz, OA; Handschin, AE; Bestmann, L; Hoerstrup, SP; Trentz, OL; Platz, A			Influence of brain injury on early posttraumatic bone metabolism	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; heterotopic ossification; osteocalcin; bone markers	CARBOXY-TERMINAL TELOPEPTIDE; PARATHYROID-HORMONE; HETEROTOPIC OSSIFICATION; ALKALINE-PHOSPHATASE; BIOCHEMICAL MARKERS; ENHANCED OSTEOGENESIS; GLUTAMATE RECEPTORS; SIGNALING PATHWAYS; NERVOUS-SYSTEM; HEAD-INJURY	Background. Various clinical studies and observations demonstrate enhanced osteogenesis in patients sustaining traumatic brain injury. It is presumed that the induction of this process starts early after trauma. The purpose of our study was to investigate humoral markers of bone metabolism during the early posttraumatic period, with special regard to traumatic brain injury. Methods. Serum concentrations of biochemical markers of bone metabolism (calcium, inorganic phosphorus, carboxyl-terminal propeptide of type 1 procollagen, pyridinoline cross-linked telopeptide domain of type 1 collagen, Ostase, osteocalcin, intact parathyroid hormone, and calcitonin) were measured in three different groups of 80 patients during the first posttraumatic week. Patients were categorized into three groups: group 1, fractures only; group II, isolated traumatic brain injury; and group III, traumatic brain injury in combination with fractures. Results. Osteocalcin levels were significantly lower in the presence of traumatic brain injury (p < .05). Elevated pyridinoline cross-linked telopeptide domain of type 1 collagen levels expressed enhanced bone resorption in all groups, but levels were significantly higher in the absence of traumatic brain injury (P < .05). Intact parathyroid hormone levels were significantly higher on days 0 and 1 in the combined presence of traumatic brain injury plus fractures. Conclusion: These results demonstrate an imbalance of bone formation and resorption parameters in patients with traumatic brain injury during the early posttraumatic period, suggesting a central regulation in bone formation. The lower levels of osteocalcin detected in this study may play an important role in patients with brain injury and the later development of posttraumatic heterotopic ossification.	Univ Zurich, Div Res, Zurich, Switzerland; Univ Zurich, Inst Clin Chem, Div Trauma Surg, Zurich, Switzerland; Univ Zurich, Inst Clin Chem, Cardiovasc Surg Clin, Zurich, Switzerland; Univ Zurich, Inst Clin Chem, Dept Surg, Zurich, Switzerland		Trentz, OA (corresponding author), Univ Zurich, Div Res, Zurich, Switzerland.						Ahmad AM, 2003, BONE, V32, P170, DOI 10.1016/S8756-3282(02)00952-3; Ahmed MAAS, 2000, J CELL PHYSIOL, V183, P163; Banovac K, 1997, SPINAL CORD, V35, P158, DOI 10.1038/sj.sc.3100380; Banse X, 2002, BONE, V31, P70, DOI 10.1016/S8756-3282(02)00800-1; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Broyles DL, 1998, CLIN CHEM, V44, P2139; Calvo MS, 1996, ENDOCR REV, V17, P333, DOI 10.1210/er.17.4.333; CHENU C, 1994, J CELL BIOL, V127, P1149, DOI 10.1083/jcb.127.4.1149; Chenu C, 2002, MICROSC RES TECHNIQ, V58, P70, DOI 10.1002/jemt.10120; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009-9120(97)00113-6; Cornish J, 1999, J BONE MINER RES, V14, P915, DOI 10.1359/jbmr.1999.14.6.915; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; ENGLAND TE, 1994, CLIN BIOCHEM, V27, P187, DOI 10.1016/0009-9120(94)90054-X; Fuller K, 1998, J ENDOCRINOL, V158, P341, DOI 10.1677/joe.0.1580341; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Goodman TA, 1997, ARTHRITIS RHEUM, V40, P1619, DOI 10.1002/art.1780400911; Hoff AO, 2002, J CLIN INVEST, V110, P1849, DOI 10.1172/JCI200214218; JENSEN LL, 1987, AM J PHYS MED REHAB, V66, P351; KERET D, 1990, CLIN ORTHOP RELAT R, V25, P254; Konttinen YT, 1996, ACTA ORTHOP SCAND, V67, P632, DOI 10.3109/17453679608997772; Li W, 2001, BONE, V29, P231, DOI 10.1016/S8756-3282(01)00572-5; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; Merle B, 2003, J CELL BIOCHEM, V90, P424, DOI 10.1002/jcb.10625; Miyakawa M, 1996, ENDOCR J, V43, P701, DOI 10.1507/endocrj.43.701; RISTELI J, 1993, CLIN CHEM, V39, P635; ROACH HI, 1994, CELL BIOL INT, V18, P617, DOI 10.1006/cbir.1994.1088; Seibel MJ, 1999, J CLIN DENSITOM, V2, P299, DOI 10.1385/JCD:2:3:299; Sexton PM, 1999, CURR MED CHEM, V6, P1067; Suzuki H, 1996, ENDOCRINOLOGY, V137, P4685, DOI 10.1210/en.137.11.4685; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Takahashi M, 2003, J CLIN DENSITOM, V6, P211, DOI 10.1385/JCD:6:3:211; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Taniguchi T, 2003, INJURY, V34, P477, DOI 10.1016/S0020-1383(02)00380-7; TEASDALE G, 1974, LANCET, V2, P81; TRENTZ OA, 2001, EUR J TRAUMA, V2, P34; Watts NB, 1999, CLIN CHEM, V45, P1359; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wu YH, 2000, J BONE MINER RES, V15, P879, DOI 10.1359/jbmr.2000.15.5.879; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; Zaidi M, 2002, J CLIN INVEST, V110, P1769, DOI 10.1172/JCI200217425	44	37	46	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2005	33	2					399	406		10.1097/01.CCM.0000152221.87477.21			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	898LE	WOS:000227077500016	15699845				2022-02-06	
J	Neary, JT; Kang, Y				Neary, JT; Kang, Y			Signaling from P2 nucleotide receptors to protein kinase cascades induced by CNS injury - Implications for reactive gliosis and neurodegeneration	MOLECULAR NEUROBIOLOGY			English	Article; Proceedings Paper	Satellite Symposium on Oxidative Mechanisms in Neurodegenerative Disorder	FEB 07-11, 2004	Guilin, PEOPLES R CHINA			Purinergic receptors; ATP; protein kinases; gliosis; trauma; ERK; Akt	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; STRETCH-INDUCED INJURY; RAT CORTICAL ASTROCYTES; PURINERGIC RECEPTORS; EXTRACELLULAR ATP; REGULATED KINASE; MESSENGER-RNA; ASTROGLIAL ACTIVATION; CULTURED ASTROCYTES	Gliosis is a hypertrophic and hyperplastic response to many types of central nervous system injury, including trauma, stroke, seizure, as well as neurodegenerative and demyelinating disorders. Reactive astrocytes, a major component of the glial scar, express molecules that can both inhibit and promote axonal regeneration. ATP, which is released upon traumatic injury, hypoxia, and cell death, contributes to the gliotic response by binding to specific cell surface astrocytic P2 nucleotide receptors and evoking characteristic features of gliosis such as increased expression of glial fibrillary acidic protein (GFAP), generation and elongation of astrocytic processes, and cellular proliferation. Here, we review recent studies that demonstrate that (1) metabotropic, P2Y, and ionotropic, P2X, receptors expressed in astrocytes are coupled to protein kinase signaling pathways that regulate cellular proliferation, differentiation, and survival such as ERK and protein kinase B/Akt and (2) these P2 receptor/protein kinase cascades are activated after trauma induced by mechanical strain. We suggest that P2 receptor/protein kinase signaling pathways might provide novel therapeutic targets to regulate the formation of reactive astrocytes and the production of molecules that affect axonal regeneration and neurodegeneration.	Univ Miami, Sch Med, VA Med Ctr, Res Serv,Dept Pathol, Miami, FL 33152 USA; Univ Miami, Sch Med, VA Med Ctr, Res Serv,Dept Biochem, Miami, FL 33152 USA; Univ Miami, Sch Med, VA Med Ctr, Res Serv,Dept Mol Biol, Miami, FL 33152 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33152 USA		Neary, JT (corresponding author), Univ Miami, Sch Med, VA Med Ctr, Res Serv,Dept Pathol, Miami, FL 33152 USA.	jneary@med.miami.edu					ABBRACCHIO MP, 1994, NEUROSCIENCE, V59, P67, DOI 10.1016/0306-4522(94)90099-X; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bhat NR, 1998, J NEUROSCI, V18, P1633; BODIN P, 1992, P ROY SOC B-BIOL SCI, V247, P131, DOI 10.1098/rspb.1992.0019; Bolego C, 1997, BRIT J PHARMACOL, V121, P1692, DOI 10.1038/sj.bjp.0701294; Brambilla R, 2002, J NEUROCHEM, V83, P1285, DOI 10.1046/j.1471-4159.2002.01239.x; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Chang-Liao KS, 2001, ELEC SOC S, V2001, P1; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Eng LF, 1987, PROG BRAIN RES <D>, V71, P439; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Floyd CL, 2004, J NEUROTRAUM, V21, P205, DOI 10.1089/089771504322778668; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Frank C, 1999, J Sci Med Sport, V2, P190, DOI 10.1016/S1440-2440(99)80173-X; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Fredholm BB, 1997, INT REV NEUROBIOL, V40, P259; Gendron Fernand-Pierre, 2003, Biomedical Research (Aligarh), V14, P47; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HOU YJ, 1995, J NEUROSCI RES, V40, P359, DOI 10.1002/jnr.490400310; HU B, 2001, J NEUROTRAUM, V18, P1161; Jacques-Silva MC, 2004, BRIT J PHARMACOL, V141, P1106, DOI 10.1038/sj.bjp.0705685; Janes KA, 2003, MOL CELL PROTEOMICS, V2, P463, DOI 10.1074/mcp.M300045-MCP200; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jope RS, 2002, MOL PSYCHIATR, V7, pS35, DOI 10.1038/sj.mp.4001017; King BF, 1996, NEUROSCIENCE, V74, P1187, DOI 10.1016/0306-4522(96)00209-6; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Meaney D, 1995, P 1995 INT RES C BIO, P233; MILLS CD, 2001, J NEUROTRAUM, V18, P1182; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Namikawa K, 2000, J NEUROSCI, V20, P2875; Neary JT, 1996, NEUROREPORT, V7, P2893, DOI 10.1097/00001756-199611250-00017; Neary JT, 1999, PROG BRAIN RES, V120, P323; Neary JT, 2004, J NEUROTRAUM, V21, P1283; Neary JT, 2003, J NEUROTRAUM, V20, P1104; NEARY JT, 1994, NEUROREPORT, V5, P1617, DOI 10.1097/00001756-199408150-00019; NEARY JT, 1994, J NEUROCHEM, V63, P490; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; Neary JT, 1998, NEUROSCI LETT, V242, P159, DOI 10.1016/S0304-3940(98)00067-6; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; NEARY JT, 1994, J NEUROCHEM, V63, P2021; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; NEARY JT, 2004, SOC NEUR ABSTR; NEARY JT, 2003, J REHABIL RES DEV, V40, P58; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Panenka W, 2001, J NEUROSCI, V21, P7135, DOI 10.1523/JNEUROSCI.21-18-07135.2001; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Ralevic V, 1998, PHARMACOL REV, V50, P413; RATHBONE MP, 1992, NEUROSCI RES, V13, P1, DOI 10.1016/0168-0102(92)90030-G; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	67	37	42	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.		2005	31	1-3					95	103		10.1385/MN:31:1-3:095			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	940BY	WOS:000230119900008	15953814				2022-02-06	
J	Farkas, O; Tamas, A; Zsombok, A; Reglodi, D; Pal, J; Buki, A; Lengvari, I; Povlishock, JT; Doczi, T				Farkas, O; Tamas, A; Zsombok, A; Reglodi, D; Pal, J; Buki, A; Lengvari, I; Povlishock, JT; Doczi, T			Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury	REGULATORY PEPTIDES			English	Article; Proceedings Paper	6th International Symposium on VIP/PACAP	SEP 01-04, 2003	Hakone, JAPAN			neuroprotection; traumatic brain injury; beta-amyloid precursor protein; corticospinal tract; traumatic axonal injury	VASOACTIVE-INTESTINAL-PEPTIDE; CEREBELLAR GRANULE NEURONS; CEREBRAL-ARTERY OCCLUSION; AXONAL INJURY; NEUROTROPHIC FACTOR; INDUCED NEUROTOXICITY; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; NERVOUS-SYSTEM; CELL-DEATH	Pituitary adenylate cyclase activating polypeptide (PACAP) is a,widely distributed neuropeptide that has numerous different actions. Recent studies have shown that PACAP exerts neuroprotective effects not only in vitro but also in vivo, in animal models of global and focal cerebral ischemia, Parkinson's disease and axonal injuries. Traumatic brain injury has an increasing mortality and morbidity and it evokes diffuse axonal injury which further contributes to its damaging effects. The aim of the present study was to examine the possible neuroprotective effect of PACAP in a rat model of diffuse axonal injury induced by impact acceleration. Axonal damage was assessed by immunohistochemistry using an antiserum against beta-amyloid precursor protein, a marker of altered axoplasmic transport considered as key feature in axonal injury. In these experiments, we have established the dose response curves for PACAP administration in traumatic axonal injury, demonstrating that a single post-injury intracerebroventricular injection of 100 mug PACAP significantly reduced the density of damaged, beta-amyloid precursor protein-immunoreactive axons in the corticospinal tract. (C) 2004 Elsevier B.V All rights reserved.	Univ Pecs, Hungarian Acad Sci, Neurohumoral Regulat Res Grp, Dept Anat,Med Fac, H-7624 Pecs, Hungary; Univ Pecs, Fac Med, Dept Cent Lab Anim Res, H-7624 Pecs, Hungary; Univ Pecs, Fac Med, Dept Neurosurg, H-7624 Pecs, Hungary; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA		Tamas, A (corresponding author), Univ Pecs, Hungarian Acad Sci, Neurohumoral Regulat Res Grp, Dept Anat,Med Fac, Szigeti 12, H-7624 Pecs, Hungary.	andrea.tamas@aok.pte.hu	Doczi, Tamas/C-5750-2009; Buki, Andras/B-1960-2010; Pal, Jozsef/I-3416-2013; Pal, Jozsef/C-4073-2009	Pal, Jozsef/0000-0001-6468-6409			Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; ARIMURA A, 1994, ANN NY ACAD SCI, V739, P228, DOI 10.1111/j.1749-6632.1994.tb19825.x; Arimura Akira, 2003, Regulatory Peptides, V115, P40; BANKS WA, 1993, J PHARMACOL EXP THER, V267, P690; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; Dibbern DA, 1997, J CLIN INVEST, V99, P2837, DOI 10.1172/JCI119476; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frechilla D, 2001, NEUROREPORT, V12, P919, DOI 10.1097/00001756-200104170-00011; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gozes I, 1999, P NATL ACAD SCI USA, V96, P4143, DOI 10.1073/pnas.96.7.4143; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; Katahira M., 2003, Regulatory Peptides, V115, P49; Kim WK, 2000, J NEUROSCI, V20, P3622, DOI 10.1523/JNEUROSCI.20-10-03622.2000; Kimura H, 2003, LARYNGOSCOPE, V113, P1000, DOI 10.1097/00005537-200306000-00016; Kong LY, 1999, NEUROSCIENCE, V91, P493, DOI 10.1016/S0306-4522(98)00606-X; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Nonaka N, 2002, PEPTIDES, V23, P2197, DOI 10.1016/S0196-9781(02)00248-6; Ohtaki H., 2003, Regulatory Peptides, V115, P53; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Onoue S, 2002, PEPTIDES, V23, P1471, DOI 10.1016/S0196-9781(02)00085-2; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Reglodi D, 2004, BEHAV BRAIN RES, V151, P303, DOI 10.1016/j.bbr.2003.09.007; SEKI T, 2003, REGUL PEPTIDES, V115, P55; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Somogyvari-Vigh A, 2000, REGUL PEPTIDES, V91, P89, DOI 10.1016/S0167-0115(00)00123-3; Somogyvari-Vigh A, 1998, ANN NY ACAD SCI, V865, P595, DOI 10.1111/j.1749-6632.1998.tb11243.x; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Tabuchi A, 2003, J NEUROSCI RES, V71, P504, DOI 10.1002/jnr.10505; Tams JW, 1999, BIOCHEM J, V341, P271, DOI 10.1042/0264-6021:3410271; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2002, EUR J NEUROSCI, V15, P1451, DOI 10.1046/j.1460-9568.2002.01981.x; Vaudry D, 2002, P NATL ACAD SCI USA, V99, P6398, DOI 10.1073/pnas.082112699; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; ZAMBONI L, 1967, J CELL BIOL, V35, P148; Zhou CJ, 2002, CURR PROTEIN PEPT SC, V3, P423, DOI 10.2174/1389203023380576	51	37	40	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-0115	1873-1686		REGUL PEPTIDES	Regul. Pept.	DEC 15	2004	123	1-3					69	75		10.1016/j.regpep.2004.05.014			7	Endocrinology & Metabolism; Physiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Endocrinology & Metabolism; Physiology	871ST	WOS:000225154400011	15518895				2022-02-06	
J	Hlatky, R; Valadka, AB; Goodman, JC; Robertson, CS				Hlatky, R; Valadka, AB; Goodman, JC; Robertson, CS			Evolution of brain tissue injury after evacuation of acute traumatic subdural hematomas	NEUROSURGERY			English	Article						brain tissue oxygen tension; lactate; microdialysis; subdural hematoma; traumatic brain injury	HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; INSPIRED OXYGEN; CT-SCAN; MORTALITY; ISCHEMIA; RAT; REDUCTION; REMOVAL; RELEASE	OBJECTIVE: Acute traumatic subdural hematoma complicated by brain parenchymal injury is associated with a 60 to 90% mortality rate. Early surgical evacuation of the mass lesion is essential for a favorable outcome, but the severity of the underlying brain injury determines the outcome, even when surgery has been prompt. The purpose of this study was to analyze tissue biochemical patterns in the brain underlying an evacuated acute subdural hematoma to identify a characteristic pattern of changes that might indicate evolving brain injury. METHODS: Prospectively collected data from 33 patients after surgical evacuation of acute subdural hematoma were analyzed. Both a brain tissue oxygen tension probe and an intracerebral microdialysis probe were placed in brain tissue exposed at surgery. On the basis of the postoperative clinical course, the patients were divided into three groups: patients with early intractable intracranial hypertension, patients with evolution of delayed traumatic injury (DTI), and patients with an uncomplicated course (the no-DTI group). RESULTS: The overall mortality rate was 46%, with 100% mortality in the intracranial hypertension group (five patients). Mortality in the DTI group was 53% compared with only 9% in the no-DTI group (P = 0.002). There were no significant differences in the initial computed tomographic scan characteristics such as thickness of the subdural hematoma or amount of midline shift, among the three groups. Physiological variables, as well as the microdialysate measures of brain biochemistry, were markedly different in the intracranial hypertension group compared with the other groups. Differences between the other two groups were more subtle but were significant. Significantly lower values of brain tissue oxygen tension (14 +/- 8 mm Hg versus 27 +/- 14 mm Hg) and higher dialysate values of lactate and pyruvate were documented in patients who developed a delayed injury compared with patients with uncomplicated courses (4.1 +/- 2.3 mmol/L versus 1.7 +/- 0.7 mmol/L for lactate, and 104 +/- 47 mumol/L versus 73 +/- 54 mumol/L for pyruvate at 24 h after injury). CONCLUSION: Evolution of DTI in the area of brain underlying an evacuated subdural hematoma is associated with a significant increase in mortality. Postoperatively decreasing brain tissue oxygen tension and increasing dialysate concentrations of lactate and pyruvate in this area may warn of evolving brain injury and evoke further diagnostic and therapeutic activity.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Charles Univ, Univ Hosp, Dept Neurosurg, Hradec Kralove, Czech Republic; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHAMBERS JW, 1951, J NEUROSURG, V8, P263, DOI 10.3171/jns.1951.8.3.0263; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Reinert M, 2002, NEUROL RES, V24, P601, DOI 10.1179/016164102101200438; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; RICHARDS T, 1974, SURGERY, V75, P253; Robertson CS, 1998, NEUROL RES, V20, pS91; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; Stahl N, 2003, ACTA NEUROL SCAND, V108, P211, DOI 10.1034/j.1600-0404.2003.00095.x; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; Verweij BH, 2001, J NEUROSURG, V95, P569, DOI 10.3171/jns.2001.95.4.0569; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Yilmazlar S, 1997, J Neurosurg Sci, V41, P379	31	37	37	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2004	55	6					1318	1324		10.1227/01.NEU.0000143029.42638.2C			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	878CB	WOS:000225623000010	15574213				2022-02-06	
J	Nelson, DW; Bellander, BM; MacCallum, RM; Axelsson, J; Alm, M; Wallin, M; Weitzberg, E; Rudehill, A				Nelson, DW; Bellander, BM; MacCallum, RM; Axelsson, J; Alm, M; Wallin, M; Weitzberg, E; Rudehill, A			Cerebral microdialysis of patients with severe traumatic brain injury exhibits highly individualistic patterns as visualized by cluster analysis with self-organizing maps	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; brain metabolism; microdialysis; intracranial pressure; cerebral perfusion pressure; cluster analysis; neural network	POSITRON-EMISSION-TOMOGRAPHY; AMINO-ACID RELEASE; SEVERE HEAD-INJURY; PERFUSION-PRESSURE; INTRACEREBRAL MICRODIALYSIS; EXTRACELLULAR GLUTAMATE; SUBSTRATE DELIVERY; ENERGY-METABOLISM; NEURAL NETWORKS; ISCHEMIA	Objective: To analyze patterns of cerebral microdialysis in patients with traumatic brain injury and, with a neural network methodology, investigate pattern relationships to intracranial pressure and cerebral perfusion pressure. Design: Retrospective. Setting. University hospital, adult neurosurgical intensive care unit. Patients: Twenty-six patients with severe traumatic brain injury. All consecutive traumatic brain injured patients (Glasgow Coma Scale less than or equal to8) with microdialysis monitoring, analyzing glutamate, lactate, pyruvate, and glucose in both penumbral and nonpenumbral tissue. Interventions: None; patients received the unit's standard neurointensive care procedure. Measurements and Main Results: We used 2084 hrs of complete microdialysis data sets (eight markers) to train Kohonen self-organizing maps. The self-organizing map algorithm is a data-clustering method that reduces high-dimensional information to a two-dimensional representation on a grid (map), retaining local relationships in the data. Maps were colored (overlaid) for intracranial pressure, cerebral perfusion pressure, and outcome, to explore relationships with underlying microdialysis patterns. The maps exhibited a striking clustering of patients, with unique microdialysis patterns that were recognizable throughout the analysis period. This also held true for most microdialysis patterns characteristic of ischemia. These patients with ischemic patterns can have good outcomes, suggesting a disparity between microdialysis values and severity of traumatic brain injury. Conclusion. Using an artificial neural network-like clustering technique, Kohonen self-organizing maps, we have shown that cerebral microdialysis, in traumatic brain injury, exhibits strikingly individualistic patterns that are identifiable throughout the analysis period. Because patients form their own clusters, microdialysis patterns, during periods of increased intracranial pressure or decreased cerebral perfusion pressure, will be found within these clusters. Consequently, no common pattern of microdialysis can be seen among patients within the range of our data. We suggest that these individualistic patterns reflect not only metabolic states of traumatic brain injury but also local gradients seen with small volume sampling. Future investigation should focus on relating these patterns, and movement within and from clusters, to metabolic states of the complex pathophysiology of traumatic brain injury.	Karolinska Univ Hosp, Dept Anaesthesiol & Intens Care, Stockholm, Sweden; Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; Stockholm Univ, Stockholm Bioinformat Ctr, S-10691 Stockholm, Sweden; Karolinska Inst, Dept Biomed Engn, Huddinge, Sweden		Nelson, DW (corresponding author), Karolinska Univ Hosp, Dept Anaesthesiol & Intens Care, Stockholm, Sweden.			Nelson, David/0000-0003-2530-8207			Baxt WG, 2002, ANN EMERG MED, V40, P575, DOI 10.1067/mem.2002.129171; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; CHENG B, 1994, STAT SCI, V9, P2, DOI 10.1214/ss/1177010638; Dybowski R, 1996, LANCET, V347, P1146, DOI 10.1016/S0140-6736(96)90609-1; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gopinath SP, 2000, ACT NEUR S, V76, P437; Gurney K., 1997, INTRO NEURAL NETWORK, V1; Hanson CW, 2001, CRIT CARE MED, V29, P427, DOI 10.1097/00003246-200102000-00038; Hillered L, 2003, SCAND CARDIOVASC J, V37, P13, DOI 10.1080/14017430310006974; Hillered L, 1999, ACT NEUR S, V75, P3; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; JENNETT B, 1975, LANCET, V1, P480; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kerr ME, 2003, CRIT CARE MED, V31, P2371, DOI 10.1097/01.CCM.0000080484.72004.C4; Kett-White R, 2002, J NEUROSURG, V96, P1013, DOI 10.3171/jns.2002.96.6.1013; Koura SS, 1998, ACT NEUR S, V71, P244; Landolt H, 1996, EUR J ANAESTH, V13, P269, DOI 10.1046/j.1365-2346.1996.00975.x; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Maas Andrew I.R., 2000, Curr Opin Crit Care, V6, P281, DOI 10.1097/00075198-200008000-00008; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; Mjolsness E, 2001, SCIENCE, V293, P2051, DOI 10.1126/science.293.5537.2051; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Peerdeman SM, 2000, INTENS CARE MED, V26, P662, DOI 10.1007/s001340051230; PRESNELL SR, 1993, ANNU REV BIOPH BIOM, V22, P283, DOI 10.1146/annurev.bb.22.060193.001435; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 1998, NEUROL RES, V20, pS91; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V128, P9, DOI 10.1111/j.1748-1716.1986.tb07943.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Whittle IR, 1998, NEUROREPORT, V9, P2821, DOI 10.1097/00001756-199808240-00025; 2000, ARTIFICIAL NEURAL NE, P45	52	37	37	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2004	32	12					2428	2436		10.1097/01.CCM.0000147688.08813.9C			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881NG	WOS:000225873600010	15599147				2022-02-06	
J	Corrigan, JD; Bogner, J				Corrigan, JD; Bogner, J			Latent factors in measures of rehabilitation outcomes after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						outcomes measurement; rehabilitation; traumatic brain injury	FUNCTIONAL ASSESSMENT SCALES; QUALITY-OF-LIFE; COMMUNITY INTEGRATION QUESTIONNAIRE; HEALTH SURVEY QUESTIONNAIRE; SYSTEMATIC BIAS; BREAST-CANCER; SURVEY SF-36; FOLLOW-UP; SATISFACTION; INDIVIDUALS	Objectives: To determine whether there is a latent structure among measures used to evaluate rehabilitation outcomes for persons with traumatic brain injury and if the construct of participation is discernible within this structure. Design: Exploratory factor analyses of 2 cross-sectional cohorts of rehabilitation patients who sustained a traumatic brain injury up to 5 years prior to assessment. Primary Measures: Community Integration Questionnaire (CIQ), Craig Handicap Assessment and Reporting Technique (CHART), Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), and the Satisfaction With Life Scale (SWLS). Results: Both factor analyses suggested a latent structure composed of 3 factors that were interpreted as representing the Activities and Participation dimensions of the World Health Organization's International Classification of Functioning, Disability and Health (ICF), and a third representing Subjective Well-Being. Low to moderate correlations were found between factors. Conclusions: The World Health Organization's ICF excludes subjective well-being; however the factor analyses indicate that it is a distinct domain not incorporated into Activities and Participation. The SF-36, CIQ, and CHART can, in combination, evaluate all 3 domains, but not alone. The SF-36 appears to be sensitive to the affective, but not the cognitive, aspect of Subjective Well-Being. A measure of life satisfaction would be a useful supplement to traditional measures of rehabilitation outcome.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Corrigan, John D./E-2921-2011; Bogner, Jennifer/E-2773-2011				BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; BRUIN AF, 2002, SOC SCI MED, V35, P1003; Carlsson M, 1996, QUAL LIFE RES, V5, P265, DOI 10.1007/BF00434748; Carlsson M, 1999, QUAL LIFE RES, V8, P245, DOI 10.1023/A:1008875306645; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIJKERS M, 1997, ASSESSING MED REHABI, P153; DIJKERS M, 2003, COMMUNITY INTEGRATIO, V2; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FREDERICK S, 1999, SUBJECTIVE WELL BEIN, P303; Fugl-Meye KS., 1991, CLIN REHABIL, V5, P25, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105]; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; GARRATT AM, 1993, BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GORDON WA, 1998, LIVING LIFE TRAUMATI; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; GRANT JP, 1986, NUTR CLIN PRACT, V1, P3; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; *HLTH ASS LAB, 2000, PART MEAS POST AC CA; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; POPE AM, 1991, DISABILITY AM NATL A; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SOKOL K, 1999, ARCH PHYS MED REHAB, V80, P974; US Department of Education Office of Special Education and Rehabilitative Services National Institute on Disability and Rehabilitation Research, 2000, LONG RANG PLAN 1999; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 1980, INT CLASS FUNCT DIS; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1993, BRAIN INJURY REHABIL, P355; WILLER B, 1997, ASSESSING MED REHABI, P127; World Health Organization, 2007, INT CLASS FUNCT DIS; Zhang L, 2002, J HEAD TRAUMA REHAB, V17, P497, DOI 10.1097/00001199-200212000-00002	47	37	37	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2004	19	6					445	458		10.1097/00001199-200411000-00003			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	873LZ	WOS:000225283100003	15602308				2022-02-06	
J	Aimaretti, G; Ambrosio, MR; Benvenga, S; Borretta, G; De Marinis, L; De Menis, E; Di Somma, C; Faustini-Fustini, M; Grottoli, S; Gasco, V; Gasperi, M; Logoluso, F; Scaroni, C; Giordano, G; Ghigo, E				Aimaretti, G; Ambrosio, MR; Benvenga, S; Borretta, G; De Marinis, L; De Menis, E; Di Somma, C; Faustini-Fustini, M; Grottoli, S; Gasco, V; Gasperi, M; Logoluso, F; Scaroni, C; Giordano, G; Ghigo, E			Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI)	GROWTH HORMONE & IGF RESEARCH			English	Article; Proceedings Paper	35th International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism	APR 04-05, 2003	Prague, CZECH REPUBLIC	Pfizer Inc		growth hormone deficiency; adulthood; diagnosis; traumatic brain injury; subarachnoid haemorrhage	PLUS-ARGININE; YOUNG-ADULTS; DIAGNOSIS	In adults, hypopituitarism and growth hormone deficiency (GHD) should be suspected and diagnosed within an appropriate clinical context. It has been demonstrated that all patients with primary hypothalamic-pituitary diseases before and after any medical intervention (defined as neurosurgery, radiotherapy and medical therapy) are at obvious risk - more than just at high risk for hypopituitarism (greater than 80%, had severe GHD). The same obvious risk applies to patients diagnosed as having congenital or acquired GHD in childhood (between 30% and 50% of patients with severe GHD after retesting). Taking into account the fragility of the infundibular hypothalamic structure, patients with other common pathological conditions of the central nervous system (CNS), such as traumatic brain injury (TBI), subarachnoid haemorrhage (SAH) or primary brain tumours (BT) with related medical intervention could be at risk for developing hypopituitarism, including GHD. GHD is the first and most common sign of pituitary impairment. Despite the risk of pituitary dysfunction and the results of some studies that these risks are greater than previously believed, neuroendocrine evaluations are still not routinely included as part of the clinical management plan for patients with TBI and SAH. Preliminary results of a multicenter study performed under the auspices of the Italian Society of Endocrinology underscore the high risk of hypopituitarism and GHD under these clinical conditions. Thus, careful screening of pituitary function should always be performed in patients following TBI and SAH. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab Dis, I-10126 Turin, Italy		Ghigo, E (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab Dis, Cso Dogliotti 14, I-10126 Turin, Italy.	ezio.ghigo@unito.it	Scaroni, Carla/G-3853-2017; Faustini-Fustini, Marco/AAU-7933-2020; Di Somma, Carolina/K-7772-2016	Scaroni, Carla/0000-0001-9396-3815; Di Somma, Carolina/0000-0002-5724-1951; ambrosio, maria rosaria/0000-0002-7911-9770			*AG HLTH CAR POL R, 1998, REH TRAUM BRAIN INJ; Aimaretti G, 2001, Pituitary, V4, P129, DOI 10.1023/A:1015306705154; Aimaretti G, 2001, J Pediatr Endocrinol Metab, V14 Suppl 5, P1233; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Aimaretti G, 2003, CLIN ENDOCRINOL, V59, P56, DOI 10.1046/j.1365-2265.2003.01794.x; Aimaretti G, 2000, J CLIN ENDOCR METAB, V85, P3693, DOI 10.1210/jc.85.10.3693; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Ceballos R, 1966, Ala J Med Sci, V3, P185; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Cornelia G, 2003, GROWTH HORM IGF RES, V13, P104, DOI 10.1016/S1096-6374(03)00010-8; DANIEL PM, 1959, LANCET, V2, P927; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; EDWARDS OM, 1986, MEDICINE, V65, P281; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lamberts SWJ, 1998, LANCET, V352, P127; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; 2001, J CLIN ENDOCRINOL ME, V83, P379	25	37	37	0	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1096-6374	1532-2238		GROWTH HORM IGF RES	Growth Horm. IGF Res.	JUN	2004	14			A			S114	S117		10.1016/j.ghir.2004.03.025			4	Cell Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Cell Biology; Endocrinology & Metabolism	827CS	WOS:000221876700026	15135791				2022-02-06	
J	Dawson, DR; Levine, B; Schwartz, ML; Stuss, DT				Dawson, DR; Levine, B; Schwartz, ML; Stuss, DT			Acute predictors of real-world outcomes following traumatic brain injury: a prospective study	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC AMNESIA; COMMUNITY INTEGRATION; RECOVERY; EMPLOYMENT; RETURN; DISABILITY; SEVERITY; COMA	Primary objective: To determine whether the recovery of acute attention and memory improves the prediction of real-world outcomes over that provided by standard demographic and injury-severity measures. Research design: Participants were recruited consecutively at the time of injury and followed prospectively at 1 (time 1, or T1) and 4 years (time 2, or T2). Methods and procedures: Measures of attention and memory and the Galveston Orientation and Amnesia Test (GOAT) were administered to 94 participants daily from the time of injury until the criterion was met. Sixty-three per cent returned at T1 and 53% returned at T2. Outcomes were psychosocial distress, return to work and/or school, and quality of life. Main outcomes and results: Recovery of attention, memory and orientation did not significantly improve prediction of outcomes at T1, but did so at T2. At T2, recovery of free recall of three words over 24 h was a more sensitive predictor of psychosocial distress and return to productivity than the GOAT. Conclusions: Free recall of three words may be a useful acute clinical test to enhance prediction of long-term outcomes.	Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Surg Neurosurg, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON, Canada		Dawson, DR (corresponding author), Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Levine, Brian/O-2725-2019; Dawson, Deirdre R/I-8882-2014; Levine, Brian/G-4328-2010	Levine, Brian/0000-0003-4343-811X; Dawson, Deirdre R/0000-0001-7517-6121; Levine, Brian/0000-0003-4343-811X			BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Brown M, 1999, MT SINAI J MED, V66, P160; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kelsey JL, 1986, METHODS OBSERVATIONA, V2nd; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; LEVINE B, UNPUB TEST AUDITORY; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; MOORE AD, 1994, BRAIN INJURY, V7, P193; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; OCONNER C, 2001, THESIS U TORONTO TOR; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wechsler D, 1987, MEMORY SCALE REVISED; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	45	37	38	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2004	18	3					221	238		10.1080/02699050310001617406			18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900001	14726283				2022-02-06	
J	Delaney, JS				Delaney, JS			Head injuries presenting to Emergency Departments in the United States from 1990 to 1999 for ice hockey, soccer, and football	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article; Proceedings Paper	1st International Symposium on Concussion in Sport	NOV, 2001	Vienna, AUSTRIA			head injuries; concussions; skull fractures; emergency department; ice hockey; soccer; football	TRAUMATIC BRAIN-INJURY; ATHLETIC NECK INJURY; HIGH-SCHOOL; MULTIVARIATE-ANALYSIS; COLLEGE FOOTBALL; CERVICAL-SPINE; PLAYERS; CONCUSSION; SPORT; EPIDEMIOLOGY	Study Objective: To examine the number and rates of head injuries occurring in the community as a whole for the team sports of ice hockey, soccer, and football by analyzing data from patients presenting to US emergency departments (EDs) from 1990 to 1999. Design: Retrospective analysis. Main Outcome Measures: Data compiled for the US Consumer Product Safety Commission using the National Electronic Injury Surveillance System were used to generate estimates for the total number of head injuries, concussions, internal head injuries, and skull fractures occurring on a national level from the years 1990 to 1999. These data were combined with yearly participation figures to generate rates of injuries presenting to the ED for each sport. Results: There were an estimated 17,008 head injuries from ice hockey, 86,697 from soccer, and 204,802 from football that presented to US EDs from 1990 to 1999. The total number ofconcussions presenting to EDs in the United States over the same period was estimated to be 4820 from ice hockey, 21,715 from soccer, and 68,861 from football. While the rates of head injuries, concussions, and combined concussions/internal head injuries/skull fractures presenting to EDs per 10,000 players were not always statistically similar for all 3 sports in each year data were available, they were usually comparable. Conclusion: While the total numbers of head injuries, concussions, and combined concussions/skull fractures/internal head injuries presenting to EDs in the United States are different for ice hockey, soccer, and football for the years studied, the yearly rates for these injuries are comparable among all 3 sports.	McGill Univ, Ctr Hlth, Dept Emergency Med, Montreal, PQ H2W 1S4, Canada; McGill Univ, Sport Med Clin, Montreal, PQ H2W 1S4, Canada		Delaney, JS (corresponding author), McGill Univ, Ctr Hlth, Dept Emergency Med, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.	j.delaney@staff.mcgill.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Cantu RC, 2000, NEUROSURGERY, V47, P673, DOI 10.1097/00006123-200009000-00029; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; Cantu RC., 1997, AM COLL SPORTS MED E, P345; Clarke KS, 1998, CLIN SPORT MED, V17, P1, DOI 10.1016/S0278-5919(05)70056-9; Clarke KS, 1998, CLIN SPORT MED, V17, P83, DOI 10.1016/S0278-5919(05)70063-6; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DALY PJ, 1990, SPORTS MED, V10, P122, DOI 10.2165/00007256-199010020-00005; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Gillogly S D, 2000, J Med Assoc Ga, V89, P39; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; GOTTESFELD SH, 2000, EMERG MED PRACT, V2, P1; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jorgensen U, 1986, Br J Sports Med, V20, P7; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Kraus J F, 1970, Med Sci Sports, V2, P162; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Molsa J, 1997, AM J SPORT MED, V25, P495, DOI 10.1177/036354659702500412; MONTGOMERY DL, 1988, SPORTS MED, V5, P99, DOI 10.2165/00007256-198805020-00003; Mueller F O, 1991, Exerc Sport Sci Rev, V19, P261; MUELLER FO, 1990, MED SCI SPORT EXER, V22, P737, DOI 10.1249/00005768-199012000-00001; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; *PED TAAO, 1988, PHYSICIAN SPORTSMED, V16, P165; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Schneider RC., 1973, HEAD NECK INJURIES F; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; STRANG I, 1978, INJURY, V10, P154; Tator CH, 1998, CLIN SPORT MED, V17, P183, DOI 10.1016/S0278-5919(05)70072-7; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Warren WL, 1998, CLIN SPORT MED, V17, P99, DOI 10.1016/S0278-5919(05)70064-8; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196	67	37	37	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2004	14	2					80	87		10.1097/00042752-200403000-00005			8	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Orthopedics; Physiology; Sport Sciences	943BO	WOS:000230327000005	15014341				2022-02-06	
J	Fainardi, E; Chieregato, A; Antonelli, V; Fagioli, L; Servadei, F				Fainardi, E; Chieregato, A; Antonelli, V; Fagioli, L; Servadei, F			Time course of CT evolution in traumatic subarachnoid haemorrhage: a study of 141 patients	ACTA NEUROCHIRURGICA			English	Article						head injury subarachnoid haemorrhage; worst CT scan; CT evolution	SEVERE HEAD-INJURY; COMPUTED TOMOGRAPHIC SCAN; FOLLOW-UP; PRACTICAL SCALE; HEMATOMAS; MODERATE; COMA; PRESSURE; BLOOD	Background. Evidence of tSAH on an admission CT scan seems to be an early predictor of evolving posttraumatic lesions. Detection of these changes requires serial CT scanners. The goal of our study was to determine the optimal timing of follow-up CT scans in head injured patients with traumatic subarachnoid haemorrhage (tSAH). Method. We reviewed the initial and follow-up CT scans in 141 patients with closed head injuries and evidence of tSAH on the initial CT scan. We used the Marshall classification to determine diffuse and focal injuries. The "worst CT scan", defined as the CT examination in which midline shift, cistern compression and/or intracranial focal lesions were greater. was also determined. Any worsening of the admission CT findings, occurring when the "worst CT examination" did not correspond to the initial CT study. was considered as a "CT evolution". Any "CT evolution" associated with a variation from a lower to a higher score in the Marshall classification score was indicated as a "significant CT evolution". Findings. The median time between injury and the first CT scan was 1.3 (IQR 1.5) hours. A CT evolution was found in 83/141 (58.9%) patients in whom the median time between the initial and worst CT scans was 27.7 hours (IQR 69.2 hours). The worst CT studies were seen more often at 12-24 hours and at 24-48 hours after the admission CT scan than in later studies. A similar temporal profile was observed when the timing of the "worst CT scan" was evaluated in 38/83 (45.8%) subjects with a "significant CT evolution". Interpretation. Our findings show that an early admission CT scan did not represent the full extent of the posttraumatic damage in more than half of our patients. They also suggest that to identify these changes in head injured patients with tSAH, CT scans should be repeated at 12-24 and possibly also at 24-48 hours from the admission CT examination to allow early detection and evacuation of evolving intracranial lesions.	Arcispedale St Anna, Dipartimento Neurosci, Unita Operat Neuroradiol, I-44100 Ferrara, Italy; Osped Gen Provinciale M Bufalini, Cesena, Italy		Fainardi, E (corresponding author), Arcispedale St Anna, Dipartimento Neurosci, Unita Operat Neuroradiol, Corso della Giovecca 203, I-44100 Ferrara, Italy.	henryfai@tin.it		Servadei, Franco/0000-0002-3595-3464; Antonelli, Vincenzo/0000-0003-4231-529X			CHESNUT R, 1999, TRAUMATIC BRAIN INJU, P81; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; JENNETT B, 1975, LANCET, V1, P480; KAKARIEKA A, 1995, CEREBROVASC DIS, V5, P403, DOI 10.1159/000107892; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; SHIGEMORI M, 1990, Neurologia Medico-Chirurgica, V30, P396, DOI 10.2176/nmc.30.396; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; TEASDALE G, 1974, LANCET, V2, P81; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Wilberger JE, 2000, NEUROSURGERY, V46, P76; YAMAKI T, 1990, ACTA NEUROCHIR, V103, P112, DOI 10.1007/BF01407516	26	37	40	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2004	146	3					257	263		10.1007/s00701-003-0207-y			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	809VR	WOS:000220664700012	15015048				2022-02-06	
J	McIntosh, A; McCrory, P; Finch, CF				McIntosh, A; McCrory, P; Finch, CF			Performance enhanced headgear: a scientific approach to the development of protective headgear	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							FOOTBALL; RUGBY	Background: There is a continuing debate about the performance of protective headgear in rugby union, rugby league, and Australian rules football. Objectives: To examine the impact energy attenuation performance of foam that could be incorporated into headgear and examine the performance of prototypes of modified headgear. Methods: Impact tests were conducted on polyethylene foams and protective headgear. Free fall drop tests with a rigid headform on to a flat rigid anvil were conducted. Resultant headform acceleration was measured. Means of the headform acceleration maxima for repeat tests were calculated. Results: Tests on polyethylene foam indicated that an increase in thickness from 10 mm to 16 mm would improve headgear performance. These modifications were incorporated in part into two headgear models: the Albion Headpro and the Canterbury brand Body Armour honeycomb headgear. The headgear tests show that significant reductions in headform acceleration were achieved by increasing the foam density and thickness. Mean headform acceleration maxima for the 16 mm thick modified rugby headgear was about 25% of that of standard headgear for lateral impact 0.3 and 0.4 m drop heights and 27% for the centre front 0.3 m drop tests. At these impacts, the headform acceleration for the modified rugby headgear was below 200 g. Conclusions: Significant improvements in impact energy attenuation performance are possible with small design changes. Whether these are sufficient to reduce the rate or severity of concussion in rugby and Australian rules football can only be shown by formal prospective studies on the field.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Univ Melbourne, Melbourne, Vic, Australia		McIntosh, A (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.	a.mcintosh@unsw.edu.au	McCrory, Paul/Q-8688-2019				Allsop D., 1991, P 35 STAPP CAR CRASH; FINCH C, 2000, SPORT HLTH, P35; HIRSCH AE, 1970, P 14 STAPP CAR CRASH, P144; MCINTOSH A, 2000, P 37 STAPP CAR CRASH; McIntosh A, 1995, P 39 STAPP CAR CRASH; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; NEWMAN J, 1980, P 24 STAPP CAR CRASH, P701; NUSHOLTZ GS, 1984, P 28 STAPP CAR CRASH, P41	10	37	37	1	23	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	FEB 1	2004	38	1					46	49		10.1136/bjsm.2002.003103			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	768JG	WOS:000188539400014	14751945	Green Published, Bronze			2022-02-06	
J	Gerhart, KA; Mellick, DC; Weintraub, AH				Gerhart, KA; Mellick, DC; Weintraub, AH			Violence-related traumatic brain injury: A population-based study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						violence; traumatic brain injury; outcomes	SPINAL-CORD-INJURY; SICKNESS IMPACT PROFILE; GUNSHOT WOUNDS; SEVERITY SCORE; HEAD-INJURY; EXPERIENCE; ASSAULT; TRENDS	Background. Most studies of traumatic brain injury (TBI) and violence are small, focus on one violent mechanism only, and are nonrepresentative. This large, population-based effort examines characteristics, circumstances of injury, treatment pathways, and outcomes of persons with TBI as a result of all types of violence, compares them with other TBI survivors, identifies a risk profile, and examines how a violent cause impacts later outcomes. Methods. This study involved medical record abstraction and telephone survey at I year postinjury of a weighted sample of 2,771 Coloradans hospitalized with TBI between January 1, 1996, and June 30, 1999. Results. People with violently incurred TBI are more likely to be young, male, members of minority groups, single, and premorbid alcohol abusers than other TBI survivors. At I year postinjury, they report less community integration and more headaches, confusion, and sensory and attentional disturbances. Predictors of these outcomes included age, gender, injury severity, and employment status. Conclusion. it appears that essentially the same factors that increase risk of sustaining a violent TBI negatively impact later outcomes as well.	Craig Hosp Res, Rocky Mt Reg Brain Injury Syst, Englewood, CO 80110 USA		Gerhart, KA (corresponding author), Craig Hosp Res, Rocky Mt Reg Brain Injury Syst, 3425 S Clarkson St, Englewood, CO 80110 USA.	kgerhart@craighospital.org			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980020] Funding Source: Medline; ODCDC CDC HHS [U17/CCU812447] Funding Source: Medline		BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; BROOKS WB, 1990, MED CARE, V28, P793, DOI 10.1097/00005650-199009000-00009; *CDCP, EP TRAUM BRAIN INJ U; *COL TRAUM BRAIN I, 2001, DAT FIL DOC COL TRAU; Cook PJ, 1999, JAMA-J AM MED ASSOC, V282, P447, DOI 10.1001/jama.282.5.447; *CRAIG HOSP RES DE, 2000, CRAIG HAND ASS REP T; Damiano AM, 1996, SICKNESS IMPACT PROF; *DEP HLTH HUM SERV, 1989, INT HEAD INJ TASK FO; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DEYO RA, 1983, SPINE, V8, P635, DOI 10.1097/00007632-198309000-00009; DIKERS M, 1991, J AM PARAPLEGIA SOC, V14, P85; DODGE GG, 1994, AM SURGEON, V60, P401; GOBNER JA, 2002, PHYS MED REHABIL, V82, P571; GROLEAU GA, 1993, J TRAUMA, V34, P366, DOI 10.1097/00005373-199303000-00010; HAHN YS, 1983, CHILD BRAIN, V10, P229; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hartzell KN, 1996, OPHTHALMOLOGY, V103, P953, DOI 10.1016/S0161-6420(96)30580-0; *J HOPK U, 1993, INJ SEV SCOR ICDM SC; KANE T, 1991, J SPINAL DISORD, V4, P306, DOI 10.1097/00002517-199109000-00007; KHELLA L, 1977, AM J PHYS MED REHAB, V56, P21; KRIEGER MD, 1995, NEUROSURG CLIN N AM, V6, P605; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX M, 1993, HLTH AFF, V12, P171; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P102, DOI 10.1097/00002060-199903000-00002; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Nobunaga AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2; Ochs HA, 1996, J AM DENT ASSOC, V127, P757, DOI 10.14219/jada.archive.1996.0311; ROSENBERG ML, 1991, VIOLENCE AM PUBL HLT; SHEPHERD JP, 1990, J ROY SOC MED, V83, P75, DOI 10.1177/014107689008300206; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; SPSS Inc, 1999, SPSS WIND VERS 10 0; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US DEP HHS, 1989, INT CLASS DIS; WATERS RL, 1992, PARAPLEGIA, V267, P14; WHITENECK G, 2002, COLORADO TRAUMATIC B; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1990, NEUROBEHAVIORAL SEQU; World Health Organization, 2007, INT CLASS FUNCT DIS; Zafonte R, 1993, J AM PARAPLEGIA SOC, V16, P94; Zafonte RD, 1997, BRAIN INJURY, V11, P403; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226; ZAFONTE RD, 1999, TOP SPINAL CORD INJ, V93, P36	48	37	41	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1045	1053		10.1097/01.TA.0000044353.69681.96			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	758TL	WOS:000187666200008	14676649				2022-02-06	
J	Glomsda, BA; Blaheta, RA; Hailer, NP				Glomsda, BA; Blaheta, RA; Hailer, NP			Inhibition of monocyte/endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil	SPINAL CORD			English	Article						mycophenolic acid; adhesion molecules; immunosuppression; mononuclear cells; spinal cord; mycophenolate metabolism	SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; P-SELECTIN; NITRIC-OXIDE; IN-VITRO; INFLAMMATORY RESPONSE; QUINOLINIC ACID	Study design: In vitro study on the effects of mycophenolate mofetil (MMF) on isolated human monocytes and endothelial cells. Objectives: Haematogenous macrophages play an essential role in the development of secondary damage following spinal cord injury (SCI), and there is evidence that the use of immunosuppressants such as MMF can reduce monocyte invasion and neuronal damage. Setting: University Hospital for Orthopaedic Surgery, Frankfurt am Main, Germany. Methods: The effects of MMF on the adhesion of human monocytes to human umbilical vein endothelial cells (HUVEC), monocyte binding to immobilised E-selectin, and monocyte expression of intercellular adhesion molecule (ICAM)-1, sialyl Lewis X (sLeX) and major histocompatibility complex (MHC)-II were studied. The binding of monocytes to E-selectin was examined by using purified and immobilised E-selectin fusion protein. Adhesion molecule expression was investigated by flow cytometry. Results: The binding of monocytes to HUVEC was significantly reduced by 30.1% after treatment of monocytes with MMF (10 mug/ml), whereas the pretreatment of HUVEC with MMF did not result in significant changes in monocyte adhesion. MMF forcefully inhibited monocyte binding to immobilised E-selectin by 55.7%. Furthermore, MMF significantly inhibited the upregulation of ICAM-1- and MHC-II-expression on monocytes stimulated with either lipopolysaccharide or interferon-gamma, whereas the expression of sLeX was not impaired. Toxic effects were excluded by propidium-iodide staining and measurement of fluorescein-diacetate metabolism. Conclusion: MMF can downregulate important monocytic adhesion molecules and inhibits monocyte adhesion to endothelial cells, thus indicating that treatment with MMF could be beneficial after SCI. Sponsorship: This study was supported by the DFG (Ha 2721/1-3), the Paul und Ursula KleinStiftung and the Stiftung Friedrichsheim.	Univ Hosp Orthopaed Surg Friedrichsheim, D-60528 Frankfurt, Germany; Goethe Univ Frankfurt, Dept Clin Pediat, Interdisciplinary Lab, D-6000 Frankfurt, Germany		Hailer, NP (corresponding author), Univ Hosp Orthopaed Surg Friedrichsheim, Marienburgstr 2, D-60528 Frankfurt, Germany.			Hailer, Nils/0000-0002-3233-2638			ALLISON AC, 1993, IMMUNOL REV, V136, P5, DOI 10.1111/j.1600-065X.1993.tb00652.x; ALLISON AC, 1993, CLIN TRANSPLANT, V7, P96; ALLISON AC, 1993, TRANSPLANT P, V25, P67; Baer PC, 2000, NEPHROL DIAL TRANSPL, V15, P184, DOI 10.1093/ndt/15.2.184; Blaheta RA, 1998, TRANSPL IMMUNOL, V6, P251, DOI 10.1016/S0966-3274(98)80015-4; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; CANNELLA B, 1990, J EXP MED, V172, P1521, DOI 10.1084/jem.172.5.1521; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753-3322(94)90005-1; CHOI DW, 1990, J NEUROSCI, V10, P2493; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DEVRIES HE, 1994, J NEUROIMMUNOL, V52, P1, DOI 10.1016/0165-5728(94)90155-4; DIJKSTRA CD, 1992, J NEUROIMMUNOL, V40, P183, DOI 10.1016/0165-5728(92)90132-5; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Engelhardt B, 1997, BLOOD, V90, P4459, DOI 10.1182/blood.V90.11.4459.4459_4459_4472; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; Farooque M, 1999, NEUROREPORT, V10, P131, DOI 10.1097/00001756-199901180-00024; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hamada Y, 1996, J NEUROCHEM, V66, P1525; HAUSER SL, 1983, J NEUROIMMUNOL, V5, P197, DOI 10.1016/0165-5728(83)90010-3; Heemann U, 1996, Transpl Immunol, V4, P64, DOI 10.1016/S0966-3274(96)80039-6; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; Laurent AF, 1996, EXP HEMATOL, V24, P59; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; Navratil E, 1997, NEUROPATH APPL NEURO, V23, P68, DOI 10.1046/j.1365-2990.1997.8298082.x; NOWAK I, 1995, CLIN CHEM, V41, P1011; OEHMICHEN M, 1983, PROG NEUROPATH, V5, P277; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Schwab JM, 2000, J NEUROIMMUNOL, V111, P122, DOI 10.1016/S0165-5728(00)00372-6; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; Stanimirovic DB, 1997, ACT NEUR S, V70, P12; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Wittig BM, 1996, INT J CANCER, V67, P80, DOI 10.1002/(SICI)1097-0215(19960703)67:1<80::AID-IJC14>3.0.CO;2-G; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347; Zhang RL, 1996, J CEREBR BLOOD F MET, V16, P1126, DOI 10.1097/00004647-199611000-00006	50	37	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	NOV	2003	41	11					610	619		10.1038/sj.sc.3101512			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	734TP	WOS:000186074300003	14569262	Bronze			2022-02-06	
J	Mussack, T; Dvorak, J; Graf-Baumann, T; Jochum, M				Mussack, T; Dvorak, J; Graf-Baumann, T; Jochum, M			Serum S-100B protein levels in young amateur soccer players after controlled heading and normal exercise	EUROPEAN JOURNAL OF MEDICAL RESEARCH			English	Article						heading; minor head injury; S-100B; soccer; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PATIENT-MANAGEMENT; DAMAGE; FOOTBALL; MARKER; TOMOGRAPHY; HISTORY; PHASE; LEAD	Background: Repeated impacts by heading might lead to significant head injuries in soccer players comparable to those of patients with accidental minor traumatic brain injury (TBI). The neuroprotein S-100B released into the circulation is suggested to be a reliable marker indicating brain damage. The objective was to evaluate the neuroprotein S-100B serum levels in young amateur soccer players early after controlled heading compared to early measurements after normal exercise as well as in other patients after minor TBI. Material and Methods: Sixty-one male amateur soccer players (median age 15.3 years) performed controlled heading aimed at the forehead for 55 minutes. Data were compared to 58 male amateur soccer players (15.9 years) performing 61 minutes of normal exercise training without head contact and 81 young male patients early after TBI who underwent computed tomography (CCT) for detection of intracranial lesions. First venous blood samples were drawn before the training sessions, second and third samples 60 and 360 minutes after heading or 64 and 355 minutes after exercise, respectively, 65 and 366 minutes after TBI. Results: Median S-100B serum levels of the heading group only slightly increased from 0.15 ng/ml to 0.18 ng/ml 60 minutes after end of training. Within 360 minutes S-100B values decreased again to 0.15 ng/ml reaching the initial values. S-100B serum values of the exercise group showed a similar transient increase exhibiting significant lower levels before exercise (0.10 ng/ml) as well as 64 minutes (0.11 ng/ml) and 355 minutes after exercise (0.09 ng/ml) compared to the heading group. According to age stratification in the heading group, starting median S-100B levels were significantly higher in subjects with 12-13 years (0.22 ng/ml) and 14-15 years (0.17 ng/ml) compared to those with 16-17 years of age (0.06 ng/ml). None of the subcollectives did reach median S-100B levels of the CCT+ group (n = 20) at admission (0.62 ng/ml) or 366 minutes later (0.32 ng/ml), which were significantly elevated compared to those of the CCT- group (n = 61) at admission (0.10 ng/ml) or 370 minutes later (0.08 ng/ml). Conclusions: Controlled repetitive heading in young amateur soccer players leads to a transient increase between 60 to 360 min after training, but does not appear to evoke a longer lasting S-100B release into serum indicating cellular brain damage. After heading S-100B levels are significantly elevated compared to normal exercise. Although soccer players with 12-13 years and 14-15 years revealed significantly higher S-100B values than with 16-17 years of age, the transient increase is independent of the age-related starting values. However, since brain damage due to abrupt heading a ball of high speed or accidental trauma during regular soccer games cannot be excluded, S-100B measurements in soccer players are initiated during video-controlled soccer games.	Univ Munich, Dept Surg, Klinikum Innenstadt, D-80336 Munich, Germany; FIFA, Med Assessment & Res Ctr, Zurich, Switzerland; Univ Munich, Klinikum Innenstadt, Dept Clin Chem & Clin Biochem, D-8000 Munich, Germany		Mussack, T (corresponding author), Univ Munich, Dept Surg, Klinikum Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	mussack@ch-i.med.uni-muenchen.de					ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Baethmann A, 1999, ACT NEUR S, V73, P93; Baethmann A, 1998, ACT NEUR S, V71, P107; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Bruce D A, 1982, Clin Sports Med, V1, P495; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hammon JW, 2000, J THORAC CARDIOV SUR, V119, P130, DOI 10.1016/S0022-5223(00)70227-3; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lehr D, 1997, J TRAUMA, V42, pS71, DOI 10.1097/00005373-199705001-00015; Lohnes JH, 1994, SPORTS INJURIES MECH, P603; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Mussack T, 2000, ACT NEUR S, V76, P393; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Reilly TT, 1976, J HUM MOV STUD, V2, P87; Roaas A, 1979, Br J Sports Med, V13, P3; Ross J, 2000, HAEMOPHILIA, V6, P41; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Schmidt-Olsen S, 1985, Br J Sports Med, V19, P161; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Thibault L.E.O.A., 1993, BIOMECHANICS IMPACT, P411; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	40	37	37	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0949-2321	2047-783X		EUR J MED RES	Eur. J. Med. Res.	OCT 22	2003	8	10					457	464					8	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	736FN	WOS:000186160900004	14594652				2022-02-06	
J	Albensi, BC; Janigro, D				Albensi, BC; Janigro, D			Traumatic brain injury and its effects on synaptic plastic	BRAIN INJURY			English	Article							LONG-TERM POTENTIATION; FLUID PERCUSSION INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; ANIMAL-MODELS; RISK FACTOR; HIPPOCAMPUS; INVOLVEMENT; MEMORY; POTASSIUM	Animal models have been used to simulate the effects of human head trauma. Some of these models have been further utilized to explore how trauma affects specific mechanisms of synaptic plasticity, a cellular model for memory consolidation. Unfortunately, these studies have been more limited in number in spite of their importance for understanding alterations in synaptic plasticity and memory impairments in trauma patients. Research in this area includes well characterized trauma models, genetically engineered animals and neuroprotective studies. One largely ignored but important idea that is entertained here is that trauma may be a crucial aetiological factor for the loss of potassium homeostasis. Moreover, high extracellular potassium has been shown to promote abnormal expression of hippocampal synaptic plasticity due to K+-induced glutamate release, thus showing important relationships among trauma, glia, potassium and synaptic plasticity. Collectively, this mini review surveys investigations of head trauma involving altered mechanisms of synaptic plasticity and how trauma may be related to increased risk for dementia.	Cleveland Clin Fdn, Dept Neurol Surg, Cleveland, OH 44195 USA		Albensi, BC (corresponding author), Cleveland Clin Fdn, Dept Neurol Surg, NB20,9500 Euclid Ave, Cleveland, OH 44195 USA.		Albensi, Benedict C/F-7304-2010; Albensi, Benedict Charles/AAJ-2359-2021	Albensi, Benedict Charles/0000-0002-7884-9261; Janigro, Damir/0000-0003-2165-5826			Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Albensi BC, 2000, SYNAPSE, V35, P151; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; BIROS MH, 1991, RESUSCITATION, V22, P283, DOI 10.1016/0300-9572(91)90036-X; BLACK JA, 1992, PROG BRAIN RES, V94, P89; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bruton C., 1988, NEUROPATHOLOGY TEMPO; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DIETZEL I, 1989, GLIA, V2, P25, DOI 10.1002/glia.440020104; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Faden AI., 1994, NEUROBIOLOGY CENTRAL, P3; FADEN AI, 1994, NEUROBIOLOGY CENTRAL, P3; Foster TC, 1999, BRAIN RES REV, V30, P236, DOI 10.1016/S0165-0173(99)00017-X; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Hebb DO, 1949, ORG BEHAV NEUROPSYCH; Holscher C, 1999, J NEUROSCI RES, V58, P62; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Janigro D, 1997, J NEUROSCI, V17, P2813; KUFFLER SW, 1967, PROC R SOC SER B-BIO, V168, P1, DOI 10.1098/rspb.1967.0047; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mesulam MM, 2000, ANN NY ACAD SCI, V924, P42; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; ORKAND R, 1986, ANN NY ACAD SCI, V4, P269; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.0.CO;2-B; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sastry B R, 1990, Adv Exp Med Biol, V268, P377; SASTRY BR, 1988, CAN J PHYSIOL PHARM, V66, P841, DOI 10.1139/y88-135; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; Sontheimer H, 1996, TRENDS NEUROSCI, V19, P325, DOI 10.1016/0166-2236(96)10039-4; SONTHEIMER H, 1994, GLIA, V11, P156, DOI 10.1002/glia.440110210; SONTHEIMER H, 1992, CAN J PHYSIOL PHARM, V70, P223; Stanton PK, 1996, HIPPOCAMPUS, V6, P35, DOI 10.1002/(SICI)1098-1063(1996)6:1<35::AID-HIPO7>3.0.CO;2-6; Toth Z, 1997, J NEUROSCI, V17, P8106; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	53	37	37	0	4	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2003	17	8					653	663		10.1080/0269905031000107142			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	691MF	WOS:000183609500003	12850950				2022-02-06	
J	Santos, JB; Schauwecker, PE				Santos, JB; Schauwecker, PE			Protection provided by cyclosporin A against excitotoxic neuronal death is genotype dependent	EPILEPSIA			English	Article						seizures; mouse strain; kainate; mitochondria; excitotoxicity; resistance	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL-ARTERY OCCLUSION; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; KAINIC ACID; IN-VITRO; IMMUNOSUPPRESSANTS CYCLOSPORINE	Purpose: Previous studies have shown that the immunosuppressant cyclosporin A (CsA), a specific blocker of the mitochondrial permeability transition (MPT) pore, can dramatically ameliorate the selective neuronal necrosis resulting from ischemia-reperfusion, traumatic brain injury, and N-methyl-D-aspartate (NMDA)-evoked neurotoxicity. The purpose of this study was to determine whether two different immunosuppressants, CsA and FK-506, could ameliorate the neuronal damage observed after kainate-induced seizures in strains that are differentially susceptible to excitotoxin-induced cell death. Methods: Excitotoxin-resistant (C57BL/6) or -susceptible (FVB/N) mice were administered kainate alone (30 mg/kg), CsA alone (5, 10, or 20 mg/kg), or one of the immunosuppressants (CsA, 5 mg/kg or 10 mg/kg; FK-506, 0.5 mg/kg) followed by kainate. After drug administration, mice were monitored continuously for the onset and extent of seizure activity. After a survival of 7 days, animals were assessed for hippocampal damage. Results: Whereas CsA alone induced no epileptogenic effects and both immunosuppressants were without effect on the induction of kainate-induced seizures, administration of CsA to excitotoxin-susceptible mice (FVB/N) virtually eliminated neuronal cell death. In contrast, induction of neuronal cell death was evident when CsA was administered to excitotoxin-resistant mice (C57BL/6). Administration of FK-506, another commonly used immunosuppressant, which lacks an effect on the MPT, had no effect on modification of susceptibility to kainate-induced cell death in either strain. Conclusions: As our data show differential protection of hippocampal neurons against excitotoxic cell death by pretreatment with CsA, these results suggest that strain-dependent differences in mitochondrial integrity and function may exist.	Univ So Calif, Dept Cell & Neurobiol, Keck Sch Med, Los Angeles, CA 90089 USA		Schauwecker, PE (corresponding author), Univ So Calif, Dept Cell & Neurobiol, Keck Sch Med, BMT 401,1333 San Pabio St, Los Angeles, CA 90089 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38696-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038696] Funding Source: NIH RePORTER		ADAMS DH, 1987, LANCET, V1, P949; Bernardi P, 1998, BBA-BIOENERGETICS, V1365, P200, DOI 10.1016/S0005-2728(98)00069-3; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Buckman JF, 2001, J NEUROSCI, V21, P5054, DOI 10.1523/JNEUROSCI.21-14-05054.2001; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Budd SL, 1996, J NEUROCHEM, V67, P2282; Butcher SP, 1997, J NEUROSCI, V17, P6939; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CROMPTON M, 1988, BIOCHEM J, V255, P357; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; FRAKLIN KBJ, 1997, MOUSE BRAIN STEREOTA; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LIPTON SA, 1994, BRAIN RES, V547, P344; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Matsuura K, 1996, BRAIN RES, V733, P101, DOI 10.1016/0006-8993(96)00686-5; Mattson Mark P., 1996, V71, P1; Moriwaki A, 1998, NEUROSCIENCE, V86, P855, DOI 10.1016/S0306-4522(98)00071-2; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; NADLER JV, 1980, BRAIN RES, V191, P387, DOI 10.1016/0006-8993(80)91289-5; NADLER JV, 1983, METHOD ENZYMOL, V103, P393; NADLER JV, 1980, BRAIN RES, V195, P47; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; OKONKWO DO, 1999, ARCH BIOCHEM BIOPHYS, V311, P219; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OLNEY JW, 1986, ADV EXPT MED BIOL, P632; PACKER MA, 1995, EUR J BIOCHEM, V234, P231, DOI 10.1111/j.1432-1033.1995.231_c.x; Pierce ET., 1971, ATLAS MOUSE BRAIN SP; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RACUSEN LC, 1990, LIFE SCI, V46, P1021, DOI 10.1016/0024-3205(90)90026-N; ROTHMAN SM, 1992, ANN NY ACAD SCI, V648, P133; Schauwecker PE, 2000, EXP NEUROL, V161, P139, DOI 10.1006/exnr.1999.7251; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Schauwecker PE, 2000, BRAIN RES, V884, P116, DOI 10.1016/S0006-8993(00)02888-2; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SCHINDER AF, 1996, J NEUROSCI, V16, P6126; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHWEIZER M, 1993, BIOCHEM PHARMACOL, V45, P641, DOI 10.1016/0006-2952(93)90138-M; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; Serkova N, 1999, J PHARMACOL EXP THER, V289, P800; Shuttleworth CWR, 2001, J NEUROSCI, V21, P4225, DOI 10.1523/JNEUROSCI.21-12-04225.2001; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; WANG GJ, 1994, J NEUROPHYSIOL, V72, P2563, DOI 10.1152/jn.1994.72.6.2563; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Wong M, 2000, EPILEPSIA, V41, P271, DOI 10.1111/j.1528-1157.2000.tb00155.x; Wszolek ZK, 1997, SEIZURE, V6, P31, DOI 10.1016/S1059-1311(97)80050-7; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3	67	37	38	0	1	BLACKWELL PUBLISHING INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0013-9580			EPILEPSIA	Epilepsia	AUG	2003	44	8					995	1002		10.1046/j.1528-1157.2003.66302.x			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	708VG	WOS:000184590000002	12887430	Bronze			2022-02-06	
J	Boivin, DB; James, FO; Santo, JB; Caliyurt, O; Chalk, C				Boivin, DB; James, FO; Santo, JB; Caliyurt, O; Chalk, C			Non-24-hour sleep-wake syndrome following a car accident	NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; PHASE SYNDROME	The authors report the case of a 39-year-old sighted woman who displayed non-24-hour sleep-wake cycles following a car accident. The phase relationship between endogenous circadian markers such as plasma melatonin and 6-sulfatoxymelatonin rhythms and self-selected sleep times was abnormal. A laboratory investigation indicated that she was sensitive to bright light as a circadian synchronizer. MRI and brain CT scans were normal, but microscopic brain damage in the vicinity of the suprachiasmatic nucleus or its output pathways is plausible.	Douglas Hosp, Res Ctr, Ctr Study & Treatment Circadian Rhythms, Verdun, PQ H4H 1R3, Canada; McGill Univ, Dept Psychiat, Montreal, PQ, Canada; McGill Univ, Montreal Gen Hosp, Dept Neurol & Neurosurg, Montreal, PQ H3G 1A4, Canada		Boivin, DB (corresponding author), Douglas Hosp, Res Ctr, Ctr Study & Treatment Circadian Rhythms, 6875 LaSalle Blvd,Suite F-1127, Verdun, PQ H4H 1R3, Canada.		Caliyurt, Okan/ABE-7339-2020	Caliyurt, Okan/0000-0002-0513-0619			Alexander MP, 1998, NEUROLOGY, V51, P336, DOI 10.1212/WNL.51.2.336; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN RA, 1991, NEUROLOGY, V41, P726, DOI 10.1212/WNL.41.5.726; CZEISLER CA, 1995, NEW ENGL J MED, V332, P6, DOI 10.1056/NEJM199501053320102; McArthur AJ, 1996, SLEEP, V19, P544, DOI 10.1093/sleep/19.7.544; Nagtegaal JE, 1997, FUNCT NEUROL, V12, P345; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; Smits MG, 2000, NEUROLOGY, V55, P902, DOI 10.1212/WNL.55.6.902; Uchiyama M, 2002, SLEEP, V25, P83, DOI 10.1093/sleep/25.1.83	10	37	38	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JUN 10	2003	60	11					1841	1843		10.1212/01.WNL.0000061482.24750.7C			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	688DT	WOS:000183418400027	12796546				2022-02-06	
J	Limbrick, DD; Sombati, S; DeLorenzo, RJ				Limbrick, DD; Sombati, S; DeLorenzo, RJ			Calcium influx constitutes the ionic basis for the maintenance of glutamate-induced extended neuronal depolarization associated with hippocampal neuronal death	CELL CALCIUM			English	Article							EXCITATORY AMINO-ACIDS; LARGE ASPINY INTERNEURONS; INTRACELLULAR CALCIUM; CELL-DEATH; IN-VITRO; STRIATAL NEURONS; CORTICAL-NEURONS; NA+/CA2+ EXCHANGE; RECEPTOR FUNCTION; RAT	Excessive activation of neuronal glutamate receptors has been implicated in the pathophysiology of stroke, epilepsy, and traumatic brain injury. Previously, it has been demonstrated that excitotoxic glutamate exposure results in the induction of an extended neuronal depolarization (END), as well as protracted elevations in free intracellular calcium ([Ca2+](i)). Both END and the prolonged [Ca2+](i) elevations were shown to correlate with subsequent neuronal death. In the current study, we used whole-cell current-clamp electrophysiology and fura-ff Ca2+ imaging to determine the electrophysiological basis of END. We found that removal of extracellular Ca2+ but not Na+ in the post-glutamate period resulted in complete reversal of END, allowing neurons to rapidly repolarize to their initial resting membrane potential (RMP). In addition, removal of extracellular Ca-2+ was sufficient to eliminate the protracted [Ca2+](i) elevations induced by excitotoxic glutamate exposure. To investigate the mechanism through which extracellular Ca-2+ was effecting these changes, pharmacolgical antagonists of well-characterized routes of Ca-2+ entry were tested for their effects on END. Antagonists of glutamate receptors and voltage-gated Ca2+ channels (VGCCs) had no significant effect on the membrane potential of neurons in END. Likewise, inhibitors of the Na+/Ca2+ exchange (NCX) were ineffective. In contrast, addition of 500 muM ZnCl2 or 100 muM GdCl3 to control extracellular medium (containing normal levels of exctracellular Ca2+) in the post-glutamate period resulted in rapid and complete reversal of END. Addition of 1 mM CdCl2 to control medium had only modest effects on END. These data provide the first direct evidence that END induced by excitotoxic glutamate exposure is caused by an influx of extracellular Ca2+ and demonstrate that the previously irreversible condition of END can be reversed by removing extracellular Ca2+. In addition, understanding the electrophysiological basis of this novel Ca2+-induced extended depolarization may provide an insight into the pathophysiology of stroke, traumatic brain injury, and other forms of neuronal injury. (C) 2003 Elsevier Science Ltd. All rights reserved.	Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA		DeLorenzo, RJ (corresponding author), Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.	rdeloren@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS25630, R01-NS23350] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS025630, R01NS023350] Funding Source: NIH RePORTER		Alessandri B, 1998, PROG BRAIN RES, V116, P303, DOI 10.1016/S0079-6123(08)60445-8; Arias C, 1998, Neurobiology (Bp), V6, P33; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Bittigau P, 1997, J CHILD NEUROL, V12, P471, DOI 10.1177/088307389701200802; BOLAND LM, 1991, BRAIN RES, V563, P142, DOI 10.1016/0006-8993(91)91527-8; Borgdorff AJ, 2000, J NEUROPHYSIOL, V83, P81, DOI 10.1152/jn.2000.83.1.81; CALABRESI P, 1995, BRAIN, V118, P1027, DOI 10.1093/brain/118.4.1027; Calabresi P, 1999, STROKE, V30, P1687, DOI 10.1161/01.STR.30.8.1687; Calabresi P, 1997, J NEUROSCI, V17, P1940; Chen QX, 1997, J NEUROSCI, V17, P4032; Chen QX, 1998, J NEUROPHYSIOL, V79, P1124, DOI 10.1152/jn.1998.79.2.1124; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; Coulter D A, 1999, Adv Neurol, V79, P725; COULTER DA, 1992, J NEUROPHYSIOL, V68, P362, DOI 10.1152/jn.1992.68.2.362; deLorenzo RJ, 1998, P NATL ACAD SCI USA, V95, P14482, DOI 10.1073/pnas.95.24.14482; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; DUBINSKY JM, 1993, ANN NY ACAD SCI, V679, P34, DOI 10.1111/j.1749-6632.1993.tb18287.x; DUBINSKY JM, 1993, J NEUROSCI, V13, P623; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; EIMERL S, 1994, J NEUROCHEM, V62, P1223; FLEISCHER JE, 1989, J CEREBR BLOOD F MET, V9, P795, DOI 10.1038/jcbfm.1989.113; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P2139, DOI 10.1152/jn.1997.77.4.2139; GRAHAM SH, 1993, NEUROSCI LETT, V160, P21, DOI 10.1016/0304-3940(93)90907-3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Hoyt KR, 1998, MOL PHARMACOL, V53, P742, DOI 10.1124/mol.53.4.742; Hyrc K, 1997, J NEUROSCI, V17, P6669; Hyrc KL, 1998, CELL CALCIUM, V24, P165, DOI 10.1016/S0143-4160(98)90126-9; Keelan J, 1999, J PHYSIOL-LONDON, V520, P797, DOI 10.1111/j.1469-7793.1999.00797.x; Kim AH, 2000, BRAIN RES, V886, P99, DOI 10.1016/S0006-8993(00)02944-9; KINARD TA, 1995, DIABETES, V44, P1461, DOI 10.2337/diabetes.44.12.1461; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; Limbrick DD, 2001, BRAIN RES, V894, P56, DOI 10.1016/S0006-8993(00)03303-5; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; LONDON RE, 1994, AM J PHYSIOL, V266, pC1313, DOI 10.1152/ajpcell.1994.266.5.C1313; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; Meldrum BS, 1999, EPILEPSY RES, V36, P189, DOI 10.1016/S0920-1211(99)00051-0; MILLER RJ, 1995, BIOCHEM SOC T, V23, P629, DOI 10.1042/bst0230629; MODY I, 1995, TRENDS PHARMACOL SCI, V16, P356, DOI 10.1016/S0165-6147(00)89070-7; Morgans CW, 1998, J NEUROSCI, V18, P2467; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NISHIMURA T, 1995, J AUTONOM NERV SYST, V51, P213, DOI 10.1016/0165-1838(94)00134-6; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Pisani A, 1999, J NEUROPHYSIOL, V81, P2508, DOI 10.1152/jn.1999.81.5.2508; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Read SJ, 1999, DRUG AGING, V14, P11, DOI 10.2165/00002512-199914010-00002; Sacchi O, 1999, J NEUROPHYSIOL, V82, P1662, DOI 10.1152/jn.1999.82.4.1662; Scheyer RD, 1998, PROG BRAIN RES, V116, P359, DOI 10.1016/S0079-6123(08)60448-3; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sherwin AL, 1999, NEUROCHEM RES, V24, P1385, DOI 10.1023/A:1022580506443; Small DL, 1999, PROG CARDIOVASC DIS, V42, P185, DOI 10.1016/S0033-0620(99)70002-2; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; Smothers CT, 1997, J PHARMACOL EXP THER, V283, P1214; SOMBATI S, 1991, BRAIN RES, V566, P316, DOI 10.1016/0006-8993(91)91716-E; SOMBATI S, 1995, J NEUROPHYSIOL, V73, P1706, DOI 10.1152/jn.1995.73.4.1706; Storozhevykh TP, 1996, INT J NEUROSCI, V88, P199, DOI 10.3109/00207459609000615; Stout AK, 1999, NEUROSCIENCE, V89, P91, DOI 10.1016/S0306-4522(98)00441-2; Tanaka E, 1999, J NEUROPHYSIOL, V81, P1872, DOI 10.1152/jn.1999.81.4.1872; Tanaka E, 1997, J NEUROPHYSIOL, V78, P891, DOI 10.1152/jn.1997.78.2.891; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Teasdale GM, 1999, ACT NEUR S, V73, P111; TYMIANSKI M, 1993, BRAIN RES, V607, P319, DOI 10.1016/0006-8993(93)91523-U; Tymianski M, 1996, ADV NEUROL, V71, P85; Vaughan J, 1999, STROKE THERAPY, P3; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WU AF, 1994, J NEUROCHEM, V63, P2136; Yamamoto S, 1997, J NEUROPHYSIOL, V78, P903, DOI 10.1152/jn.1997.78.2.903; Yu SP, 1997, EUR J NEUROSCI, V9, P1273, DOI 10.1111/j.1460-9568.1997.tb01482.x	72	37	40	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0143-4160	1532-1991		CELL CALCIUM	Cell Calcium	FEB	2003	33	2					69	81	PII S0143-4160(02)00054-4	10.1016/S0143-4160(02)00054-4			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	647LL	WOS:000181094200001	12531183				2022-02-06	
J	Kaegi, S; Schwab, ME; Dietz, V; Fouad, K				Kaegi, S; Schwab, ME; Dietz, V; Fouad, K			Electromyographic activity associated with spontaneous functional recovery after spinal cord injury in rats	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						animal model; locomotion; rehabilitation; spinal cord injury	CENTRAL PATTERN GENERATOR; PARAPLEGIC PATIENTS; LOCOMOTOR RECOVERY; WEIGHT SUPPORT; LESIONS; CATS; REGENERATION; MUSCLE; AXONS; DEGENERATION	This investigation was designed to study the spontaneous functional recovery of adult rats with incomplete spinal cord injury (SCI) at thoracic level during a time course of 2 weeks. Daily testing sessions included open field locomotor examination and electromyographic (EMG) recordings from a knee extensor (vastus lateralis, VL) and an ankle flexor muscle (tibialis anterior, TA) in the hindlimbs of treadmill walking rats. The BBB score (a locomotor score named after Basso et al. , 1995, J. Neurotrauma , 12 , 1-21) and various measures from EMG recordings were analysed (i.e. step cycle duration, rhythmicity of limb movements, flexor and extensor burst duration, EMG amplitude, root-mean-square, activity overlap between flexor and extensor muscles and hindlimb coupling). Directly after SCI, a marked drop in locomotor ability occurred in all rats with subsequent partial recovery over 14 days. The recovery was most pronounced during the first week. Significant changes were noted in the recovery of almost all analysed EMG measures. Within the 14 days of recovery, many of these measures approached control levels. Persistent abnormalities included a prolonged flexor burst and increased activity overlap between flexor and extensor muscles. Activity overlap between flexor and extensor muscles might be directly caused by altered descending input or by maladaptation of central pattern generating networks and/or sensory feedback.	Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, CH-8057 Zurich, Switzerland; Univ Zurich, Univ Hosp Balgrist, ParaCare, CH-8008 Zurich, Switzerland		Fouad, K (corresponding author), Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2G4, Canada.		Schwab, Martin E/B-6818-2016	Fouad, Karim/0000-0003-3654-7852			BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BASSO DM, 1994, RESTOR NEUROL NEUROS, V7, P95, DOI 10.3233/RNN-1994-7205; Brustein E, 1998, J NEUROPHYSIOL, V80, P1245, DOI 10.1152/jn.1998.80.3.1245; CAZALETS JR, 1995, J NEUROSCI, V15, P4943; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; de Leon RD, 1999, J NEUROPHYSIOL, V82, P359, DOI 10.1152/jn.1999.82.1.359; DIETZ V, 1995, ANN NEUROL, V37, P574, DOI 10.1002/ana.410370506; DIETZ V, 1981, BRAIN, V104, P431, DOI 10.1093/brain/104.3.431; DIETZ V, 1994, LANCET, V344, P1260, DOI 10.1016/S0140-6736(94)90751-X; Dietz V, 1998, SPINAL CORD, V36, P380, DOI 10.1038/sj.sc.3100590; EDGERTON RV, 1983, SPINAL CORD RECONSTR, P435; Edgerton V R, 1997, Adv Neurol, V72, P233; EIDELBERG E, 1981, EXP BRAIN RES, V42, P81; Fagerstedt P, 2000, EXP BRAIN RES, V134, P147, DOI 10.1007/s002210000455; Fouad K, 1997, NEUROSCI LETT, V236, P9, DOI 10.1016/S0304-3940(97)00756-8; Fouad K, 2001, CURR BIOL, V11, P1766, DOI 10.1016/S0960-9822(01)00535-8; FUNG J, 1989, ELECTROEN CLIN NEURO, V73, P233, DOI 10.1016/0013-4694(89)90124-7; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Giszter SF, 1998, J NEUROPHYSIOL, V80, P3021, DOI 10.1152/jn.1998.80.6.3021; GOLDBERGER ME, 1977, BRAIN RES, V123, P59, DOI 10.1016/0006-8993(77)90643-6; Gomez-Pinilla F, 2001, EUR J NEUROSCI, V13, P1078, DOI 10.1046/j.0953-816x.2001.01484.x; Gorska T, 1996, ACTA NEUROBIOL EXP, V56, P177; GRILLNER S, 1978, BRAIN RES, V146, P269, DOI 10.1016/0006-8993(78)90973-3; GRILLNER S, 1985, ANNU REV NEUROSCI, V8, P233, DOI 10.1146/annurev.ne.08.030185.001313; GRILLNER S, 1995, TRENDS NEUROSCI, V18, P270, DOI 10.1016/0166-2236(95)93914-J; Grillner S, 1998, BRAIN RES REV, V26, P184, DOI 10.1016/S0165-0173(98)00002-2; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797, DOI 10.1152/jn.1997.77.2.797; HELGREN ME, 1993, EXP NEUROL, V123, P17, DOI 10.1006/exnr.1993.1137; Hiersemenzel LP, 2000, NEUROLOGY, V54, P1574, DOI 10.1212/WNL.54.8.1574; Hill CE, 2001, EXP NEUROL, V171, P153, DOI 10.1006/exnr.2001.7734; Holaday J W, 1983, Adv Shock Res, V10, P95; Jiang W, 1996, J NEUROPHYSIOL, V76, P849, DOI 10.1152/jn.1996.76.2.849; Kiehn O, 1996, J NEUROPHYSIOL, V75, P1472, DOI 10.1152/jn.1996.75.4.1472; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; Loy DN, 2002, J NEUROSCI, V22, P315, DOI 10.1523/JNEUROSCI.22-01-00315.2002; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; MORI S, 1992, BRAIN DEV S, V14, P109; NOGA BR, 1991, J NEUROSCI, V11, P1691; Pearson KG, 2001, J PHYSIOL-LONDON, V533, P75, DOI 10.1111/j.1469-7793.2001.0075b.x; PEARSON KG, 1993, ANNU REV NEUROSCI, V16, P265, DOI 10.1146/annurev.ne.16.030193.001405; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; Rossignol S, 1999, PROG BRAIN RES, V123, P349, DOI 10.1016/S0079-6123(08)62870-8; Salgado-Ceballos H, 1998, BRAIN RES, V782, P126; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61; Whishaw IQ, 1998, BEHAV BRAIN RES, V93, P167, DOI 10.1016/S0166-4328(97)00152-6	52	37	37	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JUL	2002	16	2					249	258		10.1046/j.1460-9568.2002.02076.x			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	582RB	WOS:000177364000008	12169107				2022-02-06	
J	Gurkin, MA; Parikshak, M; Kralovich, KA; Horst, HM; Agarwal, V; Payne, N				Gurkin, MA; Parikshak, M; Kralovich, KA; Horst, HM; Agarwal, V; Payne, N			Indicators for tracheostomy in patients with traumatic brain injury	AMERICAN SURGEON			English	Article; Proceedings Paper	44th Annual Meeting of the Midwest-Surgical-Association	AUG 12-15, 2001	LAKE GENEVA, WI	Midwest Surg Assoc			GLASGOW COMA SCALE; MECHANICAL VENTILATION; HEAD-INJURY; MANAGEMENT; PREDICTION; SCORE	Our objective was to develop criteria to identify patients with traumatic brain injury (TBI) who require a tracheostomy (TR). From January 1994 to May 2000 all TBI patients requiring intubation on presentation and who survived >7 days were identified from our trauma registry. Demographics, Glasgow Coma Score (GCS), Injury Severity Score (ISS), and ventilator days, ICU days, hospital days, need for TR, and development of pneumonia were statistically analyzed. Of 246 patients with TBI 211 without TR and 35 with TR were identified (mean time to TR 13.3 +/- 7.0 days). Logistic regression analysis identified presenting GCS less than or equal to8, ISS greater than or equal to25, and ventilator days >7 as significant predictors for TR. Applying these three predictors to our population identified 48 patients (21 with TR, 18 without TR, and nine who died on the ventilator without TR) with a sensitivity of 60 per cent, a specificity of 87 per cent, a positive predictive value of 44 per cent, and a negative predictive value of 93 per cent. Patients with TR had lower presenting GCS and higher ventilator, ICU, and hospital days (P < 0.05). Pneumonia rates were similar. Time to neurologic recovery (GCS >= 9) was longer for the TR patients as compared with the patients without TR. We conclude that patients with TBI presenting with a GCS <= 8, an ISS >= 25, and ventilator days >7 are more likely to require TR. Performing TR late did not reduce pneumonia rates or ventilator, ICU, or hospital days. By identifying the at-risk population early TR could be performed in an attempt to decrease morbidity and length of stay.	Henry Ford Hosp, Div Trauma & Crit Care, Detroit, MI 48202 USA		Horst, HM (corresponding author), Henry Ford Hosp, Div Trauma & Crit Care, Clara Ford Pavil,4th Floor,2799 W Grand Blvd, Detroit, MI 48202 USA.						DAMELIO LF, 1994, AM SURGEON, V60, P180; Gibbons KJ, 2000, CRIT CARE MED, V28, P1663, DOI 10.1097/00003246-200005000-00076; GORDON E, 1995, J NEUROSURG ANESTH, V7, P235, DOI 10.1097/00008506-199510000-00001; HEFFNER JE, 1993, AM REV RESPIR DIS, V147, P768, DOI 10.1164/ajrccm/147.3.768; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; Koh WY, 1997, ANAESTH INTENS CARE, V25, P365, DOI 10.1177/0310057X9702500407; LESNIK I, 1992, AM SURGEON, V58, P346; MARSH HM, 1989, CHEST, V96, P190, DOI 10.1378/chest.96.1.190; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PLUMMER AL, 1989, CHEST, V96, P178, DOI 10.1378/chest.96.1.178; Qureshi AI, 2000, CRIT CARE MED, V28, P1383, DOI 10.1097/00003246-200005000-00020; RODRIGUEZ JL, 1990, SURGERY, V108, P655; Scheinhorn DJ, 1998, CRIT CARE CLIN, V14, P819, DOI 10.1016/S0749-0704(05)70032-4	14	37	41	0	2	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	APR	2002	68	4					324	328					5	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	536DE	WOS:000174684800005	11952241				2022-02-06	
J	Thomale, UW; Kroppenstedt, SN; Beyer, TF; Schaser, KD; Unterberg, AW; Stover, JF				Thomale, UW; Kroppenstedt, SN; Beyer, TF; Schaser, KD; Unterberg, AW; Stover, JF			Temporal profile of cortical perfusion and microcirculation after controlled cortical impact injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; contusion; intravital microscopy; laser doppler flowmetry; orthogonal polarization spectral imaging; secondary injury; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; EXPERIMENTAL HEAD-INJURY; LASER-DOPPLER FLOWMETRY; NITRIC-OXIDE; CEREBROSPINAL-FLUID; CONTUSION VOLUME; L-ARGININE; GLUTAMATE; NECROSIS	Impaired cerebral perfusion contributes to evolving posttraumatic tissue damage. Spontaneous reversibility of reduced perfusion within the first days after injury could make a persisting impact on secondary tissue damage less likely and needs to be considered for possible therapeutic approaches. The present study was designed to characterize the temporal profile and impact of trauma severity on cortical perfusion and microcirculation during the first 48 h after controlled cortical impact injury (CCI). In 10 rats, pericontusional cortical perfusion and microcirculation using laser Doppler flowmetry (LDF) and orthogonal polarization spectral (OPS) imaging were assessed before, and at 4, 24, and 48 h after CCI. Influence of trauma severity was studied by varying the penetration depth of the impactor rod (0.5 vs. 1 mm), thereby inducing a less and a more severe contusion. Mean arterial blood pressure (MABP), arterial blood gases, and blood glucose were monitored. With unchanged MABP and paCO(2), cortical perfusion and microcirculation were significantly impaired during the first 48 h following CCI. Hypoperfusion observed at 4 h related to vasoconstriction and microcirculatory stasis preceded a long-lasting phase of hyperperfusion at 24 and 48 h reflected by vasodilation and increased flow velocity in arterioles and venules. Hyperperfusion was mostly pronounced in rats with a less severe contusion. Following CCI, trauma severity markedly influences changes in pericontusional cortical perfusion and microcirculation. Overall, pericontusional cortical hypoperfusion observed within the early phase preceded a long lasting phase of hyperperfusion up to 48 h after CCI.	Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, D-13353 Berlin, Germany; Humboldt Univ, Virchow Med Ctr, Charite, Dept Trauma & Reconstruct Surg, D-13353 Berlin, Germany; Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA		Thomale, UW (corresponding author), Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	uthomale@charite.de					Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BAEZ S, 1977, MICROCIRCULATION, P23; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658; Fabricius M, 1997, J CEREBR BLOOD F MET, V17, P1326, DOI 10.1097/00004647-199712000-00008; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; Groner W, 1999, NAT MED, V5, P1209, DOI 10.1038/13529; Harris AG, 2000, J VASC RES, V37, P469, DOI 10.1159/000054079; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; HEIMANN A, 1994, J CEREBR BLOOD F MET, V14, P1100, DOI 10.1038/jcbfm.1994.144; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KEMPSKI OS, 1994, ACTA NEUROCHIR, P7; Klyscz T, 1997, BIOMED TECH, V42, P168, DOI 10.1515/bmte.1997.42.6.168; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Maeda T, 1997, ACT NEUR S, V70, P102; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Stover JF, 2000, J NEUROTRAUM, V17, P1171, DOI 10.1089/neu.2000.17.1171; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; THOMALE UW, J NEUROSCI METHODS, V108, P85; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZWEIFACH BW, 1974, CIRC RES, V34, P843, DOI 10.1161/01.RES.34.6.841	48	37	37	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2002	19	4					403	413		10.1089/08977150252932361			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	542XP	WOS:000175071200002	11990347	Green Accepted			2022-02-06	
J	Givner, A; Gurney, J; O'Connor, D; Kassarjian, A; LaMorte, WW; Moulton, S				Givner, A; Gurney, J; O'Connor, D; Kassarjian, A; LaMorte, WW; Moulton, S			Reimaging in pediatric neurotrauma: Factors associated with progression of intracranial injury	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	32nd Annual Meeting of the American-Pediatric-Surgical-Association	MAY 20-23, 2001	NAPLES, FL	Amer Pediatr Surg Assoc		pediatric trauma; craniocerebral trauma; head injury; computed tomography; craniotomy	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; BRAIN INJURY; TRAUMA; CHILDREN; PREDICTORS; MODERATE; HEMATOMA	Purpose: The purpose of this study was to characterize the radiologic changes that are seen in the first 24 to 48 hours after head injury and to correlate those changes with clinical findings, to determine which children are at greatest risk for progression of their neurologic injury. Methods: The authors identified 104 children (less than or equal to17 years of age) who had a second computed tomography (CT) scan of the head within 24 to 48 hours of admission. CT scans were evaluated systematically in a blinded fashion. Mechanism of injury, findings on physical examination, therapeutic measures, and changes in management were recorded from hospital medical records. The 50 children whose second CT scan showed progression of injury were compared with the 54 patients whose intracranial injuries were unchanged or improved on their second CT. Results: Twenty-six percent of patients (13 of 50) with radiographic progression of injury had an admission Glasgow coma score of 15. Progression of injury was more common, however, in patients with lower Glasgow coma scores, averaging 9 on admission and 10 at the time of the second CT. Progression of injury also was more common if the initial head CT showed 3 or more intracranial injuries, mass effect, intraventricular hemorrhage, or an epidural hematoma. Conclusions: Children with an intracranial injury identified on their initial head CT scan should undergo a second scan 24 hours after injury, especially if the initial CT shows 3 or more intracranial injuries, mass effect, intraventricular hemorrhage, or an epidural hematoma. J Pediatr Surg 37:381-385. Copyright (C) 2002 by W.B. Saunders Company.	Walter Reed Army Med Ctr, Dept Surg, Boston, MA USA; Boston Univ, Sch Med, Dept Radiol, Div Neuroradiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Radiol, Div Pediat Surg, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Surg, Div Pediat Surg, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Surg, Div Neuroradiol, Boston, MA 02118 USA		Moulton, S (corresponding author), Dowling 2419,1 Boston Med Ctr Pl, Boston, MA 02118 USA.			Kassarjian, Ara/0000-0002-9969-3227; LaMorte, Wayne/0000-0002-7813-9809			BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; BROWN FD, 1978, J NEUROSURG, V48, P1019, DOI 10.3171/jns.1978.48.6.1019; BRUNETTI J, 1979, NEURORADIOLOGY, V18, P43, DOI 10.1007/BF00346211; JAIMOVICH R, 1992, PEDIATR NEUROSURG, V17, P25, DOI 10.1159/000120562; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; LUERSSEN TG, 1995, PEDIATR NEUROSURG, V23, P34, DOI 10.1159/000120933; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; WINCHELL RJ, 1995, ANN EMERG MED, V25, P737, DOI 10.1016/S0196-0644(95)70200-8	16	37	38	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	MAR	2002	37	3					381	385		10.1053/jpsu.2002.30825			5	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pediatrics; Surgery	526ZZ	WOS:000174160700024	11877652				2022-02-06	
J	Harter, L; Keel, M; Hentze, H; Leist, M; Ertel, W				Harter, L; Keel, M; Hentze, H; Leist, M; Ertel, W			Caspase-3 activity is present in cerebrospinal fluid from patients with traumatic brain injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						apoptosis; neurons; trauma; brain; DEVD-afc; zVAD	DEATH	Loss of neurons after traumatic brain injury (TBI) might involve dysregulated. apoptosis. Activation of caspase-3 is one hallmark of apoptosis. Therefore, caspase-3 activity (cleavage of DEVD-afc) was measured in cerebrospinal fluid (CSF) samples (n = 113) from 27 patients with TBI at day I t0 14 after trauma. Caspase-3 activity was detected in 31 (27.4%) CSF samples with-highest values (> 5.5 41 muM/min) seen at day 2-5 after trauma. No caspase-3 activity was found in serum from patients or CSF from controls. The presence of activated caspase-3 in CSF suggests ongoing apoptotic processes during traumatic brain injury. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Zurich Hosp, Dept Trauma Surg, CH-8091 Zurich, Switzerland; Inst Mol & Cell Biol, Singapore 117609, Singapore; H Lundbeck & Co AS, DK-2500 Valby, Denmark		Harter, L (corresponding author), Univ Zurich Hosp, Dept Trauma Surg, CH-8091 Zurich, Switzerland.		Leist, Marcel/D-2133-2010	Leist, Marcel/0000-0002-3778-8693			Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1998, Results Probl Cell Differ, V24, P105; Love S, 2000, NEUROPATH APPL NEURO, V26, P55, DOI 10.1046/j.1365-2990.2000.00218.x; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; RINK A, 1995, AM J PATHOL, V147, P1575; STOCKER R, 1995, UPD INT CAR, V22, P196; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615	9	37	39	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	DEC 3	2001	121	1-2					76	78		10.1016/S0165-5728(01)00409-X			3	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	508NJ	WOS:000173095100010	11730942	Green Submitted			2022-02-06	
J	Aoki, M; Tamatani, M; Taniguchi, M; Yamaguchi, A; Bando, Y; Kasai, K; Miyoshi, Y; Nakamura, Y; Vitek, MP; Tohyama, M; Tanaka, H; Sugimoto, H				Aoki, M; Tamatani, M; Taniguchi, M; Yamaguchi, A; Bando, Y; Kasai, K; Miyoshi, Y; Nakamura, Y; Vitek, MP; Tohyama, M; Tanaka, H; Sugimoto, H			Hypothermic treatment restores glucose regulated protein 78 (GRP78) expression in ischemic brain	MOLECULAR BRAIN RESEARCH			English	Article						hypothermia; GRP78; neuroprotection; hippocampal neuron	FOCAL CEREBRAL-ISCHEMIA; GERBIL HIPPOCAMPUS; MILD HYPOTHERMIA; TRANSIENT ISCHEMIA; OXIDATIVE STRESS; NEURONAL DEATH; MESSENGER-RNA; RAT-BRAIN; APOPTOSIS; TEMPERATURE	Mild hypothermia is a well-known method of reducing brain damage caused by traumatic, hypoxic, and ischemic injury. To elucidate the neuroprotective mechanism induced by hypothermic treatment, we compared gene expression profiles in the hippocampus of gerbils rendered ischemic for 15 min and then reperfused for 3 h under conditions of normothermia (37 +/-0.5 degreesC) or hypothermic treatment (34 +/-0.5 degreesC). Using the differential display method, we observed significantly reduced expression of the 78 kDa glucose regulated protein (GRP78), in ischemic gerbil hippocampus that underwent normothermic reperfusion, but normal GRP78 expression in animals that underwent hypothermic reperfusion. In situ hybridization and Northern blot analysis showed GRP78 mRNA expression was reduced in the CAI region of the hippocampus under normothermic conditions, but was not reduced under hypothermic conditions. Western blot analysis also showed the levels of immunoreactive GRP78 protein decreased in neurons of the hippocampal CA-1 region under normothermia, but not under hypothermic treatments. Furthermore, adenovirus-mediated overexpression of GRP78 protects rat hippocampal neurons from cell death and inhibits the rise in intracellular calcium concentration normally induced by hydrogen peroxide. These results suggest that reduction in GRP78 expression contributes to cell damage in the ischemic brain and that hypothermia-mediated restoration of GRP78 expression is one mechanism that enhances neuronal survival. (C) 2001 Published by Elsevier Science B.V.	Osaka Univ, Grad Sch Med, Dept Traumatol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Clin Genet, Suita, Osaka 5650871, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA		Tanaka, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Traumatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Vitek, Michael/0000-0001-8140-8048			BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARDELL M, 1991, J NEUROCHEM, V57, P1814, DOI 10.1111/j.1471-4159.1991.tb06387.x; CHOI DW, 1993, RES P ARNMD, V71, P23; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CHURN SB, 1990, STROKE, V21, P1715, DOI 10.1161/01.STR.21.12.1715; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; HIGASHI T, 1994, BRAIN RES, V650, P239, DOI 10.1016/0006-8993(94)91787-6; KATO H, 1994, BRAIN RES, V634, P235, DOI 10.1016/0006-8993(94)91926-7; KAWAGOE J, 1993, BRAIN RES, V621, P121, DOI 10.1016/0006-8993(93)90306-8; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Liang P, 1997, J CELL SCI, V110, P1431; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Mattson MP, 1996, ADV NEUROL, V71, P1; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; NOWAK TS, 1985, J NEUROCHEM, V45, P1635, DOI 10.1111/j.1471-4159.1985.tb07236.x; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; TAKEDA A, 1994, BRAIN RES, V666, P120, DOI 10.1016/0006-8993(94)90292-5; Tamatani M, 2000, J NEUROCHEM, V75, P683, DOI 10.1046/j.1471-4159.2000.0750683.x; Tanaka T, 2000, AM J PATHOL, V156, P2149, DOI 10.1016/S0002-9440(10)65085-7; Wagstaff MJD, 1996, MOL BRAIN RES, V42, P236, DOI 10.1016/S0169-328X(96)00127-1; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002	32	37	41	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	NOV 1	2001	95	1-2					117	128		10.1016/S0169-328X(01)00255-8			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	494RH	WOS:000172299300013	11687283				2022-02-06	
J	Ray, SK; Matzelle, DD; Wilford, GG; Hogan, EL; Banik, NL				Ray, SK; Matzelle, DD; Wilford, GG; Hogan, EL; Banik, NL			Inhibition of calpain-mediated apoptosis by E-64 d-reduced immediate early gene (IEG) expression and reactive astrogliosis in the lesion and penumbra following spinal cord injury in rats	BRAIN RESEARCH			English	Article						spinal cord injury; E-64-d; calpain-cleaved alpha-fodrin; immediate early gene; reactive astrogliosis; apoptosis	PROGRAMMED CELL-DEATH; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN INJURY; ACTIVATED NEUTRAL PROTEASE; CENTRAL-NERVOUS-SYSTEM; C-FOS; NEURONAL APOPTOSIS; OXIDATIVE STRESS; MESSENGER-RNA; ENDOGENOUS INHIBITOR	Upregulation of calpain, a Ca2+ -activated cysteine protease, has been implicated in apoptosis and tissue degeneration in spinal cord injury (SCI) that over time spreads from the site of injury to the surrounding regions. We examined calpain content and activity, regulation of immediate early genes (IEGs) such as c-jun and c-fos, reactive astrogliosis as the expression of glial fibrillary acidic protein (GFAP), and apoptosis-related features such as caspase-3 mRNA expression and internucleosomal DNA fragmentation in 1-cm long spinal cord segments (S1, distant rostral; S2, adjacent rostral; S3, lesion or injury; S4, adjacent caudal; and S5, distant caudal) following SCI in rats. Calpain content and production of 150 kD calpain-cleaved alpha -fodrin fragment, expression of IEGs, reactive astrogliosis, and apoptotic features were highly increased in the lesion (S3), moderately in adjacent areas (S2 and S4), and slightly in distant areas (SI and S5) in SO rats when compared to sham animals. Administration of the calpain- specific inhibitor E-64-d (1 mg/kg) to SCI rats continuously for 24 h inhibited calpain activity and other factors contributing to apoptosis in the lesion and surrounding areas, indicating that calpain played a key role in the pathophysiology of SCI. The results obtained from this animal model of SCI suggest that calpain inhibitor can provide neuroprotection in patients with SCI. (C) 2001 Published by Elsevier Science B.V.	Med Univ S Carolina, Dept Neurol, Charleston, SC 29425 USA		Banik, NL (corresponding author), Med Univ S Carolina, Dept Neurol, 96 Jonathan Lucas St,Suite 309,POB 250606, Charleston, SC 29425 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-38146, NS-31622, NS-41088] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041088, R01NS031622, R01NS038146] Funding Source: NIH RePORTER		Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Arnold PM, 2000, J NEUROCHEM, V74, pS73; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; BANIK NL, 1985, J NEUROCHEM, V45, P581, DOI 10.1111/j.1471-4159.1985.tb04026.x; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Blomgren K, 1999, J BIOL CHEM, V274, P14046, DOI 10.1074/jbc.274.20.14046; BONDY SC, 1993, FREE RADICAL BIO MED, V14, P633, DOI 10.1016/0891-5849(93)90144-J; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CHAKRABARTI AK, 1988, J NEUROSCI RES, V20, P351, DOI 10.1002/jnr.490200309; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Chen J, 1998, J NEUROSCI, V18, P4914; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; CURRAN T, 1987, ONCOGENE, V2, P79; CURTIS CR, 1990, J AM VET MED ASSOC, V197, P838; DRAGUNOW M, 1994, MOL BRAIN RES, V25, P19, DOI 10.1016/0169-328X(94)90274-7; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FEINSTEIN DL, 1992, J NEUROSCI RES, V32, P1, DOI 10.1002/jnr.490320102; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HERRERA DG, 1990, NEUROSCIENCE, V35, P273, DOI 10.1016/0306-4522(90)90081-E; Juan TSC, 1996, ONCOGENE, V13, P749; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; KOISTINAHO J, 1993, NEUROREPORT, V4, P37, DOI 10.1097/00001756-199301000-00009; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Liu XZ, 1997, J NEUROSCI, V17, P5395; MANN MD, 1991, LAB ANIM SCI, V41, P6; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MCGOWAN EB, 1989, BIOCHEM BIOPH RES CO, V158, P432, DOI 10.1016/S0006-291X(89)80065-8; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Metz GAS, 2000, J NEUROTRAUM, V17, P1, DOI 10.1089/neu.2000.17.1; MILLIGAN CE, 1994, J NEUROBIOL, V25, P1005, DOI 10.1002/neu.480250809; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; MOTSENBOCKER MA, 1988, J BIOLUM CHEMILUM, V2, P9, DOI 10.1002/bio.1170020104; NAGAO S, 1994, J BIOCHEM, V115, P1178, DOI 10.1093/oxfordjournals.jbchem.a124476; NAKAMURA M, 1989, BIOCHEMISTRY-US, V28, P449, DOI 10.1021/bi00428a007; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NEUMANHAEFELIN T, 1994, J CEREB BLOOD FLOW M, V4, P206; Ni BH, 1998, J CEREBR BLOOD F MET, V18, P248, DOI 10.1097/00004647-199803000-00003; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; O'CALLAGHAN J P, 1991, Biomedical and Environmental Sciences, V4, P197; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Park DS, 1998, J NEUROSCI, V18, P830; PENNYPACKER KR, 1994, J NEUROSCI, V14, P3998; PERSSON H, 1991, NEUROSCI LETT, V130, P81, DOI 10.1016/0304-3940(91)90232-I; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Ray SK, 2000, NEUROCHEM RES, V25, P1191, DOI 10.1023/A:1007631826160; Ray SK, 2000, BRAIN RES PROTOC, V5, P305, DOI 10.1016/S1385-299X(00)00027-1; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; Ray SK, 1999, BRAIN RES, V816, P375, DOI 10.1016/S0006-8993(98)01128-7; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; Reier P.J., 1986, ASTROCYTES, V3, P263; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; SAKAI M, 1989, CANCER RES, V49, P5633; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; Tong LQ, 1998, J NEUROCHEM, V71, P447; Vanderluit JL, 2000, EUR J NEUROSCI, V12, P3469, DOI 10.1046/j.1460-9568.2000.00241.x; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	85	37	44	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 19	2001	916	1-2					115	126		10.1016/S0006-8993(01)02874-8			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	486HL	WOS:000171812300014	11597598				2022-02-06	
J	Schmidt, RH; Scholten, KJ; Maughan, PH				Schmidt, RH; Scholten, KJ; Maughan, PH			Cognitive impairment and synaptosomal choline uptake in rats following impact acceleration injury	JOURNAL OF NEUROTRAUMA			English	Article						cholinergic neurons; choline uptake; impact acceleration injury; learning and memory; traumatic brain injury; water maze	TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION INJURY; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD-INJURY; MORRIS WATER MAZE; ACETYLCHOLINE SYNTHESIS; EVOKED RELEASE; DEFICITS; MEMORY; ACETYLTRANSFERASE	Traumatic brain injury is well known to cause deficits in learning and memory, which typically improve with time. Animal studies with fluid percussion or controlled cortical impact injury have identified transient disturbances in forebrain cholinergic innervation which may contribute to such cognitive problems, This study examines the extent to which water maze performance and forebrain synaptosomal choline uptake are affected one week after injury using the newly developed impact acceleration injury model. Injury or sham injury was delivered to adult male Sprague-Dawley rats under halothane anesthesia using a 500-g 2,1-m weight drop. Based on righting reflex, injured rats were divided irate moderate (less than or equal to 12 min) or severe (>12 min) groups. Water maze testing was performed on days 5-7 postinjury, On day 7, choline uptake was determined in synaptosomes from hippocamppus, a parietal cortex, and entorhinal cortex. Maze learning was severely impaired in the severe injury group but not in the moderate injury group. Learning retention was slightly impaired in the moderate injury group and severely affected in the severe injury group. There was a very strong correlation between the severity of injury as determined by prolongation of righting times and disruption of maze learning at 1 week postinjury, There was no change in synaptosomal choline uptake in any of the forebrain regions in the severe injury group, but a slight (14%) decrease in the hippocampus and parietal cortex of the moderate injury group. Correlation analysis showed no relationship between synaptosomal choline uptake in any brain region and performance in either water maze learning or retention. This study shows that the impact acceleration model produces cognitive impairments equivalent to those seen with fluid percussion injury and controlled cortical impact. Compared with those models, the impact acceleration model does not produce a similar disruption of forebrain cholinergic nerve terminals.	Univ Utah, Dept Neurosurg, Salt Lake City, UT 84132 USA		Schmidt, RH (corresponding author), Univ Utah, Dept Neurosurg, 50 N Med Dr, Salt Lake City, UT 84132 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01866] Funding Source: Medline		BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; COOPER JR, 1994, J NEUROCHEM, V63, P395; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DACY RG, 1993, HEAD INJURY, P159; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon C. E., 1995, Society for Neuroscience Abstracts, V21, P762; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, PSYCHOLOGICAL EFFECT; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAYES RL, 1992, J HEAD TRAUMA REHAB, V7, P16; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; JOPE RS, 1979, BRAIN RES REV, V1, P313, DOI 10.1016/0165-0173(79)90009-2; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LAPCHAK PA, 1988, J NEUROCHEM, V50, P58, DOI 10.1111/j.1471-4159.1988.tb13229.x; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Levin H., 1987, HEAD INJURY, P442; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; SHAPIRO SM, 1993, MINOR HEAD TRAUMA, P1; SIMON JR, 1976, J NEUROCHEM, V26, P909, DOI 10.1111/j.1471-4159.1976.tb06472.x; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	47	37	40	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2000	17	12					1129	1139		10.1089/neu.2000.17.1129			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	379MB	WOS:000165644900002	11186227				2022-02-06	
J	Del Bigio, MR				Del Bigio, MR			Calcium-mediated proteolytic damage in white matter of hydrocephalic rats?	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	29th Annual Meeting of the Society-for-Neuroscience	OCT 23-28, 1999	MIAMI BEACH, FLORIDA	Soc Neurosci		axon; calpain; hydrocephalus; kaolin; proteolytic enzyme	TRAUMATIC BRAIN INJURY; KAOLIN-INDUCED HYDROCEPHALUS; FOCAL CEREBRAL-ISCHEMIA; INDUCED AXONAL INJURY; IMMATURE RATS; CALPAIN-I; NEONATAL HYDROCEPHALUS; CEREBROSPINAL-FLUID; SPINAL-CORD; CELL-DEATH	Hydrocephalus is a pathological dilatation of the cerebrospinal fluid (CSF)-containing ventricles of the brain. Damage to periventricular white matter is multifactorial with contributions by chronic ischemia and gradual physical distortion. Acute ischemic and traumatic brain injuries are associated with calcium-dependent activation of proteolytic enzymes. We hypothesized that hydrocephalus is associated with calcium ion accumulation and proteolytic enzyme activation in cerebral white matter Hydrocephalus was induced in immature and adult rats by injection of kaolin into the cisterna magna and several different experimental approaches were used. Using the glyoxal bis (2-hydroxyanil) method, free calcium ion was detected in periventricular white matter at sites of histological injury. Western blot determinations showed accumulation of calpain I (mu -calpain) and immunoreactivity for calpain I was increased in periventricular axons of young hydrocephalic rats. Proteolytic cleavage of a fluorogenic calpain substrate was demonstrated in white matter. Immunoreactivity for spectrin breakdown products was detected in scattered callosal axons of young hydrocephalic rats. The findings support the hypothesis that periventricular white matter damage associated with experimental hydrocephalus is due, at least in part, to calcium-activated proteolytic processes. This may have implications for supplemental drug treatments of this disorder.	Univ Manitoba, Dept Pathol, Winnipeg, MB R3E 0W3, Canada		Del Bigio, MR (corresponding author), Univ Manitoba, Dept Pathol, D212-770 Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.			Del Bigio, Marc/0000-0001-8366-0394			BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BENUCK M, 1993, LIFE SCI, V52, P877, DOI 10.1016/0024-3205(93)90517-7; Blomgren K, 1997, ANN NY ACAD SCI, V825, P104, DOI 10.1111/j.1749-6632.1997.tb48420.x; BRUNI JE, 1985, BRAIN RES REV, V9, P1, DOI 10.1016/0165-0173(85)90016-5; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CLARK G, 1981, STAINING PROCEDURES, P188; Del Bigio MR, 1998, EXP NEUROL, V154, P157, DOI 10.1006/exnr.1998.6922; DelBigio MR, 1997, J NEUROPATH EXP NEUR, V56, P1053, DOI 10.1097/00005072-199709000-00010; DelBigio MR, 1997, EXP NEUROL, V148, P256, DOI 10.1006/exnr.1997.6644; DELBIGIO MR, 1989, NEUROSURGERY, V25, P416, DOI 10.1227/00006123-198909000-00016; DELBIGIO MR, 1995, GLIA, V14, P1, DOI 10.1002/glia.440140102; DELBIGIO MR, 1993, ACTA NEUROPATHOL, V85, P573, DOI 10.1007/BF00334666; Frim DM, 1998, NEUROSURG CLIN N AM, V9, P105; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Hansen AR, 1998, NEUROSURG CLIN N AM, V9, P95; HOCHWALD GM, 1985, P SOC EXP BIOL MED, V178, P1; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KASHIWA HK, 1963, J HISTOCHEM CYTOCHEM, V11, P258, DOI 10.1177/11.2.258; KASHIWA HK, 1970, CLIN ORTHOP RELAT R, P200; KEEP RF, 1989, J NEUROL SCI, V91, P119, DOI 10.1016/0022-510X(89)90081-6; KENESSEY A, 1991, NEUROCHEM RES, V16, P1001, DOI 10.1007/BF00965843; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Li JH, 1998, MOL BRAIN RES, V53, P174, DOI 10.1016/S0169-328X(97)00295-7; LI ZH, 1995, BRAIN RES, V697, P112; Liebetrau M, 1999, NEUROREPORT, V10, P529, DOI 10.1097/00001756-199902250-00016; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASLIAH E, 1990, BRAIN RES, V531, P36, DOI 10.1016/0006-8993(90)90755-Z; Massicotte EM, 2000, J NEUROSURG, V92, P442, DOI 10.3171/jns.2000.92.3.0442; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister JP, 1998, NEUROSURG CLIN N AM, V9, P73; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SEUBERT P, 1988, BRAIN RES, V459, P226, DOI 10.1016/0006-8993(88)90638-5; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Stys PK, 1996, NEUROSCIENCE, V71, P27, DOI 10.1016/0306-4522(95)00430-0; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Thompson VF, 2000, BIOCHEM BIOPH RES CO, V267, P495, DOI 10.1006/bbrc.1999.2001; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Wells GJ, 1998, EXPERT OPIN THER PAT, V8, P1707, DOI 10.1517/13543776.8.12.1707; WOLTERS GHJ, 1979, HISTOCHEMISTRY, V62, P137, DOI 10.1007/BF00493315; WOLTERS GHJ, 1979, HISTOCHEMISTRY, V62, P1, DOI 10.1007/BF00537002; Yam PS, 1998, J NEUROTRAUM, V15, P441, DOI 10.1089/neu.1998.15.441; Zalewska T, 1998, MOL CHEM NEUROPATHOL, V33, P185, DOI 10.1007/BF02815181; Zhang YW, 1998, NEUROSCIENCE, V86, P847, DOI 10.1016/S0306-4522(98)00080-3	59	37	37	0	0	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	2000	59	11					946	954		10.1093/jnen/59.11.946			9	Clinical Neurology; Neurosciences; Pathology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	371UT	WOS:000165198200002	11089572	Bronze			2022-02-06	
J	Schiefermeier, M; Kollegger, H; Madl, C; Schwarz, C; Holzer, M; Kofler, J; Sterz, F				Schiefermeier, M; Kollegger, H; Madl, C; Schwarz, C; Holzer, M; Kofler, J; Sterz, F			Apolipoprotein E polymorphism - Survival and neurological outcome after cardiopulmonary resuscitation	STROKE			English	Article						apolipoproteins E; heart arrest; polymorphism; resuscitation; stroke outcome	HOSPITAL CARDIAC-ARREST; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; BRAIN INJURY; HEAD-INJURY; ALLELE; ASSOCIATION; PROTEIN; PLASMA; APOE	Background and Purpose-The apolipoprotein E 3/3 (apoE 3/3) genotype is associated with a reduced risk of developing Alzheimer's disease and with a favorable neurological outcome after traumatic head injury. In vitro studies suggest that the most common genotype, apoE 3/3, may be involved in neuroprotective and neuroregenerative mechanisms. The aim of this study was to determine whether the apoE 3/3 genotype has an impact on survival and neurological outcome after cardiopulmonary resuscitation. Methods-Eighty patients with cardiac arrest were investigated prospectively for their apoE genotype. Epidemiological data were assessed according to recommended guidelines. Patients were divided into 2 groups, ie, with the apoE 3/3 genotype present or absent, and tested for differences in survival and neurological outcome. Further statistical analysis with respect to survival and neurological outcome was performed by using a stepwise logistic regression analysis. Results-Patients with the apoE 3/3 genotype had a significantly higher survival rate (64% versus 33%, P=0.007) and more often a favorable neurological outcome (55% versus 27%, P=0.013) compared with patients with other apoE genotypes. The apoE 3/3 genotype was shown to be a substantial predictive factor for a favorable neurological outcome (odds ratio 3.2) and was, apart from other essential factors, predictive for survival (odds ratio 4.4) after cardiopulmonary resuscitation. Conclusions-These data give evidence that patients with the apoE 3/3 genotype have a better chance of recovery after cardiopulmonary resuscitation than do patients with apoE genotypes other than 3/3.	Univ Vienna, Dept Clin Neurol, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 4, Div Intens Care Med, A-1090 Vienna, Austria; Univ Vienna, Dept Emergency Med, A-1090 Vienna, Austria		Schiefermeier, M (corresponding author), Univ Vienna, Dept Clin Neurol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Kofler, Julia/AAJ-8032-2021				ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Behringer W, 1998, ANN INTERN MED, V129, P450, DOI 10.7326/0003-4819-129-6-199809150-00004; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Greenberg SM, 1997, ANN NEUROL, V41, P701, DOI 10.1002/ana.410410604; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; JENNETT B, 1975, LANCET, V1, P480; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; MADI C, 2000, CRIT CARE MED, V28, P721; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Mullner M, 1997, INTENS CARE MED, V23, P1138, DOI 10.1007/s001340050470; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Perers E, 1999, RESUSCITATION, V40, P133, DOI 10.1016/S0300-9572(99)00022-2; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Schiefermeier M, 2000, BRAIN, V123, P585, DOI 10.1093/brain/123.3.585; Schmidt R, 1997, STROKE, V28, P951, DOI 10.1161/01.STR.28.5.951; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; SIEST G, 1995, CLIN CHEM, V41, P1068; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; van Walraven C, 1999, ARCH INTERN MED, V159, P129, DOI 10.1001/archinte.159.2.129; Wass CT, 1996, MAYO CLIN PROC, V71, P801; WelshBohmer KA, 1997, ANN NEUROL, V42, P319, DOI 10.1002/ana.410420308; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Weston CFM, 1997, RESUSCITATION, V34, P27, DOI 10.1016/S0300-9572(96)01031-3; Yamauchi K, 1999, CLIN CHEM, V45, P497; ZHANG MY, 1994, METABOLISM, V43, P1523, DOI 10.1016/0026-0495(94)90011-6	32	37	39	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	SEP	2000	31	9					2068	2073		10.1161/01.STR.31.9.2068			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	351YT	WOS:000089188300006	10978031	Bronze			2022-02-06	
J	Umehara, F; Abe, M; Koreeda, Y; Izumo, S; Osame, M				Umehara, F; Abe, M; Koreeda, Y; Izumo, S; Osame, M			Axonal damage revealed by accumulation of beta-amyloid precursor protein in HTLV-I-associated myelopathy	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						HTLV-I; HTLV-I-associated myelopathy; axonal damage; beta-amyloid precursor protein; axonal flow; HAM/TSP	SPINAL-CORD LESIONS; VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; MULTIPLE-SCLEROSIS LESIONS; T-LYMPHOCYTES; HEAD-INJURY; HUMAN BRAIN; EXPRESSION; APP; IMMUNOREACTIVITY	We investigated the localization and extent of beta-amyloid precursor protein (APP) immunoreactivity as a sensitive marker for impairment of fast axonal transport in the spinal cords of patients with HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP). The results from this study show that APP, used as a marker of early axonal damage in HAM/TSP lesions, is more intensively expressed in areas of active-inflammatory lesions than those of inactive-chronic lesions. The close localization to the areas containing inflammation (activation of macrophage/microglia) is striking and suggests that axonal damage is closely associated with inflammation in active-chronic lesions. Although inflammatory cell infiltration in the central nervous system (CNS) is rarely found in inactive-chronic lesions, a few clusters of APP+ axons are found in the spinal cord white matter in some cases. The presence of APP+ axons without relation to inflammatory cells in inactive-chronic lesions, suggest that soluble neurotoxic factors might induce axonal changes in the CNS of HAM/TSP. The occasional myelinated fibers in the anterior and posterior spinal roots in lower thoracic to lumbar levels had APP+ axons, suggesting that spinal nerve roots can be affected in HAM/TSP, especially in lower thoracic to lumbar levels. Impairment of fast axonal transport may contribute to the development of disability in patients with HAM/TSP. (C) 2000 Elsevier Science B.V. All rights reserved.	Kagoshima Univ, Sch Med, Dept Internal Med 3, Kagoshima 890, Japan; Kagoshima Univ, Chron Viral Dis Res Ctr, Div Mol Pathol, Kagoshima 890, Japan		Umehara, F (corresponding author), Kagoshima Univ, Sch Med, Dept Internal Med 3, Sakuragaoka 8-35-1, Kagoshima 890, Japan.						Abe M, 1999, J NEUROL, V246, P358, DOI 10.1007/s004150050363; AMARATUNGA A, 1995, J NEUROCHEM, V64, P2374; An SF, 1997, J NEUROPATH EXP NEUR, V56, P1262, DOI 10.1097/00005072-199711000-00011; ARIMURA K, 1995, MUSCLE NERVE, V18, P248, DOI 10.1002/mus.880180219; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; COCHRAN E, 1991, AM J PATHOL, V139, P485; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; GEHRMANN J, 1995, GLIA, V15, P141, DOI 10.1002/glia.440150206; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GESSAIN A, 1985, LANCET, V2, P407; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; GRIFFIN JW, 1987, J NEUROPATHOL EXP NE, V36, P214; IWASAKI Y, 1990, J NEUROL SCI, V96, P103, DOI 10.1016/0022-510X(90)90060-Z; Izumo S, 1996, NEUROLOGY, V46, P1016, DOI 10.1212/WNL.46.4.1016; KATAOKA A, 1993, J NEUROL NEUROSUR PS, V56, P1213, DOI 10.1136/jnnp.56.11.1213; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MOORE GRW, 1989, ANN NEUROL, V26, P523, DOI 10.1002/ana.410260405; Moritoyo T, 1996, ANN NEUROL, V40, P84, DOI 10.1002/ana.410400114; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; OSAME M, 1987, ANN NEUROL, V21, P117, DOI 10.1002/ana.410210203; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; REFOLO LM, 1991, J NEUROSCI, V11, P3888; Sasaki S, 1999, ACTA NEUROPATHOL, V97, P463, DOI 10.1007/s004010051015; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Tsujino A, 1997, J NEUROIMMUNOL, V73, P191, DOI 10.1016/S0165-5728(96)00198-1; Umehara F, 1996, ACTA NEUROPATHOL, V91, P343, DOI 10.1007/s004010050435; UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P72, DOI 10.1097/00005072-199401000-00009; Umehara F, 1998, J NEUROPATH EXP NEUR, V57, P839, DOI 10.1097/00005072-199809000-00005; UMEHARA F, 1994, J NEUROPATH EXP NEUR, V53, P617, DOI 10.1097/00005072-199411000-00009; UMEHARA F, 1993, J NEUROPATH EXP NEUR, V52, P424, DOI 10.1097/00005072-199307000-00010; UMEHARA F, 1990, ACTA NEUROPATHOL, V80, P563, DOI 10.1007/BF00294621	34	37	37	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUN 15	2000	176	2					95	101		10.1016/S0022-510X(00)00324-5			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	350BP	WOS:000089081100003	10930590				2022-02-06	
J	Sherer, M; Bergloff, P; High, W; Nick, TG				Sherer, M; Bergloff, P; High, W; Nick, TG			Contribution of functional ratings to prediction of longterm employment outcome after traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; WORK; COMMUNITY; RETURN; SCALE	The present study investigated the contribution of functional ratings to prediction of employment outcome after traumatic brain injury (TBI). Previous studies have suggested that functional ratings obtained at a significant time post-injury can supplement neurologic, pre-injury, neuropsychologic, and other post-injury variables in predicting long-term employment outcome. Functional ratings studied were patients' needs for physical, cognitive, and behavioural supervision. This investigation also addressed the issue of predicting long-term outcome for the select group of TBI patients who receive post-acute brain injury rehabilitation. Subjects were 76 patients with TBI. The mean age (25th, 50th, and 75th percentiles) was 32 (22, 28, 39) years and mean premorbid education level was 13 (12, 12, 14) years. Predictors studied were severity of injury, premorbid education level, pre-injury substance use. and needs for physical, cognitive and behavioural supervision at discharge from postacute rehabilitation. Supervision needs ratings were obtained an average of 9.6 (4.2, 5.9, 11.2) months post-injury. Productivity status was assessed an average of 22.5 (12.6, 20.7, 30.5) months post-injury and 12.9 (4.9, 12.4, 16.6) months post-discharge from treatment. Spearman correlation coefficients revealed that premorbid educational level, pre-injury substance use, and needs for physical and behavioural supervision were related to long-term functional outcome (p < 0.05). However, multiple logistic regression analysis revealed that only level of pre-injury substance use was predictive of long-term productivity outcome once adjusted for the effects of the other predictors. Patients with no history of pre-injury substance use were more than eight times as likely to be employed at follow-up as those with a history of pre-injury substance abuse (p < 0.01).	Mississippi Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Baylor Coll Med, Houston, TX 77030 USA; Inst Rehabil & Res, Houston, TX USA		Sherer, M (corresponding author), Mississippi Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org					BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; BONTKE CF, 1991, NEUROSURG CLIN N AM, V2, P1; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V7, P296; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; HAGEN C, 1979, INTERVENTION STRATEG; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1975, LANCET          0301, P489; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Najenson T, 1980, Int Rehabil Med, V2, P17; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PONFORD JL, 1995, BRAIN INJURY, V9, P11; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SHERER M, CANCER, V80, P250; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	26	37	37	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1999	13	12					973	981					9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	264UJ	WOS:000084200600003	10628502				2022-02-06	
J	Pepe, JL; Barba, CA				Pepe, JL; Barba, CA			The metabolic response to acute traumatic brain injury and implications for nutritional support	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alimentation; metabolic response; nutrition; severe brain injury	SEVERE HEAD-INJURY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; TOTAL PARENTERAL-NUTRITION; CRITICALLY ILL PATIENTS; ENTERAL NUTRITION; PLACEMENT; GASTROPARESIS; COMPLICATIONS; CISAPRIDE; GLUCOSE	An overview of the metabolic response to acute traumatic brain injury is presented. The consequences of hypermetabolism hypercatabolism, and an altered immune function are discussed. Once a person with acute traumatic brain injury; develops this hyperdynamic state, the resultant excessive protein breakdown ensues. This can lead to malnutrition. The feeding methods used to prevent malnutrition are discussed, along with the proper alimentation to provide to diminish the hyperdynamic state and improve immune function.	St Francis Hosp & Med Ctr, Hartford, CT 06105 USA; Univ Connecticut, Hartford, CT 06112 USA		Pepe, JL (corresponding author), St Francis Hosp & Med Ctr, 114 Woodland St, Hartford, CT 06105 USA.						Akkersdijk WL, 1998, INJURY, V29, P11, DOI 10.1016/S0020-1383(97)00108-3; ALEXANDER JW, 1980, ANN SURG, V192, P505, DOI 10.1097/00000658-198010000-00009; Altmayer T, 1996, ARCH PHYS MED REHAB, V77, P1093, DOI 10.1016/S0003-9993(96)90075-1; ANTONACCI A, 1984, INFECT SURG, V3, P590; Berger WL, 1996, GASTROINTEST ENDOSC, V43, P63, DOI 10.1016/S0016-5107(96)70264-X; BIVINS BA, 1986, J TRAUMA, V26, P980, DOI 10.1097/00005373-198611000-00004; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P137, DOI 10.1111/j.1651-2227.1979.tb04975.x; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; Choudhry U, 1996, GASTROINTEST ENDOSC, V44, P164, DOI 10.1016/S0016-5107(96)70134-7; CLIFTON CL, 1991, NEUROSURGERY, V8, P10; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; DAMELIO LF, 1994, AM SURGEON, V60, P180; DEUTSCHMAN CS, 1987, J NEUROSURG, V66, P388, DOI 10.3171/jns.1987.66.3.0388; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; DISARIO JA, 1990, GASTROINTEST ENDOSC, V36, P257, DOI 10.1016/S0016-5107(90)71018-8; DREW JH, 1947, J NEUROSURG, V4, P7, DOI 10.3171/jns.1947.4.1.0007; FORD E G, 1987, Current Surgery, V44, P311; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; Harbrecht BG, 1998, AM J SURG, V176, P311, DOI 10.1016/S0002-9610(98)00206-2; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; INOUE M, 1991, J CEREBR BLOOD F MET, V11, P242, DOI 10.1038/jcbfm.1991.56; JACKSON MD, 1989, ARCH PHYS MED REHAB, V70, P553; KADAKIA SC, 1992, AM J SURG, V64, P114; KIRBY DF, 1991, JPEN-PARENTER ENTER, V15, P298, DOI 10.1177/0148607191015003298; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KUDSK KA, 1994, ARCH SURG-CHICAGO, V129, P66; Langmore SE, 1998, DYSPHAGIA, V13, P69, DOI 10.1007/PL00009559; MARIE C, 1991, CEREBROVAS BRAIN MET, V3, P29; McCarter TL, 1998, AM J GASTROENTEROL, V93, P419, DOI 10.1111/j.1572-0241.1998.00419.x; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; MILLER C H, 1991, Neurological Research, V13, P117; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; Ott L, 1990, Nutr Clin Pract, V5, P68, DOI 10.1177/011542659000500268; OTT L, 1989, NUTRITION, V5, P75; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; PETERSON VM, 1988, SURGERY, V104, P199; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; Rabeneck L, 1996, J GEN INTERN MED, V11, P287, DOI 10.1007/BF02598270; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Reed RL, 1998, J TRAUMA, V45, P388, DOI 10.1097/00005373-199808000-00034; ROBERTSON CS, 1991, J LAB CLIN MED, V118, P205; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; SPAPEN HD, 1995, CRIT CARE MED, V23, P481, DOI 10.1097/00003246-199503000-00011; STRONG RM, 1992, JPEN-PARENTER ENTER, V16, P59, DOI 10.1177/014860719201600159; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; VANWAY CW, 1991, SURG CLIN N AM, V71, P537; Weekes Elizabeth, 1996, Journal of Parenteral and Enteral Nutrition, V20, P31, DOI 10.1177/014860719602000131; WEISSMAN C, 1986, ANESTHESIOLOGY, V64, P673, DOI 10.1097/00000542-198606000-00001; WOLF DC, 1992, AM J GASTROENTEROL, V87, P1278; Yorkston KM, 1989, J HEAD TRAUMA REHAB, V4, P1; Young B, 1991, Neurosurg Clin N Am, V2, P301; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25; YOUNG B, 1987, J NEUROSURG, V67, P76, DOI 10.3171/jns.1987.67.1.0076; YOUNG B, 1992, J NEUROTRAUM, V9, pS375; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	68	37	38	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1999	14	5					462	474		10.1097/00001199-199910000-00007			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	245MW	WOS:000083113600007	10653942				2022-02-06	
J	Marsigny, B; Lecoq-Jammes, F; Cauchy, E				Marsigny, B; Lecoq-Jammes, F; Cauchy, E			Medical mountain rescue in the Mont-Blanc massif	WILDERNESS & ENVIRONMENTAL MEDICINE			English	Article						mountaineering; multiple trauma; brain concussion; hypothermia; lightning; rescue work; air ambulance	INJURY	Because of its peculiar geographic location beneath Mont-Blanc, the Chamonix Hospital plays an important role in the management of mountaineering- and skiing-related traumatic injuries. The authors. thanks to the study of 5200 mountain rescue medical reports, set out to explain the different aspects of this activity: epidemiology, specific equipment, care in the field. reception and primary survey, dispatching, common therapeutic attitudes, progress, and results. In the dangerous environment of the high mountains, emphasis is put on the physicians' experience, allowing an early evacuation in the best conditions to the hospital. Diagnosis at the scene of the accident is very basic, and the initial treatment is based on immobilization, analgesia, and sedating. In the case of resuscitation, only the vital maneuvers are performed. these actions are carried on during the short flight and improved in the crash rooms. Finally, different specific pathologies are mentioned, including cold- or heat-related injuries, exhaustion, lightning strikes, and mountain sickness.	Hosp Chamonix, Emergency Unit, F-74400 Les Bossons, Chamonix, France		Marsigny, B (corresponding author), Hosp Chamonix, Emergency Unit, 509 Route Pelerins,BP 30, F-74400 Les Bossons, Chamonix, France.						DEMARTINES N, 1991, HELV CHIR ACTA, V58, P223; DURRER B, 1993, THER UMSCH, V30, P228; FORAY J, 1982, CHIRURGIE, V108, P724; Koizumi T, 1996, J SPORT MED PHYS FIT, V36, P72; MAIR P, 1997, INT J INTENSIVE CARE, V3, P20; MALACRIDA RL, 1993, INJURY, V24, P451, DOI 10.1016/0020-1383(93)90147-X; MARTINEZ JY, 1995, THESIS LYON I U FRAN; MCLENNAN JG, 1983, AM J SPORT MED, V11, P160, DOI 10.1177/036354658301100310; Meier R, 1993, Z Unfallchir Versicherungsmed, VSuppl 1, P85; MOESCHLER O, 1992, J TRAUMA, V33, P754, DOI 10.1097/00005373-199211000-00027; Philadelphy M, 1991, Fortschr Kiefer Gesichtschir, V36, P43; RANE A, 1989, 7 JOURN NAC MED MONT, P75; REID WA, 1986, J CLIN PATHOL, V39, P1217, DOI 10.1136/jcp.39.11.1217; Rousseau JM, 1997, ANN FR ANESTH, V16, P885, DOI 10.1016/S0750-7658(97)89838-3; STERETT WI, 1994, J ORTHOP TRAUMA, V8, P310, DOI 10.1097/00005131-199408000-00006	15	37	37	0	2	WILDERNESS MEDICAL SOC	COLORADO SPRINGS	3595 E FOUNTAIN BLVD, STE A1, COLORADO SPRINGS, CO 80910 USA	1080-6032			WILD ENVIRON MED	Wildern. Environ. Med.	FAL	1999	10	3					152	156		10.1580/1080-6032(1999)010[0152:MMRITM]2.3.CO;2			5	Public, Environmental & Occupational Health; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Sport Sciences	252CR	WOS:000083483600004	10560308	Bronze			2022-02-06	
J	Lin, J; Hou, SM				Lin, J; Hou, SM			Antegrade locked nailing for humeral shaft fractures	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							DIAPHYSEAL FRACTURES; EXPERIENCE; FIXATION	Treatment results of antegrade locked nailing of acute humeral shaft fractures, including union rate and recovery of shoulder function, have been inconsistent. This led the current authors to hypothesize that implant design and surgical techniques might account for this inconsistency. In the current study, 47 fractures (38 acute; nine pathologic) in 47 patients achieved union with the techniques of closed nailing, short to long segment nailing, and fracture compression, Satisfactory recovery of shoulder function occurred because of minimal surgical trauma, prevention of impingement by the nail or locking screws, and prevention of axillary nerve injury or comminution of the humeral head, Forty-seven patients with 38 acute fractures and nine pathologic fractures were treated with humeral locked nails. Mean followup time was 21.4 months. With a single operation, all 38 acute fractures proceeded to eventual union; the average time to union was 7.8 weeks. Thirty-five patients had excellent or satisfactory recovery of shoulder function. Complications included slipout of the proximal screw, nail breakage, fragment displacement, and transient postoperative radial nerve palsy. All nine patients with pathologic fractures had substantial pain relief and increased arm function after surgery. The current study shows the reliability of antegrade locked nailing for proximal and middle third fractures of the humeral shaft.	Natl Taiwan Univ Hosp, Dept Orthoped Surg, Taipei 100, Taiwan		Lin, J (corresponding author), Natl Taiwan Univ Hosp, Dept Orthoped Surg, 7 Chung Shan S Rd, Taipei 100, Taiwan.						BALFOUR GW, 1982, J BONE JOINT SURG AM, V64, P11, DOI 10.2106/00004623-198264010-00002; BELL MJ, 1985, J BONE JOINT SURG BR, V67, P293, DOI 10.1302/0301-620X.67B2.3980544; Brumback RJ, 1996, CLIN ORTHOP RELAT R, P292; Crates J, 1998, CLIN ORTHOP RELAT R, P40; Dabezies E J, 1992, J Orthop Trauma, V6, P10; ESTERHAI JL, 1986, CLIN ORTHOP RELAT R, P228; FOSTER RJ, 1985, J BONE JOINT SURG AM, V67A, P857, DOI 10.2106/00004623-198567060-00005; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HEIM D, 1993, J TRAUMA, V35, P226, DOI 10.1097/00005373-199308000-00009; Hems TEJ, 1996, INJURY, V27, P485, DOI 10.1016/0020-1383(96)00056-3; HUNTER SG, 1982, CLIN ORTHOP RELAT R, P192; IKPEME JO, 1994, INJURY, V25, P447, DOI 10.1016/0020-1383(94)90271-2; INGMAN AM, 1994, J BONE JOINT SURG BR, V76B, P23, DOI 10.1302/0301-620X.76B1.8300675; Klenerman L, 1966, J Bone Joint Surg Br, V48, P105; KRETTEK C, 1995, CLIN ORTHOP RELAT R, P34; Lin J, 1997, CLIN ORTHOP RELAT R, P147; Lin J, 1998, CLIN ORTHOP RELAT R, P203; Lin J, 1998, J TRAUMA, V44, P859, DOI 10.1097/00005373-199805000-00019; Lin J, 1998, J TRAUMA, V45, P1051, DOI 10.1097/00005373-199812000-00013; McKee MD, 1996, J ORTHOP TRAUMA, V10, P500, DOI 10.1097/00005131-199610000-00009; Modabber MR, 1998, CLIN ORTHOP RELAT R, P93; NEER CS, 1970, J BONE JOINT SURG AM, VA 52, P1077, DOI 10.2106/00004623-197052060-00001; Redmond BJ, 1996, J BONE JOINT SURG AM, V78A, P891, DOI 10.2106/00004623-199606000-00012; Remiger AR, 1997, J ORTHOP TRAUMA, V11, P308, DOI 10.1097/00005131-199705000-00016; Riemer B.L., 1996, SCI AND PRACTICE, P241; RIEMER BL, 1991, ORTHOPEDICS, V14, P239; RIEMER BL, 1994, ORTHOPEDICS, V17, P19; RIEMER BL, 1992, ORTHOPEDICS, V15, P697; RIEMER BL, 1993, ORTHOPEDICS, V16, P1219; ROBINSON CM, 1992, J BONE JOINT SURG BR, V74, P558, DOI 10.1302/0301-620X.74B4.1624516; RODRIGUEZMERCHAN EC, 1995, J ORTHOP TRAUMA, V9, P194, DOI 10.1097/00005131-199506000-00003; Rommens PM, 1998, CLIN ORTHOP RELAT R, P26; ROMMENS PM, 1995, J BONE JOINT SURG BR, V77B, P84, DOI 10.1302/0301-620X.77B1.7822403; SARMIENTO A, 1977, J BONE JOINT SURG AM, V59, P596, DOI 10.2106/00004623-197759050-00004; SCHOPFER A, 1994, J ORTHOP TRAUMA, V8, P414, DOI 10.1097/00005131-199410000-00008; SWIONTKOWSKI MF, 1990, SURG SHOULDER, P208; Tome JL, 1998, CLIN ORTHOP RELAT R, P51; ZAGORSKI JB, 1988, J BONE JOINT SURG AM, V70A, P607, DOI 10.2106/00004623-198870040-00018; ZIMMERMAN MC, 1994, J ORTHOP TRAUMA, V8, P233, DOI 10.1097/00005131-199406000-00009	39	37	43	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	1999		365					201	210		10.1097/00003086-199908000-00025			10	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	225PR	WOS:000081970400025	10627704				2022-02-06	
J	Groswasser, Z; Melamed, S; Agranov, E; Keren, O				Groswasser, Z; Melamed, S; Agranov, E; Keren, O			Return to work as an integrative outcome measure following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							PROLONGED POSTTRAUMATIC UNAWARENESS; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; COMMUNITY INTEGRATION; SUPPORTED EMPLOYMENT; REHABILITATION; PREDICTION; CONSCIOUSNESS; SERVICES; PROGRAM	In recent years we have witnessed the growing recognition of the centrality of work involvement in the successful rehabilitation of brain injured patients. Evidence from studies conducted at Loewenstein Rehabilitation Hospital (LRH) and from other studies, points to a strong and consistent positive association between employment and social integration, leisure activities, enhanced self-esteem, and perceived quality of life. Patients surviving severe traumatic brain injury (TBI) often suffer from residual impairments in motor control, communication skills, cognition, and social behaviour. These distinctly hamper their capability to return to work and to continue working for an extended period of time. Comprehensive and integrated rehabilitation programmes, such as those employed in LRH, were proven to be effective in returning patients to stable employment. This was demonstrated in the results of our recent follow-up study of 334 severe TBI patients, which indicated that 55.7% were gainfully employed 8-13 years post-discharge from LRH.	Loewenstein Hosp & Rehabil Ctr, Dept Brain Injury Rehabil, Raanana, Israel; Natl Inst Occupat & Environm Hlth, Dept Occupat Hlth Psychol, Raanana, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel			zeevgros@ccsg.tau.ac.il					Ashley MJ, 1997, BRAIN INJURY, V11, P677; BENYISHAY Y, 1987, J HEAD TRAUMATIC REH, V1, P90; BOWLING A, 1997, MEASURING HLTH REV Q, P6; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; CORKIN C, 1984, ARCH NEUROL-CHICAGO, V41, P957; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GROSWASSER Z, 1990, J NEUROSURG, V72, P81, DOI 10.3171/jns.1990.72.1.0081; GROSWASSER Z, 1996, THESIS HEBRES U JERU; Hillier SL, 1997, BRAIN INJURY, V11, P661; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; JOHNSON R, 1987, INT DISABILITY STUDI, V9, P44; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; Klove H, 1972, Scand J Rehabil Med, V4, P55; KRAVETZ S, 1985, REHABIL PSYCHOL, V30, P195, DOI 10.1037//0090-5550.30.4.195; KRAVETZ S, 1973, THESIS U WISCONSIN; Kreutzer J S, 1991, Int Disabil Stud, V13, P162; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Marme M., 1993, J APPL REHABILITATIO, V24, P19; Maslow Abraham., 1954, MOTIVATION PERSONALI; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Najenson T, 1980, Int Rehabil Med, V2, P17; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; SHIN DC, 1978, SOC INDIC RES, V5, P475, DOI 10.1007/BF00352944; STANBROOK M, 1990, BRAIN INJURY, V4, P183; STERN JM, 1985, SCAND J REHABIL MED, P53; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; WEST MD, 1995, BRAIN INJURY, V9, P301, DOI 10.3109/02699059509008200; Wilson B, 1994, BRAIN INJURY NEUROPS, P85; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; [No title captured]	59	37	37	0	7	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-OCT	1999	9	3-4					493	504		10.1080/096020199389545			12	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	242GV	WOS:000082932900022					2022-02-06	
J	Skele, A; Schwartz, O				Skele, A; Schwartz, O			Traumatic injuries of the teeth in connection with general anaesthesia and the effect of use of mouthguards	ENDODONTICS & DENTAL TRAUMATOLOGY			English	Article						endoscopy; incidence; intubation; mouthguards; traumatic injuries	TRACHEAL INTUBATION; COMPLICATIONS	The aim of the present study was to describe the frequency of dental injuries over a 10-year period, where a mouthguard was used in approximately 10% of intubation cases or endoscopying. The types of injury are presented and the use of different types of mouthguard is discussed. Among 120086 procedures involving anaesthesia carried out in the period 1983-1992 at Bispebjerg Hospital, Copenhagen, 75 cases of dental trauma occurred. The incidence of dental traumatic injuries was 0.06%. Although eight patients had used mouthguards they were registered with traumatic injuries to the teeth in connection with general anaesthesia. Of the patients, 58% were women and 42% men, with a mean age of 61 years. Seventy-eight percent of the injuries were located in the maxilla and 91% of these involved the incisor area of the maxilla. Forty-one percent were classified as lateral luxations or mobile teeth, 47% were classified as fractured teeth, 10% tooth avulsions and the remaining 2% were classified as concussions. Because of the low frequency of traumatic dental injuries in connection with general anaesthesia and the non-significant effect of the use of mouthguards, routine use of mouthguards is not recommended. Only when a patient is to have an endoscopy done under general anaesthesia, and the surgeon or anaesthesiologist foresees problems (restricted mouth opening, extensive fixed prosthetics, extensive loss of marginal bone) is use of an individually made mouthguard indicated.	Copenhagen Hosp Corp, Rigshosp, Ctr Head & Orthopaed, Dept Oral & Maxillofacial Surg, DK-2100 Copenhagen, Denmark; Bispebjerg Hosp, Dept Oral & Maxillofacial Surg, DK-2400 Copenhagen, Denmark		Skele, A (corresponding author), Copenhagen Hosp Corp, Rigshosp, Ctr Head & Orthopaed, Dept Oral & Maxillofacial Surg, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.						Andreasen JO, 1994, TXB COLOR ATLAS TRAU; BAMFORTH BJ, 1963, ANESTH ANALG, V42, P727; BLANC VF, 1974, ANESTH ANALG, V53, P202; BONSING E, 1976, UGESKRIFT LAEGER, V5, P278; BUNKER PG, 1962, ANN OTO RHINOL LARYN, V71, P1073, DOI 10.1177/000348946207100421; DAVIS FO, 1971, ANESTH ANAL CURR RES, V50, P203; Evers W, 1967, Can Anaesth Soc J, V14, P123, DOI 10.1007/BF03003633; GRONDAHL H, 1974, GOTEBORGS TANDLAKAR, V384, P38; HAGELSTEN J O, 1968, Nordisk Medicin, V80, P1717; HENRY PJ, 1964, J AM DENT ASSOC, V68, P569, DOI 10.14219/jada.archive.1964.0140; HENRY PJ, 1969, MED J AUSTRALIA, V1, P911, DOI 10.5694/j.1326-5377.1969.tb49783.x; HYDO M, 1971, MASUI, V20, P1064; LOCKHART PB, 1986, J AM DENT ASSOC, V112, P480, DOI 10.14219/jada.archive.1986.0035; MCCARTHY G, 1977, ACTA OTO-LARYNGOL, V84, P450, DOI 10.3109/00016487709123991; NOYEK AM, 1976, J OTOLARYNGOL, V5, P468; POWELL JB, 1965, ANESTH ANAL CURR RES, V44, P357; ROSENBERG M, 1968, ANESTH ANAL CURR RES, V47, P34; WASMUTH C E, 1956, Cleve Clin Q, V23, P32; WASMUTH C E, 1960, Anesth Analg, V39, P138; Wright R B, 1974, Anesth Analg, V53, P405	20	37	39	0	2	BLACKWELL MUNKSGAARD	FREDERIKSBERG C	1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK	0109-2502			ENDOD DENT TRAUMATOL	Endod. Dent. Traumatol.	FEB	1999	15	1					33	36					4	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	161FP	WOS:000078278800006	10219152				2022-02-06	
J	Radomisli, TE; Rosen, AL				Radomisli, TE; Rosen, AL			Controversies regarding radial neck fractures in children	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							PERCUTANEOUS REDUCTION; ELBOW FRACTURES; FIXATION	Fractures of the radial neck in children are not uncommon, yet several aspects of their management remain controversial. Until a consensus is reached regarding the determination of displacement, acceptability of initial angulation, treatment, and outcome, the complication rate of these fractures will remain high. The authors recommend measuring the displacement as the angle between a line perpendicular to the articular surface of the radial head with a line down the shaft of the proximal radius. Fractures that are angulated less than 30 degrees require immobilization alone. Fractures angulated more than 30 degrees should be treated with an attempt at closed reduction, If closed reduction fails, a percutaneous reduction should be attempted before open reduction. Internal fixation should be performed using an oblique extraarticular Kirshner wire for all unstable fractures. Grading outcome based on range of motion and the presence or absence of pain is recommended. It is hoped that once the controversies surrounding these fractures are resolved, the long term results of these troublesome injuries will improve.	CUNY Mt Sinai Sch Med, Dept Orthopaed Surg, New York, NY 10029 USA		Radomisli, TE (corresponding author), CUNY Mt Sinai Sch Med, Dept Orthopaed Surg, Box 1188,1 Gustave L Levy Pl, New York, NY 10029 USA.						BERNSTEIN SM, 1993, J PEDIATR ORTHOPED, V13, P85, DOI 10.1097/01241398-199301000-00017; CREASMAN C, 1984, CLIN ORTHOP RELAT R, P40; DSOUZA S, 1993, J PEDIATR ORTHOPED, V13, P232; FAHEY J J, 1960, Instr Course Lect, V17, P13; FOWLES JV, 1986, J PEDIATR ORTHOPED, V6, P51; GASTON SR, 1953, AM J SURG, V85, P266, DOI 10.1016/0002-9610(53)90608-4; HENRIKSON B, 1969, ACTA ORTHOP SCAND, V40, P246, DOI 10.3109/17453676908989505; JONES E R L, 1971, Journal of Bone and Joint Surgery British Volume, V53, P429; KAUFMAN B, 1989, J BONE JOINT SURG BR, V71, P66, DOI 10.1302/0301-620X.71B1.2915009; LANDIN LA, 1986, ACTA ORTHOP SCAND, V57, P309, DOI 10.3109/17453678608994398; MCBRIDE ED, 1960, CLIN ORTHOP RELAT R, V16, P264; METAIZEAU JP, 1993, J PEDIATR ORTHOPED, V13, P355, DOI 10.1097/01241398-199305000-00015; NUSSBAUM AJ, 1983, J TRAUMA, V23, P40, DOI 10.1097/00005373-198301000-00008; Ortega R, 1996, J PEDIATR ORTHOPED, V16, P651, DOI 10.1097/01241398-199609000-00019; PETERS CL, 1995, J BONE JOINT SURG AM, V77A, P1070, DOI 10.2106/00004623-199507000-00014; Praemer Allan., 1992, MUSCULOSKELETAL COND; RANG M, 1983, CHILDRENS FRACTURES, P182; REIDY JA, 1963, J BONE JOINT SURG AM, V45, P1355, DOI 10.2106/00004623-196345070-00002; Rodriguez-Merchan EC, 1991, ORTHOPEDICS, V14, P697; RODRIGUEZMERCHA.EC, 1994, J TRAUMA, V37, P812; Sharrard WJW, 1971, PAEDIATRIC ORTHOPAED, P972; SPONSELLER PD, 1994, HAND CLIN, V10, P495; STEELE JA, 1992, J BONE JOINT SURG BR, V74, P760, DOI 10.1302/0301-620X.74B5.1527130; STEINBERG EL, 1988, J PEDIATR ORTHOPED, V8, P35, DOI 10.1097/01241398-198801000-00009; Tachdjian MO, 1990, PAEDIATRIC ORTHOPAED, P3137; TIBONE JE, 1981, J BONE JOINT SURG AM, V63, P100, DOI 10.2106/00004623-198163010-00013; VAHVANEN V, 1978, ACTA ORTHOP SCAND, V49, P32, DOI 10.3109/17453677809005720; WATSONJONES R, 1955, FRACTURES JOINT INJU, P515; [No title captured]	29	37	39	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0009-921X			CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	AUG	1998		353					30	39					10	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	113GH	WOS:000075541700005	9728157				2022-02-06	
J	Soustiel, JF; Bruk, B; Shik, B; Hadani, M; Feinsod, M				Soustiel, JF; Bruk, B; Shik, B; Hadani, M; Feinsod, M			Transcranial Doppler in vertebrobasilar vasospasm after subarachnoid hemorrhage	NEUROSURGERY			English	Article						basilar artery; head injury; subarachnoid hemorrhage; transcranial Doppler; vasospasm	CEREBRAL BLOOD-FLOW; HEAD-INJURY; ULTRASOUND; SONOGRAPHY; ULTRASONOGRAPHY; HEMODYNAMICS; ENDOTHELIN; VELOCITIES; ARTERIES; SPASM	OBJECTIVE: The primary objective of this study was to assess the incidence of vertebrobasilar vasospasm after subarachnoid hemorrhage (SAH) by means of transcranial Doppler ultrasonography and to evaluate the clinical significance of this phenomenon. The secondary objective was to analyze the different factors influencing the development, the severity, and the duration of vertebrobasilar vasospasm. METHODS: Fifty-seven patients with traumatic SAH and 44 patients with spontaneous SAH were evaluated and monitored by means of transcranial Doppler ultrasonography. Vasospasm of the anterior and middle cerebral arteries was defined by mean flow velocities (FVs) exceeding 120 cm per second and at least three times the FV of the internal carotid artery. Vasospasm of the basilar and vertebral arteries was defined by a mean FV exceeding 60 cm per second. RESULTS: Vasospasm of the anterior or middle cerebral arteries was found in 27 patients and was associated with vertebrobasilar spasm in 20 patients. FVs in anterior circulation vessels were neither related to the cause of the SAH nor did they correlate with the outcome. Forty-six patients (45.5%) had FVs exceeding 60 cm per second and 25 (24.8%) had FVs exceeding 85 cm per second. In 10 of these patients, direct or computed tomographic angiography showed arterial narrowing involving the vertebrobasilar system, whereas in 21 more patients, computed tomography disclosed a cerebral infarction involving the vertebrobasilar vascular territory. Vertebral artery FVs in this group were twice that of the ipsilateral carotid artery. Vertebrobasilar vasospasm was significantly more frequent after head injury, although it was not related to the type of intracranial lesion or the Glasgow Coma Scale score at admission. It did correlate, however, with outcome (P < 0.0001) and with the intensity of SAH (P < 0.0001). Delayed neurological deterioration occurred in 14 patients and was significantly more frequent in patients with basilar artery FVs above 85 cm per second (P < 0.001). Prognosis, however, could not be reliably predicted by FVs in the basilar artery, even when an FV of 110 cm per second was chosen for prediction criterion. CONCLUSION: These results suggest that vertebrobasilar vasospasm is more common than previously thought, especially in association with head injury, with which it may significantly contribute to brain stem ischemic lesions and therefore justify specific therapeutic measures.	Technion Israel Inst Technol, Rambam Maimonides Med Ctr, Dept Neurosurg, Brain Injury Appl Res Ctr, IL-31096 Haifa, Israel; Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Dept Neurosurg, IL-69978 Tel Aviv, Israel		Soustiel, JF (corresponding author), Technion Israel Inst Technol, Rambam Maimonides Med Ctr, Dept Neurosurg, Brain Injury Appl Res Ctr, POB 9102, IL-31096 Haifa, Israel.						AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Adams JH, 1982, RECENT ADV NEUROPATH, P165; ALEXANDER MJ, 1994, ACTA NEUROCHIR, P479; Barker F G 2nd, 1990, Neurosurg Clin N Am, V1, P277; CHUI M, 1983, NEUROSURGERY, V12, P542, DOI 10.1227/00006123-198305000-00011; ECHLIN FA, 1965, J NEUROSURG, V23, P1, DOI 10.3171/jns.1965.23.1.0001; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fujioka KA., 1992, TRANSCRANIAL DOPPLER, P9; GAETANI P, 1994, J NEUROL NEUROSUR PS, V57, P66, DOI 10.1136/jnnp.57.1.66; HASSLER W, 1988, J NEUROSURG, V68, P745; JENNETT B, 1975, LANCET, V1, P480; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; LAUMER R, 1993, NEUROSURGERY, V33, P1, DOI 10.1227/00006123-199307000-00001; Lindegaard K F, 1988, Acta Neurochir Suppl (Wien), V42, P81; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; NEWELL DW, 1992, TRANSCRANIAL DOPPLER, P109; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; Sahs AL, 1969, INTRACRANIAL ANEURYS; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; SLOAN MA, 1994, STROKE, V25, P2187, DOI 10.1161/01.STR.25.11.2187; SMITH RR, 1985, NEUROSURGERY, P1355; STEINMEIER R, 1993, NEUROSURGERY, V33, P10; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Wozniak MA, 1996, J NEUROIMAGING, V6, P87, DOI 10.1111/jon19966287	29	37	39	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	1998	43	2					282	291		10.1097/00006123-199808000-00061			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	103VX	WOS:000074979500054	9696081				2022-02-06	
J	Glaser, DL; Rocke, DM; Kaplan, FS				Glaser, DL; Rocke, DM; Kaplan, FS			Catastrophic falls in patients who have fibrodysplasia ossificans progressiva	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article								There have been numerous anecdotal reports of catastrophic falls in patients with fibrodysplasia ossificans progressiva, To determine the incidence of serious morbidity and mortality associated with falls in this patient population, the authors surveyed the 135 patient members of the International Fibrodysplasia Ossificans Progressiva Association and an age and gender matched control group, Eighty-one percent of the fibrodysplasia ossificans progressiva population suffered a fall resulting in injury compared with 44% of the controls, Sixty-seven percent of the falls initiated a painful flareup of fibrodysplasia ossificans progressiva leading to permanent loss of movement in almost all patients, Fifty-four percent of all falls suffered by the fibrodysplasia ossificans progressiva group led to permanent disability compared with 4% of all falls in the control group, Although trauma to the head was a common site of injury in both groups, the injury profile in the fibrodysplasia ossificans progressiva group included traumatic brain injuries, intracranial hemorrhage and death whereas the control group suffered mostly minor soft tissue lacerations. Deficiencies in coordinate gait and protective function likely accounted for the severity of injuries especially to the head in the fibrodysplasia ossificans progressiva population, Precautions are recommended that are intended to minimize the risk of injury without compromising a patient's functional level and independence, These recommendations include limitation of high risk activities, protective head gear, safety improvements in living environments, and augmentation of stabilizing and protective functions.	Univ Penn, Sch Med, Dept Orthopaed Surg, Div Metab Bone Disorders & Mol Orthopaed, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Calif Davis, Grad Sch Management, Davis, CA USA		Kaplan, FS (corresponding author), Univ Penn, Sch Med, Dept Orthopaed Surg, Div Metab Bone Disorders & Mol Orthopaed, 3400 Spruce St,Silverstein 2, Philadelphia, PA 19104 USA.		Rocke, David M/I-7044-2013	Rocke, David M/0000-0002-3958-7318; Kaplan, Frederick/0000-0003-1277-5420			COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; Everitt B. S., 1977, ANAL CONTINGENCY TAB; ROCKE DM, 1994, CLIN ORTHOP RELAT R, P243	3	37	39	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	JAN	1998		346					110	116					7	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	YT798	WOS:000071646100016	9577417				2022-02-06	
J	Williams, WH; Williams, JMG; Ghadiali, EJ				Williams, WH; Williams, JMG; Ghadiali, EJ			Autobiographical memory in traumatic brain injury: Neuropsychological and mood predictors of recall	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; CLOSED-HEAD INJURY; DEPRESSION; AMNESIA; ANXIETY; SCALE	Survivors of traumatic brain injury are often impaired in their recall of specific events. Depressed, suicidal, and post-traumatically stressed patients also tend to be over-general in autobiographical recall. In this study we examined the extent to which neurological damage and disturbed mood converge to lead to problems in autobiographical recall for survivors of traumatic brain injury. Eighteen participants completed measures of depression and anxiety (HAD), tests of general memory and immediate recall (Rivermead), and of current and premorbid verbal IQ (SCOLP). In addition they completed a 20 cue word autobiographical memory test and made causal attributions for their trauma events. Correlational analyses revealed that difficulty in autobiographical recall was related to reduced immediate recall ability and mood disturbance. Remedial implications are discussed.	Prince Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely CB6 1DN, Cambs, England; Univ Cambridge, Cambridge CB2 1TN, England; Univ Wales, Bangor, Gwynedd, Wales; Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England					williams, huw/0000-0003-0670-2620			ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; BADDELEY A, 1992, NATO ADV SCI INST SE, V65, P13; Baddeley A., 1992, SPEED CAPACITY LANGU; BADDELEY AD, 1986, AUTOBIOGRAPHICAL MEM, P225; BENEDICT RHB, 1992, J HEAD TRAUMA REHAB, V7, P84; Bond M. R., 1990, REHABILITATION ADULT, P179; Brewin C. R., 1984, J SOC CLIN PSYCHOL, V2, P156, DOI [10.1521/jscp.1984.2.2.156, DOI 10.1521/JSCP.1984.2.2.156]; BREWIN CR, 1988, BRIT J CLIN PSYCHOL, V27, P1, DOI 10.1111/j.2044-8260.1988.tb00748.x; Brooks N, 1989, Brain Inj, V3, P325, DOI 10.3109/02699058909004556; BROOKS N, 1990, REHABILITATION ADULT, P163; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BULMAN RJ, 1977, J PERS SOC PSYCHOL, V35, P351, DOI 10.1037/0022-3514.35.5.351; CIMINO CR, 1991, BRAIN COGNITION, V6, P23; CLARK DM, 1982, J ABNORM PSYCHOL, V91, P87, DOI 10.1037/0021-843X.91.2.87; EVANS J, 1992, PSYCHOL MED, V22, P399, DOI 10.1017/S0033291700030348; Evans J, 1992, CLIN REHABIL, V6, P75, DOI DOI 10.1177/026921559200600110; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; JENNETT B, 1990, REHABILITATION ADULT, P3; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; MACKINNON DF, 1989, PSYCHOBIOLOGY, V17, P247, DOI 10.1007/BF03337776; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCNALLY RJ, 1994, COGNITION EMOTION, V8, P351, DOI 10.1080/02699939408408946; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; RUSSELL D, 1982, J PERS SOC PSYCHOL, V42, P1137, DOI 10.1037//0022-3514.42.6.1137; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STAMBROOK M, 1989, CANADIAN J REHABILIT, V3, P87; STARKSTEIN SE, 1990, ARCH GEN PSYCHIAT, V47, P246, DOI 10.1001/archpsyc.1990.01810150046008; Wechsler, 1981, WECHSLER MEMORY SCAL; Williams JH, 1994, CONDITION BASED MAIN, P1; WILLIAMS JMG, 1986, J ABNORM PSYCHOL, V95, P144, DOI 10.1037/0021-843X.95.2.144; WILLIAMS JMG, 1988, PSYCHOL MED, V18, P689, DOI 10.1017/S0033291700008370; WILLIAMS JMG, 1992, NATO ADV SCI INST SE, V65, P391; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; ZAHN BS, 1989, PSYCHIAT FORUM   WIN, P6; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZOLAMORGAN S, 1983, NEUROPSYCHOLOGIA, V21, P487, DOI 10.1016/0028-3932(83)90005-2; [No title captured]	41	37	37	0	5	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	1998	8	1					43	60		10.1080/713755551			18	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	YW987	WOS:000071994900004					2022-02-06	
J	Queen, SA; Chen, MJ; Feeney, DM				Queen, SA; Chen, MJ; Feeney, DM			d-amphetamine attenuates decreased cerebral glucose utilization after unilateral sensorimotor cortex contusion in rats	BRAIN RESEARCH			English	Article						amphetamine; cerebral glucose utilization; cortical contusion; traumatic brain injury; remote functional depression	CONCUSSIVE BRAIN INJURY; EXCITATORY AMINO-ACIDS; BLOOD-FLOW; NEOCORTICAL ABLATIONS; 2-DEOXYGLUCOSE UPTAKE; CORTICAL ASTROCYTES; MOTOR RECOVERY; FOCAL ISCHEMIA; BASAL GANGLIA; CONSCIOUS RAT	Unilateral contusion injury to the sensorimotor cortex causes, among other symptoms, a transient contralateral hindlimb hemiparesis in rats. A single i.p. 2 mg/kg dose of d-amphetamine (d-AMPH) 24 h after injury accelerates spontaneous recovery from this particular deficit. The mechanism(s) of spontaneous and d-AMPH enhanced recovery are unknown but alleviation of a neuronal depression has been proposed. This quantitative CMRglu study a as designed to determine effects of cortical contusion injury and d-AMPH on CMRglu in cortical and subcortical structures. At 2 days after injury, CMRglu was significantly reduced compared to sham-operated controls only in structures ipsilateral to contusion. Affected structures included the caudate putamen, medial geniculate nucleus, lateral geniculate nucleus and the parietal cortex immediately posterior to injury. By 6 days post-contusion the hypometabolism partially reversed in all structures. A single low dose of d-AMPH significantly alleviated the post-traumatic CMRglu reduction at 2 days after injury. Importantly, while this alleviation was nut significant for any single structure, the main effect of treatment was highly significant. d-AMPH increased CMRglu at 2 days post-injury by 18-33% compared to contused/saline-treated rats. These results suggest that alleviation of neuronal metabolic depression may contribute to spontaneous and d-AMPH enhanced recovery. (C) 1997 Elsevier Science B.V.	Univ Montana, Phys Therapy Program, Dept Phys Therapy, Sch Pharm & Allied Hlth Sci, Missoula, MT 59812 USA; Utah State Univ, Dept Psychol, Logan, UT 84322 USA; Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Queen, SA (corresponding author), Univ Montana, Phys Therapy Program, Dept Phys Therapy, Sch Pharm & Allied Hlth Sci, McGill Hall,Room 026, Missoula, MT 59812 USA.						BECK T, 1995, STROKE, V26, P1107, DOI 10.1161/01.STR.26.6.1107; BECK T, 1990, J CEREBR BLOOD F MET, V10, P542, DOI 10.1038/jcbfm.1990.96; BECK T, 1987, AM J PHYSIOL, V252, pH504, DOI 10.1152/ajpheart.1987.252.3.H504; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CONTRERAS FL, 1988, J NEUROSURG, V68, P137, DOI 10.3171/jns.1988.68.1.0137; COOPER RM, 1984, EXP NEUROL, V83, P134, DOI 10.1016/0014-4886(84)90052-9; COOPER RM, 1984, EXP NEUROL, V86, P261, DOI 10.1016/0014-4886(84)90185-7; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DAUTH GW, 1985, ANN NEUROL, V17, P431, DOI 10.1002/ana.410170503; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P195, DOI 10.1038/jcbfm.1986.32; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1990, STROKE, V21, P147; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FENEY DM, IN PRESS CEREBROVASC, V1; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GILMAN S, 1987, ANN NEUROL, V22, P370, DOI 10.1002/ana.410220314; HEISS WD, 1990, J CEREBR BLOOD F MET, V10, P127, DOI 10.1038/jcbfm.1990.16; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HOSOKAWA S, 1985, BRAIN RES, V343, P8, DOI 10.1016/0006-8993(85)91152-7; Hovda D.A., 1996, NEUROTRAUMA, P1459; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; INGLIS F, 1992, J NEUROTRAUM, V9, P75, DOI 10.1089/neu.1992.9.75; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KLEIN AE, 1993, SOC NEUR ABSTR, V19, P1878; KOGURE K, 1979, STROKE, V10, P179, DOI 10.1161/01.STR.10.2.179; KROBERT K A, 1990, Society for Neuroscience Abstracts, V16, P43; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; Kuczenski R., 1983, STIMULANTS NEUROCHEM, P31; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483, DOI 10.1152/ajplegacy.1976.231.2.483; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MIES G, 1990, J CEREBR BLOOD F MET, V10, P638, DOI 10.1038/jcbfm.1990.116; NEDERGAARD M, 1988, J CEREBR BLOOD F MET, V8, P100, DOI 10.1038/jcbfm.1988.13; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; ORZI F, 1983, J CEREBR BLOOD F MET, V3, P154, DOI 10.1038/jcbfm.1983.22; Panigrahy A., 1995, Society for Neuroscience Abstracts, V21, P2119; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PELLEGRINO LJ, 1986, STEREOTAXIC ATLAS RA; PORRINO LJ, 1984, BRAIN RES, V307, P311, DOI 10.1016/0006-8993(84)90485-2; Queen SA, 1996, BRAIN RES, V724, P246, DOI 10.1016/0006-8993(96)00308-3; RISCHKE R, 1991, J CEREBR BLOOD F MET, V11, P106, DOI 10.1038/jcbfm.1991.12; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHIBUYA M, 1987, J NEURAL TRANSM, V68, P271, DOI 10.1007/BF02098503; SHIMOYAMA I, 1988, ANN NEUROL, V24, P718, DOI 10.1002/ana.410240605; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SORG O, 1991, BRAIN RES, V563, P227, DOI 10.1016/0006-8993(91)91538-C; Von Monakow C, 1969, BRAIN BEHAVIOR, P27; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; WECHSLER LR, 1979, J NEUROCHEM, V32, P15, DOI 10.1111/j.1471-4159.1979.tb04504.x; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAO H, 1995, J CEREBR BLOOD F MET, V15, P398, DOI 10.1038/jcbfm.1995.50; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU NC, 1993, P NATL ACAD SCI USA, V90, P4042, DOI 10.1073/pnas.90.9.4042	75	37	37	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 28	1997	777	1-2					42	50		10.1016/S0006-8993(97)00717-8			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YM565	WOS:000071077500005	9449411				2022-02-06	
J	Hymel, KP; Rumack, CM; Hay, TC; Strain, JD; Jenny, C				Hymel, KP; Rumack, CM; Hay, TC; Strain, JD; Jenny, C			Comparison of intracranial computed tomographic (CT) findings in pediatric abusive and accidental head trauma	PEDIATRIC RADIOLOGY			English	Article							HIGH-FIELD MR; CHILD-ABUSE; MAGNETIC-RESONANCE; CRANIOCEREBRAL TRAUMA; SUBDURAL HEMATOMAS; BRAIN TRAUMA; INJURY; HEMORRHAGE; LESIONS; FALX	Background. Child abuse specialists rely heavily on diagnostic neuroimaging. Objectives. Study objectives were: (1) to compare the frequencies of six specific intracranial CT abnormalities in accidental and nonaccidental pediatric head trauma, and (2) to assess interobserver agreement regarding these CT findings. Materials and methods. Three pediatric radiologists blindly and independently reviewed cranial CT scans of pediatric patients who sustained closed head trauma between 1991 and 1994. All patients were less than 4 years of age. Study cases included thirty-nine (50 %) with nonaccidental head trauma and thirty-nine (50 %) with accidental head trauma. Each scan was evaluated for the presence or absence of the following six intracranial findings: (1) interhemispheric falx hemorrhage, (2) subdural hemorrhage, (3) large (non-acute) extra-axial fluid, (4) basal ganglia edema, (5) posterior fossa hemorrhage, and (6) frontal-parietal shearing tear(s). Interobserver agreement was calculated as the percentage of total cases in which all reviewers agreed a specific CT finding was present or absent. Diagnosis required independent agreement by all three pediatric radiologists. The frequencies of these six intracranial CT abnormalities were compared between the two study groups by Chi-square analysis and Fisher's exact test. Results. Interobserver agreement between radiologists was greater than 80 % for all. lesions evaluated, with the exception of frontal-parietal shearing tear(s). Interhemispheric fair hemorrhage, subdural hemorrhage, large (non-acute) extra-axial fluid, and basal ganglia edema were discovered significantly more frequently in non-accidental trauma (P less than or equal to.05). Conclusion. Although not specific for child abuse, discovery of these intracranial CT abnormalities in young patients should prompt careful evaluation of family and injury circumstances for indicators of nonaccidental trauma.	UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80218 USA					Rumack, MD, Carol M/0000-0003-3648-891X; Hymel, Kent/0000-0002-1422-182X			ALEXANDER RC, 1986, J PEDIATR-US, V109, P975, DOI 10.1016/S0022-3476(86)80279-7; AOKI N, 1986, NEUROSURGERY, V18, P475, DOI 10.1227/00006123-198604000-00017; BALL WS, 1989, RADIOLOGY, V173, P609, DOI 10.1148/radiology.173.3.2813759; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; CHEAH IGS, 1994, ANN TROP PAEDIATR, V14, P325, DOI 10.1080/02724936.1994.11747737; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; DUHAIME AC, 1992, PEDIATRICS, V90, P179; FELDMAN KW, 1995, CHILD ABUSE NEGLECT, V19, P307, DOI 10.1016/S0145-2134(94)00130-8; FOBBEN ES, 1989, AM J ROENTGENOL, V153, P589, DOI 10.2214/ajr.153.3.589; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HALLER J D, 1991, Pediatrics, V87, P262; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HARWOODNASH DC, 1992, AM J NEURORADIOL, V13, P569; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MERTEN DF, 1990, PEDIATR CLIN N AM, V37, P815; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OSBORN AG, 1980, RADIOLOGY, V134, P421, DOI 10.1148/radiology.134.2.7352222; PACKER RJ, 1985, PEDIATRICS, V76, P84; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; TSAI FY, 1980, CT-J COMPUT TOMOGR, V4, P277, DOI 10.1016/0149-936X(80)90020-X; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215; ZIMMERMAN RD, 1982, AM J NEURORADIOL, V3, P635	34	37	37	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0301-0449	1432-1998		PEDIATR RADIOL	Pediatr. Radiol.	SEP	1997	27	9					743	747		10.1007/s002470050215			5	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	XX554	WOS:A1997XX55400004	9285736				2022-02-06	
J	McGann, W; Werven, G; Douglas, MM				McGann, W; Werven, G; Douglas, MM			Social competence and head injury: A practical approach	BRAIN INJURY			English	Article								Social competence assessment and training has long focused on specific skills within the clinical setting. In addition, emphasis has been placed on identifying deficits relative to an arbitrary, often idiosyncratic metric. In this article, we discuss the importance of the principles that underlie communication and which are reflected in the range of behaviours described as 'social competence'. We review methods we have found productive in the training of these principles with persons who have suffered traumatic brain injuries.	MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905		McGann, W (corresponding author), SW WASHINGTON MED CTR,400 NE MOTHER JOSEPH PL,VANCOUVER,WA 98664, USA.						Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MCFALL RM, 1982, BEHAV ASSESS, V4, P1; MCGANN W, 1995, BRAIN INJURY, V9, P93, DOI 10.3109/02699059509004575; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; PRUTTING CA, 1982, J SPEECH HEAR DISORD, V47, P123, DOI 10.1044/jshd.4702.123	5	37	38	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1997	11	9					621	628		10.1080/026990597123179			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	XT726	WOS:A1997XT72600001	9376830				2022-02-06	
J	Bombardier, CH; Ehde, D; Kilmer, J				Bombardier, CH; Ehde, D; Kilmer, J			Readiness to change alcohol drinking habits after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HEAD-INJURY; CHANGE QUESTIONNAIRE; SUBSTANCE-ABUSE; ISSUES	Objective: To describe how motivated are persons with recent traumatic brain injury (TBI) to change their alcohol drinking habits and what factors affect their motivation. Design: Survey. Setting: Acute inpatient rehabilitation program. Patients: Subjects were 50 patients with recent TBI during inpatient rehabilitation. Main Outcome Measures: Readiness to Change (RTC) questionnaire, Michigan Alcoholism Screening Test (MAST), and alcohol use questions. Results: Subjects were 36 years old; 86% were men. Eightfour percent fell in the contemplation or action phases. Comparisons with a separate medical patient sample suggested that TBI may be associated with greater contemplation of change and greater readiness to take action to change alcohol use. Multivariate analyses indicated that within the TBI sample a positive history of alcoholism, alcohol involved in the accident, and higher daily consumption were associated with greater readiness to change (especially contemplation scores). Conclusions: Soon after TBI, drinkers frequently contemplate changing their alcohol use. This situation may represent an underutilized window of opportunity to reduce postinjury alcohol use and abuse. Motivational interviewing techniques seem well suited to facilitate change during this period. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	UNIV WASHINGTON,DEPT PSYCHOL,SEATTLE,WA 98195		Bombardier, CH (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT REHABIL MED,325 9TH AVE,BOX 359740,SEATTLE,WA 98104, USA.		Ehde, Dawn/K-1883-2016; Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283; Ehde, Dawn/0000-0002-9555-2347	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U48/CCU009654, R49/CCR002570] Funding Source: Medline		BABOR TF, 1987, J STUD ALCOHOL, V48, P410, DOI 10.15288/jsa.1987.48.410; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; DONOVAN D, 1995, RES SOC ALC STEAMB S; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; GENTILELLO LM, 1988, AM J SURG, V156, P558, DOI 10.1016/S0002-9610(88)80553-1; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HEATHER N, 1993, ADDICTION, V88, P1667, DOI 10.1111/j.1360-0443.1993.tb02042.x; HEATHER N, 1993, 19 U NEW S WAL NAT D; Heinemann A. W., 1989, ALCOHOL HEALTH RES W, V13, P110; Jacobson GR, 1989, HDB ALCOHOLISM TREAT, P17; Jones G.A., 1992, NEUROREHABILITATION, V2, P27; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Miller WR, 1991, MOTIVATIONAL INTERVI; *NAT HEAD INJ FDN, 1988, SUBST AB TASK FORC W; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Selzer ML, 1971, AM J PSYCHIAT, V127, P89; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; WALLER JA, 1990, J TRAUMA, V30, P1548, DOI 10.1097/00005373-199012000-00020; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	27	37	37	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1997	78	6					592	596		10.1016/S0003-9993(97)90424-X			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	XD759	WOS:A1997XD75900005	9196466				2022-02-06	
J	Togher, L; Hand, L; Code, C				Togher, L; Hand, L; Code, C			Measuring service encounters with the traumatic brain injury population	APHASIOLOGY			English	Article; Proceedings Paper	26th Clinical Aphasiology Conference	JUN, 1996	NEWPORT, RI					Functional therapy tasks are frequently cited as being important for the successful carry-over of treatment objectives. Service encounters, such as shopping or enquiring for information on the telephone, are typical community integration activities used with the traumatically brain injured (TBI) population. This paper explores the use of systemic functional linguistics in the measurement of performance in service encounters using Generic Structure Potential (GSP) analysis. Results are presented for GSP analysis of service encounters on the telephone to a bus timetable information service, and the police, for five TBI individuals and five matched controls. Service encounters differed according to the complexity of information requested and the interpersonal, or tenor relationships between participants. Differences were evident between TBI and control interactions in the use of generic structural elements. Variation in generic structure was demonstrated across the two types of service encounter. The potential of GSP to measure the dynamic linguistic patterns in everyday TBT interactions is discussed.	LIVERPOOL AREA HLTH SERV,BRAIN INJURY UNIT,SYDNEY,NSW,AUSTRALIA		Togher, L (corresponding author), UNIV SYDNEY,FAC HLTH SCI,SCH COMMUN DISORDERS,POB 170,LIDCOMBE,NSW 2141,AUSTRALIA.		Code, Chris/F-4259-2010; Togher, Leanne/AAC-7083-2019	Togher, Leanne/0000-0002-4518-6748			Armstrong E. M, 1993, APHASIA TREATMENT WO, P263; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Brennan M., 1994, CLEARTALK POLICE RES; Eggins S., 1990, THESIS U SYDNEY; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Halliday Michael Alexander Kirkwood, 1989, LANGUAGE CONTEXT TEX; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley Leila L., 1992, Seminars in Speech and Language, V13, P264, DOI 10.1055/s-2008-1064202; HASAN R, 1984, NOTTINGHAM LINGUISTI, V13, P71; Hasan R., 1985, LANGUAGE CONTEXT TEX, P52; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Kress G., 1982, LEARNING WRITE; Martin J. R., 1985, FACTUAL WRITING EXPL; Martin J. R., 1992, ENGLISH TEXT SYSTEM; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; ODDY M, 1984, CLOSED HEAD INJURY P, P108; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SLADE D, 1994, AUST REV APPL LING S, V11, P47; SOHLBERG MM, 1989, TOP LANG DISORD, V9, P15, DOI 10.1097/00011363-198903000-00004; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; VENTOLA E, 1979, J PRAGMATICS, V3, P267, DOI 10.1016/0378-2166(79)90034-1; VENTOLA E, 1987, STRUCTURE SOCIAL INT; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205	24	37	39	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0268-7038			APHASIOLOGY	Aphasiology	APR-MAY	1997	11	4-5					491	504		10.1080/02687039708248486			14	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	WU481	WOS:A1997WU48100015		Green Submitted			2022-02-06	
J	Ho, MR; Bennett, TL				Ho, MR; Bennett, TL			Efficacy of neuropsychological rehabilitation for mild-moderate traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							COGNITIVE REHABILITATION; ISSUES	The growing literature on cognitive rehabilitation is increasingly demanding more evaluation related to the validity of such therapy. The current research addresses same of the criticisms of previous previous efficacy studies and provides support for the effectiveness of cognitive rehabilitation according to a specific treatment protocol employed at an outpatient rehabilitation program. Stringent subject selection criterion were utilized to maximize the validity of the statistical comparisons of selected pre- and post- rehabilitation neuropsychological test scores and cognitive level of functioning. Results supported improvement in performance on selected neuropsychological rest scores and cognitive functioning following cognitive rehabilitation. Limited validating evidence for behavioral indicators of level of cognitive functioning were obtained through correlations of behavioral ratings to their corresponding neuropsychological test scores. Results suggest that traditional measures of efficacy of cognitive rehabilitation may be insensitive to the cognitive sequalae of mild head injury due, in part, to compensatory strategies invoked by the subjects. (C) 1997 National Academy of Neuropsychology.	COLORADO STATE UNIV, FT COLLINS, CO 80524 USA; BRAIN INJURY RECOVERY PROGRAM, FT COLLINS, CO 80524 USA								ACIMOVIC ML, 1991, M COL HEAD INJ FDN B; BENNETT TL, 1992, J HEAD INJURY, V3, P21; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; BERROL S, 1990, ARCH NEUROL-CHICAGO, V47, P219, DOI 10.1001/archneur.1990.00530020127025; DICKER BG, 1989, J HEAD TRAUMA REHAB, V4, P73; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; GORDON WA, 1989, J HEAD TRAUMA REHAB, V4, P76; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; LEVIN HS, 1990, ARCH NEUROL-CHICAGO, V47, P223, DOI 10.1001/archneur.1990.00530020131027; LEZAK MD, 1976, NEUROPSYCHOLOGICAL A; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; MAZMANINAN PE, 1991, COGNITIVE REHABILITA; PARSONS OA, 1978, J CONSULT CLIN PSYCH, V46, P608, DOI 10.1037/0022-006X.46.4.608; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; REYNOLDS CR, 1988, EXCEPT CHILDREN, V54, P324, DOI 10.1177/001440298805400406; REYNOLDS CR, 1981, SCH PSYCHOL REV, V10, P343; ROJAS DC, 1995, ARCH CLIN NEUROPSYCH, V10, P101, DOI 10.1016/0887-6177(94)E0038-Q; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SYMONDS C, 1962, LANCET, V1, P1; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; Wolfson, 1993, HALSTEAD REITAN NEUR	23	37	38	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1997	12	1					1	11					11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	WQ271	WOS:A1997WQ27100001	14588430				2022-02-06	
J	Mautes, AEM; Fukuda, K; Noble, LJ				Mautes, AEM; Fukuda, K; Noble, LJ			Cellular response in the cerebellum after midline traumatic brain injury in the rat	NEUROSCIENCE LETTERS			English	Article						fluid percussion injury; immunocytochemistry; microglia; Purkinje cells; vermis	NITRIC-OXIDE; EDEMA; CELLS	We evaluated the response of microglia and Purkinje cells in the cerebellum at 1, 2, 3, 7 and 10 days after a midline fluid percussion brain injury. There was marked activation of microglia and a significant loss of Purkinje cells in the vermis by 7 days postinjury. These findings emphasize the vulnerability of the cerebellum to midline traumatic brain injury.	UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DEPT NEUROSURG,SAN FRANCISCO,CA 94110						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; FUKUDA K, 1996, IN PRESS J NEUROTRAU; IKEDA Y, 1990, NEUROSURGERY, V27, P1; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; NAKASHIMA MN, 1995, CELL MOL NEUROBIOL, V15, P341, DOI 10.1007/BF02089944; OHEARN E, 1993, NEUROREPORT, V4, P299, DOI 10.1097/00001756-199303000-00018; OZAWA H, 1994, BRAIN RES, V651, P345, DOI 10.1016/0006-8993(94)90717-X; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; ZIAI R, 1986, P NATL ACAD SCI USA, V83, P8420, DOI 10.1073/pnas.83.21.8420	12	37	37	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	AUG 23	1996	214	2-3					95	98		10.1016/0304-3940(96)12916-5			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VF281	WOS:A1996VF28100006	8878092				2022-02-06	
J	Cruz, J				Cruz, J			Relationship between early patterns of cerebral extraction of oxygen and outcome from severe acute traumatic brain swelling: Cerebral ischermia or cerebral viability?	CRITICAL CARE MEDICINE			English	Article						head injury; coma; intracranial pressure; oxyhemoglobin; hemodynamics; neurologic emergencies; patient outcome assessment; Glasgow Outcome Scale; brain swelling; cerebral extraction of oxygen	ACUTE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; METABOLIC-RATE; CONSUMPTION; ISCHEMIA	Objective: To evaluate outcome from severe acute traumatic diffuse brain swelling, in relation to early patterns of global cerebral extraction of oxygen. Design: Prospective, interventional study. Setting: Neuroscience intensive care unit of a university hospital. Patients: Adults (n = 205) with acute, essentially isolated brain trauma (predominantly diffuse brain swelling), undergoing routine early monitoring of cerebral extraction of oxygen and intracranial pressure, along with other monitoring modalities. Interventions: Routine neuroemergency procedures. Measurements and Main Results: Cerebral extraction of oxygen (arteriojugular oxyhemoglobin saturation difference) was measured in each patient, early in the acute phase (2 to 8 hrs postinjury), Outcome at 6 months postinjury was significantly better in patients with initially increased cerebral extraction of oxygen (>42%) than in those patients with normal (24% to 42%) or decreased (<24%) values, In contrast, no significant differences were found among these three groups with respect to age, initial Glasgow Coma Scale score, intracranial pressure, cerebral perfusion pressure, Pace,, total hemoglobin content, and time from injury when the initial measurements were performed. Conclusions: Initially increased cerebral extraction of oxygen appears to indicate global cerebral viability rather than cerebral ischemia in patients with acute traumatic diffuse brain swelling.			Cruz, J (corresponding author), MED COLL PENN & HAHNEMANN UNIV,DEPT NEUROSURG,BROAD & VINE ST,MAIL STOP 455,PHILADELPHIA,PA 19102, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR303687] Funding Source: Medline		BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; CRUZ J, 1992, J TRAUMA, V33, P304, DOI 10.1097/00005373-199208000-00022; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Cruz J., 1995, Journal of Neurotrauma, V12, P444; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Gibbs EL, 1942, J BIOL CHEM, V144, P325; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Rappaport Z H, 1981, Prog Neurol Surg, V10, P1, DOI 10.1159/000384765; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81	24	37	38	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	JUN	1996	24	6					953	956		10.1097/00003246-199606000-00013			4	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UQ807	WOS:A1996UQ80700013	8681597				2022-02-06	
J	Raskin, SA; Sohlberg, MM				Raskin, SA; Sohlberg, MM			The efficacy of prospective memory training in two adults with brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	23rd Annual Meeting of the International-Neuropsychological-Society	FEB 08-11, 1995	SEATTLE, WA	Int Neuropsychol Soc			RECOVERY; DOMAIN	Objective: Investigation of prospective memory training in traumatic brain injury (TBI). Design: Within-subject A-B-A-B study with before-after trial assessment on criterion standard neuropsychological measures and two types of generalization probes. Setting: Subjects received outpatient assessment and training in a private clinic. Patients: Two individuals with TBI were selected from 30 consecutive referrals to an outpatient clinic. Subject selection criteria included age of 20 to 55 years; acquired brain injury greater than 1 year; ability to tell time; no previous participation in cognitive rehabilitation; no previous neurologic or psychiatric disorder, substance abuse history, or learning disability; significant other available to take generalization data. Intervention: Subjects received separate blocks of two types of memory intervention; prospective memory training and retrospective memory drill. Prospective memory training consisted of repetitive administration of assigned actions to be completed at future specified times. Retrospective memory intervention required the subjects to recall their prior actions. Main Outcome Measures: Four outcome measures were used: (1) performance on the prospective memory screening test, (2) performance on criterion standard neuropsychological measures, (3) and 4) probes of everyday prospective memory. Results: Results were consistent across both subjects and suggested their ability to complete designated tasks at target times improved in both the training and community environments as a function of the prospective memory training. One subject improved from a I-minute prospective memory span to 5 minutes and the other from 2 minutes to 10 minutes. Conclusions: Preliminary data suggest that prospective memory training can improve an individual's prospective memory span and that this training generalizes to daily life.	HOSP GOOD SAMARITAN,CTR CONTINUING REHABIL,PUYALLUP,WA; UNIV OREGON,DEPT COMMUN DISORDERS & SCI,EUGENE,OR 97403		Raskin, SA (corresponding author), TRINITY COLL,DEPT PSYCHOL,HARTFORD,CT 06106, USA.		Raskin, Sarah/T-1420-2019	Raskin, Sarah/0000-0002-4310-4278			Benson D.F., 1986, FRONTAL LOBES; BUTTERS MA, 1993, J CLIN EXP NEUROPSYC, V15, P219, DOI 10.1080/01688639308402559; DAVIS HP, 1994, COLORADO NEUROPSYCHO; DELIS D, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1; FRANZEN M, NEUROPSYCHOL REV, V2, P29; Furst C., 1986, COGNITIVE REHABILITA, V4, P24; Fuster JM., 1980, PREFRONTAL CORTEX; GAGNE RM, 1962, J EXP PSYCHOL, V63, P12, DOI 10.1037/h0048703; GLISKY EL, 1988, J LEARN DISABIL-US, V21, P333, DOI 10.1177/002221948802100604; GLISKY EL, 1989, NEUROPSYCHOLOGIA, V27, P107, DOI 10.1016/0028-3932(89)90093-6; GLISKY EL, 1986, J HEAD TRAUMA REHAB, V1, P54, DOI DOI 10.1097/00001199-198609000-00009; Goldman-Rakic P. S., 1993, J HEAD TRAUMA REHAB, V8, P13; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HARRIS JE, 1982, HUM LEARN, V1, P123; HARRIS JE, 1983, EVERYDAY MEMORY ACTI; KORIAT A, 1990, MEM COGNITION, V18, P568, DOI 10.3758/BF03197099; KRESNER R, 1989, EXP BRAIN RES, V74, P163; KVAVILASHVILI L, 1992, APPL COGNITIVE PSYCH, V6, P507, DOI 10.1002/acp.2350060605; Levin HS., 1982, NEUROBEHAVIORAL CONS; Levy R. L., 1984, EVERYDAY MEMORY ACTI; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; MATEER CA, 1988, ATTENTION PROCESS TR; Meacham J. A., 1982, J APPL DEV PSYCHOL, V3, P121, DOI DOI 10.1016/0193-3973(82)90023-5; OLTON D, 1991, MEMORY ORG LOCUS CHA; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIMAMURA AP, 1988, J EXP PSYCHOL LEARN, V14, P763, DOI 10.1037/0278-7393.14.4.763; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1989, PROSPECTIVE MEMORY S; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TERRY WS, 1988, PSYCHOL REP, V62, P299, DOI 10.2466/pr0.1988.62.1.299; WEST RL, 1984, M AM PSYCH ASS TOR C; WILKENS A, 1988, PRACTICAL ASPECTS ME, P1; WILSON B, 1987, REHABILITATION MEMOR; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; WINOGRAD E, 1988, PRACTICAL ASPECTS ME, P1	41	37	38	0	11	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1996	11	3					32	51		10.1097/00001199-199606000-00007			20	Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UP774	WOS:A1996UP77400007					2022-02-06	
J	Glisky, EL; Delaney, SM				Glisky, EL; Delaney, SM			Implicit memory and new semantic learning in posttraumatic amnesia	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						dosed head injury; implicit memory; posttraumatic amnesia; rehabilitation; semantic learning	CLOSED HEAD-INJURY; IMPAIRED PATIENTS; PRACTICAL SCALE; RETENTION; ACQUISITION; KNOWLEDGE; DURATION	Whether cognitive rehabilitation should be begun in patients with closed head injury before posttraumatic amnesia (PTA) has resolved has been a matter of debate. This article reports two studies that demonstrate that PTA patients are capable of learning during PTA. The first study establishes that PTA patients show significant priming in an implicit stem completion task. The second study indicates that PTA patients can learn new semantic information using the method of vanishing cues. These results suggest that some memory systems remain functional during PTA and that early interventions may be beneficial.			Glisky, EL (corresponding author), UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85721 USA.						ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BROOKS N, 1989, ASSESSMENT BEHAV CON; CERMAK LS, 1976, NEUROPSYCHOLOGIA, V14, P311, DOI 10.1016/0028-3932(76)90025-7; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; CORKIN SH, 1987, NEUROBEHAVIOURAL REC; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; GABRIELI JDE, 1995, PSYCHOL SCI, V6, P76, DOI 10.1111/j.1467-9280.1995.tb00310.x; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1992, NEUROPSYCHOLOGIA, V30, P899, DOI 10.1016/0028-3932(92)90034-J; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; GLISKY EL, 1994, COGNITIVE NEUROPSYCH; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; Kuera H., 1967, COMPUTATIONAL ANAL P; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1992, NEUROPSYCHOLOGY MEMO; Overton DA, 1978, DRUG DISCRIMINATION; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SAINTCYR JA, 1992, NEUROPSYCHOLOGY MEMO; Schacter D. L., 1994, MEMORY SYSTEMS 1994; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; SCHACTER DL, 1990, ANN NY ACAD SCI, V608, P543, DOI 10.1111/j.1749-6632.1990.tb48909.x; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHIMAMURA AP, 1986, Q J EXP PSYCHOL-A, V38, P619, DOI 10.1080/14640748608401617; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SQUIRE LR, 1987, NEUROPSYCHOLOGIA, V25, P195, DOI 10.1016/0028-3932(87)90131-X; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1991, J EXP PSYCHOL LEARN, V17, P595, DOI 10.1037/0278-7393.17.4.595; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; WILSON BA, 1992, CLIN MANAGEMENT MEMO; Wilson BA., 1992, NEUROPSYCHOL REHABIL, V2, P231, DOI [DOI 10.1080/09602019208401410, 10.1080/09602019208401410]; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; Winocur G, 1996, NEUROPSYCHOLOGY, V10, P57, DOI 10.1037/0894-4105.10.1.57; [No title captured]	42	37	37	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1996	11	2					31	42		10.1097/00001199-199604000-00004			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UD674	WOS:A1996UD67400004					2022-02-06	
J	SchmitterEdgecombe, M				SchmitterEdgecombe, M			Effects of divided attention on implicit and explicit memory performance following severe closed head injury	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	International-Neuropsychological-Society Meeting	JAN, 1995	SEATTLE, WA	Int Neuropsychol Soc			UNCONSCIOUS INFLUENCES; HUNTINGTONS-DISEASE; RECOGNITION MEMORY; INTENTIONAL USES; INFORMATION; ALZHEIMERS; ACTIVATION; RETRIEVAL; RETENTION; AMNESIA	This study investigated the relation between attentional limitations and memory impairments in patients with dosed head injuries (CHI). Twenty-seven CHI participants (> 1 year postinjury) and 27 matched controls rated their liking of target words under conditions of full and divided attention. Participants then completed an implicit test of tachistoscopic identification (TI) and an explicit test of recognition for the target words. As expected, the results revealed impaired explicit memory but preserved perceptually driven implicit memory performance following a CHI. Contrary to what was hypothesized, a reduction in attention available at encoding did not disproportionately impair the recognition performance of the CHI patients. Finally, unlike controls, the CHI participants' priming scores on the TI task were significantly affected by dividing attention at encoding. However, this finding interacted with CHI participants' perceptual processing rates, suggesting that nonmemory cognitive factors may influence measured performances on implicit memory tests.	MEMPHIS UNIV, MEMPHIS, TN 38152 USA		SchmitterEdgecombe, M (corresponding author), WASHINGTON STATE UNIV, DEPT PSYCHOL, PULLMAN, WA 99164 USA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANDERSON CM, 1974, J VERB LEARN VERB BE, V13, P107, DOI 10.1016/S0022-5371(74)80035-6; AURENBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1; BATTIG WF, 1969, J EXPT PSYCHOL MON 2, V80; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BUCKNER RL, 1995, J NEUROSCI, V15, P12; CATTELL RB, 1973, HDB INDIVIDUAL GROUP; CERMAK LS, 1992, BRAIN COGNITION, V20, P367, DOI 10.1016/0278-2626(92)90027-J; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DYWAN J, 1993, BRAIN COGNITION, V21, P20, DOI 10.1006/brcg.1993.1002; EICH E, 1984, MEM COGNITION, V12, P105, DOI 10.3758/BF03198423; Ekstrom RB., 1976, MANUAL KIT FACTOR RE; FAHY JF, 1995, J INT NEUROPSYCH SOC, V1, P183; GARDINER JM, 1990, MEM COGNITION, V18, P579, DOI 10.3758/BF03197100; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GREENE RL, 1986, Q J EXP PSYCHOL-A, V38, P663, DOI 10.1080/14640748608401619; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; HAMANN SB, 1995, NEUROPSYCHOLOGY, V9, P3, DOI 10.1037/0894-4105.9.1.3; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; Heaton R.K., 1981, WISCONSIN CARD SORTI; HEINDEL WC, 1990, BRAIN COGNITION, V13, P282, DOI 10.1016/0278-2626(90)90053-Q; HORTON DL, 1993, J MEM LANG, V32, P39, DOI 10.1006/jmla.1993.1003; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; JACOBY LL, 1989, J EXP PSYCHOL GEN, V118, P115, DOI 10.1037/0096-3445.118.2.115; JACOBY LL, 1993, J EXP PSYCHOL GEN, V122, P139, DOI 10.1037/0096-3445.122.2.139; JENNINGS JM, 1993, PSYCHOL AGING, V8, P283, DOI 10.1037/0882-7974.8.2.283; JERNIGAN TL, 1993, NEUROPSYCHOLOGY, V7, P14, DOI DOI 10.1037/0894-4105.7.1.14; Kaplan E., 1987, MANUAL CALIFORNIA VE; KELLEY CM, 1993, J MEM LANG, V32, P1, DOI 10.1006/jmla.1993.1001; Kuera H., 1967, COMPUTATIONAL ANAL P; LEVIN HS, 1988, SCAND J REHABIL MED, P33; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MADDEN DJ, 1986, EXP AGING RES, V12, P71; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; NISSEN M, 1986, J HEAD TRAUMA REHAB, V1, P13; Parkin A. J., 1990, EUROPEAN J COGNITIVE, V2, P71, DOI [DOI 10.1080/09541449008406198, 10.1080/09541449008406198]; PARKIN AJ, 1990, MEM COGNITION, V18, P507, DOI 10.3758/BF03198483; RANDOLPH C, 1993, J CLIN EXP NEUROPSYC, V15, P853, DOI 10.1080/01688639308402603; RANDOLPH C, 1991, J CLIN EXP NEUROPSYC, V13, P479, DOI 10.1080/01688639108401065; REINITZ MT, 1994, J EXP PSYCHOL LEARN, V20, P161, DOI 10.1037/0278-7393.20.1.161; RICHARDSONKLAVEHN A, 1988, ANNU REV PSYCHOL, V39, P475, DOI 10.1146/annurev.ps.39.020188.002355; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; ROEDIGER HL, 1989, VARIETIES MEMORY CON; ROGERS WA, 1994, PSYCHOL AGING, V9, P398, DOI 10.1037/0882-7974.9.3.398; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; SCHACTER DL, 1990, DEV NEURAL BASES HIG, V608, P543; SCHMITTEREDGECO.M, 1995, 15 ANN M NAT AC NEUR; SCHMITTEREDGECO.M, IN PRESS J INT NEURO; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; SMITH ER, 1988, J EXP SOC PSYCHOL, V24, P490, DOI 10.1016/0022-1031(88)90048-0; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; SQUIRE LR, 1992, J EXP PSYCHOL LEARN, V18, P106, DOI 10.1037/0278-7393.18.1.106; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; SRINIVAS K, 1990, J MEM LANG, V29, P389, DOI 10.1016/0749-596X(90)90063-6; STANOVICH KE, 1979, MEM COGNITION, V7, P77, DOI 10.3758/BF03197588; Toth J. P., 1992, NEUROPSYCHOLOGY MEMO, P46; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; TULVING E, 1990, SCIENCE, V247, P301, DOI 10.1126/science.2296719; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler, 1997, WECHSLER ADULT INTEL; [No title captured]	65	37	38	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	APR	1996	10	2					155	167					13	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology; Neurosciences & Neurology	UD704	WOS:A1996UD70400002					2022-02-06	
J	Hornstein, A; Lennihan, L; Seliger, G; Lichtman, S; Schroeder, K				Hornstein, A; Lennihan, L; Seliger, G; Lichtman, S; Schroeder, K			Amphetamine in recovery from brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY	A chart review of dextroamphetamine treatment in 27 traumatic brain injury patients during rehabilitation therapy suggests that amphetamine treatment enhanced the recovery and functional status of 15 patients.	HELEN HAYES HOSP,DEPT NEUROL,W HAVERSTRAW,NY 10993; HELEN HAYES HOSP,DEPT INTERNAL MED,W HAVERSTRAW,NY 10993; COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY		Hornstein, A (corresponding author), HELEN HAYES HOSP,DEPT PSYCHIAT,ROUTE 9W,W HAVERSTRAW,NY 10993, USA.						*AM HEART ASS, 1988, 1989 STROK FACTS; BARRETT K, 1991, J NEUROL NEUROSUR PS, V54, P718, DOI 10.1136/jnnp.54.8.718; COOPER JR, 1986, BIOCH BASIS NEUROPHA, P293; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FLEET WS, 1987, NEUROLOGY, V37, P1765, DOI 10.1212/WNL.37.11.1765; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Kraus Jess F., 1994, P3; MALING HM, 1946, J NEUROPHYSIOL, V9, P379, DOI 10.1152/jn.1946.9.5.379; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; Robinson Robert G., 1994, P219; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Starkstein S. E., 1993, DEPRESSION NEUROLOGI, P28; URANOVA NA, 1989, J HIRNFORSCH, V30, P45	15	37	39	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1996	10	2					145	148		10.1080/026990596124647			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	UB726	WOS:A1996UB72600009	8696315				2022-02-06	
J	Spain, DA; DeWeese, C; Reynolds, MA; Richardson, JD				Spain, DA; DeWeese, C; Reynolds, MA; Richardson, JD			Transpyloric passage of feeding tubes in patients with head injuries does not decrease complications	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							GASTROSTOMY; SAFETY	Early enteral nutrition is reported to improve outcome of patients with severe closed head injuries (CHI). The efficacy and safety of nasoenteric tube (NET) feeds, however, has been questioned; the risk of aspiration is the major concern. Our purpose was to determine the rate of transpyloric migration, the efficacy of adjunctive measures to promote passage, and the effect on pulmonary complications. Seventy-four consecutive patients with moderate to severe CHI received enteral nutrition. Glasgow Coma Scale (GSC) score was 5.2 on admission and 6.9 at 48 hours, NETs were placed an average of 5.6 days after admission; an average of three abdominal films per patient mere used to assess tube position, No patients had endoscopic NET placement during this period. Ten patients required fluoroscopic placement after failure to pass spontaneously by 5 days, Overall, transpyloric passage was achieved in 32 patients (43%), whereas 42 (57%) remained intragastric, There were no differences between the postpyloric and intragastric groups in days to full feeding (5 vs. 7 days), ventilator days (11.9 vs, 12.5), intensive care unit length of stay (15.5 vs, 15.1), or incidence of pneumonia (81 vs, 69%) or aspiration (6 vs 7%), Sixty-two patients (83%) were transferred to extended care facilities and 50 (68%) were still receiving NET feedings, Spontaneous transpyloric passage of NET occurred in less than one-half of patients with severe CHI. The routine use of adjunctive measures to promote transpyloric passage was not particularly successful, had no obvious benefit, and therefore may not he necessary.			Spain, DA (corresponding author), UNIV LOUISVILLE,SCH MED,DEPT SURG,LOUISVILLE,KY 40292, USA.						BORZOTTA AP, 1994, J TRAUMA, V36, P158; BORZOTTA AP, 1993, SURG FORUM, V42, P29; DAMELIO LF, 1994, AM SURGEON, V60, P180; FAY DE, 1991, AM J GASTROENTEROL, V86, P1604; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; GRANT JP, 1983, JPEN-PARENTER ENTER, V7, P299, DOI 10.1177/0148607183007003299; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; KIVER KF, 1984, JPEN-PARENTER ENTER, V8, P95; MARIAN M, 1993, SURG GYNECOL OBSTET, V176, P475; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; RAPP RP, 1983, J NEUROSURG, V58, P401; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; STARK SP, 1991, AM SURGEON, V57, P203; STRONG RM, 1992, JPEN-PARENTER ENTER, V16, P59, DOI 10.1177/014860719201600159; Ugo P J, 1992, Nutr Clin Pract, V7, P284, DOI 10.1177/0115426592007006284; VANE DW, 1982, J PEDIATR SURG, V17, P960, DOI 10.1016/S0022-3468(82)80475-2	17	37	37	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1995	39	6					1100	1102		10.1097/00005373-199512000-00015			3	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	TL905	WOS:A1995TL90500015	7500401				2022-02-06	
J	WADE, S; DROTAR, D; TAYLOR, HG; STANCIN, T				WADE, S; DROTAR, D; TAYLOR, HG; STANCIN, T			ASSESSING THE EFFECTS OF TRAUMATIC BRAIN INJURY ON FAMILY FUNCTIONING - CONCEPTUAL AND METHODOLOGICAL ISSUES	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						TRAUMATIC BRAIN INJURY; FAMILY ADAPTATION; FAMILY ASSESSMENT; SOCIAL RESOURCES; STRESSORS	CLOSED HEAD-INJURY; CHRONICALLY ILL; RISK-FACTORS; CHILDREN; SEQUELAE; ADAPTATION; STRESS	Reviewed empirical literature published since 1975 on the effects of pediatric traumatic brain injury (TBI) on the family. Few systematic, hypothesis-driven investigations of the impact of TBI on family functioning have been conducted. However, existing findings indicate that severe TBI can adversely affect families and individual family members. Certain factors, such as poor preinjury functioning and parental psychological disorder, appear To place families at greater risk for long-term disruption. Issues associated with the conceptualization of the impact of TBI on various aspects of family functioning are discussed and methodological considerations are outlined. Special attention is given to novel strategies for studying these complex, multifaceted issues. Finally, a framework is proposed for examining the processes of family adaptation after pediatric TBI to guide future research directions.	CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; RAINBOW BABIES & CHILDRENS HOSP,CLEVELAND,OH 44106; METROHLTH MED CTR,CLEVELAND,OH 44109				Stancin, Terry/L-7993-2019		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		BIJUR PE, 1990, PEDIATRICS, V86, P337; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; Boss P., 1992, J FAM PSYCHOL, V6, P113, DOI [10.1037/0893-3200.6.2.113, DOI 10.1037/0893-3200.6.2.113]; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; COLE DA, 1989, J COUNS PSYCHOL, V36, P456, DOI 10.1037/0022-0167.36.4.456; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; Gottman J., 1993, J FAM PSYCHOL, V7, P57, DOI [DOI 10.1037/0893-3200.7.1.57, 10.1037/0893-3200.7.1.57]; GOTTMAN JM, 1992, J PERS SOC PSYCHOL, V63, P221, DOI 10.1037/0022-3514.63.2.221; Grotevant H. D., 1989, FAMILY ASSESSMENT GU; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; HU XH, 1993, CAN MED ASSOC J, V149, P421; KAZAK AE, 1989, J CONSULT CLIN PSYCH, V57, P25, DOI 10.1037/0022-006X.57.1.25; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; LEZAK M, 1987, J CLIN EXPT NEUROPSY, V10, P111; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; MCCUBBIN HI, 1982, FAMILY STRESS COPING, P00026, DOI DOI 10.1177/0730888412446710; NAKAYAMA DK, 1990, J TRAUMA, V30, P1390, DOI 10.1097/00005373-199011000-00012; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Ransom D., 1990, FAMILY VARIABLES CON, P48; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RIVARA JB, 1994, PEDIATR ANN, V23, P38, DOI 10.3928/0090-4481-19940101-09; ROLLAND JS, 1987, FAM PROCESS, V26, P203, DOI 10.1111/j.1545-5300.1987.00203.x; RUTTER M, 1983, DEV NEUROPSYCHIATRY, P83; Spielberger C.D., 1992, J FAMILY PSYCHOL, V6, P99, DOI [10.1037/0893-3200.6.2.99, DOI 10.1037/0893-3200.6.2.99]; TAYLRO HG, IN PRESS TRAUMATIC H; THOMPSON RJ, 1993, J PEDIATR PSYCHOL, V18, P549, DOI 10.1093/jpepsy/18.5.549; WAALAND P, 1991, NEUROPSYCHOL REHABIL, V1, P19; WALLANDER JL, 1989, J PEDIATR PSYCHOL, V14, P157, DOI 10.1093/jpepsy/14.2.157; [No title captured], DOI DOI 10.1097/00001199-198812000-00004; [No title captured]; [No title captured]	35	37	39	0	0	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	DEC	1995	20	6					737	752		10.1093/jpepsy/20.6.737			16	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	TK236	WOS:A1995TK23600004	8558375				2022-02-06	
J	STALLINGS, G; BOAKE, C; SHERER, M				STALLINGS, G; BOAKE, C; SHERER, M			COMPARISON OF THE CALIFORNIA VERBAL-LEARNING TEST AND THE REY AUDITORY VERBAL-LEARNING TEST IN HEAD-INJURED PATIENTS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MEMORY; FORM	Performances of moderate and severe closed-head-injury patients were compared on the California Verbal Learning Test (CVLT) and Rey Auditory Verbal Learning Test (RAVLT). Results showed that raw scores were highly correlated between tests. There were no significant between-test differences in mean raw scores. However, standard scores calculated from existing CVLT and RAVLT norms were significantly lower on the CVLT than on the RAVLT. Furthermore, there were differences between the various RAVLT norm sets. The results indicate that although the CVLT and RAVLT measure similar cognitive processes in closed-head-injury patients, there are major discrepancies in test interpretation using existing norms. Test and norm set selection significantly influence the likelihood of a patient being classified as memory-impaired.	UNIV TEXAS,SCH MED,HOUSTON,TX; BAYLOR COLL MED,HOUSTON,TX		STALLINGS, G (corresponding author), UNIV HOUSTON,DEPT PSYCHOL,4800 CALHOUN,HOUSTON,TX 77204, USA.						BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; CRAWFORD JR, 1989, J CLIN EXP NEUROPSYC, V11, P975, DOI 10.1080/01688638908400950; CROSSEN JR, 1994, J CLIN EXP NEUROPSYC, V16, P190, DOI 10.1080/01688639408402630; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DELIS D, 1987, CALIFORNIA VERBAL LE; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Ivnik R.J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MACARTNEYFILGAT.MS, 1988, ARCH CLIN NEUROPSYCH, V3, P121; REY A, 1964, LEXAMEN CLIN PSYCHOL; RYAN JJ, 1986, J CLIN EXP NEUROPSYC, V8, P611, DOI 10.1080/01688638608405179; SAVAGE RM, 1992, ARCH CLIN NEUROPSYCH, V7, P407, DOI 10.1016/0887-6177(92)90153-E; Schear JM, 1989, CLIN NEUROPSYCHOL, V3, P162; SPRREN O, 1991, COMPENDIUM NEUROPSYC; TEASDALE G, 1974, LANCET, V1, P81; Wiens A. N., 1988, CLIN NEUROPSYCHOL, V2, P67; WIENS AN, 1994, CLIN NEUROPSYCHOL, V8, P75, DOI 10.1080/13854049408401545	21	37	38	0	7	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1995	17	5					706	712		10.1080/01688639508405160			7	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	TD240	WOS:A1995TD24000006	8557811				2022-02-06	
J	BIEGON, A; JOSEPH, AB				BIEGON, A; JOSEPH, AB			DEVELOPMENT OF HU-211 AS A NEUROPROTECTANT FOR ISCHEMIC BRAIN-DAMAGE	NEUROLOGICAL RESEARCH			English	Article; Proceedings Paper	Cambridge-Healthtech-Institute Meeting on New Strategies to Prevent Neural Damage from Ischemic Stroke	OCT 27-28, 1994	BOSTON, MA	Cambridge Healthtech Inst		NMDA ANTAGONISTS; ANTIOXIDANTS; STROKE; HEAD INJURY	RAT MODEL; RECEPTOR; INJURY; OCCLUSION	HU-211 (Dexanabinol), a putative neuroprotective agent, was evaluated in a number of animal models including closed head injury, optic nerve crush, global ischemia and focal ischemia. In these models, a single injection of HU-211 given after the insult confers long term functional improvement and significant increase in neuronal survival. Neuroprotective doses of HU-211 were found to be safe in a 14 day toxicological study in two species. In terms of mechanism, the compound behaves as a noncompetitive NMDA antagonist in vitro and in vivo. It blocks NMDA stimulated calcium influx in primary neuronal culture, and head injury related calcium influx in rats. In addition, HU-211 is a potent scavenger of peroxy and hydroxy radicals in vitro and it protects cultured neurons from toxicity of radical generators. Thus, Dexanabinol holds a unique position among putative neuroprotective agents since it combines NMDA blocking activity and free radical scavenging properties in one molecule. These observations support the development of HU-211 as a novel, multiple-action treatment approach for brain damage associated with stroke, cardiac arrest and trauma.			BIEGON, A (corresponding author), PHARMOS LTD, RES & DEV, IL-76326 REHOVOT, ISRAEL.						BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; ESHHAR N, 1993, NEUROREPORT, V5, P237, DOI 10.1097/00001756-199312000-00013; ESHHAR N, 1994, J NEUROCHEM, V63, pS79; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HALLIWELL B, 1990, FREE RADICAL RES COM, V9, P1, DOI 10.3109/10715769009148569; HOWLETT AC, 1990, NEUROPHARMACOLOGY, V29, P161, DOI 10.1016/0028-3908(90)90056-W; IZUMI Y, 1993, EXP NEUROL, V121, P14, DOI 10.1006/exnr.1993.1067; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MELDRUM B, 1987, NEUROTOXINS THEIR PH, P33; NADLER V, 1993, BRAIN RES, V622, P79, DOI 10.1016/0006-8993(93)90804-V; NADLER V, 1994, AM SOC NEUR ABST, V20, P194; NADLER V, 1993, NEUROSCI LETT, V159, P1; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; VERED M, 1994, ACTA NEUROCHIR, P335; VOLPE BT, 1984, STROKE, V15, P267	26	37	39	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	AUG	1995	17	4					275	280		10.1080/01616412.1995.11740326			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	RP369	WOS:A1995RP36900006	7477742				2022-02-06	
J	LI, GH; BAKER, SP; FOWLER, C; DISCALA, C				LI, GH; BAKER, SP; FOWLER, C; DISCALA, C			FACTORS RELATED TO THE PRESENCE OF HEAD-INJURY IN BICYCLE-RELATED PEDIATRIC TRAUMA PATIENTS	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							HELMET USE; CHILDREN	Using data from the National Pediatric Trauma Registry, this study examined the characteristics of bicycle-related head injury, factors related to the presence of head injury, and different outcomes of head injury up to the time of discharge. Of the 2,333 patients ages 0 to 14 years who were admitted to trauma centers because of bicycle-related injury during 1989 through 1992, more than one-half (54%) sustained head injury, predominantly concussions and skull fractures. With adjustment for age, sex, and motor vehicle involvement, children who had pre-existing mental disorders, who did not wear a helmet at the time of injury, or who were injured on roads had a significantly increased likelihood of sustaining head injuries. Patients with a head injury were four times as likely as patients with no head injury to be treated in intensive care units, and were almost twice as likely to develop complications. Head injury was associated with an increased risk of inhospital fatality and high prevalence rates of communication and behavior impairments at discharge. Although it is urgent to increase helmet use substantially by child bicyclists, special attention should be paid to high-risk groups, such as children with mental disorders and children who are likely to ride in traffic.	TUFTS UNIV NEW ENGLAND MED CTR,RES & TRAINING CTR REHABIL & CHILDHOOD TRAUMA,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111		LI, GH (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,CTR INJURY RES & POLICY,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R29AA009963] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R29AA09963-01] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B344, R49/CCR302486] Funding Source: Medline		Baker SP, 1993, INJURIES BICYCLISTS; BERGMAN AB, 1990, AM J DIS CHILD, V144, P727, DOI 10.1001/archpedi.1990.02150300127033; BUNTAIN WL, 1985, P AM ASS AUT MED, V29, P307; CAMERON MH, 1994, ACCIDENT ANAL PREV, V26, P325, DOI 10.1016/0001-4575(94)90006-X; CUSHMAN R, 1991, AM J PUBLIC HEALTH, V81, P1044, DOI 10.2105/AJPH.81.8.1044; DANNENBERG AL, 1993, AM J PUBLIC HEALTH, V83, P667, DOI 10.2105/AJPH.83.5.667; DANNENBERG AL, 1993, PUBLIC HEALTH REP, V108, P212; EWING CL, 1983, IMPACT INJURY HEAD S; FRIEDE AM, 1985, PEDIATR CLIN N AM, V32, P141; KRAUS JF, 1987, AM J PUBLIC HEALTH, V77, P76, DOI 10.2105/AJPH.77.1.76; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; NAKAYAMA DK, 1990, J TRAUMA, V30, P1390, DOI 10.1097/00005373-199011000-00012; RIVARA FP, 1994, PEDIATRICS, V93, P567; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; TEPAS JJ, 1989, J PEDIATR SURG, V24, P156, DOI 10.1016/S0022-3468(89)80237-4; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WEISS BD, 1992, PEDIATRICS, V89, P78; WOOD T, 1988, ACCIDENT ANAL PREV, V20, P177, DOI 10.1016/0001-4575(88)90002-4; YEARGINALLSOPP M, 1992, PEDIATRICS, V89, P624; 1994, DIAGNOSTIC STATISTIC; 1986, SUGI SUPPLEMENTAL LI	22	37	37	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Inf. Crit. Care	JUN	1995	38	6					871	875		10.1097/00005373-199506000-00007			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	RG548	WOS:A1995RG54800007	7602626				2022-02-06	
J	FLANAGAN, S; MCDONALD, S; TOGHER, L				FLANAGAN, S; MCDONALD, S; TOGHER, L			EVALUATING SOCIAL SKILLS FOLLOWING TRAUMATIC BRAIN INJURY - THE BRISS AS A CLINICAL TOOL	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; BEHAVIORAL-ASSESSMENT; COMPETENCE; RECOVERY	Deficits in social behaviour are a major obstacle to the reintegration into the community of traumatically brain-injured (TBI) individuals. Recognition of the importance of social skill remediation has highlighted the need for a suitable assessment tool. The TBI population presents particular requirements with respect to the special nature of deficits which commonly occur as a result of frontal lobe impairment. The Behaviorally Referenced Rating System of Intermediate Social Skills (the BRISS) has been shown to have good psychometric properties with a TBI population. It also provides a measure of particular social skills associated with frontal lobe functioning. This study examines the ability of the verbal scales of the BRISS to identify social skill deficits at the individual client level and to detect significant changes in skills following an intervention programme involving five chronic TBI males. In the case of one client, who demonstrated significant clinical improvement in social behaviour, the BRISS was found to identify specific areas of apparent change. The difficulty of using the BRISS as a sole measure of social skills is discussed in the light of relatively large pre-intervention within-subject variability which was found with respect to some behaviours.	UNIV NEW S WALES,SCH PSYCHOL,KENSINGTON,NSW 2033,AUSTRALIA; LIDCOMBE HOSP,DEPT SPEECH PATHOL,LIDCOMBE,NSW,AUSTRALIA				McDonald, Skye/G-4118-2014; Togher, Leanne/AAC-7083-2019	McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748			ARKOWITZ H, 1975, BEHAV THER, V6, P3, DOI 10.1016/S0005-7894(75)80056-6; Boake C, 1991, COGNITIVE REHABILITA; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BORKOVEC TD, 1974, BEHAV THER, V5, P503, DOI 10.1016/S0005-7894(74)80040-7; BOWERS S, 1973, PSYCHOL REV, V80, P306; BRAUNLINGMCMORR.D, 1986, J REHABIL, V52, P39; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CROSSON B, CLIN NEUROPSYCHOLOGI, V1, P335; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; EKEHAMMAR B, 1974, PSYCHOL BULL, V81, P1026, DOI 10.1037/h0037457; ENDLER NS, 1976, PSYCHOL BULL, V89, P956; FARRELL AD, 1985, BEHAV ASSESS, V7, P155; FOWLER RS, 1972, AM J NURS, V76, P2056; GLASGOW RE, 1975, BEHAV THER, V6, P488, DOI 10.1016/S0005-7894(75)80005-0; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KAZDIN AE, 1992, METHODOLOGICAL ISSUE; Kinsella G, 1989, Int Disabil Stud, V11, P9; Levin HS., 1982, NEUROBEHAVIORAL CONS; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; Milton S. B., 1986, CLIN NEUROPSYCHOLOGY, P223, DOI [10.1007/978-1-4613-2291-7_11, DOI 10.1007/978-1-4613-2291-7_11]; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRIGATANO GP, 1986, NEUROPSYCHOLOGICAL R, P29; Prutting C., 1983, PRAGMATIC ASSESSMENT, P29; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SHAVELSON RJ, 1991, GENERALISABILITY THE; Siegel S, 1988, NONPARAMETRIC STATIS; TROWER P, 1980, J CONSULT CLIN PSYCH, V48, P327, DOI 10.1037/0022-006X.48.3.327; TWENTYMAN CT, 1975, J CONSULT CLIN PSYCH, V43, P384, DOI 10.1037/h0076743; WALLANDER JL, 1985, BEHAV ASSESS, V7, P137; Walsh K. W., 1985, UNDERSTANDING BRAIN; WOLF MM, 1978, J APPL BEHAV ANAL, V11, P203, DOI 10.1901/jaba.1978.11-203	38	37	37	0	7	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1995	9	4					321	338		10.3109/02699059509005773			18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QY080	WOS:A1995QY08000001	7640679				2022-02-06	
J	HIGH, WM; BOAKE, C; LEHMKUHL, LD				HIGH, WM; BOAKE, C; LEHMKUHL, LD			CRITICAL ANALYSIS OF STUDIES EVALUATING THE EFFECTIVENESS OF REHABILITATION AFTER TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						EFFECTIVENESS OF REHABILITATION; TRAUMATIC BRAIN INJURY; OUTCOME STUDIES; EXPERIMENTAL DESIGN	CLOSED-HEAD-INJURY; INPATIENT REHABILITATION; STROKE REHABILITATION; PRACTICAL SCALE; RECOVERY; COMA; MILD; ORIENTATION	This article critiques recent studies of the effectiveness of inpatient and outpatient rehabilitation after traumatic brain injury with respect to how well they have controlled for the nature and severity of initial brain injury, time since injury, and preinjury characteristics of the subjects. These variables potentially confound the results of studies attempting to determine whether rehabilitation after traumatic brain injury results in improved outcomes and whether it is cost effective. To advance this field of research, investigators must be more uniform and explicit in the characterization of their subjects with respect to severity of injury and preinjury characteristics and more uniform in their selection of functional outcome measures, and they must use control groups of patients who receive few services or alternative treatments.	INST REHABIL & RES,BRAIN INJURY RES CTR,HOUSTON,TX; INST REHABIL & RES,DEPT NEUROPSYCHOL,HOUSTON,TX		HIGH, WM (corresponding author), BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030, USA.						ADAMS KM, 1985, J CLIN EXP NEUROPSYC, V7, P445, DOI 10.1080/01688638508401276; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BLACK P, 1975, CIBA F S, V34; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; BOAKE C, 1993, ARCH PHYS MED REHAB, V74, P669; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DEPEDROCUESTA J, 1992, ACTA NEUROL SCAND, V86, P433; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Ebrahim, 1990, CLIN EPIDEMIOLOGY ST; EVANS SH, 1968, PSYCHOL BULL, V69, P225, DOI 10.1037/h0025666; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Granger CV, 1984, FUNCTIONAL ASSESSMEN; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HAFFEY WJ, 1989, PHYSICAL MED REHABIL; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; JENNETT B, 1975, LANCET, V1, P480; JOHNSTON M V, 1991, Brain Injury, V5, P141, DOI 10.3109/02699059109008085; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LORD FM, 1969, PSYCHOL BULL, V72, P336, DOI 10.1037/h0028108; LORD FM, 1967, PSYCHOL BULL, V68, P304, DOI 10.1037/h0025105; MACKAY LE, 1992, ARCH PHYS MED REHAB, V72, P635; MAXWELL S, 1975, PSYCHOL BULL, V82, P187, DOI 10.1037/h0076378; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUSK HA, 1969, LATE EFFECTS HEAD IN; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TEASDALE G, 1974, LANCET, V2, P81; Timmons M, 1987, J HEAD TRAUMA REHAB, V2, P64; TOBIS JS, 1982, SCAND J REHABIL MED, V14, P83; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHITENECK CG, 1992, NEUROREHABIL, V2, P31; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winer BJ., 1971, STAT PRINCIPLES EXPT; YU J, 1976, ARCH PHYS MED REHAB, V57, P38; [No title captured]	62	37	37	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	1995	10	1					14	26		10.1097/00001199-199502000-00004			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QF163	WOS:A1995QF16300003					2022-02-06	
J	RAMUNDO, ML; MCKNIGHT, T; KEMPF, J; SATKOWIAK, L				RAMUNDO, ML; MCKNIGHT, T; KEMPF, J; SATKOWIAK, L			CLINICAL PREDICTORS OF COMPUTED TOMOGRAPHIC ABNORMALITIES FOLLOWING PEDIATRIC TRAUMATIC BRAIN INJURY	PEDIATRIC EMERGENCY CARE			English	Article						HEAD TRAUMA; COMPUTED TOMOGRAPHY; GLASGOW COMA SCALE		Children commonly seek attention in emergency departments following head injury. Head computed tomography (CT) is often used to decide subsequent disposition. Clinical criteria predicting CT abnormalities would allow effective and timely treatment and minimize unnecessary procedures depleting overburdened medical resources. We prospectively compared presenting clinical features with subsequent emergent head CT in 300 children less than 19 years old over a nine-month period. The disposition of patients following imaging was also recorded. Only suspected abuse was more than 50% positively predictive in children below age two and those above age two. Two signs were more than 67% positively predictive in both age groups: focal motor deficit and pupillary asymmetry. Patients with abnormal CTs were the only children to undergo emergent neurosurgery (30%) and were nearly five times as likely to be intensively monitored. Children with normal CTs were nearly five times as likely to be observed in a routine department or at home. We conclude that no single clinical feature can predict with certainty an abnormality on immediate head CT. However, children suspected of being abused, and those with focal motor deficits or pupillary asymmetry, should be imaged. Finally, emergent CT when judiciously ordered likely reduces unforeseen morbidity and minimizes costly intensive care observation.			RAMUNDO, ML (corresponding author), CHILDRENS HOSP MED CTR AKRON,DEPT EMERGENCY MED & TRAUMA SERV,AKRON,OH 44308, USA.							0	37	37	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	1995	11	1					1	4		10.1097/00006565-199502000-00001			4	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	QH189	WOS:A1995QH18900001	7739953				2022-02-06	
J	JIANG, JY; LYETH, BG; DELAHUNTY, TM; PHILLIPS, LL; HAMM, RJ				JIANG, JY; LYETH, BG; DELAHUNTY, TM; PHILLIPS, LL; HAMM, RJ			MUSCARINIC CHOLINERGIC RECEPTOR-BINDING IN RAT-BRAIN AT 15 DAYS FOLLOWING TRAUMATIC BRAIN INJURY	BRAIN RESEARCH			English	Article						QUINUCLIDINYLBENZILATE; RECEPTOR BINDING; HOMOGENATE; HIPPOCAMPUS; BRAIN-STEM; NEOCORTEX; FLUID PERCUSSION; TRAUMATIC BRAIN INJURY	SUPPRESSION; INCREASE; DEFICITS; BEHAVIOR; MEMORY	Laboratory studies indicate that activation of muscarinic cholinergic receptors (mAChRs) at or soon after traumatic brain injury (TBI) significantly contributes to behavioral morbidity. Recent research has demonstrated that pre-injury treatment with the muscarinic antagonist scopolamine significantly reduces spatial memory deficits at 11-15 days post-TBI. In the present study, we examined mAChR binding kinetics in brain regions at 15 days after moderate (1.95 atm) fluid percussion TBI in untreated and scopolamine-treated rats. Three groups were examined: untreated TBI (n = 8), TBI with pre-injury scopolamine treatment (1.0 mg/kg, i.p., 15 min prior to injury) (n = 11), and sham-injury (n = 7). The affinity (K-d) and maximum number of binding sites (B-max) of mAChRs in hippocampus, neocortex, and brainstem were determined by [H-3]QNB binding. B-max values in TBI animals were significantly higher in hippocampus (4061 +/- 494 fmol/mg protein) and neocortex (4272 +/- 640 fmol/mg protein), but not in brainstem (833 +/- 39 fmol/mg protein) compared to sham-injured controls (hipp. 2812 +/- 218 fmol/mg/protein; neoctx. 2850 +/- 129 fmol/mg protein; brainstem 794 +/- 26 fmol/mg protein) (P < 0.05). At 15 days after injury, B-max values of mAChRs in TBI animals with pre-injury scopolamine treatment (hipp. 2850 +/- 129 fmol/mg protein; neoctx. 2948 +/- 123 fmol/mg protein) did not differ from control. In all brain regions, K-d values did not differ between groups. These results demonstrate that TBI significantly alters the binding sites of mAChRs in hippocampus and neocortex for as long as 15 days after TBI. Furthermore, these results indicate that a pharmacological treatment that improves motor and memory function outcome also normalizes aspects of mAChRs physiology. These data suggest that excessive activation of mAChRs at or soon after TBI impact contributes to long-term pathophysiological processes in TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,RICHMOND,VA 23298					Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 29995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, R01NS029995, P50NS012587] Funding Source: NIH RePORTER		ASANUMA M, 1992, ARCH INT PHARMACOD T, V315, P16; BELDHUIS HJA, 1993, NEUROSCIENCE, V55, P965, DOI 10.1016/0306-4522(93)90311-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CLIFTON GL, 1991, STROKE, V20, P1545; DEUTSCH JA, 1971, SCIENCE, V174, P788, DOI 10.1126/science.174.4011.788; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON ED, 1993, 2 GLASG INT NEUR S, P167; DIXON ED, 1992, ROLE NEUROTRANSMITTE, P213; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1993, J COGN BRAIN RES, V1, P223; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; Jiang J. Y., 1993, Society for Neuroscience Abstracts, V19, P1879; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MEYER MR, 1982, MOL PHARMACOL, V21, P280; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NODA Y, 1982, EXP NEUROL, V78, P91, DOI 10.1016/0014-4886(82)90191-1; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SIMAN RG, 1979, P NATL ACAD SCI USA, V76, P4141, DOI 10.1073/pnas.76.8.4141; TAYLOR JE, 1979, LIFE SCI, V25, P2181, DOI 10.1016/0024-3205(79)90090-0; THOMPSON AK, 1990, J PHARMACOL EXP THER, V252, P744; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725	38	37	37	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 18	1994	651	1-2					123	128		10.1016/0006-8993(94)90687-4			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NX150	WOS:A1994NX15000014	7922558				2022-02-06	
J	LEBRET, F; RUEL, P; ROSIER, H; GOARIN, JP; RIOU, B; VIARS, P				LEBRET, F; RUEL, P; ROSIER, H; GOARIN, JP; RIOU, B; VIARS, P			DIAGNOSIS OF TRAUMATIC MEDIASTINAL HEMATOMA WITH TRANSESOPHAGEAL ECHOCARDIOGRAPHY	CHEST			English	Article							BLUNT THORACIC TRAUMA; AORTIC TRANSECTION; CHEST TRAUMA; RUPTURE; INJURY; CT	In patients with blunt chest trauma, early diagnosis of mediastinal hematoma is important, because it could be associated with thoracic vessel injury. Mediastinal hematoma is generally evoked because of a widened mediastinum on chest radiograph, but radiologic diagnosis may lead to excessive angiography being performed. Transesophageal echocardiography (TEE) provides accurate views of the mediastinum and can be rapidly performed at the bedside. Thus, we conducted a prospective study to define TEE signs of mediastinal hematoma. TEE was performed in 22 thoracic trauma patients (trauma group) and in 20 brain-dead patients without thoracic trauma (control group). The positive diagnosis of mediastinal hematoma was made using thoracic surgery or computed tomographic scan. The specificity of TEE was 75 percent and sensitivity was 100 percent. In the trauma group, there was only one false positive but angiography discovered a traumatic aneurysm of the proximal right subclavian artery. No false negative was noted. We described three different TEE signs of mediastinal hematoma: (1) an increased distance between the probe and the aortic wall; (2) a double contour of the aortic wall; and (3) visualization of the ultrasound signal between the aortic wall and the visceral pleura. The distance between the esophageal probe and the aortic wall was the most accurate sign because it could be easily obtained; the threshold value for this distance was 3 mm. TEE appears to be an accurate method to diagnose traumatic mediastinal hematoma.	GRP HOSP PITIE SALPETRIERE,DIV RADIOL,PARIS,FRANCE; GRP HOSP PITIE SALPETRIERE,DEPT ANESTHESIOL,F-75634 PARIS,FRANCE								AYELLA RJ, 1977, J TRAUMA, V7, P199; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BROOKS SW, 1992, J TRAUMA, V32, P761, DOI 10.1097/00005373-199206000-00015; BROOKS SW, 1991, J TRAUMA, V31, P841, DOI 10.1097/00005373-199106000-00016; BURNEY RE, 1984, CHEST, V85, P605, DOI 10.1378/chest.85.5.605; GALVIN IF, 1991, ANN THORAC SURG, V51, P310, DOI 10.1016/0003-4975(91)90811-4; GOARIN JP, 1993, CHEST, V103, P618, DOI 10.1378/chest.103.2.618; HEIBERG E, 1983, AM J ROENTGENOL, V140, P1119, DOI 10.2214/ajr.140.6.1119; MILLER FB, 1989, SURGERY, V106, P596; MIRVIS SE, 1987, RADIOLOGY, V163, P487, DOI 10.1148/radiology.163.2.3562831; OVERFORS CO, 1978, RADIOL CLIN N AM, V16, P407; RICHARDSON P, 1991, AM J ROENTGENOL, V156, P273, DOI 10.2214/ajr.156.2.1898798; SANDOR F, 1967, THORAX, V22, P43, DOI 10.1136/thx.22.1.43; SHAPIRO MJ, 1991, J TRAUMA, V31, P835, DOI 10.1097/00005373-199106000-00015; STURM JT, 1979, SURGERY, V85, P365; WILSON RF, 1972, ARCH SURG-CHICAGO, V104, P551; WOODRING JH, 1984, RADIOLOGY, V151, P15, DOI 10.1148/radiology.151.1.6701306	17	37	38	0	1	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348	0012-3692			CHEST	Chest	FEB	1994	105	2					373	376		10.1378/chest.105.2.373			4	Critical Care Medicine; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Respiratory System	MX262	WOS:A1994MX26200016	8306731				2022-02-06	
J	WILSON, JTL; TEASDALE, GM; HADLEY, DM; WIEDMANN, KD; LANG, D				WILSON, JTL; TEASDALE, GM; HADLEY, DM; WIEDMANN, KD; LANG, D			POSTTRAUMATIC AMNESIA - STILL A VALUABLE YARDSTICK	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							BLUNT HEAD-INJURY; PRACTICAL SCALE; EARLY INDEXES; SEVERITY; SEQUELAE	Records of coma and post-traumatic amnesia (PTA) were collected for a group of 38 patients with closed head injury. The results confirmed earlier studies indicating that patients may have short or negligible coma but report prolonged PTA. Comparison of eight patients with prolonged PTA (>7 days) and short coma (<6 hours) with the rest of the group on MRI in the acute stage showed that these patients had significantly more extensive hemispheric damage. In the group as a whole both coma and PTA were related to the number of areas in central brain structures in which lesions were detected, but only PTA was significantly related to the number of hemispheric areas in which lesions were found. It is concluded that although both coma and PTA are related to brain damage they reflect disparate patterns of lesions. Assessment of PTA can thus provide additional information concerning severity of injury.	UNIV GLASGOW,INST NEUROL SCI,DEPT NEUROSURG,GLASGOW,SCOTLAND; UNIV GLASGOW,INST NEUROL SCI,DEPT NEURORADIOL,GLASGOW,SCOTLAND		WILSON, JTL (corresponding author), UNIV STIRLING,DEPT PSYCHOL,STIRLING FK9 4LA,SCOTLAND.		Wilson, Lindsay/A-3659-2009	Wilson, Lindsay/0000-0003-4113-2328	Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HADLEY DM, 1988, CLIN RADIOL, V39, P131; JENKINS A, 1986, LANCET, V2, P445; Levin H. S., 1984, NEUROPSYCHOLOGY MEMO; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mayes A., 1988, HUMAN ORGANIC MEMORY; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHORES A, 1990, AUST NZ J PSYCHIAT, V24, P133, DOI 10.3109/00048679009062895; Symonds CP, 1943, LANCET, V1, P7; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1984, HDB CLIN NEUROLOGY, V1, P185; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135; 1961, LANCET, V2, P1445	18	37	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	1994	57	2					198	201		10.1136/jnnp.57.2.198			4	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	NB044	WOS:A1994NB04400014	8126505	Green Published, Bronze			2022-02-06	
J	LUBUSKO, AA; MOORE, AD; STAMBROOK, M; GILL, DD				LUBUSKO, AA; MOORE, AD; STAMBROOK, M; GILL, DD			COGNITIVE BELIEFS FOLLOWING SEVERE TRAUMATIC BRAIN INJURY - ASSOCIATION WITH POSTINJURY EMPLOYMENT STATUS	BRAIN INJURY			English	Article							SCHOOL-LEAVERS; CONTROL SCALE; HEAD-INJURY; UNEMPLOYMENT; LOCUS; DEPRESSION; HEALTH; STRESS; LIFE; MEN	In this exploratory study, the cognitive beliefs of 19 severely traumatically brain-injured (TBI) patients were assessed to determine their association with post-injury employment status (that is, full-time, part-time or unemployed). Cognitive measures included the Multidimensional Health Locus of Control (MHLC) scale, the Revised Internal-External Scale (RIES) and the Beck Hopelessness Scale (BHS). Patients who did not return to their pre-injury level of employment (n = 10) were found to have lower MHLC Internal, higher RIES Powerful Others locus of control beliefs, and higher BHS scores as compared with a group of patients who returned to their pre-injury employment status (n = 9). In addition, longer lengths of post-traumatic amnesia, longer hospital stays and lower-prestige occupations post-injury were associated with poorer employment status. No differences were present between the groups in age, years of education, Glasgow Coma Scale on admission, length of coma, months post-injury, or pre-injury occupation. These results suggest that cognitive beliefs are a potential target for further research in TBI outcome.	UNIV MANITOBA,HLTH SCI CLIN RES CTR,DEPT PSYCHOL,NEUROPSYCHOL RES UNIT,820 SHERBROOK ST,WINNIPEG R3A 1M3,MB,CANADA; UNIV MANITOBA,HLTH SCI CLIN RES CTR,DEPT PSYCHIAT,NEUROPSYCHOL RES UNIT,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,HLTH SCI CLIN RES CTR,DEPT MED,NEUROPSYCHOL RES UNIT,WINNIPEG R3T 2N2,MANITOBA,CANADA; SOC MANITABANS & DISABILIT,WINNIPEG,MB,CANADA								ALLOY LB, 1988, BRIT J CLIN PSYCHOL, V27, P5, DOI 10.1111/j.2044-8260.1988.tb00749.x; Beck A.T., 1967, DEPRESSION CLIN; BLISHEN BR, 1967, CAN REV SOCIOL ANTHR, V4, P41; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; FEATHER NT, 1983, J ABNORM PSYCHOL, V92, P185, DOI 10.1037/0021-843X.92.2.185; FRANK RG, 1987, J CONSULT CLIN PSYCH, V55, P727; FURNHAM A, 1984, INT J MENT HEALTH, V13, P51, DOI 10.1080/00207411.1984.11448966; GRIMM BH, 1986, HDB CLIN NEUROPSYCHO, V2, P495; HOLDER EE, 1988, J CLIN PSYCHOL, V44, P753, DOI 10.1002/1097-4679(198809)44:5<753::AID-JCLP2270440514>3.0.CO;2-A; KEEFE T, 1984, SOC WORK, V29, P264, DOI 10.1093/sw/29.3.264; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KRAUSE N, 1986, J GERONTOL, V41, P617, DOI 10.1093/geronj/41.5.617; LAYTON C, 1987, PERS INDIV DIFFER, V8, P149, DOI 10.1016/0191-8869(87)90025-0; LEFCOURT H, 1981, RES LOCUS CONTROL CO, V1, P1; LEVENSON H, 1974, J PERS ASSESS, V38, P377, DOI 10.1080/00223891.1974.10119988; MELVILLE DI, 1985, PSYCHOL MED, V15, P789, DOI 10.1017/S0033291700005018; MILLER WR, 1975, J ABNORM PSYCHOL, V84, P228, DOI 10.1037/h0076720; NAGENSON T, 1974, SCANDINAVIAN J REHAB, V6, P5; Nagy VT, 1983, J SOC CLIN PSYCHOL, V1, P58; NELSON DW, 1983, AM J COMMUN PSYCHOL, V11, P705, DOI 10.1007/BF00896604; OLAFSSON O, 1986, SOC SCI MED, V22, P1105, DOI 10.1016/0277-9536(86)90177-2; PARRY G, 1988, BRIT J CLIN PSYCHOL, V27, P23, DOI 10.1111/j.2044-8260.1988.tb00750.x; PHARES EJ, 1955, THESIS OHIO STATE U; PLATT SD, 1987, BRIT J PSYCHIAT, V151, P27, DOI 10.1192/bjp.151.1.27; Seligman M., 1975, HELPLESSNESS; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STAMBROOK M, 1988, CANADIAN J REHABI S4, V1, P74; STAMBROOK M, 1990, COGNITIVE REHABILITA, V8, P26; STRICKLAND BR, 1978, J CONSULT CLIN PSYCH, V46, P1192, DOI 10.1037/0022-006X.46.6.1192; TAYLOR SE, 1982, PERS SOC PSYCHOL B, V8, P549, DOI 10.1177/0146167282083024; TIGGEMANN M, 1984, J OCCUP PSYCHOL, V57, P33, DOI 10.1111/j.2044-8325.1984.tb00145.x; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WALLSTON KA, 1978, HLTH ED MONOGRAPHS, V6; WINEFIELD HR, 1982, J PERS ASSESS, V46, P614, DOI 10.1207/s15327752jpa4606_10	35	37	37	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1994	8	1					65	70		10.3109/02699059409150959			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	MQ291	WOS:A1994MQ29100007	8124318				2022-02-06	
J	MCINTOSH, TK; FERNYAK, S; HAYES, RL; FADEN, AI				MCINTOSH, TK; FERNYAK, S; HAYES, RL; FADEN, AI			BENEFICIAL EFFECT OF THE NONSELECTIVE OPIATE ANTAGONIST NALOXONE HYDROCHLORIDE AND THE THYROTROPIN-RELEASING-HORMONE (TRH) ANALOG YM-14673 ON LONG-TERM NEUROBEHAVIORAL OUTCOME FOLLOWING EXPERIMENTAL BRAIN INJURY IN THE RAT	JOURNAL OF NEUROTRAUMA			English	Article							SPINAL-CORD INJURY; CEREBRAL BLOOD-FLOW; EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION MODEL; TRAUMATIC BRAIN; ENDOGENOUS OPIOIDS; INTRATHECAL INJECTION; DYNORPHIN; MECHANISM; RECEPTORS	Neurobehavioral dysfunction following traumatic brain injury results, in part, from delayed biochemical changes initiated by the traumatic insult. Endogenous opioid peptides have been implicated as one type of neurochemical factor involved in the delayed pathological sequelae of central nervous system (CNS) injury, including brain trauma. Both opiate antagonists and thyrotropin-releasing hormone (TRH) and its analogs, which antagonize the physiologic effects of endogenous opioids, have been shown to improve cardiovascular, cerebrovascular, metabolic, and neurologic status following both traumatic and ischemic CNS injury. The present study evaluated the ability of the opiate antagonist naloxone hydrochloride to improve posttraumatic neurologic motor function following experimental fluid-percussion brain injury in the rat, and compared the therapeutic effectiveness of naloxone to the long-acting, centrally active TRH analog YM-14673. Thirty minutes following fluid-percussion brain injury of moderate severity, animals received an intravenous bolus of either naloxone (2.0 mg/kg with constant infusion of 1.7 mg/kg/h, rt = 8), YM-14673 (1.0 mg/kg, n = 8), or saline (n = 8). Although naloxone caused a modest and nonsignificant increase in mean arterial blood pressure (MAP), YM-14673 significantly increased MAP within 5 min of administration (p < 0.05), an effect that continued up to 4 h postinjury. Postinjury administration of both naloxone and YM-14673 caused a significant improvement in neurobehavioral outcome which persisted up to 4 weeks postinjury. These results suggest that endogenous opioid peptides may	UNIV PENN,SCH MED,DEPT BIOENGN,PHILADELPHIA,PA 19104; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX; GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007		MCINTOSH, TK (corresponding author), UNIV PENN,SCH MED,DEPT NEUROSURG,105 HAYDEN,240 S 33RD ST,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS26818] Funding Source: Medline		ALVES WM, 1985, CENTRAL NERVOUS SYST, P255; ANDREWS B, 1989, J PHARMACOL EXP THER, V247, P1248; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; BAKSHI R, 1990, J NEUROSCI, V10, P3793, DOI 10.1523/JNEUROSCI.10-12-03793.1990; BASKIN DS, 1981, LANCET, V2, P272; BERRY SC, 1984, BRIT J PHARMACOL, V83, P179, DOI 10.1111/j.1476-5381.1984.tb10133.x; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CAUDLE RM, 1988, BRAIN RES, V443, P329, DOI 10.1016/0006-8993(88)91628-9; CHOI DW, 1988, EUR J PHARMACOL, V155, P27, DOI 10.1016/0014-2999(88)90399-8; DERRICK BE, 1991, BRAIN RES BULL, V27, P219, DOI 10.1016/0361-9230(91)90071-Q; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1992, AM J PHYSIOL, V263, pR909, DOI 10.1152/ajpregu.1992.263.4.R909; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1992, J NEUROSCI, V12, P425; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1988, BRAIN RES, V448, P287, DOI 10.1016/0006-8993(88)91265-6; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1984, LIFE SCI, V22, P1537; FADEN AI, 1982, NEUROLOGY, V322, P1083; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; HALL ED, 1986, PROCESSES RECOVERY N, P63; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; HOLADAY JW, 1980, BRAIN RES, V189, P295, DOI 10.1016/0006-8993(80)90032-3; HOSOBUCHI Y, 1982, SCIENCE, V215, P69, DOI 10.1126/science.6274019; HUDSON CJ, 1991, BRAIN RES, V564, P261, DOI 10.1016/0006-8993(91)91462-A; ISAAC L, 1990, BRAIN RES, V531, P83, DOI 10.1016/0006-8993(90)90760-9; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; LEVIN HS, 1991, J NEUROTRAUM, V9, pS359; LONG JB, 1987, BRAIN RES, V436, P374, DOI 10.1016/0006-8993(87)91683-0; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1158; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785, DOI 10.1152/ajpregu.1988.254.5.R785; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOISES HC, 1985, EUR J PHARMACOL, V108, P85, DOI 10.1016/0014-2999(85)90286-9; PARSONS CG, 1986, NEUROPHARMACOLOGY, V25, P217, DOI 10.1016/0028-3908(86)90045-6; PHILLIS JW, 1985, NEUROSURGERY, V17, P596, DOI 10.1227/00006123-198510000-00010; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; STEWART P, 1989, LIFE SCI, V44, P1504; STOKES BT, 1984, BRAIN RES, V290, P187, DOI 10.1016/0006-8993(84)90753-4; TURNER DM, 1984, NEUROSURGERY, V14, P688, DOI 10.1227/00006123-198406000-00008; VINK R, 1991, AM J PHYSIOL, V261, pR1527, DOI 10.1152/ajpregu.1991.261.6.R1527; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; VINK R, 1990, J NEUROSCI, V10, P3524; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZABRAMSKI JM, 1984, STROKE, V15, P621, DOI 10.1161/01.STR.15.4.621; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610	57	37	38	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	WIN	1993	10	4					373	384		10.1089/neu.1993.10.373			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	MQ818	WOS:A1993MQ81800002	8145261				2022-02-06	
